Scp160p O -
, O +
a O +
multiple O +
KH O -
- O -
domain O +
protein O -
, O +
is O +
a O +
component O +
of O +
mRNP O +
complexes O +
in O +
yeast B-Species +
Abstract O +
Scp160p O +
is O +
a O +
160 O +
kDa O +
protein O +
in O +
the O +
yeast B-Species +
Saccharomyces B-Species +
cerevisiae I-Species +
that O +
contains O +
14 O +
repeats O +
of O +
the O +
hnRNP O +
K O -
- O -
homology O +
( O -
KH O -
) O +
domain O -
, O +
and O +
demonstrates O +
significant O +
sequence O +
homology O +
to O +
a O +
family O +
of O +
proteins O +
collectively O +
known O +
as O +
vigilins O -
. O +

As O +
a O +
first O +
step O +
towards O +
defining O +
the O +
function O +
of O +
Scp160p O -
, O +
we O +
have O +
characterized O +
the O +
subcellular O +
distribution O +
and O +
in O +
vivo O +
interactions O +
of O +
this O +
protein O -
. O +

Using O +
sucrose O +
gradient O +
fractionation O +
studies O +
we O +
have O +
demonstrated O +
that O +
Scp160p O +
in O +
cytoplasmic O +
lysates O +
is O +
predominantly O +
associated O +
with O +
polyribosomes O -
. O +

Furthermore O -
, O +
we O +
have O +
found O +
that O +
Scp160p O +
is O +
released O +
from O +
polyribosomes O +
by O +
EDTA O +
in O +
the O +
form O +
of O +
a O +
large O +
complex O +
of O +
≥1300 O +
kDa O +
that O +
is O +
sensitive O +
both O +
to O +
RNase O +
and O +
NaCl O -
. O +

Using O +
affinity O -
- O -
chromatography O +
to O +
isolate O +
these O +
complexes O -
, O +
we O +
have O +
identified O +
two O +
protein O +
components O +
other O +
than O +
Scp160p O -
: O +
poly O -
( O -
A O -
) O +
binding O +
protein O -
, O +
Pab1p O -
, O +
and O +
Bfr1p O -
. O +

The O +
presence O +
of O +
Pab1p O +
confirms O +
these O +
complexes O +
to O +
be O +
mRNPs O -
. O +

The O +
presence O +
of O +
Bfr1p O +
is O +
intriguing O +
because O +
the O +
null O +
phenotype O +
for O +
this O +
gene O +
is O +
essentially O +
the O +
same O +
as O +
that O +
reported O +
for O +
scp160-null O +
cells O -
: O +
increased O +
cell O +
size O +
and O +
aberrant O +
DNA O +
content O -
. O +

These O +
results O +
demonstrate O +
that O +
Scp160p O +
associates O +
with O +
polyribosome O -
- O -
bound O +
mRNP O +
complexes O +
in O +
vivo O -
, O +
implicating O +
a O +
role O +
for O +
this O +
protein O +
in O +
one O +
or O +
more O +
levels O +
of O +
mRNA O +
metabolism O +
in O +
yeast B-Species -
. O +

INTRODUCTION O +
Scp160p O +
is O +
a O +
1222 O +
amino O +
acid O +
Saccharomyces B-Species +
cerevisiae I-Species +
protein O +
that O +
contains O +
14 O +
copies O +
of O +
the O +
hnRNP O +
K O +
homology O +
( O -
KH O -
) O +
domain O -
, O +
a O +
highly O +
conserved O +
motif O +
found O +
in O +
many O +
proteins O +
involved O +
in O +
RNA O +
metabolism O +
( O -
1 O -
) O -
. O +

KH O +
domain O -
- O -
containing O +
proteins O +
appear O +
to O +
have O +
diverse O +
functions O +
and O +
have O +
been O +
identified O +
in O +
all O +
kingdoms O +
of O +
life O -
, O +
including O +
the O +
ribosomal O +
protein O +
S3 O +
from O +
Escherichia B-Species +
coli I-Species +
( O -
1 O -
) O -
, O +
Mer1p O +
from O +
S.cerevisiae B-Species -
, O +
a O +
meiosis O -
- O -
specific O +
splicing O +
factor O +
( O -
1 O -
) O -
, O +
MEX-3 O +
from O +
Caenorhabditis B-Species +
elegans I-Species -
, O +
presumably O +
involved O +
in O +
mRNA O +
localization O +
during O +
development O +
( O -
2 O -
) O -
, O +
and O +
FMRP O -
, O +
the O +
fragile O -
- O -
X O +
mental O +
retardation O +
protein O +
in O +
humans B-Species +
( O -
3 O -
) O -
. O +

A O +
partial O +
clone O +
of O +
Scp160p O -
, O +
known O +
as O +
HX O -
, O +
was O +
one O +
of O +
the O +
first O +
multiple O -
- O -
KH O +
proteins O +
identified O +
( O -
1 O -
) O -
. O +

Whole O +
cell O +
immunofluorescence O +
studies O +
have O +
demonstrated O +
that O +
Scp160p O +
localizes O +
to O +
the O +
cytoplasm O -
, O +
with O +
enrichment O +
around O +
the O +
nuclear O +
envelope O -
, O +
and O +
what O +
appears O +
to O +
be O +
the O +
endoplasmic O +
reticulum O +
( O -
3 O -
) O -
. O +

Deletion O +
of O +
the O +
SCP160 O +
locus O +
in O +
yeast B-Species +
is O +
not O +
lethal O -
, O +
but O +
results O +
in O +
a O +
complex O +
phenotype O -
, O +
including O +
increased O +
DNA O +
content O +
per O +
cell O -
, O +
missegregation O +
of O +
genetic O +
markers O +
during O +
sporulation O -
, O +
and O +
abnormal O +
cell O +
morphology O -
, O +
including O +
increased O +
size O +
and O +
irregular O +
shape O +
( O -
4 O -
) O -
. O +

Observation O +
of O +
this O +
phenotype O +
led O +
to O +
the O +
hypothesis O +
that O +
Scp160p O +
may O +
function O +
in O +
regulating O +
ploidy O +
during O +
cell O +
division O -
. O +

More O +
recently O -
, O +
Weber O +
and O +
colleagues O +
demonstrated O +
in O +
vitro O +
RNA O +
binding O +
activity O +
of O +
Scp160p O +
using O +
northwestern O +
blot O +
analyses O -
; O +
the O +
protein O +
was O +
found O +
to O +
bind O +
efficiently O +
to O +
ribohomopolymers O +
and O +
rRNA O -
, O +
but O +
not O +
to O +
tRNA O +
( O -
5 O -
) O -
. O +

Cell O +
fractionation O +
studies O +
revealed O +
that O +
a O +
large O +
percentage O +
of O +
Scp160p O +
associates O +
with O +
membrane O -
- O -
pellets O -
, O +
and O +
is O +
released O +
by O +
treatment O +
with O +
either O +
10 O +
mM O +
EDTA O +
or O +
500 O +
mM O +
NaCl O +
( O -
5 O -
) O -
. O +

While O +
these O +
authors O +
interpreted O +
these O +
results O +
to O +
suggest O +
that O +
the O +
nuclear O +
envelope O -
/ O -
ER O +
localization O +
of O +
Scp160p O +
was O +
due O +
primarily O +
to O +
interactions O +
of O +
the O +
protein O +
with O +
membrane O -
- O -
bound O +
polyribosomes O -
, O +
clear O +
evidence O +
of O +
this O +
association O +
has O +
not O +
been O +
reported O +
( O -
5 O -
) O -
. O +

Currently O -
, O +
the O +
relationship O +
between O +
the O +
phenotype O +
of O +
scp160 O +
null O +
mutants O +
and O +
the O +
RNA O -
- O -
binding O +
activity O +
of O +
Scp160p O +
remains O +
unclear O -
. O +

Scp160p O +
demonstrates O +
significant O +
sequence O +
homology O +
( O -
~23 O -
% O +
identity O +
and O +
~40 O -
% O +
similarity O +
at O +
the O +
amino O +
acid O +
level O -
) O +
to O +
a O +
class O +
of O +
vertebrate O +
KH O -
- O -
domain O +
proteins O +
collectively O +
known O +
as O +
vigilins O -
. O +

First O +
identified O +
in O +
chicken B-Species -
, O +
vigilin O +
homologues O +
have O +
now O +
been O +
found O +
in O +
human B-Species +
( O -
6 O -
) O -
, O +
Xenopus B-Species +
laevis I-Species +
( O -
7 O -
) O -
, O +
Drosophila B-Species +
melanogaster I-Species +
( O -
8) O -
, O +
C.elegans B-Species +
( O -
5 O -
) O +
and O +
Schizosaccharomyces B-Species +
pombe I-Species -
. O +

While O +
all O +
of O +
the O +
vigilin O +
proteins O +
studied O +
to O +
date O +
are O +
reported O +
to O +
bind O +
nucleic O +
acid O -
, O +
both O +
the O +
type O +
of O +
nucleic O +
acid O +
bound O +
and O +
the O +
functional O +
significance O +
of O +
these O +
interactions O +
remain O +
unclear O -
. O +

For O +
example O -
, O +
Kruse O +
and O +
colleagues O +
reported O +
from O +
their O +
work O +
with O +
human B-Species +
cells O +
in O +
culture O +
that O +
vigilin O +
may O +
be O +
involved O +
in O +
the O +
binding O +
and O +
transport O +
of O +
tRNA O +
( O -
9–11 O -
) O -
. O +

In O +
contrast O -
, O +
Dodson O +
and O +
Shapiro O +
concluded O +
from O +
their O +
work O +
with O +
Xenopus O +
vigilin O +
that O -
, O +
in O +
response O +
to O +
estrogen O -
, O +
the O +
protein O +
bound O +
specifically O +
to O +
the O +
3′ O +
UTR O +
of O +
vitellogenin O +
mRNA O +
( O -
7,12 O -
) O -
, O +
potentially O +
stabilizing O +
the O +
message O +
( O -
13 O -
) O -
. O +

Lastly O -
, O +
DDP1 O -
, O +
the O +
Drosophila O +
homolog O +
of O +
vigilin O -
, O +
was O +
reported O +
recently O +
to O +
interact O +
with O +
the O +
dodeca O -
- O -
satellite O +
repeat O +
regions O +
of O +
centromeric O +
heterochromatin O +
in O +
embryonic O +
and O +
larval O +
cell O +
nuclei O -
, O +
suggesting O +
a O +
possible O +
role O +
for O +
this O +
protein O +
in O +
heterochromatin O +
structure O +
( O -
8) O -
. O +

The O +
goal O +
of O +
the O +
present O +
study O +
was O +
to O +
begin O +
elucidating O +
the O +
function O +
of O +
Scp160p O +
in O +
yeast B-Species +
by O +
characterizing O +
the O +
subcellular O +
distribution O +
and O +
macromolecular O +
interactions O +
of O +
this O +
protein O -
. O +

We O +
have O +
demonstrated O +
that O +
Scp160p O +
in O +
cytoplasmic O +
lysates O +
is O +
associated O +
predominantly O +
with O +
polyribosomes O -
, O +
and O +
that O +
following O +
treatment O +
with O +
EDTA O -
, O +
Scp160p O +
remains O +
in O +
an O +
RNase O -
/ O -
NaCl O -
- O -
sensitive O +
complex O +
of O +
apparent O +
molecular O +
weight O +
approximately O +
≥1300 O +
kDa O -
. O +

Affinity O +
purification O +
of O +
this O +
complex O +
revealed O +
the O +
presence O +
of O +
poly O -
( O -
A O -
) O -
-binding O +
protein O +
( O -
Pab1p O -
) O -
, O +
a O +
well O -
- O -
characterized O +
component O +
of O +
eukaryotic O +
mRNPs O +
( O -
14,15 O -
) O -
. O +

Finally O -
, O +
a O +
third O +
abundant O +
protein O +
component O +
of O +
this O +
complex O +
was O +
identified O +
as O +
Bfr1p O -
, O +
a O +
protein O +
not O +
previously O +
reported O +
to O +
associate O +
with O +
mRNPs O -
. O +

While O +
the O +
function O +
of O +
Bfr1p O +
remains O +
unknown O -
, O +
gene O +
deletion O +
reportedly O +
leads O +
to O +
a O +
phenotype O +
remarkably O +
similar O +
to O +
that O +
of O +
scp160 O +
deletion O +
( O -
16 O -
) O -
. O +

These O +
results O +
indicate O +
a O +
role O +
for O +
Scp160p O +
in O +
mRNA O +
metabolism O +
in O +
yeast B-Species -
, O +
and O +
by O +
extension O -
, O +
support O +
results O +
seen O +
with O +
Xenopus O +
vigilin O +
in O +
its O +
interactions O +
with O +
mRNA O -
. O +

To O +
our O +
knowledge O -
, O +
the O +
data O +
reported O +
here O +
demonstrate O +
Scp160p O +
to O +
be O +
the O +
first O +
example O +
of O +
a O +
KH O -
- O -
domain O +
protein O +
that O +
functions O +
as O +
a O +
component O +
of O +
polyribosome O -
- O -
associated O +
mRNP O +
complexes O +
in O +
the O +
yeast B-Species -
, O +
S.cerevisiae B-Species -
. O +

MATERIALS O +
AND O +
METHODS O +
Plasmids O -
, O +
yeast B-Species +
strains O +
and O +
culture O +
conditions O +
All O +
recombinant O +
DNA O +
manipulations O +
were O +
performed O +
according O +
to O +
standard O +
techniques O +
and O +
utilized O +
E.coli B-Species +
strain O +
XL1-Blue O +
( O -
Stratagene O -
) O -
. O +

The O +
yeast B-Species +
strain O +
JFy1511 O -
, O +
expressing O +
FLAG O -
– O -
Scp160p O -
, O +
was O +
derived O +
by O +
two O -
- O -
step O +
gene O +
replacement O +
from O +
strain O +
yJJ52 O +
( O -
MATα O +
gal7Δ102 O +
ura3 O -
- O -
52 O +
trp1 O -
- O -
289 O +
ade1 O +
lys1 O +
leu2 O -
- O -
3 O -
, O +
112 O -
; O +
generously O +
donated O +
by O +
Drs O +
Mark O +
Parthun O +
and O +
Judith O +
Jaehning O -
, O +
University O +
of O +
Colorado O +
Health O +
Sciences O +
Center O -
) O -
, O +
and O +
confirmed O +
by O +
PCR O -
. O +

The O +
wild O -
- O -
type O +
SCP160 O +
coding O +
sequence O +
was O +
obtained O +
by O +
PCR O +
amplification O +
from O +
a O +
genomic O +
DNA O +
preparation O +
from O +
yJFK1 O +
( O -
MATα O +
gal7Δ102 O +
ura3 O -
- O -
52 O +
trp1 O -
- O -
289 O +
ade1 O +
lys1 O +
leu2 O -
- O -
3 O -
, O +
112 O +
ΔGAL80::URA3 O -
) O -
, O +
using O +
a O +
16:1 O +
mixture O +
of O +
Taq O +
( O -
Fisher O +
Biotech O -
) O +
and O +
Pfu O +
( O -
Stratagene O -
) O +
DNA O +
polymerases O +
and O +
the O +
following O +
primers O -
: O +
Scp160F1 O +
( O -
5′-GCCGGTCGA O -
- O -
CTAACTGCAATGTCTGAAGAACAAACCGCTATTG-3′ O -
) O +
and O +
Scp160R1 O +
( O -
5′-GCGCGTCGACGAGCTTGTCTATCTT O -
- O -
CTTAAGG-3′ O -
) O -
. O +

A O +
wild O -
- O -
type O +
SCP160 O +
genomic O +
clone O -
, O +
containing O +
1 O +
kb O +
upstream O +
and O +
300 O +
bp O +
downstream O +
sequence O +
was O +
PCR O +
amplified O +
from O +
yJFK1 O +
genomic O +
DNA O +
using O +
the O +
primers O +
Scp160F0 O +
( O -
5′-GCCGAGCTCACACCAGCTTTGTCCTGG-3′ O -
) O +
and O +
Scp160R2 O +
( O -
5′-GCGCAAGCTTGTGCGGTA O -
- O -
TCCCAGTCTATG-3′ O -
) O -
. O +

The O +
resultant O +
clone O +
was O +
confirmed O +
by O +
dideoxy O +
sequencing O -
. O +

The O +
N O -
- O -
terminal O +
FLAG O +
and O +
HA O +
tags O +
were O +
added O +
using O +
PCR O +
with O +
the O +
primers O +
ScpFLAGF1 O -
( O -
5′-CCAT O -
- O -
TATAACTGCAATGGACTACAAGGACGACGACGACGAC O -
- O -
AAGATGTCTGAAGAACAAACCGCTATTG-3′ O -
) O +
and O +
ScpHAF1 O +
( O -
5′-CCCCCTCCTGTCGACATTATAACTGCAATGCACCA O -
- O -
TCACCATCACCATTCTGAAGAACAAACCGCTATTG-3′ O -
) O +
respectively O -
. O +

For O +
integration O -
, O +
constructs O +
containing O +
the O +
1 O +
kb O +
upstream O +
and O +
300 O +
bp O +
downstream O +
sequence O +
were O +
subcloned O +
into O +
the O +
plasmid O +
YIplac211 O +
( O -
17 O -
) O +
using O +
SacI O +
and O +
HindIII O +
restriction O +
sites O -
. O +

The O +
HA O -
- O -
tagged O +
construct O +
was O +
subcloned O +
into O +
the O +
low O +
copy O +
number O +
plasmid O -
, O +
YCplac22 O +
using O +
SacI O +
and O +
HindIII O +
restriction O +
sites O -
. O +

The O +
SCP160 O +
deletion O +
construct O +
was O +
made O +
by O +
removal O +
of O +
a O +
3.4 O +
kb O +
ApaI O -
– O -
KpnI O +
fragment O +
from O +
the O +
coding O +
region O +
of O +
this O +
construct O -
, O +
followed O +
by O +
treatment O +
with O +
Klenow O +
fragment O +
and O +
re O -
- O -
ligation O +
following O +
attachment O +
of O +
BamHI O +
linker O +
oligonucleotides O -
. O +

Genomic O +
integration O +
of O +
the O +
plasmid O +
sequences O +
and O +
subsequent O +
removal O +
of O +
the O +
endogenous O +
SCP160 O +
allele O +
were O +
achieved O +
by O +
standard O +
two O -
- O -
step O +
gene O +
replacement O +
techniques O +
( O -
18 O -
) O +
and O +
confirmed O +
by O +
PCR O -
. O +

The O +
N O -
- O -
terminally O +
HA O -
- O -
tagged O +
allele O +
of O +
BFR1 O +
was O +
generated O +
by O +
PCR O -
- O -
amplifiction O +
of O +
the O +
BFR1 O +
locus O +
from O +
wild O -
- O -
type O +
( O -
W303 O -
) O +
yeast B-Species +
genomic O +
DNA O +
using O +
the O +
primers O +
BFR1HAF1 O +
( O -
5′-CCGCGGATCCATGTACC O -
- O -
CATACGACGTCCCAGACTACGCTATGTCCTCCCAAC O -
- O -
AACACAA-3′ O -
) O +
and O +
BFR1HINDR1 O +
( O -
5′-CCGCAAGCTTGTCG O -
- O -
ACTATTTCATATGCCACAGGAAACAG-3′ O -
) O -
, O +
and O +
subcloned O +
into O +
YIPlac211 O -
. O +

The O +
BFR1 O +
promoter O +
region O +
was O +
PCR O -
- O -
amplified O +
in O +
a O +
similar O +
manner O +
using O +
the O +
primers O +
BFR1SACF1 O +
( O -
5′-CCGCGAG O -
- O -
CTCAGCATTAAGCATTCACGAGC-3′ O -
) O +
and O +
BFR1BAMR1 O +
( O -
5′-CCGCGGATCCGGCAATGGCTGTGTTGTTAGA-3′ O -
) O +
and O +
subcloned O +
into O +
the O +
appropriate O +
position O +
upstream O +
of O +
the O +
HA O -
– O -
Bfr1p O +
open O +
reading O +
frame O +
in O +
the O +
plasmid O +
backbone O -
. O +

The O +
entire O +
open O +
reading O +
frame O +
was O +
confirmed O +
by O +
dideoxy O +
sequencing O -
. O +

Finally O -
, O +
the O +
HA O -
– O -
BFR1 O +
allele O +
was O +
substituted O +
into O +
the O +
yeast B-Species +
genome O +
in O +
place O +
of O +
the O +
native O +
allele O +
using O +
linearization O +
with O +
SphI O +
and O +
standard O +
two O -
- O -
step O +
gene O +
replacement O +
techniques O -
. O +

All O +
yeast B-Species +
transformations O +
and O +
culture O +
manipulations O +
were O +
performed O +
according O +
to O +
standard O +
protocols O +
as O +
described O +
elsewhere O +
( O -
19 O -
) O -
. O +

Confirmation O +
of O +
genomic O +
integrations O +
All O +
genomic O +
integrations O +
were O +
confirmed O +
by O +
PCR O +
amplifications O +
from O +
purified O +
yeast B-Species +
genomic O +
DNA O -
. O +

For O +
scp160 O +
deletion O +
mutants O -
, O +
the O +
primers O +
Scp160PF O +
( O -
5′-GATTTCCTAACTTTCC O -
- O -
GTCTA-3′ O -
) O +
and O +
Scp160R5 O +
( O -
5′-GCGCAAGCTTCACCGCCTTATAACGAAGAC-3′ O -
) O +
that O +
flanked O +
the O +
deleted O +
region O +
were O +
used O -
. O +

Similarly O -
, O +
epitope O +
tags O +
on O +
Scp160p O +
were O +
confirmed O +
by O +
PCR O +
using O +
primers O +
that O +
flanked O +
the O +
tag O +
sequence O -
. O +

Positive O +
clones O +
were O +
further O +
confirmed O +
by O +
western O +
blot O +
analysis O +
of O +
crude O +
cell O +
lysates O +
using O +
the O +
appropriate O +
anti O -
- O -
tag O +
antibodies O -
. O +

The O +
presence O +
of O +
HA O -
– O -
Bfr1p O +
in O +
cells O +
was O +
confirmed O +
by O +
western O +
blot O +
analysis O +
of O +
soluble O +
cell O +
lysates O +
using O +
12CA5 O +
mAb O +
( O -
Boehringer O +
Mannheim O -
) O -
. O +

Polyribosome O +
isolation O +
Polyribosomes O +
were O +
isolated O +
using O +
a O +
combination O +
of O +
protocols O +
described O +
by O +
Stansfield O +
and O +
colleagues O +
( O -
20 O -
) O +
and O +
by O +
Dr O +
Maurice O +
Swanson O +
( O -
personal O +
communication O -
) O -
. O +

In O +
brief O -
, O +
a O +
100 O +
ml O +
culture O +
of O +
yeast B-Species +
was O +
grown O +
in O +
either O +
YEPD O +
or O +
Hartwell O +
synthetic O +
medium O -
, O +
to O +
early O -
- O -
log O +
phase O +
( O -
OD600 O +
= O +
1.0 O -
) O -
, O +
at O +
which O +
time O +
cyclohexamide O +
( O -
Sigma O -
) O +
was O +
added O +
directly O +
to O +
the O +
culture O +
to O +
a O +
final O +
concentration O +
of O +
100 O +
µg O -
/ O -
ml O -
. O +

The O +
culture O +
was O +
incubated O +
on O +
ice O +
for O +
15 O +
min O -
, O +
and O +
cells O +
were O +
harvested O +
by O +
centrifugation O +
( O -
4000 O +
r.p.m. O -
/ O -
10 O +
min O -
) O -
. O +

Following O +
two O +
washes O +
in O +
10 O +
ml O +
of O +
water O +
containing O +
100 O +
µg O -
/ O -
ml O +
cyclohexamide O -
, O +
cells O +
were O +
lysed O +
by O +
vortex O +
agitation O +
with O +
an O +
equal O +
volume O +
of O +
glass O +
beads O +
in O +
1 O +
ml O +
lysis O +
buffer O +
( O -
25 O +
mM O +
Tris O +
pH O +
7.2 O -
, O +
50 O +
mM O +
KCl O -
, O +
30 O +
mM O +
MgCl2 O -
, O +
5 O +
mM O +
β O -
- O -
mercaptoethanol O -
, O +
200 O +
µg O -
/ O -
ml O +
cyclohexamide O -
, O +
2 O +
µg O -
/ O -
ml O +
aprotonin O -
, O +
1 O +
mM O +
PMSF O -
, O +
0.5 O +
µg O -
/ O -
ml O +
leupeptin O -
, O +
2.9 O +
µg O -
/ O -
ml O +
E64 O -
, O +
1 O +
µg O -
/ O -
ml O +
antipain O -
, O +
0.2 O +
µg O -
/ O -
ml O +
chymostatin O -
) O -
. O +

Lysate O +
was O +
transferred O +
to O +
a O +
clean O +
microfuge O +
tube O -
, O +
and O +
centrifuged O +
10 O +
min O +
at O +
3000 O +
g O +
at O +
4 O -
° O -
C O -
. O +

The O +
supernatant O +
was O +
again O +
transferred O +
to O +
a O +
clean O +
microfuge O +
tube O +
and O +
centrifuged O +
at O +
12 O +
000 O +
g O +
for O +
15 O +
min O +
at O +
4 O -
° O -
C O -
, O +
and O +
then O +
assayed O +
for O +
absorbance O +
at O +
260 O +
nm O -
. O +

Approximately O +
12 O +
OD260 O +
units O +
were O +
loaded O +
onto O +
a O +
11 O +
ml O +
15–45 O -
% O +
sucrose O +
gradient O +
made O +
in O +
10 O +
mM O +
Tris O -
, O +
pH O +
7.4 O -
, O +
70 O +
mM O +
NH4Cl O -
, O +
4 O +
mM O +
MgOAc O -
, O +
using O +
a O +
Gradient O +
Master O +
automatic O +
system O -
, O +
and O +
the O +
gradient O +
was O +
centrifuged O +
in O +
a O +
SW41ti O +
rotor O +
( O -
Beckman O -
) O +
at O +
39 O +
000 O +
r.p.m O -
. O +

for O +
2.5 O +
h. O +
0.5 O +
ml O +
fractions O +
were O +
collected O +
using O +
an O +
Isco O +
gradient O +
fractionator O -
, O +
and O +
gradient O +
profiles O +
were O +
determined O +
by O +
monitoring O +
absorbance O +
at O +
254 O +
nm O -
. O +

For O +
EDTA O +
controls O -
, O +
lysis O +
buffer O +
containing O +
5 O +
mM O +
MgCl2 O +
was O +
used O -
, O +
and O +
30 O +
mM O +
EDTA O +
was O +
added O +
to O +
the O +
sample O +
before O +
loading O +
onto O +
the O +
gradient O -
. O +

Where O +
indicated O -
, O +
addition O +
of O +
50 O +
U O -
/ O -
ml O +
of O +
RNase O +
One O +
( O -
Promega O -
) O +
was O +
performed O +
prior O +
to O +
loading O +
the O +
sample O +
onto O +
the O +
gradient O -
. O +

Gel O +
filtration O +
chromatography O +
Gel O +
filtration O +
chromatography O +
was O +
performed O +
using O +
a O +
120 O +
ml O +
Hi O -
- O -
Prep O +
S-300 O +
Sephacryl O +
column O +
( O -
Pharmacia O -
) O +
with O +
a O +
cut O -
- O -
off O +
of O +
1300 O +
kDa O -
, O +
attached O +
to O +
an O +
FPLC O +
system O +
( O -
Pharmacia O -
) O -
. O +

The O +
column O +
had O +
been O +
calibrated O +
previously O +
using O +
the O +
following O +
molecular O +
weight O +
standards O +
( O -
Sigma O -
) O -
: O +
blue O +
dextran O +
( O -
2000 O +
kDa O -
) O -
, O +
thyroglobulin O +
( O -
669 O +
kDa O -
) O -
, O +
apoferritin O +
( O -
443 O +
kDa O -
) O -
, O +
alcohol O +
dehydrogenase O +
( O -
150 O +
kDa O -
) O -
, O +
and O +
bovine B-Species +
serum O +
albumin O +
( O -
66 O +
kDa O -
) O -
. O +

Yeast B-Species +
were O +
lysed O +
as O +
described O +
for O +
polyribosome O +
analysis O -
, O +
with O +
an O +
additional O +
clarification O +
by O +
passage O +
through O +
a O +
0.2 O +
µm O +
syringe O -
- O -
tip O +
filter O +
( O -
Acrodisc O -
) O +
and O +
run O +
over O +
the O +
column O +
at O +
a O +
rate O +
of O +
0.5 O +
ml O -
/ O -
min O +
in O +
polyribosome O +
lysis O +
buffer O +
following O +
treatment O +
with O +
the O +
indicated O +
reagents O -
. O +

Fractions O +
( O -
2.0 O +
ml O -
) O +
were O +
collected O -
, O +
from O +
which O +
12 O +
µl O +
were O +
combined O +
with O +
sample O +
buffer O +
( O -
2 O -
% O +
SDS O -
, O +
10 O -
% O +
glycerol O -
, O +
100 O +
mM O +
dithiothreitol O -
, O +
60 O +
mM O +
Tris O +
pH O +
6.8 O -
, O +
0.001 O -
% O +
bromophenol O +
blue O -
) O +
and O +
analyzed O +
by O +
western O +
blot O +
using O +
the O +
indicated O +
antibodies O -
. O +

α O -
- O -
FLAG O +
affinity O +
chromatography O +
For O +
most O +
experiments O -
, O +
one O +
liter O +
yeast B-Species +
cultures O +
were O +
grown O +
to O +
early O +
log O -
- O -
phase O +
and O +
harvested O +
by O +
centrifugation O -
. O +

Cells O +
were O +
washed O +
twice O +
in O +
T75 O +
buffer O +
( O -
25 O +
mM O +
Tris O +
pH O +
7.5 O -
, O +
75 O +
mM O +
NaCl O -
) O +
and O +
then O +
were O +
lysed O +
by O +
vortex O +
agitation O +
with O +
an O +
equal O +
volume O +
of O +
glass O +
beads O +
in O +
4 O +
ml O +
T75 O +
buffer O +
containing O +
30 O +
mM O +
EDTA O -
. O +

Lysate O +
was O +
transferred O +
to O +
a O +
clean O +
microfuge O +
tube O -
, O +
and O +
centrifuged O +
for O +
10 O +
min O +
at O +
3000 O +
g O +
at O +
4 O -
° O -
C O -
. O +

The O +
supernatant O +
was O +
again O +
transferred O +
to O +
a O +
clean O +
microfuge O +
tube O +
and O +
centrifuged O +
at O +
12 O +
000 O +
g O +
for O +
15 O +
min O +
at O +
4 O -
° O -
C O -
, O +
and O +
finally O +
passed O +
through O +
a O +
0.2 O +
µm O +
syringe O +
filter O -
. O +

Lysate O +
was O +
then O +
pre O -
- O -
purified O +
by O +
running O +
over O +
the O +
S-300 O +
gel O -
- O -
filtration O +
column O +
in O +
T75 O +
buffer O -
, O +
with O +
pooling O +
of O +
the O +
void O +
volume O +
fractions O +
( O -
~10 O +
ml O +
total O -
) O -
. O +

For O +
several O +
experiments O +
( O -
Fig. O +
5A O -
, O +
B O -
, O +
E O +
and O +
F O -
) O -
, O +
a O +
low O +
concentration O +
( O -
< O -
10 O +
µg O -
/ O -
ml O -
) O +
of O +
FLAG O +
peptide O +
( O -
N O -
- O -
DYKDDDDK O -
- O -
C O -
) O +
was O +
added O +
to O +
this O +
sample O -
. O +

This O +
void O +
material O +
was O +
then O +
loaded O +
onto O +
a O +
1 O +
ml O +
M2 O +
α O -
- O -
FLAG O +
column O +
( O -
Sigma O -
) O -
; O +
column O +
flow O -
- O -
through O +
was O +
passed O +
over O +
the O +
column O +
a O +
second O +
time O -
. O +

The O +
column O +
was O +
then O +
washed O +
extensively O +
with O +
75 O +
ml O +
T75 O +
buffer O -
; O +
material O +
bound O +
to O +
the O +
column O +
was O +
eluted O +
with O +
5 O +
ml O +
T75 O +
containing O +
184 O +
mg O -
/ O -
ml O +
FLAG O +
peptide O -
. O +

The O +
peptide O +
solution O +
was O +
allowed O +
to O +
incubate O +
on O +
the O +
column O +
for O +
20 O +
min O +
prior O +
to O +
collection O +
of O +
the O +
first O +
1 O +
ml O +
fraction O -
; O +
subsequent O +
fractions O +
were O +
collected O +
every O +
10 O +
min O -
. O +

Samples O +
of O +
crude O +
material O -
, O +
S-300 O +
void O -
, O +
α O -
- O -
FLAG O +
flow O -
- O -
through O -
, O +
first O +
and O +
last O +
wash O -
, O +
and O +
eluate O +
fractions O +
were O +
analyzed O +
by O +
western O +
blot O +
using O +
the O +
indicated O +
antibodies O -
. O +

For O +
Figure O +
5A O +
and O +
E O -
, O +
samples O +
of O +
first O +
and O +
last O +
wash O +
and O +
eluate O +
fractions O +
were O +
concentrated O -
, O +
run O +
on O +
SDS O -
– O -
PAGE O +
and O +
stained O +
with O +
colloidal O +
G250 O +
Coomassie O -
. O +

Concentration O +
of O +
samples O +
Where O +
indicated O -
, O +
samples O +
were O +
concentrated O +
using O +
the O +
method O +
of O +
Traub O +
et O +
al. O +
( O -
21 O -
) O -
. O +

400 O +
µl O +
of O +
sample O +
were O +
transferred O +
to O +
a O +
microfuge O +
tube O -
, O +
and O +
combined O +
with O +
400 O +
µl O +
of O +
methanol O -
, O +
and O +
100 O +
µl O +
of O +
chloroform O -
. O +

Samples O +
were O +
then O +
vortexed O +
vigorously O -
, O +
and O +
centrifuged O +
for O +
5 O +
min O +
at O +
12 O +
000 O +
g. O +

The O +
supernatant O +
was O +
discarded O -
, O +
leaving O +
the O +
interface O +
intact O -
, O +
and O +
an O +
additional O +
400 O +
µl O +
of O +
methanol O +
was O +
added O +
to O +
each O +
tube O -
. O +

Samples O +
were O +
then O +
inverted O +
several O +
times O -
, O +
and O +
centrifuged O +
again O +
for O +
5 O +
min O -
. O +

The O +
supernatant O +
was O +
discarded O -
, O +
and O +
the O +
protein O +
pellet O +
was O +
air O -
- O -
dried O +
and O +
resuspended O +
in O +
1 O -
× O +
sample O +
buffer O -
. O +

Western O +
blot O +
analysis O +
Western O +
blot O +
analysis O +
was O +
performed O +
essentially O +
as O +
described O +
previously O +
( O -
19 O -
) O -
. O +

Briefly O -
, O +
samples O +
to O +
be O +
analyzed O +
were O +
mixed O +
with O +
sample O +
buffer O -
, O +
boiled O -
, O +
electrophoresed O +
through O +
a O +
10 O -
% O +
SDS O -
– O -
polyacrylamide O +
gel O -
, O +
and O +
electro O -
- O -
blotted O +
onto O +
nitrocellulose O +
( O -
Bio O -
- O -
Rad O -
) O -
. O +

FLAG O -
– O -
Scp160p O +
fusion O +
protein O +
was O +
detected O +
by O +
incubation O +
of O +
the O +
filter O +
with O +
mouse B-Species +
M2 O +
anti O -
- O -
FLAG O +
monoclonal O +
antibody O +
( O -
10 O +
µg O -
/ O -
ml O +
final O +
concentration O -
) O -
, O +
followed O +
by O +
HRP O -
- O -
conjugated O +
sheep B-Species +
anti O -
- O -
mouse B-Species +
secondary O +
antibody O +
( O -
Amersham O -
) O -
, O +
diluted O +
1:5000 O +
as O +
per O +
the O +
manufacturer O -
's O +
instructions O -
, O +
and O +
ECL O +
reagent O +
( O -
Amersham O -
) O -
, O +
followed O +
by O +
exposure O +
to O +
X O -
- O -
ray O +
film O -
. O +

HA O -
- O -
tagged O +
Scp160p O +
and O +
HA O -
- O -
tagged O +
Bfr1p O +
were O +
detected O +
using O +
the O +
12CA5 O +
mAb O +
( O -
Boehringer O +
Mannheim O -
) O +
at O +
a O +
final O +
concentration O +
of O +
0.8 O +
µg O -
/ O -
ml O -
; O +
Pab1p O +
and O +
Pub1p O +
were O +
detected O +
using O +
1G1 O +
mAb O +
at O +
1:5000 O -
, O +
and O +
4C3 O +
mAb O +
at O +
1:1000 O -
, O +
respectively O -
, O +
both O +
generous O +
gifts O +
from O +
Dr O +
Maurice O +
Swanson O +
( O -
22,23 O -
) O -
. O +

Where O +
appropriate O -
, O +
films O +
were O +
analyzed O +
by O +
scanning O +
densitometry O +
( O -
Molecular O +
Dynamics O -
) O -
, O +
and O +
quantitated O +
using O +
ImageQuant O +
software O +
( O -
Molecular O +
Dynamics O -
) O -
. O +

Colloidal O +
G250 O +
coomassie O +
staining O +
Procedure O +
used O +
was O +
that O +
of O +
Neuhoff O +
( O -
24 O -
) O -
. O +

Briefly O -
, O +
a O +
one O +
liter O +
stock O +
of O +
staining O +
solution O +
was O +
prepared O +
containing O +
1 O +
g O +
Coomassie O +
brilliant O +
blue O +
G-250 O +
( O -
Sigma O -
) O -
, O +
100 O +
g O +
ammonium O +
sulfate O +
( O -
Sigma O -
) O -
, O +
and O +
11.76 O +
ml O +
85 O -
% O +
phosphoric O +
acid O +
( O -
Fisher O -
) O -
. O +

Following O +
SDS O -
– O -
PAGE O -
, O +
gels O +
were O +
fixed O +
in O +
40 O -
% O +
methanol O -
, O +
10 O -
% O +
acetic O +
acid O +
for O +
10 O +
min O -
. O +

Gels O +
were O +
then O +
rinsed O +
several O +
times O +
in O +
water O -
, O +
then O +
stained O +
using O +
40 O +
ml O +
of O +
the O +
stock O +
staining O +
solution O +
mixed O +
with O +
10 O +
ml O +
methanol O -
, O +
for O +
2 O +
h O +
at O +
room O +
temperature O -
. O +

Stain O +
was O +
then O +
poured O +
off O -
, O +
and O +
residual O +
stain O +
was O +
removed O +
by O +
rinsing O +
in O +
water O -
. O +

By O +
performing O +
a O +
standard O +
analysis O +
using O +
bovine B-Species +
serum O +
albumin O -
, O +
the O +
stain O +
was O +
able O +
to O +
detect O +
~15 O +
ng O +
total O +
protein O +
per O +
lane O -
. O +

Pichia O +
expression O +
system O +
An O +
N O -
- O -
terminally O +
HIS6 O -
/ O -
FLAG O -
- O -
tagged O +
allele O +
of O +
the O +
SCP160 O +
coding O +
sequence O +
was O +
blunt O -
- O -
end O +
sub O -
- O -
cloned O +
into O +
the O +
BamHI O -
/ O -
SnaBI O +
sites O +
of O +
the O +
Pichia O +
expression O +
vector O +
pPIC3.5 O -
K O +
( O -
Invitrogen O -
) O -
. O +

The O +
construct O +
was O +
then O +
linearized O +
using O +
SalI O +
and O +
integrated O +
into O +
the O +
genome O +
of O +
the O +
Pichia O +
strain O +
GS115 O +
( O -
Invitrogen O -
) O -
. O +

High O +
expression O +
transformants O +
were O +
selected O +
initially O +
on O +
histidine O -
- O -
deficient O +
medium O +
followed O +
by O +
selection O +
on O +
increasing O +
concentrations O +
of O +
G418 O +
( O -
US O +
Biological O -
) O -
. O +

Crude O +
lysates O +
of O +
the O +
resultant O +
transformants O +
were O +
then O +
confirmed O +
by O +
western O +
blot O +
analysis O +
with O +
the O +
anti O -
- O -
FLAG O +
antibody O +
M2 O -
, O +
and O +
the O +
best O +
expressing O +
strain O +
was O +
cultured O +
in O +
a O +
fermenter O -
, O +
harvested O -
, O +
and O +
lysed O +
by O +
agitation O +
with O +
glass O +
beads O -
. O +

To O +
purify O +
Scp160p O -
, O +
2 O +
ml O +
of O +
crude O +
lysate O +
was O +
first O +
diluted O +
to O +
10 O +
ml O +
with O +
25 O +
mM O +
Tris O -
, O +
pH O +
7.5 O -
, O +
1 O +
M O +
NaCl O -
, O +
then O +
twice O +
passed O +
over O +
a O +
1 O +
ml O +
α O -
- O -
FLAG O +
affinity O +
column O -
. O +

The O +
column O +
was O +
then O +
washed O +
with O +
75 O +
ml O +
of O +
25 O +
mM O +
Tris O -
, O +
pH O +
7.5 O -
, O +
1 O +
M O +
NaCl O -
, O +
and O +
then O +
eluted O +
with O +
184 O +
µg O -
/ O -
ml O +
FLAG O +
peptide O +
prepared O +
in O +
the O +
same O +
buffer O -
. O +

RESULTS O +
Expression O +
of O +
tagged O +
Scp160p O +
in O +
yeast B-Species +
An O +
N O -
- O -
terminal O +
FLAG O -
- O -
tagged O +
form O +
of O +
Scp160p O +
was O +
created O +
to O +
facilitate O +
detection O +
of O +
the O +
protein O +
in O +
cells O +
and O +
extracts O +
( O -
Fig. O +
1A O -
) O -
. O +

To O +
probe O +
functionality O +
of O +
this O +
fusion O +
protein O -
, O +
we O +
used O +
two O -
- O -
step O +
gene O +
replacement O +
( O -
18 O -
) O +
to O +
substitute O +
the O +
modified O +
allele O +
into O +
the O +
SCP160 O +
locus O +
of O +
haploid O +
yeast B-Species -
, O +
and O +
then O +
tested O +
the O +
morphological O +
phenotype O +
of O +
the O +
resultant O +
cells O -
. O +

All O +
strains O +
were O +
confirmed O +
by O +
PCR O +
analysis O +
of O +
the O +
SCP160 O +
locus O +
with O +
appropriate O +
primers O +
( O -
Materials O +
and O +
Methods O -
) O -
, O +
and O +
expression O +
of O +
the O +
tagged O +
protein O +
was O +
confirmed O +
by O +
western O +
blot O +
analysis O +
with O +
the O +
appropriate O +
antibody O +
( O -
M2αFLAG O -
) O +
( O -
Fig. O +
1B O -
) O -
. O +

In O +
all O +
cases O -
, O +
yeast B-Species +
expressing O +
tagged O +
Scp160p O +
in O +
place O +
of O +
the O +
native O +
protein O +
appeared O +
indistinguishable O +
from O +
the O +
corresponding O +
wild O -
- O -
type O +
strains O +
( O -
data O +
not O +
shown O -
) O -
. O +

As O +
a O +
negative O +
control O -
, O +
we O +
also O +
deleted O +
almost O +
the O +
entire O +
SCP160 O +
coding O +
region O +
from O +
the O +
genomes O +
of O +
these O +
yeast B-Species +
strains O +
( O -
Fig. O +
1A O -
) O -
, O +
and O +
confirmed O +
the O +
expected O +
mutant O +
phenotype O +
( O -
data O +
not O +
shown O -
) O -
. O +

Scp160p O +
associates O +
with O +
polyribosomes O +
To O +
test O +
the O +
hypothesis O +
that O +
Scp160p O +
associates O +
with O +
polyribosomes O +
we O +
used O +
sucrose O +
gradient O +
ultracentrifugation O +
to O +
size O -
- O -
fractionate O +
subcellular O +
components O +
of O +
lysates O +
prepared O +
from O +
yeast B-Species +
expressing O +
the O +
N O -
- O -
terminal O +
FLAG O -
- O -
tagged O +
Scp160p O +
protein O -
. O +

Western O +
blot O +
analyses O +
of O +
gradient O +
fractions O +
with O +
an O +
α O -
- O -
FLAG O +
antibody O +
( O -
M2 O -
, O +
Boehringer O +
Mannheim O -
) O -
, O +
revealed O +
a O +
160 O +
kDa O +
band O +
that O +
was O +
most O +
abundant O +
in O +
the O +
denser O +
fractions O -
, O +
consistent O +
with O +
the O +
location O +
of O +
polyribosomes O +
( O -
> O -
80S O -
) O +
( O -
Fig. O +
2A O -
, O +
solid O +
arrow O -
) O -
. O +

A O +
convenient O +
internal O +
control O +
for O +
these O +
gradients O +
was O +
provided O +
by O +
an O +
unknown O +
endogenous O +
yeast B-Species +
cross O -
- O -
reacting O +
protein O +
at O +
~100 O +
kDa O -
, O +
that O +
exemplified O +
the O +
migration O +
pattern O +
of O +
a O +
free O +
protein O -
, O +
appearing O +
only O +
in O +
the O +
upper O +
fractions O +
of O +
the O +
gradient O +
( O -
Fig. O +
2A O -
, O +
open O +
arrow O -
) O -
. O +

To O +
determine O +
whether O +
the O +
migration O +
pattern O +
of O +
Scp160p O +
in O +
these O +
sucrose O +
gradients O +
truly O +
reflected O +
association O +
with O +
yeast B-Species +
polyribosomes O -
, O +
lysates O +
were O +
pre O -
- O -
treated O +
with O +
either O +
30 O +
mM O +
EDTA O +
or O +
50 O +
U O -
/ O -
ml O +
RNase O +
One O +
( O -
Promega O -
) O +
immediately O +
prior O +
to O +
sucrose O +
gradient O +
fractionation O -
. O +

EDTA O +
chelates O +
Mg2 O -
+ O +
cations O -
, O +
resulting O +
in O +
the O +
dissociation O +
of O +
the O +
small O +
and O +
large O +
ribosomal O +
subunits O -
, O +
reflected O +
in O +
gradient O +
profiles O +
( O -
OD254 O -
) O +
by O +
the O +
disappearance O +
of O +
80S O +
monosomes O +
and O +
polyribosomes O +
along O +
with O +
a O +
marked O +
increase O +
in O +
the O +
abundance O +
of O +
free O +
ribosomal O +
subunits O +
( O -
Fig. O +
2B O -
) O -
. O +

Under O +
these O +
conditions O -
, O +
the O +
greatest O +
intensity O +
of O +
FLAG O -
– O -
Scp160p O +
signal O +
was O +
seen O +
only O +
in O +
the O +
upper O -
- O -
most O +
fractions O +
of O +
the O +
gradient O +
( O -
Fig. O +
2B O -
) O -
. O +

Alternatively O -
, O +
pre O -
- O -
treatment O +
of O +
lysates O +
with O +
RNase O -
, O +
which O +
results O +
in O +
inter O -
- O -
ribosomal O +
severing O +
of O +
translating O +
messages O -
, O +
gave O +
rise O +
to O +
a O +
large O +
pool O +
of O +
single O +
80S O +
ribosomes O +
( O -
Fig. O +
2C O -
) O -
. O +

Again O -
, O +
FLAG O -
– O -
Scp160p O +
was O +
shifted O +
to O +
the O +
uppermost O +
fractions O +
of O +
these O +
gradients O -
. O +

Although O +
some O +
of O +
the O +
Scp160p O +
signal O +
was O +
detected O +
in O +
fractions O +
larger O +
than O +
40S O -
, O +
the O +
migration O +
pattern O +
of O +
the O +
100 O +
kDa O +
cross O -
- O -
reacting O +
protein O +
in O +
these O +
experiments O +
indicated O +
that O +
RNase O +
treatment O +
caused O +
an O +
apparent O +
diffusion O +
of O +
material O +
in O +
the O +
upper O +
portion O +
of O +
the O +
gradient O -
. O +

Characterization O +
of O +
Scp160p O -
- O -
containing O +
complexes O +
following O +
EDTA O +
and O +
RNase O +
treatment O +
Gel O -
- O -
filtration O +
chromatography O +
was O +
used O +
to O +
determine O +
the O +
apparent O +
molecular O +
weight O +
of O +
Scp160p O +
following O +
its O +
release O +
from O +
polyribosomes O +
by O +
both O +
EDTA O +
and O +
RNase O +
treatment O -
. O +

Lysates O +
were O +
prepared O +
as O +
described O +
above O +
for O +
sucrose O +
gradient O +
analysis O -
, O +
but O +
were O +
instead O +
size O +
fractionated O +
over O +
a O +
Sephacryl O +
S-300 O +
Hi O -
- O -
Prep O +
column O -
, O +
with O +
an O +
inclusion O +
cut O -
- O -
off O +
of O +
1300 O +
kDa O -
. O +

As O +
expected O -
, O +
Scp160p O +
from O +
untreated O +
lysates O +
eluted O +
in O +
the O +
void O +
volume O -
, O +
confirming O +
its O +
association O +
with O +
large O +
complexes O -
, O +
ostensibly O +
polyribosomes O +
( O -
Fig. O +
3A O -
, O +
solid O +
arrow O -
) O -
. O +

In O +
EDTA O +
treated O +
lysates O -
, O +
all O +
Scp160p O +
signal O +
was O +
still O +
detected O +
in O +
the O +
void O +
volume O -
, O +
indicating O +
it O +
remained O +
in O +
a O +
complex O +
of O +
> O -
1300 O +
kDa O +
( O -
Fig. O +
3B O -
, O +
solid O +
arrow O -
) O -
. O +

In O +
contrast O -
, O +
limited O +
RNase O +
treatment O +
( O -
10 O +
min O -
) O +
resulted O +
in O +
the O +
appearance O +
of O +
an O +
Scp160p O -
- O -
containing O +
species O +
of O +
~450 O +
kDa O -
, O +
in O +
addition O +
to O +
a O +
fraction O +
still O +
visible O +
in O +
the O +
void O +
( O -
Fig. O +
3C O -
, O +
solid O +
arrow O -
) O -
. O +

More O +
extensive O +
RNase O +
treatment O +
( O -
30 O +
min O -
) O +
led O +
to O +
complete O +
conversion O +
to O +
the O +
450 O +
kDa O +
species O +
( O -
Fig. O +
3D O -
, O +
solid O +
arrow O -
) O -
. O +

Sequential O +
treatment O -
, O +
first O +
with O +
RNase O -
, O +
then O +
with O +
EDTA O -
, O +
also O +
resulted O +
in O +
a O +
450 O +
kDa O +
species O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
all O +
components O +
of O +
this O +
apparent O +
450 O +
kDa O +
complex O +
were O +
also O +
present O +
following O +
EDTA O +
treatment O +
alone O -
. O +

As O +
before O -
, O +
the O +
100 O +
kDa O -
, O +
endogenous O +
α O -
- O -
FLAG O +
cross O -
- O -
reacting O +
protein O +
( O -
Fig. O +
3 O -
, O +
open O +
arrows O -
) O +
served O +
as O +
a O +
convenient O +
internal O +
control O -
, O +
eluting O +
from O +
the O +
column O +
at O +
a O +
volume O +
consistent O +
with O +
its O +
expected O +
monomeric O +
size O -
. O +

To O +
characterize O +
further O +
the O +
stability O +
of O +
the O +
large O +
( O -
apparent O +
molecular O +
weight O +
> O -
1300 O +
kDa O -
) O -
, O +
EDTA O -
- O -
resistant O +
complex O -
, O +
lysates O +
were O +
treated O +
with O +
increasing O +
concentrations O +
of O +
NaCl O +
prior O +
to O +
size O +
fractionation O +
( O -
Fig. O +
3 O -
, O +
panels O +
E O -
, O +
F O +
and O +
G O -
) O -
. O +

As O +
shown O +
in O +
Figure O +
3E O -
, O +
at O +
75 O +
mM O +
NaCl O -
, O +
the O +
large O +
complex O +
remained O +
intact O -
. O +

However O -
, O +
at O +
a O +
NaCl O +
concentration O +
of O +
150 O +
mM O -
, O +
the O +
Scp160p O +
complex O +
was O +
partially O +
reduced O +
to O +
450 O +
kDa O -
, O +
with O +
some O +
signal O +
still O +
remaining O +
in O +
the O +
void O +
( O -
Fig. O +
3F O -
, O +
solid O +
arrow O -
) O -
. O +

Following O +
treatment O +
with O +
1 O +
M O +
NaCl O -
, O +
Scp160p O +
was O +
only O +
visible O +
as O +
the O +
450 O +
kDa O +
species O +
( O -
Fig. O +
3 O -
G O -
, O +
solid O +
arrow O -
) O -
. O +

The O +
fact O +
that O +
RNase O +
treatment O +
and O +
high O +
salt O +
both O +
generated O +
Scp160p O +
species O +
of O +
similar O +
apparent O +
molecular O +
weight O +
suggests O +
that O +
these O +
high O +
salt O +
concentrations O +
resulted O +
in O +
the O +
disassociation O +
of O +
RNA O -
, O +
and O +
perhaps O +
other O +
components O -
, O +
from O +
Scp160p O -
. O +

Pab1p O +
and O +
Bfr1p O +
are O +
present O +
in O +
EDTA O -
- O -
resistant O +
Scp160p O -
- O -
containing O +
complexes O +
To O +
determine O +
if O +
the O +
> O -
1300 O +
kDa O +
Scp160p O -
- O -
containing O +
complexes O +
remaining O +
after O +
EDTA O +
treatment O +
were O +
mRNPs O -
, O +
we O +
assayed O +
for O +
the O +
presence O +
of O +
the O +
yeast B-Species +
poly O -
( O -
A O -
) O +
binding O +
protein O -
, O +
Pab1p O -
, O +
following O +
α O -
- O -
FLAG O +
affinity O +
purification O +
as O +
illustrated O +
in O +
Figure O +
4 O -
. O +

Pab1p O +
is O +
an O +
abundant O +
and O +
well O -
- O -
characterized O +
component O +
of O +
mRNP O +
complexes O +
in O +
yeast B-Species -
, O +
as O +
well O +
as O +
higher O +
eukaryotes O +
( O -
14,15,25 O -
) O -
. O +

As O +
seen O +
in O +
Figure O +
5A O +
and O +
B O -
, O +
Pab1p O +
did O +
co O -
- O -
purify O +
with O +
FLAG O -
– O -
Scp160p O -
; O +
moreover O -
, O +
treatment O +
with O +
RNase O +
immediately O +
prior O +
to O +
FLAG O -
- O -
purification O +
completely O +
abolished O +
this O +
interaction O +
( O -
Fig. O +
5C O -
) O -
, O +
indicating O +
an O +
RNA O -
- O -
dependant O +
association O +
between O +
these O +
two O +
proteins O -
. O +

We O +
also O +
probed O +
the O +
isolated O +
complexes O +
for O +
the O +
presence O +
of O +
another O +
abundant O +
mRNP O -
- O -
component O +
protein O -
, O +
Pub1p O +
( O -
23,26 O -
) O -
. O +

Pub1p O -
, O +
as O +
opposed O +
to O +
Pab1p O -
, O +
is O +
not O +
reported O +
to O +
associate O +
with O +
polyribosomes O -
, O +
and O +
is O +
hypothesized O +
to O +
bind O +
a O +
pool O +
of O +
non O -
- O -
translatable O +
mRNAs O +
( O -
23 O -
) O -
. O +

As O +
predicted O -
, O +
Pub1p O +
did O +
not O +
co O -
- O -
purify O +
with O +
Scp160p O +
( O -
Fig. O +
5D O -
) O -
. O +

The O +
absence O +
of O +
Pub1p O +
in O +
Scp160p O -
- O -
containing O +
complexes O +
served O +
as O +
a O +
negative O +
control O -
, O +
demonstrating O +
that O +
abundant O +
RNA O -
- O -
binding O +
proteins O +
did O +
not O +
co O -
- O -
purify O +
non O -
- O -
specifically O +
by O +
this O +
protocol O -
. O +

In O +
addition O -
, O +
we O +
performed O +
mock O +
purifications O +
using O +
lysates O +
from O +
yeast B-Species +
expressing O +
the O +
wild O -
- O -
type O +
allele O +
of O +
SCP160 O +
without O +
the O +
FLAG O +
epitope O +
( O -
Fig. O +
5F O -
) O -
, O +
or O +
with O +
an O +
unrelated O +
FLAG O -
- O -
tagged O +
protein O -
, O +
human B-Species +
galactose O +
1-phosphate O +
uridylyltransferase O +
( O -
GALT O -
) O +
( O -
Fig. O +
5 O -
G O -
, O +
lower O +
panel O -
) O -
. O +

In O +
neither O +
case O +
did O +
Pab1p O +
bind O +
and O +
elute O +
from O +
the O +
FLAG O +
affinity O +
column O -
. O +

Finally O -
, O +
no O +
bands O +
were O +
visible O +
by O +
colloidal O +
G250 O +
Coomassie O +
staining O +
of O +
samples O +
from O +
the O +
mock O +
( O -
wild O -
- O -
type O -
) O +
preparations O +
( O -
Fig. O +
5E O -
) O -
, O +
further O +
demonstrating O +
the O +
specificity O +
of O +
this O +
procedure O -
. O +

By O +
colloidal O +
G250 O +
Coomassie O +
staining O +
( O -
Materials O +
and O +
Methods O -
) O +
of O +
the O +
FLAG O -
- O -
purified O +
complex O -
, O +
we O +
observed O +
in O +
addition O +
to O +
Scp160p O -
, O +
two O +
major O +
bands O -
, O +
at O +
~70 O +
kDa O +
and O +
~55 O +
kDa O -
, O +
which O +
ostensibly O +
represent O +
co O -
- O -
purifying O +
proteins O +
( O -
Fig. O +
5A O -
, O +
bottom O +
panel O -
) O -
. O +

Western O +
blot O +
analysis O +
suggested O +
that O +
the O +
~70 O +
kDa O +
species O +
is O +
Pab1p O -
. O +

To O +
identify O +
the O +
55 O +
kDa O +
protein O -
, O +
that O +
band O +
was O +
excised O +
from O +
the O +
gel O -
, O +
and O +
sent O +
to O +
the O +
Keck O +
microchemical O +
facility O +
at O +
Yale O +
University O +
for O +
analysis O +
by O +
in O +
gel O +
tryptic O +
digestion O -
, O +
followed O +
by O +
MALDI O -
- O -
mass O +
spectrometry O -
. O +

The O +
results O +
of O +
these O +
analyses O +
clearly O +
identified O +
the O +
unknown O +
protein O +
as O +
Bfr1p O -
. O +

To O +
confirm O +
this O +
result O -
, O +
an O +
N O -
- O -
terminal O +
HA O +
tag O +
was O +
engineered O +
onto O +
the O +
genomic O +
BFR1 O +
locus O +
in O +
strains O +
expressing O +
FLAG O -
- O -
tagged O +
or O +
wild O -
- O -
type O +
Scp160p O -
. O +

Scp160p O +
complexes O +
were O +
then O +
isolated O +
from O +
both O +
of O +
these O +
strains O +
using O +
the O +
protocol O +
described O +
above O -
. O +

As O +
seen O +
in O +
Figure O +
6 O -
, O +
an O +
HA O -
- O -
tagged O +
protein O +
of O +
~55 O +
kDa O +
( O -
center O +
panel O -
) O +
appears O +
in O +
α O -
- O -
FLAG O +
column O +
elutions O +
only O +
when O +
FLAG O -
– O -
Scp160p O +
is O +
also O +
present O +
( O -
top O +
panel O -
) O -
. O +

No O +
signal O +
is O +
visible O +
in O +
mock O +
purifications O +
of O +
extracts O +
where O +
Scp160p O +
is O +
not O +
FLAG O -
- O -
tagged O +
( O -
bottom O +
panel O -
) O -
. O +

Monomeric O +
Scp160p O +
migrates O +
as O +
a O +
~450 O +
kDa O +
protein O +
under O +
native O +
conditions O +
As O +
a O +
first O +
step O +
to O +
characterize O +
the O +
post O +
RNase O -
/ O -
NaCl O +
450 O +
kDa O +
Scp160p O +
species O +
we O +
compared O +
it O +
with O +
Scp160p O +
over O -
- O -
expressed O +
and O +
purified O +
from O +
an O +
exogenous O +
host O -
, O +
the O +
yeast B-Species +
Pichia B-Species +
pastoris I-Species -
. O +

The O +
purified O +
N O -
- O -
terminal O +
FLAG O -
/ O -
hexahistidine O -
- O -
tagged O +
Scp160p O +
was O +
run O +
over O +
an O +
S300 O +
gel O +
filtration O +
column O -
; O +
2 O +
ml O +
fractions O +
were O +
collected O +
and O +
analyzed O +
by O +
α O -
- O -
FLAG O +
western O +
blot O -
. O +

As O +
seen O +
in O +
Figure O +
7A O -
, O +
purified O +
Scp160p O +
eluted O +
at O +
a O +
volume O +
consistent O +
with O +
a O +
> O -
443 O +
kDa O +
protein O -
. O +

To O +
confirm O +
that O +
no O +
other O +
proteins O +
were O +
associated O +
with O +
the O +
purified O +
Scp160p O -
, O +
12 O +
µl O +
of O +
the O +
protein O +
was O +
run O +
on O +
SDS O -
– O -
PAGE O +
and O +
subjected O +
to O +
colloidal O +
G250 O +
Coomassie O +
staining O +
before O +
loading O +
on O +
the O +
S-300 O +
column O +
( O -
Fig. O +
7B O -
) O -
. O +

As O +
shown O -
, O +
no O +
bands O +
other O +
than O +
Scp160p O +
were O +
visible O -
. O +

Several O +
KH O -
- O -
domain O +
proteins O -
, O +
including O +
Sam68 O +
and O +
FMRP O -
, O +
have O +
been O +
reported O +
to O +
form O +
homodimers O +
in O +
vivo O +
( O -
27 O -
) O -
. O +

Therefore O -
, O +
we O +
explored O +
the O +
possibility O +
that O +
the O +
~450 O +
kDa O +
Scp160p O +
species O +
might O +
contain O +
two O +
or O +
more O +
copies O +
of O +
Scp160p O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
yeast B-Species +
expressing O +
FLAG O -
– O -
Scp160p O +
were O +
transfected O +
with O +
a O +
centromeric O +
plasmid O -
, O +
YCplac22–HA O -
– O -
Scp160p O -
, O +
encoding O +
a O +
distinct O -
, O +
HA O -
- O -
tagged O +
allele O +
of O +
the O +
protein O -
. O +

The O +
functionality O +
of O +
this O +
tagged O +
protein O +
had O +
previously O +
been O +
demonstrated O +
by O +
polyribosome O +
association O +
as O +
well O +
as O +
complementation O +
of O +
the O +
null O +
morphological O +
phenotype O +
in O +
cells O +
expressing O +
only O +
HA O -
– O -
Scp160p O +
( O -
data O +
not O +
shown O -
) O -
. O +

As O +
seen O +
in O +
Figure O +
7C O -
, O +
when O +
yeast B-Species +
co O -
- O -
expressing O +
the O +
two O +
alleles O +
were O +
lysed O +
and O +
the O +
FLAG O -
- O -
tagged O +
protein O +
was O +
isolated O +
as O +
described O +
above O -
, O +
no O +
HA O -
– O -
Scp160p O +
co O -
- O -
purified O +
with O +
the O +
FLAG O -
– O -
Scp160p O -
. O +

These O +
data O +
strongly O +
suggest O +
that O +
Scp160p O +
does O +
not O +
form O +
homo O -
- O -
dimers O +
or O +
higher O -
- O -
order O +
multimers O +
in O +
vivo O -
, O +
and O +
that O +
the O +
~450 O +
kDa O +
species O +
of O +
Scp160p O +
observed O +
is O +
simply O +
the O +
monomeric O +
protein O -
. O +

DISCUSSION O +
The O +
data O +
presented O +
here O +
demonstrate O +
two O +
main O +
points O +
regarding O +
the O +
biochemical O +
associations O +
and O +
function O +
of O +
Scp160p O +
in O +
yeast B-Species -
. O +

First O -
, O +
the O +
sucrose O +
gradient O +
fractionation O +
data O +
clearly O +
demonstrate O +
that O +
Scp160p O +
exists O +
primarily O +
associated O +
with O +
large O +
complexes O -
, O +
likely O +
to O +
be O +
polyribosomes O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
time O +
a O +
vigilin O +
family O +
member O +
has O +
been O +
shown O +
to O +
associate O +
with O +
polyribosomes O +
in O +
this O +
manner O -
. O +

Interestingly O -
, O +
Weber O +
and O +
colleagues O +
did O +
not O +
observe O +
sucrose O +
gradient O +
fractionation O +
data O +
consistent O +
with O +
polyribosome O +
association O +
of O +
Scp160p O +
( O -
5 O -
) O -
. O +

These O +
authors O +
hypothesized O +
that O +
Scp160p O +
associates O +
only O +
with O +
membrane O -
- O -
bound O +
polyribosomes O -
, O +
and O +
that O +
Scp160p O +
is O +
not O +
found O +
complexed O +
with O +
cytosolic O +
polyribosomes O +
( O -
5 O -
) O -
. O +

Our O +
data O +
do O +
not O +
support O +
this O +
hypothesis O -
, O +
since O +
unlike O +
Weber O +
and O +
colleagues O -
, O +
we O +
were O +
able O +
to O +
detect O +
significant O +
amounts O +
of O +
Scp160p O +
associated O +
with O +
polyribosomes O +
without O +
using O +
detergents O +
during O +
preparation O -
. O +

There O +
are O +
several O +
possible O +
explanations O +
for O +
this O +
discrepancy O -
. O +

First O -
, O +
the O +
lysate O +
buffer O +
utilized O +
by O +
that O +
group O +
contained O +
100 O +
mM O +
NaCl O -
, O +
whereas O +
our O +
buffer O +
contained O +
50 O +
mM O +
KCl O -
. O +

Our O +
data O +
shown O +
in O +
Figure O +
3 O +
suggest O +
that O +
100 O +
mM O +
NaCl O +
may O +
have O +
caused O +
an O +
instability O +
in O +
the O +
Scp160p O -
– O -
RNA O +
interaction O -
, O +
leading O +
to O +
release O +
from O +
polyribosomes O +
during O +
their O +
procedure O -
. O +

Secondly O -
, O +
Weber O -
's O +
lysate O +
buffer O +
reportedly O +
contained O +
heparin O +
to O +
inhibit O +
ribonucleases O -
; O +
a O +
number O +
of O +
reports O +
( O -
28,29 O -
) O +
suggest O +
that O +
heparin O +
can O +
disrupt O +
RNA O -
– O -
protein O +
interactions O -
. O +

Although O +
we O +
have O +
not O +
in O +
the O +
past O +
included O +
heparin O +
in O +
any O +
of O +
our O +
experiments O -
, O +
we O +
have O +
observed O +
disruption O +
of O +
the O +
polyribosome O +
association O +
in O +
buffer O +
containing O +
residual O +
diethylpyrocarbonate O -
, O +
another O +
inhibitor O +
of O +
ribonucleases O +
( O -
data O +
not O +
shown O -
) O -
. O +

Second O -
, O +
our O +
data O +
provide O +
compelling O +
evidence O +
that O +
Scp160p O +
is O +
released O +
from O +
polyribosomes O +
as O +
a O +
component O +
of O +
an O +
mRNP O +
complex O -
. O +

Since O +
Scp160p O +
does O +
not O +
remain O +
associated O +
with O +
either O +
single O +
ribosomes O +
or O +
ribosomal O +
subunits O +
following O +
treatment O +
with O +
EDTA O +
or O +
RNase O -
, O +
it O +
seems O +
unlikely O +
that O +
Scp160p O +
is O +
a O +
constitutive O +
component O +
of O +
the O +
translational O +
machinery O -
. O +

Partial O +
purification O +
of O +
the O +
EDTA O -
- O -
resistant O +
Scp160p O +
complexes O +
allowed O +
us O +
to O +
demonstrate O +
the O +
presence O +
of O +
Pab1p O +
but O +
not O +
Pub1p O +
in O +
these O +
preparations O -
, O +
which O +
is O +
consistent O +
with O +
the O +
idea O +
that O +
Scp160p O +
associates O +
with O +
polyribosomes O +
as O +
a O +
component O +
of O +
mRNP O +
complexes O -
. O +

Previously O -
, O +
Scp160p O +
had O +
been O +
shown O +
to O +
bind O +
ribohomopolymers O +
and O +
rRNA O +
in O +
vitro O -
, O +
although O +
the O +
in O +
vivo O +
nucleic O +
acid O +
targets O +
of O +
Scp160p O +
were O +
unknown O +
( O -
5 O -
) O -
. O +

The O +
presence O +
of O +
Pab1p O +
in O +
RNase O -
- O -
sensitive O +
Scp160p O +
complexes O +
indicates O +
that O +
Scp160p O +
is O +
primarily O +
bound O +
to O +
polyadenylated O +
RNAs O -
. O +

Whether O +
or O +
not O +
Scp160p O +
binds O +
only O +
specific O +
sets O +
of O +
mRNAs O +
will O +
be O +
the O +
subject O +
of O +
future O +
studies O -
. O +

In O +
addition O +
to O +
Scp160p O +
and O +
Pab1p O -
, O +
we O +
have O +
identified O +
a O +
third O +
component O +
of O +
the O +
complex O -
, O +
the O +
protein O +
Bfr1p O -
. O +

The O +
gene O -
, O +
BFR1 O -
, O +
was O +
originally O +
identified O +
in O +
a O +
screen O +
for O +
high O -
- O -
copy O +
suppressors O +
of O +
Brefeldin O -
- O -
A O +
induced O +
lethality O -
, O +
suggesting O +
a O +
role O +
in O +
the O +
secretory O +
pathway O +
( O -
16 O -
) O -
. O +

Interestingly O -
, O +
however O -
, O +
bfr1 O +
null O +
mutants O +
do O +
not O +
demonstrate O +
any O +
defects O +
in O +
the O +
secretory O +
pathway O -
, O +
but O +
rather O +
display O +
similar O +
phenotypes O +
to O +
scp160 O +
null O +
mutants O -
, O +
most O +
notably O +
increased O +
ploidy O +
and O +
increased O +
cell O +
size O +
( O -
16 O -
) O -
. O +

It O +
is O +
therefore O +
unclear O +
whether O +
Bfr1p O +
is O +
capable O +
of O +
functioning O +
in O +
both O +
RNA O +
metabolism O +
and O +
secretion O +
directly O -
, O +
or O +
if O +
the O +
Scp160p O -
– O -
Bfr1p O +
complex O +
regulates O +
the O +
expression O +
of O +
one O +
or O +
more O +
secretory O +
genes O +
at O +
the O +
post O -
- O -
transcriptional O +
level O -
. O +

Additionally O -
, O +
two O -
- O -
hybrid O +
analysis O +
indicated O +
an O +
interaction O +
of O +
Bfr1p O +
with O +
the O +
protein O +
Bbp1p O -
, O +
a O +
component O +
of O +
the O +
mitotic O +
spindle O +
apparatus O +
( O -
30 O -
) O -
. O +

While O +
Bbp1p O +
is O +
an O +
essential O +
gene O -
, O +
overexpression O +
leads O +
to O +
a O +
phenotype O +
similar O +
to O +
both O +
bfr1 O +
and O +
scp160 O +
null O +
strains O +
( O -
30 O -
) O -
. O +

Future O +
work O +
will O +
address O +
the O +
functional O +
relationship O +
between O +
Scp160p O +
and O +
Bfr1p O +
including O +
the O +
possibility O +
that O +
these O +
proteins O +
represent O +
a O +
regulatory O +
mechanism O +
connecting O +
the O +
translational O +
machinery O +
with O +
cell O +
division O +
and/or O +
the O +
secretory O +
pathway O -
. O +

Following O +
treatment O +
with O +
either O +
RNase O +
or O +
> O -
150 O +
mM O +
NaCl O -
, O +
Scp160p O +
remained O +
as O +
an O +
apparent O +
~450 O +
kDa O +
species O -
. O +

Considering O +
that O +
purified O +
Scp160p O +
alone O +
also O +
migrates O +
at O +
this O +
size O -
, O +
we O +
conclude O +
that O +
this O +
apparent O +
complex O +
may O +
consist O +
only O +
of O +
Scp160p O -
, O +
although O +
the O +
presence O +
of O +
other O +
small O +
components O +
can O -
not O +
be O +
ruled O +
out O +
at O +
this O +
time O -
. O +

Furthermore O -
, O +
by O +
utilizing O +
yeast B-Species +
co O -
- O -
expressing O +
two O +
distinct O +
epitope O -
- O -
tagged O +
versions O +
of O +
Scp160p O -
, O +
we O +
have O +
ruled O +
out O +
the O +
possibility O +
of O +
self O -
- O -
association O +
of O +
Scp160p O -
. O +

Although O +
both O +
tagged O +
proteins O +
appear O +
functional O -
, O +
it O +
remains O +
a O +
formal O +
possibility O +
that O +
the O +
tags O +
somehow O +
prevented O +
formation O +
of O +
FLAG O -
– O -
HA O +
hetero O -
- O -
complexes O -
. O +

Nonetheless O -
, O +
it O +
seems O +
most O +
likely O +
that O +
native O +
Scp160p O +
monomers O +
may O +
simply O +
migrate O +
aberrantly O +
under O +
native O +
conditions O +
due O +
to O +
an O +
unusual O +
shape O +
or O +
some O +
other O +
physical O +
property O -
. O +

In O +
conclusion O +
we O +
have O +
shown O +
convincing O +
evidence O +
that O +
Scp160p O +
exists O +
in O +
yeast B-Species +
cytoplasmic O +
extracts O +
primarily O +
associated O +
with O +
polyribosomes O -
. O +

We O +
have O +
purified O +
Scp160p O +
following O +
disruption O +
of O +
polyribosomes O +
with O +
EDTA O -
, O +
and O +
identified O +
two O +
associated O +
proteins O -
: O +
Pab1p O +
and O +
Bfr1p O -
. O +

The O +
presence O +
of O +
Pab1p O +
suggests O +
that O +
Scp160p O +
associates O +
with O +
polyribosomes O +
as O +
a O +
component O +
of O +
an O +
mRNP O -
, O +
demonstrating O +
Scp160p O +
to O +
be O +
the O +
first O +
S.cerevisiae B-Species +
multiple O -
- O -
KH O +
domain O +
protein O +
characterized O +
to O +
function O +
in O +
this O +
way O -
. O +

Mutations O +
of O +
PIK3CA O +
in O +
gastric O +
adenocarcinoma O +
Abstract O +
Background O +
Activation O +
of O +
the O +
phosphatidylinositol O +
3-kinase O +
( O -
PI3 O -
K O -
) O +
through O +
mutational O +
inactivation O +
of O +
PTEN O +
tumour O +
suppressor O +
gene O +
is O +
common O +
in O +
diverse O +
cancer O +
types O -
, O +
but O +
rarely O +
reported O +
in O +
gastric O +
cancer O -
. O +

Recently O -
, O +
mutations O +
in O +
PIK3CA O -
, O +
which O +
encodes O +
the O +
p110α O +
catalytic O +
subunit O +
of O +
PI3 O -
K O -
, O +
have O +
been O +
identified O +
in O +
various O +
human B-Species +
cancers O -
, O +
including O +
3 O +
of O +
12 O +
gastric O +
cancers O -
. O +

Eighty O +
percent O +
of O +
these O +
reported O +
mutations O +
clustered O +
within O +
2 O +
regions O +
involving O +
the O +
helical O +
and O +
kinase O +
domains O -
. O +

In O +
vitro O +
study O +
on O +
one O +
of O +
the O +
" O -
hot O -
- O -
spot O -
" O +
mutants O +
has O +
demonstrated O +
it O +
as O +
an O +
activating O +
mutation O -
. O +

Methods O +
Based O +
on O +
these O +
data O -
, O +
we O +
initiated O +
PIK3CA O +
mutation O +
screening O +
in O +
94 O +
human B-Species +
gastric O +
cancers O +
by O +
direct O +
sequencing O +
of O +
the O +
gene O +
regions O +
in O +
which O +
80 O -
% O +
of O +
all O +
the O +
known O +
PIK3CA O +
mutations O +
were O +
found O -
. O +

We O +
also O +
examined O +
PIK3CA O +
expression O +
level O +
by O +
extracting O +
data O +
from O +
the O +
previous O +
large O -
- O -
scale O +
gene O +
expression O +
profiling O +
study O -
. O +

Using O +
Significance O +
Analysis O +
of O +
Microarrays O +
( O -
SAM O -
) O -
, O +
we O +
further O +
searched O +
for O +
genes O +
that O +
show O +
correlating O +
expression O +
with O +
PIK3CA O -
. O +

Results O +
We O +
have O +
identified O +
PIK3CA O +
mutations O +
in O +
4 O +
cases O +
( O -
4.3 O -
% O -
) O -
, O +
all O +
involving O +
the O +
previously O +
reported O +
hotspots O -
. O +

Among O +
these O +
4 O +
cases O -
, O +
3 O +
tumours O +
demonstrated O +
microsatellite O +
instability O +
and O +
2 O +
tumours O +
harboured O +
concurrent O +
KRAS O +
mutation O -
. O +

Data O +
extracted O +
from O +
microarray O +
studies O +
showed O +
an O +
increased O +
expression O +
of O +
PIK3CA O +
in O +
gastric O +
cancers O +
when O +
compared O +
with O +
the O +
non O -
- O -
neoplastic O +
gastric O +
mucosae O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

SAM O +
further O +
identified O +
2910 O +
genes O +
whose O +
expression O +
levels O +
were O +
positively O +
associated O +
with O +
that O +
of O +
PIK3CA O -
. O +

Conclusion O +
Our O +
data O +
suggested O +
that O +
activation O +
of O +
the O +
PI3 O -
K O +
signalling O +
pathway O +
in O +
gastric O +
cancer O +
may O +
be O +
achieved O +
through O +
up O -
- O -
regulation O +
or O +
mutation O +
of O +
PIK3CA O -
, O +
in O +
which O +
the O +
latter O +
may O +
be O +
a O +
consequence O +
of O +
mismatch O +
repair O +
deficiency O -
. O +

Background O +
The O +
phosphatidylinositol O +
3-kinase O +
( O -
PI3K O -
) O -
-AKT O +
signalling O +
pathway O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
diverse O +
cellular O +
processes O -
, O +
including O +
cell O +
growth O -
, O +
survival O +
and O +
motility O -
. O +

Abnormal O +
activation O +
of O +
this O +
pathway O +
is O +
frequently O +
observed O +
in O +
various O +
cancer O +
types O -
, O +
leading O +
to O +
aberrant O +
cell O +
cycle O +
progression O -
, O +
altered O +
adhesion O +
and O +
motility O -
, O +
inhibition O +
of O +
apoptosis O +
and O +
induction O +
of O +
angiogenesis O +
[ O -
1 O -
] O -
. O +

It O +
has O +
been O +
previously O +
reported O +
that O +
genetic O +
alterations O +
involving O +
various O +
members O +
along O +
this O +
signalling O +
pathway O +
could O +
lead O +
to O +
its O +
activation O +
in O +
cancer O -
. O +

These O +
include O +
mutation O -
, O +
allelic O +
loss O +
or O +
promoter O +
methylation O +
of O +
the O +
negative O +
regulator O +
PTEN O +
[ O -
2 O -
] O -
; O +
or O +
alternatively O -
, O +
chromosomal O +
amplification O +
or O +
over O -
- O -
expression O +
of O +
the O +
positive O +
regulators O +
PIK3CA O +
[ O -
3 O -
- O -
5 O -
] O +
and O +
the O +
various O +
AKT O +
kinases O +
[ O -
6,7 O -
] O -
. O +

Furthermore O -
, O +
changes O +
in O +
other O +
related O +
pathways O +
that O +
are O +
commonly O +
altered O +
in O +
cancer O -
, O +
such O +
as O +
those O +
involved O +
in O +
growth O +
factor O +
stimulation O +
via O +
the O +
G O -
- O -
protein O -
- O -
coupled O +
receptors O +
or O +
through O +
direct O +
interaction O +
with O +
the O +
activated O +
form O +
of O +
small O +
GTPase O +
RAS O -
, O +
can O +
also O +
lead O +
to O +
PI3K O -
- O -
AKT O +
pathway O +
activation O +
[ O -
8 O -
] O -
. O +

Activation O +
of O +
this O +
pathway O +
results O +
in O +
the O +
phosphorylation O +
of O +
AKT O +
at O +
Thr-308 O -
/ O -
309 O +
and O +
Ser-473 O -
/ O -
474 O -
. O +

These O +
phosphorylated O +
forms O +
of O +
AKT O +
proteins O +
have O +
been O +
detected O +
by O +
Western O +
blot O +
or O +
immunohistochemistry O +
in O +
various O +
cancer O +
types O -
, O +
suggesting O +
the O +
frequent O +
activation O +
of O +
PI3K O -
- O -
AKT O +
pathway O +
in O +
the O +
carcinogenic O +
process O +
[ O -
7,9 O -
] O -
. O +

Although O +
genetic O +
changes O +
along O +
the O +
PI3K O -
- O -
AKT O +
pathway O +
have O +
been O +
repeatedly O +
documented O +
in O +
brain O -
, O +
ovarian O -
, O +
endometrial O -
, O +
breast O -
, O +
prostate O +
and O +
thyroid O +
cancers O +
[ O -
1,2 O -
] O -
, O +
reports O +
on O +
its O +
mechanism O +
of O +
activation O +
in O +
gastric O +
cancer O +
are O +
limited O -
. O +

Gastric O +
cancer O +
is O +
the O +
second O +
most O +
common O +
cancer O +
worldwide O +
but O +
its O +
molecular O +
basis O +
of O +
tumourigenesis O +
is O +
still O +
poorly O +
understood O -
. O +

Previous O +
immunohistochemical O +
study O +
has O +
demonstrated O +
the O +
presence O +
of O +
the O +
phosphorylated O +
form O +
of O +
AKT O +
in O +
78 O -
% O +
of O +
gastric O +
cancer O +
[ O -
10 O -
] O -
, O +
suggesting O +
that O +
activation O +
of O +
this O +
pathway O +
may O +
also O +
be O +
common O +
in O +
gastric O +
cancer O -
. O +

Though O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
involving O +
the O +
PTEN O +
locus O +
has O +
been O +
demonstrated O +
in O +
47 O -
% O +
of O +
gastric O +
cancer O +
in O +
a O +
recent O +
study O -
, O +
mutation O +
or O +
promoter O +
methylation O +
was O +
absent O +
even O +
in O +
cases O +
with O +
LOH O +
[ O -
11 O -
] O -
. O +

Thus O +
data O +
from O +
this O +
study O +
could O +
not O +
support O +
the O +
two O -
- O -
hit O +
inactivation O +
of O +
PTEN O +
in O +
gastric O +
cancer O -
, O +
while O +
the O +
biological O +
significance O +
of O +
PTEN O +
haploinsufficiency O +
remains O +
controversial O -
. O +

Alternatively O -
, O +
amplification O +
of O +
AKT1 O +
has O +
been O +
reported O +
in O +
a O +
single O +
case O +
of O +
gastric O +
cancer O +
[ O -
12 O -
] O -
, O +
and O +
amplification O +
of O +
PIK3CA O +
associated O +
with O +
elevated O +
mRNA O +
levels O +
has O +
been O +
found O +
in O +
36 O -
% O +
of O +
gastric O +
cancer O +
[ O -
11 O -
] O -
. O +

More O +
recently O -
, O +
Samuels O +
et O +
al. O +
screened O +
a O +
diverse O +
spectrum O +
of O +
human B-Species +
cancers O +
for O +
mutation O +
in O +
16 O +
PI3 O -
K O +
or O +
PI3K O -
- O -
like O +
genes O +
and O +
found O +
a O +
high O +
frequency O +
of O +
somatic O +
mutation O +
in O +
PIK3CA O -
, O +
which O +
encodes O +
the O +
p110α O +
catalytic O +
subunit O -
. O +

Major O +
screening O +
in O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
identified O +
PIK3CA O +
mutations O +
in O +
74 O +
out O +
of O +
234 O +
( O -
32 O -
% O -
) O +
cases O -
, O +
while O +
mutations O +
were O +
also O +
noted O +
in O +
3 O +
out O +
of O +
12 O +
( O -
25 O -
% O -
) O +
gastric O +
cancers O -
. O +

Reported O +
mutations O +
were O +
mostly O +
of O +
missense O +
type O -
, O +
and O +
clustered O +
within O +
2 O +
regions O +
in O +
the O +
helical O +
and O +
kinase O +
domains O -
. O +

Expression O +
of O +
a O +
" O -
hot O -
- O -
spot O -
" O +
mutant O -
, O +
H1047R O -
, O +
conferred O +
a O +
significant O +
up O -
- O -
regulation O +
of O +
lipid O +
kinase O +
activity O +
of O +
PIK3CA O -
, O +
suggesting O +
it O +
as O +
an O +
activating O +
mutation O +
[ O -
13 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
examined O +
a O +
series O +
of O +
94 O +
human B-Species +
gastric O +
adenocarcinomas O +
for O +
PIK3CA O +
mutation O -
. O +

We O +
have O +
also O +
examined O +
PIK3CA O +
expression O +
level O +
by O +
extracting O +
data O +
from O +
a O +
large O -
- O -
scale O +
gene O +
expression O +
profiling O +
study O +
previously O +
performed O +
for O +
these O +
cases O +
[ O -
14,15 O -
] O -
. O +

Using O +
SAM O -
, O +
genes O +
with O +
significant O +
correlating O +
expression O +
with O +
PIK3CA O +
have O +
also O +
been O +
identified O -
. O +

Methods O +
Patient O +
samples O +
preparation O +
DNA O +
samples O +
used O +
for O +
sequencing O +
were O +
prepared O +
from O +
frozen O +
tumour O +
and O +
non O -
- O -
tumour O +
gastric O +
mucosae O +
from O +
94 O +
gastric O +
cancer O +
patients O +
who O +
underwent O +
gastrectomy O +
in O +
the O +
Department O +
of O +
Surgery O -
, O +
Queen O +
Mary O +
Hospital O -
, O +
The O +
University O +
of O +
Hong O +
Kong O -
, O +
as O +
previously O +
described O +
[ O -
16 O -
] O -
. O +

Majority O +
of O +
the O +
frozen O +
samples O +
( O -
n O +
= O +
81 O -
) O +
showed O +
tumour O +
component O +
of O +
over O +
70 O -
% O -
, O +
whereas O +
in O +
13 O +
cases O +
a O +
lower O +
proportion O +
between O +
50 O +
to O +
70 O -
% O +
was O +
accepted O +
due O +
to O +
the O +
tumours O -
' O +
inherent O +
diffuse O +
infiltrative O +
nature O +
with O +
entrapment O +
of O +
non O -
- O -
neoplastic O +
components O -
. O +

Analysis O +
for O +
microsatellite O +
instability O +
( O -
MSI O -
) O -
, O +
BRAF O +
and O +
KRAS O +
mutation O +
have O +
been O +
performed O +
and O +
reported O +
previously O +
[ O -
16 O -
] O -
. O +

RNA O +
preparation O +
and O +
gene O +
expression O +
profiling O +
using O +
a O +
cDNA O +
microarray O +
containing O +
44,500 O +
cDNA O +
clones O -
, O +
representing O +
around O +
30,300 O +
unique O +
genes O -
, O +
has O +
been O +
performed O +
and O +
reported O +
in O +
90 O +
of O +
these O +
tumours O +
in O +
comparison O +
to O +
22 O +
non O -
- O -
tumour O +
gastric O +
mucosae O +
[ O -
14,15 O -
] O -
. O +

This O +
study O +
was O +
approved O +
by O +
the O +
Ethics O +
Committee O +
of O +
the O +
University O +
of O +
Hong O +
Kong O -
. O +

Mutational O +
screening O +
Mutation O +
screening O +
of O +
PIK3CA O +
was O +
performed O +
for O +
exons O +
9 O +
and O +
20 O -
, O +
covering O +
the O +
mutational O +
hotspots O -
; O +
and O +
for O +
exon O +
18 O -
, O +
from O +
which O +
a O +
mutation O +
was O +
found O +
in O +
a O +
gastric O +
cancer O -
. O +

Mutations O +
in O +
these O +
3 O +
exons O +
constituted O +
80 O -
% O +
of O +
all O +
PIK3CA O +
mutations O +
detected O +
in O +
the O +
previous O +
study O +
[ O -
13 O -
] O -
. O +

PIK3CA O +
intron O -
- O -
specific O +
external O +
amplification O +
primers O +
and O +
internal O +
sequencing O +
primers O +
were O +
designed O +
according O +
to O +
the O +
previous O +
study O +
[ O -
13 O -
] O +
with O +
some O +
modifications O +
[ O -
see O +
Additional O +
file O +
1 O -
] O -
. O +

In O +
particular O -
, O +
primers O +
for O +
exon O +
9 O +
have O +
been O +
modified O +
to O +
avoid O +
amplification O +
of O +
homologous O +
sequences O +
located O +
in O +
other O +
chromosomes O -
. O +

PCR O +
products O +
were O +
generated O +
using O +
the O +
external O +
primers O +
and O +
directly O +
sequenced O +
using O +
the O +
internal O +
primers O +
with O +
the O +
DYEnamic O -
™ O +
ET O +
Terminator O +
Cycle O +
Sequencing O +
Kit O +
( O -
Amersham O +
Biosciences O -
, O +
Freiburg O -
, O +
Germany O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instruction O -
. O +

Electrophoresis O +
was O +
performed O +
in O +
the O +
ABI O +
Prism O -
® O +
3700 O +
DNA O +
Analyzer O +
( O -
Applied O +
Biosystems O -
, O +
Foster O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

For O +
each O +
exon O -
, O +
PCR O +
products O +
were O +
generated O +
from O +
2 O +
independent O +
PCR O +
reactions O +
for O +
sequencing O +
of O +
the O +
forward O +
and O +
reverse O +
strands O -
. O +

For O +
exon O +
9 O -
, O +
2 O +
independent O +
PCR O +
followed O +
by O +
sequencing O +
of O +
the O +
forward O +
strand O +
were O +
performed O -
. O +

Analysis O +
of O +
the O +
chromatograms O +
was O +
performed O +
using O +
the O +
mutation O +
analysis O +
software O +
Mutation O +
Explorer O -
™ O +
( O -
SoftGenetics O -
, O +
State O +
College O -
, O +
PA O -
, O +
USA O -
) O -
. O +

Extraction O +
of O +
expression O +
data O +
and O +
statistical O +
analysis O +
Gene O +
expression O +
data O +
were O +
extracted O +
from O +
the O +
microarray O +
database O +
containing O +
126 O +
samples O +
( O -
90 O +
gastric O +
cancers O -
, O +
14 O +
lymph O +
node O +
metastasis O +
and O +
22 O +
non O -
- O -
tumour O +
gastric O +
mucosae O -
) O +
based O +
on O +
a O +
3-fold O +
signal O +
above O +
background O +
ratio O +
for O +
either O +
channel O +
and O +
with O +
80 O -
% O +
good O +
data O +
[ O -
14 O -
] O -
. O +

Gene O +
expression O +
data O +
from O +
20,336 O +
cDNA O +
clones O +
satisfied O +
this O +
selection O +
criteria O +
and O +
were O +
extracted O -
, O +
which O +
included O +
a O +
cDNA O +
clone O +
corresponding O +
to O +
PIK3CA O +
( O -
IMAGE O +
clone O +
number O +
345430 O -
, O +
GenBank O +
accession O +
no. O +
W72473 O -
) O -
. O +

Expression O +
data O +
for O +
PIK3CA O +
was O +
extracted O +
and O +
the O +
differences O +
in O +
expression O +
levels O +
between O +
tumour O +
and O +
non O -
- O -
tumour O +
tissues O +
were O +
examined O +
using O +
the O +
Student O -
's O +
t O -
- O -
Test O -
. O +

SAM O +
was O +
performed O +
to O +
identify O +
genes O +
with O +
significant O +
correlating O +
expression O +
with O +
PIK3CA O +
[ O -
17 O -
] O -
. O +

The O +
missing O +
values O +
in O +
the O +
dataset O +
were O +
estimated O +
by O +
a O +
K O -
- O -
nearest O +
neighbours O +
impute O +
algorithm O +
using O +
10 O +
nearest O +
neighbour O +
[ O -
18 O -
] O +
followed O +
by O +
5000 O +
permutations O +
in O +
the O +
SAM O +
analysis O -
. O +

Results O +
Among O +
the O +
94 O +
gastric O +
adenocarcinoma O +
analysed O -
, O +
we O +
have O +
detected O +
PIK3CA O +
mutation O +
in O +
4 O +
cases O -
. O +

Two O +
cases O +
harboured O +
the O +
mutation O +
A3140 O -
G O +
( O -
H1047R O -
) O +
in O +
exon O +
20 O -
, O +
and O +
the O +
other O +
2 O +
cases O +
with O +
mutations O +
G1624A O +
( O -
E542 O -
K O -
) O +
and O +
G1633A O +
( O -
E545 O -
K O -
) O +
in O +
exon O +
9 O -
. O +

Representative O +
sequence O +
chromatograms O +
are O +
shown O +
in O +
figure O +
1 O -
. O +

All O +
four O +
mutations O +
were O +
absent O +
in O +
the O +
corresponding O +
non O -
- O -
neoplastic O +
mucosae O +
and O +
thus O +
were O +
confirmed O +
as O +
somatic O +
mutations O -
. O +

Though O +
the O +
overall O +
mutation O +
frequency O +
( O -
4.3 O -
% O -
) O +
was O +
lower O +
than O +
that O +
of O +
the O +
previous O +
study O -
, O +
the O +
nature O +
of O +
the O +
4 O +
mutations O +
found O +
were O +
consistent O +
with O +
those O +
identified O +
at O +
the O +
reported O +
hotspots O -
. O +

In O +
particular O -
, O +
the O +
H1047R O +
mutation O +
has O +
been O +
reported O +
in O +
2 O +
gastric O +
cancers O +
and O +
15 O +
colorectal O +
cancers O +
[ O -
13 O -
] O -
. O +

While O +
the O +
E542 O -
K O +
and O +
the O +
E545 O -
K O +
mutations O +
were O +
not O +
found O +
in O +
gastric O +
cancer O +
in O +
the O +
previous O +
series O -
, O +
a O +
large O +
number O +
of O +
colorectal O +
tumours O +
did O +
harbour O +
these O +
2 O +
mutations O -
. O +

PIK3CA O +
mutation O +
spectrum O +
and O +
their O +
corresponding O +
clinico O -
- O -
pathological O +
features O +
were O +
listed O +
in O +
Table O +
1 O -
. O +

We O +
noted O +
a O +
higher O +
tendency O +
of O +
high O -
- O -
level O +
MSI O +
in O +
gastric O +
cancers O +
with O +
PIK3CA O +
mutations O +
( O -
3 O +
in O +
4 O -
, O +
75 O -
% O -
) O +
than O +
in O +
those O +
without O +
( O -
18 O +
in O +
90 O -
, O +
20 O -
% O -
) O -
. O +

Moreover O -
, O +
though O +
the O +
overall O +
incidence O +
of O +
KRAS O +
mutation O +
in O +
the O +
studied O +
population O +
was O +
low O +
( O -
8 O +
in O +
94 O -
) O -
, O +
2 O +
of O +
the O +
4 O +
gastric O +
cancers O +
with O +
PIK3CA O +
mutation O +
also O +
harboured O +
a O +
KRAS O +
mutation O -
. O +

Since O +
over O -
- O -
expression O +
of O +
PIK3CA O +
has O +
been O +
reported O +
in O +
gastric O +
cancer O +
[ O -
11 O -
] O -
, O +
we O +
have O +
also O +
extracted O +
PIK3CA O +
expression O +
data O +
from O +
our O +
previous O +
cDNA O +
microarray O +
study O +
of O +
these O +
cases O +
[ O -
14,15 O -
] O -
. O +

We O +
have O +
confirmed O +
that O +
expression O +
level O +
of O +
PIK3CA O +
was O +
significantly O +
higher O +
in O +
gastric O +
cancers O +
( O -
n O +
= O +
87 O -
, O +
mean O +
= O +
0.099 O -
, O +
SD O +
= O +
0.428 O -
) O +
when O +
compared O +
with O +
non O -
- O -
neoplastic O +
gastric O +
mucosae O +
( O -
n O +
= O +
22 O -
, O +
mean O +
= O +
-0.418 O -
, O +
SD O +
= O +
0.426 O -
; O +
Student O -
's O +
t O -
- O -
Test O -
, O +
p O +
< O +
0.001 O -
) O -
. O +

Using O +
PIK3CA O +
expression O +
level O +
as O +
a O +
continuous O +
variable O +
for O +
SAM O +
analysis O +
[ O -
17 O -
] O -
, O +
we O +
found O +
2910 O +
cDNA O +
clones O +
( O -
corresponding O +
to O +
about O +
2546 O +
unique O +
genes O -
) O +
whose O +
expression O +
associated O +
positively O +
with O +
PIK3CA O +
expression O +
( O -
median O +
number O +
of O +
false O +
significant O +
= O +
0.372 O -
, O +
Delta O +
= O +
1.107 O -
) O +
[ O -
see O +
Additional O +
file O +
2 O -
] O -
. O +

Interestingly O -
, O +
no O +
gene O +
was O +
found O +
to O +
be O +
negatively O +
associated O +
with O +
PIK3CA O +
expression O -
. O +

Discussion O +
In O +
this O +
study O -
, O +
we O +
have O +
reported O +
the O +
presence O +
of O +
PIK3CA O +
gene O +
mutation O +
in O +
4.3 O -
% O +
of O +
gastric O +
cancer O -
. O +

A O +
high O +
tendency O +
( O -
3 O +
in O +
4 O -
) O +
of O +
mismatch O +
repair O +
deficiency O +
was O +
noted O +
in O +
cases O +
harbouring O +
PIK3CA O +
mutation O -
. O +

Though O +
the O +
small O +
number O +
of O +
PIK3CA O +
mutations O +
in O +
our O +
study O +
may O +
not O +
justify O +
statistical O +
claim O +
of O +
significance O -
; O +
suggestion O +
of O +
such O -
, O +
despite O +
of O +
its O +
not O +
being O +
mentioned O +
by O +
the O +
authors O -
, O +
can O +
be O +
found O +
from O +
a O +
previous O +
study O +
in O +
CRC O +
by O +
Samuels O +
et O +
al O -
.. O +
From O +
their O +
study O +
of O +
33 O +
MSI O +
and O +
201 O +
microsatellite O +
stable O +
( O -
MSS O -
) O +
CRC O +
cases O -
, O +
PIK3CA O +
mutation O +
was O +
present O +
in O +
48 O -
% O +
of O +
the O +
MSI O +
tumours O -
, O +
but O +
only O +
in O +
29 O -
% O +
of O +
the O +
MSS O +
tumours O -
. O +

A O +
significant O +
association O +
would O +
have O +
been O +
revealed O +
if O +
statistical O +
analysis O +
had O +
been O +
applied O +
( O -
Fisher O -
's O +
exact O +
test O -
, O +
p O +
= O +
0.014 O -
) O +
[ O -
13 O -
] O -
. O +

Gastrointestinal O +
tract O +
cancers O +
with O +
MSI O +
are O +
known O +
to O +
have O +
a O +
different O +
molecular O +
pathway O +
of O +
tumour O +
evolution O +
compared O +
with O +
their O +
MSS O +
counterparts O +
[ O -
19,20 O -
] O -
. O +

This O +
can O +
be O +
attributed O +
to O +
their O +
propensity O +
for O +
frameshift O +
mutations O +
in O +
repeat O +
sequences O -
, O +
resulting O +
in O +
selective O +
disruption O +
of O +
genes O +
with O +
such O +
sequences O +
within O +
their O +
coding O +
regions O -
. O +

With O +
2 O +
poly O -
- O -
adenine O +
tracts O +
within O +
its O +
coding O +
region O -
, O +
PTEN O +
can O +
be O +
inactivated O +
through O +
frameshift O +
mutations O +
in O +
MSI O +
CRC O -
, O +
resulting O +
in O +
the O +
selective O +
targeting O +
of O +
the O +
PI3K O -
- O -
AKT O +
signalling O +
pathway O +
[ O -
21,22 O -
] O -
. O +

It O +
is O +
also O +
known O +
that O +
mismatch O +
repair O +
deficiency O +
would O +
lead O +
to O +
an O +
elevated O +
rate O +
of O +
missense O +
mutation O +
due O +
to O +
impaired O +
single O +
nucleotide O +
mismatch O +
repair O +
[ O -
23 O -
] O -
. O +

Thus O -
, O +
the O +
observed O +
higher O +
incidence O +
of O +
PIK3CA O +
missense O +
mutation O +
in O +
MSI O +
colorectal O +
and O +
gastric O +
cancers O +
suggests O +
yet O +
another O +
mechanism O +
for O +
the O +
activation O +
of O +
the O +
PI3K O -
- O -
AKT O +
signalling O +
pathway O +
through O +
mismatch O +
repair O +
deficiency O -
. O +

Our O +
data O +
also O +
showed O +
a O +
higher O +
tendency O +
of O +
KRAS O +
mutation O +
in O +
cases O +
with O +
PIK3CA O +
mutations O +
( O -
2 O +
in O +
4 O -
) O +
than O +
in O +
those O +
without O +
( O -
6 O +
in O +
90 O -
) O -
. O +

Yet O +
again O +
due O +
to O +
the O +
low O +
incidence O +
of O +
both O +
mutations O +
in O +
our O +
samples O -
, O +
statistical O +
significance O +
may O +
not O +
be O +
claimed O -
. O +

In O +
the O +
study O +
by O +
Samuels O +
et O +
al. O -
, O +
some O +
of O +
the O +
colorectal O +
tumours O +
with O +
PIK3CA O +
mutation O +
also O +
harboured O +
KRAS O +
or O +
BRAF O +
mutation O +
[ O -
13 O -
] O -
. O +

The O +
PI3K O -
- O -
AKT O +
pathway O +
is O +
known O +
to O +
have O +
a O +
close O +
association O +
with O +
the O +
RAS O -
- O -
MEKK O +
signalling O +
pathway O +
[ O -
8 O -
] O -
. O +

Constitutively O +
active O +
RAS O +
can O +
interact O +
with O +
the O +
catalytic O +
subunit O +
of O +
PI3 O -
K O +
and O +
lead O +
to O +
its O +
activation O -
. O +

Ras O -
- O -
dependent O +
PI3 O -
K O +
activation O +
contributes O +
to O +
the O +
transforming O +
phenotype O +
by O +
mediating O +
anchorage O -
- O -
independent O +
growth O -
, O +
cytoskeletal O +
reorganisation O +
and O +
apoptosis O +
evasion O -
. O +

It O +
has O +
been O +
observed O +
that O +
genes O +
involved O +
in O +
the O +
same O +
signalling O +
pathway O +
may O +
manifest O +
mutations O +
in O +
cancer O +
cells O +
in O +
a O +
mutually O +
exclusive O +
manner O -
, O +
presumably O +
due O +
to O +
the O +
lack O +
of O +
selective O +
growth O +
advantage O +
in O +
having O +
a O +
second O +
hit O +
in O +
the O +
already O +
altered O +
pathway O -
. O +

A O +
prominent O +
example O +
is O +
the O +
mutually O +
exclusive O +
occurrence O +
of O +
the O +
BRAF O +
hotspot O +
mutation O +
( O -
V600E O -
) O +
and O +
KRAS O +
mutations O +
in O +
colorectal O +
cancer O +
[ O -
24,25 O -
] O -
. O +

However O -
, O +
there O +
exist O +
other O +
examples O +
of O +
alterations O +
in O +
multiple O +
components O +
of O +
the O +
same O +
signalling O +
pathway O +
that O +
may O +
lead O +
to O +
a O +
multi O -
- O -
level O +
modulation O +
of O +
its O +
activity O -
. O +

For O +
example O -
, O +
non O -
- O -
V600E O +
BRAF O +
mutations O +
tend O +
to O +
occur O +
together O +
with O +
KRAS O +
mutations O +
[ O -
26 O -
] O -
, O +
and O +
inactivation O +
of O +
the O +
secreted O +
frizzled O -
- O -
related O +
proteins O +
( O -
antagonists O +
of O +
WNT O -
) O +
by O +
promoter O +
methylation O +
frequently O +
coincides O +
with O +
mutations O +
in O +
the O +
Adenomatous O +
Polyposis O +
Coli O +
gene O +
to O +
achieve O +
multi O -
- O -
level O +
activation O +
of O +
the O +
WNT O +
signalling O +
pathway O +
in O +
colorectal O +
cancers O +
[ O -
27 O -
] O -
. O +

Whether O +
PIK3CA O +
functions O +
independently O +
from O +
RAS O -
, O +
or O +
acts O +
synergistically O +
with O +
RAS O +
to O +
produce O +
additive O +
effects O +
on O +
the O +
activation O +
of O +
the O +
same O +
pathway O +
awaits O +
further O +
clarification O -
. O +

By O +
extracting O +
data O +
from O +
microarray O -
, O +
we O +
have O +
confirmed O +
the O +
up O -
- O -
regulation O +
of O +
PIK3CA O +
expression O +
in O +
gastric O +
cancer O +
tissues O +
compared O +
with O +
the O +
non O -
- O -
neoplastic O +
gastric O +
mucosae O +
and O +
identified O +
a O +
large O +
number O +
of O +
genes O +
that O +
showed O +
a O +
significant O +
positive O +
correlation O +
in O +
expression O +
level O +
with O +
PIK3CA O -
. O +

These O +
genes O +
participate O +
in O +
diverse O +
cellular O +
processes O +
with O +
177 O +
as O +
putative O +
cell O +
cycle O -
- O -
regulated O +
genes O +
[ O -
28 O -
] O +
and O +
126 O +
mapped O +
to O +
genes O +
with O +
known O +
functions O +
in O +
cell O +
cycle O +
regulation O -
, O +
cell O +
proliferation O +
or O +
DNA O +
replication O +
[ O -
see O +
Additional O +
file O +
2 O -
] O -
. O +

While O +
some O +
of O +
these O +
genes O +
maybe O +
induced O +
by O +
PIK3CA O -
, O +
others O +
maybe O +
co O -
- O -
ordinately O +
regulated O +
by O +
common O +
upstream O +
signals O -
. O +

Expression O +
data O +
set O +
at O +
one O +
point O +
was O +
limited O +
in O +
differentiating O +
the O +
above O +
cause O +
and O +
consequence O -
, O +
yet O +
it O +
certainly O +
revealed O +
the O +
complexity O +
of O +
the O +
carcinogenic O +
process O +
and O +
the O +
intricate O +
relationship O +
of O +
PIK3CA O +
signalling O +
with O +
other O +
cellular O +
processes O -
. O +

Contrary O +
to O +
our O +
expectation O -
, O +
the O +
incidence O +
of O +
PIK3CA O +
mutation O +
found O +
in O +
the O +
current O +
study O +
( O -
4 O -
% O -
) O +
is O +
much O +
lower O +
compared O +
with O +
that O +
observed O +
by O +
Samuel O +
et O +
al. O +
( O -
25 O -
% O -
) O +
[ O -
13 O -
] O -
. O +

The O +
reason O +
for O +
discrepancy O +
may O +
simply O +
be O +
a O +
result O +
of O +
sample O +
bias O +
as O +
the O +
previous O +
study O +
involved O +
only O +
a O +
small O +
number O +
of O +
gastric O +
cancers O +
( O -
n O +
= O +
12 O -
) O -
. O +

However O -
, O +
ethnic O +
differences O +
can O +
also O +
be O +
another O +
possibility O -
. O +

The O +
diverse O +
pathological O +
spectrum O +
and O +
aetiological O +
factors O +
of O +
gastric O +
cancers O +
in O +
different O +
geographical O +
locations O +
may O +
be O +
paralleled O +
by O +
differences O +
in O +
molecular O +
pathway O +
of O +
tumour O +
development O -
. O +

Since O +
our O +
current O +
study O +
is O +
only O +
based O +
on O +
a O +
Chinese O +
population O +
with O +
an O +
intermediate O +
gastric O +
cancer O +
incidence O -
, O +
further O +
studies O +
involving O +
patients O +
from O +
different O +
ethnic O +
groups O +
will O +
be O +
able O +
to O +
address O +
this O +
possibility O -
. O +

Conclusion O +
Large O -
- O -
scale O +
screening O +
of O +
gastric O +
adenocarcinomas O +
for O +
PIK3CA O +
mutations O +
revealed O +
a O +
mutation O +
incidence O +
of O +
4.3 O -
% O -
. O +

Increased O +
PIK3CA O +
expression O +
level O +
was O +
observed O +
in O +
gastric O +
tumours O +
compared O +
with O +
non O -
- O -
neoplastic O +
mucosae O -
. O +

This O +
increase O +
in O +
PIK3CA O +
level O +
was O +
associated O +
with O +
the O +
elevated O +
expression O +
of O +
a O +
large O +
number O +
of O +
genes O -
, O +
which O +
may O +
constitute O +
the O +
upstream O +
regulators O +
or O +
downstream O +
targets O +
of O +
PIK3CA O +
along O +
the O +
PI3 O -
K O +
signalling O +
pathway O -
. O +

Competing O +
interests O +
The O +
author O -
( O -
s O -
) O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O -
. O +

Authors O -
' O +
contributions O +
VSWL O +
carried O +
out O +
the O +
molecular O +
analysis O -
, O +
performed O +
data O +
analysis O +
and O +
drafted O +
the O +
manuscript O -
. O +

CWW O -
, O +
TLC O -
, O +
WZ O +
assisted O +
in O +
the O +
molecular O +
analysis O -
. O +

KMC O +
provided O +
the O +
clinical O +
data O -
. O +

ASWC O +
assisted O +
in O +
data O +
analysis O +
and O +
edited O +
the O +
manuscript O -
. O +

SS O +
and O +
XC O +
participated O +
in O +
the O +
microarray O +
study O +
and O +
data O +
analysis O -
. O +

STY O +
and O +
SYL O +
conceived O +
of O +
the O +
study O -
, O +
participated O +
in O +
its O +
design O -
, O +
coordination O +
and O +
data O +
analysis O -
, O +
and O +
edited O +
the O +
manuscript O -
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O -
. O +

Pre O -
- O -
publication O +
history O +
The O +
pre O -
- O -
publication O +
history O +
for O +
this O +
paper O +
can O +
be O +
accessed O +
here O -
: O +
Supplementary O +
Material O +

Structural O +
organization O +
and O +
interactions O +
of O +
transmembrane O +
domains O +
in O +
tetraspanin O +
proteins O +
Abstract O +
Background O +
Proteins O +
of O +
the O +
tetraspanin O +
family O +
contain O +
four O +
transmembrane O +
domains O +
( O -
TM1 O -
- O -
4 O -
) O +
linked O +
by O +
two O +
extracellular O +
loops O +
and O +
a O +
short O +
intracellular O +
loop O -
, O +
and O +
have O +
short O +
intracellular O +
N- O +
and O +
C O -
- O -
termini O -
. O +

While O +
structure O +
and O +
function O +
analysis O +
of O +
the O +
larger O +
extracellular O +
loop O +
has O +
been O +
performed O -
, O +
the O +
organization O +
and O +
role O +
of O +
transmembrane O +
domains O +
have O +
not O +
been O +
systematically O +
assessed O -
. O +

Results O +
Among O +
28 O +
human B-Species +
tetraspanin O +
proteins O -
, O +
the O +
TM1 O -
- O -
3 O +
sequences O +
display O +
a O +
distinct O +
heptad O +
repeat O +
motif O +
( O -
abcdefg O -
) O -
n O -
. O +

In O +
TM1 O -
, O +
position O +
a O +
is O +
occupied O +
by O +
structurally O +
conserved O +
bulky O +
residues O +
and O +
position O +
d O +
contains O +
highly O +
conserved O +
Asn O +
and O +
Gly O +
residues O -
. O +

In O +
TM2 O -
, O +
position O +
a O +
is O +
occupied O +
by O +
conserved O +
small O +
residues O +
( O -
Gly O -
/ O -
Ala O -
/ O -
Thr O -
) O -
, O +
and O +
position O +
d O +
has O +
a O +
conserved O +
Gly O +
and O +
two O +
bulky O +
aliphatic O +
residues O -
. O +

In O +
TM3 O -
, O +
three O +
a O +
positions O +
of O +
the O +
heptad O +
repeat O +
are O +
filled O +
by O +
two O +
leucines O +
and O +
a O +
glutamate O -
/ O -
glutamine O +
residue O -
, O +
and O +
two O +
d O +
positions O +
are O +
occupied O +
by O +
either O +
Phe O -
/ O -
Tyr O +
or O +
Val O -
/ O -
Ile O -
/ O -
Leu O +
residues O -
. O +

No O +
heptad O +
motif O +
is O +
apparent O +
in O +
TM4 O +
sequences O -
. O +

Mutations O +
of O +
conserved O +
glycines O +
in O +
human B-Species +
CD9 O +
( O -
Gly25 O +
and O +
Gly32 O +
in O +
TM1 O -
; O +
Gly67 O +
and O +
Gly74 O +
in O +
TM2 O -
) O +
caused O +
aggregation O +
of O +
mutant O +
proteins O +
inside O +
the O +
cell O -
. O +

Modeling O +
of O +
the O +
TM1-TM2 O +
interface O +
in O +
CD9 O -
, O +
using O +
a O +
novel O +
algorithm O -
, O +
predicts O +
tight O +
packing O +
of O +
conserved O +
bulky O +
residues O +
against O +
conserved O +
Gly O +
residues O +
along O +
the O +
two O +
helices O -
. O +

The O +
homodimeric O +
interface O +
of O +
CD9 O +
was O +
mapped O -
, O +
by O +
disulfide O +
cross O -
- O -
linking O +
of O +
single O -
- O -
cysteine O +
mutants O -
, O +
to O +
the O +
vicinity O +
of O +
residues O +
Leu14 O +
and O +
Phe17 O +
in O +
TM1 O +
( O -
positions O +
g O +
and O +
c O -
) O +
and O +
Gly77 O -
, O +
Gly80 O +
and O +
Ala81 O +
in O +
TM2 O +
( O -
positions O +
d O -
, O +
g O +
and O +
a O -
, O +
respectively O -
) O -
. O +

Mutations O +
of O +
a O +
and O +
d O +
residues O +
in O +
both O +
TM1 O +
and O +
TM2 O +
( O -
Gly25 O -
, O +
Gly32 O -
, O +
Gly67 O +
and O +
Gly74 O -
) O -
, O +
involved O +
in O +
intramolecular O +
TM1-TM2 O +
interaction O -
, O +
also O +
strongly O +
diminished O +
intermolecular O +
interaction O -
, O +
as O +
assessed O +
by O +
cross O -
- O -
linking O +
of O +
Cys80 O -
. O +

Conclusion O +
Our O +
results O +
suggest O +
that O +
tetraspanin O +
intra- O +
and O +
intermolecular O +
interactions O +
are O +
mediated O +
by O +
conserved O +
residues O +
in O +
adjacent O -
, O +
but O +
distinct O +
regions O +
of O +
TM1 O +
and O +
TM2 O -
. O +

A O +
key O +
structural O +
element O +
that O +
defines O +
TM1-TM2 O +
interaction O +
in O +
tetraspanins O +
is O +
the O +
specific O +
packing O +
of O +
bulky O +
residues O +
against O +
small O +
residues O -
. O +

Background O +
Tetraspanins O +
constitute O +
a O +
large O +
family O +
of O +
integral O +
membrane O +
proteins O -
, O +
characteristically O +
containing O +
4 O -
, O +
6 O +
or O +
8 O +
conserved O +
cysteine O +
residues O +
in O +
the O +
large O +
extracellular O +
loop O +
( O -
including O +
the O +
CCG O +
and O +
PxxCC O +
motifs O -
) O -
, O +
which O +
form O +
disulfide O +
bonds O -
, O +
and O +
several O +
conserved O +
polar O +
residues O +
in O +
the O +
intracellular O +
loop O +
and O +
transmembrane O +
regions O +
[ O -
1,2 O -
] O -
. O +

There O +
are O +
32 O +
putative O +
tetraspanin O +
family O +
members O +
in O +
mammals O -
, O +
37 O +
in O +
Drosophila B-Species +
melanogaster I-Species +
and O +
20 O +
in O +
Caenorhabditis B-Species +
elegans I-Species -
. O +

Tetraspanins O +
play O +
diverse O +
roles O +
in O +
cell O +
adhesion O -
, O +
migration O +
and O +
fusion O +
processes O -
, O +
cellular O +
activation O +
and O +
signaling O +
( O -
reviewed O +
in O +
refs O -
. O +

[ O -
2 O -
- O -
4 O -
] O -
) O -
. O +

Mammalian O +
tetraspanins O +
such O +
as O +
CD9 O -
, O +
CD63 O -
, O +
CD81 O -
, O +
CD82 O -
, O +
CD151 O -
, O +
rds O -
/ O -
peripherin O -
, O +
and O +
uroplakins O +
Ia O +
and O +
Ib O +
have O +
been O +
most O +
extensively O +
studied O -
, O +
with O +
mouse B-Species +
knock O -
- O -
out O +
models O +
available O +
for O +
CD9 O +
[ O -
5 O -
- O -
7 O -
] O -
, O +
CD81 O +
[ O -
8,9 O -
] O -
, O +
CD151 O +
[ O -
10 O -
] O +
and O +
a O +
few O +
others O -
. O +

However O -
, O +
the O +
majority O +
of O +
tetraspanins O +
are O +
characterized O +
very O +
little O -
, O +
if O +
at O +
all O -
, O +
at O +
genetic O -
, O +
biochemical O +
or O +
structural O +
levels O -
. O +

The O +
large O +
extracellular O +
loop O +
( O -
LEL O -
) O +
of O +
tetraspanins O +
has O +
received O +
most O +
attention O -
, O +
since O +
it O +
contains O +
functionally O +
important O +
sites O -
. O +

Sequence O +
QRD O +
( O -
194–196 O -
) O +
in O +
CD151 O +
is O +
important O +
for O +
association O +
with O +
integrins O -
, O +
which O +
has O +
functional O +
consequences O +
for O +
integrin O -
- O -
dependent O +
cell O +
spreading O +
and O +
multicellular O +
cable O +
formation O +
[ O -
11 O -
] O -
. O +

A O +
site O +
in O +
the O +
LEL O +
of O +
CD9 O -
, O +
SFQ O +
( O -
residues O +
173–175 O -
) O -
, O +
is O +
essential O +
for O +
CD9 O +
function O +
in O +
sperm O -
- O -
egg O +
fusion O +
[ O -
12 O -
] O -
. O +

The O +
crystal O +
structure O +
of O +
tetraspanin O +
CD81 O +
LEL O +
revealed O +
five O +
α O -
- O -
helixes O -
, O +
A O -
- O -
E O +
[ O -
13 O -
] O -
. O +

Helices O +
A O -
, O +
B O +
and O +
E O +
form O +
a O +
relatively O +
conserved O +
region O +
in O +
tetraspanins O -
, O +
whereas O +
the O +
region O +
between O +
helices O +
B O +
and O +
E O +
is O +
the O +
most O +
variable O +
[ O -
14 O -
] O -
. O +

Interestingly O -
, O +
the O +
variable O +
region O +
contains O +
most O +
of O +
the O +
functionally O +
important O +
sites O +
involved O +
in O +
tetraspanin O +
protein O -
- O -
protein O +
interactions O -
. O +

A O +
remarkable O +
biochemical O +
property O +
of O +
tetraspanin O +
molecules O +
is O +
their O +
ability O +
to O +
associate O +
with O +
a O +
large O +
number O +
of O +
other O +
transmembrane O +
proteins O -
, O +
including O +
integrins O -
, O +
membrane O -
- O -
associated O +
growth O +
factors O +
and O +
receptors O -
, O +
MHC O +
class O +
II O +
molecules O -
, O +
Ig O +
superfamily O +
proteins O -
, O +
and O +
each O +
other O +
[ O -
2,3,15 O -
] O -
. O +

Several O +
of O +
these O +
lateral O +
associations O +
of O +
tetraspanins O +
are O +
detected O +
in O +
" O -
mild O -
" O +
detergents O +
( O -
Brij O +
series O -
, O +
CHAPS O -
) O -
, O +
but O +
are O +
disrupted O +
by O +
" O -
strong O -
" O +
detergents O +
such O +
as O +
Triton O +
X-100 O +
or O +
SDS O -
. O +

Multiprotein O +
complexes O +
of O +
tetraspanins O +
and O +
associated O +
molecules O -
, O +
also O +
called O +
the O +
" O -
tetraspanin O +
web O -
" O +
[ O -
16 O -
] O -
, O +
may O +
represent O +
a O +
distinct O +
tetraspanin O -
- O -
enriched O +
membrane O +
microdomain O +
[ O -
17,18 O -
] O -
. O +

The O +
formation O +
of O +
this O +
microdomain O +
is O +
influenced O +
by O +
palmitoylation O +
of O +
several O +
conserved O +
juxtamembrane O +
cysteine O +
residues O +
in O +
tetraspanins O +
[ O -
19 O -
- O -
21 O -
] O -
. O +

The O +
transmembrane O +
domains O -
, O +
encompassing O +
nearly O +
half O +
of O +
a O +
tetraspanin O +
protein O -
, O +
are O +
the O +
most O +
conserved O +
part O +
of O +
the O +
molecule O +
( O -
Stipp O +
et O +
al. O +
[ O -
1 O -
] O +
and O +
this O +
study O -
) O -
. O +

However O -
, O +
very O +
little O +
functional O +
information O +
is O +
available O +
on O +
these O +
domains O -
. O +

The O +
differential O +
detergent O +
sensitivity O +
of O +
tetraspanin O -
- O -
tetraspanin O +
associations O +
suggests O +
that O +
hydrophobic O +
interactions O +
between O +
TM O +
helices O +
may O +
play O +
a O +
role O -
. O +

Indeed O -
, O +
when O +
the O +
large O +
extracellular O +
loop O +
( O -
LEL O -
) O +
of O +
CD151 O +
is O +
deleted O -
, O +
the O +
molecule O +
is O +
still O +
able O +
to O +
associate O +
with O +
other O +
tetraspanins O +
[ O -
22 O -
] O -
. O +

Thus O -
, O +
TM O +
domains O +
are O +
strong O +
candidates O +
for O +
mediating O +
tetraspanin O -
- O -
tetraspanin O +
interactions O -
. O +

The O +
importance O +
of O +
TM O +
domain O +
interactions O +
in O +
intramolecular O +
organization O +
was O +
demonstrated O +
in O +
a O +
study O +
showing O +
that O +
CD82 O +
fragment O +
TM2 O -
- O -
4 O -
, O +
lacking O +
TM1 O -
, O +
was O +
retained O +
in O +
the O +
endoplasmic O +
reticulum O -
, O +
but O +
was O +
transported O +
to O +
the O +
cell O +
surface O +
upon O +
co O -
- O -
expression O +
of O +
TM1 O +
[ O -
23 O -
] O -
. O +

This O +
in O +
vivo O +
reconstitution O +
experiment O +
demonstrated O +
a O +
strong O +
interaction O +
between O +
TM1 O +
and O +
the O +
rest O +
of O +
the O +
molecule O -
. O +

Expression O +
of O +
a O +
truncated O +
CD9 O +
molecule O +
( O -
TM3-LEL O -
- O -
TM4 O -
) O +
results O +
in O +
intracellular O +
accumulation O +
of O +
the O +
protein O +
and O +
significant O +
misfolding O +
of O +
the O +
LEL O -
, O +
as O +
judged O +
by O +
inappropriate O +
disulfide O +
formation O +
and O +
diminished O +
antibody O +
reactivity O +
( O -
our O +
unpublished O +
data O -
) O -
. O +

Similarly O -
, O +
a O +
CD9 O +
epitope O +
in O +
the O +
LEL O +
is O +
lost O +
in O +
molecules O +
lacking O +
either O +
TM2+TM3 O +
or O +
just O +
TM4 O +
[ O -
24 O -
] O -
. O +

Thus O -
, O +
TM O +
domain O +
interactions O +
and O +
packing O +
are O +
crucial O +
for O +
proper O +
folding O -
, O +
stability O +
and O +
transport O +
of O +
tetraspanin O +
molecules O -
. O +

In O +
a O +
previous O +
study O -
, O +
we O +
showed O +
that O +
covalent O +
cross O -
- O -
linking O +
of O +
membrane O -
- O -
proximal O +
cysteine O +
residues O +
can O +
be O +
used O +
as O +
a O +
tool O +
for O +
detection O +
of O +
tetraspanin O -
- O -
tetraspanin O +
associations O +
[ O -
25 O -
] O -
. O +

Inhibition O +
of O +
cysteine O +
palmitoylation O +
by O +
2-bromopalmitate O +
( O -
2-BP O -
) O +
made O +
cysteines O +
available O +
for O +
cross O -
- O -
linking O +
and O +
enabled O +
demonstration O +
of O +
specific O +
tetraspanin O +
homodimerization O +
and O +
low O +
levels O +
of O +
heterodimerization O -
. O +

We O +
concluded O +
that O +
tetraspanin O +
homodimers O -
, O +
formed O +
in O +
the O +
Golgi O -
, O +
may O +
be O +
a O +
fundamental O +
structural O +
unit O +
within O +
tetraspanin O +
microdomains O -
. O +

In O +
this O +
study O -
, O +
we O +
carried O +
out O +
detailed O +
sequence O +
analysis O +
of O +
human B-Species +
tetraspanin O +
TM O +
domains O -
. O +

We O +
show O +
that O +
a O +
heptad O +
repeat O +
containing O +
conserved O +
glycine O -
, O +
asparagine O +
and O +
large O +
hydrophobic O +
residues O +
occurs O +
in O +
TM1 O +
and O +
TM2 O +
domains O -
, O +
and O +
predict O +
tight O +
intramolecular O +
association O +
of O +
these O +
two O +
domains O +
by O +
packing O +
of O +
the O +
large O +
residues O +
against O +
the O +
small O +
residues O -
. O +

Moreover O -
, O +
by O +
using O +
cysteine O +
cross O -
- O -
linking O +
we O +
map O +
a O +
dimerization O +
interface O +
in O +
the O +
human B-Species +
CD9 O +
protein O -
, O +
and O +
show O +
that O +
conserved O +
heptad O +
motif O +
glycine O +
residues O +
are O +
also O +
important O +
for O +
intermolecular O +
CD9 O +
associations O -
. O +

Results O +
Sequence O +
analysis O +
of O +
tetraspanin O +
transmembrane O +
domains O -
: O +
presence O +
of O +
the O +
heptad O +
repeat O +
motif O +
We O +
focused O +
our O +
attention O +
on O +
28 O +
human B-Species +
tetraspanins O +
identified O +
from O +
the O +
SWISS O -
- O -
PROT O +
and O +
GenBank O +
databases O -
. O +

All O +
tetraspanins O +
have O +
in O +
common O +
four O +
hydrophobic O +
stretches O +
( O -
TM O +
domains O -
) O +
of O +
20–25 O +
residues O -
, O +
and O +
contain O +
highly O +
conserved O +
residues O +
in O +
the O +
second O +
extracellular O +
loop O -
, O +
in O +
particular O +
the O +
Cys O -
- O -
Cys O -
- O -
Gly O +
( O -
CCG O -
) O +
motif O -
. O +

Detailed O +
analysis O +
of O +
the O +
large O +
extracellular O +
loop O +
sequences O +
[ O -
14 O -
] O -
, O +
and O +
dendrograms O +
based O +
on O +
full O -
- O -
length O +
alignment O +
can O +
be O +
found O +
in O +
earlier O +
studies O +
[ O -
26,27 O -
] O -
. O +

The O +
length O +
of O +
each O +
transmembrane O +
domain O +
was O +
established O +
based O +
on O +
previous O +
sequence O +
analysis O +
of O +
tetraspanin O +
sequences O +
[ O -
27,28 O -
] O -
, O +
and O +
on O +
annotations O +
to O +
the O +
database O +
entries O -
. O +

Manual O +
adjustments O +
based O +
on O +
sequence O +
homology O +
and O +
hydrophobicity O +
profiles O +
were O +
done O +
to O +
fully O +
delineate O +
the O +
TM O +
domains O -
. O +

The O +
resulting O +
lengths O +
of O +
TM O +
domains O +
were O -
: O +
TM1 O +
– O +
23 O +
residues O -
; O +
TM2 O +
– O +
21 O +
residues O -
; O +
TM3 O +
– O +
25 O +
residues O -
; O +
TM4 O +
– O +
25 O +
residues O -
. O +

Two O +
more O +
residues O +
could O +
be O +
added O +
onto O +
the O +
N O -
- O -
terminal O +
part O +
of O +
TM2 O -
; O +
however O -
, O +
relatively O +
small O +
sequence O +
conservation O +
of O +
these O +
residues O +
among O +
tetraspanins O +
and O +
occurrence O +
of O +
polar O -
/ O -
charged O +
side O +
chains O +
in O +
some O +
tetraspanins O +
precluded O +
us O +
from O +
doing O +
so O +
for O +
the O +
global O +
alignment O -
. O +

Figures O +
1 O +
and O +
2 O +
show O +
a O +
multiple O +
sequence O +
alignment O +
of O +
four O +
TM O +
domains O +
of O +
28 O +
human B-Species +
tetraspanins O -
. O +

For O +
each O +
position O +
within O +
the O +
domains O -
, O +
consensus O +
residues O +
were O +
determined O +
and O +
classified O +
( O -
with O +
individual O +
color O +
code O -
) O +
in O +
4 O +
categories O -
: O +
1 O -
) O +
large O +
hydrophobic O +
residues O +
( O -
including O +
Val O -
, O +
Met O -
, O +
Leu O -
, O +
Ile O -
, O +
Phe O -
, O +
Tyr O -
, O +
Trp O -
) O -
, O +
2 O -
) O +
small O +
residues O +
( O -
Gly O -
, O +
Ala O -
, O +
Ser O +
and O +
Thr O -
) O -
, O +
3 O -
) O +
Cys O -
, O +
and O +
4 O -
) O +
Asn O -
. O +

When O +
more O +
than O +
two O +
types O +
of O +
residues O +
occupied O +
a O +
given O +
position O +
in O +
a O +
TM O -
, O +
a O +
dual O -
- O -
color O +
pattern O +
that O +
reflected O +
the O +
prevalence O +
of O +
the O +
particular O +
residue O +
type O +
was O +
used O +
( O -
Figure O +
1 O -
) O -
. O +

Cysteine O +
residues O +
were O +
shown O +
separately O +
due O +
to O +
their O +
importance O +
as O +
palmitoylation O +
target O +
sites O -
. O +

The O +
highly O +
conserved O +
asparagine O +
residue O +
in O +
TM1 O +
was O +
considered O +
separately O -
. O +

No O +
proline O +
residues O +
are O +
found O +
in O +
TM O +
domains O +
1–3 O +
of O +
human B-Species +
tetraspanins O -
. O +

An O +
inspection O +
of O +
the O +
multiple O +
sequence O +
alignment O +
reveals O +
a O +
repeating O +
heptad O +
amino O +
acid O +
pattern O -
, O +
( O -
abcdefg O -
) O -
n O -
, O +
in O +
TM1 O -
, O +
2 O +
and O +
3 O +
( O -
Figure O +
1 O -
, O +
2 O -
) O -
. O +

Heptad O +
repeats O +
promote O +
helical O +
coiled O +
coil O +
interactions O +
in O +
multiple O +
soluble O +
and O +
membrane O -
- O -
spanning O +
proteins O +
[ O -
29 O -
- O -
31 O -
] O -
. O +

In O +
the O +
heptad O +
repeat O -
, O +
hydrophobic O +
residues O +
in O +
positions O +
a O +
and O +
d O +
are O +
of O +
special O +
importance O -
, O +
as O +
they O +
directly O +
mediate O +
interhelical O +
contacts O +
by O +
creating O +
a O +
tight O +
knobs O -
- O -
into O -
- O -
holes O +
packing O +
in O +
the O +
coiled O +
coil O +
structure O +
[ O -
32 O -
] O -
. O +

For O +
instance O -
, O +
in O +
the O +
leucine O +
zipper O +
of O +
the O +
yeast B-Species +
transcription O +
factor O +
GCN4 O -
, O +
positions O +
a O +
and O +
d O +
contain O +
Val O +
and O +
Leu O +
residues O -
, O +
respectively O -
, O +
with O +
an O +
Asn O +
residue O +
in O +
a O +
single O +
a O +
position O +
forming O +
a O +
hydrogen O +
bond O +
across O +
the O +
GCN4 O +
dimer O +
interface O +
[ O -
33 O -
] O -
. O +

In O +
TM1 O +
of O +
tetraspanins O -
, O +
highly O +
conserved O +
Asn O -
, O +
Gly O +
and O +
Gly O +
residues O +
( O -
numbers O +
18 O -
, O +
25 O +
and O +
32 O +
in O +
the O +
CD9 O +
sequence O -
) O +
appear O +
at O +
d O +
positions O +
of O +
the O +
heptad O +
repeats O -
, O +
and O +
residues O +
14 O -
, O +
21 O +
and O +
28 O +
are O +
at O +
a O +
positions O +
( O -
Figure O +
1 O -
) O -
. O +

In O +
TM2 O -
, O +
residues O +
67 O -
, O +
74 O +
and O +
81 O +
( O -
consensus O +
Gly O -
, O +
Gly O +
and O +
Ala O -
, O +
respectively O -
) O +
occupy O +
a O +
positions O -
, O +
whereas O +
residues O +
63 O -
, O +
70 O +
and O +
77 O +
are O +
at O +
d O +
positions O -
. O +

Another O +
highly O +
conserved O +
glycine O -
, O +
Gly80 O -
, O +
occupies O +
the O +
3rd O +
g O +
position O +
in O +
TM2 O -
. O +

In O +
TM3 O -
, O +
the O +
conserved O +
pattern O +
consists O +
of O +
two O +
leucine O +
residues O +
( O -
Leu89 O +
and O +
Leu96 O -
) O +
and O +
a O +
glutamate O -
/ O -
glutamine O +
residue O +
( O -
Glu O -
/ O -
Gln103 O -
) O +
in O +
a O +
positions O +
( O -
Figure O +
2 O -
) O -
. O +

Two O +
d O +
positions O +
are O +
also O +
conserved O +
– O +
Phe O -
/ O -
Tyr92 O +
and O +
Ile O -
/ O -
Val O -
/ O -
Leu99 O -
. O +

TM4 O +
lacks O +
a O +
conserved O +
heptad O +
pattern O +
and O +
has O +
only O +
a O +
single O +
conserved O +
position O -
, O +
Glu O -
/ O -
Gln209 O +
( O -
with O +
four O +
exceptions O -
) O -
. O +

These O +
features O +
of O +
TM1 O -
- O -
4 O +
of O +
tetraspanins O +
are O +
displayed O +
on O +
helical O +
wheel O +
diagrams O +
( O -
Figure O +
3 O -
) O -
. O +

Analysis O +
of O +
TM1 O +
sequences O +
The O +
conserved O +
Asn O -
- O -
Gly O -
- O -
Gly O +
motif O -
, O +
occupying O +
designated O +
d O +
positions O +
of O +
the O +
heptad O +
repeat O -
, O +
is O +
the O +
most O +
prominent O +
structural O +
feature O +
of O +
TM1 O -
. O +

We O +
also O +
compared O +
sequences O +
of O +
CD9 O +
orthologs O +
from O +
10 O +
different O +
organisms O +
( O -
the O +
most O +
available O +
for O +
any O +
tetraspanin O -
) O +
to O +
gain O +
further O +
insight O +
into O +
conservation O +
and O +
variability O +
of O +
the O +
TM1 O +
sequence O -
. O +

As O +
shown O +
in O +
Figure O +
4 O -
, O +
positions O +
a O -
, O +
d O +
and O +
g O +
in O +
TM1 O +
are O +
among O +
the O +
most O +
conserved O +
( O -
0 O -
, O +
1 O +
and O +
1 O +
substitution O -
, O +
respectively O -
) O -
, O +
while O +
interspecies O +
variability O +
tends O +
to O +
occur O +
in O +
other O +
positions O -
: O +
b O +
( O -
5 O +
substitutions O -
) O -
, O +
c O +
( O -
4 O +
substitutions O -
) O -
, O +
e O +
( O -
4 O +
substitutions O -
) O +
and O +
f O +
( O -
4 O +
substitutions O -
) O -
. O +

Thus O -
, O +
the O +
positions O +
typically O +
involved O +
in O +
coiled O +
coil O +
interactions O +
( O -
a O +
and O +
d O -
) O +
are O +
the O +
most O +
conserved O -
. O +

When O +
residues O +
of O +
TM1 O +
are O +
plotted O +
as O +
a O +
helical O +
wheel O -
, O +
additional O +
structural O +
features O +
are O +
revealed O +
( O -
Figure O +
3 O -
) O -
. O +

There O +
are O +
highly O +
conserved O +
aliphatic O +
and O +
aromatic O +
residues O +
in O +
the O +
first O +
three O +
a O +
positions O +
of O +
the O +
heptad O +
motif O +
( O -
Phe15 O -
, O +
Trp22 O +
and O +
Leu29 O +
in O +
CD9 O -
) O -
, O +
as O +
well O +
as O +
in O +
g O +
positions O +
( O -
Leu14 O -
, O +
Phe21 O -
, O +
Val28 O +
in O +
CD9 O -
) O -
. O +

The O +
" O -
ridges O -
" O +
formed O +
by O +
these O +
bulky O +
residues O +
are O +
flanking O +
the O +
" O -
groove O -
"- O -
forming O +
Gly O +
residues O +
of O +
the O +
Asn O -
- O -
Gly O -
- O -
Gly O +
position O +
d O +
motif O -
. O +

In O +
contrast O -
, O +
b O -
, O +
c O -
, O +
e O +
and O +
f O +
positions O +
show O +
an O +
overall O +
higher O +
variability O +
among O +
tetraspanins O -
, O +
as O +
also O +
seen O +
in O +
the O +
comparison O +
of O +
CD9 O +
orthologs O +
described O +
above O -
. O +

Analysis O +
of O +
TM2 O +
sequences O +
A O +
landmark O +
feature O +
of O +
TM2 O +
in O +
tetraspanins O +
is O +
the O +
presence O +
of O +
highly O +
conserved O +
glycine O +
residues O +
( O -
Gly67 O -
, O +
74 O -
, O +
77 O +
and O +
80 O +
in O +
CD9 O -
, O +
Figure O +
1 O -
) O -
. O +

Other O +
substitutions O +
at O +
these O +
positions O +
are O +
almost O +
exclusively O +
small O +
residues O -
, O +
such O +
as O +
Ala O +
or O +
Ser O -
. O +

In O +
addition O -
, O +
Ala O -
, O +
Ser O +
or O +
Thr O +
occupy O +
position O +
81 O -
. O +

This O +
residue O -
, O +
together O +
with O +
Gly67 O +
and O +
Gly74 O -
, O +
forms O +
face O +
a O +
of O +
the O +
helix O -
. O +

Residue O +
Gly77 O +
( O -
position O +
d O -
) O +
is O +
preceded O +
by O +
conserved O -
, O +
chiefly O +
large O +
hydrophobic O +
residues O +
on O +
the O +
same O +
helical O +
face O +
( O -
Leu63 O +
and O +
Met70 O +
in O +
CD9 O -
) O -
. O +

Extremely O +
conserved O +
Gly80 O +
falls O +
into O +
heptad O +
position O +
g O +
( O -
Figure O +
3 O -
) O -
. O +

Among O +
CD9 O +
orthologs O -
, O +
heptad O +
positions O +
a O +
and O +
d O +
are O +
absolutely O +
conserved O -
, O +
whereas O +
other O +
positions O +
have O +
the O +
following O +
number O +
of O +
substitutions O -
: O +
b O +
– O +
3 O -
; O +
c O +
– O +
2 O -
; O +
e O +
– O +
1 O -
; O +
f O +
– O +
3 O -
; O +
g O +
– O +
1 O +
( O -
Figure O +
4 O -
) O -
. O +

Two O +
of O +
the O +
f O +
position O +
residues O +
in O +
TM2 O +
( O -
65 O +
and O +
79 O -
) O +
also O +
show O +
higher O +
variability O +
among O +
different O +
tetraspanins O +
( O -
Figures O +
1 O -
, O +
3 O -
) O -
. O +

Cysteine O +
residues O +
are O +
frequently O +
found O +
near O +
the O +
cytoplasmic O +
end O +
of O +
TM2 O +
helix O +
at O +
positions O +
78 O +
and O +
79 O -
; O +
these O +
cysteines O +
are O +
likely O +
to O +
be O +
palmitoylated O -
. O +

Analysis O +
of O +
TM3 O +
and O +
TM4 O +
sequences O +
The O +
TM3 O +
domain O +
provides O +
another O +
example O +
of O +
the O +
heptad O +
repeat O +
pattern O -
. O +

Position O +
a O +
is O +
occupied O +
by O +
two O +
highly O +
conserved O +
leucine O +
and O +
a O +
glutamate O -
/ O -
glutamine O +
residue O +
( O -
Leu89 O -
, O +
Leu96 O +
and O +
Glu O -
/ O -
Gln103 O +
in O +
CD9 O -
) O -
. O +

Furthermore O -
, O +
two O +
d O +
positions O +
are O +
conserved O +
– O +
Phe O -
/ O -
Tyr92 O +
( O -
aromatic O +
residue O -
) O +
and O +
Ile O -
/ O -
Val99 O +
( O -
β O -
- O -
branched O +
aliphatic O +
residue O -
; O +
Figures O +
2 O -
, O +
3 O -
) O -
. O +

In O +
addition O -
, O +
residue O +
100 O +
in O +
position O +
e O +
is O +
generally O +
Phe O +
or O +
Leu O -
. O +

Among O +
CD9 O +
orthologs O -
, O +
position O +
a O +
has O +
1 O +
substitution O -
, O +
positions O +
b O -
, O +
c O +
and O +
f O +
each O +
have O +
6 O -
, O +
positions O +
d O +
and O +
e O +
each O +
have O +
2 O -
, O +
and O +
g O +
has O +
4 O -
. O +

Thus O -
, O +
as O +
for O +
TM1 O +
and O +
TM2 O -
, O +
positions O +
a O +
and O +
d O +
are O +
among O +
the O +
most O +
conserved O -
, O +
but O +
overall O +
TM3 O +
has O +
more O +
variable O +
positions O +
than O +
TM1 O +
or O +
TM2 O +
( O -
Figure O +
3 O -
) O -
. O +

Less O +
than O +
half O +
of O +
TM3 O +
sequences O +
contain O +
cysteine O +
residues O -
, O +
and O +
those O +
tend O +
to O +
occur O +
at O +
the O +
internal O +
positions O +
of O +
the O +
helix O +
( O -
Figure O +
2 O -
) O -
. O +

TM4 O +
shows O +
less O +
conservation O +
among O +
various O +
tetraspanin O +
family O +
members O +
than O +
the O +
other O +
TM O +
domains O +
( O -
Figures O +
2 O -
, O +
3 O -
) O -
. O +

The O +
only O +
highly O +
conserved O +
feature O +
is O +
the O +
glutamate O -
/ O -
glutamine O +
residue O +
in O +
position O +
209 O -
. O +

In O +
addition O -
, O +
one O +
or O +
two O +
cysteine O +
residues O +
can O +
be O +
found O +
at O +
the O +
C O -
- O -
terminal O +
end O +
of O +
TM4 O +
in O +
some O +
tetraspanins O +
( O -
e.g. O +
CD9 O -
, O +
CD81 O -
, O +
CD151 O -
) O -
, O +
and O +
many O +
sequences O +
contain O +
additional O +
polar O +
residues O +
( O -
Arg O -
, O +
Lys O -
, O +
His O -
, O +
Asn O -
, O +
Gln O -
) O -
. O +

No O +
conserved O +
heptad O +
motif O +
was O +
identified O +
in O +
TM4 O -
, O +
as O +
also O +
confirmed O +
by O +
analysis O +
of O +
substitutions O +
in O +
CD9 O +
orthologs O +
( O -
data O +
not O +
shown O -
) O -
. O +

Mutational O +
analysis O +
of O +
conserved O +
glycine O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
The O +
conserved O +
nature O +
of O +
the O +
Asn O +
and O +
Gly O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
prompted O +
an O +
analysis O +
of O +
their O +
functional O +
role O -
. O +

To O +
this O +
end O -
, O +
we O +
have O +
probed O +
whether O +
mutations O +
of O +
these O +
residues O +
destabilize O +
the O +
protein O +
molecule O -
. O +

We O +
expressed O +
a O +
construct O +
of O +
the O +
first O +
and O +
second O +
TMs O +
of O +
CD9 O -
, O +
connected O +
by O +
the O +
small O +
extracellular O +
loop O -
, O +
and O +
tagged O +
with O +
a O +
C O -
- O -
terminal O +
green O +
fluorescent O +
protein O +
( O -
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
molecule O -
) O -
. O +

In O +
human B-Species +
rhabdomyosarcoma O +
RD O +
cells O -
, O +
the O +
wild O -
- O -
type O +
fusion O +
protein O +
localized O +
mostly O +
in O +
a O +
reticular O -
, O +
intracellular O +
pattern O -
, O +
without O +
forming O +
any O +
large O +
aggregates O +
( O -
Figure O +
5 O -
, O +
panel O +
A O -
) O -
. O +

Remarkably O -
, O +
when O +
double O +
mutants O +
Gly25Leu O +
+ O +
Gly32Leu O +
and O +
Gly67Leu O +
+ O +
Gly74Leu O +
were O +
expressed O -
, O +
the O +
protein O +
formed O +
distinct O +
large O +
aggregates O +
in O +
a O +
high O +
proportion O +
of O +
cells O +
( O -
Figure O +
5 O -
, O +
panels O +
C O +
and O +
E O -
) O -
. O +

In O +
contrast O -
, O +
double O +
mutant O +
Gly77Leu O +
+ O +
Gly80Leu O +
did O +
not O +
form O +
such O +
aggregates O +
( O -
Figure O +
5 O -
, O +
panel O +
G O -
) O -
. O +

Results O +
with O +
respective O +
single O +
mutants O +
were O +
similar O +
to O +
that O +
with O +
double O +
mutants O -
, O +
with O +
the O +
aggregation O +
being O +
somewhat O +
more O +
pronounced O +
for O +
Leu O +
substitutions O +
of O +
Gly67 O +
and O +
Gly74 O +
compared O +
to O +
Gly25 O +
and O +
Gly32 O +
mutations O -
. O +

No O +
aggregation O +
was O +
observed O +
for O +
Asn18Ser O +
and O +
Asn18Tyr O +
mutants O +
( O -
data O +
not O +
shown O -
) O -
. O +

Also O -
, O +
nearly O +
identical O +
results O +
were O +
obtained O +
with O +
human B-Species +
HT1080 O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O +

We O +
interpret O +
these O +
results O +
as O +
an O +
indication O +
that O +
aggregating O +
mutants O +
are O +
destabilized O +
or O +
misfolded O +
while O +
non O -
- O -
aggregating O +
mutants O +
retain O +
the O +
wild O -
- O -
type O +
conformation O -
. O +

Intriguingly O -
, O +
mutations O +
to O +
the O +
conserved O +
GG7 O +
motifs O +
caused O +
protein O +
aggregation O +
while O +
the O +
mutation O +
of O +
other O +
glycines O +
had O +
no O +
detectable O +
effect O -
. O +

These O +
results O +
also O +
suggest O +
that O +
wild O -
- O -
type O +
GFP O -
, O +
which O +
has O +
weak O +
tendency O +
to O +
self O -
- O -
associate O -
, O +
could O +
enhance O +
non O -
- O -
specific O +
interactions O +
of O +
destabilized O +
mutant O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
CD9 O +
moieties O -
, O +
leading O +
to O +
their O +
aggregation O -
. O +

Consistent O +
with O +
this O +
hypothesis O -
, O +
the O +
aggregation O +
of O +
Gly25Leu O +
+ O +
Gly32Leu O +
and O +
Gly67Leu O +
+ O +
Gly74Leu O +
double O +
mutants O +
was O +
suppressed O +
when O +
monomeric O +
GFP O +
molecule O -
, O +
Leu221Lys O +
[ O -
34 O -
] O +
was O +
used O +
( O -
Figure O +
5 O -
, O +
panels O +
D O +
and O +
F O -
) O -
. O +

The O +
use O +
of O +
monomeric O +
GFP O +
did O +
not O +
affect O +
intercellular O +
localization O +
of O +
wild O -
- O -
type O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
( O -
Figure O +
5 O -
, O +
panel O +
B O -
) O -
, O +
or O +
a O +
Gly77Leu O +
+ O +
Gly80Leu O +
double O +
mutant O +
( O -
Figure O +
5 O -
, O +
panel O +
H O -
) O -
. O +

In O +
summary O -
, O +
Leu O +
substitutions O +
of O +
Gly O +
residues O +
that O +
are O +
part O +
of O +
the O +
Asn O -
- O -
Gly O -
- O -
Gly O +
( O -
NGG7 O -
) O +
motif O +
in O +
TM1 O -
, O +
or O +
Gly O -
- O -
Gly O -
- O -
Ala O +
( O -
GGA7 O -
) O +
motif O +
in O +
TM2 O -
, O +
resulted O +
in O +
destabilization O +
and O +
aggregation O +
of O +
GFP O -
- O -
fused O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
proteins O -
, O +
whereas O +
substitutions O +
of O +
Gly77 O +
or O +
Gly80 O -
, O +
which O +
are O +
not O +
part O +
of O +
these O +
motifs O +
( O -
Figure O +
3 O -
) O -
, O +
failed O +
to O +
show O +
such O +
aggregation O -
. O +

Prediction O +
and O +
modelling O +
of O +
interaction O +
between O +
TM1 O +
and O +
TM2 O +
Consecutive O +
helices O +
in O +
polytopic O +
membrane O +
proteins O +
frequently O +
interact O +
[ O -
35 O -
] O -
. O +

Sequence O +
analysis O +
of O +
TM1 O +
and O +
TM2 O +
helices O +
of O +
tetraspanins O +
reveals O +
a O +
remarkable O +
complementarity O +
in O +
the O +
distribution O +
of O +
large O +
and O +
small O +
residues O +
at O +
heptad O +
positions O +
a O +
and O +
d O +
along O +
the O +
helical O +
axis O +
( O -
Figure O +
3 O -
) O -
, O +
suggesting O +
that O +
these O +
residues O +
may O +
interact O -
. O +

To O +
further O +
elucidate O +
the O +
potential O +
for O +
TM1-TM2 O +
interaction O -
, O +
the O +
putative O +
interface O +
was O +
modeled O +
using O +
a O +
novel O +
algorithm O +
that O +
considers O +
mutational O +
data O +
during O +
each O +
step O +
of O +
a O +
Monte O +
Carlo O +
simulated O +
annealing O +
cycle O +
( O -
see O +
Methods O +
for O +
details O -
) O -
. O +

Specifically O -
, O +
Gly25Leu O -
, O +
Gly32Leu O -
, O +
Gly67Leu O +
and O +
Gly74Leu O +
were O +
scored O +
as O +
disruptive O +
mutations O -
, O +
while O +
Asn18Ser O -
, O +
Gly77Leu O +
and O +
Gly80Leu O +
were O +
scored O +
as O +
silent O +
mutations O -
, O +
based O +
on O +
their O +
effects O +
on O +
protein O +
stability O +
( O -
Figure O +
5 O +
and O +
data O +
not O +
shown O -
) O -
. O +

The O +
resulting O +
model O +
predicts O +
left O -
- O -
handed O +
crossing O +
of O +
TM1 O +
and O +
TM2 O +
helices O +
at O +
an O +
angle O +
of O +
+ O -
28 O -
° O -
. O +

The O +
key O +
element O +
of O +
the O +
structure O +
is O +
the O +
apposition O +
of O +
bulky O +
and O +
small O +
heptad O +
position O +
a O +
and O +
d O +
residues O -
, O +
as O +
follows O -
: O +
Gly32-Leu63 O -
; O +
Gly67-Leu29 O -
; O +
Gly25-Met70 O -
; O +
Gly74-Trp22 O -
; O +
Asn18-Gly77 O -
; O +
Ala81-Phe15 O +
( O -
Figure O +
6 O -
) O -
. O +

Our O +
model O +
predicts O +
that O +
each O +
of O +
these O +
residue O +
pairs O +
are O +
in O +
van O +
der O +
Waals O +
contact O -
. O +

Additionally O -
, O +
two O +
potential O +
H O -
- O -
bonds O +
are O +
predicted O +
in O +
this O +
model O -
, O +
indicating O +
close O +
packing O -
: O +
Gly67 O +
Cα O +
to O +
Gly25 O +
carbonyl O +
oxygen O -
, O +
and O +
Trp22 O +
Cα O +
to O +
Met70 O +
carbonyl O +
oxygen O -
. O +

The O +
packing O +
is O +
tighter O +
in O +
the O +
ectodomain O -
- O -
proximal O +
portion O +
of O +
the O +
helices O +
( O -
Figure O +
6 O -
, O +
panel O +
B O -
) O -
, O +
as O +
determined O +
by O +
Cα O -
- O -
Cα O +
distances O +
between O +
interacting O +
residue O +
pairs O -
. O +

The O +
key O +
elements O +
of O +
the O +
model O +
are O +
corroborated O +
by O +
the O +
presence O +
of O +
apparently O +
complementary O +
substitutions O +
in O +
TM1 O +
and O +
TM2 O +
sequences O +
of O +
different O +
tetraspanins O +
( O -
Figure O +
1 O -
, O +
boxed O +
residues O -
) O -
. O +

For O +
example O -
, O +
Gly74 O +
is O +
predicted O +
to O +
interact O +
with O +
Trp22 O -
. O +

In O +
8 O +
of O +
the O +
10 O +
tetraspanins O +
that O +
contain O +
a O +
substitution O +
for O +
Gly74 O -
, O +
a O +
compensatory O +
substitution O +
occurs O +
at O +
the O +
Trp22 O +
position O +
( O -
Figure O +
1 O -
) O -
. O +

Thus O -
, O +
a O +
larger O +
non O -
- O -
glycine O +
side O +
chain O +
at O +
position O +
74 O +
may O +
necessitate O +
a O +
less O +
bulky O +
non O -
- O -
Trp O +
side O +
chain O +
in O +
position O +
22 O -
. O +

Likewise O -
, O +
the O +
presence O +
of O +
a O +
Cβ O +
at O +
position O +
25 O -
, O +
typically O +
occupied O +
by O +
glycine O -
, O +
necessitates O +
a O +
non O -
- O -
β O -
- O -
branched O +
amino O +
acid O +
at O +
position O +
70 O -
, O +
which O +
is O +
occupied O +
by O +
a O +
β O -
- O -
branched O +
residue O +
in O +
nearly O +
half O +
of O +
all O +
cases O -
. O +

Indeed O -
, O +
we O +
find O +
that O +
in O +
each O +
of O +
5 O +
cases O +
in O +
which O +
position O +
25 O +
contains O +
a O +
Cβ O -
, O +
a O +
leucine O +
residue O +
occurs O +
in O +
position O +
70 O -
. O +

This O +
analysis O +
is O +
consistent O +
with O +
our O +
molecular O +
model O +
that O +
suggests O +
Leu70 O +
will O +
pack O +
most O +
favorably O +
against O +
a O +
Cβ O +
at O +
position O +
25 O +
than O +
a O +
β O -
- O -
branched O +
residue O +
or O +
a O +
methionine O -
. O +

Role O +
of O +
TM1 O +
and O +
TM2 O +
heptad O +
motif O +
residues O +
in O +
CD9 O +
dimerization O +
To O +
probe O +
CD9 O +
dimerization O -
, O +
we O +
used O +
a O +
cysteine O -
- O -
mediated O +
cross O -
- O -
linking O +
approach O -
. O +

We O +
established O +
previously O +
a O +
simple O +
and O +
efficient O +
method O +
for O +
cysteine O -
- O -
mediated O +
cross O -
- O -
linking O +
[ O -
25 O -
] O -
. O +

After O +
cells O +
are O +
pre O -
- O -
treated O +
with O +
2-BP O +
for O +
16–24 O +
hours O +
to O +
expose O +
normally O +
palmitoylated O +
cysteines O -
, O +
the O +
cysteines O +
can O +
be O +
cross O -
- O -
linked O +
using O +
any O +
of O +
the O +
following O +
methods O -
: O +
a O -
) O +
Spontaneous O +
oxidation O +
in O +
Brij97 O +
lysates O +
( O -
a O +
condition O +
that O +
preserves O +
tetraspanin O -
- O -
tetraspanin O +
associations O -
) O -
, O +
b O -
) O +
In O +
situ O +
cross O -
- O -
linking O -
, O +
by O +
pre O -
- O -
lysis O +
oxidation O +
of O +
cells O +
with O +
Cu2 O -
+ O -
-phenanthroline O +
( O -
CuP O -
) O +
to O +
promote O +
disulfide O +
bond O +
formation O -
. O +

c O -
) O +
In O +
situ O +
cross O -
- O -
linking O +
with O +
thiol O -
- O -
reactive O +
cross O -
- O -
linking O +
agents O +
of O +
defined O +
length O +
( O -
e.g. O +
DTME O -
, O +
BMB O -
) O -
. O +

The O +
first O +
two O +
approaches O +
produce O +
in O +
essence O +
" O -
zero O -
- O -
length O -
" O +
disulfides O -
, O +
indicative O +
of O +
close O +
proximity O +
of O +
target O +
cysteines O +
and O +
presumably O +
high O +
specificity O +
of O +
interaction O -
. O +

In O +
contrast O -
, O +
chemical O +
cross O -
- O -
linkers O +
with O +
6–20 O +
Å O +
spacer O +
arm O +
may O +
cross O -
- O -
link O +
with O +
higher O +
efficiency O -
, O +
but O +
not O +
necessarily O +
higher O +
specificity O -
. O +

However O -
, O +
they O +
provide O +
advantages O +
such O +
as O +
variable O +
membrane O +
permeability O -
, O +
and O +
potential O +
linkage O +
cleavability O -
. O +

For O +
tetraspanins O +
such O +
as O +
CD9 O -
, O +
membrane O -
- O -
permeable O +
cross O -
- O -
linker O +
DTME O +
( O -
13.3 O +
Å O -
- O -
long O -
, O +
reducible O -
) O +
provides O +
highly O +
specific O +
and O +
efficient O +
cross O -
- O -
linking O +
[ O -
25 O -
] O -
. O +

Here O +
we O +
have O +
used O +
a O +
cysteine O +
cross O -
- O -
linking O +
strategy O -
, O +
in O +
combination O +
with O +
cysteine O -
- O -
scanning O +
mutagenesis O -
, O +
to O +
map O +
the O +
residues O +
from O +
TM1 O +
and O +
TM2 O +
contributing O +
to O +
the O +
CD9 O +
dimerization O +
interface O -
. O +

For O +
subsequent O +
cross O -
- O -
linking O +
experiments O +
using O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
protein O -
, O +
the O +
non O -
- O -
dimerizing O +
form O +
of O +
GFP O +
was O +
used O -
. O +

This O +
avoids O +
potential O +
GFP O -
- O -
dependent O +
dimerization O +
and O +
aggregation O +
that O +
can O +
be O +
observed O +
with O +
wild O -
- O -
type O +
GFP O -
, O +
especially O +
when O +
fusions O +
with O +
transmembrane O +
proteins O +
are O +
studied O +
[ O -
36 O -
] O -
. O +

Importantly O -
, O +
the O +
Leu221Lys O +
mutation O +
in O +
GFP O +
prevented O +
aggregation O +
of O +
mutant O +
forms O +
of O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
, O +
which O +
was O +
observed O +
with O +
wild O -
- O -
type O +
GFP O +
fusion O +
( O -
Figure O +
5 O -
) O -
. O +

The O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
fragment O +
of O +
CD9 O +
contains O +
three O +
native O +
cysteines O +
– O +
Cys9 O -
, O +
Cys78 O +
and O +
Cys79 O -
. O +

Single O -
- O -
cysteine O +
mutants O +
of O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
were O +
constructed O -
, O +
in O +
which O +
a O +
cysteine O +
was O +
placed O +
at O +
various O +
faces O +
of O +
TM1 O +
or O +
TM2 O +
while O +
all O +
of O +
the O +
wild O -
- O -
type O +
cysteines O +
were O +
simultaneously O +
replaced O +
by O +
serines O -
. O +

The O +
mutant O +
proteins O +
were O +
transiently O +
expressed O +
in O +
RD O +
cells O +
( O -
having O +
little O +
endogenous O +
CD9 O -
) O -
, O +
which O +
were O +
then O +
treated O +
for O +
16–18 O +
hours O +
with O +
2-BP O -
. O +

To O +
achieve O +
maximal O +
specificity O +
in O +
cross O -
- O -
linking O +
we O +
used O +
a O +
" O -
zero O -
- O -
length O -
" O +
agent O -
, O +
CuP. O +
First O -
, O +
single O -
- O -
cysteine O +
replacements O +
were O +
constructed O +
for O +
residues O +
Leu14 O -
, O +
Phe15 O -
, O +
Gly16 O -
, O +
Phe17 O +
and O +
Asn18 O -
, O +
covering O +
just O +
over O +
one O +
complete O +
helical O +
turn O +
at O +
the O +
beginning O +
of O +
TM1 O -
. O +

While O +
residue O +
Asn18 O +
is O +
highly O +
conserved O -
, O +
positions O +
14 O -
, O +
15 O +
and O +
17 O +
are O +
occupied O +
by O +
bulky O +
hydrophobic O +
residues O +
in O +
most O +
tetraspanins O -
, O +
whereas O +
position O +
16 O +
shows O +
less O +
conservation O +
( O -
Figures O +
1 O -
, O +
4 O -
) O -
. O +

All O +
of O +
the O +
single O -
- O -
cysteine O +
mutants O +
showed O +
diffused O +
pattern O +
of O +
protein O +
localization O -
, O +
without O +
any O +
signs O +
of O +
aggregation O -
. O +

As O +
shown O +
in O +
Figure O +
7A O -
, O +
the O +
highest O +
level O +
of O +
intermolecular O +
cross O -
- O -
linking O +
was O +
observed O +
for O +
Leu14Cys O +
and O +
Phe17Cys O +
mutants O -
, O +
a O +
lower O +
level O +
for O +
Phe15Cys O +
and O +
Gly16Cys O +
mutants O -
, O +
and O +
very O +
little O +
cross O -
- O -
linking O +
for O +
Asn18Cys O +
substitution O -
. O +

These O +
results O +
indicate O +
that O -
: O +
a O -
) O +
the O +
first O +
two O +
transmembrane O +
domains O +
of O +
CD9 O +
alone O +
can O +
mediate O +
its O +
dimerization O -
, O +
and O +
b O -
) O +
the O +
g O +
and O +
c O +
residues O +
of O +
TM1 O +
( O -
e.g. O +
Leu14 O +
and O +
Phe17 O -
, O +
Figure O +
3 O -
) O +
are O +
likely O +
to O +
be O +
part O +
of O +
the O +
intermolecular O +
interface O -
. O +

Similarly O -
, O +
single O -
- O -
cysteine O +
substitutions O +
were O +
made O +
for O +
residues O +
Gly77 O -
, O +
Gly80 O +
and O +
Ala81 O +
in O +
TM2 O -
; O +
in O +
addition O -
, O +
proteins O +
carrying O +
a O +
single O +
wild O -
- O -
type O +
cysteine O -
, O +
Cys9 O -
, O +
Cys78 O +
or O +
Cys79 O -
, O +
were O +
tested O -
. O +

No O +
protein O +
aggregation O +
was O +
observed O +
for O +
any O +
of O +
these O +
single O -
- O -
cysteine O +
mutants O -
. O +

As O +
shown O +
in O +
Figure O +
7B O -
, O +
the O +
relatively O +
low O +
level O +
of O +
intermolecular O +
cross O -
- O -
linking O +
of O +
wild O -
- O -
type O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
protein O +
was O +
enhanced O +
dramatically O +
in O +
single O -
- O -
cysteine O +
TM2 O +
mutants O +
Gly80Cys O +
and O +
Ala81Cys O -
. O +

The O +
Gly77Cys O +
mutant O +
also O +
had O +
an O +
elevated O +
level O +
of O +
cross O -
- O -
linking O -
. O +

In O +
contrast O -
, O +
any O +
of O +
the O +
three O +
native O +
cysteines O +
( O -
9 O -
, O +
78 O +
and O +
79 O -
) O +
produced O +
level O +
of O +
cross O -
- O -
linking O +
not O +
much O +
greater O +
than O +
the O +
wild O -
- O -
type O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
protein O -
. O +

Similar O +
results O +
were O +
obtained O +
with O +
cysteine O -
- O -
reactive O +
cross O -
- O -
linker O +
BMB O +
( O -
data O +
not O +
shown O -
) O -
. O +

Likewise O -
, O +
comparable O +
results O +
were O +
obtained O +
with O +
single O -
- O -
cysteine O +
mutants O +
of O +
untagged O -
, O +
full O -
- O -
length O +
CD9 O -
, O +
using O +
CuP O +
( O -
Figure O +
7C O -
) O +
as O +
well O +
as O +
DTME O +
cross O -
- O -
linker O +
( O -
data O +
not O +
shown O -
) O -
. O +

These O +
cross O -
- O -
linking O +
results O +
for O +
TM1 O +
and O +
TM2 O +
are O +
consistent O +
with O +
our O +
model O +
that O +
places O +
residues O +
Leu14 O -
, O +
Phe17 O +
and O +
Gly80 O +
on O +
the O +
same O +
side O +
of O +
the O +
TM1-TM2 O +
pair O +
( O -
Figure O +
6 O -
, O +
panel O +
C O -
) O -
. O +

The O +
strong O +
cross O -
- O -
linking O +
with O +
Leu14Cys O -
, O +
Phe17Cys O +
and O +
Gly80Cys O +
places O +
the O +
intermolecular O +
interface O +
toward O +
the O +
c O +
and O +
g O +
phases O +
of O +
the O +
TM1 O +
helix O -
, O +
and O +
the O +
g O +
phase O +
of O +
the O +
TM2 O +
helix O -
, O +
away O +
from O +
its O +
e O +
and O +
f O +
faces O +
containing O +
wild O -
- O -
type O +
cysteines O +
78 O +
and O +
79 O -
. O +

Critical O +
residues O +
at O +
the O +
TM1-TM2 O +
interface O +
also O +
affect O +
dimerization O +
indirectly O -
. O +

To O +
assess O +
specific O +
CD9 O +
dimerization O -
, O +
we O +
used O +
a O +
Gly80Cys O +
substitution O +
at O +
the O +
intermolecular O +
interface O +
for O +
cross O -
- O -
linking O -
. O +

As O +
shown O +
in O +
Figure O +
8A O -
, O +
single O +
replacements O +
of O +
conserved O +
heptad O +
residues O +
in O +
positions O +
18 O -
, O +
25 O -
, O +
32 O -
, O +
67 O +
and O +
74 O +
( O -
Asn18Ser O -
, O +
Gly25 O -
/ O -
32 O -
/ O -
67 O -
/ O -
74→Leu O -
) O +
strongly O +
decreased O +
the O +
cross O -
- O -
linking O +
mediated O +
by O +
Cys80 O -
. O +

The O +
effect O +
was O +
most O +
pronounced O +
for O +
mutations O +
of O +
residues O -
, O +
Gly32 O +
and O +
Gly67 O -
, O +
located O +
in O +
the O +
tightly O +
packed O +
extracellular O +
end O +
of O +
TM O +
helices O +
( O -
Figure O +
6 O -
) O -
. O +

In O +
contrast O -
, O +
mutations O +
of O +
residues O +
closer O +
to O +
the O +
cytoplasmic O +
end O +
of O +
TM2 O +
( O -
Gly74 O +
and O +
especially O +
Ala81 O -
) O +
had O +
only O +
modest O +
to O +
very O +
little O +
effect O +
on O +
cross O -
- O -
linking O -
. O +

Relatively O +
low O +
efficiency O +
of O +
intermolecular O +
cross O -
- O -
linking O +
via O +
native O +
residues O +
Cys9 O -
, O +
78 O -
, O +
and O +
79 O +
( O -
Figures O +
7B O -
, O -
C O -
) O +
correlates O +
well O +
with O +
the O +
predicted O +
location O +
of O +
Cys78 O +
and O +
79 O +
away O +
from O +
the O +
dimeric O +
interface O +
( O -
Figure O +
3 O -
) O -
, O +
and O +
suggests O +
that O +
the O +
extramembrane O +
N O -
- O -
terminal O +
part O +
of O +
CD9 O +
( O -
residues O +
1–13 O -
) O +
does O +
not O +
self O -
- O -
associate O -
. O +

We O +
next O +
examined O +
whether O +
mutations O +
of O +
conserved O +
Asn O +
and O +
Gly O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
decreased O +
low O -
- O -
level O +
background O +
cross O -
- O -
linking O +
via O +
native O +
cysteines O -
. O +

As O +
expected O -
, O +
these O +
mutations O +
had O +
virtually O +
no O +
effect O +
on O +
dimer O +
formation O +
of O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
( O -
Figure O +
8B O -
) O -
. O +

The O +
level O +
of O +
covalent O +
dimer O +
formed O +
was O +
not O +
diminished O +
for O +
triple O +
Asn18Ser O +
+ O +
Gly25Leu O +
+ O +
Gly32Leu O +
and O +
double O +
Gly67Leu O +
+ O +
Gly74Leu O +
mutants O -
, O +
compared O +
to O +
wild O -
- O -
type O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
CD9 O +
molecule O -
. O +

Similarly O -
, O +
the O +
same O +
triple O +
and O +
double O +
mutations O +
in O +
the O +
context O +
of O +
full O -
- O -
length O +
CD9-GFP O +
protein O +
( O -
with O +
six O +
cysteines O -
) O +
produced O +
wild O -
- O -
type O +
levels O +
of O +
cross O -
- O -
linking O +
( O -
Figure O +
8C O -
) O -
. O +

We O +
interpret O +
these O +
findings O +
as O +
evidence O +
for O +
at O +
least O +
two O +
types O +
of O +
associations O +
between O +
CD9 O +
molecules O -
: O +
primary O -
, O +
involving O +
residues O +
14 O -
, O +
17 O +
and O +
80 O -
, O +
and O +
dependent O +
on O +
integrity O +
of O +
conserved O +
heptad O +
residues O +
in O +
TM1 O +
and O +
TM2 O -
, O +
and O +
less O +
efficient O +
secondary O +
interactions O -
, O +
probably O +
representing O +
random O +
collision O +
events O -
, O +
and O +
independent O +
of O +
the O +
heptad O +
residues O +
( O -
see O +
Discussion O +
for O +
more O +
details O -
) O -
. O +

TM3 O +
and O +
TM4 O +
cysteine O +
residues O +
in O +
CD9 O +
dimerization O +
After O +
identifying O +
the O +
roles O +
of O +
conserved O +
TM1 O +
and O +
TM2 O +
residues O +
in O +
CD9 O +
dimerization O -
, O +
we O +
next O +
probed O +
whether O +
residues O +
proximal O +
to O +
TM O +
domains O +
3 O +
and O +
4 O +
are O +
also O +
involved O -
. O +

To O +
this O +
end O -
, O +
disulfide O +
cross O -
- O -
linking O +
of O +
full O -
- O -
length O +
CD9 O +
molecules O +
containing O +
3 O +
C O -
- O -
terminal O +
cysteines O +
( O -
87 O -
, O +
just O +
before O +
TM3 O -
; O +
218 O +
and O +
219 O +
in O +
TM4 O -
) O +
or O +
3 O +
N O -
- O -
terminal O +
cysteines O +
( O -
9 O -
, O +
78 O +
and O +
79 O -
) O +
was O +
compared O +
( O -
Figure O +
9 O -
) O -
. O +

We O +
found O +
that O +
the O +
C O -
- O -
terminal O +
cysteines O +
were O +
only O +
slightly O +
better O +
than O +
N O -
- O -
terminal O +
cysteines O +
with O +
respect O +
to O +
detection O +
of O +
CD9 O +
dimers O -
. O +

However O -
, O +
markedly O +
more O +
trimers O +
and O +
tetramers O +
were O +
detected O +
using O +
C O -
- O -
terminal O +
cysteines O -
. O +

Thus O -
, O +
residues O +
87 O -
, O +
218 O +
and O +
219 O +
at O +
TM3 O +
and O +
TM4 O +
in O +
CD9 O +
can O +
together O +
form O +
contacts O +
across O +
the O +
dimeric O +
interface O +
and O +
also O +
additional O +
contacts O +
with O +
other O +
neighboring O +
CD9 O +
molecules O -
. O +

Discussion O +
Here O +
we O +
provide O +
the O +
first O +
detailed O +
analysis O +
of O +
tetraspanin O +
protein O +
transmembrane O +
domains O -
. O +

First O -
, O +
we O +
show O +
1 O -
) O +
the O +
presence O +
of O +
a O +
heptad O +
repeat O +
motif O +
in O +
TM1 O +
and O +
TM2 O -
, O +
containing O +
highly O +
conserved O +
Asn O +
and O +
Gly O +
residues O -
, O +
2 O -
) O +
a O +
leucine O +
and O +
glutamate O -
/ O -
glutamine O -
- O -
containing O +
heptad O +
motif O +
in O +
TM3 O -
, O +
and O +
3 O -
) O +
high O +
variability O +
and O +
absence O +
of O +
heptad O +
repeats O +
in O +
TM4 O +
sequences O -
. O +

Second O -
, O +
we O +
provide O +
evidence O +
for O +
a O +
specific O -
, O +
intramolecular O +
interaction O +
between O +
TM1 O +
and O +
TM2 O +
domains O -
, O +
in O +
which O +
bulky O +
hydrophobic O +
residues O +
pack O +
against O +
GG7 O +
motif O -
, O +
and O +
present O +
a O +
molecular O +
model O +
for O +
this O +
interaction O -
. O +

Third O -
, O +
experimental O +
mapping O +
of O +
the O +
CD9 O +
dimerization O +
interface O +
firmly O +
establishes O +
an O +
additional O +
role O +
for O +
conserved O +
TM1 O +
and O +
TM2 O +
residues O +
in O +
dimeric O +
intermolecular O +
interactions O -
. O +

Fourth O -
, O +
preliminary O +
evidence O +
is O +
provided O +
to O +
suggest O +
that O +
TM3 O +
and O +
TM4 O +
domains O +
contribute O +
to O +
expansion O +
of O +
CD9 O +
dimers O +
into O +
higher O +
order O +
multimers O -
. O +

Conserved O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
of O +
tetraspanins O -
: O +
role O +
in O +
intramolecular O +
packing O +
We O +
hypothesized O +
that O +
the O +
first O +
two O +
transmembrane O +
domains O +
of O +
tetraspanins O +
might O +
interact O +
with O +
each O +
other O +
because O -
: O +
a O -
) O +
consecutive O +
TM O +
domains O +
frequently O +
associate O +
in O +
known O +
protein O +
3D O +
structures O +
[ O -
35 O -
] O -
, O +
and O +
b O -
) O +

they O +
both O +
contain O +
a O +
series O +
of O +
highly O +
conserved O +
amino O +
acids O +
– O +
several O +
Gly O +
residues O +
and O +
an O +
Asn O +
residue O +
( O -
Figure O +
1 O -
) O -
. O +

Conserved O +
Gly O +
residues O +
are O +
a O +
frequent O +
theme O +
in O +
the O +
organization O +
of O +
interacting O +
transmembrane O +
domains O -
. O +

Analysis O +
of O +
3D O +
helix O +
packing O +
in O +
polytopic O +
membrane O +
proteins O +
reveals O +
that O +
Gly O +
residues O +
tend O +
to O +
localize O +
in O +
buried O +
positions O -
, O +
especially O +
at O +
the O +
helix O -
- O -
helix O +
interfaces O +
and O +
helix O +
crossing O +
points O +
[ O -
37,38 O -
] O -
. O +

Due O +
to O +
the O +
absence O +
of O +
a O +
side O +
chain O -
, O +
Gly O +
provides O +
a O +
flat O +
surface O +
for O +
packing O +
of O +
a O +
side O +
chain O +
from O +
another O +
residue O -
, O +
without O +
loss O +
of O +
side O -
- O -
chain O +
entropy O +
upon O +
interaction O -
. O +

The O +
most O +
common O +
Gly O -
- O -
containing O +
motif O +
is O +
GxxxG O +
[ O -
39,40 O -
] O -
. O +

In O +
glycophorin O +
A O +
( O -
GpA O -
) O -
, O +
the O +
major O +
glycoprotein O +
in O +
erythrocyte O +
cell O +
membranes O -
, O +
Gly79 O +
and O +
Gly83 O +
are O +
part O +
of O +
the O +
LIxxGVxxGVxxT O +
sequence O +
that O +
promotes O +
homodimerization O +
of O +
parallel O +
transmembrane O +
α O -
- O -
helixes O +
[ O -
41,42 O -
] O -
. O +

In O +
the O +
GpA O +
dimerization O +
motif O -
, O +
Gly O +
residues O +
allow O +
for O +
tight O +
packing O +
in O +
the O +
right O -
- O -
handed O +
helical O +
crossing O +
[ O -
43 O -
] O -
. O +

There O +
are O +
also O +
examples O +
of O +
left O -
- O -
handed O +
helical O +
crossing O +
in O +
the O +
context O +
of O +
a O +
GxxxG O +
motif O +
[ O -
44 O -
] O -
. O +

Other O +
membrane O +
proteins O +
that O +
use O +
the O +
GxxxG O +
motif O +
for O +
homo- O +
or O +
heterodimerization O +
include O +
bacteriophage B-Species +
M13 I-Species +
coat O +
proteins O +
[ O -
45 O -
] O -
, O +
yeast B-Species +
alpha O +
factor O +
receptor O +
[ O -
46 O -
] O -
, O +
integrin O +
α O +
IIb O +
subunit O +
[ O -
47 O -
] O -
, O +
and O +
ErbB1 O +
receptor O +
tyrosine O +
kinase O +
[ O -
48 O -
] O -
. O +

Other O +
small O +
residues O -
, O +
such O +
as O +
Ala O +
and O +
Ser O -
, O +
can O +
substitute O +
for O +
Gly O +
in O +
this O +
motif O +
[ O -
49 O -
] O -
. O +

A O +
protein O +
motif O +
in O +
which O +
Gly O +
residues O +
are O +
separated O +
by O +
6 O +
other O +
residues O +
( O -
GG7 O -
) O +
is O +
also O +
common O +
in O +
transmembrane O +
helices O -
, O +
especially O +
in O +
transporter O -
/ O -
channel O -
- O -
like O +
membrane O +
proteins O +
[ O -
50 O -
] O -
. O +

However O -
, O +
the O +
structural O +
features O +
associated O +
with O +
this O +
motif O +
are O +
not O +
well O +
known O -
. O +

In O +
particular O -
, O +
it O +
is O +
unclear O +
whether O +
left O -
- O -
handed O +
GG7 O +
heptad O +
repeat O +
motif O +
( O -
as O +
opposed O +
to O +
the O +
" O -
classic O -
" O +
right O -
- O -
handed O +
GxxxG O +
motif O -
) O +
can O +
drive O +
membrane O +
helix O +
association O -
. O +

In O +
a O +
recent O +
work O +
addressing O +
this O +
issue O -
, O +
Lear O +
et O +
al. O +
[ O -
51 O -
] O +
showed O +
that O +
a O +
synthetic O +
peptide O +
containing O +
Gly O +
at O +
heptad O +
positions O +
a O +
and O +
d O +
could O +
self O -
- O -
associate O +
in O +
vitro O -
, O +
likely O +
in O +
an O +
antiparallel O +
orientation O -
. O +

Heptad O +
repeats O +
containing O +
conserved O +
Gly O +
residues O +
occur O +
in O +
TM O +
domains O +
of O +
α O +
and O +
β O +
chains O +
of O +
MHC O +
class O +
II O +
proteins O -
, O +
and O +
mutations O +
of O +
the O +
Gly O +
residues O +
disrupt O +
the O +
αβ O +
heterodimer O +
[ O -
52 O -
] O -
. O +

These O +
examples O +
demonstrate O +
that O +
Gly O -
- O -
based O +
heptad O +
motifs O +
may O +
be O +
used O +
for O +
both O +
intra- O +
and O +
intermolecular O +
associations O -
. O +

In O +
this O +
work O -
, O +
we O +
identified O +
a O +
highly O +
conserved O +
GG7 O +
motif O +
in O +
the O +
first O +
two O +
tetraspanin O +
TM O +
domains O -
. O +

The O +
GG7 O +
sequence O +
in O +
tetraspanins O +
is O +
a O +
part O +
of O +
a O +
larger O +
motif O +
that O +
also O +
includes O +
a O +
conserved O +
Asn O +
residue O +
in O +
TM1 O +
( O -
NGG7 O -
) O +
and O +
an O +
Ala O -
/ O -
Ser O -
/ O -
Thr O +
residue O +
in O +
TM2 O +
( O -
GGA7 O -
) O -
. O +

The O +
seven O -
- O -
residue O +
periodicity O +
of O +
these O +
motifs O +
strongly O +
suggests O +
their O +
involvement O +
in O +
left O -
- O -
handed O +
coiled O +
coil O +
packing O +
reminiscent O +
of O +
the O +
leucine O +
zipper O -
, O +
rather O +
than O +
right O -
- O -
handed O +
packing O +
of O +
the O +
GpA O -
- O -
like O +
GxxxG O +
motif O -
. O +

For O +
antiparallel O +
helices O -
, O +
the O +
left O -
- O -
handed O +
crossing O +
is O +
in O +
fact O +
predominant O +
over O +
the O +
right O -
- O -
handed O +
in O +
known O +
TM O +
domain O +
structures O +
[ O -
44 O -
] O -
. O +

In O +
our O +
model O -
, O +
heptad O +
Gly O +
residues O +
in O +
NGG7 O +
and O +
GGA7 O +
sequences O +
provide O +
specific O +
packing O +
between O +
antiparallel O +
tetraspanin O +
TM1 O +
and O +
TM2 O +
helices O +
by O +
allowing O +
tight O +
van O +
der O +
Waals O +
interactions O +
with O +
large O +
hydrophobic O +
residues O +
( O -
Figure O +
6 O -
) O -
. O +

Highly O +
efficient O +
packing O +
of O +
bulky O +
side O +
chains O +
against O +
glycine O +
residues O +
is O +
observed O +
in O +
known O +
transmembrane O +
protein O +
3D O +
structures O +
[ O -
38,53,54 O -
] O -
. O +

An O +
example O +
includes O +
packing O +
of O +
helices O +
M1 O +
and O +
M2 O +
in O +
potassium O +
channel O +
KcsA O -
, O +
where O +
Val91 O +
in O +
M2 O +
is O +
paired O +
with O +
Gly43 O +
in O +
M1 O -
, O +
and O +
Leu36 O +
in O +
M1 O +
contacts O +
Ala98 O +
and O +
Gly99 O +
in O +
helix O +
M2 O +
[ O -
54,55 O -
] O -
. O +

In O +
addition O +
to O +
facilitating O +
helix O -
- O -
helix O +
packing O -
, O +
Gly O +
residues O +
frequently O +
provide O +
additional O +
CαH O -
... O +

O O +
hydrogen O +
bonds O +
between O +
two O +
helices O +
[ O -
44 O -
] O -
. O +

In O +
our O +
model O -
, O +
two O +
Cα O -
- O -
backbone O +
carbonyl O +
H O -
- O -
bonds O +
are O +
predicted O +
– O +
between O +
residues O +
Gly27-Gly67 O -
, O +
and O +
Trp22-Met70 O -
. O +

Although O +
polar O +
and O +
charged O +
amino O +
acid O +
residues O +
( O -
such O +
as O +
Asn O +
in O +
the O +
TM1 O +
heptad O +
motif O -
) O +
are O +
infrequent O +
in O +
transmembrane O +
domains O -
, O +
they O +
are O +
functionally O +
important O -
. O +

Polar O +
residues O +
such O +
as O +
glutamine O -
, O +
glutamic O +
acid O -
, O +
aspartic O +
acid O +
and O +
asparagine O +
can O +
promote O +
strong O +
oligomerization O +
of O +
model O +
membrane O -
- O -
associated O +
helices O +
[ O -
56 O -
- O -
58 O -
] O -
. O +

Ruan O +
et O +
al. O +
[ O -
59 O -
] O +
used O +
asparagine O +
scanning O +
mutagenesis O +
to O +
probe O +
the O +
interface O +
of O +
self O -
- O -
associating O +
polyleucine O +
helices O +
by O +
detecting O +
their O +
enhanced O +
self O -
- O -
interaction O +
in O +
vitro O +
and O +
in O +
the O +
E. B-Species +
coli I-Species -
- O -
based O +
ToxR O +
assay O -
. O +

Thus O -
, O +
a O +
hydrogen O +
bond O +
in O +
an O +
apolar O +
environment O +
can O +
result O +
in O +
strong O -
, O +
though O +
not O +
necessarily O +
specific O -
, O +
association O +
of O +
transmembrane O +
helices O -
. O +

In O +
fact O -
, O +
mutations O +
to O +
polar O +
residues O +
in O +
transmembrane O +
proteins O +
are O +
commonly O +
associated O +
with O +
disease O +
[ O -
60 O -
] O -
. O +

Because O +
of O +
this O +
potential O +
for O +
non O -
- O -
specific O +
interactions O -
, O +
polar O +
residues O +
tend O +
to O +
localize O +
at O +
buried O +
positions O +
in O +
TM O +
domains O -
. O +

In O +
our O +
case O -
, O +
the O +
conserved O +
Asn18 O +
residue O +
in O +
CD9 O +
is O +
predicted O +
to O +
be O +
a O +
part O +
of O +
the O +
TM1-TM2 O +
interface O -
, O +
though O +
our O +
model O +
does O +
not O +
predict O +
any O +
electrostatic O +
interaction O +
between O +
Asn18 O +
and O +
TM2 O +
( O -
Figure O +
6 O -
) O -
. O +

Consistently O -
, O +
substitution O +
such O +
as O +
Asn18Tyr O +
( O -
and O +
Gly77Leu O -
) O +
in O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
protein O +
was O +
not O +
destabilizing O +
as O +
analyzed O +
by O +
protein O +
aggregation O -
. O +

Curiously O -
, O +
the O +
full O -
- O -
length O +
Asn18Ser O +
CD9 O +
migrated O +
slightly O +
slower O +
on O +
SDS O -
- O -
PAGE O +
gel O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
Asn18 O +
does O +
play O +
a O +
role O +
in O +
maintaining O +
conformation O +
of O +
the O +
molecule O -
. O +

The O +
Asn18Cys O +
single O -
- O -
cysteine O +
mutant O +
shows O +
very O +
little O +
intermolecular O +
cross O -
- O -
linking O +
( O -
Figure O +
7A O -
) O -
, O +
supporting O +
the O +
proposed O +
location O +
of O +
this O +
residue O +
at O +
the O +
intramolecular O +
interface O -
. O +

It O +
is O +
tempting O +
to O +
speculate O +
that O +
the O +
" O -
pocket O -
" O +
between O +
TM1 O +
and O +
TM2 O +
lined O +
by O +
Asn18 O +
and O +
Gly77 O +
might O +
be O +
important O +
for O +
accommodating O +
palmitate O +
moieties O +
that O +
target O +
Cys78 O +
and O +
Cys79 O +
residues O -
, O +
and/or O +
important O +
for O +
access O +
by O +
the O +
putative O +
palmitoyl O +
transferase O +
to O +
those O +
residues O -
. O +

Understanding O +
the O +
exact O +
role O +
of O +
these O +
highly O +
conserved O +
Asn18 O +
and O +
Gly77 O +
residues O +
in O +
tetraspanins O +
awaits O +
further O +
investigation O -
. O +

In O +
summary O -
, O +
we O +
identified O +
conserved O +
glycine O +
residues O +
of O +
TM1 O +
and O +
TM2 O +
of O +
tetraspanins O +
as O +
key O +
elements O +
required O +
for O +
intramolecular O +
packing O -
. O +

Mutations O +
of O +
these O +
key O +
residues O +
( O -
Gly25 O -
, O +
Gly32 O -
, O +
Gly67 O +
and O +
Gly74 O +
in O +
CD9 O -
) O +
resulted O +
in O +
protein O +
destabilization O +
and O +
aggregation O -
. O +

There O +
is O +
ample O +
evidence O +
in O +
the O +
literature O +
for O +
mutations O +
in O +
transmembrane O +
proteins O +
that O +
lead O +
to O +
protein O +
destabilization O -
, O +
misassembly O +
and O +
pathologic O +
conditions O +
[ O -
61 O -
] O -
. O +

Thus O -
, O +
we O +
have O +
identified O +
conserved O +
heptad O +
Gly O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
of O +
tetraspanins O +
as O +
plausible O +
targets O +
of O +
destabilizing O +
mutations O +
with O +
potential O +
functional O +
consequences O -
. O +

Intermolecular O +
interactions O +
in O +
tetraspanins O +
Tetraspanin O +
CD9 O +
forms O +
mostly O +
homodimers O -
, O +
but O +
also O +
a O +
low O +
level O +
of O +
heterodimers O +
with O +
CD81 O +
and O +
CD151 O +
[ O -
25 O -
] O -
. O +

Thus O -
, O +
mapping O +
the O +
dimerization O +
interface O +
is O +
an O +
important O +
next O +
step O +
in O +
structure O -
- O -
function O +
analysis O +
of O +
tetraspanins O -
. O +

Disulfide O -
- O -
mediated O +
cross O -
- O -
linking O -
, O +
often O +
in O +
combination O +
with O +
cysteine O -
- O -
scanning O +
mutagenesis O -
, O +
is O +
a O +
common O +
strategy O +
to O +
probe O +
oligomerization O +
or O +
intersubunit O +
interactions O +
of O +
transmembrane O +
proteins O +
such O +
as O +
histidine O +
kinase O +
EnvZ O +
[ O -
62 O -
] O -
, O +
M O -
( O -
3 O -
) O +
muscarinic O +
acetylcholine O +
receptor O +
[ O -
63 O -
] O -
, O +
E. B-Species +
coli I-Species +
lactose O +
permease O +
[ O -
64 O -
] O -
, O +
synaptobrevin O +
[ O -
65 O -
] O -
, O +
integrins O +
[ O -
66 O -
] O +
and O +
many O +
others O -
. O +

In O +
tetraspanins O +
such O +
as O +
CD9 O -
, O +
membrane O -
- O -
proximal O +
cysteine O +
residues O +
are O +
especially O +
useful O +
targets O +
for O +
disulfide O +
trapping O -
, O +
as O +
their O +
linkage O +
can O +
be O +
enhanced O +
by O +
pre O -
- O -
treating O +
cells O +
with O +
2-BP O -
. O +

While O +
the O +
ability O +
of O +
wild O -
- O -
type O +
cysteines O +
in O +
CD9 O +
to O +
be O +
cross O -
- O -
linked O +
may O +
indicate O +
that O +
they O +
are O +
close O +
to O +
the O +
dimerization O +
interface O -
, O +
more O +
precise O +
mapping O +
was O +
achieved O +
here O +
using O +
cysteine O -
- O -
scanning O +
mutagenesis O -
. O +

Our O +
data O +
clearly O +
identify O +
regions O -
, O +
near O +
the O +
cytoplasmic O +
face O +
of O +
TM1 O +
and O +
TM2 O -
, O +
important O +
for O +
dimerization O -
. O +

Intermolecular O +
zero O -
- O -
length O +
cross O -
- O -
linking O +
was O +
highest O +
when O +
single O +
cysteines O +
were O +
placed O +
in O +
positions O +
14 O -
, O +
17 O -
, O +
77 O -
, O +
80 O +
and O +
81 O +
in O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
molecule O -
, O +
or O +
at O +
positions O +
77 O -
, O +
80 O +
or O +
81 O +
in O +
the O +
full O -
- O -
length O +
CD9 O +
protein O -
. O +

Positions O +
14 O -
, O +
17 O +
and O +
80 O +
are O +
distinct O +
from O +
the O +
intramolecular O +
interface O +
and O +
are O +
on O +
the O +
same O +
side O +
of O +
the O +
TM1-TM2 O +
pair O +
( O -
Figure O +
6 O -
) O -
. O +

Thus O -
, O +
they O +
are O +
well O -
- O -
positioned O +
to O +
participate O +
in O +
an O +
interaction O +
with O +
another O +
molecule O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
model O +
predicts O +
that O +
wild O -
- O -
type O +
cysteines O +
( O -
Cys78 O -
, O +
79 O -
) O -
, O +
which O +
do O +
not O +
yield O +
very O +
efficient O +
zero O -
- O -
length O +
cross O -
- O -
linking O -
, O +
are O +
on O +
the O +
other O +
side O +
of O +
TM1-TM2 O +
pair O -
. O +

While O +
using O +
the O +
cysteine O +
at O +
position O +
80 O +
as O +
the O +
dimeric O +
interface O +
probe O -
, O +
mutations O +
of O +
conserved O +
residues O +
in O +
TM1 O +
and O +
TM2 O +
( O -
especially O +
Gly32 O +
and O +
Gly67 O +
to O +
Leu O -
) O +
clearly O +
reduced O +
intermolecular O +
cross O -
- O -
linking O -
. O +

We O +
do O +
not O +
suggest O +
that O +
those O +
residues O +
are O +
directly O +
involved O +
in O +
intermolecular O +
interaction O -
. O +

Rather O -
, O +
we O +
propose O +
that O +
destabilization O +
of O +
the O +
intramolecular O +
TM1-TM2 O +
interaction O +
by O +
Gly O +
to O +
Leu O +
substitutions O +
( O -
discussed O +
above O -
) O +
causes O +
an O +
overall O +
conformational O +
change O +
that O +
reduces O +
dimer O +
formation O -
. O +

An O +
Ala81Leu O +
mutation O +
did O +
not O +
reduce O +
cross O -
- O -
linking O +
via O +
Cys80 O -
, O +
even O +
though O +
single O -
- O -
cysteine O +
Ala81Cys O +
molecules O +
themselves O +
produced O +
a O +
high O +
level O +
of O +
cross O -
- O -
linking O -
. O +

These O +
results O -
, O +
together O +
with O +
data O +
on O +
Gly32Leu O +
and O +
Gly67Leu O +
mutations O -
, O +
are O +
consistent O +
with O +
our O +
model O +
predicting O +
that O +
helices O +
1 O +
and O +
2 O +
interact O +
more O +
tightly O +
near O +
the O +
extracellular O +
end O +
and O +
less O +
at O +
the O +
cytoplasmic O +
end O -
. O +

This O +
would O +
give O +
more O +
flexibility O +
to O +
a O +
cysteine O +
at O +
position O +
81 O +
and O +
also O +
limit O +
the O +
effect O +
of O +
an O +
Ala81Leu O +
mutation O -
. O +

Location O +
of O +
this O +
residue O +
at O +
the O +
membrane O -
/ O -
cytoplasmic O +
border O +
could O +
also O +
make O +
it O +
more O +
accessible O +
to O +
CuP O +
reagent O +
as O +
compared O +
to O +
residues O +
buried O +
in O +
TM O +
domain O -
, O +
thus O +
elevating O +
the O +
efficiency O +
of O +
disulfide O +
formation O +
of O +
the O +
Ala81Cys O +
mutant O -
. O +

Multiple O +
interfaces O +
in O +
tetraspanin O +
molecules O +
In O +
the O +
full O -
- O -
length O +
CD9 O +
molecules O -
, O +
the O +
3 O +
C O -
- O -
terminal O +
cysteines O +
( O -
Cys87 O -
, O +
218 O +
and O +
219 O -
) O +
located O +
at O +
or O +
in O +
TM3 O +
and O +
TM4 O +
promoted O +
efficient O +
dimer O +
and O +
even O +
more O +
efficient O +
oligomer O +
formation O +
compared O +
to O +
the O +
3 O +
N O -
- O -
terminal O +
cysteines O +
( O -
Figure O +
9 O -
) O -
. O +

Cys87 O +
alone O +
can O +
be O +
used O +
to O +
capture O +
CD9 O +
dimers O +
[ O -
25 O -
] O -
. O +

These O +
results O +
suggest O +
the O +
existence O +
of O +
two O +
dimeric O +
interfaces O +
in O +
CD9 O +
molecule O +
– O +
the O +
TM O +
1 O -
- O -
2 O -
/ O -
1 O -
- O -
2 O +
interface O +
and O +
the O +
TM O +
3 O -
- O -
4 O -
/ O -
3 O -
- O -
4 O +
interface O +
( O -
Figure O +
10 O -
) O -
. O +

In O +
a O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
molecule O -
, O +
the O +
destabilization O +
of O +
1–2 O +
interaction O -
, O +
e.g. O +
by O +
Gly→Leu O +
mutations O -
, O +
would O +
affect O +
the O +
1 O -
- O -
2 O -
/ O -
1 O -
- O -
2 O +
interface O -
, O +
as O +
discussed O +
above O -
. O +

However O -
, O +
these O +
mutations O +
would O +
not O +
interfere O +
with O +
the O +
3 O -
- O -
4 O -
/ O -
3 O -
- O -
4 O +
interface O +
in O +
a O +
full O -
- O -
length O +
molecule O -
, O +
which O +
includes O +
Cys87 O -
, O +
218 O +
and O +
219 O -
. O +

Thus O -
, O +
cross O -
- O -
linking O +
of O +
full O -
- O -
length O +
molecules O -
, O +
containing O +
all O +
6 O +
cysteine O +
residues O -
, O +
would O +
be O +
unaffected O -
, O +
as O +
seen O +
in O +
Figure O +
8C O -
. O +

Furthermore O -
, O +
wild O -
- O -
type O +
Cys9 O -
, O +
Cys78 O +
and O +
Cys79 O +
are O +
apparently O +
not O +
at O +
the O +
primary O +
1 O -
- O -
2 O -
/ O -
1 O -
- O -
2 O +
interface O -
. O +

Their O +
relative O +
inefficiency O +
in O +
cross O -
- O -
linking O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
protein O +
likely O +
reflects O +
weak O +
secondary O +
contacts O +
between O +
the O +
molecules O -
, O +
or O +
possibly O +
random O +
collision O +
events O -
. O +

Such O +
events O +
should O +
be O +
independent O +
of O +
mutations O +
in O +
the O +
conserved O +
Gly O +
residues O +
in O +
TM1 O +
and O +
TM2 O -
, O +
as O +
was O +
demonstrated O +
in O +
Figure O +
8B O -
. O +

The O +
potential O +
existence O +
of O +
two O +
interfaces O +
in O +
tetraspanin O +
molecules O -
, O +
1 O -
- O -
2 O -
/ O -
1 O -
- O -
2 O +
and O +
3 O -
- O -
4 O -
/ O -
3 O -
- O -
4 O -
, O +
should O +
provide O +
enhanced O +
flexibility O +
for O +
forming O +
additional O +
intermolecular O +
contacts O -
. O +

Current O +
understanding O +
of O +
tetraspanin O +
microdomains O +
assumes O +
a O +
few O +
strong O -
, O +
primary O +
homotypic O +
and O +
heterotypic O +
tetraspanin O +
complexes O +
( O -
e.g. O +
CD9-CD9 O -
, O +
CD9-CD81 O -
, O +
CD151-α3 O +
integrin O -
, O +
CD81-EWI2 O -
) O +
that O +
help O +
bring O +
together O +
various O +
other O +
proteins O -
, O +
forming O +
secondary O -
- O -
type O +
associations O -
. O +

Such O +
properties O +
of O +
tetraspanins O +
may O +
bring O +
signaling O +
molecules O +
such O +
as O +
protein O +
kinase O +
C O +
or O +
phosphatidylinositol O +
4-kinase O +
to O +
the O +
vicinity O +
of O +
integrins O +
[ O -
67,68 O -
] O -
. O +

The O +
organization O +
of O +
the O +
TM3 O +
domain O +
points O +
to O +
a O +
potential O +
role O +
in O +
protein O -
- O -
protein O +
interactions O -
. O +

A O +
motif O +
of O +
Leu O -
- O -
Leu O -
- O -
Glu O -
( O -
Gln O -
) O +
spaced O +
7 O +
residues O +
apart O +
( O -
heptad O +
positions O +
a O -
) O -
, O +
with O +
highly O +
conserved O +
residues O +
in O +
two O +
consecutive O +
positions O +
d O -
, O +
poses O +
as O +
a O +
likely O +
interaction O +
module O -
. O +

If O +
responsible O +
for O +
heterologous O +
protein O -
- O -
protein O +
interactions O -
, O +
it O +
would O +
form O +
another O +
distinct O +
interface O +
of O +
tetraspanin O +
molecule O -
. O +

Our O +
preliminary O +
data O +
indicate O +
that O +
replacing O +
the O +
Leu O +
and O +
Glu O +
residues O +
in O +
TM3 O +
of O +
CD9 O +
with O +
Ala O +
has O +
no O +
effect O +
on O +
cell O +
surface O +
expression O +
of O +
the O +
protein O +
and O +
its O +
dimerization O +
( O -
data O +
not O +
shown O -
) O -
. O +

It O +
remains O +
to O +
be O +
tested O +
if O +
interactions O +
with O +
other O +
proteins O +
will O +
be O +
affected O -
. O +

Similarly O -
, O +
the O +
TM4 O +
domain O +
may O +
provide O +
additional O +
contributions O +
to O +
lateral O +
tetraspanin O +
associations O -
. O +

Much O +
higher O +
sequence O +
variability O -
, O +
and O +
the O +
lack O +
of O +
a O +
distinct O +
heptad O +
pattern O +
suggests O +
that O +
TM4 O +
is O +
a O +
major O +
contributor O +
to O +
diversity O +
among O +
tetraspanin O +
complexes O -
. O +

Structure O -
- O -
function O +
analysis O +
of O +
TM3 O +
and O +
TM4 O +
domains O +
in O +
tetraspanins O +
is O +
the O +
subject O +
of O +
ongoing O +
investigation O -
. O +

Conclusion O +
We O +
have O +
defined O +
the O +
TM1-TM2 O +
intramolecular O +
interface O +
in O +
tetraspanin O +
CD9 O -
, O +
providing O +
evidence O +
for O +
glycines O +
( O -
Gly25 O +
and O +
Gly32 O +
in O +
TM1 O -
, O +
Gly67 O +
and O +
Gly74 O +
in O +
TM2 O -
) O +
packing O +
against O +
apposing O +
bulky O +
aliphatic O +
residues O -
. O +

Second O -
, O +
we O +
mapped O +
an O +
intermolecular O +
CD9 O +
interface O +
( O -
involved O +
in O +
CD9 O +
homodimer O +
formation O -
) O +
to O +
the O +
vicinity O +
of O +
residues O +
Leu14 O +
and O +
Phe17 O +
in O +
TM1 O +
and O +
Gly77 O -
, O +
Gly80 O +
and O +
Ala81 O +
in O +
TM2 O -
. O +

Finally O -
, O +
we O +
provide O +
preliminary O +
evidence O +
that O +
TM3 O +
and O +
TM4 O +
in O +
CD9 O +
may O +
contribute O +
to O +
a O +
second O +
intermolecular O +
interface O -
. O +

Key O +
CD9 O +
residues O +
involved O +
in O +
intra- O +
and O +
intermolecular O +
interactions O +
are O +
highly O +
conserved O +
throughout O +
the O +
tetraspanin O +
family O -
, O +
thus O +
suggesting O +
that O +
our O +
findings O +
will O +
apply O +
to O +
most O +
tetraspanins O -
. O +

Methods O +
Materials O +
Cell O +
culture O +
reagents O +
were O +
from O +
Invitrogen O +
( O -
Carlsbad O -
, O +
CA O -
) O -
. O +

2-bromopalmitate O +
was O +
from O +
Fluka O +
( O -
Milwaukee O -
, O +
WI O -
) O -
, O +
N O -
- O -
ethylmaleimide O +
( O -
NEM O -
) O +
and O +
1,10-phenanthroline O +
were O +
from O +
Sigma O -
- O -
Aldrich O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
, O +
and O +
chemical O +
cross O -
- O -
linkers O +
dithio O -
- O -
bis O -
- O -
maleimidoethane O +
( O -
DTME O -
) O +
and O +
1,4-Bis O -
- O -
maleimidobutane O +
( O -
BMB O -
) O +
were O +
purchased O +
from O +
Pierce O +
Endogen O +
( O -
Rockford O -
, O +
IL O -
) O -
. O +

Triton O +
X-100 O -
, O +
protease O +
inhibitor O +
cocktail O +
and O +
FuGENE O +
6 O +
transfection O +
reagent O +
were O +
obtained O +
from O +
Roche O +
( O -
Indianapolis O -
, O +
IN O -
) O -
. O +

Restriction O +
endonucleases O +
and O +
Pfu O +
DNA O +
polymerase O +
were O +
obtained O +
New O +
England O +
Biolabs O +
( O -
Beverly O -
, O +
MA O -
) O +
and O +
Stratagene O +
( O -
Carlsbad O -
, O +
CA O -
) O -
, O +
respectively O -
. O +

All O +
other O +
chemicals O +
were O +
purchased O +
from O +
Sigma O -
- O -
Aldrich O +
or O +
Fisher O +
Scientific O +
( O -
Pittsburg O -
, O +
PA O -
) O -
. O +

Sequence O +
analysis O +
Tetraspanin O +
sequences O +
were O +
obtained O +
from O +
SWISS O -
- O -
PROT O +
and O +
GenBank O +
databases O -
. O +

Locus O +
designations O -
, O +
accession O +
numbers O +
and O +
the O +
most O +
commonly O +
used O +
protein O +
names O +
are O +
summarized O +
in O +
Tables O +
1 O +
and O +
2 O -
. O +

TM O +
segments O +
were O +
delineated O +
by O +
inspection O +
of O +
hydrophobicity O +
profiles O -
, O +
using O +
database O +
annotations O +
and O +
previous O +
analyses O +
of O +
TM O +
sequences O +
as O +
a O +
guide O +
( O -
[ O -
28 O -
] O -
, O +
M. O +
Hemler O -
, O +
unpublished O -
) O -
, O +
and O +
aligned O +
manually O -
. O +

Residue O +
numbers O +
in O +
human B-Species +
CD9 O +
sequence O +
are O +
used O +
a O +
reference O +
point O +
throughout O +
the O +
study O -
. O +

DNA O +
cloning O +
and O +
mutagenesis O +
Sequence O +
encoding O +
CD9 O +
protein O +
was O +
cloned O +
into O +
vector O +
pcDNA3 O +
( O -
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
) O +
and O +
pEGFP O -
- O -
N1 O +
( O -
Clontech O -
, O +
Palo O +
Alto O -
, O +
CA O -
) O -
, O +
for O +
expression O +
of O +
untagged O +
and O +
C O -
- O -
terminally O +
GFP O -
- O -
tagged O +
CD9 O -
, O +
respectively O -
. O +

pEGFP O -
- O -
N1 O +
encoding O +
CD9 O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
-GFP O +
fusion O +
protein O +
was O +
constructed O +
by O +
subcloning O +
DNA O +
for O +
residues O +
1–83 O +
of O +
CD9 O +
into O +
HindIII O +
and O +
PstI O +
sites O +
of O +
the O +
vector O -
; O +
to O +
introduce O +
the O +
PstI O +
site O -
, O +
codon O +
GTG O +
for O +
Val82 O +
was O +
changed O +
to O +
CTG O +
( O -
coding O +
for O +
Ala O -
) O -
. O +

In O +
the O +
resulting O +
fusion O +
protein O -
, O +
there O +
is O +
a O +
13-amino O +
acid O +
linker O +
( O -
with O +
no O +
cysteines O -
) O +
between O +
CD9 O +
and O +
GFP O -
. O +

To O +
minimize O +
the O +
low O +
inherent O +
ability O +
of O +
GFP O +
to O +
homodimerize O -
, O +
which O +
could O +
potentially O +
influence O +
the O +
results O +
of O +
CD9 O +
cross O -
- O -
linking O -
, O +
we O +
used O +
a O +
monomeric O +
GFP O +
mutant O -
, O +
Leu221→Lys O +
[ O -
34 O -
] O -
, O +
for O +
cross O -
- O -
linking O +
experiments O -
. O +

Mutations O +
were O +
introduced O +
in O +
full O -
- O -
length O +
and O +
TM O -
( O -
1 O -
+ O -
2 O -
) O +
CD9 O +
proteins O +
by O +
a O +
PCR O -
- O -
based O +
strategy O +
using O +
mutagenic O +
primers O +
and O +
Pfu O +
DNA O +
polymerase O -
. O +

All O +
mutations O +
were O +
confirmed O +
by O +
DNA O +
sequencing O -
. O +

Protein O +
expression O -
, O +
microscopy O -
, O +
cysteine O +
disulfide O +
cross O -
- O -
linking O +
and O +
Western O +
blotting O +
DNA O +
constructs O +
encoding O +
TM O -
( O -
1 O -
+ O -
2 O -
) O -
-GFP O +
or O +
full O -
- O -
length O +
CD9 O +
proteins O +
were O +
transfected O +
into O +
human B-Species +
rhabdomyosarcoma O +
RD O +
cells O +
using O +
the O +
FuGENE O +
6 O +
reagent O -
. O +

Cells O +
expressing O +
GFP O +
fusion O +
proteins O +
were O +
analysed O +
by O +
fluorescence O +
microscopy O +
18–28 O +
hours O +
post O -
- O -
transfection O -
. O +

Images O +
were O +
captured O +
using O +
Spot O +
1.4.0 O +
camera O +
( O -
Diagnostic O +
Instruments O -
, O +
Sterling O +
Heights O -
, O +
MI O -
) O +
attached O +
to O +
Nikon O +
Eclipse O +
TE300 O +
microscope O -
. O +

For O +
experiments O +
involving O +
cysteine O -
- O -
mediated O +
cross O -
- O -
linking O -
, O +
cells O +
were O +
treated O +
with O +
50 O +
μM O +
2-BP O +
starting O +
24–26 O +
hours O +
post O -
- O -
transfection O +
and O +
continuing O +
for O +
16–18 O +
hours O -
. O +

Cross O -
- O -
linking O +
was O +
carried O +
out O +
by O +
incubating O +
cells O +
in O +
HBSM O +
buffer O +
( O -
25 O +
mM O +
Hepes O -
- O -
NaOH O -
, O +
pH O +
7.2 O -
, O +
150 O +
mM O +
NaCl O -
, O +
2 O +
mM O +
MgCl2 O -
) O +
containing O +
either O +
a O -
) O +
0.6 O +
mM O +
CuSO4 O +
and O +
1.8 O +
mM O +
1,10-phenanthroline O +
( O -
CuP O +
complex O -
) O +
or O +
b O -
) O +
0.2 O +
mg O -
/ O -
ml O +
homobifunctional O +
cysteine O -
- O -
reactive O +
cross O -
- O -
linker O +
( O -
e.g. O +
DTME O -
) O -
, O +
diluted O +
from O +
fresh O +
10 O +
mg O -
/ O -
ml O +
solution O +
in O +
DMSO O -
. O +

After O +
incubation O +
for O +
10–15 O +
minutes O +
( O -
with O +
CuP O -
) O +
or O +
30–45 O +
minutes O +
( O -
with O +
cross O -
- O -
linker O -
) O -
, O +
cells O +
were O +
washed O +
twice O +
for O +
10 O +
minutes O +
with O +
HBSM O +
containing O +
10 O +
mM O +
NEM O +
to O +
block O +
residual O +
free O +
cysteines O -
. O +

Cells O +
were O +
lysed O +
in O +
HBSM O +
containing O +
1 O -
% O +
Triton O +
X-100 O -
, O +
0.1 O -
% O +
SDS O +
and O +
a O +
cocktail O +
of O +
protease O +
inhibitors O +
with O +
1 O +
mM O +
EDTA O +
at O +
4 O -
° O -
C O +
for O +
45–60 O +
minutes O -
. O +

Cell O +
lysate O +
was O +
clarified O +
by O +
centrifugation O +
at O +
14,000 O +
× O +
g O +
for O +
15 O +
minutes O -
, O +
an O +
aliquot O +
was O +
removed O -
, O +
and O +
proteins O +
from O +
it O +
were O +
precipitated O +
by O +
addition O +
of O +
trichloroacetic O +
acid O +
to O +
10 O -
% O +
on O +
ice O +
followed O +
by O +
centrifugation O +
at O +
14,000 O +
× O +
g O +
for O +
10 O +
minutes O -
. O +

After O +
two O +
washes O +
with O +
ice O -
- O -
cold O +
acetone O -
, O +
protein O +
pellet O +
was O +
solubilized O +
in O +
SDS O -
- O -
PAGE O +
sample O +
buffer O +
without O +
a O +
reducing O +
agent O +
( O -
50 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
6.8 O -
, O +
1 O -
% O +
SDS O -
, O +
8 O -
% O +
glycerol O -
) O -
. O +

In O +
some O +
experiments O -
, O +
CD9 O +
protein O +
was O +
immunoprecipitated O +
using O +
monoclonal O +
antibody O +
Alb6 O +
( O -
Immunotech O -
, O +
Marseille O -
, O +
France O -
) O -
. O +

Proteins O +
were O +
separated O +
by O +
SDS O -
- O -
PAGE O +
and O +
analyzed O +
by O +
Western O +
blotting O +
using O +
monoclonal O +
antibody O +
JL-8 O +
( O -
Clontech O -
) O +
for O +
GFP O +
or O +
Alb6 O +
for O +
CD9 O -
. O +

Bands O +
from O +
X O -
- O -
ray O +
films O +
were O +
quantitated O +
using O +
GeneTools O -
™ O +
software O +
from O +
Syngene O +
( O -
Frederick O -
, O +
MD O -
) O -
. O +

Modeling O +
of O +
TM1-TM2 O +
interaction O +
An O +
atomic O +
model O +
of O +
the O +
CD9 O +
TM1-TM2 O +
dimer O +
was O +
constructed O +
with O +
a O +
Monte O +
Carlo O -
- O -
simulated O +
annealing O +
( O -
MCSA O -
) O +
algorithm O +
[ O -
69 O -
] O -
. O +

Two O +
idealized O +
α O -
- O -
helices O +
corresponding O +
to O +
TM1 O +
residues O +
Tyr12 O +
through O +
Leu35 O +
and O +
TM2 O +
residues O +
Gly59 O +
through O +
Val82 O +
were O +
docked O +
with O +
six O +
orthogonal O +
parameters O -
: O +
three O +
rigid O +
body O +
translations O +
and O +
three O +
rotations O -
. O +

During O +
each O +
step O +
of O +
a O +
MCSA O +
cycle O -
, O +
there O +
was O +
an O +
equal O +
probability O +
of O +
changing O +
either O +
one O +
parameter O +
or O +
all O +
six O +
parameters O +
to O +
random O +
values O -
. O +

A O +
conformation O -
's O +
energy O +
was O +
calculated O +
in O +
vacuo O +
with O +
the O +
AMBER O +
united O -
- O -
atom O +
force O +
field O +
for O +
van O +
der O +
Waals O +
interactions O +
[ O -
70 O -
] O -
. O +

The O +
van O +
der O +
Waals O +
term O +
was O +
modified O +
as O +
described O +
by O +
Kuhlman O +
and O +
Baker O +
[ O -
71 O -
] O -
. O +

If O +
a O +
structure O +
had O +
favorable O +
dimerization O +
energy O -
, O +
the O +
energies O +
of O +
select O +
mutants O +
were O +
calculated O -
. O +

Structures O +
were O +
selected O +
with O +
a O +
novel O +
scoring O +
function O +
that O +
maximizes O +
the O +
Boltzmann O +
probability O +
of O +
dimerization O +
for O +
silent O +
mutations O +
while O +
minimizing O +
the O +
probability O +
for O +
disruptive O +
mutations O -
. O +

Asn18Ser O -
, O +
Gly77Leu O -
, O +
and O +
Gly80Leu O +
were O +
scored O +
as O +
silent O +
mutations O +
while O +
Gly25Leu O -
, O +
Gly32Leu O -
, O +
Gly67Leu O -
, O +
and O +
Gly74Leu O +
were O +
considered O +
to O +
be O +
disruptive O -
. O +

Each O +
MCSA O +
cycle O +
consisted O +
of O +
50,000 O +
steps O +
with O +
an O +
exponential O +
temperature O +
decay O +
from O +
10,000 O +
to O +
10 O +
K. O +
Ten O +
MCSA O +
cycles O +
through O +
global O +
sample O +
space O +
were O +
used O +
to O +
restrict O +
the O +
search O +
area O -
. O +

Parameters O +
were O +
restricted O +
to O +
± O +
2 O +
standard O +
deviations O +
from O +
their O +
mean O +
value O +
for O +
structures O +
within O +
10 O +
kcal O +
of O +
the O +
best O +
structure O -
. O +

MCSA O +
cycles O +
were O +
repeated O +
as O +
described O +
above O +
with O +
additional O +
optimization O +
of O +
χ O +
values O -
: O +
rotamers O +
at O +
the O +
protein O -
- O -
protein O +
interface O +
were O +
optimized O +
with O +
Dead O +
End O +
Elimination O +
[ O -
72 O -
] O -
, O +
and O +
χ O +
values O +
were O +
further O +
optimized O +
with O +
Monte O +
Carlo O -
. O +

All O +
MCSA O +
cycles O +
converged O +
upon O +
structures O +
that O +
were O +
within O +
a O +
root O +
mean O +
squared O +
deviation O +
( O -
RMSD O -
) O +
of O +
1.5 O +
Å O +
with O +
the O +
best O +
structure O -
, O +
and O +
structures O +
that O +
scored O +
within O +
5 O +
kcal O +
of O +
the O +
best O +
score O +
had O +
an O +
RMSD O +
of O +
less O +
than O +
0.5 O +
Å O +
with O +
the O +
best O +
structure O -
. O +

List O +
of O +
abbreviations O +
2-BP O -
, O +
2-bromopalmitate O -
; O +
CuP O -
, O +
Cu2 O -
+ O -
-phenanthroline O -
; O +
DTME O -
, O +
dithio O -
- O -
bis O -
- O -
maleimidoethane O -
; O +
LEL O -
, O +
large O +
extracellular O +
loop O -
; O +
NEM O -
, O +
N O -
- O -
ethylmaleimide O -
; O +
TM O -
, O +
transmembrane O +
( O -
domain O -
) O -
. O +

Authors O -
' O +
contributions O +
OVK O +
carried O +
out O +
sequence O +
comparisons O -
, O +
mutational O +
analysis O +
and O +
cross O -
- O -
linking O +
experiments O -
, O +
and O +
drafted O +
the O +
manuscript O -
. O +

DGM O +
built O +
the O +
TM1-TM2 O +
interaction O +
model O +
and O +
contributed O +
to O +
the O +
manuscript O -
. O +

WFD O +
supervised O +
DGM O -
's O +
work O -
. O +

MEH O +
coordinated O +
the O +
whole O +
study O +
and O +
prepared O +
the O +
final O +
manuscript O -
. O +

Gender O +
differences O +
in O +
factors O +
influencing O +
insulin O +
resistance O +
in O +
elderly O +
hyperlipemic O +
non O -
- O -
diabetic O +
subjects O +
Abstract O +
Background O +
The O +
increase O +
in O +
the O +
prevalence O +
of O +
insulin O +
resistance O -
- O -
related O +
metabolic O +
syndrome O -
, O +
a O +
disorder O +
that O +
greatly O +
increases O +
the O +
risk O +
of O +
diabetes O -
, O +
heart O +
attack O +
and O +
stroke O -
, O +
is O +
alarming O -
. O +

One O +
of O +
the O +
most O +
frequent O +
and O +
early O +
symptoms O +
of O +
metabolic O +
syndrome O +
is O +
hypertriglyceridemia O -
. O +

We O +
examined O +
the O +
gender O +
differences O +
between O +
various O +
metabolic O +
factors O +
related O +
to O +
insulin O +
resistance O +
in O +
elderly O +
non O -
- O -
diabetic O +
men O +
and O +
postmenopausal O +
women O +
of O +
comparable O +
age O +
suffering O +
from O +
hypertriglyceridemia O -
, O +
and O +
compared O +
them O +
with O +
healthy O +
subjects O +
of O +
equal O +
age O -
. O +

Results O +
The O +
indexes O +
of O +
insulin O +
resistance O +
HOMA O +
IR O +
and O +
QUICKI O +
were O +
significantly O +
higher O +
in O +
both O +
hyperlipemic O +
men O +
and O +
women O +
than O +
in O +
controls O -
; O +
95 O -
% O +
confidence O +
limits O +
of O +
hyperlipemic O +
subjects O +
did O +
not O +
overlap O +
with O +
controls O -
. O +

In O +
both O +
normolipemic O +
and O +
hyperlipemic O +
men O +
and O +
women O +
serum O +
leptin O +
correlated O +
significantly O +
with O +
insulin O +
resistance O -
, O +
while O +
HDL O -
- O -
cholesterol O +
correlated O +
inversely O +
with O +
HOMA O -
- O -
IR O +
only O +
in O +
women O +
( O -
both O +
normo- O +
and O +
hyperlipemic O -
) O -
, O +
and O +
serum O +
tumor O +
necrosis O +
factor O +
α O +
( O -
TNFα O -
) O +
only O +
in O +
hyperlipemic O +
women O -
. O +

According O +
to O +
results O +
of O +
multiple O +
regression O +
analysis O +
with O +
HOMA O -
- O -
IR O +
as O +
a O +
dependent O +
variable O -
, O +
leptin O +
played O +
a O +
significant O +
role O +
in O +
determining O +
insulin O +
resistance O +
in O +
both O +
genders O -
, O +
but O +
– O +
aside O +
from O +
leptin O +
– O +
triglycerides O -
, O +
TNFα O +
and O +
decreased O +
HDL O -
- O -
cholesterol O +
were O +
significant O +
determinants O +
in O +
women O -
, O +
while O +
body O +
mass O +
index O +
and O +
decreased O +
HDL O -
- O -
cholesterol O +
were O +
significant O +
determinants O +
in O +
men O -
. O +

The O +
coefficient O +
of O +
determination O +
( O -
R2 O -
) O +
of O +
HOMA O +
IR O +
by O +
above O +
mentioned O +
metabolic O +
variables O +
was O +
in O +
women O +
above O +
60 O -
% O -
, O +
in O +
men O +
only O +
about O +
40 O -
% O -
. O +

Conclusion O +
The O +
significant O +
role O +
of O +
serum O +
leptin O +
in O +
determination O +
of O +
insulin O +
resistance O +
in O +
both O +
elderly O +
men O +
and O +
postmenopausal O +
women O +
of O +
equal O +
age O +
was O +
confirmed O -
. O +

However O -
, O +
the O +
study O +
also O +
revealed O +
significant O +
gender O +
differences O +
: O +
in O +
women O +
a O +
strong O +
influence O +
of O +
triglycerides O -
, O +
TNFα O +
and O +
decreased O +
HDL O -
- O -
cholesterol O -
, O +
in O +
men O +
only O +
a O +
mild O +
role O +
of O +
BMI O +
and O +
decreased O +
HDL O -
- O -
cholesterol O -
. O +

Background O +
In O +
association O +
with O +
pandemic O +
obesity O +
the O +
prevalence O +
of O +
the O +
insulin O +
resistance O -
- O -
related O +
metabolic O +
syndrome O +
is O +
constantly O +
growing O +
[ O -
1 O -
] O -
. O +

As O +
a O +
consequence O +
of O +
this O +
fact O -
, O +
type O +
2 O +
diabetes O +
mellitus O +
and O +
cardiovascular O +
mortality O +
occurs O +
in O +
much O +
younger O +
age O +
groups O +
[ O -
2 O -
] O -
. O +

A O +
typical O +
hyperlipemia O -
, O +
consisting O +
of O +
an O +
increase O +
of O +
serum O +
triglycerides O +
and O +
a O +
decrease O +
of O +
serum O +
HDL O -
- O -
cholesterol O -
, O +
is O +
a O +
characteristic O +
and O +
an O +
early O +
symptom O +
of O +
this O +
syndrome O +
[ O -
3 O -
] O -
. O +

With O +
increasing O +
age O -
, O +
body O +
mass O +
index O +
( O -
BMI O -
) O +
and O +
adiposity O -
, O +
insulin O +
sensitivity O +
declines O +
and O +
the O +
number O +
of O +
cardiovascular O +
risk O +
factors O +
increases O +
in O +
both O +
genders O +
[ O -
4 O -
- O -
6 O -
] O -
. O +

It O +
was O +
repeatedly O +
demonstrated O +
that O +
plasma O +
concentration O +
of O +
leptin O +
– O +
a O +
hormone O +
produced O +
mainly O +
by O +
adipose O +
tissue O +
– O +
is O +
substantially O +
higher O +
in O +
all O +
age O +
groups O +
of O +
women O +
than O +
in O +
men O +
[ O -
7 O -
- O -
10 O -
] O -
. O +

This O +
may O +
be O +
caused O +
by O +
different O +
size O +
and/or O +
distribution O +
of O +
fat O +
tissue O +
compartments O +
influenced O +
by O +
hormones O -
: O +
estrogens O +
stimulate O -
, O +
whereas O +
testosterone O +
inhibits O +
leptin O +
secretion O -
. O +

In O +
women O +
subcutaneous O +
fat O +
mass O +
prevails O +
– O +
and O +
during O +
augmentation O +
of O +
overweight O +
it O +
increases O +
– O +
while O +
in O +
men O +
intra O -
- O -
abdominal O +
fat O +
mass O +
prevails O +
[ O -
11 O -
- O -
13 O -
] O -
. O +

Subcutaneous O +
fat O +
in O +
particular O +
serves O +
as O +
a O +
substantial O +
source O +
of O +
tumor O +
necrosis O +
factor O +
α O +
( O -
TNFα O -
) O -
, O +
which O +
represents O +
one O +
of O +
the O +
factors O +
that O +
interfere O +
with O +
insulin O +
signal O +
transduction O +
into O +
the O +
cells O +
[ O -
14 O -
- O -
16 O -
] O -
. O +

Leptin O -
, O +
TNFα O +
and O +
some O +
other O +
factors O +
are O +
abundantly O +
expressed O +
in O +
adipose O +
tissue O +
and O +
contribute O +
to O +
the O +
insulin O +
resistance O +
that O +
accompanies O +
overweight O +
and O +
obesity O -
. O +

Leptin O +
correlates O +
positively O +
with O +
hyperinsulinemia O -
, O +
BMI O -
, O +
fat O +
mass O +
and O +
hypertriglyceridemia O -
, O +
respectively O -
, O +
and O +
correlates O +
inversely O +
with O +
HDL O -
- O -
cholesterol O +
and O +
lean O +
body O +
mass O +
[ O -
17 O -
- O -
25 O -
] O -
. O +

The O +
incidence O +
and O +
mortality O +
of O +
ischemic O +
heart O +
disease O +
and O +
of O +
other O +
consequences O +
of O +
atherosclerosis O +
increases O +
with O +
age O +
in O +
both O +
genders O -
, O +
especially O +
after O +
the O +
age O +
of O +
sixty O -
. O +

In O +
premenopausal O +
women O -
, O +
however O -
, O +
the O +
incidence O +
of O +
these O +
disorders O +
is O +
considerably O +
less O +
frequent O +
than O +
in O +
men O +
of O +
appropriate O +
age O -
. O +

After O +
the O +
menopause O +
the O +
prevalence O +
of O +
metabolic O +
syndrome O +
and O +
cardiovascular O +
mortality O +
in O +
women O +
gradually O +
increases O -
, O +
attaining O +
values O +
comparable O +
to O +
men O +
at O +
about O +
the O +
age O +
of O +
70 O +
[ O -
2,26 O -
] O -
. O +

Paradoxically O -
, O +
it O +
takes O +
place O +
at O +
the O +
time O +
when O +
serum O +
leptin O +
concentration O +
in O +
women O +
has O +
relatively O +
decreased O +
[ O -
27,28 O -
] O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
analyze O +
the O +
interrelations O +
between O +
several O +
metabolic O +
variables O +
and O +
factors O +
related O +
to O +
insulin O +
resistance O +
in O +
groups O +
of O +
both O +
normal O +
and O +
hyperlipemic O +
postmenopausal O +
women O +
and O +
men O +
of O +
appropriate O +
age O -
, O +
and O +
to O +
attempt O +
to O +
elucidate O +
the O +
gender O +
differences O +
and O +
some O +
pathophysiologic O +
mechanisms O +
of O +
these O +
differences O -
. O +

We O +
compared O +
homeostatic O +
indexes O +
of O +
insulin O +
resistance O +
HOMA O +
IR O +
and O +
QUICKI O -
, O +
serum O +
lipid O +
and O +
insulin O +
parameters O -
, O +
uric O +
acid O -
, O +
leptin O +
and O +
TNFα O +
between O +
groups O +
of O +
subjects O +
without O +
apparent O +
symptoms O +
of O +
metabolic O +
syndrome O -
, O +
and O +
groups O +
showing O +
mild O +
hypertriglyceridemia O +
with O +
decreased O +
HDL O -
- O -
cholesterol O -
. O +

In O +
addition O -
, O +
serum O +
concentration O +
of O +
the O +
heart O +
fraction O +
of O +
fatty O +
acid O +
binding O +
protein O +
( O -
hFATP O -
) O +
was O +
explored O +
as O +
a O +
factor O +
that O +
might O +
reflect O +
the O +
regulative O +
role O +
of O +
PPAR O +
gamma O +
in O +
lipid O +
homeostasis O +
[ O -
29,30 O -
] O -
, O +
and O +
serum O +
IgG O +
anticardiolipin O +
( O -
ACL O -
- O -
IgG O -
) O +
was O +
investigated O +
as O +
an O +
indirect O +
indicator O +
of O +
oxidized O +
lipid O +
fractions O +
related O +
to O +
atherosclerotic O +
complications O +
[ O -
31,32 O -
] O -
. O +

Methods O +
Subjects O +
The O +
study O +
was O +
carried O +
out O +
on O +
70 O +
out O -
- O -
patients O +
of O +
the O +
Metabolic O +
Center O +
at O +
the O +
hospital O +
in O +
Sternberk O -
, O +
Czech O +
Republic O -
. O +

From O +
these O -
, O +
40 O +
patients O +
( O -
20 O +
men O +
and O +
20 O +
women O -
) O +
were O +
selected O +
with O +
mild O +
hyperlipidemia O -
, O +
i.e. O +
with O +
plasma O +
triglyceride O +
concentration O +
exceeding O +
2.0 O +
mmol O -
/ O -
l O -
, O +
total O +
cholesterol O +
exceeding O +
6.0 O +
mmol O -
/ O -
l O -
, O +
LDL O +
cholesterol O +
exceeding O +
4.0 O +
mmol O -
/ O -
l O -
, O +
and O +
with O +
HDL O +
cholesterol O +
concentration O +
in O +
men O +
under O +
1.0 O +
mmol O -
/ O -
l O -
, O +
and O +
in O +
women O +
under O +
1.2 O +
mmol O -
/ O -
l O -
. O +

These O +
groups O +
were O +
denominated O +
as O +
" O -
hyperlipemic O -
" O -
. O +

Two O +
other O +
groups O +
( O -
10 O +
men O +
and O +
20 O +
women O -
) O +
with O +
approximately O +
normal O +
serum O +
values O +
of O +
these O +
variables O +
were O +
taken O +
as O +
" O -
controls O -
" O -
. O +

The O +
average O +
age O +
in O +
men O +
was O +
59.1 O +
± O +
10.6 O +
y O -
, O +
and O +
in O +
women O +
59.4 O +
± O +
10.1 O +
y O -
, O +
respectively O -
. O +

The O +
differences O +
between O +
lipid O +
parameters O +
of O +
hyperlipemic O +
and O +
control O +
groups O +
were O +
highly O +
statistically O +
significant O -
, O +
while O +
the O +
age O +
differences O +
were O +
insignificant O +
( O -
see O +
Table O +
1 O -
) O -
. O +

None O +
of O +
the O +
patients O +
had O +
clinically O +
apparent O +
diabetes O +
mellitus O -
, O +
but O +
some O +
of O +
the O +
hyperlipemic O +
patients O +
exerted O +
impaired O +
glucose O +
tolerance O +
or O +
impaired O +
fasting O +
glucose O +
( O -
values O +
between O +
6.1 O +
and O +
7.0 O +
mmol O -
/ O -
l O -
, O +
or O +
between O +
6.1 O +
and O +
7.8 O +
mmol O -
/ O -
l O -
, O +
respectively O -
) O -
. O +

None O +
of O +
the O +
patients O +
was O +
treated O +
with O +
insulin O -
, O +
peroral O +
antidiabetics O +
or O +
antihyperlipemic O +
drugs O -
; O +
some O +
of O +
them O +
were O +
treated O +
with O +
antihypertensive O +
therapy O -
. O +

No O +
signs O +
of O +
major O +
clinical O +
or O +
laboratory O +
symptoms O +
of O +
other O +
diseases O +
were O +
present O +
in O +
any O +
group O +
of O +
the O +
explored O +
patients O -
. O +

Blood O +
samples O +
were O +
obtained O +
in O +
the O +
morning O +
via O +
a O +
venipuncture O +
after O +
overnight O +
fasting O -
. O +

After O +
clotting O +
the O +
serum O +
was O +
separated O +
and O +
stored O +
at O +
-20 O -
° O +
until O +
used O -
. O +

An O +
informed O +
consent O +
was O +
obtained O +
from O +
all O +
probands O -
. O +

Body O +
mass O +
indexes O +
( O -
BMI O -
) O -
, O +
defined O +
as O +
weight O +
in O +
kilograms O +
divided O +
by O +
the O +
square O +
of O +
height O +
in O +
meters O -
, O +
were O +
calculated O -
. O +

Biochemical O +
methods O +
Serum O +
leptin O +
concentrations O +
were O +
measured O +
by O +
a O +
sandwich O +
ELISA O +
test O +
kit O +
( O -
Human B-Species +
Leptin O +
ELISA O -
, O +
BioVendor O +
Laboratory O +
Medicine O -
, O +
Inc O -
, O +
Czech O +
Republic O -
) O -
. O +

Its O +
sensitivity O +
limit O +
was O +
0.2 O +
ng O -
/ O -
ml O -
, O +
intraassay O +
CV O +
6.1 O -
% O +
at O +
the O +
level O +
of O +
7.5 O +
ng O -
/ O -
m O -
, O +
inter O -
- O -
assay O +
CV O +
8.5 O -
% O +
at O +
the O +
level O +
of O +
4.8 O +
ng O -
/ O -
ml O -
. O +

Tetramethylbenzidine O +
was O +
used O +
as O +
a O +
substrate O -
; O +
quality O +
controls O +
were O +
human B-Species +
based O -
. O +

Several O +
other O +
hormones O +
and O +
peptides O +
were O +
estimated O +
by O +
routine O +
immunochemical O +
tests O -
: O +
insulin O -
, O +
C O -
- O -
peptide O -
, O +
TNFα O +
( O -
IMMULITE O -
, O +
Diagnostic O +
Products O +
Corporation O -
, O +
Los O +
Angeles O -
, O +
CA O -
, O +
U.S.A. O -
) O -
, O +
proinsulin O +
intact O +
( O -
DAKO O -
, O +
Denmark O -
) O -
, O +
IgG O +
anticardiolipin O +
( O -
ACL O -
- O -
IgG O -
, O +
IMMCO O +
Diagnostics O -
, O +
Buffalo O -
, O +
NY O -
, O +
U.S.A. O -
) O +
and O +
heart O +
fatty O +
acid O +
binding O +
protein O +
( O -
hFABP O -
, O +
Hbt O +
HUMAN O +
H O -
- O -
FABP O -
, O +
HyCult O +
Biotechnology O -
, O +
Uden O -
, O +
the O +
Netherlands O -
) O -
. O +

Serum O +
concentration O +
of O +
glucose O -
, O +
total O +
cholesterol O -
, O +
triglycerides O -
, O +
HDL O -
- O -
cholesterol O -
, O +
LDL O -
- O -
cholesterol O -
, O +
Apoprotein O +
B O +
and O +
uric O +
acid O +
were O +
measured O +
on O +
a O +
ILAB-600 O +
biochemical O +
analyzer O +
( O -
Instrumentation O +
Laboratory O -
, O +
Lexington O -
, O +
Ma O -
, O +
U.S.A. O -
) O +
using O +
BioVendor O +
sets O -
. O +

All O +
samples O +
were O +
processed O +
and O +
examined O +
according O +
to O +
principles O +
of O +
good O +
laboratory O +
practice O +
and O +
under O +
constant O +
intralaboratory O +
and O +
external O +
quality O +
control O -
. O +

The O +
homeostatic O +
indexes O +
of O +
insulin O +
resistance O +
( O -
HOMA O +
IR O +
and O +
QUICKI O -
) O +
were O +
calculated O +
according O +
to O +
the O +
homeostasis O +
model O +
of O +
assessment O +
[ O -
33 O -
- O -
35 O -
] O +
as O +
follows O -
: O +
HOMA O +
IR O +
= O +
fasting O +
insulin O +
( O -
μU O -
/ O -
ml O -
) O +
* O +
fasting O +
glucose O +
( O -
mmol O -
/ O -
l O -
) O +
/ O +
22.5 O -
; O +
QUICKI O +
= O +
1 O +
/ O +
[ O -
log O +
fasting O +
insulin O +
( O -
μU O -
/ O -
ml O -
) O +
+ O +
log O +
fasting O +
glucose O +
( O -
mg O -
/ O -
100 O +
ml O -
) O -
] O -
. O +

Statistics O +
Statistical O +
analysis O +
was O +
performed O +
using O +
the O +
Version O +
6 O +
SAS O -
/ O -
STAT O +
software O +
( O -
SAS O +
Institute O -
, O +
Inc. O -
, O +
Cary O -
, O +
NC O -
, O +
U.S.A. O -
) O -
. O +

The O +
Shapiro O -
- O -
Wilks O +
tests O +
were O +
used O +
in O +
testing O +
the O +
normality O +
of O +
distribution O -
. O +

Some O +
of O +
the O +
data O +
obtained O +
were O +
not O +
normally O +
distributed O -
. O +

The O +
statistical O +
significance O +
of O +
differences O +
between O +
the O +
means O +
in O +
the O +
hyperlipemic O +
and O +
control O +
groups O +
were O +
evaluated O +
using O +
the O +
unpaired O +
Student O -
's O +
T O -
- O -
test O +
in O +
the O +
case O +
of O +
normal O +
distribution O +
of O +
data O +
sets O -
, O +
and O +
using O +
the O +
Kolmogorov O -
- O -
Smirnov O +
test O +
when O +
at O +
least O +
in O +
one O +
of O +
the O +
data O +
sets O +
the O +
normal O +
distribution O +
was O +
excluded O -
. O +

Spearman O -
's O +
rank O -
- O -
order O +
correlation O +
was O +
used O +
for O +
correlation O +
analysis O -
. O +

Multiple O +
regression O +
analysis O +
was O +
performed O +
using O +
HOMA O +
IR O +
indexes O +
of O +
insulin O +
resistance O +
as O +
dependent O +
variables O -
, O +
and O +
other O +
metabolic O +
and O +
hormonal O +
factors O +
( O -
lipid O +
parameters O -
, O +
BMI O -
, O +
leptin O -
, O +
TNFα O -
, O +
hFABP O -
, O +
ACL O -
- O -
IgG O -
) O +
as O +
independent O +
variables O -
. O +

The O +
so O -
- O -
called O +
step O -
- O -
down O +
regression O +
model O +
was O +
used O +
to O +
select O +
dominant O +
independent O +
variables O -
. O +

Various O +
four O -
- O -
member O +
groups O +
of O +
independent O +
( O -
explanatory O -
) O +
variables O +
were O +
used O +
for O +
the O +
analysis O +
and O +
the O +
non O -
- O -
zero O +
intercept O +
was O +
taken O +
into O +
account O -
. O +

The O +
independent O +
variables O +
were O +
then O +
dropped O -
, O +
one O +
at O +
a O +
time O -
; O +
at O +
each O +
stage O +
one O +
variable O +
making O +
the O +
least O +
contribution O +
to O +
the O +
dependent O +
variable O +
( O -
i.e. O +
that O +
showed O +
the O +
least O +
p O -
- O -
value O +
in O +
the O +
test O +
of O +
the O +
regression O +
coefficient O +
being O +
zero O -
) O +
was O +
excluded O -
. O +

The O +
coefficient O +
of O +
determination O +
R2 O -
, O +
which O +
can O +
be O +
viewed O +
as O +
a O +
percentage O +
explaining O +
the O +
total O +
variance O -
, O +
was O +
simultaneously O +
monitored O -
. O +

A O +
great O +
drop O +
in O +
R2 O +
after O +
excluding O +
some O +
independent O +
variable O +
enabled O +
selection O +
of O +
those O +
independent O +
variables O +
that O +
could O +
be O +
thought O +
to O +
be O +
the O +
most O +
important O +
determinants O +
of O +
the O +
dependent O +
variable O -
. O +

Results O +
Table O +
1 O +
demonstrates O +
mean O +
parameters O +
in O +
individual O +
groups O +
of O +
subjects O +
matched O +
according O +
to O +
sex O -
, O +
lipid O +
parameters O +
and O +
age O -
. O +

While O +
the O +
age O +
of O +
all O +
four O +
groups O +
did O +
not O +
differ O +
substantially O -
, O +
the O +
concentrations O +
of O +
total O +
serum O +
cholesterol O -
, O +
triglycerides O -
, O +
HDL O -
- O -
cholesterol O +
and O +
LDL O -
- O -
cholesterol O +
differ O +
very O +
significantly O +
in O +
both O +
male O +
and O +
female O +
hyperlipemic O +
groups O +
as O +
compared O +
with O +
controls O -
. O +

In O +
addition O -
, O +
the O +
concentration O +
of O +
triglycerides O +
in O +
control O +
women O +
was O +
significantly O +
higher O +
than O +
in O +
control O +
men O -
, O +
the O +
concentration O +
of O +
triglycerides O +
in O +
hyperlipemic O +
women O +
was O +
lower O +
than O +
in O +
hyperlipemic O +
men O -
, O +
and O +
the O +
concentration O +
of O +
HDL O -
- O -
cholesterol O +
in O +
hyperlipemic O +
women O +
was O +
very O +
significantly O +
higher O +
when O +
compared O +
with O +
hyperlipemic O +
men O -
. O +

Table O +
2 O +
shows O +
the O +
values O +
of O +
other O +
metabolic O +
and O +
insulin O +
parameters O -
, O +
factors O +
related O +
to O +
insulin O +
resistance O +
and O +
indexes O +
of O +
insulin O +
resistance O -
, O +
respectively O -
. O +

Body O +
mass O +
indexes O +
and O +
uric O +
acid O +
concentration O +
were O +
significantly O +
higher O +
in O +
hyperlipemic O +
men O +
as O +
compared O +
to O +
controls O -
, O +
but O +
not O +
in O +
hyperlipemic O +
women O -
. O +

Uric O +
acid O +
concentration O +
was O +
substantially O +
lower O +
in O +
hyperlipemic O +
women O +
than O +
in O +
hyperlipemic O +
men O -
. O +

Plasma O +
concentrations O +
of O +
glycemia O -
, O +
insulin O +
and O +
intact O +
proinsulin O +
were O +
significantly O +
higher O +
in O +
both O +
hyperlipemic O +
men O +
and O +
women O +
as O +
compared O +
with O +
controls O +
of O +
identical O +
gender O -
, O +
while O +
the O +
concentration O +
of O +
leptin O +
increased O +
only O +
in O +
hyperlipemic O +
men O -
. O +

However O -
, O +
serum O +
leptin O +
concentrations O +
of O +
both O +
control O +
and O +
hyperlipemic O +
women O +
were O +
significantly O +
higher O +
than O +
in O +
corresponding O +
groups O +
of O +
men O -
. O +

Serum O +
concentrations O +
of O +
TNFα O -
, O +
hFABP O +
and O +
ACL O -
- O -
IgG O +
in O +
hyperlipemic O +
groups O +
of O +
both O +
men O +
and O +
women O +
were O +
not O +
significantly O +
different O +
from O +
control O +
groups O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
indexes O +
of O +
insulin O +
resistance O +
HOMA O +
IR O +
and O +
QUICKI O +
differed O +
very O +
significantly O +
in O +
hyperlipemic O +
groups O +
of O +
both O +
men O +
and O +
women O +
as O +
compared O +
with O +
corresponding O +
control O +
groups O -
, O +
more O +
distinctly O +
in O +
women O -
. O +

From O +
Fig. O +
1 O -
, O +
presenting O +
95 O -
% O +
confidence O +
limits O +
of O +
insulin O +
resistance O +
indexes O +
HOMA O +
IR O +
and O +
QUICKI O -
, O +
we O +
concluded O +
that O +
in O +
groups O +
of O +
hyperlipemic O +
patients O +
of O +
both O +
genders O +
the O +
insulin O +
resistance O +
was O +
substantially O +
higher O +
than O +
in O +
control O +
groups O -
; O +
the O +
groups O +
did O +
not O +
overlap O +
each O +
other O -
. O +

In O +
Table O +
3 O +
the O +
results O +
of O +
Spearman O -
's O +
correlations O +
between O +
insulin O +
resistance O +
index O +
HOMA O +
IR O +
and O +
various O +
metabolic O +
parameters O +
are O +
presented O -
. O +

In O +
the O +
control O +
group O +
of O +
men O -
, O +
positive O +
significant O +
correlation O +
between O +
HOMA O +
IR O +
and O +
serum O +
leptin O +
concentration O -
, O +
and O +
inverse O +
significant O +
correlation O +
between O +
HOMA O +
IR O +
and O +
ACL O +
IgG O -
, O +
respectively O -
, O +
were O +
found O -
. O +

In O +
the O +
control O +
group O +
of O +
women O -
, O +
the O +
significance O +
of O +
Spearman O -
's O +
correlation O +
between O +
HOMA O +
IR O +
and O +
leptin O +
was O +
more O +
expressive O -
; O +
inverse O +
correlation O +
between O +
HOMA O +
IR O +
and O +
HDL O -
- O -
cholesterol O +
was O +
also O +
present O -
. O +

In O +
the O +
hyperlipemic O +
group O +
of O +
men O -
, O +
the O +
significance O +
of O +
the O +
correlation O +
between O +
HOMA O +
IR O +
was O +
more O +
expressive O +
in O +
relation O +
to O +
the O +
control O +
group O -
, O +
and O +
no O +
significant O +
correlation O +
between O +
HOMA O +
IR O +
and O +
ACL O +
IgG O +
was O +
found O -
. O +

In O +
the O +
hyperlipemic O +
group O +
of O +
women O -
, O +
however O -
, O +
the O +
significance O +
of O +
Spearman O -
's O +
correlation O +
between O +
HOMA O +
IR O +
and O +
serum O +
leptin O +
concentration O +
weakened O -
, O +
the O +
inverse O +
correlation O +
between O +
HOMA O +
IR O +
and O +
HDL O -
- O -
cholesterol O +
remained O +
approximately O +
unchanged O -
, O +
and O +
a O +
positive O +
correlation O +
between O +
HOMA O +
IR O +
and O +
serum O +
concentration O +
of O +
TNFα O +
appeared O -
. O +

Table O +
4 O +
shows O +
results O +
of O +
multiple O +
regression O +
analysis O -
, O +
when O +
data O +
from O +
both O +
control O +
and O +
hyperlipemic O +
groups O +
of O +
each O +
gender O +
were O +
judged O +
together O -
. O +

HOMA O +
IR O +
was O +
considered O +
as O +
a O +
dependent O +
variable O +
and O +
differently O +
changed O +
constellations O +
of O +
metabolic O +
and O +
other O +
factors O +
were O +
taken O +
as O +
independent O +
variables O -
. O +

In O +
men O -
, O +
BMI O +
and O +
leptin O +
seemed O +
to O +
play O +
a O +
main O +
role O +
in O +
influencing O +
the O +
insulin O +
resistance O +
index O +
HOMA O +
IR O -
, O +
while O +
TGL O -
, O +
ACL O +
IgG O +
and O +
LDL O -
- O -
cholesterol O +
did O -
n't O +
play O +
any O +
significant O +
role O +
( O -
see O +
left O +
columns O +
of O +
Table O +
4 O -
) O -
. O +

The O +
decreasing O +
of O +
HDL O -
- O -
cholesterol O +
concentration O +
may O +
also O +
have O +
some O +
influence O +
( O -
see O +
a O +
significant O +
drop O +
of O +
R2 O +
after O +
exclusion O +
of O +
this O +
factor O +
in O +
Table O +
4A O -
, O +
4B O -
) O -
. O +

But O +
in O +
the O +
presence O +
of O +
leptin O +
in O +
the O +
group O +
of O +
independent O +
factors O -
, O +
the O +
drop O +
of O +
R2 O +
after O +
exclusion O +
of O +
HDL O -
- O -
cholesterol O +
from O +
these O +
factors O +
was O +
minimal O +
( O -
see O +
Table O +
4C O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
after O +
the O +
exclusion O +
of O +
TNFα O +
from O +
the O +
group O +
of O +
independent O +
variables O +
( O -
see O +
Table O +
4B O -
, O +
4D O -
) O +
the O +
value O +
of O +
R2 O +
has O +
unexpectedly O +
risen O -
, O +
which O +
could O +
reflect O +
the O +
interference O +
of O +
TNFα O +
with O +
factors O +
increasing O +
the O +
insulin O +
resistance O -
. O +

In O +
women O +
( O -
see O +
right O +
columns O +
of O +
Table O +
4 O -
) O -
, O +
the O +
maximal O +
values O +
of O +
R2 O +
were O +
achieved O +
with O +
combination O +
of O +
independent O +
variables O +
containing O +
TGL O -
, O +
leptin O +
and O +
HDL O -
- O -
cholesterol O +
( O -
about O +
60 O -
% O +
influence O +
on O +
HOMA O +
IR O -
! O +

– O +
see O +
Table O +
4A O -
, O +
4B O -
, O +
4C O -
) O -
. O +

TNFα O +
seemed O +
to O +
play O +
quite O +
a O +
different O +
role O +
than O +
in O +
men O -
: O +
after O +
exclusion O +
of O +
this O +
factor O +
from O +
the O +
group O +
of O +
independent O +
factors O +
R2significantly O +
decreased O +
( O -
see O +
Table O +
4B O -
, O +
4D O -
) O -
. O +

In O +
contrast O +
to O +
men O -
, O +
the O +
role O +
of O +
BMI O +
seemed O +
to O +
be O +
minimal O -
. O +

As O +
in O +
men O -
, O +
the O +
role O +
of O +
ACL O +
IgG O +
and O +
LDL O -
- O -
cholesterol O +
in O +
influencing O +
HOMA O +
IR O +
was O +
negligible O -
, O +
but O +
in O +
contrast O +
to O +
men O -
, O +
hFABP O +
might O +
play O +
a O +
certain O +
role O +
in O +
this O +
process O +
( O -
see O +
Table O +
4D O -
) O -
. O +

Generally O -
, O +
the O +
insulin O +
resistance O +
( O -
represented O +
by O +
HOMA O +
IR O -
) O +
was O +
in O +
men O +
much O +
less O +
influenced O +
by O +
metabolic O +
variables O +
than O +
in O +
women O -
; O +
while O +
in O +
women O +
in O +
some O +
combinations O +
of O +
dependent O +
variables O +
R2 O +
reached O +
64 O +
% O -
, O +
in O +
men O +
the O +
maximal O +
value O +
of O +
R2 O +
was O +
only O +
39 O +
% O -
. O +

Discussion O +
In O +
our O +
previous O +
paper O +
[ O -
36 O -
] O -
, O +
the O +
mean O +
value O +
of O +
HOMA O +
IR O +
in O +
healthy O +
subjects O +
of O +
both O +
genders O +
and O +
of O +
age O +
comparable O +
with O +
our O +
controls O +
was O +
1.57 O +
± O +
0.87 O -
, O +
and O +
the O +
mean O +
value O +
of O +
index O +
QUICKI O +
0.366 O +
± O +
0.029 O -
, O +
respectively O -
. O +

These O +
values O -
, O +
as O +
well O +
as O +
the O +
95 O +
% O +
confidence O +
limits O -
, O +
correspond O +
to O +
values O +
found O +
in O +
controls O +
in O +
this O +
study O -
. O +

In O +
accordance O +
with O +
many O +
previous O +
papers O -
, O +
serum O +
concentrations O +
of O +
leptin O +
in O +
women O +
( O -
both O +
control O +
and O +
hyperlipemic O -
) O +
were O +
substantially O +
higher O +
than O +
in O +
men O -
. O +

In O +
the O +
control O +
group O +
of O +
women O +
the O +
correlation O +
between O +
leptin O +
and O +
HOMA O +
IR O +
was O +
highly O +
significant O -
. O +

However O -
, O +
in O +
hyperlipemic O +
women O +
the O +
significance O +
of O +
this O +
correlation O +
lessened O -
, O +
because O +
HOMA O +
IR O +
increased O +
considerably O +
( O -
and O +
significantly O -
) O +
but O +
serum O +
concentration O +
of O +
leptin O +
only O +
slightly O +
( O -
insignificantly O -
) O -
. O +

In O +
men O +
the O +
significance O +
of O +
correlations O +
between O +
serum O +
leptin O +
and O +
HOMA O +
IR O +
was O +
high O +
and O +
approximately O +
the O +
same O +
in O +
both O +
the O +
control O +
and O +
hyperlipemic O +
groups O -
, O +
because O +
the O +
values O +
of O +
HOMA O +
IR O +
as O +
well O +
as O +
serum O +
leptin O +
have O +
nearly O +
doubled O +
in O +
hyperlipemic O +
in O +
relation O +
to O +
control O +
groups O -
. O +

In O +
non O -
- O -
hyperlipemic O +
postmenopausal O +
women O +
the O +
high O +
concentration O +
of O +
serum O +
leptin O +
was O +
not O +
associated O +
with O +
higher O +
insulin O +
resistance O -
: O +
HOMA O +
IR O +
did O +
not O +
differ O +
substantially O +
from O +
men O -
. O +

A O +
significant O +
increase O +
of O +
insulin O +
resistance O +
in O +
hyperlipemic O +
women O +
was O +
associated O +
by O +
only O +
slight O +
and O +
insignificant O +
increase O +
of O +
leptin O +
concentration O -
. O +

According O +
to O +
Spearman O -
's O +
correlations O -
, O +
an O +
increase O +
of O +
serum O +
TNFα O +
and/or O +
a O +
decrease O +
of O +
HDL O -
- O -
cholesterol O +
might O +
also O +
play O +
a O +
distinct O +
role O +
in O +
this O +
respect O -
. O +

( O -
see O +
Table O +
3 O -
) O -
. O +

In O +
contrast O +
to O +
women O -
, O +
in O +
hyperlipemic O +
men O +
the O +
increase O +
of O +
insulin O +
resistance O +
index O +
was O +
approximately O +
proportional O +
with O +
the O +
increase O +
of O +
leptin O +
concentration O -
. O +

Multiple O +
regression O +
analysis O +
affirmed O +
the O +
importance O +
of O +
leptin O +
serum O +
in O +
increasing O +
of O +
insulin O +
resistance O +
in O +
both O +
genders O -
. O +

In O +
men O -
, O +
only O +
BMI O +
and O +
HDL O -
- O -
cholesterol O +
from O +
other O +
factors O +
studied O +
seemed O +
to O +
play O +
a O +
certain O +
role O -
, O +
but O +
the O +
maximal O +
values O +
of O +
influencing O +
HOMA O +
IR O +
reached O +
only O +
39 O -
% O -
, O +
with O +
leptin O +
and O +
BMI O +
being O +
the O +
more O +
important O +
factors O -
. O +

On O +
the O +
other O +
hand O -
, O +
in O +
women O +
the O +
maximal O +
determination O +
of O +
HOMA O +
IR O +
as O +
high O +
as O +
60 O -
% O +
was O +
registered O +
in O +
combination O +
of O +
serum O +
leptin O -
, O +
TGL O +
and O +
decreased O +
HDL O -
- O -
cholesterol O +
as O +
independent O +
factors O -
; O +
the O +
role O +
of O +
BMI O +
was O +
insignificant O -
. O +

It O +
is O +
not O +
known O +
how O +
leptin O +
is O +
regulated O -
. O +

A O +
strong O +
correlation O +
between O +
plasma O +
leptin O +
and O +
fasting O +
insulin O +
undoubtedly O +
exists O -
, O +
but O +
hyperleptinemia O +
in O +
both O +
obese O +
and O +
lean O +
humans B-Species +
is O +
not O +
likely O +
the O +
result O +
of O +
hyperinsulinemia O +
[ O -
37 O -
] O -
. O +

A O +
relationship O +
between O +
leptin O +
and O +
insulin O +
dependent O +
on O +
sex O +
or O +
BMI O +
was O +
reported O -
, O +
but O +
relationship O +
between O +
triglyceride O +
concentrations O +
and O +
leptin O +
was O +
independent O +
of O +
sex O -
, O +
BMI O -
, O +
and O +
insulin O +
[ O -
18,24 O -
] O -
. O +

Hyperleptinemia O -
, O +
as O +
an O +
early O +
sign O +
of O +
obesity O -
, O +
was O +
closely O +
linked O +
to O +
subcutaneous O +
fat O +
mass O +
[ O -
39,40 O -
] O -
. O +

Percentage O +
of O +
body O +
fat O +
has O +
been O +
shown O +
to O +
be O +
the O +
strongest O +
predictor O +
of O +
leptin O +
levels O +
even O +
in O +
lean O +
women O +
[ O -
41 O -
] O -
. O +

Leptin O +
was O +
highly O +
correlated O +
with O +
percentage O +
of O +
body O +
fat O +
and O +
with O +
fat O +
mass O +
in O +
adults O +
irrespective O +
of O +
gender O +
and O +
age O -
; O +
however O -
, O +
the O +
mean O +
determinant O +
of O +
leptin O +
plasma O +
concentration O +
in O +
men O +
and O +
postmenopausal O +
women O +
was O +
BMI O -
, O +
while O +
in O +
premenopausal O +
women O +
it O +
was O +
only O +
the O +
fat O +
mass O +
[ O -
42 O -
] O -
. O +

These O +
findings O +
contrast O +
with O +
our O +
results O +
showing O +
minimal O +
influence O +
of O +
BMI O +
on O +
HOMA O +
IR O +
in O +
postmenopausal O +
women O -
. O +

All O +
factors O +
mentioned O +
are O +
connected O +
with O +
fat O +
tissue O -
: O +
leptin O +
and O +
TNFα O +
are O +
directly O +
produced O +
chiefly O +
by O +
adipocytes O -
, O +
BMI O +
growth O +
is O +
obviously O +
accompanied O +
by O +
fat O +
mass O +
increase O -
, O +
and O +
the O +
typical O +
hypertriglyceridemia O +
associated O +
with O +
a O +
decrease O +
of O +
HDL O -
- O -
cholesterol O +
goes O +
along O +
with O +
obesity O +
and O +
fat O +
mass O +
growth O -
. O +

The O +
gender O +
differences O +
in O +
circulating O +
leptin O +
were O +
best O +
explained O +
by O +
percentage O +
of O +
body O +
fat O +
and O +
– O +
inversely O +
– O +
by O +
lean O +
body O +
mass O +
[ O -
25 O -
] O -
. O +

In O +
both O +
genders O +
the O +
intra O -
- O -
abdominal O +
fat O +
correlated O +
with O +
insulin O +
resistance O -
, O +
while O +
the O +
subcutaneous O +
fat O +
correlated O +
with O +
circulating O +
leptin O +
[ O -
11,12 O -
] O -
. O +

In O +
men O +
obesity O +
led O +
to O +
a O +
prevalent O +
increase O +
of O +
intra O -
- O -
abdominal O +
fat O -
, O +
while O +
in O +
women O +
of O +
subcutaneous O +
fat O +
[ O -
13 O -
] O -
. O +

Influences O +
of O +
different O +
compartments O +
of O +
adipose O +
tissues O +
could O +
elucidate O +
the O +
variability O +
of O +
correlations O +
between O +
insulin O +
resistance O +
and O +
high O +
leptin O +
concentrations O +
in O +
lean O +
and O +
obese O +
subjects O +
of O +
both O +
genders O +
[ O -
43 O -
] O -
. O +

In O +
our O +
non O -
- O -
hyperlipemic O +
postmenopausal O +
women O +
the O +
content O +
of O +
subcutaneous O +
fat O +
mass O +
might O +
be O +
higher O +
than O +
in O +
non O -
- O -
hyperlipemic O +
men O +
of O +
appropriate O +
age O -
, O +
which O +
indicated O +
a O +
higher O +
serum O +
concentration O +
of O +
leptin O -
. O +

However O -
, O +
the O +
insulin O +
resistance O +
– O +
related O +
to O +
intra O -
- O -
abdominal O +
fat O +
mass O +
– O +
did O +
not O +
differ O +
from O +
men O -
. O +

The O +
significant O +
increase O +
of O +
insulin O +
resistance O +
and O +
leptin O +
concentration O +
in O +
hyperlipemic O +
men O +
might O +
reflect O +
the O +
growing O +
content O +
of O +
both O +
subcutaneous O +
and O +
intra O -
- O -
abdominal O +
fat O +
mass O +
( O -
see O +
the O +
significant O +
increase O +
of O +
BMI O -
) O -
. O +

In O +
hyperlipemic O +
women O +
the O +
significant O +
increase O +
of O +
insulin O +
resistance O +
accompanying O +
only O +
minimal O +
insignificant O +
increase O +
of O +
leptin O +
could O +
be O +
caused O +
by O +
prevalent O +
growing O +
of O +
intra O -
- O -
abdominal O +
fat O +
mass O -
. O +

In O +
elderly O +
postmenopausal O +
women O -
, O +
an O +
association O +
between O +
leptin O +
and O +
plasma O +
lipoprotein O +
concentration O +
was O +
found O +
which O +
depended O +
on O +
adiposity O +
[ O -
17 O -
] O -
, O +
and O +
inverse O +
correlations O +
between O +
serum O +
leptin O +
and O +
HDL O -
- O -
cholesterol O +
were O +
described O +
[ O -
44 O -
] O -
. O +

In O +
our O +
study O -
, O +
insulin O +
resistance O +
in O +
women O +
seemed O +
to O +
be O +
more O +
notably O +
than O +
in O +
men O +
influenced O +
by O +
lipid O +
disorders O -
, O +
i.e. O +
positively O +
by O +
serum O +
triglycerides O +
and O +
inversely O +
by O +
HDL O -
- O -
cholesterol O -
. O +

These O +
findings O +
might O +
be O +
important O +
in O +
considering O +
the O +
concept O +
of O +
treatment O +
of O +
insulin O +
resistance O -
- O -
related O +
disorders O +
in O +
postmenopausal O +
women O -
. O +

The O +
significant O +
role O +
of O +
TNFα O +
in O +
insulin O +
resistance O -
, O +
caused O +
by O +
inhibiting O +
the O +
transduction O +
of O +
insulin O +
signaling O +
and O +
by O +
down O -
- O -
regulation O +
of O +
glucose O +
transporter O +
GLUT-4 O +
and O +
insulin O +
receptor O +
substrate-1 O -
, O +
has O +
been O +
repeatedly O +
confirmed O +
[ O -
45 O -
- O -
48 O -
] O -
. O +

Our O +
results O +
supported O +
these O +
findings O +
unambiguously O +
only O +
in O +
women O -
, O +
while O +
in O +
men O +
TNFα O +
seemed O +
paradoxically O +
to O +
interfere O +
with O +
other O +
factors O +
– O +
mainly O +
BMI O +
and O +
leptin O +
– O +
in O +
influencing O +
insulin O +
resistance O -
, O +
thus O +
playing O +
a O +
quite O +
different O +
role O -
. O +

Previously O +
it O +
was O +
found O +
[ O -
46 O -
] O +
that O +
correlation O +
between O +
serum O +
TNFα O +
on O +
the O +
one O +
side O -
, O +
and O +
insulin O -
, O +
HOMA O +
IR O -
, O +
serum O +
triglycerids O -
, O +
respectively O -
, O +
on O +
the O +
other O +
side O -
, O +
was O +
substantially O +
more O +
significant O +
in O +
women O +
than O +
in O +
men O -
. O +

Serum O +
concentration O +
of O +
TNFα O +
in O +
patients O +
with O +
type O +
2 O +
diabetes O +
of O +
both O +
genders O +
correlated O +
only O +
with O +
the O +
quantity O +
of O +
intra O -
- O -
abdominal O +
fat O +
compartment O +
[ O -
50 O -
] O -
. O +

Visceral O +
obesity O +
correlated O +
with O +
plasmatic O +
aldosterone O +
and O +
with O +
insulin O +
resistance O +
only O +
in O +
premenopausal O +
women O -
, O +
but O +
not O +
in O +
men O +
[ O -
51 O -
] O -
. O +

From O +
all O +
these O +
data O +
we O +
might O +
support O +
our O +
above O +
mentioned O +
conclusion O +
– O +
that O +
rising O +
of O +
insulin O +
resistance O +
in O +
hyperlipemic O +
women O +
was O +
associated O +
with O +
an O +
increase O +
of O +
intra O -
- O -
abdominal O +
fat O -
, O +
because O +
this O +
fat O +
mass O +
in O +
particular O +
is O +
a O +
source O +
of O +
TNFα O -
, O +
which O +
interfered O +
with O +
insulin O +
sensitivity O +
only O +
in O +
women O -
. O +

We O +
came O +
to O +
this O +
conclusion O +
irrespective O +
of O +
the O +
finding O +
that O +
the O +
increase O +
of O +
serum O +
TNFα O +
in O +
hyperlipemic O +
women O +
was O +
statistically O +
insignificant O -
; O +
results O +
of O +
Spearman O -
's O +
correlation O +
( O -
Table O +
3 O -
) O +
and O +
multiple O +
regression O +
analysis O +
confirm O +
a O +
distinct O +
role O +
of O +
this O +
factor O -
. O +

In O +
hyperlipemic O +
men O +
not O +
only O +
the O +
serum O +
concentration O +
of O +
TNFα O +
has O +
decreased O +
instead O +
of O +
increasing O -
, O +
but O +
according O +
to O +
multiple O +
regression O +
analysis O +
it O +
played O +
a O +
quite O +
different O +
role O +
in O +
influencing O +
insulin O +
sensitivity O -
, O +
interfering O +
with O +
factors O +
that O +
determined O +
insulin O +
resistance O +
( O -
leptin O +
and O +
BMI O -
) O -
. O +

In O +
the O +
control O +
group O +
of O +
men O +
IgG O +
anticardiolipin O +
was O +
inversely O +
correlated O +
to O +
HOMA O +
IR O -
. O +

The O +
significance O +
of O +
this O +
finding O +
is O +
not O +
clear O -
. O +

These O +
antibodies O +
indicate O +
vascular O +
and O +
thrombotic O +
complications O +
and O +
oxidative O +
modification O +
of O +
lipoproteins O +
[ O -
52,53 O -
] O +
and O +
may O +
represent O +
an O +
increased O +
risk O +
of O +
atherogenic O +
and O +
inflammatory O +
complications O -
. O +

In O +
this O +
case O -
, O +
however O -
, O +
their O +
growing O +
might O +
be O +
connected O +
with O +
an O +
increase O +
in O +
insulin O +
sensitivity O -
. O +

Anyway O -
, O +
ACL O +
IgG O +
evidently O +
did O +
not O +
participate O +
significantly O +
in O +
influencing O +
the O +
increase O +
of O +
insulin O +
resistance O +
associated O +
with O +
hyperlipidemia O -
, O +
although O +
other O +
anti O -
- O -
cardiolipin O +
correlations O +
could O +
be O +
masked O +
by O +
the O +
relatively O +
large O +
inter O -
- O -
individual O +
variations O +
in O +
this O +
parameter O -
. O +

Neither O +
serum O +
concentration O +
of O +
hFABP O -
, O +
a O +
factor O +
ensuring O +
transmembrane O +
transport O +
and O +
oxidative O +
metabolisation O +
of O +
long O -
- O -
chain O +
fatty O +
acids O +
[ O -
54,55 O -
] O -
, O +
was O +
significantly O +
changed O +
in O +
hyperlipemic O +
and O +
insulin O +
resistant O +
subjects O +
of O +
both O +
genders O -
. O +

This O +
factor O +
was O +
very O +
weakly O +
associated O +
only O +
with O +
HOMA O +
IR O +
in O +
women O +
( O -
see O +
Table O +
4D O -
) O -
, O +
indicating O +
that O +
enhanced O +
metabolisation O +
of O +
fatty O +
acids O +
in O +
cells O +
might O +
to O +
some O +
degree O +
contribute O +
to O +
insulin O +
resistance O -
. O +

Conclusions O +
In O +
postmenopausal O +
women O +
as O +
well O +
as O +
in O +
men O +
of O +
approximately O +
equal O +
age O +
serum O +
leptin O +
plays O +
a O +
significant O +
role O +
as O +
an O +
important O +
determinant O +
of O +
insulin O +
resistance O -
. O +

In O +
addition O +
to O +
this O +
factor O -
, O +
in O +
women O +
the O +
grade O +
of O +
insulin O +
resistance O +
is O +
very O +
considerably O +
influenced O +
by O +
serum O +
triglycerides O -
, O +
tumor O +
necrosis O +
factor O +
alpha O -
, O +
and O +
by O +
decreased O +
concentration O +
of O +
HDL O -
- O -
cholesterol O -
, O +
while O +
in O +
men O +
only O +
a O +
mild O +
influence O +
of O +
BMI O +
and O +
decreased O +
HDL O -
- O -
cholesterol O +
is O +
observed O -
. O +

These O +
findings O +
are O +
explained O +
as O +
a O +
consequence O +
of O +
gender O -
- O -
related O +
differences O +
in O +
adipose O +
tissue O +
composition O +
and/or O +
distribution O +
in O +
both O +
normal O -
- O -
weight O +
and O +
over O -
- O -
weight O +
subjects O +
and O +
should O +
be O +
taken O +
into O +
account O +
in O +
treatment O +
of O +
patients O +
with O +
metabolic O +
risk O +
factors O +
of O +
cardiovascular O +
diseases O -
. O +

List O +
of O +
abbreviations O +
HDL O -
- O -
Cholesterol O +
= O +
high O -
- O -
density O +
cholesterol O +
LDL O -
- O -
cholesterol O +
= O +
low O -
- O -
density O +
cholesterol O +
HOMA O +
IR O +
= O +
Homeostasis O +
Assessment O +
of O +
Insulin O +
Resistance O +
= O +
fasting O +
insulin O +
( O -
μU O -
/ O -
ml O -
) O +
* O +
fasting O +
glucose O +
( O -
mmol O -
/ O -
l O -
) O +
/ O +
22,5 O +
QUICKI O +
= O +
1 O +
/ O +
[ O -
log O +
fasting O +
insulin O +
( O -
μU O -
/ O -
ml O -
) O +
+ O +
log O +
fasting O +
glucose O +
( O -
mg O -
/ O -
100 O +
ml O -
) O +
] O +
TNFα O +
= O +
tumor O +
necrosis O +
factor O +
alpha O +
BMI O +
= O +
body O +
mass O +
index O +
R2 O +
= O +
coefficient O +
of O +
determination O +
hFABP O +
= O +
heart O +
fatty O +
acid O +
binding O +
protein O +
ACL O -
- O -
IgG O +
= O +
IgG O +
fraction O +
of O +
anticardiolipin O +
TGL O +
= O +
triglycerides O +
GLUT-4 O +
= O +
glucose O +
transporter-4 O +
PPARγ O +
= O +
Peroxisome O +
Proliferator O -
- O -
Associated O +
Receptor O +
gamma O +
CV O +
= O +
coefficient O +
of O +
variation O +
Authors O -
' O +
contributions O +
Dr. O +
Radka O +
Lichnovská O +
collected O +
the O +
clinical O +
material O -
, O +
performed O +
analysis O +
of O +
biochemical O +
values O +
and O +
edited O +
the O +
manuscript O -
. O +

Dr. O +
Simona O +
Gwozdziewiczová O +
performed O +
analysis O +
of O +
clinical O +
and O +
biochemical O +
data O +
and O +
edited O +
the O +
manuscript O -
. O +

Prof. O +
Jirí O +
Hrebícek O +
initiated O +
the O +
study O -
, O +
participated O +
in O +
its O +
design O +
and O +
coordination O -
, O +
and O +
wrote O +
and O +
edited O +
the O +
manuscript O -
. O +

Enp1 O -
, O +
a O +
yeast B-Species +
protein O +
associated O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O -
, O +
is O +
required O +
for O +
pre O -
- O -
rRNA O +
processing O +
and O +
40S O +
subunit O +
synthesis O +
Abstract O +
ENP1 O +
is O +
an O +
essential O +
Saccharomyces B-Species +
cerevisiae I-Species +
gene O +
encoding O +
a O +
483 O +
amino O +
acid O +
polypeptide O -
. O +

Enp1 O +
protein O +
is O +
localized O +
in O +
the O +
nucleus O +
and O +
concentrated O +
in O +
the O +
nucleolus O -
. O +

An O +
enp1 O -
- O -
1 O +
temperature O -
- O -
sensitive O +
mutant O +
inhibited O +
35S O +
pre O -
- O -
rRNA O +
early O +
processing O +
at O +
sites O +
A0 O -
, O +
A1 O +
and O +
A2 O +
as O +
shown O +
by O +
northern O +
analysis O +
of O +
steady O +
state O +
levels O +
of O +
rRNA O +
precursors O -
. O +

Pulse O -
- O -
chase O +
analysis O +
further O +
revealed O +
that O +
the O +
enp1 O -
- O -
1 O +
strain O +
was O +
defective O +
in O +
the O +
synthesis O +
of O +
20S O +
pre O -
- O -
rRNA O +
and O +
hence O +
18S O +
rRNA O -
, O +
which O +
led O +
to O +
reduced O +
formation O +
of O +
40S O +
ribosomal O +
subunits O -
. O +

Co O -
- O -
precipitation O +
analysis O +
revealed O +
that O +
Enp1 O +
was O +
associated O +
with O +
Nop1 O +
protein O -
, O +
as O +
well O +
as O +
with O +
U3 O +
and O +
U14 O +
RNAs O -
, O +
two O +
snoRNAs O +
implicated O +
in O +
early O +
pre O -
- O -
rRNA O +
processing O +
steps O -
. O +

These O +
results O +
suggest O +
a O +
direct O +
role O +
for O +
Enp1 O +
in O +
the O +
early O +
steps O +
of O +
rRNA O +
processing O -
. O +

INTRODUCTION O +
Ribosome O +
biogenesis O +
is O +
one O +
of O +
the O +
major O +
cellular O +
activities O +
in O +
eukaryotic O +
cells O -
. O +

It O +
takes O +
place O +
primarily O +
in O +
a O +
specialized O +
subnuclear O +
compartment O -
, O +
the O +
nucleolus O +
( O -
1,2 O -
) O -
. O +

In O +
the O +
yeast B-Species +
Saccharomyces B-Species +
cerevisiae I-Species -
, O +
each O +
rRNA O +
gene O +
is O +
transcribed O +
by O +
RNA O +
polymerase O +
I O +
into O +
a O +
35S O +
rRNA O +
precursor O -
, O +
consisting O +
of O +
18S O -
, O +
5.8S O +
and O +
25S O +
rRNA O +
sequences O +
flanked O +
by O +
two O +
external O +
transcribed O +
spacers O +
( O -
ETS O -
) O +
and O +
separated O +
by O +
two O +
internal O +
transcribed O +
spacers O +
( O -
ITS O -
) O +
( O -
Fig. O +
1 O -
) O -
. O +

This O +
35S O +
precursor O +
goes O +
through O +
a O +
series O +
of O +
modifications O +
and O +
processing O +
steps O +
to O +
generate O +
the O +
mature O +
18S O -
, O +
5.8S O +
and O +
25S O +
rRNAs O -
. O +

The O +
processing O +
occurs O +
first O +
at O +
sites O +
A0 O -
, O +
A1 O +
and O +
A2 O -
, O +
resulting O +
in O +
the O +
20S O +
pre O -
- O -
rRNA O +
and O +
27SA2 O +
pre O -
- O -
rRNA O -
. O +

The O +
20S O +
pre O -
- O -
rRNA O +
is O +
then O +
cleaved O -
, O +
leading O +
to O +
the O +
mature O +
18S O +
rRNA O +
found O +
in O +
the O +
40S O +
ribosomal O +
subunit O -
. O +

The O +
27SA2 O +
pre O -
- O -
rRNA O +
is O +
processed O +
through O +
two O +
alternative O +
pathways O -
. O +

The O +
majority O +
of O +
27SA2 O +
pre O -
- O -
rRNA O +
is O +
cleaved O +
at O +
sites O +
A3 O +
and O +
B2 O +
to O +
form O +
the O +
27SA3 O +
pre O -
- O -
rRNA O -
, O +
which O +
is O +
subsequently O +
processed O +
to O +
produce O +
27SBS O -
. O +

Alternatively O -
, O +
27SA2 O +
pre O -
- O -
rRNA O +
can O +
be O +
processed O +
at O +
sites O +
B1L O +
and O +
B2 O +
to O +
generate O +
27SBL O +
pre O -
- O -
rRNA O -
. O +

Both O +
27SBS O +
and O +
27SBL O +
pre O -
- O -
rRNAs O +
are O +
then O +
cleaved O +
at O +
sites O +
C1 O +
and O +
C2 O +
to O +
generate O +
the O +
mature O +
25S O +
rRNA O -
, O +
and O +
7SS O +
or O +
7SL O +
intermediates O -
, O +
which O +
are O +
then O +
processed O +
to O +
mature O +
5.8SS O +
or O +
5.8SL O +
rRNAs O +
( O -
Fig. O +
1 O -
) O -
. O +

The O +
25S O +
rRNA O +
and O +
5.8S O +
rRNA O +
are O +
the O +
RNA O +
components O +
of O +
the O +
60S O +
ribosomal O +
subunit O +
( O -
3 O -
) O -
. O +

During O +
the O +
course O +
of O +
rRNA O +
modification O +
and O +
processing O -
, O +
many O +
of O +
the O +
ribosomal O +
proteins O +
are O +
assembled O +
onto O +
the O +
rRNA O +
molecules O +
to O +
form O +
the O +
ribosome O +
complex O -
. O +

Ribosome O +
biogenesis O +
needs O +
a O +
large O +
number O +
of O +
trans O -
- O -
acting O +
factors O -
, O +
including O +
small O +
nucleolar O +
RNAs O +
( O -
snoRNAs O -
) O -
, O +
protein O +
components O +
of O +
the O +
snoRNP O +
complexes O -
, O +
rRNA O +
modifying O +
enzymes O -
, O +
endo- O +
and O +
exonucleases O -
, O +
putative O +
RNA O +
helicases O +
and O +
other O +
protein O +
factors O +
( O -
3,4 O -
) O -
. O +

In O +
yeast B-Species +
cells O +
there O +
are O +
more O +
than O +
100 O +
different O +
snoRNAs O +
playing O +
important O +
roles O +
in O +
rRNA O +
modification O +
and O +
processing O -
. O +

On O +
the O +
basis O +
of O +
their O +
structure O -
, O +
the O +
snoRNAs O +
can O +
be O +
divided O +
into O +
two O +
groups O -
: O +
the O +
box O +
C O -
/ O -
D O +
family O +
and O +
box O +
H O -
/ O -
ACA O +
family O -
. O +

Only O +
one O +
snoRNA O -
, O +
MRP O +
RNA O -
, O +
belongs O +
to O +
neither O +
family O +
( O -
5–7 O -
) O -
. O +

While O +
the O +
majority O +
of O +
the O +
snoRNAs O +
participate O +
in O +
RNA O +
pseudouridylation O +
and O +
2′-O O -
- O -
ribose O +
methylation O -
, O +
a O +
few O +
of O +
them O -
, O +
including O +
MRP O +
snoRNA O -
, O +
box O +
C O -
/ O -
D O +
snoRNAs O +
U3 O +
and O +
U14 O -
, O +
and O +
box O +
H O -
/ O -
ACA O +
snoRNAs O +
snR10 O +
and O +
snR30 O -
, O +
are O +
required O +
for O +
processing O +
of O +
the O +
pre O -
- O -
rRNA O +
( O -
8–12 O -
) O -
. O +

Not O +
only O +
are O +
U3 O -
, O +
U14 O -
, O +
snR10 O +
and O +
snR30 O +
essential O +
for O +
early O +
cleavages O +
of O +
35S O +
pre O -
- O -
rRNA O +
to O +
18S O +
rRNA O -
, O +
the O +
proteins O +
associated O +
with O +
them O -
, O +
including O +
Nop1 O -
, O +
Nop5 O -
, O +
Gar1 O +
and O +
Nop10 O -
, O +
have O +
also O +
been O +
shown O +
to O +
be O +
required O +
for O +
18S O +
rRNA O +
synthesis O +
( O -
13–16 O -
) O -
. O +

The O +
ENP1 O +
( O -
Essential O +
Nuclear O +
Protein O +
1 O -
) O +
gene O +
was O +
identified O +
in O +
a O +
genetic O +
screen O +
for O +
suppressors O +
of O +
an O +
ost4 O +
mutation O +
( O -
oligosaccharide O +
transferase O +
4 O -
) O +
( O -
17 O -
) O -
. O +

However O -
, O +
in O +
subsequent O +
studies O +
it O +
was O +
found O +
not O +
to O +
be O +
involved O +
in O +
OST4 O +
function O +
( O -
18 O -
) O -
. O +

ENP1 O +
is O +
an O +
essential O +
gene O +
encoding O +
a O +
483 O +
amino O +
acid O +
polypeptide O -
. O +

The O +
Enp1 O +
protein O +
is O +
highly O +
conserved O +
and O +
homologs O +
are O +
found O +
in O +
all O +
eukaryotes O -
. O +

The O +
yeast B-Species +
protein O +
was O +
localized O +
to O +
the O +
nucleus O +
in O +
a O +
previous O +
study O +
( O -
18 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
an O +
Enp1 O +
human B-Species +
homolog O -
, O +
called O +
bystin O -
, O +
was O +
reported O +
to O +
localize O +
to O +
the O +
cytoplasm O +
and O +
was O +
proposed O +
to O +
be O +
involved O +
in O +
cell O +
adhesion O +
( O -
19 O -
) O -
. O +

In O +
this O +
study O -
, O +
we O +
report O +
that O +
the O +
Enp1 O +
protein O +
not O +
only O +
is O +
nuclear O +
but O +
is O +
enriched O +
in O +
the O +
nucleolus O -
. O +

We O +
also O +
found O +
that O +
Enp1 O +
is O +
required O +
for O +
the O +
synthesis O +
of O +
40S O +
ribosomal O +
subunits O -
, O +
and O +
its O +
presence O +
is O +
necessary O +
for O +
the O +
pre O -
- O -
rRNA O +
processing O +
to O +
form O +
20S O +
pre O -
- O -
rRNA O +
and O +
18S O +
rRNA O -
. O +

An O +
association O +
between O +
Enp1 O +
and O +
U3 O +
and O +
U14 O +
snoRNAs O -
, O +
and O +
with O +
the O +
nucleolar O +
protein O +
Nop1 O -
, O +
was O +
established O -
. O +

We O +
also O +
found O +
that O +
human B-Species +
Enp1 O -
, O +
expressed O +
in O +
yeast B-Species -
, O +
was O +
located O +
in O +
the O +
nucleus O +
and O +
the O +
nucleolus O -
, O +
suggesting O +
that O +
the O +
function O +
of O +
this O +
protein O +
is O +
conserved O -
. O +

MATERIALS O +
AND O +
METHODS O +
Yeast B-Species +
strains O +
and O +
media O +
The O +
S.cerevisiae B-Species +
strains O +
used O +
in O +
this O +
study O +
are O +
all O +
derivatives O +
of O +
a O +
wild O -
- O -
type O +
diploid O +
strain O +
W303 O +
( O -
MATa O -
/ O -
MATα O +
ura3 O -
- O -
1 O -
/ O -
ura3 O -
- O -
1 O +
leu2 O -
- O -
3,112 O -
/ O -
leu2 O -
- O -
3,112 O +
trp1 O -
- O -
1 O -
/ O -
trp1 O -
- O -
1 O +
his3 O -
- O -
11,15 O -
/ O -
his3 O -
- O -
11,15 O +
ade2 O -
- O -
1 O -
/ O -
ade2 O -
- O -
1 O +
can1 O -
- O -
100 O -
/ O -
can1 O -
- O -
100 O -
) O +
except O +
for O +
strain O +
RS1938 O -
. O +

Strain O +
JBY45 O +
( O -
MATa O -
/ O -
MATα O +
ENP1 O -
/ O -
Δenp1::his5 O -
+ O -
) O +
was O +
constructed O +
by O +
replacing O +
one O +
copy O +
of O +
the O +
ENP1 O +
open O +
reading O +
frame O +
( O -
ORF O -
) O +
with O +
the O +
Schizosaccharomyces B-Species +
pombe I-Species +
his5 O -
+ O +
gene O +
( O -
18 O -
) O -
. O +

Strain O +
JBY46 O +
[ O -
MATa O +
Δenp1::his5+ O -
/ O -
pJB23 O +
( O -
ENP1 O -
, O +
URA3 O -
, O +
CEN6 O -
) O -
] O +
is O +
a O +
haploid O +
strain O +
derived O +
from O +
JBY45 O +
with O +
wild O -
- O -
type O +
ENP1 O +
on O +
a O +
low O +
copy O +
number O +
plasmid O -
. O +

Strain O +
JBY48 O +
[ O -
MATa O +
Δenp1::his5+ O -
/ O -
pJB19 O +
( O -
enp1 O -
- O -
1 O -
, O +
TRP1 O -
, O +
CEN6 O -
) O -
] O +
and O +
strain O +
JBY49 O +
[ O -
MATa O +
Δenp1::his5+ O -
/ O -
pJB39 O +
( O -
enp1 O -
- O -
2 O -
, O +
TRP1 O -
, O +
CEN6 O -
) O -
] O +
have O +
plasmids O +
with O +
enp1 O +
temperature O -
- O -
sensitive O +
( O -
ts O -
) O +
mutations O -
. O +

Strain O +
JBY51 O +
( O -
MATa O +
Δenp1::his5 O -
+ O +
TRP1::enp1 O -
- O -
1 O -
) O +
is O +
an O +
enp1 O +
ts O +
strain O +
generated O +
by O +
integrating O +
the O +
enp1 O -
- O -
1 O +
gene O +
at O +
the O +
chromosomal O +
trp1 O -
- O -
1 O +
locus O -
. O +

Strain O +
CWY13 O +
[ O -
MATa O +
Δenp1::his5+ O -
/ O -
pJB24 O +
( O -
pMET25-GFP O -
- O -
ENP1 O -
, O +
URA3 O -
, O +
CEN6 O -
) O -
] O +
has O +
GFP O -
- O -
ENP1 O +
under O +
control O +
of O +
the O +
MET25 O +
promoter O -
. O +

Strain O +
CWY14 O +
( O -
MATa O +
ENP1-TAP O -
) O +
was O +
created O +
by O +
fusing O +
sequences O +
encoding O +
a O +
Tandem O +
Affinity O +
Purification O +
( O -
TAP O -
) O +
tag O +
( O -
20,21 O -
) O +
to O +
the O +
3′ O +
end O +
of O +
ENP1 O -
. O +

Strain O +
YRH39 O +
( O -
MATα O +
HST2-TAP O -
) O +
was O +
created O +
by O +
fusing O +
sequences O +
encoding O +
a O +
TAP O +
tag O +
to O +
the O +
3′end O +
of O +
HST2 O -
. O +

Strain O +
RS1938 O +
( O -
Δnop1::URA3 O +
pUN100-ProtA O -
- O -
NOP1 O -
) O +
was O +
created O +
by O +
transforming O +
RS1935 O +
( O -
MATa O -
/ O -
α O +
leu2 O -
/ O -
leu2 O +
ura3 O -
/ O -
ura3 O +
lys2 O -
/ O -
lys2 O +
ade2 O -
/ O -
ade2 O +
Δnop1::URA3 O -
/ O -
NOP1 O -
) O +
with O +
pUN100-ProtA O -
- O -
NOP1 O +
( O -
strain O +
and O +
plasmid O +
supplied O +
by O +
T. O +
Schafer O -
) O -
, O +
followed O +
by O +
tetrad O +
dissection O -
. O +

Strain O +
CWY15 O +
[ O -
MATa O -
/ O -
pCW109 O +
( O -
pMET25-GFP O -
- O -
hENP1 O -
, O +
URA3 O -
, O +
CEN6 O -
) O -
] O +
has O +
a O +
human B-Species +
homolog O +
of O +
Enp1 O +
expressed O +
in O +
W303 O -
- O -
1a O -
. O +

The O +
media O +
used O +
were O +
prepared O +
as O +
described O +
( O -
22 O -
) O -
. O +

Cloning O +
of O +
ENP1 O +
pRS426-MEG1 O +
( O -
The O +
original O +
name O +
of O +
ENP1 O -
) O +
was O +
a O +
gift O +
from O +
Dr O +
William O +
J. O +
Lennarz O -
. O +

It O +
contains O +
the O +
ENP1 O +
gene O +
within O +
a O +
2.6 O +
kb O +
EcoRI O +
genomic O +
fragment O +
cloned O +
into O +
pRS426 O +
( O -
18 O -
) O -
. O +

The O +
EcoRI O +
fragment O +
was O +
subsequently O +
cloned O +
into O +
pRS314 O +
( O -
TRP1 O -
, O +
CEN6 O -
) O -
, O +
pRS316 O +
( O -
URA3 O -
, O +
CEN6 O -
) O +
and O +
pRS424 O +
( O -
TRP1 O -
, O +
2µ O -
) O +
to O +
create O +
pJB20 O -
, O +
pJB23 O +
and O +
pJB21 O -
, O +
respectively O -
. O +

pGFP O -
- O -
N O -
- O -
FUS O +
is O +
a O +
centromeric O +
plasmid O +
for O +
fusing O +
green O +
fluorescence O +
protein O +
( O -
GFP O -
) O +
to O +
a O +
polypeptide O -
's O +
N O -
- O -
terminus O +
under O +
control O +
of O +
the O +
MET25 O +
promoter O +
( O -
23 O -
) O -
. O +

Cloning O +
the O +
ENP1 O +
ORF O +
into O +
pGFP O -
- O -
N O -
- O -
FUS O +
via O +
XbaI O +
and O +
SalI O +
sites O +
generated O +
plasmid O +
pJB24 O -
. O +

pJB19 O +
( O -
enp1 O -
- O -
1 O -
, O +
TRP1 O -
, O +
CEN6 O -
) O +
contains O +
the O +
enp1 O -
- O -
1 O +
mutant O +
gene O -
. O +

The O +
human B-Species +
homolog O +
of O +
yeast B-Species +
Enp1 O +
was O +
PCR O +
amplified O +
from O +
a O +
human B-Species +
cDNA O +
clone O +
BC007340 O +
( O -
Research O +
Genetics O -
) O -
, O +
then O +
cloned O +
into O +
pGFP O -
- O -
N O -
- O -
FUS O -
, O +
p415-ADH O -
, O +
p415-GPD O +
and O +
p415-TEF O +
( O -
24 O -
) O +
via O +
XbaI O +
and O +
SalI O +
sites O +
to O +
generate O +
pCW109 O -
, O +
pCW113 O -
, O +
pCW115 O +
and O +
pCW117 O -
, O +
respectively O -
. O +

The O +
fragment O +
of O +
the O +
human B-Species +
Enp1 O +
homolog O +
( O -
amino O +
acids O +
152–437 O -
) O +
was O +
also O +
cloned O +
into O +
these O +
vectors O +
to O +
generate O +
pCW110 O -
, O +
pCW114 O -
, O +
pCW116 O +
and O +
pCW118 O -
. O +

Random O +
mutagenesis O +
of O +
ENP1 O +
to O +
generate O +
enp1 O +
ts O +
mutants O +
The O +
enp1 O +
ts O +
mutants O +
were O +
generated O +
with O +
a O +
protocol O +
introducing O +
random O +
mutations O +
by O +
PCR O +
( O -
25 O -
) O -
. O +

The O +
PCR O +
was O +
performed O +
with O +
oligonucleotides O +
ENP1-MUT5′ O +
( O -
5′-GGTGGTGTCAGT O +
AGGGGA-3′ O -
) O -
, O +
ENP1-MUT3′ O +
( O -
5′-CAGTCTGCAATATA O +
TGGAC-3′ O -
) O +
and O +
plasmid O +
template O +
pJB20 O +
( O -
see O +
above O -
) O -
. O +

The O +
nucleotide O +
concentrations O +
in O +
the O +
reaction O +
were O +
1 O +
mM O +
each O +
for O +
dATP O -
, O +
dGTP O -
, O +
dCTP O +
and O +
dTTP O -
. O +

After O +
strain O +
JBY46 O +
was O +
transformed O +
with O +
the O +
PCR O +
product O +
and O +
with O +
pJB20 O +
gapped O +
by O +
NheI O +
and O +
NsiI O -
, O +
the O +
transformants O +
were O +
replica O -
- O -
plated O +
onto O +
two O +
plates O +
containing O +
5-FOA O +
synthetic O +
medium O +
without O +
tryptophan O -
; O +
one O +
replica O +
was O +
incubated O +
at O +
23 O -
° O -
C O +
and O +
the O +
other O +
at O +
37 O -
° O -
C O -
. O +

Colonies O +
growing O +
at O +
23 O -
° O -
C O +
but O +
not O +
at O +
37 O -
° O -
C O +
were O +
picked O +
as O +
candidates O -
. O +

Since O +
approximately O +
10 O -
% O +
of O +
the O +
colonies O +
were O +
inviable O +
at O +
both O +
temperatures O -
, O +
we O +
knew O +
that O +
10 O -
% O +
of O +
the O +
ENP1 O +
PCR O +
products O +
lost O +
their O +
function O +
after O +
the O +
PCR O +
mutagenesis O -
. O +

This O +
confirmed O +
the O +
effectiveness O +
of O +
the O +
mutagenesis O +
procedure O -
. O +

Two O +
candidates O +
showed O +
good O +
growth O +
at O +
23 O -
° O -
C O +
but O +
no O +
growth O +
at O +
37 O -
° O -
C O -
. O +

They O +
were O +
named O +
strains O +
JBY48 O +
and O +
JBY49 O +
and O +
contained O +
plasmids O +
with O +
the O +
enp1 O -
- O -
1 O +
and O +
enp1 O -
- O -
2 O +
mutations O -
, O +
respectively O -
. O +

The O +
mutated O +
enp1 O -
- O -
1 O +
gene O +
on O +
pJB19 O +
was O +
cloned O +
into O +
an O +
integration O +
vector O -
, O +
pRS304 O -
, O +
as O +
an O +
EcoRI O +
fragment O -
. O +

The O +
plasmid O +
was O +
subsequently O +
linearized O +
with O +
SnaBI O +
within O +
the O +
TRP1 O +
marker O +
and O +
was O +
integrated O +
at O +
the O +
chromosomal O +
trp1 O -
- O -
1 O +
locus O +
of O +
strain O +
JBY46 O -
. O +

Selection O +
on O +
5-FOA O +
was O +
used O +
to O +
remove O +
plasmid O +
pJB23 O -
, O +
creating O +
strain O +
JBY51 O -
. O +

Sucrose O +
gradient O +
analysis O +
Polyribosome O +
preparation O +
and O +
analysis O +
were O +
carried O +
out O +
essentially O +
as O +
described O +
( O -
26 O -
) O -
. O +

Cells O +
grown O +
in O +
YPD O +
were O +
collected O +
at O +
mid O -
- O -
log O +
phase O +
( O -
OD600 O +
0.8–1.0 O -
) O +
and O +
were O +
broken O +
with O +
glass O +
beads O -
. O +

The O +
lysate O +
was O +
frozen O +
immediately O +
in O +
liquid O +
N2 O +
and O +
was O +
stored O +
at O +
–80 O -
° O -
C O -
. O +

Lysate O +
( O -
30 O +
U O +
of O +
absorbance O +
at O +
OD260 O -
) O +
was O +
layered O +
over O +
a O +
7–47 O -
% O +
( O -
w O -
/ O -
v O -
) O +
sucrose O +
gradient O -
, O +
which O +
was O +
centrifuged O +
at O +
28 O +
000 O +
r.p.m O -
. O +

for O +
5 O +
h O +
at O +
4 O -
° O -
C O +
in O +
a O +
SW28 O +
rotor O +
and O +
was O +
analyzed O +
with O +
an O +
ISCO O +
UA-5 O +
gradient O +
UV O +
detection O +
system O +
on O +
absorbency O +
at O +
254 O +
nm O -
. O +

Immunofluorescence O +
Immunofluorescence O +
analysis O +
was O +
carried O +
out O +
essentially O +
as O +
described O +
( O -
27 O -
) O -
. O +

Cells O +
were O +
fixed O +
with O +
3.7 O -
% O +
formaldehyde O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +
Antibodies O +
included O +
a O +
mouse B-Species +
monoclonal O +
anti O -
- O -
Nop1 O +
( O -
a O +
gift O +
from O +
John O +
P. O +
Aris O -
, O +
University O +
of O +
Florida O -
, O +
Gainesville O -
, O +
Florida O -
) O +
and O +
a O +
Texas O -
- O -
red O -
- O -
conjugated O +
donkey B-Species -
- O -
anti O -
- O -
mouse B-Species +
antibody O +
( O -
Jackson O +
Lab O -
) O -
, O +
both O +
used O +
at O +
1:500 O +
dilution O -
. O +

Images O +
were O +
taken O +
on O +
a O +
Zeiss O +
Axioplan2 O +
microscope O +
equipped O +
with O +
a O +
Zeiss O +
AxioCam O +
camera O -
. O +

Pulse O -
- O -
chase O +
labeling O +
analysis O +
of O +
rRNA O +
For O +
[ O -
methyl-3H O -
] O -
methionine O +
pulse O -
- O -
chase O +
analysis O -
, O +
cells O +
were O +
grown O +
in O +
synthetic O +
medium O +
without O +
methionine O +
at O +
room O +
temperature O +
or O +
37 O -
° O -
C O +
for O +
2 O +
h. O +
When O +
the O +
OD600 O +
reached O +
1.0 O -
, O +
6 O +
ml O +
of O +
the O +
culture O +
were O +
pulse O -
- O -
labeled O +
with O +
250 O +
µCi O +
[ O -
methyl-3H O -
] O -
methionine O +
( O -
Amersham O +
Pharmacia O -
) O +
for O +
3 O +
min O +
and O +
chased O +
with O +
cold O +
methionine O +
( O -
500 O +
µg O -
/ O -
ml O -
) O +
for O +
2 O -
, O +
4 O +
or O +
12 O +
min O -
. O +

For O +
each O +
time O +
point O +
of O +
the O +
chase O +
1.25 O +
ml O +
of O +
culture O +
was O +
mixed O +
with O +
ice O +
and O +
collected O -
. O +

The O +
pellets O +
were O +
frozen O +
immediately O +
in O +
liquid O +
N2 O +
and O +
stored O +
at O +
–80 O -
° O -
C O +
before O +
total O +
RNA O +
was O +
purified O +
using O +
a O +
hot O +
phenol O +
method O +
( O -
28 O -
) O -
. O +

The O +
RNAs O +
were O +
separated O +
on O +
a O +
1.2 O -
% O +
agarose O +
formaldehyde O +
gel O +
and O +
transferred O +
onto O +
Hybond O -
- O -
N+ O +
nylon O +
membranes O +
( O -
Amersham O +
Pharmacia O -
) O -
. O +

After O +
being O +
sprayed O +
with O +
EN3HANCE O +
( O -
Du O +
Pont O -
) O -
, O +
the O +
membranes O +
were O +
exposed O +
to O +
film O +
at O +
–80 O -
° O -
C O +
( O -
29 O -
) O -
. O +

Northern O +
analysis O +
Cells O +
were O +
grown O +
inYPD O +
at O +
room O +
temperature O +
or O +
37 O -
° O -
C O +
for O +
2–4 O +
h. O +
When O +
the O +
OD600 O +
reached O +
1.0 O -
, O +
10 O +
ml O +
of O +
cells O +
were O +
collected O +
and O +
frozen O +
immediately O -
. O +

Total O +
RNA O +
was O +
extracted O +
as O +
described O +
( O -
28 O -
) O -
. O +

Five O +
micrograms O +
of O +
RNA O +
were O +
separated O +
on O +
1.2 O -
% O +
agarose O +
formaldehyde O +
gels O +
( O -
for O +
high O +
molecular O +
weight O +
RNA O -
) O +
or O +
on O +
6 O -
% O +
polyacrylamide O +
7 O +
M O +
urea O +
denaturing O +
gels O +
( O -
for O +
low O +
molecular O +
weight O +
RNA O -
) O +
for O +
each O +
sample O -
. O +

The O +
RNA O +
was O +
then O +
transferred O +
to O +
Zeta O -
- O -
Probe O +
GT O +
nylon O +
membranes O +
( O -
Bio O -
- O -
Rad O -
) O -
. O +

Probes O +
for O +
hybridyzation O +
were O +
specific O +
oligonucleotides O +
end O -
- O -
labeled O +
using O +
[ O -
γ-32P O -
] O -
ATP O -
. O +

After O +
hybridization O +
and O +
washes O -
, O +
membranes O +
were O +
exposed O +
to O +
phosphorimager O +
screens O +
or O +
X O -
- O -
ray O +
films O +
( O -
29 O -
) O -
. O +

Oligonucleotides O +
specific O +
for O +
various O +
regions O +
of O +
35S O +
pre O -
- O -
rRNA O +
are O -
: O +
1 O -
, O +
GGTCTCTCTGCTGCCG O +
GAAATG O -
; O +
3 O -
, O +
AATGAGCCATTCGCAGTTTCACTG O -
; O +
4 O -
, O +
GCTCTCATGCTCTTGCCAAAAC O -
; O +
5 O -
, O +
TGTTTGTTACCT O +
CTGGGCCCCG O -
; O +
6 O -
, O +
TCCAGTTACGAAAATTCTTG O -
; O +
7 O -
, O +
CGTATCGCATTTCGCTGCGTTC O -
; O +
8 O -
, O +
GTTCGCCTAGAC O +
GCTCTCTCTTC O -
; O +
9 O -
, O +
GCGAGATTCCCCTACCCAC O -
. O +

The O +
regions O +
complementary O +
to O +
these O +
oligonucleotides O +
are O +
shown O +
in O +
Figure O +
6A O -
. O +

The O +
oligonucleotides O +
probing O +
box O +
C O -
/ O -
D O +
snoRNAs O +
are O -
: O +
U3 O -
, O +
TTCGGTTTCTCACTCACTCTGGGGTAC O -
; O +
U14 O -
, O +
GGAACCAGTCTTTCATCACCGTG O -
. O +

The O +
oligonucleotides O +
probing O +
box O +
H O -
/ O -
ACA O +
snoRNAs O +
are O -
: O +
snoRNA10 O -
, O +
CCTTG O +
CAACGGTCCTCATCCGGG O -
; O +
snoRNA30 O -
, O +
GTCCGAAGC O +
GCCATCTAGATGA O -
. O +

RNA O +
and O +
protein O +
precipitation O +
analysis O +
Cells O +
were O +
grown O +
in O +
YPD O +
( O -
1 O +
l O -
) O +
to O +
OD600 O +
1.0 O -
, O +
then O +
collected O -
, O +
washed O +
once O +
in O +
ice O -
- O -
cold O +
PBS O +
and O +
broken O +
using O +
glass O +
beads O +
in O +
10 O +
ml O +
IPP150 O +
buffer O +
( O -
10 O +
mM O +
Tris O +
pH O +
8.0 O -
, O +
150 O +
mM O +
NaCl O +
and O +
0.1 O -
% O +
NP-40 O -
) O +
with O +
protease O +
inhibitors O -
. O +

The O +
lysates O +
were O +
mixed O +
with O +
200 O +
µl O +
IgG O +
agarose O +
beads O +
for O +
2 O +
h O +
at O +
4 O -
° O -
C O -
. O +

After O +
several O +
washes O +
with O +
50 O +
ml O +
IPP150 O +
buffer O -
, O +
the O +
IgG O +
beads O +
were O +
collected O +
and O +
the O +
RNA O +
associated O +
with O +
the O +
beads O +
extracted O +
by O +
the O +
hot O +
phenol O +
method O +
( O -
28 O -
) O -
. O +

One O -
- O -
tenth O +
of O +
the O +
precipitated O +
RNA O +
was O +
then O +
separated O +
on O +
6 O -
% O +
polyacrylamide O +
7 O +
M O +
urea O +
denaturing O +
gels O +
and O +
electro O -
- O -
transferred O +
to O +
Zeta O -
- O -
Probe O +
GT O +
nylon O +
membranes O -
. O +

They O +
were O +
probed O +
with O +
[ O -
γ-32P O -
] O -
ATP O +
labeled O +
oligonucleotides O -
. O +

For O +
the O +
lanes O +
showing O +
total O +
RNA O -
, O +
2 O +
µg O +
RNA O +
prepared O +
from O +
exponentially O +
growing O +
cultures O +
were O +
loaded O -
. O +

For O +
co O -
- O -
precipitation O +
analysis O +
of O +
proteins O -
, O +
the O +
IgG O +
beads O +
were O +
resuspended O +
in O +
2 O -
× O +
Laemmli O +
sample O +
buffer O -
, O +
boiled O +
for O +
5 O +
min O +
and O +
separated O +
by O +
SDS O -
– O -
polyacrylamide O +
gel O +
electrophoresis O -
. O +

Approximately O +
1 O -
% O +
of O +
the O +
precipitate O +
was O +
loaded O +
onto O +
each O +
lane O -
. O +

For O +
the O +
total O +
protein O -
, O +
0.1 O -
% O +
of O +
the O +
extract O +
prior O +
to O +
precipitation O +
was O +
loaded O +
onto O +
each O +
lane O -
. O +

Following O +
electrophoresis O -
, O +
the O +
proteins O +
were O +
transferred O +
to O +
nitrocellulose O +
membranes O +
and O +
detected O +
using O +
anti O -
- O -
Nop1 O +
antibody O +
at O +
1:3000 O +
dilution O +
( O -
provided O +
by O +
J. O +
Aris O -
) O +
and O +
anti O -
- O -
L3 O +
antibody O +
( O -
provided O +
by O +
J. O +
Warner O -
) O +
at O +
1:3000 O +
dilution O +
followed O +
by O +
peroxidase O -
- O -
conjugated O +
anti O -
- O -
mouse B-Species +
secondary O +
antibody O +
at O +
1:5000 O +
dilution O -
. O +

The O +
antibody O +
complexes O +
were O +
detected O +
using O +
ECL O -
- O -
Plus O +
reagents O +
( O -
Amersham O +
Pharmacia O -
) O +
as O +
specified O +
by O +
the O +
manufacturer O -
. O +

RESULTS O +
Construction O +
and O +
analysis O +
of O +
ENP1 O +
temperature O -
- O -
sensitive O +
alleles O +
ENP1 O +
is O +
an O +
essential O +
yeast B-Species +
gene O +
conserved O +
among O +
eukaryotes O +
( O -
18 O -
) O -
. O +

To O +
study O +
its O +
functions O -
, O +
we O +
first O +
created O +
a O +
diploid O +
strain O -
, O +
JBY45 O -
, O +
heterozygous O +
for O +
the O +
Δenp1 O +
mutation O -
. O +

Then O +
two O +
enp1 O +
ts O +
mutant O +
alleles O +
( O -
enp1 O -
- O -
1 O +
and O +
enp1 O -
- O -
2 O -
) O +
were O +
generated O +
by O +
random O +
PCR O +
mutagenesis O -
, O +
as O +
described O +
in O +
Materials O +
and O +
Methods O -
. O +

Both O +
mutant O +
alleles O +
were O +
recessive O +
to O +
the O +
wild O -
- O -
type O +
ENP1 O +
gene O -
. O +

The O +
enp1 O -
- O -
1 O +
gene O +
was O +
integrated O +
into O +
the O +
chromosomal O +
trp1 O -
- O -
1 O +
locus O +
to O +
create O +
strain O +
JBY51 O +
and O +
all O +
subsequent O +
experiments O +
were O +
done O +
with O +
this O +
enp1 O +
allele O -
. O +

At O +
23 O -
° O -
C O +
the O +
growth O +
of O +
JBY51 O +
was O +
comparable O +
to O +
that O +
of O +
W303 O -
- O -
1a O +
( O -
ENP1 O -
) O -
, O +
but O +
at O +
37 O -
° O -
C O +
it O +
did O +
not O +
grow O +
( O -
Fig. O +
2 O -
) O -
. O +

Sequence O +
analysis O +
revealed O +
that O +
enp1 O -
- O -
1 O +
contains O +
two O +
point O +
mutations O -
, O +
resulting O +
in O +
substitutions O +
of O +
two O +
amino O +
acids O -
: O +
W242→G O +
and O +
V415→A. O +
No O +
attempt O +
was O +
made O +
to O +
determine O +
whether O +
both O +
mutations O +
were O +
required O +
for O +
the O +
ts O +
phenotype O -
. O +

Flow O +
cytometry O +
of O +
strain O +
JBY51 O +
showed O +
DNA O +
content O +
profiles O +
similar O +
to O +
those O +
of O +
the O +
wild O -
- O -
type O +
strain O +
at O +
the O +
non O -
- O -
permissive O +
temperature O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
ENP1 O +
is O +
not O +
involved O +
in O +
cell O +
cycle O +
regulation O -
. O +

Enp1 O +
is O +
enriched O +
in O +
the O +
nucleolus O +
Enp1 O +
tagged O +
at O +
the O +
C O -
- O -
terminus O +
with O +
the O +
myc O +
epitope O +
was O +
previously O +
found O +
to O +
localize O +
to O +
the O +
nucleus O +
( O -
18 O -
) O -
. O +

To O +
expand O +
this O +
analysis O -
, O +
we O +
fused O +
GFP O +
to O +
the O +
N O -
- O -
terminus O +
of O +
Enp1 O -
, O +
and O +
expressed O +
the O +
tagged O +
Enp1 O +
protein O +
under O +
control O +
of O +
the O +
MET25 O +
promoter O +
as O +
the O +
sole O +
source O +
of O +
Enp1 O +
protein O +
in O +
the O +
cells O -
. O +

Cells O +
of O +
strain O +
CWY13 O +
( O -
pMET25-GFP O -
- O -
ENP1 O -
) O +
were O +
grown O +
in O +
media O +
with O +
methionine O +
( O -
transcription O +
partially O +
repressed O -
) O +
or O +
without O +
methionine O +
( O -
transcription O +
not O +
repressed O -
) O -
. O +

Growth O +
of O +
CWY13 O +
was O +
comparable O +
to O +
that O +
of O +
wild O -
- O -
type O +
cells O +
in O +
both O +
media O +
( O -
data O +
not O +
shown O -
) O -
, O +
indicating O +
that O +
the O +
GFP O +
tagged O +
Enp1 O +
protein O +
was O +
functional O -
. O +

In O +
cells O +
cultured O +
in O +
medium O +
without O +
methionine O -
, O +
in O +
which O +
the O +
ENP O +
transcription O +
was O +
not O +
repressed O -
, O +
the O +
GFP O -
- O -
Enp1 O +
protein O +
was O +
expressed O +
at O +
a O +
high O +
level O +
and O +
showed O +
strong O +
green O +
fluorescence O +
distributed O +
throughout O +
the O +
nucleus O +
( O -
data O +
not O +
shown O -
) O -
, O +
consistent O +
with O +
the O +
original O +
observation O +
( O -
18 O -
) O -
. O +

With O +
methionine O +
added O +
to O +
the O +
medium O -
, O +
however O -
, O +
the O +
fluorescent O +
signal O +
of O +
GFP O -
- O -
Enp1 O +
was O +
weaker O +
and O +
surprisingly O +
showed O +
crescent O +
or O +
cap O -
- O -
like O +
patterns O +
typical O +
of O +
nucleolar O +
proteins O +
( O -
Fig. O +
3A O -
) O -
. O +

This O +
nucleolar O +
enrichment O +
was O +
confirmed O +
by O +
its O +
co O -
- O -
localization O +
with O +
the O +
nucleolar O +
protein O +
Nop1 O +
( O -
Fig. O +
3B O -
) O -
. O +

ENP1 O +
mutation O +
leads O +
to O +
reduced O +
levels O +
of O +
40S O +
ribosomal O +
subunits O +
The O +
nucleolar O +
enrichment O +
suggested O +
that O +
Enp1 O +
might O +
play O +
some O +
role O +
in O +
ribosome O +
synthesis O -
. O +

To O +
test O +
this O +
possibility O -
, O +
cells O +
of O +
W303 O -
- O -
1a O +
( O -
ENP1 O -
) O -
, O +
JBY51 O +
( O -
enp1 O -
- O -
1 O -
) O +
and O +
a O +
top2 O +
ts O +
strain O +
RS191 O +
( O -
30 O -
) O +
were O +
grown O +
in O +
YPD O +
at O +
23 O +
or O +
37 O -
° O -
C O +
and O +
their O +
ribosome O +
profiles O +
analyzed O +
after O +
separation O +
on O +
sucrose O +
gradients O -
. O +

At O +
23 O -
° O -
C O -
, O +
enp1 O -
- O -
1 O +
cells O +
showed O +
polysome O +
profiles O +
similar O +
to O +
those O +
of O +
the O +
wild O -
- O -
type O +
and O +
top2 O -
- O -
1 O +
strains O +
( O -
Fig. O +
4A O -
– O -
C O -
) O -
. O +

In O +
contrast O -
, O +
after O +
incubation O +
at O +
the O +
non O -
- O -
permissive O +
temperature O +
( O -
37 O -
° O -
C O -
) O +
for O +
40 O +
min O +
( O -
data O +
not O +
shown O -
) O +
and O +
2 O +
h O -
, O +
enp1 O -
- O -
1 O +
cells O +
had O +
reduced O +
levels O +
of O +
40S O +
ribosomal O +
subunits O -
, O +
80S O +
monosomes O +
and O +
polysomes O -
, O +
along O +
with O +
a O +
dramatic O +
increase O +
in O +
the O +
free O +
60S O +
subunit O +
peak O +
( O -
Fig. O +
4F O -
) O -
, O +
while O +
the O +
wild O -
- O -
type O +
and O +
top2 O -
- O -
1 O +
cells O +
showed O +
little O +
change O +
in O +
polysome O +
profile O +
at O +
37 O -
° O -
C O +
( O -
Fig. O +
4D O +
and O +
E O -
) O -
. O +

These O +
results O +
demonstrate O +
that O +
the O +
changes O +
of O +
the O +
enp1 O -
- O -
1 O +
polysome O +
profile O +
were O +
due O +
to O +
specific O +
defects O +
caused O +
by O +
the O +
enp1 O -
- O -
1 O +
mutation O -
, O +
and O +
not O +
due O +
simply O +
to O +
the O +
shift O +
to O +
37 O -
° O -
C O +
for O +
a O +
wild O -
- O -
type O +
or O +
ts O +
strain O -
. O +

The O +
processing O +
of O +
pre O -
- O -
rRNA O +
for O +
18S O +
rRNA O +
is O +
impaired O +
in O +
enp1 O +
mutants O +
In O +
most O +
cases O +
reductions O +
in O +
ribosomal O +
subunit O +
levels O +
are O +
the O +
results O +
of O +
defects O +
in O +
pre O -
- O -
rRNA O +
processing O +
or O +
ribosome O +
assembly O +
or O +
both O +
( O -
3 O -
) O -
. O +

To O +
study O +
the O +
mechanism O +
by O +
which O +
Enp1 O +
affects O +
the O +
40S O +
subunit O -
, O +
we O +
analyzed O +
the O +
effects O +
of O +
enp1 O +
mutations O +
on O +
processing O +
of O +
the O +
pre O -
- O -
rRNA O +
using O +
pulse O -
- O -
chase O +
labeling O -
. O +

[ O -
methyl-3H O -
] O -
methionine O +
is O +
preferred O +
for O +
labeling O +
rRNAs O +
in O +
pulse O -
- O -
chase O +
analysis O +
because O +
rRNAs O +
are O +
specifically O +
methylated O +
during O +
the O +
early O +
steps O +
of O +
the O +
processing O -
. O +

Cells O +
of O +
W303 O -
- O -
1a O +
( O -
ENP1 O -
) O +
and O +
JBY51 O +
( O -
enp1 O -
- O -
1 O -
) O +
were O +
grown O +
at O +
23 O +
or O +
37 O -
° O -
C O +
for O +
2 O +
h O +
before O +
they O +
were O +
labeled O +
with O +
[ O -
methyl-3H O -
] O -
methionine O +
for O +
3 O +
min O +
and O +
chased O +
with O +
cold O +
methionine O +
for O +
2 O -
, O +
4 O +
and O +
12 O +
min O -
. O +

In O +
wild O -
- O -
type O +
cells O -
, O +
the O +
labeled O +
35S O +
rRNA O +
precursor O -
, O +
27S O +
and O +
20S O +
rRNA O +
intermediates O +
were O +
rapidly O +
chased O +
into O +
mature O +
25S O +
and O +
18S O +
rRNAs O +
( O -
Fig. O +
5 O -
) O -
, O +
at O +
23 O +
or O +
37 O -
° O -
C O -
. O +

In O +
contrast O -
, O +
enp1 O -
- O -
1 O +
cells O +
showed O +
dramatic O +
changes O +
after O +
incubation O +
at O +
37 O -
° O -
C O -
. O +

Although O +
at O +
23 O -
° O -
C O +
the O +
synthesis O +
and O +
processing O +
were O +
comparable O +
to O +
those O +
of O +
wild O -
- O -
type O +
cells O -
, O +
cells O +
cultured O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h O +
had O +
neither O +
20S O +
pre O -
- O -
rRNA O +
nor O +
18S O +
rRNA O -
, O +
while O +
25S O +
rRNA O +
was O +
generated O +
at O +
normal O +
levels O -
. O +

The O +
37 O -
° O -
C O +
grown O +
enp1 O -
- O -
1 O +
cells O +
also O +
had O +
low O +
levels O +
of O +
aberrant O +
23S O +
and O +
possibly O +
21S O +
intermediates O +
( O -
Fig. O +
5 O -
) O -
. O +

The O +
defect O +
in O +
18S O +
rRNA O +
synthesis O +
was O +
further O +
supported O +
by O +
pulse O -
- O -
chase O +
experiments O +
carried O +
out O +
using O +
[ O -
5,6 O -
- O -
3H O -
] O -
uracil O -
. O +

The O +
results O +
obtained O +
were O +
essentially O +
the O +
same O -
; O +
no O +
20S O +
pre O -
- O -
rRNA O +
or O +
18S O +
rRNA O +
was O +
produced O -
, O +
while O +
processing O +
to O +
25S O +
rRNA O +
was O +
not O +
affected O +
( O -
data O +
not O +
shown O -
) O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggested O +
that O +
the O +
enp1 O +
mutation O +
leads O +
to O +
specific O +
defects O +
in O +
the O +
processing O +
pathway O +
for O +
20S O +
pre O -
- O -
rRNA O +
and O +
18S O +
rRNA O -
, O +
resulting O +
in O +
reduced O +
40S O +
subunit O +
synthesis O +
and O +
a O +
lowered O +
level O +
of O +
the O +
40S O +
subunit O -
. O +

Enp1 O +
is O +
required O +
for O +
pre O -
- O -
rRNA O +
processing O +
at O +
A0 O -
, O +
A1 O +
and O +
A2 O +
sites O +
To O +
define O +
the O +
processing O +
steps O +
affected O +
by O +
the O +
enp1 O +
mutation O -
, O +
the O +
steady O +
state O +
levels O +
of O +
rRNA O +
precursors O +
and O +
mature O +
RNAs O +
were O +
analyzed O +
by O +
northern O +
blotting O -
. O +

Total O +
RNAs O +
were O +
isolated O +
from O +
cells O +
of O +
W303 O -
- O -
1a O +
( O -
ENP1 O -
) O +
and O +
JBY51 O +
( O -
enp1 O -
- O -
1 O -
) O +
grown O +
at O +
37 O -
° O -
C O +
for O +
2 O +
or O +
4 O +
h. O +
After O +
separation O +
on O +
formaldehyde O +
agarose O -
, O +
RNAs O +
were O +
transferred O +
onto O +
nylon O +
membranes O +
and O +
probed O +
with O +
radiolabeled O +
oligonucleotides O +
specific O +
to O +
various O +
regions O +
of O +
the O +
35S O +
pre O -
- O -
rRNA O +
( O -
Fig. O +
6A O -
) O -
. O +

After O +
incubation O +
at O +
37 O -
° O -
C O -
, O +
enp1 O -
- O -
1 O +
cells O +
had O +
wild O -
- O -
type O +
levels O +
of O +
25S O +
rRNA O -
, O +
but O +
reduced O +
levels O +
of O +
18S O +
rRNA O +
( O -
Fig. O +
6B O -
) O -
. O +

A O +
probe O +
specific O +
to O +
ITS1 O +
( O -
P5 O -
) O +
further O +
revealed O +
that O +
enp1 O -
- O -
1 O +
cells O +
incubated O +
at O +
the O +
non O -
- O -
permissive O +
temperature O +
accumulated O +
two O +
aberrant O +
rRNAs O -
, O +
23S O +
and O +
21S O +
( O -
Fig. O +
6C O -
) O -
. O +

Aberrant O +
rRNA O +
processing O +
products O +
of O +
similar O +
sizes O +
have O +
been O +
described O +
in O +
numerous O +
studies O +
( O -
14,31–34 O -
) O +
and O +
result O +
from O +
defects O +
in O +
processing O +
at O +
A0 O -
, O +
A1 O +
and O +
A2 O -
. O +

Additional O +
probes O +
were O +
used O +
to O +
verify O +
the O +
origins O +
of O +
the O +
23S O +
and O +
21S O +
RNAs O +
in O +
the O +
enp1 O -
- O -
1 O +
strain O -
. O +

The O +
23S O +
product O +
was O +
detected O +
by O +
oligos O +
1 O -
, O +
2 O -
, O +
4 O +
and O +
5 O -
, O +
but O +
not O +
by O +
oligos O +
6 O -
, O +
7 O +
or O +
8 O +
( O -
Fig. O +
6D O -
, O +
E O -
, O +
C O -
, O +
F O -
, O +
G O +
and O +
data O +
not O +
shown O -
) O -
. O +

Thus O +
this O +
RNA O +
extends O +
from O +
the O +
5′ O +
end O +
of O +
the O +
35S O +
rRNA O +
to O +
the O +
A3 O +
site O -
. O +

The O +
21S O +
product O +
was O +
detected O +
by O +
oligos O +
4 O +
and O +
5 O -
, O +
but O +
not O +
by O +
oligos O +
1 O -
, O +
2 O -
, O +
6 O -
, O +
7 O +
and O +
8 O +
( O -
Fig. O +
6E O -
, O +
C O -
, O +
D O -
, O +
F O -
, O +
G O +
and O +
data O +
not O +
shown O -
) O -
, O +
indicating O +
that O +
it O +
extends O +
from O +
the O +
A1 O +
to O +
the O +
A3 O +
site O -
. O +

At O +
37 O -
° O -
C O +
the O +
enp1 O -
- O -
1 O +
cells O +
also O +
had O +
less O +
32S O +
and O +
20S O +
rRNA O +
intermediates O +
( O -
Fig. O +
6B O +
and O +
E O -
) O -
. O +

These O +
results O +
suggest O +
that O +
the O +
enp1 O +
mutation O +
led O +
to O +
complete O +
or O +
nearly O +
complete O +
inhibition O +
of O +
processing O +
at O +
site O +
A0 O +
and O +
A2 O -
, O +
and O +
partial O +
inhibition O +
of O +
processing O +
at O +
site O +
A1 O -
. O +

As O +
a O +
consequence O -
, O +
the O +
35S O +
pre O -
- O -
rRNA O +
was O +
cleaved O +
at O +
site O +
A3 O +
instead O -
, O +
producing O +
23S O +
and O +
21S O +
rRNA O +
products O -
. O +

Consistent O +
with O +
this O +
theory O -
, O +
the O +
27SA2 O +
rRNA O +
intermediate O +
level O +
was O +
greatly O +
reduced O +
in O +
enp1 O +
cells O +
at O +
37 O -
° O -
C O +
( O -
Fig. O +
6C O -
) O +
due O +
to O +
the O +
inhibition O +
of O +
processing O +
at O +
A2 O -
, O +
while O +
the O +
27SB O +
pre O -
- O -
rRNA O +
level O +
was O +
similar O +
to O +
wild O -
- O -
type O +
cells O +
( O -
Fig. O +
6 O -
G O -
) O -
. O +

Moreover O -
, O +
no O +
difference O +
in O +
the O +
5.8 O +
rRNA O +
level O +
was O +
observed O +
between O +
the O +
wild O -
- O -
type O +
cells O +
and O +
enp1 O +
cells O +
( O -
Fig. O +
6H O -
) O -
. O +

Enp1 O +
is O +
associated O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O +
and O +
with O +
Nop1 O +
It O +
has O +
previously O +
been O +
shown O +
that O +
mutations O +
in O +
the O +
U3 O -
, O +
U14 O -
, O +
snR10 O +
and O +
snR30 O +
snoRNAs O +
and O +
in O +
their O +
associated O +
proteins O +
affect O +
processing O +
of O +
35S O +
pre O -
- O -
rRNA O +
at O +
A0 O -
, O +
A1 O +
and O +
A2 O -
. O +

Because O +
of O +
the O +
similarity O +
with O +
the O +
processing O +
defects O +
of O +
enp1 O -
- O -
1 O +
strains O -
, O +
we O +
tested O +
the O +
association O +
between O +
Enp1 O +
and O +
snoRNAs O -
. O +

To O +
do O +
this O -
, O +
we O +
created O +
a O +
strain O +
in O +
which O +
a O +
TAP O +
tag O +
was O +
fused O +
to O +
the O +
C O -
- O -
terminus O +
of O +
Enp1 O -
. O +

The O +
TAP O +
tag O +
contains O +
Staphylococcus B-Species +
aureus I-Species +
Protein O +
A O +
as O +
well O +
as O +
calmodulin O -
- O -
binding O +
peptide O +
sequences O -
, O +
so O +
the O +
tagged O +
Enp1 O +
binds O +
IgG O +
beads O +
with O +
high O +
specificity O -
. O +

Cells O +
grew O +
well O +
with O +
the O +
TAP O -
- O -
tagged O +
Enp1 O +
as O +
the O +
only O +
source O +
of O +
Enp1 O +
protein O -
, O +
showing O +
that O +
it O +
was O +
functional O -
. O +

As O +
a O +
control O -
, O +
we O +
used O +
a O +
TAP O +
tag O +
on O +
an O +
unrelated O +
cytoplasmic O +
protein O -
, O +
Hst2 O -
. O +

Strain O +
CWY14 O +
( O -
ENP1-TAP O -
) O +
and O +
the O +
Hst2-TAP O +
tagged O +
strain O +
were O +
grown O +
in O +
YPD O +
to O +
mid O -
- O -
exponential O +
phase O +
before O +
being O +
harvested O -
. O +

Extracts O +
were O +
prepared O +
and O +
mixed O +
with O +
IgG O +
agarose O +
beads O +
to O +
precipitate O +
Enp1-TAP O +
and O +
associated O +
RNAs O -
. O +

Total O +
RNAs O +
were O +
extracted O +
from O +
washed O +
IgG O +
beads O -
, O +
separated O +
on O +
6 O -
% O +
polyacrylamide O +
denaturing O +
gels O -
, O +
transferred O +
to O +
nylon O +
membranes O +
and O +
probed O +
with O +
radiolabeled O +
oligonucleotides O -
. O +

Northern O +
analysis O +
revealed O +
that O +
Enp1-TAP O +
precipitates O +
were O +
enriched O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O +
relative O +
to O +
precipitates O +
from O +
the O +
Hst2-tagged O +
strain O +
( O -
Fig. O +
7A O -
) O -
. O +

The O +
Enp1-TAP O +
samples O +
were O +
not O +
enriched O +
with O +
snR30 O +
snoRNA O +
( O -
Fig. O +
7A O -
) O -
, O +
nor O +
with O +
U24 O +
or O +
U18 O +
snoRNAs O +
( O -
data O +
not O +
shown O -
) O -
. O +

We O +
found O +
no O +
change O +
in O +
the O +
levels O +
of O +
U3 O -
, O +
U14 O -
, O +
snR10 O +
and O +
snR30 O +
snoRNAs O +
in O +
the O +
enp1 O +
mutant O -
, O +
indicating O +
that O +
the O +
mutation O +
did O +
not O +
affect O +
snoRNAs O +
levels O +
( O -
Fig. O +
6I O -
) O -
. O +

The O +
results O +
indicate O +
that O +
Enp1 O +
associates O +
in O +
vivo O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O -
. O +

Much O +
less O +
U3 O +
RNA O +
co O -
- O -
immunoprecipitated O +
with O +
Enp1-TAP O +
than O +
with O +
Protein O +
A O -
- O -
tagged O +
Nop1 O -
, O +
which O +
is O +
known O +
to O +
associate O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O +
( O -
Fig. O +
7A O -
) O -
. O +

However O -
, O +
Protein O +
A O -
- O -
Nop1 O +
was O +
much O +
more O +
efficiently O +
precipitated O +
than O +
was O +
the O +
Enp1-TAP O +
protein O +
( O -
data O +
not O +
shown O -
) O -
. O +

Therefore O -
, O +
it O +
is O +
likely O +
that O +
similar O +
amounts O +
of O +
RNAs O +
are O +
associated O +
with O +
the O +
two O +
proteins O +
and O +
that O +
the O +
proteins O +
are O +
part O +
of O +
the O +
same O +
complex O -
. O +

To O +
address O +
this O +
further O -
, O +
we O +
checked O +
for O +
the O +
presence O +
of O +
Nop1 O +
in O +
the O +
Enp1-TAP O +
immunoprecipitates O -
. O +

Figure O +
7B O +
shows O +
that O +
Nop1 O +
indeed O +
is O +
in O +
the O +
Enp1 O +
precipitate O +
but O +
not O +
in O +
the O +
Hst2 O +
control O -
, O +
whereas O +
an O +
abundant O +
ribosomal O +
protein O -
, O +
L3 O -
, O +
is O +
in O +
neither O +
precipitate O -
. O +

U3 O +
and O +
U14 O +
snoRNAs O +
have O +
been O +
shown O +
to O +
interact O +
with O +
rRNA O +
precursors O +
and O +
these O +
interactions O +
are O +
required O +
for O +
pre O -
- O -
rRNA O +
processing O +
( O -
35–37 O -
) O -
. O +

Using O +
an O +
in O +
vitro O +
system O -
, O +
U3 O +
was O +
also O +
shown O +
to O +
be O +
associated O +
with O +
its O +
rRNA O +
substrate O +
and O +
processing O +
product O +
( O -
38 O -
) O -
. O +

This O +
raised O +
the O +
possibility O +
that O +
Enp1 O +
might O +
also O +
be O +
associated O +
with O +
rRNAs O +
since O +
its O +
function O +
in O +
rRNA O +
processing O +
appeared O +
linked O +
to O +
those O +
of O +
U3 O +
and O +
U14 O +
snoRNAs O -
. O +

To O +
test O +
this O +
possibility O -
, O +
we O +
further O +
analyzed O +
the O +
RNAs O +
that O +
co O -
- O -
precipiate O +
with O +
TAP O -
- O -
tagged O +
Enp1 O -
. O +

The O +
RNAs O +
were O +
separated O +
on O +
1.2 O -
% O +
agarose O +
formaldehyde O +
gels O +
or O +
on O +
polyacrylamide O +
denaturing O +
gels O -
, O +
transferred O +
to O +
nylon O +
membranes O +
and O +
probed O +
with O +
radiolabeled O +
oligonucleotides O +
for O +
pre O -
- O -
rRNAs O -
. O +

A O +
probe O +
( O -
P4 O -
; O +
see O +
Fig. O +
6 O -
) O +
specific O +
to O +
20s O +
and O +
its O +
precursors O +
revealed O +
that O +
pre O -
- O -
rRNAs O +
35S O -
, O +
33S O -
, O +
32S O +
and O +
20S O +
specifically O +
co O -
- O -
precipitated O +
with O +
Enp1-TAP O +
( O -
Fig. O +
7C O -
) O -
. O +

No O +
such O +
enrichment O +
was O +
found O +
using O +
a O +
probe O +
( O -
P8 O -
; O +
see O +
Fig. O +
6 O -
) O +
specific O +
for O +
27S O +
RNAs O +
or O +
a O +
probe O +
for O +
5.8S O +
RNA O +
( O -
Fig. O +
7C O -
) O -
. O +

These O +
results O +
clearly O +
demonstrated O +
that O +
Enp1 O +
is O +
associated O +
with O +
substrates O +
and O +
products O +
of O +
the O +
early O +
steps O +
of O +
18S O +
rRNA O +
processing O -
. O +

Comparison O +
of O +
Enp1 O +
with O +
homologs O +
in O +
other O +
organisms O +
Homologs O +
of O +
Enp1 O +
protein O +
in O +
human B-Species -
, O +
Drosophila B-Species +
and O +
Caenorhabditis B-Species +
elegans I-Species +
have O +
been O +
reported O +
( O -
18 O -
) O -
. O +

A O +
previously O +
described O +
human B-Species +
homolog O -
, O +
bystin O -
, O +
was O +
only O +
306 O +
amino O +
acids O +
in O +
length O -
, O +
and O +
lacked O +
sequences O +
corresponding O +
to O +
the O +
N O -
- O -
terminal O +
163 O +
amino O +
acids O +
of O +
yeast B-Species +
Enp1 O +
( O -
19 O -
) O -
. O +

In O +
contrast O -
, O +
we O +
identified O +
a O +
human B-Species +
expressed O +
sequence O +
tag O +
( O -
EST O -
) O -
, O +
BC007340 O +
in O +
a O +
Blast O +
search O +
that O +
revealed O +
an O +
ORF O +
of O +
1311 O +
nucleotides O +
encoding O +
a O +
437 O +
amino O +
acid O +
polypeptide O +
( O -
39 O -
) O -
. O +

Comparison O +
of O +
this O +
437 O +
amino O +
acid O +
polypeptide O +
with O +
human B-Species +
bystin O +
( O -
19 O -
) O +
showed O +
that O +
they O +
were O +
encoded O +
by O +
the O +
same O +
gene O +
on O +
human B-Species +
chromosome O +
6 O -
. O +

The O +
reported O +
sequence O +
for O +
human B-Species +
bystin O +
is O +
a O +
fragment O +
of O +
the O +
437 O +
amino O +
acid O +
human B-Species +
Enp1 O +
protein O -
, O +
due O +
to O +
a O +
truncated O +
cDNA O +
sequence O -
. O +

Also O -
, O +
a O +
sequence O +
discrepancy O +
at O +
the O +
C O -
- O -
terminus O +
is O +
due O +
to O +
inaccurate O +
DNA O +
sequence O +
of O +
the O +
human B-Species +
bystin O -
, O +
as O +
confirmed O +
by O +
available O +
human B-Species +
genome O +
and O +
EST O +
sequences O -
. O +

Searches O +
of O +
the O +
database O +
of O +
other O +
organisms O +
identified O +
Enp1 O +
homologs O +
in O +
S.pombe B-Species -
, O +
Arabidopsis B-Species +
thaliana I-Species -
, O +
C.elegans B-Species -
, O +
Drosophila B-Species +
melanogaster I-Species +
and O +
mouse B-Species -
. O +

The O +
alignment O +
of O +
the O +
homologs O +
showed O +
that O +
they O +
shared O +
homology O +
from O +
the O +
N O -
- O -
terminus O +
to O +
the O +
C O -
- O -
terminus O -
, O +
with O +
the O +
C O -
- O -
terminal O +
half O +
extremely O +
well O +
conserved O -
, O +
with O +
close O +
to O +
90 O -
% O +
similarity O +
( O -
Fig. O +
8) O -
. O +

One O +
interesting O +
observation O +
is O +
that O +
the O +
two O +
amino O +
acids O +
changed O +
in O +
the O +
enp1 O -
- O -
1 O +
mutant O -
, O +
W242 O +
and O +
V415 O -
, O +
are O +
conserved O +
among O +
all O +
homologs O -
. O +

The O +
human B-Species +
Enp1 O +
homolog O +
was O +
cloned O +
and O +
expressed O +
in O +
yeast B-Species +
and O +
tested O +
for O +
function O -
. O +

Expressed O +
under O +
the O +
control O +
of O +
ADH O -
, O +
TEF O +
or O +
GPD O +
promoter O -
, O +
the O +
human B-Species +
Enp1 O +
homolog O +
did O +
not O +
complement O +
a O +
yeast B-Species +
enp1 O +
null O +
mutant O -
. O +

However O -
, O +
a O +
GFP O +
fusion O +
to O +
the O +
N O -
- O -
terminus O +
of O +
human B-Species +
Enp1 O +
homolog O +
localized O +
to O +
the O +
nucleus O +
and O +
was O +
enriched O +
in O +
the O +
nucleolus O +
( O -
data O +
not O +
shown O -
) O -
. O +

DISCUSSION O +
ENP1 O +
is O +
a O +
yeast B-Species +
gene O +
first O +
identified O +
in O +
a O +
genetic O +
screen O +
for O +
complementation O +
of O +
mutations O +
in O +
ost4 O -
, O +
which O +
encodes O +
a O +
subunit O +
of O +
oligosaccharide O +
transferase O +
( O -
17 O -
) O -
, O +
although O +
subsequent O +
work O +
showed O +
that O +
it O +
is O +
unlikely O +
that O +
Enp1 O +
has O +
any O +
connection O +
to O +
oligosaccharide O +
transferase O +
( O -
18 O -
) O -
. O +

ENP1 O +
was O +
shown O +
to O +
be O +
essential O +
for O +
viability O +
and O +
the O +
Enp1 O +
protein O +
localized O +
to O +
the O +
nucleus O +
( O -
18 O -
) O -
. O +

When O +
we O +
re O -
- O -
examined O +
the O +
localization O +
of O +
Enp1 O -
, O +
we O +
observed O +
that O +
the O +
protein O +
was O +
enriched O +
in O +
the O +
nucleolus O -
. O +

This O +
finding O +
led O +
us O +
to O +
test O +
for O +
a O +
role O +
of O +
Enp1 O +
in O +
ribosome O +
synthesis O -
. O +

Using O +
an O +
enp1 O +
ts O +
mutant O -
, O +
we O +
found O +
that O +
depletion O +
of O +
Enp1 O +
caused O +
a O +
40S O +
ribosomal O +
subunit O +
deficiency O -
. O +

Further O +
analysis O +
revealed O +
that O +
this O +
deficiency O +
was O +
not O +
due O +
to O +
a O +
change O +
of O +
the O +
subunit O -
's O +
stability O -
, O +
but O +
to O +
a O +
defect O +
in O +
the O +
synthesis O +
of O +
the O +
subunit O -
's O +
18S O +
rRNA O +
component O -
. O +

Pulse O -
- O -
chase O +
analysis O +
of O +
RNA O +
synthesis O +
in O +
an O +
enp1 O -
- O -
1 O +
strain O +
revealed O +
that O +
no O +
20S O +
pre O -
- O -
rRNA O +
or O +
18S O +
rRNA O +
was O +
made O +
at O +
the O +
non O -
- O -
permissive O +
temperature O -
, O +
while O +
levels O +
of O +
25S O +
rRNA O +
appeared O +
normal O -
. O +

Low O +
levels O +
of O +
precursors O +
to O +
18S O +
rRNA O +
were O +
detected O +
in O +
the O +
mutants O -
, O +
and O +
they O +
were O +
extremely O +
unstable O -
. O +

Northern O +
analysis O +
of O +
steady O +
state O +
RNA O +
levels O +
demonstrated O +
that O +
the O +
enp1 O +
mutation O +
specifically O +
inhibited O +
the O +
pre O -
- O -
rRNA O +
early O +
cleavages O +
at O +
sites O +
A0 O -
, O +
A1 O +
and O +
A2 O -
, O +
which O +
are O +
required O +
for O +
the O +
production O +
of O +
the O +
20S O +
pre O -
- O -
rRNA O +
and O +
the O +
18S O +
rRNA O -
. O +

These O +
defects O +
of O +
the O +
enp1 O +
mutation O +
on O +
rRNA O +
processing O +
are O +
very O +
similar O +
to O +
those O +
caused O +
by O +
mutation O +
of O +
KRR1 O -
, O +
another O +
essential O +
nucleolar O +
gene O +
required O +
for O +
synthesis O +
of O +
the O +
40S O -
, O +
but O +
not O +
the O +
60S O +
subunit O +
( O -
40 O -
) O -
. O +

Co O -
- O -
precipitation O +
analyses O +
provided O +
strong O +
evidence O +
that O +
Enp1 O +
is O +
directly O +
involved O +
in O +
pre O -
- O -
rRNA O +
processing O -
. O +

In O +
these O +
experiments O -
, O +
TAP O -
- O -
tagged O +
Enp1 O +
bound O +
to O +
IgG O +
beads O +
specifically O +
co O -
- O -
precipitated O +
with O +
two O +
snoRNAs O -
, O +
U3 O +
and O +
U14 O -
, O +
and O +
with O +
the O +
35S O -
, O +
33S O -
, O +
32S O +
and O +
20S O +
pre O -
- O -
rRNAs O -
. O +

Among O +
the O +
more O +
than O +
100 O +
snoRNAs O +
in O +
yeast B-Species +
cells O -
, O +
U3 O -
, O +
U14 O -
, O +
snR10 O -
, O +
snR30 O +
and O +
MRP O +
RNA O +
are O +
the O +
only O +
ones O +
required O +
for O +
rRNA O +
processing O -
. O +

It O +
has O +
been O +
shown O +
that O +
mutations O +
in O +
U3 O -
, O +
U14 O -
, O +
snR10 O +
and O +
snR30 O +
snoRNAs O +
and O +
protein O +
components O +
of O +
the O +
snoRNPs O +
affect O +
processing O +
at O +
sites O +
A0 O -
, O +
A1 O +
or O +
A2 O +
( O -
15,16,41,42 O -
) O -
. O +

Enp1 O -
's O +
interaction O +
with O +
U3 O +
and O +
U14 O +
snoRNAs O +
suggests O +
that O +
Enp1 O -
's O +
function O +
in O +
rRNA O +
processing O +
involves O +
these O +
two O +
snoRNAs O -
. O +

The O +
fact O +
that O +
the O +
nucleolar O +
protein O -
, O +
Nop1 O -
, O +
known O +
to O +
bind O +
to O +
U3 O +
and O +
U14 O +
RNAs O -
, O +
also O +
was O +
found O +
in O +
the O +
Enp1 O +
precipitate O -
, O +
provides O +
additional O +
evidence O +
that O +
Enp1 O +
is O +
part O +
of O +
a O +
complex O +
involved O +
in O +
processing O +
of O +
rRNA O -
. O +

Recently O -
, O +
a O +
genome O -
- O -
wide O +
study O +
of O +
yeast B-Species +
protein O +
complexes O -
, O +
using O +
a O +
TAP O +
tag O +
method O +
similar O +
to O +
ours O -
, O +
reported O +
a O +
number O +
of O +
proteins O +
that O +
co O -
- O -
immunoprecipitated O +
with O +
Enp1 O +
( O -
43 O -
) O -
. O +

These O +
proteins O +
included O +
Imp4 O -
, O +
Kre31 O -
, O +
Kre33 O -
, O +
Mpp10 O -
, O +
Nop1 O -
, O +
Nop14 O +
and O +
Sof1 O -
, O +
all O +
of O +
which O +
have O +
been O +
implicated O +
in O +
18S O +
RNA O +
processing O +
or O +
40S O +
biogenesis O -
. O +

Very O +
recently O +
( O -
after O +
the O +
studies O +
in O +
this O +
manuscript O +
were O +
concluded O -
) O +
Grandi O +
et O +
al. O +
published O +
an O +
analysis O +
of O +
components O +
of O +
the O +
90s O +
preribosomal O +
particle O -
, O +
which O +
include O +
the O +
35S O +
pre O -
- O -
rRNA O -
, O +
U3 O +
snoRNP O +
and O +
rRNA O +
processing O +
factors O +
for O +
the O +
40S O +
subunit O +
( O -
44 O -
) O -
. O +

In O +
agreement O +
with O +
our O +
findings O -
, O +
they O +
found O +
that O +
Enp1 O +
is O +
a O +
component O +
of O +
this O +
90s O +
complex O +
and O +
also O +
of O +
a O +
smaller O +
complex O +
containing O +
the O +
20S O +
pre O -
- O -
rRNA O -
. O +

Surprisingly O -
, O +
none O +
of O +
the O +
other O +
proteins O +
involved O +
in O +
processing O +
of O +
pre O -
- O -
rRNAs O +
that O +
were O +
tested O +
associated O +
with O +
the O +
20S O +
rRNA O -
, O +
suggesting O +
that O +
those O +
proteins O -
, O +
but O +
not O +
Enp1 O -
, O +
are O +
released O +
prior O +
to O +
20S O +
pre O -
- O -
rRNA O +
formation O +
( O -
44 O -
) O -
. O +

The O +
authors O +
also O +
showed O +
co O -
- O -
precipitation O +
of O +
Enp1 O +
with O +
dimethylated O +
20S O +
pre O -
- O -
rRNA O -
, O +
which O +
is O +
formed O +
after O +
export O +
of O +
20S O +
to O +
the O +
cytoplasm O -
. O +

These O +
results O +
of O +
Grandi O +
et O +
al. O +
suggest O +
that O +
Enp1 O +
may O +
also O +
be O +
involved O +
in O +
later O +
steps O +
of O +
processing O +
or O +
nuclear O +
export O -
. O +

A O +
previous O +
study O +
on O +
the O +
Enp1 O +
human B-Species +
homolog O -
, O +
bystin O -
, O +
reported O +
that O +
the O +
protein O +
was O +
localized O +
in O +
the O +
cytoplasm O +
of O +
mammalian O +
cells O +
and O +
might O +
be O +
involved O +
in O +
cell O +
adhesion O +
( O -
19 O -
) O -
. O +

Our O +
discovery O +
of O +
the O +
437 O +
amino O +
acid O +
human B-Species +
Enp1 O +
homolog O +
revealed O +
that O +
the O +
bystin O +
studied O +
previously O +
was O +
from O +
a O +
truncated O +
library O +
cDNA O +
encoding O +
only O +
the O +
C O -
- O -
terminal O +
306 O +
amino O +
acids O -
. O +

Although O +
the O +
human B-Species +
homolog O +
of O +
Enp1 O +
did O +
not O +
complement O +
a O +
yeast B-Species +
Δenp1 O +
mutant O -
, O +
we O +
did O +
show O +
that O +
it O +
was O +
localized O +
to O +
the O +
nucleus O +
and O +
enriched O +
in O +
the O +
nucleolus O +
( O -
data O +
not O +
shown O -
) O -
. O +

This O +
strongly O +
suggests O +
that O +
the O +
conserved O +
function O +
of O +
Enp1 O +
is O +
in O +
rRNA O +
processing O -
. O +

The O +
cytoplasmic O +
localization O +
of O +
bystin O +
and O +
its O +
proposed O +
function O +
in O +
cell O +
adhesion O +
are O +
unlikely O +
to O +
reflect O +
the O +
actual O +
function O +
of O +
the O +
human B-Species +
Enp1 O +
homolog O -
. O +

It O +
will O +
be O +
important O +
to O +
study O +
the O +
nature O +
of O +
the O +
associations O +
between O +
Enp1 O +
and O +
U3 O +
and O +
U14 O +
snoRNPs O -
, O +
and O +
to O +
learn O +
more O +
about O +
the O +
exact O +
role O +
of O +
Enp1 O +
in O +
ribosomal O +
RNA O +
processing O -
. O +

Piezoelectric O +
osteotomy O +
in O +
hand O +
surgery O -
: O +
first O +
experiences O +
with O +
a O +
new O +
technique O +
Abstract O +
Background O +
In O +
hand O +
and O +
spinal O +
surgery O +
nerve O +
lesions O +
are O +
feared O +
complications O +
with O +
the O +
use O +
of O +
standard O +
oscillating O +
saws O -
. O +

Oral O +
surgeons O +
have O +
started O +
using O +
a O +
newly O +
developed O +
ultrasound O +
bone O +
scalpel O +
when O +
performing O +
precise O +
osteotomies O -
. O +

By O +
using O +
a O +
frequency O +
of O +
25–29 O +
kHz O +
only O +
mineralized O +
tissue O +
is O +
cut O -
, O +
sparing O +
the O +
soft O +
tissue O -
. O +

This O +
reduces O +
the O +
risk O +
of O +
nerve O +
lesions O -
. O +

As O +
there O +
is O +
a O +
lack O +
of O +
experience O +
with O +
this O +
technique O +
in O +
the O +
field O +
of O +
orthopaedic O +
bone O +
surgery O -
, O +
we O +
performed O +
the O +
first O +
ultrasound O +
osteotomy O +
in O +
hand O +
surgery O -
. O +

Method O +
While O +
performing O +
a O +
correctional O +
osteotomy O +
of O +
the O +
5th O +
metacarpal O +
bone O +
we O +
used O +
the O +
Piezosurgery O -
® O +
Device O +
from O +
Mectron O +
[ O -
Italy O -
] O +
instead O +
of O +
the O +
usual O +
oscillating O +
saw O -
. O +

We O +
will O +
report O +
on O +
our O +
experience O +
with O +
one O +
case O -
, O +
with O +
a O +
follow O +
up O +
time O +
of O +
one O +
year O -
. O +

Results O +

The O +
cut O +
was O +
highly O +
precise O +
and O +
there O +
were O +
no O +
vibrations O +
of O +
the O +
bone O -
. O +

The O +
time O +
needed O +
for O +
the O +
operation O +
was O +
slightly O +
longer O +
than O +
the O +
time O +
needed O +
while O +
using O +
the O +
usual O +
saw O -
. O +

Bone O +
healing O +
was O +
good O +
and O +
at O +
no O +
point O +
were O +
there O +
any O +
neurovascular O +
disturbances O -
. O +

Conclusion O +

The O +
Piezosurgery O -
® O +
Device O +
is O +
useful O +
for O +
small O +
long O +
bone O +
osteotomies O -
. O +

Using O +
the O +
fine O +
tip O +
enables O +
curved O +
cutting O +
and O +
provides O +
an O +
opportunity O +
for O +
new O +
osteotomy O +
techniques O -
. O +

As O +
the O +
device O +
selectively O +
cuts O +
bone O +
we O +
feel O +
that O +
this O +
device O +
has O +
great O +
potential O +
in O +
the O +
field O +
of O +
hand- O +
and O +
spinal O +
surgery O -
. O +

Background O +
For O +
osteotomies O +
of O +
the O +
hand O +
oscillating O +
saws O +
are O +
usually O +
used O +
[ O -
1 O -
] O -
. O +

Even O +
though O +
they O +
are O +
varied O +
in O +
size O -
, O +
they O +
are O +
not O +
very O +
precise O +
for O +
use O +
in O +
the O +
vicinity O +
of O +
nerves O +
and O +
arteries O -
. O +

They O +
also O +
pose O +
problems O +
while O +
being O +
used O +
in O +
conjunction O +
with O +
magnification O -
, O +
as O +
one O -
's O +
range O +
of O +
sight O +
and O +
focus O +
is O +
restricted O +
when O +
wearing O +
magnifying O +
glasses O -
. O +

For O +
that O +
reason O +
oral O +
surgeons O +
have O +
moved O +
to O +
using O +
the O +
newly O +
developed O +
piezoelectrical O +
bone O +
scalpel O +
when O +
operating O +
in O +
the O +
near O +
vicinity O +
of O +
nerves O +
or O +
arteries O -
. O +

The O +
tip O +
of O +
this O +
instrument O +
oscillates O +
in O +
the O +
frequency O +
of O +
ultrasound O +
[ O -
2 O -
] O -
. O +

The O +
mechanism O +
of O +
this O +
device O +
is O +
based O +
on O +
the O +
so O +
called O +
Piezo O +
– O +
Effect O -
. O +

French O +
Physicists O +
Jean O +
and O +
Marie O +
Curie O +
first O +
mentioned O +
the O +
direct O +
Piezo O -
- O -
Effect O +
1880 O -
, O +
whereby O +
certain O +
crystals O +
produce O +
electrical O +
current O +
while O +
under O +
mechanical O +
pressure O -
. O +

The O +
reciprocal O +
effect O -
, O +
by O +
which O +
the O +
crystals O +
are O +
deformed O +
when O +
under O +
electrical O +
current O -
, O +
was O +
then O +
discovered O +
a O +
while O +
later O -
. O +

This O +
is O +
the O +
effect O +
being O +
used O +
by O +
the O +
Piezosurgery O +
Device O -
® O -
. O +

In O +
this O +
device O -
, O +
the O +
electrical O +
field O +
is O +
located O +
in O +
the O +
handle O +
of O +
the O +
saw O +
[ O -
3 O -
] O -
. O +

Due O +
to O +
the O +
deformation O +
caused O +
by O +
the O +
electrical O +
current O -
, O +
a O +
cutting O +
– O +
hammering O +
movement O +
is O +
produced O +
at O +
the O +
tip O +
of O +
the O +
instrument O -
. O +

These O +
micro O +
movements O +
are O +
in O +
the O +
frequency O +
range O +
of O +
25 O +
to O +
29 O +
kHz O +
and O -
, O +
depending O +
on O +
the O +
insert O -
, O +
with O +
an O +
amplitude O +
of O +
60 O +
to O +
210 O +
μm O -
. O +

This O +
way O +
only O +
mineralized O +
tissue O +
is O +
selectively O +
cut O -
. O +

Neurovascular O +
tissue O +
and O +
other O +
soft O +
tissue O +
would O +
only O +
be O +
cut O +
by O +
a O +
frequency O +
of O +
above O +
50 O +
kHz O +
[ O -
3 O -
- O -
5 O -
] O -
. O +

Depending O +
on O +
the O +
strength O +
of O +
the O +
bone O +
and O +
the O +
blade O +
geometry O -
, O +
the O +
efficiency O +
of O +
the O +
cutting O +
can O +
be O +
regulated O +
by O +
the O +
frequency O +
modulator O +
and O +
the O +
power O +
level O -
. O +

For O +
cooling O +
there O +
is O +
an O +
integrated O +
pump O +
with O +
five O +
different O +
working O +
levels O -
. O +

This O +
pump O +
automatically O +
washes O +
physiological O +
solution O +
to O +
the O +
area O +
being O +
cut O -
. O +

The O +
cost O +
of O +
the O +
device O +
is O +
about O +
7.000 O +
USD O -
. O +

Additional O +
costs O +
per O +
operation O +
are O +
for O +
the O +
cooling O +
liquid O +
and O +
are O +
in O +
the O +
range O +
of O +
a O +
few O +
dollars O -
. O +

We O +
have O +
used O +
the O +
Piezosurgery O +
Device O -
® O +
by O +
Mectron O +
[ O -
Italy O -
] O +
[ O -
3 O -
] O +
for O +
the O +
first O +
time O +
in O +
osteotomies O +
of O +
the O +
long O +
bone O +
in O +
the O +
field O +
of O +
hand O +
surgery O -
. O +

We O +
will O +
report O +
on O +
our O +
experience O +
with O +
one O +
case O -
, O +
with O +
a O +
follow O +
up O +
time O +
of O +
one O +
year O -
. O +

Method O +
The O +
correctional O +
osteotomy O +
was O +
performed O +
on O +
a O +
23 O +
year O +
old O +
worker O +
who O +
suffered O +
a O +
malunited O +
metacarpal O +
bone O +
fracture O +
of O +
the O +
fifth O +
finger O +
on O +
his O +
dominant O +
hand O -
. O +

The O +
X O -
- O -
ray O +
revealed O +
a O +
45 O +
degree O +
angular O +
deformity O +
of O +
the O +
fifth O +
metacarpal O +
neck O +
with O +
internal O +
rotation O -
. O +

( O -
Figure O +
1 O -
) O -
. O +

The O +
operation O +
was O +
performed O +
under O +
regional O +
anesthesia O -
. O +

A O +
longitudinal O +
incision O +
was O +
made O +
over O +
the O +
fifth O +
metacarpal O -
. O +

The O +
tendon O +
of O +
the O +
extensor O +
digiti O +
minimi O +
was O +
found O +
and O +
on O +
its O +
radial O +
side O +
the O +
periosteum O +
of O +
metacarpal O +
five O +
was O +
reached O -
. O +

The O +
periosteum O +
was O +
opened O +
longitudinally O +
over O +
the O +
defect O +
as O +
usual O -
. O +

For O +
the O +
correction O +
of O +
the O +
defect O +
of O +
45 O +
degrees O -
, O +
a O +
bone O +
wedge O +
was O +
excised O -
. O +

Instead O +
of O +
using O +
the O +
traditional O +
oscillating O +
saw O -
, O +
the O +
Piezosurgery O +
Device O -
® O +
[ O -
3 O -
] O +
was O +
used O +
( O -
Figure O +
2 O -
) O -
. O +

We O +
used O +
a O +
sharp O +
hardened O +
saw O +
coated O +
with O +
titannitrid O +
( O -
Figure O +
3 O -
) O -
. O +

For O +
most O +
of O +
the O +
surgery O +
the O +
highest O +
power O +
level O -
, O +
the O +
boosted O +
burst O +
c O -
, O +
was O +
used O -
. O +

We O +
set O +
the O +
automatic O +
cooling O +
of O +
the O +
area O +
with O +
water O +
to O +
its O +
highest O +
level O -
. O +

The O +
angulation O +
and O +
rotation O +
was O +
corrected O +
and O +
fixed O +
with O +
a O +
1.5 O +
mm O +
titanium O +
five O -
- O -
hole O +
plate O +
and O +
four O +
screws O -
. O +

Closure O +
of O +
the O +
wound O +
was O +
done O +
in O +
layers O -
. O +

Mobilization O +
was O +
started O +
on O +
the O +
10th O +
postoperative O +
day O -
. O +

The O +
overall O +
time O +
of O +
observation O +
was O +
one O +
year O -
. O +

Results O +
and O +
discussion O +
The O +
Piezosurgery O -
® O +
Device O +
is O +
ideally O +
sized O +
for O +
hand O +
surgery O -
. O +

The O +
cutting O +
was O +
very O +
precise O -
. O +

The O +
edges O +
of O +
the O +
osteotomy O +
were O +
all O +
sharp O +
to O +
the O +
edge O -
, O +
there O +
was O +
no O +
need O +
to O +
split O +
the O +
bone O +
with O +
a O +
chisel O -
, O +
nor O +
was O +
there O +
the O +
danger O +
of O +
a O +
break O +
out O -
. O +

During O +
the O +
osteotomy O +
there O +
were O +
no O +
disturbing O +
vibrations O +
in O +
the O +
area O +
of O +
operation O -
. O +

This O +
absence O +
of O +
vibration O +
is O +
very O +
practical O +
for O +
operations O +
using O +
a O +
magnifier O -
. O +

Vercellotti O +
mentions O +
that O +
to O +
overcome O +
any O +
problems O +
during O +
surgery O -
, O +
instead O +
of O +
increasing O +
pressure O +
on O +
the O +
hand O +
piece O -
, O +
as O +
in O +
traditional O +
techniques O -
, O +
it O +
is O +
necessary O +
to O +
find O +
the O +
correct O +
pressure O +
to O +
achieve O +
the O +
desired O +
result O -
. O +

With O +
piezoelectric O +
surgery O -
, O +
increasing O +
the O +
working O +
pressure O +
above O +
a O +
certain O +
limit O +
impedes O +
the O +
vibrations O +
of O +
the O +
insert O +
[ O -
4 O -
] O -
. O +

We O +
have O +
also O +
experienced O +
this O +
in O +
our O +
study O -
. O +

The O +
instrument O +
can O +
be O +
moved O +
in O +
all O +
directions O +
comparable O +
to O +
a O +
pen O -
. O +

The O +
tip O +
of O +
the O +
instrument O +
is O +
exchangeable O -
. O +

Using O +
the O +
fine O +
tip O +
enables O +
multiplanar O +
as O +
well O +
as O +
curved O +
cutting O -
. O +

Because O +
of O +
the O +
automatic O +
water O +
cooling O +
during O +
the O +
whole O +
procedure O -
, O +
there O +
is O +
always O +
a O +
clear O +
view O +
onto O +
the O +
object O -
. O +

This O +
is O +
something O +
oral O +
surgeons O +
found O +
especially O +
useful O +
[ O -
6 O -
] O -
. O +

The O +
authors O +
mention O +
that O +
the O +
downside O +
of O +
the O +
device O +
is O +
the O +
relative O +
slow O +
sawing O +
process O -
. O +

We O +
needed O +
about O +
30 O +
seconds O +
for O +
one O +
cut O +
of O +
the O +
relatively O +
small O +
bone O -
. O +

This O +
is O +
about O +
20 O +
seconds O +
longer O +
than O +
the O +
time O +
needed O +
for O +
cutting O +
with O +
the O +
usual O +
saw O -
. O +

Although O +
the O +
power O +
can O +
be O +
regulated O +
with O +
the O +
power O +
box O +
and O +
the O +
use O +
of O +
different O +
scalpels O -
, O +
we O +
agree O +
with O +
other O +
authors O +
that O +
the O +
optimal O +
use O +
of O +
this O +
device O +
is O +
in O +
surgeries O +
of O +
small O +
bones O +
where O +
precise O +
and O +
soft O +
tissue O +
friendly O +
cutting O +
is O +
required O +
[ O -
7 O -
] O -
. O +

As O +
other O +
literature O +
has O +
shown O -
, O +
the O +
device O +
selectively O +
cuts O +
bone O +
while O +
sparing O +
nerves O +
and O +
other O +
soft O +
tissue O +
[ O -
2,3 O -
] O -
. O +

This O +
allows O +
for O +
minimal O +
invasive O +
surgeries O +
with O +
limited O +
retraction O +
of O +
soft O +
tissue O +
and O +
minimal O +
stripping O +
of O +
the O +
periosteum O -
, O +
saves O +
time O +
and O +
might O +
have O +
a O +
positive O +
effect O +
on O +
the O +
healing O +
process O -
. O +

Our O +
aim O +
of O +
the O +
first O +
time O +
use O +
of O +
the O +
Piezosurgery O -
® O +
Device O +
in O +
hand O +
surgery O +
was O +
to O +
check O +
its O +
usability O +
in O +
osteotomies O +
of O +
tubular O +
bones O -
. O +

The O +
preparation O +
of O +
the O +
bone O +
was O +
done O +
in O +
the O +
usual O +
manner O +
as O +
is O +
done O +
when O +
cutting O +
with O +
an O +
oscillating O +
saw O -
. O +

The O +
reason O +
for O +
this O +
was O +
to O +
fully O +
visualize O +
the O +
cutting O +
process O +
using O +
this O +
new O +
device O -
, O +
although O +
in O +
the O +
future O -
, O +
it O +
should O +
be O +
possible O +
to O +
minimize O +
the O +
bony O +
exposure O -
. O +

In O +
our O +
patient O +
the O +
postoperative O +
healing O +
of O +
the O +
wound O +
and O +
the O +
bone O +
consolidation O +
( O -
Figure O +
4 O -
) O +
were O +
smooth O -
. O +

The O +
duration O +
of O +
postoperative O +
sick O +
leave O +
was O +
four O +
weeks O +
which O +
is O +
more O +
rapid O +
than O +
the O +
usual O +
recovery O +
period O -
. O +

The O +
patient O +
regained O +
full O +
use O +
of O +
his O +
finger O +
according O +
to O +
the O +
state O +
before O +
the O +
fracture O -
. O +

At O +
no O +
point O +
was O +
there O +
any O +
loss O +
of O +
sensitivity O -
. O +

The O +
patient O +
as O +
well O +
as O +
the O +
surgeons O +
were O +
fully O +
satisfied O +
with O +
the O +
result O -
. O +

Conclusion O +

The O +
Piezosurgery O -
® O +
Device O +
is O +
a O +
useful O +
device O +
for O +
small O +
long O +
bone O +
osteotomies O -
. O +

We O +
feel O +
that O +
this O +
device O +
has O +
great O +
potential O +
in O +
the O +
field O +
of O +
hand- O +
and O +
spinal O +
surgery O -
. O +

As O +
the O +
device O +
selectively O +
cuts O +
bone O -
, O +
considerable O +
nerve O +
lesions O +
can O +
be O +
avoided O +
and O +
minimal O +
invasive O +
surgeries O +
are O +
possible O -
. O +

Using O +
the O +
fine O +
tip O +
enables O +
curved O +
cutting O +
and O +
provides O +
an O +
opportunity O +
for O +
new O +
osteotomy O +
techniques O -
. O +

Competing O +
interests O +
The O +
author O -
( O -
s O -
) O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O -
. O +

Authors O -
' O +
contributions O +
DJH O +
initiated O +
and O +
coordinated O +
the O +
new O +
application O +
of O +
Piezosurgery O -
® O +
device O +
and O +
wrote O +
the O +
publication O -
. O +

StSt O +
lead O +
the O +
osteotomy O +
as O +
he O +
was O +
experienced O +
with O +
this O +
tool O +
from O +
oral O +
surgery O -
. O +

He O +
played O +
a O +
major O +
part O +
in O +
writing O +
the O +
technical O +
aspects O -
. O +

OVK O +
was O +
the O +
treating O +
surgeon O -
, O +
performed O +
the O +
operation O +
and O +
evaluated O +
the O +
new O +
tool O -
. O +

SS O +
performed O +
a O +
literature O +
review O +
and O +
wrote O +
part O +
of O +
the O +
publication O -
. O +

PH O +
was O +
the O +
treating O +
chief O +
surgeon O -
, O +
evaluated O +
the O +
new O +
tool O +
and O +
lead O +
the O +
treatment O +
in O +
all O +
aspects O -
. O +

Consent O +
We O +
obtained O +
oral O +
consent O +
from O +
the O +
patient O +
but O +
could O +
not O +
obtain O +
written O +
consent O -
. O +

Pre O -
- O -
publication O +
history O +
The O +
pre O -
- O -
publication O +
history O +
for O +
this O +
paper O +
can O +
be O +
accessed O +
here O -
: O +

Alexithymia O +
and O +
anxiety O +
in O +
female O +
chronic O +
pain O +
patients O +
Abstract O +
Objectives O +
Alexithymia O +
is O +
highly O +
prevalent O +
among O +
chronic O +
pain O +
patients O -
. O +

Pain O +
is O +
a O +
remarkable O +
cause O +
for O +
high O +
levels O +
of O +
chronic O +
anxiety O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
prevalence O +
of O +
alexithymia O +
and O +
to O +
determine O +
anxiety O +
levels O +
among O +
DSM O -
- O -
IV O +
somatoform O +
pain O +
disorder O +
( O -
chronic O +
pain O -
) O +
female O +
patients O +
and O +
to O +
examine O +
the O +
relationship O +
between O +
alexithymia O +
and O +
the O +
self O -
- O -
reporting O +
of O +
pain O -
. O +

Methods O +
Thirty O +
adult O +
females O +
( O -
mean O +
age O -
: O +
34,63 O +
± O +
10,62 O +
years O -
) O -
, O +
who O +
applied O +
to O +
the O +
outpatient O +
psychiatry O +
clinic O +
at O +
a O +
public O +
hospital O +
with O +
the O +
diagnosis O +
of O +
chronic O +
pain O +
disorder O +
( O -
DSM O -
- O -
IV O -
) O -
, O +
were O +
included O +
in O +
the O +
study O -
. O +

Thirty O +
seven O +
healthy O +
females O +
( O -
mean O +
age O -
: O +
34,46 O +
± O +
7,43 O +
years O -
) O -
, O +
who O +
matched O +
for O +
sociodemographic O +
features O +
with O +
the O +
patient O +
group O -
, O +
consisted O +
the O +
control O +
group O -
. O +

A O +
sociodemographic O +
data O +
form O -
, O +
26-item O +
Toronto O +
Alexithymia O +
Scale O +
( O -
TAS-26 O -
) O -
, O +
Spielberger O +
Trait O +
Anxiety O +
Inventory O +
( O -
STAI O -
) O +
were O +
administered O +
to O +
each O +
subject O +
and O +
information O +
was O +
obtained O +
on O +
several O +
aspects O +
of O +
the O +
patients O -
' O +
pain O -
, O +
including O +
intensity O +
( O -
measured O +
by O +
VAS O -
) O -
, O +
and O +
duration O -
. O +

Results O +
Chronic O +
pain O +
patients O +
were O +
found O +
significantly O +
more O +
alexithymic O +
than O +
controls O -
. O +

There O +
was O +
a O +
positive O +
correlation O +
between O +
TAS-26 O +
scores O +
and O +
the O +
duration O +
of O +
pain O -
. O +

The O +
alexithymic O +
and O +
nonalexithymic O +
group O +
did O +
not O +
differ O +
in O +
their O +
perception O +
of O +
pain O -
. O +

Neither O +
positive O +
correlation O +
nor O +
significant O +
difference O +
was O +
found O +
between O +
alexithymia O +
and O +
trait O +
anxiety O +
in O +
pain O +
patients O -
. O +

Discussion O +
Alexithymia O +
may O +
be O +
important O +
in O +
addressing O +
the O +
diversity O +
of O +
subjective O +
factors O +
involved O +
in O +
pain O -
. O +

The O +
conceptualization O +
of O +
alexithymia O +
as O +
a O +
personality O +
trait O +
as O +
well O +
as O +
a O +
secondary O +
state O +
reaction O +
is O +
underlined O +
by O +
our O +
data O -
. O +

Background O +
The O +
original O +
definition O +
of O +
alexithymia O +
is O +
the O +
inability O +
to O +
identify O +
and O +
use O +
verbal O +
language O +
to O +
describe O +
feelings O +
[ O -
1,2 O -
] O -
. O +

Alexithymia O +
has O +
been O +
associated O +
with O +
a O +
variety O +
of O +
psychiatric O +
disorders O +
as O +
well O +
as O +
physical O +
illness O +
[ O -
3 O -
- O -
10 O -
] O -
. O +

As O +
a O +
measure O -
, O +
Toronto O +
Alexithymia O +
Scale O +
was O +
significantly O +
correlated O +
with O +
the O +
measures O +
of O +
the O +
tendency O +
to O +
experience O +
and O +
report O +
physical O +
signs O +
and O +
symptoms O +
[ O -
11 O -
] O -
. O +

Several O +
studies O +
have O +
found O +
a O +
high O +
prevalence O +
of O +
alexithymia O +
in O +
pain O +
patients O -
. O +

Chronic O +
pain O +
patients O +
frequently O +
exhibit O +
many O +
of O +
the O +
core O +
features O +
of O +
alexithymia O -
, O +
such O +
as O +
problems O +
in O +
identifying O +
and O +
describing O +
subjective O +
feelings O -
, O +
impoverished O +
imaginative O +
abilities O -
, O +
and O +
excessive O +
preoccupation O +
with O +
physical O +
symptoms O +
and O +
external O +
events O -
. O +

Although O +
several O +
studies O +
have O +
found O +
a O +
high O +
prevalence O +
of O +
alexithymia O +
in O +
pain O +
patients O -
, O +
the O +
way O +
alexithymia O +
may O +
possibly O +
influence O +
pain O +
experience O +
is O +
still O +
unclear O +
[ O -
12,13 O -
] O -
. O +

DSM O -
- O -
IV O -
- O -
TR O +
defines O +
pain O +
disorder O +
as O +
the O +
presence O +
of O +
pain O +
that O +
is O +
" O -
the O +
predominant O +
focus O +
of O +
clinical O +
attention O -
" O +
[ O -
14 O -
] O -
. O +

In O +
chronic O +
pain O +
disorder O -
, O +
patients O +
complain O +
of O +
chronic O +
pain O -
, O +
for O +
which O +
no O +
physical O +
etiology O +
could O +
be O +
found O +
or O +
the O +
underlying O +
disorder O +
is O +
insufficient O +
in O +
explaining O +
the O +
symptoms O -
. O +

The O +
pain O +
causes O +
clinically O +
significant O +
distress O +
or O +
impairment O +
in O +
social O -
, O +
occupational O -
, O +
or O +
other O +
important O +
areas O +
of O +
functioning O -
. O +

Psychological O +
factors O +
are O +
judged O +
to O +
have O +
an O +
important O +
role O +
in O +
the O +
onset O -
, O +
severity O -
, O +
exacerbation O -
, O +
or O +
maintenance O +
of O +
the O +
pain O +
[ O -
15 O -
] O -
. O +

The O +
alexithymic O +
person O -
's O +
difficulty O +
in O +
identifying O +
and O +
describing O +
feelings O +
may O +
increase O +
symptom O +
reporting O +
by O +
several O +
mechanisms O -
. O +

Consequently O -
, O +
due O +
to O +
the O +
difficulty O +
to O +
experience O +
and O +
express O +
emotions O -
, O +
alexithymia O +
has O +
been O +
linked O +
with O +
somatosensory O +
amplification O -
, O +
which O +
is O +
the O +
tendency O +
to O +
focus O +
on O +
benign O +
somatic O +
sensations O -
. O +

Alexithymic O +
subjects O +
are O +
considered O +
to O +
focus O +
on O +
somatic O +
manifestations O +
of O +
emotional O +
arousal O -
, O +
resulting O +
in O +
misinterpretation O +
of O +
somatic O +
sensations O +
as O +
signs O +
of O +
physical O +
illness O +
[ O -
12,13,16 O -
] O -
. O +

Accordingly O -
, O +
previous O +
studies O +
have O +
found O +
evidence O +
of O +
an O +
association O +
between O +
alexithymia O +
and O +
the O +
development O +
of O +
functional O +
somatic O +
symptoms O -
, O +
as O +
seen O +
in O +
patients O +
with O +
somatoform O +
disorders O -
. O +

On O +
the O +
other O +
hand O -
, O +
alexithymia O +
may O +
also O +
occur O +
as O +
a O +
secondary O +
state O +
reaction O +
in O +
response O +
to O +
severe O +
and O +
chronic O +
medical O +
illness O +
[ O -
17 O -
- O -
21 O -
] O -
. O +

Based O +
on O +
previous O +
findings O -
, O +
these O +
factors O +
are O +
worth O +
receiving O +
more O +
attention O +
in O +
terms O +
of O +
clinical O +
research O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
prevalence O +
of O +
alexithymia O +
among O +
DSM O -
- O -
IV O +
somatoform O +
pain O +
disorder O +
( O -
chronic O +
pain O -
) O +
female O +
patients O +
and O +
to O +
examine O +
the O +
relationship O +
between O +
alexithymia O +
and O +
the O +
self O -
- O -
reporting O +
of O +
pain O +
in O +
this O +
group O +
of O +
patients O -
. O +

Besides O -
, O +
the O +
study O +
searched O +
for O +
the O +
anxiety O +
levels O +
of O +
chronic O +
pain O +
patients O +
with O +
or O +
without O +
alexithymia O -
. O +

Materials O +
and O +
methods O +
Sample O +
The O +
sample O +
consisted O +
of O +
30 O +
females O +
who O +
applied O +
to O +
the O +
outpatient O +
psychiatry O +
clinic O +
at O +
a O +
public O +
hospital O +
and O +
who O +
met O +
DSM O -
- O -
IV O +
diagnostic O +
criteria O +
for O +
chronic O +
pain O +
disorder O -
. O +

Patients O +
with O +
concomitant O +
psychiatric O +
disorders O -
, O +
such O +
as O +
major O +
depression O -
, O +
anxiety O +
disorders O +
and O +
somatoform O +
disorders O +
other O +
than O +
pain O +
disorder O +
were O +
excluded O -
. O +

Patients O +
either O +
directly O +
applied O +
to O +
the O +
psychiatry O +
clinic O +
themselves O +
or O +
were O +
referred O +
for O +
psychiatric O +
assessment O +
from O +
another O +
outpatient O +
clinic O -
, O +
mainly O +
physical O +
medicine O +
and O +
rehabilitation O -
. O +

After O +
complete O +
description O +
of O +
the O +
study O -
, O +
written O +
informed O +
consent O +
was O +
obtained O +
from O +
each O +
subject O -
. O +

The O +
control O +
group O +
was O +
37 O +
healthy O +
females O -
, O +
who O +
matched O +
for O +
age O -
, O +
and O +
education O +
with O +
the O +
subjects O -
. O +

All O +
subjects O +
participated O +
voluntarily O +
in O +
the O +
study O +
and O +
gave O +
consent O +
after O +
the O +
procedure O +
had O +
been O +
fully O +
explained O +
to O +
them O -
. O +

The O +
mean O +
age O +
of O +
the O +
patients O +
and O +
the O +
healthy O +
controls O +
was O +
34,63 O +
± O +
10,62 O +
( O -
range O -
: O +
16–62 O -
) O +
and O +
34,46 O +
± O +
7,43 O +
( O -
range O -
: O +
22–57 O -
) O +
years O +
and O +
the O +
educational O +
level O +
was O +
6,13 O +
± O +
3,03 O +
( O -
range O -
: O +
5–11 O -
) O +
and O +
6,59 O +
± O +
2,9 O +
( O -
range O -
: O +
5–14 O -
) O +
years O -
, O +
respectively O -
. O +

There O +
were O +
no O +
significant O +
differences O +
between O +
the O +
two O +
groups O +
with O +
respect O +
to O +
age O +
( O -
t O +
= O +
0,79 O -
, O +
df O +
= O +
65 O -
, O +
P O +
> O +
0,05 O -
) O -
, O +
educational O +
level O +
( O -
t O +
= O +
1,02 O -
, O +
df O +
= O +
65 O -
, O +
P O +
> O +
0,05 O -
) O -
, O +
and O +
marital O +
status O +
( O -
x2 O +
= O +
0,51 O -
, O +
df O +
= O +
1 O -
, O +
P O +
> O +
0,05 O -
) O -
. O +

Measures O +
A O +
detailed O +
sociodemographic O +
data O +
form O +
was O +
used O +
for O +
all O +
subjects O -
. O +

All O +
participants O +
were O +
applied O +
Structured O +
Clinical O +
Interview O +
for O +
DSM O -
- O -
IV O +
( O -
SCID O -
- O -
I O -
) O +
[ O -
22 O -
] O -
, O +
Turkish O +
version O +
[ O -
23 O -
] O -
. O +

Regarding O +
the O +
pain O +
assessment O -
, O +
information O +
was O +
first O +
obtained O +
on O +
several O +
aspects O +
of O +
the O +
patients O -
' O +
pain O -
, O +
such O +
as O +
intensity O -
, O +
and O +
duration O -
. O +

Pain O +
intensity O +
was O +
measured O +
by O +
Visual O +
Analogue O +
Scale O +
( O -
VAS O -
) O -
, O +
using O +
a O +
horizontal O +
10-cm O +
line O +
with O +
the O +
statement O +
' O -
no O +
pain O +
at O +
all O -
' O +
at O +
the O +
extreme O +
left O -
- O -
hand O +
end O +
and O +
' O -
the O +
worst O +
possible O +
pain O -
' O +
or O +
' O -
unbearable O -
' O +
at O +
the O +
right O -
- O -
hand O +
extreme O -
. O +

VAS O +
is O +
scored O +
by O +
measuring O +
the O +
distance O +
from O +
the O +
end O +
of O +
the O +
scale O +
indicating O +
absence O +
of O +
pain O +
( O -
or O +
no O +
distress O +
or O +
no O +
pain O +
relief O -
) O +
to O +
the O +
place O +
marked O +
by O +
the O +
patient O +
[ O -
24 O -
] O -
. O +

The O +
psychometric O +
scales O +
used O +
in O +
the O +
study O +
were O +
the O +
26-item O +
Toronto O +
Alexithymia O +
Scale O +
( O -
TAS-26 O -
] O +
and O +
the O +
Trait O +
Anxiety O +
Inventory O +
( O -
STAI O -
) O -
, O +
which O +
were O +
both O +
validated O +
in O +
Turkish O +
population O +
studies O +
[ O -
25 O -
- O -
28 O -
] O -
. O +

TAS O +
is O +
a O +
psychometrically O +
well O +
validated O +
and O +
reliable O +
instrument O +
in O +
the O +
assessment O +
of O +
alexithymia O -
. O +

TAS O +
has O +
been O +
validated O +
in O +
Turkish O +
studies O +
as O +
a O +
true O +
or O +
false O +
scale O -
. O +

Twenty O -
- O -
six O +
items O +
are O +
scored O +
either O +
as O +
1 O +
or O +
0 O +
and O +
the O +
higher O +
scores O +
indicate O +
higher O +
degrees O +
of O +
alexithymia O -
. O +

TAS O +
has O +
an O +
interval O +
consistency O +
of O +
0.65 O +
[ O -
Kuder O -
- O -
Richardson O -
) O +
and O +
test O -
- O -
retest O +
reliability O +
is O +
r O +
= O +
0.71 O -
, O +
p O +
< O +
0.01 O +
in O +
Turkish O +
reliability O +
and O +
validity O +
study O -
. O +

The O +
sample O +
was O +
divided O +
into O +
nonalexithymic O +
and O +
alexityhmic O +
groups O -
, O +
with O +
the O +
recommended O +
cut O -
- O -
off O +
score O +
of O +
11 O +
[ O -
27 O -
] O -
. O +

Spielberger O +
Trait O +
Anxiety O +
Inventory O +
( O -
STAI O -
) O +
is O +
one O +
of O +
the O +
two O +
sections O +
of O +
the O +
Spielberger O +
Anxiety O +
Inventory O +
( O -
the O +
other O -
, O +
measuring O +
state O +
anxiety O -
) O -
. O +
' O +

Trait O +
anxiety O -
' O +
has O +
been O +
defined O +
as O +
anxiety O +
proneness O -
, O +
that O +
is O -
, O +
the O +
tendency O +
to O +
respond O +
to O +
situations O +
perceived O +
as O +
threatening O +
with O +
elevations O +
in O +
the O +
intensity O +
of O +
state O +
anxiety O +
[ O -
26 O -
] O -
. O +

Statistical O +
analysis O +
In O +
order O +
to O +
determine O +
the O +
relative O +
importance O +
of O +
a O +
number O +
of O +
factors O +
in O +
pain O +
disorders O -
, O +
we O +
used O +
both O +
correlation O +
analyses O -
. O +

The O +
alexithymic O +
and O +
nonalexithymic O +
groups O +
were O +
compared O +
using O +
the O +
independent O +
sample O +
t O -
- O -
tests O +
on O +
scores O +
of O +
psychological O +
tests O -
. O +

The O +
statistical O +
procedure O -
, O +
which O +
was O +
carried O +
out O +
by O +
a O +
SPSS O +
package O +
program O +
for O +
Windows O +
using O +
Chi O -
- O -
square O -
, O +
Fisher O -
's O +
exact O +
test O -
, O +
two O +
tailed O +
t O +
test O +
and O +
Pearson O +
correlation O +
coefficients O -
, O +
was O +
also O +
used O +
to O +
determine O +
group O +
differences O +
( O -
alexithymics O +
versus O +
nonalexithymics O -
) O +
in O +
sociodemographic O +
variables O +
and O +
various O +
aspects O +
of O +
pain O -
. O +

Results O +
In O +
the O +
chronic O +
pain O +
group O -
, O +
56.7 O -
% O +
of O +
patients O +
( O -
n O +
= O +
17 O -
) O +
had O +
a O +
score O +
greater O +
than O +
11 O +
on O +
the O +
TAS-26 O -
, O +
and O +
were O +
considered O +
alexithymic O -
. O +

The O +
mean O +
TAS-26 O +
score O +
of O +
the O +
alexithymic O +
group O +
( O -
n O +
= O +
17 O -
) O +
was O +
17.88 O +
± O +
3.43 O +
and O +
the O +
nonalexithymic O +
group O +
( O -
n O +
= O +
13 O -
) O +
was O +
8.39 O +
± O +
2.02 O -
. O +

Age O +
( O -
t O +
= O +
1,38 O -
, O +
df O +
= O +
28 O -
, O +
p O +
> O +
0,18 O -
) O -
, O +
education O +
( O -
t O +
= O +
-0,21 O -
, O +
df O +
= O +
28 O -
, O +
p O +
> O +
0,16 O -
) O +
and O +
marital O +
status O +
( O -
x2 O +
= O +
0,27 O -
, O +
df O +
= O +
1 O -
, O +
p O +
> O +
0,87 O -
) O +
were O +
not O +
associated O +
with O +
alexithymia O +
( O -
Table O +
1 O -
) O -
. O +

In O +
the O +
control O +
group O -
, O +
24,3 O -
% O +
of O +
patients O +
( O -
n O +
= O +
9 O -
) O +
were O +
alexithymic O +
according O +
to O +
TAS-26 O -
. O +

The O +
mean O +
TAS-26 O +
score O +
of O +
the O +
alexithymic O +
group O +
( O -
n O +
= O +
9 O -
) O +
was O +
13,82 O +
± O +
1,93 O +
and O +
the O +
nonalexithymic O +
group O +
( O -
n O +
= O +
28 O -
) O +
was O +
10,33 O +
± O +
0,86 O -
. O +

Alexithymia O +
was O +
not O +
associated O +
with O +
age O +
( O -
t O +
= O +
-1,08 O -
, O +
df O +
= O +
35 O -
, O +
p O +
> O +
0,29 O -
) O -
, O +
educational O +
level O +
( O -
t O +
= O +
1,1 O -
, O +
df O +
= O +
35 O -
, O +
p O +
> O +
0,28 O -
) O -
, O +
or O +
marital O +
status O +
( O -
x2 O +
= O +
0,74 O -
, O +
df O +
= O +
1 O -
, O +
p O +
> O +
0,79 O -
) O +
or O +
anxiety O +
levels O +
in O +
the O +
control O +
subjects O +
( O -
Table O +
1 O -
) O -
. O +

The O +
duration O +
and O +
severity O +
of O +
pain O -
, O +
TAS-26 O +
scores O -
, O +
and O +
STAI O +
scores O +
of O +
the O +
female O +
pain O +
patients O +
are O +
shown O +
in O +
Table O +
2 O -
. O +

Comparison O +
of O +
the O +
alexithymics O +
with O +
nonalexithymics O +
on O +
either O +
the O +
severity O +
of O +
pain O +
or O +
pain O +
duration O +
showed O +
no O +
statistical O +
significance O +
( O -
t O +
= O +
0,64 O -
, O +
df O +
= O +
28 O -
, O +
p O +
> O +
0,52 O -
, O +
t O +
= O +
2,05 O -
, O +
df O +
= O +
28 O -
, O +
p O +
> O +
0,05 O -
, O +
respectively O -
) O -
. O +

TAS-26 O +
score O +
and O +
duration O +
of O +
pain O +
were O +
found O +
positively O +
correlated O +
( O -
r O +
= O +
0,50 O -
, O +
n O +
= O +
30 O -
, O +
p O +
> O +
0,005 O -
) O -
. O +

STAI O +
( O -
trait O -
) O +
scores O +
of O +
the O +
alexithymics O +
in O +
the O +
pain O +
group O +
did O +
not O +
significantly O +
differ O +
from O +
the O +
nonlalexithymics O +
( O -
t O +
= O +
0,06 O -
, O +
df O +
= O +
28 O -
, O +
p O +
> O +
0,95 O -
) O +
and O +
besides O -
, O +
TAS-26 O +
and O +
STAI O +
scores O +
were O +
not O +
correlated O +
( O -
r O +
= O +
0,06 O -
, O +
p O +
> O +
0,72 O -
) O -
. O +

In O +
summary O -
, O +
there O +
are O +
three O +
points O +
to O +
be O +
emphasized O -
. O +

First O -
, O +
chronic O +
pain O +
patients O +
were O +
found O +
significantly O +
more O +
alexithymic O +
than O +
controls O +
( O -
56,7 O -
% O +
to O +
24,3 O -
% O -
) O -
. O +

Second O -
, O +
a O +
positive O +
correlation O +
was O +
observed O +
between O +
TAS-26 O +
scores O +
and O +
duration O +
of O +
pain O -
. O +

Third O -
, O +
neither O +
positive O +
correlation O +
nor O +
significant O +
difference O +
was O +
found O +
between O +
alexithymia O +
and O +
trait O +
anxiety O +
in O +
pain O +
patients O -
. O +

Discussion O +
The O +
results O +
of O +
the O +
present O +
study O +
suggest O +
that O +
patients O +
with O +
chronic O +
pain O +
disorder O +
are O +
more O +
alexithymic O +
than O +
individuals O +
with O +
no O +
pain O -
. O +

This O +
finding O +
is O +
consistent O +
with O +
results O +
obtained O +
with O +
earlier O +
measures O +
of O +
alexithymia O +
[ O -
11 O -
- O -
13 O -
] O -
. O +

Although O +
they O +
may O +
share O +
common O +
clinical O +
features O -
, O +
alexithymia O +
and O +
somatoform O +
pain O +
are O +
independent O +
constructs O -
. O +

Alexithymia O +
may O +
be O +
a O +
consequence O +
to O +
the O +
effects O +
of O +
severe O +
physical O +
symptoms O -
, O +
such O +
as O +
a O +
reduced O +
quality O +
of O +
life O +
and O +
limitations O +
in O +
daily O +
activities O -
. O +

Besides O -
, O +
alexithymia O +
may O +
be O +
conceptualized O +
as O +
a O +
personality O +
trait O +
as O +
well O +
as O +
a O +
secondary O +
state O +
reaction O +
[ O -
2,3,15 O -
- O -
17 O -
] O -
. O +

In O +
this O +
study O -
, O +
the O +
question O +
investigated O +
was O +
whether O +
alexithymia O +
has O +
any O +
correlation O +
with O +
the O +
duration O +
or O +
severity O +
of O +
the O +
pain O +
itself O -
. O +

There O +
were O +
no O +
significant O +
differences O +
between O +
alexithymic O +
and O +
nonalexitymic O +
patients O +
on O +
self O +
reports O +
of O +
current O +
pain O +
severity O -
. O +

This O +
is O +
in O +
accordance O +
with O +
Cox O -
's O +
study O +
[ O -
1994 O -
] O +
in O +
which O +
it O +
was O +
further O +
pointed O +
out O +
that O +
alexithymic O +
patients O +
were O +
found O +
to O +
use O +
significantly O +
more O +
verbal O +
descriptors O +
of O +
pain O +
compared O +
to O +
nonalexithymic O +
patients O +
[ O -
13 O -
] O -
. O +

In O +
our O +
study O -
, O +
pain O +
intensity O +
was O +
only O +
evaluated O +
by O +
using O +
VAS O -
. O +

One O +
problem O +
in O +
trying O +
to O +
measure O +
the O +
intensity O +
of O +
pain O +
is O +
the O +
lack O +
of O +
an O +
objective O +
way O -
. O +

Pain O +
is O +
a O +
subjective O +
experience O +
and O +
each O +
patient O +
may O +
communicate O +
in O +
a O +
different O +
way O -
, O +
verbally O +
or O +
nonverbally O +
[ O -
29 O -
] O -
. O +

Patients O +
in O +
this O +
sample O +
were O +
sufferers O +
of O +
chronic O +
pain O -
, O +
who O +
had O +
already O +
chosen O +
an O +
approved O +
way O +
of O +
expressing O +
their O +
distress O -
. O +

Since O +
this O +
is O +
true O +
regardless O +
of O +
alexithymia O -
, O +
alexithymic O +
groups O +
and O +
nonalexithymic O +
groups O +
in O +
this O +
sample O +
showed O +
no O +
difference O +
on O +
pain O +
severity O -
. O +

The O +
positive O +
correlation O +
between O +
alexithymia O +
and O +
the O +
duration O +
of O +
pain O +
in O +
this O +
sample O +
supports O +
the O +
assumption O +
of O +
a O +
two O -
- O -
way O +
hypothesis O -
. O +

It O +
is O +
often O +
assumed O +
that O +
pain O +
can O +
be O +
caused O +
by O +
alexithymic O +
personality O +
traits O +
and O +
also O +
that O +
severe O +
and O +
chronic O +
pain O +
may O +
cause O +
emotional O +
change O -
. O +

One O +
of O +
the O +
limitations O +
of O +
this O +
study O +
is O +
that O +
because O +
of O +
the O +
cross O -
- O -
sectional O +
design O -
, O +
we O +
are O +
unable O +
to O +
draw O +
conclusions O +
about O +
the O +
direction O +
of O +
causality O +
between O +
alexithymia O +
and O +
pain O -
. O +

The O +
duration O +
of O +
the O +
patients O -
' O +
pain O +
could O +
approximately O +
be O +
determined O -
, O +
yet O +
the O +
preexisting O +
level O +
of O +
alexithymia O +
was O +
not O +
known O -
. O +

In O +
the O +
usual O +
absence O +
of O +
internal O +
stimuli O -
, O +
alexithymic O +
person O +
may O +
be O +
expected O +
to O +
maintain O +
an O +
external O +
focus O +
of O +
attention O -
, O +
such O +
as O +
pain O -
. O +

Symptom O +
chronicity O +
may O +
force O +
the O +
alexithymic O +
person O +
to O +
attent O +
to O +
and O +
amplify O +
this O +
somatic O +
sensation O -
. O +

Difficulties O +
in O +
the O +
ability O +
to O +
identify O +
and O +
differentiate O +
emotions O +
and O +
somatic O +
experiences O +
are O +
core O +
features O +
of O +
the O +
alexithymic O +
construct O -
. O +

Therefore O -
, O +
alexithymic O +
patients O +
might O +
be O +
expected O +
to O +
differ O +
from O +
nonalexithymic O +
ones O +
in O +
their O +
anxiety O +
levels O -
. O +

Yet O -
, O +
in O +
our O +
pain O +
group O +
alexithymic O +
patients O +
showed O +
no O +
significant O +
difference O +
from O +
the O +
nonalexithymics O +
on O +
trait O +
anxiety O -
. O +

Besides O -
, O +
alexithymia O +
and O +
anxiety O +
were O +
not O +
correlated O +
at O +
all O -
. O +

The O +
reasons O +
may O +
be O +
lying O +
in O +
the O +
specific O +
characteristics O +
of O +
this O +
patient O +
group O +
itself O -
. O +

The O +
study O +
included O +
patients O +
suffering O +
from O +
chronic O +
symptoms O -
; O +
with O +
an O +
average O +
of O +
7,44 O +
± O +
6,82 O +
years O +
of O +
pain O +
in O +
the O +
alexithymic O +
and O +
3,31 O +
± O +
2,79 O +
years O +
in O +
the O +
nonalexithymic O +
groups O -
. O +

Persistency O +
of O +
any O +
physical O +
symptom O +
may O +
bring O +
along O +
alexithymia O +
as O +
a O +
coping O +
strategy O -
. O +

In O +
their O +
paper O -
, O +
Crook O +
and O +
Tunks O +
( O -
1988 O -
) O +
examined O +
the O +
types O +
of O +
coping O +
strategies O +
used O +
by O +
persistent O +
pain O +
sufferers O +
and O +
addressed O +
to O +
the O +
importance O +
to O +
alter O +
their O +
attitudes O +
and O +
behavior O +
that O +
tend O +
toward O +
catastrophizing O -
, O +
avoidance O +
and O +
withdrawal O -
, O +
rather O +
than O +
simply O +
concentrate O +
on O +
trying O +
to O +
teach O +
them O +
techniques O +
for O +
' O -
coping O +
with O +
stress O -
' O +
to O +
help O +
persistent O +
pain O +
sufferers O +
[ O -
30 O -
] O -
. O +

Sufferers O +
of O +
chronic O +
symptoms O +
in O +
this O +
sample O +
were O +
members O +
of O +
a O +
subgroup O +
who O +
have O +
been O +
seeking O +
medical O +
care O +
for O +
a O +
long O +
time O +
and O +
besides O +
given O +
the O +
chance O +
of O +
being O +
referred O +
to O +
a O +
psychiatrist O -
. O +

Therefore O -
, O +
alexithymic O +
or O +
not O -
, O +
their O +
anxiety O +
might O +
have O +
induced O +
unique O +
coping O +
strategies O +
and O +
illness O +
behavior O -
. O +

Alexithymia O +
may O +
be O +
important O +
in O +
addressing O +
the O +
diversity O +
of O +
subjective O +
factors O +
involved O +
in O +
pain O +
[ O -
31 O -
] O -
. O +

It O +
is O +
not O +
known O +
whether O +
it O +
should O +
be O +
addressed O +
in O +
the O +
treatment O +
of O +
pain O +
patients O -
, O +
but O +
a O +
high O +
level O +
of O +
alexithymia O +
may O +
effect O +
the O +
nature O +
of O +
assessment O -
. O +

In O +
summary O -
, O +
the O +
conceptualization O +
of O +
alexithymia O +
as O +
a O +
personality O +
trait O +
as O +
well O +
as O +
a O +
secondary O +
state O +
reaction O +
is O +
underlined O +
by O +
our O +
data O -
. O +

However O -
, O +
regarding O +
the O +
cross O -
- O -
sectional O +
design O +
of O +
this O +
study O -
, O +
only O +
limited O +
conclusions O +
can O +
be O +
drawn O +
about O +
the O +
nature O +
of O +
the O +
causal O +
relationship O +
between O +
alexithymia O +
and O +
chronic O +
pain O -
. O +

Therefore O -
, O +
future O +
longitudinal O +
studies O +
assessing O +
the O +
cause O +
of O +
alexithymic O +
characteristics O +
are O +
required O +
to O +
fully O +
elucidate O +
the O +
concepts O +
of O +
primary O +
and O +
secondary O +
alexithymia O -
. O +

The O +
role O +
of O +
the O +
muscarinic O +
system O +
in O +
regulating O +
estradiol O +
secretion O +
varies O +
during O +
the O +
estrous O +
cycle O -
: O +
the O +
hemiovariectomized O +
rat B-Species +
model O +
Abstract O +
There O +
is O +
evidence O +
that O +
one O +
gonad O +
has O +
functional O +
predominance O -
. O +

The O +
present O +
study O +
analyzed O +
the O +
acute O +
effects O +
of O +
unilateral O +
ovariectomy O +
( O -
ULO O -
) O +
and O +
blocking O +
the O +
cholinergic O +
system O -
, O +
by O +
injecting O +
atropine O +
sulfate O +
( O -
ATR O -
) O -
, O +
on O +
estradiol O +
( O -
E2 O -
) O +
serum O +
concentrations O +
during O +
the O +
estrous O +
cycle O -
. O +

The O +
results O +
indicate O +
that O +
ULO O +
effects O +
on O +
E2 O +
concentrations O +
are O +
asymmetric O -
, O +
vary O +
during O +
the O +
estrous O +
cycle O -
, O +
and O +
partially O +
depend O +
on O +
the O +
cholinergic O +
innervation O -
. O +

Background O +
Estradiol O +
secretion O +
is O +
regulated O +
by O +
pituitary O +
[ O -
follicle O +
stimulating O +
hormone O +
( O -
FSH O -
) O +
and O +
luteinizing O +
hormones O +
( O -
LH O -
) O -
, O +
prolactin O -
, O +
and O +
adrenocorticotropin O +
( O -
ACTH O -
) O -
] O -
. O +

The O +
effects O +
of O +
these O +
hormones O +
are O +
modulated O +
by O +
neurotransmitters O +
released O +
by O +
the O +
intrinsic O +
ovarian O +
innervation O +
near O +
the O +
follicular O +
wall O -
. O +

Acetylcholine O +
produced O +
by O +
the O +
follicle O +
may O +
be O +
one O +
of O +
the O +
neurotransmitters O +
participating O +
in O +
modulating O +
the O +
effects O +
of O +
pituitary O +
hormones O +
on O +
the O +
follicle O +
[ O -
1 O -
- O -
3 O -
] O -
. O +

Evidence O +
suggesting O +
that O +
one O +
gonad O +
has O +
functional O +
predominance O +
in O +
mammals O +
and O +
birds O +
have O +
been O +
published O +
[ O -
1,4 O -
- O -
8 O -
] O -
. O +

In O +
previous O +
studies O +
we O +
have O +
shown O +
that O +
unilateral O +
ovariectomy O +
( O -
ULO O -
) O +
modifies O +
progesterone O +
and/or O +
testosterone O +
serum O +
concentrations O -
, O +
and O +
that O +
the O +
effects O +
of O +
ULO O +
depend O +
on O +
both O -
, O +
the O +
stage O +
of O +
the O +
estrous O +
cycle O +
when O +
ULO O +
was O +
performed O +
and O +
the O +
ovary O +
( O -
left O +
or O +
right O -
) O +
remaining O +
in O +
situ O +
[ O -
9 O -
- O -
11 O -
] O -
. O +

Asymmetry O +
in O +
ovarian O +
functions O +
has O +
been O +
explained O +
by O +
differences O +
in O +
the O +
ovarian O +
innervation O +
participating O +
in O +
modulating O +
the O +
effects O +
of O +
gonadotropin O +
on O +
the O +
ovarian O +
follicles O +
[ O -
1,6 O -
] O -
. O +

Kawakami O +
et O +
al O +
[ O -
12 O -
] O +
showed O +
that O +
electrical O +
stimulation O +
of O +
the O +
medial O +
basal O +
pre O -
- O -
chiasmatic O +
area O -
, O +
the O +
ventro O -
- O -
medial O +
hypothalamus O -
, O +
and O +
the O +
areas O +
in O +
the O +
mesencephalon O +
of O +
hypophysectomized O +
and O +
adrenalectomized O +
female O +
rats B-Species +
resulted O +
in O +
a O +
significant O +
increase O +
of O +
estradiol O +
( O -
E2 O -
) O +
and O +
progesterone O +
( O -
P4 O -
) O +
plasma O +
concentrations O +
in O +
the O +
contra O -
- O -
lateral O +
ovarian O +
venous O +
blood O -
. O +

In O +
turn O -
, O +
stimulating O +
the O +
dorsal O +
hippocampus O -
, O +
the O +
lateral O +
amygdala O -
, O +
and O +
the O +
mesencephalic O +
areas O +
resulted O +
in O +
lower O +
E2 O +
and O +
P4 O +
concentrations O -
. O +

Ovarian O +
denervation O +
of O +
rats B-Species +
in O +
proestrus O +
stage O +
blocks O +
E2 O +
secretion O +
induced O +
by O +
stimulating O +
the O +
medial O +
basal O +
pre O -
- O -
chiasmatic O +
area O -
. O +

In O +
addition O -
, O +
the O +
electrochemical O +
stimulation O +
in O +
proestrus O +
day O +
of O +
the O +
medial O +
basal O +
pre O -
- O -
chiasmatic O +
area O +
of O +
untreated O +
rats B-Species +
increased O +
E2 O +
and O +
P4 O +
concentrations O +
in O +
serum O -
. O +

This O +
effect O +
was O +
not O +
observed O +
when O +
stimulation O +
was O +
applied O +
to O +
the O +
pre O -
- O -
optic O +
supra O -
- O -
chiasmatic O +
area O -
. O +

According O +
to O +
the O +
authors O -
' O +
interpretation O +
of O +
the O +
results O -
, O +
the O +
efferent O +
neural O +
system O +
connecting O +
the O +
brain O +
and O +
the O +
ovaries O +
is O +
supplementary O +
to O +
the O +
brain O -
- O -
pituitary O -
- O -
ovarian O +
hormonal O +
mechanisms O +
regulating O +
ovarian O +
steroid O +
secretion O -
, O +
and O +
the O +
system O +
may O +
be O +
required O +
for O +
adjusting O +
ovarian O +
responsiveness O +
and O +
sensitivity O +
to O +
gonadotropins O +
[ O -
12,13 O -
] O -
. O +

Gerendai O +
et O +
al. O +
[ O -
14 O -
] O +
described O +
a O +
multi O -
- O -
synaptic O +
neural O +
pathway O +
between O +
the O +
central O +
nervous O +
system O +
and O +
the O +
ovaries O -
, O +
with O +
the O +
vagus O +
nerve O +
being O +
one O +
of O +
the O +
main O +
neural O +
pathways O -
. O +

In O +
ULO O +
treated O +
rats B-Species -
, O +
bi O -
- O -
lateral O +
sectioning O +
the O +
vagus O +
nerve O +
( O -
ventral O +
or O +
dorsal O -
) O +
results O +
in O +
lower O +
compensatory O +
ovarian O +
hypertrophy O -
. O +

The O +
effects O +
of O +
sectioning O +
the O +
left O +
vagus O +
nerve O +
depend O +
on O +
the O +
remaining O +
ovary O +
in O +
situ O -
: O +
rats B-Species +
with O +
the O +
left O +
ovary O +
in O +
situ O +
had O +
a O +
larger O +
proportion O +
of O +
ovulating O +
animals O -
, O +
compensatory O +
ovarian O +
hypertrophy O +
and O +
number O +
of O +
ova O +
shed O -
. O +

In O +
turn O -
, O +
rats B-Species +
with O +
the O +
right O +
ovary O +
in O +
situ O +
showed O +
a O +
decrease O +
in O +
all O +
parameters O +
studied O +
[ O -
15 O -
] O -
. O +

Based O +
on O +
available O +
information O -
, O +
the O +
present O +
study O +
aims O +
to O +
analyze O +
if O +
changes O +
in O +
E2 O +
secretion O +
by O +
the O +
left O +
and O +
right O +
ovaries O +
vary O +
during O +
the O +
estrous O +
cycle O -
, O +
using O +
the O +
unilateral O +
ovariectomized O +
animal O +
as O +
a O +
model O +
of O +
study O -
. O +

We O +
also O +
investigated O +
if O -
, O +
throughout O +
estrous O +
cycle O +
diestrus O +
1 O +
( O -
D1 O -
) O -
, O +
diestrus O +
2 O +
( O -
D2 O -
) O +
and O +
proestrus O +
( O -
P O -
) O -
, O +
the O +
cholinergic O +
system O +
modulates O +
E2 O +
secretion O +
in O +
an O +
asymmetric O +
way O -
. O +

For O +
this O +
purpose O -
, O +
we O +
analyzed O +
the O +
effects O +
of O +
injecting O +
ATR O +
at O +
13.00 O +
h O +
to O +
rats B-Species +
on O +
D1 O -
, O +
D2 O +
or O +
P O +
with O +
or O +
without O +
unilateral O +
or O +
bilateral O +
ovariectomy O -
. O +

Materials O +
and O +
methods O +
The O +
study O +
was O +
performed O +
with O +
virgin O +
adult O +
female O +
rats B-Species +
( O -
195–225-g O +
body O +
weight O -
) O +
of O +
the O +
CIIZ O -
- O -
V O +
strain O +
from O +
our O +
own O +
stock O -
. O +

Animals O +
were O +
kept O +
under O +
controlled O +
lighting O +
conditions O +
( O -
lights O +
on O +
from O +
05:00 O +
to O +
19:00 O +
h O -
) O -
, O +
with O +
free O +
access O +
to O +
food O +
( O -
Purina O +
S.A. O -
, O +
Mexico O -
) O +
and O +
tap O +
water O -
; O +
following O +
NIH O +
Guide O +
parameters O +
for O +
the O +
care O +
of O +
laboratory O +
animals O -
. O +

The O +
Committee O +
of O +
the O +
Facultad O +
de O +
Estudios O +
Superiores O +
Zaragoza O +
approved O +
the O +
experimental O +
protocols O -
. O +

Estrous O +
cycles O +
were O +
monitored O +
by O +
daily O +
vaginal O +
smears O -
. O +

Only O +
rats B-Species +
showing O +
at O +
least O +
two O +
consecutive O +
4-day O +
cycles O +
were O +
used O +
in O +
the O +
experiment O -
. O +

All O +
surgeries O +
were O +
performed O +
under O +
ether O +
anesthesia O -
, O +
between O +
13:00–13:15 O +
hours O -
. O +

Rats B-Species +
were O +
sacrificed O +
by O +
decapitation O +
one O +
hour O +
after O +
treatment O -
. O +

Experimental O +
groups O +
Rats B-Species +
were O +
randomly O +
allotted O +
to O +
one O +
of O +
the O +
experimental O +
groups O +
described O +
below O -
. O +

Animals O +
from O +
different O +
experimental O +
groups O +
were O +
treated O +
simultaneously O +
and O +
sacrificed O +
one O +
hour O +
after O +
surgery O -
. O +

The O +
number O +
of O +
animals O +
used O +
in O +
each O +
experimental O +
group O +
is O +
presented O +
in O +
Tables O +
1 O -
, O +
2 O +
and O +
3 O -
. O +

Control O +
group O +
( O -
N O +
= O +
48 O -
) O -
. O +

Non O -
- O -
treated O +
cyclic O +
rats B-Species +
sacrificed O +
at O +
14:00 O +
h O +
on O +
D1 O +
( O -
17 O +
rats B-Species -
) O -
, O +
D2 O +
( O -
19 O +
rats B-Species -
) O +
and O +
P O +
( O -
12 O +
rats B-Species -
) O -
. O +

Ether O +
anesthesia O +
( O -
N O +
= O +
24 O -
) O -
: O +
Groups O +
of O +
rats B-Species -
, O +
on O +
specific O +
stages O +
( O -
D1 O -
, O +
D2 O +
or O +
P O -
) O +
of O +
the O +
estrous O +
cycle O -
, O +
were O +
anesthetized O +
for O +
10 O +
min O +
and O +
sacrificed O +
one O +
hour O +
later O -
. O +

Unilateral O +
peritoneal O +
perforation O +
( O -
sham O +
operation O -
) O +
( O -
N O +
= O +
53 O -
) O -
: O +
A O +
unilateral O +
incision O +
was O +
performed O +
2-cm O +
below O +
the O +
last O +
rib O -
; O +
affecting O +
skin O -
, O +
muscle O -
, O +
and O +
peritoneum O -
. O +

The O +
ovaries O +
were O +
not O +
injured O +
or O +
manipulated O -
. O +

After O +
surgical O +
procedures O +
the O +
wound O +
was O +
sealed O -
. O +

Bilateral O +
peritoneal O +
perforation O +
( O -
sham O +
operation O +
2 O -
) O +
( O -
N O +
= O +
27 O -
) O -
. O +

A O +
bilateral O +
incision O +
below O +
the O +
last O +
rib O -
, O +
including O +
skin O +
and O +
muscle O -
, O +
was O +
performed O -
. O +

The O +
ovaries O +
were O +
not O +
injured O +
or O +
manipulated O -
. O +

After O +
surgical O +
procedures O +
the O +
wound O +
was O +
sealed O -
. O +

Unilateral O +
ovariectomy O +
( O -
ULO O -
) O +
( O -
N O +
= O +
50 O -
) O -
: O +
A O +
unilateral O +
incision O +
below O +
the O +
last O +
rib O -
, O +
including O +
skin O +
and O +
muscle O +
was O +
performed O -
, O +
and O +
the O +
right O +
or O +
left O +
ovary O +
was O +
extirpated O -
. O +

The O +
wound O +
was O +
subsequently O +
sealed O -
. O +

Bilateral O +
ovariectomy O +
( O -
N O +
= O +
23 O -
) O -
: O +
A O +
bilateral O +
incision O +
below O +
the O +
last O +
rib O -
, O +
including O +
skin O +
and O +
muscle O +
was O +
performed O -
, O +
and O +
the O +
ovaries O +
removed O -
. O +

The O +
wound O +
was O +
subsequently O +
sealed O -
. O +

Blocking O +
the O +
cholinergic O +
system O +
To O +
analyze O +
the O +
effects O +
of O +
blocking O +
the O +
cholinergic O +
system O -
, O +
groups O +
of O +
animals O +
were O +
injected O +
with O +
atropine O +
sulfate O +
( O -
ATR O -
, O +
Sigma O +
Chem O -
. O +

Co. O +
St. O +
Louis O -
, O +
Mo. O -
) O -
. O +

ATR O +
was O +
injected O +
one O +
hour O +
before O +
surgery O +
at O +
doses O +
known O +
to O +
block O +
ovulation O -
: O +
in O +
D1 O -
, O +
100 O +
mg O -
/ O -
kg O +
body O +
weight O +
( O -
b.w O -
. O -
) O -
; O +
in O +
D2 O -
, O +
300 O +
mg O -
/ O -
kg O +
b.w O -
. O -
; O +
and O +
in O +
P O -
, O +
700 O +
mg O -
/ O -
kg O +
b.w O -
. O +

[ O -
16 O -
] O -
. O +

One O +
hour O +
after O +
ATR O +
treatment O -
, O +
rats B-Species +
were O +
randomly O +
allotted O +
to O +
one O +
of O +
the O +
following O +
treatments O -
: O +
unilateral O +
peritoneal O +
perforation O -
, O +
bilateral O +
peritoneal O +
perforation O -
, O +
ULO O -
, O +
or O +
bilateral O +
ovariectomy O -
. O +

All O +
animals O +
were O +
sacrificed O +
one O +
hour O +
after O +
surgery O -
. O +

For O +
control O +
purposes O -
, O +
untreated O +
rats B-Species -
, O +
on O +
D1 O -
, O +
D2 O +
or O +
P O -
, O +
were O +
injected O +
with O +
ATR O +
in O +
the O +
same O +
dose O +
as O +
in O +
their O +
corresponding O +
treatment O +
group O -
. O +

The O +
animals O +
were O +
sacrificed O +
two O +
hours O +
after O +
treatment O -
. O +

Autopsy O +
procedures O +
Animals O +
were O +
sacrificed O +
by O +
decapitation O -
. O +

The O +
blood O +
of O +
the O +
trunk O +
was O +
collected O +
in O +
a O +
test O +
tube O -
, O +
allowed O +
to O +
clot O +
at O +
room O +
temperature O +
for O +
30 O +
minutes O +
and O +
centrifuged O +
at O +
3,000 O +
rpm O +
for O +
15 O +
minutes O -
. O +

Serum O +
was O +
stored O +
at O +
-20 O -
° O -
C O -
, O +
until O +
E2 O +
concentrations O +
were O +
measured O -
. O +

Hormone O +
assay O +
Concentrations O +
of O +
E2 O +
in O +
serum O +
were O +
measured O +
by O +
Radio O -
- O -
Immuno O -
- O -
Assay O +
( O -
RIA O -
) O -
; O +
using O +
kits O +
purchased O +
from O +
Diagnostic O +
Products O +
( O -
Los O +
Angeles O -
, O +
CA O -
) O -
. O +

Results O +
are O +
expressed O +
in O +
pg O -
/ O -
ml O -
. O +

The O +
Intra- O +
and O +
inter O -
- O -
assay O +
variation O +
coefficients O +
were O +
6.9 O -
% O +
and O +
10.8 O +
% O -
, O +
respectively O -
. O +

Statistics O +
Data O +
on O +
hormonal O +
concentrations O +
in O +
serum O +
were O +
analyzed O +
using O +
multivariate O +
analysis O +
of O +
variance O +
( O -
MANOVA O -
) O +
followed O +
by O +
Tukey O -
's O +
test O -
. O +

Differences O +
in O +
serum O +
hormone O +
concentrations O +
between O +
two O +
groups O +
were O +
analyzed O +
by O +
Student O -
's O +
t O -
- O -
test O -
. O +

A O +
probability O +
value O +
of O +
less O +
than O +
5 O -
% O +
was O +
considered O +
significant O -
. O +

Results O +
Effects O +
of O +
ether O +
anesthesia O +
and O +
unilateral O +
or O +
bilateral O +
perforation O +
of O +
the O +
peritoneum O +
In O +
the O +
control O +
group O -
, O +
animals O +
sacrificed O +
on O +
P O +
showed O +
significantly O +
higher O +
E2 O +
serum O +
concentration O +
than O +
animals O +
sacrificed O +
on O +
D1 O +
or O +
D2 O +
( O -
D1 O -
: O +
55.3 O +
± O +
8.0 O -
; O +
D2 O -
: O +
59.1 O +
± O +
7.9 O -
; O +
P O -
: O +
158.4 O +
± O +
1.8 O -
) O -
. O +

Compared O +
to O +
the O +
control O +
group O -
, O +
ether O +
anesthesia O +
treatment O +
did O +
not O +
modify O +
E2 O +
serum O +
concentrations O +
( O -
D1 O -
: O +
62.9 O +
± O +
8.4 O -
; O +
D2 O -
: O +
69.5 O +
± O +
12.0 O -
; O +
P O -
: O +
164.1 O +
± O +
17.6 O -
) O -
. O +

Since O +
ether O +
anesthesia O +
did O +
not O +
modify O +
E2 O +
serum O +
concentrations O -
, O +
treatment O +
results O +
are O +
compared O +
to O +
their O +
respective O +
control O +
group O -
. O +

The O +
effects O +
on O +
E2 O +
serum O +
concentrations O +
of O +
unilaterally O +
or O +
bilaterally O +
perforating O +
the O +
peritoneum O +
depended O +
on O +
the O +
side O +
of O +
the O +
peritoneum O +
and O +
the O +
stage O +
of O +
the O +
estrous O +
cycle O +
when O +
perforation O +
surgery O +
was O +
performed O -
. O +

Perforating O +
the O +
left O +
peritoneum O +
on O +
D1 O +
resulted O +
in O +
lower O +
E2 O +
serum O +
concentrations O +
( O -
55 O -
% O -
) O -
, O +
while O +
bilateral O +
perforation O -
, O +
or O +
perforating O +
the O +
right O +
side O +
of O +
the O +
peritoneum O -
, O +
had O +
no O +
apparent O +
effects O +
( O -
Table O +
1 O -
) O -
. O +

Perforating O +
the O +
right O +
side O +
of O +
the O +
peritoneum O +
on O +
D2 O +
day O +
resulted O +
in O +
E2 O +
concentration O +
increases O +
( O -
184 O -
% O -
) O -
, O +
while O +
perforating O +
the O +
left O +
side O +
resulted O +
in O +
a O +
decrease O +
( O -
51 O -
% O -
) O +
of O +
E2 O +
serum O +
concentrations O -
. O +

Bilateral O +
perforation O +
had O +
no O +
apparent O +
effects O +
on O +
hormone O +
concentrations O -
. O +

Perforating O +
the O +
peritoneum O +
on O +
P O +
phase O +
( O -
left O -
, O +
right O +
or O +
bilateral O -
) O +
resulted O +
in O +
hormone O +
serum O +
concentration O +
decreases O +
( O -
Left O +
30 O -
% O -
; O +
Right O +
50 O -
% O -
; O +
Bilateral O +
41 O -
% O -
) O -
. O +

Results O +
are O +
summarized O +
in O +
Table O +
1 O -
. O +

Effects O +
of O +
unilateral O +
or O +
bilateral O +
ovariectomy O +
When O +
surgery O +
was O +
performed O +
on O +
D1 O -
, O +
no O +
significant O +
differences O +
in O +
E2 O +
serum O +
concentrations O +
were O +
observed O +
between O +
rats B-Species +
with O +
ULO O +
( O -
animals O +
with O +
intact O +
left O +
or O +
right O +
ovary O +
in O +
situ O -
) O +
or O +
perforation O +
of O +
the O +
peritoneum O +
( O -
Figure O +
1 O -
) O -
. O +

Animals O +
with O +
the O +
left O +
intact O +
ovary O +
in O +
situ O +
showed O +
significantly O +
higher O +
E2 O +
serum O +
concentrations O +
than O +
animals O +
with O +
the O +
right O +
intact O +
ovary O +
in O +
situ O +
( O -
61.5 O +
± O +
9.4 O +
vs. O +
17.3 O +
± O +
4.3 O -
, O +
p O +
< O +
0.05 O +
Student O -
's O +
t O +
test O -
) O -
. O +

Compared O +
to O +
animals O +
with O +
unilateral O +
perforation O +
of O +
the O +
peritoneum O -
, O +
animals O +
with O +
right O +
ULO O +
( O -
left O +
ovary O +
in O +
situ O -
) O +
performed O +
on O +
D2 O +
had O +
lower O +
E2 O +
serum O +
concentrations O +
( O -
55 O -
% O -
) O -
. O +

Such O +
differences O +
were O +
not O +
observed O +
in O +
rats B-Species +
with O +
left O +
ULO O +
( O -
Figure O +
1 O -
) O -
. O +

As O +
in O +
rats B-Species +
treated O +
on O +
D1 O -
, O +
E2 O +
serum O +
concentrations O +
were O +
significantly O +
higher O +
in O +
animals O +
treated O +
on O +
D2 O +
with O +
the O +
left O +
ovary O +
in O +
situ O +
( O -
right O +
ULO O -
) O +
than O +
in O +
animals O +
with O +
the O +
right O +
ovary O +
in O +
situ O +
( O -
49.5 O +
± O +
10.8 O +
vs. O +
26.0 O +
± O +
6.9 O -
) O -
. O +

In O +
animals O +
treated O +
on O +
P O -
, O +
right O +
ULO O +
( O -
left O +
ovary O +
in O +
situ O -
) O +
resulted O +
in O +
higher O +
E2 O +
( O -
180 O -
% O -
) O +
serum O +
concentrations O +
than O +
in O +
animals O +
with O +
unilateral O +
peritoneum O +
perforation O -
. O +

ULO O +
performed O +
on O +
the O +
left O +
side O +
( O -
right O +
ovary O +
in O +
situ O -
) O -
, O +
resulted O +
in O +
significantly O +
lower O +
( O -
45 O -
% O -
) O +
E2 O +
serum O +
concentrations O +
compared O +
to O +
rats B-Species +
with O +
a O +
unilateral O +
perforation O +
of O +
the O +
peritoneum O +
( O -
Figure O +
1 O -
) O -
. O +

As O +
observed O +
in O +
rats B-Species +
treated O +
on O +
D1 O +
or O +
D2 O -
, O +
when O +
the O +
intact O +
left O +
ovary O +
remains O +
in O +
situ O -
, O +
estradiol O +
serum O +
concentrations O +
were O +
significantly O +
higher O +
than O +
in O +
animals O +
with O +
the O +
intact O +
right O +
ovary O +
in O +
situ O +
( O -
142.0 O +
± O +
14.1 O +
vs. O +
61.5 O +
± O +
6.0 O -
) O -
. O +

Compared O +
to O +
animals O +
with O +
a O +
bilateral O +
perforation O +
of O +
the O +
peritoneum O -
, O +
bilateral O +
ovariectomy O +
resulted O +
in O +
significantly O +
lower O +
E2 O +
serum O +
concentrations O -
, O +
regardless O +
of O +
the O +
stage O +
of O +
the O +
estrous O +
cycle O +
surgery O +
performed O +
( O -
D1 O +
74 O -
% O -
; O +
D2 O +
73 O -
% O -
; O +
P O +
84 O -
% O -
) O -
. O +

Results O +
are O +
summarized O +
in O +
Table O +
2 O -
. O +

Effects O +
of O +
blocking O +
the O +
cholinergic O +
system O +
Injecting O +
ATR O +
on O +
D1 O +
or O +
P O +
resulted O +
in O +
E2 O +
serum O +
concentrations O +
decreases O +
( O -
84 O -
% O +
and O +
67 O -
% O -
, O +
respectively O -
) O -
, O +
and O +
had O +
no O +
apparent O +
effects O +
on O +
E2 O +
serum O +
concentrations O +
when O +
injected O +
on O +
D2 O +
( O -
Table O +
3 O -
) O -
. O +

Figure O +
2 O +
shows O +
that O +
the O +
effects O +
of O +
blocking O +
the O +
cholinergic O +
system O +
of O +
rats B-Species +
with O +
unilateral O +
perforation O +
of O +
the O +
peritoneum O +
depended O +
on O +
both O -
, O +
the O +
side O +
( O -
left O +
or O +
right O -
) O +
and O +
the O +
phase O +
of O +
the O +
estrous O +
when O +
surgery O +
was O +
performed O -
. O +

Injecting O +
ATR O +
on O +
D1 O +
or O +
D2 O +
resulted O +
in O +
a O +
significant O +
drop O +
in O +
E2 O +
serum O +
concentrations O +
in O +
animals O +
with O +
sham O +
treatment O +
on O +
the O +
right O +
side O -
. O +

Blocking O +
the O +
cholinergic O +
system O +
of O +
rats B-Species +
with O +
left O +
side O +
peritoneum O +
perforation O +
on O +
D1 O +
or O +
P O +
resulted O +
in O +
a O +
drop O +
in O +
E2 O +
serum O +
concentrations O +
( O -
52 O -
% O -
; O +
47 O -
% O -
, O +
respectively O -
) O -
, O +
while O +
the O +
same O +
treatment O +
performed O +
on O +
D2 O +
resulted O +
in O +
a O +
significant O +
E2 O +
concentrations O +
increase O +
( O -
157 O -
% O -
) O -
. O +

Figure O +
3 O +
shows O +
the O +
effects O +
of O +
blocking O +
the O +
cholinergic O +
system O +
of O +
rats B-Species +
with O +
ULO O -
. O +

ATR O +
treatment O +
on O +
D1 O +
or O +
P O +
stages O +
performed O +
on O +
rats B-Species +
with O +
the O +
left O +
ovary O +
in O +
situ O +
resulted O +
in O +
a O +
significant O +
drop O +
of O +
E2 O +
serum O +
concentrations O +
( O -
65 O -
% O -
; O +
62 O -
% O +
respectively O -
) O -
. O +

Such O +
effects O +
were O +
not O +
observed O +
in O +
rats B-Species +
treated O +
on O +
D2 O -
. O +

When O +
ATR O +
treatment O +
was O +
performed O +
on O +
rats B-Species +
with O +
the O +
right O +
ovary O +
in O +
situ O +
on O +
D1 O -
, O +
E2 O +
serum O +
concentrations O +
were O +
lower O +
( O -
48 O -
% O -
) O +
than O +
in O +
ULO O +
animals O -
. O +

Blocking O +
the O +
cholinergic O +
system O +
on O +
D2 O +
resulted O +
in O +
E2 O +
serum O +
concentrations O +
increase O +
( O -
159 O -
% O -
) O -
. O +

When O +
the O +
treatment O +
was O +
performed O +
on O +
P O -
, O +
no O +
significant O +
differences O +
in O +
E2 O +
serum O +
concentrations O +
were O +
observed O -
. O +

Compared O +
to O +
bilateral O +
treatment O -
, O +
perforation O +
of O +
the O +
peritoneum O +
or O +
bilateral O +
ovariectomy O -
, O +
ATR O +
treatment O +
on O +
D1 O +
resulted O +
in O +
significant O +
E2 O +
serum O +
concentrations O +
decreases O -
, O +
90 O -
% O +
in O +
bilateral O +
peritoneal O +
perforation O +
and O +
60 O -
% O +
in O +
bilateral O +
ovariectomized O +
animals O -
. O +

Blocking O +
the O +
cholinergic O +
system O +
on O +
D2 O -
, O +
to O +
rats B-Species +
with O +
bilateral O +
perforation O +
of O +
the O +
peritoneum O +
or O +
bilateral O +
ovariectomy O +
resulted O +
in O +
E2 O +
serum O +
concentrations O +
increases O +
( O -
159 O -
% O +
and O +
253 O -
% O +
respectively O -
) O -
, O +
while O +
injecting O +
ATR O +
to O +
animals O +
treated O +
on O +
P O +
had O +
no O +
apparent O +
effects O +
( O -
Figure O +
4 O -
) O -
. O +

Discussion O +
The O +
results O +
obtained O +
in O +
the O +
present O +
study O +
suggest O +
that O +
the O +
ability O +
to O +
compensate O +
the O +
secretion O +
of O +
E2 O +
by O +
the O +
missing O +
ovary O +
is O +
different O +
between O +
the O +
right O +
and O +
left O +
ovaries O +
and O +
varies O +
during O +
the O +
estrous O +
cycle O -
. O +

Similarly O -
, O +
our O +
results O +
suggest O +
that O +
the O +
cholinergic O +
system O +
participates O +
in O +
regulating O +
E2 O +
secretion O +
by O +
the O +
ovary O -
, O +
and O +
that O +
such O +
participation O +
varies O +
depending O +
on O +
the O +
ovary O +
remaining O +
in O +
situ O +
and O +
the O +
stage O +
of O +
the O +
estrous O +
cycle O +
when O +
the O +
surgical O +
procedure O +
was O +
performed O -
. O +

Previously O -
, O +
we O +
suggested O +
the O +
existence O +
of O +
a O +
neural O +
pathway O +
arising O +
from O +
the O +
peritoneum O +
that O +
participates O +
in O +
regulating O +
E2 O +
[ O -
9 O -
] O -
, O +
P4 O +
[ O -
10 O -
] O +
and O +
testosterone O +
secretion O +
[ O -
11 O -
] O -
. O +

In O +
the O +
rat B-Species -
, O +
the O +
sensory O +
information O +
arising O +
from O +
the O +
peritoneum O +
is O +
sent O +
to O +
the O +
nucleus O +
tractus O +
solitarius O +
and O +
stimulates O +
neurokinine O -
- O -
B O +
receptors O +
[ O -
17 O -
] O -
. O +

Since O +
perforating O +
the O +
peritoneum O +
unilaterally O +
on O +
each O +
day O +
of O +
the O +
estrous O +
cycle O +
changed O +
E2 O +
serum O +
concentrations O -
, O +
we O +
think O +
that O +
each O +
side O +
of O +
the O +
peritoneum O +
sends O +
different O +
neural O +
information O +
through O +
the O +
superior O +
ovarian O +
nerve O +
( O -
SON O -
) O +
to O +
the O +
ovary O +
and O +
the O +
central O +
nervous O +
system O -
, O +
perhaps O +
reaching O +
nuclei O +
related O +
to O +
the O +
vagus O +
nerve O -
. O +

A O +
study O +
analyzing O +
the O +
distribution O +
of O +
sensory O +
neurons O +
innervating O +
the O +
peritoneum O +
showed O +
that O +
when O +
tracer O +
was O +
placed O +
on O +
the O +
area O +
where O +
the O +
peritoneum O +
covers O +
the O +
abdominal O +
wall O -
, O +
labeled O +
neurons O +
were O +
observed O +
only O +
in O +
the O +
ipsilateral O +
dorsal O +
root O +
ganglia O +
[ O -
18 O -
] O -
. O +

The O +
authors O +
suggest O +
that O +
most O +
of O +
the O +
parietal O +
peritoneum O +
receives O +
sensory O +
nerves O +
from O +
dorsal O +
root O +
ganglia O -
, O +
and O +
visceral O +
peritoneum O +
from O +
both O -
, O +
the O +
spinal O +
and O +
vagus O +
nerves O -
. O +

According O +
to O +
Stener O -
- O -
Victorin O +
et O +
al. O +
( O -
19 O -
) O +
repeated O +
electro O -
- O -
acupunture O +
treatments O +
in O +
rats B-Species +
with O +
polycystic O +
ovary O +
syndrome O +
( O -
PCO O -
) O -
, O +
induced O +
by O +
a O +
single O +
injection O +
of O +
estradiol O +
valerate O -
, O +
resulted O +
in O +
lower O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O +
concentrations O +
at O +
the O +
ovarian O +
level O +
than O +
in O +
non O -
- O -
electro O -
- O -
acupunture O +
treated O +
PCO O +
rats B-Species -
. O +

In O +
our O +
experiments O -
, O +
perforating O +
the O +
peritoneum O +
affected O +
the O +
same O +
somatic O +
segments O +
employed O +
by O +
Stener O -
- O -
Victorin O +
et O -
. O +

al. O +
[ O -
19 O -
] O -
. O +

We O +
presume O +
that O +
peritoneum O +
surgery O +
resulted O +
in O +
an O +
increase O +
of O +
NGF O +
concentrations O +
at O +
the O +
ovarian O +
level O -
, O +
which O +
in O +
turn O +
induced O +
hyper O -
- O -
androgenism O -
, O +
as O +
observed O +
in O +
women O +
with O +
PCO O +
[ O -
20 O -
] O -
. O +

Previously O -
, O +
we O +
showed O +
that O +
the O +
unilateral O +
perforation O +
of O +
the O +
peritoneum O +
results O +
in O +
a O +
significant O +
increase O +
in O +
testosterone O +
serum O +
concentrations O +
[ O -
11 O -
] O -
. O +

Because O +
E2 O +
serum O +
concentrations O +
did O +
not O +
increase O +
after O +
left O +
or O +
bilateral O +
perforation O +
of O +
the O +
peritoneum O -
, O +
we O +
suppose O +
that O +
the O +
neural O +
information O +
originating O +
from O +
the O +
peritoneum O +
inhibits O +
the O +
mechanisms O +
regulating O +
aromatase O +
activity O +
within O +
the O +
follicle O -
. O +

One O +
of O +
the O +
ovaries O -
' O +
sources O +
of O +
catecholamines O +
arrives O +
through O +
the O +
SON O -
. O +

In O +
the O +
ovary O -
, O +
the O +
SON O +
fibers O +
are O +
mainly O +
distributed O +
in O +
the O +
peri O -
- O -
follicular O +
theca O +
layer O -
, O +
and O +
in O +
close O +
relation O +
with O +
the O +
cells O +
of O +
the O +
theca O +
interna O +
[ O -
21,22 O -
] O -
. O +

Sectioning O +
the O +
SON O +
of O +
rats B-Species +
in O +
P O +
results O +
in O +
a O +
sudden O +
drop O +
of O +
P4 O +
and O +
E2 O +
concentrations O +
in O +
the O +
ovarian O +
vein O +
effluent O +
[ O -
23 O -
] O -
, O +
while O +
the O +
same O +
procedure O +
on O +
estrus O +
did O +
not O +
modify O +
E2 O +
concentrations O +
[ O -
24 O -
] O -
. O +

Therefore O -
, O +
it O +
is O +
possible O +
that O +
perforating O +
the O +
peritoneum O +
modifies O +
the O +
type O +
and/or O +
rate O +
of O +
information O +
arriving O +
to O +
the O +
ovary O +
via O +
the O +
SON O -
. O +

Another O +
possibility O +
is O +
that O +
perforating O +
the O +
left O +
side O +
of O +
the O +
peritoneum O +
results O +
in O +
an O +
increase O +
release O +
of O +
ovarian O +
gamma O +
amino O +
butyric O +
acid O +
( O -
GABA O -
) O -
, O +
and O +
a O +
subsequent O +
increase O +
of O +
E2 O +
concentrations O -
. O +

According O +
to O +
Erdö O -
, O +
et O -
. O +

al. O +
[ O -
25 O -
] O +
and O +
Laszlo O -
, O +
et O -
. O +

al. O +
[ O -
26 O -
] O -
, O +
injecting O +
GABA O +
into O +
pseudo O -
- O -
pregnant O +
rats B-Species +
increases O +
E2 O +
concentration O +
in O +
the O +
blood O -
. O +

Present O +
results O +
indicate O +
that O +
injecting O +
ATR O -
, O +
before O +
unilateral O +
or O +
bilateral O +
perforation O +
of O +
the O +
peritoneum O -
, O +
to O +
rats B-Species +
in O +
D1 O +
or O +
P O -
, O +
results O +
in O +
lower O +
E2serum O +
concentrations O -
; O +
leading O +
us O +
to O +
think O +
that O +
some O +
of O +
the O +
neural O +
fibers O +
present O +
in O +
the O +
peritoneum O +
are O +
muscarinic O -
. O +

It O +
is O +
also O +
possible O +
that O +
blocking O +
the O +
cholinergic O +
innervation O -
, O +
by O +
ATR O +
treatment O -
, O +
results O +
in O +
lower O +
adrenaline O +
and O +
norepinephrine O +
release O +
by O +
the O +
adrenal O +
medulla O -
. O +

Our O +
results O -
, O +
and O +
those O +
of O +
others O -
, O +
suggest O +
that O +
stimulating O +
on O +
D2 O +
the O +
sensory O +
receptors O +
located O +
on O +
the O +
left O +
side O +
of O +
the O +
peritoneum O +
triggers O +
an O +
E2 O +
secretion O +
inhibitory O +
mechanism O -
, O +
that O +
the O +
sensory O +
pathway O +
arising O +
from O +
the O +
right O +
side O +
has O +
a O +
stimulatory O +
effect O -
, O +
and O +
that O +
both O +
are O +
mediated O +
by O +
the O +
cholinergic O +
muscarinic O +
system O -
. O +

Previously O -
, O +
we O +
showed O +
that O +
injecting O +
ATR O +
to O +
rats B-Species +
in O +
D2 O +
results O +
in O +
increases O +
of O +
P4 O +
serum O +
concentrations O +
originating O +
from O +
the O +
adrenals O +
[ O -
8 O -
] O -
, O +
without O +
having O +
apparent O +
effects O +
on O +
testosterone O +
serum O +
concentrations O +
[ O -
11 O -
] O -
. O +

Since O +
P4 O +
and O +
androgens O +
are O +
precursors O +
in O +
the O +
synthesis O +
of O +
E2 O -
, O +
we O +
presume O +
that O +
this O +
mechanism O +
may O +
explain O +
the O +
increase O +
in O +
E2 O +
serum O +
concentrations O +
observed O +
in O +
rats B-Species +
with O +
peritoneum O +
perforation O +
previously O +
injected O +
with O +
ATR O -
. O +

Another O +
possibility O +
explaining O +
the O +
differences O +
on O +
E2 O +
secretion O +
regulation O +
during O +
the O +
estrous O +
cycle O +
is O +
that O +
the O +
effects O +
of O +
the O +
cholinergic O +
system O +
take O +
place O +
through O +
changes O +
at O +
the O +
celiac O +
ganglion O +
level O -
. O +

According O +
to O +
Aguado O +
and O +
Ojeda O +
[ O -
23 O -
] O -
, O +
acetylcholine O +
inhibits O +
P4 O +
secretion O +
in O +
the O +
celiac O +
ganglion O -
- O -
SON O -
- O -
ovary O +
preparation O +
obtained O +
from O +
rats B-Species +
in O +
D1 O +
or O +
D2 O -
, O +
while O +
the O +
preparation O +
obtained O +
from O +
rats B-Species +
in O +
P O +
resulted O +
in O +
only O +
a O +
moderate O +
stimulation O -
. O +

Since O +
there O +
is O +
evidence O +
that O +
fibers O +
from O +
the O +
vagus O +
nerve O +
innervate O +
neurons O +
in O +
the O +
celiac O +
ganglion O +
[ O -
27 O -
] O -
, O +
we O +
presume O +
that O +
the O +
cholinergic O +
system O +
modulates O +
the O +
sympathetic O +
post O -
- O -
ganglionar O +
activity O +
and O +
the O +
secretory O +
ability O +
of O +
the O +
ovaries O +
through O +
the O +
SON O -
. O +

Conclusion O +
Based O +
on O +
the O +
differences O +
in O +
E2 O +
serum O +
concentrations O +
in O +
rats B-Species +
with O +
ULO O -
, O +
present O +
results O +
suggest O +
that O +
the O +
capacity O +
to O +
release O +
E2 O +
by O +
the O +
left O +
and O +
right O +
ovaries O +
varies O +
during O +
the O +
estrous O +
cycle O -
. O +

We O +
presume O +
that O +
the O +
left O +
ovary O +
releases O +
more O +
E2 O +
than O +
the O +
right O +
one O -
. O +

As O +
previously O +
proposed O -
, O +
another O +
possibility O +
is O +
that O +
neural O +
communication O +
between O +
the O +
ovaries O +
modulates O +
E2 O +
secretion O -
. O +

Molecular O +
polymorphism O -
, O +
differentiation O +
and O +
introgression O +
in O +
the O +
period O +
gene O +
between O +
Lutzomyia B-Species +
intermedia I-Species +
and O +
Lutzomyia B-Species +
whitmani I-Species +
Abstract O +
Background O +
Lutzomyia B-Species +
intermedia I-Species +
and O +
Lutzomyia B-Species +
whitmani I-Species +
( O -
Diptera O -
: O +
Psychodidae O -
) O +
are O +
important O +
and O +
very O +
closely O +
related O +
vector O +
species O +
of O +
cutaneous O +
leishmaniasis O +
in O +
Brazil O -
, O +
which O +
are O +
distinguishable O +
by O +
a O +
few O +
morphological O +
differences O -
. O +

There O +
is O +
evidence O +
of O +
mitochondrial O +
introgression O +
between O +
the O +
two O +
species O +
but O +
it O +
is O +
not O +
clear O +
whether O +
gene O +
flow O +
also O +
occurs O +
in O +
nuclear O +
genes O -
. O +

Results O +
We O +
analyzed O +
the O +
molecular O +
variation O +
within O +
the O +
clock O +
gene O +
period O +
( O -
per O -
) O +
of O +
these O +
two O +
species O +
in O +
five O +
different O +
localities O +
in O +
Eastern O +
Brazil O -
. O +

AMOVA O +
and O +
Fst O +
estimates O +
showed O +
no O +
evidence O +
for O +
geographical O +
differentiation O +
within O +
species O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
values O +
were O +
highly O +
significant O +
for O +
both O +
analyses O +
between O +
species O -
. O +

The O +
two O +
species O +
show O +
no O +
fixed O +
differences O +
and O +
a O +
higher O +
number O +
of O +
shared O +
polymorphisms O +
compared O +
to O +
exclusive O +
mutations O -
. O +

In O +
addition O -
, O +
some O +
haplotypes O +
that O +
are O +
" O -
typical O -
" O +
of O +
one O +
species O +
were O +
found O +
in O +
some O +
individuals O +
of O +
the O +
other O +
species O +
suggesting O +
either O +
the O +
persistence O +
of O +
old O +
polymorphisms O +
or O +
the O +
occurrence O +
of O +
introgression O -
. O +

Two O +
tests O +
of O +
gene O +
flow O -
, O +
one O +
based O +
on O +
linkage O +
disequilibrium O +
and O +
a O +
MCMC O +
analysis O +
based O +
on O +
coalescence O -
, O +
suggest O +
that O +
the O +
two O +
species O +
might O +
be O +
exchanging O +
alleles O +
at O +
the O +
per O +
locus O -
. O +

Conclusion O +
Introgression O +
might O +
be O +
occurring O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
in O +
period O -
, O +
a O +
gene O +
controlling O +
behavioral O +
rhythms O +
in O +
Drosophila O -
. O +

This O +
result O +
raises O +
the O +
question O +
of O +
whether O +
similar O +
phenomena O +
are O +
occurring O +
at O +
other O +
loci O +
controlling O +
important O +
aspects O +
of O +
behavior O +
and O +
vectorial O +
capacity O -
. O +

Background O +

The O +
Phlebotominae O +
sand O +
flies O +
Lutzomyia B-Species +
intermedia I-Species +
Lutz O +
& O +
Neiva O +
1912 O +
and O +
Lutzomyia B-Species +
whitmani I-Species +
Antunes O +
& O +
Coutinho O +
1912 O +
are O +
vectors O +
of O +
cutaneous O +
leishmaniasis O +
in O +
Brazil O -
. O +

These O +
are O +
closely O +
related O +
species O +
that O +
can O +
be O +
only O +
distinguished O +
by O +
a O +
few O +
morphological O +
differences O +
[ O -
1 O -
] O +
and O +
both O +
show O +
high O +
anthropophily O +
and O +
reported O +
natural O +
infections O +
with O +
Leishmania O +
in O +
different O +
regions O +
of O +
Brazil O +
[ O -
2 O -
] O -
. O +

Despite O +
their O +
importance O +
as O +
vectors O -
, O +
only O +
a O +
handful O +
of O +
studies O +
have O +
been O +
carried O +
out O +
in O +
these O +
two O +
species O +
using O +
molecular O +
techniques O +
[ O -
3 O -
- O -
6 O -
] O -
. O +

One O +
of O +
the O +
most O +
important O +
findings O +
from O +
an O +
epidemiological O +
perspective O +
is O +
the O +
evidence O +
obtained O +
for O +
introgression O +
between O +
the O +
two O +
species O +
using O +
mitochondrial O +
DNA O +
[ O -
4 O -
] O -
. O +

This O +
was O +
particularly O +
interesting O +
because O +
apparently O -
, O +
only O +
lineages O +
of O +
L. B-Species +
whitmani I-Species +
sympatric O +
with O +
L. B-Species +
intermedia I-Species +
have O +
been O +
involved O +
in O +
cutaneous O +
leishmaniasis O +
transmission O +
in O +
the O +
peridomestic O +
environment O +
[ O -
4 O -
] O -
, O +
which O +
suggests O +
that O +
genes O +
controlling O +
aspects O +
of O +
vectorial O +
capacity O +
could O +
be O +
passing O +
from O +
one O +
species O +
to O +
the O +
other O -
. O +

In O +
fact O -
, O +
mitochondrial O +
introgression O +
has O +
been O +
reported O +
in O +
other O +
sand O +
fly O +
species O +
[ O -
7,8 O -
] O +
suggesting O +
that O +
might O +
be O +
a O +
common O +
phenomenon O +
in O +
these O +
insect O +
vectors O -
. O +

However O -
, O +
because O +
mitochondrial O +
genes O +
can O +
introgress O +
relatively O +
easily O +
between O +
closely O +
related O +
species O +
[ O -
9 O -
] O -
, O +
it O +
becomes O +
important O +
to O +
examine O +
whether O +
introgression O +
can O +
occur O +
with O +
nuclear O +
genes O -
. O +

The O +
Drosophila O +
period O +
( O -
per O -
) O +
gene O +
homologue O +
was O +
isolated O +
in O +
sand O +
flies O +
by O +
Peixoto O +
et O +
al. O +
[ O -
10 O -
] O -
. O +

This O +
circadian O +
clock O +
gene O +
was O +
originally O +
identified O +
using O +
mutagenesis O +
by O +
Konopka O +
and O +
Benzer O +
[ O -
11 O -
] O -
, O +
but O +
is O +
also O +
known O +
to O +
control O +
the O +
differences O +
in O +
the O +
" O -
lovesong O -
" O +
rhythms O +
between O +
D. B-Species +
melanogaster I-Species +
and O +
D. B-Species +
simulans I-Species +
[ O -
12 O -
] O -
, O +
that O +
are O +
important O +
to O +
the O +
sexual O +
isolation O +
between O +
these O +
two O +
species O +
[ O -
13 O -
- O -
15 O -
] O -
. O +

In O +
addition O -
, O +
per O +
was O +
implicated O +
in O +
the O +
control O +
of O +
species O -
- O -
specific O +
circadian O +
mating O +
rhythms O +
in O +
Drosophila O +
and O +
Bractocera O -
, O +
which O +
might O +
also O +
constitute O +
a O +
reproductive O +
isolation O +
mechanism O +
[ O -
16 O -
- O -
18 O -
] O -
. O +

Thus O +
per O +
may O +
possibly O +
represent O +
an O +
example O +
of O +
a O +
Drosophila O +
speciation O +
gene O +
[ O -
19 O -
] O -
, O +
and O +
in O +
fact O +
it O +
has O +
been O +
used O +
as O +
a O +
molecular O +
marker O +
in O +
a O +
number O +
of O +
speciation O +
and O +
evolutionary O +
studies O -
, O +
not O +
only O +
in O +
Drosophila O +
( O -
reviewed O +
in O +
[ O -
20 O -
] O -
) O +
but O +
also O +
in O +
other O +
insects O +
( O -
e.g. O +
[ O -
21 O -
] O -
) O +
including O +
sand O +
flies O +
[ O -
22 O -
- O -
24 O -
] O -
. O +

Because O +
per O +
controls O +
the O +
circadian O +
clock O +
in O +
different O +
insects O +
[ O -
25 O -
] O -
, O +
it O +
is O +
almost O +
certainly O +
involved O +
in O +
the O +
rhythms O +
of O +
activity O +
and O +
biting O +
of O +
sand O +
flies O +
[ O -
26 O -
] O -
, O +
which O +
are O +
very O +
important O +
to O +
leishmaniasis O +
transmission O -
. O +

In O +
addition O -
, O +
per O +
might O +
be O +
involved O +
in O +
reproductive O +
isolation O +
in O +
sand O +
flies O -
, O +
via O +
mating O +
rhythms O -
, O +
or O +
via O +
their O +
" O -
lovesongs O -
" O +
[ O -
2,27 O -
] O -
. O +

per O +
is O +
thus O +
a O +
particularly O +
interesting O +
marker O -
, O +
among O +
the O +
few O +
available O -
, O +
for O +
an O +
introgression O +
analysis O +
in O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species -
. O +

Evidence O +
for O +
introgression O +
in O +
per O +
might O +
suggest O +
that O +
gene O +
flow O +
between O +
these O +
two O +
vector O +
species O +
is O +
occurring O +
at O +
other O +
genes O +
controlling O +
important O +
aspects O +
of O +
behavior O +
and O +
vectorial O +
capacity O -
. O +

It O +
might O +
also O +
suggest O +
that O +
per O +
does O +
not O +
have O +
a O +
strong O +
role O +
in O +
their O +
reproductive O +
isolation O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
analyzed O +
the O +
molecular O +
variation O +
within O +
the O +
per O +
gene O +
of O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
in O +
five O +
different O +
localities O +
in O +
Eastern O +
Brazil O -
. O +

Results O +
Polymorphism O +
and O +
divergence O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
A O +
total O +
of O +
68 O +
sequences O +
from O +
L. B-Species +
intermedia I-Species +
and O +
53 O +
from O +
L. B-Species +
whitmani I-Species +
homologue O +
to O +
a O +
fragment O +
of O +
the O +
period O +
gene O +
were O +
analyzed O +
from O +
populations O +
of O +
five O +
localities O +
in O +
Eastern O +
Brazil O +
( O -
Fig O +
1 O -
) O -
. O +

The O +
alignment O +
of O +
72 O +
variable O +
sites O +
is O +
shown O +
in O +
Fig O +
2 O -
. O +

Although O +
most O +
of O +
the O +
changes O +
are O +
either O +
synonymous O +
or O +
occur O +
within O +
the O +
58 O +
bp O +
intron O -
, O +
non O -
- O -
synonymous O +
substitutions O +
are O +
observed O +
causing O +
9 O +
amino O +
acid O +
differences O +
among O +
the O +
sequences O +
( O -
Fig O +
2 O -
) O -
. O +

Table O +
1 O +
shows O +
the O +
number O +
of O +
sequences O +
of O +
each O +
population O +
of O +
the O +
two O +
species O -
, O +
the O +
number O +
of O +
polymorphic O +
sites O +
( O -
S O -
) O +
and O +
the O +
estimates O +
of O +
molecular O +
polymorphism O +
θ O +
( O -
based O +
on O +
the O +
total O +
number O +
of O +
mutations O -
) O +
and O +
π O -
. O +

Table O +
1 O +
also O +
shows O +
the O +
Tajima O -
's O +
[ O -
28 O -
] O +
and O +
Fu O +
& O +
Li O -
's O +
[ O -
29 O -
] O +
statistics O -
. O +

Within O +
each O +
species O -
, O +
all O +
populations O +
present O +
similar O +
levels O +
of O +
polymorphism O +
with O +
the O +
exception O +
of O +
L. B-Species +
whitmani I-Species +
from O +
Ilhéus O -
, O +
which O +
seems O +
to O +
be O +
less O +
polymorphic O +
than O +
the O +
others O -
. O +

This O +
population O +
was O +
also O +
the O +
only O +
one O +
presenting O +
a O +
significant O +
value O +
in O +
the O +
Fu O +
& O +
Li O +
test O +
but O +
only O +
at O +
the O +
5 O -
% O +
level O -
. O +

Finally O -
, O +
the O +
last O +
column O +
of O +
Table O +
1 O +
presents O +
the O +
recombination O +
estimator O +
γ O +
[ O -
30 O -
] O +
indicating O +
that O +
both O +
species O +
show O +
evidence O +
of O +
intragenic O +
recombination O +
in O +
the O +
per O +
gene O -
. O +

To O +
investigate O +
the O +
level O +
of O +
intra O +
and O +
interspecific O +
differences O -
, O +
initially O +
an O +
AMOVA O +
was O +
carried O +
out O +
as O +
shown O +
in O +
Table O +
2 O -
. O +

The O +
results O +
show O +
a O +
non O -
- O -
significant O +
within O +
species O +
and O +
a O +
significant O +
between O +
species O +
molecular O +
variation O +
at O +
the O +
per O +
locus O -
. O +

Table O +
3 O +
shows O +
a O +
more O +
detailed O +
analysis O +
of O +
the O +
intraspecific O +
differentiation O +
among O +
populations O +
of O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species -
. O +

None O +
of O +
the O +
pairwise O +
and O +
overall O +
fixation O +
indexes O +
( O -
Fst O -
) O +
are O +
significant O +
in O +
the O +
case O +
of O +
L. B-Species +
intermedia I-Species +
and O +
only O +
one O +
( O -
Posse O +
× O +
Ilhéus O -
) O +
has O +
a O +
borderline O +
significant O +
value O +
in O +
L. B-Species +
whitmani I-Species -
. O +

The O +
results O +
therefore O +
show O +
that O +
no O +
significant O +
geographical O +
heterogeneity O +
was O +
detected O +
among O +
the O +
populations O +
of O +
the O +
two O +
species O -
. O +

The O +
estimated O +
number O +
of O +
migrants O +
per O +
generation O -
, O +
based O +
on O +
the O +
overall O +
Fst O +
values O -
, O +
is O +
20.683 O +
for O +
L. B-Species +
intermedia I-Species +
and O +
23.125 O +
for O +
L. B-Species +
whitmani I-Species -
. O +

Table O +
4 O +
shows O +
measures O +
for O +
DNA O +
divergence O +
between O +
species O +
( O -
Dxy O +
and O +
Da O -
) O -
, O +
as O +
well O +
as O +
the O +
Fst O +
and O +
Nm O +
values O +
considering O +
each O +
species O +
as O +
a O +
unique O +
population O -
. O +

Dxy O +
is O +
the O +
average O +
number O +
of O +
nucleotide O +
substitutions O +
per O +
site O +
between O +
alleles O +
from O +
two O +
different O +
populations O +
and O +
Da O +
is O +
the O +
number O +
of O +
net O +
nucleotide O +
substitutions O +
between O +
two O +
populations O -
. O +

Table O +
4 O +
also O +
shows O +
the O +
number O +
of O +
polymorphisms O +
exclusive O +
for O +
each O +
species O +
( O -
Sint O +
and O +
Swhit O -
) O -
, O +
the O +
number O +
of O +
shared O +
polymorphisms O +
( O -
Ss O -
) O +
and O +
the O +
number O +
of O +
fixed O +
differences O +
( O -
Sf O -
) O +
between O +
species O -
. O +

As O +
one O +
can O +
note O -
, O +
there O +
is O +
a O +
high O +
number O +
of O +
shared O +
polymorphisms O +
between O +
species O -
, O +
and O +
no O +
fixed O +
differences O +
between O +
them O +
suggesting O +
either O +
the O +
persistence O +
of O +
ancestral O +
polymorphisms O +
or O +
the O +
occurrence O +
of O +
introgression O -
. O +

In O +
fact O -
, O +
there O +
is O +
one O +
shared O +
haplotype O +
between O +
the O +
two O +
species O +
( O -
IPO13 O -
, O +
WPO10 O +
and O +
WPO19 O -
) O +
and O +
three O +
L. B-Species +
whitmani I-Species +
sequences O +
( O -
WAC02 O -
, O +
WPO13 O +
and O +
WPO14 O -
) O +
which O +
show O +
only O +
one O +
nucleotide O +
difference O +
to O +
" O -
typical O -
" O +
L. B-Species +
intermedia I-Species +
haplotypes O +
( O -
see O +
also O +
below O -
) O -
. O +

Genealogy O +
of O +
period O +
sequences O +
A O +
phylogenetic O +
analysis O +
of O +
the O +
period O +
gene O +
sequences O +
from O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
was O +
carried O +
out O +
with O +
the O +
Minimum O +
Evolution O +
method O +
using O +
the O +
Kimura O +
2-parameter O +
distance O +
( O -
Fig O +
3 O -
) O -
. O +

A O +
sequence O +
from O +
L. B-Species +
umbratilis I-Species -
, O +
a O +
related O +
species O +
from O +
the O +
same O +
subgenus O +
Nyssomyia O -
, O +
was O +
used O +
as O +
outgroup O +
[ O -
24 O -
] O -
. O +

The O +
tree O +
shows O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
as O +
non O -
- O -
monophyletic O -
. O +

However O -
, O +
despite O +
the O +
low O +
bootstrap O +
values O -
, O +
which O +
are O +
below O +
50 O -
% O +
in O +
most O +
cases O -
, O +
there O +
is O +
a O +
large O +
group O +
that O +
contains O +
most O +
L. B-Species +
intermedia I-Species +
sequences O +
and O +
a O +
second O +
large O +
group O +
with O +
most O +
L. B-Species +
whitmani I-Species +
sequences O -
. O +

A O +
few O +
other O +
sequences O +
are O +
clustered O +
outside O +
these O +
two O +
main O +
groups O -
. O +

It O +
is O +
interesting O +
to O +
note O +
that O +
there O +
are O +
three O +
L. B-Species +
whitmani I-Species +
alleles O +
( O -
WAC2 O -
, O +
WPO13 O +
and O +
WPO14 O -
) O +
inside O +
L. B-Species +
intermedia I-Species +
main O +
group O -
, O +
as O +
well O +
as O +
one O +
L. B-Species +
intermedia I-Species +
allele O +
( O -
ICP16 O -
) O +
inside O +
the O +
L. B-Species +
whitmani I-Species +
main O +
group O -
. O +

In O +
addition O -
, O +
a O +
second O +
L. B-Species +
intermedia I-Species +
allele O +
( O -
IPO13 O -
) O +
is O +
a O +
shared O +
haplotype O +
between O +
the O +
two O +
species O +
as O +
mentioned O +
above O -
. O +

Again O -
, O +
the O +
results O +
suggest O +
either O +
the O +
persistence O +
of O +
ancestral O +
polymorphisms O +
or O +
the O +
occurrence O +
of O +
introgression O +
between O +
the O +
two O +
species O -
. O +

Very O +
similar O +
results O +
were O +
obtained O +
using O +
the O +
maximum O +
likelihood O +
algorithm O +
as O +
implemented O +
in O +
PAUP O +
4.0b10 O +
software O +
[ O -
31 O -
] O +
( O -
data O +
not O +
shown O -
) O -
. O +

As O +
mentioned O +
before O -
, O +
there O +
is O +
evidence O +
of O +
intragenic O +
recombination O +
in O +
the O +
per O +
gene O +
fragment O +
of O +
both O +
species O +
( O -
see O +
Table O +
1 O -
) O +
and O +
for O +
that O +
reason O +
the O +
bifurcating O +
tree O +
shown O +
in O +
Fig O +
3 O +
has O +
to O +
be O +
viewed O +
with O +
caution O -
, O +
as O +
different O +
regions O +
of O +
the O +
gene O +
might O +
have O +
different O +
phylogenetic O +
histories O +
[ O -
32 O -
] O -
. O +

Therefore O -
, O +
we O +
constructed O +
Minimum O +
Evolution O +
trees O +
with O +
the O +
two O +
most O +
polymorphic O +
non O -
- O -
recombining O +
blocks O +
of O +
the O +
per O +
gene O +
fragment O +
identified O +
using O +
the O +
Hudson O +
and O +
Kaplan O +
[ O -
33 O -
] O +
method O +
available O +
in O +
the O +
DNAsp O +
4.1 O +
program O +
[ O -
34 O -
] O -
. O +

We O +
did O +
not O +
observed O +
major O +
changes O +
in O +
the O +
genealogy O +
of O +
the O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
per O +
sequences O -
, O +
especially O +
regarding O +
the O +
five O +
haplotypes O +
( O -
ICP16 O -
, O +
IPO13 O -
, O +
WAC2 O -
, O +
WPO13 O +
and O +
WPO14 O -
) O +
that O +
clearly O +
cluster O +
with O +
sequences O +
of O +
the O +
other O +
species O +
( O -
data O +
not O +
shown O -
) O -
. O +

Finally O -
, O +
a O +
haplotype O +
network O +
was O +
estimated O +
from O +
per O +
sequences O +
using O +
statistical O +
parsimony O -
, O +
as O +
described O +
by O +
Templeton O +
et O +
al. O +
[ O -
35 O -
] O +
and O +
implemented O +
in O +
the O +
TCS1.21 O +
software O +
[ O -
36 O -
] O +
( O -
Fig O +
4 O -
) O -
. O +

A O +
small O +
number O +
of O +
ambiguities O +
were O +
resolved O +
as O +
suggested O +
by O +
Crandall O +
and O +
Templeton O +
[ O -
37 O -
] O -
. O +

The O +
haplotype O +
network O +
shows O +
connections O +
between O +
sequences O +
from O +
each O +
species O -
, O +
separating O +
most O +
of O +
the O +
sequences O +
of O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
in O +
two O +
groups O -
. O +

No O +
intraspecific O +
geographical O +
structuring O +
was O +
found O -
. O +

Once O +
again O -
, O +
some O +
of O +
the O +
L. B-Species +
whitmani I-Species +
sequences O +
( O -
WAC2 O -
, O +
WAC10 O -
, O +
WPO13 O +
and O +
WPO14 O -
) O +
appear O +
more O +
closely O +
related O +
to O +
L. B-Species +
intermedia I-Species +
haplotypes O -
. O +

In O +
addition O -
, O +
one O +
L. B-Species +
intermedia I-Species +
allele O +
( O -
ICP16 O -
) O +
is O +
connected O +
by O +
a O +
small O +
number O +
of O +
mutations O +
to O +
some O +
of O +
the O +
main O +
L. B-Species +
whitmani I-Species +
haplotypes O +
and O +
IPO13 O +
is O +
a O +
shared O +
haplotype O +
between O +
the O +
two O +
species O -
. O +

These O +
results O +
confirm O +
the O +
same O +
putative O +
introgressed O +
sequences O +
indicated O +
by O +
the O +
phylogenetic O +
reconstructions O -
. O +

LD O +
test O +
of O +
introgression O +
We O +
tested O +
the O +
hypothesis O +
of O +
gene O +
flow O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
using O +
a O +
method O +
based O +
on O +
linkage O +
disequilibrium O +
( O -
LD O -
) O +
developed O +
by O +
Machado O +
et O +
al. O +
[ O -
38 O -
] O -
. O +

In O +
this O +
test O -
, O +
x O +
is O +
the O +
difference O +
between O +
the O +
average O +
LD O +
found O +
among O +
all O +
pairs O +
of O +
shared O +
polymorphisms O +
( O -
DSS O -
) O +
between O +
the O +
two O +
species O +
and O +
the O +
average O +
LD O +
among O +
all O +
pairs O +
of O +
sites O +
for O +
which O +
one O +
member O +
is O +
a O +
shared O +
polymorphism O +
and O +
the O +
other O +
is O +
an O +
exclusive O +
polymorphism O +
( O -
DSX O -
) O -
. O +

In O +
case O +
of O +
gene O +
flow O +
x O +
should O +
tend O +
to O +
be O +
positive O +
[ O -
see O +
[ O -
38 O -
] O +
for O +
more O +
details O -
] O -
. O +

Because O +
of O +
limitations O +
on O +
the O +
total O +
number O +
of O +
sequences O +
that O +
could O +
be O +
handled O +
by O +
the O +
WH O +
program O +
we O +
could O +
not O +
perform O +
the O +
simulations O +
with O +
all O +
sequences O -
. O +

Therefore O -
, O +
we O +
carried O +
out O +
the O +
LD O +
test O +
of O +
introgression O +
between O +
each O +
pair O +
of O +
sympatric O +
populations O +
of O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
from O +
the O +
localities O +
of O +
Posse O -
, O +
Afonso O +
Claudio O +
and O +
Corte O +
de O +
Pedra O -
. O +

The O +
input O +
files O +
were O +
prepared O +
using O +
the O +
values O +
of O +
recombination O +
and O +
linkage O +
disequilibrium O +
calculated O +
by O +
the O +
SITES O +
program O +
[ O -
30 O -
] O +
for O +
each O +
population O +
( O -
data O +
not O +
shown O -
) O -
. O +

Although O +
no O +
significant O +
values O +
were O +
found O +
for O +
the O +
smaller O +
samples O +
of O +
Afonso O +
Claudio O +
and O +
Corte O +
de O +
Pedra O -
, O +
the O +
results O +
( O -
Table O +
5 O -
) O +
present O +
evidence O +
for O +
introgression O +
in O +
the O +
period O +
gene O +
in O +
both O +
directions O +
( O -
from O +
L. B-Species +
intermedia I-Species +
to O +
L. B-Species +
whitmani I-Species +
and O +
vice O -
- O -
versa O -
) O +
in O +
the O +
locality O +
of O +
Posse O -
. O +

Isolation O +
with O +
Migration O +
model O +
To O +
further O +
examine O +
the O +
gene O +
flow O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
we O +
used O +
the O +
IM O +
software O +
[ O -
39 O -
] O -
. O +

The O +
Isolation O +
with O +
Migration O +
model O +
has O +
six O +
demographic O +
parameters O +
that O +
include O +
two O +
migration O +
rates O -
, O +
one O +
for O +
each O +
population O -
. O +

The O +
IM O +
software O +
estimates O +
the O +
posterior O +
probability O +
for O +
each O +
of O +
the O +
model O +
parameters O -
, O +
fitting O +
the O +
Isolation O +
with O +
Migration O +
model O +
to O +
the O +
data O -
. O +

One O +
of O +
the O +
assumptions O +
of O +
this O +
model O +
is O +
that O +
the O +
loci O +
studied O +
do O +
not O +
have O +
internal O +
recombination O -
. O +

Therefore O -
, O +
we O +
identified O +
four O +
different O +
non O -
- O -
recombining O +
blocks O +
of O +
our O +
fragment O +
of O +
per O -
, O +
which O +
were O +
then O +
treated O +
as O +
different O +
loci O +
in O +
the O +
analysis O -
. O +

The O +
four O -
- O -
gametes O +
test O +
[ O -
33 O -
] O +
implemented O +
in O +
DnaSP4.1 O +
was O +
used O +
for O +
the O +
identification O +
of O +
possible O +
recombination O +
events O -
. O +

Since O +
the O +
program O +
estimates O +
parameters O +
for O +
a O +
pair O +
of O +
closely O +
related O +
populations O +
or O +
species O -
, O +
all O +
sequences O +
of O +
each O +
species O +
were O +
used O +
in O +
the O +
analysis O +
as O +
a O +
single O +
population O -
. O +

We O +
performed O +
MCMC O +
runs O +
using O +
the O +
IM O +
software O +
with O +
different O +
seed O +
numbers O -
, O +
in O +
order O +
to O +
guarantee O +
convergence O +
of O +
the O +
sample O -
. O +

Maximum O +
likelihood O +
estimates O +
of O +
migration O +
parameters O +
revealed O +
a O +
non O -
- O -
zero O +
value O +
for O +
both O +
species O -
, O +
m1 O +
= O +
1.398 O +
and O +
m2 O +
= O +
1.014 O +
( O -
m1 O +
– O +
from O +
L. B-Species +
whitmani I-Species +
towards O +
L. B-Species +
intermedia I-Species -
; O +
m2 O +
– O +
from O +
L. B-Species +
whitmani I-Species +
towards O +
L. B-Species +
intermedia I-Species -
) O -
. O +

Fig O +
5 O +
shows O +
the O +
posterior O +
distributions O +
for O +
migration O +
rates O +
and O +
reveals O +
a O +
null O +
probability O +
for O +
the O +
absence O +
of O +
migration O +
from O +
L. B-Species +
whitmani I-Species +
towards O +
L. B-Species +
intermedia I-Species -
. O +

In O +
addition O -
, O +
the O +
absence O +
of O +
migration O +
in O +
the O +
opposite O +
direction O +
is O +
not O +
included O +
in O +
the O +
95 O -
% O +
confidence O +
interval O +
( O -
values O +
range O +
from O +
0.222 O +
to O +
8.898 O -
) O -
, O +
thus O +
supporting O +
the O +
presence O +
of O +
migration O +
in O +
both O +
directions O -
. O +

The O +
conversion O +
of O +
the O +
migration O +
rate O +
estimate O +
to O +
population O +
migration O +
rate O +
per O +
generation O +
( O -
m1 O +
and O +
m2 O -
) O +
is O +
not O +
accurate O +
when O +
the O +
population O +
size O +
is O +
based O +
on O +
a O +
single O +
locus O -
. O +

However O -
, O +
the O +
average O +
of O +
the O +
migrant O +
number O +
per O +
generation O +
for O +
both O +
species O +
was O +
very O +
close O +
to O +
the O +
Nm O +
estimate O +
based O +
on O +
Fst O +
values O +
( O -
Nm O +
~0.49 O +
in O +
Table O +
4 O -
, O +
m1 O +
~0.52 O +
and O +
m2 O +
~0.34 O -
) O -
. O +

Discussion O +
There O +
is O +
some O +
evidence O +
that O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
might O +
represent O +
sibling O -
- O -
species O +
complexes O +
in O +
Brazil O -
. O +

Lutzomyia B-Species +
neivai I-Species +
Pinto O +
1926 O -
, O +
a O +
sibling O +
of O +
L. B-Species +
intermedia I-Species +
is O +
found O +
in O +
parts O +
of O +
Southern O +
and O +
Western O +
Brazil O +
and O +
some O +
other O +
countries O +
of O +
South O +
America O +
[ O -
40 O -
] O -
. O +

The O +
present O +
study O +
did O +
not O +
include O +
populations O +
of O +
this O +
species O -
. O +

In O +
the O +
case O +
of O +
L. B-Species +
whitmani I-Species -
, O +
mitochondrial O +
data O +
[ O -
3,6 O -
] O +
indicates O +
three O +
main O +
lineages O +
in O +
Brazil O -
: O +
an O +
Amazonian O +
group O -
, O +
a O +
North O -
- O -
South O +
group O +
and O +
a O +
Northeast O +
group O -
. O +

We O +
did O +
not O +
find O +
strong O +
evidence O +
of O +
a O +
geographical O +
differentiation O +
in O +
the O +
period O +
gene O +
among O +
populations O +
of O +
L. B-Species +
whitmani I-Species +
although O +
one O +
of O +
the O +
pairwise O +
Fst O +
comparisons O +
( O -
Posse O +
× O +
Ilhéus O -
) O +
was O +
significant O +
at O +
the O +
5 O -
% O +
level O -
. O +

When O +
we O +
compare O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species -
, O +
we O +
find O +
a O +
highly O +
significant O +
Fst O +
value O +
( O -
0.3373 O -
) O -
, O +
which O +
is O +
however O +
smaller O +
than O +
that O +
observed O +
for O +
the O +
period O +
gene O +
between O +
sympatric O +
siblings O +
of O +
Lutzomyia B-Species +
longipalpis I-Species +
( O -
Fst O +
= O +
0.3952 O -
) O +
[ O -
23 O -
] O -
, O +
a O +
complex O +
of O +
cryptic O +
species O +
that O +
are O +
vectors O +
of O +
American O +
visceral O +
leishmaniasis O -
. O +

Therefore O -
, O +
despite O +
the O +
presence O +
of O +
diagnostic O +
morphological O +
characters O +
to O +
identify O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
[ O -
1 O -
] O +
the O +
level O +
of O +
molecular O +
divergence O +
in O +
period O +
is O +
not O +
as O +
high O +
as O +
the O +
cryptic O +
L. B-Species +
longipalpis I-Species +
siblings O -
. O +

Even O +
though O +
it O +
is O +
hard O +
to O +
distinguish O +
introgression O +
from O +
the O +
persistence O +
of O +
ancestral O +
polymorphisms O -
, O +
a O +
test O +
of O +
gene O +
flow O +
based O +
on O +
the O +
signature O +
introgression O +
leaves O +
on O +
the O +
patterns O +
of O +
linkage O +
disequilibrium O +
[ O -
38 O -
] O +
as O +
well O +
as O +
simulations O +
that O +
fit O +
the O +
" O -
Isolation O +
with O +
Migration O -
" O +
model O +
to O +
the O +
data O +
suggest O +
that O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
might O +
be O +
exchanging O +
alleles O +
at O +
the O +
per O +
locus O -
. O +

This O +
is O +
further O +
supported O +
by O +
the O +
presence O +
of O +
shared O +
haplotypes O +
between O +
the O +
two O +
species O +
in O +
Posse O +
and O +
very O +
similar O +
sequences O +
in O +
all O +
sympatric O +
populations O -
. O +

There O +
is O +
mounting O +
evidence O +
that O +
introgression O +
plays O +
a O +
major O +
role O +
in O +
the O +
evolution O +
of O +
closely O +
related O +
insect O +
vector O +
species O -
. O +

Introgression O +
among O +
vectors O +
may O +
have O +
important O +
epidemiological O +
consequences O -
. O +

Gene O +
flow O +
in O +
loci O +
that O +
affect O +
vectorial O +
capacity O -
, O +
such O +
as O +
those O +
controlling O +
host O +
preference O +
and O +
susceptibility O +
to O +
parasite O +
infection O -
, O +
can O +
change O +
the O +
transmission O +
patterns O +
and O +
consequently O +
make O +
the O +
disease O +
control O +
a O +
harder O +
task O -
. O +

Introgression O +
of O +
genes O +
that O +
control O +
adaptation O +
to O +
particular O +
types O +
of O +
environment O +
can O +
also O +
have O +
a O +
major O +
impact O +
on O +
the O +
spread O +
of O +
vector O -
- O -
borne O +
diseases O +
as O +
was O +
proposed O +
for O +
the O +
major O +
African O +
malaria O +
vector O +
Anopheles B-Species +
gambiae I-Species +
[ O -
41 O -
] O -
. O +

The O +
same O +
can O +
be O +
said O +
about O +
genes O +
controlling O +
insecticide O +
resistance O -
. O +

For O +
example O -
, O +
Weill O +
et O +
al. O +
[ O -
42 O -
] O +
found O +
a O +
kdr O +
mutation O +
responsible O +
for O +
pyrethroid O +
resistance O +
in O +
the O +
Mopti O +
form O +
of O +
Anopheles B-Species +
gambiae I-Species -
, O +
a O +
normally O +
susceptible O +
taxon O +
of O +
this O +
species O +
complex O -
. O +

Sequence O +
analysis O +
reveals O +
that O +
this O +
resistant O +
allele O +
probably O +
originates O +
through O +
introgression O +
from O +
the O +
Savanna O +
form O -
. O +

Although O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
are O +
closely O +
related O +
and O +
only O +
distinguished O +
by O +
a O +
few O +
morphological O +
differences O -
, O +
they O +
do O +
show O +
differentiation O +
in O +
some O +
other O +
important O +
traits O -
. O +

For O +
example O -
, O +
in O +
Posse O -
, O +
one O +
of O +
the O +
localities O +
we O +
studied O -
, O +
the O +
two O +
species O +
show O +
differences O +
in O +
abundance O +
during O +
the O +
year O -
. O +

L. B-Species +
intermedia I-Species +
is O +
more O +
abundant O +
in O +
the O +
summer O +
while O +
L. B-Species +
whitmani I-Species +
is O +
more O +
frequent O +
in O +
the O +
winter O +
months O +
[ O -
2 O -
] O -
. O +

They O +
also O +
show O +
differences O +
in O +
microhabitat O +
preferences O -
, O +
L. B-Species +
intermedia I-Species +
being O +
more O +
common O +
in O +
the O +
peridomestic O +
area O +
while O +
L. B-Species +
whitmani I-Species +
is O +
found O +
mainly O +
in O +
the O +
surrounding O +
forest O +
[ O -
2 O -
] O -
. O +

In O +
addition O -
, O +
the O +
two O +
species O +
show O +
marked O +
differences O +
in O +
their O +
tendencies O +
to O +
bite O +
humans B-Species +
in O +
the O +
early O +
morning O -
, O +
with O +
L. B-Species +
whitmani I-Species +
showing O +
higher O +
feeding O +
rates O +
than O +
L. B-Species +
intermedia I-Species +
[ O -
26 O -
] O -
. O +

Therefore O -
, O +
despite O +
the O +
evidence O +
of O +
introgression O +
in O +
the O +
period O +
gene O +
in O +
this O +
locality O -
, O +
there O +
are O +
important O +
ecological O +
and O +
behavioral O +
differences O +
between O +
the O +
two O +
species O +
in O +
Posse O +
suggesting O +
that O +
gene O +
flow O +
is O +
probably O +
rather O +
limited O +
in O +
loci O +
controlling O +
these O +
traits O -
. O +

Hence O -
, O +
it O +
is O +
yet O +
not O +
clear O +
whether O +
introgression O +
has O +
played O +
an O +
important O +
role O +
in O +
the O +
evolution O +
of O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species -
. O +

Further O +
work O +
with O +
other O +
genes O +
might O +
help O +
clarify O +
the O +
issue O -
. O +

Conclusion O +
Evidence O +
for O +
introgression O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
obtained O +
using O +
mitochondrial O +
DNA O +
[ O -
4 O -
] O +
seems O +
to O +
be O +
corroborated O +
by O +
our O +
data O +
on O +
the O +
period O +
gene O -
, O +
a O +
nuclear O +
marker O -
. O +

Nevertheless O -
, O +
considering O +
that O +
period O +
is O +
potentially O +
involved O +
in O +
reproductive O +
isolation O +
and O +
might O +
be O -
, O +
therefore O -
, O +
less O +
prone O +
to O +
introgression O +
than O +
the O +
" O -
average O -
" O +
gene O +
[ O -
43 O -
] O -
, O +
it O +
is O +
possible O +
that O +
much O +
higher O +
levels O +
of O +
gene O +
flow O +
between O +
the O +
two O +
species O +
occur O +
at O +
other O +
genes O -
. O +

It O +
might O -
, O +
on O +
the O +
other O +
hand O -
, O +
suggest O +
that O +
this O +
behavioral O +
gene O -
, O +
or O +
at O +
least O +
the O +
fragment O +
we O +
analyzed O -
, O +
did O +
not O +
play O +
a O +
role O +
in O +
speciation O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species -
. O +

In O +
fact O +
the O +
same O +
has O +
been O +
suggested O +
for O +
some O +
Drosophila O +
species O +
[ O -
44 O -
] O +
despite O +
per O -
's O +
role O +
controlling O +
lovesong O +
and O +
mating O +
rhythm O +
differences O +
between O +
D. B-Species +
melanogaster I-Species +
and O +
D. B-Species +
simulans I-Species +
[ O -
13 O -
- O -
16 O -
] O -
. O +

Although O +
the O +
evidence O +
for O +
introgression O +
in O +
the O +
per O +
gene O +
between O +
L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
is O +
not O +
overwhelming O -
, O +
it O +
does O +
indicate O +
the O +
need O +
to O +
extend O +
this O +
analysis O +
to O +
other O +
loci O +
in O +
the O +
future O -
. O +

We O +
are O +
currently O +
isolating O +
new O +
molecular O +
markers O +
in O +
the O +
two O +
species O +
to O +
carry O +
out O +
a O +
multi O -
- O -
locus O +
approach O +
[ O -
39 O -
] O +
that O +
might O +
help O +
determining O +
how O +
much O +
variation O +
in O +
gene O +
flow O +
and O +
differentiation O +
there O +
is O +
across O +
the O +
genome O +
of O +
these O +
two O +
very O +
important O +
leishmaniasis O +
vectors O -
. O +

Methods O +
Sand O +
fly O +
samples O +
Sand O +
fly O +
samples O +
used O +
in O +
this O +
work O +
were O +
all O +
the O +
F1 O +
generation O +
from O +
wild O +
collected O +
females O +
from O +
the O +
Brazilian O +
localities O +
of O +
Posse O +
( O -
Petrópolis O -
, O +
Rio O +
de O +
Janeiro O +
State O -
, O +
22 O -
° O -
30 O -
'S O +
43 O -
° O -
10'W O -
) O -
, O +
Jacarepaguá O +
( O -
Rio O +
de O +
Janeiro O -
, O +
Rio O +
de O +
Janeiro O +
State O -
, O +
22 O -
° O -
55 O -
'S O +
43 O -
° O -
21'W O -
) O -
, O +
Afonso O +
Claudio O +
( O -
Espírito O +
Santo O +
State O -
, O +
20 O -
° O -
04 O -
'S O +
41 O -
° O -
07'W O -
) O -
, O +
Corte O +
de O +
Pedra O +
( O -
Presidente O +
Tancredo O +
Neves O -
, O +
Bahia O +
State O -
, O +
13 O -
° O -
27 O -
'S O +
39 O -
° O -
25'W O -
) O +
and O +
Ilhéus O +
( O -
Bahia O +
State O -
, O +
14 O -
° O -
50 O -
'S O +
39 O -
° O -
06'W O -
) O -
. O +

L. B-Species +
intermedia I-Species +
and O +
L. B-Species +
whitmani I-Species +
were O +
identified O +
according O +
to O +
Young O +
and O +
Duncan O +
[ O -
1 O -
] O -
. O +

The O +
progeny O +
of O +
each O +
wild O +
caught O +
female O +
was O +
raised O +
separately O +
according O +
to O +
Souza O +
et O +
al. O +
[ O -
45 O -
] O +
and O +
only O +
one O +
F1 O +
male O +
of O +
each O +
female O +
was O +
used O +
for O +
the O +
molecular O +
analysis O -
, O +
which O +
included O +
68 O +
individuals O +
of O +
L. B-Species +
intermedia I-Species +
( O -
12 O +
from O +
Afonso O +
Claudio O -
, O +
18 O +
from O +
Posse O -
, O +
20 O +
from O +
Corte O +
de O +
Pedra O +
and O +
18 O +
from O +
Jacarepaguá O -
) O +
and O +
51 O +
individuals O +
of O +
L. B-Species +
whitmani I-Species +
( O -
12 O +
from O +
Afonso O +
Claudio O -
, O +
17 O +
from O +
Posse O -
, O +
3 O +
from O +
Corte O +
de O +
Pedra O +
and O +
19 O +
from O +
Ilhéus O -
) O -
. O +

Note O +
that O -
, O +
although O +
the O +
distribution O +
of O +
the O +
two O +
species O +
shows O +
considerable O +
overlap O +
in O +
Eastern O +
Brazil O -
, O +
in O +
many O +
localities O +
only O +
one O +
species O +
is O +
found O +
or O +
is O +
far O +
more O +
abundant O +
than O +
the O +
other O -
. O +

There O +
are O +
also O +
seasonal O +
and O +
microhabitat O +
differences O +
in O +
abundance O +
between O +
them O +
in O +
areas O +
of O +
sympatry O +
[ O -
2 O -
] O -
. O +

DNA O +
methods O +
Genomic O +
DNA O +
was O +
prepared O +
according O +
to O +
Jowett O +
[ O -
46 O -
] O +
with O +
slight O +
modifications O +
and O +
the O +
PCR O +
was O +
carried O +
out O +
for O +
30 O +
cycles O +
at O +
95 O -
° O -
C O +
for O +
30 O +
sec O -
, O +
60 O -
° O -
C O +
for O +
30 O +
sec O +
and O +
72 O -
° O -
C O +
for O +
30 O +
sec O -
, O +
using O +
Abgene O -
, O +
Amersham O +
Biosciences O +
or O +
Biotools O +
reagents O +
according O +
to O +
manufacturers O +
directions O -
. O +

The O +
per O +
primer O +
sequences O +
are O -
: O +
5llper2 O -
: O +
5'-AGCATCCTTTTGTAGCAAAC-3 O -
' O +
( O -
forward O -
) O +
and O +
3llper2 O -
: O +
5'-TCAGATGAACTCTTGCTGTC-3 O -
' O +
( O -
reverse O -
) O -
. O +

These O +
primers O +
amplify O +
a O +
486 O +
bp O +
fragment O +
of O +
the O +
sand O +
fly O +
per O +
gene O +
homologue O +
that O +
includes O +
part O +
of O +
the O +
PAS O -
/ O -
CLD O +
domain O -
, O +
an O +
intron O +
( O -
58 O +
bp O -
) O +
and O +
the O +
beginning O +
of O +
the O +
perS O +
domain O +
[ O -
24 O -
] O -
. O +

The O +
amplified O +
fragments O +
were O +
cloned O +
using O +
the O +
pMOSBlue O +
blunt O +
ended O +
cloning O +
kit O +
( O -
Amersham O +
Biosciences O -
) O +
and O +
plasmid O +
DNA O +
preparation O +
was O +
carried O +
out O +
using O +
the O +
" O -
Flexiprep O -
" O +
Kit O +
( O -
Amersham O +
Biosciences O -
) O -
. O +

Cloned O +
PCR O +
fragments O +
were O +
sequenced O +
at O +
Fundação O +
Oswaldo O +
Cruz O +
and O +
at O +
University O +
of O +
Leicester O +
using O +
ABI O +
377 O +
sequencers O -
. O +

With O +
the O +
exception O +
of O +
two O +
L. B-Species +
whitmani I-Species +
individuals O +
from O +
Corte O +
de O +
Pedra O +
( O -
see O +
below O -
) O -
, O +
only O +
one O +
sequence O +
of O +
each O +
sand O +
fly O +
( O -
representing O +
one O +
of O +
the O +
two O +
possible O +
alleles O -
) O +
was O +
used O +
in O +
the O +
analysis O +
but O +
an O +
average O +
of O +
three O +
sequences O +
per O +
individual O +
were O +
obtained O +
in O +
order O +
to O +
check O +
possible O +
PCR O +
induced O +
mutations O -
. O +

In O +
addition O -
, O +
PCR O +
fragments O +
were O +
also O +
sequenced O +
directly O +
in O +
some O +
cases O +
for O +
the O +
same O +
reason O -
. O +

In O +
the O +
case O +
of O +
the O +
two O +
L. B-Species +
whitmani I-Species +
mentioned O +
above O +
6 O +
and O +
9 O +
clones O +
were O +
sequenced O +
respectively O +
from O +
specimens O +
WCP01 O +
and O +
WCP03 O +
to O +
determine O +
both O +
alleles O +
simply O +
to O +
increase O +
the O +
size O +
of O +
this O +
small O +
sample O -
. O +

Negative O +
controls O +
were O +
performed O +
for O +
all O +
amplification O +
reactions O -
. O +

In O +
addition O -
, O +
PCR O -
, O +
cloning O +
and O +
sequencing O +
were O +
repeated O +
for O +
two O +
individuals O +
to O +
confirm O +
putative O +
introgressed O +
sequences O +
and O +
to O +
exclude O +
the O +
possibility O +
that O +
they O +
were O +
the O +
result O +
of O +
PCR O +
contamination O -
. O +

Finally O -
, O +
for O +
at O +
least O +
two O +
individuals O +
with O +
putative O +
introgressed O +
sequences O -
, O +
we O +
could O +
define O +
the O +
other O +
allele O +
from O +
additional O +
clones O +
( O -
not O +
included O +
in O +
the O +
analysis O -
) O -
, O +
which O +
showed O +
to O +
be O +
typical O +
of O +
the O +
species O -
, O +
indicating O +
no O +
identification O +
problems O -
. O +

The O +
sequences O +
were O +
submitted O +
to O +
GenBank O +
( O -
accession O +
numbers O +
AY927062 O +
to O +
AY927182 O -
) O -
. O +

Sequence O +
analyses O +
The O +
preliminary O +
sequence O +
editing O +
was O +
carried O +
out O +
using O +
the O +
Wisconsin O +
Package O +
Version O +
9.1 O -
, O +
Genetics O +
Computer O +
Group O +
( O -
GCG O -
) O -
, O +
Madison O -
, O +
and O +
ClustalX O +
[ O -
47 O -
] O +
was O +
used O +
to O +
perform O +
the O +
multiple O +
alignment O -
. O +

Analyses O +
of O +
population O +
polymorphisms O +
and O +
differentiation O +
between O +
populations O +
were O +
carried O +
out O +
using O +
DNAsp4.1 O +
[ O -
34 O -
] O +
and O +
ProSeq O +
[ O -
48 O -
] O +
softwares O -
, O +
while O +
Arlequin O +
v. O +
2.0 O +
[ O -
49 O -
] O +
was O +
used O +
for O +
an O +
analysis O +
of O +
molecular O +
variance O +
( O -
AMOVA O -
) O +
between O +
populations O -
. O +

The O +
Minimum O +
Evolution O +
phylogenetic O +
tree O +
was O +
constructed O +
using O +
MEGA O +
3.1 O +
software O +
[ O -
50 O -
] O -
. O +

The O +
haplotype O +
network O +
was O +
estimated O +
using O +
TCS1.21 O +
[ O -
36 O -
] O -
. O +

Recombination O +
and O +
linkage O +
disequilibrium O +
analyses O +
were O +
performed O +
using O +
the O +
DNAsp4.1 O +
and O +
SITES O +
program O +
[ O -
30 O -
] O -
. O +

Linkage O +
disequilibrium O +
simulations O +
were O +
carried O +
out O +
by O +
the O +
WH O +
program O +
[ O -
51,52 O -
] O +
and O +
Markov O +
Chain O +
Monte O +
Carlo O +
( O -
MCMC O -
) O +
simulations O +
of O +
the O +
isolation O +
with O +
migration O +
model O +
were O +
performed O +
using O +
the O +
algorithm O +
implemented O +
in O +
the O +
IM O +
program O +
[ O -
39 O -
] O -
. O +

Authors O -
' O +
contributions O +
CJM O +
generate O +
and O +
analyzed O +
all O +
the O +
data O +
and O +
drafted O +
the O +
manuscript O -
. O +

NAS O +
and O +
CAC O +
collected O +
and O +
maintained O +
sand O +
fly O +
samples O -
. O +

CPK O +
helped O +
to O +
write O +
the O +
manuscript O +
and O +
supervised O +
CJM O +
during O +
her O +
stay O +
in O +
Leicester O -
. O +

AAP O +
is O +
the O +
principal O +
investigator O -
, O +
participated O +
in O +
its O +
design O +
and O +
coordination O -
, O +
and O +
helped O +
to O +
write O +
the O +
manuscript O -
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O -
. O +

A O +
disease O -
- O -
specific O +
measure O +
of O +
health O -
- O -
related O +
quality O +
of O +
life O +
for O +
use O +
in O +
adults O +
with O +
immune O +
thrombocytopenic O +
purpura O -
: O +
Its O +
development O +
and O +
validation O +
Abstract O +
Background O +
No O +
validated O +
disease O -
- O -
specific O +
measures O +
are O +
available O +
to O +
assess O +
health O -
- O -
related O +
quality O +
of O +
life O +
( O -
HRQoL O -
) O +
in O +
adult O +
subjects O +
with O +
immune O +
thrombocytopenic O +
purpura O +
( O -
ITP O -
) O -
. O +

Therefore O -
, O +
we O +
sought O +
to O +
develop O +
and O +
validate O +
the O +
ITP O -
- O -
Patient O +
Assessment O +
Questionnaire O +
( O -
ITP O -
- O -
PAQ O -
) O +
for O +
adult O +
subjects O +
with O +
ITP O -
. O +

Methods O +
Information O +
from O +
literature O +
reviews O -
, O +
focus O +
groups O +
with O +
subjects O -
, O +
and O +
clinicians O +
were O +
used O +
to O +
develop O +
50 O +
ITP O -
- O -
PAQ O +
items O -
. O +

Factor O +
analyses O +
were O +
conducted O +
to O +
develop O +
the O +
scale O +
structure O +
and O +
reduce O +
the O +
number O +
of O +
items O -
. O +

The O +
final O +
44-item O +
ITP O -
- O -
PAQ O -
, O +
which O +
includes O +
ten O +
scales O +
[ O -
Symptoms O +
( O -
S O -
) O -
, O +
Bother O -
- O -
Physical O +
Health O +
( O -
B O -
) O -
, O +
Fatigue O -
/ O -
Sleep O +
( O -
FT O -
) O -
, O +
Activity O +
( O -
A O -
) O -
, O +
Fear O +
( O -
FR O -
) O -
, O +
Psychological O +
Health O +
( O -
PH O -
) O -
, O +
Work O +
( O -
W O -
) O -
, O +
Social O +
Activity O +
( O -
SA O -
) O -
, O +
Women O -
's O +
Reproductive O +
Health O +
( O -
RH O -
) O -
, O +
and O +
Overall O +
( O -
QoL O -
) O -
] O -
, O +
was O +
self O -
- O -
administered O +
to O +
adult O +
ITP O +
subjects O +
at O +
baseline O +
and O +
7–10 O +
days O +
later O -
. O +

Test O -
- O -
retest O +
reliability O -
, O +
internal O +
consistency O +
reliability O -
, O +
construct O +
and O +
known O +
groups O +
validity O +
of O +
the O +
final O +
ITP O -
- O -
PAQ O +
were O +
evaluated O -
. O +

Results O +
Seventy O -
- O -
three O +
subjects O +
with O +
ITP O +
completed O +
the O +
questionnaire O +
twice O -
. O +

Test O -
- O -
retest O +
reliability O -
, O +
as O +
measured O +
by O +
the O +
intra O -
- O -
class O +
correlation O -
, O +
ranged O +
from O +
0.52–0.90 O -
. O +

Internal O +
consistency O +
reliability O +
was O +
demonstrated O +
with O +
Cronbach O -
's O +
alpha O +
for O +
all O +
scales O +
above O +
the O +
acceptable O +
level O +
of O +
0.70 O +
( O -
range O -
: O +
0.71–0.92 O -
) O -
, O +
except O +
for O +
RH O +
( O -
0.66 O -
) O -
. O +

Construct O +
validity O -
, O +
assessed O +
by O +
correlating O +
ITP O -
- O -
PAQ O +
scales O +
with O +
established O +
measures O +
( O -
Short O +
Form-36 O +
v.1 O -
, O +
SF-36 O +
and O +
Center O +
for O +
Epidemiologic O +
Studies O +
Depression O +
Scale O -
, O +
CES O -
- O -
D O -
) O -
, O +
was O +
demonstrated O +
through O +
moderate O +
correlations O +
between O +
the O +
ITP O -
- O -
PAQ O +
SA O +
and O +
SF-36 O +
Social O +
Function O +
scales O +
( O -
r O +
= O +
0.67 O -
) O -
, O +
and O +
between O +
ITP O -
- O -
PAQ O +
PH O +
and O +
SF-36 O +
Mental O +
Health O +
Scales O +
( O -
r O +
= O +
0.63 O -
) O -
. O +

Moderate O +
to O +
strong O +
inter O -
- O -
scale O +
correlations O +
were O +
reported O +
between O +
ITP O -
- O -
PAQ O +
scales O +
and O +
the O +
CES O -
- O -
D O -
, O +
except O +
for O +
the O +
RH O +
scale O -
. O +

Known O +
groups O +
validity O +
was O +
evaluated O +
by O +
comparing O +
mean O +
scores O +
for O +
groups O +
that O +
differed O +
clinically O -
. O +

Statistically O +
significant O +
differences O +
( O -
p O +
< O +
0.01 O -
) O +
were O +
observed O +
when O +
subjects O +
were O +
categorized O +
by O +
treatment O +
status O +
[ O -
S O -
, O +
FT O -
, O +
B O -
, O +
A O -
, O +
PH O -
, O +
and O +
QoL O -
, O +
perceived O +
effectiveness O +
of O +
ITP O +
treatment O +
[ O -
S O -
] O -
, O +
and O +
time O +
elapsed O +
since O +
ITP O +
diagnosis O +
[ O -
PH O -
] O -
. O +

Conclusion O +
Results O +
provide O +
preliminary O +
evidence O +
of O +
the O +
reliability O +
and O +
validity O +
of O +
the O +
ITP O -
- O -
PAQ O +
in O +
adult O +
subjects O +
with O +
ITP O -
. O +

Further O +
work O +
should O +
be O +
conducted O +
to O +
assess O +
the O +
responsiveness O +
and O +
to O +
estimate O +
the O +
minimal O +
clinical O +
important O +
difference O +
of O +
the O +
ITP O -
- O -
PAQ O +
to O +
more O +
fully O +
understand O +
the O +
impact O +
of O +
ITP O +
and O +
its O +
treatments O +
on O +
HRQoL. O +
Background O +
Immune O +
thrombocytopenic O +
purpura O +
( O -
ITP O -
) O +
is O +
a O +
disorder O +
characterized O +
by O +
autoimmune O -
- O -
mediated O +
platelet O +
destruction O +
and O +
suboptimal O +
platelet O +
production O +
[ O -
1 O -
- O -
3 O -
] O +
that O +
results O +
in O +
a O +
decrease O +
in O +
the O +
number O +
of O +
circulating O +
platelets O +
and O +
increases O +
the O +
risk O +
of O +
bleeding O +
events O -
. O +

The O +
estimated O +
prevalence O +
rate O +
for O +
ITP O +
in O +
the O +
United O +
States O +
is O +
9.5 O -
/ O -
100,000 O +
[ O -
4 O -
] O -
. O +

Adult O +
women O +
are O +
disproportionately O +
affected O +
by O +
the O +
disorder O -
, O +
with O +
a O +
female O +
to O +
male O +
ratio O +
of O +
nearly O +
two O +
to O +
one O +
[ O -
5 O -
] O -
. O +

The O +
disorder O +
rarely O +
remits O +
spontaneously O +
in O +
adult O +
subjects O +
[ O -
1 O -
] O -
. O +

The O +
mortality O +
rate O +
is O +
relatively O +
low O +
( O -
< O +
1 O -
% O -
) O +
[ O -
6 O -
] O +
in O +
adults O +
less O +
than O +
65 O +
years O +
of O +
age O -
. O +

Morbidity O +
increases O +
above O +
age O +
65 O -
, O +
primarily O +
as O +
a O +
result O +
of O +
an O +
increase O +
in O +
age O -
- O -
related O +
major O +
bleeding O +
events O +
[ O -
7 O -
] O -
. O +

Initial O +
therapy O +
for O +
ITP O +
consists O +
of O +
some O +
combination O +
of O +
glucocorticoids O -
, O +
intravenous O +
immune O +
globulin O +
( O -
IVIg O -
) O +
or O +
anti O -
- O -
D O +
[ O -
8 O -
] O -
. O +

Splenectomy O +
is O +
often O +
considered O +
if O +
these O +
therapies O +
fail O -
. O +

Approximately O +
two O -
- O -
thirds O +
of O +
patients O +
treated O +
with O +
splenectomy O +
achieve O +
a O +
sustained O +
remission O +
[ O -
1,5,9 O -
] O -
. O +

Patients O +
who O +
fail O +
splenectomy O +
are O +
treated O +
with O +
a O +
wide O +
variety O +
of O +
agents O +
including O +
corticosteroids O -
, O +
danazol O -
, O +
and O +
chemotherapeutic O +
agents O -
. O +

Morbidity O +
and O +
mortality O +
in O +
these O +
refractory O +
patients O +
are O +
substantial O +
[ O -
1,6,8 O -
] O -
. O +

Patient O -
- O -
reported O +
outcomes O +
( O -
PRO O -
) O -
, O +
including O +
health O -
- O -
related O +
quality O +
of O +
life O +
( O -
HRQoL O -
) O +
measures O -
, O +
are O +
critical O +
components O +
for O +
evaluating O +
and O +
understanding O +
treatment O +
effects O +
from O +
the O +
subject O -
's O +
perspective O -
. O +

The O +
Food O +
and O +
Drug O +
Administration O +
( O -
FDA O -
) O +
indicates O +
that O +
PRO O +
measures O +
are O +
important O +
to O +
assess O +
because O +
they O +
may O -
: O +
1 O -
) O +
detect O +
treatment O +
effects O +
known O +
only O +
to O +
the O +
subject O -
; O +
2 O -
) O +
understand O +
the O +
subject O -
's O +
perspective O +
regarding O +
treatment O +
effect O -
; O +
or O +
3 O -
) O +
provide O +
information O +
not O +
included O +
in O +
a O +
clinician O -
's O +
subject O +
notes O +
[ O -
10 O -
] O -
. O +

Furthermore O -
, O +
the O +
Committee O +
for O +
Medicinal O +
Products O +
for O +
Human B-Species +
Use O +
of O +
the O +
European O +
Medicines O +
Agency O +
defines O +
HRQoL O +
as O +
" O -
the O +
subject O -
's O +
subjective O +
perception O +
of O +
the O +
impact O +
of O +
his O +
disease O +
and O +
its O +
treatment O -
( O -
s O -
) O +
on O +
his O +
daily O +
life O -
, O +
physical O -
, O +
psychological O +
and O +
social O +
functioning O +
and O +
well O -
- O -
being O -
" O +
[ O -
11 O -
] O -
. O +

Currently O -
, O +
limited O +
data O +
are O +
available O +
on O +
the O +
assessment O +
of O +
the O +
impact O +
of O +
symptoms O +
in O +
adult O +
subjects O +
with O +
ITP O -
. O +

Symptoms O +
of O +
ITP O -
, O +
such O +
as O +
spontaneous O +
bruising O -
, O +
menorrhagia O -
, O +
mucosal O +
bleeding O +
and O +
prolonged O +
bleeding O +
with O +
injury O -
, O +
may O +
significantly O +
affect O +
HRQoL O +
in O +
ITP O +
subjects O +
[ O -
12 O -
] O -
. O +

Treatments O +
for O +
chronic O +
ITP O +
can O +
also O +
be O +
associated O +
with O +
substantial O +
side O +
effects O +
[ O -
5,8 O -
] O -
. O +

In O +
addition O -
, O +
subjects O +
who O +
are O +
resistant O +
to O +
current O +
therapies O +
are O +
likely O +
to O +
experience O +
an O +
even O +
greater O +
decrement O +
to O +
their O +
HRQoL O +
than O +
responders O +
to O +
treatment O -
. O +

Thus O -
, O +
restoring O +
and/or O +
maintaining O +
quality O +
of O +
life O +
should O +
be O +
an O +
important O +
goal O +
of O +
treatment O -
. O +

While O +
the O +
primary O +
markers O +
for O +
ITP O +
include O +
hematologic O +
measures O +
such O +
as O +
platelet O +
counts O -
, O +
clinical O +
measures O +
typically O +
do O +
not O +
assess O +
a O +
subject O -
's O +
functioning O +
and O +
well O -
- O -
being O -
. O +

Therefore O -
, O +
subjects O +
and O +
physicians O +
may O +
want O +
to O +
weigh O +
the O +
impact O +
of O +
ITP O +
therapies O +
on O +
HRQoL O +
endpoints O +
when O +
making O +
treatment O +
decisions O -
. O +

Previously O -
, O +
no O +
validated O +
disease O -
- O -
specific O +
measures O +
were O +
available O +
to O +
evaluate O +
quality O +
of O +
life O +
in O +
adult O +
ITP O +
subjects O -
; O +
however O -
, O +
two O +
disease O -
- O -
specific O +
HRQoL O +
questionnaires O +
have O +
been O +
developed O +
for O +
use O +
in O +
children O +
with O +
ITP O +
[ O -
13,14 O -
] O -
. O +

Thus O -
, O +
we O +
sought O +
to O +
develop O +
a O +
questionnaire O +
that O +
would O +
be O +
appropriate O +
to O +
assess O +
the O +
impact O +
of O +
ITP O +
symptoms O +
and O +
its O +
treatments O +
on O +
HRQoL O +
in O +
adult O +
subjects O -
. O +

The O +
objective O +
of O +
this O +
current O +
manuscript O +
is O +
to O +
describe O +
the O +
development O +
and O +
initial O +
validation O +
of O +
a O +
newly O +
developed O +
HRQoL O +
questionnaire O +
for O +
use O +
in O +
adult O +
subjects O +
with O +
ITP O -
. O +

Methods O +
Overview O +
A O +
newly O +
developed O +
questionnaire O -
, O +
which O +
assesses O +
issues O +
of O +
importance O +
to O +
ITP O +
subjects O -
, O +
was O +
developed O +
based O +
on O +
available O +
published O +
literature O -
, O +
existing O +
questionnaires O -
, O +
expert O +
clinical O +
opinion O -
, O +
and O +
input O +
from O +
subjects O +
with O +
ITP O -
. O +

Subjects O +
and O +
Procedures O +
To O +
develop O +
the O +
questionnaire O -
, O +
three O +
focus O +
groups O +
with O +
ITP O +
subjects O +
were O +
conducted O +
in O +
geographically O +
diverse O +
locations O +
( O -
San O +
Diego O -
, O +
CA O -
, O +
New O +
York O -
, O +
NY O -
, O +
and O +
Oklahoma O +
City O -
, O +
OK O -
) O -
. O +

Each O +
of O +
the O +
three O +
sites O +
recruited O +
a O +
convenience O +
sample O +
of O +
five O +
to O +
eight O +
ITP O +
subjects O +
who O +
were O +
being O +
treated O +
on O +
an O +
outpatient O +
basis O -
. O +

To O +
be O +
eligible O -
, O +
subjects O +
were O +
required O +
to O +
have O +
active O +
disease O +
and O +
be O +
≥ O +
18 O +
years O +
of O +
age O -
. O +

Although O +
platelet O +
count O +
data O +
were O +
not O +
required O +
for O +
participation O +
in O +
the O +
focus O +
groups O -
, O +
clinicians O +
at O +
each O +
site O +
considered O +
the O +
subjects O +
to O +
have O +
active O +
disease O -
, O +
usually O +
an O +
indication O +
that O +
platelet O +
levels O +
have O +
dropped O +
below O +
120 O +
× O +
109L O +
and O +
the O +
subject O +
requires O +
treatment O +
and/or O +
more O +
frequent O +
monitoring O -
. O +

In O +
total O -
, O +
23 O +
ITP O +
subjects O +
participated O +
in O +
the O +
focus O +
groups O +
after O +
providing O +
their O +
informed O +
consent O -
. O +

To O +
validate O +
the O +
questionnaire O -
, O +
a O +
convenience O +
sample O +
of O +
subjects O +
was O +
recruited O +
from O +
the O +
same O +
three O +
clinical O +
sites O +
in O +
New O +
York O -
, O +
NY O -
, O +
Oklahoma O +
City O -
, O +
OK O -
, O +
and O +
La O +
Jolla O -
, O +
CA O -
. O +

Subjects O +
were O +
eligible O +
if O +
they O +
were O +
≥ O +
18 O +
years O +
of O +
age O -
, O +
had O +
active O +
disease O -
, O +
and O +
were O +
willing O +
to O +
complete O +
a O +
self O -
- O -
administered O +
questionnaire O +
at O +
two O +
time O +
points O -
. O +

Target O +
enrollment O +
was O +
roughly O +
72 O +
subjects O +
( O -
24 O +
subjects O +
from O +
each O +
site O -
) O -
. O +

The O +
study O +
protocol O +
was O +
approved O +
by O +
a O +
local O +
institutional O +
review O +
board O +
at O +
each O +
site O +
and O +
was O +
carried O +
out O +
in O +
accordance O +
with O +
Good O +
Clinical O +
Practice O +
and O +
International O +
Conference O +
on O +
Harmonization O +
guidelines O +
and O +
the O +
Declaration O +
of O +
Helsinki O -
. O +

Written O +
informed O +
consent O +
was O +
obtained O +
from O +
each O +
subject O +
prior O +
to O +
enrollment O -
. O +

Creation O +
of O +
Questionnaire O -
/ O -
Item O +
Selection O +
A O +
trained O +
moderator O +
led O +
all O +
focus O +
groups O +
using O +
a O +
detailed O +
discussion O +
guide O -
. O +

Subjects O +
discussed O +
their O +
ITP O +
history O -
, O +
treatment O -
, O +
ITP O +
symptoms O -
, O +
and O +
the O +
impact O +
of O +
ITP O +
on O +
daily O +
activities O -
. O +

Each O +
focus O +
group O +
lasted O +
approximately O +
three O +
hours O -
, O +
and O +
subjects O +
were O +
provided O +
with O +
an O +
honorarium O +
for O +
their O +
time O -
. O +

Following O +
the O +
focus O +
group O +
session O -
, O +
all O +
subjects O +
completed O +
a O +
questionnaire O +
which O +
included O +
the O +
SF-36 O +
v1 O +
[ O -
15 O -
] O +
and O +
ITP O -
- O -
specific O +
questions O -
. O +

The O +
ITP O -
- O -
specific O +
items O +
were O +
developed O +
based O +
on O +
clinical O +
input O +
[ O -
12,16 O -
- O -
18 O -
] O -
. O +

The O +
ITP O -
- O -
specific O +
items O +
assessed O +
the O +
impact O +
of O +
ITP O +
on O +
the O +
subject O -
's O +
overall O +
quality O +
of O +
life O -
, O +
relationships O -
, O +
ability O +
to O +
sleep O -
, O +
menstruation O -
/ O -
gynecological O +
history O -
, O +
and O +
sexual O +
activity O -
. O +

The O +
ITP O -
- O -
specific O +
questions O +
also O +
assessed O +
the O +
subject O -
's O +
response O +
to O +
ITP O +
treatments O +
and O +
any O +
side O +
effects O -
. O +

Transcripts O +
of O +
the O +
focus O +
groups O +
were O +
summarized O +
and O +
reviewed O +
by O +
the O +
study O +
team O -
. O +

The O +
initial O +
draft O +
of O +
the O +
ITP O +
Subject O +
Assessment O +
Questionnaire O +
( O -
ITP O -
- O -
PAQ O -
) O +
was O +
developed O +
after O +
reviewing O +
information O +
from O +
the O +
literature O +
searches O -
, O +
existing O +
questionnaires O -
, O +
expert O +
opinion O -
, O +
focus O +
group O +
transcripts O -
, O +
and O +
the O +
questionnaire O +
responses O +
from O +
the O +
focus O +
group O +
subjects O -
. O +

The O +
initial O +
ITP O -
- O -
PAQ O +
consisted O +
of O +
50 O +
items O +
that O +
assesses O +
the O +
impact O +
of O +
ITP O +
in O +
the O +
areas O +
of O +
physical O +
health O -
, O +
mental O +
health O -
, O +
work O -
, O +
social O +
activity O -
, O +
reproductive O +
health O +
( O -
relevant O +
for O +
women O +
only O -
) O -
, O +
and O +
overall O +
quality O +
of O +
life O -
. O +

Factor O +
analyses O +
were O +
conducted O +
which O +
yielded O +
six O +
unique O +
domains O -
. O +

The O +
impact O +
of O +
ITP O +
on O +
physical O +
health O +
was O +
measured O +
by O +
four O +
scales O +
that O +
evaluated O +
ITP O -
- O -
related O +
symptoms O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
and O +
Activity O -
. O +

Its O +
impact O +
on O +
mental O +
health O +
was O +
measured O +
by O +
two O +
scales O +
that O +
evaluated O +
psychological O +
distress O +
and O +
fear O -
. O +

A O +
copy O +
of O +
the O +
questionnaire O +
can O +
be O +
obtained O +
by O +
contacting O +
Janet O +
L. O +
Nichol O +
and O +
sample O +
items O +
are O +
included O +
Table O +
2 O -
. O +

Statistical O +
Analyses O +
A O +
validation O +
study O +
was O +
conducted O +
to O +
evaluate O +
the O +
psychometric O +
properties O +
of O +
the O +
newly O +
developed O +
ITP O -
- O -
PAQ O +
questionnaire O +
so O +
that O +
it O +
could O +
be O +
used O +
to O +
measure O +
the O +
impact O +
of O +
ITP O +
in O +
adult O +
subjects O +
in O +
future O +
studies O -
. O +

Standard O +
psychometric O +
methods O +
were O +
used O +
to O +
evaluate O +
the O +
reliability O +
and O +
validity O +
of O +
the O +
questionnaire O +
[ O -
19,20 O -
] O -
. O +

Eligible O +
subjects O +
completed O +
the O +
baseline O +
questionnaire O +
at O +
the O +
site O +
or O +
by O +
mail O +
after O +
providing O +
telephone O +
consent O -
. O +

An O +
informed O +
consent O +
form O +
and O +
baseline O +
questionnaire O +
was O +
mailed O +
to O +
those O +
subjects O +
who O +
gave O +
their O +
initial O +
consent O +
via O +
telephone O -
. O +

These O +
completed O +
documents O +
were O +
returned O +
by O +
mail O +
to O +
the O +
investigators O -
. O +

At O +
follow O +
up O -
, O +
each O +
subject O +
was O +
mailed O +
the O +
same O +
questionnaire O +
and O +
asked O +
to O +
complete O +
it O +
a O +
second O +
time O +
( O -
for O +
evaluating O +
test O -
- O -
retest O +
reliability O -
) O +
approximately O +
two O +
weeks O +
later O -
. O +

Additionally O -
, O +
subjects O +
completed O +
the O +
SF-36 O +
and O +
the O +
CES O -
- O -
D O -
[ O -
21 O -
] O +
for O +
validation O +
purposes O +
at O +
both O +
assessments O -
. O +

Demographic O +
and O +
clinical O +
characteristics O +
were O +
also O +
solicited O +
in O +
order O +
to O +
more O +
fully O +
describe O +
the O +
study O +
population O -
. O +

Each O +
study O +
subject O +
received O +
an O +
honorarium O +
for O +
completing O +
the O +
questionnaires O -
. O +

Scale O +
creation O +
and O +
confirmatory O +
factor O +
analysis O +
Confirmatory O +
factor O +
analyses O +
were O +
conducted O +
to O +
test O +
the O +
hypothesized O +
structure O +
of O +
the O +
scales O -
. O +

Two O +
models O +
using O +
LISREL O +
version O +
8 O +
were O +
tested O +
[ O -
22 O -
] O -
. O +

The O +
first O +
model O +
consisted O +
of O +
all O +
50 O +
HRQoL O +
items O +
and O +
10 O +
factors O -
, O +
whereas O +
the O +
second O +
model O +
consisted O +
of O +
a O +
subset O +
of O +
the O +
50-item O +
correlation O +
matrix O -
. O +

Only O +
women O +
respond O +
to O +
the O +
six O +
items O +
comprising O +
the O +
Reproductive O +
Health O +
scale O -
, O +
so O +
the O +
items O +
were O +
not O +
included O +
in O +
the O +
second O +
LISREL O +
model O +
to O +
avoid O +
estimation O +
biases O -
. O +

The O +
remaining O +
44 O +
items O +
were O +
analyzed O -
. O +

Model O +
fit O +
was O +
evaluated O +
using O +
the O +
goodness O -
- O -
of O -
- O -
fit O +
( O -
GFI O -
) O -
, O +
the O +
normed O +
fit O +
index O +
( O -
NFI O -
) O -
, O +
the O +
non O -
- O -
normed O +
fit O +
index O +
( O -
NNFI O -
) O -
, O +
the O +
comparative O +
fit O +
index O +
( O -
CIF O -
) O -
, O +
and O +
the O +
root O +
mean O +
square O +
error O +
of O +
approximation O +
( O -
RMSEA O -
) O -
. O +

For O +
the O +
confirmatory O +
models O -
, O +
index O +
values O +
greater O +
than O +
0.95 O +
indicate O +
better O +
fit O -
, O +
and O +
RMSEA O +
values O +
less O +
than O +
0.05 O +
are O +
considered O +
evidence O +
of O +
adequate O +
fit O +
[ O -
23 O -
] O -
. O +

Reliability O +
and O +
stability O +
Two O +
forms O +
of O +
reliability O +
were O +
assessed O -
: O +
test O -
- O -
retest O +
reliability O +
and O +
internal O +
consistency O +
reliability O -
. O +

Test O -
- O -
retest O +
reliability O -
, O +
a O +
measure O +
of O +
the O +
degree O +
to O +
which O +
the O +
questionnaire O +
yields O +
stable O +
scores O +
over O +
a O +
short O +
period O +
of O +
time O +
( O -
assuming O +
there O +
is O +
no O +
underlying O +
change O -
) O -
, O +
was O +
measured O +
by O +
the O +
intra O -
- O -
class O +
correlation O +
coefficient O +
( O -
ICC O -
) O +
[ O -
24,25 O -
] O -
. O +

An O +
ICC O +
of O +
≥ O +
0.70 O +
was O +
considered O +
acceptable O +
[ O -
26 O -
] O -
. O +

Internal O +
consistency O +
reliability O -
, O +
the O +
extent O +
to O +
which O +
items O +
within O +
each O +
scale O +
correlate O +
with O +
each O +
other O +
to O +
form O +
a O +
multi O -
- O -
item O +
scale O -
, O +
was O +
assessed O +
using O +
Cronbach O -
's O +
alpha O +
[ O -
25,27 O -
] O -
. O +

Data O +
from O +
both O +
assessments O +
were O +
used O +
to O +
evaluate O +
internal O +
consistency O +
reliability O -
. O +

An O +
alpha O +
coefficient O +
of O +
≥ O +
0.70 O +
was O +
considered O +
acceptable O -
, O +
which O +
is O +
the O +
commonly O +
accepted O +
minimal O +
standard O +
for O +
reliability O +
coefficients O +
endorsed O +
by O +
the O +
Scientific O +
Advisory O +
Committee O +
of O +
the O +
Medical O +
Outcomes O +
Trust O +
[ O -
26 O -
] O -
. O +

Construct O +
Validity O +
Construct O +
validity O +
was O +
assessed O +
by O +
examining O +
the O +
inter O -
- O -
scale O +
correlations O +
between O +
the O +
ITP O -
- O -
PAQ O +
and O +
the O +
CES O -
- O -
D O +
and O +
the O +
ITP O -
- O -
PAQ O +
with O +
the O +
SF-36 O +
and O +
by O +
examining O +
the O +
strength O +
of O +
the O +
within O +
ITP O -
- O -
PAQ O +
scale O +
correlations O +
[ O -
25,28 O -
] O -
. O +

For O +
both O +
inter O -
- O -
scale O +
and O +
intra O -
- O -
scale O +
correlations O -
, O +
we O +
made O +
a O +
priori O +
hypotheses O +
about O +
the O +
directionality O +
and O +
magnitude O +
of O +
the O +
correlation O +
and O +
observed O +
the O +
extent O +
to O +
which O +
hypothesized O +
relationships O +
held O -
. O +

For O +
example O -
, O +
we O +
hypothesized O +
that O +
the O +
scales O +
of O +
the O +
ITP O -
- O -
PAQ O +
would O +
be O +
negatively O +
correlated O +
with O +
the O +
CES O -
- O -
D O +
and O +
positively O +
correlated O +
with O +
those O +
of O +
the O +
SF-36 O -
. O +

We O +
expected O +
the O +
Pearson O +
correlations O +
to O +
be O +
moderate O +
in O +
size O -
. O +

Known O +
Groups O +
Known O +
groups O +
validity O +
evaluates O +
the O +
ability O +
of O +
the O +
measure O +
to O +
discriminate O +
between O +
groups O +
known O +
to O +
be O +
clinically O +
different O +
[ O -
28 O -
] O -
. O +

We O +
only O +
collected O +
patient O -
- O -
reported O +
information O +
using O +
the O +
questionnaire O +
and O +
did O +
not O +
collect O +
clinical O +
information O +
such O +
as O +
platelet O +
counts O -
. O +

Therefore O -
, O +
the O +
following O +
four O +
criteria O +
were O +
identified O +
as O +
proxies O +
for O +
severity O -
: O +
• O +
Currently O +
on O +
treatment O +
• O +
Splenectomy O +
status O +
• O +
Subjects O -
' O +
self O -
- O -
perception O +
of O +
the O +
effectiveness O +
of O +
current O +
medication O +
• O +
Length O +
of O +
time O +
since O +
diagnosis O +

It O +
was O +
hypothesized O +
that O +
subjects O +
not O +
being O +
treated O -
, O +
who O +
did O +
not O +
have O +
a O +
splenectomy O -
, O +
who O +
perceived O +
their O +
medication O +
to O +
be O +
more O +
effective O -
, O +
and O +
who O +
had O +
been O +
diagnosed O +
with O +
ITP O +
for O +
a O +
longer O +
time O +
would O +
be O +
healthier O +
and O +
therefore O +
report O +
higher O +
HRQoL O +
scores O -
. O +

In O +
contrast O -
, O +
subjects O +
on O +
any O +
treatment O -
, O +
who O +
had O +
received O +
a O +
splenectomy O -
, O +
who O +
perceived O +
their O +
medication O +
to O +
be O +
less O +
effective O -
, O +
and O +
who O +
were O +
diagnosed O +
more O +
recently O +
would O +
report O +
worse O +
HRQoL. O +
In O +
addition O -
, O +
subjects O +
were O +
also O +
categorized O +
by O +
gender O -
. O +

Subjects O +
were O +
categorized O +
into O +
two O +
groups O +
for O +
each O +
of O +
the O +
analyses O -
: O +
female O +
vs. O +
male O -
, O +
intact O +
spleen O +
vs. O +
removed O +
spleen O -
, O +
currently O +
on O +
ITP O +
treatment O +
vs. O +
not O +
currently O +
on O +
ITP O +
treatment O -
, O +
subject O -
's O +
perception O +
of O +
the O +
effectiveness O +
of O +
their O +
current O +
ITP O +
medication O +
( O -
extremely O -
/ O -
moderately O +
effective O +
vs. O +
not O +
at O +
all O +
effective O -
) O -
, O +
and O +
ITP O +
diagnosis O +
less O +
than O +
one O +
year O +
ago O +
vs. O +
ITP O +
diagnosis O +
more O +
than O +
one O +
year O +
ago O -
. O +

Results O +
Demographics O +
and O +
clinical O +
characteristics O +
Table O +
1 O +
describes O +
the O +
demographic O +
and O +
clinical O +
characteristics O +
of O +
the O +
73 O +
subjects O +
included O +
in O +
the O +
validation O +
analyses O -
. O +

The O +
majority O +
were O +
female O +
( O -
77 O -
% O -
) O +
and O +
Caucasian O +
( O -
84 O -
% O -
) O -
. O +

The O +
mean O +
age O +
was O +
45 O +
years O +
( O -
SD O +
= O +
15.7 O -
) O -
, O +
and O +
most O +
of O +
the O +
subjects O +
had O +
been O +
diagnosed O +
with O +
ITP O +
for O +
at O +
least O +
five O +
years O +
( O -
57 O -
% O -
) O -
. O +

Fifty O -
- O -
two O +
percent O +
of O +
the O +
subjects O +
reported O +
that O +
they O +
were O +
currently O +
taking O +
medications O +
for O +
their O +
ITP O -
. O +

Furthermore O -
, O +
58 O -
% O +
indicated O +
that O +
they O +
had O +
a O +
splenectomy O -
. O +

Among O +
the O +
42 O +
subjects O +
who O +
had O +
a O +
splenectomy O -
, O +
55 O -
% O +
reported O +
that O +
the O +
removal O +
of O +
their O +
spleen O +
did O +
not O +
cure O +
their O +
ITP O -
. O +

With O +
one O +
exception O -
, O +
the O +
remaining O +
subjects O +
did O +
not O +
provide O +
a O +
response O -
. O +

Confirmatory O +
factor O +
analysis O +
The O +
first O +
confirmatory O +
factor O +
analysis O +
of O +
the O +
50-item O +
and O +
ten O +
factors O +
model O +
converged O +
in O +
28 O +
iterations O -
. O +

However O -
, O +
neither O +
the O +
inter O -
- O -
item O +
correlation O +
matrix O +
nor O +
the O +
inter O -
- O -
factor O +
correlation O +
matrix O +
was O +
positive O -
- O -
definite O -
, O +
which O +
suggests O +
that O +
the O +
proposed O +
model O +
is O +
wrong O +
for O +
the O +
data O +
or O +
the O +
data O +
are O +
inadequate O +
for O +
the O +
model O -
[ O -
22 O -
] O -
. O +

The O +
chi O -
- O -
square O +
value O +
of O +
the O +
model O +
was O +
316.64 O +
with O +
1129 O +
degrees O +
of O +
freedom O +
( O -
p O +
= O +
1.0 O -
) O -
, O +
which O +
does O +
not O +
support O +
the O +
hypothesized O +
scale O +
structure O +
of O +
the O +
initial O +
ITP O -
- O -
PAQ O -
. O +

The O +
confirmatory O +
analysis O +
of O +
this O +
LISREL O +
model O +
indicate O +
that O +
computing O +
domain O +
scores O +
for O +
the O +
Physical O +
Health O +
and O +
Mental O +
Health O +
domains O +
is O +
not O +
appropriate O +
for O +
the O +
ITP O -
- O -
PAQ O -
. O +

The O +
second O +
LISREL O +
model O +
was O +
analyzed O +
to O +
confirm O +
the O +
scale O +
structure O -
, O +
excluding O +
the O +
Reproductive O +
Health O +
scale O -
. O +

For O +
this O +
model O -
, O +
126 O +
parameters O +
were O +
estimated O -
: O +
46 O +
factor O +
loadings O -
, O +
44 O +
error O +
terms O -
, O +
and O +
36 O +
inter O -
- O -
factor O +
correlations O -
. O +

The O +
model O +
converged O +
in O +
39 O +
iterations O -
, O +
with O +
a O +
chi O -
- O -
square O +
value O +
of O +
1043.10 O +
with O +
864 O +
degrees O +
of O +
freedom O +
( O -
p O +
< O +
0.01 O -
) O -
. O +

The O +
Goodness O +
of O +
Fit O +
Index O +
( O -
GFI O -
) O -
, O +
Normed O +
Fit O +
Index O +
( O -
NFI O -
) O -
, O +
Non O -
- O -
normed O +
Fit O +
Index O +
( O -
NNFI O -
) O -
, O +
and O +
Comparative O +
Fit O +
Index O +
( O -
CFI O -
) O +
was O +
0.60 O -
, O +
0.63 O -
, O +
0.91 O -
, O +
and O +
0.92 O -
, O +
respectively O -
, O +
and O +
the O +
RMSEA O +
was O +
0.05 O +
[ O -
90 O -
% O +
CI O -
, O +
0.04–0.065 O -
] O -
. O +

Furthermore O -
, O +
the O +
inter O -
- O -
factor O +
correlations O +
ranged O +
form O +
0.33 O +
between O +
the O +
Symptoms O +
and O +
Work O +
scales O +
to O +
0.96 O +
between O +
the O +
Bother O -
- O -
Physical O +
Health O +
and O +
Overall O +
QoL O +
scales O -
. O +

In O +
addition O +
to O +
the O +
confirmatory O +
factor O +
analyses O -
, O +
Cronbach O -
's O +
alphas O +
and O +
item O -
- O -
to O -
- O -
total O +
correlations O +
were O +
used O +
for O +
item O +
reduction O -
. O +

Items O +
with O +
low O +
factor O +
loadings O +
and O +
item O -
- O -
to O -
- O -
total O +
correlations O +
that O +
reduced O +
the O +
internal O +
consistency O +
were O +
eliminated O -
. O +

Although O +
initial O +
factor O +
analyses O +
identified O +
six O +
domains O +
for O +
future O +
use O -
, O +
the O +
final O +
version O +
of O +
the O +
ITP O -
- O -
PAQ O +
contained O +
44 O +
items O +
that O +
included O +
the O +
following O +
ten O +
scales O -
: O +
Symptoms O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
Activity O -
, O +
Fear O -
, O +
Psychological O +
Health O -
, O +
Work O -
, O +
Social O +
Activity O -
, O +
Women O -
's O +
Reproductive O +
Health O -
, O +
and O +
Overall O +
QoL. O +
Table O +
2 O +
provides O +
information O +
on O +
the O +
number O +
of O +
items O -
, O +
item O +
variability O +
and O +
sample O +
items O +
from O +
each O +
scale O +
of O +
the O +
questionnaire O -
. O +

Each O +
scale O +
is O +
scored O +
from O +
0 O +
to O +
100 O -
, O +
with O +
higher O +
scores O +
representing O +
better O +
quality O +
of O +
life O -
. O +

Test O -
- O -
retest O +
reliability O +
Of O +
the O +
73 O +
subjects O +
who O +
completed O +
the O +
first O +
administration O +
of O +
the O +
questionnaire O -
, O +
most O +
of O +
the O +
subjects O +
completed O +
the O +
second O +
questionnaire O +
within O +
a O +
15-day O +
period O +
( O -
75 O -
% O -
) O -
, O +
during O +
which O +
subjects O +
were O +
expected O +
to O +
remain O +
clinically O +
stable O -
. O +

However O -
, O +
20 O -
% O +
of O +
the O +
73 O +
subjects O +
completed O +
the O +
questionnaire O +
within O +
three O +
weeks O +
following O +
the O +
first O +
administration O -
. O +

The O +
remaining O +
5 O -
% O +
of O +
subjects O +
completed O +
it O +
between O +
four O +
and O +
nine O +
weeks O +
after O +
the O +
first O +
" O -
test O -
. O +

" O +
ICC O -
's O +
were O +
computed O +
for O +
the O +
entire O +
sample O +
( O -
n O +
= O +
73 O -
) O +
and O +
for O +
a O +
sub O -
- O -
sample O +
of O +
respondents O +
who O +
completed O +
the O +
second O +
questionnaire O +
within O +
three O +
weeks O +
( O -
n O +
= O +
69 O -
) O -
. O +

With O +
the O +
exception O +
of O +
the O +
Bother O -
- O -
Physical O +
Health O +
and O +
Activity O +
scales O -
, O +
all O +
scales O +
had O +
acceptable O +
test O -
- O -
retest O +
reliability O +
( O -
ICC O +
≥ O +
0.70 O -
) O +
as O +
measured O +
by O +
the O +
ICC O +
( O -
Table O +
3 O -
) O -
. O +

For O +
the O +
entire O +
sample O -
, O +
ICC O +
values O +
ranged O +
from O +
0.52–0.90 O -
, O +
while O +
ICC O +
values O +
for O +
the O +
sub O -
- O -
sample O +
ranged O +
from O +
0.56–0.89 O -
. O +

Internal O +
consistency O +
reliability O +
Internal O +
consistency O +
reliability O -
, O +
measured O +
by O +
Cronbach O -
's O +
alpha O -
, O +
ranged O +
from O +
0.66 O +
to O +
0.92 O +
( O -
Table O +
3 O -
) O -
. O +

With O +
the O +
exception O +
of O +
the O +
Reproductive O +
Health O +
scale O -
, O +
Cronbach O -
's O +
alpha O +
coefficients O +
exceeded O +
the O +
acceptable O +
level O +
of O +
0.70 O -
. O +

Cronbach O -
's O +
alpha O +
for O +
the O +
Symptoms O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
and O +
Activity O +
scales O +
ranged O +
from O +
0.71–0.89 O -
, O +
while O +
Cronbach O -
's O +
alpha O +
for O +
the O +
Psychological O +
Health O +
and O +
Fear O +
scales O +
ranged O +
from O +
0.87–0.92 O -
. O +

Additionally O -
, O +
Cronbach O -
's O +
alphas O +
for O +
the O +
Social O +
Activity O -
, O +
Work O -
, O +
Reproductive O +
Health O -
, O +
and O +
Overall O +
QoL O +
scales O +
were O +
0.72 O -
, O +
0.86 O -
, O +
0.66 O -
, O +
and O +
0.89 O -
, O +
respectively O -
. O +

Construct O +
validity O +
Table O +
4 O +
displays O +
the O +
results O +
of O +
inter O -
- O -
scale O +
Pearson O +
correlation O +
coefficients O +
for O +
the O +
initial O +
test O +
administration O +
of O +
the O +
ITP O -
- O -
PAQ O -
. O +

As O +
expected O -
, O +
the O +
Symptoms O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
and O +
Activity O +
scales O +
were O +
moderately O +
to O +
strongly O +
inter O -
- O -
correlated O +
based O +
on O +
the O +
data O +
from O +
the O +
initial O +
administration O +
( O -
correlation O +
coefficients O +
ranged O +
from O +
0.56–0.75 O -
; O +
p O +
< O +
0.05 O -
) O -
. O +

The O +
Overall O +
QoL O +
scale O +
was O +
moderately O +
to O +
strongly O +
correlated O +
with O +
the O +
other O +
ITP O -
- O -
PAQ O +
scales O -
, O +
with O +
the O +
exception O +
of O +
the O +
Reproductive O +
Health O +
scale O -
. O +

In O +
addition O +
to O +
examining O +
the O +
correlations O +
within O +
the O +
ITP O -
- O -
PAQ O +
scales O -
, O +
construct O +
validity O +
was O +
also O +
assessed O +
by O +
comparing O +
the O +
ITP O -
- O -
PAQ O +
scale O +
scores O +
with O +
those O +
of O +
the O +
CES O -
- O -
D O +
and O +
the O +
SF-36 O -
. O +

The O +
CES O -
- O -
D O +
was O +
negatively O +
correlated O +
with O +
all O +
ITP O -
- O -
PAQ O +
scales O -
, O +
except O +
for O +
the O +
Reproductive O +
Health O +
scale O -
. O +

Other O +
than O +
the O +
Reproductive O +
Health O +
scale O -
, O +
Pearson O +
correlations O +
ranged O +
from O +
-0.37 O +
to O +
-0.70 O +
( O -
p O +
< O +
0.05 O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O +

Most O +
of O +
the O +
ITP O -
- O -
PAQ O +
scales O +
were O +
moderately O +
correlated O +
with O +
the O +
SF-36 O +
scales O -
; O +
however O -
, O +
the O +
Reproductive O +
Health O +
scale O +
was O +
not O +
significantly O +
correlated O +
with O +
any O +
of O +
the O +
SF-36 O +
scales O -
. O +

The O +
mean O +
SF-36 O +
scores O +
of O +
the O +
subjects O +
with O +
ITP O +
were O +
compared O +
to O +
those O +
of O +
the O +
general O +
U.S. O +
population O +
norms O +
[ O -
15 O -
] O -
. O +

Results O +
from O +
t O -
- O -
tests O +
indicate O +
that O +
there O +
were O +
statistically O +
significant O +
differences O +
( O -
p O +
< O +
0.05 O -
) O +
in O +
SF-36 O +
mean O +
scores O +
between O +
subjects O +
with O +
ITP O +
( O -
range O -
, O +
43.04–72.86 O -
) O +
and O +
the O +
general O +
U.S. O +
population O +
( O -
range O -
, O +
60.86–84.15 O -
) O -
. O +

Subjects O +
with O +
ITP O +
reported O +
lower O +
scores O +
on O +
each O +
SF-36 O +
scale O +
compared O +
to O +
the O +
US O +
norm O +
( O -
data O +
not O +
shown O -
) O -
. O +

Known O +
groups O +
validity O +
Subjects O +
were O +
categorized O +
into O +
two O +
groups O +
according O +
to O +
gender O -
, O +
splenectomy O +
status O -
, O +
current O +
ITP O +
treatment O +
status O -
, O +
subject O -
's O +
perception O +
of O +
the O +
effectiveness O +
of O +
ITP O +
treatment O -
, O +
and O +
time O +
elapsed O +
since O +
ITP O +
diagnosis O -
. O +

When O +
subjects O +
were O +
grouped O +
according O +
to O +
gender O +
or O +
splenectomy O +
status O -
, O +
no O +
statistically O +
significant O +
differences O +
were O +
observed O +
for O +
any O +
of O +
the O +
ITP O -
- O -
PAQ O +
scales O +
( O -
data O +
not O +
shown O -
) O -
. O +

Subjects O +
who O +
were O +
currently O +
receiving O +
treatment O +
for O +
ITP O +
reported O +
lower O +
scores O +
on O +
all O +
ITP O -
- O -
PAQ O +
scales O +
compared O +
to O +
subjects O +
who O +
were O +
not O +
currently O +
receiving O +
treatment O -
. O +

Statistically O +
significant O +
differences O +
( O -
p O +
< O +
0.01 O -
) O +
were O +
reported O +
for O +
the O +
following O +
ITP O -
- O -
PAQ O +
scales O +
when O +
subjects O +
were O +
categorized O +
by O +
treatment O +
status O -
: O +
Symptoms O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
Activity O -
, O +
Psychological O +
Health O -
, O +
and O +
Overall O +
QoL O +
( O -
Figure O +
1 O -
) O -
. O +

When O +
subjects O +
were O +
categorized O +
by O +
effectiveness O +
of O +
ITP O +
treatment O -
, O +
statistically O +
significant O +
differences O +
( O -
p O +
< O +
0.05 O -
) O +
were O +
observed O +
for O +
the O +
Symptoms O +
and O +
Activity O +
scales O +
( O -
Figure O +
1 O -
) O -
, O +
while O +
statistically O +
significant O +
differences O +
were O +
only O +
found O +
for O +
the O +
Psychological O +
Health O +
scale O +
when O +
subjects O +
were O +
categorized O +
according O +
to O +
time O +
elapsed O +
since O +
ITP O +
diagnosis O +
( O -
data O +
not O +
shown O -
) O -
. O +

Subjects O +
who O +
had O +
been O +
diagnosed O +
with O +
ITP O +
for O +
< O +
1 O +
year O +
had O +
a O +
lower O +
mean O +
score O +
on O +
the O +
Psychological O +
Health O +
scale O +
compared O +
to O +
subjects O +
who O +
had O +
been O +
diagnosed O +
with O +
ITP O +
for O +
at O +
least O +
one O +
year O +
( O -
50.38 O +
vs. O +
66.46 O -
, O +
respectively O -
; O +
p O +
= O +
0.02 O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O +

Discussion O +
The O +
goal O +
of O +
this O +
study O +
was O +
to O +
develop O +
and O +
undertake O +
initial O +
validation O +
analyses O +
of O +
the O +
ITP O -
- O -
PAQ O +
as O +
a O +
tool O +
for O +
measuring O +
HRQoL O +
specifically O +
related O +
to O +
adult O +
subjects O +
with O +
ITP O -
. O +

The O +
results O +
of O +
this O +
study O +
provide O +
preliminary O +
evidence O +
of O +
the O +
reliability O +
and O +
validity O +
of O +
the O +
ITP O -
- O -
PAQ O +
in O +
this O +
population O -
. O +

The O +
results O +
indicate O +
that O -
, O +
with O +
the O +
exception O +
of O +
the O +
Reproductive O +
Health O +
scale O -
, O +
the O +
questionnaire O +
has O +
good O +
internal O +
consistency O -
. O +

The O +
Reproductive O +
Health O +
scale O +
may O +
not O +
have O +
reached O +
an O +
acceptable O +
level O +
because O +
the O +
items O +
could O +
in O +
fact O +
be O +
measuring O +
slightly O +
different O +
concepts O -
. O +

For O +
example O -
, O +
the O +
Reproductive O +
Health O +
scale O +
includes O +
items O +
that O +
assess O +
symptom O +
bother O +
related O +
to O +
menstruation O +
in O +
addition O +
to O +
items O +
that O +
ask O +
how O +
ITP O +
impacts O +
reproductive O +
choices O -
, O +
such O +
as O +
becoming O +
pregnant O -
, O +
giving O +
birth O -
, O +
and O +
adopting O +
children O -
. O +

Perhaps O -
, O +
the O +
symptom O +
bother O +
items O +
in O +
this O +
scale O +
may O +
fit O +
more O +
appropriately O +
with O +
the O +
Bother O -
- O -
Physical O +
Health O +
scale O -
, O +
and O +
the O +
reproductive O +
choice O +
items O +
could O +
comprise O +
a O +
separate O +
scale O -
. O +

Most O +
of O +
the O +
ITP O -
- O -
PAQ O +
scales O +
also O +
demonstrated O +
acceptable O +
test O -
- O -
retest O +
reliability O -
, O +
even O +
though O +
the O +
time O +
interval O +
between O +
test O +
and O +
retest O +
administrations O +
of O +
the O +
questionnaire O +
exceeded O +
the O +
targeted O +
time O +
interval O +
of O +
seven O +
to O +
ten O +
days O -
. O +

However O -
, O +
two O +
scales O -
, O +
the O +
Bother O -
- O -
Physical O +
Health O +
and O +
Activity O +
scales O -
, O +
reported O +
ICC O +
values O +
below O +
the O +
acceptable O +
value O +
of O +
0.70 O -
. O +

In O +
addition O +
to O +
the O +
lag O +
between O +
the O +
two O +
administrations O +
of O +
the O +
questionnaire O -
, O +
subjects O +
may O +
have O +
experienced O +
an O +
increase O +
in O +
bother O +
and/or O +
a O +
decrease O +
in O +
activity O +
due O +
to O +
ITP O +
during O +
the O +
extended O +
time O +
interval O -
. O +

Additionally O -
, O +
the O +
comparatively O +
low O +
ICC O +
values O +
of O +
the O +
Bother O -
- O -
Physical O +
Health O +
and O +
Activity O +
scales O +
may O +
be O +
due O +
in O +
part O +
to O +
the O +
relatively O +
low O +
number O +
of O +
items O +
contained O +
in O +
each O +
of O +
these O +
scales O +
( O -
four O +
and O +
two O +
items O -
, O +
respectively O -
) O +
compared O +
to O +
the O +
Symptoms O +
scale O +
which O +
contains O +
six O +
items O -
. O +

In O +
general O -
, O +
the O +
construct O +
validity O +
of O +
the O +
questionnaire O +
was O +
supported O +
by O +
inter O -
- O -
scale O +
correlations O -
. O +

As O +
expected O -
, O +
the O +
Bother O -
- O -
Physical O +
Health O -
, O +
Symptoms O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
and O +
Activity O +
scales O +
were O +
more O +
strongly O +
correlated O +
to O +
one O +
another O +
than O +
with O +
other O +
scales O -
. O +

However O -
, O +
the O +
Reproductive O +
Health O +
scale O +
had O +
a O +
lower O +
internal O +
consistency O +
reliability O +
and O +
it O +
was O +
weakly O +
correlated O +
with O +
the O +
ITP O -
- O -
PAQ O +
scales O -
, O +
the O +
SF-36 O -
, O +
and O +
the O +
CES O -
- O -
D O -
, O +
possibly O +
due O +
to O +
the O +
differing O +
concepts O +
measured O +
by O +
the O +
items O +
within O +
this O +
scale O +
or O +
the O +
all O -
- O -
female O +
sample O -
. O +

Most O +
of O +
the O +
ITP O -
- O -
PAQ O +
scales O +
were O +
moderately O +
correlated O +
with O +
the O +
SF-36 O +
scales O +
and O +
the O +
CES O -
- O -
D O -
; O +
however O -
, O +
correlations O +
between O +
some O +
of O +
the O +
scales O +
were O +
< O +
0.40 O +
( O -
e.g. O -
, O +
Fear O +
and O +
SF-36 O +
Mental O +
Health O -
, O +
0.30 O -
; O +
p O +
< O +
0.05 O -
) O -
. O +

This O +
low O +
correlation O +
could O +
be O +
due O +
to O +
the O +
ITP O -
- O -
PAQ O +
assessing O +
fear O +
associated O +
with O +
ITP O +
( O -
e.g. O -
, O +
fear O +
of O +
having O +
a O +
bleeding O +
episode O -
) O -
, O +
while O +
the O +
SF-36 O +
provides O +
a O +
more O +
general O +
assessment O +
of O +
mental O +
health O +
issues O +
( O -
e.g. O -
, O +
felt O +
downhearted O +
and O +
blue O -
) O -
. O +

The O +
known O -
- O -
groups O +
validity O +
results O +
indicate O +
that O +
some O +
of O +
the O +
ITP O -
- O -
PAQ O +
scales O +
( O -
Symptoms O -
, O +
Fatigue O -
/ O -
Sleep O -
, O +
Bother O -
- O -
Physical O +
Health O -
, O +
Activity O -
, O +
Psychological O +
Health O -
, O +
and O +
Overall O +
QoL O +
scales O -
) O +
were O +
able O +
to O +
differentiate O +
ITP O +
subjects O +
who O +
were O +
currently O +
receiving O +
ITP O +
treatment O +
from O +
those O +
who O +
were O +
not O +
receiving O +
treatment O +
for O +
ITP O -
, O +
providing O +
preliminary O +
evidence O +
of O +
the O +
ITP O -
- O -
PAQ O -
's O +
ability O +
to O +
distinguish O +
between O +
groups O +
known O +
to O +
be O +
different O -
. O +

However O -
, O +
the O +
ITP O -
- O -
PAQ O +
scales O +
were O +
generally O +
unable O +
to O +
distinguish O +
between O +
subjects O +
when O +
they O +
were O +
grouped O +
by O +
gender O -
, O +
splenectomy O +
status O -
, O +
perceived O +
effectiveness O +
of O +
treatment O +
and O +
length O +
of O +
time O +
since O +
ITP O +
diagnosis O -
. O +

The O +
ITP O -
- O -
PAQ O +
may O +
not O +
be O +
able O +
to O +
differentiate O +
between O +
female O +
and O +
male O +
subjects O +
because O +
the O +
disorder O +
may O +
affect O +
females O +
and O +
males O +
similarly O -
. O +

Additionally O -
, O +
significant O +
differences O +
may O +
not O +
have O +
been O +
observed O +
between O +
subjects O +
who O +
have O +
undergone O +
splenectomy O +
and O +
subjects O +
who O +
have O +
not O +
because O +
55 O -
% O +
of O +
subjects O +
who O +
had O +
a O +
splenectomy O +
indicated O +
that O +
it O +
did O +
not O +
cure O +
their O +
ITP O -
. O +

Specifically O -
, O +
the O +
known O -
- O -
groups O +
could O +
be O +
defined O +
as O +
' O -
subjects O +
without O +
a O +
splenectomy O -
' O +
versus O +
' O -
subjects O +
with O +
a O +
failed O +
splenectomy O -
' O +
( O -
for O +
whom O +
QoL O +
likely O +
worsened O -
) O +
versus O +
' O -
subjects O +
with O +
a O +
successful O +
splenectomy O -
' O +
( O -
for O +
whom O +
QoL O +
may O +
have O +
improved O -
) O -
. O +

In O +
the O +
future O -
, O +
to O +
assess O +
whether O +
the O +
ITP O -
- O -
PAQ O +
scales O +
can O +
differentiate O +
between O +
groups O +
of O +
subjects O -
, O +
it O +
may O +
be O +
worthwhile O +
to O +
categorize O +
subjects O +
by O +
a O +
more O +
clinically O +
relevant O +
measure O -
, O +
such O +
as O +
platelet O +
count O -
. O +

Several O +
limitations O +
should O +
be O +
considered O +
when O +
interpreting O +
our O +
findings O -
. O +

Subjects O +
were O +
drawn O +
from O +
a O +
convenience O +
sample O -
. O +

The O +
study O +
population O +
was O +
fairly O +
homogeneous O -
, O +
comprised O +
primarily O +
of O +
Caucasian O +
female O +
subjects O -
. O +

The O +
data O +
was O +
validated O +
using O +
only O +
patient O -
- O -
reported O +
data O +
collected O +
via O +
questionnaire O -
. O +

The O +
lack O +
of O +
clinical O +
data O +
in O +
this O +
initial O +
validation O +
study O +
will O +
be O +
addressed O +
in O +
on O -
- O -
going O +
pivotal O +
trials O +
that O +
will O +
collect O +
clinical O +
data O +
such O +
as O +
platelet O +
counts O +
and O +
platelet O +
response O -
. O +

In O +
addition O -
, O +
the O +
time O +
interval O +
between O +
the O +
initial O +
and O +
retest O +
administration O +
of O +
the O +
questionnaire O +
may O +
have O +
been O +
too O +
lengthy O +
to O +
properly O +
evaluate O +
the O +
test O -
- O -
retest O +
reliability O -
. O +

Because O +
25 O -
% O +
of O +
subjects O +
did O +
not O +
complete O +
the O +
questionnaire O +
within O +
the O +
targeted O +
fifteen O +
day O +
interval O -
, O +
those O +
subjects O +
may O +
have O +
undergone O +
clinical O +
changes O +
that O +
may O +
have O +
affected O +
their O +
responses O -
. O +

In O +
future O +
validation O +
studies O +
platelet O +
counts O +
or O +
type O +
of O +
platelet O +
response O +
should O +
be O +
used O +
to O +
identify O +
a O +
stable O +
cohort O +
for O +
the O +
test O -
- O -
retest O +
analyses O -
. O +

Furthermore O -
, O +
the O +
criteria O +
used O +
to O +
categorize O +
the O +
subjects O +
for O +
the O +
known O +
groups O +
validity O +
evaluation O +
may O +
not O +
have O +
been O +
sufficient O +
to O +
allow O +
for O +
the O +
ITP O -
- O -
PAQ O +
scales O +
to O +
detect O +
differences O +
between O +
groups O -
. O +

Grouping O +
the O +
subjects O +
by O +
a O +
different O +
criterion O -
, O +
such O +
as O +
a O +
relevant O +
clinical O +
measure O -
, O +
may O +
bolster O +
the O +
findings O +
for O +
its O +
known O +
groups O +
validity O -
. O +

Conclusion O +
The O +
primary O +
goal O +
of O +
this O +
manuscript O +
was O +
to O +
describe O +
the O +
development O +
of O +
a O +
new O +
ITP O -
- O -
specific O +
HRQoL O +
questionnaire O +
for O +
adults O +
with O +
ITP O +
and O +
to O +
present O +
our O +
initial O +
findings O +
on O +
the O +
psychometric O +
properties O +
of O +
this O +
questionnaire O -
. O +

The O +
results O +
of O +
this O +
initial O +
validation O +
study O +
indicate O +
that O +
the O +
questionnaire O +
generally O +
has O +
acceptable O +
reliability O +
and O +
validity O -
. O +

We O +
plan O +
to O +
conduct O +
additional O +
analyses O +
using O +
more O +
objective O +
clinical O +
measures O +
such O +
as O +
platelet O +
counts O +
as O +
a O +
criterion O +
for O +
known O +
groups O +
validity O -
. O +

Further O +
validation O +
work O +
should O +
also O +
be O +
conducted O +
to O +
assess O +
its O +
responsiveness O +
and O +
to O +
estimate O +
its O +
minimal O +
clinical O +
important O +
difference O +
value O +
so O +
that O +
it O +
can O +
become O +
a O +
more O +
widely O +
used O +
HRQoL O +
measure O +
in O +
the O +
ITP O +
population O -
. O +

Competing O +
interests O +
The O +
validation O +
study O +
design O -
, O +
analysis O -
, O +
interpretation O +
of O +
results O -
, O +
and O +
the O +
writing O +
of O +
the O +
manuscript O +
represent O +
the O +
joint O +
collaboration O +
of O +
all O +
authors O +
of O +
this O +
study O -
, O +
which O +
was O +
funded O +
solely O +
by O +
Amgen O -
, O +
Inc O -
, O +
Thousand O +
Oaks O -
, O +
California O -
, O +
USA O -
. O +

Ovation O +
Research O +
Group O +
provided O +
no O +
additional O +
funding O +
for O +
this O +
study O -
. O +

The O +
decision O +
to O +
submit O +
this O +
manuscript O +
for O +
publication O +
was O +
subject O +
to O +
the O +
approval O +
of O +
Amgen O -
, O +
Inc. O +
and O +
all O +
authors O -
. O +

Gary O +
Okano O +
and O +
Janet O +
Nichol O +
are O +
employees O +
of O +
Amgen O -
, O +
Inc. O +
James O +
Bussel O +
is O +
an O +
employee O +
of O +
Weill O +
Cornell O +
Medical O +
Center O -
. O +

James O +
George O +
is O +
employed O +
by O +
the O +
University O +
of O +
Oklahoma O +
Health O +
Sciences O +
Center O -
. O +

Robert O +
McMillan O +
is O +
a O +
Professor O +
Emeritus O +
of O +
the O +
Scripps O +
Research O +
Institute O -
. O +

Susan O +
Mathias O +
is O +
an O +
employee O +
of O +
Ovation O +
Research O +
Group O -
. O +

Authors O -
' O +
contributions O +
SDM O +
supervised O +
the O +
interpretation O +
of O +
the O +
results O +
from O +
the O +
validation O +
study O -
, O +
and O +
drafted O +
the O +
manuscript O -
. O +

JBB O -
, O +
JNG O -
, O +
RM O -
, O +
and O +
JLN O +
provided O +
clinical O +
expertise O +
in O +
the O +
development O +
of O +
the O +
questionnaire O -
, O +
and O +
participated O +
in O +
the O +
design O +
and O +
execution O +
of O +
the O +
study O -
. O +

GJO O +
assisted O +
in O +
interpreting O +
the O +
results O +
and O +
drafting O +
the O +
manuscript O -
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O -
. O +

Integration O +
in O +
primary O +
community O +
care O +
networks O +
( O -
PCCNs O -
) O -
: O +
examination O +
of O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
financial O -
, O +
and O +
information O +
infrastructures O +
in O +
a O +
national O +
demonstration O +
project O +
in O +
Taiwan O +
Abstract O +
Background O +
Taiwan O -
's O +
primary O +
community O +
care O +
network O +
( O -
PCCN O -
) O +
demonstration O +
project O -
, O +
funded O +
by O +
the O +
Bureau O +
of O +
National O +
Health O +
Insurance O +
on O +
March O +
2003 O -
, O +
was O +
established O +
to O +
discourage O +
hospital O +
shopping O +
behavior O +
of O +
people O +
and O +
drive O +
the O +
traditional O +
fragmented O +
health O +
care O +
providers O +
into O +
cooperate O +
care O +
models O -
. O +

Between O +
2003 O +
and O +
2005 O -
, O +
268 O +
PCCNs O +
were O +
established O -
. O +

This O +
study O +
profiled O +
the O +
individual O +
members O +
in O +
the O +
PCCNs O +
to O +
study O +
the O +
nature O +
and O +
extent O +
to O +
which O +
their O +
network O +
infrastructures O +
have O +
been O +
integrated O +
among O +
the O +
members O +
( O -
clinics O +
and O +
hospitals O -
) O +
within O +
individual O +
PCCNs O -
. O +

Methods O +
The O +
thorough O +
questionnaire O +
items O -
, O +
covering O +
the O +
network O +
working O +
infrastructures O +
– O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
financial O -
, O +
and O +
information O +
integration O +
in O +
PCCNs O -
, O +
were O +
developed O +
with O +
validity O +
and O +
reliability O +
confirmed O -
. O +

One O +
thousand O +
five O +
hundred O +
and O +
fifty O -
- O -
seven O +
clinics O +
that O +
had O +
belonged O +
to O +
PCCNs O +
for O +
more O +
than O +
one O +
year O -
, O +
based O +
on O +
the O +
2003–2005 O +
Taiwan O +
Primary O +
Community O +
Care O +
Network O +
List O -
, O +
were O +
surveyed O +
by O +
mail O -
. O +

Nine O +
hundred O +
and O +
twenty O -
- O -
eight O +
clinic O +
members O +
responded O +
to O +
the O +
surveys O +
giving O +
a O +
59.6 O +
% O +
response O +
rate O -
. O +

Results O +

Overall O -
, O +
the O +
PCCNs O -
' O +
members O +
had O +
higher O +
involvement O +
in O +
the O +
governance O +
infrastructure O -
, O +
which O +
was O +
usually O +
viewed O +
as O +
the O +
most O +
important O +
for O +
establishment O +
of O +
core O +
values O +
in O +
PCCNs O -
' O +
organization O +
design O +
and O +
management O +
at O +
the O +
early O +
integration O +
stage O -
. O +

In O +
addition O -
, O +
it O +
found O +
that O +
there O +
existed O +
a O +
higher O +
extent O +
of O +
integration O +
of O +
clinical O -
, O +
marketing O -
, O +
and O +
information O +
infrastructures O +
among O +
the O +
hospital O -
- O -
clinic O +
member O +
relationship O +
than O +
those O +
among O +
clinic O +
members O +
within O +
individual O +
PCCNs O -
. O +

The O +
financial O +
infrastructure O +
was O +
shown O +
the O +
least O +
integrated O +
relative O +
to O +
other O +
functional O +
infrastructures O +
at O +
the O +
early O +
stage O +
of O +
PCCN O +
formation O -
. O +

Conclusion O +

There O +
was O +
still O +
room O +
for O +
better O +
integrated O +
partnerships O -
, O +
as O +
evidenced O +
by O +
the O +
great O +
variety O +
of O +
relationships O +
and O +
differences O +
in O +
extent O +
of O +
integration O +
in O +
this O +
study O -
. O +

In O +
addition O +
to O +
provide O +
how O +
the O +
network O +
members O +
have O +
done O +
for O +
their O +
initial O +
work O +
at O +
the O +
early O +
stage O +
of O +
network O +
forming O +
in O +
this O +
study O -
, O +
the O +
detailed O +
surveyed O +
items O -
, O +
the O +
concepts O +
proposed O +
by O +
the O +
managerial O +
and O +
theoretical O +
professionals O -
, O +
could O +
be O +
a O +
guide O +
for O +
those O +
health O +
care O +
providers O +
who O +
have O +
willingness O +
to O +
turn O +
their O +
business O +
into O +
multi O -
- O -
organizations O -
. O +

Background O +
Taiwan O -
's O +
National O +
Health O +
Insurance O +
( O -
NHI O -
) O +
under O +
the O +
control O +
of O +
the O +
Bureau O +
of O +
National O +
Health O +
Insurance O +
( O -
BNHI O -
) O -
, O +
was O +
launched O +
in O +
March O +
1995 O +
to O +
replace O +
its O +
social O +
insurance O +
system O +
that O +
was O +
covering O +
59 O -
% O +
of O +
its O +
population O -
: O +
government O +
employees O -
, O +
labourers O -
, O +
farmers O +
and O +
servicemen O +
[ O -
1 O -
] O -
. O +

By O +
June O +
2003 O +
the O +
number O +
of O +
people O +
insured O +
had O +
reached O +
21,956,729 O +
( O -
99 O -
% O -
) O -
. O +

There O +
were O +
17,259 O +
medical O +
providers O +
( O -
92 O -
% O -
) O -
, O +
including O +
575 O +
hospitals O +
and O +
16,684 O +
clinics O +
contracted O +
with O +
the O +
BNHI O +
for O +
serving O +
the O +
enrolled O +
population O -
. O +

The O +
unique O +
phenomenon O +
characterized O +
in O +
Taiwan O +
health O +
care O +
industry O +
different O +
from O +
those O +
in O +
the O +
western O +
countries O +
is O +
the O +
freedom O +
of O +
patients O +
to O +
choose O +
the O +
health O +
care O +
providers O +
they O +
want O -
, O +
no O +
matter O +
what O +
their O +
disease O +
severity O +
is O -
. O +

Furthermore O -
, O +
Taiwan O +
people O +
favor O +
the O +
larger O +
scales O +
of O +
facilities O +
and O +
this O +
fallacy O +
leads O +
to O +
the O +
phenomenon O +
of O +
big O -
- O -
hospital O +
shopping O -
. O +

For O +
example O -
, O +
people O +
choose O +
the O +
medical O +
centers O +
which O +
are O +
accredited O +
as O +
the O +
highest O +
level O +
of O +
medical O +
science O +
in O +
Taiwan O +
when O +
they O +
only O +
suffer O +
from O +
a O +
common O +
cold O -
. O +

In O +
the O +
spring O +
of O +
2003 O -
, O +
the O +
SARS O +
epidemic O +
viciously O +
attacked O +
the O +
health O +
of O +
Taiwan O -
's O +
people O -
. O +

The O +
people O -
's O +
freedom O +
to O +
choose O +
medical O +
providers O +
caused O +
the O +
national O +
health O +
authority O +
to O +
barely O +
control O +
and O +
traced O +
the O +
flow O +
of O +
epidemic O -
. O +

This O +
event O +
made O +
Taiwan O +
national O +
health O +
authorities O +
rethink O +
what O +
happened O +
and O +
how O +
it O +
damaged O +
under O +
the O +
traditional O +
fragmented O +
health O +
care O +
providers O +
in O +
Taiwan O -
. O +

One O +
health O +
reform O +
launched O +
was O +
named O +
the O +
" O -
Primary O +
Community O +
Care O +
Network O +
( O -
PCCN O -
) O +
demonstration O +
project O -
" O -
, O +
a O +
nationwide O +
health O +
care O +
financing O +
program O +
funded O +
by O +
the O +
Bureau O +
of O +
National O +
Health O +
Insurance O +
( O -
BNHI O -
) O +
in O +
March O +
2003 O +
and O +
it O +
was O +
a O +
new O +
model O +
for O +
the O +
Taiwan O +
government O +
to O +
redefine O +
the O +
role O +
of O +
family O +
physicians O +
in O +
the O +
health O +
care O +
delivery O +
system O -
. O +

A O +
PCCN O +
in O +
Taiwan O +
consists O +
of O +
a O +
group O +
of O +
clinic O +
physicians O +
whose O +
medical O +
jobs O +
are O +
viewed O +
as O +
family O +
care O +
and O +
at O +
least O +
one O +
hospital O +
for O +
secondary O +
or O +
tertiary O +
care O -
. O +

The O +
idea O +
of O +
member O +
component O +
design O +
in O +
PCCNs O +
was O +
aimed O +
to O +
lead O +
the O +
Taiwan O +
citizens O +
to O +
choose O +
one O +
clinic O +
physician O +
as O +
their O +
personal O +
family O +
physician O +
for O +
health O +
maintenance O +
and O +
this O +
family O +
physician O +
also O +
would O +
have O +
the O +
responsibility O +
of O +
referring O +
the O +
patients O +
to O +
specialty O +
care O +
if O +
necessary O -
. O +

From O +
a O +
national O +
health O +
authority O +
perspective O -
, O +
they O +
expected O +
the O +
Taiwan O +
people O +
to O +
put O +
an O +
end O +
to O +
their O +
fallacy O +
that O +
" O -
bigger O +
is O +
better O -
" O +
for O +
health O +
care O +
organizations O +
and O +
establish O +
the O +
idea O +
of O +
" O -
human B-Species +
health O -
" O -
, O +
starting O +
with O +
prevention O +
and O +
primary O +
care O -
, O +
followed O +
by O +
secondary O +
or O +
tertiary O +
care O -
, O +
emphasizing O +
health O +
promotion O +
and O +
maintenance O +
instead O +
of O +
disease O +
curing O -
. O +

Furthermore O -
, O +
it O +
could O +
decrease O +
the O +
inappropriateness O +
of O +
medical O +
usage O -
, O +
i.e. O -
, O +
over O -
- O -
uses O +
of O +
secondary O +
and O +
tertiary O +
medical O +
services O +
in O +
the O +
high O -
- O -
tech O +
hospitals O -
. O +

In O +
addition O -
, O +
the O +
national O +
health O +
authority O +
was O +
expected O +
to O +
drive O +
the O +
traditional O +
fragmented O +
heath O +
care O +
providers O +
into O +
coordinated O +
medical O +
multidisciplinary O +
teams O +
and O +
share O +
the O +
limited O +
medical O +
resources O +
through O +
the O +
PCCN O +
demonstration O +
project O -
. O +

In O +
summary O -
, O +
the O +
PCCN O +
demonstration O +
project O +
was O +
aimed O +
to O -
: O +
1 O -
) O +
change O +
the O +
traditional O +
patients O -
' O +
customs O +
of O +
freely O +
choosing O +
health O +
care O +
organizations O +
and O +
establish O +
referral O +
channels O +
along O +
the O +
continuum O +
of O +
care O -
, O +
and O +
2 O -
) O +
establish O +
partnerships O +
among O +
the O +
primary O +
care O +
clinics O +
and O +
hospitals O +
to O +
provide O +
a O +
continuum O +
of O +
health O +
care O +
services O -
. O +

It O +
was O +
also O +
expected O +
to O +
establish O +
the O +
primary O +
care O +
system O +
of O +
family O +
physicians O +
to O +
provide O +
whole O -
- O -
people O +
health O +
care O +
and O +
improve O +
care O +
quality O +
[ O -
1 O -
] O -
. O +

Partnership O +
structures O +
in O +
the O +
PCCNs O +
represent O +
the O +
virtual O +
vertical O +
( O -
i.e. O -
, O +
between O +
the O +
member O +
clinics O +
and O +
hospitals O -
) O +
and O +
virtual O +
horizontal O +
( O -
i.e. O -
, O +
among O +
the O +
member O +
clinics O -
) O +
aspects O +
of O +
organizing O -
, O +
which O +
designate O +
the O +
formal O +
relationships O +
between O +
individuals O +
and O +
the O +
total O +
network O +
and O +
include O +
organizational O +
design O +
to O +
ensure O +
effective O +
communication O -
, O +
coordination O -
, O +
and O +
integration O +
across O +
the O +
total O +
network O -
. O +

Each O +
PCCN O +
consists O +
of O +
five O +
to O +
ten O +
clinics O -
: O +
half O +
of O +
them O +
should O +
offer O +
the O +
services O +
of O +
general O +
medicine O -
, O +
internal O +
medicine O -
, O +
surgery O -
, O +
obstetrics O +
and O +
gynecology O -
, O +
pediatric O -
, O +
or O +
family O +
medicine O -
. O +

And O +
each O +
PCCN O +
has O +
a O +
central O +
headquarters O -
, O +
usually O +
in O +
one O +
of O +
the O +
clinic O +
facilities O -
, O +
to O +
coordinate O +
and O +
integrate O +
the O +
network O -
. O +

All O +
the O +
clinic O +
physicians O +
in O +
a O +
PCCN O +
are O +
assigned O +
the O +
roles O +
of O +
" O -
family O +
physicians O -
" O +
or O +
" O -
gatekeepers O -
" O +
who O +
recruit O +
people O +
from O +
the O +
local O +
community O -
, O +
keep O +
background O +
and O +
medical O +
files O +
on O +
them O -
, O +
certify O +
family O +
physician O +
education O +
training O +
programs O -
, O +
and O +
hold O +
office O +
hours O +
in O +
the O +
member O +
hospital O -
, O +
where O +
they O +
serve O +
as O +
joint O +
faculty O +
members O +
for O +
further O +
medical O +
consultations O +
or O +
medical O +
utilizations O +
of O +
labs O +
and O +
tests O -
, O +
if O +
necessary O -
. O +

In O +
addition O -
, O +
the O +
hospital O +
member O +
is O +
asked O +
to O +
help O +
clinic O +
physicians O +
in O +
their O +
network O +
to O +
set O +
up O +
a O +
medical O +
information O +
system O -
, O +
share O +
hospital O +
resources O +
( O -
medical O +
equipment O +
and O +
library O +
literature O -
) O +
with O +
the O +
clinic O +
physicians O +
in O +
their O +
network O +
and O +
establish O +
referral O +
channels O +
among O +
the O +
network O +
members O -
. O +

Furthermore O -
, O +
this O +
new O +
demonstration O +
model O +
tries O +
to O +
minimize O +
the O +
barriers O +
to O +
patient O +
access O +
by O +
setting O +
up O +
24-hour O +
a O +
day O -
, O +
7-day O +
a O +
week O +
medical O +
consultation O +
telephone O +
lines O +
for O +
providing O +
urgent O +
services O +
onsite O +
and O +
for O +
taking O +
care O +
of O +
the O +
patients O +
whose O +
family O +
physicians O -
' O +
practices O +
are O +
closed O +
to O +
assure O +
seamless O +
care O +
channels O -
. O +

The O +
BNHI O +
funded O +
these O +
extra O +
demonstration O +
actions O -
, O +
at O +
around O +
one O +
hundred O +
thousand O +
US O +
dollars O +
( O -
i.e. O -
, O +
NT$3,500,000 O -
) O +
for O +
each O +
PCCN O +
under O +
the O +
current O +
fee O -
- O -
for O -
- O -
service O +
payment O +
system O +
[ O -
1 O -
] O -
. O +

Figure O +
1 O +
describes O +
the O +
organizational O +
structure O +
of O +
individual O +
PCCNs O +
introduced O +
in O +
the O +
demonstration O +
project O +
in O +
Taiwan O -
. O +

To O +
date O -
, O +
the O +
PCCN O +
demonstration O +
project O +
has O +
been O +
in O +
operation O +
for O +
more O +
than O +
three O +
years O -
. O +

There O +
have O +
been O +
268 O +
PCCNs O +
formed O +
in O +
the O +
period O +
of O +
2003 O +
to O +
2005 O +
around O +
Taiwan O -
. O +

The O +
geographical O +
distributions O +
of O +
PCCNs O +
and O +
their O +
members O +
were O +
described O +
in O +
Table O +
1 O -
. O +

Analyzing O +
all O +
1,557 O +
participating O +
clinic O +
members O +
in O +
the O +
demonstration O +
project O +
in O +
terms O +
of O +
medical O +
specialties O -
, O +
they O +
cover O +
general O +
medicine O -
, O +
internal O +
medicine O -
, O +
surgeries O -
, O +
obstetrics O +
and O +
gynecology O -
, O +
pediatrics O -
, O +
family O +
medicines O -
, O +
otolaryngology O -
, O +
ophthalmology O -
, O +
rehabilitation O +
medicine O -
, O +
dermatology O -
, O +
and O +
psychiatry O -
, O +
with O +
237 O +
clinics O +
providing O +
more O +
than O +
two O +
specialties O -
. O +

On O +
the O +
other O +
hand O -
, O +
each O +
PCCN O +
recruits O +
at O +
least O +
one O +
district O +
or O +
regional O +
accredited O +
hospital O +
for O +
acute O +
care O +
demands O +
( O -
required O +
for O +
network O +
members O -
) O +
and O +
a O +
medical O +
center O +
for O +
tertiary O +
care O +
support O +
( O -
not O +
required O +
for O +
network O +
members O -
) O -
. O +

There O +
are O +
6 O +
medical O +
centers O -
, O +
52 O +
regional O +
hospitals O -
, O +
and O +
71 O +
district O +
hospitals O +
joining O +
in O +
the O +
demonstration O +
project O -
. O +

See O +
Table O +
1 O +
for O +
more O +
detailed O +
information O +
about O +
the O +
PCCN O +
members O -
. O +

To O +
date O -
, O +
there O +
have O +
been O +
few O +
empirical O +
studies O +
of O +
the O +
working O +
relationships O +
that O +
have O +
developed O +
between O +
members O +
of O +
the O +
PCCN O +
program O -
. O +

Partnership O +
needs O +
a O +
method O +
to O +
determine O +
at O +
an O +
early O +
stage O -
, O +
to O +
make O +
sure O +
whether O +
they O +
are O +
making O +
the O +
most O +
of O +
collaboration O +
[ O -
2 O -
] O +
and O +
the O +
acceptance O +
of O +
the O +
contracting O +
networks O +
in O +
Taiwan O +
as O +
an O +
organizational O +
innovation O +
worthy O +
of O +
greater O +
diffusion O +
deserves O +
to O +
be O +
explored O -
. O +

Therefore O -
, O +
this O +
study O +
used O +
a O +
structured O +
questionnaire O +
to O +
characterize O +
the O +
relationship O +
among O +
the O +
members O +
in O +
the O +
individual O +
PCCNs O -
, O +
with O +
regard O +
to O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
financing O -
, O +
as O +
well O +
as O +
information O +
integration O +
infrastructures O -
. O +

The O +
results O +
of O +
this O +
study O +
provide O +
descriptive O +
analyses O +
in O +
detail O +
to O +
map O +
the O +
partnership O +
developments O -
, O +
to O +
enrich O +
the O +
body O +
of O +
knowledge O +
of O +
the O +
partner O +
relationships O +
and O +
to O +
help O +
policy O +
makers O +
understand O +
the O +
coordinated O +
efforts O +
of O +
these O +
health O +
care O +
providers O +
which O +
have O +
developed O +
under O +
this O +
system O -
. O +

It O +
also O +
provides O +
the O +
recommendations O +
for O +
heath O +
policy O +
decision O -
- O -
making O +
and O +
management O +
of O +
networks O +
of O +
health O +
care O +
providers O +
for O +
the O +
future O +
involvement O -
. O +

Methods O +
This O +
study O +
was O +
aimed O +
at O +
providing O +
descriptive O +
analyses O +
to O +
map O +
the O +
partnership O +
development O -
. O +

To O +
understand O +
the O +
actual O +
integration O +
actions O +
done O +
by O +
network O +
members O -
, O +
the O +
theoretical O +
concept O +
employed O +
by O +
network O +
partnerships O +
were O +
described O +
and O +
then O +
the O +
derived O +
survey O +
instrument O +
was O +
developed O -
. O +

Theoretical O +
framework O +
for O +
organization O +
design O +
of O +
network O +
integration O +
The O +
rapid O +
organizational O +
changes O +
in O +
the O +
health O +
care O +
industry O +
have O +
driven O +
theorists O +
from O +
every O +
discipline O +
and O +
across O +
the O +
world O +
to O +
seek O +
an O +
approach O +
that O +
allows O +
organizations O +
to O +
flourish O -
. O +

Organization O +
theory O +
allows O +
investigators O +
to O +
profile O +
an O +
organization O +
from O +
the O +
aspect O +
of O +
patterns O +
and O +
regularities O +
in O +
organizational O +
design O +
and O +
behavior O -
. O +

In O +
the O +
early O +
20th O +
century O -
, O +
classical O +
management O +
theorists O +
claimed O +
that O +
an O +
organization O +
has O +
" O -
a O +
best O +
way O -
" O +
to O +
be O +
organized O +
and O +
managed O +
[ O -
3 O -
] O -
. O +

That O +
implied O +
that O +
all O +
organizations O +
would O +
own O +
the O +
" O -
same O -
" O +
organizational O +
styles O +
or O +
structures O -
. O +

In O +
the O +
1960s O -
, O +
several O +
theorists O +
[ O -
4 O -
- O -
8 O -
] O +
challenged O +
this O +
assumption O +
by O +
applying O +
a O +
" O -
contingency O +
approach O -
" O +
to O +
propose O +
that O +
there O +
is O +
no O +
best O +
way O +
to O +
organize O +
an O +
organization O -
, O +
and O +
that O +
the O +
effectiveness O +
of O +
an O +
organizational O +
structure O +
varies O +
with O +
the O +
situation O +
of O +
an O +
organization O -
. O +

Furthermore O -
, O +
it O +
is O +
proposed O +
that O +
the O +
best O +
way O +
to O +
organize O +
an O +
organization O +
depends O +
on O +
the O +
nature O +
of O +
the O +
environment O +
to O +
which O +
the O +
organization O +
relates O -
. O +

Contingency O +
theory O +
delineates O +
the O +
concepts O +
" O -
organization O -
's O +
internal O +
features O -
, O -
" O +
" O -
the O +
demands O +
of O +
organizational O +
environments O -
, O -
" O +
" O -
best O +
adaptation O -
, O -
" O +
and O -
, O +
the O +
most O +
important O +
and O +
difficult O +
of O +
all O -
, O +
" O -
best O +
match O -
" O +
[ O -
9 O -
] O -
. O +

Lawrence O +
& O +
Lorsch O +
[ O -
7 O -
] O +
argued O +
that O +
environments O +
characterized O +
by O +
uncertainty O +
and O +
rapid O +
rates O +
of O +
change O +
in O +
market O +
conditions O +
or O +
technology O +
impose O +
different O +
demands O -
, O +
including O +
constraints O +
and O +
opportunities O -
, O +
on O +
organizations O +
than O +
do O +
placid O +
and O +
stable O +
environments O -
. O +

Similarly O +
to O +
Lawrence O +
and O +
Lorsch O -
's O +
views O +
mentioned O +
above O -
, O +
Galbraith O +
[ O -
10,11 O -
] O +
stressed O +
the O +
contingency O +
perspective O +
on O +
information O +
processing O -
. O +

The O +
information O -
- O -
processing O +
approach O +
emphasizes O +
that O +
environment O -
, O +
size O -
, O +
and O +
technology O +
impose O +
different O +
information O -
- O -
processing O +
requirements O +
on O +
organizations O -
, O +
and O +
thus O +
an O +
organization O +
must O +
be O +
designed O +
to O +
encourage O +
information O +
flow O +
in O +
both O +
vertical O +
and O +
horizontal O +
directions O +
to O +
achieve O +
the O +
overall O +
tasks O +
of O +
the O +
organization O +
and O -
, O +
finally O -
, O +
organizational O +
effectiveness O +
[ O -
11 O -
- O -
14 O -
] O -
. O +

Some O +
theorists O +
have O +
criticized O +
conventional O +
contingency O +
theorists O +
who O +
presume O +
that O +
organizational O +
structure O +
is O +
driven O +
by O +
the O +
environment O -
. O +

Child O +
[ O -
15 O -
] O -
, O +
Miller O +
[ O -
16 O -
] O -
, O +
Van O +
de O +
Ven O +
and O +
Drazin O +
[ O -
17 O -
] O -
, O +
and O +
Tushman O +
and O +
Romanelli O +
[ O -
18 O -
] O +
raised O +
such O +
criticisms O -
; O +
they O +
argued O +
that O +
organizations O +
become O +
what O +
they O +
are O +
not O +
only O +
because O +
of O +
the O +
environment O -
, O +
but O +
also O +
because O +
of O +
choices O +
made O +
by O +
members O -
, O +
especially O +
choices O +
about O +
strategy O +
and O +
organizational O +
design O -
. O +

As O +
Thompson O -
's O +
words O +
in O +
the O +
book O +
Organizations O +
in O +
Action O +
[ O -
8 O -
] O +
put O +
it O -
, O +
" O -
organizations O +
are O +
not O +
determined O +
simply O +
by O +
their O +
environments O +
( O -
p.27 O -
) O -
. O +

" O +
He O +
also O +
pointed O +
out O +
that O +
" O -
administration O +
may O +
innovate O +
on O +
any O +
or O +
all O +
of O +
the O +
necessary O +
dimensions O -
, O +
but O +
only O +
to O +
the O +
extent O +
that O +
innovations O +
are O +
acceptable O +
to O +
those O +
on O +
whom O +
the O +
organization O +
can O +
and O +
must O +
depend O -
. O -
" O +

Instead O +
of O +
assuming O +
that O +
administrators O +
are O +
highly O +
constrained O +
in O +
their O +
decisions O -
, O +
strategic O +
contingency O +
theorists O +
emphasized O +
" O -
the O +
importance O +
of O +
choice O -
, O -
" O +
that O +
is O -
, O +
" O -
the O +
freedom O +
of O +
agency O -
" O +
[ O -
15 O -
] O -
. O +

Furthermore O -
, O +
Pfeffer O +
[ O -
19 O -
] O +
explicitly O +
pointed O +
out O +
that O +
" O -
organizational O +
structures O +
are O +
the O +
outcomes O +
of O +
political O +
contests O +
within O +
organizations O +
( O -
p.38 O -
) O -
. O +

" O +
Daft O +
[ O -
14 O -
] O +
proposed O +
a O +
top O +
management O +
model O +
to O +
delineate O +
how O +
" O -
a O +
strategy O +
is O +
a O +
plan O +
for O +
interacting O +
with O +
the O +
competitive O +
environment O +
to O +
achieve O +
organizational O +
goals O -
. O -
" O +

He O +
stated O +
that O +
the O +
major O +
responsibility O +
of O +
top O +
management O +
is O +
to O +
determine O +
the O +
goals O -
, O +
strategy O -
, O +
and O +
design O +
of O +
an O +
organization O +
to O +
adapt O +
to O +
a O +
changing O +
environment O -
. O +

To O +
assess O +
the O +
external O +
and O +
internal O +
environments O +
of O +
an O +
organization O +
seems O +
to O +
be O +
the O +
first O +
task O +
for O +
top O +
managers O +
in O +
defining O +
an O +
organization O -
's O +
goals O +
and O +
missions O -
. O +

Then O -
, O +
guided O +
by O +
the O +
goals O +
and O +
missions O +
of O +
the O +
organization O -
, O +
top O +
managers O +
shape O +
the O +
design O +
of O +
the O +
organization O -
, O +
including O +
structural O +
forms O -
, O +
information O +
system O -
, O +
technology O -
, O +
human B-Species +
resources O -
, O +
organizational O +
culture O -
, O +
and O +
inter O -
- O -
organizational O +
linkages O -
, O +
to O +
achieve O +
the O +
final O +
organizational O +
performance O -
. O +

Integration O +
refers O +
to O +
the O +
mechanisms O +
of O +
coordination O -
, O +
the O +
ways O +
guided O +
to O +
partnership O +
goals O +
to O +
fit O +
internal O +
and O +
external O +
conditions O +
[ O -
7,20,21 O -
] O -
. O +

In O +
the O +
early O +
1990s O -
, O +
proposals O +
for O +
US O +
national O +
health O +
care O +
reform O +
recognized O +
the O +
need O +
for O +
integrating O +
mechanisms O +
to O +
achieve O +
both O +
financial O +
success O +
and O +
quality O +
of O +
care O +
of O +
a O +
well O -
- O -
organized O +
system O +
of O +
care O +
[ O -
22,23 O -
] O -
. O +

Several O +
researchers O +
also O +
viewed O +
inter O -
- O -
organizational O +
cooperation O +
as O +
resource O +
exchanges O -
, O +
including O +
client O +
referrals O -
, O +
money O -
, O +
and O +
staff O +
[ O -
24 O -
- O -
27 O -
] O -
. O +

From O +
practical O +
ways O +
of O +
viewing O +
integration O -
, O +
the O +
success O +
of O +
integration O +
lies O +
in O +
the O +
coordinative O +
mechanisms O +
and O +
partnership O +
working O +
that O +
support O +
it O +
[ O -
28 O -
] O -
, O +
including O +
an O +
administrative O +
organization O +
that O +
coordinates O +
the O +
operations O +
of O +
various O +
health O +
care O +
services O -
; O +
a O +
management O +
information O +
system O +
that O +
integrates O +
clinical O -
, O +
utilization O -
, O +
and O +
financial O +
data O +
and O +
follows O +
clients O +
across O +
different O +
settings O -
; O +
a O +
care O +
coordination O +
program O +
such O +
as O +
case O +
management O +
or O +
disease O +
management O +
that O +
works O +
with O +
clients O +
to O +
arrange O +
health O +
care O +
services O -
; O +
and O +
a O +
financial O +
mechanism O +
that O +
enables O +
pooling O +
of O +
funds O +
across O +
services O +
[ O -
29 O -
- O -
35 O -
] O -
. O +

Fox O +
[ O -
36 O -
] O +
suggested O +
the O +
success O +
of O +
integrated O +
health O +
networks O +
should O +
ensure O +
that O +
the O +
new O +
business O +
link O +
such O +
aspects O +
as O +
technology O -
, O +
functional O +
skills O -
, O +
customer O +
access O -
, O +
management O -
, O +
or O +
products O +
that O +
can O +
be O +
shared O +
across O +
both O +
the O +
core O +
and O +
the O +
new O +
business O -
; O +
to O +
conduct O +
market O +
financial O +
evaluation O -
; O +
to O +
share O +
the O +
risk O +
of O +
vertical O +
integration O +
with O +
outside O +
entities O -
, O +
to O +
develop O +
the O +
management O +
structure O +
that O +
can O +
reflect O +
the O +
degree O +
of O +
coordination O +
necessary O +
to O +
support O +
the O +
core O +
business O +
activities O -
; O +
to O +
ensure O +
that O +
the O +
integration O +
strategy O +
meets O +
the O +
needs O +
of O +
customers O -
, O +
including O +
medical O +
treatment O -
, O +
the O +
use O +
of O +
medical O +
technology O -
, O +
and O +
the O +
preferred O +
methods O +
of O +
purchase O -
; O +
and O +
to O +
measure O +
the O +
new O +
business O +
by O +
its O +
value O +
to O +
the O +
enterprise O +
as O +
a O +
whole O -
, O +
rather O +
than O +
by O +
its O +
profitability O +
as O +
a O +
stand O -
- O -
alone O +
entity O -
. O +

In O +
summary O -
, O +
the O +
effects O +
that O +
integration O +
in O +
inter O -
- O -
organizational O +
designs O +
has O +
on O +
network O +
management O +
were O +
substantial O +
from O +
a O +
managerial O +
perspective O -
. O +

Borrowing O +
the O +
ideas O +
of O +
strategic O +
contingency O +
perspective O +
[ O -
8,15,19 O -
] O +
and O +
top O +
management O +
model O +
[ O -
14 O -
] O -
, O +
it O +
could O +
be O +
imply O +
that O +
success O +
( O -
organization O +
performance O -
) O +
in O +
reengineering O +
a O +
network O +
lies O +
in O +
the O +
integration O +
of O +
process O +
and O +
services O +
( O -
see O +
Figure O +
1 O -
) O -
, O +
including O +
leadership O -
/ O -
governing O +
structure O -
, O +
teamwork O +
between O +
disciplines O +
and O +
patient O +
care O -
, O +
financial O +
planning O -
, O +
and O +
information O +
systems O -
, O +
characterized O +
as O +
the O +
constructs O +
of O +
governance O -
, O +
clinical O -
, O +
financial O -
, O +
and O +
information O +
infrastructures O -
, O +
respectively O -
, O +
in O +
this O +
study O -
. O +

In O +
addition O -
, O +
another O +
construct O -
, O +
marketing O +
infrastructure O -
, O +
was O +
especially O +
important O +
and O +
designed O +
to O +
explore O +
for O +
PCCNs O +
in O +
this O +
study O +
because O +
of O +
patients O -
' O +
freedom O +
of O +
making O +
healthcare O +
choice O +
and O +
the O +
traditional O +
fragmented O +
health O +
care O +
systems O +
by O +
individual O +
health O +
care O +
organizations O +
in O +
Taiwan O -
. O +

One O +
major O +
reason O +
for O +
Taiwan O +
people O -
's O +
hospital O +
shopping O +
preferences O +
was O +
that O +
Taiwan O +
people O +
usually O +
believe O +
the O +
bigger O +
the O +
facility O -
, O +
the O +
better O +
capacities O +
a O +
facility O +
has O +
no O +
matter O +
on O +
any O +
aspect O +
from O +
medical O +
professionals O +
to O +
tangible O +
medical O +
equipment O +
and O +
plants O -
. O +

And O +
this O +
fallacy O +
made O +
the O +
public O +
want O +
to O +
overuse O +
the O +
facility O +
with O +
high O -
- O -
tech O +
medical O +
services O +
no O +
matter O +
if O +
it O +
fits O +
their O +
needs O -
. O +

From O +
the O +
health O +
policy O +
and O +
management O +
perspectives O -
, O +
therefore O -
, O +
the O +
health O +
care O +
providers O +
were O +
encouraged O +
to O +
market O +
their O +
services O +
as O +
a O +
new O +
corporate O +
identity O +
and O +
brand O +
strategy O +
[ O -
37 O -
] O -
, O +
including O +
offering O +
tangible O +
resources O +
such O +
as O +
books O -
, O +
libraries O -
, O +
medical O +
equipment O -
, O +
and O +
intangible O +
resources O +
such O +
as O +
knowledge O +
and O +
information O +
exchanges O +
( O -
education O -
) O +
and O +
reputation O +
sharing O +
one O +
another O +
among O +
PCCN O +
members O -
. O +

Furthermore O -
, O +
through O +
the O +
process O +
of O +
marketing O +
resource O +
exchanges O -
, O +
therefore O -
, O +
each O +
PCCN O +
could O +
establish O +
the O +
images O +
of O +
" O -
one O +
system O -
, O +
one O +
brand O +
and O +
quality O -
" O +
for O +
the O +
public O +
and O +
for O +
the O +
health O +
care O +
providers O -
. O +

It O +
also O +
makes O +
it O +
be O +
more O +
visible O +
to O +
the O +
public O -
. O +

The O +
five O +
integration O +
infrastructures O +
of O +
network O +
management O +
were O +
constructed O +
as O +
a O +
conceptual O +
framework O +
in O +
this O +
study O +
to O +
help O +
to O +
portray O +
how O +
the O +
PCCN O +
members O +
have O +
done O -
. O +

The O +
survey O +
instrument O +
development O +
was O +
described O +
in O +
the O +
following O -
. O +

Survey O +
instrument O +
development O -
: O +
integration O +
infrastructures O +
and O +
measurements O +
of O +
partnerships O +
Based O +
on O +
the O +
five O +
integration O +
infrastructures O +
of O +
network O +
management O -
, O +
the O +
structured O +
questionnaire O +
were O +
derived O +
from O +
extensive O +
literature O +
reviews O -
. O +

Governance O +
infrastructure O +
Governance O +
assumes O +
the O +
broad O +
responsibility O +
for O +
organizational O +
goals O +
and O +
survival O +
and O +
involves O +
the O +
series O +
process O +
of O +
setting O +
and O +
monitoring O +
organizational O +
goals O +
and O +
strategy O +
development O +
through O +
a O +
board O +
of O +
representatives O +
[ O -
38 O -
] O -
. O +

Governance O +
or O +
administrative O +
integration O +
infrastructure O +
in O +
establishing O +
network O +
partnerships O +
refers O +
to O +
administrative O +
structures O +
( O -
or O +
responsibilities O -
) O +
created O +
to O +
facilitate O +
communication O -
, O +
clear O +
lines O +
of O +
authority O -
, O +
accountability O -
, O +
and O +
responsibility O +
for O +
patient O +
care O +
services O -
; O +
to O +
negotiate O +
budgets O +
and O +
financial O +
trade O -
- O -
offs O -
; O +
and O +
to O +
present O +
a O +
cohesive O -
, O +
consistent O +
message O +
in O +
interactions O +
with O +
external O +
agencies O +
and O +
the O +
community O +
[ O -
29,39 O -
- O -
41 O -
] O +
and O +
most O +
important O +
for O +
members O +
in O +
contract O +
agreements O -
, O +
to O +
manage O +
participation O +
[ O -
33 O -
] O -
. O +

From O +
a O +
multidisciplinary O +
perspective O -
, O +
Mitchell O +
and O +
Shortell O +
[ O -
42 O -
] O +
applied O +
the O +
concepts O +
of O +
governance O +
and O +
management O +
characteristics O +
in O +
effective O +
community O +
health O +
partnerships O -
. O +

The O +
construct O +
of O +
governance O +
involved O +
several O +
tasks O -
, O +
including O +
setting O +
priorities O +
for O +
strategic O +
goals O -
, O +
choosing O +
the O +
membership O +
composition O -
, O +
obtaining O +
the O +
necessary O +
financial O +
resources O -
, O +
and O +
setting O +
up O +
the O +
accountability O +
systems O -
, O +
and O +
so O +
on O -
. O +

The O +
construct O +
of O +
the O +
management O +
refers O +
to O +
the O +
tasks O +
of O +
engaging O +
and O +
maintaining O +
organizational O +
members O -
' O +
interest O +
in O +
a O +
shared O +
vision O +
and O +
mission O -
, O +
providing O +
appropriate O +
structures O +
and O +
coordination O +
mechanisms O +
for O +
the O +
specified O +
strategies O -
, O +
promoting O +
constructive O +
conflicts O +
and O +
managing O +
destructive O +
conflicts O -
, O +
implementing O +
information O +
systems O +
to O +
monitor O +
the O +
dynamics O -
, O +
adjusting O +
the O +
leadership O +
in O +
the O +
overall O +
membership O -
, O +
and O +
so O +
on O -
. O +

The O +
issues O +
of O +
governance O +
and O +
administrative O +
integration O +
in O +
the O +
PCCNs O +
could O +
include O +
[ O -
2,38,40,41,43 O -
- O -
47 O -
] O -
: O +
• O +
planning O +
the O +
shared O +
visions O +
and O +
missions O +
• O +
determining O +
the O +
shared O +
service O +
strategies O -
, O +
cooperation O +
priorities O -
, O +
policies O +
and O +
principles O +
• O +
identifying O +
the O +
information O +
needed O +
and O +
how O +
to O +
get O +
it O +
• O +
organizing O +
the O +
network O +
dynamics O +
and O +
member O +
roles O +
• O +
leading O +
and O +
managing O +
the O +
conflicts O +
and O +
communication O +
• O +
designing O +
and O +
controlling O +
the O +
shared O +
network O +
performance O +
systems O -
, O +
including O +
indicator O +
settings O -
, O +
feedbacks O -
, O +
and O +
accountability O -
. O +

Clinical O +
infrastructure O +
The O +
idea O +
of O +
care O +
integration O +
begins O +
through O +
such O +
public O +
programs O +
that O +
include O +
social O +
workers O +
in O +
public O +
welfare O +
departments O -
, O +
caseworkers O +
in O +
mental O +
health O -
, O +
or O +
nurses O +
in O +
public O +
health O +
departments O -
. O +

In O +
the O +
late O +
1980s O -
, O +
care O +
integration O +
was O +
deemed O +
necessary O +
for O +
the O +
streamlining O +
of O +
care O +
and O +
negotiating O +
the O +
maze O +
of O +
long O -
- O -
term O +
care O +
services O -
. O +

At O +
that O +
time O -
, O +
it O +
was O +
referred O +
to O +
as O +
service O +
coordination O +
or O +
case O +
management O -
, O +
or O +
in O +
other O +
related O +
terms O +
[ O -
29 O -
] O -
. O +

The O +
purpose O +
of O +
care O +
integration O +
is O +
to O +
work O +
directly O +
with O +
patients O +
and O +
their O +
families O +
over O +
time O +
to O +
help O +
them O +
arrange O +
and O +
manage O +
the O +
complex O +
resources O +
that O +
patients O +
may O +
need O +
to O +
maintain O +
health O +
and O +
independent O +
functioning O -
. O +

At O +
the O +
same O +
time O -
, O +
care O +
integration O +
is O +
used O +
to O +
achieve O +
the O +
most O +
cost O -
- O -
effective O +
use O +
possible O +
of O +
scarce O +
resources O -
, O +
by O +
steering O +
patients O +
to O +
the O +
health O -
, O +
social O -
, O +
and O +
support O +
services O +
most O +
appropriate O +
for O +
them O +
at O +
a O +
given O +
time O +
[ O -
29 O -
] O -
. O +

Conrad O +
and O +
Dowling O +
[ O -
33 O -
] O +
pointed O +
out O +
that O +
to O +
coordinate O +
and O +
integrate O +
patient O +
care O +
relies O +
on O +
connecting O +
patient O +
services O +
at O +
the O +
different O +
stages O +
of O +
the O +
patient O +
care O +
processes O -
. O +

Care O +
coordination O +
in O +
integrated O +
networks O +
can O +
be O +
achieved O +
through O +
integration O +
of O +
training O +
programs O +
and O +
some O +
clinical O +
services O -
, O +
provision O +
of O +
complementary O +
clinical O +
capabilities O -
, O +
clinical O +
geographic O +
proximity O +
design O -
, O +
clear O +
role O +
definition O +
of O +
each O +
institution O -
, O +
commitment O +
and O +
flexibility O +
of O +
leaderships O +
and O +
medical O +
staffs O -
, O +
and O +
the O +
support O +
of O +
a O +
large O +
referring O +
physician O +
groups O +
embracing O +
the O +
affiliation O +
concepts O +
[ O -
48 O -
] O -
. O +

The O +
issues O +
of O +
clinical O +
integration O +
in O +
the O +
PCCNs O +
could O +
include O +
[ O -
48 O -
- O -
50 O -
] O -
: O +
• O +
planning O +
and O +
differentiating O +
target O +
markets O +
based O +
on O +
the O +
clinical O +
services O +
of O +
the O +
network O +
members O +
• O +
uniting O +
individual O +
clinical O +
professionals O +
for O +
clinical O +
project O +
planning O +
• O +
designing O +
patient O -
- O -
centered O +
care O +
or O +
case O +
management O +
teams O +
• O +
establishing O +
committees O +
responsible O +
for O +
patient O -
- O -
centered O +
case O +
report O +
meetings O -
, O +
case O +
referral O -
, O +
transfer O -
, O +
and O +
tracing O -
, O +
file O +
management O +
( O -
record O +
and O +
information O +
exchanges O -
) O -
, O +
clinical O +
quality O +
management O +
( O -
quality O +
assurance O -
, O +
improvement O -
, O +
risk O +
and O +
malpractice O +
management O -
, O +
and O +
utilization O +
review O -
) O -
, O +
and O +
medical O +
continuing O +
education O +
and O +
on O -
- O -
job O +
education O -
. O +

Marketing O +
infrastructure O +
Marketing O +
integration O +
refers O +
to O +
how O +
to O +
work O +
together O +
as O +
a O +
whole O +
both O +
from O +
the O +
provider O +
and O +
patient O +
perspectives O -
. O +

One O +
of O +
the O +
case O +
reports O +
interviewing O +
developing O +
integrated O +
delivery O +
system O +
or O +
networks O +
realized O +
that O +
the O +
most O +
important O +
thing O +
is O +
how O +
an O +
integrated O +
system O +
or O +
network O +
is O +
promoted O +
and O +
what O +
is O +
promoted O +
for O +
the O +
consumers O +
[ O -
51 O -
] O -
, O +
including O +
focusing O +
on O +
product O +
development O -
, O +
making O +
sure O +
the O +
branding O +
holds O +
together O -
, O +
marketing O +
directly O +
to O +
consumers O -
, O +
demonstrating O +
values O +
to O +
consumers O -
, O +
and O +
even O +
conducting O +
marketing O +
research O +
to O +
make O +
efforts O +
for O +
the O +
long O +
term O -
. O +

In O +
a O +
health O +
care O +
network O +
with O +
several O +
organizational O +
members O +
and O +
target O +
patients O -
, O +
the O +
marketing O +
infrastructure O +
in O +
PCCNs O +
here O +
refers O +
to O +
provider O +
members O -
' O +
marketing O -
, O +
meaning O +
the O +
resource O +
sharing O +
and O +
market O +
development O +
in O +
a O +
PCCN O +
as O +
a O +
whole O -
. O +

The O +
issues O +
of O +
the O +
marketing O +
integration O +
in O +
the O +
PCCNs O +
could O +
include O +
[ O -
37,52 O -
- O -
54 O -
] O -
: O +
• O +
sharing O +
the O +
literature O +
and O +
facility O +
publications O +
among O +
the O +
network O +
members O +
•uniting O +
public O +
promotions O +
such O +
as O +
united O +
activities O -
, O +
electronic O +
and O +
paper O +
media O +
for O +
enhancing O +
the O +
network O +
reputation O +
as O +
" O -
one O +
system O -
, O +
one O +
brand O +
and O +
quality O -
" O +
• O +
differentiating O +
target O +
markets O +
of O +
the O +
network O +
for O +
competing O +
in O +
the O +
medical O +
industry O -
. O +

Financial O +
infrastructure O +
Comprehensive O -
, O +
flexible O -
, O +
and O +
adequate O +
financing O +
is O +
a O +
goal O +
of O +
the O +
ideal O +
continuum O +
of O +
care O -
. O +

That O +
component O +
is O +
the O +
most O +
critical O +
and O +
challenging O +
to O +
manage O +
under O +
the O +
changes O +
in O +
the O +
health O +
care O +
delivery O +
environment O -
. O +

Gillies O +
et O +
al. O +
[ O -
30 O -
] O +
suggested O +
that O +
integrating O +
financial O +
management O +
across O +
operating O +
units O +
adds O +
the O +
greatest O +
value O +
to O +
systems O +
or O +
organizations O -
. O +

In O +
one O +
case O +
study O -
, O +
Bramson O +
et O +
al. O +
[ O -
55 O -
] O +
also O +
showed O +
that O +
reducing O +
costs O +
through O +
joint O +
purchasing O +
by O +
the O +
radiology O +
departments O +
of O +
a O +
vertically O +
integrated O +
health O +
system O +
could O +
yield O +
substantial O +
savings O -
. O +

The O +
issues O +
of O +
the O +
financial O +
integration O +
in O +
the O +
PCCNs O +
could O +
include O -
: O +
• O +
budgeting O +
• O +
uniting O +
equipment O -
, O +
medical O +
materials O -
, O +
and O +
drug O +
purchasing O +
and O +
routine O +
administrative O +
stuff O +
management O +
• O +
pooling O +
recruitment O +
funds O +
• O +
designing O +
a O +
financial O +
risk O +
and O +
sharing O +
mechanism O -
. O +

Information O +
infrastructure O +
Information O +
is O +
an O +
essential O +
component O +
of O +
an O +
organization O -
. O +

A O +
complete O +
information O +
system O +
can O +
help O +
an O +
organization O +
to O +
integrate O +
its O +
individual O +
units O +
and O +
efficiently O +
manage O +
the O +
continuum O -
. O +

The O +
ideal O +
information O +
system O +
for O +
a O +
continuum O +
of O +
care O +
was O +
conceived O +
of O +
and O +
formed O +
in O +
the O +
mid-1980s O +
[ O -
56 O -
] O -
. O +

During O +
the O +
late O +
1980s O -
, O +
computer O +
technology O +
began O +
to O +
make O +
an O +
information O +
system O +
feasible O +
and O +
affordable O +
through O +
new O +
computer O +
chips O +
with O +
expanded O +
capability O +
and O +
networking O +
technology O -
. O +

In O +
the O +
1990s O -
, O +
the O +
individual O +
services O +
of O +
the O +
continuum O +
upgraded O +
their O +
information O +
systems O +
to O +
combine O +
clinical O -
, O +
financial O -
, O +
and O +
utilization O +
data O +
[ O -
29 O -
] O -
. O +

Some O +
studies O +
have O +
argued O +
that O +
the O +
quality O +
of O +
information O +
systems O +
can O +
drive O +
costs O +
down O -
, O +
because O +
a O +
good O +
information O +
system O +
can O +
give O +
physicians O +
easy O +
electronic O +
access O +
to O +
complete O +
the O +
documentation O +
of O +
the O +
patients O -
' O +
clinical O +
records O -
, O +
better O +
inform O +
them O +
about O +
reimbursement O +
and O +
capitation O +
issues O -
, O +
help O +
them O +
easily O +
associate O +
and O +
manage O +
cases O +
together O -
, O +
and O +
achieve O +
a O +
higher O +
level O +
of O +
professional O +
satisfaction O +
[ O -
57,58 O -
] O -
. O +

Using O +
Inova O +
Health O +
System O -
, O +
an O +
integrated O +
delivery O +
system O +
in O +
northern O +
Virginia O -
, O +
as O +
an O +
example O -
, O +
Wager O -
, O +
Heda O -
, O +
and O +
Austin O +
[ O -
59 O -
] O +
showed O +
that O +
by O +
developing O +
a O +
health O +
information O +
network O +
within O +
an O +
integrated O +
delivery O +
system O -
, O +
Inova O +
can O +
have O +
a O +
clinical O +
transaction O +
system O +
for O +
hospitals O +
and O +
other O +
entities O -
, O +
a O +
data O +
repository O +
for O +
decision O +
support O +
and O +
outcome O +
management O -
, O +
a O +
managed O +
care O +
information O +
system O +
to O +
support O +
managed O +
care O +
and O +
capitation O +
contracts O -
, O +
and O +
greater O +
capability O +
to O +
acquire O +
physicians O -
. O +

The O +
issues O +
of O +
information O +
coordination O +
include O +
[ O -
60 O -
- O -
68 O -
] O -
: O +
• O +
establishing O +
an O +
electronic O +
medical O +
record O +
system O -
, O +
regional O +
information O +
network O +
for O +
patient O +
clinical O +
and O +
administrative O +
data O -
, O +
clinical O +
service O +
arrangements O +
and O +
administrative O +
work O +
• O +
uniting O +
the O +
system O +
information O +
management O +
and O +
web O +
pages O -
. O +

The O +
structured O +
questionnaire O +
was O +
developed O +
with O +
the O +
wording O +
of O +
practical O +
managerial O +
actions O +
based O +
on O +
the O +
five O +
concepts O +
just O +
mentioned O -
. O +

There O +
were O +
19 O +
survey O +
items O +
on O +
governance O +
infrastructure O -
, O +
25 O +
on O +
clinical O +
infrastructure O -
, O +
13 O +
on O +
marketing O +
infrastructure O -
, O +
20 O +
on O +
financial O +
infrastructure O -
, O +
and O +
7 O +
on O +
information O +
infrastructure O -
. O +

All O +
84 O +
items O +
were O -
, O +
simultaneously O -
, O +
applied O +
to O +
examine O +
the O +
relationships O +
of O +
the O +
clinic O -
's O +
peer O +
members O +
and O +
the O +
relationship O +
of O +
clinic O +
and O +
hospital O +
members O +
in O +
a O +
PCCN O -
, O +
and O +
it O +
resulted O +
in O +
a O +
total O +
of O +
168 O +
survey O +
questions O -
. O +

The O +
detailed O +
information O +
of O +
the O +
item O +
questions O +
was O +
listed O +
in O +
Table O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
, O +
6 O -
. O +

The O +
structured O +
questionnaires O +
were O +
drafted O +
from O +
previous O +
literatures O +
and O +
then O +
examined O +
by O +
two O +
academic O +
professors O +
for O +
theoretical O +
accuracy O -
. O +

Then O +
one O +
pilot O +
study O +
was O +
pre O -
- O -
tested O +
for O +
the O +
PCCN O +
pioneers O +
( O -
i.e. O -
, O +
92 O +
network O +
clinic O +
members O -
) O +
and O +
116 O +
hospital O +
providers O +
which O +
have O +
partner O +
relationships O +
with O +
other O +
health O +
care O +
organizations O +
( O -
i.e. O -
, O +
hospitals O -
, O +
clinics O -
, O +
long O -
- O -
term O +
care O +
facilities O -
) O -
. O +

The O +
wordings O +
and O +
meanings O +
of O +
each O +
question O +
item O +
were O +
revised O +
to O +
assure O +
content O +
validity O -
. O +

The O +
Cronbach O +
α O +
values O +
for O +
the O +
five O +
integration O +
constructs O +
– O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
finance O -
, O +
and O +
information O +
infrastructure O +
were O +
0.946 O -
, O +
0.958 O -
, O +
0.932 O -
, O +
0.944 O -
, O +
and O +
0.898 O +
for O +
the O +
measures O +
of O +
clinic O -
- O -
clinic O +
member O +
relationships O -
; O +
and O +
0.945 O -
, O +
0.949 O -
, O +
0.916 O -
, O +
0.948 O -
, O +
and O +
0.896 O +
for O +
the O +
measures O +
of O +
clinic O -
- O -
hospital O +
member O +
relationships O -
. O +

Study O +
subjects O +
To O +
find O +
the O +
member O +
partnership O -
, O +
we O +
sent O +
questionnaires O +
to O +
1,557 O +
individual O +
clinics O +
which O +
had O +
belonged O +
to O +
PCCNs O +
for O +
at O +
least O +
one O +
year O -
, O +
based O +
on O +
information O +
contained O +
in O +
the O +
Taiwan O +
Primary O +
Community O +
Care O +
Network O +
List O +
( O -
Bureau O +
of O +
National O +
Health O +
Insurance O +
2003 O -
, O +
2004 O +
and O +
2005 O -
) O -
. O +

We O +
let O +
clinic O +
members O +
in O +
all O +
PCCNs O +
point O +
out O +
how O +
they O +
coordinate O +
with O +
their O +
peer O +
clinic O +
members O +
and O +
hospital O +
members O +
within O +
a O +
PCCN O +
because O +
individual O +
clinic O +
members O +
could O +
be O +
better O +
informants O +
than O +
hospital O +
members O -
, O +
which O +
need O +
to O +
deal O +
with O +
multiple O +
clinic O +
relationships O +
and O +
therefore O +
might O +
find O +
it O +
hard O +
to O +
describe O +
the O +
coordination O +
involvement O +
one O +
by O +
one O +
with O +
clinic O +
members O -
. O +

Moreover O -
, O +
networks O +
form O +
for O +
various O +
reasons O +
and O +
it O +
might O +
lead O +
to O +
the O +
various O +
involvements O +
by O +
individual O +
network O +
members O +
( O -
i.e. O -
, O +
hospital O +
and O +
clinic O +
members O -
) O -
. O +

Therefore O -
, O +
using O +
the O +
participating O +
clinics O +
as O +
individual O +
survey O +
units O -
, O +
the O +
results O +
could O +
portray O +
the O +
overall O +
dynamics O +
and O +
processes O +
more O +
authentically O +
and O +
detailed O +
throughout O +
all O +
PCCNs O +
in O +
the O +
demonstration O +
project O -
. O +

Nine O +
hundred O +
and O +
twenty O -
- O -
eight O +
clinics O +
responded O +
( O -
59.6 O +
% O -
) O -
, O +
with O +
239 O +
clinics O +
in O +
the O +
Taipei O +
region O -
, O +
165 O +
in O +
the O +
northern O +
region O -
, O +
241 O +
in O +
the O +
central O +
region O -
, O +
108 O +
in O +
the O +
southern O +
region O -
, O +
150 O +
in O +
the O +
Kao O -
- O -
Ping O +
region O -
, O +
and O +
15 O +
in O +
the O +
eastern O +
region O +
of O +
Taiwan O -
. O +

Ten O +
clinics O +
had O +
not O +
mentioned O +
their O +
practicing O +
locations O -
. O +

There O +
is O +
no O +
statistically O +
significant O +
difference O +
in O +
geographical O +
distribution O +
between O +
the O +
respondents O +
and O +
the O +
study O +
population O +
( O -
χ2 O +
= O +
4.208 O -
, O +
p O +
> O +
0.05 O -
) O -
. O +

Analytical O +
techniques O +
The O +
data O +
was O +
first O +
analyzed O +
descriptively O +
with O +
frequency O +
counts O +
( O -
percentage O -
) O +
for O +
each O +
survey O +
item O -
, O +
instead O +
of O +
using O +
mean O +
as O +
a O +
statistical O +
method O -
, O +
because O +
the O +
variation O +
among O +
the O +
respondents O +
may O +
not O +
represent O +
the O +
normal O +
distribution O +
and O +
it O +
might O +
ignore O +
the O +
extreme O +
values O +
for O +
the O +
respondents O -
' O +
answers O -
. O +

To O +
compare O +
how O +
the O +
respondents O +
perceived O +
the O +
strength O +
of O +
integration O +
existing O +
in O +
clinic O -
- O -
clinic O +
and O +
clinic O -
- O -
hospital O +
relationships O -
, O +
paired O +
t O -
- O -
tests O +
were O +
performed O +
for O +
individual O +
survey O +
items O -
, O +
using O +
the O +
original O +
numerical O +
scores O -
. O +

Results O +
Profiling O +
the O +
partnerships O +
in O +
Taiwan O +
PCCNs O -
: O +
governance O +
infrastructure O +
With O +
regard O +
to O +
the O +
governance O +
infrastructures O -
, O +
the O +
frequency O +
was O +
counted O +
for O +
each O +
survey O +
item O +
with O +
recalculated O +
scales O -
: O +
disagree O +
( O -
Likert O +
scale O +
1 O +
and O +
2 O -
) O -
, O +
fair O +
( O -
Likert O +
scale O +
3 O -
) O -
, O +
and O +
agree O +
( O -
Likert O +
scale O +
4 O +
and O +
5 O -
) O +
with O +
individual O +
items O -
. O +

In O +
clinic O -
- O -
clinic O +
relationship O +
( O -
Table O +
2 O -
) O -
, O +
the O +
majority O +
of O +
clinic O +
members O +
agree O +
that O +
the O +
determined O +
deals O +
were O +
obeyed O +
( O -
Table O +
2 O -
, O +
item O +
1 O -
: O +
88.69 O -
% O -
) O -
, O +
the O +
goals O +
and O +
strategies O +
of O +
members O +
were O +
well O -
- O -
understood O +
( O -
Table O +
2 O -
, O +
item O +
16 O -
: O +
79.74 O -
% O -
) O -
, O +
and O +
the O +
united O +
principals O +
for O +
individual O +
members O +
were O +
developed O +
( O -
Table O +
2 O -
, O +
item O +
15 O -
: O +
79.42 O -
% O -
) O -
. O +

The O +
higher O +
percentages O +
were O +
also O +
found O +
in O +
clinic O -
- O -
hospital O +
relationship O +
in O +
the O +
same O +
items O +
( O -
Table O +
2 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
establishing O +
fair O +
coordination O +
mechanism O +
( O -
Table O +
2 O -
, O +
item O +
11 O -
: O +
27.91 O -
% O -
) O -
, O +
designing O +
and O +
employing O +
the O +
network O +
performance O +
indicators O +
( O -
Table O +
2 O -
, O +
item O +
3 O -
: O +
21.23 O -
% O -
) O -
, O +
and O +
establishing O +
communication O +
models O +
and O +
channels O +
( O -
Table O +
2 O -
, O +
item O +
12 O -
: O +
19.94 O -
% O -
) O +
still O +
occupied O +
higher O +
percentages O +
not O +
developed O +
and O +
deserved O +
to O +
been O +
made O +
the O +
focus O +
of O +
more O +
efforts O +
in O +
the O +
future O -
. O +

Paired O +
t O -
- O -
test O +
analyses O +
for O +
all O +
individual O +
survey O +
items O +
of O +
governance O +
infrastructure O +
showed O +
that O +
the O +
deals O +
obeyed O +
( O -
Table O +
2 O -
, O +
item1 O -
) O +
and O +
plans O +
and O +
goals O +
controlled O +
( O -
Table O +
2 O -
, O +
item O +
2 O -
) O +
were O +
achieved O +
more O +
in O +
clinic O -
- O -
clinic O +
relationships O +
than O +
those O +
in O +
clinic O -
- O -
hospital O +
relationships O -
; O +
however O -
, O +
the O +
design O +
of O +
network O +
performance O +
indicators O +
( O -
Table O +
2 O -
, O +
item O +
3 O -
) O -
, O +
development O +
of O +
disintegration O +
policy O +
and O +
principals O +
( O -
Table O +
2 O -
, O +
item O +
8) O -
, O +
and O +
the O +
establishment O +
of O +
fair O +
coordination O +
mechanism O +
( O -
Table O +
2 O -
, O +
item O +
11 O -
) O +
were O +
reached O +
more O +
in O +
clinic O -
- O -
hospital O +
relationships O +
than O +
those O +
in O +
clinic O -
- O -
clinic O +
relationships O -
. O +

Profiling O +
the O +
partnerships O +
in O +
Taiwan O +
PCCNs O -
: O +
clinical O +
infrastructure O +
Examining O +
the O +
extent O +
of O +
clinical O +
infrastructure O +
for O +
network O +
members O -
, O +
establishing O +
two O -
- O -
directed O +
patient O +
referral O +
systems O +
and O +
patient O +
referral O +
information O +
files O +
( O -
Table O +
3 O -
, O +
items O +
35 O +
& O +
37 O -
) O +
and O +
uniting O +
medical O +
continuing O +
education O +
and O +
on O -
- O -
job O +
education O +
( O -
Table O +
3 O -
, O +
item O +
34 O -
) O +
were O +
shown O +
at O +
a O +
highly O +
implemented O +
rate O +
in O +
clinic O -
- O -
clinic O +
( O -
more O +
than O +
70 O -
% O -
) O +
and O +
clinic O -
- O -
hospital O +
( O -
more O +
than O +
80 O -
% O -
) O +
relationships O -
. O +

On O +
the O +
other O +
hand O -
, O +
network O +
members O +
had O +
higher O +
percentages O +
( O -
more O +
than O +
40 O -
% O -
) O +
not O +
to O +
think O +
about O +
the O +
possible O +
integration O +
mechanisms O +
including O +
establishing O +
committees O +
to O +
deal O +
with O +
medical O +
malpractice O +
( O -
Table O +
3 O -
, O +
item O +
44 O -
) O -
, O +
planning O +
and O +
differentiating O +
clinical O +
market O +
areas O +
( O -
Table O +
3 O -
, O +
item O +
20 O -
) O -
, O +
and O +
designing O +
patient O -
- O -
centered O +
case O +
management O +
teams O +
( O -
Table O +
3 O -
, O +
item O +
22 O -
) O -
. O +

Overall O -
, O +
there O +
was O +
better O +
clinical O +
integration O +
involvement O +
for O +
all O +
the O +
described O +
items O +
in O +
clinic O -
- O -
hospital O +
relationships O +
than O +
those O +
in O +
clinic O -
- O -
clinic O +
relationships O +
within O +
a O +
network O +
in O +
this O +
study O +
( O -
see O +
Table O +
3 O -
, O +
paired O +
t O -
- O -
tests O -
, O +
p O +
< O +
0.05 O -
) O -
. O +

Profiling O +
the O +
partnerships O +
in O +
Taiwan O +
PCCNs O -
: O +
marketing O +
infrastructure O +
For O +
marketing O +
planning O -
, O +
the O +
clinics O +
had O +
better O +
integrated O +
marketing O +
activities O +
with O +
their O +
respective O +
hospitals O +
than O +
with O +
peer O +
clinic O +
members O +
within O +
PCCNs O +
for O +
all O +
studied O +
items O +
( O -
Table O +
4 O -
, O +
paired O +
t O -
- O -
test O -
, O +
p O +
< O +
0.05 O -
) O -
. O +

Examining O +
the O +
clinic O -
- O -
clinic O +
relationships O -
, O +
uniting O +
social O +
activities O +
( O -
Table O +
4 O -
, O +
item O +
53 O -
) O -
, O +
sharing O +
the O +
individual O +
facility O +
reports O +
for O +
updated O +
services O +
( O -
Table O +
4 O -
, O +
item O +
46 O -
) O -
, O +
public O +
promotion O +
( O -
Table O +
4 O -
, O +
item O +
54 O -
) O -
, O +
and O +
uniting O +
and O +
joining O +
the O +
facility O +
activities O +
( O -
Table O +
4 O -
, O +
item O +
51 O -
) O +
were O +
the O +
top O +
four O +
marketing O +
works O +
done O +
among O +
clinic O +
members O +
( O -
more O +
than O +
60 O -
% O +
implemented O +
rate O -
) O -
; O +
and O +
those O +
items O +
also O +
showed O +
a O +
higher O +
implemented O +
rate O +
( O -
more O +
than O +
70 O -
% O -
) O +
between O +
clinic O +
and O +
hospital O +
members O -
. O +

On O +
the O +
other O +
hand O -
, O +
facility O +
assets O +
such O +
as O +
reports O +
( O -
Table O +
4 O -
, O +
item O +
49 O -
) O -
, O +
and O +
professional O +
literatures O +
and O +
books O +
( O -
Table O +
4 O -
, O +
item O +
45 O -
) O +
were O +
not O +
well O -
- O -
shared O +
among O +
clinic O +
members O +
( O -
" O -
never O -
- O -
thinking O -
" O +
rate O -
: O +
42.13 O -
% O -
) O -
. O +

In O +
addition O -
, O +
uniting O +
the O +
network O +
publication O +
could O +
make O +
more O +
efforts O +
in O +
the O +
future O +
( O -
" O -
never O -
- O -
thinking O -
" O +
rate O +
in O +
item O +
50 O -
: O +
39.98 O -
% O -
) O -
. O +

The O +
room O +
for O +
clinic O -
- O -
hospital O +
partnership O +
to O +
think O +
about O +
acting O +
was O +
kind O +
of O +
different O +
from O +
those O +
in O +
the O +
clinic O -
- O -
clinic O +
relationship O -
. O +

In O +
addition O +
to O +
the O +
uniting O +
publication O +
that O +
can O +
be O +
encouraged O +
to O +
improve O +
the O +
clinic O -
- O -
hospital O +
relationship O +
( O -
Table O +
4 O -
, O +
item O +
50 O -
: O +
27.48 O -
% O -
) O -
, O +
cooperating O +
in O +
research O +
projects O +
( O -
Table O +
4 O -
, O +
item O +
52 O -
: O +
25.00 O -
% O -
) O +
and O +
identifying O +
and O +
differentiating O +
target O +
markets O +
( O -
Table O +
4 O -
, O +
item O +
57 O -
: O +
24.57 O -
% O -
) O +
had O +
still O +
more O +
opportunities O +
to O +
be O +
focused O +
on O +
in O +
the O +
future O -
. O +

Profiling O +
the O +
partnerships O +
in O +
Taiwan O +
PCCNs O -
: O +
financial O +
infrastructure O +
The O +
PCCN O +
members O +
were O +
found O +
to O +
have O +
a O +
lower O +
extent O +
of O +
financial O +
integration O +
as O +
evidenced O +
by O +
higher O +
percentage O +
of O +
' O -
' O -
never O +
thinking O -
' O -
' O +
scale O +
about O +
the O +
survey O +
items O +
on O +
almost O +
all O +
items O +
( O -
see O +
Table O +
5 O -
) O -
. O +

Slightly O +
more O +
integration O +
( O -
that O +
is O -
, O +
' O -
' O -
acting O -
' O -
' O +
rate O -
) O +
was O +
found O +
in O +
only O +
four O +
items O +
both O +
in O +
clinic O -
- O -
clinic O +
relationships O +
and O +
in O +
clinic O -
- O -
hospital O +
relationships O -
, O +
including O +
uniting O +
budget O +
planning O +
( O -
Table O +
5 O -
: O +
item O +
58 O -
) O -
, O +
sharing O +
places O -
, O +
materials O -
, O +
and O +
equipment O +
( O -
Table O +
5 O -
: O +
item O +
68 O -
) O -
, O +
uniting O +
budgeting O +
for O +
certain O +
services O +
( O -
Table O +
5 O -
: O +
items O +
72 O -
) O -
, O +
and O +
designing O +
the O +
resource O +
distribution O +
principals O +
based O +
on O +
the O +
whole O +
network O +
goals O +
( O -
Table O +
5 O -
: O +
item O +
77 O -
) O -
. O +

Further O +
examining O +
the O +
financial O +
infrastructure O +
in O +
clinic O -
- O -
clinic O +
relationship O +
and O +
clinic O -
- O -
hospital O +
relationship O -
, O +
paired O -
- O -
t O +
tests O +
revealed O +
that O +
clinic O -
- O -
hospital O +
partnerships O +
were O +
involved O +
more O +
in O +
places O -
, O +
materials O -
, O +
and O +
equipment O +
sharing O +
and O +
maintenance O +
( O -
Table O +
5 O -
, O +
items O +
62 O +
and O +
68 O -
) O +
( O -
p O +
< O +
0.05 O -
) O +
and O +
higher O +
financial O +
infrastructure O +
coordination O +
exists O +
in O +
clinic O -
- O -
clinic O +
relationships O +
( O -
Table O +
5 O -
, O +
items O +
58 O -
, O +
59 O -
, O +
63–65 O -
, O +
72 O -
, O +
74 O -
, O +
75 O -
, O +
and O +
77 O -
) O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Profiling O +
the O +
partnerships O +
in O +
Taiwan O +
PCCNs O -
: O +
information O +
infrastructure O +
There O +
was O +
significantly O +
greater O +
integration O +
of O +
information O +
in O +
clinic O -
- O -
hospital O +
than O +
clinic O -
- O -
clinic O +
relationships O +
in O +
all O +
items O +
in O +
this O +
category O +
( O -
Table O +
6 O -
, O +
paired O +
t O -
- O -
tests O -
, O +
p O +
< O +
0.001 O -
) O -
. O +

The O +
greatest O +
integration O +
was O +
found O +
in O +
electronic O +
patient O +
records O +
( O -
Table O +
6 O -
: O +
item O +
78 O -
) O -
, O +
followed O +
by O +
information O +
integration O +
for O +
patient O +
data O +
( O -
Table O +
6 O -
: O +
item O +
79 O -
) O +
and O +
clinical O +
service O +
arrangements O +
( O -
Table O +
6 O -
: O +
item O +
81 O -
) O -
. O +

The O +
lowest O +
level O +
of O +
integration O +
in O +
information O +
infrastructure O +
was O +
found O +
in O +
administrative O +
works O +
such O +
as O +
registration O -
, O +
billing O +
and O +
so O +
on O +
( O -
Table O +
6 O -
: O +
item O +
82 O -
, O +
' O -
' O -
never O -
- O -
thinking O -
' O -
' O +
rate O +
more O +
than O +
50 O -
% O -
) O +
within O +
network O +
members O -
. O +

Discussion O +
In O +
this O +
study O -
, O +
we O +
surveyed O +
943 O +
clinics O +
that O +
had O +
belonged O +
to O +
Taiwan O +
PCCNs O +
for O +
more O +
than O +
a O +
year O +
to O +
understand O +
the O +
nature O +
and O +
extent O +
of O +
integration O +
to O +
which O +
they O +
and O +
their O +
associated O +
PCCN O +
members O +
( O -
clinics O +
and O +
hospitals O -
) O +
had O +
in O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
financial O -
, O +
and O +
information O +
infrastructures O -
. O +

It O +
was O +
found O +
a O +
wide O +
variance O +
in O +
the O +
kind O +
and O +
degree O +
of O +
integration O +
among O +
them O +
and O +
a O +
lot O +
of O +
room O +
for O +
better O +
integration O +
( O -
Table O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
, O +
6 O -
) O -
. O +

From O +
the O +
governance O +
perspective O -
, O +
we O +
found O +
lower O +
integration O +
was O +
found O +
in O +
the O +
establishment O +
of O +
fair O +
coordination O +
mechanism O +
( O -
Table O +
2 O -
: O +
item O +
11 O -
) O +
among O +
member O +
clinics O +
and O +
member O +
hospitals O -
. O +

Coordination O +
could O +
be O +
viewed O +
from O +
different O +
perspectives O -
, O +
including O +
the O +
use O +
of O +
standardized O +
languages O +
and O +
forms O -
, O +
organizational O +
rules O +
and O +
procedures O -
, O +
the O +
establishment O +
of O +
common O +
rules O -
, O +
policies O -
, O +
and O +
procedures O -
, O +
and O +
the O +
monitoring O +
through O +
memos O -
, O +
reports O -
, O +
and O +
a O +
computerized O +
information O +
system O +
[ O -
69,70 O -
] O -
. O +

Facing O +
the O +
cumbersome O +
integration O +
processes O -
, O +
it O +
suggests O +
that O +
each O +
PCCN O -
's O +
headquarters O +
should O +
become O +
actively O +
involved O +
and O +
clarify O +
the O +
authority O -
, O +
responsibility O +
and O +
accountability O +
of O +
individual O +
members O -
, O +
identify O +
the O +
potential O +
conflict O +
sources O -
, O +
and O +
publicize O +
the O +
rules O +
and O +
regulation O +
of O +
network O +
integration O +
dynamics O +
covering O +
decision O +
making O +
processes O -
, O +
market O +
planning O -
, O +
clinical O +
teamwork O +
designs O -
, O +
and O +
financial O +
reports O +
of O +
individual O +
network O +
members O -
. O +

These O +
actions O +
could O +
enhance O +
the O +
trust O +
and O +
respect O +
of O +
network O +
members O +
one O +
another O +
and O +
could O +
improve O +
the O +
small O +
extent O +
of O +
integration O +
found O +
in O +
this O +
study O +
about O +
the O +
mechanisms O +
for O +
communication O +
models O +
and O +
channels O +
in O +
the O +
PCCNs O +
( O -
Table O +
2 O -
: O +
item O +
12 O -
) O -
. O +

From O +
the O +
network O +
management O +
perspective O -
, O +
communication O +
could O +
occur O +
between O +
the O +
various O +
entities O +
such O +
as O +
between O +
hospital O +
and O +
clinics O -
, O +
primary O +
care O +
physicians O +
and O +
specialists O -
, O +
managers O +
and O +
clinical O +
professionals O -
, O +
and O +
even O +
among O +
the O +
clinical O +
professionals O +
in O +
the O +
network O -
. O +

To O +
develop O +
effective O +
and O +
timely O +
communication O +
channels O +
was O +
the O +
key O +
for O +
the O +
management O +
of O +
integrated O +
organizations O +
[ O -
30 O -
- O -
32 O -
] O +
and O +
could O +
alleviate O +
the O +
tensions O +
that O +
sometimes O +
occur O +
in O +
the O +
dynamics O +
of O +
the O +
multi O -
- O -
organizations O -
. O +

In O +
this O +
study O -
, O +
it O +
was O +
found O +
a O +
low O +
level O +
of O +
involvement O +
of O +
medical O +
teams O +
in O +
medical O +
projects O -
, O +
patient O -
- O -
centered O +
case O +
management O -
, O +
and O +
case O +
report O +
meetings O +
among O +
the O +
network O +
members O +
( O -
Table O +
3 O -
: O +
item O +
21 O -
, O +
22 O -
, O +
and O +
23 O -
) O +
from O +
a O +
clinical O +
integration O +
perspective O -
. O +

Several O +
researchers O +
have O +
addressed O +
that O +
clinical O +
integration O +
providing O +
a O +
process O +
of O +
medical O +
management O -
, O +
care O +
management O -
, O +
case O +
management O -
, O +
and O +
patient O +
management O +
designed O +
to O +
transform O +
the O +
traditionally O +
fragmented O +
delivery O +
system O +
into O +
a O +
more O +
cohesive O +
system O +
[ O -
71 O -
] O -
, O +
and O +
lead O +
to O +
higher O +
service O +
quality O +
and O +
assure O +
financial O +
objectives O +
[ O -
72,73 O -
] O -
. O +

More O +
attention O +
could O +
be O +
paid O +
to O +
these O +
activities O +
in O +
the O +
future O -
. O +

In O +
addition O -
, O +
it O +
was O +
also O +
found O +
less O +
integration O +
in O +
planning O +
and O +
differentiating O +
clinical O +
market O +
areas O +
( O -
Table O +
3 O -
, O +
item O +
20 O -
) O +
among O +
the O +
network O +
members O +
in O +
the O +
category O +
of O +
clinical O +
infrastructure O -
. O +

This O +
may O +
result O +
from O +
the O +
existing O +
specialty O +
diversities O +
in O +
individual O +
PCCNs O -
, O +
which O +
might O +
not O +
need O +
to O +
involve O +
planning O +
and O +
differentiating O +
market O +
area O +
based O +
on O +
the O +
members O -
' O +
clinical O +
services O +
at O +
the O +
early O +
stage O +
of O +
network O +
development O -
. O +

There O +
was O +
more O +
involvement O +
in O +
marketing O +
efforts O +
in O +
clinic O -
- O -
hospital O +
relationships O +
than O +
in O +
clinic O -
- O -
clinic O +
relationships O -
. O +

Generally O +
speaking O -
, O +
hospitals O +
have O +
more O +
resources O +
( O -
i.e. O -
, O +
money O -
, O +
human B-Species +
resources O -
, O +
materials O -
, O +
and O +
physical O +
assets O -
) O +
than O +
clinics O -
, O +
which O +
might O +
explain O +
the O +
stronger O +
marketing O +
involvements O +
between O +
the O +
clinic O +
and O +
hospital O +
members O -
, O +
including O +
the O +
library O +
sharing O +
( O -
books O +
and O +
literatures O -
) O -
, O +
facility O +
brochure O +
dissemination O -
, O +
public O +
promoting O -
, O +
and O +
medical O +
research O +
cooperation O -
. O +

These O +
integration O +
efforts O +
also O +
meet O +
the O +
expectation O +
of O +
the O +
national O +
health O +
authority O +
for O +
resource O +
sharing O +
and O +
medical O +
quality O +
image O +
enhancement O +
among O +
the O +
health O +
care O +
providers O -
. O +

Financial O +
infrastructure O +
was O +
found O +
to O +
be O +
the O +
least O +
integrated O -
, O +
with O +
most O +
items O +
never O +
considered O -
. O +

Perhaps O +
the O +
only O +
reason O +
for O +
the O +
higher O +
score O +
of O +
budget O +
planning O +
activities O +
( O -
Table O +
5 O -
: O +
items O +
58 O +
and O +
77 O -
) O +
was O +
that O +
BHNI O +
required O +
each O +
PCCN O +
to O +
design O +
and O +
determine O +
its O +
budgeting O +
arrangement O +
in O +
advance O +
before O +
joining O +
the O +
demonstration O +
project O -
. O +

While O +
slightly O +
more O +
financial O +
involvement O +
was O +
made O +
among O +
network O +
members O +
( O -
Table O +
5 O -
: O +
items O +
68 O -
, O +
72 O +
& O +
73 O -
) O -
, O +
possibly O +
due O +
to O +
similar O +
needs O -
, O +
there O +
remains O +
a O +
lot O +
of O +
room O +
for O +
financial O +
integration O +
in O +
the O +
future O -
. O +

There O +
was O +
a O +
need O +
for O +
networks O +
to O +
develop O +
electronic O +
information O +
systems O -
, O +
though O +
creating O +
and O +
managing O +
an O +
integrated O +
information O +
system O +
involves O +
very O +
detailed O +
work O -
. O +

Most O +
of O +
the O +
clinics O +
surveyed O +
have O +
focused O +
more O +
on O +
the O +
individual O +
public O +
members O -
' O +
administrative O +
works O +
such O +
as O +
filing O +
patient O +
medical O +
records O -
, O +
collecting O +
and O +
managing O +
network O +
patient O +
clinical O +
data O -
, O +
and O +
scheduling O +
clinical O +
services O -
, O +
which O +
were O +
required O +
by O +
the O +
BNHI O -
. O +

The O +
factors O +
for O +
the O +
health O +
care O +
managers O +
to O +
adopt O +
the O +
integrated O +
clinical O +
information O +
systems O +
include O +
the O +
decision O +
of O +
make O +
or O +
buy O -
, O +
adoption O +
leadership O -
, O +
adoption O +
objectives O -
, O +
implementation O +
leadership O -
, O +
phased O +
versus O +
simultaneous O +
implementation O -
, O +
parallel O +
systems O -
, O +
information O +
technology O +
implementation O +
policies O +
and O +
practices O -
, O +
use O +
levels O +
and O +
resistance O -
, O +
and O +
realized O +
benefits O +
and O +
return O +
on O +
investment O +
calculation O +
[ O -
66 O -
] O -
, O +
which O +
might O +
be O +
very O +
cumbersome O +
and O +
time O -
- O -
consuming O -
. O +

It O +
suggests O +
that O +
the O +
network O +
partners O +
might O +
be O +
engaged O -
, O +
firstly O -
, O +
more O +
in O +
simpler O +
network O +
cooperation O +
such O +
as O +
the O +
administrative O +
systems O +
for O +
patient O +
admission O +
to O +
the O +
network O +
members O +
and O +
establishing O +
united O +
web O +
pages O +
for O +
patients O +
to O +
access O +
their O +
family O +
physicians O +
and O +
network O +
members O +
for O +
medical O +
and O +
public O +
promotion O +
purposes O -
. O +

And O +
for O +
further O +
integrated O +
information O +
investments O -
, O +
efforts O +
must O +
be O +
redirected O +
for O +
network O +
members O +
to O +
work O +
together O +
to O +
define O +
the O +
approach O +
to O +
specific O +
classes O +
of O +
integration O +
for O +
the O +
long O +
term O +
[ O -
74 O -
] O -
. O +

Conclusion O +
This O +
study O +
tried O +
to O +
portray O +
and O +
trace O +
how O +
the O +
facility O +
participants O +
were O +
involved O +
in O +
the O +
Taiwan O +
PCCNs O -
. O +

It O +
was O +
found O +
that O +
Taiwan O +
PCCNs O -
' O +
members O +
had O +
higher O +
involvement O +
in O +
the O +
governance O +
infrastructure O -
, O +
which O +
was O +
usually O +
viewed O +
as O +
the O +
most O +
important O +
for O +
establishment O +
of O +
core O +
values O +
in O +
PCCNs O -
' O +
organization O +
design O +
and O +
management O -
. O +

There O +
existed O +
a O +
higher O +
extent O +
of O +
integration O +
of O +
clinical O -
, O +
marketing O -
, O +
and O +
information O +
infrastructures O +
among O +
the O +
hospital O -
- O -
clinic O +
member O +
relationship O +
than O +
those O +
among O +
clinic O +
members O +
within O +
individual O +
PCCNs O -
. O +

The O +
financial O +
infrastructure O +
was O +
shown O +
the O +
least O +
integrated O +
relative O +
to O +
other O +
functional O +
infrastructures O +
at O +
the O +
early O +
stage O +
of O +
PCCN O +
formation O -
. O +

Page O +
[ O -
43 O -
] O +
argued O +
that O +
networks O +
form O +
and O +
grow O +
for O +
various O +
reasons O -
, O +
however O -
, O +
only O +
some O +
of O +
them O +
could O +
be O +
compatible O +
with O +
the O +
iterative O +
processes O +
of O +
collaboration O -
. O +

Some O +
participants O +
in O +
the O +
PCCNs O +
may O +
simply O +
seek O +
short O -
- O -
term O +
economic O +
gains O +
and O +
have O +
little O +
interest O +
in O +
joint O +
learning O +
and O +
continuous O +
improvement O -
. O +

From O +
an O +
organizational O +
design O +
perspective O -
, O +
the O +
old O +
phrase O +
proposed O +
by O +
the O +
wisdom O +
of O +
the O +
saying O +
about O +
developing O +
the O +
integrated O +
organizations O +
( O -
networks O -
) O +
should O +
be O +
– O +
" O -
coming O +
together O +
is O +
the O +
beginning O -
, O +
and O +
working O +
together O +
is O +
the O +
success O -
. O -
" O +

Page O +
[ O -
43 O -
] O +
examined O +
the O +
virtual O +
provider O +
organizations O +
such O +
as O +
physician O -
- O -
hospital O +
organizations O +
and O +
pointed O +
out O +
the O +
issue O +
of O +
the O +
provider O +
attitudes O +
and O +
behaviors O +
as O +
the O +
critically O +
successful O +
continuous O +
improvements O +
in O +
the O +
health O +
care O +
environments O -
. O +

A O +
wide O +
variance O +
of O +
degree O +
of O +
network O +
integration O +
in O +
Taiwan O +
PCCNs O +
still O +
leaves O +
room O +
to O +
improve O -
. O +

In O +
this O +
study O -
, O +
the O +
thoroughly O +
surveyed O +
items O -
, O +
that O +
is O -
, O +
the O +
potential O +
network O +
design O +
content O -
, O +
were O +
employed O -
. O +

In O +
addition O +
to O +
provide O +
how O +
the O +
network O +
members O +
have O +
done O +
their O +
initial O +
work O +
at O +
the O +
early O +
stage O +
of O +
network O +
forming O +
in O +
this O +
study O -
, O +
the O +
detailed O +
surveyed O +
items O -
, O +
the O +
concepts O +
proposed O +
by O +
the O +
managerial O +
and O +
theoretical O +
professionals O -
, O +
could O +
be O +
also O +
a O +
guide O +
for O +
those O +
health O +
care O +
providers O +
who O +
have O +
a O +
willingness O +
to O +
join O +
multi O -
- O -
organizations O -
. O +

It O +
suggests O +
that O +
health O +
care O +
providers O +
could O +
take O +
more O +
detailed O +
looks O +
about O +
those O +
surveyed O +
items O +
and O +
give O +
some O +
possible O +
opportunities O +
to O +
create O +
the O +
potential O +
actions O -
. O +

Further O +
research O +
could O +
be O +
empirically O +
done O +
to O +
explore O +
the O +
relative O +
influence O +
of O +
these O +
integration O +
mechanisms O +
on O +
the O +
effectiveness O +
of O +
organizational O +
partnerships O -
. O +

The O +
partnerships O +
within O +
each O +
PCCN O +
represent O +
various O +
relationships O +
that O +
depend O +
on O +
how O +
much O +
the O +
members O +
are O +
engaged O +
in O +
the O +
projects O -
. O +

In O +
addition O +
to O +
the O +
macro O +
concepts O +
including O +
governance O -
, O +
clinical O -
, O +
marketing O -
, O +
financial O -
, O +
and O +
information O +
infrastructures O +
explored O +
in O +
this O +
study O -
, O +
other O +
managerial O +
issues O +
for O +
integrated O +
organizations O +
were O +
also O +
suggested O +
such O +
as O +
formation O +
of O +
an O +
integrated O +
cultural O +
atmosphere O -
, O +
human B-Species +
resources O +
management O -
, O +
physician O +
involvement O -
, O +
mission O +
and O +
commitment O +
establishment O -
, O +
from O +
micro O +
organizational O +
behavior O +
perspective O +
[ O -
30 O -
- O -
32,34,36,75,76 O -
] O -
. O +

Micro O +
managerial O +
and O +
longitudinal O +
research O +
designs O +
could O +
be O +
employed O +
to O +
more O +
precisely O +
catch O +
the O +
never O +
completing O +
integration O +
efforts O +
in O +
the O +
future O -
. O +

Abbreviations O +
primary O +
community O +
care O +
network O +
( O -
PCCN O -
) O -
; O +
Bureau O +
of O +
National O +
Health O +
Insurance O +
( O -
BNHI O -
) O +
Competing O +
interests O +
The O +
author O -
( O -
s O -
) O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O -
. O +

Authors O -
' O +
contributions O +
BYJL O +
independently O +
designed O +
and O +
conducted O +
this O +
study O -
. O +

Pre O -
- O -
publication O +
history O +
The O +
pre O -
- O -
publication O +
history O +
for O +
this O +
paper O +
can O +
be O +
accessed O +
here O -
: O +

Recombinant O +
activated O +
protein O +
C O +
in O +
sepsis O -
: O +
endothelium O +
protection O +
or O +
endothelium O +
therapy O -
? O +

Abstract O +
Endothelium O +
dysfunction O +
is O +
one O +
of O +
the O +
hallmarks O +
of O +
sepsis O -
. O +

Looney O +
and O +
Mattay O -
, O +
in O +
the O +
previous O +
issue O +
of O +
Critical O +
Care O -
, O +
highlight O +
the O +
role O +
of O +
activated O +
protein O +
C O +
( O -
APC O -
) O +
as O +
a O +
protective O +
endothelial O +
drug O +
in O +
septic O +
situations O -
. O +

Nevertheless O -
, O +
the O +
results O +
of O +
in O +
vivo O +
studies O +
are O +
less O +
explicit O +
and O +
it O +
remains O +
uncertain O +
whether O +
these O +
properties O +
are O +
relevant O +
in O +
human B-Species +
septic O +
shock O -
. O +

Before O +
considering O +
recombinant O +
APC O +
( O -
rAPC O -
) O +
as O +
a O +
therapeutic O +
drug O +
for O +
the O +
endothelium O -
, O +
we O +
have O +
to O +
demonstrate O +
its O +
efficiency O +
to O +
protect O +
or O +
to O +
reduce O +
endothelium O +
injury O +
when O +
infused O +
a O +
long O +
time O +
after O +
the O +
septic O +
challenge O -
. O +

Nevertheless O -
, O +
if O +
rAPC O +
is O +
efficient O +
when O +
infused O +
in O +
the O +
early O +
phase O +
of O +
septic O +
challenge O -
, O +
we O +
thus O +
need O +
to O +
treat O +
our O +
patients O +
earlier O -
. O +

At O +
the O +
least O -
, O +
genetically O +
engineered O +
variants O +
have O +
been O +
designed O +
with O +
greater O +
anti O -
- O -
apoptotic O +
activity O +
and O +
reduced O +
anticoagulant O +
activity O +
relative O +
to O +
wild O -
- O -
type O +
APC O -
. O +

Further O +
studies O +
are O +
needed O +
to O +
demonstrate O +
the O +
usefulness O +
of O +
these O +
variants O +
in O +
septic O +
shock O +
therapy O -
. O +

The O +
use O +
of O +
recombinant O +
activated O +
protein O +
C O +
( O -
rAPC O -
) O +
is O +
one O +
of O +
the O +
hottest O +
topics O +
in O +
septic O +
shock O +
therapy O -
. O +

The O +
pivotal O +
phase O +
3 O +
placebo O -
- O -
controlled O +
Protein O +
C O +
Worldwide O +
Evaluation O +
in O +
Severe O +
Sepsis O +
( O -
PROWESS O -
) O +
clinical O +
trial O +
demonstrated O +
a O +
19.4 O -
% O +
relative O +
risk O +
reduction O +
in O +
28-day O +
mortality O +
( O -
6.1 O -
% O +
absolute O +
risk O +
reduction O -
) O +
with O +
an O +
increased O +
risk O +
( O -
3.5 O -
% O +
versus O +
2.0 O -
% O -
) O +
of O +
serious O +
bleeding O +
events O +
compared O +
with O +
placebo O -
. O +

Two O +
recent O +
and O +
important O +
articles O +
have O +
highlighted O +
the O +
role O +
of O +
APC O +
as O +
a O +
protective O +
endothelial O +
drug O +
[ O -
1 O -
] O +
and O +
as O +
a O +
cyto O -
- O -
protective O +
drug O +
[ O -
2 O -
] O -
. O +

Beneficial O +
effects O +
of O +
rAPC O +
in O +
the O +
PROWESS O +
study O +
were O +
thought O +
to O +
be O +
related O +
to O +
a O +
reduction O +
in O +
coagulation O +
and O -
, O +
to O +
a O +
lesser O +
extent O -
, O +
to O +
a O +
reduction O +
in O +
inflammatory O +
response O +
to O +
sepsis O +
[ O -
3 O -
] O -
. O +

Post O -
- O -
PROWESS O +
investigations O +
have O +
been O +
associated O +
with O +
a O +
myriad O +
of O +
cellular O +
or O +
animal O +
studies O +
demonstrating O +
that O +
rAPC O -
, O +
through O +
reactions O +
mediated O +
by O +
endothelial O +
protein O +
C O +
receptor O +
and O +
the O +
effector O +
receptor O -
, O +
protease O +
activated O +
receptor-1 O -
, O +
acts O +
directly O +
on O +
cells O +
to O +
exert O +
multiple O +
cytoprotective O +
effects O +
including O -
: O +
down O +
regulation O +
of O +
pro O -
- O -
inflammatory O +
gene O +
expression O +
[ O -
4 O -
] O -
; O +
anti O -
- O -
inflammatory O +
activities O +
[ O -
5 O -
] O -
; O +
anti O -
- O -
apoptotic O +
activity O +
[ O -
6 O -
] O -
; O +
and O +
protection O +
of O +
endothelial O +
barrier O +
function O +
[ O -
1,2 O -
] O -
. O +

Endothelium O +
dysfunction O +
is O +
one O +
of O +
the O +
hallmarks O +
of O +
sepsis O +
[ O -
7 O -
] O -
. O +

Sepsis O -
, O +
per O +
se O -
, O +
may O +
induce O +
phenotypic O +
modulations O +
of O +
the O +
endothelium O +
through O +
direct O +
or O +
indirect O +
interaction O +
of O +
the O +
endothelial O +
layer O +
with O +
components O +
of O +
the O +
bacterial O +
wall O -
, O +
inducing O +
a O +
myriad O +
of O +
host O -
- O -
derived O +
factors O +
from O +
endothelial O +
cells O -
. O +

Phenotypic O +
modifications O +
include O +
changes O +
in O +
pro O -
- O -
coagulant O +
and O +
proadhesive O +
properties O -
, O +
increased O +
endothelial O +
permeability O -
, O +
endothelial O +
cell O +
apoptosis O +
and O +
changes O +
in O +
vasomotor O +
properties O -
; O +
the O +
last O +
of O +
these O +
is O +
crucial O +
since O +
vasoplegia O +
is O +
directly O +
related O +
to O +
septic O +
shock O +
mortality O -
. O +

Recent O +
animal O +
and O +
human B-Species +
data O +
have O +
suggested O +
that O +
rAPC O +
may O +
improve O +
both O +
vascular O +
and O +
myocardial O +
dysfunction O +
and O +
vascular O +
reactivity O +
to O +
catecholamine O +
during O +
endotoxin O +
and/or O +
septic O +
challenge O +
[ O -
8,9 O -
] O -
. O +

From O +
bench O +
to O +
bedside O +
Experimental O +
evidence O +
supports O +
a O +
role O +
of O +
APC O +
in O +
maintaining O +
the O +
integrity O +
of O +
the O +
endothelium O +
through O +
both O +
direct O +
and O +
indirect O +
mechanisms O -
. O +

Nevertheless O -
, O +
the O +
results O +
of O +
in O +
vivo O +
studies O +
are O +
less O +
explicit O -
. O +

In O +
a O +
retrospective O +
study O +
of O +
septic O +
shock O +
in O +
humans B-Species -
, O +
Monnet O +
and O +
colleagues O +
[ O -
9 O -
] O +
demonstrated O +
that O +
APC O +
infusion O +
was O +
associated O +
with O +
a O +
decrease O +
in O +
the O +
amount O +
of O +
delivered O +
norepinephrine O -
. O +

Wiel O +
and O +
colleagues O +
[ O -
10 O -
] O +
demonstrated O +
in O +
a O +
rabbit B-Species +
model O +
of O +
endotoxin O +
induced O +
shock O +
that O +
APC O +
decreased O +
aorta O +
endothelial O +
injury O -
. O +

By O +
contrast O -
, O +
in O +
a O +
lung O +
model O +
of O +
endotoxin O +
induced O +
inflammation O -
, O +
Robriquet O +
and O +
colleagues O +
[ O -
11 O -
] O +
demonstrated O +
a O +
trend O +
to O +
an O +
increased O +
vascular O +
permeability O +
using O +
high O +
doses O +
of O +
human B-Species +
APC O -
. O +

This O +
last O +
result O +
was O +
in O +
sharp O +
contrast O +
with O +
the O +
results O +
obtained O +
by O +
Nick O +
and O +
colleagues O +
[ O -
12 O -
] O +
in O +
a O +
human B-Species +
model O +
of O +
pulmonary O +
endotoxin O +
administration O -
. O +

APC O +
appears O +
to O +
improve O +
mortality O +
in O +
septic O +
shock O +
with O +
a O +
high O +
APACHE O +
2 O +
score O +
and O +
is O +
potentially O +
detrimental O +
in O +
severe O +
sepsis O -
. O +

In O +
rats O -
, O +
APC O +
markedly O +
decreased O +
tumour O +
necrosis O +
factor O +
concentrations O +
whereas O +
they O +
remained O +
unchanged O +
in O +
either O +
human B-Species +
septic O +
shock O +
or O +
endotoxemia O -
. O +

The O +
question O +
arises O -
, O +
therefore O -
, O +
as O +
to O +
whether O +
it O +
is O +
truly O +
possible O +
to O +
reconcile O +
all O +
these O +
discrepancies O -
? O +

Moreover O -
, O +
can O +
these O +
stirring O +
laboratory O +
data O +
be O +
translated O +
into O +
clinical O +
practice O -
? O +

Limitations O +
of O +
experimental O +
studies O -
: O +
endothelium O +
protection O +
versus O +
endothelium O +
therapy O +
Clearly O -
, O +
in O +
cellular O +
and O +
animal O +
models O -
, O +
rAPC O +
has O +
been O +
given O +
either O +
as O +
a O +
pre O -
- O -
treatment O +
or O +
concurrent O +
with O +
septic O +
challenge O -
. O +

This O +
mode O +
of O +
administration O +
favours O +
the O +
anti O -
- O -
inflammatory O +
effects O +
of O +
rAPC O -
, O +
which O +
are O +
particularly O +
efficient O +
in O +
murine O +
models O +
in O +
protecting O +
the O +
endothelium O +
from O +
cytokine O -
- O -
mediated O +
apoptosis O +
or O +
upregulation O +
of O +
endothelial O +
adhesion O +
molecules O -
. O +

Thus O -
, O +
studies O +
using O +
post O -
- O -
injury O +
treatment O +
are O +
needed O +
in O +
models O +
that O +
mimic O +
septic O +
shock O -
, O +
such O +
as O +
experimental O +
pneumonia O +
or O +
peritonitis O +
treated O +
by O +
antibiotics O +
and O +
volume O +
resuscitation O -
, O +
and O +
where O +
the O +
effects O +
of O +
rAPC O +
would O +
be O +
investigated O +
16 O +
to O +
24 O +
hours O +
after O +
septic O +
challenge O -
. O +

If O +
we O +
can O +
demonstrate O +
the O +
efficiency O +
of O +
rAPC O +
to O +
protect O +
or O +
to O +
reduce O +
endothelium O +
injury O +
in O +
these O +
conditions O -
, O +
we O +
can O +
ultimately O +
postulate O +
that O +
rAPC O +
is O +
also O +
a O +
therapeutic O +
drug O +
for O +
the O +
endothelium O -
. O +

The O +
earlier O +
the O +
better O +
If O +
rAPC O +
is O +
efficient O +
when O +
infused O +
in O +
the O +
early O +
phase O +
of O +
septic O +
challenge O -
, O +
we O +
thus O +
need O +
to O +
treat O +
our O +
patients O +
earlier O -
. O +

At O +
least O +
two O +
studies O +
suggest O +
that O +
treatment O +
with O +
rAPC O +
within O +
24 O +
hours O +
may O +
carry O +
a O +
larger O +
survival O +
advantage O +
for O +
patients O +
with O +
severe O +
sepsis O -
, O +
compared O +
with O +
those O +
treated O +
more O +
than O +
24 O +
hours O +
after O +
organ O +
dysfunction O +
[ O -
13 O -
] O -
. O +

Interventions O +
directed O +
at O +
specific O +
endpoints O -
, O +
when O +
initiated O +
early O +
in O +
the O +
' O -
golden O +
hours O -
' O +
of O +
a O +
patient O -
's O +
condition O -
, O +
seem O +
to O +
be O +
promising O +
[ O -
14 O -
] O -
. O +

The O +
beneficial O +
effects O +
of O +
earlier O +
administration O +
of O +
rAPC O +
to O +
appropriate O +
patients O +
may O +
fit O +
into O +
this O +
paradigm O -
. O +

The O +
future O +
Extensive O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
have O +
focused O +
on O +
the O +
cytoprotective O +
effects O +
of O +
APC O +
and O +
most O +
authors O +
agree O +
that O +
its O +
anticoagulant O +
and O +
cytoprotective O +
effects O +
are O +
mediated O +
by O +
distinct O +
APC O +
structural O +
features O -
. O +

Positively O +
charged O +
residues O +
in O +
surface O +
loops O +
in O +
the O +
APC O +
protease O +
domain O +
have O +
been O +
identified O +
as O +
participating O +
in O +
the O +
anticoagulant O +
activity O +
but O +
not O +
in O +
cellular O +
effects O -
. O +

Hence O -
, O +
variants O +
have O +
been O +
designed O +
with O +
greater O +
anti O -
- O -
apoptotic O +
activity O +
and O +
reduced O +
anticoagulant O +
activity O +
relative O +
to O +
wild O -
- O -
type O +
APC O +
[ O -
2 O -
] O -
. O +

Whether O +
these O +
genetically O +
engineered O +
variants O +
actually O +
provide O +
superior O +
pharmacological O +
properties O +
remains O +
to O +
be O +
elucidated O +
in O +
vivo O -
. O +

Such O +
investigations O +
may O +
allow O +
the O +
design O +
of O +
therapeutic O +
APC O +
variants O +
with O +
decreased O +
anticoagulant O +
activity O +
to O +
reduce O +
the O +
risk O +
of O +
bleeding O +
on O +
the O +
one O +
hand O -
, O +
but O +
also O +
with O +
normal O +
cytoprotective O +
properties O +
in O +
order O +
to O +
retain O +
full O +
beneficial O +
effects O +
on O +
sepsis O +
outcome O -
. O +

Abbreviations O +
PROWESS O +
= O +
Protein O +
C O +
Worldwide O +
Evaluation O +
in O +
Severe O +
Sepsis O -
; O +
rAPC O +
= O +
recombinant O +
activated O +
protein O +
C. O +
Competing O +
interests O +
BL O +
has O +
received O +
reimbursements O +
and O +
funding O +
from O +
Eli O +
Lilly O -
, O +
France O -
. O +

The O +
comparative O +
analysis O +
of O +
statistics O -
, O +
based O +
on O +
the O +
likelihood O +
ratio O +
criterion O -
, O +
in O +
the O +
automated O +
annotation O +
problem O +
Abstract O +
Background O +
This O +
paper O +
discusses O +
the O +
problem O +
of O +
automated O +
annotation O -
. O +

It O +
is O +
a O +
continuation O +
of O +
the O +
previous O +
work O +
on O +
the O +
A4-algorithm O +
( O -
Adaptive O +
algorithm O +
of O +
automated O +
annotation O -
) O +
developed O +
by O +
Leontovich O +
and O +
others O -
. O +

Results O +
A O +
number O +
of O +
new O +
statistics O +
for O +
the O +
automated O +
annotation O +
of O +
biological O +
sequences O +
is O +
introduced O -
. O +

All O +
these O +
statistics O +
are O +
based O +
on O +
the O +
likelihood O +
ratio O +
criterion O -
. O +

Conclusion O +
Some O +
of O +
the O +
statistics O +
yield O +
a O +
prediction O +
quality O +
that O +
is O +
significantly O +
higher O +
( O -
up O +
to O +
1.5 O +
times O +
higher O -
) O +
in O +
comparison O +
with O +
the O +
results O +
obtained O +
with O +
the O +
A4-procedure O -
. O +

Background O +
Many O +
biological O +
databanks O -
, O +
both O +
dealing O +
with O +
protein O +
sequences O +
( O -
e.g. O -
, O +
SWISS O -
- O -
PROT O -
) O +
and O +
nucleotide O +
sequences O +
( O -
e.g. O -
, O +
GeneBank O -
) O -
, O +
contain O +
not O +
only O +
primary O +
structures O +
of O +
sequences O +
( O -
i.e. O -
, O +
sequences O +
of O +
letters O +
– O +
amino O +
acids O +
or O +
nucleotides O -
) O -
, O +
but O +
also O +
information O +
about O +
functions O +
and O +
properties O +
of O +
these O +
sequences O -
. O +

This O +
information O +
is O +
stored O +
in O +
so O +
called O +
description O +
fields O +
of O +
the O +
sequences O -
. O +

There O +
exist O +
different O +
types O +
of O +
description O +
fields O +
– O +
KW O +
( O -
KeyWords O -
) O -
, O +
DE O +
( O -
Descriptions O -
) O -
, O +
... O -
, O +
FT O +
( O -
Feature O +
Table O -
) O -
, O +
... O -
; O +
elements O +
of O +
description O +
fields O +
are O +
referred O +
to O +
as O +
words O -
. O +

Words O +
from O +
KW O -
, O +
DE O -
, O +
... O +
fields O +
describe O +
a O +
sequence O +
as O +
a O +
whole O -
, O +
while O +
words O +
from O +
FT O +
fields O +
correspond O +
to O +
certain O +
positions O +
( O -
letters O -
) O +
of O +
a O +
sequence O -
. O +

The O +
automated O +
annotation O +
problem O +
can O +
be O +
described O +
as O +
follows O -
. O +

Consider O +
a O +
biological O +
sequence O +
( O -
referred O +
to O +
as O +
a O +
query O +
sequence O -
) O +
with O +
known O +
primary O +
structure O +
( O -
i.e. O +
letter O +
sequence O -
) O +
but O +
unknown O +
properties O +
and O +
functions O +
( O -
i.e. O -
, O +
description O +
fields O -
) O -
. O +

The O +
task O +
is O +
to O +
determine O +
functions O +
and O +
properties O +
of O +
this O +
sequence O +
( O -
in O +
other O +
words O -
, O +
to O +
restore O +
its O +
description O +
fields O -
) O +
on O +
the O +
basis O +
of O +
the O +
primary O +
structure O -
. O +

The O +
annotation O +
should O +
be O +
fully O +
automated O -
. O +

This O +
is O +
the O +
subject O +
of O +
the O +
current O +
paper O -
. O +

There O +
are O +
two O +
main O +
approaches O +
to O +
the O +
solution O +
of O +
this O +
problem O -
. O +

In O +
the O +
first O +
approach O +
( O -
it O +
can O +
be O +
called O +
a O +
static O +
one O -
) O +
a O +
certain O +
fixed O +
protein O +
classification O +
( O -
grouping O +
proteins O +
according O +
to O +
similarity O +
in O +
structure O +
and/or O +
functions O -
) O -
, O +
specified O +
beforehand O -
, O +
is O +
used O -
: O +
for O +
a O +
query O +
protein O +
the O +
search O +
of O +
a O +
relative O +
group O +
( O -
super O +
family O -
) O +
is O +
performed O +
on O +
the O +
basis O +
of O +
primary O +
structures O -
, O +
and O +
properties O -
/ O -
functions O +
of O +
this O +
group O +
are O +
extended O +
to O +
the O +
query O +
protein O -
. O +

An O +
example O +
of O +
this O +
approach O +
is O +
described O +
in O +
the O +
paper O +
by O +
W. O +
Fleischmann O +
et O +
al. O +
[ O -
1 O -
] O -
, O +
it O +
uses O +
the O +
protein O +
classification O +
( O -
more O +
than O +
1000 O +
families O -
) O -
, O +
stored O +
in O +
the O +
Prosite O +
databank O -
. O +

The O +
second O +
approach O +
( O -
it O +
can O +
be O +
called O +
a O +
dynamic O +
or O +
an O +
adaptive O +
one O -
) O +
does O +
not O +
use O +
protein O +
classification O -
. O +

Instead O -
, O +
a O +
" O -
dynamic O -
" O +
collection O +
of O +
bank O +
sequences O +
that O +
are O +
similar O +
to O +
a O +
query O +
sequence O +
is O +
generated O -
, O +
and O +
then O +
common O +
properties O -
/ O -
functions O +
of O +
these O +
bank O +
sequences O +
are O +
extended O +
to O +
the O +
query O +
sequence O -
. O +

One O +
of O +
the O +
first O +
examples O +
of O +
this O +
approach O +
was O +
described O +
by O +
M.A. O +
Andrade O +
et O +
al. O +
[ O -
2 O -
] O -
. O +

In O +
this O +
paper O +
the O +
prediction O +
was O +
based O +
on O +
so O +
called O +
word O +
reliability O +
function O +
– O +
a O +
function O +
depending O +
on O +
the O +
degree O +
of O +
similarity O +
between O +
a O +
query O +
sequence O +
and O +
corresponding O +
bank O +
sequences O -
. O +

In O +
other O +
examples O +
of O +
annotation O +
procedures O +
based O +
on O +
the O +
dynamic O +
approach O +
prediction O +
was O +
performed O +
in O +
a O +
" O -
naive O -
" O +
way O +
– O +
all O +
properties O -
/ O -
functions O +
of O +
similar O +
proteins O +
were O +
extended O +
to O +
a O +
query O +
protein O -
, O +
or O +
using O +
stochastic O +
methods O +
– O +
only O +
properties O -
/ O -
functions O +
that O +
are O +
most O +
frequent O +
for O +
the O +
collection O +
of O +
similar O +
proteins O +
were O +
extended O +
( O -
see O +
[ O -
3,4 O -
] O -
) O -
. O +

The O +
current O +
paper O +
uses O +
the O +
dynamic O +
approach O -
. O +

This O +
paper O +
is O +
a O +
sequel O +
to O +
paper O +
[ O -
5 O -
] O +
that O +
describes O +
the O +
A4 O +
algorithm O +
( O -
the O +
Adaptive O +
Algorithm O +
of O +
Automated O +
Annotation O -
) O -
, O +
so O +
results O +
of O +
the O +
paper O +
[ O -
5 O -
] O +
are O +
constantly O +
used O +
here O -
. O +

The O +
A4 O +
algorithm O +
is O +
based O +
on O +
a O +
stochastic O +
approach O -
. O +

More O +
precisely O -
, O +
it O +
is O +
based O +
on O +
the O +
notion O +
of O +
transfer O +
probabilities O -
. O +

Transfer O +
probabilities O +
are O +
the O +
probabilities O +
of O +
word O +
transfer O +
( O -
extension O -
) O +
from O +
description O +
fields O +
of O +
one O +
sequence O +
to O +
description O +
fields O +
of O +
another O +
sequence O -
; O +
they O +
depend O +
on O +
the O +
measure O +
of O +
similarity O +
between O +
sequences O -
. O +

Transfer O +
probabilities O +
are O +
evaluated O +
on O +
the O +
basis O +
of O +
word O +
transfer O +
frequencies O +
in O +
the O +
found O +
collection O +
of O +
sequences O +
similar O +
to O +
a O +
query O +
sequence O -
. O +

For O +
each O +
word O +
from O +
description O +
fields O +
of O +
sequences O +
included O +
in O +
the O +
collection O +
the O +
prediction O +
of O +
the O +
fact O +
that O +
this O +
word O +
belongs O +
( O -
or O +
does O +
not O +
belong O -
) O +
to O +
the O +
description O +
field O +
of O +
a O +
query O +
sequence O +
is O +
performed O -
; O +
this O +
prediction O +
is O +
based O +
on O +
transfer O +
probabilities O -
. O +

In O +
the O +
current O +
paper O +
we O +
introduce O +
and O +
analyze O +
a O +
number O +
of O +
new O +
statistics O +
for O +
the O +
prediction O -
. O +

All O +
of O +
them O +
are O +
based O +
on O +
the O +
likelihood O +
ratio O +
criterion O +
[ O -
6 O -
] O +
( O -
which O +
is O +
the O +
most O +
powerful O +
criterion O -
) O -
. O +

As O +
in O +
[ O -
5 O -
] O -
, O +
all O +
these O +
statistics O +
are O +
evaluated O +
using O +
transfer O +
probabilities O -
. O +

Two O +
approaches O +
to O +
statistics O +
definition O +
are O +
introduced O -
: O +
a O +
" O -
discrete O -
" O +
approach O +
and O +
a O +
" O -
continuous O -
" O +
approach O -
. O +

A O +
detailed O +
analysis O +
and O +
comparison O +
of O +
introduced O +
statistics O +
are O +
performed O +
and O +
the O +
best O +
statistics O +
are O +
selected O -
. O +

The O +
emphasis O +
is O +
on O +
a O +
precise O +
description O +
of O +
the O +
way O +
these O +
statistics O +
can O +
be O +
constructed O +
using O +
well O -
- O -
known O +
concepts O +
from O +
statistical O +
decision O +
theory O -
. O +

The O +
current O +
A4 O +
algorithm O +
uses O +
SPKW O +
as O +
a O +
language O +
of O +
annotation O -
. O +

Of O +
course O -
, O +
it O +
is O +
possible O +
to O +
use O +
GO O +
terms O +
in O +
A4 O +
as O +
well O -
. O +

That O +
would O +
facilitate O +
comparison O +
with O +
other O +
approaches O -
. O +

However O -
, O +
at O +
the O +
current O +
stage O +
of O +
our O +
research O +
we O +
test O +
and O +
choose O +
" O -
the O +
best O +
decision O +
making O +
algorithm O -
" O -
, O +
not O +
" O -
the O +
best O +
annotation O +
terminology O -
" O -
. O +

Obviously O -
, O +
which O +
annotation O +
is O +
used O +
hardly O +
matters O +
for O +
the O +
problem O +
of O +
finding O +
the O +
optimal O +
" O -
decision O +
making O +
algorithm O -
" O +
Results O +
Algorithm O +
description O +
Generation O +
of O +
a O +
collection O +
of O +
similar O +
sequences O +
First O -
, O +
we O +
introduce O +
some O +
notation O -
. O +

For O +
the O +
sake O +
of O +
brevity O +
we O +
write O +
" O -
a O +
word O +
ω O +
belongs O +
to O +
a O +
sequence O +
π O -
" O +
instead O +
of O +
" O -
a O +
word O +
ω O +
belongs O +
to O +
description O +
fields O +
of O +
a O +
sequence O +
π O -
" O -
. O +

If O +
ω O +
is O +
a O +
KW O -
- O -
type O +
word O +
( O -
to O +
be O +
definite O -
, O +
further O +
in O +
the O +
paper O +
we O +
consider O +
only O +
amino O -
- O -
acid O +
sequences O +
and O +
KW O -
- O -
type O +
words O -
) O -
, O +
we O +
write O +
ω O +
∈ O +
KW O -
[ O -
π O -
] O -
. O +

The O +
application O +
of O +
an O +
annotation O +
procedure O +
to O +
an O +
unannotated O +
amino O -
- O -
acid O +
query O +
sequence O +
( O -
i.e. O -
, O +
the O +
prediction O +
of O +
description O +
fields O -
) O +
starts O +
with O +
generating O +
a O +
collection O +
of O +
sequences O +
similar O +
to O +
this O +
query O +
sequence O +
with O +
known O +
description O +
fields O -
. O +

These O +
similar O +
sequences O +
are O +
selected O +
from O +
a O +
certain O +
databank O +
that O +
contains O +
annotated O +
amino O -
- O -
acid O +
sequences O -
, O +
e.g. O -
, O +
SWISS O -
- O -
PROT O -
. O +

There O +
exist O +
different O +
approaches O +
to O +
the O +
generation O +
of O +
a O +
collection O +
of O +
similar O +
sequences O +
( O -
see O +
[ O -
7 O -
] O -
) O -
. O +

This O +
collections O +
can O +
be O +
generated O +
on O +
the O +
basis O +
of O +
global O +
alignments O +
between O +
a O +
query O +
sequence O +
and O +
bank O +
sequences O +
( O -
global O +
alignments O +
can O +
be O +
constructed O -
, O +
e.g. O -
, O +
by O +
CLUSTAL O +
procedure O -
) O +
using O +
an O +
identity O +
percentage O +
or O -
, O +
more O +
generally O -
, O +
a O +
similarity O +
percentage O +
as O +
a O +
similarity O +
measure O -
. O +

Another O +
variant O +
is O +
to O +
use O +
local O +
alignments O +
( O -
i.e. O -
, O +
alignments O +
of O +
most O +
similar O +
fragments O +
of O +
compared O +
sequences O -
, O +
see O +
[ O -
7 O -
] O -
) O +
instead O +
of O +
global O +
alignments O -
. O +

Local O +
alignments O +
can O +
be O +
constructed O -
, O +
for O +
example O -
, O +
by O +
a O +
well O -
- O -
known O +
BLAST O +
procedure O +
[ O -
7,8 O -
] O -
, O +
in O +
which O +
sum O +
of O +
weights O +
or O +
a O +
corresponding O +
e O -
- O -
value O +
serves O +
as O +
a O +
measure O +
of O +
similarity O +
between O +
fragments O +
( O -
and O +
thus O +
between O +
compared O +
sequences O -
) O -
. O +

Other O +
alignment O +
procedures O +
are O +
also O +
acceptable O -
; O +
alignment O +
procedure O +
selection O +
does O +
not O +
play O +
a O +
critical O +
role O -
. O +

Since O +
we O +
build O +
on O +
the O +
A4 O +
procedure O -
, O +
we O +
briefly O +
summarize O +
that O +
approach O -
. O +

In O +
the O +
A4 O +
procedure O +
a O +
collection O +
of O +
similar O +
sequences O +
is O +
generated O +
on O +
the O +
basis O +
of O +
local O +
alignments O +
of O +
a O +
special O +
type O -
. O +

These O +
alignments O +
are O +
constructed O +
by O +
the O +
DotHelix O +
procedure O +
( O -
[ O -
9 O -
] O -
) O -
, O +
in O +
which O +
the O +
" O -
power O -
" O +
( O -
sum O +
of O +
weights O +
divided O +
by O +
the O +
root O +
of O +
the O +
length O +
of O +
the O +
local O +
alignment O -
, O +
see O +
[ O -
9,10 O -
] O +
for O +
details O -
) O +
serves O +
as O +
a O +
similarity O +
measure O -
. O +

Each O +
local O +
alignment O +
constructed O +
by O +
DotHelix O +
procedure O +
is O +
a O +
chain O +
of O +
closely O +
located O +
gapless O +
local O +
alignments O -
. O +

Local O +
alignments O +
that O +
are O +
generated O +
during O +
the O +
construction O +
of O +
a O +
collection O +
of O +
similar O +
sequences O +
are O +
referred O +
to O +
as O +
primary O +
local O +
alignments O -
. O +

Each O +
sequence O +
from O +
a O +
collection O +
of O +
similar O +
sequences O +
π1, O -
... O -
,πn O +
can O +
have O +
several O +
corresponding O +
primary O +
local O +
alignments O -
, O +
but O +
for O +
the O +
sake O +
of O +
simplicity O +
we O +
assume O +
that O +
each O +
similar O +
sequence O +
πi O +
has O +
exactly O +
one O +
corresponding O +
primary O +
local O +
alignment O -
, O +
the O +
one O +
with O +
the O +
maximum O +
similarity O +
measure O -
. O +

Let O +
μi O +
denote O +
the O +
similarity O +
measure O +
( O -
power O -
) O +
of O +
a O +
primary O +
alignment O +
that O +
corresponds O +
to O +
πi O -
. O +

The O +
value O +
of O +
μi O +
characterizes O +
the O +
measure O +
of O +
similarity O +
between O +
fragments O +
that O +
constitute O +
this O +
alignment O -
; O +
at O +
the O +
same O +
time O +
μi O +
can O +
be O +
treated O +
as O +
a O +
measure O +
of O +
similarity O +
between O +
the O +
whole O +
query O +
sequence O +
π0 O +
and O +
the O +
whole O +
similar O +
sequence O +
πi O -
. O +

We O +
assume O +
that O +
similar O +
sequences O +
are O +
ordered O +
in O +
such O +
a O +
way O +
that O +
μ1 O +
≥ O +
μ2 O +
≥ O -
... O +

≥ O +
μn O -
. O +

The O +
exact O +
stochastic O +
formulation O +
of O +
the O +
problem O +
Let O +
π0 O +
be O +
an O +
unannotated O +
amino O -
- O -
acid O +
query O +
sequence O -
, O +
π1, O -
... O -
,πn O +
be O +
a O +
collection O +
of O +
sequences O +
similar O +
to O +
π0 O -
, O +
and O +
ω O +
be O +
a O +
word O +
that O +
belongs O +
to O +
some O +
similar O +
sequences O +
( O -
i.e. O -
, O +
ω O +
∈ O +
KW O -
[ O -
πi O -
] O -
. O +

for O +
at O +
least O +
one O +
similar O +
sequence O +
πi O -
) O -
. O +

The O +
task O +
is O +
to O +
predict O +
whether O +
this O +
word O +
ω O +
belongs O +
to O +
the O +
query O +
sequence O +
π0 O +
or O +
not O -
. O +

Let O +
us O +
put O +
ξi O +
= O +
1 O -
, O +
if O +
ω O +
∈ O +
KW O -
[ O -
πi O -
] O -
, O +
and O +
ξi O +
= O +
0 O -
, O +
if O +
ω O +
∉ O +
KW O -
[ O -
πi O -
] O +
( O -
i O +
= O +
1, O -
... O -
,n O -
) O -
. O +

we O +
also O +
put O +
ξ0 O +
= O +
1 O -
, O +
if O +
ω O +
∈ O +
KW O -
[ O -
π0 O -
] O -
, O +
and O +
ξ0 O +
= O +
0 O -
, O +
if O +
ω O +
∉ O +
KW O -
[ O -
π0 O -
] O -
. O +

Variables O +
ξi O +
can O +
be O +
treated O +
as O +
random O +
variates O +
Actually O -
, O +
they O +
depend O +
on O +
ω O -
. O +

For O +
the O +
sake O +
of O +
brevity O +
we O +
write O +
ξi O +
instead O +
of O +
ξi O -
( O -
ω O -
) O -
. O +

In O +
this O +
notation O +
the O +
problem O +
can O +
be O +
stated O +
as O +
follows O -
. O +

Measures O +
of O +
similarity O +
μi O +
between O +
the O +
query O +
sequence O +
π0 O +
and O +
similar O +
sequences O +
πi O +
and O +
values O +
of O +
random O +
variates O +
ξi O -
, O +
i O +
= O +
1, O -
... O -
,n O -
, O +
are O +
given O -
. O +

The O +
task O +
is O +
to O +
determine O +
whether O +
the O +
word O +
ω O +
belongs O +
to O +
the O +
query O +
sequence O +
π0 O +
or O +
not O -
. O +

In O +
other O +
words O -
, O +
two O +
hypotheses O +
are O +
considered O -
, O +
H1 O +
: O +
ξ0 O +
= O +
1 O +
( O -
i.e. O -
, O +
ω O +
∈ O +
KW O -
[ O -
π0 O -
] O -
) O -
, O +
and O +
H0 O +
: O +
ξ0 O +
= O +
0 O +
( O -
i.e. O -
, O +
ω O +
∉ O +
KW O -
[ O -
π0 O -
] O -
) O -
, O +
and O +
the O +
task O +
is O +
to O +
construct O +
a O +
procedure O +
that O +
allows O +
to O +
decide O +
which O +
hypothesis O +
is O +
true O +
on O +
the O +
basis O +
of O +
ξ O +
= O +
( O -
ξ1, O -
... O -
,ξn O -
) O -
. O +

As O +
announced O +
in O +
the O +
introduction O -
, O +
we O +
base O +
our O +
procedures O +
on O +
the O +
likelihood O +
ratio O -
. O +

Let O +
us O +
recall O +
the O +
famous O +
Bayes O -
' O +
Theorem O +
that O +
can O +
be O +
written O +
as O +
P O -
{ O -
H1|ξ O -
} O -
P O -
{ O -
H0|ξ O -
} O -
=P O -
{ O -
ξ0=1|ξ O -
} O -
P O -
{ O -
ξ0=0|ξ O -
} O -
=P O -
{ O -
ξ0=1,ξ O -
} O -
/ O -
P O -
{ O -
ξ O -
} O -
P O -
{ O -
ξ0=0,ξ O -
} O -
/ O -
P O -
{ O -
ξ O -
} O -
=P O -
{ O -
ξ|ξ0=1 O -
} O -
P O -
{ O -
ξ|ξ0=0 O -
} O -
⋅P O -
{ O -
ξ0=1 O -
} O -
P O -
{ O -
ξ0=0 O -
} O -
. O +
Here O +
the O +
left O +
part O +
is O +
the O +
posterior O +
odds O -
, O +
that O +
is O +
the O +
ratio O +
of O +
a O +
posteriori O +
probabilities O +
of O +
hypotheses O +
H1 O +
and O +
H0 O +
( O -
a O +
posteriori O +
means O +
that O +
values O +
ξ1, O -
... O -
,ξn O +
are O +
known O -
) O -
. O +

It O +
is O +
equal O +
to O +
the O +
product O +
of O +
the O +
likelihood O +
ratio O +
P O -
{ O -
ξ|ξ0=1 O -
} O -
P O -
{ O -
ξ|ξ0=0 O -
} O +
( O -
i.e. O -
, O +
the O +
ratio O +
of O +
probabilities O +
that O +
the O +
set O +
of O +
values O +
ξ O +
= O +
ξ O -
( O -
ω O -
) O +
is O +
realized O +
for O +
the O +
word O +
ω O +
given O +
the O +
conditions O +
ξ0 O +
= O +
1 O +
and O +
ξ0 O +
= O +
0 O +
respectively O -
) O +
and O +
the O +
prior O +
odds O -
, O +
that O +
is O +
the O +
ratio O +
of O +
a O +
priori O +
probabilities O +
of O +
hypotheses O +
H1 O +
and O +
H0 O -
. O +

Statistical O +
decision O +
theory O +
tells O +
us O +
that O +
the O +
optimal O +
prediction O +
procedure O +
should O +
be O +
based O +
on O +
the O +
statistic O +
P O -
{ O -
H1|ξ O -
} O -
P O -
{ O -
H0|ξ O -
} O +
or O +
equivalently O +
on O +
the O +
likelihood O +
ratio O -
. O +

For O +
any O +
statistic O +
a O +
threshold O +
value O +
should O +
be O +
specified O +
for O +
the O +
procedure O -
: O +
if O +
the O +
value O +
of O +
the O +
statistic O +
is O +
greater O +
than O +
the O +
threshold O -
, O +
hypothesis O +
H1 O +
is O +
accepted O -
, O +
otherwise O +
hypothesis O +
H0 O +
is O +
accepted O -
. O +

The O +
threshold O +
value O +
should O +
be O +
selected O +
in O +
such O +
a O +
way O +
that O +
the O +
total O +
number O +
of O +
incorrect O +
predictions O +
( O -
i.e. O -
, O +
the O +
sum O +
of O +
the O +
number O +
of O +
type O +
1 O +
errors O +
and O +
the O +
number O +
of O +
type O +
2 O +
errors O -
) O +
would O +
be O +
minimal O -
. O +

It O +
is O +
clear O +
that O +
if O +
the O +
prior O +
odds O +
are O +
equal O +
to O +
1 O -
, O +
then O +
a O +
threshold O +
value O +
of O +
one O +
should O +
be O +
selected O +
for O +
the O +
likelihood O +
ratio O -
; O +
total O +
number O +
of O +
errors O +
would O +
( O -
theoretically O -
) O +
be O +
minimal O +
for O +
this O +
threshold O -
. O +

Surely O -
, O +
the O +
assumption O +
that O +
the O +
ratio O +
of O +
a O +
priori O +
hypothesis O +
probabilities O +
equals O +
1 O +
does O +
not O +
seem O +
to O +
be O +
natural O -
. O +

Indeed O -
, O +
the O +
number O +
of O +
considered O +
words O +
that O +
do O +
not O +
belong O +
to O +
a O +
query O +
sequence O +
is O +
much O +
greater O +
( O -
approximately O +
8 O +
times O +
greater O -
) O +
than O +
the O +
number O +
of O +
considered O +
words O +
that O +
belong O +
to O +
a O +
query O +
sequence O -
. O +

But O +
statistics O +
that O +
are O +
obtained O +
from O +
the O +
assumption O +
that O +
this O +
a O +
priori O +
ratio O +
equals O +
1 O -
, O +
and O +
the O +
assumption O +
that O +
this O +
a O +
priori O +
ratio O +
does O +
not O +
equal O +
1 O -
, O +
but O +
is O +
constant O +
( O -
i.e. O -
, O +
it O +
does O +
not O +
depend O +
on O +
a O +
word O +
ω O -
) O +
are O +
equivalent O -
. O +

Essentially O +
these O +
are O +
the O +
same O +
statistics O +
( O -
only O +
the O +
threshold O +
value O +
should O +
be O +
changed O -
: O +
a O +
value O +
P O -
{ O -
ξ0=0 O -
} O -
P O -
{ O -
ξ0=1 O -
} O +
should O +
be O +
taken O +
instead O +
of O +
1 O -
; O +
as O +
it O +
was O +
noted O -
, O +
this O +
value O +
approximately O +
equals O +
8 O +
in O +
our O +
data O -
) O -
. O +

Therefore O -
, O +
we O +
assume O +
from O +
now O +
on O +
that O +
the O +
ratio O +
of O +
a O +
priori O +
hypothesis O +
probabilities O +
equals O +
1 O -
. O +

Thus O +
all O +
considered O +
statistics O +
are O +
based O +
on O +
the O +
likelihood O +
ratio O +
( O -
1 O -
) O -
P O -
{ O -
ξ|ξ0=1 O -
} O -
P O -
{ O -
ξ|ξ0=0 O -
} O +
Assumption O +
of O +
independence O +
of O +
variables O +
ξi O -
. O +

Transfer O +
probabilities O +
By O +
virtue O +
of O +
equation O +
( O -
1 O -
) O +
we O +
need O +
to O +
estimate O +
conditional O +
probabilities O +
P O -
{ O -
ξ|ξ0 O +
= O +
ε O -
} O -
, O +
where O +
ε O +
= O +
1 O +
or O +
0 O +
in O +
order O +
to O +
calculate O +
the O +
likelihood O +
ratio O -
. O +

Our O +
derivation O +
of O +
these O +
estimates O +
uses O +
the O +
assumption O +
that O +
variables O +
ξi O -
, O +
i O +
= O +
1, O -
... O -
,n O -
, O +
are O +
independent O +
in O +
the O +
aggregate O -
. O +

Surely O -
, O +
this O +
assumption O +
is O +
false O -
. O +

In O +
reality O +
variables O +
ξi O +
are O +
dependent O -
, O +
and O +
the O +
dependence O +
is O +
considerably O +
strong O -
. O +

Nevertheless O -
, O +
in O +
our O +
definition O +
of O +
the O +
likelihood O +
ratio O +
statistic O +
( O -
and O +
the O +
statistic O +
that O +
is O +
the O +
logarithm O +
of O +
the O +
likelihood O +
ratio O -
) O +
we O +
use O +
the O +
independence O +
assumption O -
. O +

Since O +
variables O +
ξi O +
are O +
not O +
independent O -
, O +
one O +
can O +
not O +
assert O +
that O +
the O +
obtained O +
statistics O +
are O +
the O +
most O +
powerful O -
, O +
but O +
these O +
statistics O +
can O +
be O +
still O +
quite O +
good O -
. O +

In O +
decision O +
theory O -
, O +
this O +
approach O +
is O +
known O +
as O +
the O +
naive O +
Bayes O +
procedure O -
. O +

The O +
independence O +
of O +
variables O +
ξi O +
implies O +
the O +
equality O +
( O -
2 O -
) O -
P O -
{ O -
ξ|ξ0 O -
= O -
ε O -
} O -
=∏i=1nP O -
{ O -
ξi|ξ0 O -
= O -
ε O -
} O -
,ε=1,0 O +
Each O +
variable O +
ξi O +
has O +
exactly O +
two O +
possible O +
values O -
: O +
1 O +
and O +
0 O -
. O +

Thus O -
, O +
everything O +
is O +
reduced O +
to O +
the O +
following O +
four O +
conditional O +
probabilities O -
: O +
( O -
3 O -
) O -
P O -
{ O -
ξi O +
= O +
1|ξ0 O +
= O +
1 O -
} O -
, O +
P O -
{ O -
ξi O +
= O +
0|ξ0= O +
1 O -
} O -
, O +
P O -
{ O -
ξi O +
= O +
1|ξ0 O +
= O +
0 O -
} O -
, O +
P O -
{ O -
ξi O +
= O +
0|ξ0 O +
= O +
0 O -
} O -
. O +
In O +
addition O -
, O +
it O +
is O +
clear O +
that O +
( O -
4 O -
) O -
P O -
{ O -
ξi=1|ξ0=1 O -
} O -
+P O -
{ O -
ξi=0|ξ0=1 O -
} O -
=1,P O -
{ O -
ξi=1|ξ0=0 O -
} O -
+P O -
{ O -
ξi=0|ξ0=0 O -
} O -
=1 O -
, O +
so O +
actually O +
everything O +
is O +
reduced O +
to O +
two O +
conditional O +
probabilities O +
P O -
{ O -
ξi O +
= O +
1|ξ0 O +
= O +
1 O -
} O -
, O +
P O -
{ O -
ξi O +
= O +
1|ξ0= O +
0 O -
} O -
. O +
Conditional O +
probabilities O +
( O -
3 O -
) O +
are O +
a O +
special O +
case O +
of O +
conditional O +
probabilities O +
of O +
the O +
type O +
P O -
{ O -
ξi O +
= O +
ε1|ξj O +
= O +
ε2 O -
} O -
, O +
where O +
ε1 O -
, O +
ε2 O +
= O +
1 O +
or O +
0 O -
, O +
i O -
, O +
j O +
= O +
0,1, O -
... O -
,n O +
( O -
above O +
special O +
case O +
corresponds O +
to O +
j O +
= O +
0 O -
) O -
. O +

We O +
call O +
all O +
this O +
conditional O +
probabilities O +
transfer O +
probabilities O +
and O +
denote O +
them O +
by O +
P O -
{ O -
ξi O -
= O -
ε1|ξj O -
= O -
ε2 O -
} O -
=pε1|ε2 O -
. O +

Transfer O +
probabilities O +
depend O +
on O +
i O -
, O +
j O +
( O -
and O +
certainly O +
on O +
the O +
word O +
ω O -
) O -
: O +
pε1|ε2 O -
= O -
pε1|ε2 O -
( O -
i O -
, O -
j;ω O -
) O -
. O +

Conditional O +
probabilities O +
play O +
a O +
central O +
role O +
in O +
our O +
procedure O -
. O +

According O +
to O +
equation O +
( O -
4 O -
) O -
, O +
it O +
suffices O +
to O +
explain O +
how O +
transfer O +
probabilities O +
p1|1 O -
, O +
p1|0 O +
are O +
evaluated O -
. O +

We O +
suppose O +
that O +
transfer O +
probabilities O +
satisfy O +
the O +
following O +
assumptions O +
( O -
" O -
axioms O -
" O -
) O +
( O -
the O +
sense O +
of O +
these O +
assumptions O +
is O +
obvious O -
) O -
. O +

Assumption O +
1 O -
) O +

For O +
a O +
fixed O +
word O +
ω O +
and O +
for O +
sequences O +
π0 O -
, O +
π1, O -
... O -
,πn O +
( O -
i.e. O -
, O +
for O +
the O +
sequence O +
π0 O +
and O +
sequences O +
similar O +
to O +
π0 O -
) O +
transfer O +
probabilities O +
depend O +
only O +
on O +
the O +
measure O +
of O +
similarity O +
between O +
sequences O -
. O +

Thus O -
, O +
we O +
have O -
: O +
p1|1 O +
= O +
p1|1 O +
( O -
i O -
, O +
j;ω O -
) O +
= O +
p1|1 O -
( O -
μij;ω O -
) O +
= O +
p1|1 O -
( O -
μij O -
) O +
= O +
1 O +
- O +
p0|1 O -
( O -
μij O -
) O -
, O +
p1|0 O +
= O +
p1|0 O +
( O -
i O -
, O +
j;ω O -
) O +
= O +
p1|0 O -
( O -
μij;ω O -
) O +
= O +
p1|0 O -
( O -
μij O -
) O +
= O +
1 O +
- O +
p0|0 O -
( O -
μij O -
) O -
, O +
where O +
μij O +
is O +
the O +
measure O +
of O +
similarity O +
between O +
sequences O +
πi O -
, O +
πj O -
( O -
i O -
, O +
j O +
= O +
0,1, O -
... O -
,n O -
) O -
. O +

Particularly O -
, O +
if O +
one O +
of O +
these O +
sequences O +
is O +
the O +
query O +
sequence O +
π0 O +
and O +
μj O +
is O +
the O +
measure O +
of O +
similarity O +
between O +
πj O -
, O +
π0 O -
, O +
we O +
have O +
( O -
5 O -
) O -
P O -
{ O -
ξj O +
= O +
1|ξ0 O +
= O +
1 O -
} O +
= O +
p1|1 O -
( O -
μj O -
) O -
, O +
P O -
{ O -
ξj O +
= O +
1|ξ0 O +
= O +
0 O -
} O +
= O +
p1|0 O -
( O -
μj O -
) O -
. O +

Assumption O +
2 O -
) O +
Transfer O +
probabilities O +
( O -
for O +
an O +
arbitrary O +
fixed O +
word O +
ω O -
) O +
depend O +
on O +
similarity O +
measure O +
μ O +
monotonically O -
: O +
the O +
probability O +
p1|1 O -
( O -
μ O -
) O +
increases O +
( O -
does O +
not O +
decrease O -
) O +
and O +
the O +
probability O +
p1|0 O -
( O -
μ O -
) O -
decreases O +
( O -
does O +
not O +
increase O -
) O +
as O +
μ O +
increases O -
. O +

Assumption O +
3 O -
) O +
The O +
inequality O +
( O -
6 O -
) O -
p1|1 O -
( O -
μ O -
) O +
> O +
p1|0 O -
( O -
μ O -
) O +
always O +
holds O +
( O -
if O +
μ O +
> O +
0 O -
) O -
. O +

Transfer O +
probabilities O +
are O +
evaluated O +
on O +
the O +
basis O +
of O +
the O +
measure O +
of O +
similarity O +
between O +
similar O +
sequences O +
for O +
which O +
it O +
is O +
known O +
whether O +
ω O +
∈ O +
KW O -
[ O -
πi O -
] O +
using O +
the O +
so O +
called O +
isotonic O +
regression O +
procedure O +
( O -
see O +
[ O -
11 O -
] O -
) O -
. O +

( O -
In O +
[ O -
5 O -
] O +
this O +
procedure O +
was O +
referred O +
to O +
as O +
monotonization O +
procedure O -
) O -
. O +

Results O +
of O +
this O +
procedure O +
are O +
piecewise O -
- O -
constant O +
monotonous O +
functions O +
of O +
the O +
similarity O +
measure O +
μ O +
that O +
increase O +
( O -
do O +
not O +
decrease O -
) O +
for O +
probabilities O +
p1|1 O -
( O -
μ O -
) O +
and O +
decrease O +
( O -
do O +
not O +
increase O -
) O +
for O +
probabilities O +
p1|0 O -
( O -
μ O -
) O -
. O +

We O +
briefly O +
recall O +
the O +
isotonic O +
regression O +
problem O -
. O +

Let O +
one O +
have O +
two O +
number O +
sets O +
( O -
i.e. O -
, O +
a O +
set O +
of O +
points O +
in O +
the O +
plain O -
) O +
xi O -
, O +
yi O -
, O +
i O +
= O +
1, O -
... O -
,n O -
, O +
for O +
which O +
x1 O +
≤ O +
x2 O +
≤ O -
... O -
≤ O +
xn O -
. O +

The O +
task O +
is O +
to O +
find O +
values O +
z1 O -
, O +
z2, O -
... O -
,zn O -
, O +
z1 O +
≤ O +
z2 O +
≤ O -
... O +

≤ O +
zn O -
, O +
that O +
minimize O +
the O +
deviation O +
∑i=1n O -
( O -
zi−yi O -
) O -
2 O -
. O +

This O +
is O +
the O +
monotone O -
- O -
increasing O +
isotonic O +
regression O +
problem O -
. O +

The O +
monotone O -
- O -
decreasing O +
isotonic O +
regression O +
problem O +
is O +
similar O -
; O +
the O +
only O +
difference O +
is O +
that O +
here O +
z1 O +
≥ O +
z2 O +
≥ O -
... O +

≥ O +
zn O -
. O +

The O +
isotonic O +
regression O +
procedure O +
constructs O +
a O +
monotonic O +
number O +
sequence O +
z1, O -
... O -
,zn O +
( O -
while O +
in O +
linear O +
regression O +
values O +
of O +
zi O +
are O +
linearly O +
expressed O +
in O +
terms O +
of O +
xi O +
: O +
zi O +
= O +
αxi O +
+ O +
β O -
) O -
. O +

An O +
algorithm O +
for O +
the O +
solution O +
of O +
isotonic O +
regression O +
problem O +
can O +
be O +
easily O +
constructed O -
. O +

We O +
do O +
not O +
describe O +
it O +
here O -
. O +

We O +
only O +
note O +
that O +
each O +
zi O +
is O +
the O +
mean O +
value O +
of O +
{ O -
yj O -
} O +
over O +
a O +
window O +
of O +
variable O +
length O -
: O +

Li O -
: O -
zi= O -
( O -
∑j O -
= O -
t O -
( O -
i O -
) O -
t O -
( O -
i O -
) O -
+L O -
( O -
i O -
) O -
−1yi O -
) O -
/ O -
Li O -
. O +

For O +
different O +
indices O +
these O +
windows O +
either O +
coincide O +
or O +
do O +
not O +
overlap O -
, O +
and O +
the O +
i O -
- O -
th O +
window O +
contains O +
i. O +
We O +
also O +
note O +
that O +
the O +
values O +
of O +
xi O +
are O +
not O +
essential O +
in O +
the O +
isotonic O +
regression O +
problem O -
, O +
only O +
the O +
order O +
of O +
values O +
of O +
yi O +
is O +
essential O -
. O +

To O +
obtain O +
the O +
transfer O +
probabilities O +
using O +
isotonic O +
regression O +
we O +
proceed O +
as O +
follows O -
. O +

For O +
the O +
evaluation O +
of O +
p1|1 O +
we O +
consider O +
pairs O +
of O +
similar O +
sequences O +
πi O -
, O +
πj O +
that O +
satisfy O +
the O +
condition O +
ω O +
∈ O +
KW O -
[ O -
πi O -
] O -
. O +

Let O +
μij O +
denote O +
the O +
measure O +
of O +
similarity O +
between O +
sequences O +
πi O -
, O +
πj O -
. O +

We O +
put O +
ξij O +
= O +
1 O +
if O +
the O +
word O +
ω O +
belongs O +
to O +
the O +
sequence O +
πj O -
, O +
and O +
put O +
ξij O +
= O +
0 O +
if O +
ω O +
does O +
not O +
belong O +
to O +
πj O +
( O -
recall O +
that O +
the O +
word O +
ω O +
belongs O +
to O +
πi O -
) O -
. O +

Then O +
we O +
apply O +
the O +
monotone O -
- O -
increasing O +
isotonic O +
regression O +
procedure O +
to O +
the O +
collection O +
of O +
points O +
( O -
μij O -
, O +
ξij O -
) O -
, O +
where O +
μij O +
are O +
in O +
ascending O +
order O -
. O +

The O +
resulting O +
values O +
are O +
the O +
estimates O +
of O +
the O +
transfer O +
probabilities O +
p1|1 O -
( O -
μij O -
) O -
. O +

Similarly O -
, O +
applying O +
the O +
monotone O -
- O -
decreasing O +
isotonic O +
regression O +
procedure O +
to O +
the O +
collection O +
of O +
points O +
( O -
μij O -
, O +
ξij O -
) O +
that O +
correspond O +
to O +
pairs O +
of O +
similar O +
sequences O +
πi O -
, O +
πj O +
for O +
which O +
ω O +
does O +
not O +
belong O +
to O +
πi O -
, O +
we O +
obtain O +
values O +
of O +
the O +
transfer O +
probabilities O +
p1|0 O -
( O -
μij O -
) O -
. O +

As O +
we O +
noted O -
, O +
the O +
probabilities O +
p1|1 O -
, O +
p1|0 O +
are O +
supposed O +
to O +
satisfy O +
condition O +
( O -
6 O -
) O -
. O +

Therefore O -
, O +
if O +
it O +
turns O +
out O +
that O +
functions O +
p1|1 O -
( O -
μ O -
) O -
, O +
p1|0 O -
( O -
μ O -
) O -
obtained O +
after O +
the O +
application O +
of O +
isotonic O +
regression O +
procedure O +
do O +
not O +
satisfy O +
this O +
condition O +
for O +
some O +
values O +
of O +
μ O -
, O +
then O +
we O +
consider O +
that O +
probabilities O +
p1|1 O -
, O +
p1|0 O +
are O +
not O +
defined O +
for O +
these O +
values O +
of O +
μ O -
. O +

Hence O -
, O +
it O +
is O +
possible O +
that O +
transfer O +
probabilities O +
are O +
defined O +
only O +
for O +
sufficiently O +
large O +
values O +
of O +
μ O -
, O +
but O +
not O +
for O +
all O +
μ O -
. O +

In O +
particular O -
, O +
it O +
is O +
possible O +
that O +
for O +
some O +
words O +
there O +
are O +
no O +
values O +
of O +
μ O +
such O +
that O +
inequality O +
( O -
6 O -
) O +
holds O -
. O +

These O +
words O +
are O +
referred O +
to O +
as O +
degenerate O +
words O -
. O +

Statistics O +
description O +
All O +
statistics O +
considered O +
in O +
this O +
paper O +
are O +
based O +
on O +
the O +
likelihood O +
ratio O +
criterion O -
, O +
that O +
is O +
on O +
formula O +
( O -
1 O -
) O +
under O +
the O +
assumption O +
of O +
independence O +
of O +
variables O +
ξi O +
( O -
formula O +
( O -
2 O -
) O -
) O -
. O +

Two O +
approaches O +
are O +
used O +
in O +
the O +
definitions O +
of O +
these O +
statistics O -
. O +

One O +
of O +
them O +
can O +
be O +
called O +
a O +
" O -
discrete O -
" O +
approach O -
; O +
the O +
other O +
can O +
be O +
called O +
a O +
" O -
continuous O -
" O +
approach O -
. O +

The O +
discrete O +
approach O +
is O +
based O +
directly O +
on O +
formulae O +
( O -
1 O -
) O -
, O +
( O -
2 O -
) O +
and O +
the O +
definition O +
of O +
transfer O +
probabilities O -
. O +

It O +
follows O +
from O +
( O -
5 O -
) O +
that O +
the O +
following O +
formulae O +
for O +
conditional O +
probabilities O +
hold O -
: O +
P O -
{ O -
ξi|ξ0 O +
= O +
1 O -
} O +
= O +
p1|1 O -
( O -
μi O -
) O -
, O +
if O +
ξi O +
= O +
1 O -
, O +
P O -
{ O -
ξi|ξ0 O +
= O +
1 O -
} O +
= O +
p0|1 O -
( O -
μi O -
) O +
= O +
1 O +
- O +
p1|1 O -
( O -
μi O -
) O -
, O +
if O +
ξi O +
= O +
0 O -
, O +
and O +
hence O +
( O -
7 O -
) O -
P O -
{ O -
ξi|ξ0=1 O -
} O -
= O -
( O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
⋅ O -
( O -
p1|1 O -
( O -
μi O -
) O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
) O -
ξi O -
. O +

Similarly O -
, O +
( O -
8 O -
) O -
P O -
{ O -
ξi|ξ0=0 O -
} O -
= O -
( O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
⋅ O -
( O -
p1|0 O -
( O -
μi O -
) O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
ξi O -
. O +

Relations O +
( O -
7 O -
) O -
, O +
( O -
8) O +
together O +
with O +
( O -
1 O -
) O -
, O +
( O -
2 O -
) O +
imply O +
the O +
following O +
formula O +
for O +
the O +
logarithm O +
of O +
the O +
likelihood O +
ratio O -
: O +
( O -
9 O -
) O -
T O -
( O -
1 O -
) O -
( O -
ξ;ω O -
) O -
=T O -
( O -
1 O -
) O -
( O -
ξ O -
) O -
=ln⁡ O -
( O -
∏i=1nP O -
{ O -
ξi|ξ0=1 O -
} O -
P O -
{ O -
ξi|ξ0=0 O -
} O -
) O -
=α0+∑i=1nαi⋅ξi O -
, O +
where O +
( O -
10 O -
) O -
α0=∑i=1nα0i O -
, O -
α0i O -
= O -
ln⁡1−p1|1 O -
( O -
μi O -
) O -
1−p1|0 O -
( O -
μi O -
) O -
<0 O +
( O -
11 O -
) O -
αi O -
= O -
ln⁡p1|1 O -
( O -
μi O -
) O -
( O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
p1|0 O -
( O -
μi O -
) O -
( O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
>0 O -
. O +

One O +
can O +
see O +
that O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
can O +
be O +
expressed O +
as O +
a O +
linear O +
combination O +
of O +
the O +
ξi O -
. O +

As O +
we O +
noted O -
, O +
theoretically O +
the O +
best O +
threshold O +
value O +
for O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
is O +
equal O +
to O +
1n1 O +
= O +
0 O -
. O +

However O -
, O +
that O +
is O +
only O +
theoretical O -
. O +

As O +
the O +
assumption O +
of O +
independence O +
of O +
variables O +
ξi O +
is O +
incorrect O +
and O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
is O +
only O +
a O +
rough O +
estimate O +
of O +
logarithm O +
of O +
the O +
likelihood O +
ratio O -
, O +
the O +
best O +
threshold O +
value O +
is O +
not O +
necessarily O +
equal O +
to O +
zero O +
( O -
and O +
this O +
threshold O +
does O +
not O +
really O +
equal O +
zero O +
in O +
practice O -
) O -
. O +

Let O +
us O +
put O +
η O -
= O -
η O -
( O -
ω O -
) O -
=T O -
( O -
1 O -
) O -
−α0∑i=1nαi O -
. O +

From O +
the O +
definition O +
of O +
η O +
and O +
relations O +
( O -
9 O -
) O -
– O -
( O -
11 O -
) O +
it O +
follows O +
that O +
( O -
12 O -
) O -
η=∑i=1na^iξi O -
, O +
where O +
( O -
13 O -
) O -
a^i O -
= O -
ln⁡p1|1 O -
( O -
μi O -
) O -
( O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
p1|0 O -
( O -
μi O -
) O -
( O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
∑i=1nln⁡p1|1 O -
( O -
μi O -
) O -
( O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
p1|0 O -
( O -
μi O -
) O -
( O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
>0 O -
. O +

We O +
note O +
that O +
( O -
14 O -
) O -
∑i=1na^i=1 O -
. O +

The O +
variable O +
η O -
( O -
ω O -
) O +
can O +
be O +
treated O +
as O +
a O +
second O +
statistic O -
. O +

Its O +
values O +
lie O +
between O +
0 O +
and O +
1 O -
. O +

Statistics O +
T O -
( O -
1 O -
) O +
and O +
η O +
are O +
linearly O +
dependent O -
, O +
and O +
hence O +
for O +
a O +
fixed O +
word O +
ω O +
these O +
statistics O +
are O +
equivalent O -
. O +

However O -
, O +
the O +
coefficients O +
α0 O +
and O +
αi O -
( O -
i O +
= O +
1, O -
... O -
,n O -
) O +
are O +
different O +
for O +
different O +
words O +
ω O -
, O +
so O +
the O +
relation O +
between O +
thresholds O -
, O +
used O +
in O +
the O +
prediction O -
, O +
is O +
different O +
for O +
different O +
words O -
; O +
consequently O -
, O +
the O +
statistics O +
T O -
( O -
1 O -
) O +
and O +
η O +
are O +
not O +
equivalent O +
for O +
the O +
whole O +
totality O +
of O +
words O +
( O -
We O +
will O +
see O +
later O +
that O +
if O +
thresholds O +
are O +
well O -
- O -
chosen O -
, O +
then O +
η O +
leads O +
to O +
better O +
results O +
than O +
T O -
( O -
1 O -
) O -
) O -
. O +

The O +
other O +
approach O +
to O +
the O +
definition O +
of O +
statistics O -
, O +
used O +
in O +
the O +
annotation O +
procedure O -
, O +
starts O +
from O +
a O +
linear O +
combination O +
η=∑i=1naiξi O +
of O +
the O +
ξi O +
as O +
in O +
formula O +
( O -
12 O -
) O -
. O +

Here O +
coefficients O +
αi O +
are O +
not O +
necessarily O +
given O +
by O +
( O -
13 O -
) O -
, O +
but O +
should O +
be O +
positive O +
and O +
satisfy O +
the O +
relation O +
( O -
14 O -
) O -
. O +

This O +
approach O +
uses O +
the O +
assumption O +
that O +
η O +
has O +
the O +
normal O +
distribution O -
. O +

Certainly O +
this O +
assumption O +
is O +
not O +
correct O +
( O -
at O +
least O +
because O +
the O +
inequality O +
0 O +
≤ O +
η O +
≤ O +
1 O +
always O +
holds O -
) O -
. O +

Nevertheless O -
, O +
we O +
use O +
this O +
assumption O +
( O -
and O -
, O +
similarly O +
to O +
the O +
discrete O +
approach O -
, O +
the O +
assumption O +
of O +
independence O +
of O +
variables O +
ξi O -
( O -
ω O -
) O -
) O -
. O +

( O -
As O +
the O +
normal O +
distribution O +
is O +
continuous O -
, O +
this O +
approach O +
can O +
be O +
called O +
" O -
continuous O -
" O -
) O -
. O +

Thus O -
, O +
we O +
consider O +
a O +
random O +
variable O +
( O -
15 O -
) O -
η=∑i=1naiξi O +
and O +
assume O +
that O +
it O +
has O +
a O +
normal O +
distribution O -
. O +

Denote O +
by O +
M1η O -
= O -
M O -
( O -
η|ξ0=1 O -
) O -
,D1η O -
= O -
D O -
( O -
η|ξ0=1 O -
) O -
=σ12,M0η O -
= O -
M O -
( O -
η|ξ0=0 O -
) O -
,D0η O -
= O -
D O -
( O -
η|ξ0=0 O -
) O -
=σ02 O +
the O +
conditional O +
expectations O +
and O +
dispersions O +
of O +
η O +
given O +
that O +
ξ0 O +
= O +
1 O +
or O +
0 O +
respectively O -
. O +

We O +
have O +
M1η O +
= O +
∑aiM O -
( O -
ξi|ξ0 O +
= O +
1 O -
) O +
= O +
∑aip1|1 O -
( O -
μi O -
) O -
, O +
M0η O +
= O +
∑aip1|0 O -
( O -
μi O -
) O -
. O +

Further O -
, O +
the O +
assumption O +
of O +
independence O +
of O +
ξi O -
( O -
ω O -
) O +
implies O +
that O +
D1η O -
= O -
σ12=∑iai2⋅p1|1 O -
( O -
μi O -
) O -
⋅ O -
( O -
1−p1|1 O -
( O -
μi O -
) O -
) O -
,D0η O -
= O -
σ02=∑iai2⋅p1|0 O -
( O -
μi O -
) O -
⋅ O -
( O -
1−p1|0 O -
( O -
μi O -
) O -
) O -
. O +

( O -
We O +
note O +
that O +
it O +
is O +
the O +
only O +
place O +
where O +
the O +
independence O +
of O +
ξi O +
is O +
used O -
; O +
therefore O -
, O +
the O +
assumption O +
of O +
independence O +
of O +
ξi O +
is O +
not O +
as O +
essential O +
in O +
this O +
approach O +
as O +
it O +
was O +
in O +
the O +
definition O +
of O +
the O +
statistic O +
T O -
( O -
1 O -
) O -
) O -
. O +

It O +
follows O +
from O +
the O +
assumption O +
of O +
a O +
normal O +
distribution O +
that O +
in O +
cases O +
ξ0 O +
= O +
1 O +
and O +
0 O +
the O +
variables O +
( O -
16 O -
) O -
η−M1ησ1 O +
and O +
η−M0ησ0 O +
have O +
standard O +
normal O +
distribution O +
N O -
( O -
0,1 O -
) O +
As O +
above O -
, O +
we O +
use O +
the O +
logarithm O +
of O +
the O +
likelihood O +
ratio O +
as O +
a O +
statistic O +
and O +
in O +
addition O +
assume O +
that O +
the O +
ratio O +
of O +
a O +
priori O +
hypothesis O +
probabilities O +
is O +
equal O +
to O +
1 O -
. O +

Let O +
us O +
denote O +
this O +
statistic O +
by O +
T O -
( O -
2 O -
) O -
. O +

Relation O +
( O -
16 O -
) O +
implies O +
that O +
T O -
( O -
2 O -
) O -
( O -
λ O -
) O -
=ln⁡P O -
{ O -
λ≤η≤λ+dλ|ξ0=1 O -
} O -
P O -
{ O -
λ≤η≤λ+dλ|ξ0=0 O -
} O -
=ln⁡ O -
( O -
1 O -
/ O -
2π⋅σ1 O -
) O -
⋅exp⁡ O -
{ O -
−12⋅ O -
( O -
( O -
λ−M1η O -
) O -
/ O -
σ1 O -
) O -
2 O -
} O -
( O -
1 O -
/ O -
2π⋅σ0 O -
) O -
⋅exp⁡ O -
{ O -
12⋅ O -
( O -
( O -
λ−M0η O -
) O -
/ O -
σ0 O -
) O -
2 O -
} O -
=12⋅ O -
{ O -
( O -
( O -
λ−M0η O -
) O -
/ O -
σ0 O -
) O -
2− O -
( O -
( O -
λ−M1η O -
) O -
/ O -
σ1 O -
) O -
2 O -
} O -
+ln⁡ O -
( O -
σ0 O -
/ O -
σ1 O -
) O -
. O +

Another O +
variant O +
of O +
this O +
statistic O +
– O +
statistic O +
T^ O -
( O -
2 O -
) O +
– O +
was O +
used O +
in O +
the O +
paper O +
[ O -
5 O -
] O -
. O +

The O +
statistic O +
T^ O -
( O -
2 O -
) O +
is O +
the O +
ratio O +
of O +
type O +
1 O +
error O +
to O +
type O +
2 O +
error O +
: O +
( O -
17 O -
) O -
T^ O -
( O -
2 O -
) O -
( O -
λ O -
) O -
=ln⁡P O -
( O -
1 O -
) O -
( O -
λ O -
) O -
P O -
( O -
2 O -
) O -
( O -
λ O -
) O -
=ln⁡Φ O -
( O -
( O -
λ−M1η O -
) O -
/ O -
σ1 O -
) O -
1−Φ O -
( O -
( O -
λ−M0η O -
) O -
/ O -
σ0 O -
) O -
, O +
where O +
Φ O -
( O -
x O -
) O +
is O +
the O +
cumulative O +
normal O +
distribution O +
function O -
: O +
Φ O -
( O -
x O -
) O -
=12π∫−∞xe−z22dz O -
. O +

The O +
statistics O +
η O +
and O +
T^ O -
( O -
2 O -
) O +
are O +
equivalent O +
for O +
an O +
arbitrary O +
fixed O +
word O +
ω O +
( O -
although O +
not O +
equivalent O +
for O +
the O +
whole O +
totality O +
of O +
words O -
) O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
statistics O +
η O +
and O +
T O -
( O -
2 O -
) O +
are O +
not O +
necessarily O +
equivalent O -
, O +
as O +
the O +
dependence O +
of O +
T O -
( O -
2 O -
) O +
on O +
η O +
may O +
turn O +
out O +
to O +
be O +
not O +
monotonic O -
. O +

Moreover O -
, O +
it O +
is O +
never O +
monotonic O +
for O +
all O +
values O +
of O +
η O -
. O +

However O -
, O +
we O +
are O +
interested O +
only O +
in O +
values O +
0 O +
≤ O +
η O +
≤ O +
1 O -
, O +
and O +
usually O +
( O -
though O +
not O +
always O -
) O +
the O +
dependence O +
of O +
T O -
( O -
2 O -
) O +
on O +
η O +
is O +
monotonous O +
for O +
these O +
values O +
of O +
η O -
, O +
and O +
in O +
this O +
case O +
the O +
statistics O +
η O +
and O +
T O -
( O -
2 O -
) O +
are O +
equivalent O +
( O -
for O +
a O +
fixed O +
word O +
ω O -
) O -
. O +

Furthermore O -
, O +
even O +
in O +
the O +
case O +
where O +
the O +
dependence O +
is O +
not O +
monotonic O -
, O +
the O +
monotonicity O +
is O +
violated O +
only O +
for O +
the O +
values O +
of O +
η O +
close O +
either O +
to O +
0 O +
or O +
to O +
1 O -
, O +
and O +
the O +
lack O +
of O +
monotonicity O +
can O +
be O +
disregarded O -
. O +

We O +
still O +
have O +
to O +
discuss O +
the O +
question O +
of O +
the O +
choice O +
of O +
coefficients O +
ai O +
in O +
( O -
15 O -
) O -
. O +

One O +
of O +
the O +
variants O +
was O +
described O +
above O -
: O +
formula O +
( O -
13 O -
) O +
can O +
be O +
applied O -
. O +

Another O +
variant O +
was O +
introduced O +
in O +
[ O -
5 O -
] O -
. O +

This O +
variant O +
can O +
be O +
described O +
as O +
follows O -
. O +

As O +
above O -
, O +
we O +
assume O +
that O +
the O +
variate O +
η O +
= O +
∑aiξi O +
has O +
a O +
normal O +
distribution O -
. O +

Each O +
set O +
of O +
coefficients O +
ai O +
and O +
each O +
threshold O +
value O +
λ O +
have O +
corresponding O +
theoretical O +
frequencies O +
of O +
type O +
1 O +
and O +
type O +
2 O +
errors O +
P O -
( O -
1 O -
) O -
( O -
λ O -
) O -
, O +
P O -
( O -
2 O -
) O -
( O -
λ O -
) O -
. O +

The O +
idea O +
is O +
to O +
take O +
the O +
set O +
of O +
coefficients O +
{ O -
ai O -
} O +
that O +
gives O +
the O +
minimum O +
sum O +
P O -
( O -
1 O -
) O -
( O -
λ O -
) O +
+ O +
P O -
( O -
2 O -
) O -
( O -
λ O -
) O -
, O +
where O +
λ O +
is O +
the O +
best O +
threshold O +
value O +
for O +
this O +
coefficient O +
set O -
. O +

However O -
, O +
analytically O +
it O +
is O +
very O +
cumbersome O -
, O +
so O +
the O +
following O +
simplification O +
was O +
implemented O -
. O +

For O +
a O +
fixed O +
set O +
of O +
coefficients O +
{ O -
ai O -
} O +
we O +
select O +
the O +
threshold O +
value O +
λ O +
such O +
that O +
the O +
frequency O +
of O +
type O +
1 O +
errors O +
is O +
equal O +
to O +
the O +
frequency O +
of O +
type O +
2 O +
errors O -
: O +
P O -
( O -
1 O -
) O -
( O -
λ O -
) O +
= O +
P O -
( O -
2 O -
) O -
( O -
λ O -
) O -
. O +

Then O +
we O +
find O +
the O +
set O +
of O +
coefficients O +
that O +
minimizes O +
these O +
frequencies O +
P O -
( O -
1 O -
) O -
( O -
λ O -
) O +
= O +
P O -
( O -
2 O -
) O -
( O -
λ O -
) O -
. O +

Here O +
the O +
search O +
of O +
the O +
coefficient O +
set O +
can O +
be O +
reduced O +
to O +
a O +
conditional O +
extremum O +
problem O -
. O +

The O +
A4 O +
algorithm O +
uses O +
an O +
iterated O +
procedure O +
for O +
the O +
solution O +
of O +
this O +
problem O +
( O -
see O +
[ O -
5 O -
] O -
) O -
. O +

In O +
order O +
to O +
optimize O +
the O +
automated O +
annotation O +
procedure O -
, O +
that O +
is O +
to O +
increase O +
the O +
prediction O +
quality O -
, O +
certain O +
modifications O +
of O +
the O +
procedure O +
were O +
introduced O -
. O +

For O +
each O +
statistic O +
( O -
η O -
, O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O -
) O +
many O +
variants O +
( O -
up O +
to O +
36 O -
) O -
, O +
including O +
the O +
variant O +
that O +
was O +
described O +
above O -
, O +
were O +
considered O +
– O +
each O +
variant O +
corresponds O +
to O +
a O +
certain O +
combination O +
of O +
these O +
modifications O -
. O +

Some O +
variants O +
really O +
turned O +
out O +
to O +
be O +
better O +
than O +
the O +
variants O +
described O +
above O -
. O +

A O +
simplified O +
scheme O +
of O +
modifications O +
( O -
and O +
thereby O +
of O +
statistic O +
variants O -
) O +
can O +
be O +
described O +
as O +
follows O -
. O +

1 O -
) O +
What O +
primary O +
local O +
alignments O +
are O +
considered O -
? O +

In O +
the O +
described O +
variant O +
of O +
statistics O +
only O +
one O +
primary O +
local O +
alignment O +
( O -
the O +
one O +
with O +
the O +
maximum O +
power O -
) O +
was O +
considered O -
. O +

Meanwhile O -
, O +
all O +
constructed O +
local O +
alignments O +
with O +
sufficiently O +
high O +
power O +
can O +
be O +
considered O -
, O +
as O +
it O +
was O +
done O +
in O +
[ O -
5 O -
] O -
. O +

In O +
this O +
case O +
indices O +
i O +
in O +
( O -
9 O -
) O -
, O +
( O -
12 O -
) O -
, O +
( O -
15 O -
) O +
correspond O +
not O +
to O +
individual O +
similar O +
sequences O -
, O +
but O +
to O +
primary O +
local O +
alignments O +
of O +
this O +
sequences O -
. O +

2 O -
) O +
Are O +
the O +
lengths O +
of O +
primary O +
local O +
alignments O +
taken O +
into O +
consideration O -
? O +

In O +
the O +
described O +
variant O +
lengths O +
of O +
primary O +
local O +
alignments O +
were O +
not O +
taken O +
into O +
consideration O -
, O +
but O +
these O +
lengths O +
can O +
be O +
considered O +
as O +
well O -
. O +

In O +
this O +
case O +
indices O +
i O +
in O +
( O -
9 O -
) O -
, O +
( O -
12 O -
) O -
, O +
( O -
15 O -
) O +
correspond O +
not O +
to O +
similar O +
sequences O +
or O +
primary O +
local O +
alignments O -
, O +
but O +
to O +
individual O +
positions O +
of O +
these O +
primary O +
local O +
alignments O +
( O -
as O +
in O +
case O +
of O +
FT O -
- O -
type O +
words O -
) O -
. O +

In O +
this O +
case O +
the O +
total O +
number O +
of O +
variates O +
ξi O +
is O +
equal O +
to O +
the O +
overall O +
length O +
of O +
all O +
primary O +
local O +
alignments O -
. O +

For O +
these O +
variants O +
of O +
statistics O +
long O +
local O +
alignments O +
turn O +
out O +
to O +
be O +
more O +
significant O +
than O +
short O +
local O +
alignments O +
with O +
the O +
same O +
power O -
. O +

3 O -
) O +
How O +
are O +
the O +
coefficients O +
ai O +
calculated O -
? O +

The O +
coefficients O +
ai O +
in O +
( O -
15 O -
) O +
can O +
be O +
calculated O +
using O +
different O +
methods O +
– O +
either O +
formula O +
( O -
13 O -
) O +
can O +
be O +
used O -
, O +
or O +
an O +
iterative O +
method O +
( O -
described O +
in O +
[ O -
5 O -
] O -
) O +
can O +
be O +
applied O -
. O +

( O -
For O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
the O +
coefficients O +
ai O +
are O +
always O +
calculated O +
using O +
formula O +
( O -
13 O -
) O -
) O -
. O +

As O +
there O +
are O +
3 O +
modifications O -
, O +
the O +
total O +
number O +
of O +
basic O +
variants O +
( O -
in O +
the O +
described O +
simplified O +
scheme O -
) O +
equals O +
23 O +
= O +
8 O +
( O -
and O +
for O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
it O +
equals O +
4 O -
) O -
. O +

So O -
, O +
variants O +
of O +
the O +
statistics O +
η O -
, O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O +
are O +
considered O +
in O +
this O +
paper O -
. O +

Moreover O -
, O +
for O +
the O +
purpose O +
of O +
comparison O +
( O -
as O +
in O +
the O +
paper O +
[ O -
5 O -
] O -
) O +
the O +
simple O +
statistic O +
( O -
18 O -
) O -
q O -
= O -
q O -
( O -
ω O -
) O -
=∑inξin O +
( O -
the O +
frequency O +
of O +
occurrence O +
of O +
a O +
word O +
ω O +
in O +
the O +
collection O +
of O +
similar O +
sequences O -
) O +
is O +
also O +
considered O -
. O +

Finally O +
we O +
quote O +
a O +
scheme O +
of O +
the O +
A4 O +
algorithm O +
in O +
Figure O +
1 O +
( O -
this O +
scheme O +
is O +
essentially O +
taken O +
from O +
[ O -
5 O -
] O -
) O -
. O +

A O +
short O +
description O +
of O +
each O +
stage O +
can O +
be O +
found O +
in O +
[ O -
5 O -
] O -
. O +

Here O +
we O +
only O +
note O +
that O +
the O +
most O +
time O -
- O -
consuming O +
stage O +
is O +
the O +
first O +
one O +
– O +
the O +
generation O +
of O +
a O +
collection O +
of O +
similar O +
sequences O -
. O +

We O +
also O +
note O +
that O +
in O +
the O +
current O +
investigation O +
regions O +
were O +
not O +
determined O -
, O +
and O +
the O +
prediction O +
was O +
performed O +
for O +
the O +
whole O +
query O +
sequence O -
. O +

Testing O +
results O +
Testing O +
scheme O +
A O +
collection O +
of O +
518 O +
sequences O -
, O +
randomly O +
selected O +
from O +
SWISS O -
- O -
PROT O +
databank O -
, O +
was O +
generated O -
. O +

Note O +
that O +
only O +
initially O +
annotated O +
sequences O +
( O -
i.e. O -
, O +
sequences O +
whose O +
description O +
fields O +
were O +
not O +
obtained O +
by O +
the O +
extension O +
from O +
similar O +
sequences O -
) O +
were O +
selected O -
. O +

The O +
prediction O +
was O +
performed O +
for O +
KW O -
- O -
type O +
words O -
. O +

All O +
selected O +
sequences O +
were O +
divided O +
into O +
two O +
groups O -
. O +

The O +
first O +
group O +
contained O +
210 O +
sequences O -
. O +

This O +
group O +
was O +
used O +
during O +
the O +
" O -
learning O +
stage O -
" O -
: O +
the O +
procedure O +
was O +
applied O +
to O +
all O +
sequences O +
from O +
the O +
group O -
, O +
and O +
values O +
of O +
procedure O +
parameters O +
( O -
including O +
optimal O +
threshold O +
values O -
) O +
that O +
minimize O +
the O +
total O +
number O +
of O +
errors O +
for O +
the O +
first O +
group O +
were O +
selected O -
. O +

The O +
remaining O +
308 O +
sequences O +
were O +
used O +
for O +
the O +
" O -
main O +
testing O -
" O +
that O +
was O +
performed O +
using O +
parameter O +
values O +
obtained O +
on O +
the O +
basis O +
of O +
" O -
learning O -
" O +
results O -
. O +

A O +
list O +
of O +
all O +
these O +
308 O +
sequences O +
is O +
given O +
in O +
Additional O +
file O +
1 O -
. O +

The O +
total O +
number O +
of O +
KW O -
- O -
type O +
words O +
in O +
the O +
description O +
fields O +
of O +
308 O +
selected O +
sequences O -
, O +
used O +
as O +
query O +
sequences O -
, O +
was O +
equal O +
to O +
1176 O +
( O -
the O +
positive O +
prediction O +
was O +
preferable O +
for O +
these O +
words O -
) O -
. O +

As O +
it O +
was O +
noted O -
, O +
a O +
collection O +
of O +
similar O +
sequences O +
was O +
generated O +
for O +
each O +
query O +
sequence O -
; O +
the O +
number O +
of O +
sequences O +
in O +
these O +
collections O +
equaled O +
100 O -
. O +

Then O +
the O +
list O +
of O +
all O +
KW O -
- O -
type O +
words O +
from O +
description O +
fields O +
of O +
similar O +
sequences O +
was O +
formed O -
. O +

The O +
majority O +
of O +
these O +
words O +
belonged O +
only O +
to O +
one O +
similar O +
sequence O -
. O +

All O +
such O +
words O +
are O +
degenerate O -
, O +
transfer O +
probabilities O +
are O +
not O +
defined O +
for O +
them O -
. O +

At O +
the O +
same O +
time O +
nearly O +
all O +
these O +
words O +
did O +
not O +
belong O +
to O +
the O +
query O +
sequence O -
. O +

Hence O +
it O +
was O +
sensible O +
to O +
perform O +
prediction O +
only O +
for O +
words O +
that O +
belonged O +
to O +
at O +
least O +
two O +
similar O +
sequences O -
. O +

For O +
all O +
these O +
words O +
transfer O +
probabilities O +
were O +
evaluated O -
, O +
non O -
- O -
degenerate O +
words O +
( O -
i.e. O -
, O +
words O +
with O +
defined O +
transfer O +
probabilities O -
) O +
were O +
determined O -
, O +
and O +
the O +
prediction O +
was O +
performed O +
( O -
for O +
both O +
degenerate O +
and O +
non O -
- O -
degenerate O +
words O -
) O -
. O +

Table O +
1 O +
shows O +
certain O +
characteristics O +
of O +
sequences O +
used O +
for O +
the O +
testing O -
. O +

The O +
average O +
number O +
of O +
words O +
considered O +
per O +
query O +
sequence O +
equals O +
30 O +
and O +
the O +
entire O +
range O +
was O +
from O +
3 O +
to O +
67 O -
. O +

Final O +
results O +
Testing O +
results O +
are O +
presented O +
in O +
Table O +
2 O -
. O +

The O +
table O +
contains O +
testing O +
results O +
for O +
the O +
basic O +
statistics O +
η O -
, O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O +
as O +
well O +
as O +
for O +
the O +
statistics O +
q O +
and O +
SAnd O -
, O +
included O +
into O +
the O +
table O +
for O +
the O +
purpose O +
of O +
comparison O +
( O -
See O +
the O +
Discussion O +
section O -
) O -
. O +

Each O +
line O +
of O +
the O +
table O +
corresponds O +
to O +
a O +
certain O +
variant O +
of O +
studied O +
statistics O -
. O +

The O +
first O +
column O +
shows O +
which O +
statistic O +
and O +
which O +
variant O +
of O +
this O +
statistic O +
corresponds O +
to O +
a O +
line O -
. O +

Variants O +
are O +
given O +
in O +
square O +
brackets O -
: O +
the O +
first O +
number O +
equals O +
0 O +
if O +
lengths O +
of O +
primary O +
local O +
alignments O +
are O +
not O +
considered O -
, O +
and O +
1 O +
otherwise O -
; O +
the O +
second O +
number O +
equals O +
0 O +
if O +
the O +
coefficients O +
ai O +
are O +
calculated O +
using O +
formula O +
( O -
13 O -
) O -
, O +
and O +
1 O +
if O +
the O +
coefficients O +
ai O +
are O +
calculated O +
using O +
the O +
iterative O +
procedure O +
( O -
for O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
the O +
second O +
number O +
is O +
always O +
0 O -
) O -
. O +

The O +
second O +
column O +
contains O +
the O +
number O +
N1 O +
of O +
type O +
1 O +
errors O +
( O -
i.e. O -
, O +
number O +
of O +
cases O +
when O +
the O +
prediction O +
for O +
a O +
word O +
that O +
belongs O +
to O +
description O +
fields O +
of O +
a O +
query O +
sequence O +
is O +
negative O -
) O -
. O +

The O +
third O +
column O +
contains O +
the O +
number O +
N2 O +
of O +
type O +
2 O +
errors O +
( O -
i.e. O -
, O +
number O +
of O +
cases O +
when O +
the O +
prediction O +
for O +
a O +
word O +
that O +
does O +
not O +
belong O +
to O +
description O +
fields O +
of O +
a O +
query O +
sequence O +
is O +
positive O -
) O -
. O +

The O +
forth O +
column O +
contains O +
the O +
total O +
number O +
of O +
errors O +
Nall O +
= O +
N1 O +
+ O +
N2 O -
. O +

The O +
next O +
columns O +
contain O +
sums O +
P O -
( O -
1 O -
) O +
+ O +
P O -
( O -
2 O -
) O +
and O +
P O -
( O -
1 O -
) O +
+ O +
P O -
( O -
+ O -
) O -
, O +
where O +
P O -
( O -
1 O -
) O +
is O +
the O +
proportion O +
of O +
type O +
1 O +
errors O -
, O +
P O -
( O -
2 O -
) O +
is O +
the O +
proportion O +
of O +
type O +
2 O +
errors O -
, O +
and O +
P O -
( O -
+ O -
) O +
is O +
the O +
ratio O +
of O +
false O +
positive O +
predictions O +
to O +
the O +
total O +
number O +
of O +
predictions O -
: O +
P O -
( O -
1 O -
) O -
=N1nq O -
, O +
P O -
( O -
2 O -
) O -
=N2nall−nq O -
, O +
P O -
( O -
+ O -
) O -
=N2n+ O +
( O -
nall O +
is O +
the O +
total O +
number O +
of O +
words O +
for O +
which O +
the O +
prediction O +
is O +
performed O -
, O +
i.e. O -
, O +
total O +
number O +
of O +
KW O -
- O -
type O +
words O +
in O +
description O +
fields O +
of O +
all O +
sequences O -
, O +
similar O +
to O +
at O +
least O +
one O +
query O +
sequence O -
, O +
nq O +
is O +
the O +
number O +
of O +
words O +
( O -
from O +
the O +
list O +
of O +
these O +
nall O +
words O -
) O +
that O +
belong O +
to O +
query O +
sequences O -
, O +
n+ O +
is O +
the O +
total O +
number O +
of O +
words O +
for O +
which O +
the O +
prediction O +
is O +
positive O -
; O +
here O +
nall O +
= O +
9236 O -
, O +
nq O +
= O +
1176 O -
, O +
nall O +
- O +
nq O +
= O +
8060 O -
; O +
the O +
value O +
of O +
n+ O +
of O +
depends O +
on O +
the O +
threshold O +
evaluated O +
for O +
the O +
given O +
version O +
of O +
statistic O +
at O +
the O +
" O -
learning O +
stage O -
" O -
) O -
. O +

Lines O +
are O +
ordered O +
according O +
to O +
the O +
prediction O +
quality O -
: O +
higher O +
lines O +
correspond O +
to O +
statistic O +
variants O +
with O +
lower O +
total O +
number O +
of O +
errors O -
. O +

For O +
a O +
fixed O +
statistic O -
, O +
lines O +
that O +
correspond O +
to O +
the O +
best O +
variant O +
of O +
this O +
statistic O +
( O -
i.e. O -
, O +
for O +
the O +
variant O +
that O +
leads O +
to O +
the O +
lowest O +
total O +
number O +
of O +
errors O -
) O +
are O +
marked O -
. O +

Recall O +
that O +
the O +
statistic O +
T^ O -
( O -
2 O -
) O -
[ O -
1,0 O -
] O +
is O +
exactly O +
the O +
statistic O +
that O +
was O +
considered O +
in O +
[ O -
5 O -
] O +
( O -
note O +
that O +
it O +
is O +
the O +
best O +
variant O +
for O +
the O +
statistic O +
T^ O -
( O -
2 O -
) O -
) O -
. O +

The O +
results O +
could O +
also O +
have O +
been O +
presented O +
as O +
a O +
confusion O +
table O +
as O +
laid O +
out O +
in O +
Table O +
3 O -
, O +
but O +
doing O +
so O +
for O +
all O +
variants O +
would O +
take O +
a O +
lot O +
of O +
space O -
. O +

The O +
testing O +
results O +
showed O +
that O +
the O +
first O +
modification O +
( O -
consideration O +
of O +
all O +
primary O +
local O +
alignments O +
or O +
only O +
one O +
primary O +
local O +
alignment O +
with O +
the O +
maximum O +
power O -
) O +
did O +
not O +
significantly O +
affect O +
the O +
prediction O +
quality O -
, O +
so O +
results O +
are O +
only O +
presented O +
for O +
one O +
case O +
( O -
all O +
local O +
alignments O +
are O +
considered O -
, O +
similarly O +
to O +
[ O -
5 O -
] O -
) O -
. O +

Note O +
that O +
the O +
results O +
presented O +
in O +
the O +
Table O +
correspond O +
to O +
the O +
whole O +
totality O +
of O +
words O +
including O +
degenerate O +
words O +
( O -
though O +
statistics O +
η O -
, O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O -
, O +
T O -
( O -
nik O -
) O +
were O +
evaluated O +
only O +
for O +
non O -
- O -
degenerate O +
words O -
, O +
for O +
degenerate O +
words O +
the O +
prediction O +
was O +
performed O +
on O +
the O +
basis O +
of O +
the O +
statistic O +
q O -
, O +
i.e. O -
, O +
on O +
the O +
basis O +
of O +
word O +
frequency O -
) O -
. O +

In O +
particular O -
, O +
the O +
total O +
number O +
of O +
errors O +
includes O +
errors O +
for O +
degenerate O +
words O -
. O +

It O +
is O +
worth O +
noticing O +
that O +
the O +
total O +
number O +
of O +
errors O +
for O +
degenerate O +
words O +
in O +
case O +
of O +
the O +
best O +
choice O +
of O +
threshold O +
q0 O +
for O +
the O +
frequency O +
q O -
( O -
ω O -
) O +
turned O +
out O +
to O +
be O +
surprisingly O +
small O -
: O +
only O +
13 O +
( O -
whereas O +
the O +
number O +
of O +
errors O +
for O +
the O +
whole O +
totality O +
of O +
words O +
was O +
220 O -
) O -
; O +
these O +
errors O +
included O +
twelve O +
type O +
1 O +
errors O +
and O +
one O +
type O +
2 O +
error O +
( O -
recall O +
that O +
the O +
prediction O +
was O +
performed O +
for O +
2029 O +
degenerate O +
words O -
, O +
and O +
the O +
prediction O +
was O +
incorrect O +
only O +
in O +
13 O +
cases O -
) O -
. O +

Such O +
a O +
small O +
number O +
of O +
errors O +
can O +
seemingly O +
be O +
explained O +
by O +
the O +
fact O +
that O +
for O +
degenerate O +
words O +
the O +
frequency O +
q O -
( O -
ω O -
) O +
is O +
nearly O +
always O +
close O +
either O +
to O +
1 O +
or O +
to O +
0 O -
, O +
otherwise O +
in O +
almost O +
all O +
cases O +
transfer O +
probabilities O +
p1|1 O -
, O +
p1|0 O +
can O +
be O +
defined O +
for O +
at O +
least O +
some O +
values O +
of O +
similarity O +
measure O +
μ O +
and O +
hence O +
a O +
word O +
ω O +
turns O +
out O +
to O +
be O +
non O -
- O -
degenerate O -
. O +

We O +
also O +
note O +
that O +
along O +
with O +
type O +
1 O +
and O +
type O +
2 O +
errors O +
other O +
errors O +
can O +
occur O -
, O +
as O +
it O +
is O +
possible O +
that O +
some O +
words O +
from O +
description O +
fields O +
of O +
a O +
query O +
sequence O +
do O +
not O +
belong O +
to O +
description O +
fields O +
of O +
similar O +
sequences O +
and O +
hence O +
the O +
prediction O +
is O +
not O +
performed O +
for O +
these O +
words O +
at O +
all O -
. O +

However O -
, O +
we O +
used O +
a O +
large O +
number O +
of O +
similar O +
sequences O +
( O -
100 O -
) O +
for O +
the O +
prediction O -
, O +
so O +
such O +
errors O +
were O +
extremely O +
rare O +
( O -
only O +
two O +
words O +
for O +
the O +
whole O +
test O +
set O +
of O +
518 O +
sequences O -
, O +
whereas O +
the O +
number O +
of O +
words O +
for O +
which O +
the O +
prediction O +
was O +
performed O +
equaled O +
9236 O -
) O -
. O +

Hence O -
, O +
in O +
our O +
case O +
these O +
errors O +
can O +
be O +
disregarded O -
. O +

Statistical O +
analysis O +
showed O +
that O +
the O +
precision O +
of O +
the O +
evaluation O +
of O +
N1 O -
, O +
N2 O -
, O +
Nall O +
is O +
reasonable O -
: O +
it O +
can O +
be O +
checked O +
that O +
the O +
relative O +
precision O +
of O +
Nall O +
( O -
the O +
standard O +
error O +
of O +
ln O -
( O -
Nall O -
) O -
) O +
is O +
in O +
the O +
order O +
of O +
7–10 O -
% O +
which O +
is O +
in O +
line O +
with O +
the O +
relative O +
precision O +
of O +
a O +
Poisson O +
random O +
variable O +
that O +
is O +
given O +
by O +
1 O -
/ O -
Nall O -
. O +

However O -
, O +
since O +
the O +
" O -
methods O -
" O +
( O -
the O +
statistics O +
and O +
their O +
variants O -
) O +
are O +
compared O +
on O +
the O +
same O +
sequences O -
, O +
the O +
standard O +
error O +
for O +
the O +
comparison O +
between O +
methods O +
is O +
much O +
smaller O +
due O +
to O +
the O +
high O +
correlation O +
of O +
results O +
for O +
the O +
same O +
sequence O +
and O +
is O +
in O +
the O +
order O +
of O +
2–4 O -
% O -
. O +

This O +
implies O +
that O +
" O -
methods O -
" O +
for O +
which O +
Nall O +
differ O +
by O +
more O +
than O +
10 O -
% O +
can O +
considered O +
to O +
be O +
significantly O +
different O -
. O +

This O +
shows O +
that O +
size O +
of O +
the O +
experiment O +
with O +
210 O +
randomly O +
selected O +
sequences O +
in O +
the O +
learning O +
stage O +
and O +
308 O +
sequences O +
in O +
the O +
testing O +
stage O +
is O +
large O +
enough O +
to O +
obtain O +
valid O +
statements O +
about O +
the O +
accuracy O +
of O +
the O +
proposed O +
methodology O +
and O +
allows O +
statistical O +
comparisons O +
of O +
different O +
statistics O +
and O +
variants O -
. O +

When O +
the O +
set O +
of O +
tested O +
sequences O +
is O +
fixed O -
, O +
the O +
total O +
number O +
of O +
errors O +
Nall O +
is O +
an O +
objective O +
characteristic O +
of O +
prediction O +
quality O -
, O +
and O +
the O +
optimal O +
threshold O +
values O +
( O -
selected O +
during O +
the O +
" O -
learning O +
stage O -
" O -
) O +
provide O +
exactly O +
the O +
minimum O +
of O +
the O +
total O +
number O +
of O +
errors O -
. O +

However O -
, O +
if O +
different O +
testing O +
results O +
( O -
based O +
on O +
different O +
sets O +
of O +
query O +
sequences O -
) O +
are O +
compared O -
, O +
then O +
absolute O +
numbers O +
of O +
errors O +
can O +
not O +
be O +
treated O +
as O +
a O +
procedure O +
quality O +
measure O -
, O +
and O +
relative O +
quantities O +
( O -
proportions O -
) O +
should O +
be O +
considered O +
instead O +
of O +
absolute O +
quantities O -
. O +

Usually O +
a O +
sum O +
of O +
the O +
proportion O +
of O +
type O +
1 O +
errors O +
and O +
the O +
proportion O +
of O +
type O +
2 O +
errors O +
P O -
( O -
1 O -
) O +
+ O +
P O -
( O -
2 O -
) O +
is O +
used O +
as O +
a O +
quality O +
measure O -
; O +
values O +
of O +
this O +
sum O +
are O +
presented O +
in O +
the O +
fifth O +
column O +
of O +
Table O +
2 O -
. O +

However O -
, O +
in O +
our O +
situation O +
the O +
number O +
of O +
words O +
nall O +
- O +
nq O +
that O +
do O +
not O +
belong O +
to O +
query O +
sequences O +
is O +
much O +
larger O +
than O +
nq O -
, O +
and O +
for O +
the O +
majority O +
of O +
these O +
words O +
it O +
is O +
obvious O +
that O +
they O +
do O +
not O +
belong O +
to O +
a O +
query O +
sequence O -
. O +

Consequently O -
, O +
in O +
case O +
of O +
optimal O +
parameter O +
values O +
the O +
proportion O +
of O +
type O +
2 O +
errors O +
P O -
( O -
2 O -
) O +
is O +
small O -
, O +
it O +
is O +
considerably O +
smaller O +
than O +
P O -
( O -
1 O -
) O -
. O +

Thus O +
the O +
quantity O +
P O -
( O -
1 O -
) O +
+ O +
P O -
( O -
2 O -
) O +
is O +
not O +
representative O +
in O +
our O +
case O +
( O -
see O +
[ O -
5 O -
] O -
) O -
. O +

The O +
ratio O +
P O -
( O -
+ O -
) O +
of O +
the O +
number O +
of O +
wrong O +
positive O +
predictions O +
to O +
the O +
total O +
number O +
of O +
positive O +
predictions O +
is O +
more O +
representative O +
than O +
P O -
( O -
2 O -
) O -
. O +

Hence O -
, O +
it O +
is O +
natural O +
to O +
measure O +
procedure O +
quality O +
by O +
the O +
sum O +
P O -
( O -
1 O -
) O +
+ O +
P O -
( O -
+ O -
) O -
. O +

Exactly O +
this O +
procedure O +
quality O +
measure O +
was O +
used O +
in O +
[ O -
5 O -
] O -
. O +

In O +
medical O +
decision O +
making O +
( O -
diagnostic O +
testing O -
) O +
the O +
terms O +
sensitivity O +
( O -
sens O +
= O +
1 O +
- O +
P O -
( O -
1 O -
) O -
) O +
and O +
specificity O +
( O -
spec O +
= O +
1 O +
- O +
P O -
( O -
2 O -
) O -
) O +
are O +
frequently O +
used O +
to O +
quantify O +
the O +
accuracy O +
of O +
a O +
procedure O -
, O +
while O +
the O +
quantity O +
1 O +
- O +
P O -
( O -
+ O -
) O +
is O +
known O +
as O +
the O +
positive O +
predictive O +
value O -
. O +

Alternative O +
terminology O +
is O +
discussed O +
in O +
[ O -
12 O -
] O -
. O +

The O +
ROC O +
curve O +
plotting O +
sens O +
against O +
1 O +
- O +
spec O +
is O +
a O +
popular O +
way O +
of O +
showing O +
the O +
overall O +
performance O +
of O +
a O +
diagnostic O +
test O +
without O +
specification O +
of O +
a O +
cut O +
off O +
value O -
. O +

It O +
is O +
also O +
used O +
and O +
discussed O +
in O +
[ O -
12 O -
] O -
, O +
but O +
with O +
different O +
labels O +
for O +
the O +
axes O -
. O +

Figure O +
2 O +
contains O +
ROC O +
curves O +
for O +
the O +
best O +
variants O +
of O +
the O +
statistics O +
( O -
i.e. O -
, O +
for O +
variants O +
that O +
were O +
marked O +
in O +
Table O +
2 O -
) O +
applied O +
to O +
the O +
non O -
- O -
degenerate O +
words O -
. O +

Discussion O +
Overall O +
comparison O +
of O +
the O +
statistics O +
T O -
( O -
1 O -
) O -
, O +
η O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O +
Mean O +
values O +
of O +
Nall O +
( O -
where O +
averaging O +
is O +
performed O +
over O +
all O +
variants O +
presented O +
in O +
Table O +
2 O -
) O +
for O +
different O +
statistics O +
are O +
the O +
following O -
: O +
241 O +
for O +
η O -
, O +
310 O +
for O +
T O -
( O -
1 O -
) O -
, O +
320 O +
for O +
T O -
( O -
2 O -
) O -
, O +
and O +
356 O +
for O +
T^ O -
( O -
2 O -
) O +
( O -
recall O +
that O +
differences O +
in O +
the O +
order O +
of O +
10 O -
% O +
can O +
be O +
considered O +
to O +
be O +
significant O -
) O -
. O +

These O +
numbers O +
show O +
that O +
the O +
statistics O +
can O +
clearly O +
be O +
ordered O +
with O +
respect O +
to O +
the O +
prediction O +
quality O -
: O +
the O +
best O +
statistic O +
is O +
η O -
, O +
then O +
comes O +
T O -
( O -
1 O -
) O -
, O +
then O +
T O -
( O -
2 O -
) O -
, O +
and O +
finally O +
T^ O -
( O -
2 O -
) O -
. O +

For O +
the O +
comparison O +
of O +
the O +
statistics O +
η O -
, O +
T O -
( O -
1 O -
) O -
, O +
as O +
well O +
as O +
for O +
the O +
comparison O +
of O +
statistics O +
the O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O +
this O +
conclusion O +
is O +
obvious O -
. O +

For O +
the O +
comparison O +
of O +
the O +
statistics O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O +
it O +
seems O +
to O +
be O +
less O +
obvious O -
, O +
but O +
the O +
consideration O +
of O +
variants O +
in O +
which O +
the O +
calculation O +
of O +
coefficients O +
ai O +
is O +
performed O +
using O +
formula O +
( O -
13 O -
) O +
( O -
i.e. O -
, O +
variants O +
[ O -
0,0 O -
] O +
and O +
[ O -
1,0 O -
] O -
; O +
recall O +
that O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
has O +
only O +
such O +
variants O -
) O +
clearly O +
shows O +
that O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
is O +
considerably O +
better O +
than O +
T O -
( O -
2 O -
) O -
. O +

The O +
same O +
conclusion O +
can O +
be O +
drawn O +
from O +
the O +
comparison O +
of O +
ROC O +
curves O +
presented O +
in O +
Fig. O +
2 O -
. O +

Testing O +
results O +
show O +
that O +
the O +
prediction O +
quality O +
for O +
the O +
best O +
variant O +
of O +
the O +
statistic O +
η O +
( O -
see O +
the O +
first O +
line O +
of O +
Table O +
2 O -
) O +
is O +
much O +
higher O +
( O -
higher O +
by O +
50 O -
% O -
) O +
in O +
comparison O +
with O +
results O +
of O +
[ O -
5 O -
] O +
( O -
see O +
the O +
line O +
of O +
Table O +
2 O +
that O +
corresponds O +
to O +
T^ O -
( O -
2 O -
) O -
[ O -
0,1 O -
] O -
) O -
. O +

That O +
is O +
the O +
most O +
striking O +
finding O +
of O +
the O +
current O +
paper O -
. O +

It O +
is O +
interesting O +
to O +
see O +
that O +
the O +
statistic O +
η O +
turned O +
out O +
to O +
be O +
better O +
than O +
T O -
( O -
1 O -
) O -
: O +
the O +
latter O +
would O +
be O +
expected O +
to O +
be O +
better O +
as O +
it O +
equals O +
the O +
logarithm O +
of O +
the O +
likelihood O +
ratio O +
( O -
in O +
reality O -
, O +
it O +
does O +
not O +
equal O +
this O +
logarithm O +
because O +
the O +
ξi O +
are O +
not O +
independent O -
) O -
. O +

We O +
suppose O +
that O +
this O +
fact O +
can O +
be O +
explained O +
as O +
follows O -
. O +

Recall O +
that O +
T O -
( O -
1 O -
) O +
and O +
η O +
are O +
equivalent O +
for O +
an O +
arbitrary O +
fixed O +
word O +
ω O -
. O +

These O +
statistics O +
turn O +
out O +
to O +
be O +
not O +
equivalent O +
only O +
if O +
they O +
are O +
compared O +
on O +
the O +
whole O +
totality O +
of O +
words O -
. O +

It O +
is O +
worth O +
noting O +
that O +
the O +
variation O +
of O +
the O +
values O +
of O +
the O +
statistic O +
T O -
( O -
1 O -
) O +
( O -
i.e. O -
, O +
the O +
difference O +
between O +
values O +
of O +
T O -
( O -
1 O -
) O +
in O +
cases O +
ξ1 O +
= O -
.... O -
= O +
ξn O +
= O +
0 O +
and O +
ξ1 O +
= O -
.... O -
= O +
ξn O +
= O +
1 O -
) O +
significantly O +
depends O +
on O +
a O +
word O +
ω O -
: O +
for O +
some O +
words O +
these O +
values O +
vary O +
from O +
-700 O +
to O +
700 O -
, O +
for O +
some O +
other O +
from O +
-0.01 O +
to O +
0.01 O -
. O +

In O +
principle O -
, O +
the O +
optimal O +
threshold O +
value O +
is O +
different O +
for O +
different O +
words O -
. O +

As O +
the O +
ranges O +
of O +
T O -
( O -
1 O -
) O +
values O +
essentially O +
vary O -
, O +
then O +
it O +
is O +
probable O +
that O +
optimal O +
thresholds O +
also O +
essentially O +
vary O -
. O +

The O +
optimal O +
threshold O +
for O +
the O +
whole O +
totality O +
of O +
words O +
is O +
a O +
certain O +
mean O +
value O +
of O +
thresholds O +
over O +
individual O +
words O +
ω O -
. O +

Since O +
the O +
optimal O +
thresholds O +
are O +
significantly O +
different O +
for O +
different O +
words O -
, O +
the O +
quality O +
of O +
the O +
mean O +
is O +
low O -
: O +
for O +
certain O +
words O +
( O -
e.g. O -
, O +
words O +
with O +
small O +
variation O +
of O +
T O -
( O -
1 O -
) O -
) O +

this O +
mean O +
is O +
completely O +
unrepresentative O -
. O +

In O +
the O +
same O +
time O -
, O +
the O +
range O +
of O +
values O +
of O +
η O +
is O +
the O +
same O +
for O +
all O +
words O +
( O -
these O +
values O +
lie O +
between O +
0 O +
and O +
1 O -
) O -
. O +

Consequently O -
, O +
the O +
difference O +
between O +
optimal O +
thresholds O +
for O +
individual O +
words O +
is O +
probably O +
not O +
so O +
significant O -
, O +
and O +
the O +
mean O +
gives O +
better O +
quality O +
for O +
individual O +
words O +
in O +
comparison O +
with O +
T O -
( O -
1 O -
) O -
. O +

From O +
the O +
point O +
of O +
view O +
of O +
prediction O +
quality O +
the O +
statistic O +
T O -
( O -
2 O -
) O +
turned O +
out O +
to O +
be O +
worse O +
than O +
T O -
( O -
1 O -
) O -
. O +

It O +
is O +
not O +
surprising O -
, O +
because O +
during O +
the O +
derivation O +
of O +
the O +
formula O +
for O +
T O -
( O -
2 O -
) O +
along O +
with O +
the O +
incorrect O +
assumption O +
of O +
independence O +
of O +
ξi O +
we O +
also O +
made O +
the O +
incorrect O +
assumption O +
of O +
the O +
normal O +
distribution O +
of O +
η O -
. O +

This O +
consideration O +
is O +
applicable O +
to O +
T^ O -
( O -
2 O -
) O +
as O +
well O -
. O +

Since O +
the O +
cut O -
- O -
off O +
points O +
for O +
these O +
statistics O +
are O +
determined O +
empirically O +
in O +
the O +
test O +
set O +
and O +
validated O +
in O +
the O +
training O +
set O -
, O +
the O +
violation O +
of O +
the O +
normality O +
assumption O +
does O +
not O +
invalidate O +
the O +
procedures O +
as O +
such O -
, O +
but O +
might O +
affect O +
their O +
performance O -
. O +

Effect O +
of O +
procedure O +
modifications O +
The O +
next O +
issue O +
is O +
the O +
dependence O +
of O +
prediction O +
quality O +
on O +
procedure O +
modifications O -
. O +

One O +
can O +
see O +
that O +
for O +
a O +
fixed O +
statistic O +
the O +
prediction O +
quality O +
significantly O +
depends O +
on O +
the O +
choice O +
of O +
the O +
variant O -
. O +

Thus O -
, O +
the O +
introduction O +
of O +
modifications O +
turned O +
out O +
to O +
be O +
effective O -
. O +

It O +
is O +
interesting O +
that O +
all O +
statistics O +
for O +
which O +
coefficients O +
aj O +
can O +
be O +
calculated O +
in O +
different O +
ways O +
( O -
these O +
are O +
the O +
statistics O +
η O -
, O +
T O -
( O -
2 O -
) O +
T^ O -
( O -
2 O -
) O -
) O +
prediction O +
quality O +
was O +
better O +
in O +
case O +
when O +
these O +
coefficients O +
were O +
calculated O +
using O +
the O +
iterative O +
procedure O -
. O +

At O +
the O +
same O +
time O +
the O +
dependence O +
of O +
prediction O +
quality O +
on O +
the O +
modification O +
related O +
to O +
the O +
consideration O +
of O +
lengths O +
of O +
primary O +
local O +
alignments O +
is O +
more O +
intricate O -
: O +
for O +
the O +
statistic O +
η O -
, O +
and O +
to O +
a O +
lesser O +
extent O +
for O +
the O +
statistics O +
T O -
( O -
1 O -
) O -
, O +
T O -
( O -
2 O -
) O -
, O +
the O +
results O +
are O +
better O +
if O +
lengths O +
of O +
primary O +
local O +
alignments O +
are O +
considered O -
, O +
but O +
for O +
the O +
statistic O +
T^ O -
( O -
2 O -
) O +
results O +
are O +
better O +
when O +
lengths O +
of O +
primary O +
local O +
alignments O +
are O +
not O +
considered O -
. O +

Currently O +
reasons O +
of O +
this O +
fact O +
are O +
not O +
clear O +
for O +
us O -
. O +

As O +
it O +
was O +
noted O -
, O +
the O +
dependence O +
of O +
results O +
on O +
modifications O +
dealing O +
with O +
the O +
number O +
of O +
considered O +
primary O +
local O +
alignments O +
for O +
similar O +
sequences O +
is O +
not O +
essential O -
. O +

( O -
However O -
, O +
we O +
note O +
that O +
for O +
nearly O +
all O +
variants O +
that O +
were O +
described O +
above O +
as O +
well O +
as O +
variants O +
that O +
were O +
not O +
described O -
, O +
prediction O +
quality O +
is O +
better O +
in O +
case O +
when O +
all O +
primary O +
local O +
alignments O +
are O +
considered O -
) O -
. O +

Comparison O +
with O +
other O +
procedures O +
For O +
the O +
purpose O +
of O +
comparison O +
we O +
compared O +
our O +
findings O +
with O +
the O +
simple O +
statistic O +
q O -
( O -
ω O -
) O +
( O -
the O +
frequency O +
of O +
word O +
occurrence O +
in O +
the O +
list O +
of O +
similar O +
sequences O -
, O +
see O +
( O -
18 O -
) O -
) O +
was O +
also O +
considered O -
, O +
using O +
a O +
threshold O +
of O +
q O +
= O +
0.422 O -
. O +

As O +
expected O -
, O +
q O -
( O -
ω O -
) O +
gave O +
essentially O +
worse O +
results O +
in O +
comparison O +
with O +
T O -
( O -
1 O -
) O -
, O +
η O -
, O +
T O -
( O -
2 O -
) O -
, O +
T^ O -
( O -
2 O -
) O +
( O -
see O +
Table O +
2 O -
) O -
. O +

Furthermore O -
, O +
we O +
compared O +
our O +
results O +
with O +
the O +
results O -
, O +
which O +
predicts O +
all O +
of O +
the O +
words O +
for O +
which O +
there O +
is O +
among O +
similar O +
sequences O +
at O +
least O +
one O +
sequence O +
with O +
a O +
power O +
above O +
a O +
certain O +
threshold O -
. O +

Such O +
an O +
approach O +
was O +
used O +
by O +
Andrade O +
M. O +
et O +
al. O +
[ O -
2 O -
] O -
. O +

This O +
is O +
the O +
statistics O +
SAnd O +
as O +
already O +
mentioned O +
in O +
Table O +
2 O -
. O +

It O +
is O +
defined O +
as O +
SAnd O -
( O -
ω O -
) O +
= O +
max O +
μj O -
, O +
where O +
μj O +
is O +
the O +
measure O +
of O +
similarity O +
between O +
sequences O +
π0 O -
, O +
πj O -
, O +
and O +
the O +
maximum O +
is O +
taken O +
on O +
the O +
j O +
for O +
which O +
ξj O -
( O -
ω O -
) O +
= O +
1 O +
( O -
i.e. O +
the O +
word O +
belongs O +
to O +
these O +
sequences O -
) O -
. O +

In O +
our O +
application O +
similarity O +
is O +
measured O +
by O +
the O +
power O +
value O +
( O -
see O +
[ O -
9,10 O -
] O -
) O +
as O +
used O +
in O +
the O +
other O +
statistics O +
in O +
this O +
paper O +
and O +
mentioned O +
before O -
, O +
while O +
[ O -
2 O -
] O +
used O +
the O +
E O -
- O -
value O -
. O +

That O +
makse O +
the O +
cut O -
- O -
offs O +
hard O +
to O +
compare O -
. O +

The O +
results O +
for O +
these O +
statistics O +
are O +
given O +
in O +
the O +
same O +
Table O +
2 O -
. O +

The O +
results O +
were O +
better O +
than O +
in O +
the O +
statistics O +
q O -
( O -
ω O -
) O -
, O +
but O +
worse O +
than O +
in O +
any O +
of O +
our O +
statistics O -
. O +

Surprisingly O -
, O +
it O +
turned O +
out O +
that O +
the O +
prediction O +
quality O +
is O +
better O +
when O +
only O +
some O +
similar O +
sequences O +
( O -
e.g. O -
, O +
10 O +
from O +
100 O -
) O +
are O +
used O +
for O +
the O +
evaluation O +
of O +
a O +
statistic O +
( O -
but O +
not O +
for O +
the O +
evaluation O +
of O +
transfer O +
probabilities O -
! O -
) O -
. O +

It O +
means O +
that O +
a O +
large O +
part O +
of O +
similar O +
sequences O +
only O +
leads O +
to O +
an O +
increase O +
of O +
" O -
noise O -
" O -
. O +

( O -
See O +
[ O -
13 O -
] O +
for O +
details O -
. O -
) O +

We O +
would O +
also O +
like O +
to O +
mention O +
the O +
work O +
[ O -
14 O -
] O +
on O +
FunCat O +
categories O +
containing O +
a O +
set O +
of O +
about O +
7,500 O +
well O +
annotated O +
proteins O +
and O +
providing O +
a O +
benchmarking O +
for O +
different O +
methods O +
of O +
automated O +
annotation O -
. O +

It O +
would O +
be O +
interesting O +
to O +
apply O +
our O +
procedure O +
to O +
this O +
database O -
, O +
but O +
that O +
has O +
not O +
been O +
realized O +
yet O -
. O +

We O +
did O +
not O +
attempt O +
at O +
this O +
stage O +
to O +
apply O +
our O +
approach O +
to O +
the O +
GO O +
annotation O -
. O +

It O +
would O +
be O +
interesting O +
further O +
research O +
to O +
switch O +
to O +
GO O +
data O +
and O +
to O +
compare O +
our O +
approach O +
with O +
other O +
approaches O +
in O +
the O +
literature O -
. O +

There O +
is O +
a O +
similarity O +
with O +
the O +
approach O +
of O +
Kajan O +
et O +
al. O +
[ O -
15 O -
] O -
. O +

They O +
also O +
base O +
their O +
procedures O +
on O +
the O +
likelihood O +
ratio O -
, O +
but O +
use O +
approximations O +
based O +
on O +
maximal O +
similarity O +
( O -
or O +
minimal O +
distance O -
) O -
, O +
while O +
we O +
attempt O +
to O +
estimate O +
the O +
likelihood O +
ratio O +
from O +
pairwise O +
comparisons O +
within O +
the O +
set O +
of O +
similar O +
sequences O -
. O +

There O +
is O +
also O +
an O +
interesting O +
relation O +
with O +
the O +
GOPET O +
tool O +
presented O +
in O +
[ O -
16 O -
] O +
based O +
on O +
earlier O +
work O +
by O +
the O +
same O +
authors O +
[ O -
17 O -
] O -
. O +

These O +
authors O +
use O +
a O +
number O +
of O +
characteristics O +
of O +
the O +
set O +
of O +
found O +
similar O +
sequences O +
for O +
term O +
( O -
word O -
) O -
, O +
such O +
as O +
maximal O +
e O -
- O -
value O -
, O +
frequency O +
of O +
the O +
term O +
etc O -
. O -
, O +
as O +
a O +
coordinates O +
of O +
decision O +
making O +
space O -
. O +

They O +
use O +
more O +
features O +
while O +
we O +
concentrate O +
on O +
the O +
similarity O -
. O +

That O +
might O +
be O +
an O +
advantage O +
for O +
their O +
method O -
. O +

On O +
the O +
other O +
hand O +
we O +
try O +
to O +
use O +
the O +
information O +
from O +
all O +
similar O +
sequences O +
in O +
an O +
optimal O +
way O +
relying O +
on O +
statistical O +
decision O +
theory O +
by O +
means O +
of O +
the O +
use O +
of O +
transfer O +
probabilities O +
and O +
the O +
concept O +
of O +
likelihood O +
ratio O -
. O +

It O +
is O +
an O +
interesting O +
topic O +
of O +
further O +
research O +
to O +
compare O +
the O +
two O +
methods O -
. O +

So O +
far O +
we O +
only O +
predicted O +
the O +
presence O +
of O +
a O +
key O +
word O -
. O +

It O +
is O +
quite O +
a O +
challenge O +
to O +
obtain O +
a O +
true O +
prediction O +
of O +
function O -
. O +

Conclusion O +
The O +
main O +
conclusion O +
of O +
the O +
paper O +
is O +
that O +
the O +
introduction O +
of O +
the O +
concept O +
of O +
likelihood O +
ratio O +
coming O +
from O +
statistical O +
decision O +
theory O +
is O +
very O +
helpful O +
in O +
the O +
development O +
of O +
automated O +
annotation O +
procedures O -
. O +

We O +
obtained O +
a O +
substantial O +
improvement O +
when O +
compared O +
with O +
our O +
previous O +
results O -
. O +

We O +
are O +
sure O +
that O +
there O +
is O +
room O +
for O +
further O +
improvement O -
. O +

Issues O +
for O +
further O +
research O +
are O +
the O +
size O +
of O +
the O +
set O +
of O +
similar O +
sequences O +
and O +
the O +
combination O +
of O +
different O +
statistics O +
into O +
a O +
" O -
super O -
- O -
predictor O -
" O -
. O +

Authors O -
' O +
contributions O +
A.M. O +
Leontovich O +
and O +
H.C. O +
van O +
Houwelingen O +
developed O +
the O +
approach O -
. O +

A.M. O +
Leontovich O +
developed O +
the O +
methodology O +
and O +
the O +
algorithms O +
in O +
cooperation O +
with O +
K.Y. O +
Tokmachev O +
and O +
H.C. O +
van O +
Houwelingen O -
. O +

K.Y. O +
Tokmachev O +
carried O +
out O +
all O +
computations O -
. O +

Supplementary O +
Material O +

Carbonic O +
Anhydrase O +
Inhibitors O -
. O +

Part O +
541 O -
: O +
Metal O +
Complexes O +
of O +
Heterocyclic O +
Sulfonamides O -
: O +
A O +
New O +
Class O +
of O +
Antiglaucoma O +
Agents O +
Abstract O +
Metal O +
complexes O +
of O +
heterocyclic O +
sulfonamides O +
possessing O +
carbonic O +
anhydrase O +
( O -
CA O -
) O +
inhibitory O +
properties O +
were O +
recently O +
shown O +
to O +
be O +
useful O +
as O +
intraocular O +
pressure O +
( O -
IOP O -
) O +
lowering O +
agents O +
in O +
experimental O +
animals O -
, O +
and O +
might O +
be O +
developed O +
as O +
a O +
novel O +
class O +
of O +
antiglaucoma O +
drugs O -
. O +

Here O +
we O +
report O +
the O +
synthesis O +
of O +
a O +
heterocyclic O +
sulfonamide O +
CA O +
inhibitor O +
and O +
of O +
the O +
metal O +
complexes O +
containing O +
main O +
group O +
metal O +
ions O -
, O +
such O +
as O +
Be O -
( O -
II O -
) O -
, O +
Mg O -
( O -
II O -
) O -
, O +
Al O -
( O -
III O -
) O -
, O +
Zn O -
( O -
II O -
) O -
, O +
Cd O -
( O -
II O -
) O +
and O +
Hg O -
( O -
II O -
) O +
and O +
the O +
new O +
sulfonamide O +
as O +
well O +
as O +
5-amino-1,3,4-thiadiazole-2-sulfonamide O +
as O +
ligands O -
. O +

The O +
new O +
complexes O +
were O +
characterized O +
by O +
standard O +
physico O -
- O -
chemical O +
procedures O -
, O +
and O +
assayed O +
as O +
inhibitors O +
of O +
three O +
CA O +
isozymes O -
, O +
CA O +
I O -
, O +
II O +
and O +
IV O -
. O +

Some O +
of O +
them O +
( O -
but O +
not O +
the O +
parent O +
sulfonamides O -
) O +
strongly O +
lowered O +
IOP O +
in O +
rabbits B-Species +
when O +
administered O +
as O +
a O +
2 O -
% O +
solution O +
into O +
the O +
eye O -
. O +

CARBONIC O +
ANHYDRASE O +
INHIBITORS O -
. O +

Part O +
54 O +
METAL O +
COMPLEXES O +
OF O +
HETEROCYCLIC O +
SULFONAMIDES O -
: O +
A O +
NEW O +
CLASS O +
OF O +
ANTIGLAUCOMA O +
AGENTS O +
Claudiu O +
T. O +
Supuran O +

* O -
, O +
Andrea O +
Scozzafava O +
and O +
Andrei O +
Jitianu O +
2 O +
Universit O -
& O +
degli O +
Studi O -
, O +
Dipartimento O +
di O +
Chimica O -
, O +
Laboratorio O +
di O +
Chimica O +
Inorganica O +

e O +
Bioinorganica O -
, O +
Via O +
Gino O +
Capponi O +
7 O -
, O +
1 O -
- O -
50121 O -
, O +
Florence O -
, O +
Italy O +
2 O +

" O -
I.G. O +
Murgulescu O -
" O +
Institute O +
of O +
Physical O +
Chemistry O -
, O +
Academia O +
Romana O -
, O +
Spl O -
. O +

Independentei O +
202 O -
, O +
R-77208 O +
Bucharest O -
, O +
Roumania O +
Abstract O -
: O +
Metal O +
complexes O +
of O +
heterocyclic O +
sulfonamides O +
possessing O +
carbonic O +
anhydrase O +
( O -
CA O -
) O +
inhibitory O +
properties O +
were O +
recently O +
shown O +
to O +
be O +
useful O +
as O +
intraocular O +
pressure O +
( O -
IOP O -
) O +
lowering O +
agents O +
in O +
experimental O +
animals O -
, O +
and O +
might O +
be O +
developed O +
as O +
a O +
novel O +
class O +
of O +
antiglaucoma O +
drugs O -
. O +

Here O +
we O +
report O +
the O +
synthesis O +
of O +
a O +
heterocyclic O +
sulfonamide O +
CA O +
inhibitor O +
and O +
of O +
the O +
metal O +
complexes O +
containing O +
main O +
group O +
metal O +
ions O -
, O +
such O +
as O +
Be O -
( O -
II O -
) O -
, O +
Mg O -
( O -
II O -
) O -
, O +
AI O -
( O -
III O -
) O -
, O +
Zn O -
( O -
II O -
) O -
, O +
Cd O -
( O -
II O -
) O +
and O +
Hg O -
( O -
II O -
) O +
and O +
the O +
new O +
sulfonamide O +
as O +
well O +
as O +
5-amino O -
- O -
l,3,4thiadiazole-2-sulfonamide O +
as O +
ligands O -
. O +

The O +
new O +
complexes O +
were O +
characterized O +
by O +
standard O +
physico O -
- O -
chemical O +
procedures O -
, O +
and O +
assayed O +
as O +
inhibitors O +
of O +
three O +
CA O +
isozymes O -
, O +
CA O +
I O -
, O +
II O +
and O +
IV O -
. O +

Some O +
of O +
them O +
( O -
but O +
not O +
the O +
parent O +
sulfonamides O -
) O +
strongly O +
lowered O +
IOP O +
in O +
rabbits B-Species +
when O +
administered O +
as O +
a O +
2 O -
% O +
solution O +
into O +
the O +
eye O -
. O +

Introduction O +
Sulfonamides O +
possessing O +
carbonic O +
anhydrase O +
( O -
CA O -
, O +
EC O +
4.2.1.1 O -
) O +
inhibitory O +
properties O +
[ O -
2 O -
] O +
such O +
as O +
acetazolamide O +
1 O -
, O +
methazolamide O +
2 O -
, O +
ethoxzolamide O +
3 O +
and O +
dichlorophenamide O +
4 O +
have O +
been O +
used O +
for O +
more O +
than O +
40 O +
years O +
as O +
pressure O +
lowering O +
systemic O +
drugs O +
in O +
the O +
treatment O +
of O +
open O -
- O -
angle O +
glaucoma O +
[ O -
3,4 O -
] O -
. O +

Their O +
effect O +
is O +
due O +
to O +
inhibition O +
of O +
at O +
least O +
two O +
CA O +
isozymes O +
present O +
within O +
cilliary O +
processes O +
of O +
the O +
eye O -
, O +
ie O -
, O +
CA O +
II O +
and O +
CA O +
IV O -
, O +
which O +
is O +
followed O +
by O +
lowered O +
bicarbonate O +
formation O +
and O +
reduction O +
of O +
aqueous O +
humor O +
secretion O +
[ O -
5 O -
- O -
7 O -
] O -
. O +

Their O +
main O +
drawback O +
is O +
constituted O +
by O +
side O +
effects O +
such O +
as O +
fatigue O -
, O +
augmented O +
diuresis O -
, O +
or O +
paresthesias O -
, O +
due O +
to O +
CA O +
inhibition O +
in O +
other O +
tissues O -
/ O -
organs O +
than O +
the O +
target O +
one O -
, O +
ie O -
, O +
the O +
eye O +
[ O -
8 O -
] O -
. O +

N O -
-- O -
N O +
XN O -
-- O -
N O +
EtO O +
S O +
NH O +
2 O +
O O +
NH O +
O O -
: O -
S----O O +
NHEt O +
The O +
above O -
- O -
mentioned O +
side O +
effects O +
are O +
absent O +
in O +
the O +
case O +
in O +
which O +
the O +
inhibitor O +
has O +
topical O +
activity O -
, O +
and O +
is O +
applied O +
directly O +
into O +
the O +
eye O -
. O +

This O +
route O +
has O +
been O +
demonstrated O +
only O +
in O +
1983 O +
by O +
Maren O -
's O +
group O +
[ O -
9 O -
] O +
and O +
was O +
followed O +
by O +
the O +
development O +
of O +
the O +
first O +
clinical O +
agent O +
of O +
this O +
type O -
, O +
dorzolamide O +
5 O +
[ O -
10,11 O +
] O -
. O +

Dorzolamide O +
( O -
Trusopt O -
) O +
has O +
been O +
introduced O +
in O +
clinical O +
use O +
in O +
1995 O +
in O +
USA O +
and O +
Europe O +
and O +
it O +
constituted O +
the O +
beginning O +
of O +
a O +
radically O +
new O +
treatment O +
of O +
glaucoma O -
, O +
devoid O +
of O +
the O +
severe O +
side O +
effects O +
observed O +
with O +
the O +
systemic O +
inhibitors O +
[ O -
4 O -
- O -
6 O -
] O -
. O +

The O +
success O +
of O +
topical O +
antiglaucoma O +
CA O +
inhibitors O +
fostered O +
much O +
research O +
in O +
the O +
synthesis O +
and O +
clinical O +
evaluation O +
of O +
other O +
types O +
of O +
such O +
compounds O +
[ O -
12 O -
- O -
15 O -
] O -
. O +

307 O +
Vol O -
. O +

4 O -
, O +
No. O +
6 O -
, O +
1997 O +
Metal O +
Complexes O +
of O +
Heterocyclic O +
Sulfonamides O -
: O +
A O +
New O +
Class O +
ofAntiglaucoma O +
Agents O +
On O +
the O +
other O +
hand O -
, O +
metal O +
complexes O +
of O +
heterocyclic O +
sulfonamides O +
of O +
type O +
1 O -
- O -
5 O +
have O +
been O +
recently O +
prepared O +
by O +
two O +
groups O +
16 O -
- O -
20 O -
] O -
, O +
and O +
it O +
was O +
proved O +
that O +
they O +
possess O +
much O +
stronger O +
CA O +
inhibitory O +
properties O +
than O +
the O +
sulfonamides O +
from O +
which O +
they O +
were O +
prepared O +
18 O -
- O -
22 O -
] O -
. O +

Although O +
the O +
mechanism O +
of O +
CA O +
inhibition O +
of O +
the O +
metal O +
complexes O +
is O +
presently O +
unknown O -
, O +
it O +
was O +
hypothesized O +
that O +
their O +
increased O +
inhibitory O +
power O +
might O +
be O +
due O +
to O +
two O +
processes O -
, O +
occurring O +
separately O +
or O +
in O +
concert O -
, O +
ie O -
, O +
( O -
i O -
) O +
dissociation O +
of O +
the O +
complex O +
inhibitor O +
in O +
sulfonamide O +
anions O +
and O +
metal O +
ions O +
( O -
in O +
diluted O +
solution O -
) O -
, O +
which O +
in O +
turn O +
both O +
interact O +
thereafter O +
with O +
the O +
enzyme O -
, O +
at O +
different O +
binding O +
sites O -
, O +
and O +
( O -
ii O -
) O +
direct O +
interaction O +
of O +
the O +
undissociated O +
complex O +
with O +
the O +
enzyme O -
, O +
and O +
more O +
specifically O +
with O +
the O +
hydrophilic O +
patch O +
at O +
the O +
entrance O +
of O +
CA O +
II O +
active O +
site O +
[ O -
23 O -
] O -
, O +
this O +
being O +
the O +
isozyme O +
most O +
susceptible O +
to O +
inhibition O +
with O +
this O +
class O +
of O +
compounds O +
[ O -
2,22 O -
] O -
. O +

Whether O +
initially O +
the O +
first O +
mechanism O +
of O +
action O +
mentioned O +
above O +
was O +
favored O +
by O +
us O +
[ O -
22 O -
] O -
, O +
recent O +
evidences O +
suggested O +
that O +
the O +
undissociated O +
complex O +
might O +
be O +
the O +
inhibitory O +
species O -
, O +
at O +
least O +
for O +
some O +
isozymes O +
[ O -
24 O -
] O -
. O +

Since O +
metal O +
complexes O +
are O +
much O +
more O +
inhibitory O +
than O +
the O +
parent O +
sulfonamide O +
from O +
which O +
they O +
were O +
prepared O -
, O +
it O +
appeared O +
of O +
interest O +
to O +
test O +
whether O +
this O +
property O +
might O +
be O +
useful O +
for O +
their O +
use O +
in O +
lowering O +
IOP O +
in O +
experimental O +
animals O +
and O +
whence O +
as O +
a O +
possible O +
glaucoma O +
therapy O -
. O +

Recently O +
we O +
proved O +
[ O -
25 O -
, O +
26 O -
] O +
that O +
some O +
metal O +
complexes O +
of O +
heterocyclic O +
sulfonamides O +
( O -
which O +
themselves O +
do O +
not O +
possess O +
IOP O +
lowering O +
properties O -
) O +
act O +
as O +
very O +
powerful O +
such O +
agents O +
when O +
administered O +
as O +
diluted O +
solutions O +
directly O +
into O +
the O +
eye O +
of O +
experimental O +
animals O -
, O +
and O +
would O +
thus O +
offer O +
the O +
possibility O +
of O +
developing O +
such O +
totally O +
novel O +
drugs O -
. O +

Here O +
we O +
report O +
the O +
synthesis O +
of O +
a O +
heterocyclic O +
sulfonamide O +
possessing O +
strong O +
CA O +
inhibitory O +
properties O -
, O +
ie O -
, O +
5- O -
( O -
chloroacetamido O -
) O -
-l,3,4-thiadiazole-2-sulfonamide O -
, O +
and O +
of O +
the O +
metal O +
complexes O +
of O +
this O +
sulfonamide O +
and O +
of O +
5-amino-1,3,4-thiadiazole-2-sulfonamide O -
, O +
containing O +
some O +
main O +
group O +
metal O +
ions O -
. O +

The O +
new O +
compounds O +
have O +
been O +
characterized O +
by O +
standard O +
physico O -
- O -
chemical O +
procedures O -
, O +
and O +
were O +
assayed O +
as O +
inhibitors O +
of O +
three O +
CA O +
isozymes O -
, O +
hCA O +
I O -
, O +
hCA O +
II O +
and O +
bCA O +
IV O +
( O -
h O +
human B-Species -
; O +
b O +
bovine B-Species -
; O +
these O +
are O +
the O +
isozymes O +
considered O +
to O +
play O +
a O +
critical O +
role O +
in O +
aqueous O +
humour O +
secretion O +
within O +
the O +
eye O +
of O +
higher O +
vertebrates O +
[ O -
2 O -
- O -
5 O -
] O -
) O -
. O +

Materials O +
and O +
Methods O +
Melting O +
points O +
were O +
recorded O +
with O +
a O +
heating O +
plate O +
microscope O +
and O +
are O +
not O +
corrected O -
. O +

IR O +
spectra O +
were O +
recorded O +
in O +
KBr O +
pellets O +
with O +
a O +
Carl O +
Zeiss O +
IR-80 O +
instrument O -
. O +

1H O -
- O -
NMR O +
spectra O +
were O +
recorded O +
in O +
DMSO O -
- O -
d6 O +
as O +
solvent O -
, O +
with O +
a O +
Bruker O +
CPX200 O +
instrument O -
. O +

Chemical O +
shifts O +
are O +
reported O +
as O +
values O -
, O +
relative O +
to O +
Me4Si O +
as O +
internal O +
standard O -
. O +

Conductimetric O +
measurements O +
were O +
done O +
at O +
room O +
temperature O +
( O -
1 O +
mM O +
concentration O +
of O +
complex O -
) O +
in O +
DMSO O +
solution O +
with O +
a O +
Fisher O +
conductimeter O -
. O +

Elemental O +
analyses O +
were O +
done O +
by O +
combustion O +
for O +
C O -
, O +
H O -
, O +
N O +
with O +
an O +
automated O +
Carlo O +
Erba O +
analyzer O -
, O +
and O +
gravimetrically O +
for O +
the O +
metal O +
ions O -
, O +
and O +
were O +
0.4 O -
% O +
of O +
the O +
theoretical O +
values O -
. O +

Thermogravimetric O +
measurements O +
were O +
done O +
in O +
air O -
, O +
at O +
a O +
heating O +
rate O +
of O +
10C O -
/ O -
min O -
. O -
, O +
with O +
a O +
Perkin O +
Elmer O +
3600 O +
thermobalance O -
. O +

Sulfonamides O +
used O +
as O +
standards O +
in O +
the O +
enzymatic O +
assay O +
( O -
except O +
for O +
5 O -
) O -
, O +
acetazolamide O -
, O +
pyridine O -
, O +
and O +
chloroacetyl O +
chloride O +
used O +
for O +
the O +
preparation O +
of O +
compound O +
7 O -
, O +
solvents O +
as O +
well O +
as O +
inorganic O +
reagents O +
were O +
from O +
Sigma O -
, O +
Merck O +
and O +
Carlo O +
Erba O -
. O +

5-Amino O -
- O -
l,3,4-thiadiazole-2-sulfonamide O +
6 O +
was O +
prepared O +
from O +
acetazolamide O +
by O +
literature O +
procedures O +
[ O -
27 O -
] O -
, O +
by O +
desacetylation O +
with O +
concentrated O +
hydrochloric O +
acid O -
, O +
followed O +
by O +
neutralization O +
with O +
sodium O +
bicarbonate O +
of O +
the O +
corresponding O +
hydrochloride O +
( O -
Scheme O +
1 O -
) O -
. O +

Dorzolamide O +
hydrochloride O +
5 O +
was O +
from O +
Merck O -
, O +
Sharp O +
and O +
Dohme O +
or O +
was O +
prepared O +
as O +
described O +
by O +
Ponticello O +
et O +
al O +
10,11 O +
] O -
. O +

Human B-Species +
CA O +
and O +
CA O +
II O +
cDNAs O +
were O +
expressed O +
in O +
Escherichia O +
coli O +
strain O +
BL21 O +
( O -
DE3 O -
) O +
from O +
the O +
plasmids O +
pACA O -
/ O -
hCA O +
I O +
and O +
pACAdaCA O +
II O +
described O +
by O +
Forsman O +
et O +
al. O +
[ O -
28 O -
] O +
( O -
the O +
two O +
plasmids O +
were O +
a O +
gift O +
from O +
Prof. O +
Sven O +
Lindskog O -
, O +
Umea O +
University O -
, O +
Sweden O -
) O -
. O +

Cell O +
growth O +
conditions O +
were O +
those O +
described O +
by O +
Lindskog O -
's O +
group O +
[ O -
29 O -
] O -
, O +
and O +
enzymes O +
were O +
purified O +
by O +
affinity O +
chromatography O +
according O +
to O +
the O +
method O +
of O +
Khalifah O +
et O +
al O +
[ O -
30 O -
] O -
. O +

Enzyme O +
concentrations O +
were O +
determined O +
spectrophotometrically O +
at O +
280 O +
nm O -
, O +
utilizing O +
a O +
molar O +
absorptivity O +
of O +
49 O +
mM O -
- O -
l.cm-1 O +
for O +
hCA O +
and O +
54 O +
mM O -
- O -
l.cm-1 O +
for O +
hCA O +
II O -
, O +
respectively O -
, O +
based O +
on O +
M O +
28.85 O +
kDa O +
for O +
hCA O +
I O -
, O +
and O +
29.3 O +
kDa O +
for O +
hCA O +
II O -
, O +
respectively O +
[ O -
31,32 O -
] O -
. O +

bCA O +
IV O +
was O +
isolated O +
from O +
bovine B-Species +
lung O +
microsomes O +
as O +
described O +
by O +
Maren O +
et O +
al O -
, O +
and O +
its O +
concentration O +
has O +
been O +
determined O +
by O +
titration O +
with O +
ethoxzolamide O +
[ O -
33 O -
] O -
. O +

Synthesis O +
of O +
5- O -
( O -
chloroacetamido O -
) O -
- O +
l O -
, O +
3 O -
, O +
4-thiadiazole-2-sulfonamide O +
7 O +
An O +
amount O +
of O +
1.80 O +
g O +
( O -
10 O +
mmol O -
) O +
of O +
5-amino-1,3,4-thiadiazole-2-sulfonamide O +
6 O +
was O +
suspended O +
in O +
20 O +
mL O +
of O +
anhydrous O +
acetonitrile O +
and O +
0.9 O +
mL O +
( O -
0.87 O -
g O -
, O +
11 O +
mmol O -
) O +
of O +
pyridine O +
added O -
. O +

The O +
mixture O +
was O +
magnetically O +
stirred O +
at O +
4 O +
C O +
for O +
10 O +
minutes O -
, O +
then O +
10.5 O +
mmol O +
of O +
monochloroacetyl O +
chloride O -
, O +
dissolved O +
in O +
3 O +
mL O +
acetonitrile O -
, O +
were O +
added O +
dropwise O +
for O +
5 O +
min O -
, O +
and O +
stirring O +
was O +
continued O +
for O +
other O +
2 O +
hours O +
at O +
room O +
temperature O -
. O +

After O +
an O +
additional O +
30 O +
min O +
of O +
refluxation O -
, O +
followed O +
by O +
cooling O -
, O +
the O +
precipitated O +
crystals O +
were O +
filtered O +
and O +
recrystallized O +
from O +
ethanol O -
. O +

Yield O +
of O +
62 O -
% O +
white O +
crystals O -
, O +
mp O +
246 O -
- O -
248 O +
o O +
lit O +
[ O -
34 O -
] O +
mp O +
IR O +
( O -
KBr O -
) O -
, O +
cm O -
- O -
l O -
: O +
590 O -
, O +
610 O -
, O +
660 O -
, O +
790 O -
, O +
935 O -
, O +
1090 O -
, O +
1115 O -
, O +
1170 O -
, O +
1350 O -
, O +
1400 O -
, O +
1550 O -
, O +
1650 O -
, O +
1720 O -
, O +
2870 O -
, O +
3280 O +
3370 O +
( O -
broad O -
) O -
; O +
UV O +
spectrum O -
, O +
, O -
max O -
, O +
nm O +
( O -
lg O -
) O -
: O +
255 O +
( O -
3.50 O -
) O -
; O +
288 O +
( O -
4.37 O -
) O +
H O -
- O -
NMR O +
( O -
DMSO O -
- O -
d6 O -
) O -
, O +
i O -
, O +
ppm O -
: O +
2.96 O +
( O -
s O -
, O +
2H O -
, O +
CH2 O -
) O -
; O +
8.20 O +
( O -
s O -
, O +
2H O -
, O +
SOzNH2 O -
) O -
; O +
12.22 O +
( O -
s O -
, O +
1H O -
, O +
CONH O -
) O -
. O +

Analysis O -
, O +
found O -
: O +
C O -
, O +
18.56 O -
; O +
H O -
, O +
1.88 O -
; O +
N O -
, O +
21.76 O -
; O +
S O -
, O +
24.62 O +
% O -
; O +
C4HsC1N403S2 O +
requires O -
" O +
C O -
, O +
18.72 O -
; O +
H O -
, O +
1.96 O -
; O +
N O -
, O +
21.83 O -
; O +
S O -
, O +
24.98 O +
% O -
. O +

General O +
procedure O +
for O +
the O +
preparation O +
of O +
compounds O +
8 O -
- O -
20 O +
An O +
amount O +
of O +
6 O +
mmol O +
of O +
sodium O +
salt O +
of O +
sulfonamides O +
6 O +
or O +
7 O +
was O +
prepared O +
by O +
reacting O +
the O +
corresponding O +
sulfonamide O +
with O +
the O +
required O +
amount O +
of O +
an O +
alcoholic O +
1N O +
NaOH O +
solution O -
, O +
in O +
ethanol O +
as O +
solvent O -
. O +

To O +
this O +
308 O +
Claudiu O +
T. O +
Supuran O +
et O +
al. O +
Metal O -
- O -
Based O +
Drugs O +
solution O +
was O +
added O +
the O +
aqueous O +
metal O +
salt O +
( O -
Zn O -
( O -
II O -
) O -
, O +
Mg O -
( O -
II O -
) O -
, O +
AI O -
( O -
III O -
) O -
, O +
Cd O -
( O -
II O -
) O +
chlorides O -
, O +
and O +
Be O -
( O -
II O -
) O -
, O +
Pb O -
( O -
II O -
) O +
and O +
Hg O -
( O -
II O -
) O +
nitrate O -
) O +
solution O -
, O +
working O +
in O +
molar O +
ratios O +
RSOzNH- O +
Mn+ O +
of O +
2:1 O +
for O +
the O +
divalent O +
cations O +
and O +
3:1 O +
for O +
the O +
trivalent O +
cation O -
, O +
respectively O -
. O +

The O +
aqueous O -
- O -
alcoholic O +
reaction O +
mixture O +
was O +
heated O +
on O +
a O +
steam O +
bath O +
for O +
one O +
hour O -
, O +
adjusting O +
the O +
pH O +
at O +
7 O +
if O +
necessary O -
, O +
and O +
after O +
being O +
cooled O +
at O +
0 O +
C O +
the O +
precipitated O +
complexes O +
were O +
filtered O +
and O +
thoroughly O +
washed O +
with O +
alcohol O -
- O -
water O +
1:1 O +
( O -
v O -
/ O -
v O -
) O +
and O +
air O +
dried O -
. O +

Yields O +
were O +
in O +
the O +
range O +
of O +
85 O -
- O -
90 O +
% O -
. O +

The O +
obtained O +
white O +
powders O +
of O +
compounds O +
8 O -
- O -
20 O +
melted O +
with O +
decomposition O +
at O +
temperatures O +
higher O +
than O +
350 O +
C O -
, O +
and O +
were O +
poorly O +
soluble O +
in O +
water O +
and O +
alcohol O -
, O +
but O +
had O +
good O +
solubilities O +
in O +
DMSO O -
, O +
DMF O +
as O +
well O +
as O +
mixtures O +
of O +
DMSO O -
- O -
water O -
, O +
DMF O -
- O -
water O -
. O +

Pharmacology O +
Carbonic O +
anhydrase O +
inhibition O +
Initial O +
rates O +
of O +
4-nitrophenyl O +
acetate O +
hydrolysis O +
catalysed O +
by O +
different O +
CA O +
isozymes O +
were O +
monitored O +
spectrophotometrically O -
, O +
at O +
400 O +
rim O -
, O +
with O +
a O +
Cary O +
3 O +
instrument O +
interfaced O +
with O +
an O +
IBM O +
compatible O +
PC O +
[ O -
35 O -
] O -
. O +

Solutions O +
of O +
substrate O +
were O +
prepared O +
in O +
anhydrous O +
acetonitrile O -
; O +
the O +
substrate O +
concentrations O +
varied O +
between O +
2.10 O -
- O -
2 O +
and O +
1.10 O -
- O -
6 O +
M O -
, O +
working O +
at O +
25C O -
. O +

A O +
molar O +
absorption O +
coefficient O +
of O +
18,400 O +
M O -
- O -
l.cm-1 O +
was O +
used O +
for O +
the O +
4-nitrophenolate O +
formed O +
by O +
hydrolysis O -
, O +
in O +
the O +
conditions O +
of O +
the O +
experiments O +
( O -
pH O +
7.40 O -
) O -
, O +
as O +
reported O +
in O +
the O +
literature O +
[ O -
35 O -
] O -
. O +

Non O -
- O -
enzymatic O +
hydrolysis O +
rates O +
were O +
always O +
subtracted O +
from O +
the O +
observed O +
rates O -
. O +

Duplicate O +
experiments O +
were O +
done O +
for O +
each O +
inhibitor O +
concentration O -
, O +
and O +
the O +
values O +
reported O +
throughout O +
the O +
paper O +
are O +
the O +
mean O +
of O +
such O +
results O -
. O +

Stock O +
solutions O +
of O +
inhibitor O +
( O -
1 O +
mM O -
) O +
were O +
prepared O +
in O +
distilled O -
- O -
deionized O +
water O +
with O +
1020 O -
% O +
( O -
v O -
/ O -
v O -
) O +
DMSO O +
( O -
which O +
is O +
not O +
inhibitory O +
at O +
these O +
concentrations O +
[ O -
2 O -
] O -
) O +
and O +
dilutions O +
up O +
to O +
0.01 O +
nM O +
were O +
done O +
thereafter O +
with O +
distilled O -
- O -
deionized O +
water O -
. O +

Inhibitor O +
and O +
enzyme O +
solutions O +
were O +
preincubated O +
together O +
for O +
10 O +
min O +
at O +
room O +
temperature O +
prior O +
to O +
assay O -
, O +
in O +
order O +
to O +
allow O +
for O +
the O +
formation O +
of O +
the O +
E O -
- O -
I O +
complex O -
. O +

The O +
inhibition O +
constant O +
KI O +
was O +
determined O +
as O +
described O +
by O +
Pocket O +
and O +
Stone O +
[ O -
35 O -
] O -
. O +

Enzyme O +
concentrations O +
were O +
3.3 O +
nM O +
for O +
hCA O +
II O -
, O +
l0 O +
nM O +
for O +
hCA O +
and O +
34 O +
nM O +
for O +
bCA O +
IV O +
( O -
this O +
isozyme O +
has O +
a O +
decreased O +
esterase O +
activity O +
[ O -
36 O -
] O +
and O +
higher O +
concentrations O +
had O +
to O +
be O +
used O +
for O +
the O -
- O -
measurements O -
) O -
. O +

Measurement O +
of O +
tonometric O +
lOP O +
Adult O +
male O +
New O +
Zealand O +
albino O +
rabbits B-Species +
weighing O +
2 O -
- O -
3 O +
kg O +
were O +
used O +
in O +
the O +
experiments O +
( O -
three O +
animals O +
were O +
used O +
for O +
each O +
inhibitor O +
studied O -
) O -
. O +

The O +
experimental O +
procedures O +
conform O +
to O +
the O +
Association O +
for O +
Research O +
in O +
Vision O +
and O +
Ophthalmology O +
Resolution O +
on O +
the O +
use O +
of O +
animals O -
. O +

The O +
rabbits B-Species +
were O +
kept O +
in O +
individual O +
cages O +
with O +
food O +
and O +
water O +
provided O +
ad O +
libitum O -
. O +

The O +
animals O +
were O +
maintained O +
on O +
a O +
12 O +
h O -
: O +
12 O +
h O +
light O -
/ O -
dark O +
cycle O +
in O +
a O +
temperature O +
controlled O +
room O -
, O +
at O +
22 O -
- O -
26 O +
C. O +
Solutions O +
of O +
inhibitors O +
( O -
2 O +
% O -
, O +
by O +
weight O -
) O +
were O +
obtained O +
in O +
DMSOwater O +
( O -
2:3 O -
, O +
v O -
/ O -
v O -
) O +
due O +
to O +
the O +
low O +
water O +
solubility O +
of O +
some O +
of O +
these O +
derivatives O -
. O +

Control O +
experiments O +
with O +
DMSO O +
( O -
at O +
the O +
same O +
concentration O +
as O +
that O +
used O +
for O +
obtaining O +
the O +
inhibitors O +
solutions O +
showed O +
that O +
it O +
does O +
not O +
possess O +
IOP O +
lowering O +
or O +
increasing O +
effects O -
. O +

IOP O +
was O +
measured O +
using O +
a O +
Digilab O +
30R O +
pneumatonometer O +
( O -
BioRad O -
, O +
Cambridge O -
, O +
MA O -
, O +
USA O -
) O +
as O +
described O +
by O +
Maren O -
's O +
group O +
[ O -
37 O -
- O -
39 O -
] O -
. O +

The O +
pressure O +
readings O +
were O +
matched O +
with O +
two O -
- O -
point O +
standard O +
pressure O +
measurements O +
at O +
least O +
twice O +
each O +
day O +
using O +
a O +
Digilab O +
Calibration O +
verifier O -
. O +

All O +
IOP O +
measurements O +
were O +
done O +
by O +
the O +
same O +
investigator O +
with O +
the O +
same O +
tonometer O -
. O +

One O +
drop O +
of O +
0.2 O +
% O +
oxybuprocaine O +
hydrochloride O +
( O -
novesine O -
, O +
Sandoz O -
) O +
diluted O +
1"1 O +
with O +
saline O +
was O +
instilled O +
in O +
each O +
eye O +
immediately O +
before O +
each O +
set O +
of O +
pressure O +
measurements O -
. O +

IOP O +
was O +
measured O +
three O +
times O +
at O +
each O +
time O +
interval O -
, O +
and O +
the O +
means O +
reported O -
. O +

IOP O +
was O +
measured O +
first O +
immediately O +
before O +
drug O +
administration O -
, O +
then O +
at O +
30 O +
min O +
after O +
the O +
instillation O +
of O +
the O +
pharmacological O +
agent O -
, O +
and O +
then O +
each O +
30 O +
minutes O +
for O +
a O +
period O +
of O +
several O +
hours O -
. O +

For O +
all O +
IOP O +
experiments O +
drug O +
was O +
administered O +
to O +
only O +
one O +
eye O -
, O +
leaving O +
the O +
contralateral O +
eye O +
as O +
an O +
untreated O +
control O -
. O +

The O +
ocular O +
hypotensive O +
activity O +
is O +
expressed O +
as O +
the O +
average O +
difference O +
in O +
IOP O +
between O +
the O +
treated O +
and O +
control O +
eye O -
, O +
in O +
this O +
way O +
minimizing O +
the O +
diurnal O -
, O +
seasonal O +
and O +
interindividual O +
variations O +
commonly O +
observed O +
in O +
the O +
rabbit B-Species +
[ O -
37 O -
- O -
39 O -
] O -
. O +

All O +
data O +
are O +
expressed O +
as O +
mean O +
SE O -
, O +
using O +
a O +
one O -
- O -
tailed O +
test O -
. O +

Results O +
and O +
Discussion O +
Reaction O +
of O +
5-amino O -
- O -
l,3,4-thiadiazole-2-sulfonamide O +
6 O +
[ O -
19b O -
] O +
with O +
chloroacteyl O +
chloride O +
in O +
the O +
presence O +
of O +
pyridine O +
afforded O +
5- O -
( O -
chloroacetamido O -
) O -
-l,3,4-thiadiazole-2-sulfonamide O +
7 O -
, O +
by O +
the O +
procedure O +
already O +
reported O +
by O +
Young O +
et O +
al. O +
[ O -
34 O -
] O +
( O -
Scheme O +
1 O -
) O -
. O +

The O +
sulfonamide O +
7 O +
has O +
been O +
characterized O +
by O +
elemental O +
analysis O +
and O +
spectroscopic O +
methods O +
which O +
confirmed O +
its O +
structure O +
( O -
only O +
its O +
m.p O -
. O +
has O +
been O +
reported O +
in O +
ref O -
. O +

[ O -
34 O -
] O -
) O -
. O +

The O +
sodium O +
salt O +
of O +
sulfonamides O +
6 O +
and O +
7 O -
, O +
obtained O +
in O +
situ O +
from O +
the O +
corresponding O +
sulfonamide O +
and O +
sodium O +
hydroxide O -
, O +
were O +
then O +
used O +
for O +
the O +
preparation O +
of O +
coordination O +
compounds O -
, O +
containing O +
the O +
following O +
metal O +
ions O -
: O +
Be O -
( O -
II O -
) O -
, O +
Mg O -
( O -
II O -
) O -
, O +
Al O -
( O -
III O -
) O -
, O +
Zn O -
( O -
II O -
) O -
, O +
Cd O -
( O -
II O -
) O +
and O +
Hg O -
( O -
II O -
) O -
. O +

Mention O +
should O +
be O +
made O +
that O +
although O +
5-amino O -
- O -
l,3,4-thiadiazole-2-sulfonamide O +
6 O +
is O +
the O +
parent O +
compound O +
of O +
important O +
sulfonamide O +
CA O +
inhibitors O -
, O +
such O +
as O +
acetazolamide O -
, O +
benzolamide O -
, O +
methazolamide O -
, O +
etc O -
. O -
, O +
its O +
coordination O +
chemistry O +
has O +
been O +
scarcely O +
investigated O +
up O +
to O +
now O +
[ O -
22 O -
, O +
40 O -
] O -
. O +

The O +
new O +
complexes O +
prepared O +
in O +
this O +
work O +
are O +
shown O +
in O +
Table O +
I. O +
Both O +
compounds O +
containing O +
the O +
sulfonamide O -
- O -
deprotonated O +
species O +
of O +
sulfonamide O +
7 O +
( O -
LH O -
) O -
, O +
as O +
well O +
as O +
complexes O +
in O +
which O +
the O +
anion O +
of O +
5amino-1,3,4-thiadiazole-2-sulfonamide O +
( O -
tda O -
) O +
act O +
as O +
ligands O -
, O +
have O +
been O +
prepared O -
. O +

In O +
fact O +
in O +
another O +
work O +
[ O -
40 O -
] O +
it O +
was O +
documented O +
that O +
in O +
some O +
cases O -
, O +
sulfonamides O +
derived O +
from O +
this O +
ring O +
system O +
may O +
undergo O +
hydrolysis O +
to O +
309 O +
Vol O -
. O +

4 O -
, O +
No. O +
6 O -
, O +
1997 O +
Metal O +
Complexes O +
of O +
Heterocyclic O +
Sulfonamides O -
. O -
" O +

A O +
New O +
Class O +
ofAntiglaucoma O +
Agents O +
the O +
moiety O +
substituting O +
the O +
5 O +
position O -
, O +
with O +
the O +
formation O +
of O +
5-amino O -
- O -
l,3,4-thiadiazole-2-sulfonamide O +
6 O -
, O +
which O +
thereafter O +
coordinates O +
metal O +
ions O +
present O +
in O +
solution O -
. O +

N O +
CIH O +
N O +
I O +
N O +
+ O -
NaHCO O +
2 O +
N O +
2 O +
S O -
' O +
-NaCl O +
I O +
S O +
N O +
II O +
SO2NH O +
1_12 O +
O O +
Py O -
/ O -
MeCN O +
6Htda O +
+ O -
CIOCCH2CI O +
0 O +
Cl O +
CH O +
2 O +
Scheme O +
1 O +
HN O +
.I O +

N O +
N O +
S O +
7 O -
: O +
LH O +
II O +
SqNH O +
Thus O -
, O +
the O +
X O -
- O -
ray O +
crystal O +
structure O +
of O +
the O +
complex O +
[ O -
Zn O -
( O -
tda O -
) O -
2 O -
( O -
NH3 O -
) O -
] O -
.H20 O +
prepared O +
in O +
this O +
way O +
has O +
recently O +
been O +
reported O +
by O +
this O +
group O +
[ O -
40 O -
] O -
. O +

On O +
the O +
other O +
hand O -
, O +
when O +
the O +
ligand O +
7 O +
has O +
not O +
been O +
hydrolyzed O +
( O -
during O +
the O +
preparation O +
of O +
the O +
coordination O +
compounds O -
) O +
in O +
the O +
presence O +
of O +
the O +
metal O +
ion O +
to O +
5-amino O -
- O -
l,3,4-thiadiazole-2sulfonamide O +
and O +
chloroacetate O -
, O +
the O +
metal O +
complexes O +
contining O +
6 O +
as O +
ligand O +
have O +
been O +
prepared O +
from O +
the O +
last O +
( O -
pure O -
) O +
compound O +
( O -
as O +
sodium O +
salt O -
) O +
and O +
the O +
corresponding O +
metal O +
salt O -
, O +
by O +
the O +
general O +
procedure O +
described O +
in O +
the O +
Experimental O +
part O -
. O +

Table O +

I O -
: O +
Prepared O +
complexes O +
8 O -
- O -
20 O -
, O +
containing O +
the O +
conjugate O +
bases O +
of O +
sulfonamides O +
6 O +
and O +
7 O +
as O +
ligands O +
and O +
their O +
elemental O +
analysis O +
data O -
. O +

L O +
stands O +
for O +
the O +
sulfonamide O +
deprotonated O +
species O +
of O +
7 O -
, O +
whereas O +
tda O +
for O +
the O +
sulfonamide O +
deprotonated O +
species O +
of O +
5-amino-1,3,4-thiadiazole-2-sulfonamide O +
6 O -
. O +

No. O +
8 O +
9 O +
10 O +
11 O +
12 O +
13 O +
14 O +
15 O +
16 O +
17 O +
18 O +
19 O +
20 O +
Complex O +
Yield O +
( O -
% O -
) O +
% O -
Ma O +
Analysis O +
( O -
calculated O -
/ O -
found O -
) O +
% O -
H O +
b O +
% O -
C O +
b O +
13.0 O -
/ O -
13.1 O +
11.0 O -
/ O -
10.8 O +
11.3 O -
/ O -
11.4 O +
10.2 O -
/ O -
10.1 O +
8.5 O -
/ O -
8.1 O +
7.9 O -
/ O -
7.9 O +
12.7 O -
/ O -
12.8 O +
18.4 O -
/ O -
18.1 O +
18.1 O -
/ O -
17.9 O +
16.6 O -
/ O -
16.2 O +
15.3 O -
/ O -
14.9 O +
13.4 O -
/ O -
13.3 O +
12.7 O -
/ O -
12.5 O +
1.6 O -
/ O -
1.3 O +
2.7 O -
/ O -
2.3 O +
1.4 O -
/ O -
1.1 O +
1.2 O -
/ O -
1.2 O +
1.0 O -
/ O -
1.2 O +
1.6 O -
/ O -
1.3 O +
1.6 O -
/ O -
1.6 O +
1.5 O -
/ O -
1.5 O +
1.5 O -
/ O -
1.3 O +
1.3 O -
/ O -
1.4 O +
1.2 O -
/ O -
1.1 O +
1.1 O -
/ O -
1.2 O +
1.0 O -
/ O -
1.0 O +
% O -
N O +
b O +
30.4 O -
/ O -
30.2 O +
25.6 O -
/ O -
25.5 O +
26.4 O -
/ O -
26.4 O +

13.7 O -
/ O -
23.3 O +
20.0 O -
/ O -
19.8 O +

18.6 O -
/ O -
18.5 O +
29.7 O -
/ O -
29.6 O +

21.5 O -
/ O -
21.3 O +
21.1 O -
/ O -
20.8 O +

19.4 O -
/ O -
19.3 O +
17.9 O -
/ O -
17.8 O +
15.7 O -
/ O -
15.6 O +
14.8 O -
/ O -
14.6 O +
[ O -
Be O -
( O -
tda O -
) O -
2 O -
] O +
[ O -
Mg O -
( O -
tda O -
) O -
2 O -
] O -
.3 O +
H20 O +
[ O -
Zn O -
( O -
tda O -
) O -
2 O -
] O +
[ O -
Cd O -
( O -
tda O -
) O -
2 O -
] O +
[ O -
Hg O -
( O -
tda O -
) O -
2 O -
] O +
[ O -
Pb O -
( O -
tda O -
) O -
z O -
( O -
OH2 O -
) O -
2 O -
] O +
[ O -
Al O -
( O -
tda O -
) O -
3 O -
] O +
[ O -
BeL2 O -
] O +
[ O -
ALL3 O -
] O +
[ O -
ZnL2 O -
] O +
[ O -
CdL2 O -
] O +
[ O -
HgL2 O -
] O +
[ O -
PbLz O -
( O -
OH2 O -
) O -
2 O -
] O +
78 O +
76 O +
83 O +
90 O +
95 O +
84 O +
72 O +
75 O +
59 O +
87 O +
88 O +
92 O +
95 O +
2.4 O -
/ O -
2.5 O +
5.5 O -
/ O -
5.1 O +
15.4 O -
/ O -
15.0 O +
23.8 O -
/ O -
24.1 O +
35.8 O -
/ O -
35.7 O +
34.4 O -
/ O -
34.7 O +
4.7 O -
/ O -
4.4 O +
1.7 O -
/ O -
1.6 O +
3.4 O -
/ O -
3.5 O +
11.3 O -
/ O -
11.5 O +
18.0 O -
/ O -
18.1 O +
28.1 O -
/ O -
28.3 O +
27.4 O -
/ O -
27.2 O +
aBy O +
gravimetry O -
; O +
bBy O +
combustion O -
. O +

The O +
new O +
complexes O +
have O +
also O +
been O +
characterized O +
by O +
spectroscopic O -
, O +
conductimetric O +
and O +
thermogravimetric O +
measurements O +
( O -
Table O +
II O -
) O -
. O +

By O +
comparing O +
the O +
IR O +
spectra O +
of O +
the O +
complexes O +
and O +
the O +
corresponding O +
ligands O -
, O +
the O +
following O +
observations O +
should O +
be O +
made O -
: O +
( O -
i O -
) O +
the O +
shift O +
of O +
the O +
two O +
sulfonamido O +
vibrations O +
( O -
both O +
the O +
symmetric O +
as O +
well O +
as O +
the O +
the O +
assymetric O +
one O -
) O -
, O +
towards O +
lower O +
wavenumbers O +
in O +
the O +
spectra O +
of O +
the O +
complexes O -
, O +
as O +
compared O +
to O +
the O +
spectra O +
of O +
the O +
corresponding O +
ligand O +
( O -
Table O +
II O -
) O -
, O +
as O +
already O +
documented O +
previously O +
for O +
similar O +
complexes O +
[ O -
13 O -
- O -
22 O -
] O -
. O +

This O +
is O +
a O +
direct O +
indication O +
that O +
the O +
deprotonated O +
sulfonamido O +
310 O +
Claudiu O +
T. O +
Supuran O +
et O +
al. O +
Metal O -
- O -
Based O +
Drugs O +
moieties O +
of O +
the O +
ligands O +
interacts O +
with O +
the O +
metal O +
ions O +
in O +
the O +
newly O +
prepared O +
coordination O +
compounds O -
; O +
( O -
ii O -
) O +
the O +
amide O +
vibrations O +
( O -
the O +
most O +
intense O +
such O +
bands O +
at O +
1670 O -
- O -
1680 O +
cm-1 O -
) O +
of O +
ligand O +
7 O +
appear O +
unchanged O +
in O +
the O +
IR O +
spectra O +
of O +
complexes O +
15 O -
- O -
20 O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
these O +
moieties O +
do O +
not O +
participate O +
in O +
coordination O +
of O +
the O +
metal O +
ions O -
; O +
( O -
iii O -
) O +
the O +
C O -
- O -
N O +
stretching O +
vibration O +
in O +
the O +
spectra O +
of O +
the O +
prepared O +
complexes O +
is O +
shifted O +
with O +
5 O -
- O -
20 O +
cm-1 O +
towards O +
lower O +
wavenumbers O -
, O +
as O +
compared O +
to O +
the O +
same O +
vibration O +
in O +
the O +
spectra O +
of O +
sulfonamides O +
6 O +
and O +
7 O -
, O +
indicating O +
that O +
one O +
of O +
the O +
endocyclic O +
nitrogens O +
of O +
the O +
thiadiazolic O +
ring O +
( O -
presumably O +
N3 O -
) O +
acts O +
as O +
donor O +
atom O -
, O +
as O +
already O +
documented O +
by O +
X O -
- O -
ray O +
crystallographic O +
and O +
spectroscopic O +
determinations O +
on O +
complexes O +
of O +
other O +
sulfonamides O +
( O -
such O +
as O +
1 O -
- O -
3 O -
) O +
with O +
divalent O +
metal O +
ions O +
[ O -
13 O -
- O -
22 O -
] O +
( O -
Table O +
II O -
) O -
; O +
( O -
iv O -
) O +
changes O +
in O +
the O +
region O +
3100 O -
- O -
3160 O +
cm- O -
, O +
as O +
the O +
bands O +
present O +
in O +
the O +
spectra O +
of O +
sulfonamides O +
6 O -
, O +
7 O +
are O +
present O +
in O +
the O +
spectra O +
of O +
complexes O +
8 O -
- O -
20 O +
too O -
, O +
but O +
they O +
are O +
not O +
well O +
resolved O -
, O +
and O +
have O +
a O +
smaller O +
intensity O -
. O +

This O +
is O +
probably O +
due O +
to O +
deprotonation O +
of O +
the O +
SO2NH2 O +
moiety O +
and O +
participation O +
in O +
the O +
binding O +
of O +
cations O -
; O +
( O -
v O -
) O +
the O +
amino O +
vibrations O +
from O +
3320 O +
cm- O +
in O +
the O +
spectra O +
of O +
6 O +
appear O +
unchanged O +
in O +
the O +
spectra O +
of O +
its O +
complexes O +
8 O -
- O -
14 O +
( O -
data O +
not O +
s.hown O -
) O -
. O +

In O +
the O +
1H O -
- O -
NMR O +
spectra O +
of O +
compound O +
6 O +
and O +
its O +
metal O +
complexes O -
, O +
the O +
signal O +
of O +
the O +
amino O +
group O +
has O +
been O +
evidenced O +
as O +
a O +
broad O +
singlet O +
centered O +
at O +
4.54 O +
ppm O +
( O -
Table O +
II O -
) O -
, O +
which O +
is O +
not O +
exchangeable O +
by O +
addition O +
of O +
D20 O +
into O +
the O +
NMR O +
tube O -
, O +
in O +
contrast O +
to O +
the O +
sulfonamido O +
NH2 O +
protons O +
( O -
which O +
readily O +
exchange O -
) O -
. O +

This O +
proves O +
that O +
the O +
5-amino O +
moiety O +
is O +
not O +
involved O +
in O +
binding O +
the O +
metal O +
ions O -
, O +
as O +
already O +
shown O +
in O +
the O +
X O -
- O -
ray O +
crystallographic O +
work O +
of O +
the O +
complex O +
[ O -
Zn O -
( O -
tda O -
) O -
z O -
( O -
NH3 O -
) O -
] O -
.H20 O +
previously O +
reported O +
[ O -
40 O -
] O -
. O +

For O +
sulfonamide O +
7 O +
the O +
CONH O +
proton O +
resonates O +
as O +
a O +
singlet O +
at O +
12.22 O +
ppm O -
. O +

In O +
complexes O +
15 O -
- O -
20 O +
only O +
very O +
minor O +
shifts O +
of O +
this O +
signal O +
were O +
evidenced O +
( O -
Table O +
II O -
) O -
, O +
proving O +
basically O +
that O +
the O +
CONH O +
moiety O +
does O +
not O +
interact O +
with O +
the O +
metal O +
ions O +
in O +
these O +
complexes O -
. O +

Table O +
II O -
: O +
Spectroscopic O -
, O +
thermogravimetric O +
and O +
conductimetric O +
data O +
for O +
compounds O +
6 O -
- O -
20 O -
. O +

1H O -
- O -
NMR O +
Spectrab O +
Comp O -
. O +

IR O +
Spectraa O +
, O -
cm-1 O +
as O +
v O -
( O -
C O -
= O -
N O -
) O +
CONH O -
, O +
i O +
( O -
ppm O -
) O +
v O -
( O -
SO2 O -
) O -
S O -
; O +
v O -
( O -
SO2 O -
) O +
6 O +
8 O +
9 O +
10 O +
11 O +
TG O +
analysisc O +
calc. O -
/ O -
found O +
Conductimetryd O +
AM O +
( O -
-1 O +
x O +
cm2x O +
mol- O -
) O +
2 O +
7 O +
4 O +
5 O +
3 O +
2 O +
2 O +
6 O +
3 O +
4 O +
2 O +
9 O +
3 O +
2 O +
8 O +
12 O +
13 O +
14 O +
7 O +
15 O +
16 O +
17 O +
18 O +
19 O +
20 O +
1170 O -
; O +
1150 O -
; O +
1150 O -
; O +
1145 O -
; O +
1145 O -
; O +
1140 O -
; O +
1145 O -
; O +
1150 O -
; O +
1170 O -
; O +
1130 O -
; O +
1140 O -
; O +
1140 O -
; O +
1150 O -
; O +
1140 O -
; O +
1145 O -
; O +
1350 O +
1300 O +
1305 O +
1300 O +
1305 O +
1300 O +
1300 O +
1300 O +
1350 O +
1335 O +
1330 O +
1330 O +
1330 O +
1335 O +
1330 O +
1610 O +
1600 O +
1600 O +
1600 O +
1600 O +
1590 O +
1605 O +
1605 O +
1610 O +
1605 O +
1610 O +
1610 O +
1605 O +

1600 O +
1600 O +
A O +
A O +
A O +
A O +
A O +
A O +
A O +
e O +
e O +
12.3 O -
/ O -
12.1f O +
e O +
e O +
e O +
5.9 O -
/ O -
5.7 O -
g O +
A O +
12.22 O +
( O -
1H O -
) O +
12.19 O +
( O -
2H O -
) O +
12.18 O +
( O -
3H O -
) O +
12.20 O +
( O -
2H O -
) O +
12.18 O +
( O -
2H O -
) O +
12.19 O +
( O -
2H O -
) O +
12.21 O +
( O -
2H O -
) O +
e O +
e O +
e O +
e O +
e O +
e O +
e O +
4.7 O -
/ O -
4.8 O -
g O +
a O +
In O +
KBr O -
; O +
bin O +
DMSO O -
- O -
d6 O -
; O +
A O +
the O +
signal O +
of O +
the O +
5-amino O +
group O +
of O +
6 O +
( O -
appearing O +
in O +
the O +
ligand O +
at O +
4.54 O +
ppm O +
as O +
a O +
broad O +
singlet O -
) O +
appears O +
at O +
the O +
same O +
chemical O +
shift O +
( O -
4.50 O +
4.55 O +
ppm O -
) O +
in O +
complexes O +
8 O -
- O -
14 O -
; O +
cWeight O +
loss O +
between O +
70 O -
- O -
250 O +
C O -
; O +
d O +
mM O +
solution O -
, O +
in O +
DMF O -
, O +
at O +
25C O -
; O +
e O +
No O +
weight O +
loss O +
seen O +
under O +
250 O +
C O -
; O +
fCorresponding O +
to O +
three O +
lattice O +
water O +
molecules O +
lost O +
at O +
70 O -
- O -
110C O -
, O +
and O +
gCorresponding O +
to O +
two O +
coordinated O +
water O +
molecules O -
, O +
lost O +
at O +
160 O -
- O -
180 O +
C. O +
Thermogravimetric O +
analysis O +
showed O +
the O +
presence O +
of O +
uncoordinated O +
water O +
molecules O +
in O +
the O +
molecule O +
of O +
complex O +
9 O +
( O -
the O +
three O +
waters O +
were O +
lost O +
in O +
a O +
single O +
step O -
, O +
between O +
70 O -
- O -
110 O +
C O -
) O +
and O +
of O +
coordinated O +
water O +
in O +
the O +
molecules O +
of O +
the O +
lead O -
( O -
II O -
) O +
derivatives O +
13 O +
and O +
20 O -
. O +

All O +
these O +
compounds O +
behaved O +
as O +
non O -
- O -
electrolytes O +
in O +
DMF O +
as O +
solvent O +
( O -
Table O +
II O -
) O -
. O +

Mention O +
should O +
be O +
made O +
that O +
the O +
Mg O -
( O -
II O -
) O +
complex O +
of O +
sulfonamide O +
7 O +
could O +
not O +
be O +
isolated O -
. O +

Instead O -
, O +
only O +
the O +
correponding O +
complex O +
of O +
5-amino O -
- O -
l,3,4-thiadiazole O +
has O +
been O +
obtained O +
from O +
reaction O +
mixtures O +
containing O +
magnesium O +
salts O +
and O +
the O +
sodium O +
salt O +
of O +
7 O -
, O +
probably O +
due O +
to O +
a O +
metal O +
ion O +
assisted O +
hydrolysis O +
of O +
7 O +
to O +
6 O +
and O +
chloroacetate O -
. O +

Generally O +
such O +
hydrolytic O +
processes O +
involve O +
highly O +
acidic O +
conditions O +
and O +
prolonged O +
heating O +
of O +
the O +
5-alkylamido-1,3,4-thiadiazole-2-sulfonamide O +
derivatives O +
[ O -
41 O +
] O -
, O +
but O +
they O +
might O +
become O +
milder O +
by O +
taking O +
into O +
account O +
the O +
putative O +
catalytic O +
effect O +
of O +
Mg2 O -
+ O +
ions O +
reported O +
here O -
. O +

The O +
data O +
shown O +
above O +
lead O +
to O +
the O +
conclusion O +
that O +
ligand O +
7 O +
shares O +
a O +
common O +
coordination O +
chemistry O +
with O +
acetazolamide O +
1 O +
with O +
which O +
it O +
is O +
structurally O +
related O -
, O +
whereas O +
6 O +
probably O +
also O +
behaves O +
similarly O +
to O +
acetazolamide O +
in O +
the O +
sense O +
that O +
the O +
5-amino O +
group O +
seems O +
not O +
to O +
be O +
involved O +
in O +
coordinating O +
metal O +
ions O -
, O +
at O +
311 O +
Vol O -
. O +

4 O -
, O +
No. O +
6 O -
, O +
1997 O +
Metal O +
Complexes O +
of O +
Heterocyclic O +
Sulfonamides O -
: O +

A O +
New O +
Class O +
ofAntiglaucoma O +
Agents O +
least O +
in O +
the O +
complexes O +
reported O +
by O +
us O +
here O +
( O -
and O +
also O +
in O +
the O +
compound O +
characterized O +
by O +
X O -
- O -
ray O +
crystallography O +
mentioned O +
above O +
[ O -
40 O -
] O -
) O -
. O +

Thus O -
, O +
in O +
all O +
complexes O +
reported O +
here O +
these O +
sulfonamides O +
( O -
as O +
monodeprotonated O +
species O +
at O +
the O +
SO2NH O +
2 O +
moieties O -
) O +
act O +
as O +
bidentate O +
ligands O -
, O +
through O +
the O +
endocyclic O +
N-3 O +
and O +
the O +
NH- O +
groups O -
. O +

The O +
proposed O +
formulae O +
of O +
the O +
new O +
complxes O +
are O +
shown O +
below O -
. O +

Except O +
for O +
the O +
two O +
Pb O -
( O -
II O -
) O +
complexes O +
13 O +
and O +
20 O -
, O +
as O +
well O +
as O +
the O +
AI O -
( O -
III O -
) O +
derivatives O +
14 O +
and O +
16 O -
, O +
which O +
presumably O +
are O +
pseudo O -
- O -
octahedral O -
, O +
the O +
other O +
derivatives O +
are O +
supposed O +
to O +
contain O +
tetrahedral O +
M O -
( O -
II O -
) O +
ions O -
. O +

R O +
R O +
13"R O +
= O +
20 O -
" O +
R= O +
H2N O +
CICH2CONH O +
14 O -
: O +
R O +
= O +
16 O -
: O +
R O +
= O +
H2N O +
CICH2CONH O +
The O +
compounds O +
6 O -
- O -
20 O +
together O +
with O +
the O +
standard O +
CA O +
inhibitors O +
1 O -
- O -
5 O +
were O +
assayed O +
for O +
inhibition O +
against O +
three O +
isozymes O -
, O +
hCA O +
I O -
, O +
hCA O +
II O +
and O +
bCA O +
IV O +
( O -
Table O +
III O -
) O -
. O +

As O +
seen O +
from O +
the O +
above O +
data O -
, O +
the O +
chloracetamido O +
derivative O +
is O +
more O +
inhibitory O +
than O +
acetazolamide O -
, O +
methazolamide O +
and O +
dichlorophenamide O -
, O +
whereas O +
the O +
unacylated O +
compound O +
6 O +
is O +
less O +
inhibitory O +
than O +
the O +
above O +
sulfonamides O -
. O +

The O +
metal O +
complexes O +
820 O +
are O +
much O +
more O +
inhibitory O +
than O +
the O +
sulfonamides O +
from O +
which O +
they O +
derive O +
6 O -
, O +
7 O +
and O +
than O +
all O +
other O +
simple O +
sulfonamides O +
assayed O -
. O +

They O +
behave O +
similarly O +
to O +
the O +
metal O +
complexes O +
of O +
acetazolamide O -
, O +
methazolamide O +
or O +
dorzolamide O +
previously O +
reported O +
by O +
this O +
group O -
, O +
which O +
were O +
all O +
more O +
inhibitory O +
than O +
the O +
parent O +
sulfonamide O +
from O +
which O +
were O +
prepared O +
[ O -
16 O -
- O -
22 O -
, O +
40 O -
] O -
. O +

Particularly O +
strong O +
inhibition O +
was O +
observed O +
for O +
the O +
Zn O -
( O -
II O -
) O -
, O +
Hg O -
( O -
II O -
) O -
, O +
Pb O -
( O -
II O -
) O +
and O +
Cd O -
( O -
II O -
) O +
complexes O -
, O +
especially O +
against O +
CA O +
II O +
and O +
CA O +
IV O -
, O +
the O +
isozymes O +
critical O +
for O +
aqueous O +
humor O +
formation O -
. O +

In O +
vivo O +
IOP O +
lowering O +
experiments O +
were O +
done O +
in O +
rabbits B-Species +
with O +
some O +
of O +
the O +
new O +
compounds O +
prepared O +
in O +
the O +
present O +
work O -
, O +
such O +
as O +
the O +
sulfonamides O +
6 O +
and O +
7 O -
, O +
and O +
their O +
Zn O -
( O -
II O -
) O +
complexes O -
, O +
which O +
were O +
among O +
the O +
strong O +
CA O +
II O +
and O +
CA O +
IV O +
inhibitors O +
in O +
the O +
obtained O +
series O -
. O +

Some O +
of O +
the O +
IOP O +
lowering O +
data O +
at O +
half O +
an O +
hour O +
and O +
one O +
hour O +
after O +
the O +
instillation O +
of O +
one O +
drop O +
of O +
2 O +
% O +
solution O +
of O +
inhibitor O +
within O +
the O +
rabbit B-Species +
eye O +
are O +
shown O +
in O +
312 O +
Claudiu O +
T. O +
Supuran O +
et O +
al. O +
Metal O -
- O -
Based O +
Drugs O +
Table O +
IV O -
, O +
with O +
dorzolamide O +
( O -
at O +
the O +
same O +
concentration O -
) O +
as O +
standard O -
. O +

In O +
Fig. O +
the O +
time O +
dependence O +
of O +
IOP O +
lowering O +
with O +
dorzolamide O +
5 O +
and O +
the O +
two O +
Zn O -
( O -
II O -
) O +
complexes O +
10 O +
and O +
17 O +
is O +
presented O -
. O +

Table O +
III O -
. O +

CA O +
inhibition O +
data O +
with O +
the O +
standard O +
inhibitors O +
1 O -
- O -
5 O -
, O +
the O +
sulfonamides O +
6 O +
and O +
7 O -
, O +
and O +
their O +
metal O +
complexes O +
8 O -
- O -
20 O -
. O +

No O +
1 O +
2 O +
3 O +
4 O +
5 O +
6 O +
7 O +
8 O +
9 O +
10 O +
11 O +
12 O +
13 O +
14 O +
15 O +
16 O +
17 O +
18 O +
19 O +
20 O +
a O +
Inhibitor O +
KI O +
hCA O +
Ia O +
900 O +
780 O +
25 O +
1200 O +
> O -
50,000 O +
1550 O +
640 O +
1050 O +

350 O +
50 O +
40 O +
12 O +
80 O +
240 O +
120 O +
80 O +
40 O +
40 O +
9 O +
15 O +
( O -
nM O -
) O +
bCA O +
IVb O +
220 O +
240 O +
13 O +
380 O +
43 O +
780 O +
24 O +
540 O +
220 O +
25 O +
19 O +
10 O +
26 O +
110 O +
12 O +
16 O +
9 O +
10 O +
5 O +
10 O +
hCA O +
IIa O +
12 O +
14 O +
8 O +
38 O +
9 O +
230 O +
5 O +
190 O +
110 O +
15 O +
14 O +
7 O +
10 O +
76 O +
5 O +
4 O +
3 O +
3 O +
2 O +
5 O +
Acetazolamide O +
Methazolamide O +
Ethoxzolamide O +
Dichlorophenamide O +
Dorzolamide O +
Human B-Species +
( O -
cloned O -
) O +
isozymes O -
; O +
b O +
From O +
bovine B-Species +
lung O +
microsomes O -
. O +

Table O +
IV O -
: O +
IOP O +
lowering O +
following O +
topical O +
application O +
of O +
CA O +
inhibitors O -
, O +
half O +
an O +
hour O +
and O +
one O +
hour O +
after O +
instillation O +
into O +
the O +
eye O +
of O +
a O +
drop O +
( O -
50 O +
L O -
) O +
of O +
2 O +
% O +
solution O +
of O +
inhibitor O -
. O +

Inhibitor O +
lOP O +
SE O +
1 O -
/ O -
2 O +
h O +
a O +
( O -
mm O +
Hg O -
) O +
lh O +
4.1 O +
0.15 O +
0 O +
0.09 O +
0 O +
0.09 O +
5.0 O +
0.12 O +
8.1 O +
0.21 O +
Dorzolamide O +
5 O +
6 O +
7 O +
10 O +
17 O +
a O +
2.2 O +
0.10 O +
0 O +
0.10 O +
0 O +
0.10 O +
2.00.09 O +
8.0 O +
0.14 O +
IOP O +
IOP O +
control O +
eye O -
" O +
IOP O +
treated O +
eye O +
( O -
N O +
3 O -
) O -
. O +

As O +
seen O +
from O +
the O +
above O +
data O -
, O +
the O +
sulfonamides O +
6 O +
and O +
7 O +
are O +
totally O +
ineffective O +
as O +
lOP O +
lowering O +
agents O -
, O +
similarly O +
to O +
the O +
classical O +
clinically O +
used O +
inhibitors O +
of O +
type O +
1 O -
- O -
5 O +
[ O -
2,3 O -
] O -
. O +

On O +
the O +
other O +
hand O -
, O +
dorzolamide O -
, O +
the O +
first O +
topical O +
sulfonamide O +
used O +
clinically O +
in O +
the O +
treatment O +
of O +
glaucoma O +
is O +
an O +
effective O +
such O +
agent O -
, O +
with O +
a O +
decrease O +
of O +
lOP O +
of O +
around O +
4 O +
mm O +
Hg O -
, O +
one O +
hour O +
after O +
administration O +
directly O +
into O +
the O +
eye O +
( O -
Table O +
IV O -
) O -
. O +

From O +
the O +
data O +
of O +
this O +
table O -
, O +
it O +
is O +
obvious O +
that O +
the O +
metal O +
complexes O +
of O +
heterocyclic O +
sulfonamides O +
investigated O +
by O +
us O +
behave O +
as O +
much O +
more O +
effective O +
IOP O +
lowering O +
agents O +
than O +
dorzolamide O -
, O +
and O +
their O +
effect O +
is O +
generally O +
longerlasting O +
( O -
Fig. O +
1 O -
) O -
. O +

A O +
last O +
remark O +
should O +
be O +
made O +
about O +
the O +
possible O +
mechanism O +
of O +
action O +
of O +
the O +
new O +
class O +
of O +
IOP O +
lowering O +
agents O -
. O +

Obviously O -
, O +
their O +
activity O +
is O +
due O +
to O +
inhibition O +
of O +
CA O +
isozymes O +
present O +
in O +
the O +
cilliary O +
processes O +
within O +
the O +
eye O -
, O +
similarly O +
to O +
other O +
topically O +
active O +
sulfonamides O +
[ O -
2 O -
- O -
6 O -
] O -
. O +

The O +
fact O +
that O +
the O +
sulfonamide O +
per O +
se O +
is O +
inactive O +
via O +
the O +
topical O +
route O -
, O +
whereas O +
the O +
metal O +
complexes O +
result O +
much O +
better O +
than O +
the O +
drug O +
313 O +
Vol O -
. O +

4 O -
, O +
No. O +
6 O -
, O +
1997 O +
Metal O +
Complexes O +
of O +
Heterocyclic O +
Sulfonamides O -
. O -
" O +

A O +
New O +
Class O +
ofAntiglaucoma O +
Agents O +
dorzolamide O -
, O +
indicates O +
that O +
the O +
presence O +
of O +
metal O +
ions O +
in O +
the O +
molecules O +
of O +
these O +
CA O +
inhibitors O +
is O +
essential O +
and O +
confers O +
them O +
completely O +
new O +
properties O -
. O +

Lowering O +
of O +
IOP O +
( O -
ram O +
Hg O -
) O +
" O -
|| O -
, O +
/ O +
" O -
, O +
, O +
' O -
" O -
, O -
. O -
, O +
, O -
< O +
.7 O -
, O +
/ O +
/ O +
.6 O +
-0 O +
-10 O +
0 O +
2 O +
Time O +
( O -
hours O -
) O +
Fig O +
l O -
" O +
Time O +
dependence O +
of O +
IOP O +
lowering O +
with O +
dorzolamide O +
( O -
curve O +
1 O -
) O -
; O +
the O +
zinc O +
complex O +
10 O +
( O -
curve O +
3 O -
) O +
and O +
the O +
zinc O +
complex O +
17 O +
( O -
curve O +
3 O -
) O -
, O +
after O +
topical O +
administration O +
of O +
one O +
drop O +
of O +
2 O +
% O +
solution O +
of O +
inhibitor O +
in O +
rabbit B-Species -
. O +

Preliminary O +
results O +
from O +
this O +
laboratory O +
indicate O +
that O +
the O +
metal O +
complexes O +
of O +
topically O +
active O +
sulfonamides O +
show O +
also O +
increased O +
lOP O +
lowering O +
effects O +
with O +
respect O +
to O +
the O +
complexes O +
prepared O +
in O +
the O +
present O +
study O +
[ O -
42 O -
] O -
. O +

Our O +
hypothesis O +
is O +
that O +
the O +
presence O +
of O +
the O +
metal O +
ion O +
in O +
the O +
molecules O +
of O +
these O +
complex O +
inhibitors O +
induces O +
a O +
dramatic O +
change O +
in O +
their O +
physico O -
- O -
chemical O +
properties O +
as O +
compared O +
to O +
those O +
of O +
the O +
parent O +
sulfonamide O -
. O +

This O +
phenomenon O +
is O +
certainly O +
governed O +
by O +
the O +
strong O +
polarization O +
induced O +
by O +
the O +
metal O +
ions O -
. O +

In O +
this O +
way O -
, O +
it O +
is O +
quite O +
probable O +
that O +
the O +
right O +
balance O +
between O +
the O +
lipo- O +
and O +
hydrosolubility O +
of O +
these O +
compounds O +
is O +
achieved O -
, O +
which O +
has O +
been O +
considered O +
to O +
be O +
the O +
critical O +
factor O +
for O +
not O +
observing O +
topical O +
activity O +
in O +
the O +
classical O +
CA O +
inhibitors O -
, O +
such O +
as O +
acetazolamide O -
, O +
methazolamide O +
and O +
ethoxzolamide O -
, O +
which O +
were O +
either O +
too O +
lipophilic O +
or O +
too O +
hy.drosoluble O +
[ O -
2,3 O -
] O -
. O +

So O -
, O +
by O +
choosing O +
different O +
metal O +
ions O +
and O +
diverse O +
sulfonamides O -
, O +
much O +
larger O +
possibilities O +
arise O +
to O +
finely O +
tune O +
the O +
pharmacological O +
properties O +
which O +
strongly O +
influence O +
the O +
value O +
of O +
a O +
drug O -
. O +

In O +
conclusion O +
we O +
describe O +
here O +
a O +
novel O +
class O +
of O +
lOP O +
lowering O +
agents O -
, O +
ie O -
, O +
the O +
metal O +
complexes O +
of O +
sulfonamide O +
CA O +
inhibitors O -
. O +

These O +
derivatives O +
appear O +
to O +
be O +
very O +
active O +
and O +
longer O +
lasting O +
than O +
the O +
drug O +
dorzolamide O -
, O +
and O +
might O +
constitute O +
the O +
premises O +
for O +
a O +
new O +
generation O +
of O +
antiglaucoma O +
drugs O -
. O +

Acknowledgments O -
. O +

We O +
are O +
grateful O +
to O +
Prof. O +
S. O +
Lindskog O +
( O -
Umea O +
Univ O -
. O -
, O +
Sweden O -
) O +
for O +
the O +
gift O +
of O +
the O +
hCA O +
and O +
II O +
plasmids O -
. O +

References O +
Preceding O +
part O +
of O +
this O +
series O -
" O +
Supuran O +
CT O -
, O +
Scozzafava O +
A O -
, O +
Ilies O +
MA O -
, O +
Iorga O +
B O -
, O +
Cristea O +
T O -
, O +
Chiraleu O +
F O -
, O +
Banciu O +
MD O +
( O -
1997 O -
) O +

Eur O +
J O +
Med O +
Chem O -
, O +
submitted O -
. O +

2 O +
Supuran O +
CT O +
( O -
1994 O -
) O +
" O -
Carbonic O +
anhydrase O +
inhibitors O -
" O +
In O +
Carbonic O +
Anhydrase O +
and O +
Modulation O +
of O +
Physiologic O +
and O +
Pathologic O +
Processes O +
in O +
the O +
Organism O -
, O +
( O +

Puscas O +
I O -
, O +
Ed O -
) O +
Helicon O -
, O +
Timisoara O -
, O +
pp O -
. O +

29 O -
- O -
111 O -
. O +

3 O +
Maren O +
TH O +
( O -
1991 O -
) O +
" O -
The O +
links O +
among O +
biochemistry O -
, O +
physiology O +
and O +
pharmacology O +
in O +
carbonic O +
anhydrase O +
mediated O +
systems O -
" O -
. O +

In O +
Carbonic O +
Anhydrase O +
From O +
Biochemistry O +
and O +
Genetics O +
to O +
Physiology O +
and O +
Clinical O +
Medicine O -
, O +
( O -
Botr6 O +
F O -
, O +
Gros O +
G O -
, O +
Storey O +
BT O +
Eds O -
) O +
VCH O -
, O +
Weinheim O -
, O +
pp O -
. O +

186 O -
- O -
207 O -
. O +
4 O +
Bayer O +
A O -
, O +
Ferrari O +
F O -
, O +
Maren O +
TH O -
, O +
Erb O +
C O +
( O -
1996 O -
) O +
dFr O +
Ophtalrnol O +
19 O -
, O +
3:57 O -
- O -
362 O -
. O +
: O -
5 O +
Maren O +
TH O -
, O +
Conroy O +
CW O -
, O +
Wynns O +
GC O -
, O +
Levy O +
NS O +
( O -
1997 O -
) O +
d O +
Ocul O +
Pharrnacol O +
Therapeut O +
13 O -
, O +
23 O -
- O -
30 O -
. O +
6 O +
Sugrue O +
MF O +
( O -
1996 O -
) O +
d O +
Ocul O +
Pharmacol O +
Ther O +
12,363 O -
- O -
376 O -
. O +

7 O +
Bartlett O +
JD O -
, O +
Jaanus O +
SD O +
( O -
1989 O -
) O +
" O -
Carbonic O +
anhydrase O +
inhibitors O -
" O -
. O +

In O +
Clinical O +
Ocular O +
Pharmacology O -
, O +
Second O +
Edition O -
, O +
Butterworths O +
Publishers O -
, O +
Boston O -
, O +
pp O -
. O +

2:54 O -
- O -
263 O -
. O +
8 O +
Alward O +
PD O -
, O +
Wilensky O +
JT O +
( O -
1981 O -
) O +
Arch O +
Ophthalmo199 O -
, O +
1973 O -
- O -
1976 O -
. O +

314 O +
Claudiu O +
T. O +
Supuran O +
et O +
al. O +
Metal O -
- O -
Based O +
Drugs O +
9 O +
Maren O +
TH O -
, O +
Jankowska O +
L O -
, O +
Sanyal O +
G O -
, O +
Edelhauser O +
HF O +
( O -
1983 O -
) O +
Exp O +
Eye O +
Res O +
36 O -
, O +
457 O -
- O -
480 O -
. O +
10 O +
a O -
) O +

Ponticello O +
GS O -
, O +
Freedman O +
MB O -
, O +
Habecker O +
CN O -
, O +
Lyle O +
PA O -
, O +
Schwam O +
H O -
, O +
Varga O +
SL O -
, O +
Christy O +
ME O -
, O +
Randall O +
WC O -
, O +
Baldwin O +
JJ O -
( O -
1987 O -
) O +

J O +
Med O +
Chem O +
30 O -
, O +
591 O -
- O -
597 O -
; O +
b O -
) O +
Greer O +
J O -
, O +
Erickson O +
JW O -
, O +
Baldwin O +
JJ O -
, O +
Varney O +
MD O +
( O -
1994 O -
) O +

J O +
Med O +
Chem O +
37 O -
, O +
1035 O -
- O -
1054 O -
. O +
11 O +
Baldwin O +
JJ O -
, O +
Ponticello O +
GS O -
, O +
Anderson O +
GS O -
, O +
Christy O +
ME O -
, O +
Murcko O +
MA O -
, O +
Randall O +
WC O -
, O +
Schwam O +
H O -
, O +
Sugrue O +
MF O -
, O +
Springer O +
JP O -
, O +
Gautheron O +
P O -
, O +
Grove O +
J O -
, O +
Mallorga O +
P O -
, O +
Viader O +
MP O -
, O +
McKeever O +
BM O -
, O +
Navia O +
MA O +
( O -
1989 O -
) O +

J O +
Med O +
Chem O +
32 O -
, O +
2510 O -
- O -
2513 O -
. O +

12 O +
Chow O +
K O -
, O +
Lai O +
R O -
, O +
Holmes O +
JM O -
, O +
Wijono O +
M O -
, O +
Wheeler O +
LA O -
, O +
Garst O +
ME O +
( O -
1996 O -
) O +
EurJMed O +
Chem O +
31 O -
, O +
175 O -
- O -
186 O -
. O +

13 O +
Supuran O +
CT O -
, O +
Nicolae O +
A O -
, O +
Popescu O +
A O +
( O -
1996 O -
) O +
Eur O +
JMed O +
Chem O +
31 O -
, O +
431 O -
- O -
438 O -
. O +

14 O +
Supuran O +
CT O -
, O +
Popescu O +
A O -
, O +
Ilisiu O +
M O -
, O +
Costandache O +
A O -
, O +
Banciu O +
MD O +
( O -
1996 O -
) O +

Eur O +
JMed O +
Chem O +
31 O -
, O +
439 O -
- O -
448 O -
. O +

15 O +
Supuran O +
CT O -
, O +
Scozzafava O +
A O -
, O +
Popescu O +
A O -
, O +
Bobes O -
- O -
Tureac O +
R O -
, O +
Banciu O +
A O -
, O +
Creanga O +
A O -
, O +
Bobes O -
- O -
Tureac O +
G O -
, O +
Banciu O +
MD O +
( O -
1997 O -
) O +

Eur O +
JMed O +
Chem O +
32 O -
, O +
445 O -
- O -
452 O -
. O +

16 O +
Alzuet O +
G O -
, O +
Casanova O +
J O -
, O +
Ramirez O +
JA O -
, O +
Borras O +
J O -
, O +
Carugo O +
O O +
( O -
1995 O -
) O +
J O +
Inorg O +
Bioehem O +
57 O -
, O +
219 O -
- O -
234 O -
. O +

17 O +
Sumalan O +
SL O -
, O +
Casanova O +
J O -
, O +
Alzuet O +
G O -
, O +
Borras O +
J O -
, O +
Castifieiras O +
A O -
, O +
Supuran O +
CT O +
( O -
1996 O -
) O +

J O +
Inorg O +
Biochem O +
62 O -
, O +
3139 O -
. O +

18 O +
a O -
) O +
Supuran O +
CT O +
( O -
1995 O -
) O +
Metal O +
Based O +
Drugs O +
2 O -
, O +
327 O -
- O -
330 O -
; O +
b O -
) O +
Scozzafava O +
A O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +

Metal O +
Based O +
Drugs O +
4 O -
, O +
19 O -
- O -
26 O -
. O +

19 O +
a O -
) O +
Borras O +
J O -
, O +
Cristea O +
T O -
, O +
Supuran O +
CT O +
( O -
1996 O -
) O -
, O +
Main O +
Group O +
Met O +
Chem O +
19 O -
, O +
339 O -
- O -
346 O -
; O +
b O -
) O +
Jitianu O +
A O -
, O +
Ilies O +
MA O -
, O +
Briganti O +
F O -
, O +
Scozzafava O +
A O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +

Metal O +
Based O +
Drugs O +
4 O -
, O +
1 O -
- O -
7 O -
. O +
20 O +
a O -
) O +

Supuran O +
CT O -
, O +
Scozzafava O +
A O +
( O -
1997 O -
) O +
J O +
Enzyme O +
Inhibition O +
12 O -
, O +
37 O -
- O -
51 O -
; O +
b O -
) O +
Supuran O +
CT O -
, O +
Briganti O +
F O -
, O +
Scozzafava O +
A O +
( O -
1997 O -
) O +
J O +
Enzyme O +
Inhibition O +
12 O -
, O +
175 O -
- O -
190 O -
. O +

21 O +
Mincione O +
G O -
, O +
Scozzafava O +
A O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +

Metal O +
Based O +
Drugs O +
4 O -
, O +
27 O -
- O -
34 O -
. O +
22 O +
Alzuet O +
G O -
, O +
Ferrer O +
S O -
, O +
Borras O +
J O -
, O +
Supuran O +
CT O +
( O -
1994 O -
) O +
Roum O +
Chem O +
Quart O +
Rev O +
2 O -
, O +
283 O -
- O -
300 O -
. O +

23 O +
Briganti O +
F O -
, O +
Mangani O +
S O -
, O +
Orioli O +
P O -
, O +
Scozzafava O +
A O -
, O +
Vernaglione O +
G O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +
Biochemistry O +
36 O -
, O +
10384 O -
- O -
10392 O -
. O +

24 O +
Borras O +
J O -
, O +
Casanova O +
J O -
, O +
Cristea O +
T O -
, O +
Gheorghe O +
A O -
, O +
Scozzafava O +
A O -
, O +
Supuran O +
CT O -
, O +
Tudor O +
V O +
( O -
1996 O -
) O +
Metal O +
Based O +
Drugs O +
3 O -
, O +
143 O -
- O -
148 O -
. O +

25 O +
Supuran O +
CT O -
, O +
Mincione O +
F O -
, O +
Scozzafava O +
A O -
, O +
Briganti O +
F O -
, O +
Mincione O +
G O -
, O +
Ilies O +
MA O +
( O -
1997 O -
) O +
Eur O +
J O +
Med O +
Chem O -
, O +
in O +
press O -
. O +

26 O +
Supuran O +
CT O -
, O +
Scozzafava O +
A O -
, O +
Saramet O +
I O -
, O +
Banciu O +
MD O +
( O -
1997 O -
) O +
J O +
Enzyme O +
Inhibition O -
, O +
in O +
press O -
. O +

27 O +
Jitianu O +
A O -
, O +
Ilies O +
MA O -
, O +
Scozzafava O +
A O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +

Main O +
Group O +
Met O +
Chem O +
20 O -
, O +
151 O -
- O -
156 O -
. O +

28 O +
Forsman O +
C O -
, O +
Behravan O +
G O -
, O +
Osterman O +
A O -
, O +
Jonsson O +
BH O +
( O -
1988 O -
) O +
Acta O +
Chem O +
Scand O +
B42 O -
, O +
314 O -
- O -
318 O -
. O +

29 O +
Behravan O +
G O -
, O +
Jonasson O +
P O -
, O +
Jonsson O +
BH O -
, O +
Lindskog O +
S O +
( O -
1991 O -
) O +
Eur O +
JBiochem O +
198 O -
, O +
589 O -
- O -
592 O -
. O +
30 O +
Khalifah O +
RG O -
, O +
Strader O +
DJ O -
, O +
Bryant O +
SH O -
, O +
Gibson O +
SM O +
( O -
1977 O -
) O +
Biochemistry O +
16 O -
, O +
2241 O -
- O -
2247 O -
. O +

31 O +
Nyman O +
PO O -
, O +
Lindskog O +
S O +
( O -
1964 O -
) O +
Biochim O +
Biophys O +
Acta O +
85 O -
, O +
141 O -
- O -
151 O -
. O +

32 O +
Henderson O +
LE O -
, O +
Henriksson O +
D O -
, O +
Nyman O +
PO O +
( O -
1976 O -
) O -
JBiol O +
Chem O +
251 O -
, O +
5457 O -
- O -
5463 O -
. O +

33 O +
Maren O +
TH O -
, O +
Wynns O +
GC O -
, O +
Wistrand O +
PJ O +
( O -
1993 O -
) O +
Mol O +
Pharmaco144 O -
, O +
901 O -
- O -
906 O -
. O +

34 O +
Young O +
RW O -
, O +
Wood O +
KH O -
, O +
Vaughan O +
JR O -
, O +
Anderson O +
GW O +
( O -
1956 O -
) O +
J O +
Am O +
Chem O +
Soc O +
78 O -
, O +
4649 O -
- O -
4654 O -
. O +

35 O +
Pocker O +
Y O -
, O +
Stone O +
JT O +
( O -
1967 O -
) O +
Biochemistry O +
6 O -
, O +
668 O -
- O -
678 O -
. O +
36 O +
Baird O +
TT O -
, O +
Waheed O +
A O -
, O +
Okuyama O +
T O -
, O +
Sly O +
WS O -
, O +
Fierke O +
CA O +
( O -
1997 O -
) O +
Biochemistry O +
36 O -
, O +
2669 O -
- O -
2678 O -
. O +

37 O +
Maren O +
TH O -
, O +
Bar O -
- O -
Ilan O +
A O -
, O +
Conroy O +
CW O -
, O +
Brechue O +
WF O +
( O -
1990 O -
) O +
Exp O +
Eye O +
Res O +
50 O -
, O +
27 O -
- O -
36 O -
. O +

38 O +
Maren O +
TH O -
, O +
Brechue O +
WF O -
, O +
Bar O -
- O -
Ilan O +
A O +
( O -
1992 O -
) O +

Exp O +
Eye O +
Res O +
55 O -
, O +
73 O -
- O -
79 O -
. O +

39 O +
Brechue O +
WF O -
, O +
Maren O +
TH O +
( O -
1993 O -
) O +

Invest O +
Ophthalmol O +
Vis O +
Sci O +
34 O -
, O +
2581 O -
- O -
2587 O -
. O +

40 O +
Borja O +
P O -
, O +
Alzuet O +
G O -
, O +
Server O -
- O -
Carri6 O +
J O -
, O +
Borras O +
J O -
, O +
Supuran O +
CT O +
( O -
1997 O -
) O +
J O +
Biol O +
Inorg O +
Chem O +
( O -
JBIC O -
) O -
, O +
in O +
press O -
. O +

41 O +
Supuran O +
CT O -
, O +
Balaban O +
AT O -
, O +
Gheorghiu O +
MD O -
, O +
Schiketanz O +
A O -
, O +
Dinculescu O +
A O -
, O +
Puscas O +
I O +
( O -
1990 O -
) O +
Rev O +
Roum O +
Chim O +
35 O -
, O +
399 O -
- O -
405 O -
. O +

42 O +
Supuran O +
CT O -
, O +
Scozzafava O +
A O +
( O -
1997 O -
) O +
unpublished O +
results O -
. O +

Received O -
: O +
September O +
24 O -
, O +
1997 O +
Accepted O -
: O +
October O +
17 O -
, O +
1997 O +
Received O +
in O +
revised O +
camera O -
- O -
ready O +
format O -
" O +
October O +
23 O -
, O +
1997 O +
315 O +

Purinergic O +
signalling O +
in O +
the O +
subretinal O +
space O -
: O +
a O +
role O +
in O +
the O +
communication O +
between O +
the O +
retina O +
and O +
the O +
RPE O +
Abstract O +
The O +
retinal O +
pigment O +
epithelium O +
( O -
RPE O -
) O +
is O +
separated O +
from O +
the O +
photoreceptor O +
outer O +
segments O +
by O +
the O +
subretinal O +
space O -
. O +

While O +
the O +
actual O +
volume O +
of O +
this O +
space O +
is O +
minimal O -
, O +
the O +
communication O +
that O +
occurs O +
across O +
this O +
microenvironment O +
is O +
important O +
to O +
the O +
visual O +
process O -
, O +
and O +
accumulating O +
evidence O +
suggests O +
the O +
purines O +
ATP O +
and O +
adenosine O +
contribute O +
to O +
this O +
communication O -
. O +

P1 O +
and O +
P2 O +
receptors O +
are O +
localized O +
to O +
membranes O +
on O +
both O +
the O +
photoreceptor O +
outer O +
segments O +
and O +
on O +
the O +
apical O +
membrane O +
of O +
the O +
RPE O +
which O +
border O +
subretinal O +
space O -
. O +

ATP O +
is O +
released O +
across O +
the O +
apical O +
membrane O +
of O +
the O +
RPE O +
into O +
this O +
space O +
in O +
response O +
to O +
various O +
triggers O +
including O +
glutamate O +
and O +
chemical O +
ischemia O -
. O +

This O +
ATP O +
is O +
dephosphorylated O +
into O +
adenosine O +
by O +
a O +
series O +
of O +
ectoenzymes O +
on O +
the O +
RPE O +
apical O +
membrane O -
. O +

Regulation O +
of O +
release O +
and O +
ectoenzyme O +
activity O +
in O +
response O +
to O +
light O -
- O -
sensitive O +
signals O +
can O +
alter O +
the O +
balance O +
of O +
purines O +
in O +
subretinal O +
space O -
, O +
and O +
thus O +
coordinate O +
communication O +
across O +
subretinal O +
space O +
with O +
the O +
visual O +
process O -
. O +

Introduction O +
The O +
retinal O +
pigment O +
epithelium O +
( O -
RPE O -
) O +
lies O +
between O +
the O +
outer O +
segments O +
of O +
the O +
photoreceptors O +
and O +
the O +
choroidal O +
blood O +
supply O +
( O -
Fig. O +
1 O -
) O -
. O +

The O +
RPE O +
combines O +
the O +
functions O +
of O +
epithelial O +
and O +
glial O +
cells O -
, O +
providing O +
a O +
barrier O +
while O +
also O +
supporting O +
the O +
neural O +
photoreceptors O +
and O +
modulating O +
their O +
function O -
. O +

Tight O +
communication O +
between O +
photoreceptors O +
and O +
the O +
RPE O +
is O +
critical O +
to O +
coordinate O +
the O +
multiple O +
levels O +
of O +
interaction O -
, O +
and O +
the O +
purinergic O +
contribution O +
to O +
this O +
communication O +
is O +
becoming O +
apparent O -
. O +

The O +
relevance O +
of O +
this O +
purinergic O +
input O +
is O +
emphasized O +
by O +
the O +
many O +
functional O +
effects O +
of O +
P1 O +
and O +
P2 O +
receptor O +
stimulation O +
and O +
by O +
the O +
multiple O +
mechanisms O +
in O +
place O +
to O +
regulate O +
subretinal O +
levels O +
of O +
purine O +
agonists O -
. O +

As O +
the O +
dynamics O +
of O +
ATP O +
release O +
and O +
extracellular O +
conversion O +
into O +
adenosine O +
will O +
modify O +
agonist O +
availability O -
, O +
the O +
modulation O +
of O +
these O +
processes O +
can O +
exert O +
a O +
temporal O +
control O +
on O +
purinergic O +
signaling O -
. O +

The O +
following O +
review O +
will O +
outline O +
the O +
main O +
interactions O +
between O +
the O +
RPE O +
and O +
photoreceptors O -
, O +
describe O +
the O +
effects O +
of O +
stimulating O +
purinergic O +
receptors O +
on O +
both O +
sides O +
of O +
subretinal O +
space O -
, O +
and O +
summarize O +
how O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
and O +
adenosine O +
are O +
manipulated O +
in O +
this O +
microenvironment O -
. O +

Fig. O +
1Schematic O +
illustration O +
of O +
the O +
key O +
components O +
of O +
purinergic O +
signaling O +
in O +
the O +
subretinal O +
microenvironment O -
. O +

Stimulation O +
of O +
P2 O +
receptors O +
on O +
the O +
RPE O +
can O +
enhance O +
transepithelial O +
fluid O +
absorption O +
while O +
P1 O +
receptors O +
can O +
modulate O +
phagocytosis O -
. O +

ATP O +
released O +
through O +
CFTR O +
and O +
other O +
Cl− O +
channels O +
can O +
stimulate O +
P2 O +
receptors O +
or O +
be O +
converted O +
to O +
ADP O -
, O +
AMP O -
, O +
and O +
adenosine O +
( O -
Ado O -
) O +
by O +
a O +
series O +
of O +
ectonucleotidases O +
present O +
on O +
the O +
apical O +
membrane O +
of O +
the O +
RPE O -
. O +

By O +
controlling O +
the O +
balance O +
of O +
extracellular O +
purines O +
available O +
to O +
stimulate O +
these O +
receptors O +
these O +
mechanisms O +
can O +
control O +
levels O +
of O +
endogenous O +
purines O +
available O +
to O +
activate O +
the O +
receptors O -
. O +

While O +
theoretically O +
possible O -
, O +
it O +
remains O +
to O +
be O +
determined O +
whether O +
these O +
subretinal O +
purines O +
can O +
actually O +
stimulate O +
photoreceptors O +
Purines O +
and O +
subretinal O +
space O +
RPE O -
- O -
photoreceptor O +
interactions O +
across O +
the O +
subretinal O +
space O +
The O +
outer O +
segments O +
of O +
the O +
rods O +
and O +
cones O +
are O +
responsible O +
for O +
the O +
initial O +
stages O +
of O +
vision O -
, O +
converting O +
photon O +
energy O +
into O +
a O +
series O +
of O +
enzymatic O +
reactions O +
that O +
close O +
the O +
light O -
- O -
sensitive O +
channels O +
on O +
the O +
photoreceptor O +
plasma O +
membrane O -
, O +
hyperpolarize O +
the O +
cells O -
, O +
and O +
reduce O +
the O +
release O +
of O +
glutamate O +
from O +
the O +
synaptic O +
terminals O +
[ O -
1 O -
, O +
2 O -
] O -
. O +

Efficient O +
photoreceptor O +
function O +
depends O +
upon O +
both O +
short O -
- O -
term O +
and O +
long O -
- O -
term O +
support O +
from O +
the O +
RPE O -
. O +

The O +
critical O +
nature O +
of O +
these O +
interactions O +
is O +
evident O +
from O +
the O +
rapid O +
degeneration O +
of O +
photoreceptors O +
in O +
the O +
absence O +
of O +
a O +
healthy O +
RPE O +
layer O +
and O +
by O +
the O +
RPE O +
localization O +
of O +
defective O +
gene O +
product O +
in O +
some O +
forms O +
of O +
hereditary O +
photoreceptor O +
degeneration O +
[ O -
3 O -
] O -
. O +

The O +
apical O +
membrane O +
of O +
the O +
RPE O +
is O +
separated O +
from O +
the O +
plasma O +
membrane O +
of O +
the O +
outer O +
segments O +
by O +
an O +
extracellular O +
space O +
of O +
only O +
10–20 O +
nm O +
[ O -
4 O -
] O -
. O +

Although O +
small O -
, O +
this O +
subretinal O +
space O +
contains O +
a O +
highly O +
structured O +
matrix O +
which O +
ensheathes O +
the O +
outer O +
segments O +
and O +
extends O +
to O +
the O +
RPE O +
[ O -
5 O -
, O +
6 O -
] O -
. O +

The O +
presence O +
of O +
enzymes O +
within O +
this O +
interphotoreceptor O +
matrix O +
emphasizes O +
that O +
this O +
extracellular O +
space O +
itself O +
is O +
functionally O +
active O +
[ O -
7 O -
, O +
8 O -
] O -
. O +

This O +
intimate O +
anatomical O +
relationship O +
between O +
photoreceptors O +
and O +
the O +
RPE O +
reflects O +
multiple O +
functional O +
interactions O -
. O +

For O +
example O -
, O +
the O +
RPE O +
accepts O -
, O +
recycles O -
, O +
and O +
exports O +
central O +
components O +
of O +
the O +
phototransduction O +
process O +
[ O -
9 O -
] O -
. O +

The O +
outer O +
segments O +
are O +
continuously O +
resynthesized O -
, O +
and O +
the O +
phagocytosis O -
, O +
degradation O -
, O +
and O +
processing O +
of O +
shed O +
outer O +
segment O +
tips O +
by O +
the O +
RPE O +
cells O +
is O +
central O +
to O +
this O +
renewal O +
[ O -
10 O -
] O -
. O +

The O +
ion O +
channels O +
and O +
transporters O +
on O +
the O +
apical O +
membrane O +
of O +
the O +
RPE O +
help O +
regulate O +
the O +
ionic O +
composition O +
of O +
the O +
subretinal O +
space O +
[ O -
11 O -
] O -
. O +

As O +
extracellular O +
levels O +
of O +
ions O +
can O +
modify O +
the O +
ionic O +
driving O +
forces O +
across O +
the O +
photoreceptor O +
plasma O +
membrane O -
, O +
these O +
RPE O +
transporters O +
can O +
influence O +
the O +
state O +
of O +
neural O +
activity O -
. O +

The O +
transport O +
of O +
fluid O +
and O +
ions O +
from O +
the O +
apical O +
membrane O +
to O +
basolateral O +
membrane O +
of O +
the O +
RPE O +
is O +
also O +
one O +
of O +
the O +
main O +
forces O +
keeping O +
the O +
retina O +
attached O +
[ O -
12 O -
] O -
. O +

The O +
control O +
of O +
photoreceptor O +
activity O +
by O +
light O +
gives O +
a O +
rapid O +
temporal O +
dependence O +
to O +
some O +
interactions O +
between O +
the O +
photoreceptors O +
and O +
the O +
RPE O -
. O +

The O +
volume O +
of O +
subretinal O +
space O +
increases O +
in O +
response O +
to O +
light O +
[ O -
13 O -
] O -
, O +
linking O +
small O +
changes O +
in O +
the O +
ionic O +
composition O +
of O +
the O +
subretinal O +
space O +
with O +
activity O +
of O +
the O +
RPE O +
transport O +
mechanisms O +
which O +
maintain O +
this O +
volume O +
[ O -
14 O -
, O +
15 O -
] O -
. O +

Other O +
processes O +
are O +
controlled O +
on O +
a O +
diurnal O +
cycle O -
. O +

The O +
shed O +
tips O +
of O +
the O +
outer O +
segments O +
are O +
phagocytosed O +
by O +
the O +
RPE O +
soon O +
after O +
the O +
onset O +
of O +
light O +
[ O -
16 O -
, O +
17 O -
] O -
. O +

These O +
processes O +
can O +
both O +
be O +
modulated O +
by O +
purine O +
levels O +
in O +
subretinal O +
space O -
, O +
indicating O +
purinergic O +
regulation O +
is O +
important O +
over O +
multiple O +
time O +
scales O -
. O +

Purinergic O +
receptors O +
on O +
photoreceptors O +
A2 O +
adenosine O +
receptors O +
were O +
localized O +
to O +
both O +
the O +
inner O +
and O +
outer O +
segments O +
of O +
photoreceptor O +
outer O +
segments O +
over O +
a O +
decade O +
ago O +
by O +
Blazynski O +
and O +
colleagues O +
[ O -
18 O -
] O -
, O +
with O +
more O +
recent O +
reports O +
emphasizing O +
their O +
functional O +
role O -
. O +

A2 O +
agonists O +
inhibit O +
the O +
L O -
- O -
type O +
Ca2 O -
+ O +
channel O +
on O +
rod O +
outer O +
segments O +
[ O -
19 O -
] O +
and O +
can O +
inhibit O +
the O +
synaptic O +
release O +
of O +
glutamate O +
from O +
rods O -
, O +
suggesting O +
changes O +
in O +
adenosine O +
levels O +
in O +
subretinal O +
space O +
could O +
modulate O +
light O +
sensitivity O +
[ O -
20 O -
] O -
. O +

The O +
A2 O +
agonist O +
DPMA O +
and O +
the O +
adenosine O +
deaminase O +
inhibitor O +
EHNA O +
reduce O +
mRNA O +
for O +
opsin O +
in O +
rods O -
, O +
suggesting O +
that O +
endogenous O +
levels O +
of O +
adenosine O +
can O +
downregulate O +
opsin O +
message O +
at O +
night O +
[ O -
21 O -
] O -
. O +

EHNA O +
and O +
the O +
A2A O +
receptor O +
agonist O +
CGS21680 O +
also O +
increase O +
the O +
survival O +
of O +
chick O +
embryonic O +
photoreceptors O +
in O +
culture O +
[ O -
22 O -
] O -
, O +
indicating O +
a O +
long O -
- O -
term O +
neuroprotective O +
role O +
for O +
adenosine O -
. O +

P2 O +
receptors O +
are O +
also O +
present O +
in O +
the O +
photoreceptors O -
. O +

mRNA O +
for O +
the O +
P2X2 O +
receptor O +
is O +
expressed O +
in O +
the O +
photoreceptor O +
cell O +
bodies O -
, O +
with O +
immunohistochemical O +
localization O +
of O +
the O +
protein O +
to O +
outer O +
segments O +
[ O -
23 O -
] O -
. O +

In O +
situ O +
hybridization O +
indicates O +
the O +
photoreceptor O +
layer O +
has O +
the O +
highest O +
level O +
of O +
P2Y2 O +
receptor O +
of O +
any O +
region O +
in O +
the O +
rabbit B-Species +
retina O -
, O +
although O +
staining O +
was O +
not O +
pronounced O +
in O +
monkey O +
[ O -
24 O -
] O -
. O +

P2X7 O +
receptors O +
have O +
recently O +
been O +
localized O +
to O +
photoreceptor O +
synaptic O +
terminals O -
, O +
with O +
evidence O +
for O +
ecto O -
- O -
ATPase O +
activity O +
in O +
the O +
synapse O -
, O +
and O +
functional O +
evidence O +
suggesting O +
ATP O +
augments O +
transmission O +
of O +
the O +
light O +
response O +
by O +
rods O +
[ O -
25 O -
] O -
. O +

It O +
was O +
suggested O +
that O +
ATP O +
might O +
be O +
co O -
- O -
released O +
from O +
photoreceptors O +
with O +
glutamate O -
, O +
although O +
this O +
remains O +
to O +
be O +
tested O +
directly O -
. O +

Purinergic O +
receptors O +
on O +
the O +
RPE O +
Stimulation O +
of O +
P1 O +
receptors O +
can O +
have O +
a O +
considerable O +
impact O +
on O +
RPE O +
cells O -
. O +

A2 O +
receptors O +
have O +
been O +
recognized O +
on O +
cultured O +
and O +
fresh O +
RPE O +
cells O +
for O +
some O +
time O +
[ O -
26 O -
, O +
27 O -
] O -
, O +
with O +
in O +
situ O +
hybridization O +
confirming O +
the O +
presence O +
of O +
A2A O +
receptors O +
in O +
rat B-Species +
RPE O +
[ O -
28 O -
] O -
. O +

Stimulation O +
of O +
A2 O +
receptors O +
reduces O +
the O +
rate O +
of O +
rod O +
outer O +
segment O +
phagocytosis O +
by O +
RPE O +
cells O +
[ O -
29 O -
] O -
, O +
while O +
application O +
of O +
adenosine O +
to O +
the O +
apical O +
membrane O +
of O +
chick O +
RPE O +
cells O +
increases O +
the O +
basolateral O +
Cl- O +
conductance O -
, O +
the O +
transepithelial O +
potential O -
, O +
and O +
the O +
c O -
- O -
wave O -
, O +
and O +
decreases O +
the O +
hyperpolarization O +
of O +
the O +
basal O +
membrane O +
in O +
response O +
to O +
light O +
[ O -
30 O -
] O -
. O +

Although O +
adenosine O +
alone O +
does O +
not O +
increase O +
intracellular O +
Ca2 O -
+ O +
levels O +
[ O -
31 O -
] O -
, O +
adenosine O +
acts O +
synergistically O +
with O +
ATP O +
to O +
elevate O +
Ca2 O -
+ O +
levels O +
in O +
human B-Species +
RPE O +
cells O +
by O +
stimulating O +
both O +
A1 O +
and O +
A2A O +
receptors O +
[ O -
32 O -
, O +
33 O -
] O -
. O +

Stimulation O +
of O +
A1 O +
receptors O +
with O +
high O +
doses O +
of O +
NECA O +
increases O +
the O +
active O +
transport O +
of O +
fluorescein O +
across O +
the O +
RPE O -
, O +
while O +
activation O +
of O +
A2A O +
receptors O +
decreases O +
this O +
transport O -
, O +
and O +
by O +
extension O -
, O +
transport O +
of O +
the O +
ions O +
that O +
underlie O +
fluid O +
movement O +
[ O -
34 O -
] O -
. O +

Stimulation O +
of O +
A1 O +
and O +
A2A O +
receptors O +
produces O +
analogous O +
increases O +
and O +
decreases O -
, O +
respectively O -
, O +
in O +
the O +
absorption O +
of O +
subretinal O +
fluid O +
blebs O -
. O +

This O +
is O +
consistent O +
with O +
the O +
negative O +
coupling O +
of O +
the O +
A1 O +
receptor O +
and O +
the O +
positive O +
coupling O +
of O +
the O +
A2 O +
receptors O +
to O +
adenylate O +
cyclase O -
, O +
as O +
increasing O +
cAMP O +
inhibits O +
the O +
transport O +
of O +
fluid O +
across O +
the O +
RPE O +
towards O +
the O +
choroid O +
[ O -
35–37 O -
] O -
. O +

The O +
agonist O +
2-Cl O +
adenosine O +
reverses O +
the O +
deficit O +
in O +
phosphoinositide O +
metabolism O +
found O +
in O +
diabetic O +
RPE O +
cells O +
[ O -
38 O -
] O -
, O +
suggesting O +
effects O +
on O +
metabolism O +
in O +
addition O +
to O +
transport O +
and O +
phagocytosis O -
. O +

Multiple O +
P2 O +
receptors O +
have O +
been O +
localized O +
to O +
the O +
RPE O -
. O +

The O +
P2Y2 O +
receptor O +
was O +
initially O +
characterized O +
in O +
cultured O +
human B-Species +
RPE O +
[ O -
31 O -
] O -
, O +
with O +
subsequent O +
reports O +
localizing O +
transcript O +
for O +
P2Y1 O -
, O +
P2Y2 O -
, O +
P2Y4 O -
, O +
and O +
P2Y6 O +
in O +
the O +
rat B-Species +
RPE O -
/ O -
choroid O +
[ O -
39 O -
] O +
and O +
for O +
P2Y1 O +
and O +
P2Y12 O +
receptors O +
in O +
ARPE-19 O +
cells O +
[ O -
40 O -
] O -
, O +
and O +
functionally O +
identifying O +
a O +
P2X O +
receptor O +
in O +
rat B-Species +
RPE O +
cells O +
[ O -
41 O -
] O -
. O +

ATP O -
, O +
ADP O -
, O +
and O +
UTP O +
induce O +
numerous O +
effects O +
on O +
RPE O +
physiology O +
[ O -
32 O -
, O +
33 O -
, O +
42 O -
, O +
43 O -
] O -
. O +

While O +
these O +
effects O +
likely O +
involve O +
multiple O +
different O +
receptor O +
types O -
, O +
the O +
contributions O +
of O +
the O +
P2Y2 O +
receptor O +
have O +
been O +
explored O +
in O +
most O +
detail O +
to O +
date O -
. O +

The O +
P2Y2 O +
receptor O +
has O +
been O +
specifically O +
localized O +
to O +
the O +
apical O +
membrane O +
of O +
fresh O +
bovine B-Species +
RPE O +
cells O -
, O +
and O +
addition O +
of O +
ATP O +
to O +
this O +
membrane O +
transiently O +
elevates O +
Ca2 O -
+ O -
, O +
activates O +
a O +
basolateral O +
Cl- O +
conductance O -
, O +
inhibits O +
an O +
apical O +
K+ O +
conductance O -
, O +
and O +
increases O +
the O +
apical O +
to O +
basolateral O +
flow O +
of O +
fluid O +
[ O -
43 O -
] O -
. O +

This O +
increased O +
absorption O +
of O +
fluid O +
from O +
the O +
subretinal O +
space O +
suggests O +
P2Y2 O +
receptor O +
stimulation O +
could O +
reduce O +
the O +
excess O +
fluid O +
that O +
accumulates O +
in O +
retinal O +
edemas O -
, O +
and O +
several O +
reports O +
have O +
supported O +
this O +
theory O -
. O +

ATP O -
, O +
UTP O -
, O +
and O +
the O +
P2Y2 O +
receptor O +
agonist O +
INS37217 O +
decrease O +
the O +
size O +
of O +
subretinal O +
fluid O +
blebs O +
when O +
injected O +
into O +
subretinal O +
space O +
of O +
rats B-Species +
[ O -
44 O -
] O -
. O +

In O +
both O +
normal O +
and O +
rds O +
+ O -
/- O +
mice B-Species +
with O +
experimentally O +
induced O +
detachment O -
, O +
INS31217 O +
improves O +
the O +
ERG O +
recovery O +
and O +
decreased O +
cell O +
death O +
[ O -
45 O -
] O -
. O +

INS37217 O +
also O +
reduces O +
subretinal O +
blebs O +
in O +
rabbits B-Species +
[ O -
46 O -
] O -
. O +

Injection O +
of O +
another O +
P2Y2 O +
agonist O -
, O +
INS542 O -
, O +
increases O +
the O +
active O +
transport O +
of O +
fluorescein O +
across O +
the O +
RPE O -
, O +
consistent O +
with O +
this O +
upregulation O +
of O +
ion O +
and O +
fluid O +
transport O +
across O +
the O +
tissue O +
[ O -
47 O -
] O -
. O +

Together O +
these O +
experiments O +
emphasize O +
the O +
clinical O +
potential O +
of O +
treating O +
retinal O +
edema O +
with O +
P2Y2 O +
agonists O -
. O +

Regulation O +
of O +
purine O +
levels O +
in O +
subretinal O +
space O +
While O +
synthesized O +
purinergic O +
agonists O +
may O +
prove O +
useful O +
in O +
treating O +
some O +
ocular O +
disorders O -
, O +
the O +
endogenous O +
activation O +
of O +
P1 O +
and O +
P2 O +
receptors O +
in O +
the O +
subretinal O +
microenvironment O +
will O +
ultimately O +
be O +
determined O +
by O +
availability O +
of O +
agonists O -
. O +

These O +
levels O +
are O +
largely O +
controlled O +
by O +
the O +
release O +
of O +
ATP O +
into O +
the O +
subretinal O +
space O -
, O +
its O +
conversion O +
into O +
other O +
purines O +
including O +
adenosine O -
, O +
and O +
the O +
manipulation O +
of O +
adenosine O +
by O +
enzymes O +
or O +
transporters O -
. O +

Recent O +
work O +
has O +
increased O +
our O +
understanding O +
of O +
both O +
the O +
stimuli O +
that O +
initiate O +
changes O +
in O +
subretinal O +
purine O +
levels O +
and O +
the O +
mechanisms O +
that O +
mediate O +
these O +
changes O -
. O +

Release O +
of O +
ATP O +
by O +
the O +
RPE O +
At O +
least O +
some O +
of O +
the O +
ATP O +
capable O +
of O +
stimulating O +
the O +
purinergic O +
receptors O +
on O +
RPE O +
cells O +
is O +
released O +
from O +
the O +
RPE O +
itself O -
. O +

The O +
resulting O +
autocrine O +
stimulation O +
ensures O +
local O +
delivery O -
, O +
and O +
control O -
, O +
of O +
purines O +
to O +
initiate O +
the O +
physiologic O +
changes O +
in O +
the O +
RPE O -
. O +

The O +
release O +
of O +
ATP O +
by O +
RPE O +
cells O +
is O +
triggered O +
by O +
multiple O +
stimuli O +
including O +
osmotic O +
stress O -
, O +
bFGF O -
, O +
UTP O -
, O +
NMDA O -
, O +
glutamate O -
, O +
and O +
ATP O +
[ O -
39 O -
, O +
40 O -
, O +
48–51 O -
] O -
. O +

The O +
ATP O +
release O +
following O +
activation O +
of O +
NMDA O +
receptors O +
by O +
glutamate O +
may O +
have O +
the O +
most O +
interesting O +
implications O +
for O +
communication O +
across O +
subretinal O +
space O -
, O +
given O +
that O +
glutamate O +
confers O +
the O +
light O +
signal O +
from O +
photoreceptors O +
to O +
the O +
rest O +
of O +
the O +
visual O +
system O -
. O +

Glutamate O +
and O +
the O +
specific O +
receptor O +
agonist O +
NMDA O +
triggers O +
ATP O +
release O +
from O +
ARPE-19 O +
cells O -
, O +
with O +
the O +
release O +
inhibited O +
by O +
NMDA O +
antagonist O +
MK-801 O -
, O +
and O +
by O +
DCKA O -
, O +
which O +
inhibits O +
the O +
glycine O +
B O +
binding O +
site O +
on O +
NMDA O +
receptors O +
[ O -
51 O -
, O +
52 O -
] O -
. O +

Although O +
NMDA O +
raises O +
intracellular O +
Ca2 O -
+ O +
levels O -
, O +
this O +
increase O +
is O +
prevented O +
by O +
eliminating O +
ATP O +
with O +
apyrase O -
, O +
indicating O +
autostimulation O +
through O +
released O +
ATP O +
is O +
responsible O +
for O +
this O +
Ca2 O -
+ O +
signal O -
. O +

NMDA O +
also O +
triggers O +
a O +
release O +
of O +
ATP O +
when O +
applied O +
to O +
the O +
intact O +
bovine B-Species +
RPE O +
eyecup O +
[ O -
51 O -
] O -
. O +

The O +
NMDA O +
receptors O +
and O +
the O +
ATP O +
release O +
sites O +
have O +
been O +
functionally O +
identified O +
to O +
the O +
apical O +
membrane O +
of O +
the O +
bovine B-Species +
RPE O -
, O +
suggesting O +
the O +
neurotransmitter O +
interactions O +
could O +
amplify O +
the O +
signal O +
from O +
any O +
glutamate O +
reaching O +
subretinal O +
space O -
. O +

The O +
ability O +
of O +
both O +
UTP O +
and O +
ATP O +
to O +
stimulate O +
release O +
of O +
ATP O +
from O +
the O +
RPE O +
supports O +
the O +
theory O +
that O +
the O +
system O +
acts O +
to O +
amplify O +
signals O -
. O +

When O +
applied O +
at O +
greater O +
than O +
1 O +
μM O -
, O +
ATP O +
triggers O +
a O +
secondary O +
release O +
of O +
ATP O +
peaking O +
10 O +
min O +
after O +
the O +
initial O +
stimuli O +
[ O -
40 O -
] O -
. O +

UTP O +
also O +
initiates O +
a O +
release O +
in O +
extracellular O +
ATP O +
with O +
a O +
similar O +
delay O +
[ O -
48 O -
] O -
. O +

The O +
rise O +
in O +
ATP O +
triggered O +
by O +
UTP O +
is O +
inhibited O +
by O +
the O +
Cl- O +
channel O +
blocker O +
NPPB O -
, O +
and O +
UDP O +
is O +
much O +
less O +
effective O +
at O +
triggering O +
release O +
than O +
UTP O -
; O +
both O +
observations O +
suggest O +
the O +
P2Y2 O +
receptor O +
contributes O +
to O +
the O +
increase O +
in O +
ATP O +
more O +
than O +
diphosphokinase O -
, O +
although O +
influence O +
from O +
the O +
enzyme O +
can O -
not O +
be O +
ruled O +
out O +
[ O -
53 O -
] O -
. O +

Recent O +
evidence O +
suggests O +
that O +
ischemia O +
may O +
lead O +
to O +
the O +
release O +
of O +
ATP O +
from O +
RPE O +
cells O -
. O +

Chemical O +
ischemia O +
triggers O +
a O +
substantial O +
ATP O +
release O +
from O +
cardiac O +
myocytes O +
[ O -
54 O -
] O -
, O +
while O +
changes O +
in O +
oxygen O +
levels O +
trigger O +
ATP O +
release O +
in O +
central O +
chemoreceptors O +
[ O -
55 O -
] O -
. O +

We O +
found O +
that O +
exposure O +
to O +
sodium O +
cyanide O +
led O +
to O +
a O +
rapid O +
release O +
of O +
ATP O +
from O +
ARPE-19 O +
cells O +
( O -
Fig. O +
2 O -
) O -
. O +

As O +
hypoxic O +
and/or O +
ischemic O +
challenge O +
may O +
lead O +
to O +
changes O +
in O +
the O +
expression O +
of O +
growth O +
factors O +
in O +
RPE O +
cells O +
during O +
certain O +
ocular O +
disorders O +
such O +
as O +
macular O +
degeneration O +
[ O -
56 O -
] O -
, O +
and O +
as O +
purines O +
can O +
induce O +
expression O +
of O +
VEGF O +
in O +
other O +
cells O +
[ O -
57 O -
] O -
, O +
this O +
ATP O +
release O +
may O +
contribute O +
to O +
growth O +
factor O +
signaling O +
by O +
the O +
diseased O +
RPE O -
. O +

Fig. O +
2Chemical O +
ischemia O +
triggers O +
ATP O +
release O +
from O +
ARPE-19 O +
cells O -
. O +

ATP O +
release O +
was O +
measured O +
in O +
the O +
bath O +
directly O +
from O +
cells O +
plated O +
in O +
96-well O +
plates O +
to O +
which O +
the O +
luciferin- O +
luciferase O +
reaction O +
mixture O +
was O +
added O +
[ O -
51 O -
] O -
. O +

Left O +
Levels O +
of O +
ATP O +
in O +
the O +
bath O +
after O +
addition O +
of O +
5 O +
mM O +
NaCN O +
to O +
the O +
cells O -
. O +

Measurement O +
began O +
1 O +
min O +
after O +
addition O +
of O +
NaCN O +
or O +
control O +
solution O +
to O +
wells O -
. O +

Right O +
Levels O +
of O +
ATP O +
measured O +
at O +
the O +
peak O -
, O +
3 O +
min O +
after O +
addition O +
of O +
NaCN O +
( O -
n O +
= O +
12 O -
) O -
. O +

Levels O +
were O +
normalized O +
to O +
concurrent O +
levels O +
in O +
control O +
( O -
n O +
= O +
14 O -
) O -
. O +

Symbols O +
and O +
bars O +
represent O +
mean O +
± O +
SE O -
, O +
* O -
p O +
< O +
0.001 O +
The O +
particular O +
conduit O +
for O +
ATP O +
release O +
varies O +
with O +
the O +
stimuli O -
. O +

The O +
release O +
in O +
response O +
to O +
hypotonic O +
challenge O +
is O +
largely O +
dependent O +
upon O +
CFTR O -
, O +
as O +
it O +
was O +
prevented O +
by O +
the O +
specific O +
CFTR O +
inhibitor O +
CFTR172 O +
in O +
addition O +
to O +
the O +
more O +
general O +
blocker O +
glybenclamide O +
[ O -
50 O -
] O -
. O +

While O +
the O +
precise O +
mechanisms O +
by O +
which O +
CFTR O +
contributes O +
to O +
this O +
release O +
are O +
not O +
yet O +
known O -
, O +
a O +
role O +
for O +
CFTR O +
in O +
ATP O +
release O +
into O +
subretinal O +
space O +
is O +
consistent O +
with O +
the O +
reduction O +
of O +
certain O +
ERG O +
components O +
in O +
cftr O +
- O -
/ O -
- O +
mice B-Species +
[ O -
58 O -
] O +
and O +
with O +
the O +
ability O +
of O +
apical O +
ATP O +
to O +
activate O +
conductances O +
associated O +
with O +
these O +
ERG O +
components O +
[ O -
43 O -
] O -
. O +

The O +
release O +
of O +
ATP O +
is O +
also O +
largely O +
blocked O +
by O +
the O +
vesicular O +
transport O +
inhibitor O +
brefeldin O +
A O -
, O +
suggesting O +
the O +
two O +
processes O +
occurred O +
in O +
series O +
whereby O +
ATP O +
efflux O +
follows O +
the O +
insertion O +
of O +
vesicles O +
containing O +
CFTR O +
into O +
the O +
plasma O +
membrane O -
. O +

Although O +
the O +
Ca2 O -
+ O +
chelator O +
BAPTA O +
blocks O +
this O +
ATP O +
release O +
[ O -
50 O -
] O -
, O +
raising O +
Ca2 O -
+ O +
alone O +
with O +
ionophore O +
ionomycin O +
does O +
not O +
itself O +
initiate O +
release O +
[ O -
48 O -
] O -
. O +

This O +
necessary O +
but O +
not O +
sufficient O +
contribution O +
of O +
Ca2 O -
+ O +
also O +
supports O +
a O +
role O +
for O +
vesicular O +
insertion O -
. O +

In O +
contrast O +
to O +
the O +
release O +
following O +
hypotonic O +
challenge O -
, O +
the O +
ATP O +
release O +
in O +
response O +
to O +
NMDA O +
does O +
not O +
involve O +
CFTR O +
[ O -
51 O -
] O -
. O +

Release O +
is O +
blocked O +
by O +
NPPB O -
, O +
however O -
, O +
suggesting O +
another O +
type O +
of O +
anion O +
channel O +
could O +
serve O +
as O +
a O +
conduit O +
for O +
ATP O +
release O -
. O +

The O +
presence O +
of O +
parallel O +
mechanisms O +
coexisting O +
on O +
the O +
same O +
cell O +
for O +
ATP O +
release O +
triggered O +
by O +
either O +
agonists O +
or O +
by O +
cell O +
swelling O +
has O +
also O +
been O +
reported O +
in O +
astrocytes O +
[ O -
59 O -
] O +
and O +
may O +
reflect O +
the O +
multiple O +
roles O +
of O +
purinergic O +
signaling O +
within O +
a O +
given O +
tissue O -
. O +

As O +
both O +
stimuli O +
lead O +
to O +
release O +
across O +
the O +
apical O +
membrane O +
into O +
subretinal O +
space O -
, O +
both O +
are O +
expected O +
to O +
influence O +
signaling O +
in O +
the O +
microenvironment O -
. O +

Interconversion O +
of O +
purines O +
in O +
subretinal O +
space O +
The O +
interconversion O +
of O +
nucleotides O +
and O +
nucleosides O +
each O +
capable O +
of O +
stimulating O +
distinct O +
receptors O +
makes O +
the O +
purinergic O +
signaling O +
system O +
of O +
particular O +
interest O +
in O +
a O +
confined O +
region O +
such O +
as O +
the O +
subretinal O +
space O -
. O +

The O +
main O +
enzymes O +
responsible O +
for O +
dephosphorylating O +
extracellular O +
ATP O +
on O +
the O +
RPE O +
cells O +
have O +
been O +
analyzed O +
and O +
a O +
basic O +
understanding O +
of O +
their O +
regulation O +
has O +
begun O -
. O +

This O +
section O +
first O +
describes O +
the O +
enzymes O +
that O +
act O +
on O +
ATP O +
and O +
ADP O -
, O +
followed O +
by O +
enzymes O +
which O +
convert O +
AMP O +
into O +
adenosine O -
. O +

The O +
dephosphorylation O +
of O +
extracellular O +
ATP O +
by O +
RPE O +
cells O +
involves O +
enzymes O +
from O +
multiple O +
families O +
[ O -
40 O -
] O -
, O +
as O +
found O +
in O +
airway O +
epithelial O +
cells O +
[ O -
60 O -
] O -
. O +

Degradation O +
of O +
ATP O +
by O +
the O +
apical O +
membrane O +
of O +
the O +
fresh O +
bovine B-Species +
eyecup O +
and O +
by O +
ARPE-19 O +
cells O +
is O +
inhibited O +
by O +
ARL67156 O +
or O +
βγmATP O -
. O +

Message O +
for O +
eNPP1 O -
, O +
eNPP2 O -
, O +
and O +
eNPP3 O +
is O +
present O +
in O +
ARPE-19 O +
cells O -
, O +
consistent O +
with O +
the O +
preference O +
of O +
βγmATP O +
for O +
members O +
of O +
the O +
eNPP O +
family O +
[ O -
61 O -
] O -
. O +

The O +
cells O +
also O +
express O +
NTPDase2 O -
, O +
and O +
NTPDase3 O -
, O +
although O +
the O +
intermittent O +
presence O +
of O +
NTPDase1 O +
likely O +
reflects O +
a O +
regulated O +
process O +
[ O -
40 O -
] O -
. O +

Ecto O -
- O -
alkaline O +
phosphatase O +
has O +
no O +
effect O +
on O +
ATP O +
degradation O +
in O +
RPE O +
cells O -
, O +
in O +
contrast O +
to O +
its O +
considerable O +
contribution O +
in O +
airway O +
epithelium O +
[ O -
62 O -
] O -
. O +

The O +
putative O +
contribution O +
from O +
diphosphokinases O +
to O +
interconversion O +
of O +
subretinal O +
purines O +
is O +
presently O +
unknown O -
. O +

Extracellular O +
AMP O +
is O +
rapidly O +
dephosphorylated O +
into O +
adenosine O +
in O +
subretinal O +
space O -
. O +

The O +
production O +
of O +
adenosine O +
from O +
ATP O +
at O +
the O +
apical O +
membrane O +
of O +
the O +
bovine B-Species +
RPE O +
eyecup O +
is O +
inhibited O +
by O +
the O +
ecto-5′-nucleotidase O +
inhibitor O +
αβmADP O -
, O +
confirming O +
a O +
role O +
for O +
this O +
enzyme O +
[ O -
63 O -
] O -
. O +

The O +
enzyme O +
is O +
localized O +
to O +
rat B-Species +
RPE O +
and O +
ARPE-19 O +
cells O +
immunohistochemically O -
. O +

Degradation O +
of O +
5′AMP O +
is O +
highest O +
near O +
the O +
subretinal O +
space O +
of O +
rat B-Species +
retina O +
[ O -
63 O -
] O -
, O +
although O +
localization O +
in O +
mouse B-Species +
indicated O +
larger O +
amounts O +
of O +
ecto-5′-nucleotidase O +
at O +
the O +
tips O +
of O +
adjacent O +
Müller O +
cells O +
[ O -
64 O -
] O -
. O +

Levamisole O +
does O +
not O +
inhibit O +
the O +
dephosphorylation O +
of O +
5′AMP O +
by O +
the O +
RPE O -
, O +
consistent O +
with O +
the O +
absence O +
of O +
substantial O +
ecto O -
- O -
alkaline O +
phosphatase O +
in O +
subretinal O +
space O -
. O +

The O +
presence O +
of O +
light O +
may O +
alter O +
the O +
levels O +
of O +
adenosine O +
in O +
subretinal O +
space O -
. O +

Epinephrine O +
is O +
released O +
at O +
the O +
onset O +
of O +
light O +
[ O -
65 O -
] O +
and O +
stimulation O +
of O +
the O +
RPE O +
with O +
epinephrine O +
can O +
decrease O +
activity O +
of O +
ecto-5′-nucleotidase O +
[ O -
63 O -
] O -
. O +

While O +
norepinephrine O +
and O +
phenylephrine O +
lead O +
to O +
similar O +
decreases O +
in O +
enzyme O +
activity O -
, O +
prazosin O +
and O +
corynanthine O +
block O +
the O +
effects O +
of O +
norepinephrine O -
, O +
implicating O +
the O +
α1 O +
epinephrine O +
receptor O +
in O +
the O +
inhibition O +
of O +
ecto-5′-nucleotidase O +
[ O -
63 O -
] O -
. O +

The O +
kinetics O +
of O +
inhibition O +
are O +
consistent O +
with O +
cleavage O +
of O +
the O +
nucleotidase O +
from O +
its O +
GPI O +
anchor O -
. O +

The O +
phagocytosis O +
of O +
rod O +
outer O +
segments O +
is O +
maximal O +
shortly O +
after O +
light O +
onset O +
[ O -
16 O -
] O -
, O +
and O +
this O +
phagocytosis O +
is O +
inhibited O +
by O +
adenosine O +
[ O -
29 O -
] O -
. O +

The O +
ability O +
of O +
epinephrine O +
released O +
by O +
the O +
illuminated O +
retina O +
to O +
reduce O +
ecto-5′-nucleotidase O +
activity O +
and O +
consequently O +
adenosine O +
levels O +
may O +
relieve O +
this O +
inhibition O +
and O +
enhance O +
the O +
rate O +
of O +
phagocytosis O +
at O +
light O +
onset O -
. O +

Physiologic O +
effects O +
of O +
subretinal O +
purines O +
on O +
the O +
RPE O +
and O +
photoreceptors O +
The O +
number O +
of O +
purinergic O +
receptors O +
on O +
both O +
photoreceptor O +
and O +
RPE O +
membranes O +
suggests O +
purines O +
make O +
multiple O +
contributions O +
to O +
the O +
physiology O +
of O +
the O +
outer O +
retina O -
. O +

Our O +
increased O +
understanding O +
of O +
how O +
agonist O +
levels O +
in O +
subretinal O +
space O +
are O +
controlled O +
has O +
begun O +
to O +
indicate O +
how O +
and O +
when O +
this O +
contribution O +
may O +
occur O -
. O +

Future O +
research O +
will O +
involve O +
applying O +
these O +
findings O +
from O +
isolated O +
systems O +
to O +
intact O +
RPE O -
- O -
photoreceptor O +
models O -
, O +
and O +
pursuing O +
the O +
role O +
of O +
defective O +
purinergic O +
regulation O +
in O +
ocular O +
disease O -
. O +

While O +
it O +
is O +
unlikely O +
that O +
ATP O +
released O +
across O +
the O +
apical O +
membrane O +
of O +
the O +
RPE O +
can O +
diffuse O +
to O +
these O +
P2 O +
receptors O +
in O +
the O +
outer O +
plexiform O +
layer O +
given O +
the O +
ecto O -
- O -
ATPase O +
activity O +
in O +
the O +
synaptic O +
clef O +
[ O -
25 O -
] O -
, O +
stimulation O +
of O +
receptors O +
elsewhere O +
on O +
the O +
photoreceptor O +
membrane O +
is O +
possible O -
. O +

It O +
would O +
be O +
interesting O +
to O +
determine O +
whether O +
ATP O +
released O +
from O +
the O +
RPE O +
and O +
converted O +
to O +
adenosine O +
by O +
ecto O -
- O -
nucleotidases O +
can O +
actually O +
modulate O +
the O +
response O +
to O +
light O +
by O +
stimulating O +
the O +
A2A O +
receptors O +
on O +
photoreceptor O +
outer O +
segments O -
. O +

The O +
impact O +
of O +
purinergic O +
signaling O +
on O +
chronic O +
ocular O +
diseases O +
is O +
also O +
of O +
interest O -
, O +
such O +
as O +
the O +
role O +
of O +
ischemia O -
- O -
driven O +
ATP O +
release O +
in O +
VEGF O +
production O -
. O +

While O +
the O +
small O +
size O +
of O +
subretinal O +
space O +
can O +
complicate O +
pharmacologic O +
manipulation O +
within O +
the O +
intact O +
RPE O -
- O -
photoreceptor O +
complex O -
, O +
molecular O +
approaches O +
may O +
provide O +
new O +
insight O +
into O +
how O +
endogenous O +
purines O +
in O +
subretinal O +
space O +
affect O +
the O +
physiology O -
, O +
and O +
pathophysiology O -
, O +
of O +
both O +
RPE O +
and O +
photoreceptors O -
. O +

Genomic O -
- O -
Bioinformatic O +
Analysis O +
of O +
Transcripts O +
Enriched O +
in O +
the O +
Third O -
- O -
Stage O +
Larva O +
of O +
the O +
Parasitic O +
Nematode O +
Ascaris B-Species +
suum I-Species +
Abstract O +
Differential O +
transcription O +
in O +
Ascaris B-Species +
suum I-Species +
was O +
investigated O +
using O +
a O +
genomic O -
- O -
bioinformatic O +
approach O -
. O +

A O +
cDNA O +
archive O +
enriched O +
for O +
molecules O +
in O +
the O +
infective O +
third O -
- O -
stage O +
larva O +
( O -
L3 O -
) O +
of O +
A. B-Species +
suum I-Species +
was O +
constructed O +
by O +
suppressive O -
- O -
subtractive O +
hybridization O +
( O -
SSH O -
) O -
, O +
and O +
a O +
subset O +
of O +
cDNAs O +
from O +
3075 O +
clones O +
subjected O +
to O +
microarray O +
analysis O +
using O +
cDNA O +
probes O +
derived O +
from O +
RNA O +
from O +
different O +
developmental O +
stages O +
of O +
A. B-Species +
suum I-Species -
. O +

The O +
cDNAs O +
( O -
n O +
= O +
498 O -
) O +
shown O +
by O +
microarray O +
analysis O +
to O +
be O +
enriched O +
in O +
the O +
L3 O +
were O +
sequenced O +
and O +
subjected O +
to O +
bioinformatic O +
analyses O +
using O +
a O +
semi O -
- O -
automated O +
pipeline O +
( O -
ESTExplorer O -
) O -
. O +

Using O +
gene O +
ontology O +
( O -
GO O -
) O -
, O +
235 O +
of O +
these O +
molecules O +
were O +
assigned O +
to O +
' O -
biological O +
process O -
' O +
( O -
n O +
= O +
68 O -
) O -
, O +
' O -
cellular O +
component O -
' O +
( O -
n O +
= O +
50 O -
) O -
, O +
or O +
' O -
molecular O +
function O -
' O +
( O -
n O +
= O +
117 O -
) O -
. O +

Of O +
the O +
91 O +
clusters O +
assembled O -
, O +
56 O +
molecules O +
( O -
61.5 O -
% O -
) O +
had O +
homologues O -
/ O -
orthologues O +
in O +
the O +
free O -
- O -
living O +
nematodes O +
Caenorhabditis B-Species +
elegans I-Species +
and O +
C. B-Species +
briggsae I-Species +
and/or O +
other O +
organisms O -
, O +
whereas O +
35 O +
( O -
38.5 O -
% O -
) O +
had O +
no O +
significant O +
similarity O +
to O +
any O +
sequences O +
available O +
in O +
current O +
gene O +
databases O -
. O +

Transcripts O +
encoding O +
protein O +
kinases O -
, O +
protein O +
phosphatases O +
( O -
and O +
their O +
precursors O -
) O -
, O +
and O +
enolases O +
were O +
abundantly O +
represented O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species -
, O +
as O +
were O +
molecules O +
involved O +
in O +
cellular O +
processes O -
, O +
such O +
as O +
ubiquitination O +
and O +
proteasome O +
function O -
, O +
gene O +
transcription O -
, O +
protein O -
– O -
protein O +
interactions O -
, O +
and O +
function O -
. O +

In O +
silico O +
analyses O +
inferred O +
the O +
C. B-Species +
elegans I-Species +
orthologues O -
/ O -
homologues O +
( O -
n O +
= O +
50 O -
) O +
to O +
be O +
involved O +
in O +
apoptosis O +
and O +
insulin O +
signaling O +
( O -
2 O -
% O -
) O -
, O +
ATP O +
synthesis O +
( O -
2 O -
% O -
) O -
, O +
carbon O +
metabolism O +
( O -
6 O -
% O -
) O -
, O +
fatty O +
acid O +
biosynthesis O +
( O -
2 O -
% O -
) O -
, O +
gap O +
junction O +
( O -
2 O -
% O -
) O -
, O +
glucose O +
metabolism O +
( O -
6 O -
% O -
) O -
, O +
or O +
porphyrin O +
metabolism O +
( O -
2 O -
% O -
) O -
, O +
although O +
34 O +
( O -
68 O -
% O -
) O +
of O +
them O +
could O +
not O +
be O +
mapped O +
to O +
a O +
specific O +
metabolic O +
pathway O -
. O +

Small O +
numbers O +
of O +
these O +
50 O +
molecules O +
were O +
predicted O +
to O +
be O +
secreted O +
( O -
10 O -
% O -
) O -
, O +
anchored O +
( O -
2 O -
% O -
) O -
, O +
and/or O +
transmembrane O +
( O -
12 O -
% O -
) O +
proteins O -
. O +

Functionally O -
, O +
17 O +
( O -
34 O -
% O -
) O +
of O +
them O +
were O +
predicted O +
to O +
be O +
associated O +
with O +
( O -
non O -
- O -
wild O -
- O -
type O -
) O +
RNAi O +
phenotypes O +
in O +
C. B-Species +
elegans I-Species -
, O +
the O +
majority O +
being O +
embryonic O +
lethality O +
( O -
Emb O -
) O +
( O -
13 O +
types O -
; O +
58.8 O -
% O -
) O -
, O +
larval O +
arrest O +
( O -
Lva O -
) O +
( O -
23.5 O -
% O -
) O +
and O +
larval O +
lethality O +
( O -
Lvl O -
) O +
( O -
47 O -
% O -
) O -
. O +

A O +
genetic O +
interaction O +
network O +
was O +
predicted O +
for O +
these O +
17 O +
C. B-Species +
elegans I-Species +
orthologues O -
, O +
revealing O +
highly O +
significant O +
interactions O +
for O +
nine O +
molecules O +
associated O +
with O +
embryonic O +
and O +
larval O +
development O +
( O -
66.9 O -
% O -
) O -
, O +
information O +
storage O +
and O +
processing O +
( O -
5.1 O -
% O -
) O -
, O +
cellular O +
processing O +
and O +
signaling O +
( O -
15.2 O -
% O -
) O -
, O +
metabolism O +
( O -
6.1 O -
% O -
) O -
, O +
and O +
unknown O +
function O +
( O -
6.7 O -
% O -
) O -
. O +

The O +
potential O +
roles O +
of O +
these O +
molecules O +
in O +
development O +
are O +
discussed O +
in O +
relation O +
to O +
the O +
known O +
roles O +
of O +
their O +
homologues O -
/ O -
orthologues O +
in O +
C. B-Species +
elegans I-Species +
and O +
some O +
other O +
nematodes O -
. O +

The O +
results O +
of O +
the O +
present O +
study O +
provide O +
a O +
basis O +
for O +
future O +
functional O +
genomic O +
studies O +
to O +
elucidate O +
molecular O +
aspects O +
governing O +
larval O +
developmental O +
processes O +
in O +
A. B-Species +
suum I-Species +
and/or O +
the O +
transition O +
to O +
parasitism O -
. O +

Introduction O +
Parasitic O +
nematodes O +
are O +
of O +
major O +
socio O -
- O -
economic O +
importance O +
in O +
animals O -
. O +

For O +
example O -
, O +
hundreds O +
of O +
millions O +
of O +
people O +
are O +
infected O +
with O +
geohelminths O +
( O -
soil O -
- O -
transmitted O +
worms O -
) O -
, O +
such O +
as O +
blood O -
- O -
feeding O +
hookworms O +
Ancylostoma B-Species +
duodenale I-Species +
and/or O +
Necator B-Species +
americanus I-Species -
, O +
Trichuris B-Species +
trichiura I-Species +
and O +
Ascaris O +
spp O -
. O +

[ O -
1 O -
] O -
, O +
causing O +
serious O +
adverse O +
effects O +
on O +
human B-Species +
health O -
, O +
particularly O +
in O +
children O -
. O +

Similarly O -
, O +
parasitic O +
nematodes O +
of O +
livestock O -
, O +
such O +
as O +
pigs B-Species -
, O +
also O +
cause O +
substantial O +
economic O +
losses O +
due O +
to O +
subclinical O +
and O +
clinical O +
diseases O -
, O +
with O +
billions O +
of O +
dollars O +
spent O +
annually O +
on O +
the O +
treatment O +
and O +
control O +
of O +
gastro O -
- O -
intestinal O +
nematodes O -
. O +

In O +
addition O +
to O +
the O +
socioeconomic O +
impact O +
that O +
these O +
parasites O +
have O -
, O +
there O +
is O +
potential O +
for O +
the O +
emergence O +
of O +
resistance O +
in O +
them O +
against O +
all O +
of O +
the O +
main O +
classes O +
of O +
( O -
nematocidal O -
) O +
compounds O +
used O +
to O +
treat O +
the O +
diseases O +
they O +
cause O +
[ O -
2 O -
] O -
– O -
[ O -
5 O -
] O -
. O +

Therefore O -
, O +
there O +
is O +
a O +
significant O +
need O +
to O +
work O +
toward O +
discovering O +
new O +
compounds O +
to O +
control O +
these O +
parasites O -
. O +

Gaining O +
an O +
improved O +
understanding O +
of O +
the O +
molecular O +
basis O +
of O +
parasite O +
development O +
provides O +
such O +
an O +
avenue O -
. O +

Compared O +
with O +
the O +
free O -
- O -
living O +
nematode O +
Caenorhabditis B-Species +
elegans I-Species -
, O +
there O +
is O +
very O +
little O +
information O +
on O +
fundamental O +
molecular O +
aspects O +
of O +
development O +
in O +
parasitic O +
nematodes O +
[ O -
6 O -
] O -
– O -
[ O -
8 O -
] O -
. O +

Since O +
the O +
genome O +
sequence O +
of O +
C. B-Species +
elegans I-Species +
was O +
published O +
in O +
1998 O +
[ O -
9 O -
] O -
, O +
many O +
aspects O +
of O +
the O +
molecular O +
biology O +
of O +
this O +
nematode O +
have O +
been O +
elucidated O -
. O +

For O +
instance O -
, O +
microarray O +
analyses O +
have O +
been O +
used O +
to O +
examine O +
developmental O +
and O +
gender O -
- O -
enriched O +
gene O +
expression O +
[ O -
10 O -
] O -
, O -
[ O -
11 O -
] O -
, O +
and O +
the O +
functions O +
of O +
more O +
than O +
96 O -
% O +
of O +
the O +
C. B-Species +
elegans I-Species +
genes O +
have O +
been O +
assessed O +
by O +
double O -
- O -
stranded O +
RNA O +
interference O +
( O -
RNAi O -
, O +
or O +
gene O +
silencing O -
; O +
[ O -
12 O -
] O -
) O +
[ O -
13 O -
] O -
– O -
[ O -
18 O -
] O -
. O +

Comparative O +
analyses O +
of O +
genetic O +
data O +
sets O +
have O +
shown O +
that O +
parasitic O +
nematodes O +
usually O +
share O +
∼50–70 O -
% O +
of O +
genes O +
with O +
C. B-Species +
elegans I-Species +
( O -
e.g. O -
, O +
[ O -
19 O -
] O -
, O -
[ O -
20 O -
] O -
) O -
. O +

There O +
is O +
similarity O +
in O +
other O +
features O +
( O -
such O +
as O +
basic O +
body O +
plan O +
and O +
moulting O -
) O +
between O +
C. B-Species +
elegans I-Species +
and O +
parasitic O +
nematodes O -
, O +
suggesting O +
that O +
some O +
molecular O +
pathways O +
are O +
relatively O +
conserved O +
[ O -
8 O -
] O -
, O -
[ O -
21 O -
] O -
. O +

Understanding O +
the O +
pathways O +
linked O +
to O +
basic O +
nematode O +
biology O +
and O +
development O +
could O +
have O +
important O +
implications O +
for O +
finding O +
new O +
ways O +
of O +
disrupting O +
these O +
pathways O +
and O +
thus O +
facilitate O +
the O +
identification O +
of O +
new O +
drug O +
targets O -
. O +

Despite O +
the O +
advances O +
in O +
genomic O +
technologies O +
[ O -
7 O -
] O -
, O +
[ O -
22 O -
] O -
– O -
[ O -
29 O -
] O +
and O +
the O +
study O +
of O +
C. B-Species +
elegans I-Species -
, O +
there O +
is O +
a O +
paucity O +
of O +
information O +
on O +
the O +
genomics O +
of O +
parasitic O +
nematodes O +
of O +
animals O -
, O +
particularly O +
in O +
relation O +
to O +
development O -
. O +

Also O +
considering O +
the O +
major O +
socioeconomic O +
impact O +
of O +
Ascaris O +
and O +
ascariasis O +
in O +
humans B-Species +
and O +
pigs B-Species +
[ O -
30 O -
] O -
– O -
[ O -
32 O -
] O -
, O +
several O +
characteristics O -
, O +
including O +
the O +
large O +
size O +
of O +
the O +
adult O +
worm O +
( O -
providing O +
the O +
opportunity O +
of O +
investigating O +
individual O +
organ O +
systems O +
and O +
tissues O -
) O -
, O +
the O +
ability O +
to O +
maintain O +
Ascaris O +
in O +
the O +
pig B-Species -
, O +
store O +
eggs O +
and O +
culture O +
larvae O +
in O +
vitro O +
for O +
relatively O +
long O +
periods O +
of O +
time O +
( O -
months O +
to O +
years O -
) O +
[ O -
32 O -
] O +
as O +
well O +
as O +
the O +
discovery O +
that O +
RNAi O +
achieves O +
" O -
cross O -
- O -
species O -
" O +
gene O +
silencing O +
for O +
a O +
selected O +
number O +
of O +
genes O +
[ O -
33 O -
] O -
, O -
[ O -
34 O -
] O +
and O +
the O +
imminent O +
genome O +
sequence O +
( O -
http://www.sanger.ac.uk/Projects/Helminths/ O -
) O +
all O +
indicate O +
that O +
Ascaris O +
could O +
serve O +
as O +
a O +
powerful O +
model O +
system O +
for O +
investigating O +
reproductive O +
and O +
developmental O +
processes O +
in O +
nematodes O -
. O +

In O +
the O +
present O +
study O -
, O +
Ascaris O +
from O +
pigs B-Species +
was O +
used O +
to O +
study O +
molecules O +
abundantly O +
transcribed O +
in O +
the O +
infective O +
third O -
- O -
stage O +
larva O +
( O -
L3 O -
) O -
. O +

Following O +
the O +
oral O +
ingestion O +
of O +
Ascaris O +
eggs O +
by O +
the O +
host O +
( O -
human B-Species +
or O +
pig B-Species -
) O -
, O +
L3s O +
are O +
released O +
and O +
then O +
invade O -
/ O -
penetrate O +
predominantly O +
the O +
caecal O +
wall O +
[ O -
35 O -
] O +
to O +
then O +
undergo O +
hepato O -
- O -
pulmonary O +
migration O -
, O +
after O +
which O +
ultimately O +
the O +
adult O +
females O +
and O +
males O +
establish O +
and O +
develop O +
in O +
the O +
small O +
intestine O +
[ O -
36 O -
] O -
, O -
[ O -
37 O -
] O -
. O +

The O +
molecular O +
mechanisms O +
linked O +
to O +
host O +
invasion O +
and O +
parasite O +
development O +
are O +
largely O +
unknown O -
. O +

Here O -
, O +
we O +
constructed O +
an O +
L3-enriched O +
cDNA O +
library O +
using O +
the O +
method O +
of O +
suppressive O -
- O -
subtractive O +
hybridization O +
( O -
SSH O -
) O -
, O +
explored O +
transcription O +
of O +
a O +
representative O +
subset O +
of O +
molecules O +
by O +
microarray O +
analysis O +
and O +
conducted O +
bioinformatic O +
analyses O +
to O +
characterize O +
these O +
molecules O -
, O +
map O +
them O +
to O +
biochemical O +
pathways O +
and O +
predict O +
genetic O +
interactions O +
based O +
on O +
comparisons O +
with O +
C. B-Species +
elegans I-Species +
and/or O +
other O +
organisms O -
. O +

Materials O +
and O +
Methods O +
Production O +
of O +
Different O +
Developmental O +
Stages O +
of O +
Ascaris O +
Experimental O +
pigs B-Species +
( O -
8–12 O +
weeks O +
of O +
age O -
) O +
were O +
purchased O +
from O +
and O +
maintained O +
in O +
the O +
Experimental O +
Animal O +
Center O +
of O +
South O +
China O +
Agricultural O +
University O -
. O +

These O +
pigs B-Species +
were O +
treated O +
humanely O -
, O +
according O +
to O +
the O +
Animal O +
Ethics O +
procedures O +
and O +
guidelines O +
of O +
the O +
People O -
's O +
Republic O +
of O +
China O -
. O +

Adult O +
worms O +
( O -
males O +
and O +
females O -
) O +
of O +
A. B-Species +
suum I-Species +
were O +
collected O +
from O +
the O +
small O +
intestines O +
of O +
pigs B-Species +
from O +
an O +
abattoir O +
in O +
Shenzhen O -
, O +
China O -
. O +

Infective O +
eggs O +
and O +
infective O +
L3s O +
of O +
A. B-Species +
suum I-Species +
were O +
produced O +
according O +
to O +
the O +
methods O +
described O +
previously O +
[ O -
38 O -
] O -
. O +

In O +
brief O -
, O +
eggs O +
from O +
the O +
uteri O +
of O +
adult O +
females O +
of O +
A. B-Species +
suum I-Species +
were O +
collected O +
and O +
incubated O +
at O +
28 O -
° O -
C O +
for O +
28 O +
days O +
to O +
allow O +
them O +
to O +
develop O +
to O +
infective O +
eggs O +
( O -
containing O +
infective O +
L3s O -
) O -
. O +

To O +
obtain O +
pure O +
infective O +
L3s O -
, O +
7.5 O -
% O +
v O -
/ O -
v O +
sodium O +
hypochlorite O +
was O +
used O +
to O +
treat O +
the O +
larvated O +
eggs O +
at O +
37 O -
° O -
C O +
overnight O +
and O +
then O +
the O +
eggs O +
were O +
shaken O +
with O +
glass O -
- O -
beads O -
; O +
then O -
, O +
the O +
exsheathed O +
L3s O +
and O +
shells O +
were O +
separated O +
by O +
density O +
gradient O +
centrifugation O +
using O +
lymphocyte O +
separating O +
medium O +
( O -
LSM O -
) O +
[ O -
38 O -
] O -
. O +

Following O +
the O +
experimental O +
infection O +
of O +
helminth O -
- O -
free O +
pigs B-Species +
with O +
infective O +
Ascaris O +
eggs O +
as O +
described O +
previously O +
[ O -
39 O -
] O -
, O +
the O +
L3s O +
from O +
livers O +
and O +
in O +
lungs O +
as O +
well O +
as O +
L4s O +
in O +
intestines O +
were O +
isolated O +
according O +
to O +
an O +
established O +
method O +
[ O -
40 O -
] O -
. O +

All O +
parasite O +
materials O +
were O +
snap O -
- O -
frozen O +
in O +
liquid O +
nitrogen O +
prior O +
to O +
storage O +
at O +
−70 O -
° O -
C O -
. O +

Construction O +
of O +
the O +
cDNA O +
Library O +
by O +
Subtractive O -
- O -
Suppressive O +
Hybridization O +
( O -
SSH O -
) O +
Total O +
RNA O +
was O +
isolated O +
from O +
adult O +
females O +
and O +
males O -
, O +
different O +
larval O +
stages O +
or O +
eggs O +
of O +
A. B-Species +
suum I-Species +
using O +
TriPure O +
reagent O +
( O -
Roche O -
) O +
as O +
recommended O +
by O +
the O +
manufacturer O -
. O +

Equal O +
amounts O +
of O +
total O +
RNA O +
from O +
each O +
stage O +
or O +
sex O +
were O +
pooled O -
. O +

The O +
mRNA O +
was O +
isolated O +
using O +
the O +
Oligotex O +
mRNA O +
Kit O +
( O -
Qiagen O -
) O -
, O +
following O +
the O +
manufacturer O -
's O +
protocol O -
. O +

SSH O +
was O +
carried O +
out O +
using O +
the O +
PCR O -
- O -
Select O +
cDNA O +
Subtraction O +
kit O +
( O -
Clontech O -
) O -
, O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

In O +
brief O -
, O +
cDNA O +
synthesized O +
from O +
mRNAs O +
from O +
infective O +
L3s O +
was O +
subtracted O +
against O +
cDNA O +
synthesized O +
from O +
the O +
pooled O +
mRNA O +
from O +
all O +
other O +
stages O +
included O +
herein O -
. O +

The O +
SSH O +
library O +
was O +
constructed O +
using O +
infective O +
L3s O +
as O +
the O +
tester O +
and O +
pooled O +
cDNAs O +
from O +
all O +
other O +
stages O +
as O +
the O +
driver O -
. O +

The O +
effectiveness O +
of O +
this O +
subtraction O +
process O +
has O +
already O +
been O +
demonstrated O +
in O +
previous O +
studies O +
[ O -
41 O -
] O -
, O -
[ O -
42 O -
] O -
. O +

The O +
cDNA O +
obtained O +
following O +
SSH O +
was O +
cloned O +
into O +
the O +
pGEM O -
- O -
T O +
Easy O +
plasmid O +
vector O +
( O -
Promega O -
) O +
and O +
competent O +
Escherichia B-Species +
coli I-Species +
( O -
JM109 O -
) O +
transformed O -
. O +

Positive O +
clones O -
, O +
picked O +
randomly O +
( O -
based O +
on O +
blue O -
/ O -
white O +
selection O -
) O -
, O +
were O +
grown O +
overnight O +
in O +
Luria O +
Bertani O +
( O -
LB O -
) O +
medium O +
( O -
shaking O -
, O +
37 O -
° O -
C O -
) O -
. O +

Individual O +
inserts O +
were O +
PCR O -
- O -
amplified O +
using O +
" O -
nested O +
primers O -
" O +
1 O +
and O +
2R O +
from O +
the O +
Subtraction O +
kit O +
( O -
Clontech O -
) O +
and O +
examined O +
by O +
agarose O +
electrophoresis O -
. O +

Preparation O +
of O +
Microarray O +
Slides O +
Clones O +
( O -
n O +
= O +
3075 O -
) O +
from O +
the O +
subtracted O +
library O +
were O +
picked O +
and O +
cultured O +
overnight O +
in O +
LB O +
containing O +
ampicillin O +
( O -
1000 O +
IU O -
/ O -
ml O -
) O +
in O +
sealed O +
96-well O +
blocks O -
. O +

Five O +
µl O +
of O +
culture O +
suspension O +
from O +
each O +
well O +
were O +
transferred O +
into O +
individual O +
wells O +
thermocycling O +
( O -
96-well O -
) O +
plates O +
and O +
the O +
inserts O +
PCR O -
- O -
amplified O +
using O +
primers O +
1 O +
and O +
2R O -
. O +

Following O +
a O +
10 O +
min O +
denaturation O +
step O +
at O +
94 O -
° O -
C O -
, O +
the O +
amplification O +
proceeded O +
for O +
25 O +
cycles O +
of O +
10 O +
s O +
at O +
94 O -
° O -
C O -
, O +
30 O +
s O +
at O +
68 O -
° O -
C O +
and O +
1.5 O +
min O +
at O +
72 O -
° O -
C O -
, O +
with O +
a O +
final O +
extension O +
for O +
5 O +
min O +
at O +
72 O -
° O -
C O -
. O +

Products O +
were O +
resolved O +
in O +
agarose O +
gels O -
, O +
ethanol O +
precipitated O -
, O +
re O -
- O -
suspended O +
in O +
16 O +
µl O +
of O +
" O -
spotting O +
solution O -
" O +
( O -
Shanghai O +
BioStar O +
Genechip O -
, O +
Inc O -
) O +
to O +
a O +
final O +
concentration O +
of O +
∼500 O +
ng O +
per O +
µl O -
, O +
before O +
being O +
printed O +
on O +
to O +
glass O +
slides O +
( O -
in O +
duplicate O -
) O +
using O +
a O +
robotic O +
arrayer O -
. O +

Sixteen O +
blanks O +
( O -
using O +
spotting O +
solution O +
only O -
) O +
and O +
the O +
same O +
number O +
of O +
negative O +
( O -
irrelevant O +
cDNAs O +
with O +
no O +
relationship O +
to O +
Ascaris O -
) O +
were O +
also O +
printed O +
on O +
to O +
slides O +
and O +
served O +
as O +
negative O +
controls O -
; O +
β O -
- O -
actin O +
of O +
A. B-Species +
suum I-Species +
served O +
as O +
a O +
positive O +
control O +
to O +
assess O +
the O +
efficiency O +
of O +
labeling O +
and O +
hybridization O -
. O +

The O +
slides O +
were O +
air O -
- O -
dried O +
for O +
2 O +
h O -
, O +
and O +
cDNA O +
in O +
the O +
spots O +
were O +
cross O -
- O -
linked O +
at O +
254 O +
mJ. O +
The O +
printed O +
slides O +
were O +
stored O +
at O +
4 O -
° O -
C O -
. O +

Labeling O +
of O +
cDNA O +
Probes O +
with O +
Fluorescent O +
Dyes O -
, O +
and O +
Microarray O +
Analysis O +
The O +
cDNAs O +
produced O +
from O +
total O +
RNA O +
from O +
A. B-Species +
suum I-Species +
eggs O -
, O +
infective O +
L3s O -
, O +
L3s O +
isolated O +
from O +
pig B-Species +
liver O +
or O +
lung O -
, O +
fourth O -
- O -
stage O +
larvae O +
( O -
L4s O -
) O -
, O +
adult O +
males O +
or O +
females O +
[ O -
as O +
described O +
in O +
the O +
section O +
' O -
Construction O +
of O +
the O +
cDNA O +
Library O +
by O +
Subtractive O -
- O -
Suppressive O +
Hybridization O +
( O -
SSH O -
) O -
' O -
] O +
were O +
labeled O +
with O +
cyanine O +
dyes O -
. O +

Cy3 O +
or O +
Cy5-dCTP O +
was O +
incorporated O +
into O +
cDNA O +
produced O +
from O +
30 O +
µg O +
of O +
total O +
RNA O +
by O +
direct O +
labeling O +
in O +
a O +
reverse O +
transcription O +
reaction O +
using O +
an O +
oligo O +
( O -
dT O -
) O +
primer O -
. O +

Labeled O +
cDNA O +
was O +
purified O +
using O +
DyeEx O +
columns O +
( O -
Qiagen O -
) O -
. O +

Microarray O +
slides O +
were O +
incubated O +
with O +
a O +
pre O -
- O -
hybridization O +
solution O +
[ O -
5 O -
× O -
SSC O -
, O +
1 O -
% O +
bovine B-Species +
serum O +
albumin O +
( O -
BSA O -
) O -
, O +
0.1 O -
% O +
sodium O +
dodecyl O -
- O -
sulphate O +
( O -
SDS O -
) O -
] O +
for O +
6 O +
h O +
at O +
42 O -
° O -
C O -
. O +

After O +
pre O -
- O -
hybridization O -
, O +
the O +
microarray O +
slides O +
were O +
incubated O +
with O +
' O -
pooled O -
' O +
Cy3 O +
and O +
Cy5-labeled O +
probes O +
in O +
hybridization O +
solution O +
( O -
5 O -
× O -
SSC O -
, O +
1 O -
% O +
BSA O -
, O +
0.1 O -
% O +
SDS O -
) O -
, O +
in O +
the O +
dark O +
at O +
42 O -
° O -
C O +
for O +
18 O +
h O -
, O +
and O +
then O +
washed O +
in O +
solution O +
I O +
( O -
1 O -
× O -
SSC O -
, O +
0.2 O -
% O +
SDS O -
) O +
for O +
10 O +
min O -
, O +
followed O +
by O +
solution O +
II O +
( O -
0.1 O -
× O -
SSC O -
, O +
0.2 O -
% O +
SDS O -
) O +
for O +
10 O +
min O +
at O +
60 O -
° O -
C O -
, O +
according O +
to O +
the O +
protocols O +
provided O +
by O +
Shanghai O +
BioStar O +
Genechip O -
, O +
Inc. O +
A O +
" O -
dye O +
flip O -
" O +
was O +
carried O +
out O +
to O +
control O +
for O +
any O +
bias O +
in O +
hybridization O +
signal O +
between O +
the O +
Cy O -
- O -
labeled O +
cDNA O +
probes O +
( O -
produced O +
for O +
two O +
distinct O +
mRNA O +
populations O -
) O -
. O +

The O +
slides O +
were O +
dried O +
and O +
scanned O +
( O -
ScanArray O +
4000 O +
scanner O -
) O +
using O +
image O +
acquisition O +
software O +
( O -
Shanghai O +
BioStar O +
Genechip O +
Inc. O -
) O +
and O +
a O +
range O +
of O +
laser O +
power O +
and O +
photo O -
- O -
multiplier O +
tube O +
intensities O -
. O +

The O +
mean O +
hybridization O +
signal O +
( O -
derived O +
from O +
four O +
replicates O +
of O +
the O +
same O +
array O -
) O +
were O +
corrected O +
for O +
background O -
, O +
normalized O +
[ O -
43 O -
] O -
, O +
log2-transformed O +
and O +
then O +
subjected O +
to O +
statistical O +
analysis O +
employing O +
the O +
students O +
t O -
- O -
test O +
in O +
a O +
spreadsheet O +
( O -
Excel O -
, O +
Microsoft O -
, O +
USA O -
) O -
. O +

The O +
microarray O +
data O +
were O +
analysed O +
for O +
differential O +
cDNA O +
hybridization O +
( O -
> O -
2.0-fold O +
to O +
114.3-fold O -
) O +
between O +
L3 O +
and O +
each O +
of O +
the O +
other O +
stages O +
( O -
eggs O -
, O +
lung O +
and O +
liver O +
L3s O -
, O +
L4 O -
, O +
adult O +
female O +
and O +
adult O +
male O -
) O -
. O +

Verification O +
of O +
Differential O +
Hybridization O +
by O +
Reverse O +
Transcription O -
- O -
Coupled O +
Polymerase O +
Chain O +
Reaction O +
( O -
RT O -
- O -
PCR O -
) O +
Analysis O +
For O +
a O +
subset O +
( O -
n O +
= O +
17 O -
) O +
of O +
representative O +
ESTs O +
( O -
rESTs O -
) O -
, O +
RT O -
- O -
PCR O +
was O +
used O +
to O +
verify O +
the O +
differential O +
transcription O +
recorded O +
by O +
microarray O +
analysis O -
. O +

Double O -
- O -
stranded O +
cDNA O +
was O +
synthesized O +
from O +
total O +
RNA O +
( O -
separately O -
) O +
from O +
each O +
stage O +
or O +
sex O +
of O +
A. B-Species +
suum I-Species +
using O +
reverse O +
transcriptase O +
( O -
Superscript O +
III O -
, O +
Invitrogen O -
) O -
. O +

Briefly O -
, O +
5 O +
µg O +
of O +
total O +
RNA O +
were O +
added O +
to O +
14 O +
µl O +
of O +
H2O O +
and O +
1 O +
µl O +
of O +
oligo O +
d O -
( O -
T O -
) O -
n O +
= O +
12–18 O +
primer O +
( O -
0.5 O +
µg O -
/ O -
µl O -
) O -
, O +
heated O +
to O +
70 O +
° O -
C O +
for O +
10 O +
min O +
and O +
chilled O +
on O +
ice O -
. O +

First- O +
and O +
second O -
- O -
strand O +
cDNAs O +
were O +
synthesized O +
via O +
the O +
addition O +
of O +
4 O +
µl O +
of O +
first O -
- O -
strand O +
cDNA O +
buffer O +
( O -
250 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
8.3 O -
, O +
375 O +
mM O +
KCl O +
and O +
15 O +
mM O +
MgCl2 O -
) O -
, O +
2 O +
µl O +
of O +
0.1 O +
M O +
dithiothreitol O -
, O +
and O +
1 O +
µl O +
of O +
10 O +
mM O +
of O +
each O +
dNTP O -
, O +
followed O +
by O +
an O +
incubation O +
at O +
25 O +
° O -
C O +
( O -
10 O +
min O -
) O -
, O +
42 O +
° O -
C O +
( O -
50 O +
min O -
) O +
and O +
70 O +
° O -
C O +
( O -
15 O +
min O -
) O -
. O +

One O -
- O -
tenth O +
of O +
each O +
double O -
- O -
stranded O +
cDNA O +
produced O +
was O +
then O +
used O +
as O +
a O +
template O +
in O +
the O +
PCR O -
. O +

The O +
transcripts O +
were O +
amplified O +
from O +
individual O +
cDNAs O +
by O +
PCR O +
using O +
oligonucleotide O +
primers O +
( O -
sequences O +
available O +
upon O +
request O -
) O +
designed O +
to O +
each O +
EST O -
. O +

The O +
PCR O +
amplification O +
of O +
a O +
portion O +
( O -
209 O +
bp O -
) O +
of O +
the O +
β O -
- O -
actin O +
gene O +
( O -
accession O +
no. O +
BI594141 O -
) O +
using O +
forward O +
primer O +
( O -
5′-CTCGAAACAAGAATACGATG-3′ O -
) O +
and O +
reverse O +
primer O +
( O -
5′- O +
ACATGTGCCGTTGTATGATG-3′ O -
) O -
, O +
previously O +
determined O +
to O +
be O +
present O +
in O +
all O +
developmental O +
stages O +
and O +
both O +
sexes O +
of O +
A. B-Species +
suum I-Species +
[ O -
44 O -
] O -
, O +
served O +
as O +
a O +
positive O +
control O -
. O +

Samples O +
without O +
template O +
( O -
no O -
- O -
DNA O +
controls O -
) O +
were O +
included O +
in O +
each O +
PCR O +
run O -
. O +

The O +
following O +
cycling O +
conditions O +
were O +
employed O -
: O +
one O +
cycle O +
at O +
94 O +
° O -
C O +
( O -
5 O +
min O -
) O -
, O +
94 O +
° O -
C O +
( O -
30 O +
s O -
) O -
, O +
60 O +
° O -
C O +
( O -
30 O +
s O -
) O +
and O +
72 O +
° O -
C O +
( O -
30 O +
s O -
) O +
for O +
30 O +
cycles O -
, O +
followed O +
by O +
a O +
final O +
extension O +
of O +
70 O +
° O -
C O +
( O -
7 O +
min O -
) O -
. O +

Following O +
the O +
PCR O -
, O +
5 O +
µl O +
of O +
individual O +
amplicons O +
were O +
resolved O +
in O +
ethidium O +
bromide O -
- O -
stained O +
agarose O +
gels O +
( O -
2 O -
% O -
) O +
and O +
then O +
photographed O +
upon O +
transillumination O -
. O +

The O +
relative O +
band O +
intensities O +
were O +
analyzed O +
using O +
UVIsoft O +
Image O +
Acquisition O +
and O +
Analysis O +
software O +
( O -
UVITEC O -
) O -
. O +

The O +
specificity O +
and O +
identity O +
of O +
individual O +
amplicons O +
were O +
confirmed O +
by O +
direct O +
sequencing O +
using O +
the O +
same O +
primers O +
( O -
separately O -
) O +
as O +
employed O +
for O +
their O +
amplification O -
. O +

Sequencing O +
and O +
Bioinformatics O +
Analyses O +
Clones O +
from O +
the O +
SSH O +
cDNA O +
library O +
with O +
increased O +
hybridization O +
in O +
microarray O +
analysis O +
to O +
the O +
infective O +
L3 O +
compared O +
with O +
other O +
stages O +
were O +
sequenced O +
using O +
standard O +
technology O +
[ O -
45 O -
] O -
. O +

The O +
nucleotide O +
sequences O +
have O +
been O +
deposited O +
in O +
the O +
GenBank O +
database O +
under O +
accession O +
numbers O +
ES290984-ES291074 O -
. O +

Following O +
the O +
processing O +
of O +
the O +
sequences O +
( O -
i.e. O -
, O +
removal O +
of O +
vector O +
sequences O -
, O +
quality O +
assurance O +
and O +
clustering O -
) O -
, O +
contigs O +
or O +
singletons O +
from O +
individual O +
clusters O +
were O +
subjected O +
to O +
BLASTx O +
( O -
NCBI O -
: O +
www.ncbi.nlm.nih.gov O -
) O +
and O +
BLASTn O +
( O -
EMBL O -
- O -
EBI O +
Parasite O +
Genome O +
Blast O +
Server O -
: O +
www.ebi.ac.uk O -
) O +
analysis O +
to O +
identify O +
putative O +
homologues O +
in O +
C. B-Species +
elegans I-Species -
, O +
other O +
nematodes O +
and O +
other O +
organisms O +
( O -
e O -
- O -
value O +
of O +
≤1e-05 O -
) O -
. O +

Peptides O +
inferred O +
from O +
ESTs O +
were O +
classified O +
functionally O +
using O +
Interproscan O +
( O -
available O +
at O +
http://www.ebi.ac.uk/InterProScan/ O -
) O +
employing O +
the O +
default O +
search O +
parameters O -
. O +

WormBase O +
( O -
www.wormbase.org O -
) O +
was O +
interrogated O +
extensively O +
for O +
relevant O +
information O +
on O +
C. B-Species +
elegans I-Species +
homologues O -
/ O -
orthologues O -
, O +
including O +
RNAi O +
phenotypic O -
, O +
transcriptomic O -
, O +
proteomic O +
and O +
interactomic O +
data O -
. O +

ESTs O +
with O +
homologues O -
/ O -
orthologues O +
in O +
C. B-Species +
elegans I-Species +
and O +
other O +
nematodes O +
were O +
also O +
subjected O +
to O +
analysis O +
employing O +
the O +
KEGG O +
Orthology O -
- O -
Based O +
Annotation O +
System O +
( O -
KOBAS O -
) O +
( O -
www.kobas.cbi.pku.edu.cn O -
) O -
, O +
which O +
predicts O +
the O +
biochemical O +
pathways O +
in O +
which O +
molecules O +
are O +
involved O -
. O +

The O +
open O +
reading O +
frames O +
( O -
ORFs O -
) O +
inferred O +
from O +
selected O +
ESTs O +
with O +
orthologues O +
in O +
C. B-Species +
elegans I-Species +
were O +
also O +
subjected O +
to O +
" O -
secretome O +
analysis O -
" O +
using O +
the O +
program O +
SignalP O +
v.2.0 O +
www.cbs.dtu.dk/services/SignalP/ O -
) O -
, O +
employing O +
both O +
the O +
neural O +
network O +
and O +
hidden O +
Markov O +
models O +
to O +
predict O +
signal O +
peptides O +
and/or O +
anchors O +
[ O -
46 O -
] O -
– O -
[ O -
48 O -
] O -
. O +

Also O -
, O +
transmembrane O +
domains O +
were O +
predicted O +
using O +
the O +
program O +
TMHMM O +
( O -
www.cbs.dtu.dk/services/TMHMM/ O -
; O +
[ O -
49 O -
] O -
– O -
[ O -
51 O -
] O -
) O -
, O +
and O +
subcellular O +
localization O +
inferred O +
employing O +
the O +
program O +
WoLF O +
PSORT O +
( O -
http://wolfpsort.org/ O -
; O +
[ O -
52 O -
] O -
) O -
. O +

The O +
method O +
established O +
by O +
Zhong O +
and O +
Sternberg O +
[ O -
53 O -
] O +
was O +
used O +
to O +
predict O +
the O +
interactions O +
for O +
C. B-Species +
elegans I-Species +
orthologues O +
of O +
the O +
L3-enriched O +
molecules O +
from O +
Ascaris O -
. O +

In O +
brief O -
, O +
interaction O -
, O +
phenotypic O -
, O +
expression O +
and O +
gene O +
ontology O +
data O +
from O +
fruitfly B-Species -
, O +
yeast B-Species -
, O +
mouse B-Species +
and O +
human B-Species +
were O +
integrated O +
using O +
a O +
naïve O +
Bayesian O +
model O +
to O +
predict O +
genetic O +
interactions O +
among O +
C. B-Species +
elegans I-Species +
genes O +
( O -
[ O -
45 O -
] O -
, O -
[ O -
53 O -
] O -
; O +
Zhong O +
and O +
Sternberg O -
, O +
unpublished O -
) O -
. O +

The O +
predicted O +
networks O +
resulting O +
from O +
the O +
analyses O +
were O +
saved O +
in O +
a O +
graphic O +
display O +
file O +
( O -
gdf O -
) O +
format O +
and O +
examined O +
using O +
the O +
graph O +
exploration O +
system O +
available O +
at O +
http://graphexploration.cond.org/. O +
Images O +
were O +
labeled O +
and O +
saved O +
in O +
the O +
joint O +
photographic O +
experts O +
group O +
( O -
jpeg O -
) O +
format O -
. O +

Results O +
To O +
identify O +
molecules O +
transcribed O +
abundantly O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species -
, O +
an O +
enriched O +
cDNA O +
library O +
was O +
constructed O +
by O +
SSH O -
. O +

From O +
a O +
total O +
of O +
3075 O +
clones O +
from O +
this O +
library O -
, O +
2921 O +
( O -
95 O -
% O -
) O +
were O +
shown O +
to O +
contain O +
an O +
insert O +
( O -
which O +
could O +
be O +
amplified O +
by O +
PCR O -
) O -
. O +

From O +
2671 O +
( O -
92 O -
% O -
) O +
of O +
these O +
clones O -
, O +
amplicons O +
representing O +
single O +
bands O +
of O +
∼400 O +
to O +
600 O +
bp O +
in O +
size O +
were O +
produced O -
. O +

These O +
latter O +
amplicons O +
were O +
arrayed O +
( O -
in O +
duplicate O -
) O +
on O +
to O +
slides O +
and O +
then O +
hybridized O +
with O +
Cy3-labeled O +
L3-cDNA O +
or O +
with O +
Cy5-labeled O +
cDNA O +
from O +
eggs O -
, O +
liver O -
/ O -
lung O +
L3s O -
, O +
L4s O -
, O +
adult O +
female O +
or O +
adult O +
male O +
of O +
Ascaris O -
. O +

Dye O +
flip O +
was O +
conducted O +
to O +
verify O +
the O +
hybridization O +
data O -
. O +

Of O +
the O +
2671 O +
( O -
duplicate O -
) O +
spots O -
, O +
1526 O +
had O +
a O +
significant O +
difference O +
in O +
hybridization O +
between O +
infective O +
L3 O +
cDNA O +
and O +
cDNAs O +
from O +
all O +
other O +
stages O +
or O +
sexes O +
of O +
A. B-Species +
suum I-Species -
, O +
of O +
which O +
515 O +
had O +
a O +
> O -
2.0-fold O +
increased O +
hybridization O +
for O +
the O +
L3 O -
. O +

In O +
order O +
to O +
independently O +
verify O +
the O +
hybridization O +
results O +
in O +
the O +
microarray O -
, O +
a O +
PCR O -
- O -
based O +
analysis O +
of O +
a O +
selected O +
subset O +
( O -
n O +
= O +
17 O -
) O +
clones O +
was O +
conducted O +
using O +
specific O +
primer O +
pairs O -
. O +

Having O +
verified O +
the O +
specificity O +
and O +
identity O +
of O +
individual O +
amplicons O +
by O +
sequencing O -
, O +
PCR O +
results O +
were O +
reproducible O +
( O -
based O +
on O +
multiple O +
runs O +
on O +
different O +
days O -
) O +
and O +
∼94 O -
% O +
( O -
16 O +
of O +
17 O -
) O +
concordant O +
with O +
those O +
of O +
the O +
microarray O +
analysis O +
( O -
not O +
shown O -
) O -
. O +

There O +
was O +
complete O +
concordance O +
for O +
representative O +
clones O +
associated O +
with O +
a O +
differential O +
signal O +
of O +
≥3.0-fold O +
in O +
the O +
microarray O -
. O +

The O +
clones O +
linked O +
to O +
the O +
515 O +
spots O +
representing O +
increased O +
transcription O +
( O -
> O -
2.0-fold O -
) O +
in O +
infective O +
L3 O +
compared O +
with O +
the O +
other O +
developmental O +
stages O +
or O +
sexes O +
included O +
were O +
subjected O +
to O +
sequencing O -
. O +

The O +
498 O +
sequences O +
( O -
length O -
: O +
550±115 O +
bp O -
) O +
determined O +
were O +
then O +
subjected O +
to O +
detailed O +
bioinformatic O +
analyses O -
. O +

There O +
were O +
91 O +
unique O +
clusters O +
( O -
accession O +
numbers O +
ES290984-ES291074 O -
) O -
, O +
of O +
which O +
55 O +
were O +
singletons O +
( O -
sequences O +
determined O +
once O -
) O -
. O +

Of O +
56 O +
molecules O +
( O -
61.5 O -
% O -
) O +
with O +
significant O +
similarity O +
to O +
sequences O +
other O +
than O +
A. B-Species +
suum I-Species +
in O +
the O +
databases O +
interrogated O -
, O +
50 O +
( O -
54.9 O -
% O -
) O +
had O +
C. B-Species +
elegans I-Species +
or O +
C. B-Species +
briggsae I-Species +
homologues O -
, O +
and O +
six O +
had O +
similarity O +
to O +
ESTs O +
already O +
sequenced O +
from O +
ascaridoid O +
and/or O +
other O +
parasitic O +
nematodes O -
, O +
and/or O +
other O +
organisms O +
( O -
Table O +
1 O -
) O -
. O +

A O +
significant O +
proportion O +
( O -
38.4 O -
% O -
) O +
did O +
not O +
have O +
any O +
similarity O +
in O +
sequence O +
to O +
any O +
organisms O +
for O +
which O +
data O +
are O +
presently O +
available O -
. O +

Comparative O +
analysis O +
specifically O +
against O +
A. B-Species +
suum I-Species +
EST O +
data O +
sets O +
( O -
n∼42,000 O -
) O +
available O +
in O +
public O +
databases O +
confirmed O +
independently O +
that O +
the O +
majority O +
of O +
molecules O +
( O -
> O -
60 O -
% O -
) O +
were O +
present O +
exclusively O +
in O +
the O +
infective O +
L3 O +
stage O +
or O +
were O +
orphans O -
. O +

As O +
gene O +
ontology O +
( O -
GO O -
) O +
provides O +
a O +
hierarchy O +
that O +
unifies O +
the O +
descriptions O +
of O +
biological O -
, O +
cellular O +
and O +
molecular O +
functions O +
[ O -
54 O -
] O -
, O +
this O +
approach O +
was O +
employed O +
to O +
predict O +
the O +
classification O +
and O +
gene O +
function O +
of O +
molecules O +
enriched O +
in O +
infective O +
L3 O +
of O +
A. B-Species +
suum I-Species -
. O +

A O +
summary O +
of O +
the O +
GO O +
categories O +
of O +
these O +
molecules O +
is O +
displayed O +
in O +
Fig. O +
1 O -
. O +

Of O +
the O +
91 O +
contigs O -
, O +
32 O +
( O -
35 O -
% O -
) O +
could O +
be O +
functionally O +
assigned O +
to O +
' O -
biological O +
process O -
' O +
( O -
n O +
= O +
38 O -
) O -
, O +
' O -
cellular O +
component O -
' O +
( O -
n O +
= O +
17 O -
) O +
and O +
' O -
molecular O +
function O -
' O +
( O -
n O +
= O +
64 O -
) O -
. O +

The O +
most O +
common O +
subcategories O +
were O +
gluconeogenesis O +
( O -
13 O -
% O -
) O +
and O +
metabolic O +
process O +
( O -
13 O -
% O -
) O +
within O +
' O -
biological O +
process O -
' O -
, O +
extracellular O +
region O +
( O -
24 O -
% O -
) O +
within O +
' O -
cellular O +
component O -
' O -
, O +
and O +
catalytic O +
activity O +
( O -
11 O -
% O -
) O +
and O +
phosphoenolpyruvate O +
carboxykinase O +
activity O +
( O -
8 O -
% O -
) O +
within O +
' O -
molecular O +
function O -
' O +
( O -
Table O +
S1 O -
) O -
. O +

A O +
focused O +
KOBAS O +
analysis O +
inferred O +
the O +
50 O +
C. B-Species +
elegans I-Species +
orthologues O -
/ O -
homologues O +
to O +
be O +
involved O +
in O +
apoptosis O +
and O +
insulin O +
signaling O +
( O -
2 O -
% O -
) O -
, O +
ATP O +
synthesis O +
( O -
2 O -
% O -
) O -
, O +
carbon O +
metabolism O +
( O -
6 O -
% O -
) O -
, O +
fatty O +
acid O +
biosynthesis O +
( O -
2 O -
% O -
) O -
, O +
gap O +
junction O +
( O -
2 O -
% O -
) O -
, O +
glucose O +
metabolism O +
( O -
6 O -
% O -
) O +
or O +
porphyrin O +
metabolism O +
( O -
2 O -
% O -
) O -
, O +
although O +
34 O +
( O -
68 O -
% O -
) O +
of O +
them O +
could O +
not O +
be O +
mapped O +
to O +
a O +
specific O +
metabolic O +
pathway O +
( O -
Table O +
2 O -
) O -
. O +

Of O +
these O +
50 O +
molecules O -
, O +
small O +
numbers O +
were O +
predicted O +
to O +
be O +
secreted O +
( O -
10 O -
% O -
) O -
, O +
anchored O +
( O -
2 O -
% O -
) O +
and/or O +
transmembrane O +
( O -
12 O -
% O -
) O +
proteins O +
( O -
Table O +
2 O -
) O -
. O +

Functionally O -
, O +
17 O +
( O -
34 O -
% O -
) O +
of O +
the O +
50 O +
molecules O +
were O +
associated O +
with O +
( O -
non O -
- O -
wild O -
- O -
type O -
) O +
RNAi O +
phenotypes O +
in O +
C. B-Species +
elegans I-Species -
, O +
the O +
majority O +
displaying O +
embryonic O +
lethality O +
( O -
Emb O -
) O +
( O -
13 O +
types O -
; O +
58.8 O -
% O -
) O -
, O +
larval O +
arrest O +
( O -
Lva O -
) O +
( O -
23.5 O -
% O -
) O +
and O +
larval O +
lethality O +
( O -
Lvl O -
) O +
( O -
47 O -
% O -
) O +
( O -
Table O +
2 O -
) O -
. O +

Extending O +
this O +
analysis O -
, O +
a O +
relatively O +
complex O +
genetic O +
interaction O +
network O +
was O +
predicted O +
for O +
the O +
17 O +
C. B-Species +
elegans I-Species +
orthologues O +
( O -
i.e. O -
, O +
with O +
non O -
- O -
wild O -
- O -
type O +
RNAi O +
phenotypes O -
) O +
( O -
see O +
Table O +
S2 O -
) O -
. O +

Statistically O +
highly O +
significant O +
interactions O +
were O +
predicted O +
for O +
nine O +
of O +
the O +
C. B-Species +
elegans I-Species +
genes O -
; O +
the O +
top O +
five O +
interactors O +
are O +
displayed O +
in O +
Fig. O +
2 O -
. O +

The O +
gene O +
ontology O +
categories O +
for O +
eight O +
selected O +
C. B-Species +
elegans I-Species +
genes O +
( O -
F33D11.10 O -
, O +
F55A12.8 O -
, O +
kin-2 O -
, O +
mec-12 O -
, O +
mup-2 O -
, O +
pab-1 O -
, O +
rpl-22 O +
and O +
T21B10.2 O -
) O +
included O -
: O +
embryonic O +
development O -
, O +
egg O +
hatching O -
, O +
larval O +
development O +
and/or O +
growth O -
. O +

The O +
other O +
categories O +
included O -
: O +
positive O +
regulation O +
of O +
growth O +
rate O +
( O -
F55A12.8 O -
, O +
kin-2 O -
, O +
mup-2 O -
, O +
pab-1 O -
, O +
rpl-22 O +
and O +
T21B10.2 O -
) O +
and O +
gamete O +
generation O +
and O +
locomotory O +
behaviour O +
( O -
kin-2 O -
, O +
mup-2 O -
, O +
pab-1 O +
and O +
F55A12.8 O -
, O +
kin-2 O -
, O +
mup-2 O -
, O +
respectively O -
) O -
. O +

The O +
C. B-Species +
elegans I-Species +
homologue O +
egl-3 O +
was O +
predicted O +
to O +
be O +
involved O +
in O +
proteolysis O +
( O -
see O +
www.wormbase.org O -
) O -
. O +

All O +
nine O +
C. B-Species +
elegans I-Species +
orthologues O +
were O +
predicted O +
to O +
interact O +
directly O +
with O +
a O +
total O +
of O +
296 O +
( O -
range O -
: O +
5–75 O -
) O +
other O +
genes O +
and O -
, O +
in O +
particular O -
, O +
a O +
direct O +
genetic O +
interaction O +
was O +
predicted O +
between O +
pab-1 O +
and O +
T21B10.2 O +
( O -
Fig. O +
2 O -
) O -
. O +

The O +
296 O +
interactors O +
were O +
associated O +
with O +
embryonic O +
and O +
larval O +
development O +
( O -
n O +
= O +
198 O -
; O +
66.9 O -
% O -
) O -
, O +
information O +
storage O +
and O +
processing O +
( O -
n O +
= O +
15 O -
; O +
5.1 O -
% O -
) O -
, O +
cellular O +
processes O +
and O +
signalling O +
( O -
n O +
= O +
45 O -
; O +
15.2 O -
% O -
) O +
and O +
metabolism O +
( O -
n O +
= O +
18 O -
; O +
6.1 O -
% O -
) O -
; O +
the O +
precise O +
function O +
of O +
some O +
of O +
the O +
interactors O +
( O -
n O +
= O +
20 O -
; O +
6.7 O -
% O -
) O +
is O +
presently O +
unknown O +
( O -
Table O +
S2 O -
) O -
. O +

Discussion O +
The O +
present O +
study O +
investigated O +
transcripts O +
in O +
infective O +
L3s O +
of O +
A. B-Species +
suum I-Species +
using O +
a O +
genomic O -
- O -
bioinformatic O +
platform O -
. O +

The O +
focus O +
was O +
on O +
comparisons O +
with O +
C. B-Species +
elegans I-Species +
homologues O -
/ O -
orthologues O -
, O +
because O +
the O +
entire O +
genome O +
sequence O +
of O +
this O +
nematode O +
is O +
known O +
[ O -
9 O -
] O +
and O +
because O +
there O +
is O +
a O +
wealth O +
of O +
information O +
on O +
the O +
localization O +
and O +
functionality O +
of O +
its O +
molecules O +
( O -
www.wormbase.org O -
; O +
http://elegans.bcgsc.bc.ca/knockout.shtml O -
) O -
. O +

The O +
functions O +
of O +
most O +
genes O +
in O +
C. B-Species +
elegans I-Species +
have O +
been O +
assessed O +
using O +
RNAi O +
( O -
e.g. O -
, O +
[ O -
14 O -
] O -
, O -
[ O -
15 O -
] O -
, O -
[ O -
17 O -
] O -
, O -
[ O -
55 O -
] O -
, O -
[ O -
56 O -
] O -
) O +
in O +
the O +
hermaphroditic O +
stage O -
, O +
whereas O +
there O +
is O +
a O +
paucity O +
of O +
functional O +
information O +
available O +
for O +
Ascaris O +
and O +
other O +
parasitic O +
nematodes O +
of O +
animals O +
[ O -
57 O -
] O -
, O -
[ O -
58 O -
] O -
. O +

Following O +
the O +
microarray O +
analysis O +
of O +
> O -
2500 O +
ESTs O +
from O +
the O +
SSH O +
library O -
, O +
498 O +
cDNAs O +
inferred O +
to O +
be O +
enriched O +
in O +
the O +
L3 O -
, O +
based O +
on O +
hybridization O +
signal O -
, O +
were O +
sequenced O +
and O +
subjected O +
to O +
comprehensive O +
in O +
silico O +
analyses O -
. O +

Of O +
the O +
91 O +
clusters O +
of O +
molecules O +
categorized O -
, O +
50 O +
( O -
54.9 O -
% O -
) O +
had O +
C. B-Species +
elegans I-Species +
homologues O -
/ O -
orthologues O +
with O +
loss O -
- O -
of O -
- O -
function O +
phenotypes O +
could O +
be O +
mapped O +
to O +
key O +
pathways O -
. O +

The O +
statistically O +
significant O +
genetic O +
interactions O +
predicted O +
for O +
9 O +
of O +
the O +
50 O +
C. B-Species +
elegans I-Species +
orthologues O +
[ O -
namely O +
egl-3 O -
, O +
F33D11.10 O -
, O +
F55A12.8 O -
, O +
kin-2 O -
, O +
mec-12 O -
, O +
mup-2 O -
, O +
pab-1 O -
, O +
rpl-22 O +
and O +
T21B10.2 O +
( O +
= O +
enol-1 O -
) O -
] O +
and O +
the O +
interaction O +
network O +
included O +
genes O +
encoding O +
kinases O -
, O +
alpha O -
- O -
tubulins O -
, O +
enolases O -
, O +
troponin O +
and O +
other O +
named O +
and O +
unnamed O +
proteins O -
. O +

Eight O +
of O +
these O +
molecules O +
( O -
enol-1 O -
, O +
pab-1 O -
, O +
F33D11.10 O -
, O +
rpl-22 O -
, O +
F55A12.8 O +
mec-12 O -
, O +
mup-2 O +
and O +
kin-2 O -
) O +
have O +
known O +
or O +
predicted O +
roles O +
in O +
embryonic O +
and O +
larval O +
growth O +
and O +
development O -
, O +
gamete O +
generation O -
, O +
locomotory O +
behaviour O +
or O +
other O +
biological O +
processes O +
in O +
C. B-Species +
elegans I-Species +
( O -
see O +
www.wormbase.org O -
) O -
. O +

The O +
enolase O +
encoded O +
by O +
enol-1 O +
is O +
predicted O +
to O +
play O +
a O +
role O +
in O +
glycolysis O -
, O +
gluconeogenesis O -
, O +
phenylalanine O -
, O +
tyrosine O +
and O +
tryptophan O +
biosynthesis O +
( O -
cf O -
. O +

[ O -
59 O -
] O -
) O -
. O +

Since O +
glucose O +
is O +
the O +
main O +
source O +
for O +
ATP O +
production O -
, O +
the O +
alteration O +
in O +
these O +
key O +
glycolytic O +
enzymes O +
may O +
lead O +
to O +
cellular O +
dysfunction O -
, O +
such O +
as O +
impaired O +
ion O -
- O -
motive O +
ATPase O +
required O +
to O +
maintain O +
potential O +
gradients O -
, O +
operate O +
pumps O +
and O +
maintain O +
membrane O +
lipid O +
asymmetry O +
[ O -
60 O -
] O -
. O +

Bioinformatic O +
analysis O +
for O +
transmembrane O +
helices O +
( O -
TMHMM O -
) O +
and O +
peptide O +
signal O +
sequences O +
( O -
SignalP O -
) O +
predicted O +
ENOL-1 O +
to O +
be O +
a O +
non O -
- O -
secreted O +
protein O +
localized O +
to O +
the O +
cytoplasm O +
( O -
cf O -
. O +

Table O +
2 O -
) O -
. O +

Nonetheless O -
, O +
enolases O +
are O +
often O +
detected O +
in O +
the O +
excretory O -
/ O -
secretory O +
( O -
ES O -
) O +
products O +
of O +
parasitic O +
helminths O -
, O +
including O +
adult O +
A. B-Species +
suum I-Species +
[ O -
61 O -
] O -
, O +
and O +
appear O +
to O +
play O +
a O +
role O +
in O +
the O +
triggering O +
of O +
nitric O +
oxide O +
production O +
by O +
host O +
cells O -
. O +

The O +
enol-1 O +
orthologue O +
of O +
C. B-Species +
elegans I-Species +
has O +
been O +
predicted O +
to O +
interact O +
specifically O +
with O +
the O +
polyadenylate O +
binding O +
protein O +
gene O -
, O +
pab-1 O -
, O +
inferred O +
to O +
be O +
involved O +
in O +
coordinated O +
gene O +
transcription O +
and O +
expression O +
during O +
normal O +
larval O +
development O +
[ O -
16 O -
] O -
. O +

Poly O -
( O -
A O -
) O -
-binding O +
proteins O +
( O -
PABPs O -
) O +
are O +
recognized O +
to O +
be O +
central O +
to O +
the O +
regulation O +
of O +
mRNA O +
translation O +
and O +
stability O +
[ O -
62 O -
] O -
. O +

Present O +
evidence O +
suggests O +
that O +
the O +
expression O +
of O +
PAB-1 O +
is O +
regulated O +
by O +
an O +
oligo O -
- O -
pyrimidine O +
tract O +
in O +
response O +
to O +
cell O +
growth O +
and O +
relates O +
to O +
coordinated O +
growth O +
regulation O +
in O +
C. B-Species +
elegans I-Species +
[ O -
62 O -
] O -
. O +

Furthermore O -
, O +
gene O +
silencing O +
of O +
pab-1 O +
and O +
its O +
selected O +
interactors O +
( O -
see O +
Fig. O +
2 O -
) O +
leads O +
to O +
embryonic O +
lethal O +
( O -
Emb O -
) O -
, O +
slow O +
growth O +
( O -
Slo O -
) O +
and O +
sterile O +
progeny O +
( O -
Stp O -
) O +
phenotypes O +
( O -
see O +
www.wormbase.org O -
) O -
. O +

Another O +
gene O +
( O -
F33D11.10 O -
; O +
EST O +
code O +
4F10 O -
; O +
see O +
Table O +
2 O -
) O +
which O +
encodes O +
an O +
ATP O -
- O -
dependent O +
RNA O +
helicase O +
and O +
is O +
associated O +
with O +
embryonic O +
lethal O +
( O -
Emb O -
) O +
and O +
larval O +
lethal O +
( O -
Lvl O -
) O +
RNAi O +
phenotypes O -
, O +
was O +
shown O +
to O +
be O +
highly O +
transcribed O +
in O +
infective O +
L3s O +
of O +
A. B-Species +
suum I-Species -
. O +

Helicases O +
are O +
involved O +
in O +
a O +
variety O +
of O +
RNA O +
metabolic O +
processes O -
, O +
including O +
translation O +
initiation O -
, O +
pre O -
- O -
mRNA O +
splicing O -
, O +
pre O -
- O -
rRNA O +
processing O -
, O +
rRNA O +
maturation O +
and O +
RNA O +
degradation O +
[ O -
63 O -
] O -
, O +
and O +
are O +
crucial O +
for O +
life O +
cycle O +
progression O -
, O +
sex O +
determination O +
and O +
early O +
embryogenesis O +
in O +
C. B-Species +
elegans I-Species +
[ O -
60 O -
] O -
. O +

The O +
high O +
transcription O +
levels O +
of O +
a O +
homologue O -
/ O -
orthologue O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species +
might O +
suggest O +
a O +
similar O +
role O +
in O +
this O +
ascaridoid O -
. O +

Similarly O -
, O +
the O +
coordination O +
of O +
the O +
expression O +
of O +
a O +
large O +
number O +
of O +
genes O +
is O +
required O +
for O +
normal O +
growth O +
and O +
cell O +
proliferation O +
during O +
larval O +
development O -
. O +

The O +
high O +
transcription O +
level O +
for O +
the O +
ribosomal O +
protein O +
gene O +
homologue O +
rpl-22 O +
( O -
large O +
subunit O +
family O +
member O -
; O +
EST O +
code O +
26G12 O -
, O +
see O +
Table O +
2 O -
) O +
in O +
the O +
infective O +
L3 O +
of O +
A. B-Species +
suum I-Species +
compared O +
with O +
other O +
developmental O +
stages O +
is O +
likely O +
to O +
reflect O +
the O +
substantial O +
rate O +
of O +
cell O +
growth O +
in O +
this O +
stage O +
[ O -
64 O -
] O -
. O +

The O +
gene O +
( O -
F55A12.8 O -
, O +
EST O +
code O +
4G11 O -
; O +
see O +
Table O +
2 O -
) O +
encoding O +
an O +
acetyl O -
- O -
transferase O +
with O +
a O +
putative O +
ATPase O +
domain O -
, O +
shown O +
to O +
be O +
enriched O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species -
, O +
was O +
predicted O +
to O +
interact O +
with O +
75 O +
other O +
genes O +
all O +
involved O +
in O +
energy O +
production O +
and/or O +
RNA O +
processing O +
( O -
see O +
Table O +
S2 O -
) O -
. O +

Several O +
molecules O +
involved O +
in O +
ATP O +
synthesis O +
and O +
mitochondrial O +
pathways O +
( O -
e.g. O -
, O +
cytochrome O +
oxidase O +
c O +
subunits O +
1 O -
, O +
2 O +
and O +
3 O -
, O +
ADP O -
/ O -
ATP O +
translocases O -
, O +
NADH O +
dehydrogenases O -
, O +
ATPases O +
and O +
ATP O +
synthetases O -
) O +
have O +
been O +
reported O +
previously O +
to O +
be O +
highly O +
represented O +
in O +
the O +
L3 O +
stage O +
of O +
Anisakis B-Species +
simplex I-Species +
[ O -
65 O -
] O -
, O +
thus O +
supporting O +
the O +
proposal O +
that O +
substantial O +
energy O +
is O +
required O +
for O +
larval O +
development O +
as O +
well O +
as O +
the O +
transition O +
from O +
the O +
free O -
- O -
living O +
to O +
the O +
parasitic O +
stage O +
and O +
the O +
invasion O +
of O +
the O +
host O -
. O +

There O +
is O +
also O +
likely O +
to O +
be O +
a O +
substantial O +
energy O +
requirement O +
for O +
muscle O +
contraction O +
linked O +
to O +
larval O +
motility O +
in O +
A. B-Species +
suum I-Species -
, O +
as O +
the O +
L3s O +
penetrate O +
the O +
caecal O +
wall O +
in O +
the O +
porcine O +
host O -
, O +
before O +
undergoing O +
hepato O -
- O -
pulmonary O +
migration O +
[ O -
35 O -
] O -
. O +

Accordingly O -
, O +
genes O +
encoding O +
a O +
specialized O +
tubulin O +
expressed O +
in O +
mechanoreceptors O +
( O -
mec-12 O -
, O +
EST O +
code O +
13E09 O -
) O +
and O +
a O +
troponin O +
( O -
mup-2 O -
, O +
EST O +
code O +
01G03 O -
; O +
see O +
Table O +
2 O -
) O -
, O +
both O +
predicted O +
to O +
interact O +
with O +
a O +
total O +
number O +
of O +
32 O +
tubulin- O +
and O +
myosin O -
- O -
encoding O +
genes O -
, O +
also O +
supported O +
a O +
link O +
to O +
extensive O +
muscle O +
contraction O +
and O +
motility O +
in O +
A. B-Species +
suum I-Species +
L3s O -
. O +

Also O -
, O +
neuroactive O +
peptides O +
are O +
required O +
to O +
regulate O +
the O +
responsiveness O +
of O +
nematode O +
larvae O +
to O +
mechanical O +
stimuli O +
[ O -
66 O -
] O -
. O +

A O +
homologue O +
encoded O +
by O +
egl-3 O +
was O +
shown O +
to O +
be O +
highly O +
transcribed O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species -
; O +
EGL-3 O +
is O +
predicted O +
to O +
be O +
a O +
pro O -
- O -
hormone O +
convertase O +
involved O +
in O +
the O +
maturation O +
of O +
neuropeptides O +
and O +
could O +
be O +
associated O +
with O +
mechano O -
- O -
sensory O +
responses O +
and O +
touch O +
sensitivity O +
linked O +
to O +
the O +
host O +
invasion O -
. O +

A O +
regulatory O +
subunit O +
of O +
a O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
( O -
kin-2 O -
, O +
EST O +
code O +
22H01 O -
; O +
see O +
Table O +
2 O -
) O +
was O +
predicted O +
to O +
interact O +
with O +
72 O +
other O +
genes O +
all O +
involved O +
in O +
diverse O +
cellular O +
processes O -
, O +
such O +
as O +
nuclear O +
trafficking O -
, O +
and O +
DNA O +
replication O +
and O +
repair O +
( O -
see O +
Table O +
S2 O -
) O -
. O +

Based O +
on O +
gene O +
ontology O +
terms O -
, O +
kin-2 O +
is O +
implicated O +
in O +
gamete O +
generation O -
, O +
growth O -
, O +
larval O +
development O -
, O +
post O -
- O -
embryonic O +
body O +
morphogenesis O -
, O +
signal O +
transduction O +
and/or O +
protein O +
amino O +
acid O +
phosphorylation O +
( O -
see O +
Table O +
S2 O -
) O -
. O +

Gene O +
silencing O +
of O +
kin-2 O +
in O +
C. B-Species +
elegans I-Species +
leads O +
to O +
phenotypes O -
, O +
such O +
as O +
larval O +
lethal O +
( O -
Lvl O -
) O -
, O +
larval O +
arrest O +
( O -
Lva O -
) O -
, O +
body O +
morphology O +
defect O +
( O -
Bmd O -
) O -
, O +
dumpy O +
( O -
Dpy O -
) O -
, O +
uncoordinated O +
( O -
Unc O -
) O +
and O +
sterile O +
progeny O +
( O -
Stp O -
) O +
( O -
www.wormbase.org O -
) O -
, O +
suggesting O +
that O +
its O +
homologue O +
in O +
A. B-Species +
suum I-Species +
is O +
central O +
to O +
larval O +
maturation O -
. O +

The O +
KOBAS O +
analysis O +
predicted O +
the O +
protein O +
KIN-2 O +
to O +
be O +
involved O +
in O +
the O +
insulin O -
- O -
signaling O +
pathway O -
, O +
previously O +
implicated O +
in O +
controlling O +
the O +
exit O +
from O +
dauer O +
in O +
C. B-Species +
elegans I-Species +
and O +
the O +
activation O +
of O +
L3s O +
of O +
the O +
canine B-Species +
hookworm I-Species -
, O +
Ancylostoma B-Species +
caninum I-Species -
, O +
following O +
exsheathment O +
[ O -
67 O -
] O -
. O +

In O +
a O +
recent O +
study O -
, O +
Brand O +
and O +
Hawdon O +
[ O -
68 O -
] O +
were O +
able O +
to O +
inhibit O +
( O -
with O +
a O +
phosphoinositide-3-OH O -
- O -
kinase O +
inhibitor O -
) O +
the O +
activation O +
of O +
infective O +
L3s O +
of O +
both O +
of O +
the O +
hookworms O +
Ancylostoma B-Species +
caninum I-Species +
and O +
Ancylostoma B-Species +
ceylanicum I-Species +
via O +
the O +
insulin O +
signaling O +
pathway O -
, O +
thus O +
lending O +
some O +
credence O +
to O +
the O +
hypothesis O +
that O +
this O +
pathway O +
plays O +
an O +
critical O +
role O +
in O +
regulating O +
the O +
transition O +
from O +
the O +
free O -
- O -
living O +
to O +
the O +
parasitic O +
stage O +
[ O -
68 O -
] O -
. O +

Recently O -
, O +
it O +
has O +
been O +
proposed O +
that O +
transcriptional O +
and O +
feeding O +
responses O +
to O +
serum O -
- O -
stimulation O +
in O +
Ancylostoma B-Species +
caninum I-Species +
are O +
regulated O +
by O +
parallel O +
systems O -
, O +
with O +
the O +
insulin O +
signaling O +
pathway O +
playing O +
a O +
significant O +
role O +
in O +
the O +
' O -
resumption O +
of O +
feeding O -
' O +
in O +
activated O +
larvae O +
[ O -
69 O -
] O -
. O +

Protein O +
kinases O +
are O +
also O +
likely O +
to O +
be O +
involved O +
in O +
pathways O +
linked O +
to O +
sexual O +
maturation O +
in O +
developing O +
larvae O -
. O +

As O +
already O +
proposed O +
for O +
adult O +
stages O +
of O +
H. B-Species +
contortus I-Species +
[ O -
45 O -
] O -
, O +
the O +
protein O +
kinase O +
gene O +
cdk-1 O +
is O +
predicted O +
to O +
play O +
a O +
pivotal O +
role O +
in O +
the O +
germline O -
, O +
oogenesis O +
and O +
spermiogenesis O +
pathways O +
of O +
this O +
parasitic O +
nematode O -
. O +

Other O +
protein O +
kinases O -
, O +
such O +
as O +
PEPCK O -
, O +
and O +
phosphatases O -
, O +
were O +
shown O +
herein O +
to O +
be O +
transcribed O +
at O +
high O +
levels O +
in O +
the O +
L3 O +
stage O +
compared O +
with O +
other O +
developmental O +
stages O +
of O +
A. B-Species +
suum I-Species +
( O -
see O +
Table O +
2 O -
) O -
, O +
which O +
is O +
in O +
accordance O +
to O +
findings O +
reported O +
recently O +
for O +
Anisakis B-Species +
simplex I-Species +
[ O -
65 O -
] O -
. O +

Due O +
to O +
their O +
major O +
regulatory O +
effects O +
in O +
eukaryotic O +
signaling O +
events O +
and O +
regulatory O +
and O +
sensory O +
functions O -
, O +
protein O +
kinases O +
have O +
been O +
considered O +
interesting O +
targets O +
for O +
anti O -
- O -
parasitic O +
drugs O +
[ O -
70 O -
] O -
. O +

In O +
conclusion O -
, O +
this O +
study O +
has O +
given O +
some O +
interesting O +
insights O +
into O +
early O +
molecular O +
processes O +
in O +
the O +
L3 O +
of O +
A. B-Species +
suum I-Species -
. O +

Approximately O +
60 O -
% O +
of O +
the O +
transcripts O +
enriched O +
in O +
the O +
L3 O +
stage O +
of O +
A. B-Species +
suum I-Species +
have O +
homologues O -
/ O -
orthologues O +
in O +
C. B-Species +
elegans I-Species -
. O +

The O +
bioinformatic O +
analyses O +
of O +
selected O +
molecules O +
suggest O +
that O +
a O +
complex O +
genetic O +
network O +
regulates O +
or O +
controls O +
larval O +
growth O +
and O +
development O +
in O +
A. B-Species +
suum I-Species +
L3s O -
, O +
and O +
some O +
of O +
these O +
might O +
be O +
involved O +
in O +
or O +
regulate O +
the O +
switch O +
from O +
the O +
free O -
- O -
living O +
to O +
the O +
parasitic O +
stage O -
. O +

Some O +
caution O +
is O +
warranted O +
in O +
drawing O +
conclusions O +
regarding O +
molecular O +
mechanisms O +
regulating O +
the O +
transition O +
to O +
parasitism O +
in O +
parasitic O +
nematodes O +
from O +
information O +
on O +
C. B-Species +
elegans I-Species -
, O +
as O +
latter O +
is O +
a O +
free O -
- O -
living O +
nematode O -
. O +

Also O -
, O +
while O +
the O +
method O +
of O +
data O +
integration O +
is O +
essential O +
for O +
the O +
reliable O +
prediction O +
of O +
genetic O +
interactions O -
, O +
it O +
might O +
limit O +
the O +
capacity O +
of O +
the O +
approach O +
somewhat O +
to O +
infer O +
nematode O -
- O -
specific O +
interactions O -
. O +

As O +
additional O +
datasets O +
of O +
genes O +
and O +
gene O +
functions O +
become O +
available O +
for O +
various O +
parasitic O +
nematodes O -
, O +
more O +
informed O +
inferences O +
can O +
be O +
made O +
regarding O +
the O +
functions O +
of O +
nematode O -
- O -
specific O +
genes O -
, O +
particularly O +
those O +
involved O +
in O +
the O +
transition O +
to O +
parasitism O -
. O +

The O +
imminent O +
genome O +
sequence O +
of O +
A. B-Species +
suum I-Species +
( O -
http://www.sanger.ac.uk/Projects/Helminths/ O -
) O +
should O +
all O +
assist O +
in O +
this O +
endeavour O -
. O +

Also O -
, O +
functional O +
analysis O +
of O +
selected O +
molecules O +
representing O +
selected O +
ESTs O +
identified O +
herein O -
, O +
utilizing O +
gene O +
silencing O +
approaches O +
established O +
recently O +
[ O -
33 O -
] O -
, O -
[ O -
34 O -
] O -
, O +
could O +
provide O +
some O +
insights O +
into O +
developmental O +
processes O +
in O +
Ascaris O +
and O +
related O +
ascaridoid O +
nematodes O +
and O +
provide O +
avenues O +
for O +
the O +
development O +
of O +
novel O +
approaches O +
for O +
their O +
control O -
. O +

Supporting O +
Information O +

Emergence O +
of O +
Delayed O +
Methylmercury O +
Toxicity O +
after O +
Perinatal O +
Exposure O +
in O +
Metallothionein O -
- O -
Null O +
and O +
Wild O -
- O -
Type O +
C57BL O +
Mice B-Species +
Abstract O +
Background O +
Although O +
a O +
long O +
latency O +
period O +
of O +
toxicity O +
after O +
exposure O +
to O +
methylmercury O +
( O -
MeHg O -
) O +
is O +
known O +
to O +
exist O +
in O +
humans B-Species -
, O +
few O +
animal O +
studies O +
have O +
addressed O +
this O +
issue O -
. O +

Substantiation O +
of O +
delayed O +
MeHg O +
toxicity O +
in O +
animals O +
would O +
affect O +
the O +
risk O +
evaluation O +
of O +
MeHg O -
. O +

Objectives O +
Our O +
goal O +
in O +
this O +
study O +
was O +
to O +
demonstrate O +
the O +
existence O +
of O +
a O +
latency O +
period O +
in O +
a O +
rodent O +
model O +
in O +
which O +
the O +
toxicity O +
of O +
perinatal O +
MeHg O +
exposure O +
becomes O +
apparent O +
only O +
later O +
in O +
life O -
. O +

Our O +
study O +
included O +
metallothionein O +
( O -
MT O -
) O +
knockout O +
mice B-Species +
because O +
studies O +
have O +
suggested O +
the O +
potential O +
susceptibility O +
of O +
this O +
strain O +
to O +
the O +
neurodevelopmental O +
toxicity O +
of O +
MeHg O -
. O +

Methods O +
Pregnant O +
MT O -
- O -
null O +
and O +
wild O -
- O -
type O +
C57Bl O -
/ O -
6J O +
mice B-Species +
were O +
exposed O +
to O +
MeHg O +
through O +
their O +
diet O +
containing O +
5 O +
μg O +
Hg O -
/ O -
g O +
during O +
gestation O +
and O +
early O +
lactation O -
. O +

We O +
examined O +
behavioral O +
functions O +
of O +
the O +
offspring O +
using O +
frequently O +
used O +
paradigms O -
, O +
including O +
open O +
field O +
behavior O +
( O -
OPF O -
) O -
, O +
passive O +
avoidance O +
( O -
PA O -
) O -
, O +
and O +
the O +
Morris O +
water O +
maze O +
( O -
MM O -
) O -
, O +
at O +
ages O +
of O +
12–13 O +
and O +
52–53 O +
weeks O -
. O +

Results O +
At O +
12 O +
weeks O +
of O +
age O -
, O +
behavioral O +
effects O +
of O +
MeHg O +
were O +
not O +
detected O -
, O +
except O +
for O +
OPF O +
performance O +
in O +
MeHg O -
- O -
exposed O +
MT O -
- O -
null O +
females O -
. O +

At O +
52 O +
weeks O +
of O +
age O -
, O +
the O +
MeHg O -
- O -
exposed O +
groups O +
showed O +
poorer O +
performance O +
both O +
in O +
PA O +
and O +
MM O -
, O +
and O +
their O +
OPF O +
activity O +
differed O +
from O +
controls O -
. O +

These O +
effects O +
of O +
MeHg O +
appeared O +
exaggerated O +
in O +
the O +
MT O -
- O -
null O +
strain O -
. O +

The O +
brain O +
Hg O +
concentration O +
had O +
leveled O +
off O +
by O +
13 O +
weeks O +
of O +
age O -
. O +

Conclusions O +
The O +
results O +
suggest O +
the O +
existence O +
of O +
a O +
long O +
latency O +
period O +
after O +
perinatal O +
exposure O +
to O +
low O -
- O -
level O +
MeHg O -
, O +
in O +
which O +
the O +
behavioral O +
effects O +
emerged O +
long O +
after O +
the O +
leveling O -
- O -
off O +
of O +
brain O +
Hg O +
levels O -
. O +

Hence O -
, O +
the O +
initial O +
toxicologic O +
event O +
responsible O +
for O +
the O +
late O +
effects O +
should O +
have O +
occurred O +
before O +
this O +
leveling O -
- O -
off O +
of O +
brain O +
Hg O -
. O +

Methylmercury O +
( O -
MeHg O -
) O +
poses O +
serious O +
and O +
practical O +
concerns O +
for O +
human B-Species +
populations O +
regarding O +
perinatal O +
exposure O -
. O +

Fish O -
, O +
especially O +
large O +
predator O +
( O -
carnivore O -
) O +
fish O +
species O -
, O +
accumulate O +
high O +
concentrations O +
of O +
MeHg O +
through O +
the O +
marine O +
food O +
chain O -
, O +
and O +
exposure O +
of O +
pregnant O +
women O +
to O +
MeHg O +
through O +
the O +
consumption O +
of O +
fish O +
has O +
evoked O +
widespread O +
concern O +
due O +
to O +
potential O +
effects O +
on O +
offspring O -
. O +

Two O +
large O -
- O -
scale O +
cohort O +
studies O +
in O +
fish O -
- O -
eating O +
populations O +
of O +
Seychelles O +
and O +
Faroe O +
islanders O +
are O +
being O +
conducted O -
; O +
although O +
the O +
former O +
has O +
not O +
found O +
consistent O +
adverse O +
developmental O +
effects O +
of O +
MeHg O +
( O -
Myers O +
et O +
al. O +
2007 O -
) O -
, O +
the O +
latter O +
has O +
reported O +
adverse O +
effects O +
( O -
Debes O +
et O +
al. O +
2006 O -
) O -
. O +

Fundamental O +
reasons O +
for O +
this O +
discrepancy O +
have O +
not O +
been O +
completely O +
elucidated O -
, O +
and O +
many O +
questions O +
remain O +
regarding O +
the O +
neurotoxicity O +
of O +
MeHg O -
, O +
despite O +
extensive O +
study O -
. O +

Among O +
the O +
unanswered O +
questions O +
is O +
whether O +
there O +
is O +
a O +
long O +
latency O +
period O +
for O +
behavioral O +
manifestations O +
after O +
exposure O +
to O +
MeHg O +
( O -
Clarkson O +
and O +
Magos O +
2006 O -
; O +
Landrigan O +
et O +
al. O +
2005 O -
; O +
Rice O +
1996 O -
; O +
Weiss O +
et O +
al. O +
2005a O -
, O +
2005b O -
) O -
. O +

Typical O +
examples O +
of O +
latent O +
toxicity O +
in O +
humans B-Species -
, O +
including O +
both O +
acute O +
and O +
chronic O +
MeHg O +
exposures O -
, O +
have O +
been O +
described O +
in O +
detail O +
elsewhere O +
( O -
Weiss O +
et O +
al. O +
2005a O -
) O -
. O +

Davidson O +
et O +
al. O +
( O -
2006 O -
) O +
recently O +
suggested O +
that O +
effects O +
of O +
perinatal O +
exposure O +
to O +
MeHg O +
may O +
emerge O +
9 O +
years O +
after O +
birth O +
in O +
the O +
Seychelles O +
cohort O -
. O +

Consequently O -
, O +
risk O +
assessments O +
of O +
MeHg O +
exposure O +
could O +
be O +
inaccurate O +
because O +
studies O +
( O -
human B-Species +
or O +
animal O -
) O +
usually O +
do O +
not O +
focus O +
on O +
later O +
stages O +
of O +
life O +
and O +
therefore O +
could O +
miss O +
delayed O +
effects O -
. O +

The O +
possibility O +
of O +
delayed O +
toxicity O +
is O +
exemplified O +
by O +
the O +
expanded O +
Barker O +
hypothesis O -
, O +
which O +
posits O +
that O +
the O +
origin O +
of O +
some O +
neurodegenerative O +
diseases O +
such O +
as O +
Parkinson O +
and O +
Alzheimer O +
diseases O +
lies O +
in O +
early O +
exposure O +
to O +
environmental O +
chemicals O +
( O -
Landrigan O +
et O +
al. O +
2005 O -
) O -
. O +

Although O +
epidemiologic O +
evidence O +
would O +
be O +
ideal O +
for O +
exploring O +
the O +
possibility O +
of O +
delayed O +
toxicity O +
( O -
and O -
, O +
indeed O -
, O +
data O +
from O +
epidemiologic O +
studies O +
form O +
the O +
basis O +
of O +
current O +
risk O +
assessment O +
for O +
developmental O +
toxicity O +
of O +
MeHg O -
) O -
, O +
considering O +
the O +
complex O +
effects O +
of O +
numerous O +
potential O +
confounders O +
and O +
the O +
existence O +
of O +
multiple O +
exposures O +
in O +
human B-Species +
populations O -
, O +
animal O +
models O +
would O +
likely O +
make O +
important O +
contributions O +
to O +
this O +
field O -
. O +

Although O +
numerous O +
animal O +
studies O +
have O +
described O +
the O +
developmental O +
neurotoxicity O +
of O +
MeHg O +
( O -
Watanabe O +
and O +
Satoh O -
, O +
1996 O -
) O -
, O +
few O +
have O +
addressed O +
the O +
latency O +
issue O -
. O +

Few O +
studies O +
have O +
evaluated O +
the O +
neurobehavioral O +
effects O +
in O +
rodents O +
longitudinally O +
beyond O +
6 O +
months O +
after O +
perinatal O +
exposure O -
. O +

Spyker O +
( O -
1975 O -
) O +
addressed O +
this O +
issue O +
in O +
her O +
pioneering O +
work O -
, O +
reporting O +
the O +
late O +
development O +
of O +
behavioral O +
toxicity O +
in O +
mice B-Species +
prenatally O +
exposed O +
to O +
MeHg O -
; O +
it O +
appeared O -
, O +
however O -
, O +
that O +
the O +
substantial O +
mortality O +
and O +
retarded O +
growth O +
among O +
the O +
exposed O +
mice B-Species +
were O +
apparent O +
before O +
weaning O -
, O +
indicating O +
that O +
the O +
doses O +
used O +
( O -
even O +
though O +
some O +
lower O +
dose O +
levels O +
were O +
included O -
) O +
exerted O +
severe O +
toxicity O -
. O +

Using O +
a O +
relatively O +
complex O +
schedule O -
- O -
controlled O +
operant O +
behavior O +
method O -
, O +
rats B-Species +
whose O +
parents O +
were O +
exposed O +
to O +
MeHg O +
( O -
0.5 O +
or O +
6.4 O +
mg O -
/ O -
L O -
) O +
from O +
4 O +
weeks O +
before O +
mating O +
and O +
continuing O +
to O +
postnatal O +
day O +
( O -
PND O -
) O +
16 O +
were O +
shown O +
to O +
be O +
less O +
sensitive O +
to O +
a O +
change O +
in O +
the O +
reinforcement O +
schedule O +
than O +
were O +
their O +
nonexposed O +
counterparts O +
at O +
28–32 O +
months O +
of O +
age O +
( O -
Newland O +
et O +
al. O +
2004 O -
) O -
. O +

Mice B-Species +
that O +
were O +
perinatally O +
exposed O +
to O +
1 O +
or O +
3 O +
mg O -
/ O -
L O +
MeHg O +
in O +
drinking O +
water O +
did O +
not O +
show O +
significant O +
deviation O +
from O +
controls O +
in O +
behavioral O +
performance O +
( O -
motor O +
performance O -
, O +
memory O -
, O +
and O +
learning O -
) O +
at O +
5 O -
, O +
15 O -
, O +
or O +
26 O +
months O +
of O +
age O -
, O +
but O +
the O +
lifetime O -
- O -
exposed O +
groups O +
did O +
show O +
a O +
significant O +
deviation O +
( O -
Weiss O +
et O +
al. O +
2005c O -
) O -
. O +

The O +
existence O +
of O +
a O +
latency O +
period O +
( O -
i.e. O -
, O +
the O +
absence O +
of O +
effects O +
earlier O +
in O +
life O +
followed O +
by O +
the O +
emergence O +
of O +
effects O +
at O +
a O +
later O +
stage O +
of O +
life O -
) O +
has O +
not O +
been O +
demonstrated O +
in O +
any O +
rodent O +
study O -
. O +

In O +
nonhuman O +
primates O -
, O +
delayed O +
emergence O +
of O +
the O +
signs O +
of O +
neurotoxicity O +
was O +
observed O +
several O +
years O +
after O +
the O +
cessation O +
of O +
a O +
7-year O +
postnatal O +
exposure O +
( O -
Rice O +
1996 O -
) O -
. O +

Metallothionein O +
( O -
MT O -
) O +
protects O +
against O +
the O +
toxicities O +
of O +
a O +
variety O +
of O +
metals O -
. O +

We O +
examined O +
the O +
neurotoxicity O +
and O +
developmental O +
toxicity O +
of O +
metallic O +
Hg O +
in O +
MT O +
I O -
/ O -
II O -
- O -
knockout O +
mice B-Species +
( O -
Yoshida O +
et O +
al. O +
2004 O -
) O +
and O +
demonstrated O +
the O +
susceptibility O +
of O +
this O +
genetically O +
manipulated O +
strain O +
to O +
the O +
toxicity O +
of O +
metallic O +
Hg O -
. O +

In O +
contrast O +
to O +
metallic O +
Hg O -
, O +
MeHg O +
does O +
not O +
induce O +
MT O -
, O +
and O +
MT O +
would O +
not O +
substantially O +
influence O +
the O +
kinetics O +
of O +
MeHg O +
( O -
Yasutake O +
et O +
al. O +
1998 O -
) O -
. O +

Several O +
reports O -
, O +
however O -
, O +
have O +
demonstrated O +
protective O +
effects O +
of O +
MT O +
against O +
MeHg O +
toxicity O -
, O +
which O +
was O +
ascribed O +
to O +
the O +
radical O +
scavenging O +
effect O +
of O +
MT O +
( O -
Yao O +
et O +
al. O +
2000 O -
) O -
. O +

We O +
also O +
showed O +
that O +
perinatal O +
exposure O +
to O +
MeHg O +
results O +
in O +
altered O +
metabolism O +
of O +
thyroid O +
hormones O +
in O +
neonates O +
that O +
was O +
more O +
distinct O +
in O +
MT O -
- O -
null O +
strains O +
than O +
their O +
wild O -
- O -
type O +
counterparts O +
( O -
Mori O +
et O +
al. O +
2006 O -
) O -
. O +

The O +
vulnerability O +
of O +
the O +
MT O -
- O -
null O +
strain O +
suggests O +
that O +
delayed O +
neurobehavioral O +
toxicity O +
due O +
to O +
MeHg O -
, O +
if O +
it O +
does O +
exist O -
, O +
might O +
be O +
more O +
distinctive O +
in O +
this O +
strain O -
. O +

By O +
utilizing O +
the O +
MT O -
- O -
null O +
strain O -
, O +
we O +
aimed O +
to O +
answer O +
the O +
following O +
two O +
questions O -
: O +
First O -
, O +
could O +
we O +
generate O +
a O +
model O +
in O +
which O +
the O +
toxicity O +
of O +
MeHg O +
would O +
emerge O +
or O +
at O +
least O +
become O +
exaggerated O +
later O +
in O +
life O +
as O +
opposed O +
to O +
earlier O +
in O +
life O +
( O -
i.e. O -
, O +
at O +
3–6 O +
months O -
, O +
which O +
was O +
the O +
timing O +
for O +
most O +
of O +
the O +
earlier O +
studies O +
that O +
used O +
behavioral O +
evaluations O -
) O -
? O +

Second O -
, O +
would O +
the O +
MT O -
- O -
null O +
strain O +
be O +
affected O +
more O +
than O +
its O +
parent O +
C57BL O +
strain O -
? O +

Answering O +
either O +
of O +
these O +
questions O +
not O +
only O +
could O +
influence O +
the O +
risk O +
evaluation O +
of O +
MeHg O -
, O +
but O +
it O +
could O +
also O +
lead O +
to O +
a O +
better O +
understanding O +
of O +
the O +
mechanism O +
of O +
toxicity O +
for O +
perinatal O +
MeHg O +
exposure O -
. O +

To O +
address O +
these O +
issues O -
, O +
we O +
used O +
three O +
behavioral O +
paradigms O -
, O +
the O +
open O +
field O +
( O -
OPF O -
) O -
, O +
passive O +
avoidance O +
( O -
PA O -
) O -
, O +
and O +
Morris O +
( O -
water O -
) O +
maze O +
( O -
MM O -
) O +
tests O -
, O +
which O +
are O +
often O +
used O +
in O +
this O +
field O +
and O +
which O +
we O +
used O +
in O +
our O +
previous O +
studies O +
on O +
the O +
effects O +
of O +
Hg O +
vapor O +
( O -
Yoshida O +
et O +
al. O +
2004 O -
, O +
2006 O -
) O -
. O +

Performances O +
in O +
the O +
MM O +
and O +
PA O +
are O +
said O +
to O +
be O +
the O +
most O +
sensitive O +
to O +
aging O +
( O -
Gower O +
and O +
Lamberty O +
1993 O -
) O -
. O +

We O +
used O +
a O +
dose O +
of O +
5 O +
μg O +
MeHg O -
/ O -
g O +
in O +
the O +
diet O -
, O +
which O +
resulted O +
in O +
a O +
brain O +
Hg O +
level O +
relevant O +
to O +
human B-Species +
risk O +
assessment O -
. O +

We O +
evaluated O +
the O +
behavioral O +
end O +
points O +
twice O -
, O +
once O +
around O +
3 O +
months O +
of O +
age O +
and O +
the O +
other O +
time O +
around O +
1 O +
year O -
; O +
the O +
latter O +
time O +
roughly O +
corresponds O +
to O +
the O +
period O +
when O +
many O +
behavioral O +
performances O -
, O +
including O +
OPF O +
( O -
Acevedoa O +
et O +
al. O +
2006 O -
; O +
Carrie O +
et O +
al. O +
1999 O -
; O +
Gower O +
and O +
Lamberty O +
1993 O -
) O -
, O +
PA O +
( O -
Gower O +
and O +
Lamberty O +
1993 O -
) O -
, O +
and O +
MM O +
( O -
Bach O +
et O +
al. O +
1999 O -
; O +
Carrie O +
et O +
al. O +
1999 O -
) O -
, O +
show O +
alterations O +
in O +
this O +
mouse B-Species +
strain O -
. O +

Materials O +
and O +
Methods O +
Animals O +
and O +
MeHg O +
exposure O +
OLA129 O -
/ O -
C57BL O -
/ O -
6J O +
strain O +
mice B-Species +
( O -
wild O +
type O -
) O +
and O +
MT O +
I O -
/ O -
II O -
- O -
knockout O +
mice B-Species +
( O -
MT O -
- O -
null O -
) O +
of O +
this O +
strain O +
were O +
provided O +
by O +
K.H. O +
Choo O +
of O +
the O +
Murdoch O +
Institute O -
, O +
Parkville O -
, O +
Australia O +
( O -
Michalska O +
and O +
Choo O +
1993 O -
) O +
and O +
were O +
of O +
a O +
mixed O +
genetic O +
background O +
of O +
129 O -
/ O -
Ola O +
and O +
C57BL O -
/ O -
6 O +
strains O -
. O +

F1 O +
hybrid O +
mice B-Species +
were O +
mated O +
with O +
C57BL O -
/ O -
6 O +
mice B-Species +
for O +
six O +
generations O +
at O +
the O +
National O +
Institute O +
for O +
Environmental O +
Studies O +
( O -
Tsukuba O -
, O +
Japan O -
) O -
. O +

At O +
10 O +
weeks O +
of O +
age O -
, O +
single O +
male O +
and O +
female O +
mice B-Species +
were O +
allowed O +
to O +
cohabit O -
; O +
every O +
female O +
mouse B-Species +
was O +
checked O +
each O +
morning O +
for O +
the O +
presence O +
of O +
a O +
vaginal O +
plug O -
. O +

When O +
a O +
plug O +
was O +
confirmed O -
, O +
the O +
day O +
was O +
designated O +
as O +
day O +
0 O +
of O +
gestation O +
( O -
GD0 O -
) O -
. O +

The O +
diet O -
, O +
NIH-07PLD O +
formula O +
( O -
CLEA O +
Japan O -
, O +
Inc. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
contained O +
vitamins O +
and O +
trace O +
elements O +
as O +
follows O +
( O -
per O +
kilogram O +
diet O -
) O -
: O +
3.2 O +
mg O +
CuSO4 O -
, O +
88 O +
mg O +
FeSO4 O -
, O +
149 O +
mg O +
MnSO4 O -
, O +
25 O +
mg O +
ZnCO3 O -
, O +
1.6 O +
mg O +
Ca O -
( O -
IO3 O -
) O -
2 O -
, O +
11 O +
mg O +
vitamin O +
B1 O -
, O +
4.7 O +
mg O +
vitamin O +
B2 O -
, O +
1.9 O +
mg O +
vitamin O +
B6 O -
, O +
44 O +
mg O +
vitamin O +
E O -
, O +
in O +
addition O +
to O +
5 O +
μg O +
MeHg O -
/ O -
g O -
. O +

This O +
diet O +
was O +
fed O +
to O +
the O +
pregnant O +
mice B-Species +
starting O +
from O +
GD0 O +
through O +
10 O +
days O +
after O +
delivery O +
( O -
i.e. O -
, O +
PND10 O -
) O -
. O +

Thereafter O -
, O +
we O +
switched O +
mice B-Species +
to O +
a O +
diet O +
that O +
did O +
not O +
contain O +
MeHg O -
. O +

We O +
chose O +
GD0 O +
as O +
the O +
beginning O +
of O +
exposure O +
because O +
exposures O +
that O +
started O +
before O +
conception O +
often O +
resulted O +
in O +
fairly O +
high O +
Hg O +
concentrations O +
in O +
fetal O -
/ O -
neonatal O +
brains O +
( O -
Kakita O +
et O +
al. O +
2003 O -
) O -
, O +
and O +
we O +
chose O +
PND10 O +
to O +
cover O +
the O +
early O +
neonatal O +
period O -
, O +
in O +
which O +
considerable O +
brain O +
growth O +
occurs O -
. O +

In O +
our O +
experimental O +
setting O -
, O +
the O +
neonatal O +
mice B-Species +
started O +
to O +
eat O +
from O +
the O +
diet O +
bucket O +
and O +
drink O +
from O +
the O +
water O +
bottle O +
from O +
PND10 O +
onward O -
. O +

Control O +
mice B-Species +
were O +
kept O +
on O +
the O +
same O +
diet O +
but O +
without O +
MeHg O +
( O -
< O +
0.01 O +
μg O +
Hg O -
/ O -
g O -
) O -
. O +

On O +
PND1 O -
, O +
to O +
avoid O +
the O +
confounding O +
effects O +
due O +
to O +
different O +
litter O +
size O -
, O +
we O +
reduced O +
each O +
litter O +
to O +
six O +
pups O +
( O -
three O +
males O +
and O +
three O +
females O +
when O +
possible O -
) O -
, O +
and O +
on O +
PND10 O -
, O +
two O +
males O +
and O +
two O +
females O +
from O +
each O +
litter O +
were O +
killed O +
for O +
chemical O +
analyses O -
. O +

The O +
remaining O +
male O +
and O +
female O +
offspring O +
per O +
litter O +
were O +
weaned O +
on O +
PND28 O +
and O +
used O +
for O +
subsequent O +
behavioral O +
analyses O +
( O -
either O +
at O +
12–13 O +
weeks O +
or O +
52–53 O +
weeks O -
, O +
depending O +
on O +
the O +
litter O -
) O +
as O +
described O +
below O -
. O +

We O +
measured O +
body O +
weights O +
of O +
the O +
weaned O +
mice B-Species +
every O +
2 O +
weeks O -
. O +

Thus O -
, O +
four O +
experimental O +
groups O +
were O +
used O +
( O -
with O +
or O +
without O +
MeHg O +
exposure O +
for O +
two O +
strains O -
) O -
, O +
and O +
each O +
group O +
consisted O +
of O +
12–13 O +
litters O -
. O +

For O +
half O +
of O +
the O +
litters O -
, O +
the O +
behavioral O +
analyses O +
were O +
conducted O +
at O +
12–13 O +
weeks O +
of O +
age O -
, O +
and O +
upon O +
completion O +
of O +
the O +
behavioral O +
analyses O -
, O +
the O +
animals O +
were O +
killed O +
under O +
ether O +
anesthesia O -
. O +

We O +
then O +
dissected O +
the O +
organs O +
( O -
brain O -
, O +
liver O -
, O +
and O +
kidneys O -
) O +
for O +
Hg O +
analyses O -
. O +

For O +
the O +
remaining O +
half O +
of O +
the O +
litters O -
, O +
we O +
conducted O +
the O +
behavioral O +
tests O +
at O +
52–53 O +
weeks O +
of O +
age O -
. O +

The O +
mice B-Species +
were O +
treated O +
humanely O +
and O +
with O +
regard O +
to O +
alleviation O +
of O +
suffering O +
according O +
to O +
the O +
National O +
Institute O +
for O +
Environmental O +
Studies O -
' O +
Guidelines O +
for O +
Animal O +
Welfare O +
and O +
the O +
guidelines O +
of O +
St. O +
Marianna O +
University O -
. O +

Behavioral O +
evaluations O +
The O +
details O +
of O +
each O +
behavioral O +
procedure O +
have O +
been O +
described O +
elsewhere O +
( O -
Yoshida O +
et O +
al. O +
2006 O -
) O -
. O +

Brief O +
descriptions O +
follow O -
. O +

For O +
the O +
OPF O +
test O -
, O +
we O +
used O +
an O +
OPF O +
apparatus O +
( O -
Ohara O +
Co. O -
, O +
Ltd. O -
, O +
Tokyo O -
, O +
Japan O -
) O +
with O +
a O +
60 O +
× O +
60-cm O +
floor O +
surrounded O +
by O +
walls O +
60 O +
cm O +
high O -
. O +

The O +
experimental O +
room O +
light O +
was O +
turned O +
off O -
, O +
and O +
a O +
dim O +
light O +
of O +
80 O +
lux O +
was O +
lit O +
during O +
the O +
experiment O -
. O +

We O +
placed O +
a O +
mouse B-Species +
in O +
the O +
center O +
of O +
the O +
floor O +
and O +
monitored O +
its O +
behavior O +
for O +
10 O +
min O +
using O +
a O +
CCD O +
camera O +
connected O +
to O +
a O +
computer O -
. O +

The O +
position O +
of O +
the O +
center O +
of O +
gravity O +
was O +
calculated O +
by O +
image O -
- O -
analyzing O +
software O -
, O +
which O +
was O +
used O +
to O +
calculate O +
the O +
total O +
distance O +
traveled O +
by O +
the O +
mouse B-Species +
as O +
well O +
as O +
the O +
positional O +
preference O +
( O -
either O +
center O +
or O +
peripheral O -
, O +
where O +
peripheral O +
was O +
defined O +
as O +
the O +
area O +
within O +
10 O +
cm O +
from O +
the O +
wall O -
) O -
. O +

We O +
cleaned O +
the O +
OPF O +
apparatus O +
with O +
70 O -
% O +
ethanol O +
between O +
trials O -
. O +

The O +
apparatus O +
for O +
the O +
PA O +
test O +
( O -
Ohara O +
Co. O +
Ltd. O -
) O +
consisted O +
of O +
a O +
light O +
compartment O +
that O +
illuminated O +
by O +
a O +
400-lux O +
light O +
and O +
a O +
dark O +
compartment O +
with O +
black O +
opaque O +
walls O +
and O +
lids O -
. O +

The O +
two O +
compartments O +
were O +
separated O +
by O +
a O +
mobile O +
guillotine O +
door O -
. O +

On O +
the O +
first O +
day O +
( O -
training O +
trial O -
) O -
, O +
we O +
placed O +
each O +
mouse B-Species +
in O +
the O +
light O +
compartment O +
facing O +
away O +
from O +
the O +
guillotine O +
door O -
, O +
which O +
was O +
closed O -
. O +

After O +
30 O +
sec O +
of O +
introduction O -
, O +
the O +
door O +
was O +
opened O -
; O +
when O +
the O +
mouse B-Species +
entered O +
the O +
dark O +
compartment O -
, O +
a O +
brief O +
electric O +
shock O +
( O -
4 O +
mA O +
for O +
2 O +
sec O -
) O +
was O +
delivered O +
through O +
the O +
metal O +
grid O +
floor O -
. O +

This O +
would O +
force O +
the O +
mouse B-Species +
back O +
to O +
the O +
light O +
component O -
. O +

The O +
interval O +
between O +
the O +
opening O +
of O +
the O +
door O +
and O +
the O +
entry O +
to O +
the O +
dark O +
room O +
( O -
in O +
seconds O -
) O +
was O +
recorded O +
and O +
defined O +
as O +
the O +
latency O -
. O +

On O +
the O +
next O +
day O -
, O +
the O +
same O +
procedure O +
was O +
repeated O -
, O +
but O +
without O +
the O +
electric O +
shock O +
( O -
retaining O +
trail O -
) O -
. O +

In O +
this O +
PA O +
paradigm O -
, O +
aversive O +
learning O +
was O +
assumed O +
to O +
be O +
established O +
in O +
the O +
training O +
trial O -
, O +
and O +
we O +
used O +
its O +
retention O +
in O +
the O +
retaining O +
trail O +
as O +
the O +
index O +
of O +
learning O -
. O +

Between O +
each O +
individual O +
trial O -
, O +
we O +
cleaned O +
the O +
apparatus O +
with O +
ethanol O -
. O +

The O +
cutoff O +
time O +
of O +
the O +
retention O +
session O +
was O +
300 O +
sec. O +
The O +
MM O +
test O +
apparatus O +
( O -
Ohara O +
Co. O -
, O +
Ltd. O -
) O +
was O +
a O +
round O -
- O -
shaped O +
water O +
pool O +
with O +
a O +
diameter O +
of O +
120 O +
cm O -
. O +

A O +
small O +
platform O +
was O +
submerged O +
in O +
the O +
water O -
, O +
which O +
provided O +
a O +
place O +
for O +
mice B-Species +
to O +
escape O +
from O +
the O +
water O +
( O -
i.e. O -
, O +
an O +
aversive O +
stimulus O -
, O +
water O +
temperature O +
= O +
23 O +
± O +
1 O -
° O -
C O -
) O -
. O +

The O +
water O +
was O +
made O +
opaque O +
by O +
adding O +
white O +
paint O +
so O +
that O +
the O +
mouse B-Species +
could O +
not O +
see O +
the O +
submerged O +
platform O -
. O +

In O +
each O +
trial O -
, O +
we O +
released O +
a O +
mouse B-Species +
into O +
the O +
pool O +
from O +
a O +
determined O +
position O +
along O +
the O +
wall O -
, O +
and O +
the O +
performance O +
of O +
the O +
mouse B-Species +
was O +
monitored O +
by O +
a O +
CCD O +
camera O -
/ O -
image O +
analyzer O -
. O +

The O +
time O +
required O +
to O +
reach O +
the O +
platform O +
was O +
recorded O -
. O +

If O +
a O +
mouse B-Species +
could O +
not O +
find O +
the O +
platform O +
within O +
60 O +
sec O +
after O +
release O -
, O +
it O +
was O +
led O +
to O +
the O +
platform O +
and O +
placed O +
on O +
it O +
for O +
20 O +
sec O +
before O +
being O +
removed O -
. O +

In O +
these O +
cases O -
, O +
a O +
latency O +
of O +
60 O +
sec O +
was O +
recorded O -
. O +

We O +
conducted O +
the O +
trial O +
once O +
a O +
day O +
up O +
to O +
the O +
fifth O +
day O +
for O +
each O +
mouse B-Species -
, O +
and O +
the O +
order O +
of O +
each O +
mouse B-Species +
was O +
counterbalanced O +
across O +
the O +
day O -
. O +

On O +
the O +
sixth O +
day O -
, O +
a O +
transfer O +
test O +
( O -
or O +
probe O +
test O -
) O -
, O +
which O +
is O +
a O +
trial O +
without O +
the O +
platform O -
, O +
was O +
conducted O -
; O +
in O +
this O +
procedure O -
, O +
we O +
counted O +
the O +
number O +
of O +
times O +
that O +
the O +
mouse B-Species +
crossed O +
the O +
position O +
where O +
the O +
platform O +
had O +
been O -
. O +

Tissue O +
Hg O +
concentration O +
The O +
tissue O +
samples O +
were O +
homogenized O +
( O -
10 O -
% O +
weight O -
/ O -
volume O -
) O +
in O +
distilled O +
water O +
using O +
a O +
Polytron O +
homogenizer O +
( O -
Kinematica O +
GmbH O -
, O +
Littau O -
, O +
Switzerland O -
) O -
. O +

We O +
determined O +
Hg O +
levels O +
in O +
the O +
homogenates O +
by O +
the O +
oxygen O +
combustion O -
– O -
gold O +
amalgamation O +
method O +
( O -
Ohkawa O +
et O +
al. O +
1977 O -
) O +
using O +
an O +
atomic O +
absorption O +
Hg O +
detector O +
MD-1 O +
( O -
Nippon O +
Instruments O -
, O +
Co. O +
Ltd. O -
, O +
Osaka O -
, O +
Japan O -
) O -
. O +

To O +
ensure O +
the O +
accuracy O +
of O +
the O +
measurement O -
, O +
we O +
included O +
reference O +
material O +
from O +
a O +
dogfish O +
( O -
DORM-2 O -
; O +
National O +
Research O +
Council O +
of O +
Canada O -
, O +
Ottawa O -
, O +
Ontario O -
, O +
Canada O -
) O +
with O +
a O +
certified O +
value O +
of O +
4.64 O +
± O +
0.26 O +
μg O -
/ O -
g O +
in O +
the O +
analyses O -
; O +
the O +
observed O +
values O +
fell O +
within O +
the O +
certified O +
range O -
. O +

The O +
detection O +
limit O +
of O +
the O +
measurement O +
was O +
0.1 O +
ng O +
Hg O -
. O +

Statistics O +
We O +
analyzed O +
behavioral O +
data O +
for O +
OPF O +
and O +
PA O +
by O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O -
, O +
taking O +
sex O -
, O +
strain O -
, O +
and O +
MeHg O +
exposure O +
as O +
the O +
factors O -
. O +

All O +
the O +
interactions O +
among O +
these O +
factors O +
were O +
put O +
into O +
the O +
model O -
. O +

When O +
any O +
of O +
the O +
interactions O +
was O +
highly O +
significant O -
, O +
we O +
analyzed O +
the O +
data O +
separately O +
in O +
an O +
appropriate O +
way O -
; O +
for O +
example O -
, O +
if O +
sex O +
× O +
Hg O +
was O +
significant O -
, O +
the O +
data O +
for O +
males O +
and O +
females O +
were O +
separately O +
analyzed O +
for O +
the O +
effects O +
of O +
strain O +
and O +
Hg O -
. O +

Whenever O +
appropriate O -
, O +
ANOVAs O +
were O +
followed O +
by O +
Mann O -
- O -
Whitney O +
U O +
or O +
Student O -
's O +
t O -
- O -
tests O -
, O +
depending O +
on O +
the O +
nature O +
and O +
distribution O +
of O +
the O +
variables O -
. O +

We O +
analyzed O +
data O +
for O +
the O +
MM O +
by O +
repeated O -
- O -
measures O +
ANOVA O -
, O +
taking O +
the O +
exposure O +
as O +
between O -
- O -
group O +
and O +
trials O +
as O +
within O -
- O -
group O +
variables O -
. O +

The O +
test O +
was O +
performed O +
for O +
each O +
of O +
the O +
four O +
sex O +
and O +
strain O +
combinations O +
separately O -
. O +

The O +
significance O +
level O +
was O +
set O +
at O +
p O +
< O +
0.05 O -
. O +

Results O +
Body O +
weight O +
Up O +
to O +
20 O +
weeks O +
of O +
age O -
, O +
the O +
body O +
weight O +
values O +
of O +
the O +
control O +
and O +
MeHg O -
- O -
exposed O +
groups O +
were O +
not O +
different O -
, O +
regardless O +
of O +
strain O +
or O +
sex O -
. O +

After O +
28 O +
weeks O -
, O +
except O +
for O +
the O +
wild O -
- O -
type O +
female O +
groups O -
, O +
the O +
MeHg O -
- O -
exposed O +
groups O +
weighed O +
significantly O +
less O +
than O +
the O +
controls O +
( O -
Figure O +
1 O -
) O -
. O +

OPF O +
At O +
12 O +
weeks O +
of O +
age O -
, O +
a O +
three O -
- O -
way O +
ANOVA O +
of O +
the O +
locomotion O +
distance O +
revealed O +
that O +
only O +
strain O +
was O +
a O +
significant O +
factor O +
( O -
p O +
< O +
0.001 O -
) O -
, O +
reflecting O +
the O +
longer O +
distance O +
traveled O +
by O +
the O +
MT O -
- O -
null O +
mice B-Species +
( O -
Figure O +
2A O -
) O -
. O +

Strain O +
was O +
also O +
a O +
significant O +
factor O +
for O +
the O +
proportion O +
of O +
the O +
central O -
- O -
area O +
locomotion O +
( O -
Figure O +
3A O -
) O -
, O +
and O +
Hg O +
exposure O +
marginally O +
affected O +
this O +
outcome O -
. O +

In O +
MT O -
- O -
null O +
females O -
, O +
the O +
proportion O +
of O +
central O -
- O -
area O +
locomotion O +
was O +
higher O +
in O +
MeHg O -
- O -
exposed O +
mice B-Species +
than O +
in O +
the O +
controls O -
; O +
this O +
difference O +
was O +
not O +
observed O +
in O +
any O +
other O +
strain O -
– O -
sex O +
combination O -
. O +

At O +
52 O +
weeks O +
of O +
age O -
, O +
the O +
strain O +
× O +
Hg O +
interaction O +
was O +
highly O +
significant O +
( O -
p O +
< O +
0.001 O -
) O +
in O +
an O +
ANOVA O +
of O +
locomotion O +
distance O +
( O -
Figure O +
2B O -
) O -
; O +
MeHg O +
exposure O +
was O +
associated O +
with O +
decreased O +
locomotion O +
distance O +
in O +
wild O -
- O -
type O +
mice B-Species +
and O +
with O +
increased O +
distance O +
in O +
MT O -
- O -
null O +
mice B-Species -
. O +

A O +
strain O -
- O -
wise O +
two O -
- O -
way O +
ANOVA O +
( O -
with O +
sex O +
and O +
Hg O +
as O +
the O +
factors O -
) O +
revealed O +
that O +
only O +
Hg O +
was O +
significant O +
in O +
both O +
strains O +
( O -
p O +
< O +
0.01 O -
) O -
. O +

Regarding O +
the O +
proportion O +
of O +
the O +
central O -
- O -
area O +
locomotion O -
, O +
the O +
effects O +
of O +
MeHg O +
appeared O +
to O +
depend O +
on O +
sex O +
[ O -
i.e. O -
, O +
sex O +
× O +
Hg O +
was O +
highly O +
significant O +
( O -
p O +
< O +
0.001 O -
) O +
in O +
the O +
three O -
- O -
way O +
ANOVA O -
; O +
Figure O +
3B O -
] O -
. O +

Indeed O -
, O +
a O +
sex O -
- O -
wise O +
two O -
- O -
way O +
ANOVA O +
showed O +
significant O +
effects O +
of O +
Hg O +
only O +
in O +
females O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

PA O +
At O +
12 O +
weeks O +
of O +
age O -
, O +
all O +
the O +
groups O +
showed O +
prolonged O +
latency O +
in O +
the O +
second O +
( O -
retention O -
) O +
trial O -
, O +
and O +
no O +
consistent O +
effect O +
of O +
MeHg O +
was O +
recognized O +
regardless O +
of O +
strain O +
or O +
sex O +
( O -
Figure O +
4A O -
) O -
. O +

At O +
52 O +
weeks O +
of O +
age O -
, O +
a O +
three O -
- O -
way O +
ANOVA O +
revealed O +
a O +
significant O +
interaction O +
between O +
strain O +
and O +
Hg O +
( O -
p O +
< O +
0.05 O -
) O -
; O +
strain O -
- O -
wise O +
two O -
- O -
way O +
ANOVAs O +
revealed O +
a O +
significant O +
effect O +
of O +
Hg O +
on O +
learning O +
in O +
MT O -
- O -
null O +
mice B-Species +
of O +
both O +
sexes O -
; O +
these O +
groups O +
of O +
mice B-Species +
showed O +
significantly O +
shorter O +
( O -
less O +
than O +
half O -
) O +
latency O +
times O +
compared O +
to O +
control O +
mice B-Species +
( O -
Figure O +
4B O -
) O -
. O +

A O +
notable O +
difference O +
between O +
the O +
results O +
at O +
52 O +
weeks O +
of O +
age O +
and O +
those O +
at O +
12 O +
weeks O +
was O +
that O +
many O +
of O +
the O +
tested O +
mice B-Species +
exceeded O +
the O +
cutoff O +
time O +
in O +
the O +
retention O +
trials O +
at O +
52 O +
weeks O -
, O +
except O +
for O +
the O +
MT O -
- O -
null O +
groups O -
. O +

MM O +
At O +
13 O +
weeks O +
of O +
age O -
, O +
repeated O -
- O -
measures O +
ANOVA O +
did O +
not O +
indicate O +
any O +
effects O +
of O +
MeHg O +
( O -
Figure O +
5A O -
) O -
. O +

At O +
52 O +
weeks O +
of O +
age O +
( O -
Figure O +
5B O -
) O -
, O +
wild O -
- O -
type O +
males O +
and O +
MT O -
- O -
null O +
females O +
shared O +
the O +
same O +
statistical O +
results O -
; O +
Hg O +
as O +
well O +
as O +
the O +
Hg O +
× O +
trial O +
interaction O +
were O +
statistically O +
significant O -
. O +

Thus O -
, O +
in O +
both O +
cases O -
, O +
the O +
MeHg O +
groups O +
showed O +
a O +
longer O +
latency O -
, O +
hampering O +
learning O +
performance O -
. O +

Tissue O +
Hg O +
concentration O +
At O +
PND10 O -
, O +
which O +
was O +
immediately O +
after O +
the O +
exposure O -
, O +
brain O +
Hg O +
concentrations O +
of O +
the O +
neonatal O +
mice B-Species +
were O +
approximately O +
≤ O +
0.5 O +
μg O -
/ O -
g O +
( O -
Table O +
1 O -
) O -
. O +

Although O +
the O +
MT O -
- O -
null O +
mice B-Species +
and O +
females O +
showed O +
slightly O +
higher O +
brain O +
Hg O +
concentrations O +
than O +
the O +
corresponding O +
wild O -
- O -
type O +
group O +
and O +
males O -
, O +
respectively O -
, O +
neither O +
of O +
these O +
differences O +
was O +
significant O -
. O +

At O +
13 O +
weeks O -
, O +
when O +
the O +
behavioral O +
tests O +
were O +
completed O -
, O +
the O +
brain O +
Hg O +
concentration O +
was O +
comparable O +
to O +
the O +
control O +
( O -
nonexposed O -
) O +
level O +
( O -
approximately O +
5 O +
ng O -
/ O -
g O +
in O +
both O +
the O +
exposed O +
and O +
control O +
brains O -
) O -
. O +

Interestingly O -
, O +
MT O -
- O -
null O +
mice B-Species +
had O +
a O +
significantly O +
lower O +
brain O +
Hg O +
concentration O +
than O +
the O +
corresponding O +
wild O -
- O -
type O +
groups O -
. O +

Discussion O +
Results O +
of O +
the O +
present O +
study O +
demonstrate O +
the O +
delayed O +
emergence O +
of O +
neurobehavioral O +
toxicity O +
due O +
to O +
perinatal O +
MeHg O +
exposure O -
, O +
which O +
presumably O +
developed O +
after O +
brain O +
MeHg O +
concentrations O +
had O +
leveled O +
off O -
. O +

This O +
emergent O +
toxicity O +
was O +
exaggerated O +
in O +
MT O -
- O -
null O +
mice B-Species +
and O +
was O +
more O +
distinct O +
in O +
females O -
. O +

To O +
our O +
knowledge O -
, O +
our O +
findings O +
show O +
the O +
first O +
clear O -
- O -
cut O +
demonstrations O +
of O +
a O +
long O +
latency O +
period O +
of O +
MeHg O +
neurobehavioral O +
toxicity O +
in O +
rodents O +
and O +
possible O +
genetic O +
susceptibility O +
for O +
the O +
emergent O +
toxicity O -
. O +

The O +
exposure O +
level O +
should O +
be O +
considered O +
before O +
discussing O +
the O +
end O +
points O -
. O +

On O +
PND10 O -
, O +
immediately O +
after O +
the O +
cessation O +
of O +
MeHg O +
exposure O -
, O +
the O +
brain O +
Hg O +
concentration O +
was O +
approximately O +
0.5 O +
μg O -
/ O -
g O -
, O +
regardless O +
of O +
the O +
strain O +
or O +
sex O -
. O +

In O +
a O +
previous O +
study O -
, O +
the O +
brain O +
Hg O +
concentration O +
in O +
mice B-Species +
perinatally O +
exposed O +
to O +
6 O +
mg O +
MeHg O -
/ O -
L O +
( O -
via O +
water O -
) O +
peaked O +
between O +
PND0 O +
and O +
PND4 O +
and O +
was O +
approximately O +
three O +
times O +
higher O +
than O +
on O +
PND21 O +
( O -
Goulet O +
et O +
al. O +
2003 O -
) O -
. O +

Therefore O -
, O +
the O +
peak O +
brain O +
Hg O +
concentration O -
, O +
which O +
is O +
presumably O +
observed O +
around O +
birth O -
, O +
can O +
be O +
estimated O +
as O +
about O +
3-fold O +
higher O +
than O +
that O +
on O +
PND10 O +
and O +
would O +
be O +
approximately O +
1.5 O +
μg O -
/ O -
g O +
( O -
0.5 O +
μg O -
/ O -
g O +
× O +
3 O -
) O -
, O +
which O +
is O +
one O +
of O +
the O +
lowest O +
levels O +
among O +
recent O +
rodent O +
studies O -
. O +

As O +
shown O +
by O +
Sakamoto O +
et O +
al. O +
( O -
2002 O -
) O +
in O +
their O +
Figure O +
2 O -
, O +
prenatal O +
exposure O +
of O +
rats B-Species +
to O +
MeHg O +
showed O +
a O +
peak O +
brain O +
Hg O +
concentration O +
around O +
PND1 O +
that O +
was O +
four O +
to O +
five O +
times O +
greater O +
than O +
the O +
level O +
on O +
PND10 O -
. O +

Also O -
, O +
Newland O +
and O +
Rasmussen O +
( O -
2000 O -
) O +
reported O +
a O +
slight O +
alteration O +
of O +
a O +
complex O +
operant O +
behavior O +
in O +
rats B-Species +
at O +
ages O +
< O +
2 O +
years O +
at O +
brain O +
Hg O +
concentrations O +
as O +
low O +
as O +
0.5 O +
μg O -
/ O -
g O +
at O +
birth O -
, O +
although O +
statistical O +
significance O +
of O +
this O +
particular O +
effect O +
was O +
not O +
clear O -
. O +

It O +
should O +
be O +
noted O +
that O +
rats B-Species +
have O +
different O +
Hg O +
kinetics O +
( O -
Hirayama O +
and O +
Yasutake O +
1986 O -
; O +
Yasutake O +
and O +
Hirayama O +
1990 O -
) O +
due O +
to O +
the O +
high O +
affinity O +
of O +
rat O +
hemoglobin O +
for O +
MeHg O +
( O -
Clarkson O +
and O +
Magos O +
2006 O -
) O -
. O +

The O +
most O +
important O +
observation O +
of O +
the O +
present O +
study O +
was O +
that O +
the O +
effects O +
of O +
low O -
- O -
level O +
MeHg O +
exposure O +
were O +
detected O +
only O +
at O +
later O +
stages O +
in O +
the O +
lives O +
of O +
the O +
mice B-Species -
. O +

Except O +
for O +
the O +
central O -
- O -
area O +
occupancy O +
in O +
OPF O +
in O +
MT O -
- O -
null O +
females O -
, O +
no O +
statistically O +
significant O +
effects O +
of O +
MeHg O +
were O +
observed O +
in O +
any O +
of O +
the O +
three O +
behavioral O +
tests O +
at O +
12 O +
weeks O +
of O +
age O -
. O +

In O +
contrast O -
, O +
significant O +
effects O +
were O +
observed O +
in O +
all O +
three O +
tests O +
at O +
52 O +
weeks O +
of O +
age O -
. O +

The O +
brain O +
Hg O +
concentration O +
of O +
the O +
exposed O +
groups O +
had O +
leveled O +
off O +
and O +
was O +
not O +
distinguishable O +
from O +
the O +
non O -
- O -
exposed O +
group O +
at O +
13 O +
weeks O +
of O +
age O -
, O +
immediately O +
after O +
the O +
first O +
phase O +
of O +
the O +
behavioral O +
testing O -
. O +

Therefore O -
, O +
in O +
the O +
present O +
study O -
, O +
there O +
was O +
a O +
latency O +
period O +
in O +
which O +
the O +
dose O +
and O +
effects O +
could O +
not O +
be O +
detected O -
, O +
although O +
effects O +
were O +
observed O +
9 O +
months O +
later O -
. O +

Another O +
notable O +
observation O +
was O +
that O +
the O +
emergent O +
manifestation O +
of O +
toxicity O +
was O +
also O +
recognized O +
in O +
the O +
suppression O +
of O +
body O +
weight O +
( O -
except O +
for O +
wild O -
- O -
type O +
females O -
) O -
, O +
which O +
only O +
became O +
apparent O +
on O +
or O +
after O +
28 O +
weeks O +
of O +
age O -
. O +

The O +
existence O +
of O +
a O +
latency O +
period O +
of O +
as O +
long O +
as O +
several O +
years O +
after O +
chronic O +
( O -
7 O +
years O +
from O +
birth O -
) O -
, O +
low O -
- O -
level O +
exposure O +
to O +
MeHg O +
has O +
been O +
described O +
in O +
nonhuman O +
primates O +
( O -
Rice O +
1996 O -
) O -
. O +

In O +
that O +
case O -
, O +
however O -
, O +
the O +
Hg O +
concentration O +
in O +
the O +
brain O +
remained O +
elevated O -
, O +
presumably O +
as O +
a O +
result O +
of O +
the O +
long O +
exposure O -
. O +

Indeed O -
, O +
Rice O +
( O -
1996 O -
) O +
argued O +
that O +
the O +
minute O +
amount O +
of O +
residual O +
brain O +
Hg O +
could O +
have O +
caused O +
the O +
delayed O +
toxicity O -
. O +

This O +
was O +
clearly O +
not O +
the O +
case O +
in O +
the O +
present O +
study O +
because O +
the O +
Hg O +
concentration O +
leveled O +
off O +
around O +
the O +
time O +
of O +
the O +
first O +
phase O +
of O +
the O +
behavioral O +
study O -
. O +

The O +
absence O +
of O +
behavioral O +
effects O +
at O +
12 O +
weeks O +
of O +
age O +
ruled O +
out O +
the O +
possibility O +
that O +
the O +
residual O +
behavioral O +
effects O +
were O +
due O +
to O +
elevated O +
Hg O +
early O +
in O +
life O -
. O +

Therefore O -
, O +
the O +
behavioral O +
toxicity O +
that O +
surfaced O +
at O +
52 O +
weeks O +
of O +
age O +
must O +
have O +
had O +
its O +
origin O +
before O +
the O +
brain O +
Hg O +
concentration O +
leveled O +
off O +
( O -
at O +
or O +
before O +
13 O +
weeks O +
of O +
age O -
) O -
, O +
although O +
the O +
redistribution O +
of O +
Hg O +
to O +
the O +
brain O +
from O +
other O +
sites O +
of O +
deposition O -
, O +
such O +
as O +
the O +
liver O -
, O +
can O -
not O +
be O +
completely O +
excluded O -
. O +

The O +
long O +
silent O +
period O +
before O +
the O +
manifestations O +
of O +
toxicity O +
emerged O +
suggests O +
that O +
a O +
slow O +
process O +
plays O +
a O +
role O +
in O +
this O +
latent O +
toxicity O -
. O +

Although O +
an O +
example O +
of O +
a O +
slow O +
process O +
is O +
aging O -
, O +
52 O +
weeks O +
of O +
age O +
might O +
not O +
be O +
sufficiently O +
old O +
for O +
a O +
mouse B-Species +
to O +
be O +
considered O +
aged O +
in O +
the O +
physiologic O +
sense O +
because O +
C57BL O -
/ O -
6 O +
mice B-Species +
have O +
a O +
relatively O +
long O +
life O +
span O +
among O +
mouse B-Species +
strains O +
[ O -
median O +
survival O +
of O +
27–31 O +
months O +
( O -
Gower O +
and O +
Lamberty O +
1993 O -
) O -
] O +
and O +
a O +
survival O +
rate O +
at O +
18–19 O +
months O +
as O +
high O +
as O +
90 O -
% O +
( O -
Institute O +
on O +
Aging O +
HP O -
) O +
( O -
National O +
Institute O +
on O +
Aging O +
2008 O -
) O -
. O +

Nevertheless O -
, O +
various O +
behavioral O +
examinations O +
have O +
shown O +
age O -
- O -
related O +
changes O +
in O +
the O +
performance O +
of O +
mice B-Species +
at O +
approximately O +
1 O +
year O +
of O +
age O +
in O +
the O +
OPF O +
( O -
Acevedoa O +
et O +
al. O +
2006 O -
; O +
Carrie O +
et O +
al. O +
1999 O -
) O -
, O +
MM O +
( O -
Bach O +
et O +
al. O +
1999 O -
; O +
Carrie O +
et O +
al. O +
1999 O -
) O -
, O +
and O +
PA O +
( O -
Gower O +
and O +
Lamberty O +
1993 O -
) O +
tests O -
. O +

The O +
observed O +
effects O +
of O +
MeHg O -
, O +
including O +
the O +
deterioration O +
in O +
the O +
PA O +
and O +
MM O +
and O +
suppression O +
in O +
the O +
OPF O +
( O -
in O +
wild O -
- O -
type O +
mice B-Species -
) O -
, O +
were O +
consistent O +
with O +
these O +
reported O +
effects O +
of O +
aging O +
on O +
behavioral O +
function O +
( O -
in O +
the O +
sense O +
described O +
above O -
) O -
, O +
except O +
for O +
the O +
increased O +
OPF O +
activity O +
in O +
the O +
MT O -
- O -
null O +
mice B-Species -
. O +

Regardless O +
of O +
its O +
neural O +
basis O -
, O +
the O +
basis O +
of O +
neurobehavioral O +
toxicity O +
should O +
be O +
sought O +
in O +
early O +
life O +
stages O +
when O +
the O +
brain O +
Hg O +
concentration O +
is O +
highly O +
elevated O +
( O -
approximately O +
1.5 O +
μg O -
/ O -
g O +
at O +
its O +
peak O -
) O -
. O +

Some O +
in O +
vivo O +
experiments O +
have O +
demonstrated O +
several O +
candidate O +
mechanisms O +
of O +
perinatal O +
exposure O +
to O +
MeHg O -
, O +
including O +
abnormal O +
migration O +
of O +
neurons O +
and/or O +
glias O +
( O -
Kakita O +
et O +
al. O +
2003 O -
; O +
Rodier O +
et O +
al. O +
1984 O -
) O -
, O +
but O +
at O +
higher O +
Hg O +
concentrations O -
. O +

Using O +
exactly O +
the O +
same O +
exposure O +
protocol O +
as O +
the O +
present O +
study O -
, O +
we O +
found O +
suppressed O +
activity O +
of O +
type O +
III O +
iodo O -
- O -
thyronine O +
deiodinase O -
, O +
a O +
thyroid O +
hormone O -
- O -
metabolizing O +
enzyme O -
, O +
in O +
the O +
brains O +
of O +
PND10 O +
mouse B-Species +
neonates O +
( O -
Mori O +
et O +
al. O +
2006 O -
) O -
, O +
consistent O +
with O +
our O +
previous O +
study O +
of O +
higher O +
MeHg O +
doses O +
( O -
Watanabe O +
et O +
al. O +
1999 O -
) O -
. O +

This O +
perturbation O +
could O +
be O +
one O +
of O +
the O +
candidate O +
mechanisms O +
responsible O +
for O +
the O +
later O +
anomalous O +
behaviors O +
because O +
even O +
a O +
transient O +
change O +
in O +
thyroid O +
hormones O +
during O +
the O +
critical O +
period O +
of O +
perinatal O +
life O +
exerts O +
long O -
- O -
term O +
consequences O +
( O -
Auso O +
et O +
al. O +
2004 O -
) O -
. O +

The O +
effects O +
of O +
MeHg O +
at O +
52 O +
weeks O +
of O +
age O +
were O +
influenced O +
by O +
two O +
potential O +
modifying O +
factors O -
, O +
sex O +
and O +
strain O -
. O +

In O +
the O +
OPF O -
, O +
while O +
the O +
locomotion O +
was O +
affected O +
in O +
both O +
strains O +
( O -
although O +
the O +
direction O +
was O +
opposite O -
) O -
, O +
center O +
occupancy O +
was O +
significantly O +
increased O +
only O +
in O +
the O +
MT O -
- O -
null O +
mice B-Species -
. O +

In O +
addition O -
, O +
the O +
effects O +
on O +
PA O +
were O +
significant O +
only O +
in O +
MT O -
- O -
null O +
mice B-Species -
, O +
whereas O +
MeHg O +
at O +
a O +
higher O +
dose O +
was O +
reported O +
to O +
worsen O +
PA O +
performance O +
in O +
rats B-Species +
( O -
6–8 O +
weeks O +
of O +
age O -
; O +
Sakamoto O +
et O +
al. O +
2002 O -
) O -
. O +

In O +
addition O -
, O +
body O +
weight O +
gain O +
was O +
suppressed O +
in O +
both O +
male O +
and O +
female O +
MT O -
- O -
null O +
mice B-Species -
, O +
whereas O +
in O +
wild O -
- O -
type O +
mice B-Species +
the O +
suppression O +
was O +
observed O +
only O +
in O +
males O -
. O +

Taken O +
together O -
, O +
the O +
MT O -
- O -
null O +
strain O +
appeared O +
to O +
be O +
slightly O +
more O +
susceptible O +
to O +
the O +
late O -
- O -
emergent O +
effects O +
of O +
MeHg O -
. O +

Several O +
lines O +
of O +
evidence O +
have O +
shown O +
that O +
MT O -
- O -
I O -
, O -
II O +
is O +
protective O +
against O +
the O +
toxicity O +
of O +
MeHg O +
( O -
Leiva O -
- O -
Presa O +
et O +
al. O +
2004 O -
; O +
Yao O +
et O +
al. O +
2000 O -
) O -
, O +
and O +
the O +
present O +
results O +
were O +
basically O +
consistent O +
with O +
these O +
reports O -
. O +

We O +
have O +
also O +
reported O +
the O +
susceptibility O +
of O +
the O +
MT O -
- O -
null O +
strain O +
to O +
the O +
neurotoxic O +
effects O +
of O +
metallic O +
Hg O +
( O -
Yoshida O +
et O +
al. O +
2004 O -
, O +
2006 O -
) O -
. O +

The O +
difference O +
in O +
the O +
susceptibility O +
to O +
MeHg O +
between O +
sexes O +
is O +
still O +
debated O +
( O -
Clarkson O +
and O +
Magos O +
2006 O -
; O +
National O +
Research O +
Council O +
2000 O -
; O +
Vahter O +
2007 O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
some O +
responses O +
to O +
MeHg O +
were O +
different O +
between O +
the O +
sexes O -
, O +
including O +
OPF O +
performance O +
at O +
12 O +
and O +
52 O +
weeks O +
of O +
age O +
and O +
MM O +
performance O +
at O +
52 O +
weeks O -
. O +

The O +
fact O +
that O +
the O +
MT O -
- O -
null O +
female O +
group O +
was O +
the O +
only O +
group O +
affected O +
by O +
MeHg O +
at O +
12 O +
weeks O +
may O +
suggest O +
the O +
particular O +
susceptibility O +
of O +
females O +
in O +
this O +
strain O -
. O +

This O +
point O +
needs O +
to O +
be O +
clarified O +
in O +
further O +
experiments O -
. O +

The O +
question O +
remains O +
of O +
why O +
MT O -
- O -
null O +
mice B-Species +
are O +
susceptible O +
to O +
the O +
delayed O +
neurotoxicity O +
of O +
perinatal O +
MeHg O -
. O +

Apparently O +
kinetics O +
play O +
only O +
a O +
minor O +
role O +
because O +
the O +
strain O +
did O +
not O +
show O +
distinct O +
effects O +
on O +
the O +
brain O +
Hg O +
concentration O +
at O +
PND10 O -
. O +

The O +
significantly O +
lower O +
brain O +
Hg O +
concentration O +
in O +
MT O -
- O -
null O +
mice B-Species +
compared O +
with O +
corresponding O +
wild O -
- O -
type O +
mice B-Species +
at O +
13 O +
weeks O +
of O +
age O +
indicated O +
that O +
MT O -
- O -
I O -
, O -
II O +
might O +
play O +
a O +
significant O +
role O +
in O +
the O +
retention O +
of O +
Hg O +
( O -
or O +
MeHg O -
) O -
. O +

This O +
is O +
consistent O +
with O +
the O +
results O +
of O +
studies O +
of O +
metallic O +
Hg O +
exposure O +
( O -
Yoshida O +
et O +
al. O +
2004 O -
, O +
2005 O -
) O -
; O +
a O +
lower O +
brain O +
Hg O +
concentration O +
may O +
not O +
guarantee O +
lower O +
toxicity O -
, O +
supporting O +
the O +
protective O +
role O +
of O +
the O +
protein O -
. O +

Earlier O +
studies O +
suggest O +
that O +
brain O +
MT O -
- O -
I O -
, O -
II O +
has O +
an O +
important O +
role O +
both O +
in O +
the O +
response O +
to O +
oxidative O +
injury O +
( O -
Potter O +
et O +
al. O +
2007 O -
) O +
and O +
in O +
the O +
process O +
of O +
aging O +
( O -
Kojima O +
et O +
al. O +
1999 O -
) O -
. O +

Therefore O -
, O +
the O +
lack O +
of O +
MT O +
can O +
exaggerate O +
the O +
toxicity O +
of O +
MeHg O +
by O +
enhancing O +
the O +
initial O +
effects O +
due O +
to O +
oxygen O +
radicals O +
and/or O +
by O +
accelerating O +
functional O +
aging O -
. O +

Apart O +
from O +
this O -
, O +
an O +
intriguing O +
possibility O +
is O +
that O +
the O +
brain O -
- O -
specific O +
isoform O -
, O +
MT O -
- O -
III O -
, O +
might O +
contribute O +
to O +
the O +
results O +
we O +
obtained O +
because O +
the O +
expression O +
of O +
MT O -
- O -
III O -
, O +
together O +
with O +
MT O -
- O -
I O -
, O +
is O +
increased O +
in O +
the O +
brain O +
of O +
old O +
rats B-Species -
, O +
resulting O +
in O +
the O +
low O +
availability O +
of O +
free O +
zinc O +
for O +
synapses O +
( O -
Mocchegiani O +
et O +
al. O +
2004 O -
) O -
. O +

The O +
age O -
- O -
dependent O +
expressions O +
of O +
MT O +
isoforms O +
might O +
be O +
modified O +
in O +
MT O -
- O -
null O +
mice B-Species -
. O +

Results O +
of O +
the O +
present O +
study O +
might O +
allow O +
the O +
possibility O +
of O +
alternative O +
interpretations O +
due O +
to O +
some O +
potentially O +
confounding O +
factors O -
. O +

For O +
example O -
, O +
except O +
for O +
the O +
wild O -
- O -
type O +
females O -
, O +
we O +
observed O +
significant O +
differences O +
in O +
body O +
weight O +
between O +
MeHg O -
- O -
exposed O +
and O +
non O -
- O -
exposed O +
groups O -
. O +

Because O +
these O +
differences O +
only O +
became O +
clear O +
later O +
in O +
life O -
, O +
they O +
might O +
be O +
associated O +
with O +
the O +
toxicity O +
that O +
also O +
emerged O +
later O +
in O +
life O -
. O +

Manipulation O +
of O +
body O +
weight O +
in O +
rodents O +
alters O +
activity O +
levels O -
, O +
although O +
the O +
reported O +
results O +
are O +
not O +
always O +
consistent O +
with O +
each O +
other O +
( O -
Harrison O +
and O +
Archer O +
1987 O -
; O +
Samuelsson O +
et O +
al. O +
2008 O -
) O -
. O +

Also O -
, O +
the O +
differential O +
performance O +
in O +
PA O +
could O +
be O +
related O +
with O +
the O +
potential O +
effects O +
of O +
MeHg O +
on O +
( O -
electric O -
) O +
shock O +
sensitivity O -
, O +
which O +
we O +
did O +
not O +
examine O -
. O +

At O +
least O +
one O +
high O -
- O -
dose O +
study O +
with O +
adult O +
rats B-Species +
showed O +
reduced O +
electric O +
sensitivity O +
due O +
to O +
mercury O +
exposure O +
( O -
Wu O +
et O +
al. O +
1985 O -
) O -
. O +

These O +
possibilities O +
need O +
to O +
be O +
addressed O +
in O +
future O +
studies O -
. O +

To O +
summarize O -
, O +
the O +
present O +
results O +
suggest O +
that O +
an O +
initial O +
( O -
or O +
triggering O -
) O +
toxicologic O +
event O +
occurs O +
before O +
the O +
brain O +
Hg O +
concentration O +
stabilizes O +
and O +
that O +
the O +
nature O +
of O +
this O +
event O +
should O +
be O +
either O +
an O +
acceleration O +
of O +
the O +
aging O +
process O +
or O +
interaction O +
with O +
the O +
aging O +
process O -
. O +

Thus O -
, O +
by O +
identifying O +
the O +
physiologic O +
events O +
associated O +
with O +
the O +
functional O +
aging O +
of O +
the O +
examined O +
behavioral O +
tasks O -
, O +
the O +
fundamental O +
toxicologic O +
scar O +
might O +
be O +
revealed O -
. O +

Potentiation O +
of O +
Nerve O +
Growth O +
Factor O -
- O -
Induced O +
Neurite O +
Outgrowth O +
by O +
Fluvoxamine O -
: O +
Role O +
of O +
Sigma-1 O +
Receptors O -
, O +
IP3 O +
Receptors O +
and O +
Cellular O +
Signaling O +
Pathways O +
Abstract O +
Background O +
Selective O +
serotonin O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
have O +
been O +
widely O +
used O +
and O +
are O +
a O +
major O +
therapeutic O +
advance O +
in O +
psychopharmacology O -
. O +

However O -
, O +
their O +
pharmacology O +
is O +
quite O +
heterogeneous O -
. O +

The O +
SSRI O +
fluvoxamine O -
, O +
with O +
sigma-1 O +
receptor O +
agonism O -
, O +
is O +
shown O +
to O +
potentiate O +
nerve O -
- O -
growth O +
factor O +
( O -
NGF O -
) O -
-induced O +
neurite O +
outgrowth O +
in O +
PC O +
12 O +
cells O -
. O +

However O -
, O +
the O +
precise O +
cellular O +
and O +
molecular O +
mechanisms O +
underlying O +
potentiation O +
by O +
fluvoxamine O +
are O +
not O +
fully O +
understood O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
roles O +
of O +
cellular O +
signaling O +
pathways O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
fluvoxamine O +
and O +
sigma-1 O +
receptor O +
agonists O -
. O +

Methods O +
and O +
Findings O +
The O +
effects O +
of O +
three O +
SSRIs O +
( O -
fluvoxamine O -
, O +
sertraline O -
, O +
paroxetine O -
) O +
and O +
three O +
sigma-1 O +
receptor O +
agonists O +
( O -
SA4503 O -
, O +
4-phenyl-1- O -
( O -
4-phenylbutyl O -
) O +
piperidine O +
( O -
PPBP O -
) O -
, O +
and O +
dehydroepiandrosterone O +
( O -
DHEA O -
) O -
-sulfate O -
) O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
were O +
examined O -
. O +

Also O +
examined O +
were O +
the O +
effects O +
of O +
the O +
sigma-1 O +
receptor O +
antagonist O +
NE-100 O -
, O +
inositol O +
1,4,5-triphosphate O +
( O -
IP3 O -
) O +
receptor O +
antagonist O -
, O +
and O +
specific O +
inhibitors O +
of O +
signaling O +
pathways O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
selective O +
sigma-1 O +
receptor O +
agonist O +
SA4503 O -
. O +

Fluvoxamine O +
( O -
but O +
not O +
sertraline O +
or O +
paroxetine O -
) O +
and O +
the O +
sigma-1 O +
receptor O +
agonists O +
SA4503 O -
, O +
PPBP O -
, O +
and O +
DHEA O -
- O -
sulfate O +
significantly O +
potentiated O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O +

The O +
potentiation O +
by O +
fluvoxamine O +
and O +
the O +
three O +
sigma-1 O +
receptor O +
agonists O +
was O +
blocked O +
by O +
co O -
- O -
administration O +
of O +
the O +
selective O +
sigma-1 O +
receptor O +
antagonist O +
NE-100 O -
, O +
suggesting O +
that O +
sigma-1 O +
receptors O +
play O +
a O +
role O +
in O +
blocking O +
the O +
enhancement O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

Moreover O -
, O +
the O +
potentiation O +
by O +
SA4503 O +
was O +
blocked O +
by O +
co O -
- O -
administration O +
of O +
the O +
IP3 O +
receptor O +
antagonist O +
xestospongin O +
C. O +
In O +
addition O -
, O +
the O +
specific O +
inhibitors O +
of O +
phospholipase O +
C O +
( O -
PLC O -
- O -
γ O -
) O -
, O +
phosphatidylinositol O +
3-kinase O +
( O -
PI3 O -
K O -
) O -
, O +
p38MAPK O -
, O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O -
, O +
and O +
the O +
Ras O -
/ O -
Raf O -
/ O -
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
signaling O +
pathways O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
. O +

Conclusion O +
These O +
findings O +
suggest O +
that O +
stimulation O +
of O +
sigma-1 O +
receptors O +
and O +
subsequent O +
interaction O +
with O +
IP3 O +
receptors O -
, O +
PLC O -
- O -
γ O -
, O +
PI3 O -
K O -
, O +
p38MAPK O -
, O +
JNK O -
, O +
and O +
the O +
Ras O -
/ O -
Raf O -
/ O -
MAPK O +
signaling O +
pathways O +
are O +
involved O +
in O +
the O +
mechanisms O +
of O +
action O +
of O +
sigma-1 O +
receptor O +
agonists O +
such O +
as O +
fluvoxamine O +
and O +
SA4503 O -
. O +

Introduction O +
Selective O +
serotonin O +
( O -
5-HT O -
; O +
5-hydroxytryptamine O -
) O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
have O +
emerged O +
as O +
a O +
major O +
therapeutic O +
advance O +
in O +
psychopharmacology O -
. O +

SSRIs O +
are O +
the O +
treatment O +
of O +
choice O +
for O +
many O +
indications O -
, O +
including O +
major O +
depressive O +
disorder O -
, O +
dysthymia O -
, O +
panic O +
disorder O -
, O +
obsessive O -
- O -
compulsive O +
disorder O -
, O +
eating O +
disorders O -
, O +
and O +
premenstrual O +
dysphoric O +
disorder O -
. O +

In O +
contrast O -
, O +
it O +
is O +
well O +
known O +
that O +
their O +
pharmacology O +
is O +
quite O +
heterogeneous O -
, O +
although O +
all O +
of O +
them O +
block O +
5-HT O +
transporters O -
, O +
thus O +
increasing O +
5-HT O +
levels O +
throughout O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
[ O -
1 O -
] O -
– O -
[ O -
9 O -
] O -
. O +

Accumulating O +
evidence O +
suggests O +
that O +
sigma-1 O +
receptors O -
, O +
which O +
are O +
intracellular O +
endoplasmic O +
reticulum O +
( O -
ER O -
) O +
proteins O -
, O +
are O +
involved O +
in O +
both O +
the O +
neuroplasticity O +
and O +
pathophysiology O +
of O +
neuropsychiatric O +
diseases O +
such O +
as O +
major O +
depressive O +
disorder O -
, O +
anxiety O -
, O +
schizophrenia O -
, O +
and O +
Alzheimer O -
's O +
disease O +
[ O -
10 O -
] O -
– O -
[ O -
18 O -
] O -
. O +

Previously O -
, O +
we O +
reported O +
that O +
some O +
SSRIs O +
possess O +
high O +
to O +
moderate O +
affinities O +
for O +
sigma-1 O +
receptors O +
in O +
the O +
rat B-Species +
brain O -
. O +

The O +
rank O +
order O +
of O +
SSRIs O +
affinities O +
for O +
sigma-1 O +
receptors O +
is O +
fluvoxamine O +
( O -
Ki O +
= O +
36 O +
nM O -
) O -
>sertraline O +
( O -
Ki O +
= O +
57 O +
nM O -
) O -
>>paroxetine O +
( O -
Ki O +
= O +
1893 O +
nM O -
) O +
[ O -
19 O -
] O -
. O +

Recently O -
, O +
we O +
reported O +
that O +
fluvoxamine O -
, O +
but O +
not O +
paroxetine O -
, O +
significantly O +
ameliorated O +
cognitive O +
deficits O +
in O +
mice B-Species +
after O +
repeated O +
phencyclidine O +
administration O -
, O +
and O +
that O +
the O +
effects O +
of O +
fluvoxamine O +
were O +
antagonized O +
by O +
co O -
- O -
administration O +
of O +
the O +
selective O +
sigma-1 O +
receptor O +
antagonist O +
NE-100 O +
[ O -
20 O -
] O -
, O +
suggesting O +
that O +
sigma-1 O +
receptors O +
are O +
involved O +
in O +
the O +
mechanism O +
of O +
action O +
of O +
fluvoxamine O +
[ O -
9 O -
] O -
. O +

Interestingly O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
sigma-1 O +
receptor O +
agonists O +
including O +
fluvoxamine O +
could O +
potentiate O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O -
-induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O -
, O +
and O +
that O +
NE-100 O +
blocked O +
the O +
potentiation O +
by O +
sigma-1 O +
receptor O +
agonists O -
, O +
suggesting O +
sigma-1 O +
receptors O +
are O +
involved O +
in O +
neuroplasticity O +
[ O -
21 O -
] O -
. O +

However O -
, O +
the O +
precise O +
cellular O +
mechanisms O +
underlying O +
the O +
potentiation O +
by O +
sigma-1 O +
receptor O +
agonists O +
are O +
not O +
fully O +
understood O +
[ O -
13 O -
] O -
, O +
[ O -
21 O -
] O -
. O +

It O +
is O +
therefore O +
of O +
great O +
interest O +
to O +
study O +
the O +
precise O +
cellular O +
mechanisms O +
underlying O +
the O +
enhancement O +
by O +
fluvoxamine O +
on O +
NGF O -
- O -
induced O +
neurite O +
sprouting O +
in O +
PC12 O +
cells O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
examined O +
the O +
effects O +
of O +
three O +
SSRIs O +
( O -
fluvoxamine O -
, O +
sertraline O -
, O +
paroxetine O -
) O -
, O +
as O +
well O +
as O +
the O +
effects O +
of O +
a O +
sigma-1 O +
receptor O +
agonist O +
( O -
4-phenyl-1- O -
( O -
4-phenylbutyl O -
) O +
piperidine O +
( O -
PPBP O -
) O -
, O +
dehydroepiandrosterone O -
- O -
sulphate O +
( O -
DHEA O -
) O -
-sulfate O -
) O +
[ O -
9 O -
] O -
, O +
[ O -
22 O -
] O -
– O -
[ O -
28 O -
] O +
and O +
the O +
selective O +
sigma-1 O +
receptor O +
agonist O +
SA4503 O +
[ O -
29 O -
] O -
, O +
[ O -
30 O -
] O -
, O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O -
. O +

Furthermore O -
, O +
it O +
is O +
also O +
known O +
that O +
sigma-1 O +
receptors O +
have O +
been O +
shown O +
to O +
interact O +
with O +
IP3 O +
receptors O +
( O -
17,18 O -
) O -
. O +

Therefore O -
, O +
we O +
examined O +
the O +
effects O +
of O +
NE-100 O +
and O +
xestospongin O +
C O +
( O -
a O +
selective O +
inositol O +
1,4,5-triphosphate O +
( O -
IP3 O -
) O +
receptor O +
antagonist O -
) O +
[ O -
31 O -
] O +
in O +
order O +
to O +
investigate O +
the O +
roles O +
of O +
sigma-1 O +
receptors O +
and O +
IP3 O +
receptors O +
in O +
the O +
mechanisms O +
underlying O +
the O +
enhancement O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
. O +

Moreover O -
, O +
we O +
examined O +
the O +
effects O +
of O +
specific O +
inhibitors O +
of O +
several O +
cellular O +
signaling O +
targets O +
on O +
the O +
enhancement O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
, O +
since O +
several O +
signal O +
transduction O +
molecules O +
have O +
been O +
implicated O +
in O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
[ O -
32 O -
] O -
. O +

Materials O +
and O +
Methods O +
Drugs O +
The O +
drugs O +
were O +
obtained O +
from O +
the O +
following O +
sources O -
: O +
fluvoxamine O +
maleate O +
( O -
Solvay O +
Seiyaku O +
K.K. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
; O +
paroxetine O +
hydrochloride O -
, O +
dehydroepiandosterone O -
- O -
sulfate O +
( O -
DHEA O -
- O -
sulfate O -
) O -
, O +
LY294002 O +
( O -
Sigma O -
- O -
Aldrich O -
, O +
St O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
; O +
sertraline O +
( O -
Toronto O +
Research O +
Chemicals O +
Inc. O -
, O +
North O +
York O -
, O +
ON O -
, O +
Canada O -
) O -
; O +
SA4503 O +
( O -
M O -
's O +
Science O +
Corporation O -
, O +
Kobe O -
, O +
Japan O -
) O -
; O +
NGF O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
) O -
; O +
xestospongin O +
C O -
, O +
lovastatin O -
, O +
PD98059 O -
, O +
GW5074 O -
, O +
SB203580 O -
, O +
MEK O +
1 O -
/ O -
2 O +
inhibitor O +
( O -
SL327 O -
) O -
, O +
and O +
SP600125 O +
( O -
Calbiochem O -
- O -
Novabiochem O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O +

The O +
selective O +
sigma-1 O +
receptor O +
antagonists O +
NE-100 O +
and O +
4-phenyl-1- O -
( O -
4-phenylbutyl O -
) O +
piperidine O +
( O -
PPBP O -
) O +
were O +
synthesized O +
in O +
our O +
laboratory O -
. O +

Other O +
drugs O +
were O +
purchased O +
from O +
commercial O +
sources O -
. O +

Cell O +
culture O +
PC12 O +
sells O +
( O -
RIKEN O +
Cell O +
Bank O -
, O +
Tsukuba O -
, O +
Japan O -
) O +
were O +
cultured O +
at O +
37 O -
° O -
C O -
, O +
5 O -
% O +
CO2 O +
with O +
Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
( O -
DMEM O -
) O +
supplemented O +
with O +
5 O -
% O +
heat O -
- O -
inactivated O +
fetal O +
bovine B-Species +
serum O +
( O -
FBS O -
) O -
, O +
10 O -
% O +
heat O -
- O -
inactivated O +
horse B-Species +
serum O -
, O +
and O +
1 O -
% O +
penicillin O -
. O +

The O +
medium O +
was O +
changed O +
two O +
or O +
three O +
times O +
a O +
week O -
. O +

PC12 O +
cells O +
were O +
plated O +
onto O +
24-well O +
tissue O +
culture O +
plates O +
coated O +
with O +
poly O -
- O -
D O -
- O -
lysine O -
/ O -
laminin O -
. O +

Cells O +
were O +
plated O +
at O +
relatively O +
low O +
density O +
( O -
0.25 O -
× O -
104 O +
cells O -
/ O -
cm2 O -
) O +
in O +
DMEM O +
medium O +
containing O +
0.5 O -
% O +
FBS O -
, O +
1 O -
% O +
penicillin O +
streptomycin O -
. O +

Medium O +
containing O +
a O +
minimal O +
level O +
of O +
serum O +
( O -
0.5 O -
% O +
FBS O -
) O +
was O +
used O -
, O +
since O +
serum O +
is O +
known O +
to O +
contain O +
steroid O +
hormones O +
that O +
bind O +
to O +
sigma-1 O +
receptors O +
[ O -
21 O -
] O -
. O +

First O -
, O +
we O +
examined O +
the O +
optimal O +
concentration O +
of O +
NGF O +
for O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O -
. O +

NGF O +
( O -
2.5 O -
, O +
5 O -
, O +
10 O -
, O +
20 O -
, O +
40 O +
ng O -
/ O -
ml O -
) O +
increased O +
the O +
number O +
of O +
cells O +
with O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Figure O +
1 O -
) O -
. O +

In O +
the O +
subsequent O +
studies O -
, O +
2.5 O +
ng O -
/ O -
ml O +
of O +
NGF O +
was O +
used O +
to O +
study O +
the O +
potentiating O +
effects O +
of O +
sigma-1 O +
receptor O +
agonists O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

Twenty O -
- O -
four O +
hours O +
after O +
plating O -
, O +
the O +
medium O +
was O +
replaced O +
with O +
DMEM O +
medium O +
containing O +
0.5 O -
% O +
FBS O +
and O +
1 O -
% O +
penicillin O +
streptomycin O +
with O +
NGF O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O +
with O +
or O +
without O +
several O +
drugs O -
. O +

Quantification O +
of O +
neurite O +
sprouting O +
Five O +
days O +
after O +
incubation O +
with O +
NGF O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O +
with O +
or O +
without O +
the O +
several O +
drugs O -
, O +
morphometric O +
analysis O +
was O +
performed O +
on O +
digitized O +
images O +
of O +
live O +
cells O +
taken O +
under O +
phase O -
- O -
contrast O +
illumination O +
with O +
an O +
inverted O +
microscope O +
linked O +
to O +
a O +
camera O -
. O +

Images O +
of O +
three O +
fields O +
per O +
well O +
were O +
taken O -
, O +
with O +
an O +
average O +
of O +
100 O +
cells O +
per O +
field O -
. O +

Differentiated O +
cells O +
were O +
counted O +
by O +
visual O +
examination O +
of O +
the O +
field O -
; O +
only O +
cells O +
that O +
had O +
at O +
least O +
one O +
neurite O +
with O +
a O +
length O +
equal O +
to O +
the O +
cell O +
body O +
diameter O +
were O +
counted O -
, O +
and O +
were O +
then O +
expressed O +
as O +
a O +
percentage O +
of O +
the O +
total O +
cells O +
in O +
the O +
field O -
. O +

The O +
counting O +
was O +
performed O +
in O +
a O +
blinded O +
manner O -
. O +

Immunocytochemistry O +
Cells O +
were O +
fixed O +
for O +
30 O +
min O +
at O +
room O +
temperature O +
with O +
4 O -
% O +
paraformaldehyde O +
then O +
permeabilized O +
with O +
0.2 O -
% O +
Triton O +
and O +
blocked O +
with O +
1.5 O -
% O +
normal O +
goat B-Species +
serum O -
, O +
0.1 O -
% O +
bovine B-Species +
serum O +
albumin O +
( O -
BSA O -
) O +
in O +
0.1 O +
M O +
phosphate O -
- O -
buffer O +
saline O +
for O +
1 O +
h O +
to O +
reduce O +
nonspecific O +
binding O -
. O +

Cells O +
were O +
incubated O +
overnight O +
at O +
4 O -
° O -
C O +
with O +
anti O -
- O -
microtubule O -
- O -
associated O +
protein O +
2 O +
( O -
MAP-2 O -
) O +
antibodies O +
( O -
1∶1000 O +
dilution O +
in O +
blocking O +
solution O -
, O +
Chemicon O +
International O -
, O +
Temecula O -
, O +
CA O -
, O +
USA O -
) O -
. O +

The O +
immunolabeling O +
was O +
visualized O +
with O +
secondary O +
antibodies O +
conjugated O +
to O +
Alexa-488 O +
( O -
1∶1000 O -
; O +
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
, O +
USA O -
) O -
. O +

MAP-2 O +
immuncytochemistry O +
was O +
visualized O +
with O +
a O +
fluorescence O +
microscope O +
( O -
Axiovert O +
200 O -
, O +
Carl O +
Zeiss O -
, O +
Oberkocken O -
, O +
Germany O -
) O -
. O +

Statistical O +
analysis O +
Data O +
are O +
expressed O +
as O +
means±S.E.M. O +
Statistical O +
analysis O +
was O +
performed O +
by O +
using O +
one O -
- O -
way O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
and O +
the O +
post O +
hoc O +
Bonferroni O -
/ O -
Dunn O +
test O -
. O +

P O +
values O +
less O +
than O +
0.05 O +
were O +
considered O +
statistically O +
significant O -
. O +

Results O +
Effects O +
of O +
SSRIs O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
Fluvoxamine O +
( O -
0.1 O -
, O +
1.0 O -
, O +
or O +
10 O +
µM O -
) O +
significantly O +
increased O +
the O +
number O +
of O +
cells O +
with O +
neurite O +
outgrowth O +
by O +
NGF O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O +
in O +
PC12 O +
cells O -
, O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Figure O +
2 O +
and O +
4 O -
) O -
. O +

In O +
contrast O -
, O +
sertraline O +
( O -
0.1 O -
, O +
1.0 O -
, O +
or O +
10 O +
µM O -
) O +
and O +
paroxetine O +
( O -
0.1 O -
, O +
1.0 O -
, O +
or O +
10 O +
µM O -
) O +
did O +
not O +
increase O +
the O +
number O +
of O +
cells O +
with O +
neurite O +
outgrowth O +
by O +
NGF O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O -
. O +

A O +
higher O +
concentration O +
( O -
10 O +
µM O -
) O +
of O +
paroxetine O +
and O +
sertraline O +
significantly O +
decreased O +
the O +
number O +
of O +
cells O +
with O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
, O +
suggesting O +
the O +
cellular O +
toxicity O +
of O +
these O +
drugs O +
in O +
PC12 O +
cells O +
( O -
Figure O +
2 O -
) O -
. O +

Role O +
of O +
sigma-1 O +
receptors O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
fluvoxamine O +
and O +
SA4503 O +
The O +
selective O +
and O +
potent O +
sigma-1 O +
receptor O +
agonist O +
SA4503 O +
( O -
0.01 O -
, O +
0.1 O -
, O +
or O +
1.0 O +
µM O -
) O +
significantly O +
increased O +
the O +
number O +
of O +
cells O +
with O +
neurite O +
outgrowth O +
by O +
NGF O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O +
in O +
PC12 O +
cells O -
, O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Figure O +
3 O +
and O +
4 O -
) O -
. O +

In O +
addition O -
, O +
other O +
sigma-1 O +
receptor O +
agonists O -
– O -
PPBP O +
( O -
0.1 O -
, O +
1.0 O -
, O +
or O +
10 O +
µM O -
) O +
[ O -
22 O -
] O -
– O -
[ O -
26 O -
] O +
and O +
DHEA O -
- O -
sulphate O +
( O -
0.1 O -
, O +
1.0 O -
, O +
or O +
10 O +
µM O -
) O +
[ O -
9 O -
] O -
, O +
[ O -
27 O -
] O -
, O +
[ O -
28 O -
] O -
–significantly O +
increased O +
the O +
number O +
of O +
such O +
cells O -
, O +
also O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Figure O +
3 O -
) O -
. O +

In O +
the O +
absence O +
of O +
NGF O -
, O +
sigma-1 O +
receptor O +
agonists O +
did O +
not O +
produce O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O +

To O +
investigate O +
the O +
role O +
of O +
sigma-1 O +
receptors O -
, O +
we O +
examined O +
the O +
effects O +
of O +
NE-100 O +
( O -
a O +
selective O +
sigma-1 O +
receptor O +
antagonist O -
) O +
on O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
fluvoxamine O -
, O +
SA4503 O -
, O +
PPBP O -
, O +
and O +
DHEA O -
- O -
sulphate O -
. O +

Co O -
- O -
administration O +
of O +
NE-100 O +
( O -
1.0 O +
µM O -
) O +
significantly O +
blocked O +
such O +
potentiation O +
by O +
fluvoxamine O +
( O -
10 O +
µM O -
) O -
, O +
SA4503 O +
( O -
1.0 O +
µM O -
) O -
, O +
PPBP O +
( O -
10 O +
µM O -
) O -
, O +
or O +
DHEA O -
- O -
sulphate O +
( O -
10 O +
µM O -
) O +
( O -
Figure O +
2 O +
and O +
3 O -
) O -
. O +

Furthermore O -
, O +
administration O +
of O +
NE-100 O +
( O -
1.0 O +
µM O -
) O +
alone O +
did O +
not O +
alter O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
( O -
Figure O +
2 O -
) O -
. O +

Role O +
of O +
IP3 O +
receptors O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
Sigma-1 O +
receptors O +
have O +
been O +
shown O +
to O +
interact O +
with O +
IP3 O +
receptors O +
( O -
17,18,33–35 O -
) O -
. O +

To O +
investigate O +
the O +
role O +
of O +
IP3 O +
receptors O +
in O +
the O +
effects O +
of O +
SA4503 O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
, O +
we O +
examined O +
the O +
effects O +
of O +
xestospongin O +
C O +
( O -
a O +
selective O -
, O +
reversible O -
, O +
and O +
membrane O -
- O -
permeable O +
inhibitor O +
of O +
IP3 O +
receptors O -
) O +
[ O -
31 O -
] O +
on O +
the O +
effects O +
of O +
SA4503 O +
on O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

Co O -
- O -
administration O +
of O +
xestospongin O +
C O +
( O -
1.0 O +
µM O -
) O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
( O -
1.0 O +
µM O -
) O +
( O -
Figure O +
5 O -
) O -
. O +

Furthermore O -
, O +
administration O +
of O +
xestospongin O +
C O +
( O -
1.0 O +
µM O -
) O +
alone O +
did O +
not O +
alter O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
( O -
Figure O +
5 O -
) O -
. O +

Role O +
of O +
signaling O +
molecules O +
proximal O +
to O +
TrkA O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
Next O -
, O +
we O +
examined O +
the O +
effects O +
of O +
the O +
specific O +
inhibitors O +
of O +
PLC O -
- O -
γ O -
, O +
PI3 O -
K O -
, O +
p38 O +
MAPK O -
, O +
and O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O -
, O +
since O +
these O +
signaling O +
molecules O +
are O +
activated O +
upon O +
the O +
addition O +
of O +
NGF O +
[ O -
36 O -
] O -
. O +

The O +
PLC O -
- O -
γ O +
inhibitor O +
( O -
U73122 O -
; O +
1.0 O +
µM O -
) O -
, O +
PI3 O -
K O +
inhibitor O +
( O -
LY294002 O -
; O +
1.0 O +
µM O -
) O -
, O +
p38 O +
MAPK O +
inhibitor O +
( O -
SB203580 O -
; O +
1.0 O +
µM O -
) O -
, O +
and O +
JNK O +
inhibitor O +
( O -
SP600125 O -
; O +
1.0 O +
µM O -
) O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
( O -
1.0 O +
µM O -
) O +
( O -
Figure O +
6 O -
) O -
. O +

In O +
contrast O -
, O +
these O +
inhibitors O +
alone O +
did O +
not O +
alter O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
( O -
Figure O +
6 O -
) O -
. O +

Role O +
of O +
Raf O -
/ O -
Ras O -
/ O -
ERK O -
/ O -
MAPK O +
pathway O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
The O +
Raf O -
/ O -
Ras O -
/ O -
ERK O -
/ O -
MAPK O +
pathway O +
is O +
known O +
to O +
be O +
involved O +
in O +
NGF O -
- O -
induced O +
outgrowth O +
[ O -
32 O -
] O -
. O +

Therefore O -
, O +
we O +
examined O +
the O +
effects O +
of O +
this O +
pathway O -
's O +
specific O +
inhibitors O -
. O +

The O +
Ras O +
inhibitor O +
( O -
GW5074 O -
; O +
1.0 O +
µM O -
) O -
, O +
Raf O +
inhibitor O +
( O -
lovastatin O -
; O +
1.0 O +
µM O -
) O -
, O +
MEK1 O -
/ O -
2 O +
inhibitor O +
( O -
SL327 O -
; O +
1.0 O +
µM O -
) O -
, O +
and O +
MAPK O +
inhibitor O +
( O -
PD98059 O -
; O +
1.0 O +
µM O -
) O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O +
( O -
1.0 O +
µM O -
) O +
( O -
Figure O +
7 O -
) O -
. O +

In O +
contrast O -
, O +
these O +
inhibitors O +
alone O +
did O +
not O +
alter O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
( O -
Figure O +
7 O -
) O -
. O +

Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
found O +
that O +
fluvoxamine O +
( O -
but O +
not O +
sertraline O +
or O +
paroxetine O -
) O +
and O +
the O +
sigma-1 O +
receptor O +
agonists O +
( O -
SA4503 O -
, O +
PPBP O -
, O +
DHEA O -
- O -
sulfate O -
) O +
could O +
potentiate O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O -
, O +
and O +
that O +
the O +
effects O +
of O +
these O +
drugs O +
were O +
blocked O +
by O +
co O -
- O -
incubation O +
with O +
the O +
selective O +
sigma-1 O +
receptor O +
antagonist O +
NE-100 O -
. O +

These O +
findings O +
suggest O +
that O +
agonism O +
at O +
sigma-1 O +
receptors O +
for O +
these O +
drugs O +
is O +
involved O +
in O +
the O +
mechanisms O +
underlying O +
the O +
drugs O -
' O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

As O +
shown O +
in O +
Figure O +
1 O -
, O +
NGF O +
increased O +
the O +
number O +
of O +
cells O +
with O +
neurite O +
outgrowth O +
in O +
PC12 O -
, O +
in O +
a O +
concentration O +
dependent O +
manner O -
. O +

To O +
examine O +
whether O +
or O +
not O +
the O +
NGF O +
levels O +
are O +
altered O +
by O +
incubation O +
with O +
sigma-1 O +
receptor O +
agonists O -
, O +
we O +
measured O +
the O +
levels O +
of O +
NGF O +
in O +
PC12 O +
cells O +
with O +
or O +
without O +
sigma-1 O +
receptor O +
agonist O +
SA4503 O -
. O +

No O +
differences O +
of O +
NGF O +
levels O +
were O +
shown O +
in O +
the O +
between O +
control O +
group O +
and O +
SA4503-treated O +
group O +
( O -
data O +
not O +
shown O -
) O -
. O +

It O +
is O -
, O +
therefore O -
, O +
unlikely O +
that O +
the O +
potentaition O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
sigma-1 O +
receptor O +
agonists O +
might O +
be O +
due O +
to O +
increased O +
levels O +
of O +
NGF O -
. O +

Unlike O +
fluvoxamine O -
, O +
sertraline O -
, O +
which O +
has O +
a O +
moderate O +
affinity O +
for O +
sigma-1 O +
receptors O -
, O +
did O +
not O +
alter O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

The O +
reasons O +
underlying O +
this O +
discrepancy O +
between O +
these O +
two O +
SSRIs O +
are O +
currently O +
unclear O -
. O +

One O +
possibility O +
may O +
involve O +
the O +
difference O +
in O +
pharmacological O +
actions O +
( O -
agonist O +
vs. O +
antagonist O -
) O +
between O +
these O +
SSRIs O +
at O +
sigma-1 O +
receptors O -
. O +

Interestingly O -
, O +
we O +
recently O +
found O +
that O -
, O +
in O +
a O +
novel O +
object O +
recognition O +
test O -
, O +
phencyclidine O -
- O -
induced O +
cognitive O +
deficits O +
could O +
be O +
significantly O +
improved O +
by O +
subsequent O +
subchronic O +
( O -
14 O +
days O -
) O +
administration O +
of O +
fluvoxamine O -
, O +
but O +
not O +
of O +
sertraline O -
, O +
suggesting O +
that O +
sigma-1 O +
receptor O +
agonism O +
is O +
involved O +
in O +
fluvoxamine O -
's O +
mechanism O +
of O +
action O +
[ O -
9 O -
] O -
, O +
Ishima O +
et O +
al. O -
, O +
submitted O -
. O +

Taken O +
together O -
, O +
these O +
findings O +
suggest O +
that O +
fluvoxamine O +
and O +
sertraline O +
may O +
function O +
as O +
an O +
agonist O +
and O +
an O +
antagonist O +
at O +
sigma-1 O +
receptors O -
, O +
respectively O -
, O +
although O +
further O +
study O +
is O +
necessary O -
. O +

Another O +
possibility O +
may O +
be O +
that O +
other O +
pharmacological O +
activities O +
of O +
sertraline O +
mask O +
the O +
effects O +
of O +
sigma-1 O +
receptor O +
agonism O -
. O +

In O +
this O +
study O -
, O +
we O +
also O +
found O +
that O +
high O +
concentration O +
( O -
10 O +
µM O -
) O +
of O +
paroxetine O +
and O +
sertraline O -
, O +
but O +
not O +
fluvoxamine O -
, O +
showed O +
cytotoxicity O +
in O +
PC12 O +
cells O -
, O +
suggesting O +
that O +
fluvoxamine O +
may O +
be O +
a O +
safe O +
drug O +
than O +
paroxetine O +
and O +
sertraline O -
. O +

Sigma-1 O +
receptors O +
have O +
been O +
shown O +
to O +
affect O +
intracellular O +
Ca2 O -
+ O +
signaling O -
, O +
although O +
the O +
precise O +
molecular O +
and O +
cellular O +
mechanisms O +
underlying O +
this O +
effect O +
are O +
unknown O -
. O +

Sigma-1 O +
receptors O +
bind O +
to O +
IP3 O +
receptors O +
in O +
ER O -
, O +
and O +
sigma-1 O +
receptors O +
regulate O +
Ca2 O -
+ O +
release O +
from O +
intracellular O +
Ca2 O -
+ O +
storage O +
sites O +
[ O -
12 O -
] O -
. O +

Very O +
recently O -
, O +
Hayashi O +
and O +
Su O +
[ O -
17 O -
] O +
reported O +
that O +
sigma-1 O +
receptors O +
function O +
as O +
novel O +
ligand O -
- O -
operated O +
chaperones O +
that O +
specifically O +
target O +
mitochondrion O -
- O -
associated O +
ER O +
membrane O -
. O +

Furthermore O -
, O +
sigma-1 O +
receptors O +
form O +
Ca2 O -
+ O -
-sensitive O +
chaperone O +
machinery O +
with O +
another O +
chaperone O -
, O +
BiP O -
, O +
and O +
prolong O +
Ca2 O -
+ O +
signaling O +
from O +
ER O +
into O +
mitochondria O +
by O +
stabilizing O +
IP3 O +
receptors O +
at O +
mitochondrion O -
- O -
associated O +
ER O +
membrane O +
[ O -
17 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
found O +
that O +
the O +
IP3 O +
receptor O +
antagonist O +
xestospongin O +
C O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
, O +
suggesting O +
the O +
role O +
of O +
IP3 O +
receptors O +
on O +
sigma-1 O +
receptor O -
- O -
mediated O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

Therefore O -
, O +
it O +
is O +
likely O +
that O +
stimulation O +
at O +
sigma-1 O +
receptors O +
by O +
sigma-1 O +
receptor O +
agonists O +
and O +
subsequent O +
interaction O +
with O +
IP3 O +
receptors O +
are O +
involved O +
in O +
the O +
mechanism O +
underlying O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
sigma-1 O +
receptor O +
agonists O -
. O +

NGF O +
binds O +
to O +
the O +
high O -
- O -
affinity O +
tyrosine O +
receptor O +
TrkA O -
, O +
initiating O +
several O +
signaling O +
pathways O +
affecting O +
both O +
morphological O +
and O +
transcriptional O +
targets O +
[ O -
32 O -
] O -
, O +
[ O -
36 O -
] O -
, O +
[ O -
37 O -
] O -
. O +

The O +
signaling O +
molecules O -
, O +
including O +
PLC O -
- O -
γ O -
, O +
PI3 O -
K O -
, O +
p38 O +
MAPK O -
, O +
and O +
JNK O -
, O +
are O +
activated O +
upon O +
the O +
addition O +
of O +
NGF O +
[ O -
38 O -
] O -
. O +

PLC O -
- O -
γ O +
catalyzes O +
the O +
hydrolysis O +
of O +
phosphatidylinositol-4,5-bisphosphate O +
( O -
PIP2 O -
) O +
to O +
diacylglycerol O +
( O -
DAG O -
) O +
and O +
inositol O +
triphosphate O +
( O -
IP3 O -
) O -
. O +

DAG O +
activates O +
protein O +
kinase O +
C O -
, O +
and O +
IP3 O +
promotes O +
transient O +
release O +
of O +
Ca2 O -
+ O +
from O +
the O +
ER O +
[ O -
39 O -
] O -
. O +

The O +
pathway O +
via O +
PLC O -
- O -
γ O +
is O +
responsible O +
for O +
NGF O -
- O -
induced O +
cell O +
differentiation O +
[ O -
40 O -
] O +
and O +
neurite O +
outgrowth O +
[ O -
41 O -
] O -
. O +

Furthermore O -
, O +
stimulation O +
of O +
PI3 O -
K O +
is O +
reported O +
to O +
be O +
involved O +
in O +
the O +
promotion O +
of O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O +
[ O -
42 O -
] O -
. O +

In O +
this O +
study O -
, O +
we O +
found O +
that O +
the O +
PLC O -
- O -
γ O +
inhibitor O +
U73122 O +
and O +
the O +
PI3 O -
K O +
inhibitor O +
LY294002 O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
. O +

Moreover O -
, O +
we O +
found O +
that O +
both O +
the O +
p38MAPK O +
inhibitor O +
SB203580 O +
and O +
the O +
JNK O +
inhibitor O +
SP600125 O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
. O +

In O +
addition O -
, O +
it O +
is O +
also O +
interesting O +
that O +
neurite O +
outgrowth O +
induced O +
by O +
low O +
concentration O +
( O -
2.5 O +
ng O -
/ O -
ml O -
) O +
of O +
NGF O +
was O +
not O +
blocked O +
by O +
these O +
inihibitors O -
, O +
consistent O +
with O +
a O +
previous O +
report O +
[ O -
43 O -
] O -
, O +
[ O -
44 O -
] O -
, O +
suggesting O +
the O +
existence O +
of O +
novel O +
pathway O -
( O -
s O -
) O +
for O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O -
. O +

These O +
findings O +
suggest O +
that O +
the O +
PLC O -
- O -
γ O -
, O +
PI3 O -
K O -
, O +
p38MAPK O -
, O +
and O +
JNK O +
signaling O +
pathways O +
are O +
involved O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
sigma-1 O +
receptor O +
agonists O +
( O -
Figure O +
8) O -
. O +

In O +
addition O -
, O +
we O +
found O +
that O +
the O +
specific O +
inhibitors O +
for O +
the O +
Raf O -
/ O -
Ras O -
/ O -
MEK O -
/ O -
MAPK O +
pathways O +
significantly O +
blocked O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
SA4503 O -
, O +
suggesting O +
that O +
these O +
pathways O +
are O +
involved O +
in O +
the O +
potentiation O +
of O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
by O +
sigma-1 O +
receptor O +
agonists O +
( O -
Figure O +
8) O -
. O +

Our O +
recent O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
study O +
demonstrated O +
that O -
, O +
after O +
a O +
single O +
oral O +
administration O -
, O +
fluvoxamine O +
bound O +
to O +
sigma-1 O +
receptors O +
in O +
the O +
living O +
human B-Species +
brain O +
[ O -
45 O -
] O -
. O +

This O +
finding O +
suggests O +
that O +
sigma-1 O +
receptors O +
are O +
involved O +
in O +
the O +
mechanism O +
of O +
action O +
of O +
fluvoxamine O +
in O +
the O +
human B-Species +
brain O +
[ O -
45 O -
] O -
. O +

Taken O +
together O -
, O +
the O +
past O +
and O +
present O +
findings O +
suggest O +
that O -
, O +
unlike O +
paroxetine O +
and O +
sertraline O -
, O +
the O +
SSRI O +
fluvoxamine O -
, O +
with O +
its O +
sigma-1 O +
receptor O +
agonistic O +
activity O -
, O +
might O +
be O +
a O +
unique O +
therapeutic O +
drug O +
for O +
neuropsychiatric O +
diseases O -
. O +

In O +
conclusion O -
, O +
the O +
present O +
results O +
suggest O +
that O -
, O +
as O +
a O +
sigma-1 O +
receptor O +
agonist O -
, O +
fluvoxamine O +
could O +
potentiate O +
the O +
NGF O -
- O -
induced O +
neurite O +
outgrowth O +
in O +
PC12 O +
cells O -
. O +

Furthermore O -
, O +
it O +
is O +
likely O +
that O +
interaction O +
with O +
IP3 O +
receptors O +
and O +
several O +
subsequent O +
signaling O +
molecules O +
are O +
involved O +
in O +
the O +
mechanism O +
underlying O +
the O +
pharmacological O +
action O +
of O +
sigma-1 O +
receptor O +
agonists O -
. O +

Therefore O -
, O +
it O +
is O +
likely O +
that O +
sigma-1 O +
receptor O +
agonists O +
such O +
as O +
fluvoxamine O +
and O +
DHEA O -
- O -
sulfate O -
, O +
which O +
are O +
available O +
around O +
the O +
world O -
, O +
would O +
be O +
unique O +
therapeutic O +
drugs O +
for O +
neuropsychiatric O +
diseases O -
. O +

A O +
Novel O +
Role O +
of O +
the O +
NRF2 O +
Transcription O +
Factor O +
in O +
the O +
Regulation O +
of O +
Arsenite O -
- O -
Mediated O +
Keratin O +
16 O +
Gene O +
Expression O +
in O +
Human B-Species +
Keratinocytes O +
Abstract O +
Background O +
Inorganic O +
sodium O +
arsenite O +
( O -
iAs O -
) O +
is O +
a O +
ubiquitous O +
environmental O +
contaminant O +
and O +
is O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
skin O +
hyperkeratosis O +
and O +
cancer O -
. O +

Objectives O +
We O +
investigated O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
regulation O +
of O +
the O +
keratin O +
16 O +
( O -
K16 O -
) O +
gene O +
by O +
iAs O +
in O +
the O +
human B-Species +
keratinocyte O +
cell O +
line O +
HaCaT. O +
Methods O +
We O +
performed O +
reverse O +
transcriptase O +
polymerase O +
chain O +
reaction O -
, O +
luciferase O +
assays O -
, O +
Western O +
blots O -
, O +
and O +
electrophoretic O +
mobility O +
shift O +
assays O +
to O +
determine O +
the O +
transcriptional O +
regulation O +
of O +
the O +
K16 O +
gene O +
by O +
iAs O -
. O +

We O +
used O +
gene O +
overexpression O +
approaches O +
to O +
elucidate O +
the O +
nuclear O +
factor O +
erythroid O -
- O -
derived O +
2 O +
related O +
factor O +
2 O +
( O -
NRF2 O -
) O +
involved O +
in O +
the O +
K16 O +
induction O -
. O +

Results O +
iAs O +
induced O +
the O +
mRNA O +
and O +
protein O +
expression O +
of O +
K16 O -
. O +

We O +
also O +
found O +
that O +
the O +
expression O +
of O +
K16 O +
was O +
transcriptionally O +
induced O +
by O +
iAs O +
through O +
activator O +
protein-1–like O +
sites O +
and O +
an O +
antioxidant O +
response O +
element O +
( O -
ARE O -
) O +
in O +
its O +
gene O +
promoter O +
region O -
. O +

Treatment O +
with O +
iAs O +
also O +
enhanced O +
the O +
production O +
and O +
translocation O +
of O +
the O +
NRF2 O +
transcription O +
factor O -
, O +
an O +
ARE O -
- O -
binding O +
protein O -
, O +
into O +
the O +
nucleus O +
without O +
modification O +
of O +
its O +
mRNA O +
expression O -
. O +

In O +
addition O -
, O +
iAs O +
elongated O +
the O +
half O -
- O -
life O +
of O +
the O +
NRF2 O +
protein O -
. O +

When O +
overexpressed O +
in O +
HaCaT O +
cells O -
, O +
NRF2 O +
was O +
also O +
directly O +
involved O +
in O +
not O +
only O +
the O +
up O -
- O -
regulation O +
of O +
the O +
detoxification O +
gene O +
thioredoxin O +
but O +
also O +
K16 O +
gene O +
expression O -
. O +

Conclusions O +
Our O +
data O +
clearly O +
indicate O +
that O +
the O +
K16 O +
gene O +
is O +
a O +
novel O +
target O +
of O +
NRF2 O -
. O +

Furthermore O -
, O +
our O +
findings O +
also O +
suggest O +
that O +
NRF2 O +
has O +
opposing O +
roles O +
in O +
the O +
cell O -
— O -
in O +
the O +
activation O +
of O +
detoxification O +
pathways O +
and O +
in O +
promoting O +
the O +
development O +
of O +
skin O +
disorders O -
. O +

Inorganic O +
sodium O +
arsenite O +
( O -
iAs O -
) O -
, O +
a O +
ubiquitous O +
element O -
, O +
is O +
one O +
of O +
the O +
most O +
toxic O +
metals O +
present O +
in O +
the O +
natural O +
environment O +
( O -
Bagla O +
and O +
Kaiser O +
1996 O -
) O -
. O +

Arsenicals O +
are O +
found O +
as O +
naturally O +
occurring O +
constituents O +
of O +
soil O -
, O +
food O -
, O +
and O +
drinking O +
water O +
( O -
Wu O +
et O +
al. O +
1989 O -
; O +
Yoshida O +
et O +
al. O +
2004 O -
) O -
, O +
and O +
exposure O +
to O +
iAs O +
has O +
been O +
associated O +
with O +
a O +
variety O +
of O +
disease O +
outcomes O -
, O +
including O +
disorders O +
of O +
the O +
skin O -
, O +
urinary O +
bladder O -
, O +
liver O -
, O +
and O +
lung O +
( O -
Tchounwou O +
et O +
al. O +
2004 O -
) O -
. O +

In O +
particular O -
, O +
skin O +
hyperkeratosis O +
is O +
a O +
characteristic O +
dermatologic O +
lesion O +
associated O +
with O +
ingestion O +
of O +
arsenic O +
from O +
contaminated O +
groundwater O +
( O -
McLellan O +
2002 O -
; O +
Yoshida O +
et O +
al. O +
2004 O -
) O -
. O +

There O +
is O +
also O +
a O +
significant O +
association O +
between O +
hyperkeratosis O -
, O +
nonmelanoma O +
skin O +
cancer O +
( O -
e.g. O -
, O +
basal O +
cell O +
carcinoma O +
and O +
squamous O +
cell O +
carcinoma O -
) O -
, O +
and O +
Bowen O +
disease O +
( O -
Col O +
et O +
al. O +
1999 O -
; O +
Rossman O +
et O +
al. O +
2004 O -
) O -
. O +

Furthermore O -
, O +
the O +
pathologic O +
features O +
associated O +
with O +
arsenic O -
- O -
induced O +
hyperkeratosis O +
present O +
as O +
typical O +
acanthotic O +
types O +
of O +
psoriasis O -
- O -
like O +
keratosis O -
, O +
characterized O +
by O +
the O +
aberrant O +
proliferation O +
and O +
terminal O +
differentiation O +
of O +
epidermal O +
keratinocytes O +
( O -
Lee O +
et O +
al. O +
2006 O -
) O -
. O +

Many O +
epidemiologic O +
studies O +
have O +
shown O +
that O +
hyperkeratoses O +
are O +
the O +
most O +
frequent O +
precursor O +
lesions O +
of O +
some O +
skin O +
cancers O +
( O -
Bagla O +
and O +
Kaiser O +
1996 O -
; O +
Col O +
et O +
al. O +
1999 O -
) O -
. O +

The O +
keratins O +
are O +
the O +
most O +
prominent O +
cytoskeletal O +
proteins O +
in O +
keratinocytes O +
and O +
comprise O +
a O +
large O +
family O +
of O +
proteins O +
that O +
form O +
intermediate O +
filament O +
networks O +
in O +
all O +
epithelial O +
cell O +
types O +
( O -
Moll O +
et O +
al. O +
1982 O -
) O -
. O +

Keratin O +
16 O +
( O -
K16 O +
) O +
and O +
keratin O +
6 O +
( O -
K6 O -
) O +
genes O +
are O +
constitutively O +
expressed O +
in O +
a O +
number O +
of O +
stratified O +
epithelial O +
levels O -
, O +
including O +
the O +
palmar O +
and O +
plantar O +
epidermis O +
( O -
Moll O +
et O +
al. O +
1982 O -
) O -
. O +

In O +
skin O +
diseases O +
characterized O +
by O +
aberrant O +
proliferation O +
and O +
differentiation O -
, O +
such O +
as O +
psoriasis O +
and O +
cancer O -
, O +
K16 O +
is O +
detectable O +
at O +
higher O +
levels O +
compared O +
with O +
normal O +
tissue O +
( O -
Haider O +
et O +
al. O +
2006 O -
) O -
. O +

Furthermore O -
, O +
the O +
tissue O -
- O -
specific O +
overexpression O +
of O +
wild O -
- O -
type O +
K16 O +
in O +
the O +
epidermis O +
of O +
transgenic O +
mice B-Species +
results O +
in O +
the O +
hyperproliferation O +
of O +
keratinocytes O +
and O +
aberrant O +
keratinization O +
of O +
cornified O +
layers O -
, O +
leading O +
to O +
hyperkeratosis O +
of O +
the O +
skin O +
( O -
Takahashi O +
et O +
al. O +
1994 O -
) O -
. O +

Nuclear O +
factor O +
erythoid O -
- O -
derived O +
2 O +
related O +
factor O +
2 O +
( O -
NRF2 O -
) O -
, O +
a O +
" O -
cap O +
' O -
n O -
' O +
collar O -
" O +
basic O +
leucine O +
zipper O +
transcription O +
factor O -
, O +
regulates O +
a O +
transcriptional O +
program O +
that O +
maintains O +
cellular O +
redox O +
homeostasis O +
and O +
protects O +
cells O +
from O +
oxidative O +
stress O +
and O +
xenobiotic O +
agents O +
( O -
Ishii O +
et O +
al. O +
2000 O -
; O +
Moi O +
et O +
al. O +
1994 O -
) O -
. O +

Several O +
detoxifying O +
and O +
antioxidant O +
genes O -
, O +
including O +
glutathione O -
- O -
S O -
- O -
transferases O +
( O -
GSTs O -
) O -
, O +
heme O +
oxygenase-1 O +
( O -
HMOX1 O -
) O -
, O +
and O +
thioredoxin O +
( O -
TXN O -
) O -
, O +
are O +
regulated O +
by O +
NRF2 O +
through O +
the O +
antioxidant O +
responsive O +
element O +
( O -
ARE O -
) O +
in O +
the O +
respective O +
promoter O +
regions O +
of O +
these O +
genes O +
( O -
McMahon O +
et O +
al. O +
2001 O -
; O +
Wakabayashi O +
et O +
al. O +
2004 O -
) O -
. O +

NRF2 O +
is O +
held O +
in O +
the O +
cytoplasm O +
by O +
a O +
cytoskeletal O -
- O -
associated O +
specific O +
inhibitory O +
protein O +
( O -
kelch O -
- O -
like O +
ECH O -
- O -
associated O +
protein O +
1 O -
; O +
KEAP1 O -
) O +
under O +
normal O +
cellular O +
redox O +
state O +
conditions O -
, O +
where O +
it O +
is O +
continuously O +
targeted O +
by O +
the O +
proteasomal O +
degradation O +
pathway O +
( O -
McMahon O +
et O +
al. O +
2003 O -
) O -
. O +

Upon O +
exposure O +
of O +
the O +
cell O +
to O +
oxidative O +
stress O +
or O +
electrophiles O -
, O +
NRF2 O +
can O +
escape O +
this O +
KEAP1-mediated O +
repression O -
, O +
translocate O +
to O +
the O +
nucleus O -
, O +
and O +
activate O +
the O +
expression O +
of O +
its O +
target O +
genes O +
( O -
Dinkova O -
- O -
Kostova O +
et O +
al. O +
2002 O -
; O +
McMahon O +
et O +
al. O +
2003 O -
) O -
. O +

Recently O -
, O +
studies O +
of O +
Keap1– O -
/ O -
–mice O +
have O +
shown O +
that O +
NRF2 O +
accumulates O +
in O +
the O +
nucleus O +
and O +
constitutively O +
activates O +
the O +
transcription O +
of O +
its O +
target O +
genes O -
, O +
even O +
in O +
the O +
absence O +
of O +
stress O +
signals O +
( O -
Wakabayashi O +
et O +
al. O +
2003 O -
) O -
. O +

Most O +
interestingly O -
, O +
however O -
, O +
the O +
skin O -
, O +
esophagus O -
, O +
and O +
forestomach O +
of O +
Keap1-deficient O +
mice B-Species +
show O +
cornified O +
layer O +
and O +
hyperkeratosis O +
phenotypes O -
. O +

In O +
addition O -
, O +
previous O +
studies O +
have O +
also O +
shown O +
that O +
the O +
expression O +
of O +
NRF2 O +
and O +
ARE O -
- O -
controlled O +
genes O +
is O +
induced O +
by O +
iAs O +
in O +
some O +
cell O +
types O +
( O -
Pi O +
et O +
al. O +
2003 O -
; O +
Sakurai O +
et O +
al. O +
2005 O -
) O -
. O +

Furthermore O -
, O +
histochemical O +
analyses O +
have O +
indicated O +
that O +
the O +
expression O +
of O +
K16 O +
is O +
increased O +
in O +
Bowen O +
disease O -
, O +
basal O +
cell O +
carcinoma O -
, O +
and O +
squamous O +
cell O +
carcinoma O +
induced O +
by O +
arsenicals O +
( O -
Yu O +
et O +
al. O +
1993 O -
) O -
. O +

However O -
, O +
it O +
remains O +
to O +
be O +
determined O +
whether O +
NRF2 O +
can O +
regulate O +
the O +
transcriptional O +
activation O +
of O +
K16 O +
upon O +
iAs O +
exposure O +
in O +
human B-Species +
keratinocytes O -
. O +

Hence O -
, O +
these O +
findings O +
prompted O +
us O +
to O +
investigate O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
regulation O +
of O +
the O +
K16 O +
gene O +
by O +
iAs O -
- O -
induced O +
NRF2 O +
mediation O -
. O +

Materials O +
and O +
Methods O +
Chemicals O +
and O +
reagents O +
A O +
purified O +
preparation O +
of O +
inorganic O +
sodium O +
arsenite O +
( O -
iAs O -
; O +
NaAsO2 O -
; O +
Merck O -
, O +
Darmstadt O -
, O +
Germany O -
) O +
was O +
dissolved O +
in O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O +
and O +
added O +
directly O +
to O +
the O +
culture O +
medium O -
. O +

A O +
fresh O +
iAs O +
solution O +
was O +
prepared O +
for O +
each O +
new O +
experiment O -
. O +

Cycloheximide O +
( O -
CHX O -
) O -
, O +
dimethyl O -
- O -
sulfoxide O +
( O -
DMSO O -
) O -
, O +
and O +
a O +
protease O +
inhibitor O +
cocktail O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O +

CHX O +
was O +
dissolved O +
in O +
DMSO O +
and O +
stored O +
–20 O -
° O -
C O +
until O +
use O -
. O +

Cells O +
and O +
culture O +
conditions O +
The O +
human B-Species +
keratinocyte O +
HaCaT O +
cell O +
line O +
was O +
obtained O +
from O +
N.E. O +
Fusenig O +
( O -
German O +
Cancer O +
Research O +
Center O -
, O +
Heidelberg O -
, O +
Germany O -
) O -
. O +

Cells O +
were O +
maintained O +
in O +
monolayer O +
cultures O +
in O +
95 O -
% O +
air O +
and O +
5 O -
% O +
CO2 O +
at O +
37 O -
° O -
C O +
in O +
Dulbecco O -
's O +
modified O +
Eagles O +
medium O +
( O -
DMEM O -
) O +
supplemented O +
with O +
10 O -
% O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
) O -
, O +
50 O +
U O -
/ O -
mL O +
penicillin O +
and O +
50 O +
mg O -
/ O -
mL O +
streptomycin O +
and O +
nonessential O +
amino O +
acids O +
( O -
Gibco O +
BRL O -
, O +
Paisley O -
, O +
UK O -
) O -
. O +

RNA O +
preparation O +
and O +
semiquantitative O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O +
( O -
RT O -
- O -
PCR O -
) O +
analysis O +
We O +
determined O +
RNA O +
expression O +
levels O +
by O +
semiquantitative O +
RT O -
- O -
PCR O +
analysis O +
as O +
described O +
previously O +
( O -
Sugioka O +
et O +
al. O +
2004 O -
) O -
. O +

Total O +
RNA O +
was O +
isolated O +
from O +
HaCaT O +
cells O +
using O +
the O +
GeneElute O +
Mammalian O +
Total O +
RNA O +
Kit O +
( O -
Sigma O -
) O -
. O +

The O +
specific O +
primers O +
used O +
for O +
first O -
- O -
strand O +
cDNA O +
synthesis O +
and O +
PCR O +
were O +
as O +
follows O -
: O +
K16 O +
[ O -
forward O -
, O +
5′-GAT O +
GCT O +
TGC O +
TCT O +
GAG O +
AGG O +
TC-3′ O -
, O +
and O +
reverse O -
, O +
5′-CCA O +
GCA O +
AGA O +
TCT O +
GGT O +
ACT O +
CC-3′ O -
; O +
Gene O +
Bank O +
accession O +
no. O +
NM_005557 O +
( O -
National O +
Center O +
for O +
Biotechnology O +
Information O +
2007 O -
) O -
] O -
; O +
c O -
- O -
Jun O +
( O -
forward O -
, O +
5′-CCT O +
GTT O +
GCG O +
GCC O +
CCG O +
AAA O +
CT-3′ O -
, O +
and O +
reverse O -
, O +
5′-ACC O +
ATG O +
CCT O +
GCC O +
CCG O +
TTG O +
AC-3′ O -
; O +
NM_002228 O -
) O -
; O +
c O -
- O -
Fos O +
( O -
forward O -
, O +
5′-TTT O +
GCC O +
TAA O +
CCG O +
CCA O +
CGA O +
TGA O +
T-3′ O -
, O +
and O +
reverse O -
, O +
5′-TTG O +
CCG O +
CTT O +
TCT O +
GCC O +
ACC O +
TC-3′ O -
; O +
NM_005252 O -
) O -
; O +
NRF2 O +
( O -
forward O -
, O +
5′-AGA O +
TTC O +
ACA O +
GGC O +
CTT O +
TCT O +
CG-3′ O -
, O +
and O +
reverse O -
, O +
5′-CAG O +
CTC O +
TCC O +
CTA O +
CCG O +
TTG O +
GA-3′ O -
; O +
AF323119 O -
) O -
; O +
KEAP1 O +
( O -
forward O -
, O +
5′-CAG O +
AGG O +
TGG O +
TGG O +
TGT O +
TGC O +
TTA O +
T-3′ O -
, O +
and O +
reverse O -
, O +
5′-AGC O +
TCG O +
TTC O +
ATG O +
ATG O +
CCA O +
AAG-3′ O -
; O +
NM_012289 O -
) O -
; O +
TXN O +
( O -
forward O -
, O +
5′-CAG O +
GGG O +
AAT O +
GAA O +
AGA O +
AAG O +
G-3′ O -
, O +
and O +
reverse O -
, O +
5′-CAA O +
GGT O +
GAA O +
GCA O +
GAT O +
CG-3′ O -
; O +
NM_003329 O -
) O -
, O +
and O +
glyceraldehyde O +
3-phosphate O +
dehydrogenase O +
( O -
GAPDH O -
) O +
as O +
a O +
loading O +
control O +
( O -
forward O -
, O +
5′-ACC O +
ACA O +
GTC O +
CAT O +
GCC O +
ATC O +
AC-3′ O -
, O +
and O +
reverse O -
, O +
5′-TCC O +
ACC O +
ACC O +
CTG O +
TTG O +
CTG O +
TA-3′ O -
, O +
NM_002046 O -
) O -
. O +

PCR O +
products O +
were O +
separated O +
on O +
a O +
1.8 O -
% O +
agarose O +
gel O +
and O +
stained O +
with O +
ethidium O +
bromide O -
. O +

Western O +
blot O +
analysis O +
We O +
performed O +
Western O +
blot O +
analysis O +
as O +
described O +
previously O +
( O -
Sugioka O +
et O +
al. O +
2004 O -
) O -
. O +

Briefly O -
, O +
nuclear O +
and O +
cytoplasmic O +
proteins O +
were O +
extracted O +
using O +
the O +
NE O -
- O -
PER O +
nuclear O +
and O +
cytoplasmic O +
extraction O +
kit O +
( O -
Pierce O -
, O +
Rockford O -
, O +
IL O -
, O +
USA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

For O +
protein O +
extraction O -
, O +
the O +
cells O +
were O +
lysed O +
in O +
a O +
buffer O +
containing O +
complete O +
protease O +
inhibitor O +
cocktail O -
. O +

We O +
measured O +
protein O +
concentrations O +
using O +
the O +
DC O +
Protein O +
Assay O +
Kit O +
( O -
Bio O -
- O -
Rad O -
, O +
Richmond O -
, O +
CA O -
, O +
USA O -
) O -
. O +

Equal O +
amounts O +
of O +
protein O +
were O +
then O +
resolved O +
by O +
sodium O +
dodecyl O +
sulfate O -
- O -
polyacrylamide O +
gel O +
electrophoresis O +
( O -
SDS O -
- O -
PAGE O -
) O +
and O +
transferred O +
to O +
a O +
polyvinylidene O +
fluoride O +
membrane O +
( O -
Amersham O +
Biosciences O -
, O +
Bucks O -
, O +
UK O -
) O -
. O +

Immunoblotting O +
was O +
carried O +
out O +
with O +
specific O +
antibodies O +
in O +
Tris O -
- O -
buffered O +
saline O +
with O +
0.05 O -
% O +
Tween O +
20 O -
. O +

The O +
primary O +
antibodies O +
were O +
as O +
follows O -
: O +
K16 O +
( O -
Neomarkers O -
, O +
Fremont O -
, O +
CA O -
, O +
USA O -
) O -
, O +
NRF2 O +
and O +
KEAP1 O +
( O -
Santa O +
Cruz O +
Biotechnology O -
, O +
Santa O +
Cruz O -
, O +
CA O -
, O +
USA O -
) O -
, O +
c O -
- O -
Jun O +
( O -
Cell O +
Signaling O -
, O +
Beverly O -
, O +
MA O -
, O +
USA O -
) O -
, O +
and O +
β O -
- O -
actin O +
( O -
Sigma O -
) O -
. O +

After O +
washing O -
, O +
the O +
membranes O +
were O +
probed O +
with O +
horseradish B-Species +
peroxidase O -
- O -
conjugated O +
secondary O +
antibodies O +
and O +
developed O +
by O +
chemiluminescence O +
using O +
the O +
ECL O +
Plus O +
Detection O +
Kit O +
( O -
Amersham O +
Biosciences O -
) O -
. O +

Plasmids O -
, O +
transfections O -
, O +
and O +
luciferase O +
assays O +
Human B-Species +
K16 O +
promoter O +
regions O +
of O +
varying O +
lengths O +
( O -
pXK-1 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
- O -
1 O -
, O +
and O +
5 O -
- O -
2 O -
) O +
were O +
provided O +
by O +
Y O -
- O -
N O +
Wang O +
( O -
National O +
Cheng O +
Kung O +
University O -
, O +
Taiwan O -
) O -
. O +

These O +
DNA O +
fragments O +
were O +
prepared O +
from O +
HaCaT O +
cells O +
and O +
were O +
ligated O +
into O +
the O +
pXP-1 O +
luciferase O +
vector O +
( O -
Wang O +
and O +
Chang O +
2003 O -
) O -
. O +

The O +
p3xARE O -
/ O -
Luc O +
vector O -
, O +
harboring O +
three O +
tandem O +
repeats O +
of O +
ARE O -
, O +
was O +
donated O +
by O +
X.L. O +
Chen O +
( O -
Discovery O +
Research O -
, O +
AtheroGenics O +
Inc. O -
, O +
Alpharetta O -
, O +
GA O -
, O +
USA O -
) O +
( O -
Chen O +
et O +
al. O +
2003 O -
) O -
. O +

The O +
wild O -
- O -
type O +
NRF2 O +
expression O +
vector O +
( O -
WT O -
- O -
NRF2 O -
) O +
was O +
a O +
gift O +
from O +
H.S. O +

So O +
( O -
Wonkwang O +
University O +
School O +
of O +
Medicine O -
, O +
Korea O -
) O +
( O -
So O +
et O +
al. O +
2006 O -
) O -
. O +

NRF2 O +
cDNA O +
was O +
subcloned O +
into O +
a O +
pcDNA3.1 O -
( O -
+ O -
) O +
vector O +
( O -
Invitrogen O -
, O +
San O +
Diego O -
, O +
CA O -
, O +
USA O -
) O -
. O +

For O +
the O +
transfection O +
of O +
reporter O +
plasmids O -
, O +
we O +
seeded O +
HaCaT O +
cells O +
into O +
six O -
- O -
well O +
plates O +
at O +
a O +
density O +
of O +
80 O -
% O +
the O +
previous O +
day O -
. O +

Cells O +
were O +
then O +
transfected O +
with O +
a O +
total O +
of O +
each O +
luciferase O +
reporter O +
construct O +
( O -
2.5 O +
μg O -
) O +
using O +
LipofectAMINE O +
plus O +
( O -
Invitrogen O -
) O -
. O +

To O +
control O +
for O +
the O +
efficiency O +
of O +
transfection O -
, O +
Renilla O +
luciferase O +
gene O +
expression O +
was O +
monitored O +
using O +
either O +
the O +
pRL O -
- O -
CMV O +
or O +
pRL O -
- O -
TK O +
vectors O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
USA O -
) O -
. O +

For O +
overexpression O +
of O +
WT O -
- O -
NRF2 O -
, O +
we O +
normalized O +
the O +
total O +
plasmid O +
concentration O +
using O +
the O +
pcDNA3.1 O -
( O -
+ O -
) O +
empty O +
vector O -
. O +

Thirty O -
- O -
six O +
hours O +
after O +
transfection O -
, O +
the O +
medium O +
was O +
replaced O +
with O +
fresh O +
medium O +
containing O +
either O +
vehicle O +
( O -
PBS O -
) O +
or O +
iAs O +
for O +
6 O +
hr O -
. O +

After O +
iAs O +
exposure O -
, O +
we O +
harvested O +
cells O +
and O +
analyzed O +
them O +
for O +
luciferase O +
activity O +
using O +
a O +
Dual O -
- O -
Luciferase O +
Reporter O +
Assay O +
System O +
( O -
Promega O -
) O -
. O +

For O +
the O +
investigation O +
of O +
the O +
role O +
of O +
NRF2 O +
in O +
regulating O +
K16 O +
gene O +
expression O -
, O +
transfection O +
of O +
an O +
NRF2 O +
expression O +
plasmid O +
into O +
HaCaT O +
cells O +
was O +
carried O +
out O +
using O +
LipofectAMINE O +
2000 O +
( O -
Invitrogen O -
) O -
. O +

Cells O +
were O +
cultured O +
in O +
100-mm O +
plates O +
24 O +
hr O +
before O +
transfection O -
. O +

The O +
expression O +
plasmid O +
WT O -
- O -
NRF2 O +
( O -
15 O +
μg O -
) O +
was O +
then O +
transfected O +
into O +
the O +
cells O +
for O +
48–60 O +
hr O -
. O +

As O +
a O +
negative O +
control O -
, O +
we O +
used O +
15 O +
μg O +
of O +
the O +
pcDNA3.1 O -
( O -
+ O -
) O +
empty O +
vector O -
. O +

Electrophoretic O +
mobility O -
- O -
shift O +
assays O +
( O -
EMSA O -
) O +
We O +
extracted O +
and O +
measured O +
nuclear O +
proteins O +
as O +
described O +
above O -
. O +

Nuclear O +
protein O -
/ O +
DNA O +
complexes O +
were O +
subjected O +
to O +
electrophoresis O +
in O +
nondenaturing O +
5 O -
% O +
polyacrylamide O +
gels O +
containing O +
2 O -
% O +
glycerol O +
in O +
0.25 O -
% O +
Tris O -
- O -
borate O -
/ O -
EDTA O +
buffer O +
and O +
transferred O +
to O +
Hybond O -
- O -
N+ O +
nylon O +
transfer O +
membranes O +
( O -
Amersham O +
Biosciences O -
) O +
for O +
detection O +
using O +
the O +
Light O -
- O -
Shift O +
EMSA O +
kit O +
( O -
Pierce O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
, O +
with O +
minor O +
modifications O -
. O +

We O +
incubated O +
10-μg O +
aliquots O +
of O +
nuclear O +
extract O +
with O +
the O +
DNA O +
probe O +
in O +
a O +
binding O +
reaction O +
buffer O +
containing O +
10 O +
mM O +
Tris O -
/ O -
HCl O +
( O -
pH O +
7.6 O -
) O -
, O +
50 O +
mM O +
KCl O -
, O +
0.5 O +
mM O +
dithiothreitol O -
, O +
0.25 O +
mM O +
EDTA O -
, O +
5 O -
% O +
glycerol O -
, O +
2.5 O +
mM O +
MgCl2 O -
, O +
0.05 O -
% O +
NP-40 O +
detergent O -
, O +
and O +
2 O +
μg O +
of O +
poly O -
( O -
dI O -
- O -
dC O -
) O -
·poly O -
( O -
dI O -
- O -
dC O -
) O +
for O +
30 O +
min O +
at O +
room O +
temperature O -
. O +

For O +
supershift O +
assays O -
, O +
2 O +
μg O +
of O +
either O +
a O +
polyclonal O +
anti O -
- O -
NRF2 O +
or O +
an O +
anti O -
- O -
c O -
- O -
Jun O +
antibody O +
( O -
Santa O +
Cruz O +
Biotechnology O -
) O +
was O +
added O +
with O +
the O +
nuclear O +
protein O +
for O +
2 O +
hr O +
at O +
4 O -
° O -
C O +
before O +
the O +
labeled O +
oligonucleotide O +
probe O +
was O +
added O -
. O +

Biotin O -
- O -
labeled O -
, O +
double O -
- O -
stranded O +
oligonucleotides O +
WT O -
- O -
K16ARE O +
( O -
–157 O -
/ O -
–132 O -
, O +
5′-GGGGAACCTGGAGTCAGCAGT O -
- O -
TAGGA-3′ O -
) O -
, O +
containing O +
an O +
ARE O +
site O +
( O -
–148 O -
/ O +
–140 O -
, O +
underlined O -
) O +
in O +
the O +
human B-Species +
K16 O +
promoter O +
region O -
, O +
and O +
Mut O -
- O -
K16ARE O +
( O -
5′-GGGGAA O -
- O -
CCTGGAGTCAaaAGTTAGGA-3′ O -
, O +
mutated O +
GC O +
box O +
in O +
the O +
ARE O -
) O +
were O +
prepared O +
by O +
Fasmac O +
( O -
Kanagawa O -
, O +
Japan O -
) O -
. O +

A O +
consensus O +
ARE O +
probe O +
was O +
purchased O +
from O +
Panomics O -
, O +
Inc. O +
( O -
Redwood O +
City O -
, O +
CA O -
, O +
USA O -
) O -
. O +

For O +
competition O +
binding O +
of O +
the O +
K16 O +
ARE O -
- O -
complexes O -
, O +
we O +
used O +
an O +
unlabeled O +
AP-1 O +
consensus O +
oligonucleotide O +
( O -
5′-TATC O -
- O -
GATAAGCTATGAGTCATCCGGG-3′ O -
) O -
. O +

The O +
binding O +
specificity O +
was O +
confirmed O +
in O +
each O +
case O +
by O +
the O +
addition O +
of O +
a O +
100-fold O +
molar O +
excess O +
of O +
unlabeled O +
oligonucleotide O -
. O +

CHX O +
chase O +
experiment O +
We O +
investigated O +
the O +
posttranscriptional O +
regulation O +
of O +
both O +
the O +
steady O -
- O -
state O +
levels O +
and O +
half O -
- O -
life O +
of O +
the O +
NRF2 O +
protein O +
by O +
CHX O +
chase O +
analysis O -
. O +

Cells O +
were O +
incubated O +
in O +
serum O -
- O -
free O +
medium O +
in O +
the O +
absence O +
or O +
presence O +
of O +
iAs O +
for O +
6 O +
hr O -
. O +

The O +
culture O +
medium O +
was O +
then O +
replaced O +
with O +
serum O -
- O -
free O +
medium O +
containing O +
CHX O +
( O -
100 O +
μg O -
/ O -
mL O -
) O -
. O +

We O +
prepared O +
cell O +
lysates O +
at O +
0 O -
, O +
10 O -
, O +
30 O -
, O +
60 O -
, O +
120 O -
, O +
and O +
240 O +
min O +
after O +
iAs O +
treatment O -
. O +

Whole O -
- O -
cell O +
lysates O +
were O +
resolved O +
by O +
SDS O -
- O -
PAGE O +
and O +
immunoblotted O +
with O +
antibodies O +
against O +
NRF2 O -
. O +

Statistics O +
All O +
the O +
data O +
generated O +
from O +
at O +
least O +
three O +
independent O +
experiments O +
and O +
expressed O +
as O +
the O +
mean O +
± O +
SD O +
were O +
analyzed O +
by O +
the O +
Student O -
's O +
t O -
- O -
test O -
. O +

Statistical O +
comparisons O +
were O +
made O +
by O +
logarithmic O +
transformation O +
of O +
the O +
normalized O +
values O -
. O +

We O +
considered O +
p O -
- O -
values O +
< O +
0.01 O +
to O +
be O +
statistically O +
significant O -
. O +

Results O +
K16 O +
expression O +
is O +
induced O +
by O +
iAs O +
in O +
HaCaT O +
cells O +
We O +
wanted O +
to O +
determine O +
whether O +
the O +
K16 O +
mRNA O +
is O +
transcriptionally O +
regulated O +
by O +
iAs O -
, O +
and O +
treated O +
HaCaT O +
cells O +
with O +
this O +
compound O +
for O +
various O +
time O +
periods O +
over O +
a O +
range O +
of O +
doses O -
. O +

After O +
treatment O +
of O +
HaCaT O +
cells O +
with O +
1–20 O +
μM O +
iAs O -
, O +
the O +
expression O +
of O +
K16 O +
mRNA O +
was O +
increased O +
compared O +
with O +
the O +
control O +
at O +
6 O +
hr O +
( O -
Figure O +
1A O -
) O +
but O +
had O +
declined O +
to O +
basal O +
levels O +
at O +
24 O +
hr O -
. O +

The O +
increase O +
in O +
the O +
K16 O +
protein O +
levels O +
after O +
6 O +
hr O +
of O +
iAs O +
exposure O +
was O +
just O +
detectable O +
at O +
10–20 O +
μM O -
, O +
but O +
a O +
dose O -
- O -
dependent O +
increase O +
was O +
more O +
evident O +
at O +
10 O +
hr O +
( O -
Figure O +
1B O -
) O -
. O +

This O +
enhancement O +
of O +
K16 O +
expression O +
had O +
declined O +
to O +
basal O +
levels O +
at O +
24 O +
hr O -
. O +

Identification O +
of O +
the O +
iAs O +
responsive O +
region O +
in O +
the O +
K16 O +
gene O +
promoter O +
To O +
investigate O +
the O +
mechanisms O +
underlying O +
the O +
transactivation O +
of O +
the O +
K16 O +
gene O +
by O +
iAs O -
, O +
we O +
first O +
examined O +
the O +
response O +
of O +
the O +
K16 O +
regulatory O +
region O +
to O +
this O +
compound O +
using O +
a O +
luciferase O +
reporter O +
gene O +
assay O -
. O +

The O +
dose O -
- O -
dependent O +
activation O +
of O +
K16 O +
transcription O +
after O +
iAs O +
treatment O +
was O +
observed O +
with O +
a O +
construct O +
containing O +
a O +
515-bp O +
fragment O +
of O +
the O +
K16 O +
promoter O +
( O -
Figure O +
2A O -
) O -
. O +

To O +
further O +
elucidate O +
the O +
region O +
containing O +
the O +
iAs O +
responsive O +
element O -
, O +
we O +
examined O +
a O +
series O +
of O +
deletions O +
of O +
the O +
5′-flanking O +
region O +
of O +
K16 O +
gene O -
. O +

The O +
ARE O +
sequence O +
in O +
the O +
pXK-5–1 O +
vector O +
contains O +
an O +
activator O +
protein-1 O +
( O -
AP-1 O -
) O -
–like O +
element O +
followed O +
by O +
a O +
GC O +
box O -
. O +

As O +
shown O +
in O +
Figure O +
2B O -
, O +
an O +
enhancement O +
in O +
the O +
reporter O +
activity O +
levels O +
was O +
observed O +
for O +
the O +
promoter O +
constructs O -
, O +
pXK-1 O -
, O +
3 O -
, O +
4 O -
, O +
and O +
5 O -
- O -
1 O -
, O +
in O +
response O +
to O +
20 O +
μM O +
iAs O -
. O +

A O +
decline O +
in O +
reporter O +
activity O -
, O +
however O -
, O +
depended O +
on O +
the O +
number O +
of O +
AP-1–like O +
sites O -
, O +
and O +
the O +
results O +
for O +
the O +
pXK-5 O -
- O -
1 O +
construct O +
show O +
also O +
that O +
ARE O +
is O +
activated O +
by O +
iAs O -
. O +

In O +
contrast O -
, O +
no O +
significant O +
activation O +
was O +
observed O +
using O +
a O +
pXK-5 O -
- O -
2 O +
construct O +
in O +
response O +
to O +
20 O +
μM O +
iAs O -
. O +

Expression O +
of O +
AP-1 O +
transcriptions O +
factor O +
and O +
c O -
- O -
Jun O +
production O +
following O +
iAs O +
treatment O +
We O +
examined O +
AP-1 O +
transcription O +
factors O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
expression O +
in O +
iAs O -
- O -
treated O +
HaCaT O +
cells O +
by O +
semiquantitative O +
RT O -
- O -
PCR O -
. O +

iAs O -
- O -
induced O +
c O -
- O -
Jun O +
expression O +
was O +
observed O +
during O +
the O +
first O +
3 O +
hr O +
after O +
treatment O +
( O -
data O +
not O +
shown O -
) O -
. O +

An O +
appreciable O +
induction O +
of O +
c O -
- O -
Jun O +
was O +
also O +
confirmed O +
after O +
6 O +
hr O -
, O +
but O +
this O +
was O +
down O -
- O -
regulated O +
by O +
24 O +
hr O +
after O +
iAs O +
treatment O +
( O -
Figure O +
3A O -
) O -
. O +

In O +
contrast O -
, O +
the O +
expression O +
of O +
c O -
- O -
Fos O +
was O +
only O +
transiently O +
detectable O +
at O +
3 O +
hr O +
( O -
data O +
not O +
shown O -
) O +
but O +
was O +
not O +
observed O +
during O +
the O +
6–24 O +
hr O +
period O +
of O +
this O +
experiment O -
. O +

As O +
shown O +
in O +
Figure O +
3B O -
, O +
iAs O -
- O -
enhanced O +
c O -
- O -
Jun O +
production O +
can O +
be O +
observed O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
at O +
6 O +
hr O -
, O +
but O +
it O +
declines O +
from O +
10 O +
to O +
24 O +
hr O -
. O +

iAs O +
potently O +
induces O +
the O +
translocation O +
of O +
NRF2 O +
and O +
activates O +
the O +
ARE O +
of O +
the O +
K16 O +
promoter O +
The O +
results O +
of O +
our O +
reporter O +
assays O +
suggested O +
that O +
iAs O +
stimulates O +
not O +
only O +
the O +
AP-1–like O +
sites O +
but O +
also O +
the O +
ARE O +
site O +
within O +
the O +
K16 O +
gene O +
promoter O +
in O +
HaCaT O +
cells O +
( O -
Figure O +
3 O -
) O -
. O +

In O +
addition O -
, O +
several O +
oxidative O +
stress O +
agents O +
and O +
toxic O +
chemicals O -
, O +
including O +
iAs O -
, O +
have O +
been O +
reported O +
to O +
induce O +
the O +
expression O +
of O +
ARE O -
- O -
dependent O +
genes O +
in O +
several O +
cell O +
types O +
( O -
Pi O +
et O +
al. O +
2003 O -
; O +
Sakurai O +
et O +
al. O +
2005 O -
) O -
. O +

On O +
the O +
basis O +
of O +
our O +
observations O +
and O +
some O +
recent O +
reports O -
, O +
we O +
thus O +
hypothesized O +
that O +
iAs O +
would O +
have O +
the O +
ability O +
to O +
activate O +
the O +
ARE O +
of O +
the O +
K16 O +
gene O +
promoter O +
directly O -
, O +
resulting O +
in O +
the O +
induction O +
of O +
K16 O +
expression O +
in O +
HaCaT O +
cells O -
. O +

To O +
confirm O +
that O +
the O +
K16 O +
ARE O +
indeed O +
functions O +
as O +
an O +
iAs O -
- O -
responsive O +
transcriptional O +
control O +
element O -
, O +
we O +
performed O +
transient O +
transfections O +
of O +
HaCaT O +
cells O +
with O +
a O +
p3xARE O -
/ O -
Luc O +
construct O +
and O +
then O +
subjected O +
these O +
cells O +
to O +
iAs O +
for O +
6 O +
hr O -
. O +

As O +
shown O +
in O +
Figure O +
4A O -
, O +
treatment O +
of O +
HaCaT O +
cells O +
with O +
iAs O +
results O +
in O +
a O +
dramatic O +
increase O +
in O +
ARE O -
- O -
driven O +
promoter O +
activity O -
. O +

Likewise O -
, O +
EMSA O +
using O +
a O +
consensus O +
ARE O +
probe O +
show O +
that O +
iAs O -
- O -
induced O +
ARE O -
- O -
binding O +
complexes O +
increase O +
markedly O -
, O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
( O -
Figure O +
4B O -
) O -
. O +

These O +
results O +
indicate O +
that O +
iAs O +
has O +
the O +
ability O +
to O +
activate O +
the O +
ARE O -
- O -
driven O +
genes O -
. O +

We O +
performed O +
further O +
EMSA O +
experiments O +
using O +
an O +
ARE O +
probe O +
specific O +
to O +
the O +
K16 O +
proximal O +
promoter O +
region O +
( O -
WT O -
- O -
K16ARE O -
) O +
and O +
found O +
that O +
K16ARE O -
– O -
nuclear O +
protein O +
complexes O +
formation O +
is O +
augmented O +
by O +
iAs O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Figure O +
4C O -
) O -
. O +

Moreover O -
, O +
the O +
formation O +
of O +
these O +
complexes O +
is O +
specifically O +
inhibited O +
by O +
the O +
addition O +
of O +
excess O +
unlabeled O +
oligonucleotide O +
competitor O +
( O -
Figure O +
4B O -
, O -
C O -
) O -
, O +
whereas O +
an O +
excess O +
of O +
an O +
unlabeled O +
AP-1 O +
probe O +
competes O +
only O +
marginally O +
for O +
K16ARE O +
binding O +
( O -
Figure O +
4C O -
) O -
. O +

The O +
NRF2 O +
transcription O +
factor O +
has O +
been O +
shown O +
to O +
bind O +
to O +
AREs O +
upon O +
translocation O +
into O +
the O +
nucleus O -
, O +
resulting O +
in O +
the O +
induction O +
of O +
ARE O -
- O -
mediated O +
genes O +
( O -
Wakabayashi O +
et O +
al. O +
2004 O -
) O -
. O +

To O +
examine O +
whether O +
iAs O +
induces O +
and O +
translocates O +
NRF2 O +
into O +
the O +
nucleus O +
in O +
HaCaT O +
cells O -
, O +
we O +
treated O +
these O +
cells O +
with O +
iAs O +
for O +
either O +
3 O +
or O +
6 O +
hr O -
. O +

As O +
shown O +
in O +
Figure O +
4D O -
, O +
a O +
dose O -
- O -
dependent O +
accumulation O +
of O +
NRF2 O +
protein O +
was O +
observed O +
in O +
the O +
nucleus O +
upon O +
treatment O +
with O +
iAs O +
for O +
6 O +
hr O -
. O +

This O +
was O +
not O +
observed O +
in O +
the O +
parallel O +
experiment O +
performed O +
over O +
the O +
3-hr O +
time O +
course O -
. O +

Supershift O +
EMSA O +
analysis O +
using O +
an O +
NRF2 O +
antibody O +
showed O +
that O +
the O +
iAs O -
- O -
induced O +
and O +
iAs O -
- O -
translocated O +
NRF2 O +
protein O +
binds O +
to O +
the O +
WT O -
- O -
K16ARE O +
probe O +
containing O +
the O +
ARE O +
sequence O +
of O +
the O +
K16 O +
proximal O +
promoter O +
region O +
( O -
5′-GGAGTCAGC-3′ O -
) O +
that O +
comprises O +
an O +
AP-1–like O +
site O +
and O +
a O +
GC O +
box O -
, O +
whereas O +
the O +
supershift O +
of O +
c O -
- O -
Jun O +
was O +
not O +
observed O +
( O -
Figure O +
4E O -
) O -
. O +

To O +
identify O +
whether O +
the O +
GC O +
box O +
is O +
dispensable O +
for O +
the O +
iAs O -
- O -
stimulated O +
binding O +
activity O +
of O +
NRF2 O -
, O +
we O +
next O +
performed O +
EMSA O +
analyses O +
with O +
either O +
WT- O +
or O +
a O +
Mut O -
- O -
K16ARE O +
probe O +
containing O +
an O +
intact O +
AP-1–like O +
element O +
but O +
a O +
mutated O +
GC O +
box O -
. O +

As O +
shown O +
in O +
Figure O +
4F O -
, O +
the O +
K16ARE O -
– O -
nuclear O +
protein O +
complexes O +
and O +
supershifted O +
bands O +
that O +
were O +
enhanced O +
by O +
iAs O +
treatment O +
were O +
largely O +
abolished O +
by O +
the O +
addition O +
of O +
the O +
Mut O -
- O -
K16ARE O +
probe O -
. O +

iAs O +
stabilizes O +
the O +
NRF2 O +
protein O +
We O +
examined O +
the O +
effects O +
of O +
iAs O +
treatment O +
on O +
the O +
function O +
of O +
KEAP1 O +
in O +
HaCaT O +
cells O -
. O +

Treatment O +
with O +
iAs O +
did O +
not O +
alter O +
the O +
expression O +
levels O +
of O +
KEAP1 O +
mRNA O +
or O +
protein O +
over O +
either O +
a O +
3 O +
or O +
6 O +
hr O +
time O +
course O +
( O -
Figure O +
5A O -
) O -
. O +

Next O -
, O +
we O +
examined O +
the O +
effects O +
of O +
iAs O +
on O +
the O +
expression O +
of O +
NRF2 O +
mRNA O +
in O +
HaCaT O +
cells O -
. O +

Exposure O +
to O +
iAs O +
did O +
not O +
significantly O +
alter O +
the O +
steady O -
- O -
state O +
levels O +
of O +
NRF2 O +
mRNA O +
( O -
data O +
not O +
shown O -
) O -
. O +

Production O +
of O +
NRF2 O +
protein O -
, O +
however O -
, O +
was O +
observed O +
to O +
increase O +
in O +
both O +
a O +
dose O -
- O -
and O +
time O -
- O -
dependent O +
manner O +
( O -
Figure O +
4D O -
) O -
. O +

To O +
further O +
examine O +
the O +
stabilization O +
of O +
NRF2 O +
protein O +
by O +
iAs O -
, O +
we O +
monitored O +
the O +
decay O +
of O +
basal O +
and O +
iAs O -
- O -
induced O +
NRF2 O +
proteins O +
after O +
inhibition O +
of O +
protein O +
synthesis O +
by O +
CHX O +
( O -
Figure O +
5B O -
) O -
. O +

The O +
results O +
of O +
this O +
analysis O +
revealed O +
that O +
the O +
NRF2 O +
protein O +
levels O +
decrease O +
by O +
approximately O +
50 O -
% O +
within O +
30 O +
min O +
of O +
treatment O +
with O +
CHX O +
in O +
cells O +
that O +
had O +
not O +
been O +
exposed O +
to O +
iAs O -
. O +

Only O +
trace O +
amounts O +
of O +
NRF2 O +
are O +
then O +
detectable O +
after O +
60 O +
min O +
of O +
exposure O +
to O +
CHX O +
in O +
these O +
cells O -
. O +

The O +
HaCaT O +
cells O +
were O +
then O +
pretreated O +
with O +
iAs O +
for O +
6 O +
hr O +
before O +
their O +
exposure O +
to O +
CHX O +
in O +
a O +
similar O +
timecourse O +
experiment O -
. O +

The O +
levels O +
of O +
NRF2 O +
in O +
these O +
iAs O -
- O -
treated O +
cells O +
were O +
again O +
found O +
to O +
decrease O +
by O +
about O +
50 O -
% O -
, O +
but O +
only O +
after O +
120 O +
min O +
of O +
CHX O +
exposure O -
. O +

NRF2 O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
K16 O +
gene O +
expression O +
in O +
HaCaT O +
cells O +
To O +
confirm O +
the O +
functional O +
role O +
of O +
NRF2 O +
in O +
the O +
induction O +
of O +
K16 O +
gene O +
expression O +
by O +
iAs O -
, O +
we O +
investigated O +
whether O +
the O +
expression O +
of O +
K16 O +
mRNA O +
is O +
induced O +
by O +
the O +
overexpression O +
of O +
NRF2 O +
( O -
WT O -
- O -
NRF2 O -
) O +
in O +
HaCaT O +
cells O -
. O +

We O +
also O +
investigated O +
the O +
expression O +
of O +
the O +
detoxification O +
gene O +
TXN O -
, O +
which O +
is O +
highly O +
induced O +
by O +
a O +
variety O +
of O +
oxidative O +
stimuli O +
through O +
NRF2-mediated O +
ARE O +
transactivation O +
( O -
Kim O +
et O +
al. O +
2001 O -
) O -
. O +

The O +
expression O +
of O +
TXN O +
gene O +
in O +
untransfected O +
cells O +
after O +
treatment O +
with O +
iAs O +
was O +
stronger O +
than O +
that O +
of O +
the O +
control O +
cells O +
( O -
Figure O +
6A O -
) O -
. O +

When O +
the O +
cells O +
were O +
transfected O +
with O +
WT O -
- O -
NRF2 O +
and O +
then O +
treated O +
with O +
or O +
without O +
iAs O -
, O +
the O +
expression O +
of O +
TXN O +
mRNA O +
was O +
augmented O +
markedly O +
compared O +
with O +
the O +
empty O -
- O -
vector O +
control O -
. O +

Similarly O -
, O +
the O +
expression O +
of O +
K16 O +
mRNA O +
was O +
also O +
induced O +
in O +
cells O +
transfected O +
with O +
WT O -
- O -
NRF2 O +
in O +
the O +
absence O +
or O +
presence O +
of O +
iAs O -
. O +

We O +
next O +
performed O +
a O +
transient O +
transfection O +
of O +
HaCaT O +
cells O +
with O +
the O +
pXK-5–1 O +
luciferase O +
vector O +
together O +
with O +
the O +
WT O -
- O -
NRF2 O +
vector O -
. O +

The O +
overexpression O +
of O +
NRF2 O +
in O +
increasing O +
concentrations O +
resulted O +
in O +
significant O +
enhancement O +
of O +
the O +
ARE O -
- O -
mediated O +
K16 O +
promoter O +
activation O +
( O -
Figure O +
6B O -
) O -
. O +

Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
showed O +
for O +
the O +
first O +
time O +
that O +
iAs O +
induces O +
the O +
transcriptional O +
activation O +
of O +
K16 O +
in O +
the O +
human B-Species +
keratinocyte O +
cell O +
line O -
, O +
HaCaT O -
, O +
through O +
the O +
ARE O +
present O +
in O +
its O +
gene O +
promoter O -
. O +

It O +
has O +
been O +
reported O +
previously O +
that O +
treatment O +
with O +
iAs O +
enhances O +
the O +
production O +
and O +
translocation O +
of O +
NRF2 O +
into O +
the O +
nucleus O +
in O +
several O +
cell O +
types O -
. O +

However O -
, O +
until O +
now O +
it O +
has O +
remained O +
uncertain O +
whether O +
the O +
induction O +
of O +
NRF2 O +
by O +
iAs O +
mediates O +
the O +
transcriptional O +
activation O +
of O +
the O +
K16 O +
gene O +
in O +
keratinocytes O -
. O +

In O +
our O +
current O +
experiments O -
, O +
we O +
demonstrated O +
that O +
iAs O +
elongates O +
the O +
half O -
- O -
life O +
of O +
the O +
NRF2 O +
protein O -
, O +
which O +
results O +
in O +
its O +
increased O +
expression O +
levels O -
. O +

Furthermore O -
, O +
this O +
iAs O -
- O -
induced O +
NRF2 O +
protein O +
was O +
shown O +
to O +
bind O +
to O +
the O +
ARE O +
sequences O +
in O +
the O +
promoter O +
region O +
of O +
the O +
K16 O +
gene O -
. O +

Finally O -
, O +
by O +
overexpressing O +
NRF2 O -
, O +
we O +
have O +
clarified O +
that O +
its O +
induction O +
is O +
involved O +
in O +
not O +
only O +
the O +
gene O +
expression O +
of O +
the O +
detoxification O +
gene O +
TXN O -
, O +
but O +
also O +
in O +
the O +
upregulation O +
of O +
K16 O +
expression O +
in O +
HaCaT O +
cells O +
through O +
the O +
ARE O +
in O +
the O +
K16 O +
gene O +
promoter O -
. O +

These O +
experiments O +
indicate O +
an O +
important O +
and O +
novel O +
function O +
for O +
NRF2 O +
in O +
the O +
regulation O +
of O +
K16 O +
in O +
keratinocytes O +
and O +
also O +
help O +
to O +
further O +
explain O +
the O +
molecular O +
mechanisms O +
underlying O +
arsenic O -
- O -
mediated O +
epidermal O +
hyperkeratosis O -
. O +

In O +
our O +
present O +
experiments O -
, O +
the O +
expression O +
levels O +
of O +
K16 O +
mRNA O +
and O +
protein O +
were O +
indeed O +
found O +
to O +
be O +
enhanced O +
by O +
iAs O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Figure O +
1 O -
) O -
. O +

In O +
addition O -
, O +
luciferase O +
assays O +
of O +
the O +
K16 O +
promoter O +
revealed O +
that O +
iAs O +
enhances O +
its O +
activity O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O -
, O +
which O +
is O +
stimulated O +
by O +
AP-1–like O +
sites O +
and O +
an O +
ARE O +
( O -
Figure O +
2 O -
) O -
. O +

The O +
promoter O +
of O +
the O +
human B-Species +
K16 O +
gene O +
was O +
recently O +
cloned O +
and O +
sequenced O -
, O +
and O +
several O +
AP-1–like O +
sites O +
were O +
found O +
within O +
the O +
–515-bp O +
region O +
of O +
the O +
gene O +
( O -
Wang O +
and O +
Chang O +
2003 O -
) O -
. O +

AP-1 O +
transcription O +
factor O +
can O +
be O +
formed O +
by O +
the O +
dimerization O +
of O +
either O +
Jun O +
or O +
Jun O -
/ O -
Fos O +
family O +
members O +
( O -
Eferl O +
and O +
Wagner O +
2003 O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
increased O +
expression O +
of O +
c O -
- O -
Jun O -
, O +
but O +
not O +
c O -
- O -
Fos O +
was O +
evident O +
in O +
the O +
nuclei O +
of O +
HaCaT O +
cells O +
after O +
iAs O +
treatment O +
( O -
Figure O +
3 O -
) O -
. O +

Our O +
findings O +
thus O +
suggest O +
that O +
the O +
activation O +
of O +
c O -
- O -
Jun O -
/ O -
AP-1 O +
is O +
one O +
of O +
the O +
essential O +
steps O +
in O +
the O +
regulation O +
of O +
K16 O +
gene O +
expression O +
by O +
iAs O +
exposure O +
in O +
HaCaT O +
cells O -
. O +

It O +
has O +
been O +
well O +
documented O +
that O +
the O +
ARE O +
core O +
sequence O +
includes O +
an O +
AP-1–like O +
binding O +
site O +
( O -
TGAC O -
/ O -
GTCA O -
) O -
, O +
followed O +
by O +
a O +
GC O +
box O +
( O -
Rushmore O +
et O +
al. O +
1991 O -
; O +
Xie O +
et O +
al. O +
1995 O -
) O -
. O +

We O +
have O +
found O +
in O +
our O +
current O +
analyses O +
that O +
the O +
AP-1–like O +
site O +
within O +
the O +
K16 O +
promoter O +
region O +
from O +
–148 O +
to O +
–140 O +
bp O +
( O -
5′-GGAGTCAGC-3′ O -
) O +
resembles O +
a O +
consensus O +
ARE O +
sequence O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
AREs O +
can O +
be O +
specifically O +
bound O +
by O +
complexes O +
of O +
several O +
basic O -
- O -
leucine O +
zipper O +
transcription O +
factors O -
, O +
including O +
NRF2 O +
( O -
Ishii O +
et O +
al. O +
2000 O -
; O +
Moi O +
et O +
al. O +
1994 O -
) O -
. O +

NRF2 O +
heterodimerizes O +
with O +
either O +
AP-1 O +
or O +
small O +
MAF O +
( O -
MAFG O -
, O +
MAFK O -
, O +
and O +
MAFF O -
) O +
proteins O +
( O -
MAF O -
, O +
v O -
- O -
maf O +
musculoaponeurotic O +
fibrosarcoma O +
oncogene O +
homolog O -
) O +
and O +
binds O +
to O +
the O +
ARE O +
to O +
induce O +
the O +
transcription O +
of O +
ARE O -
- O -
mediated O +
genes O +
( O -
Motohashi O +
et O +
al. O +
2002 O -
) O -
. O +

In O +
the O +
present O +
investigation O -
, O +
EMSA O +
and O +
supershift O +
assays O +
showed O +
that O +
the O +
NRF2 O +
proteins O +
in O +
the O +
nuclei O +
bind O +
to O +
the O +
ARE O +
sequences O +
of O +
K16 O +
promoter O +
region O +
after O +
iAs O +
exposure O -
. O +

iAs O -
- O -
induced O +
c O -
- O -
Jun O -
, O +
however O -
, O +
does O +
not O +
bind O +
to O +
this O +
ARE O +
( O -
Figure O +
4E O -
) O -
. O +

c O -
- O -
Jun O +
may O +
thus O +
act O +
on O +
other O +
AP-1 O +
sites O +
within O +
the O +
K16 O +
promoter O +
region O -
. O +

These O +
results O +
also O +
suggest O +
that O +
other O +
heterodimer O +
partners O +
of O +
NRF2 O +
are O +
involved O +
in O +
the O +
ARE O +
regulation O +
of O +
K16 O +
promoter O +
region O +
underlying O +
iAs O -
- O -
mediated O +
the O +
K16 O +
gene O +
expression O -
. O +

Gel O +
shifts O +
with O +
an O +
K16Mut O -
- O -
ARE O +
probe O +
( O -
harboring O +
a O +
mutation O +
in O +
the O +
ARE O +
GC O +
box O -
) O +
clearly O +
show O +
that O +
the O +
ARE O +
sequence O +
in O +
the O +
K16 O +
promoter O -
, O +
particularly O +
the O +
terminal O +
GC O +
dinucleotide O -
, O +
is O +
essential O +
for O +
mediating O +
iAs O -
- O -
induced O +
K16 O +
transactivation O +
and O +
NRF2 O +
binding O +
( O -
Figure O +
4F O -
) O -
. O +

Several O +
investigations O +
have O +
suggested O +
that O +
the O +
GC O +
nucleotides O +
within O +
the O +
ARE O +
are O +
essential O +
for O +
both O +
the O +
basal O +
and O +
oxidative O +
stress O -
– O -
induced O +
activities O +
of O +
the O +
ARE O -
- O -
related O +
genes O -
, O +
NAD O -
( O -
P O -
) O -
H O +
dehydrogenase O +
quinone O +
1 O +
( O -
NQO1 O -
) O +
and O +
glutamate O -
- O -
cysteine O +
ligase O +
catalytic O +
subunit O +
( O -
GCLC O -
) O +
( O -
Wasserman O +
and O +
Fahl O +
1997 O -
; O +
Wild O +
et O +
al. O +
1998 O -
) O -
. O +

Our O +
current O +
results O +
are O +
consistent O +
with O +
these O +
earlier O +
studies O +
in O +
showing O +
that O +
the O +
formation O +
of O +
the O +
iAs O -
- O -
responsive O +
NRF2 O -
/ O -
ARE O +
complexes O +
is O +
reduced O +
by O +
a O +
mutation O +
in O +
the O +
GC O +
box O -
. O +

Collectively O -
, O +
our O +
present O +
observations O +
reveal O +
a O +
new O +
molecular O +
mechanism O +
in O +
which O +
iAs O -
- O -
induced O +
K16 O +
gene O +
expression O +
is O +
also O +
regulated O +
by O +
activation O +
NRF2 O -
/ O -
ARE O +
pathways O -
. O +

It O +
has O +
been O +
widely O +
accepted O +
that O +
oxidative O +
stress O +
disrupts O +
sequestration O +
of O +
NRF2 O +
by O +
KEAP1 O -
, O +
permits O +
NRF2 O +
translocation O +
to O +
the O +
nucleus O -
, O +
and O +
transactivates O +
the O +
expression O +
of O +
various O +
NRF2-mediated O +
genes O +
( O -
Dinkova O -
- O -
Kostova O +
et O +
al. O +
2002 O -
; O +
McMahon O +
et O +
al. O +
2003 O -
) O -
. O +

Our O +
present O +
study O +
showed O +
that O +
iAs O +
elongates O +
the O +
half O -
- O -
life O +
of O +
the O +
NRF2 O +
protein O +
but O +
has O +
no O +
effects O +
upon O +
KEAP1 O +
expression O +
( O -
Figure O +
5 O -
) O -
. O +

Other O +
studies O +
have O +
also O +
demonstrated O +
that O +
the O +
production O +
of O +
NRF2 O +
is O +
increased O +
by O +
various O +
inducers O +
via O +
posttranscriptional O +
control O +
( O -
Nguyen O +
et O +
al. O +
2003 O -
; O +
Stewart O +
et O +
al. O +
2003 O -
) O -
. O +

Several O +
earlier O +
reports O +
also O +
indicated O +
that O +
either O +
oxidative O +
stress O +
or O +
antioxidant O +
substances O +
stabilize O +
the O +
expression O +
of O +
the O +
NRF2 O +
protein O -
, O +
either O +
by O +
directly O +
modifying O +
the O +
cysteine O +
residues O +
on O +
KEAP1 O +
to O +
disrupt O +
the O +
NRF2 O -
/ O -
KEAP1 O +
complex O +
( O -
Dinkova O -
- O -
Kostova O +
et O +
al. O +
2002 O -
) O +
or O +
by O +
facilitating O +
the O +
release O +
of O +
NRF2 O +
through O +
the O +
phosphorylation O +
of O +
the O +
NRF2 O -
/ O -
KEAP1 O +
complex O +
( O -
Bloom O +
and O +
Jaiswal O +
2003 O -
) O -
. O +

These O +
findings O +
are O +
largely O +
consistent O +
with O +
our O +
present O +
finding O +
that O +
iAs O +
stabilizes O +
the O +
expression O +
of O +
NRF2 O +
in O +
HaCaT O +
cells O +
by O +
elongating O +
the O +
protein O +
half O -
- O -
life O -
. O +

Recently O -
, O +
Wakabayashi O +
et O +
al. O +
( O -
2003 O -
) O +
demonstrated O +
that O +
NRF2 O +
accumulates O +
in O +
the O +
nucleus O +
at O +
constitutively O +
high O +
levels O +
and O +
produces O +
various O +
cytoprotective O +
genes O +
in O +
embryonic O +
fibroblast- O +
and O +
liver O -
- O -
derived O +
Keap1-null O +
mice B-Species -
. O +

Surprisingly O -
, O +
these O +
Keap1-deficient O +
mice B-Species +
also O +
show O +
a O +
thicker O +
stratum O +
corneum O +
epidermis O -
, O +
abnormal O +
keratinization O -
, O +
and O +
cornification O +
in O +
the O +
esophagus O +
and O +
forestomach O +
( O -
hyperkeratosis O -
) O -
. O +

K6 O +
was O +
found O +
to O +
be O +
strongly O +
expressed O +
in O +
the O +
esophageal O +
epithelium O +
of O +
these O +
mice B-Species -
. O +

These O +
results O +
indicate O +
that O +
K6 O +
is O +
also O +
a O +
target O +
gene O +
of O +
NRF2 O -
. O +

In O +
addition O -
, O +
the O +
promoter O +
of O +
the O +
K6 O +
gene O +
bears O +
a O +
remarkable O +
sequence O +
similarity O +
to O +
the O +
K16 O +
promoter O +
( O -
Jiang O +
et O +
al. O +
1993 O -
) O -
. O +

Therefore O -
, O +
we O +
examined O +
whether O +
K16 O +
gene O +
expression O +
is O +
also O +
regulated O +
by O +
NRF2 O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
gene O +
expression O +
and O +
transactivation O +
of O +
K16 O +
were O +
dramatically O +
induced O +
by O +
transfection O +
with O +
WT O -
- O -
NRF2 O +
via O +
in O +
HaCaT O +
cells O -
, O +
clearly O +
demonstrating O +
that O +
NRF2 O +
acts O +
as O +
a O +
direct O +
transcriptional O +
regulator O +
of O +
the O +
K16 O +
gene O +
( O -
Figure O +
6 O -
) O -
. O +

In O +
addition O -
, O +
we O +
also O +
showed O +
that O +
transfection O +
of O +
HaCaT O +
cells O +
with O +
WT O -
- O -
NRF2 O +
induces O +
the O +
expression O +
of O +
detoxification O +
gene O +
TXN O +
( O -
Figure O +
6A O -
) O -
. O +

NRF2 O +
may O +
thus O +
have O +
a O +
major O +
role O +
to O +
play O +
in O +
the O +
development O +
of O +
hyperkeratosis O -
, O +
whereas O +
the O +
expression O +
and O +
induction O +
of O +
NRF2 O +
is O +
implicated O +
in O +
cell O +
protection O +
against O +
a O +
variety O +
of O +
genotoxic O +
and O +
cytotoxic O +
effects O -
. O +

Hence O -
, O +
based O +
on O +
these O +
results O +
and O +
on O +
the O +
findings O +
from O +
studies O +
of O +
Keap1 O +
knockout O +
mice B-Species -
, O +
iAs O +
may O +
both O +
cause O +
hyperkeratosis O +
and O +
induce O +
detoxification O +
enzymes O +
via O +
the O +
modification O +
of O +
NRF2 O -
. O +

Given O +
that O +
there O +
are O +
both O +
beneficial O +
and O +
adverse O +
effects O +
of O +
NRF2 O +
activity O -
, O +
caution O +
will O +
therefore O +
be O +
needed O +
when O +
using O +
antioxidants O +
for O +
prevention O +
and O +
therapy O -
. O +

Although O +
further O +
investigations O +
are O +
needed O -
, O +
we O +
believe O +
that O +
our O +
findings O +
provide O +
important O +
clues O +
for O +
the O +
design O +
of O +
future O +
therapies O +
for O +
arsenic O -
- O -
mediated O +
hyperkeratosis O +
and O +
for O +
treatments O +
involving O +
the O +
molecular O +
targeting O +
of O +
NRF2 O -
. O +

Conclusion O +
Our O +
findings O +
clearly O +
demonstrate O +
that O +
the O +
induction O +
of O +
the O +
K16 O +
gene O +
in O +
human B-Species +
keratinocytes O +
by O +
iAs O +
depends O +
on O +
NRF2 O +
activation O -
. O +

Our O +
results O +
thus O +
represent O +
a O +
valuable O +
initial O +
effort O +
to O +
elucidate O +
the O +
relationship O +
between O +
the O +
K16 O +
gene O +
and O +
the O +
NRF2 O +
transcription O +
factor O -
, O +
which O +
may O +
be O +
responsible O +
for O +
hyperkeratosis O -
. O +

Identification O +
and O +
Analysis O +
of O +
Co O -
- O -
Occurrence O +
Networks O +
with O +
NetCutter O +
Abstract O +
Background O +
Co O -
- O -
occurrence O +
analysis O +
is O +
a O +
technique O +
often O +
applied O +
in O +
text O +
mining O -
, O +
comparative O +
genomics O -
, O +
and O +
promoter O +
analysis O -
. O +

The O +
methodologies O +
and O +
statistical O +
models O +
used O +
to O +
evaluate O +
the O +
significance O +
of O +
association O +
between O +
co O -
- O -
occurring O +
entities O +
are O +
quite O +
diverse O -
, O +
however O -
. O +

Methodology O -
/ O -
Principal O +
Findings O +
We O +
present O +
a O +
general O +
framework O +
for O +
co O -
- O -
occurrence O +
analysis O +
based O +
on O +
a O +
bipartite O +
graph O +
representation O +
of O +
the O +
data O -
, O +
a O +
novel O +
co O -
- O -
occurrence O +
statistic O -
, O +
and O +
software O +
performing O +
co O -
- O -
occurrence O +
analysis O +
as O +
well O +
as O +
generation O +
and O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O -
. O +

We O +
show O +
that O +
the O +
overall O +
stringency O +
of O +
co O -
- O -
occurrence O +
analysis O +
depends O +
critically O +
on O +
the O +
choice O +
of O +
the O +
null O -
- O -
model O +
used O +
to O +
evaluate O +
the O +
significance O +
of O +
co O -
- O -
occurrence O +
and O +
find O +
that O +
random O +
sampling O +
from O +
a O +
complete O +
permutation O +
set O +
of O +
the O +
bipartite O +
graph O +
permits O +
co O -
- O -
occurrence O +
analysis O +
with O +
optimal O +
stringency O -
. O +

We O +
show O +
that O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
is O +
the O +
most O +
natural O +
co O -
- O -
occurrence O +
probability O +
distribution O +
when O +
vertex O +
degrees O +
of O +
the O +
bipartite O +
graph O +
are O +
variable O -
, O +
which O +
is O +
usually O +
the O +
case O -
. O +

Calculation O +
of O +
Poisson O -
- O -
binomial O +
P O -
- O -
values O +
is O +
difficult O -
, O +
however O -
. O +

Therefore O -
, O +
we O +
propose O +
a O +
fast O +
bi O -
- O -
binomial O +
approximation O +
for O +
calculation O +
of O +
P O -
- O -
values O +
and O +
show O +
that O +
this O +
statistic O +
is O +
superior O +
to O +
other O +
measures O +
of O +
association O +
such O +
as O +
the O +
Jaccard O +
coefficient O +
and O +
the O +
uncertainty O +
coefficient O -
. O +

Furthermore O -
, O +
co O -
- O -
occurrence O +
analysis O +
of O +
more O +
than O +
two O +
entities O +
can O +
be O +
performed O +
using O +
the O +
same O +
statistical O +
model O -
, O +
which O +
leads O +
to O +
increased O +
signal O -
- O -
to O -
- O -
noise O +
ratios O -
, O +
robustness O +
towards O +
noise O -
, O +
and O +
the O +
identification O +
of O +
implicit O +
relationships O +
between O +
co O -
- O -
occurring O +
entities O -
. O +

Using O +
NetCutter O -
, O +
we O +
identify O +
a O +
novel O +
protein O +
biosynthesis O +
related O +
set O +
of O +
genes O +
that O +
are O +
frequently O +
coordinately O +
deregulated O +
in O +
human B-Species +
cancer O +
related O +
gene O +
expression O +
studies O -
. O +

NetCutter O +
is O +
available O +
at O +
http://bio.ifom-ieo-campus.it/NetCutter/ O -
) O -
. O +

Conclusion O +
Our O +
approach O +
can O +
be O +
applied O +
to O +
any O +
set O +
of O +
categorical O +
data O +
where O +
co O -
- O -
occurrence O +
analysis O +
might O +
reveal O +
functional O +
relationships O +
such O +
as O +
clinical O +
parameters O +
associated O +
with O +
cancer O +
subtypes O +
or O +
SNPs O +
associated O +
with O +
disease O +
phenotypes O -
. O +

The O +
stringency O +
of O +
our O +
approach O +
is O +
expected O +
to O +
offer O +
an O +
advantage O +
in O +
a O +
variety O +
of O +
applications O -
. O +

Introduction O +
Biological O +
research O +
has O +
experienced O +
a O +
paradigm O +
shift O +
in O +
the O +
last O +
decade O +
catalyzed O +
by O +
the O +
availability O +
of O +
genome O +
sequences O +
and O +
the O +
resulting O +
development O +
of O +
high O -
- O -
throughput O +
technologies O -
. O +

The O +
large O +
data O +
volumes O +
produced O +
by O +
these O +
novel O +
technologies O +
are O +
often O +
published O +
as O +
supplementary O +
material O +
and/or O +
stored O +
in O +
extensive O +
data O +
repositories O +
[ O -
1 O -
] O -
. O +

Functional O +
interpretation O +
of O +
these O +
data O +
is O +
an O +
ongoing O +
challenge O -
. O +

Co O -
- O -
occurrence O +
analysis O -
, O +
based O +
on O +
the O +
hypothesis O +
that O +
co O -
- O -
occurring O +
entities O +
are O +
functionally O +
linked O -
, O +
is O +
a O +
technique O +
that O +
has O +
been O +
used O +
in O +
three O +
main O +
areas O +
of O +
biological O +
research O -
: O +
Co O -
- O -
occurrence O +
of O +
genes O +
in O +
sequenced O +
genomes O +
relies O +
on O +
the O +
fact O +
that O +
proteins O +
do O +
not O +
function O +
in O +
isolation O +
and O +
are O +
dependent O +
on O +
other O +
proteins O -
, O +
either O +
as O +
direct O +
binding O +
partners O -
, O +
or O +
as O +
catalysts O +
of O +
substrates O -
. O +

Thus O -
, O +
when O +
two O +
proteins O +
significantly O +
co O -
- O -
occur O +
in O +
a O +
large O +
number O +
of O +
genomes O +
or O +
can O +
be O +
observed O +
as O +
fusion O +
proteins O +
in O +
a O +
subset O +
of O +
genomes O -
, O +
they O +
are O +
likely O +
to O +
be O +
binding O +
partners O +
or O +
enzymes O +
needed O +
for O +
a O +
specific O +
metabolic O +
pathway O -
. O +

Examples O +
of O +
those O +
studies O +
have O +
been O +
reported O +
by O +
[ O -
2 O -
] O -
– O -
[ O -
7 O -
] O -
. O +

Text O +
mining O +
is O +
a O +
quickly O +
evolving O +
field O +
that O +
aims O +
at O +
developing O +
technologies O +
helping O +
to O +
cope O +
with O +
the O +
functional O +
interpretation O +
of O +
large O +
volumes O +
of O +
publications O -
. O +

Co O -
- O -
occurrence O +
of O +
gene O +
names O +
in O +
publication O +
abstracts O -
, O +
entire O +
publications O -
, O +
or O +
other O +
gene O -
- O -
related O +
databases O +
has O +
been O +
used O +
to O +
derive O +
co O -
- O -
occurrence O +
networks O +
with O +
clear O +
evidence O +
that O +
edges O +
in O +
those O +
networks O +
are O +
reflecting O +
functionally O +
relevant O +
relationships O +
[ O -
8 O -
] O -
– O -
[ O -
11 O -
] O -
. O +

Gene O +
names O +
have O +
also O +
been O +
analyzed O +
for O +
co O -
- O -
occurrence O +
with O +
other O +
entities O +
such O +
as O +
mutations O +
[ O -
12 O -
] O -
, O +
chemical O +
compounds O +
[ O -
13 O -
] O -
, O +
and O +
disease O +
related O +
keywords O +
[ O -
14 O -
] O -
. O +

From O +
the O +
resulting O +
networks O -
, O +
hypotheses O +
about O +
candidate O +
genes O +
involved O +
in O +
inherited O +
diseases O +
and O +
drug O +
targets O +
can O +
be O +
derived O -
. O +

Clustering O +
of O +
gene O +
related O +
publications O +
using O +
keywords O +
has O +
been O +
applied O +
to O +
enhance O +
the O +
quality O +
of O +
gene O +
expression O +
clusters O +
[ O -
15 O -
] O -
, O +
[ O -
16 O -
] O -
. O +

More O +
general O +
( O -
non O +
gene O -
- O -
centric O -
) O +
approaches O +
try O +
to O +
organize O +
the O +
literature O +
into O +
functional O +
areas O +
based O +
on O +
co O -
- O -
occurrence O +
of O +
MeSH O +
terms O -
, O +
keywords O -
, O +
diseases O -
, O +
phenotypes O -
, O +
chemicals O -
, O +
and O +
similar O +
objects O +
of O +
biomedical O +
research O +
interest O +
[ O -
17 O -
] O -
– O -
[ O -
21 O -
] O -
. O +

Co O -
- O -
occurrence O +
analysis O +
of O +
transcription O +
factor O +
binding O +
motifs O +
has O +
been O +
carried O +
out O +
in O +
a O +
variety O +
of O +
slightly O +
differing O +
ways O +
in O +
a O +
wide O +
range O +
of O +
organisms O -
, O +
including O +
humans B-Species -
. O +

[ O -
22 O -
] O -
– O -
[ O -
33 O -
] O -
. O +

The O +
underlying O +
hypothesis O +
is O +
that O +
co O -
- O -
regulated O +
genes O -
, O +
identified O +
usually O +
by O +
gene O +
expression O +
studies O -
, O +
should O +
contain O +
specific O +
combinations O +
of O +
transcription O +
factor O +
binding O +
motifs O +
in O +
their O +
upstream O +
regulatory O +
regions O -
, O +
the O +
identification O +
of O +
which O +
would O +
allow O +
the O +
reverse O -
- O -
engineering O +
of O +
transcription O +
regulatory O +
networks O +
[ O -
34 O -
] O -
. O +

We O +
have O +
recently O +
applied O +
co O -
- O -
occurrence O +
analysis O +
to O +
studying O +
published O +
gene O +
expression O +
signatures O +
and O +
showed O +
that O +
co O -
- O -
occurrence O +
patterns O +
of O +
genes O +
reflect O +
cancer O +
signaling O +
pathways O +
[ O -
35 O -
] O -
. O +

Although O +
co O -
- O -
occurrence O +
analysis O +
has O +
a O +
respectable O +
history O -
, O +
the O +
methodologies O +
used O +
in O +
the O +
studies O +
mentioned O +
above O +
could O +
not O +
be O +
easily O +
applied O +
to O +
studying O +
gene O +
expression O +
signatures O -
. O +

There O +
are O +
three O +
main O +
reasons O +
that O +
dictated O +
the O +
use O +
of O +
a O +
different O +
approach O -
. O +

First O -
, O +
gene O +
expression O +
signatures O +
can O +
vary O +
in O +
size O +
by O +
orders O +
of O +
magnitude O -
. O +

Obviously O -
, O +
the O +
larger O +
a O +
signature O +
the O +
more O +
likely O +
it O +
is O +
to O +
find O +
two O +
or O +
more O +
genes O +
co O -
- O -
occurring O +
in O +
that O +
signature O -
. O +

Thus O -
, O +
the O +
significance O +
of O +
co O -
- O -
occurrences O +
must O +
be O +
evaluated O +
in O +
the O +
presence O +
of O +
considerable O +
heterogeneity O +
of O +
co O -
- O -
occurrence O +
probabilities O +
among O +
gene O +
lists O -
. O +

As O +
a O +
consequence O -
, O +
the O +
statistics O +
used O +
to O +
evaluate O +
the O +
significance O +
of O +
co O -
- O -
occurrence O +
events O +
must O +
reflect O +
this O +
heterogeneity O -
. O +

In O +
particular O -
, O +
it O +
must O +
be O +
based O +
on O +
list O -
- O -
specific O +
co O -
- O -
occurrence O +
probabilities O -
. O +

Second O -
, O +
in O +
the O +
vast O +
majority O +
of O +
previous O +
studies O -
, O +
co O -
- O -
occurrence O +
is O +
analyzed O +
for O +
pair O -
- O -
wise O +
combinations O +
of O +
co O -
- O -
occurring O +
entities O -
. O +

We O +
found O +
that O +
the O +
resulting O +
stringency O +
of O +
this O +
approach O +
is O +
not O +
adequate O +
for O +
the O +
analysis O +
of O +
published O +
gene O +
expression O +
signatures O +
[ O -
35 O -
] O -
. O +

Third O -
, O +
the O +
null O -
- O -
model O +
against O +
which O +
the O +
significance O +
of O +
co O -
- O -
occurrences O +
is O +
tested O +
does O +
not O +
work O +
well O +
for O +
gene O +
expression O +
signatures O -
. O +

A O +
common O +
procedure O +
is O +
to O +
use O +
generic O +
randomization O +
of O +
the O +
entire O +
data O +
set O +
under O +
analysis O +
or O +
to O +
select O +
subsets O +
of O +
data O +
entries O +
randomly O +
for O +
comparison O +
purposes O -
. O +

However O -
, O +
gene O +
expression O +
signatures O +
are O +
composed O +
of O +
distinct O +
gene O +
sets O +
and O +
the O +
null O -
- O -
model O +
must O +
maintain O +
this O +
property O -
, O +
which O +
is O +
not O +
guaranteed O +
using O +
these O +
approaches O -
. O +

Furthermore O -
, O +
the O +
list O -
- O -
specific O +
nature O +
of O +
co O -
- O -
occurrence O +
probabilities O +
can O -
not O +
be O +
dealt O +
with O +
properly O -
. O +

NetCutter O +
was O +
developed O +
to O +
address O +
these O +
challenges O +
and O +
to O +
provide O +
a O +
generic O +
tool O +
for O +
generating O +
and O +
analyzing O +
co O -
- O -
occurrence O +
networks O -
. O +

Although O +
NetCutter O +
has O +
been O +
developed O +
for O +
the O +
analysis O +
of O +
gene O +
expression O +
signatures O -
, O +
it O +
is O +
based O +
on O +
abstract O +
concepts O +
that O +
make O +
it O +
applicable O +
to O +
a O +
wide O +
variety O +
of O +
problems O -
. O +

The O +
input O +
is O +
represented O +
by O +
a O +
bipartite O +
graph O +
that O +
is O +
composed O +
of O +
list O -
- O -
entry O +
pairs O -
, O +
which O +
are O +
stored O +
in O +
tab O -
- O -
separated O +
text O +
format O -
. O +

Co O -
- O -
occurrence O +
of O +
entries O +
in O +
lists O +
is O +
analyzed O +
using O +
pair O -
- O -
wise O +
or O +
higher O +
order O +
combinations O +
of O +
entries O -
. O +

The O +
significance O +
of O +
co O -
- O -
occurrence O +
is O +
tested O +
using O +
a O +
novel O +
bi O -
- O -
binomial O +
approximation O +
of O +
Poisson O -
- O -
binomial O +
statistics O +
( O -
which O +
is O +
a O +
binomial O +
distribution O +
with O +
trial O +
specific O +
probabilities O -
) O +
that O +
handles O +
list O -
- O -
length O -
- O -
heterogeneity O +
properly O +
and O +
provides O +
a O +
novel O +
measure O +
of O +
association O +
that O +
is O +
found O +
to O +
be O +
superior O +
to O +
the O +
Jaccard O +
and O +
the O +
uncertainty O +
coefficients O -
. O +

Occurrence O +
probabilities O +
are O +
obtained O +
from O +
an O +
edge O -
- O -
swapping O +
procedure O +
that O +
maintains O +
vertex O +
degrees O +
in O +
the O +
underlying O +
bipartite O +
graph O +
and O +
distinct O +
sets O +
of O +
entries O +
per O +
list O -
. O +

As O +
we O +
shall O +
see O +
below O -
, O +
this O +
procedure O +
has O +
a O +
number O +
of O +
advantages O +
over O +
other O +
possible O +
null O -
- O -
models O +
and O +
permits O +
co O -
- O -
occurrence O +
analysis O +
with O +
near O +
maximum O +
stringency O -
. O +

Last O +
but O +
not O +
least O -
, O +
NetCutter O +
is O +
equipped O +
with O +
a O +
number O +
of O +
algorithms O +
for O +
the O +
identification O +
of O +
network O +
communities O -
, O +
vertex O +
ranking O -
, O +
and O +
convenience O +
tools O +
needed O +
in O +
the O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O -
, O +
or O +
any O +
undirected O +
graph O -
. O +

We O +
illustrate O +
the O +
utility O +
of O +
NetCutter O +
in O +
the O +
identification O +
of O +
corresponding O +
clusters O +
of O +
genes O +
and O +
publications O +
from O +
the O +
PubLiME O +
data O +
set O -
. O +

PubLiME O +
( O -
Published O +
Lists O +
of O +
Microarray O +
Experiments O -
) O +
is O +
a O +
repository O +
of O +
published O +
cancer O +
related O +
gene O +
expression O +
signatures O +
( O -
http://bio.ifom-ieo-campus.it/Publime O -
) O -
. O +

The O +
concept O +
of O +
cluster O +
correspondence O +
follows O +
from O +
the O +
bipartite O +
graph O +
representation O +
of O +
the O +
data O -
. O +

Reversing O +
the O +
list O -
- O -
entry O +
order O +
in O +
the O +
bipartite O +
graph O +
permits O +
identifying O +
communities O +
of O +
entries O +
as O +
well O +
as O +
communities O +
of O +
lists O -
. O +

We O +
show O +
that O +
communities O +
of O +
publications O +
corresponding O +
to O +
communities O +
of O +
genes O +
in O +
the O +
PubLiME O +
data O +
set O +
can O +
be O +
used O +
to O +
generate O +
hypotheses O +
about O +
the O +
putative O +
function O +
of O +
gene O +
communities O -
. O +

Results O +
The O +
bipartite O +
graph O +
model O +
of O +
co O -
- O -
occurrence O +
analysis O +
Co O -
- O -
occurrence O +
analysis O +
using O +
NetCutter O +
is O +
based O +
on O +
the O +
abstraction O +
of O +
list O -
- O -
entry O +
pairs O -
. O +

Any O +
entity O +
that O +
co O -
- O -
occurs O +
with O +
some O +
other O +
entity O +
must O +
be O +
confined O +
to O +
some O +
sort O +
of O +
container O +
where O +
co O -
- O -
occurrence O +
is O +
observed O -
. O +

For O +
example O -
, O +
in O +
the O +
case O +
of O +
gene O +
name O +
co O -
- O -
occurrence O +
in O +
PubMed O +
abstracts O -
, O +
the O +
abstract O +
is O +
the O +
container O +
and O +
the O +
gene O +
names O +
are O +
the O +
co O -
- O -
occurring O +
entities O -
. O +

Similarly O -
, O +
co O -
- O -
occurrence O +
of O +
transcription O +
factor O +
binding O +
motifs O +
is O +
observed O +
in O +
gene O +
promoters O -
. O +

The O +
promoters O +
are O +
the O +
containers O +
where O +
motif O +
entities O +
co O -
- O -
occur O -
. O +

The O +
containers O +
generally O +
host O +
more O +
than O +
one O +
entity O +
( O -
otherwise O +
co O -
- O -
occurrence O +
would O +
be O +
impossible O -
) O +
and O +
can O +
be O +
conveniently O +
interpreted O +
as O +
lists O -
. O +

The O +
co O -
- O -
occurring O +
entities O +
are O +
the O +
list O +
entries O -
. O +

Lists O +
and O +
entries O +
form O +
a O +
bipartite O +
graph O +
with O +
one O +
part O +
of O +
the O +
graph O +
representing O +
lists O +
and O +
the O +
other O +
part O +
representing O +
entries O -
. O +

The O +
presence O +
of O +
a O +
given O +
entry O +
in O +
a O +
given O +
list O +
is O +
indicated O +
by O +
an O +
edge O +
between O +
the O +
corresponding O +
list O +
and O +
entry O +
vertices O -
. O +

It O +
is O +
required O +
that O +
each O +
entry O +
can O +
be O +
linked O +
to O +
the O +
same O +
list O +
only O +
once O -
. O +

Without O +
loss O +
of O +
generality O -
, O +
let O -
's O +
consider O +
genes O +
as O +
entries O +
and O +
PubMedID_listIDs O +
as O +
lists O +
in O +
the O +
following O -
, O +
unless O +
otherwise O +
specified O +
( O -
Fig. O +
1A O -
) O -
. O +

This O +
interpretation O +
of O +
lists O +
and O +
entries O +
has O +
been O +
applied O +
in O +
the O +
co O -
- O -
occurrence O +
analysis O +
of O +
published O +
gene O +
expression O +
signatures O +
[ O -
35 O -
] O -
. O +

Occurrence O +
probabilities O +
and O +
null O -
- O -
models O +
A O +
prerequisite O +
for O +
co O -
- O -
occurrence O +
analysis O +
is O +
the O +
availability O +
of O +
occurrence O +
probabilities O +
of O +
genes O +
per O +
list O -
. O +

The O +
occurrence O +
probabilities O +
can O +
be O +
derived O +
from O +
randomizing O +
the O +
bipartite O +
graph O +
and O +
are O +
dependent O +
on O +
the O +
choice O +
of O +
the O +
null O -
- O -
model O -
. O +

A O +
null O -
- O -
model O +
creates O +
an O +
occurrence O +
probability O +
matrix O +
where O +
the O +
occurrence O +
probability O +
for O +
each O +
list O -
– O -
gene O +
pair O +
is O +
listed O -
. O +

As O +
a O +
general O +
property O +
of O +
this O +
matrix O -
, O +
the O +
sum O +
of O +
all O +
matrix O +
elements O +
must O +
equal O +
the O +
number O +
of O +
edges O +
in O +
the O +
bipartite O +
graph O -
. O +

This O +
is O +
because O +
each O +
edge O +
is O +
linked O +
to O +
either O +
side O +
of O +
the O +
bipartite O +
graph O +
with O +
certainty O +
and O +
therefore O +
the O +
sum O +
of O +
occurrence O +
probabilities O +
over O +
all O +
lists O +
( O -
which O +
can O +
be O +
calculated O +
as O +
the O +
row O +
sum O +
if O +
genes O +
are O +
listed O +
vertically O +
or O +
as O +
the O +
column O +
sum O +
if O +
genes O +
are O +
listed O +
horizontally O -
) O +
followed O +
by O +
summing O +
the O +
results O +
over O +
all O +
genes O +
must O +
be O +
1 O +
for O +
every O +
edge O -
. O +

The O +
number O +
of O +
matrix O +
elements O +
is O +
given O +
by O +
# O -
genes*#lists O +
and O +
therefore O +
the O +
average O +
occurrence O +
probability O +
for O +
any O +
null O -
- O -
model O +
must O +
be O +
# O -
edges O -
/ O -
( O -
#genes*#lists O -
) O -
. O +

As O +
a O +
consequence O -
, O +
different O +
null O -
- O -
models O +
will O +
only O +
be O +
distinguished O +
by O +
the O +
way O +
they O +
attribute O +
occurrence O +
probabilities O +
to O +
vertices O +
with O +
different O +
vertex O +
degrees O +
but O +
not O +
by O +
the O +
average O +
occurrence O +
probability O -
. O +

We O +
consider O +
six O +
different O +
strategies O +
to O +
randomize O +
the O +
bipartite O +
graph O -
. O +

First O -
, O +
we O +
could O +
reconnect O +
all O +
edges O +
of O +
the O +
graph O +
randomly O -
. O +

The O +
probability O +
of O +
being O +
connected O +
by O +
an O +
edge O +
for O +
a O +
given O +
list O -
- O -
gene O +
pair O +
is O +
given O +
by O +
( O -
1 O -
/ O -
#genes O -
) O -
* O -
( O -
1 O -
/ O -
#lists O -
) O -
. O +

Since O +
there O +
are O +
# O -
edges O +
edges O +
to O +
be O +
reconnected O -
, O +
the O +
occurrence O +
probability O +
for O +
a O +
single O +
list O -
- O -
gene O +
pair O +
is O +
# O -
edges O -
/ O -
( O -
#genes*#lists O -
) O -
, O +
i.e. O +
equal O +
to O +
the O +
average O +
occurrence O +
probability O -
. O +

Thus O -
, O +
this O +
model O +
provides O +
equal O +
occurrence O +
probabilities O +
for O +
all O +
gene O -
- O -
list O +
pairs O +
and O +
does O +
not O +
consider O +
vertex O +
degrees O -
. O +

We O +
call O +
this O +
model O +
the O +
generic O +
randomization O +
( O -
GR O -
) O +
model O +
in O +
the O +
following O -
. O +

Second O -
, O +
we O +
could O +
disconnect O +
the O +
edges O +
on O +
only O +
the O +
list O +
side O +
of O +
the O +
bipartite O +
graph O +
and O +
reconnect O +
them O +
randomly O -
. O +

The O +
occurrence O +
probability O +
of O +
a O +
gene O +
vertex O +
would O +
be O +
given O +
by O +
( O -
gene O +
vertex O +
degree O -
) O -
/ O -
#lists O -
. O +

The O +
sum O +
of O +
these O +
probabilities O +
over O +
all O +
lists O +
is O +
equal O +
to O +
the O +
gene O +
vertex O +
degree O +
and O +
the O +
sum O +
of O +
all O +
gene O +
vertex O +
degrees O +
is O +
equal O +
to O +
the O +
total O +
number O +
of O +
edges O -
. O +

Thus O -
, O +
the O +
sum O +
of O +
all O +
matrix O +
elements O +
is O +
equal O +
to O +
the O +
number O +
of O +
edges O -
, O +
as O +
required O -
. O +

Since O +
this O +
model O +
considers O +
gene O +
vertex O +
degrees O -
, O +
we O +
call O +
it O +
the O +
gene O +
vertex O +
degree O +
( O -
GVD O -
) O +
model O -
. O +

Third O -
, O +
we O +
disconnect O +
the O +
edges O +
on O +
the O +
gene O +
side O +
of O +
the O +
bipartite O +
graph O +
and O +
reconnect O +
them O +
randomly O -
. O +

The O +
probability O +
of O +
a O +
list O +
vertex O +
being O +
connected O +
to O +
a O +
gene O +
would O +
be O +
given O +
by O +
( O -
list O +
vertex O +
degree O -
) O -
/ O -
#genes O -
. O +

The O +
sum O +
of O +
these O +
probabilities O +
over O +
all O +
genes O +
is O +
equal O +
to O +
the O +
list O +
vertex O +
degree O +
and O +
the O +
sum O +
of O +
all O +
list O +
vertex O +
degrees O +
is O +
equal O +
to O +
the O +
total O +
number O +
of O +
edges O -
. O +

Again O -
, O +
the O +
sum O +
of O +
all O +
matrix O +
elements O +
is O +
equal O +
to O +
the O +
total O +
number O +
of O +
edges O -
. O +

Since O +
this O +
model O +
considers O +
list O +
vertex O +
degrees O -
, O +
we O +
call O +
it O +
the O +
list O +
vertex O +
degree O +
( O -
LVD O -
) O +
model O -
. O +

In O +
model O +
four O +
and O +
five O -
, O +
we O +
reconnect O +
edges O +
considering O +
both O +
gene O +
and O +
list O +
vertex O +
degrees O +
and O +
allow O +
multiple O +
edges O +
between O +
list O -
- O -
gene O +
pairs O -
. O +

The O +
occurrence O +
probabilities O +
in O +
model O +
four O +
are O +
calculated O +
according O +
to O +
the O +
binomial O +
distribution O -
. O +

We O +
calculate O +
the O +
probability O +
of O +
a O +
list O -
- O -
gene O +
pair O +
for O +
being O +
connected O +
as O +
the O +
cumulative O +
binomial O +
probability O +
of O +
the O +
list O -
- O -
gene O +
pair O +
being O +
chosen O +
at O +
least O +
once O +
in O +
the O +
process O +
of O +
randomly O +
reconnecting O +
the O +
edges O -
. O +

This O +
can O +
be O +
achieved O +
by O +
setting O +
the O +
number O +
of O +
trials O +
equal O +
to O +
the O +
gene O +
vertex O +
degree O -
, O +
the O +
probability O +
of O +
success O +
equal O +
to O +
the O +
list O +
vertex O +
degree O +
divided O +
by O +
the O +
total O +
number O +
of O +
edges O -
, O +
and O +
the O +
number O +
of O +
successes O +
equal O +
to O +
0 O -
. O +

The O +
occurrence O +
probability O +
of O +
a O +
list O -
- O -
gene O +
pair O +
is O +
then O +
given O +
by O +
the O +
complement O +
of O +
this O +
probability O -
. O +

This O +
model O +
is O +
called O +
the O +
binomial O +
( O -
BN O -
) O +
model O -
. O +

In O +
model O +
five O -
, O +
we O +
calculate O +
occurrence O +
probabilities O +
according O +
to O +
the O +
hypergeometric O +
distribution O -
. O +

The O +
number O +
of O +
successes O +
in O +
the O +
sample O +
is O +
equal O +
to O +
0 O -
, O +
the O +
sample O +
size O +
is O +
equal O +
to O +
the O +
gene O +
vertex O +
degree O -
, O +
the O +
number O +
of O +
successes O +
in O +
the O +
population O +
is O +
set O +
to O +
the O +
list O +
vertex O +
degree O -
, O +
and O +
the O +
population O +
size O +
is O +
the O +
total O +
number O +
of O +
edges O -
. O +

Again O -
, O +
the O +
occurrence O +
probability O +
of O +
a O +
list O -
- O -
gene O +
pair O +
is O +
obtained O +
as O +
the O +
complement O +
of O +
this O +
probability O -
. O +

We O +
call O +
this O +
model O +
the O +
hypergeometric O +
( O -
HG O -
) O +
model O -
. O +

Calculating O +
occurrence O +
probabilities O +
in O +
this O +
manner O +
does O +
not O +
guarantee O +
that O +
the O +
matrix O +
elements O +
add O +
up O +
to O +
the O +
total O +
number O +
of O +
edges O -
. O +

Therefore O -
, O +
the O +
matrices O +
are O +
normalized O +
such O +
that O +
this O +
condition O +
is O +
satisfied O +
by O +
multiplying O +
each O +
matrix O +
element O +
with O +
the O +
factor O +
# O -
edges O -
/ O -
( O -
observed O +
matrix O +
sum O -
) O -
, O +
which O +
is O +
generally O +
quite O +
close O +
to O +
1 O -
, O +
however O -
. O +

In O +
model O +
six O -
, O +
we O +
again O +
consider O +
vertex O +
degrees O -
, O +
but O +
we O +
require O +
that O +
each O +
list O +
is O +
composed O +
of O +
distinct O +
sets O +
of O +
genes O -
. O +

Thus O -
, O +
multiple O +
edges O +
are O +
forbidden O -
. O +

This O +
condition O +
is O +
satisfied O +
by O +
applying O +
an O +
edge O -
- O -
swapping O +
procedure O +
during O +
graph O +
randomization O -
. O +

Edge O -
- O -
swapping O +
works O +
by O +
randomly O +
choosing O +
two O +
list O -
- O -
gene O +
pairs O +
from O +
the O +
bipartite O +
graph O +
and O +
prior O +
to O +
performing O +
the O +
edge O -
- O -
swap O -
, O +
a O +
test O +
is O +
performed O +
to O +
ensure O +
that O +
the O +
two O +
genes O +
are O +
not O +
already O +
linked O +
to O +
the O +
respective O +
target O +
lists O -
. O +

This O +
procedure O +
is O +
performed O +
a O +
large O +
number O +
of O +
times O -
. O +

To O +
ensure O +
complete O +
randomization O +
of O +
the O +
graph O -
, O +
the O +
number O +
of O +
swaps O +
performed O +
should O +
be O +
significantly O +
larger O +
than O +
the O +
number O +
of O +
edges O -
. O +

After O +
performing O +
R O +
randomizations O +
of O +
the O +
graph O +
and O +
counting O +
the O +
number O +
of O +
times O +
a O +
gene O +
has O +
been O +
linked O +
to O +
a O +
particular O +
list O -
, O +
division O +
of O +
this O +
number O +
by O +
R O +
gives O +
the O +
occurrence O +
probability O +
of O +
a O +
gene O +
in O +
a O +
given O +
list O -
. O +

As O +
will O +
be O +
shown O +
below O -
, O +
edge O -
- O -
swapping O +
produces O +
occurrence O +
probabilities O +
that O +
closely O +
approximate O +
occurrence O +
probabilities O +
obtained O +
by O +
generating O +
a O +
complete O +
permutation O +
set O +
of O +
the O +
bipartite O +
graph O -
, O +
counting O +
the O +
number O +
of O +
times O +
a O +
gene O +
is O +
found O +
part O +
of O +
a O +
list O -
, O +
and O +
dividing O +
this O +
number O +
by O +
the O +
total O +
number O +
of O +
permutations O -
. O +

In O +
the O +
permutation O +
model O -
, O +
the O +
sum O +
of O +
occurrence O +
probabilities O +
of O +
a O +
gene O +
over O +
all O +
lists O +
equals O +
the O +
gene O +
vertex O +
degree O +
( O -
see O +
below O -
) O +
and O +
thus O +
the O +
sum O +
of O +
all O +
matrix O +
elements O +
is O +
the O +
number O +
of O +
edges O -
. O +

Since O +
permutation O +
sets O +
of O +
bipartite O +
graphs O +
are O +
difficult O +
to O +
calculate O -
, O +
we O +
use O +
the O +
edge O -
- O -
swapping O +
procedure O +
as O +
a O +
close O +
approximation O +
and O +
call O +
this O +
model O +
the O +
edge O -
- O -
swapping O +
( O -
ES O -
) O +
model O -
. O +

Fig. O +
1 O +
shows O +
the O +
occurrence O +
probabilities O +
of O +
the O +
different O +
null O -
- O -
models O +
for O +
the O +
bipartite O +
graph O +
shown O +
in O +
Fig. O +
1A O -
. O +

The O +
GR O +
model O +
yields O +
identical O +
occurrence O +
probabilities O +
for O +
all O +
list O -
- O -
gene O +
pairs O -
, O +
which O +
is O +
equal O +
to O +
the O +
average O +
occurrence O +
probability O +
in O +
all O +
models O -
. O +

In O +
the O +
other O +
models O -
, O +
the O +
occurrence O +
probabilities O +
deviate O +
to O +
varying O +
extent O +
from O +
the O +
average O +
occurrence O +
probability O +
as O +
a O +
function O +
of O +
vertex O +
degrees O -
. O +

In O +
the O +
GVD O +
model O -
, O +
the O +
deviations O +
are O +
a O +
function O +
of O +
gene O +
vertex O +
degree O +
and O +
in O +
the O +
LVD O +
model O +
the O +
deviations O +
are O +
dependent O +
on O +
list O +
vertex O +
degrees O -
. O +

In O +
the O +
remaining O +
models O -
, O +
the O +
deviations O +
are O +
functions O +
of O +
both O +
the O +
gene O +
and O +
the O +
list O +
vertex O +
degrees O -
. O +

In O +
all O +
cases O -
, O +
larger O +
than O +
average O +
occurrence O +
probabilities O +
are O +
obtained O +
for O +
larger O +
vertex O +
degrees O +
at O +
the O +
expense O +
of O +
smaller O +
than O +
average O +
occurrence O +
probabilities O +
for O +
smaller O +
vertex O +
degrees O -
. O +

From O +
these O +
data O -
, O +
it O +
is O +
difficult O +
to O +
choose O +
the O +
most O +
effective O +
null O -
- O -
model O -
. O +

A O +
hint O +
can O +
be O +
gleaned O +
from O +
gene1 O -
, O +
however O -
. O +

Gene1 O +
is O +
present O +
in O +
all O +
lists O -
. O +

Therefore O -
, O +
the O +
co O -
- O -
occurrence O +
probability O +
of O +
gene1 O +
with O +
other O +
genes O -
, O +
which O +
is O +
calculated O +
by O +
multiplying O +
the O +
occurrence O +
probabilities O +
of O +
gene1 O +
and O +
geneX O +
for O +
every O +
list O +
under O +
study O -
, O +
should O +
depend O +
only O +
on O +
the O +
occurrence O +
probability O +
of O +
this O +
other O +
gene O -
. O +

In O +
other O +
words O -
, O +
the O +
occurrence O +
probability O +
of O +
gene1 O +
in O +
all O +
lists O +
should O +
be O +
1.0 O -
. O +

Only O +
two O +
models O +
satisfy O +
this O +
constraint O -
: O +
The O +
GVD O +
and O +
the O +
ES O +
models O -
. O +

Since O +
the O +
GVD O +
model O +
does O +
not O +
consider O +
list O +
vertex O +
degrees O -
, O +
it O +
seems O +
that O +
the O +
ES O +
model O +
is O +
the O +
preferred O +
null O -
- O -
model O -
. O +

Expected O +
number O +
of O +
co O -
- O -
occurrences O +
As O +
a O +
general O +
criterion O +
for O +
comparing O +
the O +
effectiveness O +
of O +
different O +
null O -
- O -
models O -
, O +
we O +
have O +
to O +
compare O +
them O +
for O +
the O +
number O +
of O +
expected O +
co O -
- O -
occurrences O -
. O +

The O +
most O +
effective O +
null O -
- O -
model O +
will O +
be O +
the O +
one O +
that O +
maximizes O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O -
. O +

If O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
is O +
larger O -
, O +
an O +
observed O +
number O +
of O +
co O -
- O -
occurrences O +
in O +
a O +
real O +
bipartite O +
graph O +
will O +
be O +
less O +
significant O +
and O +
thus O +
such O +
a O +
null O -
- O -
model O +
permits O +
co O -
- O -
occurrence O +
analysis O +
with O +
higher O +
stringency O -
. O +

The O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
depends O +
in O +
an O +
obvious O +
fashion O +
on O +
the O +
list O +
vertex O +
degree O -
. O +

If O +
pair O -
- O -
wise O +
co O -
- O -
occurrences O +
are O +
considered O -
, O +
the O +
number O +
of O +
co O -
- O -
occurrences O +
in O +
a O +
list O +
of O +
vertex O +
degree O +
N O +
is O +
given O +
by O +
the O +
binomial O +
coefficient O +
N O +
over O +
2 O -
. O +

Larger O +
lists O +
will O +
give O +
rise O +
to O +
more O +
co O -
- O -
occurrences O +
and O +
the O +
number O +
increases O +
quickly O +
with O +
list O +
vertex O +
degree O -
. O +

The O +
dependency O +
of O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
on O +
the O +
gene O +
vertex O +
degree O +
is O +
less O +
obvious O +
and O +
depends O +
strongly O +
on O +
the O +
null O -
- O -
model O -
. O +

A O +
gene O +
that O +
is O +
part O +
of O +
a O +
list O +
with O +
vertex O +
degree O +
N O +
will O +
give O +
rise O +
to O +
N-1 O +
co O -
- O -
occurrences O +
in O +
that O +
list O -
. O +

The O +
null O -
- O -
model O +
permits O +
calculating O +
the O +
probability O +
to O +
find O +
this O +
gene O +
in O +
a O +
given O +
list O -
. O +

Thus O -
, O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
of O +
a O +
gene O +
is O +
given O +
by O +
the O +
sum O +
of O +
expected O +
co O -
- O -
occurrences O +
in O +
all O +
lists O +
where O +
for O +
a O +
single O +
list O +
the O +
expected O +
co O -
- O -
occurrences O +
are O +
given O +
by O +
( O -
Nl−1 O -
) O -
*pl O -
. O +

Nl O +
is O +
the O +
list O +
vertex O +
degree O +
and O +
pl O +
is O +
the O +
occurrence O +
probability O +
of O +
the O +
gene O +
in O +
that O +
list O +
as O +
determined O +
by O +
the O +
null O -
- O -
model O -
. O +

We O +
used O +
the O +
PubLiME O +
data O +
set O +
[ O -
35 O -
] O +
to O +
calculate O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
with O +
different O +
null O -
- O -
models O -
. O +

The O +
results O +
are O +
shown O +
in O +
Fig O +
2A O -
. O +

The O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
was O +
calculated O +
for O +
all O +
genes O +
in O +
all O +
lists O +
using O +
all O +
null O -
- O -
models O +
and O +
the O +
sum O +
of O +
expected O +
co O -
- O -
occurrences O +
per O +
gene O +
is O +
shown O +
as O +
a O +
scatter O +
plot O +
with O +
the O +
gene O +
vertex O +
degree O +
on O +
the O +
x O -
- O -
axis O +
and O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
on O +
the O +
y O -
- O -
axis O -
. O +

The O +
results O +
in O +
Fig. O +
2A O +
suggest O +
the O +
following O +
ranking O +
of O +
null O -
- O -
models O -
: O +
GR O -
< O -
GVD O -
< O -
LVD O -
< O -
BN O +
= O +
HG O -
< O -
ES O -
. O +

The O +
BN O +
and O +
the O +
HG O +
models O +
perform O +
in O +
an O +
essentially O +
identical O +
way O -
. O +

However O -
, O +
the O +
ES O +
model O +
is O +
the O +
model O +
that O +
yields O +
the O +
largest O +
estimates O +
of O +
expected O +
co O -
- O -
occurrences O -
. O +

The O +
results O +
are O +
also O +
in O +
line O +
with O +
the O +
intuitive O +
expectation O +
that O +
genes O +
with O +
higher O +
vertex O +
degree O +
give O +
rise O +
to O +
more O +
co O -
- O -
occurrences O -
. O +

However O -
, O +
it O +
can O +
be O +
seen O +
that O +
this O +
is O +
not O +
true O +
for O +
all O +
null O -
- O -
models O -
. O +

In O +
particular O -
, O +
it O +
is O +
not O +
true O +
for O +
the O +
GR O +
and O +
the O +
LVD O +
models O -
, O +
which O +
do O +
not O +
consider O +
gene O +
vertex O +
degrees O -
. O +

As O +
outlined O +
above O -
, O +
it O +
is O +
expected O +
that O +
the O +
null O -
- O -
model O +
that O +
yields O +
the O +
highest O +
estimates O +
of O +
expected O +
co O -
- O -
occurrences O +
should O +
permit O +
co O -
- O -
occurrence O +
analysis O +
with O +
the O +
highest O +
stringency O -
. O +

In O +
Fig. O +
2B O -
, O +
this O +
hypothesis O +
is O +
tested O +
directly O +
again O +
using O +
the O +
PubLiME O +
data O +
set O +
[ O -
35 O -
] O -
. O +

For O +
all O +
null O -
- O -
models O -
, O +
co O -
- O -
occurrence O +
analysis O +
was O +
carried O +
out O +
using O +
module O +
size O +
3 O +
and O +
support O +
5 O +
( O -
co O -
- O -
occurrence O +
modules O +
must O +
be O +
present O +
in O +
at O +
least O +
five O +
publications O -
) O -
. O +

The O +
choice O +
of O +
these O +
parameters O +
has O +
been O +
discussed O +
in O +
[ O -
35 O -
] O -
. O +

The O +
number O +
of O +
co O -
- O -
occurrence O +
modules O +
was O +
then O +
determined O +
that O +
have O +
a O +
Z O -
- O -
score O +
higher O +
or O +
equal O +
than O +
the O +
cut O -
- O -
off O +
shown O +
in O +
Fig. O +
2B O -
. O +

The O +
Z O -
- O -
score O +
is O +
calculated O +
from O +
the O +
mean O +
and O +
variance O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
as O +
shown O +
in O +
the O +
Materials O +
and O +
Methods O +
section O +
and O +
published O +
in O +
[ O -
35 O -
] O -
. O +

More O +
details O +
on O +
the O +
probability O +
distribution O +
will O +
be O +
provided O +
below O -
. O +

The O +
GR O +
and O +
GVD O +
models O +
perform O +
very O +
poorly O +
and O +
identify O +
large O +
numbers O +
of O +
modules O +
with O +
high O +
Z O -
- O -
scores O -
. O +

The O +
LVD O +
model O +
performs O +
a O +
little O +
better O +
and O +
approximates O +
the O +
BN O +
and O +
HG O +
models O +
at O +
higher O +
Z O -
- O -
score O +
cut O -
- O -
offs O -
. O +

The O +
BN O +
and O +
HG O +
models O +
give O +
essentially O +
identical O +
results O -
. O +

However O -
, O +
the O +
ES O +
model O +
is O +
the O +
model O +
that O +
yields O +
the O +
fewest O +
number O +
of O +
significant O +
co O -
- O -
occurrence O +
modules O +
and O +
is O +
thus O +
the O +
most O +
stringent O -
. O +

The O +
increased O +
stringency O +
of O +
the O +
ES O +
model O +
over O +
the O +
BN O +
and O +
HG O +
models O +
is O +
also O +
reflected O +
in O +
a O +
higher O +
signal O -
- O -
to O -
- O -
noise O +
ratio O +
calculated O +
as O +
the O +
number O +
of O +
significant O +
co O -
- O -
occurrence O +
modules O +
in O +
the O +
real O +
bipartite O +
graph O +
divided O +
by O +
the O +
number O +
of O +
modules O +
found O +
in O +
a O +
randomized O +
bipartite O +
graph O +
( O -
Fig. O +
2C O -
) O -
. O +

The O +
reason O +
for O +
the O +
superior O +
stringency O +
of O +
the O +
ES O +
model O +
over O +
all O +
other O +
models O +
can O +
be O +
explained O +
by O +
examining O +
the O +
average O +
occurrence O +
probability O +
per O +
gene O +
and O +
list O +
vertex O +
degree O -
. O +

Fig. O +
2D O +
and O +
E O +
show O +
the O +
average O +
occurrence O +
probability O +
of O +
genes O +
with O +
the O +
same O +
gene O +
vertex O +
degree O +
as O +
a O +
function O +
of O +
the O +
gene O +
vertex O +
degree O -
. O +

It O +
can O +
be O +
seen O +
that O +
the O +
ES O +
model O +
yields O +
higher O +
occurrence O +
probability O +
estimates O +
for O +
genes O +
with O +
higher O +
vertex O +
degrees O +
as O +
compared O +
to O +
the O +
BN O +
and O +
HG O +
models O -
. O +

In O +
GR O +
and O +
LVD O +
models O -
, O +
gene O +
vertex O +
degrees O +
are O +
ignored O +
and O +
occurrence O +
probabilities O +
for O +
genes O +
with O +
large O +
vertex O +
degree O +
are O +
very O +
small O -
, O +
which O +
is O +
compensated O +
by O +
larger O +
occurrence O +
probabilities O +
for O +
genes O +
with O +
small O +
vertex O +
degree O -
. O +

The O +
GVD O +
model O +
is O +
identical O +
to O +
the O +
ES O +
model O +
in O +
this O +
setting O -
. O +

Fig. O +
2E O +
shows O +
the O +
average O +
occurrence O +
probability O +
of O +
all O +
lists O +
with O +
the O +
same O +
vertex O +
degree O +
as O +
a O +
function O +
of O +
list O +
vertex O +
degree O -
. O +

It O +
can O +
be O +
seen O +
that O +
the O +
ES O +
model O +
provides O +
higher O +
occurrence O +
probability O +
estimates O +
for O +
large O +
lists O +
as O +
compared O +
to O +
the O +
BN O +
and O +
HG O +
models O -
. O +

In O +
this O +
setting O -
, O +
the O +
LVD O +
model O +
performs O +
like O +
the O +
ES O +
model O +
while O +
the O +
GR O +
and O +
GVD O +
models O +
yield O +
small O +
occurrence O +
probabilities O +
for O +
large O +
lists O -
. O +

Since O +
it O +
has O +
been O +
shown O +
above O +
that O +
long O +
lists O +
and O +
genes O +
with O +
high O +
vertex O +
degree O +
are O +
responsible O +
for O +
a O +
large O +
part O +
of O +
the O +
total O +
number O +
of O +
co O -
- O -
occurrences O +
for O +
the O +
most O +
stringent O +
null O -
- O -
models O -
, O +
the O +
null O -
- O -
model O +
that O +
provides O +
larger O +
occurrence O +
probability O +
estimates O +
for O +
genes O +
and O +
lists O +
with O +
high O +
vertex O +
degree O +
at O +
the O +
expense O +
of O +
lower O +
estimates O +
for O +
smaller O +
degrees O +
will O +
be O +
the O +
most O +
stringent O +
because O +
large O +
occurrence O +
probabilities O +
make O +
co O -
- O -
occurrence O +
more O +
likely O +
and O +
thus O +
less O +
significant O -
. O +

By O +
these O +
criteria O -
, O +
the O +
ES O +
model O +
is O +
the O +
most O +
stringent O +
of O +
all O +
models O +
tested O -
. O +

The O +
ES O +
model O +
as O +
an O +
approximation O +
of O +
the O +
permutation O +
null O -
- O -
model O +
The O +
data O +
shown O +
above O +
have O +
revealed O +
that O +
the O +
ES O +
model O +
is O +
the O +
best O +
of O +
the O +
models O +
tested O -
. O +

One O +
may O +
wonder O -
, O +
however O -
, O +
whether O +
yet O +
more O +
effective O +
null O -
- O -
models O +
can O +
be O +
found O -
. O +

An O +
obvious O +
choice O +
would O +
be O +
the O +
permutation O +
model O -
. O +

In O +
the O +
permutation O +
model O -
, O +
a O +
complete O +
permutation O +
set O +
of O +
the O +
bipartite O +
graph O +
is O +
created O +
such O +
that O +
each O +
list O +
is O +
composed O +
of O +
distinct O +
sets O +
of O +
genes O -
. O +

The O +
number O +
of O +
graphs O +
where O +
a O +
gene O +
is O +
present O +
in O +
a O +
given O +
list O +
divided O +
by O +
the O +
total O +
number O +
of O +
permutations O +
then O +
provides O +
the O +
occurrence O +
probability O +
estimate O -
. O +

The O +
permutation O +
model O +
is O +
the O +
ideal O +
null O -
- O -
model O +
because O +
it O +
is O +
exhaustive O -
. O +

The O +
problem O +
is O +
that O +
a O +
complete O +
permutation O +
set O +
of O +
bipartite O +
graphs O +
of O +
some O +
complexity O +
is O +
very O +
time O +
consuming O +
to O +
calculate O -
. O +

For O +
example O -
, O +
the O +
simple O +
bipartite O +
graph O +
from O +
Fig. O +
1A O +
is O +
part O +
of O +
a O +
permutation O +
set O +
of O +
455 O +
graphs O -
. O +

The O +
number O +
of O +
permutations O +
is O +
increasing O +
quickly O +
as O +
the O +
numbers O +
of O +
genes O +
and O +
lists O +
grow O -
. O +

However O -
, O +
since O +
edge O -
- O -
swapping O +
ensures O +
that O +
gene O +
lists O +
are O +
composed O +
of O +
distinct O +
sets O +
of O +
genes O -
, O +
each O +
edge O -
- O -
swap O +
produces O +
a O +
graph O +
that O +
is O +
part O +
of O +
the O +
permutation O +
set O +
of O +
the O +
bipartite O +
graph O -
. O +

Edge O -
- O -
swapping O +
can O +
thus O +
be O +
viewed O +
as O +
a O +
random O +
sampling O +
procedure O +
from O +
the O +
permutation O +
set O +
of O +
the O +
bipartite O +
graph O -
. O +

Therefore O -
, O +
occurrence O +
probability O +
estimates O +
derived O +
by O +
edge O -
- O -
swapping O +
should O +
approximate O +
those O +
obtained O +
from O +
the O +
permutation O +
model O -
. O +

We O +
generated O +
a O +
complete O +
permutation O +
set O +
of O +
the O +
graph O +
shown O +
in O +
Fig. O +
1A O +
to O +
verify O +
this O +
hypothesis O -
. O +

The O +
results O +
are O +
shown O +
in O +
Fig. O +
3 O -
. O +

Fig. O +
3A O +
shows O +
how O +
the O +
number O +
of O +
possible O +
permutations O +
can O +
be O +
calculated O -
. O +

Gene1 O +
is O +
present O +
in O +
all O +
lists O +
and O +
does O +
not O +
have O +
an O +
impact O +
on O +
the O +
total O +
number O +
of O +
permutations O -
. O +

Gene2 O -
, O +
having O +
vertex O +
degree O +
two O -
, O +
is O +
present O +
in O +
two O +
out O +
of O +
three O +
lists O +
in O +
one O +
out O +
of O +
three O +
possible O +
ways O -
. O +

The O +
remaining O +
genes O +
have O +
vertex O +
degree O +
1 O +
and O +
can O +
be O +
freely O +
chosen O +
to O +
fill O +
the O +
empty O +
slots O -
. O +

We O +
can O +
now O +
count O +
exactly O +
how O +
many O +
times O +
a O +
gene O +
is O +
linked O +
to O +
a O +
list O +
and O +
divide O +
these O +
counts O +
by O +
455 O -
, O +
the O +
size O +
of O +
the O +
permutation O +
set O -
, O +
to O +
obtain O +
exact O +
occurrence O +
probabilities O -
. O +

These O +
numbers O +
are O +
shown O +
in O +
graphical O +
form O +
in O +
Fig. O +
3B O +
and O +
in O +
numerical O +
form O +
in O +
Fig. O +
3C O -
. O +

Fig. O +
3B O +
also O +
shows O +
the O +
occurrence O +
probability O +
estimates O +
obtained O +
by O +
edge O -
- O -
swapping O +
side O -
- O -
by O -
- O -
side O +
to O +
the O +
exact O +
occurrence O +
probabilities O -
. O +

The O +
graph O +
in O +
Fig. O +
1A O +
was O +
subjected O +
to O +
edge O -
- O -
swapping O +
1000 O +
times O +
and O +
the O +
number O +
of O +
times O +
a O +
gene O +
was O +
found O +
present O +
in O +
a O +
list O +
was O +
divided O +
by O +
1000 O +
to O +
obtain O +
the O +
occurrence O +
probability O -
. O +

At O +
each O +
run O -
, O +
100 O +
random O +
edge O +
swaps O +
were O +
performed O +
to O +
ensure O +
complete O +
randomization O +
of O +
the O +
graph O -
. O +

This O +
procedure O +
was O +
repeated O +
10 O +
times O +
and O +
the O +
mean O +
and O +
standard O +
deviation O +
of O +
occurrence O +
probability O +
estimates O +
for O +
each O +
gene O +
in O +
each O +
list O +
are O +
shown O -
. O +

In O +
all O +
cases O -
, O +
the O +
mean O +
differs O +
from O +
the O +
real O +
probability O +
by O +
less O +
than O +
two O +
standard O +
deviations O -
, O +
in O +
most O +
cases O +
by O +
less O +
than O +
one O +
standard O +
deviation O -
. O +

Thus O -
, O +
edge O -
- O -
swapping O +
provides O +
reliable O +
estimates O +
of O +
exact O +
occurrence O +
probabilities O +
as O +
determined O +
from O +
a O +
complete O +
permutation O +
set O -
. O +

As O +
an O +
interesting O +
observation O -
, O +
we O +
provide O +
evidence O +
that O +
occurrence O +
probabilities O +
are O +
non O -
- O -
linear O +
functions O +
of O +
vertex O +
degrees O +
in O +
the O +
edge O -
- O -
swapping O +
model O -
. O +

This O +
is O +
illustrated O +
in O +
Fig. O +
3C O -
. O +

Individual O +
and O +
average O +
occurrence O +
probabilities O +
are O +
shown O +
as O +
a O +
function O +
of O +
gene O +
and O +
list O +
vertex O +
degrees O -
. O +

Non O -
- O -
linearity O +
of O +
individual O +
occurrence O +
probabilities O +
can O +
be O +
verified O +
from O +
the O +
counts O +
table O +
underneath O +
the O +
plots O -
. O +

However O -
, O +
the O +
average O +
occurrence O +
probability O +
is O +
found O +
to O +
depend O +
on O +
vertex O +
degrees O +
in O +
a O +
linear O +
fashion O +
instead O -
. O +

This O +
is O +
a O +
consequence O +
of O +
the O +
fact O +
that O +
occurrence O +
probabilities O +
of O +
a O +
gene O +
over O +
all O +
lists O +
add O +
up O +
to O +
the O +
gene O +
vertex O +
degree O +
and O +
that O +
the O +
occurrence O +
probabilities O +
of O +
all O +
genes O +
for O +
a O +
given O +
list O +
add O +
up O +
to O +
the O +
list O +
vertex O +
degree O -
. O +

At O +
the O +
same O +
time O -
, O +
since O +
the O +
most O +
stringent O +
permutation O +
based O +
null O -
- O -
model O +
predicts O +
non O -
- O -
linear O +
dependencies O +
of O +
individual O +
occurrence O +
probabilities O +
on O +
vertex O +
degrees O -
, O +
assuming O +
such O +
linearity O +
in O +
statistical O +
models O +
of O +
co O -
- O -
occurrence O +
will O +
be O +
linked O +
to O +
loss O +
of O +
stringency O -
. O +

We O +
conclude O +
that O +
the O +
ES O +
null O -
- O -
model O +
is O +
the O +
null O -
- O -
model O +
that O +
permits O +
co O -
- O -
occurrence O +
analysis O +
with O +
the O +
highest O +
stringency O +
among O +
the O +
models O +
tested O +
and O +
that O +
it O +
closely O +
approximates O +
occurrence O +
probabilities O +
derived O +
from O +
an O +
ideal O +
permutation O +
model O -
. O +

The O +
increased O +
stringency O +
of O +
the O +
ES O +
model O +
over O +
other O +
models O +
is O +
a O +
consequence O +
of O +
higher O +
occurrence O +
probabilities O +
for O +
genes O +
and O +
list O +
with O +
high O +
vertex O +
degrees O -
, O +
which O +
are O +
giving O +
rise O +
to O +
a O +
large O +
part O +
of O +
all O +
co O -
- O -
occurrences O +
in O +
the O +
bipartite O +
graph O -
. O +

Since O +
large O +
occurrence O +
probabilities O +
make O +
co O -
- O -
occurrence O +
more O +
likely O -
, O +
the O +
analysis O +
becomes O +
more O +
stringent O -
. O +

Co O -
- O -
occurrence O +
probabilities O +
Co O -
- O -
occurrence O +
analysis O +
can O +
be O +
thought O +
of O +
as O +
a O +
Bernoulli O +
experiment O +
with O +
a O +
binomial O +
outcome O +
( O -
a O +
given O +
combination O +
of O +
entries O +
is O +
either O +
present O +
or O +
not O +
present O +
in O +
a O +
given O +
list O -
) O -
. O +

Thus O -
, O +
the O +
Binomial O +
distribution O +
( O -
BD O -
) O +
is O +
a O +
natural O +
choice O +
for O +
judging O +
the O +
significance O +
of O +
the O +
number O +
of O +
co O -
- O -
occurrences O -
. O +

However O -
, O +
the O +
BD O +
is O +
defined O +
for O +
a O +
probability O +
of O +
success O +
which O +
is O +
equal O +
in O +
all O +
trials O -
. O +

The O +
list O -
- O -
specific O +
nature O +
of O +
occurrence O +
probabilities O +
is O +
not O +
compatible O +
with O +
this O +
condition O +
( O -
analysis O +
of O +
each O +
list O +
represents O +
one O +
trial O -
) O -
, O +
which O +
means O +
that O +
co O -
- O -
occurrence O +
analysis O +
in O +
the O +
presence O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
is O +
better O +
described O +
as O +
a O +
series O +
of O +
Poisson O +
trials O -
, O +
where O +
the O +
probability O +
of O +
success O +
varies O +
from O +
trial O +
to O +
trial O -
. O +

Therefore O -
, O +
the O +
significance O +
of O +
co O -
- O -
occurrences O +
must O +
be O +
evaluated O +
using O +
a O +
binomial O +
distribution O +
with O +
trial O -
- O -
specific O +
probabilities O -
, O +
i.e. O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
( O -
PBD O -
) O -
. O +

The O +
probability O +
of O +
success O +
in O +
a O +
single O +
Poisson O +
trial O +
can O +
be O +
calculated O +
by O +
multiplying O +
the O +
list O -
- O -
specific O +
occurrence O +
probabilities O +
for O +
the O +
combination O +
of O +
genes O +
under O +
study O -
. O +

The O +
number O +
of O +
occurrence O +
probabilities O +
that O +
need O +
to O +
be O +
multiplied O +
is O +
equal O +
to O +
the O +
module O +
size O -
, O +
i.e. O +
the O +
number O +
of O +
genes O +
whose O +
combination O +
is O +
studied O -
. O +

An O +
observed O +
number O +
of O +
co O -
- O -
occurrences O +
for O +
a O +
combination O +
of O +
genes O +
can O +
then O +
be O +
evaluated O +
using O +
the O +
PBD O -
, O +
which O +
is O +
given O +
by O +
the O +
formula O +
[ O -
36 O -
] O -
: O -
( O -
18 O -
) O +
The O +
structure O +
of O +
this O +
formula O +
is O +
very O +
similar O +
to O +
the O +
structure O +
of O +
the O +
formula O +
used O +
to O +
calculate O +
the O +
binomial O +
distribution O -
, O +
except O +
that O +
multiplication O +
with O +
a O +
binomial O +
coefficient O +
is O +
replaced O +
by O +
summation O +
over O +
individual O +
terms O -
, O +
which O +
makes O +
calculation O +
of O +
P O -
- O -
values O +
using O +
( O -
18 O -
) O +
inefficient O +
( O -
note O +
that O +
equation O +
numbering O +
starts O +
in O +
the O +
Materials O +
and O +
Methods O +
section O -
) O -
. O +

Here O -
, O +
Ak O +
denotes O +
the O +
kth O +
set O +
of O +
indices O +
of O +
the O +
i O +
lists O +
where O +
genes O +
are O +
co O -
- O -
occurring O +
( O -
" O -
success O -
" O -
) O -
. O +

There O +
are O +
possible O +
sets O +
and O +
summation O +
is O +
carried O +
out O +
accordingly O -
. O +

denotes O +
the O +
set O +
of O +
indices O +
of O +
N−i O +
lists O +
where O +
genes O +
are O +
not O +
co O -
- O -
occurring O +
( O -
" O -
failure O -
" O -
) O -
. O +

[ O -
36 O -
] O +
have O +
reported O +
two O +
fast O +
procedures O +
for O +
calculating O +
exact O +
PBD O +
P O -
- O -
values O -
. O +

However O -
, O +
both O +
procedures O +
work O +
with O +
probability O +
ratios O +
and O +
suffer O +
from O +
numerical O +
overflow O -
/ O -
underflow O +
problems O +
for O +
large O +
numbers O +
of O +
trials O -
. O +

NetCutter O +
uses O +
two O +
workarounds O +
to O +
circumvent O +
this O +
problem O -
. O +

One O +
is O +
based O +
on O +
using O +
Poisson O -
- O -
binomial O +
Z O -
- O -
scores O -
, O +
which O +
can O +
be O +
calculated O +
very O +
easily O +
instead O +
( O -
see O +
below O -
) O -
. O +

The O +
other O +
relies O +
on O +
a O +
fast O +
approximation O +
procedure O +
for O +
calculating O +
Poisson O -
- O -
binomial O +
P O -
- O -
values O -
, O +
which O +
we O +
call O +
bi O -
- O -
binomial O +
approximation O +
( O -
BBA O -
) O +
or O +
bi O -
- O -
binomial O +
distribution O +
( O -
BBD O -
) O -
. O +

Z O -
- O -
scores O +
and O +
P O -
- O -
values O +
of O +
BBD O +
Given O +
the O +
mean O +
μ O +
( O -
1 O -
) O +
and O +
variance O +
σ2 O +
( O -
2 O -
) O +
of O +
PBD O +
( O -
see O +
Materials O +
and O +
Methods O -
) O -
, O +
the O +
Z O -
- O -
score O +
associated O +
with O +
a O +
given O +
number O +
of O +
co O -
- O -
occurrences O +
x O +
is O +
obtained O +
as: O -
( O -
19 O -
) O +
Considering O +
the O +
structure O +
of O +
formulae O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
( O -
Materials O +
and O +
Methods O +
section O -
) O -
, O +
PBD O +
Z O -
- O -
scores O +
can O +
be O +
calculated O +
very O +
easily O +
and O +
provide O +
a O +
simple O +
estimate O +
of O +
the O +
significance O +
of O +
co O -
- O -
occurrence O +
modules O -
. O +

However O -
, O +
in O +
contrast O +
to O +
normally O +
distributed O +
Z O -
- O -
scores O -
, O +
binomial O +
and O +
Poisson O -
- O -
binomial O +
Z O -
- O -
scores O +
do O +
not O +
correspond O +
to O +
the O +
same O +
P O -
- O -
value O +
for O +
different O +
sets O +
of O +
probabilities O +
of O +
success O -
. O +

To O +
see O +
this O -
, O +
calculate O +
for O +
example O +
the O +
probability O +
of O +
success O +
in O +
a O +
series O +
of O +
100 O +
Bernoulli O +
trials O +
with O +
success O +
probability O +
0.1 O +
and O +
0.9 O +
for O +
the O +
expectation O +
of O +
10 O +
and O +
90 O +
successes O -
, O +
respectively O -
. O +

The O +
Z O -
- O -
score O +
will O +
be O +
0 O +
in O +
both O +
cases O +
but O +
the O +
corresponding O +
cumulative O +
P O -
- O -
values O +
are O +
0.5832 O +
and O +
0.5487 O -
. O +

Therefore O -
, O +
exact O +
levels O +
of O +
significance O +
can O -
not O +
be O +
derived O +
from O +
Z O -
- O -
scores O +
alone O -
. O +

Thus O -
, O +
a O +
fast O +
and O +
reliable O +
procedure O +
for O +
calculating O +
Poisson O -
- O -
binomial O +
P O -
- O -
values O +
is O +
needed O -
. O +

The O +
BBD O +
approximation O +
was O +
developed O +
to O +
solve O +
this O +
problem O -
. O +

The O +
BBD O +
approximation O +
of O +
PBD O +
P O -
- O -
values O +
follows O +
from O +
the O +
relationship O +
between O +
the O +
variance O +
of O +
PBD O +
and O +
the O +
population O +
variance O +
of O +
trial O -
- O -
specific O +
probabilities O +
of O +
success O -
. O +

This O +
relationship O +
is O +
shown O +
in O +
Materials O +
and O +
Methods O +
to O +
be O +
described O +
by O +
( O -
4 O -
) O -
: O -
( O -
4 O -
) O +
This O +
equation O +
shows O +
that O +
there O +
is O +
an O +
inverse O +
linear O +
relationship O +
between O +
the O +
population O +
variance O +
S2 O +
of O +
the O +
N O +
trial O +
probabilities O +
and O +
the O +
variance O +
of O +
PBD O +
σ2 O -
, O +
which O +
means O +
that O +
PBD O +
becomes O +
increasingly O +
narrow O +
as O +
the O +
variance O +
of O +
trial O +
probabilities O +
grows O -
. O +

It O +
also O +
shows O +
that O -
, O +
for O +
constant O +
mean O +
μ O +
and O +
number O +
of O +
trials O +
N O -
, O +
the O +
shape O +
of O +
PBD O +
depends O +
only O +
on O +
the O +
variance O +
of O +
trial O +
probabilities O -
. O +

Therefore O -
, O +
relationship O +
( O -
4 O -
) O +
suggests O +
an O +
easy O +
way O +
to O +
approximate O +
PBD O +
P O -
- O -
values O -
. O +

The O +
P O -
- O -
value O +
can O +
be O +
obtained O +
by O +
constructing O +
a O +
set O +
of O +
trial O +
probabilities O +
with O +
equal O +
variance O +
as O +
the O +
original O +
set O +
of O +
trial O +
probabilities O -
, O +
which O -
, O +
however O -
, O +
are O +
not O +
all O +
different O -
. O +

In O +
other O +
words O -
, O +
the O +
series O +
of O +
Poisson O +
trials O +
can O +
be O +
replaced O +
by O +
two O +
sets O +
of O +
Bernoulli O +
trials O +
with O +
trial O +
probabilities O +
p1 O +
and O +
p2 O +
constructed O +
such O +
that O +
the O +
variance O +
is O +
equal O +
to O +
the O +
original O +
set O +
of O +
trial O +
probabilities O -
. O +

This O +
strategy O +
is O +
illustrated O +
in O +
Fig. O +
4 O +
and O +
explains O +
why O +
this O +
approximation O +
is O +
called O +
bi O -
- O -
binomial O -
. O +

The O +
details O +
on O +
how O +
to O +
obtain O +
the O +
values O +
of O +
the O +
two O +
sets O +
of O +
Bernoulli O +
trial O +
probabilities O +
and O +
the O +
number O +
of O +
trials O +
with O +
p1 O +
and O +
p2 O +
as O +
probabilities O +
of O +
success O +
are O +
provided O +
in O +
the O +
Materials O +
and O +
Methods O +
section O -
. O +

The O +
precision O +
of O +
the O +
BBD O +
approximation O +
is O +
discussed O +
in O +
supplementary O +
material O +
Simulation O +
S1 O -
. O +

In O +
order O +
to O +
evaluate O +
whether O +
BBD O +
P O -
- O -
values O +
as O +
a O +
significance O +
measure O +
of O +
co O -
- O -
occurrence O +
offer O +
an O +
advantage O +
over O +
other O +
measures O +
such O +
as O +
the O +
Jaccard O +
coefficient O +
or O +
the O +
uncertainty O +
coefficient O -
, O +
pair O -
- O -
wise O +
co O -
- O -
occurrence O +
of O +
two O +
genes O +
in O +
200 O +
lists O +
with O +
and O +
without O +
list O -
- O -
length O -
- O -
heterogeneity O +
was O +
studied O +
( O -
Fig. O +
5 O -
) O -
. O +

Each O +
gene O +
is O +
assumed O +
to O +
occur O +
in O +
100 O +
lists O -
. O +

Therefore O -
, O +
the O +
occurrence O +
probabilities O +
of O +
both O +
genes O +
over O +
all O +
200 O +
lists O +
must O +
add O +
up O +
to O +
100 O -
, O +
regardless O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O -
. O +

For O +
simplicity O -
, O +
occurrence O +
probabilities O +
of O +
both O +
genes O +
are O +
assumed O +
to O +
be O +
equal O +
in O +
any O +
particular O +
list O -
. O +

The O +
co O -
- O -
occurrence O +
probability O +
in O +
a O +
list O +
is O +
then O +
given O +
by O +
the O +
square O +
of O +
the O +
occurrence O +
probability O +
in O +
that O +
list O -
. O +

For O +
all O +
possible O +
co O -
- O -
occurrences O +
from O +
0 O +
to O +
100 O -
, O +
the O +
Jaccard O +
and O +
uncertainty O +
coefficients O +
were O +
calculated O +
as O +
detailed O +
in O +
the O +
Materials O +
and O +
Methods O +
section O -
. O +

In O +
addition O -
, O +
cumulative O +
BBD O +
P O -
- O -
values O +
were O +
calculated O +
using O +
the O +
co O -
- O -
occurrence O +
probabilities O +
as O +
trial O +
probabilities O -
. O +

To O +
illustrate O +
the O +
advantage O +
of O +
BBD O +
over O +
BD O +
as O +
co O -
- O -
occurrence O +
probability O +
distribution O -
, O +
cumulative O +
BD O +
P O -
- O -
values O +
of O +
a O +
BD O +
with O +
the O +
same O +
mean O +
as O +
BBD O +
but O +
constant O +
trial O +
probabilities O +
is O +
shown O -
. O +

These O +
trial O +
probabilities O +
can O +
be O +
obtained O +
by O +
dividing O +
the O +
mean O +
of O +
BBD O +
by O +
the O +
number O +
of O +
lists O -
. O +

Three O +
different O +
cases O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
are O +
considered O +
in O +
Fig. O +
5 O -
: O +
No O +
heterogeneity O +
( O -
standard O +
deviation O +
0 O -
) O -
, O +
heterogeneity O +
with O +
standard O +
deviation O +
0.283 O +
and O +
heterogeneity O +
with O +
standard O +
deviation O +
0.401 O +
in O +
the O +
occurrence O +
probabilities O -
. O +

The O +
Jaccard O +
and O +
uncertainty O +
coefficients O +
are O +
by O +
definition O +
insensitive O +
to O +
list O -
- O -
length O -
- O -
heterogeneity O +
because O +
differences O +
in O +
co O -
- O -
occurrence O +
probabilities O +
in O +
a O +
given O +
list O +
can O -
not O +
be O +
considered O +
in O +
their O +
calculation O -
. O +

This O +
is O +
because O +
both O +
coefficients O +
are O +
defined O +
by O +
the O +
counts O +
of O +
the O +
four O +
list O +
classes O -
: O +
both O +
genes O +
absent O -
, O +
both O +
genes O +
present O -
, O +
first O +
gene O +
absent O +
second O +
gene O +
present O -
, O +
and O +
first O +
gene O +
present O +
second O +
gene O +
absent O -
, O +
i.e. O +
by O +
the O +
corresponding O +
contingency O +
table O -
, O +
which O +
does O +
not O +
change O +
with O +
different O +
list O -
- O -
length O -
- O -
heterogeneity O -
. O +

In O +
the O +
absence O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O -
, O +
the O +
cumulative O +
P O -
- O -
values O +
of O +
BD O +
and O +
BBD O +
( O -
which O +
are O +
perfectly O +
overlapping O +
as O +
expected O -
) O +
assume O +
0.5 O +
at O +
50 O +
co O -
- O -
occurrences O -
, O +
which O +
corresponds O +
to O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
calculated O +
as O +
( O -
50 O +
= O +
100 O +
occurrences O +
per O +
gene O -
/ O -
200 O +
lists O -
) O +
ˆ2 O -
* O -
200 O +
lists O -
. O +

The O +
uncertainty O +
coefficient O +
is O +
found O +
to O +
be O +
0 O +
and O +
the O +
Jaccard O +
coefficient O +
is O +
0.33333 O +
at O +
that O +
point O -
. O +

When O +
there O +
is O +
modest O +
list O -
- O -
length O -
- O -
heterogeneity O +
( O -
standard O +
deviation O +
0.283 O -
) O -
, O +
the O +
mean O +
of O +
BBD O +
is O +
shifting O +
to O +
the O +
right O -
. O +

This O +
is O +
because O +
the O +
sum O +
of O +
squares O +
of O +
varying O +
occurrence O +
probabilities O +
( O -
i.e. O +
the O +
sum O +
of O +
co O -
- O -
occurrence O +
probabilities O +
used O +
as O +
trial O +
probabilities O -
, O +
which O +
is O +
equal O +
to O +
the O +
mean O +
of O +
BBD O -
) O +
is O +
always O +
larger O +
than O +
the O +
sum O +
of O +
squares O +
of O +
constant O +
occurrence O +
probabilities O +
with O +
the O +
same O +
average O +
occurrence O +
probability O +
( O -
0.5 O -
) O -
. O +

The O +
corresponding O +
BD O +
in O +
the O +
presence O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
is O +
obtained O +
by O +
dividing O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
by O +
the O +
total O +
number O +
of O +
lists O -
, O +
which O +
means O +
assuming O +
equal O +
co O -
- O -
occurrences O +
in O +
all O +
lists O -
. O +

This O +
visualization O +
is O +
shown O +
to O +
illustrate O +
how O +
BBD O +
( O -
which O +
is O +
narrower O +
than O +
the O +
corresponding O +
BD O -
) O +
gives O +
rise O +
to O +
a O +
steeper O +
cumulative O +
distribution O +
of O +
P O -
- O -
values O +
and O +
as O +
a O +
consequence O +
to O +
more O +
significant O +
P O -
- O -
values O +
for O +
numbers O +
of O +
co O -
- O -
occurrence O +
that O +
are O +
far O +
from O +
the O +
expectation O -
. O +

As O +
the O +
level O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
grows O +
( O -
standard O +
deviation O +
of O +
occurrence O +
probabilities O +
0.401 O -
) O -
, O +
the O +
mean O +
of O +
BBD O +
is O +
shifted O +
even O +
further O +
to O +
the O +
right O +
and O +
BBD O +
P O -
- O -
values O +
are O +
distributed O +
in O +
a O +
still O +
steeper O +
fashion O +
as O +
compared O +
to O +
corresponding O +
BD O +
P O -
- O -
values O +
and O +
the O +
interval O +
of O +
non O -
- O -
significant O +
co O -
- O -
occurrences O +
is O +
shrinking O +
further O -
. O +

With O +
modest O +
list O -
- O -
length O -
- O -
heterogeneity O -
, O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
is O +
66 O -
, O +
which O +
is O +
associated O +
with O +
a O +
Jaccard O +
coefficient O +
of O +
0.49 O +
and O +
an O +
uncertainty O +
coefficient O +
of O +
0.075 O -
. O +

In O +
the O +
case O +
of O +
large O +
list O -
- O -
length O -
- O -
heterogeneity O -
, O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
is O +
82 O +
with O +
J O +
= O +
0.69 O +
and O +
UC O +
= O +
0.32 O -
. O +

Taken O +
together O -
, O +
these O +
data O +
show O +
that O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
varies O +
strongly O +
with O +
the O +
level O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
and O +
that O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
is O +
associated O +
with O +
different O +
values O +
of O +
UC O +
and O +
J. O +
To O +
complicate O +
matters O +
further O -
, O +
66 O +
co O -
- O -
occurrences O +
( O -
J O +
= O +
0.49 O -
, O +
UC O +
= O +
0.075 O -
) O +
represent O +
significant O +
positive O +
association O +
( O -
PBBD O +
= O +
0.996 O -
) O +
with O +
equal O +
list O +
lengths O -
, O +
no O +
significant O +
association O +
with O +
modest O +
differences O +
in O +
list O +
length O +
( O -
PBBD O +
= O +
0.536 O -
) O +
and O +
strongly O +
negative O +
association O +
( O -
meaning O +
one O +
gene O +
excludes O +
the O +
other O -
) O +
with O +
strong O +
list O -
- O -
length O -
- O -
heterogeneity O +
( O -
PBBD O +
= O +
0.00016 O -
) O -
. O +

Thus O -
, O +
the O +
same O +
J O +
and O +
UC O +
association O +
measure O +
is O +
obtained O +
for O +
positive O -
, O +
negative O -
, O +
and O +
absence O +
of O +
association O -
. O +

Therefore O -
, O +
the O +
meaning O +
of O +
these O +
measures O +
can O -
not O +
be O +
interpreted O +
properly O +
in O +
the O +
absence O +
of O +
knowledge O +
about O +
the O +
occurrence O +
probabilities O +
of O +
the O +
co O -
- O -
occurring O +
entities O -
. O +

Furthermore O -
, O +
the O +
data O +
in O +
Fig. O +
5 O +
also O +
show O +
that O +
neither O +
J O +
nor O +
UC O +
can O +
distinguish O +
between O +
positive O +
and O +
negative O +
association O +
while O +
this O +
is O +
easy O +
with O +
cumulative O +
BBD O +
P O -
- O -
values O -
: O +
Large O +
P O -
- O -
values O +
mean O +
positive O +
association O +
and O +
low O +
P O -
- O -
values O +
mean O +
negative O +
association O -
. O +

In O +
summary O -
, O +
we O +
conclude O +
that O +
BBD O +
provides O +
a O +
novel O +
association O +
measure O +
that O +
offers O +
a O +
number O +
of O +
advantages O +
over O +
the O +
existing O +
contingency O +
table O +
based O +
association O +
measures O +
Jaccard O +
coefficient O +
and O +
uncertainty O +
coefficient O -
. O +

The O +
results O +
in O +
Fig. O +
5 O +
also O +
show O +
that O +
significance O +
of O +
association O +
depends O +
critically O +
on O +
the O +
specific O +
distribution O +
of O +
co O -
- O -
occurring O +
entities O +
over O +
lists O +
of O +
varying O +
length O +
( O -
because O +
this O +
distribution O +
determines O +
the O +
occurrence O +
probabilities O -
) O +
and O +
that O +
contingency O +
table O +
based O +
methods O +
( O -
which O +
can O -
not O +
capture O +
this O +
distribution O -
) O +
should O +
be O +
avoided O +
in O +
the O +
presence O +
of O +
significant O +
list O -
- O -
length O -
- O -
heterogeneity O -
. O +

Generation O +
of O +
co O -
- O -
occurrence O +
networks O +
and O +
the O +
identification O +
of O +
communities O +
The O +
procedures O +
outlined O +
above O +
allow O +
the O +
identification O +
of O +
significant O +
co O -
- O -
occurrence O +
modules O +
in O +
any O +
type O +
of O +
bipartite O +
graph O -
. O +

Three O +
user O +
defined O +
parameters O +
have O +
an O +
impact O +
on O +
the O +
stringency O +
of O +
co O -
- O -
occurrence O +
analysis O -
: O +
The O +
module O +
size O -
, O +
the O +
support O -
, O +
and O +
the O +
Z O -
- O -
score O -
/ O -
P O -
- O -
value O +
cutoff O -
. O +

The O +
module O +
size O +
determines O +
how O +
many O +
entries O +
will O +
be O +
tested O +
for O +
co O -
- O -
occurrence O -
, O +
the O +
support O +
sets O +
a O +
lower O +
boundary O +
on O +
the O +
required O +
number O +
of O +
co O -
- O -
occurrences O -
, O +
and O +
the O +
Z O -
- O -
score O -
/ O -
P O -
- O -
value O +
cutoff O +
sets O +
the O +
significance O +
threshold O -
. O +

In O +
general O -
, O +
higher O +
module O +
size O +
leads O +
to O +
more O +
stringent O +
co O -
- O -
occurrence O +
analysis O +
at O +
the O +
cost O +
of O +
computational O +
complexity O -
. O +

The O +
support O +
parameter O +
allows O +
limiting O +
this O +
complexity O +
by O +
filtering O +
out O +
co O -
- O -
occurrence O +
modules O +
which O +
co O -
- O -
occur O +
less O +
frequently O +
than O +
required O +
by O +
the O +
support O -
. O +

The O +
significance O +
cutoff O +
permits O +
adjusting O +
the O +
signal O -
- O -
to O -
- O -
noise O +
ratio O -
, O +
which O +
is O +
calculated O +
as O +
the O +
number O +
of O +
co O -
- O -
occurrence O +
modules O +
observed O +
in O +
the O +
real O +
versus O +
a O +
randomized O +
bipartite O +
graph O -
. O +

The O +
impact O +
of O +
these O +
parameters O +
on O +
the O +
stringency O +
of O +
co O -
- O -
occurrence O +
analysis O +
has O +
been O +
reported O +
previously O +
for O +
the O +
PubLiME O +
data O +
set O +
[ O -
35 O -
] O +
and O +
is O +
illustrated O +
in O +
a O +
simulation O +
study O +
provided O +
as O +
supplementary O +
material O +
Simulation O +
S1 O -
. O +

From O +
the O +
set O +
of O +
significant O +
co O -
- O -
occurrence O +
modules O -
, O +
a O +
co O -
- O -
occurrence O +
network O +
is O +
generated O +
by O +
considering O +
each O +
entry O +
a O +
vertex O +
and O +
drawing O +
an O +
edge O +
between O +
any O +
two O +
vertices O -
, O +
which O +
have O +
been O +
part O +
of O +
the O +
same O +
significant O +
co O -
- O -
occurrence O +
module O +
[ O -
35 O -
] O -
. O +

An O +
important O +
question O +
in O +
the O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O +
regards O +
the O +
presence O +
of O +
network O +
communities O -
. O +

Communities O +
can O +
be O +
understood O +
as O +
groups O +
of O +
vertices O +
with O +
the O +
property O +
that O +
the O +
number O +
of O +
edges O +
running O +
within O +
groups O +
is O +
larger O +
than O +
expected O +
by O +
chance O +
and O +
that O +
the O +
number O +
of O +
edges O +
running O +
between O +
groups O +
is O +
lower O +
than O +
expected O +
by O +
chance O +
[ O -
37 O -
] O -
. O +

This O +
problem O +
of O +
partitioning O +
a O +
graph O +
is O +
often O +
referred O +
to O +
as O +
the O +
graph O -
- O -
cut O +
problem O +
( O -
hence O +
the O +
name O +
NetCutter O -
) O -
. O +

NetCutter O +
is O +
built O +
on O +
the O +
Java O +
Universal O +
Network O +
and O +
Graph O +
framework O +
( O -
JUNG O -
) O +
software O +
package O +
( O -
http://jung.sourceforge.net O -
) O -
, O +
which O +
provides O +
algorithms O +
for O +
solving O +
this O +
problem O -
. O +

In O +
particular O -
, O +
NetCutter O +
implements O +
the O +
Bicomponent O +
clustering O +
algorithm O +
[ O -
38 O -
] O -
, O +
the O +
Edge O -
- O -
Betweenness O +
clustering O +
algorithm O +
[ O -
39 O -
] O -
, O +
and O +
the O +
Exact O +
Flow O +
Community O +
algorithm O +
[ O -
40 O -
] O -
. O +

Furthermore O -
, O +
there O +
is O +
a O +
clustering O +
tool O +
that O +
is O +
not O +
part O +
of O +
the O +
JUNG O +
package O -
, O +
namely O +
an O +
algorithm O +
identifying O +
communities O +
using O +
eigenvectors O +
of O +
the O +
modularity O +
matrix O +
[ O -
37 O -
] O -
. O +

The O +
code O +
for O +
this O +
algorithm O +
was O +
kindly O +
provided O +
by O +
Mark O +
Newman O +
in O +
C++ O +
and O +
ported O +
to O +
Java O -
. O +

In O +
addition O +
to O +
these O +
tools O -
, O +
NetCutter O +
provides O +
a O +
number O +
of O +
convenience O +
functions O +
for O +
the O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O -
, O +
such O +
as O +
testing O +
the O +
significance O +
of O +
lists O +
reporting O +
a O +
set O +
of O +
entries O +
making O +
up O +
a O +
network O +
community O -
, O +
ranking O +
of O +
vertices O -
, O +
random O +
graph O +
generators O +
for O +
topological O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O -
, O +
and O +
others O -
. O +

Details O +
on O +
all O +
functions O +
are O +
provided O +
in O +
the O +
NetCutter O +
software O +
documentation O -
. O +

One O +
of O +
the O +
possible O +
applications O +
of O +
NetCutter O +
is O +
illustrated O +
below O -
. O +

This O +
application O +
is O +
tightly O +
linked O +
to O +
the O +
bipartite O +
graph O +
representation O +
of O +
the O +
data O -
. O +

Namely O -
, O +
NetCutter O +
can O +
be O +
used O +
to O +
perform O +
co O -
- O -
occurrence O +
analysis O +
of O +
genes O +
or O +
list O +
derived O +
from O +
the O +
same O +
bipartite O +
graph O -
. O +

The O +
network O +
communities O +
identified O +
in O +
each O +
both O +
reflect O +
the O +
same O +
underlying O +
structure O +
of O +
the O +
bipartite O +
graph O -
. O +

In O +
the O +
case O +
of O +
gene O +
expression O +
signatures O +
stored O +
in O +
PubLiME O -
, O +
clusters O +
of O +
genes O +
correspond O +
to O +
clusters O +
of O +
publications O -
, O +
which O +
can O +
reveal O +
possible O +
functions O +
of O +
gene O +
clusters O -
. O +

Cluster O +
correspondence O +
and O +
association O +
studies O +
The O +
co O -
- O -
occurrence O +
analysis O +
of O +
the O +
PubLiME O +
data O +
set O +
published O +
previously O +
[ O -
35 O -
] O +
identified O +
5 O +
major O +
network O +
communities O +
of O +
genes O +
with O +
consistent O +
functional O +
annotations O +
that O +
are O +
deregulated O +
in O +
cancer O +
related O +
gene O +
expression O +
signatures O -
. O +

This O +
analysis O +
was O +
performed O +
by O +
considering O +
all O +
genes O +
mentioned O +
in O +
a O +
particular O +
publication O +
as O +
a O +
single O +
signature O -
, O +
even O +
though O +
they O +
might O +
have O +
been O +
part O +
of O +
different O +
tables O +
and O +
cluster O +
analyses O -
. O +

Here O +
we O +
present O +
an O +
advanced O +
analysis O +
of O +
the O +
PubLiME O +
data O +
set O +
where O +
each O +
table O +
and/or O +
cluster O +
identified O +
in O +
a O +
given O +
publication O +
is O +
considered O +
as O +
a O +
separate O +
signature O -
. O +

This O +
brings O +
the O +
total O +
number O +
of O +
signatures O +
to O +
be O +
analyzed O +
to O +
1015 O +
comprising O +
a O +
total O +
of O +
7358 O +
differentially O +
regulated O +
genes O +
derived O +
from O +
233 O +
publications O +
reporting O +
cancer O +
related O +
signatures O +
derived O +
from O +
human B-Species +
samples O -
. O +

We O +
use O +
this O +
analysis O +
to O +
illustrate O +
three O +
major O +
points O -
: O +
First O -
, O +
the O +
set O +
of O +
communities O +
reported O +
previously O +
is O +
reproduced O +
by O +
this O +
more O +
fine O -
- O -
grained O +
analysis O -
. O +

Second O -
, O +
the O +
set O +
of O +
gene O +
communities O +
corresponds O +
to O +
a O +
set O +
of O +
publication O +
communities O -
. O +

Third O -
, O +
associations O +
between O +
publications O +
and O +
gene O +
communities O +
can O +
be O +
calculated O +
with O +
higher O +
stringency O +
using O +
the O +
edge O -
- O -
swapping O +
null O -
- O -
model O +
in O +
conjunction O +
with O +
bi O -
- O -
binomial O +
P O -
- O -
values O +
as O +
compared O +
to O +
binomial O +
or O +
hypergeometric O +
statistics O -
. O +

The O +
bipartite O +
graph O +
to O +
be O +
analyzed O +
is O +
composed O +
of O +
PubMedID_listID O -
- O -
gene O +
pairs O +
( O -
see O +
supplementary O +
material O +
Table O +
S1 O -
) O -
. O +

Co O -
- O -
occurrence O +
analysis O +
was O +
carried O +
out O +
in O +
two O +
ways O -
: O +
First O -
, O +
gene O +
co O -
- O -
occurrence O +
was O +
analyzed O +
and O +
communities O +
of O +
co O -
- O -
occurring O +
genes O +
were O +
defined O +
by O +
edge O -
- O -
betweenness O +
clustering O +
as O +
described O +
in O +
Materials O +
and O +
Methods O -
. O +

Second O -
, O +
co O -
- O -
occurrence O +
of O +
PubMedID_listIDs O +
was O +
analyzed O -
. O +

To O +
this O +
end O -
, O +
the O +
order O +
of O +
PubMedID_listID O -
- O -
gene O +
pairs O +
was O +
reversed O +
to O +
form O +
GENE O -
- O -
PUBMEDID_LISTID O +
pairs O -
. O +

Thus O -
, O +
the O +
lists O +
in O +
the O +
resulting O +
bipartite O +
graph O +
are O +
formed O +
by O +
genes O +
and O +
the O +
entries O +
are O +
the O +
PubMedID_listIDs O +
where O +
the O +
genes O +
are O +
reported O +
as O +
differentially O +
regulated O -
. O +

Occurrence O +
probabilities O +
for O +
the O +
reversed O +
bipartite O +
graph O +
can O +
be O +
obtained O +
by O +
transposing O +
the O +
occurrence O +
probability O +
matrix O +
of O +
the O +
original O +
bipartite O +
graph O -
. O +

Since O +
the O +
gene O +
communities O +
identified O +
in O +
gene O +
co O -
- O -
occurrence O +
analysis O +
reflect O +
the O +
structure O +
inherent O +
in O +
the O +
bipartite O +
graph O +
( O -
which O +
is O +
not O +
affected O +
by O +
reversing O +
the O +
list O -
- O -
entry O +
order O -
) O -
, O +
co O -
- O -
occurrence O +
analysis O +
of O +
the O +
reversed O +
bipartite O +
graph O +
will O +
result O +
in O +
PubMedID_listID O +
communities O +
that O +
reflect O +
the O +
same O +
underlying O +
structure O +
in O +
the O +
bipartite O +
graph O -
. O +

In O +
other O +
words O -
, O +
PubMedID_listID O +
communities O +
correspond O +
to O +
gene O +
communities O -
. O +

In O +
less O +
abstract O +
terms O -
, O +
the O +
PubMedID_listID O +
communities O +
should O +
correspond O +
to O +
sets O +
of O +
publications O +
that O +
report O +
similar O +
sets O +
of O +
genes O +
as O +
differentially O +
regulated O -
. O +

The O +
identification O +
of O +
communities O +
of O +
publications O +
can O +
help O +
the O +
researcher O +
to O +
easily O +
identify O +
publications O +
studying O +
genes O +
in O +
a O +
gene O +
community O +
that O +
is O +
of O +
interest O +
to O +
the O +
researcher O -
. O +

The O +
results O +
of O +
both O +
types O +
of O +
co O -
- O -
occurrence O +
analysis O +
are O +
displayed O +
in O +
Fig. O +
6 O -
. O +

Fig. O +
6A O +
shows O +
the O +
gene O +
clusters O +
identified O -
. O +

The O +
clusters O +
are O +
named O +
after O +
significant O +
enrichments O +
of O +
gene O +
categories O +
as O +
determined O +
by O +
functional O +
category O +
enrichment O +
using O +
DAVID O +
[ O -
41 O -
] O -
. O +

The O +
P O -
- O -
values O +
shown O +
are O +
Benjamini O +
corrected O +
for O +
multiple O +
testing O +
as O +
reported O +
by O +
DAVID O -
. O +

The O +
clusters O +
are O +
very O +
similar O +
to O +
the O +
clusters O +
published O +
previously O +
[ O -
35 O -
] O -
. O +

There O +
is O +
one O +
new O +
cluster O +
that O +
is O +
strongly O +
enriched O +
for O +
ribosomal O +
proteins O +
( O -
" O -
protein O +
biosynthesis O -
" O +
cluster O -
) O -
, O +
which O +
has O +
not O +
reached O +
significance O +
in O +
our O +
previous O +
analysis O -
. O +

The O +
" O -
surface O +
antigen O -
" O +
cluster O +
contains O +
many O +
genes O +
that O +
had O +
been O +
reported O +
as O +
part O +
of O +
the O +
" O -
signal O +
transduction O -
" O +
cluster O -
. O +

Altogether O -
, O +
however O -
, O +
these O +
results O +
strongly O +
support O +
the O +
notion O +
that O +
the O +
gene O +
clusters O +
in O +
the O +
PubLiME O +
data O +
set O +
can O +
be O +
reproduced O +
by O +
the O +
more O +
fine O -
- O -
grained O +
analysis O +
that O +
considers O +
sublists O +
in O +
each O +
publication O +
as O +
separate O +
signatures O -
. O +

The O +
corresponding O +
clusters O +
of O +
PubMedID_listIDs O +
are O +
shown O +
in O +
Fig. O +
6B O -
. O +

There O +
are O +
five O +
clusters O -
, O +
which O +
have O +
been O +
named O +
after O +
their O +
corresponding O +
gene O +
cluster O -
. O +

Only O +
one O +
cluster O +
( O -
the O +
" O -
extracellular O +
matrix O -
- O -
immune O +
response O +
cluster O -
" O -
) O +
can O -
not O +
be O +
separated O +
by O +
edge O -
- O -
betweenness O +
clustering O +
at O +
the O +
point O +
of O +
maximal O +
graph O +
modularity O -
. O +

To O +
see O +
that O +
this O +
naming O +
is O +
indeed O +
justified O -
, O +
we O +
needed O +
to O +
investigate O +
how O +
strongly O +
a O +
given O +
PubMedID_listID O +
is O +
associated O +
with O +
a O +
given O +
gene O +
cluster O -
, O +
i.e. O +
how O +
significant O +
is O +
the O +
overlap O +
of O +
the O +
genes O +
reported O +
in O +
a O +
gene O +
cluster O +
and O +
the O +
genes O +
reported O +
in O +
a O +
PubMedID_listID O -
. O +

Binomial O +
or O +
hypergemetric O +
statistics O +
are O +
generally O +
used O +
to O +
calculate O +
this O +
significance O -
. O +

However O -
, O +
the O +
bipartite O +
graph O +
model O +
in O +
conjunction O +
with O +
the O +
edge O -
- O -
swapping O +
null O -
- O -
model O +
offers O +
a O +
more O +
fine O -
- O -
grained O +
approach O +
based O +
on O +
bi O -
- O -
binomial O +
statistics O -
. O +

The O +
edge O -
- O -
swapping O +
null O -
- O -
model O +
determines O +
occurrence O +
probabilities O +
in O +
such O +
a O +
way O +
that O +
the O +
number O +
of O +
genes O +
in O +
a O +
given O +
PubMedID_listID O +
is O +
associated O +
with O +
insignificant O +
P O -
- O -
values O +
in O +
the O +
context O +
of O +
the O +
complete O +
bipartite O +
graph O -
. O +

However O -
, O +
when O +
a O +
subset O +
of O +
genes O +
is O +
analyzed O -
, O +
e.g. O +
all O +
the O +
genes O +
that O +
are O +
reported O +
in O +
a O +
particular O +
list O -
, O +
the O +
P O -
- O -
value O +
associated O +
with O +
the O +
number O +
of O +
genes O +
contained O +
in O +
this O +
list O +
will O +
likely O +
be O +
highly O +
significant O +
according O +
to O +
how O +
unlikely O +
it O +
is O +
to O +
obtain O +
all O +
the O +
genes O +
contained O +
in O +
a O +
given O +
list O +
in O +
a O +
random O +
draw O +
from O +
all O +
genes O +
present O +
in O +
the O +
bipartite O +
graph O -
. O +

Thus O -
, O +
PubMedID_listID O +
association O +
with O +
a O +
set O +
of O +
genes O +
in O +
the O +
bipartite O +
graph O +
model O +
can O +
be O +
calculated O +
in O +
the O +
following O +
way O -
: O +
The O +
set O +
of O +
genes O +
that O +
is O +
used O +
to O +
analyze O +
association O +
is O +
used O +
to O +
extract O +
a O +
subgraph O +
from O +
the O +
original O +
bipartite O +
graph O +
where O +
occurrence O +
probabilities O +
for O +
each O +
gene O -
- O -
PubMedID_listID O +
pair O +
are O +
identical O +
to O +
those O +
in O +
the O +
original O +
bipartite O +
graph O +
( O -
i.e. O +
they O +
are O +
not O +
recalculated O +
by O +
edge O -
- O -
swapping O -
) O -
. O +

The O +
vertex O +
degree O +
of O +
the O +
PubMedID_listID O +
vertices O +
in O +
the O +
subgraph O +
indicates O +
the O +
number O +
of O +
genes O +
contained O +
in O +
each O +
PubMedID_listID O +
overlapping O +
with O +
the O +
set O +
of O +
genes O +
used O +
to O +
extract O +
the O +
subgraph O -
. O +

From O +
the O +
occurrence O +
probabilities O +
of O +
the O +
genes O +
in O +
a O +
given O +
PubMedID_listID O -
, O +
the O +
bi O -
- O -
binomial O +
P O -
- O -
value O +
can O +
then O +
be O +
calculated O +
for O +
every O +
list O +
vertex O +
degree O +
observed O +
in O +
the O +
subgraph O -
. O +

In O +
Fig. O +
7 O -
, O +
the O +
significance O +
of O +
association O +
of O +
the O +
PubMedID_listIDs O +
( O -
see O +
Fig. O +
6B O -
) O +
with O +
the O +
cell O +
cycle O +
cluster O +
of O +
genes O +
( O -
Fig. O +
6A O -
) O +
is O +
calculated O -
. O +

For O +
comparison O -
, O +
binomial O +
and O +
hypergeometric O +
P O -
- O -
values O +
are O +
also O +
shown O -
. O +

It O +
can O +
be O +
seen O +
that O +
the O +
bi O -
- O -
binomial O +
P O -
- O -
value O +
is O +
larger O +
than O +
the O +
binomial O +
and O +
hypergeometric O +
P O -
- O -
values O -
, O +
which O +
means O +
that O +
the O +
strength O +
of O +
association O +
is O +
evaluated O +
in O +
a O +
more O +
stringent O +
manner O +
using O +
BBD O +
statistics O +
( O -
see O +
Discussion O +
for O +
an O +
explanation O +
of O +
this O +
observation O -
) O -
. O +

The O +
analysis O +
of O +
significant O +
associations O +
between O +
PubMedID_listIDs O +
and O +
gene O +
clusters O +
now O +
permit O +
answering O +
the O +
question O +
whether O +
there O +
is O +
correspondence O +
between O +
gene O +
clusters O +
and O +
PubMedID_listID O +
clusters O -
. O +

The O +
naming O +
of O +
PubMedID_listID O +
clusters O +
shown O +
in O +
Fig. O +
6B O +
is O +
based O +
on O +
the O +
number O +
of O +
PubMedID_listID O +
that O +
are O +
significantly O +
associated O +
with O +
gene O +
clusters O +
shown O +
in O +
Fig. O +
6A O -
. O +

First O -
, O +
for O +
each O +
gene O +
cluster O -
, O +
all O +
the O +
PubMedID_listIDs O +
that O +
are O +
associated O +
with O +
that O +
cluster O +
with O +
more O +
than O +
95 O -
% O +
confidence O +
( O -
i.e. O +
cumulative O +
bi O -
- O -
binomial O +
P O -
- O -
values O -
> O +
= O +
0.95 O -
) O +
were O +
identified O -
. O +

Second O -
, O +
the O +
number O +
of O +
significant O +
PubMedID_listIDs O +
in O +
each O +
PubMedID_listID O +
cluster O +
was O +
counted O +
for O +
every O +
gene O +
cluster O -
. O +

The O +
significance O +
of O +
this O +
number O +
was O +
then O +
calculated O +
using O +
binomial O +
statistics O -
. O +

The O +
results O +
of O +
this O +
analysis O +
are O +
shown O +
in O +
Table O +
1 O -
. O +

Negative O +
decadic O +
logarithms O +
of O +
the O +
binomial O +
P O -
- O -
value O +
are O +
displayed O -
. O +

It O +
is O +
apparent O +
that O +
each O +
PubMedID_listID O +
cluster O +
is O +
strongly O +
associated O +
with O +
at O +
least O +
one O +
gene O +
cluster O -
, O +
except O +
for O +
the O +
" O -
extracellular O +
matrix O -
- O -
immune O +
response O -
" O +
cluster O -
, O +
which O +
is O +
associated O +
with O +
two O +
gene O +
clusters O -
. O +

The O +
strength O +
of O +
these O +
associations O +
suggests O +
that O +
the O +
PubMedID_listID O +
clusters O +
are O +
indeed O +
corresponding O +
to O +
the O +
gene O +
clusters O +
and O +
that O +
both O +
the O +
gene O +
and O +
the O +
PubMedID_listID O +
clusters O +
reflect O +
the O +
structure O +
of O +
the O +
bipartite O +
graph O +
representing O +
the O +
PubLiME O +
data O +
set O -
. O +

Details O +
about O +
all O +
the O +
lists O +
analyzed O +
are O +
attached O +
as O +
supplementary O +
material O +
Table O +
S2 O -
. O +

Looking O +
at O +
these O +
lists O -
, O +
some O +
general O +
conclusions O +
about O +
the O +
gene O +
clusters O +
can O +
be O +
drawn O -
. O +

Cell O +
cycle O +
cluster O +
genes O +
have O +
been O +
found O +
deregulated O +
in O +
a O +
wide O +
variety O +
of O +
tumor O +
types O +
such O +
as O +
colon O +
cancer O -
, O +
breast O +
cancer O -
, O +
in O +
biliary O +
tract O +
cancer O -
, O +
pancreatic O +
cancer O -
, O +
gastric O +
cancer O -
, O +
prostate O +
cancer O -
, O +
T O -
- O -
cell O +
leukemia O -
, O +
glioma O -
, O +
acute O +
lymphoblastic O +
and O +
myeloblastic O +
leukemias O -
, O +
soft O +
tissue O +
sarcoma O -
, O +
neuroblastoma O -
, O +
as O +
well O +
as O +
in O +
a O +
number O +
of O +
cellular O +
model O +
systems O +
in O +
response O +
to O +
different O +
stimuli O -
. O +

Thus O -
, O +
the O +
cell O +
cycle O +
cluster O +
seems O +
to O +
consist O +
of O +
genes O +
with O +
a O +
general O +
role O +
in O +
oncogenesis O -
. O +

The O +
surface O +
antigen O +
cluster O +
instead O +
seems O +
to O +
be O +
derived O +
preferentially O +
from O +
studies O +
on O +
leukemia O -
. O +

The O +
interferon O +
cluster O +
genes O +
are O +
found O +
deregulated O +
in O +
virus O +
induced O +
pathologies O +
such O +
as O +
papilloma O +
virus O +
induced O +
cervical O +
cancer O -
, O +
and O +
viral O +
hepatitis O -
. O +

Immune O +
response O +
cluster O +
genes O +
were O +
reported O +
as O +
differentially O +
regulated O +
in O +
inflammatory O +
conditions O +
such O +
as O +
ulcerative O +
colitis O -
, O +
Crohn O -
's O +
disease O -
, O +
and O +
Helicobacter B-Species +
pylori I-Species +
infections O -
. O +

Genes O +
of O +
the O +
extracellular O +
matrix O +
cluster O +
seem O +
to O +
be O +
associated O +
with O +
cancer O +
progression O +
studies O +
and O +
metastatic O +
potential O -
. O +

For O +
the O +
protein O +
biosynthesis O +
cluster O -
, O +
there O +
are O +
15 O +
signatures O +
that O +
are O +
significantly O +
enriched O +
for O +
those O +
genes O -
. O +

The O +
cancers O +
studied O +
comprise O +
medulloblastoma O -
, O +
glioblastoma O -
, O +
pancreatic O +
cancer O -
, O +
soft O +
tissue O +
sarcoma O -
, O +
lung O +
carcinoma O -
, O +
breast O +
carcinoma O -
, O +
prostate O +
carcinoma O -
, O +
multiple O +
myeloma O -
, O +
and O +
lymphocytic O +
leukemia O -
. O +

The O +
genes O +
are O +
also O +
found O +
deregulated O +
in O +
response O +
to O +
DNA O +
damage O -
. O +

Although O +
the O +
number O +
of O +
signatures O +
is O +
limited O -
, O +
the O +
variation O +
in O +
conditions O +
where O +
the O +
genes O +
are O +
deregulated O +
is O +
compatible O +
with O +
the O +
hypothesis O +
that O +
protein O +
biosynthesis O +
genes O -
, O +
as O +
cell O +
cycle O +
genes O -
, O +
are O +
deregulated O +
in O +
many O +
cancer O +
types O -
, O +
which O +
might O +
reflect O +
the O +
general O +
property O +
of O +
cancer O +
cells O +
to O +
divide O +
and O +
grow O +
in O +
an O +
uncontrolled O +
fashion O -
. O +

Discussion O +
Here O +
we O +
have O +
investigated O +
basic O +
aspects O +
of O +
co O -
- O -
occurrence O +
analysis O +
and O +
present O +
a O +
software O +
tool O -
, O +
NetCutter O -
, O +
which O +
can O +
be O +
used O +
to O +
identify O +
and O +
analyze O +
generic O +
co O -
- O -
occurrence O +
networks O -
. O +

In O +
NetCutter O -
, O +
a O +
co O -
- O -
occurrence O +
data O +
set O +
is O +
represented O +
as O +
a O +
bipartite O +
graph O +
with O +
one O +
part O +
representing O +
lists O +
and O +
the O +
other O +
part O +
list O +
entries O +
whose O +
co O -
- O -
occurrence O +
patterns O +
are O +
studied O -
. O +

The O +
bipartite O +
graph O +
representation O +
of O +
co O -
- O -
occurrence O +
data O +
sets O +
allows O +
the O +
efficacy O +
of O +
different O +
null O -
- O -
models O +
to O +
be O +
tested O +
systematically O -
. O +

We O +
have O +
shown O +
that O +
an O +
edge O -
- O -
swapping O +
procedure O +
used O +
to O +
randomize O +
the O +
bipartite O +
graph O +
generates O +
a O +
null O -
- O -
model O +
that O +
allows O +
co O -
- O -
occurrence O +
analysis O +
with O +
the O +
highest O +
stringency O -
. O +

The O +
other O +
null O -
- O -
models O +
tested O +
here O +
tend O +
to O +
underestimate O +
occurrence O +
probabilities O +
of O +
entries O +
per O +
list O +
for O +
lists O +
and O +
genes O +
with O +
high O +
vertex O +
degrees O -
, O +
i.e. O +
for O +
lists O +
and O +
genes O +
where O +
most O +
co O -
- O -
occurrences O +
are O +
observed O -
. O +

As O +
a O +
result O -
, O +
co O -
- O -
occurrences O +
are O +
judged O +
more O +
significant O +
than O +
they O +
really O +
are O -
. O +

Co O -
- O -
occurrence O +
data O +
sets O +
with O +
exactly O +
equal O +
lists O +
lengths O +
are O +
likely O +
to O +
be O +
the O +
exception O +
from O +
the O +
rule O -
. O +

It O +
can O +
be O +
assumed O +
that O +
some O +
list O -
- O -
length O -
- O -
heterogeneity O +
will O +
be O +
present O +
in O +
most O +
circumstances O -
. O +

An O +
important O +
consequence O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
regards O +
the O +
co O -
- O -
occurrence O +
probability O +
distribution O +
used O +
to O +
evaluate O +
the O +
significance O +
of O +
the O +
observed O +
number O +
of O +
co O -
- O -
occurrences O -
. O +

Co O -
- O -
occurrence O +
analysis O +
in O +
the O +
presence O +
of O +
list O -
- O -
length O -
- O -
heterogeneity O +
is O +
best O +
performed O +
using O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
( O -
a O +
binomial O +
distribution O +
with O +
trial O +
specific O +
probabilities O -
) O -
. O +

However O -
, O +
calculating O +
Poisson O -
- O -
binomial O +
P O -
- O -
values O +
for O +
large O +
numbers O +
of O +
lists O +
is O +
difficult O +
using O +
existing O +
procedures O +
[ O -
36 O -
] O -
. O +

We O +
have O +
presented O +
an O +
approximation O +
to O +
the O +
Poisson O -
- O -
binomial O +
distribution O -
, O +
called O +
bi O -
- O -
binomial O +
distribution O -
, O +
which O +
is O +
based O +
on O +
replacing O +
the O +
set O +
of O +
Poisson O +
trials O +
by O +
two O +
sets O +
of O +
Bernoulli O +
trials O -
. O +

The O +
resulting O +
distribution O +
reproduces O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
nearly O +
exactly O +
and O +
its O +
P O -
- O -
values O +
can O +
be O +
calculated O +
with O +
ease O +
even O +
for O +
thousands O +
of O +
lists O +
( O -
see O +
also O +
supplementary O +
material O +
Simulation O +
S1 O +
for O +
details O +
on O +
the O +
precision O +
of O +
BBD O -
) O -
. O +

Importantly O -
, O +
BBD O +
provides O +
a O +
novel O +
measure O +
of O +
association O -
, O +
which O +
is O +
shown O +
to O +
be O +
superior O +
to O +
existing O +
measures O +
such O +
as O +
the O +
Jaccard O +
coefficient O +
and O +
the O +
uncertainty O +
coefficient O -
, O +
whose O +
values O +
can O -
not O +
be O +
interpreted O +
properly O +
in O +
the O +
absence O +
of O +
knowledge O +
about O +
the O +
occurrence O +
probabilities O +
of O +
co O -
- O -
occurring O +
entities O -
. O +

It O +
is O +
worth O +
noting O +
that O +
Poisson O -
- O -
binomial O +
Z O -
- O -
scores O +
are O +
distinguished O +
from O +
Gaussian O +
Z O -
- O -
scores O +
by O +
the O +
fact O +
that O +
they O +
do O +
not O +
correspond O +
to O +
the O +
same O +
P O -
- O -
value O +
for O +
different O +
PBDs O -
, O +
BBDs O -
, O +
and O +
even O +
BDs O -
. O +

This O +
is O +
because O +
the O +
Z O -
- O -
score O +
is O +
an O +
explicit O +
part O +
of O +
the O +
function O +
defining O +
the O +
normal O +
probability O +
density O +
while O +
it O +
is O +
not O +
part O +
of O +
the O +
definitions O +
of O +
BD O -
, O +
PBD O -
, O +
and O +
BBD O +
densities O -
. O +

As O +
a O +
consequence O -
, O +
the O +
simple O +
Poisson O -
- O -
binomial O +
Z O -
- O -
score O +
based O +
approach O +
to O +
evaluating O +
significance O +
of O +
co O -
- O -
occurrence O +
must O +
be O +
complemented O +
with O +
the O +
BBD O +
to O +
approximate O +
Poisson O -
- O -
binomial O +
P O -
- O -
values O +
in O +
order O +
to O +
enable O +
multiple O +
testing O +
corrections O +
and O +
to O +
allow O +
calculation O +
of O +
confidence O +
levels O +
in O +
association O +
studies O +
precisely O -
. O +

However O -
, O +
NetCutter O +
is O +
equipped O +
with O +
a O +
bipartite O +
graph O +
randomization O +
tool O +
that O +
permits O +
measuring O +
the O +
number O +
of O +
false O +
positives O +
due O +
to O +
multiple O +
testing O +
directly O +
by O +
comparing O +
the O +
number O +
of O +
significant O +
co O -
- O -
occurrence O +
modules O +
in O +
the O +
real O +
bipartite O +
graph O +
to O +
the O +
corresponding O +
number O +
in O +
a O +
randomized O +
version O +
thereof O -
. O +

Randomization O +
is O +
performed O +
by O +
edge O -
- O -
swapping O +
in O +
order O +
to O +
preserve O +
vertex O +
degrees O -
. O +

The O +
resulting O +
signal O -
- O -
to O -
- O -
noise O +
ratios O +
that O +
are O +
plotted O +
for O +
each O +
Z O -
- O -
score O -
/ O -
P O -
- O -
value O +
cutoff O +
provide O +
a O +
highly O +
reliable O +
and O +
visually O +
intuitive O +
defense O +
mechanism O +
against O +
false O +
positives O +
( O -
see O +
also O +
supplementary O +
material O +
Simulation O +
S1 O -
) O -
. O +

In O +
the O +
vast O +
majority O +
of O +
co O -
- O -
occurrence O +
studies O -
, O +
pair O -
- O -
wise O +
co O -
- O -
occurrences O +
have O +
been O +
analyzed O +
using O +
different O +
statistical O +
models O -
. O +

We O +
have O +
observed O +
that O +
the O +
stringency O +
of O +
pair O -
- O -
wise O +
co O -
- O -
occurrence O +
analysis O +
is O +
far O +
below O +
the O +
stringency O +
of O +
co O -
- O -
occurrence O +
analysis O +
using O +
higher O +
order O +
combinations O +
of O +
co O -
- O -
occurring O +
entities O +
[ O -
35 O -
] O -
. O +

In O +
NetCutter O -
, O +
co O -
- O -
occurrence O +
analysis O +
is O +
preceded O +
by O +
occurrence O +
analysis O -
, O +
i.e. O +
the O +
occurrence O +
probability O +
of O +
each O +
entry O +
in O +
each O +
list O +
is O +
determined O -
. O +

Starting O +
from O +
occurrence O +
probabilities O -
, O +
co O -
- O -
occurrence O +
probabilities O +
for O +
any O +
size O +
of O +
co O -
- O -
occurrence O +
modules O +
under O +
study O +
can O +
be O +
obtained O +
by O +
multiplying O +
the O +
respective O +
list O -
- O -
specific O +
occurrence O +
probabilities O -
. O +

Given O +
the O +
list O -
- O -
specific O +
co O -
- O -
occurrence O +
probabilities O -
, O +
bi O -
- O -
binomial O +
P O -
- O -
values O +
are O +
then O +
calculated O +
in O +
exactly O +
the O +
same O +
way O +
for O +
any O +
module O +
size O -
. O +

As O +
a O +
consequence O -
, O +
NetCutter O +
can O +
perform O +
co O -
- O -
occurrence O +
analysis O +
for O +
higher O +
order O +
combinations O +
of O +
co O -
- O -
occurring O +
entries O +
( O -
i.e. O +
larger O +
module O +
sizes O -
) O +
using O +
the O +
same O +
statistical O +
model O -
. O +

One O +
of O +
the O +
benefits O +
of O +
using O +
higher O +
module O +
sizes O +
is O +
robustness O +
of O +
the O +
analyses O +
in O +
the O +
presence O +
of O +
noise O -
. O +

This O +
is O +
because O +
each O +
edge O +
in O +
the O +
resulting O +
co O -
- O -
occurrence O +
network O +
is O +
evaluated O +
many O +
times O +
since O +
every O +
pair O +
of O +
co O -
- O -
occurring O +
entries O +
can O +
be O +
part O +
of O +
many O +
higher O +
order O +
co O -
- O -
occurrence O +
modules O +
[ O -
35 O -
] O -
. O +

Another O +
advantage O +
is O +
that O +
implicit O +
relationships O +
between O +
entries O -
, O +
which O +
have O +
never O +
occurred O +
together O +
[ O -
18 O -
] O -
, O +
can O +
be O +
derived O +
as O +
a O +
natural O +
by O -
- O -
product O +
of O +
using O +
module O +
sizes O +
larger O +
than O +
2 O -
. O +

As O +
shown O +
in O +
a O +
simulation O +
study O +
( O -
supplementary O +
material O +
Simulation O +
S1 O -
) O -
, O +
the O +
result O +
is O +
a O +
dramatic O +
reduction O +
of O +
misclassifications O +
at O +
higher O +
module O +
sizes O -
. O +

NetCutter O +
can O +
be O +
used O +
to O +
calculate O +
the O +
strength O +
of O +
association O +
between O +
a O +
subset O +
of O +
entries O +
and O +
lists O +
reporting O +
those O +
entries O -
. O +

In O +
this O +
case O -
, O +
the O +
analysis O +
is O +
performed O +
on O +
a O +
subgraph O +
of O +
the O +
original O +
bipartite O +
graph O -
. O +

The O +
subgraph O +
can O +
correspond O +
to O +
communities O +
of O +
entries O +
in O +
the O +
co O -
- O -
occurrence O +
network O -
, O +
or O +
any O +
set O +
of O +
entries O +
of O +
interest O -
. O +

NetCutter O +
will O +
then O +
calculate O +
the O +
significance O +
of O +
observing O +
a O +
given O +
number O +
of O +
occurrences O +
of O +
an O +
entry O +
in O +
the O +
user O +
defined O +
subset O +
of O +
lists O +
using O +
bi O -
- O -
binomal O +
statistics O -
. O +

This O +
analysis O +
mode O +
corresponds O +
to O +
association O +
studies O +
with O +
the O +
advantage O +
that O +
the O +
structure O +
of O +
the O +
underlying O +
bipartite O +
graph O +
( O -
i.e. O +
list O +
length O +
heterogeneity O -
) O +
is O +
considered O +
and O +
handled O +
appropriately O +
using O +
the O +
bi O -
- O -
binomial O +
distribution O -
. O +

As O +
a O +
consequence O -
, O +
association O +
studies O +
can O +
be O +
performed O +
with O +
higher O +
stringency O -
. O +

This O +
result O +
can O +
be O +
understood O +
by O +
examining O +
the O +
occurrence O +
probability O +
matrix O +
that O +
is O +
implicitly O +
assumed O +
in O +
performing O +
binomial O +
or O +
hypergeometric O +
tests O +
for O +
the O +
significance O +
of O +
overlaps O -
. O +

In O +
both O +
tests O -
, O +
a O +
gene O +
is O +
assumed O +
to O +
have O +
an O +
equal O +
opportunity O +
to O +
be O +
present O +
in O +
a O +
list O -
. O +

Therefore O -
, O +
the O +
probability O +
of O +
success O +
for O +
a O +
gene O +
to O +
be O +
part O +
of O +
a O +
list O +
is O +
given O +
by O +
the O +
list O +
vertex O +
degree O +
divided O +
by O +
the O +
total O +
number O +
of O +
genes O -
. O +

In O +
other O +
words O -
, O +
both O +
tests O +
are O +
implicitly O +
based O +
on O +
the O +
list O +
vertex O +
degree O +
model O -
, O +
which O +
has O +
been O +
shown O +
previously O +
to O +
underestimate O +
the O +
occurrence O +
probability O +
and O +
the O +
expected O +
number O +
of O +
co O -
- O -
occurrences O +
for O +
genes O +
with O +
high O +
vertex O +
degree O +
( O -
see O +
Fig. O +
2A O -
) O -
. O +

Since O +
the O +
BBD O +
P O -
- O -
values O +
are O +
calculated O +
from O +
the O +
ES O -
- O -
model O -
, O +
which O +
assigns O +
higher O +
occurrence O +
probabilities O +
to O +
genes O +
with O +
higher O +
vertex O +
degree O +
and O +
more O +
expected O +
co O -
- O -
occurrences O -
, O +
the O +
observed O +
number O +
of O +
overlaps O +
between O +
a O +
set O +
of O +
genes O +
of O +
interest O +
and O +
the O +
content O +
of O +
a O +
given O +
list O +
( O -
which O +
can O +
be O +
viewed O +
as O +
co O -
- O -
occurrence O +
of O +
the O +
overlapping O +
genes O +
in O +
that O +
list O -
) O +
will O +
be O +
judged O +
less O +
significant O +
when O +
the O +
overlapping O +
genes O +
are O +
of O +
high O +
vertex O +
degree O +
( O -
and O +
vice O +
versa O +
when O +
the O +
overlapping O +
genes O +
are O +
of O +
low O +
vertex O +
degree O -
) O +
as O +
compared O +
to O +
binomial O +
or O +
hypergeometric O +
tests O -
. O +

Since O +
the O +
BBD O +
P O -
- O -
values O +
are O +
derived O +
from O +
the O +
most O +
stringent O +
ES O +
null O -
- O -
model O -
, O +
BBD O +
P O -
- O -
values O +
provide O +
a O +
more O +
reliable O +
estimate O +
for O +
the O +
significance O +
of O +
overlap O -
. O +

Co O -
- O -
occurrence O +
analysis O +
of O +
data O +
represented O +
as O +
bipartite O +
graphs O +
permits O +
visualizing O +
the O +
structure O +
of O +
the O +
bipartite O +
graph O +
either O +
as O +
communities O +
of O +
list O +
entries O +
( O -
genes O -
) O +
or O +
as O +
communities O +
of O +
lists O +
( O -
PubMedID_ListID O -
) O +
in O +
co O -
- O -
occurrence O +
networks O -
. O +

We O +
have O +
analyzed O +
the O +
PubLiME O +
data O +
set O +
for O +
the O +
presence O +
of O +
corresponding O +
gene O +
and O +
list O +
clusters O -
. O +

In O +
addition O +
to O +
previously O +
published O +
clusters O +
of O +
genes O -
, O +
we O +
describe O +
a O +
novel O +
gene O +
cluster O +
that O +
is O +
composed O +
of O +
protein O +
biosynthesis O +
associated O +
genes O +
[ O -
35 O -
] O -
. O +

We O +
found O +
that O +
the O +
corresponding O +
clusters O +
of O +
PubMedID_ListID O +
( O -
gene O +
expression O +
signatures O -
) O +
are O +
in O +
general O +
strongly O +
enriched O +
for O +
genes O +
reported O +
in O +
the O +
corresponding O +
gene O +
cluster O +
and O +
that O +
interrogation O +
of O +
corresponding O +
clusters O +
can O +
be O +
used O +
to O +
deduct O +
hypotheses O +
about O +
the O +
putative O +
function O +
of O +
gene O +
clusters O -
. O +

In O +
addition O +
to O +
co O -
- O -
occurrence O +
analysis O -
, O +
NetCutter O +
offers O +
a O +
number O +
of O +
tools O +
for O +
the O +
analysis O +
of O +
co O -
- O -
occurrence O +
networks O -
, O +
or O +
any O +
undirected O +
graph O -
. O +

In O +
particular O -
, O +
community O +
identification O +
is O +
supported O +
by O +
four O +
different O +
community O +
identification O +
algorithms O -
. O +

NetCutter O +
also O +
offers O +
a O +
range O +
of O +
convenience O +
functions O +
that O +
are O +
of O +
help O +
in O +
network O +
analysis O -
. O +

Worthy O +
of O +
mentioning O +
are O +
the O +
random O +
graph O +
generators O +
that O +
can O +
provide O +
control O +
graphs O +
for O +
topological O +
studies O -
. O +

The O +
complete O +
set O +
of O +
options O +
is O +
described O +
in O +
the O +
software O +
documentation O -
. O +

In O +
summary O -
, O +
we O +
present O +
a O +
general O +
framework O +
for O +
co O -
- O -
occurrence O +
analysis O +
with O +
many O +
potential O +
applications O -
. O +

We O +
illustrate O +
a O +
number O +
of O +
advantages O +
of O +
using O +
the O +
bipartite O +
graph O +
representation O +
of O +
data O +
and O +
the O +
associated O +
statistics O -
. O +

In O +
particular O -
, O +
the O +
identification O +
of O +
corresponding O +
clusters O +
permits O +
the O +
identification O +
of O +
functional O +
subunits O +
such O +
as O +
gene O +
clusters O +
on O +
the O +
one O +
hand O -
, O +
and O +
the O +
generation O +
of O +
hypotheses O +
about O +
the O +
function O +
of O +
those O +
units O +
by O +
analyzing O +
the O +
corresponding O +
list O +
clusters O +
on O +
the O +
other O +
hand O -
. O +

Future O +
developments O +
will O +
be O +
directed O +
towards O +
the O +
analysis O +
of O +
data O +
sets O +
that O +
are O +
considerably O +
larger O +
than O +
the O +
data O +
sets O +
analyzed O +
so O +
far O -
. O +

For O +
example O -
, O +
co O -
- O -
occurrence O +
analysis O +
might O +
be O +
of O +
interest O +
for O +
the O +
analysis O +
of O +
single O +
nucleotide O +
polymorphism O +
( O -
SNP O -
) O +
data O +
sets O +
and O +
association O +
studies O +
of O +
genome O +
variability O +
with O +
disease O -
. O +

Each O +
patient O +
is O +
characterized O +
by O +
a O +
specific O +
range O +
of O +
SNPs O -
. O +

Co O -
- O -
occurrence O +
patterns O +
of O +
patients O +
according O +
to O +
their O +
SNPs O +
could O +
be O +
compared O +
to O +
clinical O +
parameters O +
with O +
the O +
aim O +
of O +
identifying O +
genomic O +
regions O +
associated O +
with O +
disease O -
. O +

The O +
increased O +
stringency O +
of O +
association O +
studies O +
offered O +
by O +
NetCutter O +
may O +
be O +
of O +
use O +
in O +
the O +
analysis O +
of O +
polygenic O +
diseases O +
where O +
conventional O +
methods O +
fail O -
. O +

For O +
being O +
useful O +
in O +
this O +
setting O -
, O +
NetCutter O +
must O +
be O +
capable O +
of O +
analyzing O +
bipartite O +
graphs O +
with O +
millions O +
instead O +
of O +
thousands O +
of O +
vertices O -
. O +

Materials O +
and O +
Methods O +
Implementation O +
of O +
NetCutter O +
NetCutter O +
is O +
written O +
in O +
Java O +
using O +
NetBeans6 O +
software O +
( O -
http://www.netbeans.info/ O -
) O +
and O +
tested O +
on O +
the O +
Java O +
Runtime O +
environment O +
1.6.0.0 O -
. O +

on O +
a O +
Windows O +
XP O +
Professional O +
computer O -
. O +

The O +
Java O +
Runtime O +
environment O -
, O +
which O +
can O +
be O +
downloaded O +
from O +
http://java.sun.com/ O -
, O +
must O +
be O +
installed O +
on O +
a O +
computer O +
that O +
is O +
intended O +
to O +
run O +
NetCutter O -
. O +

NetCutter O +
is O +
provided O +
as O +
a O +
single O +
jar O +
file O +
and O +
should O +
run O +
by O +
double O +
clicking O +
the O +
jar O +
file O -
, O +
provided O +
that O +
the O +
Java O +
runtime O +
environment O +
is O +
properly O +
installed O -
. O +

NetCutter O +
makes O +
use O +
of O +
the O +
following O +
software O +
packages O +
and O +
classes O -
: O +
JUNG O +
version O +
1.3 O +
( O -
http://jung.sourceforge.net/download.html O -
) O -
, O +
Apache O +
Jakarta O +
Commons O +
Collections O +
3.1 O +
( O -
http://jakarta.apache.org/commons/collections/ O -
) O -
, O +
Cern O +
Colt O +
Scientific O +
Library O +
1.2.0 O +
( O -
http://dsd.lbl.gov/hoschek/colt/ O -
) O -
, O +
Xerces O +
( O -
http://xerces.apache.org/xerces2-j/index.html O -
) O -
, O +
Jama O +
( O -
http://math.nist.gov/javanumerics/jama/ O -
) O -
, O +
Netlib O +
Java O +
LAPACK O +
( O -
http://www.netlib.org/lapack/ O -
) O -
, O +
JFreeChart O +
( O -
http://www.jfree.org/jfreechart/ O -
) O -
, O +
partition.java O +
( O -
http://astro.u-strasbg.fr/fmurtagh/mda-sw/java/partition.java O -
) O -
. O +

Bi O -
- O -
binomial O +
approximation O +
of O +
Poisson O -
- O -
binomial O +
distribution O +
The O +
Poisson O -
- O -
binomial O +
distribution O +
( O -
binomial O +
distribution O +
with O +
trial O +
specific O +
probabilities O -
) O +
has O +
recently O +
been O +
proposed O +
as O +
a O +
statistic O +
that O +
properly O +
handles O +
largely O +
differing O +
sizes O +
of O +
gene O +
expression O +
signatures O +
in O +
meta O -
- O -
analysis O +
of O +
gene O +
expression O +
data O +
[ O -
35 O -
] O -
. O +

Z O -
- O -
scores O +
have O +
been O +
used O +
to O +
estimate O +
the O +
significance O +
of O +
co O -
- O -
occurrence O +
because O +
P O -
- O -
value O +
calculation O +
is O +
cumbersome O +
and O +
error O +
prone O -
. O +

Two O +
methods O +
reported O +
by O +
[ O -
36 O -
] O +
suffer O +
from O +
numerical O +
overflow O -
/ O -
underflow O +
problems O +
when O +
large O +
numbers O +
of O +
Poisson O +
trials O +
with O +
probabilities O +
deviating O +
significantly O +
from O +
0.5 O +
are O +
being O +
analyzed O -
. O +

Therefore O -
, O +
we O +
propose O +
a O +
fast O +
approximation O +
of O +
P O -
- O -
values O +
based O +
on O +
a O +
bi O -
- O -
binomial O +
distribution O -
. O +

The O +
bi O -
- O -
binomial O +
distribution O +
is O +
a O +
special O +
case O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
where O +
the O +
probability O +
of O +
success O +
can O +
assume O +
only O +
two O +
values O -
. O +

In O +
order O +
to O +
achieve O +
a O +
good O +
approximation O +
of O +
the O +
underlying O +
Poisson O -
- O -
binomial O +
distribution O -
, O +
the O +
values O +
of O +
these O +
two O +
probabilities O +
and O +
the O +
number O +
of O +
trials O +
where O +
they O +
are O +
assumed O +
must O +
be O +
determined O +
carefully O -
. O +

As O +
is O +
shown O +
in O +
the O +
following O -
, O +
the O +
values O +
of O +
the O +
two O +
trial O +
probabilities O +
and O +
their O +
number O +
of O +
occurrences O +
follow O +
from O +
the O +
formula O +
used O +
to O +
calculate O +
the O +
variance O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
and O +
from O +
the O +
formula O +
yielding O +
the O +
population O +
variance O +
of O +
trial O +
probabilities O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
to O +
be O +
approximated O -
. O +

The O +
mean O +
μ O +
and O +
the O +
variance O +
σ2 O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
are O +
given O +
by O +
equation O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O -
, O +
respectively. O -
( O -
1 O -
) O -
( O -
2 O -
) O -
pi O +
is O +
the O +
trial O -
- O -
specific O +
probability O +
of O +
success O +
and O +
N O +
is O +
the O +
total O +
number O +
of O +
trials O -
. O +

For O +
the O +
sake O +
of O +
completeness O -
, O +
a O +
formal O +
proof O +
of O +
equation O +
( O -
1 O -
) O +
is O +
reported O +
as O +
supplementary O +
material O +
Proof O +
S1 O +
and O +
the O +
proof O +
of O +
equation O +
( O -
2 O -
) O +
can O +
be O +
obtained O +
in O +
an O +
analogous O +
fashion O -
. O +

The O +
population O +
variance O +
S2 O +
of O +
trial O +
probabilities O +
pi O +
is O +
given O +
by O +
equation O +
( O -
3 O -
) O -
. O -
( O -
3 O -
) O +
Rearranging O +
equation O +
( O -
3 O -
) O +
considering O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
leads O +
to O +
( O -
4 O -
) O +
and O +
( O -
5 O -
) O -
, O +
where O +
pa O +
denotes O +
the O +
average O +
trial O +
probability O +
of O +
success O +
and O +
qa O +
its O +
complement. O -
( O -
4 O -
) O -
( O -
5 O -
) O -
Now O +
let O -
's O +
define O +
two O +
trial O +
probabilities O +
p1 O +
and O +
p2 O -
, O +
which O +
are O +
used O +
N1 O +
and O +
N2 O +
times O +
during O +
the O +
Poisson O +
trials O -
, O +
respectively O -
. O +

Thus O -
, O +
N1 O +
and O +
N2 O +
add O +
up O +
to O +
N. O -
( O -
6 O -
) O +
Considering O +
( O -
1 O -
) O -
, O +
the O +
average O +
trial O +
probability O +
pa O +
can O +
then O +
be O +
obtained O +
from O +
( O -
7 O -
) O -
. O -
( O -
7 O -
) O +
Using O +
( O -
7 O -
) O -
, O +
p1 O +
can O +
thus O +
be O +
calculated O +
as O +
( O -
8 O -
) O -
. O -
( O -
8 O -
) O +
Similarly O -
, O +
considering O +
( O -
2 O -
) O -
, O +
the O +
variance O +
σ2 O +
is O +
given O +
by O +
( O -
9 O -
) O -
. O -
( O -
9 O -
) O +
Substituting O +
p1 O +
in O +
( O -
9 O -
) O +
using O +
( O -
8) O +
followed O +
by O +
substituting O +
σ2 O +
in O +
( O -
5 O -
) O +
by O +
( O -
9 O -
) O +
leads O +
to O +
a O +
quadratic O +
equation O +
for O +
p2 O +
as O +
a O +
function O +
of O +
pa O -
, O +
N O -
, O +
and O +
S2 O -
, O +
as O +
shown O +
in O +
equation O +
( O -
10 O -
) O -
. O -
( O -
10 O -
) O +
The O +
solution O +
to O +
( O -
10 O -
) O +
is O +
given O +
by O +
( O -
11 O -
) O -
. O -
( O -
11 O -
) O +
Setting O +
p2 O +
to O -
( O -
12 O -
) O -
p1 O +
can O +
be O +
obtained O +
from O +
( O -
8) O +
and O +
shown O +
to O +
be O +
given O +
by O +
formula O +
( O -
13 O -
) O -
: O -
( O -
13 O -
) O -
Choosing O +
p2 O +
as O -
( O -
12a O -
) O -
leads O +
to O +
p1 O -
( O -
13a O -
) O +
Comparing O +
( O -
13a O -
) O +
to O +
( O -
12 O -
) O +
and O +
( O -
12a O -
) O +
to O +
( O -
13 O -
) O -
, O +
it O +
can O +
be O +
seen O +
that O +
the O +
formulae O +
are O +
identical O +
except O +
for O +
the O +
fact O +
that O +
N1 O +
and O +
N2 O +
are O +
reversed O -
. O +

Since O +
the O +
assignment O +
of O +
which O +
set O +
of O +
trials O +
is O +
called O +
N1 O +
and O +
which O +
set O +
of O +
trials O +
is O +
called O +
N2 O +
is O +
completely O +
arbitrary O -
, O +
we O +
can O +
limit O +
the O +
remaining O +
analysis O +
on O +
( O -
12 O -
) O +
and O +
( O -
13 O -
) O +
without O +
loss O +
of O +
generality O -
. O +

Note O +
that O +
( O -
12 O -
) O +
and O +
( O -
13 O -
) O +
do O +
not O +
guarantee O +
that O +
p1 O +
and O +
p2 O +
are O +
always O +
confined O +
between O +
0 O +
and O +
1 O +
for O +
any O +
combination O +
of O +
N1 O +
and O +
N2 O -
. O +

While O +
probabilities O +
smaller O +
than O +
0 O +
or O +
bigger O +
than O +
1 O +
would O +
still O +
result O +
in O +
a O +
distribution O +
with O +
the O +
same O +
overall O +
variance O +
as O +
the O +
original O +
distribution O -
, O +
P O -
- O -
value O +
calculation O +
will O +
be O +
imprecise O +
because O +
the O +
tails O +
of O +
the O +
distribution O +
will O +
deviate O +
significantly O +
from O +
the O +
original O +
distribution O -
. O +

Thus O -
, O +
we O +
need O +
to O +
define O +
the O +
values O +
N1 O +
and O +
N2 O +
in O +
such O +
a O +
way O +
that O +
p2 O -
< O +
= O +
1 O +
and O +
p1 O -
> O +
= O +
0 O -
. O +

This O +
can O +
be O +
achieved O +
by O +
evaluating O +
( O -
12 O -
) O +
and O +
( O -
13 O -
) O -
. O +

Evaluating O +
( O -
12 O -
) O +
for O +
the O +
condition O +
that O +
p2 O -
< O +
= O +
1 O -
, O +
solving O +
the O +
resulting O +
inequality O +
for O +
N2 O -
, O +
and O +
considering O +
( O -
5 O -
) O -
, O +
which O +
relates O +
S2 O +
and O +
σ2 O -
, O +
we O +
obtain O +
( O -
14 O -
) O -
. O -
( O -
14 O -
) O +
Similarly O -
, O +
evaluating O +
( O -
13 O -
) O +
for O +
the O +
condition O +
p1 O -
> O +
= O +
0 O -
, O +
solving O +
the O +
resulting O +
inequality O +
for O +
N2 O -
, O +
considering O +
( O -
5 O -
) O -
, O +
which O +
relates O +
S2 O +
and O +
σ2 O -
, O +
and O +
defining O +
μf O +
the O +
expected O +
number O +
of O +
failures O +
as O +
N O +
* O +
( O -
1−pa O -
) O +
( O -
15 O -
) O -
, O -
( O -
15 O -
) O -
we O +
obtain O +
( O -
16 O -
) O -
( O -
16 O -
) O +
The O +
meaning O +
of O +
these O +
boundaries O +
is O +
best O +
illustrated O +
by O +
considering O +
a O +
Poisson O -
- O -
binomial O +
distribution O +
whose O +
variance O +
is O +
0 O -
, O +
i.e. O +
that O +
assumes O +
1 O +
at O +
X O +
= O +
μ O +
and O +
0 O +
otherwise O -
. O +

In O +
this O +
case O +
( O -
14 O -
) O +
requires O +
N2 O -
< O +
= O +
μ O +
while O +
( O -
16 O -
) O +
requires O +
N2 O -
> O +
= O +
μ O -
. O +

These O +
conditions O +
can O +
only O +
be O +
fulfilled O +
contemporaneously O +
when O +
N2 O +
is O +
set O +
to O +
μ O -
. O +

Intuitively O -
, O +
this O +
means O +
that O +
there O +
are O +
μ O +
trials O +
with O +
probability O +
of O +
success O +
1 O +
and O +
N−μ O +
trials O +
with O +
probability O +
of O +
0 O -
, O +
resulting O +
in O +
a O +
Poisson O -
- O -
binomial O +
distribution O +
with O +
variance O +
σ2 O +
= O +
0 O +
and O +
mean O +
μ O -
. O +

When O +
σ2 O +
is O +
larger O +
than O +
0 O -
, O +
the O +
choice O +
of O +
N1 O +
and O +
N2 O +
is O +
more O +
flexible O -
. O +

However O -
, O +
since O +
the O +
choice O +
of O +
N2 O +
= O +
μ O +
is O +
valid O +
for O +
all O +
possible O +
values O +
of O +
σ2 O -
, O +
this O +
is O +
how O +
NetCutter O +
determines O +
N1 O +
and O +
N2 O -
. O +

When O +
μ O +
is O +
not O +
an O +
integer O -
, O +
N2 O +
is O +
set O +
to O +
the O +
integer O +
closest O +
to O +
μ O -
. O +

Having O +
determined O +
p2 O +
( O -
12 O -
) O +
and O +
p1 O +
( O -
13 O -
) O +
as O +
well O +
a O +
N1 O +
and O +
N2 O +
( O -
14 O -
, O +
16 O -
, O +
6 O -
) O -
, O +
we O +
can O +
now O +
calculate O +
the O +
bi O -
- O -
binomial O +
approximation O +
of O +
the O +
Poisson O -
- O -
binomial O +
distribution O +
in O +
a O +
fashion O +
that O +
is O +
very O +
similar O +
to O +
calculate O +
the O +
binomial O +
P O -
- O -
value O -
. O +

With O +
q1 O +
= O +
1−p1 O +
and O +
q2 O +
= O +
1−p2 O +
we O +
obtain: O -
( O -
17 O -
) O +
The O +
summation O +
is O +
necessary O +
because O +
i O +
successes O +
can O +
be O +
obtained O +
from O +
any O +
combination O +
of O +
j O +
p1 O +
and O +
i−j O +
p2 O +
trials O -
, O +
where O +
j O +
can O +
assume O +
any O +
value O +
from O +
0 O +
to O +
i. O +
Calculating O +
Jaccard O +
and O +
uncertainty O +
coefficients O +
For O +
the O +
purpose O +
of O +
comparing O +
the O +
efficacy O +
of O +
the O +
bi O -
- O -
binomial O +
distribution O +
as O +
a O +
significance O +
measure O +
of O +
co O -
- O -
occurrence O -
, O +
Jaccard O +
and O +
uncertainty O +
coefficients O +
( O -
which O +
are O +
also O +
called O +
measures O +
of O +
association O -
) O +
were O +
calculated O +
using O +
the O +
formulae O -
: O +
The O +
Jaccard O +
coefficient O +
J O +
is O +
calculated O +
as O +
the O +
number O +
of O +
times O +
A O +
and O +
B O +
occur O +
together O +
divided O +
by O +
the O +
number O +
of O +
times O +
A O +
occurs O +
without O +
B O +
plus O +
the O +
number O +
of O +
times O +
B O +
occurs O +
without O +
A O +
plus O +
the O +
number O +
of O +
times O +
A O +
and O +
B O +
occur O +
together O +
[ O -
42 O -
] O -
. O +

The O +
uncertainty O +
coefficient O +
[ O -
42 O -
] O +
is O +
calculated O +
as O -
: O -
H O +
is O +
the O +
entropy O +
associated O +
with O +
A O -
, O +
B O -
, O +
and O +
AB O -
. O +

For O +
A O -
, O +
the O +
entropy O +
is O +
calculated O +
from O +
the O +
probabilities O +
of O +
A O +
occurring O +
in O +
n1 O +
out O +
of O +
N O +
lists O +
( O -
n1 O -
/ O -
N O -
) O +
and O +
A O +
not O +
occurring O +
in O +
n2 O +
out O +
of O +
N O +
lists O +
( O -
n2 O -
/ O -
N O -
) O -
. O +

Analogous O +
calculations O +
lead O +
to O +
the O +
entropy O +
associated O +
with O +
B. O +
For O +
H O -
( O -
A O -
, O -
B O -
) O -
, O +
the O +
probabilities O +
of O +
A O +
occurring O +
without O +
B O -
, O +
B O +
occurring O +
without O +
A O -
, O +
A O +
and O +
B O +
occurring O +
together O -
, O +
and O +
neither O +
A O +
nor O +
B O +
occurring O +
in O +
the O +
lists O +
are O +
used O -
. O +

Co O -
- O -
occurrence O +
analysis O +
of O +
the O +
PubLiME O +
data O +
set O +
The O +
bipartite O +
graph O +
to O +
be O +
analyzed O +
is O +
composed O +
of O +
27619 O +
PubMedID_listID O -
- O -
gene O +
pairs O +
( O -
see O +
supplementary O +
material O +
Table O +
S1 O -
) O -
. O +

Edge O -
- O -
swapping O +
( O -
1000 O +
simulations O -
, O +
see O +
above O -
) O +
was O +
used O +
to O +
determine O +
occurrence O +
probabilities O +
and O +
gene O +
co O -
- O -
occurrence O +
was O +
analyzed O +
using O +
module O +
size O +
3 O +
( O -
co O -
- O -
occurrence O +
of O +
three O +
genes O -
) O -
, O +
bi O -
- O -
binomial O +
Z O -
- O -
score O +
cutoff O +
6 O -
, O +
bi O -
- O -
binomial O +
P O -
- O -
value O +
cutoff O +
1.0E-5 O -
, O +
and O +
support O +
5 O -
. O +

Supplementary O +
material O +
Simulation O +
S1 O +
provides O +
details O +
on O +
why O +
module O +
size O +
3 O +
is O +
chosen O -
. O +

The O +
support O +
parameter O +
ensures O +
that O +
each O +
3-gene O +
co O -
- O -
occurrence O +
module O +
is O +
present O +
in O +
at O +
least O +
5 O +
signatures O -
. O +

We O +
identified O +
1654 O +
significant O +
modules O +
in O +
the O +
test O +
data O +
compared O +
to O +
5 O +
modules O +
in O +
a O +
randomized O +
bipartite O +
graph O -
, O +
corresponding O +
to O +
a O +
signal O -
- O -
to O -
- O -
noise O +
ratio O +
of O +
331 O -
. O +

The O +
co O -
- O -
occurrence O +
network O +
was O +
generated O +
from O +
the O +
significant O +
co O -
- O -
occurrence O +
modules O +
by O +
drawing O +
an O +
edge O +
between O +
each O +
pair O +
wise O +
combination O +
of O +
genes O +
that O +
are O +
part O +
of O +
the O +
same O +
co O -
- O -
occurrence O +
module O -
. O +

Gene O +
communities O +
were O +
identified O +
in O +
this O +
network O +
by O +
edge O -
- O -
betweenness O +
clustering O +
removing O +
4 O +
edges O -
, O +
which O +
resulted O +
in O +
a O +
maximal O +
network O +
modularity O +
of O +
0.63 O -
. O +

Modularity O +
is O +
calculated O +
as O +
described O +
by O +
[ O -
43 O -
] O -
. O +

For O +
the O +
identification O +
of O +
PubMedID_listID O +
clusters O -
, O +
the O +
PubMedID_listID O -
- O -
gene O +
pairs O +
in O +
the O +
original O +
bipartite O +
graph O +
were O +
reversed O +
to O +
form O +
gene O -
- O -
PubMedID_listID O +
pairs O -
. O +

Occurrence O +
probabilities O +
were O +
obtained O +
by O +
transposing O +
the O +
original O +
occurrence O +
probability O +
matrix O +
determined O +
by O +
edge O -
- O -
swapping O +
as O +
described O +
above O -
. O +

PubMedID_listID O +
co O -
- O -
occurrence O +
was O +
analyzed O +
using O +
module O +
size O +
5 O -
, O +
Z O -
- O -
score O +
cutoff O +
6 O -
, O +
bi O -
- O -
binomial O +
P O -
- O -
value O +
cutoff O +
1.0E-5 O -
, O +
and O +
support O +
3 O -
. O +

Please O +
note O +
that O +
the O +
choice O +
of O +
these O +
parameters O +
is O +
dictated O +
by O +
the O +
parameters O +
used O +
in O +
gene O +
co O -
- O -
occurrence O +
analysis O -
. O +

The O +
reversal O +
of O +
the O +
bipartite O +
graph O +
necessitates O +
the O +
support O +
parameter O +
used O +
in O +
gene O +
co O -
- O -
occurrence O +
analysis O +
( O -
5 O -
) O +
to O +
be O +
used O +
as O +
module O +
size O +
in O +
PubMedID_listID O +
co O -
- O -
occurrence O +
analysis O +
and O +
the O +
module O +
size O +
used O +
in O +
gene O +
co O -
- O -
occurrence O +
analysis O +
( O -
3 O -
) O +
to O +
be O +
used O +
as O +
the O +
support O +
parameter O +
in O +
PubMedID_listID O +
co O -
- O -
occurrence O +
analysis O +
if O +
the O +
scope O +
of O +
the O +
analysis O +
is O +
the O +
identification O +
of O +
PubMedID_listID O +
clusters O +
that O +
correspond O +
to O +
gene O +
clusters O +
identified O +
before O -
. O +

The O +
significance O +
cutoffs O +
remain O +
unchanged O -
. O +

PubMedID_listID O +
co O -
- O -
occurrence O +
analysis O +
revealed O +
448 O +
significant O +
co O -
- O -
occurrence O +
modules O +
in O +
the O +
real O +
bipartite O +
graph O +
and O +
6 O +
significant O +
co O -
- O -
occurrence O +
modules O +
in O +
the O +
randomized O +
bipartite O +
graph O +
with O +
a O +
signal O -
- O -
to O -
- O -
noise O +
ratio O +
of O +
75 O -
. O +

Communities O +
in O +
the O +
resulting O +
co O -
- O -
occurrence O +
network O +
were O +
identified O +
by O +
edge O -
- O -
betweenness O +
clustering O +
removing O +
130 O +
edges O -
. O +

The O +
resulting O +
maximal O +
network O +
modularity O +
was O +
found O +
to O +
be O +
0.47 O -
. O +

Supporting O +
Information O +

Personal O +
and O +
environmental O +
correlates O +
of O +
active O +
travel O +
and O +
physical O +
activity O +
in O +
a O +
deprived O +
urban O +
population O +
Abstract O +
Background O +
Environmental O +
characteristics O +
may O +
be O +
associated O +
with O +
patterns O +
of O +
physical O +
activity O +
in O +
general O +
or O +
with O +
particular O +
types O +
of O +
physical O +
activity O +
such O +
as O +
active O +
travel O +
( O -
walking O +
or O +
cycling O +
for O +
transport O -
) O -
. O +

However O -
, O +
most O +
studies O +
in O +
this O +
field O +
have O +
been O +
conducted O +
in O +
North O +
America O +
and O +
Australia O -
, O +
and O +
hypotheses O +
about O +
putative O +
correlates O +
should O +
be O +
tested O +
in O +
a O +
wider O +
range O +
of O +
sociospatial O +
contexts O -
. O +

We O +
therefore O +
examined O +
the O +
contribution O +
of O +
putative O +
personal O +
and O +
environmental O +
correlates O +
of O +
active O +
travel O +
and O +
overall O +
physical O +
activity O +
in O +
deprived O +
urban O +
neighbourhoods O +
in O +
Glasgow O -
, O +
Scotland O +
as O +
part O +
of O +
the O +
baseline O +
for O +
a O +
longitudinal O +
study O +
of O +
the O +
effects O +
of O +
opening O +
a O +
new O +
urban O +
motorway O +
( O -
freeway O -
) O -
. O +

Methods O +
We O +
conducted O +
a O +
postal O +
survey O +
of O +
a O +
random O +
sample O +
of O +
residents O +
( O -
n O +
= O +
1322 O -
) O -
, O +
collecting O +
data O +
on O +
socioeconomic O +
status O -
, O +
perceptions O +
of O +
the O +
local O +
environment O -
, O +
travel O +
behaviour O -
, O +
physical O +
activity O +
and O +
general O +
health O +
and O +
wellbeing O +
using O +
a O +
new O +
14-item O +
neighbourhood O +
rating O +
scale O -
, O +
a O +
travel O +
diary O -
, O +
the O +
short O +
form O +
of O +
the O +
International O +
Physical O +
Activity O +
Questionnaire O +
( O -
IPAQ O -
) O +
and O +
the O +
SF-8 O -
. O +

We O +
analysed O +
the O +
correlates O +
of O +
active O +
travel O +
and O +
overall O +
physical O +
activity O +
using O +
multivariate O +
logistic O +
regression O -
, O +
first O +
building O +
models O +
using O +
personal O +
( O -
individual O +
and O +
household O -
) O +
explanatory O +
variables O +
and O +
then O +
adding O +
environmental O +
variables O -
. O +

Results O +
Active O +
travel O +
was O +
associated O +
with O +
being O +
younger O -
, O +
living O +
in O +
owner O -
- O -
occupied O +
accommodation O -
, O +
not O +
having O +
to O +
travel O +
a O +
long O +
distance O +
to O +
work O +
and O +
not O +
having O +
access O +
to O +
a O +
car O -
, O +
whereas O +
overall O +
physical O +
activity O +
was O +
associated O +
with O +
living O +
in O +
social O +
rented O +
accommodation O +
and O +
not O +
being O +
overweight O -
. O +

After O +
adjusting O +
for O +
personal O +
characteristics O -
, O +
neither O +
perceptions O +
of O +
the O +
local O +
environment O +
nor O +
the O +
objective O +
proximity O +
of O +
respondents O -
' O +
homes O +
to O +
motorway O +
or O +
major O +
road O +
infrastructure O +
explained O +
much O +
of O +
the O +
variance O +
in O +
active O +
travel O +
or O +
overall O +
physical O +
activity O -
, O +
although O +
we O +
did O +
identify O +
a O +
significant O +
positive O +
association O +
between O +
active O +
travel O +
and O +
perceived O +
proximity O +
to O +
shops O -
. O +

Conclusion O +
Apart O +
from O +
access O +
to O +
local O +
amenities O -
, O +
environmental O +
characteristics O +
may O +
have O +
limited O +
influence O +
on O +
active O +
travel O +
in O +
deprived O +
urban O +
populations O +
characterised O +
by O +
a O +
low O +
level O +
of O +
car O +
ownership O -
, O +
in O +
which O +
people O +
may O +
have O +
less O +
capacity O +
for O +
making O +
discretionary O +
travel O +
choices O +
than O +
the O +
populations O +
studied O +
in O +
most O +
published O +
research O +
on O +
the O +
environmental O +
correlates O +
of O +
physical O +
activity O -
. O +

Background O +
Until O +
recently O -
, O +
research O +
on O +
correlates O +
of O +
physical O +
activity O +
was O +
dominated O +
by O +
studies O +
of O +
individual O +
demographic O +
and O +
psychosocial O +
characteristics O +
[ O -
1 O -
] O -
. O +

This O +
reflected O +
an O +
emphasis O +
on O +
promoting O +
sport O -
, O +
recreation O +
or O +
health O -
- O -
directed O +
exercise O +
using O +
techniques O +
to O +
encourage O +
individual O +
behaviour O +
change O +
[ O -
2 O -
] O -
. O +

However O -
, O +
there O +
is O +
little O +
evidence O +
that O +
such O +
approaches O +
are O +
effective O +
in O +
increasing O +
physical O +
activity O +
in O +
the O +
medium O -
- O -
to O -
- O -
long O +
term O +
[ O -
3 O -
] O -
. O +

If O +
habitual O +
patterns O +
of O +
behaviour O +
are O +
environmentally O +
cued O -
, O +
sustained O +
change O +
is O +
likely O +
to O +
require O +
a O +
supportive O +
environment O +
in O +
which O +
people O +
can O +
be O +
active O +
[ O -
4,5 O -
] O -
. O +

There O +
is O +
therefore O +
increasing O +
interest O +
in O +
the O +
influence O +
of O +
the O +
social O +
and O +
physical O +
environment O +
on O +
physical O +
activity O -
. O +

With O +
respect O +
to O +
the O +
physical O +
( O -
natural O +
or O +
built O -
) O +
environment O -
, O +
a O +
growing O +
body O +
of O +
evidence O +
suggests O +
that O +
certain O +
environmental O +
characteristics O +
may O +
be O +
associated O +
with O +
patterns O +
of O +
physical O +
activity O +
in O +
general O +
or O +
with O +
particular O +
types O +
of O +
physical O +
activity O +
such O +
as O +
walking O +
or O +
cycling O +
as O +
modes O +
of O +
transport O +
[ O -
4 O -
- O -
10 O -
] O -
. O +

Among O +
the O +
correlates O +
most O +
frequently O +
identified O +
in O +
such O +
reviews O +
– O +
some O +
ascertained O +
using O +
' O -
objective O -
' O +
measures O -
, O +
and O +
others O +
in O +
terms O +
of O +
people O -
's O +
perceptions O +
– O +
are O +
the O +
aesthetic O +
quality O +
of O +
the O +
surroundings O -
, O +
the O +
presence O +
of O +
pavements O +
( O -
sidewalks O -
) O -
, O +
the O +
convenience O +
of O +
facilities O +
for O +
being O +
active O -
, O +
the O +
availability O +
of O +
green O +
space O -
, O +
access O +
to O +
amenities O +
( O -
destinations O -
) O +
within O +
walking O +
or O +
cycling O +
distance O -
, O +
safety O +
from O +
traffic O +
and O +
personal O +
attack O -
, O +
and O +
the O +
lack O +
of O +
heavy O +
traffic O -
. O +

Some O +
of O +
these O +
local O +
characteristics O +
reflect O +
higher O -
- O -
order O +
aspects O +
of O +
urban O +
design O +
and O +
spatial O +
policy O +
such O +
as O +
population O +
density O -
, O +
connectivity O +
and O +
mixed O +
land O +
use O +
[ O -
6,8 O -
] O -
. O +

Importantly O -
, O +
different O +
characteristics O +
may O +
be O +
associated O +
with O +
different O +
types O +
of O +
physical O +
activity O -
; O +
for O +
example O -
, O +
Owen O +
and O +
colleagues O +
found O +
that O +
the O +
aesthetic O +
quality O +
of O +
the O +
surroundings O +
was O +
associated O +
with O +
walking O +
for O +
exercise O +
or O +
recreation O +
and O +
with O +
walking O +
in O +
general O -
, O +
but O +
not O +
with O +
walking O +
for O +
transport O -
, O +
whereas O +
perceptions O +
of O +
traffic O +
were O +
associated O +
with O +
walking O +
for O +
transport O +
and O +
walking O +
in O +
general O -
, O +
but O +
not O +
with O +
walking O +
for O +
exercise O +
or O +
recreation O +
[ O -
5 O -
] O -
. O +

Despite O +
the O +
growing O +
volume O +
of O +
published O +
studies O +
in O +
this O +
field O -
, O +
many O +
authors O +
remain O +
circumspect O +
in O +
their O +
interpretation O +
of O +
the O +
available O +
evidence O -
. O +

Giles O -
- O -
Corti O +
and O +
Donovan O +
have O +
described O +
access O +
to O +
a O +
supportive O +
physical O +
environment O +
as O +
a O +
necessary O -
, O +
but O +
insufficient O -
, O +
condition O +
for O +
an O +
increase O +
in O +
physical O +
activity O +
in O +
the O +
population O +
[ O -
11 O -
] O -
, O +
while O +
Handy O +
found O +
' O -
convincing O -
' O +
evidence O +
of O +
an O +
association O +
between O +
physical O +
activity O +
and O +
the O +
built O +
environment O +
in O +
general O +
but O +
' O -
less O +
convincing O -
' O +
evidence O +
as O +
to O +
which O +
specific O +
environmental O +
characteristics O +
were O +
most O +
strongly O +
associated O +
[ O -
7 O -
] O -
. O +

One O +
limitation O +
of O +
the O +
available O +
evidence O +
is O +
that O +
most O +
research O +
has O +
been O +
conducted O +
in O +
North O +
America O +
and O +
Australia O +
[ O -
9,12 O -
] O -
, O +
and O +
it O +
is O +
not O +
clear O +
whether O +
associations O +
observed O +
in O +
those O +
countries O +
are O +
generalisable O +
to O +
other O +
settings O +
with O +
different O +
aggregate O +
socioeconomic O +
characteristics O +
( O -
e.g. O +
wealth O +
or O +
access O +
to O +
private O +
cars O -
) O +
or O +
environmental O +
characteristics O +
( O -
e.g. O +
climate O -
, O +
patterns O +
of O +
land O +
use O -
, O +
or O +
availability O +
of O +
public O +
transport O -
) O -
. O +

For O +
example O -
, O +
North O +
American O +
researchers O +
are O +
often O +
interested O +
in O +
the O +
presence O +
or O +
absence O +
of O +
pavements O +
( O -
sidewalks O -
) O -
, O +
but O +
it O +
is O +
unusual O +
for O +
streets O +
in O +
the O +
United O +
Kingdom O +
( O -
UK O -
) O +
not O +
to O +
have O +
a O +
pavement O +
or O +
footpath O +
beside O +
them O -
. O +

Hypotheses O +
about O +
putative O +
environmental O +
correlates O +
of O +
physical O +
activity O +
therefore O +
need O +
to O +
be O +
tested O +
in O +
a O +
wider O +
range O +
of O +
settings O -
. O +

A O +
more O +
profound O +
limitation O +
of O +
the O +
available O +
evidence O +
is O +
that O +
identifying O +
a O +
relationship O +
between O -
, O +
for O +
example O -
, O +
urban O +
form O +
and O +
walking O +
for O +
transport O +
is O +
not O +
the O +
same O +
thing O +
as O +
showing O +
that O +
changing O +
the O +
built O +
environment O +
will O +
lead O +
to O +
a O +
change O +
in O +
behaviour O +
[ O -
13 O -
] O -
. O +

Few O +
researchers O +
have O +
taken O +
up O +
the O +
opportunity O +
( O -
or O +
challenge O -
) O +
presented O +
by O +
' O -
natural O +
experiments O -
' O +
to O +
investigate O +
the O +
effects O +
of O +
environmental O +
interventions O +
on O +
physical O +
activity O +
[ O -
14 O -
] O -
. O +

We O +
therefore O +
established O +
a O +
longitudinal O +
study O +
to O +
examine O +
changes O +
associated O +
with O +
the O +
opening O +
of O +
a O +
new O +
urban O +
section O +
of O +
the O +
M74 O +
motorway O +
( O -
freeway O -
) O +
currently O +
under O +
construction O +
in O +
Glasgow O -
, O +
Scotland O -
. O +

The O +
rationale O +
and O +
design O +
for O +
this O +
study O +
have O +
been O +
described O +
previously O +
[ O -
15 O -
] O -
. O +

It O +
is O +
claimed O +
that O +
the O +
new O +
motorway O -
, O +
which O +
will O +
mostly O +
pass O +
through O +
or O +
close O +
to O +
densely O -
- O -
populated O +
urban O +
neighbourhoods O -
, O +
will O +
contribute O +
to O +
the O +
regeneration O +
of O +
a O +
region O +
which O +
includes O +
some O +
of O +
the O +
most O +
deprived O +
and O +
least O +
healthy O +
working O -
- O -
class O +
communities O +
in O +
Europe O +
[ O -
16 O -
] O -
. O +

It O +
is O +
also O +
claimed O +
that O +
the O +
new O +
motorway O +
will O +
divert O +
traffic O +
from O +
local O +
streets O -
, O +
reduce O +
traffic O +
noise O +
and O +
bring O +
new O +
local O +
employment O +
opportunities O -
, O +
thereby O +
improving O +
characteristics O +
of O +
the O +
local O +
environment O +
held O +
to O +
be O +
associated O +
with O +
active O +
travel O -
. O +

Others O +
claim O +
that O +
the O +
new O +
motorway O +
will O +
encourage O +
car O +
use O -
, O +
degrade O +
the O +
aesthetic O +
quality O +
of O +
the O +
surroundings O +
and O +
reduce O +
the O +
safety O +
and O +
attractiveness O +
of O +
routes O +
for O +
pedestrians O +
and O +
cyclists O +
across O +
the O +
line O +
of O +
the O +
motorway O +
– O +
all O +
changes O +
which O +
may O +
be O +
expected O +
to O +
discourage O +
active O +
travel O +
[ O -
15 O -
] O -
. O +

The O +
eventual O +
aim O +
of O +
the O +
M74 O +
study O +
will O +
be O +
to O +
assess O +
the O +
effects O +
of O +
this O +
major O +
modification O +
to O +
the O +
urban O +
built O +
environment O +
and O +
transport O +
infrastructure O +
on O +
perceptions O +
of O +
the O +
local O +
environment O +
and O +
on O +
population O +
health O +
and O +
health O -
- O -
related O +
behaviour O -
, O +
the O +
primary O +
outcome O +
of O +
interest O +
being O +
a O +
change O +
in O +
the O +
quantity O +
of O +
' O -
active O +
travel O -
' O +
( O -
walking O +
and O +
cycling O +
for O +
transport O -
) O -
. O +

In O +
this O +
paper O -
, O +
we O +
report O +
findings O +
from O +
the O +
cross O -
- O -
sectional O +
( O -
baseline O -
) O +
phase O +
of O +
the O +
study O +
which O +
contribute O +
evidence O +
on O +
the O +
environmental O +
correlates O +
of O +
physical O +
activity O +
in O +
this O +
comparatively O +
deprived O +
urban O +
population O -
. O +

We O +
focus O +
on O +
two O +
specific O +
hypotheses O -
: O +
first O -
, O +
that O +
levels O +
of O +
active O +
travel O +
and O +
overall O +
physical O +
activity O +
vary O +
with O +
demographic O +
and O +
socioeconomic O +
characteristics O -
, O +
but O +
not O +
necessarily O +
in O +
the O +
same O +
way O -
; O +
second O -
, O +
that O +
these O +
relationships O +
may O +
be O +
partly O +
explained O +
by O +
the O +
perceived O +
characteristics O +
of O +
the O +
local O +
environment O +
in O +
which O +
people O +
live O +
and O +
by O +
their O +
objectively O -
- O -
assessed O +
proximity O +
to O +
motorway O +
and O +
major O +
road O +
infrastructure O -
. O +

Methods O +
Delineation O +
of O +
study O +
areas O +
We O +
used O +
spatially O +
referenced O +
census O +
and O +
transport O +
infrastructure O +
data O +
held O +
and O +
analysed O +
in O +
a O +
geographical O +
information O +
system O +
( O -
GIS O -
) O -
, O +
combined O +
with O +
field O +
visits O -
, O +
to O +
delineate O +
three O +
study O +
areas O +
in O +
Glasgow O +
with O +
similar O +
aggregate O +
socioeconomic O +
characteristics O +
and O +
broadly O +
similar O +
topographical O +
characteristics O +
apart O +
from O +
their O +
proximity O +
to O +
urban O +
motorway O +
infrastructure O +
( O -
Table O +
1 O -
, O +
Figure O +
1 O -
) O -
. O +

All O +
three O +
study O +
areas O +
extended O +
from O +
inner O +
mixed O -
- O -
use O +
districts O +
close O +
to O +
the O +
city O +
centre O +
to O +
residential O +
suburbs O -
, O +
contained O +
major O +
arterial O +
roads O +
other O +
than O +
motorways O -
, O +
and O +
contained O +
a O +
mixture O +
of O +
housing O +
stock O +
including O +
traditional O +
high O -
- O -
density O +
tenements O -
, O +
high O -
- O -
rise O +
flats O +
and O +
new O +
housing O +
developments O +
( O -
Figure O +
2 O -
) O -
. O +

Sampling O +
and O +
survey O +
administration O +
We O +
used O +
the O +
Royal O +
Mail O +
Postcode O +
Address O +
File O +
( O -
PAF O -
) O +
( O -
version O +
2005.3 O -
) O +
to O +
identify O +
all O +
residential O +
addresses O +
whose O +
unit O +
postcode O +
( O -
zip O +
code O -
) O +
was O +
within O +
one O +
of O +
the O +
study O +
areas O +
( O -
total O +
n O +
= O +
35601 O -
) O +
and O +
drew O +
a O +
random O +
sample O +
of O +
3000 O +
households O +
from O +
each O +
area O -
. O +

Unit O +
postcodes O +
( O -
e.g. O +
G12 O +
8RZ O -
) O +
are O +
the O +
smallest O +
available O +
unit O +
of O +
postal O +
geography O +
in O +
the O +
UK O -
; O +
residential O +
unit O +
postcodes O +
cover O +
about O +
15 O +
addresses O +
on O +
average O -
. O +

We O +
sent O +
the O +
survey O +
to O +
all O +
households O +
( O -
total O +
n O +
= O +
9000 O -
) O +
between O +
28 O +
September O +
and O +
4 O +
October O +
2005 O +
and O +
resent O +
the O +
survey O +
to O +
all O +
non O -
- O -
responding O +
households O +
between O +
26 O +
and O +
31 O +
October O +
2005 O -
. O +

We O +
alerted O +
households O +
to O +
the O +
survey O +
by O +
means O +
of O +
a O +
postcard O +
sent O +
a O +
few O +
days O +
in O +
advance O -
, O +
used O +
coloured O +
paper O +
for O +
some O +
of O +
the O +
survey O +
materials O -
, O +
and O +
posted O +
survey O +
packs O +
in O +
white O +
envelopes O +
printed O +
with O +
the O +
university O +
crest O -
; O +
these O +
techniques O +
have O +
been O +
shown O +
in O +
a O +
meta O -
- O -
analysis O +
to O +
be O +
associated O +
with O +
increased O +
response O +
rates O +
to O +
postal O +
surveys O +
[ O -
17 O -
] O -
. O +

We O +
asked O +
householders O +
to O +
ensure O +
that O +
the O +
questionnaire O +
was O +
completed O +
by O +
a O +
resident O +
aged O +
16 O +
or O +
over O -
; O +
if O +
more O +
than O +
one O +
resident O +
was O +
eligible O -
, O +
we O +
asked O +
householders O +
to O +
select O +
the O +
person O +
with O +
the O +
most O +
recent O +
birthday O -
. O +

Respondents O +
who O +
consented O +
to O +
follow O -
- O -
up O +
were O +
entered O +
into O +
a O +
prize O +
draw O +
to O +
win O +
a O +
£ O -
50 O +
( O -
€ O -
63 O -
; O +
US$ O -
92 O -
) O +
gift O +
voucher O -
. O +

Responses O +
received O +
more O +
than O +
three O +
months O +
after O +
the O +
first O +
mailing O +
wave O +
were O +
disregarded O +
in O +
analysis O -
. O +

Data O +
collection O +
The O +
questionnaire O +
included O +
items O +
on O +
demographic O +
and O +
socioeconomic O +
characteristics O -
, O +
health O +
and O +
wellbeing O +
( O -
including O +
the O +
the O +
SF-8 O +
scale O -
) O -
, O +
perceptions O +
of O +
the O +
local O +
environment O -
, O +
travel O +
behaviour O +
and O +
the O +
short O +
form O +
of O +
the O +
International O +
Physical O +
Activity O +
Questionnaire O +
( O -
IPAQ O -
) O +
( O -
Additional O +
file O +
1 O -
) O -
. O +

We O +
developed O +
a O +
new O +
' O -
neighbourhood O +
scale O -
' O +
to O +
assess O +
perceptions O +
of O +
relevant O +
characteristics O +
of O +
the O +
local O +
environment O +
( O -
aesthetics O -
, O +
green O +
space O -
, O +
access O +
to O +
amenities O -
, O +
convenience O +
of O +
routes O -
, O +
traffic O -
, O +
road O +
safety O +
and O +
personal O +
safety O -
) O -
. O +

The O +
development O -
, O +
principal O +
components O +
analysis O +
and O +
reliability O +
of O +
the O +
items O +
in O +
this O +
scale O +
and O +
the O +
derivation O +
and O +
reliability O +
of O +
summary O +
variables O +
are O +
reported O +
in O +
an O +
accompanying O +
paper O +
[ O -
18 O -
] O -
. O +

Data O +
cleaning O +
and O +
derivation O +
of O +
variables O +
Demographic O +
and O +
socioeconomic O +
characteristics O +
We O +
excluded O +
from O +
analysis O +
all O +
respondents O +
who O +
failed O +
to O +
enter O +
their O +
age O +
or O +
sex O -
. O +

We O +
then O +
examined O +
the O +
distributions O +
of O +
all O +
raw O +
variables O +
and O +
carried O +
out O +
range O +
and O +
consistency O +
checks O +
to O +
identify O +
any O +
anomalous O +
values O +
or O +
variables O +
with O +
a O +
high O +
proportion O +
of O +
missing O +
responses O -
. O +

As O +
a O +
consequence O -
, O +
we O +
collapsed O +
responses O +
on O +
distance O +
to O +
place O +
of O +
work O +
or O +
study O -
, O +
housing O +
tenure O -
, O +
car O +
access O +
and O +
working O +
situation O +
into O +
fewer O +
categories O +
by O +
merging O +
categories O +
with O +
small O +
numbers O +
of O +
responses O -
; O +
we O +
also O +
disregarded O +
household O +
composition O +
and O +
working O +
situation O +
of O +
spouse O +
or O +
partner O +
in O +
analysis O +
because O +
of O +
the O +
large O +
numbers O +
of O +
missing O +
values O +
for O +
these O +
variables O -
. O +

Health O +
and O +
wellbeing O +
We O +
calculated O +
body O +
mass O +
index O +
( O -
BMI O -
) O +
by O +
converting O -
, O +
where O +
necessary O -
, O +
self O -
- O -
reported O +
heights O +
and O +
weights O +
from O +
imperial O +
to O +
metric O +
units O +
and O +
dividing O +
the O +
height O +
in O +
metres O +
by O +
the O +
square O +
of O +
the O +
weight O +
in O +
kilograms O -
; O +
we O +
also O +
categorised O +
respondents O +
into O +
quintiles O +
of O +
BMI O -
. O +

We O +
calculated O +
physical O +
( O -
PCS-8 O -
) O +
and O +
mental O +
( O -
MCS-8 O -
) O +
health O +
summary O +
scores O +
from O +
the O +
SF-8 O +
data O +
and O +
scaled O +
these O +
to O +
population O +
norms O +
using O +
the O +
method O +
and O +
coefficients O +
given O +
in O +
the O +
SF-8 O +
manual O +
[ O -
19 O -
] O -
. O +

Objective O +
environmental O +
characteristics O +
We O +
linked O +
each O +
record O +
to O +
the O +
unit O +
postcode O +
of O +
residence O -
. O +

We O +
then O +
constructed O +
concentric O +
buffers O +
at O +
100-metre O +
intervals O +
up O +
to O +
500 O +
metres O +
around O +
the O +
routes O +
and O +
access O +
points O +
of O +
existing O +
and O +
planned O +
motorways O +
and O +
around O +
the O +
network O +
of O +
other O +
major O +
( O -
A- O +
and O +
B- O +
class O -
) O +
roads O -
, O +
and O +
assigned O +
each O +
respondent O +
to O +
a O +
category O +
of O +
proximity O +
to O +
each O +
type O +
of O +
road O +
infrastructure O +
( O -
within O +
100 O +
metres O -
, O +
101–200 O +
metres O -
, O +
etc O -
. O -
) O +

based O +
on O +
the O +
location O +
of O +
the O +
centroid O +
of O +
their O +
unit O +
postcode O -
. O +

Travel O +
behaviour O +
For O +
travel O +
time O +
analysis O +
we O +
included O +
travel O +
diaries O +
which O +
recorded O +
no O +
travel O +
at O +
all O -
, O +
but O +
we O +
disregarded O +
travel O +
data O +
from O +
respondents O +
who O +
had O +
not O +
been O +
at O +
home O +
on O +
the O +
day O +
of O +
the O +
travel O +
diary O -
, O +
whose O +
questionnaire O +
had O +
been O +
misprinted O +
such O +
that O +
the O +
travel O +
diary O +
pages O +
were O +
unusable O -
, O +
who O +
had O +
recorded O +
journeys O +
without O +
reporting O +
valid O +
quantitative O +
data O +
on O +
the O +
durations O +
of O +
those O +
journeys O -
, O +
or O +
whose O +
completed O +
travel O +
diary O +
appeared O +
implausible O -
. O +

We O +
also O +
disregarded O +
journeys O +
whose O +
purpose O +
was O +
not O +
stated O +
or O +
was O +
beyond O +
the O +
scope O +
of O +
the O +
travel O +
diary O +
( O -
Additional O +
file O +
1 O -
, O +
page O +
8) O -
. O +

We O +
summed O +
the O +
reported O +
travel O +
time O +
for O +
each O +
mode O +
of O +
transport O -
, O +
calculated O +
a O +
total O +
travel O +
time O +
by O +
active O +
modes O +
( O -
walking O +
plus O +
cycling O -
) O +
and O +
by O +
all O +
modes O +
combined O -
, O +
and O +
calculated O +
the O +
proportion O +
of O +
total O +
travel O +
time O +
contributed O +
by O +
each O +
mode O +
of O +
transport O -
. O +

Physical O +
activity O +
We O +
cleaned O +
and O +
analysed O +
IPAQ O +
data O +
in O +
accordance O +
with O +
the O +
IPAQ O +
scoring O +
protocol O +
. O +

We O +
therefore O +
disregarded O +
physical O +
activity O +
data O +
from O +
respondents O +
who O +
had O +
reported O +
more O +
than O +
16 O +
hours O +
of O +
physical O +
activity O +
per O +
day O +
or O +
who O +
had O +
missing O +
or O +
internally O +
inconsistent O +
data O +
on O +
the O +
frequency O +
or O +
duration O +
of O +
any O +
of O +
the O +
three O +
categories O +
of O +
physical O +
activity O +
( O -
walking O -
, O +
moderate O -
- O -
intensity O +
activity O +
or O +
vigorous O +
activity O -
) O -
. O +

We O +
also O +
recoded O +
reported O +
durations O +
of O +
activity O +
of O +
less O +
than O +
ten O +
minutes O +
to O +
zero O -
, O +
and O +
of O +
greater O +
than O +
180 O +
minutes O +
to O +
180 O +
minutes O -
. O +

We O +
calculated O +
the O +
estimated O +
total O +
physical O +
activity O +
energy O +
expenditure O +
for O +
each O +
respondent O +
( O -
MET O -
- O -
min O -
/ O -
week O -
) O +
and O +
used O +
a O +
combination O +
of O +
frequency O -
, O +
duration O +
and O +
total O +
energy O +
expenditure O +
to O +
assign O +
each O +
respondent O +
to O +
a O +
' O -
high O -
' O -
, O +
' O -
moderate O -
' O +
or O +
' O -
low O -
' O +
category O +
of O +
overall O +
physical O +
activity O +
in O +
accordance O +
with O +
the O +
prescribed O +
IPAQ O +
algorithm O -
. O +

The O +
' O -
high O -
' O +
category O +
corresponds O +
to O +
a O +
sufficient O +
level O +
of O +
physical O +
activity O +
to O +
meet O +
current O +
public O +
health O +
recommendations O +
for O +
adults O +
[ O -
20 O -
] O -
. O +

Analysis O +
We O +
considered O +
it O +
unlikely O +
that O +
the O +
statistical O +
assumptions O +
required O +
for O +
linear O +
regression O +
could O +
be O +
met O +
because O +
the O +
distributions O +
of O +
time O +
spent O +
walking O +
and O +
cycling O +
and O +
of O +
estimated O +
total O +
physical O +
activity O +
energy O +
expenditure O +
were O +
both O +
strongly O +
positively O +
skewed O +
and O +
dominated O +
by O +
a O +
large O +
number O +
of O +
zero O +
values O +
which O +
meant O +
that O +
the O +
data O +
were O +
not O +
amenable O +
to O +
log O -
- O -
transformation O -
. O +

We O +
therefore O +
modelled O +
the O +
correlates O +
of O +
active O +
travel O +
and O +
physical O +
activity O +
using O +
multivariate O +
logistic O +
regression O -
. O +

We O +
defined O +
' O -
active O +
travel O -
' O +
as O +
a O +
binary O +
condition O +
achieved O +
by O +
any O +
respondent O +
who O +
had O +
reported O +
at O +
least O +
30 O +
minutes O +
of O +
travel O +
by O +
walking O -
, O +
cycling O +
or O +
both O +
in O +
their O +
travel O +
diary O -
, O +
reflecting O +
the O +
current O +
recommendation O +
that O +
adults O +
should O +
accumulate O +
at O +
least O +
30 O +
minutes O +
of O +
moderate O -
- O -
intensity O +
physical O +
activity O +
on O +
most O +
days O +
of O +
the O +
week O +
[ O -
20 O -
] O -
, O +
and O +
we O +
defined O +
' O -
physical O +
activity O -
' O +
as O +
a O +
binary O +
condition O +
achieved O +
by O +
any O +
respondent O +
whose O +
overall O +
physical O +
activity O +
was O +
categorised O +
as O +
' O -
high O -
' O +
using O +
IPAQ O -
. O +

We O +
then O +
built O +
separate O +
multivariate O +
models O +
for O +
active O +
travel O +
and O +
physical O +
activity O +
following O +
the O +
method O +
of O +
Hosmer O +
and O +
Lemeshow O +
[ O -
21 O -
] O -
, O +
first O +
including O +
only O +
' O -
personal O -
' O +
( O -
individual O +
or O +
household O -
) O +
variables O +
and O +
then O +
adding O +
' O -
environmental O -
' O +
variables O +
( O -
Additional O +
file O +
2 O -
) O -
. O +

Results O +
Response O +
We O +
received O +
1345 O +
completed O +
questionnaires O -
. O +

After O +
subtracting O +
from O +
the O +
numerator O +
23 O +
completed O +
questionnaires O +
with O +
missing O +
critical O +
demographic O +
data O +
( O -
age O +
or O +
sex O -
) O -
, O +
and O +
after O +
subtracting O +
from O +
the O +
denominator O +
676 O +
addresses O +
from O +
which O +
survey O +
packs O +
were O +
returned O +
as O +
undeliverable O -
, O +
this O +
left O +
1322 O +
valid O +
responses O +
to O +
be O +
entered O +
into O +
analysis O +
– O +
a O +
response O +
rate O +
of O +
1322 O -
/ O -
( O -
9000 O -
- O -
676 O -
) O +
= O +
15.9 O -
% O -
. O +

Characteristics O +
of O +
study O +
participants O +
Demographic O +
and O +
socioeconomic O +
characteristics O +
Respondents O +
were O +
aged O +
between O +
16 O +
and O +
89 O +
years O +
( O -
median O +
age O +
48 O +
years O -
) O -
. O +

804 O +
( O -
61 O -
% O -
) O +
were O +
women O -
. O +

Only O +
136 O +
( O -
26 O -
% O -
) O +
of O +
the O +
men O +
and O +
145 O +
( O -
18 O -
% O -
) O +
of O +
the O +
women O +
reported O +
having O +
access O +
to O +
a O +
bicycle O -
. O +

For O +
those O +
who O +
usually O +
travelled O +
to O +
a O +
place O +
of O +
work O +
or O +
study O -
, O +
the O +
median O +
reported O +
distance O +
was O +
3.5 O +
miles O +
( O -
about O +
5.5 O +
kilometres O -
) O -
. O +

Other O +
characteristics O +
of O +
study O +
participants O +
are O +
summarised O +
in O +
Table O +
2 O -
. O +

Health O +
and O +
wellbeing O +
25 O -
% O +
of O +
respondents O +
reported O +
difficulty O +
walking O +
for O +
a O +
quarter O +
of O +
a O +
mile O -
, O +
39 O -
% O +
reported O +
a O +
long O -
- O -
term O +
health O +
problem O +
or O +
disability O -
, O +
and O +
50 O -
% O +
were O +
overweight O +
( O -
median O +
BMI O +
25.1 O +
kg O -
/ O -
m2 O -
) O -
. O +

The O +
median O +
mental O +
health O +
summary O +
score O +
( O -
MCS-8 O -
) O +
was O +
significantly O +
lower O +
( O -
i.e. O +
poorer O -
) O +
than O +
the O +
population O +
norm O +
( O -
median O +
47.3 O -
, O +
95 O -
% O +
CI O +
46.4 O +
to O +
48.1 O -
) O -
; O +
the O +
median O +
physical O +
health O +
summary O +
score O +
( O -
PCS-8 O -
) O +
was O +
not O +
significantly O +
different O +
from O +
the O +
population O +
norm O +
( O -
median O +
50.9 O -
, O +
95 O -
% O +
CI O +
49.6 O +
to O +
51.7 O -
) O -
. O +

Descriptive O +
data O +
on O +
travel O +
behaviour O +
and O +
physical O +
activity O +
Travel O +
behaviour O +
1099 O +
travel O +
diaries O +
were O +
suitable O +
for O +
travel O +
time O +
analysis O -
. O +

Men O +
and O +
women O +
were O +
equally O +
likely O +
to O +
have O +
returned O +
usable O +
travel O +
time O +
data O -
, O +
but O +
respondents O +
who O +
were O +
older O -
, O +
retired O -
, O +
or O +
living O +
in O +
social O +
rented O +
accommodation O +
or O +
who O +
did O +
not O +
have O +
access O +
to O +
a O +
car O +
were O +
less O +
likely O +
to O +
have O +
returned O +
usable O +
data O -
. O +

On O +
average O -
, O +
respondents O +
recorded O +
about O +
an O +
hour O -
's O +
travel O +
per O +
day O +
( O -
mean O +
61.5 O +
minutes O -
, O +
median O +
50.0 O +
minutes O -
) O -
, O +
of O +
which O +
a O +
minority O +
was O +
spent O +
using O +
active O +
modes O +
of O +
transport O +
( O -
walking O +
or O +
cycling O -
: O +
mean O +
20.0 O +
minutes O -
, O +
median O +
10.0 O +
minutes O -
) O +
( O -
Table O +
3 O -
) O -
. O +

304 O +
respondents O +
( O -
28 O -
% O -
) O +
recorded O +
at O +
least O +
30 O +
minutes O +
of O +
active O +
travel O -
, O +
of O +
whom O +
294 O +
( O -
97 O -
% O -
) O +
recorded O +
at O +
least O +
30 O +
minutes O +
of O +
walking O -
. O +

Physical O +
activity O +
833 O +
respondents O +
returned O +
complete O +
physical O +
activity O +
data O +
suitable O +
for O +
analysis O -
. O +

Women O +
and O +
respondents O +
who O +
were O +
older O -
, O +
retired O -
, O +
or O +
living O +
in O +
social O +
rented O +
accommodation O +
or O +
who O +
did O +
not O +
have O +
access O +
to O +
a O +
car O +
were O +
less O +
likely O +
to O +
have O +
returned O +
usable O +
data O -
. O +

Respondents O +
reported O +
a O +
mean O +
of O +
318 O +
minutes O -
' O +
walking O +
per O +
week O +
and O +
a O +
mean O +
estimated O +
total O +
physical O +
activity O +
energy O +
expenditure O +
of O +
3000 O +
MET O -
- O -
minutes O +
per O +
week O +
( O -
Table O +
4 O -
) O -
. O +

Only O +
316 O +
respondents O +
( O -
38 O -
% O -
) O +
were O +
categorised O +
as O +
having O +
achieved O +
a O +
' O -
high O -
' O +
( O -
i.e. O +
sufficient O -
) O +
level O +
of O +
physical O +
activity O -
. O +

Correlates O +
of O +
active O +
travel O +
Active O +
travel O +
was O +
significantly O +
associated O +
with O +
being O +
younger O -
, O +
living O +
in O +
owner O -
- O -
occupied O +
accommodation O -
, O +
not O +
having O +
to O +
travel O +
more O +
than O +
four O +
miles O +
to O +
work O -
, O +
having O +
access O +
to O +
a O +
bicycle O -
, O +
not O +
having O +
access O +
to O +
a O +
car O -
, O +
and O +
the O +
absence O +
of O +
any O +
difficulty O +
walking O -
. O +

The O +
final O +
best O +
model O +
of O +
the O +
' O -
personal O -
' O +
correlates O +
of O +
active O +
travel O +
provided O +
satisfactory O +
goodness O -
- O -
of O -
- O -
fit O +
( O -
Hosmer O +
and O +
Lemeshow O +
test O -
: O +
χ2 O +
= O +
13.04 O -
, O +
df O +
= O +
8 O -
; O +
P O +
= O +
0.11 O -
) O +
and O +
explained O +
nearly O +
one O -
- O -
fifth O +
of O +
the O +
total O +
variance O +
in O +
active O +
travel O +
( O -
Nagelkerke O -
's O +
R2 O +
= O +
18.7 O -
% O -
) O +
( O -
Table O +
5 O -
) O -
. O +

Adding O +
' O -
environmental O -
' O +
variables O +
to O +
the O +
model O +
showed O +
an O +
additional O +
significant O +
positive O +
association O +
between O +
active O +
travel O +
and O +
perceived O +
proximity O +
to O +
shops O -
, O +
and O +
an O +
additional O +
significant O +
negative O +
association O +
between O +
active O +
travel O +
and O +
perceived O +
road O +
safety O +
for O +
cyclists O -
. O +

The O +
final O +
best O +
model O +
of O +
the O +
personal O +
and O +
environmental O +
correlates O +
of O +
active O +
travel O +
also O +
provided O +
satisfactory O +
goodness O -
- O -
of O -
- O -
fit O +
( O -
Hosmer O +
and O +
Lemeshow O +
test O -
: O +
χ2 O +
= O +
10.61 O -
, O +
df O +
= O +
8 O -
; O +
P O +
= O +
0.23 O -
) O +
and O +
explained O +
slightly O +
more O +
of O +
the O +
total O +
variance O +
in O +
active O +
travel O +
than O +
did O +
the O +
personal O +
model O +
alone O +
( O -
Nagelkerke O -
's O +
R2 O +
= O +
20.1 O -
% O -
) O +
( O -
Figure O +
3 O -
) O -
. O +

In O +
order O +
to O +
aid O +
interpretation O -
, O +
we O +
also O +
partitioned O +
the O +
dataset O +
into O +
two O +
strata O +
( O -
' O -
No O +
car O +
available O -
' O +
and O +
' O -
Car O +
available O -
' O -
) O +
and O +
refitted O +
the O +
final O +
model O +
separately O +
to O +
each O +
stratum O +
of O +
the O +
dataset O +
( O -
Table O +
6 O -
) O -
. O +

This O +
showed O +
that O +
the O +
subset O +
of O +
respondents O +
with O +
no O +
access O +
to O +
a O +
car O +
accounted O +
for O +
the O +
significant O +
overall O +
relationship O +
between O +
active O +
travel O +
and O +
access O +
to O +
a O +
bicycle O -
, O +
whereas O +
those O +
with O +
access O +
to O +
a O +
car O +
accounted O +
for O +
the O +
significant O +
overall O +
relationships O +
with O +
distance O +
to O +
place O +
of O +
work O +
or O +
study O +
and O +
perceptions O +
of O +
the O +
local O +
environment O -
. O +

The O +
relationship O +
with O +
difficulty O +
walking O +
was O +
also O +
stronger O +
in O +
this O +
group O +
than O +
in O +
those O +
without O +
access O +
to O +
a O +
car O -
. O +

Correlates O +
of O +
physical O +
activity O +
Physical O +
activity O +
was O +
significantly O +
associated O +
with O +
living O +
in O +
social O -
- O -
rented O +
accommodation O -
, O +
not O +
being O +
overweight O -
, O +
and O +
the O +
absence O +
of O +
any O +
difficulty O +
walking O -
. O +

The O +
final O +
best O +
model O +
of O +
the O +
' O -
personal O -
' O +
correlates O +
of O +
physical O +
activity O +
provided O +
satisfactory O +
goodness O -
- O -
of O -
- O -
fit O +
( O -
Hosmer O +
and O +
Lemeshow O +
test O -
: O +
χ2 O +
= O +
3.89 O -
, O +
df O +
= O +
7 O -
; O +
P O +
= O +
0.89 O -
) O +
and O +
explained O +
about O +
one O -
- O -
sixth O +
of O +
the O +
total O +
variance O +
in O +
physical O +
activity O +
( O -
Nagelkerke O -
's O +
R2 O +
= O +
15.9 O -
% O -
) O +
( O -
Table O +
7 O -
) O -
. O +

Adding O +
' O -
environmental O -
' O +
variables O +
to O +
the O +
model O +
showed O +
an O +
additional O +
significant O +
negative O +
association O +
between O +
physical O +
activity O +
and O +
perception O +
of O +
traffic O +
volume O +
( O -
i.e. O +
respondents O +
who O +
perceived O +
there O +
to O +
be O +
a O +
higher O +
volume O +
of O +
traffic O +
were O +
more O +
likely O +
to O +
report O +
physical O +
activity O -
) O -
. O +

The O +
final O +
best O +
model O +
of O +
the O +
personal O +
and O +
environmental O +
correlates O +
of O +
physical O +
activity O +
also O +
provided O +
satisfactory O +
goodness O -
- O -
of O -
- O -
fit O +
( O -
Hosmer O +
and O +
Lemeshow O +
test O -
: O +
χ2 O +
= O +
3.86 O -
, O +
df O +
= O +
8 O -
; O +
P O +
= O +
0.87 O -
) O +
and O +
explained O +
slightly O +
more O +
of O +
the O +
total O +
variance O +
in O +
physical O +
activity O +
than O +
did O +
the O +
personal O +
model O +
alone O +
( O -
Nagelkerke O -
's O +
16.6 O -
% O -
) O +
( O -
Figure O +
3 O -
) O -
. O +

Discussion O +
Principal O +
findings O +
In O +
this O +
deprived O +
urban O +
population O -
, O +
the O +
likelihood O +
of O +
reporting O +
active O +
travel O +
was O +
associated O +
with O +
being O +
younger O -
, O +
living O +
in O +
owner O -
- O -
occupied O +
accommodation O -
, O +
not O +
having O +
to O +
travel O +
a O +
long O +
distance O +
to O +
work O +
and O +
not O +
having O +
access O +
to O +
a O +
car O -
, O +
whereas O +
overall O +
physical O +
activity O +
was O +
associated O +
with O +
living O +
in O +
social O -
- O -
rented O +
accommodation O +
and O +
not O +
being O +
overweight O -
. O +

After O +
adjusting O +
for O +
individual O +
and O +
household O +
characteristics O -
, O +
neither O +
perceptions O +
of O +
the O +
local O +
environment O +
nor O +
the O +
objective O +
proximity O +
of O +
respondents O -
' O +
homes O +
to O +
motorway O +
or O +
major O +
road O +
infrastructure O +
appeared O +
to O +
explain O +
much O +
of O +
the O +
variance O +
in O +
active O +
travel O +
or O +
overall O +
physical O +
activity O -
, O +
although O +
we O +
did O +
find O +
a O +
significant O +
positive O +
association O +
between O +
active O +
travel O +
and O +
perceived O +
proximity O +
to O +
shops O -
. O +

Representativeness O +
and O +
completeness O +
of O +
survey O +
data O +
Our O +
difficulty O +
in O +
obtaining O +
a O +
representative O +
sample O +
of O +
the O +
resident O +
population O +
is O +
not O +
unique O +
to O +
our O +
study O -
. O +

Although O +
our O +
final O +
response O +
rate O +
was O +
low O -
, O +
it O +
was O +
almost O +
identical O +
to O +
that O +
achieved O +
in O +
a O +
recent O +
population O -
- O -
based O +
intervention O +
study O +
elsewhere O +
in O +
Glasgow O +
[ O -
22 O -
] O -
. O +

Some O +
of O +
the O +
challenges O +
of O +
recruiting O +
research O +
participants O +
in O +
areas O +
of O +
deprivation O +
have O +
been O +
described O +
elsewhere O +
[ O -
23 O -
] O -
; O +
these O +
are O +
superimposed O +
on O +
a O +
downward O +
trend O +
in O +
participation O +
in O +
even O +
the O +
best O -
- O -
resourced O +
national O +
population O +
surveys O +
[ O -
24 O -
] O +
and O +
an O +
upward O +
( O -
and O +
socially O +
biased O -
) O +
trend O +
in O +
opt O -
- O -
outs O +
from O +
the O +
main O +
alternative O +
sampling O +
frame O -
, O +
the O +
edited O +
electoral O +
register O +
[ O -
25 O -
] O -
. O +

Although O +
our O +
achieved O +
sample O +
contained O +
a O +
higher O +
proportion O +
of O +
respondents O +
from O +
owner O -
- O -
occupied O +
and O +
car O -
- O -
owning O +
households O +
than O +
predicted O +
from O +
2001 O +
census O +
data O +
for O +
the O +
same O +
census O +
output O +
areas O -
, O +
these O +
differences O +
may O +
be O +
partly O +
accounted O +
for O +
by O +
an O +
upward O +
background O +
trend O +
in O +
owner O +
occupation O +
and O +
car O +
access O +
between O +
2001 O +
and O +
2005 O -
. O +

Our O +
achieved O +
sample O +
is O +
still O +
clearly O +
disadvantaged O +
overall O -
, O +
in O +
terms O +
of O +
socioeconomic O +
and O +
health O +
status O -
, O +
compared O +
with O +
the O +
country O +
as O +
a O +
whole O -
. O +

It O +
also O +
contains O +
sufficient O +
heterogeneity O +
to O +
enable O +
us O +
to O +
examine O -
, O +
in O +
time O -
, O +
how O +
the O +
effects O +
of O +
the O +
intervention O +
are O +
distributed O +
between O +
socioeconomic O +
groups O -
. O +

We O +
therefore O +
consider O +
our O +
achieved O +
sample O +
fit O +
for O +
purpose O -
. O +

We O +
had O +
to O +
disregard O +
a O +
substantial O +
proportion O +
of O +
cases O +
in O +
analysis O +
because O +
respondents O +
had O +
returned O +
unusable O +
travel O +
time O +
data O +
or O +
had O +
returned O +
physical O +
activity O +
data O +
that O +
were O +
incomplete O -
, O +
internally O +
inconsistent O +
or O +
included O +
a O +
' O -
Do O -
n't O +
know O -
' O +
response O +
and O +
were O +
therefore O +
unacceptable O +
according O +
to O +
the O +
IPAQ O +
scoring O +
protocol O -
. O +

Most O +
published O +
studies O +
using O +
the O +
same O -
, O +
short O +
form O +
of O +
IPAQ O +
have O +
either O +
not O +
reported O +
the O +
distribution O +
of O +
the O +
continuous O +
summary O +
measures O +
or O +
have O +
not O +
reported O +
data O +
for O +
the O +
UK O +
separately O +
from O +
those O +
for O +
other O +
countries O +
where O +
higher O +
levels O +
of O +
physical O +
activity O +
are O +
reported O -
. O +

Despite O +
the O +
high O +
proportion O +
of O +
missing O +
physical O +
activity O +
data O +
in O +
our O +
dataset O -
, O +
however O -
, O +
the O +
aggregate O +
continuous O +
data O +
we O +
obtained O +
were O +
broadly O +
comparable O +
to O +
those O +
reported O +
in O +
Rütten O +
and O +
colleagues O -
' O +
study O +
of O +
a O +
random O +
sample O +
of O +
UK O +
adults O +
[ O -
26 O -
] O -
. O +

We O +
could O +
have O +
included O +
more O +
cases O +
in O +
physical O +
activity O +
analysis O +
by O -
, O +
for O +
example O -
, O +
imputing O +
missing O +
values O -
, O +
but O +
the O +
results O +
would O +
not O +
have O +
been O +
comparable O +
with O +
others O -
' O +
owing O +
to O +
the O +
substantial O +
deviations O +
from O +
the O +
scoring O +
protocol O +
which O +
would O +
have O +
been O +
required O -
. O +

The O +
frequency O +
of O +
unusable O +
responses O +
was O +
not O +
reported O +
in O +
the O +
international O +
multi O -
- O -
centre O +
study O +
which O +
originally O +
established O +
the O +
validity O +
and O +
reliability O +
of O +
IPAQ O +
[ O -
27 O -
] O -
. O +

It O +
is O +
possible O +
that O +
offering O +
a O +
' O -
Do O -
n't O +
know O -
' O +
option O +
in O +
the O +
self O -
- O -
completed O +
IPAQ O +
questionnaire O +
encourages O +
respondents O +
to O +
select O +
this O +
rather O +
than O +
to O +
enter O +
what O +
may O +
be O +
a O +
reasonably O +
precise O +
estimate O +
of O +
the O +
actual O +
time O +
spent O +
in O +
physical O +
activity O -
; O +
the O +
respondent O +
has O +
no O +
way O +
of O +
knowing O +
that O +
a O +
single O +
' O -
Do O -
n't O +
know O -
' O +
response O +
will O +
result O +
in O +
all O +
of O +
their O +
physical O +
activity O +
data O +
being O +
disregarded O +
in O +
analysis O -
. O +

This O +
should O +
be O +
considered O +
in O +
any O +
future O +
revision O +
of O +
the O +
IPAQ O +
questionnaire O +
and O +
scoring O +
protocol O -
. O +

Contribution O +
of O +
active O +
travel O +
to O +
overall O +
physical O +
activity O +
The O +
explanatory O +
variables O +
that O +
were O +
significantly O +
associated O +
with O +
active O +
travel O +
but O +
not O +
with O +
physical O +
activity O +
( O -
distance O +
to O +
place O +
of O +
work O +
or O +
study O -
, O +
access O +
to O +
a O +
bicycle O -
, O +
access O +
to O +
a O +
car O -
, O +
perceived O +
proximity O +
to O +
shops O -
, O +
and O +
perceived O +
road O +
safety O +
for O +
cyclists O -
) O +
all O +
have O +
an O +
obvious O +
intuitive O +
relationship O +
with O +
the O +
use O +
of O +
walking O +
or O +
cycling O +
as O +
modes O +
of O +
transport O -
. O +

That O +
they O +
were O +
not O +
significantly O +
associated O +
with O +
overall O +
physical O +
activity O +
suggests O +
either O +
that O +
active O +
travel O +
contributes O +
only O +
a O +
minority O +
of O +
respondents O -
' O +
overall O +
physical O +
activity O +
or O +
that O +
other O +
factors O +
not O +
measured O +
in O +
this O +
study O +
are O +
more O +
important O +
correlates O +
of O +
overall O +
physical O +
activity O +
than O +
those O +
which O +
determine O +
active O +
travel O -
. O +

A O +
crude O +
comparision O +
of O +
the O +
quantity O +
of O +
active O +
travel O +
reported O +
in O +
the O +
one O -
- O -
day O +
travel O +
diaries O +
with O +
the O +
quantities O +
of O +
physical O +
activity O +
reported O +
using O +
IPAQ O +
suggests O +
that O +
on O +
average O -
, O +
active O +
travel O +
may O +
indeed O +
make O +
only O +
a O +
small O +
( O -
~15 O -
% O -
) O +
contribution O +
to O +
overall O +
physical O +
activity O +
in O +
this O +
study O +
population O -
. O +

However O -
, O +
the O +
real O +
contribution O +
may O +
be O +
substantially O +
greater O +
than O +
this O +
if O -
, O +
as O +
has O +
been O +
shown O +
previously O -
, O +
respondents O +
tend O +
to O +
over O -
- O -
report O +
their O +
physical O +
activity O +
using O +
IPAQ O +
[ O -
28 O -
] O -
. O +

There O +
can O +
be O +
little O +
doubt O +
that O +
active O +
travel O +
makes O +
a O +
substantial O +
contribution O +
to O +
the O +
total O +
quantity O +
of O +
walking O +
reported O +
in O +
this O +
study O +
population O -
. O +

Irrespective O +
of O +
the O +
true O +
contribution O +
of O +
active O +
travel O +
to O +
overall O +
physical O +
activity O -
, O +
however O -
, O +
it O +
remains O +
likely O +
that O +
other O +
unmeasured O +
personal O +
and O +
social O +
factors O +
beyond O +
the O +
scope O +
of O +
this O +
study O +
may O +
be O +
more O +
important O +
correlates O +
of O +
overall O +
physical O +
activity O -
. O +

Socio O -
- O -
spatial O +
patterning O +
of O +
active O +
travel O +
and O +
overall O +
physical O +
activity O +
Respondents O +
living O +
in O +
owner O -
- O -
occupied O +
households O +
were O +
more O +
likely O +
to O +
report O +
active O +
travel O +
than O +
those O +
living O +
in O +
social O -
- O -
rented O +
accommodation O -
, O +
but O +
less O +
likely O +
to O +
report O +
sufficient O +
overall O +
physical O +
activity O -
. O +

Since O +
neither O +
working O +
situation O +
nor O +
perceived O +
financial O +
situation O +
emerged O +
as O +
significantly O +
associated O +
with O +
active O +
travel O +
or O +
overall O +
physical O +
activity O -
, O +
housing O +
tenure O +
and O +
car O +
access O +
are O +
the O +
remaining O +
explanatory O +
variables O +
in O +
this O +
dataset O +
which O +
can O +
be O +
interpreted O +
as O +
markers O +
of O +
socioeconomic O +
status O -
. O +

Although O +
having O +
access O +
to O +
a O +
car O +
clearly O +
reflects O +
the O +
possession O +
of O +
a O +
material O +
asset O -
, O +
it O +
has O +
been O +
argued O +
that O +
this O +
is O +
a O +
less O +
direct O +
marker O +
of O +
socioeconomic O +
status O +
than O +
some O +
other O +
markers O +
because O -
, O +
in O +
Scotland O +
at O +
least O -
, O +
access O +
to O +
a O +
car O +
is O +
a O +
more O -
- O -
or O -
- O -
less O +
essential O +
requirement O +
for O +
living O +
in O +
many O +
rural O +
areas O -
, O +
whereas O +
it O +
is O +
possible O +
to O +
live O +
in O +
a O +
dense O +
urban O +
settlement O +
such O +
as O +
Glasgow O +
without O +
using O +
a O +
car O -
. O +

In O +
the O +
final O +
models O +
in O +
this O +
study O -
, O +
therefore O -
, O +
housing O +
tenure O +
may O +
be O +
regarded O +
as O +
the O +
primary O +
marker O +
of O +
socioeconomic O +
status O -
. O +

The O +
findings O +
consequently O +
suggest O +
conflicting O +
socioeconomic O +
gradients O +
in O +
prevalence O -
: O +
more O +
advantaged O +
respondents O +
were O +
more O +
likely O +
to O +
report O +
active O +
travel O -
, O +
but O +
more O +
disadvantaged O +
respondents O +
were O +
more O +
likely O +
to O +
report O +
sufficient O +
overall O +
physical O +
activity O -
. O +

The O +
higher O +
prevalence O +
of O +
sufficient O +
overall O +
physical O +
activity O +
among O +
the O +
more O +
disadvantaged O +
despite O +
their O +
lower O +
propensity O +
for O +
active O +
travel O +
is O +
likely O +
to O +
reflect O +
higher O +
quantities O +
of O +
physical O +
activity O +
in O +
other O +
domains O -
, O +
particularly O +
occupational O +
and O +
domestic O +
activities O -
, O +
since O +
leisure O -
- O -
time O +
physical O +
activity O +
tends O +
to O +
be O +
higher O +
among O +
more O +
advantaged O +
groups O +
[ O -
29 O -
] O -
. O +

Environmental O +
characteristics O -
: O +
paradoxical O -
, O +
unmeasured O -
, O +
or O +
irrelevant O -
? O +

The O +
two O +
environmental O +
variables O +
that O +
emerged O +
as O +
significantly O +
associated O +
with O +
active O +
travel O -
, O +
particularly O +
among O +
those O +
without O +
access O +
to O +
a O +
car O -
, O +
were O +
perceived O +
proximity O +
to O +
shops O +
and O +
perceived O +
road O +
safety O +
for O +
cyclists O -
. O +

The O +
positive O +
association O +
with O +
perceived O +
proximity O +
to O +
shops O +
suggests O +
that O +
for O +
active O +
travel O +
to O +
be O +
undertaken O +
in O +
this O +
population O -
, O +
it O +
may O +
be O +
more O +
important O +
that O +
people O +
live O +
close O +
to O +
the O +
amenities O +
they O +
need O +
than O +
that O +
they O +
live O +
in O +
an O +
environment O +
with O +
more O +
favourable O +
subjective O +
or O +
discretionary O +
considerations O +
such O +
as O +
attractiveness O +
or O +
noise O -
. O +

This O +
would O +
be O +
consistent O +
with O +
an O +
understanding O +
that O +
walking O +
as O +
a O +
mode O +
of O +
transport O +
is O +
primarily O +
a O +
way O +
of O +
undertaking O +
journeys O +
which O +
have O +
to O +
be O +
made O +
anyway O -
, O +
as O +
opposed O +
to O +
more O +
discretionary O +
( O -
recreational O -
) O +
forms O +
of O +
walking O +
which O +
may O +
be O +
more O +
susceptible O +
to O +
the O +
influence O +
of O +
less O -
- O -
structural O +
characteristics O -
. O +

Although O +
the O +
negative O +
association O +
with O +
perceived O +
road O +
safety O +
for O +
cyclists O +
appears O +
counter O -
- O -
intuitive O -
, O +
similar O +
' O -
paradoxical O +
inverse O +
relationships O -
' O +
have O +
been O +
reported O +
elsewhere O -
, O +
for O +
example O +
by O +
Titze O +
and O +
colleagues O +
in O +
a O +
study O +
of O +
the O +
correlates O +
of O +
cycling O +
among O +
students O +
[ O -
30 O -
] O +
and O +
by O +
Humpel O +
and O +
colleagues O +
in O +
a O +
study O +
of O +
correlates O +
of O +
walking O +
for O +
pleasure O +
[ O -
31 O -
] O -
. O +

Titze O +
and O +
colleagues O +
suggest O +
that O +
respondents O +
who O +
cycle O +
regularly O +
are O +
more O +
likely O +
to O +
be O +
aware O +
of O -
, O +
and O +
report O -
, O +
the O +
danger O +
posed O +
by O +
traffic O +
than O +
non O -
- O -
cyclists O +
or O +
infrequent O +
cyclists O -
. O +

A O +
similar O +
phenomenon O +
could O +
explain O +
the O +
negative O +
association O +
between O +
physical O +
activity O +
and O +
perception O +
of O +
traffic O +
volume O -
. O +

Overall O -
, O +
the O +
influence O +
of O +
the O +
putative O +
environmental O +
characteristics O +
examined O +
in O +
this O +
study O +
on O +
active O +
travel O +
and O +
physical O +
activity O +
appeared O +
small O +
compared O +
with O +
that O +
of O +
the O +
personal O +
characteristics O +
found O +
to O +
be O +
significant O -
, O +
and O +
including O +
environmental O +
characteristics O +
in O +
the O +
models O +
did O +
not O +
substantially O +
modify O +
the O +
influence O +
of O +
personal O +
characteristics O -
. O +

On O +
the O +
one O +
hand O -
, O +
this O +
could O +
reflect O +
an O +
artefact O +
of O +
the O +
research O +
methods O +
( O -
a O +
false O +
negative O +
error O -
) O -
, O +
which O +
could O +
have O +
arisen O +
in O +
various O +
ways O -
. O +

In O +
particular O -
, O +
the O +
' O -
wrong O -
' O +
environmental O +
exposure O +
may O +
have O +
been O +
measured O -
, O +
in O +
that O +
the O +
environmental O +
characteristics O +
examined O +
were O +
those O +
of O +
the O +
immediate O +
surroundings O +
of O +
respondents O -
' O +
homes O -
, O +
whereas O +
the O +
propensity O +
to O +
choose O +
active O +
modes O +
of O +
transport O +
may O +
be O +
more O +
strongly O +
influenced O +
by O +
the O +
characteristics O +
of O +
the O +
environment O +
elsewhere O +
on O +
their O +
routes O +
[ O -
30 O -
] O -
, O +
for O +
example O +
the O +
perceived O +
danger O +
of O +
cycling O +
in O +
the O +
city O +
centre O +
– O +
an O +
association O +
which O +
may O +
be O +
absent O -
, O +
or O +
at O +
least O +
diluted O -
, O +
when O +
the O +
' O -
exposure O -
' O +
examined O +
is O +
limited O +
to O +
the O +
residential O +
environment O -
. O +

It O +
could O +
also O +
be O +
argued O +
that O +
the O +
apparently O +
weak O +
influence O +
of O +
environmental O +
characteristics O +
in O +
this O +
study O +
reflects O +
a O +
reliance O +
on O +
respondents O -
' O +
perceptions O +
which O +
have O +
not O +
been O +
objectively O +
verified O +
and O +
may O +
therefore O +
be O +
a O +
weak O +
proxy O +
for O +
the O +
' O -
true O -
' O +
objectively O -
- O -
measured O +
characteristics O +
of O +
their O +
surroundings O -
. O +

However O -
, O +
as O +
recent O +
reviews O +
have O +
pointed O +
out O -
, O +
the O +
current O +
weight O +
of O +
evidence O +
for O +
objective O +
environmental O +
correlates O +
of O +
walking O +
is O +
no O +
greater O +
than O +
that O +
for O +
subjective O +
environmental O +
correlates O +
[ O -
5 O -
] O +
and O +
it O +
is O +
entirely O +
plausible O +
that O +
people O -
's O +
perceptions O +
of O +
their O +
environment O +
may O +
be O +
at O +
least O +
as O +
important O +
as O +
their O +
objective O +
conditions O +
in O +
influencing O +
their O +
behaviour O +
[ O -
6 O -
] O -
. O +

On O +
the O +
other O +
hand O -
, O +
we O +
may O +
have O +
demonstrated O +
a O +
real O +
absence O +
of O +
any O +
major O +
association O -
. O +

Although O +
at O +
first O +
sight O +
this O +
appears O +
at O +
odds O +
with O +
the O +
growing O +
body O +
of O +
review O -
- O -
level O +
evidence O +
for O +
environmental O +
correlates O +
of O +
physical O +
activity O -
, O +
Wendel O -
- O -
Vos O +
and O +
colleagues O +
noted O +
that O +
of O +
all O +
the O +
environmental O +
factors O +
examined O +
in O +
all O +
the O +
studies O +
included O +
in O +
their O +
review O -
, O +
analysis O +
showed O +
a O +
' O -
null O +
association O -
' O +
in O +
76 O -
% O +
of O +
cases O +
[ O -
9 O -
] O -
, O +
and O +
our O +
finding O +
that O +
personal O +
factors O +
account O +
for O +
a O +
much O +
larger O +
proportion O +
of O +
the O +
variance O +
in O +
active O +
travel O +
or O +
physical O +
activity O +
than O +
is O +
accounted O +
for O +
by O +
environmental O +
factors O +
is O +
consistent O +
with O +
those O +
of O +
some O +
other O +
European O +
studies O +
[ O -
32,33 O -
] O -
. O +

In O +
the O +
particular O +
context O +
of O +
this O +
study O -
, O +
residents O +
may O +
simply O +
have O +
adapted O +
to O +
adverse O +
conditions O +
in O +
their O +
local O +
environment O +
in O +
the O +
ways O +
identified O +
by O +
Hedges O +
in O +
a O +
qualitative O +
study O +
of O +
people O +
living O +
close O +
to O +
new O +
roads O +
built O +
in O +
the O +
UK O +
in O +
the O +
1970s O +
[ O -
34 O -
] O +
– O +
particularly O +
by O +
attitudinal O +
adaptation O -
, O +
which O +
Hedges O +
characterises O +
as O +
developing O +
an O +
attitude O +
that O +
it O +
is O +
futile O +
to O +
resist O -
. O +

One O +
can O +
imagine O +
that O +
in O +
the O +
most O +
deprived O +
areas O +
of O +
Glasgow O -
, O +
people O +
may O +
have O +
become O +
resigned O +
to O +
the O +
nature O +
of O +
their O +
surroundings O -
, O +
seeing O +
them O +
as O +
inevitable O +
and O +
not O +
amenable O +
to O +
change O +
either O +
through O +
environmental O +
improvement O +
or O +
through O +
their O +
moving O +
to O +
another O +
area O -
. O +

Conclusion O +
After O +
demographic O +
and O +
socioeconomic O +
characteristics O +
were O +
taken O +
into O +
account O -
, O +
neither O +
perceptions O +
of O +
the O +
local O +
environment O +
nor O +
objective O +
proximity O +
to O +
major O +
road O +
infrastructure O +
appeared O +
to O +
explain O +
much O +
of O +
the O +
variance O +
in O +
active O +
travel O +
or O +
overall O +
physical O +
activity O +
in O +
this O +
study O -
. O +

Our O +
study O +
population O +
may O +
be O +
both O +
objectively O +
constrained O +
by O +
their O +
socioeconomic O +
circumstances O +
( O -
including O +
comparatively O +
limited O +
access O +
to O +
private O +
cars O -
) O +
and O +
adapted O +
to O +
living O +
in O +
conditions O +
which O +
others O +
would O +
consider O +
to O +
pose O +
a O +
barrier O +
to O +
active O +
travel O -
. O +

Under O +
these O +
circumstances O -
, O +
environmental O +
characteristics O +
which O +
have O +
been O +
found O +
to O +
influence O +
discretionary O +
active O +
travel O +
in O +
studies O +
in O +
other O -
, O +
more O +
affluent O +
populations O +
may O +
simply O +
be O +
irrelevant O +
in O +
a O +
population O +
which O +
is O +
more O +
captive O +
in O +
its O +
travel O +
choices O -
. O +

Environmental O +
correlates O +
of O +
active O +
travel O +
should O +
not O +
be O +
assumed O +
to O +
be O +
generalisable O +
between O +
populations O -
; O +
researchers O +
should O +
continue O +
to O +
test O +
hypotheses O +
about O +
putative O +
environmental O +
correlates O +
in O +
different O +
settings O -
, O +
and O +
policymakers O +
should O +
recognise O +
that O +
the O +
effects O +
of O +
interventions O +
to O +
change O +
the O +
environment O +
are O +
likely O +
to O +
vary O +
between O +
populations O +
and O +
between O +
socioeconomic O +
groups O +
within O +
populations O -
. O +

Competing O +
interests O +
This O +
paper O +
is O +
based O +
on O +
material O +
contained O +
in O +
the O +
first O +
author O -
's O +
PhD O +
thesis O -
. O +

Authors O -
' O +
contributions O +
DO O +
had O +
the O +
original O +
idea O +
for O +
the O +
study O -
, O +
designed O +
the O +
study O +
and O +
the O +
survey O +
materials O -
, O +
applied O +
for O +
ethical O +
approval O -
, O +
cleaned O +
and O +
coded O +
the O +
survey O +
data O -
, O +
carried O +
out O +
all O +
the O +
geographical O +
and O +
statistical O +
analyses O +
and O +
wrote O +
the O +
paper O -
. O +

MP O +
was O +
DO O -
's O +
PhD O +
supervisor O -
. O +

RM O -
, O +
NM O -
, O +
MP O +
and O +
SP O +
constituted O +
the O +
steering O +
group O +
for O +
the O +
study O -
, O +
contributed O +
to O +
and O +
advised O +
on O +
the O +
design O +
of O +
the O +
study O +
and O +
the O +
interpretation O +
of O +
the O +
emerging O +
findings O -
, O +
and O +
contributed O +
to O +
the O +
critical O +
revision O +
of O +
the O +
paper O -
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O -
. O +

Supplementary O +
Material O +

TOPS++FATCAT O -
: O +
Fast O +
flexible O +
structural O +
alignment O +
using O +
constraints O +
derived O +
from O +
TOPS+ O +
Strings O +
Model O +
Abstract O +
Background O +
Protein O +
structure O +
analysis O +
and O +
comparison O +
are O +
major O +
challenges O +
in O +
structural O +
bioinformatics O -
. O +

Despite O +
the O +
existence O +
of O +
many O +
tools O +
and O +
algorithms O -
, O +
very O +
few O +
of O +
them O +
have O +
managed O +
to O +
capture O +
the O +
intuitive O +
understanding O +
of O +
protein O +
structures O +
developed O +
in O +
structural O +
biology O -
, O +
especially O +
in O +
the O +
context O +
of O +
rapid O +
database O +
searches O -
. O +

Such O +
intuitions O +
could O +
help O +
speed O +
up O +
similarity O +
searches O +
and O +
make O +
it O +
easier O +
to O +
understand O +
the O +
results O +
of O +
such O +
analyses O -
. O +

Results O +
We O +
developed O +
a O +
TOPS++FATCAT O +
algorithm O +
that O +
uses O +
an O +
intuitive O +
description O +
of O +
the O +
proteins O -
' O +
structures O +
as O +
captured O +
in O +
the O +
popular O +
TOPS O +
diagrams O +
to O +
limit O +
the O +
search O +
space O +
of O +
the O +
aligned O +
fragment O +
pairs O +
( O -
AFPs O -
) O +
in O +
the O +
flexible O +
alignment O +
of O +
protein O +
structures O +
performed O +
by O +
the O +
FATCAT O +
algorithm O -
. O +

The O +
TOPS++FATCAT O +
algorithm O +
is O +
faster O +
than O +
FATCAT O +
by O +
more O +
than O +
an O +
order O +
of O +
magnitude O +
with O +
a O +
minimal O +
cost O +
in O +
classification O +
and O +
alignment O +
accuracy O -
. O +

For O +
beta O -
- O -
rich O +
proteins O +
its O +
accuracy O +
is O +
better O +
than O +
FATCAT O -
, O +
because O +
the O +
TOPS+ O +
strings O +
models O +
contains O +
important O +
information O +
of O +
the O +
parallel O +
and O +
anti O -
- O -
parallel O +
hydrogen O -
- O -
bond O +
patterns O +
between O +
the O +
beta O -
- O -
strand O +
SSEs O +
( O -
Secondary O +
Structural O +
Elements O -
) O -
. O +

We O +
show O +
that O +
the O +
TOPS++FATCAT O +
errors O -
, O +
rare O +
as O +
they O +
are O -
, O +
can O +
be O +
clearly O +
linked O +
to O +
oversimplifications O +
of O +
the O +
TOPS O +
diagrams O +
and O +
can O +
be O +
corrected O +
by O +
the O +
development O +
of O +
more O +
precise O +
secondary O +
structure O +
element O +
definitions O -
. O +

Software O +
Availability O +
The O +
benchmark O +
analysis O +
results O +
and O +
the O +
compressed O +
archive O +
of O +
the O +
TOPS++FATCAT O +
program O +
for O +
Linux O +
platform O +
can O +
be O +
downloaded O +
from O +
the O +
following O +
web O +
site O -
: O +
Conclusion O +
TOPS++FATCAT O +
provides O +
FATCAT O +
accuracy O +
and O +
insights O +
into O +
protein O +
structural O +
changes O +
at O +
a O +
speed O +
comparable O +
to O +
sequence O +
alignments O -
, O +
opening O +
up O +
a O +
possibility O +
of O +
interactive O +
protein O +
structure O +
similarity O +
searches O -
. O +

Background O +
Structural O +
biology O +
is O +
one O +
of O +
the O +
most O +
successful O +
fields O +
of O +
modern O +
biology O -
. O +

Over O +
50,000 O +
solved O +
protein O +
structures O +
illustrate O +
details O +
of O +
many O +
specific O +
biological O +
processes O -
. O +

The O +
same O +
data O +
also O +
provide O +
us O +
with O +
information O +
about O +
the O +
global O +
features O +
of O +
protein O +
structure O +
space O +
and O +
can O +
be O +
studied O +
to O +
discover O +
the O +
evolutionary O -
, O +
physical O -
, O +
and O +
mathematical O +
rules O +
governing O +
them O -
. O +

How O +
many O +
fundamentally O +
different O +
protein O +
shapes O +
( O -
folds O -
) O +
are O +
there O -
? O +

How O +
do O +
protein O +
structures O +
evolve O -
? O +

How O +
do O +
new O +
structural O +
features O +
appear O -
, O +
and O +
if O +
they O +
are O +
coupled O +
with O +
changes O +
in O +
function O -
, O +
how O +
does O +
this O +
process O +
occur O -
? O +

Such O +
questions O +
can O +
be O +
studied O +
by O +
classifying O -
, O +
comparing O +
and O +
analyzing O +
known O +
protein O +
structures O -
. O +

Two O +
different O -
, O +
but O +
synergistic O +
strategies O +
are O +
typically O +
used O +
for O +
this O +
purpose O -
. O +

In O +
classification O +
systems O +
such O +
as O +
SCOP O +
[ O -
1 O -
] O +
or O +
CATH O +
[ O -
2 O -
] O -
, O +
human B-Species +
intuition O +
is O +
used O +
to O +
simplify O +
the O +
description O +
of O +
protein O +
structures O +
to O +
a O +
manageable O +
size O -
, O +
and O +
a O +
human B-Species +
eye O -
, O +
sometimes O +
supported O +
by O +
automated O +
analysis O -
, O +
can O +
recognize O +
patterns O +
and O +
types O +
of O +
structures O -
. O +

In O +
the O +
second O +
approach O -
, O +
specialized O +
comparison O +
algorithms O -
, O +
such O +
as O +
DALI O +
[ O -
3 O -
] O -
, O +
CE O +
[ O -
4 O -
] O -
, O +
or O +
FATCAT O +
[ O -
5 O -
] O +
can O +
be O +
used O +
to O +
calculate O +
a O +
distance O -
- O -
like O +
metric O +
in O +
the O +
protein O +
structure O +
space O -
. O +

This O +
in O +
turn O +
can O +
be O +
used O +
to O +
cluster O +
proteins O +
into O +
groups O -
. O +

Many O +
such O +
algorithms O +
have O +
been O +
developed O +
over O +
the O +
past O +
few O +
decades O +
and O +
have O +
been O +
mostly O +
used O +
for O +
the O +
classification O +
of O +
protein O +
structures O +
into O +
families O -
. O +

An O +
exact O +
solution O +
of O +
an O +
alignment O +
between O +
two O +
structures O +
is O +
formally O +
equivalent O +
to O +
a O +
threading O +
problem O +
and O +
is O +
therefore O +
NP O -
- O -
complete O +
[ O -
6 O -
] O -
. O +

However O -
, O +
a O +
practical O +
solution O +
can O +
be O +
obtained O +
by O +
heuristics O +
reducing O +
the O +
problem O +
to O +
a O +
manageable O +
size O +
[ O -
7 O -
] O -
. O +

In O +
human B-Species +
classification O +
systems O -
, O +
the O +
protein O +
is O +
usually O +
reduced O +
to O +
a O +
set O +
of O +
several O +
structural O +
elements O -
, O +
which O +
obviously O +
involve O +
many O +
arbitrary O +
thresholds O -
. O +

Automated O +
algorithms O +
have O +
the O +
same O +
problem O +
and O +
also O +
suffer O +
from O +
inconsistencies O +
between O +
different O +
numerical O +
measures O +
of O +
protein O +
structure O +
similarity O +
[ O -
8 O -
] O -
. O +

Interestingly O -
, O +
despite O +
these O +
problems O -
, O +
results O +
of O +
different O +
approaches O +
are O +
broadly O +
similar O -
. O +

They O +
all O +
identify O +
approximately O +
a O +
few O +
hundred O +
general O +
classes O +
of O +
protein O +
structures O -
, O +
usually O +
called O +
folds O +
[ O -
1 O -
] O +
or O +
topologies O +
[ O -
2 O -
] O -
, O +
distinguished O +
by O +
how O +
the O +
main O +
chain O +
of O +
the O +
protein O +
folds O +
around O +
itself O +
in O +
the O +
three O -
- O -
dimensional O +
space O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
comparison O +
of O +
different O +
approaches O -
, O +
both O +
between O +
and O +
within O +
the O +
two O +
classes O -
, O +
shows O +
that O +
fold O -
/ O -
topologies O +
( O -
or O +
cluster O -
) O +
definitions O +
are O +
somewhat O +
fuzzy O -
, O +
with O +
some O +
proteins O +
being O +
occasionally O +
difficult O +
to O +
classify O +
and O +
joining O +
different O +
groups O +
depending O +
on O +
various O +
assumptions O -
. O +

This O +
lead O +
some O +
to O +
question O +
the O +
concept O +
of O +
the O +
fold O +
[ O -
9 O -
] O -
, O +
but O +
practical O +
application O +
of O +
protein O +
structure O +
comparison O +
leaves O +
little O +
doubt O +
that O +
protein O +
structure O +
space O +
has O +
some O +
natural O +
granularity O +
that O +
overlaps O +
well O +
with O +
the O +
traditional O +
fold O +
classification O -
. O +

Comparison O +
and O +
classification O +
of O +
protein O +
structures O +
is O +
significantly O +
simplified O +
by O +
the O +
fact O +
that O +
proteins O +
have O +
naturally O +
modular O +
structures O -
, O +
being O +
mostly O +
composed O +
of O +
locally O +
regular O +
structures O -
: O +
alpha O +
helices O +
and O +
beta O +
strands O -
. O +

These O +
two O +
types O +
of O +
secondary O +
structures O +
constitute O +
a O +
little O +
over O +
50 O -
% O +
of O +
an O +
average O +
protein O -
's O +
length O -
. O +

With O +
the O +
average O +
length O +
of O +
a O +
secondary O +
structure O +
being O +
around O +
10 O +
amino O +
acids O -
, O +
this O +
makes O +
it O +
possible O +
to O +
describe O +
protein O +
structure O +
as O +
an O +
arrangement O +
of O +
a O +
much O +
smaller O +
number O +
of O +
elements O -
. O +

Protein O +
structures O +
are O +
often O +
visualized O +
in O +
a O +
simplified O +
form O -
, O +
with O +
the O +
so O -
- O -
called O +
ribbon O +
diagram O +
with O +
secondary O +
structures O +
shown O +
as O +
helices O +
and O +
arrows O +
being O +
the O +
most O +
popular O +
( O -
see O +
Figure O +
1 O -
) O -
. O +

This O +
picture O +
can O +
be O +
simplified O +
further O +
by O +
showing O +
individual O +
secondary O +
structure O +
elements O +
as O +
simple O +
symbols O +
( O -
circles O +
or O +
boxes O -
/ O -
triangles O -
) O -
. O +

These O +
depictions O -
, O +
called O +
fold O +
diagrams O -
, O +
originally O +
proposed O +
in O +
the O +
70s O +
[ O -
10 O -
- O -
12 O -
] O +
are O +
best O +
captured O +
by O +
a O +
TOPS O +
( O -
Topology O +
of O +
Protein O +
Structures O -
) O +
algorithm O -
, O +
which O +
attempts O +
to O +
automate O +
the O +
process O +
of O +
creation O +
of O +
the O +
topology O +
cartoon O +
[ O -
13 O -
] O -
. O +

While O +
useful O +
in O +
protein O +
classification O -
, O +
such O +
simplified O +
descriptions O +
are O +
not O +
used O +
in O +
the O +
most O +
popular O +
automated O +
protein O +
structure O +
comparison O +
algorithms O +
such O +
as O +
DALI O +
[ O -
3 O -
] O +
or O +
CE O +
[ O -
4 O -
] O -
. O +

Kleywegt O +
and O +
Jones O +
developed O +
a O +
method O +
for O +
finding O +
similar O +
motifs O +
based O +
on O +
comparing O +
distance O +
matrices O +
that O +
are O +
constructed O +
by O +
representing O +
protein O +
as O +
a O +
set O +
of O +
SSEs O +
with O +
their O +
directional O +
vectors O +
and O +
angle O +
between O +
those O +
vectors O +
[ O -
14 O -
] O -
. O +

Programs O +
that O +
used O +
SSEs O +
either O +
for O +
structure O +
comparison O +
based O +
on O +
hierarchical O +
superposition O +
of O +
both O +
SSEs O +
and O +
atomic O +
representation O +
[ O -
15 O -
] O +
or O +
for O +
finding O +
common O +
substructures O +
in O +
the O +
comparison O +
process O +
based O +
on O +
subgraph O +
isomorphism O -
, O +
such O +
as O +
[ O -
16,17 O -
] O +
and O +
recent O +
applications O +
of O +
the O +
TOPS O +
diagram O +
[ O -
18,19 O -
] O -
, O +
usually O +
struggle O +
with O +
translating O +
the O +
comparison O +
results O +
from O +
the O +
secondary O +
structure O +
to O +
the O +
individual O +
residue O +
level O -
. O +

Although O +
the O +
SSM O +
method O +
uses O +
graph O -
- O -
matching O +
procedures O +
at O +
the O +
SSE O +
level O +
followed O +
by O +
an O +
interactive O +
3D O +
alignment O +
of O +
the O +
protein O +
C O -
- O -
alpha O +
atom O +
[ O -
20 O -
] O -
, O +
it O +
lacks O +
the O +
topological O +
relationships O +
between O +
the O +
SSEs O -
, O +
which O +
are O +
essential O +
features O +
in O +
identifying O +
common O +
scaffolds O +
in O +
distantly O +
related O +
proteins O -
. O +

A O +
TOPS O +
pattern O +
was O +
used O +
to O +
guide O +
the O +
sequence O +
alignment O -
, O +
for O +
instance O -
, O +
to O +
build O +
multiple O +
structural O +
alignments O +
of O +
the O +
distantly O +
related O +
family O +
of O +
beta O -
- O -
rich O +
protein O +
domains O +
[ O -
21 O -
] O -
. O +

The O +
Multiple O +
Sequence O +
Alignment O +
Tool O +
( O -
MSAT O -
) O +
automates O +
this O +
approach O -
, O +
merging O +
it O +
with O +
a O +
popular O +
ClustalW O +
program O +
[ O -
22 O -
] O -
. O +

DALI O +
[ O -
3 O -
] O -
, O +
CE O +
[ O -
4 O -
] O +
or O +
FATCAT O +
[ O -
5 O -
] O +
introduce O +
their O +
own O +
methods O +
of O +
decomposing O +
the O +
protein O +
structure O +
into O +
smaller O +
units O -
, O +
such O +
as O +
7 O +
× O +
7 O +
dense O +
distance O +
map O +
fragments O +
( O -
DALIs O -
) O +
or O +
aligned O +
fragment O +
pairs O +
( O -
AFPs O -
) O +
( O -
CE O +
and O +
FATCAT O -
) O -
. O +

The O +
large O +
number O +
of O +
such O +
fragments O +
and O +
the O +
combinations O +
of O +
the O +
fragments O +
that O +
need O +
to O +
be O +
evaluated O +
by O +
structure O +
comparison O +
programs O +
is O +
the O +
main O +
reason O +
for O +
the O +
significant O +
computational O +
requirements O +
of O +
such O +
algorithms O -
. O +

However O -
, O +
more O +
importantly O -
, O +
TOPS+ O +
method O +
is O +
used O +
here O +
to O +
enable O +
a O +
structural O +
comparison O +
that O +
takes O +
into O +
account O +
flexibility O +
in O +
protein O +
structures O +
and O +
not O +
only O +
classifies O +
the O +
differences O -
, O +
but O +
also O +
can O +
recognize O +
such O +
rearrangements O +
– O +
which O +
is O +
a O +
first O +
such O +
application O +
using O +
the O +
SSEs O +
language O -
. O +

In O +
this O +
contribution O -
, O +
we O +
explore O +
the O +
question O +
of O +
whether O +
it O +
would O +
be O +
possible O +
to O +
combine O +
insights O +
provided O +
by O +
topology O +
diagrams O +
into O +
automated O +
protein O +
structure O +
alignment O +
algorithms O -
, O +
focusing O +
on O +
the O +
FATCAT O +
program O +
developed O +
previously O +
in O +
our O +
group O -
. O +

Methods O +
Flexible O +
structure O +
alignment O +
method O +
FATCAT O +
FATCAT O +
[ O -
5 O -
] O +
is O +
a O +
unique O +
structure O +
alignment O +
method O +
that O +
allows O +
for O +
flexibility O +
in O +
the O +
structures O +
being O +
compared O -
. O +

It O +
builds O +
the O +
alignment O +
by O +
chaining O +
aligned O +
fragment O +
pairs O +
( O -
AFPs O -
) O +
[ O -
23 O -
] O +
together O +
using O +
a O +
unified O +
scoring O +
function O +
where O +
AFP O +
extensions O -
, O +
gaps O -
, O +
and O +
twists O +
each O +
have O +
their O +
specific O +
scores O +
( O -
Figure O +
2 O -
) O -
. O +

Introducing O +
a O +
twist O +
into O +
the O +
alignment O +
is O +
penalized O -
, O +
but O +
this O +
penalty O +
may O +
be O +
compensated O +
for O +
by O +
the O +
gain O +
in O +
the O +
score O +
of O +
the O +
resulting O +
alignment O +
( O -
i.e. O -
, O +
longer O +
alignment O +
and/or O +
better O +
RMSD O -
) O -
. O +

Rigid O +
alignment O +
can O +
be O +
treated O +
as O +
a O +
special O +
case O -
, O +
in O +
which O +
no O +
twist O +
is O +
allowed O +
in O +
chaining O +
AFPs O -
. O +

FATCAT O +
program O +
provides O +
alignment O +
in O +
both O -
, O +
" O -
rigid O -
" O +
mode O +
and O +
" O -
flexible O -
" O +
( O -
default O -
) O +
mode O -
. O +

FATCAT O -
, O +
as O +
well O +
as O +
most O +
other O +
protein O +
structure O +
comparison O +
programs O -
, O +
is O +
very O +
slow O +
when O +
compared O +
to O +
sequence O +
alignments O -
. O +

The O +
computing O +
time O +
of O +
FATCAT O +
is O +
determined O +
by O +
the O +
size O +
of O +
the O +
collection O +
of O +
AFPs O +
detected O +
between O +
the O +
two O +
structures O +
being O +
compared O -
. O +

FATCAT O +
is O +
available O +
from O +
a O +
server O +
with O +
an O +
option O +
to O +
search O +
in O +
SCOP O +
or O +
PDB O +
databases O +
for O +
similar O +
structures O -
. O +

This O +
search O +
typically O +
takes O +
between O +
8 O +
to O +
16 O +
hours O +
of O +
CPU O +
time O -
, O +
and O +
this O +
is O +
the O +
main O +
obstacle O +
to O +
broader O +
use O +
of O +
this O +
option O -
. O +

FATCAT O +
has O +
been O +
used O +
to O +
construct O +
a O +
Flexible O +
Structure O +
Neighborhood O +
( O -
FSN O -
) O +
database O +
that O +
contains O +
pre O -
- O -
computed O +
results O +
of O +
structure O +
similarity O +
searches O +
and O +
it O +
takes O +
several O +
weeks O +
of O +
CPU O +
time O +
to O +
update O +
the O +
FSN O +
database O -
. O +

Other O +
protein O +
structure O +
comparison O +
resources O -
, O +
such O +
as O +
DALI O +
or O +
CE O +
have O +
very O +
similar O +
problems O -
. O +

TOPS O +
cartoons O +
and O +
TOPS O +
graph O +
models O +
As O +
discussed O +
in O +
the O +
Background O -
, O +
TOPS O +
cartoons O +
capture O +
the O +
simplified O -
, O +
fold O -
- O -
level O +
description O +
of O +
protein O +
structure O +
and O +
at O +
the O +
same O +
time O +
can O +
be O +
automated O +
[ O -
24 O -
] O -
. O +

The O +
TOPS O +
algorithm O +
uses O +
structural O +
features O +
such O +
as O +
hydrogen O +
bonds O +
and O +
chirality O +
of O +
the O +
beta O +
strands O +
to O +
provide O +
a O +
scoring O +
function O +
to O +
optimize O +
the O +
cartoon O +
( O -
see O +
Figure O +
1 O -
( O -
b O -
) O -
) O -
. O +

In O +
TOPS O -
, O +
the O +
secondary O +
structural O +
elements O +
( O -
SSEs O -
) O +
are O +
derived O +
from O +
the O +
DSSP O +
program O +
[ O -
25 O -
] O -
. O +

Based O +
on O +
TOPS O +
cartoons O -
, O +
a O +
formal O +
graph O +
model O +
and O +
graph O -
- O -
based O +
definitions O +
of O +
protein O +
topology O +
and O +
pattern O +
discovery O +
and O +
comparison O +
methods O +
were O +
developed O +
[ O -
26,27 O -
] O -
. O +

The O +
TOPS O +
database O +
and O +
comparison O -
, O +
pattern O +
discovery O +
and O +
matching O +
programs O +
are O +
accessible O +
from O +
. O +

Novel O +
TOPS+ O +
and O +
TOPS+ O +
strings O +
models O +
The O +
TOPS O +
model O +
was O +
further O +
enhanced O +
to O +
incorporate O +
features O +
such O +
as O +
protein O -
- O -
ligand O +
interaction O +
information O +
and O +
more O +
detailed O +
secondary O +
structural O +
segment O +
information O -
. O +

This O +
enhanced O +
model O +
is O +
called O +
TOPS+ O +
model O +
( O -
see O +
Figure O +
3a O -
) O -
. O +

This O +
TOPS+ O +
model O +
can O +
be O +
described O +
formally O +
in O +
a O +
TOPS+ O +
strings O +
language O +
( O -
Figure O +
3b O -
) O +
at O +
a O +
reduced O +
linear O +
level O -
. O +

The O +
enhanced O +
TOPS+ O +
strings O +
models O +
can O +
be O +
used O +
in O +
fast O +
string O -
- O -
based O +
structure O +
matching O +
and O +
comparison O -
, O +
at O +
the O +
same O +
time O +
avoiding O +
issues O +
of O +
NP O -
- O -
completeness O +
associated O +
with O +
graph O +
alignments O -
. O +

In O +
detail O -
, O +
each O +
node O +
( O -
SSE O +
segment O -
) O +
of O +
the O +
TOPS+ O +
strings O +
is O +
described O +
by O +
its O +
type O -
, O +
orientation O -
, O +
PDB O +
start O +
number O -
, O +
segment O +
length O -
, O +
total O +
number O +
of O +
incoming O +
( O -
InArc O -
) O +
and O +
outgoing O +
( O -
OutArc O -
) O +
arcs O +
( O -
edges O -
) O -
, O +
total O +
number O +
of O +
ArcTypes O -
, O +
and O +
total O +
number O +
of O +
ligand O +
arcs O +
( O -
LigArc O -
) O -
. O +

The O +
type O +
of O +
the O +
segment O +
( O -
SSEType O -
) O +
could O +
be O +
one O +
of O +
[ O -
E O -
, O +
e O -
, O +
H O -
, O +
h O -
, O +
U O -
, O +
u O -
] O -
, O +
where O -
, O +
" O -
E O -
" O +
and O +
" O -
e O -
" O +
represent O +
the O +
" O -
up"- O +
and O +
" O -
down O -
"- O -
oriented O +
beta O +
strands O -
; O +
" O -
H O -
" O +
and O +
" O -
h O -
" O +
indicate O +
the O +
" O -
up"- O +
and O +
" O -
down O -
"- O -
oriented O +
alpha O +
helices O -
; O +
and O +
" O -
U O -
" O +
and O +
" O -
u O -
" O +
represent O +
ligand O -
- O -
bound O +
and O +
ligand O -
- O -
free O +
loops O -
. O +

The O +
InArcType O +
can O +
be O +
classified O +
as O +
an O -
/ O -
a O +
[ O -
R O -
, O +
L O -
, O +
P O -
, O +
A O -
] O -
, O +
where O +
" O -
R O -
" O +
and O +
" O -
L O -
" O +
represent O +
right O +
and O +
left O +
chiralities O -
; O +
and O +
" O -
P O -
" O +
and O +
" O -
A O -
" O +
represent O +
parallel O +
and O +
anti O -
- O -
parallel O +
hydrogen O +
bonds O -
, O +
respectively O -
. O +

The O +
OutArcType O +
is O +
represented O +
in O +
a O +
similar O +
manner O +
by O +
[ O -
R O -
' O -
, O +
L O -
' O -
, O +
P O -
' O -
, O +
A O -
' O -
] O -
. O +

Ligand O +
arcs O +
are O +
indicated O +
by O +
LT O +
= O +
AA O -
, O +
where O +
LT O +
is O +
the O +
ligand O +
type O +
and O +
AA O +
is O +
the O +
PDB O +
number O -
. O +

For O +
example O -
, O +
Figure O +
3 O -
( O -
a O -
) O +
and O +
3 O -
( O -
b O -
) O +
contain O +
visual O +
representations O +
of O +
TOPS+ O +
and O +
TOPS+ O +
strings O +
models O -
, O +
respectively O -
, O +
for O +
the O +
protein O +
domain O +
d1fnb_1 O -
. O +

Here O +
the O +
triangles O +
represent O +
the O +
beta O +
strands O -
; O +
the O +
red O +
curve O +
represents O +
the O +
alpha O +
helix O -
; O +
gray O +
ellipsoids O +
indicate O +
loops O -
; O +
and O +
green O +
arcs O +
indicate O +
hydrogen O +
bonds O +
between O +
two O +
beta O +
strands O -
, O +
called O +
anti O -
- O -
parallel O +
beta O +
sheets O -
. O +

The O +
length O +
of O +
a O +
TOPS+ O +
strings O +
model O +
is O +
defined O +
by O +
number O +
of O +
SSEs O -
; O +
thus O -
, O +
the O +
length O +
of O +
d1fnb_1 O +
is O +
19 O -
. O +

For O +
further O +
details O -
, O +
see O +
[ O -
28 O -
] O -
. O +

TOPS+ O +
strings O +
comparison O +
method O +
TOPS+ O +
is O +
a O +
comparison O +
method O +
that O +
computes O +
a O +
distance O +
between O +
TOPS+ O +
strings O +
models O +
of O +
two O +
proteins O +
based O +
on O +
a O +
dynamic O +
programming O +
approach O +
and O +
identifies O +
the O +
longest O +
common O +
subsequence O +
( O -
LCS O -
) O -
, O +
consisting O +
of O +
the O +
list O +
of O +
the O +
topologically O +
equivalent O +
SSEs O +
between O +
two O +
proteins O -
. O +

For O +
example O -
, O +
Figure O +
3 O -
( O -
c O -
) O +
shows O +
the O +
TOPS+ O +
strings O +
alignment O +
between O +
Dihydropteridine O +
reductase O +
proteins O +
from O +
rat O +
( O -
1dhr O -
) O +
and O +
human B-Species +
( O -
1hdr O -
) O -
. O +

The O +
TOPS+ O +
strings O +
models O +
for O +
1dhr O +
and O +
1hdr O +
are O +
represented O +
by O +
a O +
linear O +
string O -
- O -
model O -
, O +
where O +
a O +
yellow O +
triangle O +
and O +
red O +
curves O +
indicate O +
the O +
beta O +
strands O +
and O +
alpha O +
helices O +
in O +
their O +
" O -
up O -
" O +
or O +
" O -
down O -
" O +
orientations O -
, O +
respectively O -
. O +

The O +
grey O +
line O +
and O +
purple O +
stubs O +
represent O +
the O +
loop O +
regions O +
and O +
the O +
NAD O +
ligand O +
interactions O -
, O +
respectively O -
. O +

Note O +
that O +
the O +
ligand O -
- O -
interaction O +
information O +
is O +
optional O +
and O +
in O +
this O +
work O +
we O +
have O +
not O +
used O +
it O -
. O +

The O +
incoming O +
and O +
outgoing O +
arcs O +
are O +
depicted O +
in O +
the O +
SSEs O +
( O -
top O +
and O +
bottom O +
of O +
the O +
beta O +
strands O -
) O -
, O +
where O +
red O +
and O +
green O +
arcs O +
represent O +
the O +
parallel O +
and O +
anti O -
- O -
parallel O +
hydrogen O -
- O -
bond O +
interactions O +
that O +
show O +
beta O -
- O -
sheet O +
information O -
, O +
while O +
yellow O +
and O +
blue O +
arcs O +
indicate O +
the O +
right O +
and O +
left O +
chirality O +
relationships O +
between O +
the O +
SSEs O -
. O +

A O +
pink O +
arrow O +
between O +
the O +
TOPS+ O +
strings O +
elements O +
indicates O +
the O +
conserved O +
SSE O -
. O +

The O +
dotted O +
arrows O +
indicate O +
the O +
conserved O +
alpha O +
helices O +
and O +
beta O +
strands O -
, O +
while O +
the O +
plain O +
arrows O +
indicate O +
the O +
conserved O +
loop O +
regions O -
. O +

TOPS++FATCAT O +
method O +
In O +
this O +
work O -
, O +
we O +
want O +
to O +
test O +
the O +
general O +
idea O +
of O +
pruning O +
the O +
search O +
space O +
of O +
the O +
FATCAT O +
comparison O +
process O +
using O +
topological O +
constraints O +
derived O +
from O +
the O +
TOPS+ O +
strings O +
alignment O -
. O +

Many O +
of O +
the O +
AFPs O +
considered O +
in O +
the O +
FATCAT O +
alignment O +
could O +
be O +
easily O +
eliminated O +
from O +
the O +
comparison O +
by O +
constraining O +
the O +
alignment O +
region O -
. O +

Here O +
we O +
explore O +
constraints O +
obtained O +
from O +
the O +
TOPS+ O +
strings O +
alignment O -
, O +
which O +
identifies O +
topologically O +
equivalent O +
secondary O +
structure O +
elements O +
( O -
alpha O +
helices O -
, O +
beta O +
strands O -
, O +
and O +
loops O -
) O +
for O +
this O +
purpose O -
. O +

Such O +
equivalences O +
define O +
blocks O +
that O +
restrict O +
the O +
alignment O +
region O -
; O +
AFPs O +
that O +
fall O +
outside O +
these O +
regions O +
are O +
simply O +
not O +
considered O +
( O -
see O +
Figure O +
4 O -
( O -
b O -
) O -
) O -
. O +

We O +
introduce O +
a O +
parameter O +
r O +
to O +
control O +
the O +
strictness O +
of O +
constraints O +
by O +
TOPS+ O +
strings O +
alignments O -
; O +
r O +
equals O +
0 O +
if O +
the O +
alignment O +
region O +
is O +
strictly O +
restrained O +
by O +
TOPS+ O +
strings O +
alignment O -
, O +
and O +
r O +
is O +
set O +
to O +
1 O +
by O +
default O +
in O +
our O +
program O +
to O +
allow O +
certain O +
flexibility O +
to O +
the O +
constrained O +
alignment O +
region O +
( O -
Figure O +
4 O -
( O -
c O -
) O -
) O -
. O +

We O +
then O +
can O +
speed O +
up O +
the O +
FATCAT O +
alignment O +
by O +
considering O +
only O +
the O +
AFPs O +
within O +
the O +
constrained O +
alignment O +
area O +
( O -
Figure O +
4 O -
( O -
d O -
) O -
) O -
. O +

The O +
rigid O +
structural O +
alignment O +
can O +
be O +
treated O +
as O +
a O +
special O +
case O +
of O +
TOPS++FATCAT O -
, O +
in O +
which O +
no O +
twist O +
is O +
allowed O +
in O +
chaining O +
AFPs O -
. O +

However O -
, O +
the O +
TOPS++FATCAT O +
program O +
provides O +
alignment O +
in O +
both O -
, O +
" O -
rigid O -
" O +
mode O +
and O +
" O -
flexible O -
" O +
mode O +
( O -
default O -
) O -
. O +

Benchmarking O +
For O +
benchmarking O +
and O +
comparison O -
, O +
we O +
have O +
used O +
the O +
PDB40 O +
dataset O +
of O +
1,901 O +
protein O +
domain O +
pairs O +
( O -
DP O -
) O +
corresponding O +
to O +
SCOP O +
version O +
1.61 O +
from O +
the O +
ASTRAL O +
database O +
[ O -
29 O -
] O -
. O +

Table O +
1 O +
provides O +
the O +
SCOP O +
superfamily O +
level O +
homolog O +
versus O +
non O -
- O -
homolog O +
statistics O +
for O +
the O +
four O +
main O +
SCOP O +
classes O +
i.e. O -
, O +
all O -
- O -
alpha O -
, O +
all O -
- O -
beta O -
, O +
alpha O -
/ O -
beta O -
, O +
alpha+beta O -
, O +
and O +
all O +
proteins O +
regardless O +
of O +
their O +
structural O +
classes O -
. O +

Evaluation O +
Analyses O +
We O +
performed O +
the O +
Receiver O +
Operating O +
Characteristics O +
( O -
ROC O -
) O +
curve O +
and O +
the O +
AUC O +
( O -
Area O +
Under O +
the O +
ROC O +
Curve O -
) O +
analyses O +
to O +
compare O +
the O +
performance O +
of O +
the O +
TOPS++FATCAT O +
method O +
with O +
the O +
original O +
FATCAT O +
method O -
, O +
using O +
SCOP O +
classification O +
at O +
the O +
superfamily O +
level O +
as O +
a O +
standard O +
of O +
comparison O +
[ O -
30 O -
] O -
. O +

Results O +
ROC O +
and O +
AUC O +
Analyses O +
We O +
have O +
compared O +
the O +
performance O +
of O +
the O +
TOPS++FATCAT O +
method O +
against O +
the O +
original O +
FATCAT O +
method O +
using O +
the O +
SCOP O +
classification O +
information O +
at O +
the O +
superfamily O +
level O -
. O +

We O +
have O +
plotted O +
the O +
ROC O +
curves O +
based O +
on O +
P O -
- O -
values O +
obtained O +
from O +
the O +
FATCAT O +
and O +
the O +
TOPS++FATCAT O +
methods O -
. O +

We O +
have O +
plotted O +
the O +
ROC O +
curves O +
separately O +
for O +
the O +
main O +
SCOP O +
classes O -
, O +
i.e. O -
, O +
all O -
- O -
alpha O -
, O +
all O -
- O -
beta O -
, O +
alpha O -
/ O -
beta O -
, O +
alpha+beta O -
, O +
and O +
all O +
proteins O +
regardless O +
of O +
the O +
class O +
they O +
belong O +
to O +
( O -
see O +
Figure O +
5 O -
( O -
a O -
) O +
to O +
5 O -
( O -
e O -
) O -
) O -
. O +

In O +
the O +
graph O -
, O +
the O +
x- O +
and O +
y O -
- O -
axes O +
represent O +
the O +
false O +
positive O +
and O +
true O +
positive O +
rates O +
of O +
the O +
performance O +
of O +
the O +
comparison O +
methods O +
respectively O -
. O +

In O +
the O +
legend O -
, O +
rF O -
- O -
pvalue O +
and O +
fF O -
- O -
pvalue O +
indicate O +
results O +
from O +
the O +
rigid O +
and O +
flexible O +
FATCAT O +
methods O -
, O +
respectively O -
; O +
similarly O -
, O +
rT2F O -
- O -
pvalue O +
and O +
fT2F O -
- O -
pvalue O +
represent O +
the O +
rigid O +
and O +
flexible O +
TOPS++FATCAT O +
methods O -
, O +
respectively O -
. O +

We O +
have O +
calculated O +
the O +
AUC O +
values O +
for O +
all O +
the O +
SCOP O +
classes O +
based O +
on O +
ROC O +
curves O +
obtained O +
from O +
the O +
FATCAT O +
and O +
TOPS++FATCAT O +
methods O +
with O +
the O +
flexible O -
/ O -
rigid O +
options O +
( O -
see O +
Table O +
2 O -
) O -
. O +

For O +
all O +
protein O +
classes O -
, O +
the O +
rigid O +
FATCAT O +
performs O +
best O -
, O +
usually O +
followed O +
by O +
the O +
flexible O +
FATCAT O -
, O +
the O +
rigid O +
TOPS++FATCAT O -
, O +
and O +
the O +
flexible O +
TOPS++FATCAT O -
. O +

The O +
performance O +
of O +
all O +
four O +
methods O +
is O +
best O +
for O +
all O +
alpha O +
and O +
all O +
beta O +
proteins O -
, O +
and O +
all O +
four O +
perform O +
markedly O +
worse O +
( O -
but O +
similar O +
to O +
each O +
other O -
) O +
for O +
alpha O -
/ O -
beta O +
proteins O -
. O +

Only O +
alpha+beta O +
proteins O +
show O +
a O +
clear O +
difference O +
between O +
the O +
FATCAT O +
and O +
TOPS++FATCAT O +
methods O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
the O +
TOPS+ O +
strings O +
models O +
consider O +
the O +
parallel O +
and O +
anti O -
- O -
parallel O +
properties O +
of O +
the O +
beta O -
- O -
sheet O +
information O +
in O +
the O +
form O +
of O +
total O +
number O +
of O +
incoming O +
and O +
outgoing O +
arcs O +
with O +
their O +
ArcTypes O -
. O +

Thus O -
, O +
the O +
TOPS++FATCAT O +
method O +
discriminates O +
the O +
protein O +
domain O +
pairs O +
more O +
efficiently O +
compared O +
to O +
the O +
original O +
FATCAT O +
method O -
. O +

For O +
example O -
, O +
in O +
the O +
all O -
- O -
beta O +
protein O +
domain O +
pairs O -
, O +
both O +
the O +
flexible O +
and O +
the O +
rigid O +
TOPS++FATCAT O +
methods O +
perform O +
well O -
. O +

The O +
flexible O +
TOPS++FATCAT O +
method O +
covers O +
nearly O +
84 O -
% O +
of O +
protein O +
domains O +
with O +
0 O -
% O +
false O +
positives O -
, O +
but O +
the O +
flexible O +
and O +
rigid O +
FATCAT O +
methods O +
cover O +
only O +
76 O -
% O +
and O +
49 O -
% O +
of O +
the O +
true O +
positives O -
, O +
respectively O -
, O +
with O +
0 O -
% O +
false O +
positives O -
. O +

The O +
zoomed O -
- O -
in O +
version O +
of O +
the O +
ROC O +
curves O +
with O +
up O +
to O +
10 O -
% O +
false O +
positives O +
for O +
all O -
- O -
beta O +
rich O +
protein O +
families O +
is O +
shown O +
in O +
Figure O +
5 O -
( O -
f O -
) O -
; O +
where O +
both O +
the O +
rigid O +
TOPS++FATCAT O +
( O -
green O -
) O +
and O +
flexible O +
( O -
red O -
) O +
TOPS++FATCAT O +
methods O +
have O +
coverage O +
rates O +
of O +
82 O -
% O +
and O +
84 O -
% O +
true O +
positives O +
respectively O +
with O +
0 O -
% O +
false O +
positives O -
. O +

The O +
overall O +
results O +
for O +
all O +
protein O +
classes O +
show O +
that O +
TOPS++FATCAT O +
performance O +
is O +
only O +
slightly O +
lower O +
( O -
3%–7 O -
% O +
AUC O +
value O +
difference O +
( O -
see O +
Table O +
2 O -
) O -
) O +
as O +
compared O +
to O +
FATCAT O +
while O +
providing O +
a O +
significant O -
, O +
more O +
than O +
10-fold O +
speedup O +
( O -
see O +
next O +
section O -
) O -
. O +

AFP O +
and O +
Runtime O +
Analyses O +
We O +
tested O +
both O +
the O +
FATCAT O +
and O +
TOPS++FATCAT O +
methods O +
using O +
the O +
Mac O +
OS O +
X O +
version O +
10.4.10 O +
computer O +
system O +
with O +
a O +
2 O +
× O +
2.66-GHz O +
Dual O -
- O -
Core O +
Intel O +
Xeon O +
processor O +
and O +
1-GB O +
667 O +
MHz O +
memory O -
. O +

We O +
have O +
performed O +
runtime O +
analysis O +
on O +
1,901 O +
protein O +
domain O +
pairs O +
and O +
counted O +
the O +
total O +
number O +
of O +
AFPs O +
and O +
the O +
corresponding O +
runtime O +
from O +
both O +
the O +
FATCAT O +
and O +
the O +
TOPS++FATCAT O +
methods O -
. O +

The O +
results O +
show O +
an O +
exponential O +
increase O +
in O +
AFPs O +
( O -
Figure O +
6 O -
( O -
b O -
) O -
) O +
and O +
corresponding O +
runtime O +
( O -
Figure O +
6 O -
( O -
a O -
) O -
) O +
for O +
the O +
FATCAT O +
method O +
as O +
compared O +
to O +
the O +
TOPS++FATCAT O +
method O +
( O -
see O +
Table O +
3 O -
) O +
For O +
example O -
, O +
the O +
average O +
number O +
of O +
AFPs O +
for O +
the O +
TOPS++FATCAT O +
method O +
is O +
530 O -
, O +
but O +
the O +
average O +
number O +
of O +
AFPs O +
for O +
the O +
FATCAT O +
method O +
is O +
15,019 O -
. O +

This O +
represents O +
the O +
number O +
of O +
average O +
AFPs O +
used O +
by O +
the O +
FATCAT O +
method O +
is O +
increased O +
by O +
a O +
factor O +
of O +
28 O +
( O -
see O +
Table O +
3 O -
) O -
. O +

This O +
result O +
leads O +
to O +
the O +
conclusion O +
that O +
TOPS++FATCAT O +
is O +
22 O +
times O +
faster O +
compared O +
to O +
the O +
FATCAT O +
because O +
this O +
method O +
must O +
take O +
into O +
account O +
more O +
number O +
of O +
AFPs O +
in O +
the O +
comparison O +
process O +
( O -
see O +
Table O +
3 O -
) O -
. O +

Case O +
Studies O +
While O +
the O +
overall O +
accuracy O +
of O +
both O +
rigid O +
and O +
flexible O +
FATCAT O +
methods O +
is O +
better O +
than O +
their O +
TOPS++FATCAT O +
equivalents O -
, O +
an O +
interesting O +
example O +
where O +
the O +
opposite O +
is O +
true O +
lies O +
in O +
the O +
comparison O +
of O +
two O +
proteins O -
, O +
d2trxa O -
_ O +
( O -
108 O +
aa O -
) O +
from O +
Escherichia B-Species +
coli I-Species +
and O +
d1kte O -
_ O -
_ O +
( O -
105 O +
aa O -
) O +
from O +
Sus B-Species +
scrofa I-Species +
( O -
pig B-Species -
) O +
from O +
the O +
thioredoxin O -
- O -
like O +
superfamily O -
. O +

For O +
this O +
pair O -
, O +
the O +
flexible_TOPS++FATCAT O +
method O +
provides O +
an O +
alignment O +
with O +
88 O +
equivalent O +
positions O +
with O +
1.67 O +
Å O +
chain O +
RMSD O +
and O +
3.06 O +
Å O +
of O +
optimal O +
RMSD O +
without O +
any O +
twist O -
, O +
giving O +
the O +
alignment O +
with O +
10 O -
% O +
sequence O +
identity O +
( O -
see O +
Table O +
4 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
flexible_FATCAT O +
method O +
provides O +
an O +
alignment O +
with O +
86 O +
aligned O +
positions O +
using O +
a O +
twist O +
in O +
the O +
C O -
- O -
terminal O +
region O -
; O +
it O +
has O +
a O +
higher O +
chain O +
RMSD O +
of O +
5.14 O +
Å O -
, O +
and O +
its O +
optimal O +
RMSD O +
is O +
3.48 O +
Å. O +
For O +
more O +
information O +
regarding O +
the O +
chain O +
and O +
optimal O +
RMSDs O +
refer O +
[ O -
5 O -
] O -
. O +

The O +
flexible_FATCAT O +
method O +
uses O +
the O +
twist O +
to O +
align O +
a O +
helix O +
in O +
the O +
C O -
- O -
terminal O +
region O -
, O +
which O +
is O +
positioned O +
incorrectly O +
with O +
a O +
beta O -
- O -
sheet O +
core O +
( O -
see O +
Table O +
4 O -
) O -
. O +

Figure O +
7 O -
( O -
a O -
) O +
shows O +
the O +
superposition O +
of O +
d2trxa O -
_ O +
( O -
gray O -
) O +
and O +
d1kte O -
_ O -
_ O +
( O -
orange O -
) O +
domains O +
from O +
the O +
flexible_FATCAT O +
method O -
, O +
where O +
the O +
blue O +
color O +
indicates O +
the O +
d1kte O -
_ O -
_ O +
protein O +
domain O +
from O +
the O +
flexible_TOPS++FATCAT O +
method O -
. O +

The O +
incorrect O +
alignment O +
of O +
the O +
C O -
- O -
terminal O +
domain O +
alpha O +
helix O +
of O +
the O +
d1kte O -
_ O -
_ O +
domain O +
( O -
orange O -
) O +
is O +
visible O +
in O +
the O +
core O +
of O +
the O +
beta O -
- O -
sheet O +
region O -
. O +

Figure O +
7 O -
( O -
b O -
) O +
and O +
7 O -
( O -
c O -
) O +
shows O +
the O +
AFPs O +
from O +
the O +
flexible_FATCAT O +
and O +
flexible_TOPS++FATCAT O +
methods O -
, O +
respectively O -
. O +

The O +
hinge O +
region O +
provides O +
a O +
twist O +
in O +
the O +
flexible_FATCAT O +
method O +
indicated O +
by O +
an O +
arrow O +
and O +
the O +
AFPs O +
represented O +
by O +
a O +
different O +
color O +
( O -
see O +
Figure O +
7 O -
( O -
b O -
) O -
) O -
. O +

In O +
this O +
case O -
, O +
the O +
alignment O +
constraints O +
from O +
the O +
TOPS+ O +
strings O +
alignment O +
allow O +
the O +
TOPS++FATCAT O +
method O +
to O +
avoid O +
a O +
spurious O +
alignment O -
. O +

The O +
Erythrocruorin O +
protein O +
domain O +
d1eca O -
_ O -
_ O +
( O -
136 O +
aa O -
) O +
from O +
Chironomus B-Species +
thummi I-Species +
and O +
the O +
Phycocyanin O +
alpha O +
subunit O +
protein O +
domain O +
d1cpca O -
_ O +
( O -
162 O +
aa O -
) O +
from O +
Fremyella B-Species +
diplosiphon I-Species +
( O -
Cyanobacterium O -
) O +
belong O +
to O +
the O +
Globin O -
- O -
like O +
superfamily O -
. O +

For O +
these O +
protein O +
domain O +
pairs O -
, O +
the O +
FATCAT O +
method O +
provides O +
a O +
better O +
alignment O +
with O +
120 O +
and O +
118 O +
aligned O +
positions O +
with O +
the O +
chain O +
RMSD O +
of O +
4.02 O +
Å O +
based O +
on O +
the O +
flexible O +
and O +
rigid O +
options O -
, O +
respectively O -
. O +

The O +
flexible_TOPS++FATCAT O +
method O +
gives O +
an O +
alignment O +
of O +
63 O +
aligned O +
positions O +
with O +
the O +
3.23 O +
Å O +
optimal O +
RMSD O +
and O +
the O +
6.28 O +
Å O +
chain O +
RMSD O -
. O +

In O +
this O +
case O -
, O +
the O +
flexible_TOPS++FATCAT O +
method O +
misses O +
the O +
N O -
- O -
terminal O +
region O +
helix O +
and O +
misaligns O +
some O +
helices O -
. O +

For O +
example O -
, O +
Figure O +
8 O -
( O -
a O -
) O +
shows O +
the O +
superposition O +
of O +
d1eca O -
_ O -
_ O +
( O -
gray O -
) O +
and O +
d1cpca O -
_ O +
( O -
orange O -
) O +
domains O +
from O +
the O +
flexible_FATCAT O +
method O -
, O +
while O +
d1cpca O -
_ O +
( O -
blue O -
) O +
domain O +
is O +
from O +
the O +
flexible_TOPS++FATCAT O +
method O -
. O +

The O +
AFP O +
chaining O +
alignment O +
and O +
the O +
actual O +
alignment O +
from O +
FATCAT O +
are O +
shown O +
in O +
Figure O +
8 O -
( O -
b O -
) O +
and O +
8 O -
( O -
e O -
) O -
, O +
respectively O -
. O +

Figure O +
8 O -
( O -
c O -
) O +
shows O +
the O +
AFP O +
alignment O +
from O +
TOPS++FATCAT O -
, O +
in O +
which O +
this O +
method O +
misses O +
the O +
N O -
- O -
terminal O +
region O +
and O +
incorrectly O +
aligns O +
some O +
of O +
the O +
C O -
- O -
terminal O +
regions O +
( O -
see O +
Figure O +
8 O -
( O -
d O -
) O -
) O -
. O +

However O -
, O +
the O +
rigid_TOPS++FATCAT O +
method O +
produces O +
an O +
alignment O +
of O +
108 O +
aligned O +
positions O +
with O +
optimal O +
and O +
chain O +
RMSDs O +
of O +
3.22 O +
Å O +
and O +
6.28 O +
Å O +
respectively O -
. O +

In O +
general O -
, O +
TOPS O +
comparison O +
does O +
not O +
work O +
well O +
for O +
alpha O -
- O -
rich O +
proteins O +
due O +
to O +
the O +
lack O +
of O +
hydrogen O +
bonds O +
between O +
SSEs O +
[ O -
26 O -
] O -
. O +

The O +
same O +
is O +
true O +
for O +
TOPS+ O +
strings O +
comparison O +
to O +
some O +
extent O -
; O +
however O -
, O +
this O +
method O +
takes O +
advantage O +
of O +
ligand O -
- O -
interaction O +
information O +
to O +
compare O +
protein O +
domains O +
more O +
efficiently O -
; O +
for O +
example O +
the O +
DNA O +
binding O +
motifs O +
such O +
as O +
helix O -
- O -
turn O -
- O -
helix O +
and O +
helix O -
- O -
loop O -
- O -
helix O +
can O +
be O +
easily O +
recognized O +
[ O -
28 O -
] O -
. O +

However O -
, O +
we O +
have O +
not O +
explored O +
that O +
ligand O +
pattern O +
discovery O +
option O +
within O +
the O +
TOPS+ O +
strings O +
comparison O +
in O +
this O +
paper O -
. O +

In O +
addition O -
, O +
the O +
TOPS+ O +
strings O +
alignment O +
provides O +
only O +
a O +
basic O +
alignment O -
; O +
the O +
scoring O +
function O +
to O +
find O +
the O +
best O +
alignment O +
has O +
not O +
been O +
optimized O -
. O +

These O +
problems O +
can O +
be O +
addressed O +
in O +
future O +
development O +
by O +
considering O +
the O +
advanced O +
TOPS+ O +
and O +
TOPS+ O +
strings O +
models O +
based O +
on O +
helix O -
- O -
helix O +
packing O +
relationships O +
and O +
SSE O -
- O -
ligand O +
interaction O +
properties O +
together O +
with O +
the O +
right O +
and O +
left O +
chiralities O -
. O +

Furthermore O -
, O +
the O +
TOPS+ O +
strings O +
comparison O +
can O +
be O +
optimized O +
in O +
both O +
the O +
comparison O +
process O +
as O +
well O +
as O +
in O +
the O +
alignment O +
process O +
in O +
order O +
to O +
take O +
into O +
account O +
indels O +
( O -
insertion O -
/ O -
deletion O -
) O +
of O +
SSEs O +
which O +
exist O +
in O +
nature O +
across O +
the O +
different O +
members O +
of O +
the O +
protein O +
superfamilies O +
[ O -
31 O -
] O -
. O +

Discussion O +
and O +
conclusion O +
The O +
overall O +
results O +
for O +
all O +
protein O +
classes O +
show O +
that O +
TOPS++FATCAT O +
performance O +
is O +
only O +
slightly O +
lower O +
( O -
3%–7 O -
% O +
AUC O +
value O +
difference O -
) O +
as O +
compared O +
to O +
FATCAT O +
while O +
providing O +
a O +
significant O -
, O +
more O +
than O +
10-fold O +
speedup O -
. O +

The O +
main O +
reason O +
for O +
the O +
discrepancies O +
is O +
that O +
TOPS+ O +
strings O +
alignments O +
occasionally O +
misalign O +
the O +
secondary O +
structure O +
elements O +
and O +
subsequent O +
FATCAT O +
alignment O -
, O +
constrained O +
by O +
the O +
TOPS+ O +
strings O +
alignment O -
, O +
can O -
not O +
overcome O +
the O +
earlier O +
errors O -
. O +

There O +
is O +
a O +
clear O +
trade O -
- O -
off O +
between O +
the O +
runtime O +
and O +
the O +
accuracy O -
; O +
limiting O +
the O +
pool O +
of O +
fragments O +
being O +
compared O +
speeds O +
up O +
the O +
algorithm O +
but O +
results O +
in O +
( O -
slightly O -
) O +
lower O +
accuracy O -
. O +

At O +
the O +
same O +
time O -
, O +
these O +
results O +
offer O +
clear O +
suggestions O +
for O +
future O +
development O -
. O +

Using O +
a O +
more O +
advanced O +
version O +
of O +
the O +
TOPS+ O +
strings O +
comparison O +
method O +
would O +
remove O +
some O +
of O +
the O +
false O +
positives O +
might O +
be O +
at O +
a O +
cost O +
of O +
significantly O +
slowing O +
the O +
total O +
performance O +
of O +
the O +
TOPS++FATCAT O +
method O -
. O +

Authors O -
' O +
contributions O +
MV O +
developed O +
the O +
TOPS++FATCAT O +
algorithm O -
, O +
performed O +
the O +
calculations O +
and O +
prepared O +
the O +
figures O -
, O +
YY O +
provided O +
advice O +
and O +
oversight O +
in O +
the O +
project O -
, O +
verified O +
the O +
code O +
and O +
provided O +
FATCAT O +
results O +
for O +
comparison O -
, O +
AG O +
contributed O +
to O +
the O +
original O +
idea O +
and O +
to O +
writing O +
of O +
the O +
manuscript O -
. O +

A O +
life O +
threatening O +
uterine O +
inversion O +
and O +
massive O +
post O +
partum O +
hemorrhage O +
caused O +
by O +
placenta O +
accrete O +
during O +
Caesarean O +
section O +
in O +
a O +
primigravida O -
: O +
a O +
case O +
report O +
Abstract O +
Background O +
A O +
32-year O -
- O -
old O +
Caucasian O +
primigravida O +
was O +
admitted O +
for O +
elective O +
Caesarean O +
Section O +
at O +
36 O +
weeks O +
and O +
6 O +
days O +
with O +
the O +
diagnosis O +
of O +
preeclampsia O -
. O +

Case O +
presentation O +
Traction O +
of O +
the O +
umbilical O +
cord O +
after O +
delivery O +
of O +
a O +
healthy O +
baby O +
resulted O +
in O +
uterine O +
inversion O -
. O +

The O +
placenta O +
was O +
found O +
to O +
be O +
densely O +
adherent O +
to O +
the O +
posterior O +
uterine O +
wall O -
. O +

Piecemeal O +
excision O +
of O +
the O +
placenta O +
as O +
close O +
as O +
possible O +
to O +
the O +
uterine O +
lining O +
was O +
then O +
performed O -
. O +

Conclusion O +
In O +
this O +
way O +
we O +
were O +
able O +
to O +
control O +
a O +
massive O +
post O +
partum O +
hemorrhage O +
and O +
preserve O +
the O +
fertility O +
of O +
the O +
patient O -
. O +

Background O +
Placenta O +
accreta O +
is O +
defined O +
as O +
abnormal O +
adherence O -
, O +
either O +
in O +
whole O +
or O +
in O +
part O +
of O +
the O +
afterbirth O +
to O +
the O +
underlying O +
uterine O +
wall O -
. O +

Placenta O +
accreta O +
and O +
other O +
pathological O +
placentations O +
( O -
such O +
as O +
increta O -
, O +
percreta O -
) O +
are O +
rare O +
complications O +
of O +
pregnancy O +
with O +
potential O +
life O +
threatening O +
and O +
fertility O +
threatening O +
consequences O -
. O +

The O +
incidence O +
of O +
placenta O +
accreta O +
has O +
increased O +
ten O +
times O +
over O +
the O +
last O +
fifteen O +
years O -
, O +
which O +
reflects O +
the O +
increase O +
in O +
the O +
rate O +
of O +
Caesarean O +
Sections O +
( O -
CS O -
) O +
[ O -
1 O -
] O -
. O +

Placenta O +
accreta O +
has O +
become O +
the O +
most O +
important O +
cause O +
of O +
peripartum O +
hysterectomy O -
. O +

A O +
life O +
threatening O +
acute O +
uterine O +
inversion O +
and O +
massive O +
PPH O +
can O +
be O +
caused O +
by O +
placenta O +
accreta O +
during O +
CS O +
but O +
seldom O +
in O +
a O +
primigravida O +
( O -
Figure O +
1 O -
) O -
. O +

Case O +
presentation O +
A O +
32 O +
year O +
old O -
, O +
primigravida O -
, O +
was O +
admitted O +
in O +
a O +
District O +
General O +
Hospital O +
for O +
elective O +
Caesarean O +
section O +
at O +
36 O +
weeks O +
and O +
6 O +
days O +
with O +
the O +
diagnosis O +
of O +
preeclampsia O -
. O +

She O +
had O +
two O +
antenatal O +
ultrasound O +
examinations O +
showing O +
a O +
healthy O +
fetus O +
and O +
posterior O +
fundal O +
placenta O -
. O +

The O +
patient O +
had O +
lower O +
segment O +
CS O +
of O +
a O +
healthy O +
male O +
infant O +
under O +
spinal O +
anesthesia O -
. O +

The O +
placenta O +
was O +
found O +
to O +
be O +
densely O +
adherent O +
to O +
the O +
posterior O +
uterine O +
wall O -
. O +

Traction O +
of O +
the O +
umbilical O +
cord O +
was O +
applied O +
and O +
subsequently O +
resulted O +
in O +
uterine O +
inversion O -
. O +

The O +
placenta O +
was O +
removed O +
by O +
' O -
piecemeal O -
' O +
excising O +
as O +
close O +
as O +
possible O +
to O +
the O +
uterine O +
lining O -
. O +

About O +
80 O -
% O +
of O +
the O +
placental O +
tissue O +
was O +
removed O +
until O +
the O +
uterine O +
inversion O +
was O +
corrected O -
. O +

The O +
uterus O +
was O +
closed O +
in O +
two O +
layers O -
. O +

Two O +
intra O -
- O -
abdominal O +
drains O +
were O +
sited O -
. O +

The O +
estimated O +
blood O +
loss O +
was O +
2.5 O +
litres O +
and O +
five O +
units O +
of O +
blood O +
were O +
transfused O +
together O +
with O +
2 O +
units O +
of O +
FFP O +
during O +
intra O -
- O -
operative O +
and O +
post O -
- O -
operative O +
period O -
. O +

In O +
addition O -
, O +
the O +
patient O +
was O +
treated O +
with O +
intravenous O +
oxytocin O +
infusion O -
, O +
pr O +
misoprostol O +
and O +
antibiotics O -
. O +

On O +
the O +
second O +
post O +
partum O +
day O -
, O +
vaginal O +
Doppler O +
ultrasound O +
scan O +
showed O +
significant O +
amount O +
of O +
placental O +
tissues O +
with O +
increased O +
vascularity O +
measuring O +
2.7 O +
× O +
6.6 O +
× O +
6.8 O +
cms O +
within O +
the O +
endometrial O +
cavity O +
( O -
Figure O +
2 O -
) O -
. O +

The O +
patient O +
was O +
discharged O +
on O +
the O +
fifth O +
post O -
- O -
operative O +
day O +
with O +
a O +
conservative O +
management O -
. O +

A O +
follow O +
up O +
Ultrasound O +
scan O +
after O +
two O +
weeks O +
showed O +
reduction O +
of O +
placental O +
mass O +
( O -
Figure O +
3 O -
) O -
. O +

In O +
addition O -
, O +
there O +
was O +
significant O +
decrease O +
in O +
serum O +
beta O +
HCG O +
levels O +
from O +
2300 O +
u O -
/ O -
L O +
on O +
day O +
1 O +
to O +
13 O +
u O -
/ O -
L O +
at O +
four O +
weeks O +
post O +
operatively O -
. O +

The O +
patient O +
remained O +
with O +
minimal O +
vaginal O +
bleeding O +
without O +
abdominal O +
pain O -
. O +

She O +
had O +
two O +
normal O +
periods O +
after O +
stopping O +
breastfeeding O +
and O +
was O +
feeling O +
well O -
. O +

She O +
was O +
discharged O +
from O +
the O +
early O +
pregnancy O +
unit O -
. O +

Discussion O +
A O +
life O -
- O -
threatening O +
uterine O +
inversion O +
can O +
be O +
rarely O +
caused O +
by O +
placenta O +
accreta O +
[ O -
2 O -
] O -
. O +

Placenta O +
accreta O +
classically O +
presents O +
with O +
retained O +
placenta O +
and O +
hemorrhage O -
. O +

The O +
association O +
between O +
uterine O +
inversion O +
and O +
placenta O +
accreta O +
is O +
unclear O -
, O +
however O -
, O +
strong O +
traction O +
on O +
the O +
umbilical O +
cord O +
with O +
fundal O +
placenta O -
, O +
excessive O +
fundal O +
pressure O -
, O +
relaxed O +
uterus O -
, O +
short O +
umbilical O +
cord O -
, O +
uterine O +
anomalies O +
and O +
antepartum O +
use O +
of O +
magnesium O +
sulphate O +
are O +
known O +
associated O +
factors O +
[ O -
2 O -
] O -
. O +

Uterine O +
inversion O +
and O +
retain O +
placenta O +
accreta O +
can O +
both O +
be O +
fatal O +
complications O +
[ O -
3 O -
] O -
. O +

In O +
the O +
case O +
described O +
the O +
placenta O +
accreta O +
was O +
complicated O +
by O +
uterine O +
inversion O +
and O +
subsequent O +
massive O +
post O +
partum O +
hemorrhage O -
, O +
significantly O +
increasing O +
the O +
risk O +
of O +
maternal O +
mortality O -
. O +

Massive O +
post O +
partum O +
hemorrhage O +
is O +
a O +
major O +
cause O +
of O +
maternal O +
mortality O +
in O +
the O +
United O +
Kingdom O +
( O -
why O +
women O +
die O +
latest O +
report O -
) O +
[ O -
4 O -
] O -
. O +

In O +
this O +
case O -
, O +
the O +
placenta O +
was O +
clamped O +
as O +
close O +
to O +
the O +
uterine O +
cavity O +
as O +
possible O +
and O +
cut O -
. O +

The O +
base O +
of O +
the O +
placenta O +
was O +
overrun O +
with O +
haemostatic O +
sutures O +
and O +
this O +
was O +
repeated O +
until O +
as O +
much O +
of O +
the O +
placenta O +
as O +
possible O +
was O +
removed O +
( O -
Figure O +
4 O -
) O -
. O +

Placental O +
removal O +
enabled O +
correction O +
of O +
uterine O +
inversion O -
. O +

Despite O +
the O +
many O +
conditions O +
associated O +
with O +
uterine O +
inversion O +
risk O +
assessment O +
is O +
often O +
lacking O +
making O +
the O +
condition O +
usually O +
unexpected O +
at O +
the O +
time O +
of O +
presentation O -
. O +

The O +
association O +
between O +
abnormal O +
placentation O +
such O +
as O +
placenta O +
accreta O +
and O +
uterine O +
inversion O +
is O +
well O +
supported O +
[ O -
2 O -
] O -
. O +

Therefore O -
, O +
we O +
advocate O +
antenatal O +
evaluation O +
and O +
risk O +
assessment O +
for O +
placenta O +
accreta O +
[ O -
5 O -
] O -
. O +

Prenatal O +
Ultrasound O +
reported O +
sensitivity O +
of O +
94 O -
% O +
and O +
specificity O +
of O +
79 O -
% O +
for O +
placenta O +
accreta O -
, O +
but O +
offer O +
no O +
more O +
than O +
provisional O +
diagnostic O +
probability O +
statement O +
[ O -
6 O -
] O -
. O +

Moreover O -
, O +
because O +
45 O -
% O +
of O +
placenta O +
accreta O +
cases O +
were O +
not O +
detected O +
by O +
ultrasound O -
, O +
it O +
is O +
important O +
to O +
consider O +
avoiding O +
manual O +
removal O +
of O +
placenta O +
if O +
there O +
were O +
intraoperative O +
signs O +
of O +
accreta O +
[ O -
6 O -
] O -
. O +

If O +
clinically O +
or O +
sonographically O +
the O +
patient O +
is O +
suspected O +
antenatally O +
to O +
be O +
at O +
risk O +
of O +
placenta O +
accreta O -
, O +
appropriate O +
management O +
options O +
should O +
be O +
considered O -
, O +
such O +
as O +
attempted O +
conservative O +
management O +
or O +
hysterectomy O +
and O +
counseling O +
provided O +
about O +
potential O +
sequelae O +
[ O -
6 O -
] O -
. O +

The O +
traditional O +
management O +
is O +
abdominal O +
hysterectomy O -
, O +
but O +
this O +
operation O +
terminates O +
fertility O +
and O +
may O +
have O +
devastating O +
psychological O +
effects O -
. O +

However O -
, O +
in O +
correct O +
circumstances O -
, O +
a O +
conservative O +
approach O +
may O +
be O +
suitable O -
. O +

Conservative O +
management O +
of O +
abnormally O +
invasive O +
placentation O +
can O +
be O +
effective O +
and O +
fertility O +
can O +
be O +
preserved O -
. O +

It O +
should O +
be O +
only O +
considered O +
in O +
highly O +
selected O +
cases O +
when O +
blood O +
loss O +
is O +
minimal O +
and O +
there O +
is O +
wish O +
for O +
fertility O +
preservation O +
[ O -
7 O -
] O -
. O +

For O +
women O +
who O +
want O +
to O +
preserve O +
their O +
fertility O +
the O +
placenta O +
should O +
be O +
left O +
intact O +
if O +
possible O +
after O +
caesarean O +
delivery O +
as O +
this O +
approach O +
lowers O +
the O +
risk O +
of O +
subsequent O +
hysterectomy O +
from O +
85 O -
% O +
to O +
15 O -
% O -
. O +

For O +
women O +
who O +
have O +
completed O +
their O +
family O -
, O +
hysterectomy O +
with O +
placenta O +
left O +
in O +
situ O +
is O +
preferable O +
to O +
lower O +
the O +
maternal O +
morbidity O +
rates O +
[ O -
6 O -
] O -
. O +

This O +
case O +
report O +
involved O +
conservative O +
management O -
. O +

Peripartum O +
hysterectomy O +
was O +
avoided O +
and O +
the O +
aim O +
was O +
to O +
preserve O +
fertility O -
. O +

Prophylactic O +
antibiotics O -
, O +
post O +
partum O +
oxytocics O +
and O +
the O +
use O +
of O +
misoprostol O +
post O +
operatively O +
helped O +
to O +
prevent O +
further O +
post O +
partum O +
hemorrhage O -
. O +

When O +
a O +
patient O +
isinitially O +
opted O +
for O +
conservative O +
management O -
, O +
the O +
possibility O +
of O +
recurrence O +
should O +
be O +
discussed O +
[ O -
8 O -
] O -
. O +

Furthermore O -
, O +
placentation O +
should O +
be O +
carefully O +
monitored O +
for O +
recurrence O +
in O +
any O +
subsequent O +
pregnancy O -
, O +
particularly O +
if O +
the O +
placenta O +
is O +
located O +
at O +
the O +
same O +
site O +
as O +
the O +
previous O +
placenta O +
accreta O -
. O +

Conservative O +
treatment O +
for O +
placenta O +
accreta O +
may O +
be O +
an O +
alternative O +
procedure O +
in O +
some O +
selected O +
cases O -
. O +

Conclusion O +
We O +
suggest O +
an O +
alternative O +
approach O +
for O +
managing O +
uterine O +
inversion O +
caused O +
by O +
placenta O +
accreta O +
that O +
involved O +
conservative O +
management O -
. O +

This O +
way O +
hysterectomy O +
was O +
avoided O +
and O +
fertility O +
was O +
preserved O -
. O +

Abbreviations O +
CS O -
: O +
Caesarean O +
Section O -
; O +
FFP O -
: O +

Fresh O +
Frozen O +
Plasma O +
Consent O +
Written O +
informed O +
consent O +
was O +
obtained O +
from O +
the O +
patient O +
for O +
publication O +
of O +
this O +
case O +
report O +
and O +
accompanying O +
images O -
. O +

A O +
copy O +
of O +
the O +
written O +
consent O +
is O +
available O +
for O +
review O +
by O +
the O +
Editor O +
– O +
in O +
Chief O +
of O +
this O +
journal O -
. O +

Competing O +
interests O +
The O +
authors O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O -
. O +

Authors O -
' O +
contributions O +
All O +
authors O +
have O +
made O +
substantial O +
contribution O +
to O +
concept O +
this O +
case O +
report O -
. O +

Neurogenin2 O +
Directs O +
Granule O +
Neuroblast O +
Production O +
and O +
Amplification O +
while O +
NeuroD1 O +
Specifies O +
Neuronal O +
Fate O +
during O +
Hippocampal O +
Neurogenesis O +
Abstract O +
The O +
specification O +
and O +
differentiation O +
of O +
dentate O +
gyrus O +
granule O +
neurons O +
in O +
the O +
hippocampus O +
require O +
temporally O +
and O +
spatially O +
coordinated O +
actions O +
of O +
both O +
intrinsic O +
and O +
extrinsic O +
molecules O -
. O +

The O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
transcription O +
factor O +
Neurogenin2 O +
( O -
Ngn2 O -
) O +
and O +
NeuroD1 O +
are O +
key O +
regulators O +
in O +
these O +
processes O -
. O +

Based O +
on O +
existing O +
classification O -
, O +
we O +
analyzed O +
the O +
molecular O +
events O +
occurring O +
during O +
hippocampal O +
neurogenesis O -
, O +
primarily O +
focusing O +
on O +
juvenile O +
animals O -
. O +

We O +
found O +
that O +
Ngn2 O +
is O +
transiently O +
expressed O +
by O +
late O +
type-2a O +
amplifying O +
progenitors O -
. O +

The O +
Ngn2 O +
progenies O +
mature O +
into O +
hippocampal O +
granule O +
neurons O -
. O +

Interestingly O -
, O +
the O +
loss O +
of O +
Ngn2 O +
at O +
early O +
stages O +
of O +
development O +
leads O +
to O +
a O +
robust O +
reduction O +
in O +
neurogenesis O -
, O +
but O +
does O +
not O +
disturb O +
granule O +
neuron O +
maturation O +
per O +
se O -
. O +

We O +
found O +
that O +
the O +
role O +
of O +
Ngn2 O +
is O +
to O +
maintain O +
progenitors O +
in O +
an O +
undifferentiated O +
state O -
, O +
allowing O +
them O +
to O +
amplify O +
prior O +
to O +
their O +
maturation O +
into O +
granule O +
neurons O +
upon O +
NeuroD1 O +
induction O -
. O +

When O +
we O +
overexpressed O +
Ngn2 O +
and O +
NeuroD1 O +
in O +
vivo O -
, O +
we O +
found O +
NeuroD1 O +
to O +
exhibit O +
a O +
more O +
pronounced O +
neuron O -
- O -
inductive O +
effect O -
, O +
leading O +
to O +
granule O +
neuron O +
commitment O -
, O +
than O +
that O +
displayed O +
by O +
Ngn2 O -
. O +

Finally O -
, O +
we O +
observed O +
that O +
all O +
markers O +
expressed O +
during O +
the O +
transcriptional O +
control O +
of O +
hippocampal O +
neurogenesis O +
in O +
rodents O +
are O +
also O +
present O +
in O +
the O +
human B-Species +
hippocampus O -
. O +

Taken O +
together O -
, O +
we O +
demonstrate O +
a O +
critical O +
role O +
of O +
for O +
Ngn2 O +
and O +
NeuroD1 O +
in O +
controlling O +
neuronal O +
commitment O +
and O +
hippocampal O +
granule O +
neuroblast O +
formation O -
, O +
both O +
during O +
embryonic O +
development O +
and O +
in O +
post O -
- O -
natal O +
hippocampal O +
granule O +
neurogenesis O -
. O +

Introduction O +
Neurons O +
are O +
born O +
not O +
only O +
during O +
development O +
of O +
the O +
central O +
nervous O +
system O -
, O +
but O +
neurogenesis O +
also O +
continues O +
into O +
adulthood O -
. O +

In O +
both O +
rodent B-Species +
and O +
human B-Species +
adult O +
brain O -
, O +
neurogenesis O +
is O +
active O +
in O +
two O +
distinct O +
zones O +
of O +
the O +
forebrain O -
: O +
the O +
subventricular O +
zone O +
( O -
SVZ O -
) O +
of O +
the O +
lateral O +
ventricle O +
and O +
the O +
subgranular O +
zone O +
( O -
SGZ O -
) O +
of O +
the O +
hippocampal O +
dentate O +
gyrus O +
( O -
DG O -
) O +
[ O -
1 O -
] O -
– O -
[ O -
5 O -
] O -
. O +

The O +
molecular O +
mechanism O +
underlying O +
neurogenesis O +
in O +
the O +
DG O +
is O +
not O +
fully O +
understood O -
. O +

Clearly O -
, O +
a O +
cascade O +
of O +
transcriptional O +
events O +
controls O +
the O +
specification O +
of O +
neuronal O +
identity O +
in O +
the O +
DG O +
[ O -
3 O -
] O -
, O +
[ O -
6 O -
] O -
– O -
[ O -
8 O -
] O -
, O +
but O +
details O +
of O +
the O +
expression O +
pattern O +
and O +
function O +
of O +
each O +
transcription O +
factor O +
remain O +
elusive O -
. O +

The O +
paired O -
- O -
box O +
homeodomain O +
transcription O +
factor O +
Pax6 O +
and O +
the O +
bHLH O +
transcription O +
factors O +
Ngn2 O +
and O +
NeuroD1 O +
are O +
important O +
when O +
cells O +
acquire O +
a O +
pan O -
- O -
neuronal O +
character O +
and O +
a O +
specific O +
neuronal O +
subtype O +
[ O -
9 O -
] O -
, O +
[ O -
10 O -
] O -
. O +

In O +
the O +
developing O +
neocortex O -
, O +
Pax6 O +
is O +
expressed O +
in O +
dividing O +
radial O +
glial O +
cells O +
at O +
the O +
ventricular O +
surface O +
[ O -
9 O -
] O -
. O +

In O +
the O +
adult O +
hippocampus O -
, O +
Pax6 O +
is O +
expressed O +
in O +
astrocytes O +
in O +
the O +
SGZ O +
and O +
are O +
considered O +
to O +
be O +
the O +
true O +
stem O +
cells O +
[ O -
9 O -
] O -
, O +
[ O -
11 O -
] O -
. O +

Loss- O +
and O +
gain O -
- O -
of O -
- O -
function O +
studies O +
indicate O +
that O +
Pax6 O +
is O +
involved O +
in O +
regulating O +
the O +
proliferation O +
of O +
neocortical O +
and O +
hippocampal O +
progenitors O +
[ O -
9 O -
] O -
, O +
[ O -
12 O -
] O -
– O -
[ O -
16 O -
] O -
. O +

During O +
neocorticogenesis O -
, O +
high O +
concentrations O +
of O +
Pax6 O +
induce O +
the O +
expression O +
of O +
the O +
bHLH O +
transcription O +
factor O +
Neurogenin2 O +
( O -
Ngn2 O -
) O +
[ O -
17 O -
] O -
. O +

In O +
turn O -
, O +
Ngn2 O +
causes O +
cell O +
cycle O +
exit O +
[ O -
18 O -
] O -
, O +
an O +
event O +
that O +
takes O +
place O +
when O +
NeuroD1 O +
starts O +
to O +
be O +
expressed O +
[ O -
19 O -
] O -
. O +

In O +
the O +
developing O +
hippocampus O -
, O +
the O +
absence O +
of O +
Ngn2 O +
leads O +
to O +
a O +
reduced O +
number O +
of O +
granule O +
neurons O +
[ O -
20 O -
] O -
. O +

NeuroD1 O -
, O +
on O +
the O +
other O +
hand O -
, O +
is O +
essential O +
for O +
the O +
differentiation O +
and O +
survival O +
of O +
hippocampal O +
granule O +
neurons O +
[ O -
10 O -
] O -
. O +

Interestingly O -
, O +
in O +
the O +
absence O +
of O +
Ngn2 O -
, O +
NeuroD1 O +
can O +
still O +
be O +
activated O +
and O +
neuronal O +
differentiation O +
can O +
still O +
take O +
place O +
[ O -
20 O -
] O -
. O +

This O +
has O +
led O +
to O +
the O +
idea O +
that O +
the O +
primary O +
role O +
of O +
Ngn2 O +
is O +
not O +
to O +
direct O +
neuronal O +
differentiation O -
. O +

Only O +
a O +
small O +
number O +
of O +
studies O +
have O +
addressed O +
the O +
role O +
of O +
Ngn2 O +
and O +
NeuroD1 O +
in O +
hippocampal O +
neurogenesis O +
[ O -
10 O -
] O -
, O +
[ O -
20 O -
] O -
, O +
[ O -
21 O -
] O -
. O +

Therefore O -
, O +
we O +
now O +
re O -
- O -
examine O +
their O +
roles O +
in O +
hippocampal O +
neurogenesis O +
in O +
detail O -
, O +
using O +
gain- O +
and O +
loss O -
- O -
of O -
- O -
function O +
experiments O -
. O +

We O +
first O +
establish O +
a O +
hierarchy O +
of O +
transcriptional O +
events O +
that O +
occur O +
during O +
neurogenesis O +
in O +
the O +
DG O +
and O +
then O +
define O +
the O +
place O +
that O +
Ngn2 O -
, O +
NeuroD1 O +
and O +
other O +
transcription O +
factors O +
have O +
in O +
this O +
cascade O -
. O +

We O +
find O +
that O +
a O +
lack O +
of O +
Ngn2 O +
expression O +
result O +
in O +
a O +
markedly O +
smaller O +
hippocampus O +
and O +
an O +
almost O +
complete O +
absence O +
of O +
the O +
DG O -
. O +

We O +
show O +
that O +
Ngn2 O +
is O +
required O +
for O +
granule O +
neuroblasts O +
production O -
/ O -
amplification O -
. O +

Gain O -
- O -
of O -
- O -
function O +
of O +
NeuroD1 O +
during O +
development O +
of O +
the O +
DG O +
results O +
in O +
an O +
efficient O +
generation O +
of O +
granule O +
neuroblasts O -
, O +
an O +
effect O +
that O +
we O +
do O +
not O +
observe O +
when O +
we O +
overexpress O +
Ngn2 O -
. O +

Finally O -
, O +
we O +
demonstrate O +
that O +
the O +
same O +
transcription O +
factors O +
and O +
cellular O +
markers O +
seen O +
in O +
mouse B-Species +
and O +
rat B-Species +
tissue O +
are O +
also O +
present O +
in O +
the O +
human B-Species +
hippocampus O -
. O +

Results O +
Expression O +
of O +
transcription O +
factors O +
and O +
cellular O +
markers O +
define O +
different O +
phases O +
of O +
postnatal O +
hippocampal O +
granule O +
neuron O +
maturation O +
We O +
first O +
analyzed O +
in O +
detail O +
the O +
chronology O +
of O +
expression O +
of O +
different O +
transcription O +
factors O +
and O +
cell O -
- O -
specific O +
markers O +
during O +
DG O +
granule O +
neuron O +
formation O +
and O +
correlated O +
our O +
findings O +
to O +
the O +
previously O +
established O +
classification O +
of O +
adult O +
hippocampal O +
neurogenesis O +
[ O -
3 O -
] O -
. O +

The O +
current O +
classification O +
describes O +
hippocampal O +
stem O +
cells O +
and O +
progenies O +
into O +
three O +
categories O +
( O -
type-1 O -
, O +
-2 O +
and O +
-3 O +
cells O -
) O +
depending O +
on O +
the O +
markers O +
they O +
express O +
as O +
they O +
mature O -
. O +

In O +
the O +
adult O +
mouse B-Species +
DG O -
, O +
only O +
a O +
very O +
small O +
proportion O +
of O +
cells O +
undergo O +
mitosis O +
at O +
any O +
one O +
given O +
time O +
[ O -
22 O -
] O -
. O +

Consequently O -
, O +
in O +
adult O +
animals O +
it O +
is O +
difficult O +
to O +
analyze O +
which O +
transcription O +
factors O +
are O +
involved O +
in O +
the O +
transition O +
phase O +
from O +
one O +
cell O +
category O +
to O +
the O +
next O -
. O +

Therefore O -
, O +
we O +
studied O +
2 O +
week O -
- O -
old O +
rodents O +
which O +
have O +
higher O +
numbers O +
of O +
maturing O +
granule O +
neurons O +
in O +
the O +
DG O -
. O +

We O +
performed O +
triple O +
immunohistochemistry O +
for O +
all O +
markers O +
of O +
interest O +
and O +
compared O +
results O +
from O +
2 O +
week- O +
and O +
2 O +
month O -
- O -
old O +
mice B-Species +
( O -
Figure O +
1 O +
and O +
figure O +
S1 O -
) O -
. O +

We O +
first O +
confirmed O +
that O +
stem O +
cells O +
in O +
the O +
SGZ O +
exhibit O +
characteristics O +
of O +
radial O +
glia O +
[ O -
3 O -
] O -
, O +
[ O -
11 O -
] O -
, O +
[ O -
16 O -
] O -
. O +

They O +
extend O +
radial O +
processes O +
from O +
the O +
SGZ O +
to O +
the O +
apex O +
of O +
the O +
subgranular O +
layer O +
( O -
SGL O -
) O +
and O +
the O +
basal O +
molecular O +
layer O -
. O +

Moreover O -
, O +
they O +
express O +
the O +
intermediate O +
filament O +
protein O +
nestin O -
, O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
and O +
glial O +
glutamate O +
transporter O +
( O -
GLAST O -
) O +
[ O -
16 O -
] O +
( O -
Figure O +
1A O +
and O +
B O +
and O +
figure O +
S1A O +
and O +
S1B O -
) O -
. O +

The O +
GFAP- O +
and O +
GLAST+ O +
cells O +
are O +
defined O +
as O +
type-1 O +
cells O +
[ O -
3 O -
] O -
. O +

They O +
also O +
express O +
the O +
paired O -
- O -
homeodomain O +
transcription O +
factor O +
Pax6 O +
( O -
Figure O +
1B O -
) O -
. O +

These O +
radial O +
glia O -
- O -
like O +
stem O +
cells O +
divide O +
relatively O +
infrequently O -
, O +
and O +
are O +
believed O +
to O +
undergo O +
symmetric O +
division O +
( O -
giving O +
rise O +
to O +
two O +
identical O +
stem O +
cells O -
) O +
under O +
some O +
conditions O -
. O +

They O +
can O +
also O +
divide O +
asymmetrically O +
and O +
give O +
rise O +
to O +
a O +
new O +
stem O +
cell O +
and O +
one O +
neuronal O +
progenitor O -
, O +
which O +
usually O +
is O +
defined O +
as O +
a O +
type-2 O +
cell O +
( O -
Figure O +
2B O -
) O +
[ O -
3 O -
] O -
. O +

Type-2 O +
cells O +
are O +
divided O +
into O +
two O +
different O +
populations O -
: O +
type-2a O +
expressing O +
nestin O +
and O +
type-2b O +
co O -
- O -
expressing O +
nestin O +
and O +
doublecortin O +
( O -
Dcx O -
) O +
[ O -
23 O -
] O -
. O +

Based O +
on O +
a O +
previous O +
report O +
[ O -
24 O -
] O -
, O +
we O +
examined O +
the O +
expression O +
pattern O +
of O +
the O +
T O -
- O -
domain O +
transcription O +
factors O +
Tbr1 O +
and O +
Tbr2 O -
. O +

We O +
found O +
that O +
Tbr2 O +
is O +
expressed O +
in O +
type-2a O +
cells O -
, O +
in O +
agreement O +
with O +
a O +
recent O +
report O +
[ O -
25 O -
] O -
. O +

In O +
the O +
SGZ O +
of O +
2 O +
week O -
- O -
old O +
mice B-Species -
, O +
we O +
found O +
an O +
average O +
of O +
50–70 O +
Tbr2 O -
+ O +
cells O +
per O +
30 O +
µm O -
- O -
thick O +
section O +
throughout O +
the O +
rostro O -
- O -
caudal O +
axis O +
of O +
the O +
dorsal O +
hippocampus O -
. O +

This O +
number O +
was O +
reduced O +
by O +
35 O -
% O +
in O +
2 O +
month O -
- O -
old O +
mice B-Species +
( O -
Figure O +
1C O +
with O +
figure O +
S1C O +
and O +
data O +
not O +
shown O -
) O -
. O +

As O +
opposed O +
to O +
Tbr1 O +
( O -
Figure O +
1D O +
and O +
figure O +
S1D O -
) O -
, O +
Tbr2 O -
+ O +
cells O +
did O +
not O +
co O -
- O -
express O +
Dcx O +
or O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
1C O +
and O +
figure O +
S1C O -
) O -
. O +

We O +
observed O +
that O +
Tbr1-immuoreactivity O +
gradually O +
decreased O +
as O +
neurons O +
matured O +
and O +
started O +
to O +
express O +
NeuN O +
( O -
Figure O +
1H O +
and O +
figure O +
S1H O -
) O -
. O +

Thus O -
, O +
Tbr2 O +
labels O +
type-2 O +
cells O -
, O +
while O +
Tbr1 O +
is O +
expressed O +
by O +
immature O +
granule O +
neurons O -
. O +

We O +
then O +
examined O +
the O +
molecular O +
phenotype O +
of O +
type-3 O +
cells O -
, O +
a O +
cell O +
type O +
that O +
transiently O +
expresses O +
Calretinin O +
[ O -
26 O -
] O -
. O +

We O +
hypothesized O +
that O +
hippocampal O +
type-3 O +
cells O +
might O +
also O +
express O +
the O +
bHLH O +
transcription O +
factor O +
NeuroD1 O -
, O +
known O +
to O +
partially O +
overlap O +
with O +
Tbr2 O +
and O +
Tbr1 O +
in O +
different O +
brain O +
regions O +
[ O -
24 O -
] O -
. O +

We O +
found O +
that O +
NeuroD1 O +
expression O +
in O +
the O +
hippocampus O +
starts O +
in O +
Tbr2 O -
+ O +
cells O +
and O +
extends O +
to O +
post O -
- O -
mitotic O +
Tbr1 O -
+ O +
cells O -
, O +
which O +
also O +
express O +
the O +
hippocampal O +
granule O +
identity O +
transcription O +
factor O +
Prox1 O +
( O -
Figure O +
1 O -
G O +
and O +
1I O +
and O +
figure O +
S1 O -
G O +
and O +
S1I O -
) O -
. O +

While O +
Tbr1 O +
expression O +
ceases O +
during O +
granule O +
maturation O -
, O +
that O +
of O +
NeuroD1 O +
is O +
weakly O +
maintained O +
when O +
NeuN O +
expression O +
starts O +
( O -
Figure O +
1 O -
G O +
and O +
1H O +
and O +
figure O +
S1 O -
G O +
and O +
S1H O -
) O -
. O +

We O +
found O +
that O +
calretinin O +
expression O +
decreased O +
during O +
granule O +
neuron O +
maturation O -
, O +
before O +
NeuroD1 O +
was O +
reduced O +
( O -
Figure O +
1F O -
) O -
. O +

Thus O +
NeuroD1 O +
is O +
expressed O +
in O +
type-2b O +
and O +
type-3 O +
cells O -
, O +
as O +
well O +
as O +
immature O +
granule O +
neurons O -
. O +

Finally O -
, O +
we O +
found O +
that O +
NeuroD2 O +
starts O +
to O +
be O +
expressed O +
just O +
after O +
NeuroD1 O +
and O -
, O +
unlike O +
NeuroD1 O -
, O +
continues O +
to O +
be O +
highly O +
expressed O +
in O +
mature O +
neurons O +
( O -
Figure O +
1J O +
and O +
data O +
not O +
shown O -
) O -
. O +

Mash1 O +
and O +
Ngn2 O +
define O +
the O +
early O +
versus O +
late O +
type-2a O +
stage O +
in O +
2 O +
weeks O +
old O +
mice B-Species +
Having O +
established O +
the O +
hierarchy O +
of O +
transcription O +
factors O +
and O +
cellular O +
markers O +
appearing O +
during O +
hippocampal O +
neurogenesis O -
, O +
we O +
set O +
out O +
to O +
clarify O +
the O +
position O +
of O +
the O +
two O +
bHLH O +
transcription O +
factors O +
Ngn2 O +
and O +
Mash1 O -
, O +
in O +
this O +
process O -
. O +

We O +
found O +
that O +
more O +
than O +
90 O -
% O +
of O +
Ngn2-immunoreactive O +
cells O +
are O +
Pax6 O +
positive O +
( O -
Figure O +
2A O -
) O -
, O +
and O +
almost O +
all O +
co O -
- O -
express O +
Tbr2 O +
( O -
Figure O +
2B O -
) O -
. O +

Thus O -
, O +
Ngn2 O +
appears O +
to O +
be O +
expressed O +
by O +
type-2a O +
cells O -
. O +

As O +
our O +
antibodies O +
against O +
Ngn2 O +
and O +
NeuroD1 O +
were O +
made O +
in O +
the O +
same O +
species O -
, O +
we O +
could O +
not O +
determine O +
if O +
there O +
was O +
an O +
overlap O +
between O +
these O +
two O +
proteins O -
. O +

However O -
, O +
by O +
comparing O +
their O +
overlapping O +
expression O +
pattern O +
with O +
that O +
of O +
Tbr2 O -
, O +
we O +
propose O +
that O +
some O +
Ngn2 O -
+ O +
cells O +
co O -
- O -
express O +
NeuroD1 O -
, O +
and O +
that O +
they O +
appear O +
at O +
the O +
onset O +
of O +
NeuroD1 O +
expression O +
and O +
downregulation O +
of O +
Ngn2 O -
. O +

We O +
base O +
this O +
assumption O +
on O +
the O +
facts O +
that O +
more O +
than O +
50 O -
% O +
of O +
the O +
Tbr2 O -
+ O +
cells O +
are O +
Ngn2 O -
+ O +
and O +
more O +
than O +
50 O -
% O +
of O +
Tbr2 O -
+ O +
cells O +
also O +
express O +
NeuroD1 O -
. O +

The O +
expression O +
of O +
Ngn2 O +
in O +
adult O +
hippocampus O +
was O +
hard O +
to O +
detect O +
using O +
immunohistochemistry O +
due O +
to O +
the O +
low O +
expression O +
of O +
the O +
protein O +
( O -
data O +
not O +
shown O -
) O -
. O +

However O -
, O +
it O +
is O +
present O -
, O +
as O +
previously O +
described O +
using O +
reporter O +
mice B-Species +
and O +
as O +
revealed O +
by O +
in O +
situ O +
hybridization O +
[ O -
21 O -
] O -
. O +

We O +
next O +
examined O +
the O +
expression O +
of O +
Mash1 O +
and O +
compared O +
it O +
with O +
that O +
of O +
Ngn2 O -
, O +
Pax6 O +
and O +
Tbr2 O -
. O +

We O +
found O +
some O +
Mash1 O -
+ O +
cells O +
( O -
10–20 O +
cells O +
per O +
section O -
) O +
in O +
the O +
dorsal O +
hippocampus O -
. O +

Almost O +
all O +
of O +
them O +
co O -
- O -
expressed O +
Pax6 O +
( O -
Figure O +
2C O -
) O -
. O +

Only O +
few O +
cells O +
co O -
- O -
expressed O +
Tbr2 O +
( O -
Figure O +
2D O -
) O +
or O +
Ngn2 O +
( O -
Figure O +
2E O -
) O -
, O +
suggesting O +
that O +
Mash1 O +
is O +
downregulated O +
when O +
these O +
two O +
proteins O +
are O +
expressed O -
. O +

None O +
of O +
the O +
Mash1-expressing O +
cells O +
were O +
positive O +
for O +
NeuroD1 O +
( O -
Figure O +
2F O -
) O -
. O +

Mash1 O -
+ O +
cells O +
were O +
still O +
undergoing O +
mitosis O +
( O -
Figure O +
2C O -
) O +
and O +
consequently O +
over O +
90 O -
% O +
of O +
them O +
co O -
- O -
labeled O +
with O +
the O +
cell O -
- O -
cycle O +
marker O +
Ki67 O +
( O -
Figure O +
S1J O -
) O -
. O +

Taken O +
together O -
, O +
we O +
show O +
that O +
Mash1 O +
and O +
Ngn2 O +
are O +
expressed O +
in O +
early O +
and O +
late O +
stages O +
of O +
maturation O +
of O +
type2a O +
progenitors O -
, O +
respectively O -
, O +
and O +
that O +
both O +
transcription O +
factors O +
are O +
co O -
- O -
expressed O +
briefly O +
when O +
cells O +
transit O +
from O +
early O +
to O +
late O +
phase O +
type2a O +
cells O -
. O +

Ngn2 O +
progenies O +
become O +
hippocampal O +
granule O +
neurons O +
Previous O +
work O +
has O +
shown O +
that O +
in O +
Mash1 O +
null O +
mutant O +
mice B-Species +
hippocampal O +
neurogenesis O +
is O +
not O +
reduced O +
and O +
the O +
hippocampus O +
is O +
not O +
malformed O +
[ O -
20 O -
] O -
. O +

Therefore O +
we O +
focused O +
our O +
initial O +
analysis O +
on O +
the O +
role O +
of O +
Ngn2 O +
in O +
hippocampal O +
neurogenesis O -
. O +

We O +
characterized O +
the O +
fate O +
of O +
Ngn2-expressing O +
cells O +
using O +
Ngn2 O +
Knock O -
- O -
in O +
green O +
fluorescent O +
protein O +
( O -
GFP O -
) O +
mice B-Species +
( O -
Ngn2+ O -
/ O -
GFP O -
) O +
[ O -
27 O -
] O -
. O +

In O +
the O +
SGZ O +
of O +
2 O +
week O -
- O -
old O +
hippocampi O -
, O +
we O +
found O +
bright O +
GFP O -
- O -
expressing O +
cells O +
that O +
were O +
positive O +
for O +
Tbr2 O +
( O -
Figure O +
2H O -
) O -
, O +
the O +
immature O +
neuronal O +
marker O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
2I O -
) O +
and O +
NeuroD1 O +
( O -
Figure O +
2J O -
) O -
. O +

Furthermore O -
, O +
Prox1 O -
+ O -
, O +
NeuroD2 O -
+ O +
and O +
calretinin+ O +
cells O +
were O +
also O +
weakly O +
positive O +
for O +
GFP O -
. O +

We O +
made O +
similar O +
observations O +
in O +
2 O +
month O -
- O -
old O +
mice B-Species +
( O -
data O +
not O +
shown O -
) O +
confirming O +
earlier O +
published O +
results O +
[ O -
21 O -
] O -
) O -
. O +

We O +
did O +
not O +
observe O +
Mash1+ O -
/ O -
GFP+ O +
and O +
NeuN+ O -
/ O -
GFP+ O +
cells O +
( O -
Figure O +
2 O -
G O -
) O -
. O +

These O +
data O +
from O +
Ngn2+ O -
/ O -
GFP O +
mice B-Species +
are O +
entirely O +
consistent O +
with O +
our O +
earlier O +
observations O +
using O +
immunocytochemistry O +
to O +
label O +
Ngn2-expressing O +
cells O +
and O +
with O +
GFP O +
undergoing O +
slow O +
degradation O +
after O +
the O +
expression O +
of O +
Ngn2 O +
has O +
ceased O -
. O +

Importantly O -
, O +
none O +
of O +
the O +
GFP O -
- O -
expressing O +
cells O -
, O +
including O +
those O +
only O +
weakly O +
fluorescent O -
, O +
residing O +
in O +
the O +
SGL O +
expressed O +
the O +
astrocytic O +
marker O +
GFAP O +
or O +
the O +
oligodendrocytic O +
markers O +
CNPase O +
( O -
data O +
not O +
shown O -
) O -
. O +

Taken O +
together O -
, O +
the O +
data O +
show O +
that O +
Ngn2 O +
progenies O +
become O +
neurons O +
and O +
never O +
generate O +
astrocytes O +
or O +
oligodendrocytes O -
. O +

Marked O +
reduction O +
of O +
hippocampal O +
granule O +
neurons O +
in O +
absence O +
of O +
Ngn2 O +
To O +
determine O +
the O +
role O +
of O +
Ngn2 O +
during O +
the O +
initiation O +
of O +
hippocampal O +
granule O +
neurogenesis O -
, O +
we O +
analyzed O +
the O +
hippocampus O +
of O +
mice B-Species +
lacking O +
Ngn2 O +
( O -
Ngn2GFP O -
/ O -
GFP O -
) O -
. O +

In O +
contrast O +
to O +
the O +
mice B-Species +
use O +
by O +
Galichet O +
and O +
coworkers O -
, O +
our O +
mice B-Species +
have O +
a O +
lifespan O +
of O +
only O +
2 O +
weeks O +
after O +
birth O -
. O +

Therefore O -
, O +
we O +
analyzed O +
2 O +
week O -
- O -
old O +
and O +
younger O +
mice B-Species -
. O +

Consistent O +
with O +
previous O +
observations O +
[ O -
20 O -
] O -
, O +
the O +
hippocampus O +
in O +
Ngn2GFP O -
/ O -
GFP O +
mutants O +
is O +
clearly O +
malformed O +
( O -
Figure O +
3A O -
) O -
. O +

In O +
two O +
week O -
- O -
old O +
Ngn2GFP O -
/ O -
GFP O +
mice B-Species -
, O +
the O +
ventral O +
blade O +
of O +
the O +
DG O +
is O +
completely O +
absent O -
. O +

Already O +
on O +
postnatal O +
day O +
1–2 O -
, O +
the O +
ventral O +
blade O +
of O +
the O +
DG O +
is O +
malformed O +
along O +
its O +
whole O +
rostro O -
- O -
caudal O +
axis O +
( O -
Figure O +
3B O -
) O -
. O +

As O +
neither O +
migration O +
defects O +
nor O +
cell O +
death O +
cause O +
the O +
reduced O +
number O +
of O +
hippocampal O +
neurons O +
in O +
Ngn2 O +
null O +
mice B-Species +
[ O -
20 O -
] O -
, O +
we O +
asked O +
if O +
Ngn2 O +
is O +
necessary O +
for O +
production O +
of O +
hippocampal O +
granule O +
neuroblasts O -
. O +

We O +
first O +
injected O +
2 O +
day O -
- O -
old O +
mouse B-Species +
pups O +
with O +
BrdU O +
2 O +
hours O +
prior O +
to O +
sacrifice O -
, O +
allowing O +
us O +
to O +
evaluate O +
cell O +
proliferation O +
and O +
ongoing O +
neurogenesis O -
. O +

We O +
also O +
injected O +
BrdU O +
into O +
female O +
mice B-Species +
on O +
their O +
final O +
day O +
of O +
pregnancy O +
and O +
examined O +
the O +
brains O +
of O +
their O +
pups O +
48 O +
hours O +
later O +
( O -
corresponding O +
to O +
P1–P2 O +
old O +
pups O -
) O -
. O +

This O +
allowed O +
us O +
to O +
assess O +
the O +
number O +
of O +
neurons O +
derived O +
from O +
the O +
last O +
day O +
of O +
intrauterine O +
development O -
. O +

Regardless O +
of O +
whether O +
the O +
mice B-Species +
were O +
WT O +
or O +
hetero O -
/ O -
homozygous O +
mutant O +
pups O -
, O +
we O +
found O +
cells O +
that O +
had O +
incorporated O +
BrdU O +
in O +
the O +
hippocampal O +
subventricular O +
zone O +
( O -
hSVZ O -
) O -
, O +
fimbria O +
and O +
the O +
DG O +
( O -
Figure O +
4A O +
and O +
B O -
; O +
[ O -
28 O -
] O -
) O -
, O +
suggesting O +
that O +
progenitors O +
originating O +
in O +
the O +
hSVZ O +
divide O +
while O +
migrating O +
towards O +
the O +
DG O -
. O +

Most O +
of O +
them O +
were O +
organized O +
in O +
chains O +
typical O +
of O +
migrating O +
cells O +
( O -
Figure O +
4A O +
and O +
B O +
and O +
figure O +
S2 O -
) O -
. O +

In O +
Ngn2GFP O -
/ O -
GFP O +
mutant O +
mice B-Species +
injected O +
with O +
BrdU O +
2 O +
hours O +
prior O +
to O +
sacrifice O -
, O +
we O +
observed O +
a O +
decrease O +
in O +
the O +
number O +
of O +
BrdU+ O +
cells O +
compared O +
to O +
heterozygous O +
littermates O -
. O +

Thus O -
, O +
the O +
numbers O +
of O +
newborn O +
cells O +
were O +
reduced O +
in O +
the O +
hSVZ O -
/ O -
fimbria O +
( O -
133.3±7.5 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
69.7±5.0 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
) O +
and O +
DG O +
( O -
132.0±9.1 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
42.6±2.2 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
) O -
( O -
Figure O +
4C O +
and O +
D O -
) O -
. O +

We O +
also O +
examined O +
the O +
number O +
of O +
newborn O +
cells O +
differentiating O +
into O +
neurons O -
, O +
and O +
identified O +
them O +
by O +
the O +
co O -
- O -
expression O +
of O +
BrdU O +
and O +
NeuroD1 O -
. O +

As O +
expected O -
, O +
they O +
were O +
relatively O +
few O +
in O +
numbers O +
because O +
the O +
short O +
delay O +
( O -
2 O +
hours O -
) O +
between O +
BrdU O +
administration O +
and O +
sacrifice O +
in O +
this O +
first O +
experimental O +
paradigm O -
. O +

In O +
Ngn2GFP O -
/ O -
GFP O +
null O +
mutants O -
, O +
we O +
found O +
the O +
number O +
of O +
cells O +
differentiating O +
into O +
neurons O +
to O +
be O +
reduced O +
by O +
60 O -
% O +
and O +
71 O -
% O +
in O +
the O +
hSVZ O -
/ O -
fimbria O +
( O -
8.6±1.4 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
3.4±0.5 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
) O +
and O +
DG O +
( O -
9.7±1.1 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
2.8±0.6 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
) O -
, O +
respectively O -
, O +
( O -
Figure O +
4E O +
and O +
F O -
) O -
. O +

As O +
a O +
result O -
, O +
the O +
number O +
of O +
NeuroD1 O -
+ O +
cells O +
in O +
the O +
DG O +
was O +
reduced O +
by O +
80 O -
% O +
( O -
580.3±27.7 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
116.2±7.3 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
; O +
Figure O +
4 O -
G O -
) O -
. O +

We O +
obtained O +
similar O +
results O +
in O +
the O +
second O +
paradigm O -
, O +
i.e. O +
in O +
mice B-Species +
that O +
we O +
sacrificed O +
48 O +
hours O +
after O +
BrdU O +
administration O +
and O +
in O +
which O +
a O +
larger O +
number O +
of O +
the O +
newborn O +
cells O +
had O +
time O +
to O +
mature O +
into O +
neurons O -
. O +

In O +
this O +
case O -
, O +
the O +
number O +
of O +
BrdU+ O -
/ O -
NeuroD1 O -
+ O +
cells O +
in O +
the O +
DG O +
was O +
reduced O +
by O +
73 O -
% O +
of O +
Ngn2GFP O -
/ O -
GFP O +
mutant O +
animals O +
( O -
91.5±24.1 O +
for O +
Ngn2+ O -
/ O -
GFP O +
vs O +
26.4±3.3 O +
for O +
Ngn2GFP O -
/ O -
GFP O -
) O +
( O -
Figure O +
4J O -
) O -
. O +

We O +
found O +
no O +
differences O +
in O +
the O +
proportion O +
of O +
BrdU+ O +
cells O +
that O +
expressed O +
NeuroD1 O +
in O +
Ngn2+ O -
/ O -
GFP O +
and O +
Ngn2GFP O -
/ O -
GFP O +
mice B-Species +
( O -
14.2±1.0 O -
% O +
and O +
17.4±1.8 O -
% O +
respectively O -
; O +
Figure O +
4 O -
K O -
) O -
. O +

This O +
shows O +
that O +
the O +
few O +
cells O +
that O +
manage O +
to O +
proliferate O +
in O +
the O +
Ngn2 O +
null O +
mice B-Species +
have O +
the O +
same O +
ability O +
to O +
differentiate O +
into O +
neurons O +
as O +
those O +
in O +
mice B-Species +
with O +
one O +
Ngn2 O +
allele O -
. O +

Interestingly O -
, O +
the O +
absence O +
of O +
Ngn2 O +
did O +
not O +
alter O +
the O +
identity O +
of O +
neurons O +
in O +
the O +
DG O +
granule O +
layer O +
in O +
2 O +
week O -
- O -
old O +
Ngn2 O +
null O +
mice B-Species -
. O +

The O +
maturing O +
granule O +
progenitors O +
sequentially O +
expressed O +
Pax6 O -
, O +
Tbr2 O +
( O -
Figure O +
S3A O +
and O +
S3B O -
) O -
, O +
NeuroD1 O +
and O +
Calretinin O +
( O -
Figure O +
4L O -
) O -
, O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
4N O -
) O -
, O +
Tbr1 O +
( O -
data O +
not O +
shown O -
) O +
and O +
Prox1 O +
( O -
Figure O +
4 O -
M O -
) O -
. O +

We O +
confirmed O +
that O +
the O +
same O +
transcriptional O +
cascade O +
is O +
active O +
in O +
the O +
20 O -
% O +
( O -
compared O +
to O +
mice B-Species +
with O +
one O +
Ngn2 O +
allele O -
) O +
residual O +
granule O +
neurons O +
that O +
are O +
formed O +
two O +
day O -
- O -
old O +
in O +
Ngn2GFP O -
/ O -
GFP O +
mice B-Species +
( O -
Figure O +
S3D O -
– O -
G O +
and O +
data O +
not O +
shown O -
) O -
. O +

We O +
next O +
investigated O +
if O +
the O +
cells O +
that O +
failed O +
to O +
develop O +
into O +
neurons O +
in O +
Ngn2GFP O -
/ O -
GFP O +
mutant O +
mice B-Species -
, O +
became O +
glial O +
cells O -
. O +

We O +
found O +
that O +
cells O +
expressing O +
GFP O +
never O +
co O -
- O -
labeled O +
with O +
the O +
astrocyte O +
marker O +
GFAP O +
( O -
Figure O +
4N O -
) O +
or O +
the O +
oligodendrocyte O +
marker O +
CNPase O +
( O -
data O +
not O +
shown O -
) O -
. O +

Altogether O -
, O +
our O +
results O +
show O +
that O +
Ngn2 O +
plays O +
an O +
important O +
role O +
during O +
the O +
production O -
/ O -
amplification O +
of O +
hippocampal O +
granule O +
neuroblasts O -
, O +
but O +
not O +
the O +
acquisition O +
of O +
the O +
granule O +
neuron O +
identity O +
( O -
Figure O +
S7 O -
) O -
. O +

Ngn2 O +
controls O +
the O +
amplification O +
of O +
granule O +
neuron O +
progenitors O +
We O +
next O +
monitored O +
the O +
mitogenic O +
activity O +
of O +
Ngn2 O -
+ O +
cells O +
in O +
the O +
DG O +
of O +
2 O +
week O -
- O -
old O +
WT O +
mice B-Species -
. O +

We O +
observed O +
that O +
over O +
50 O -
% O +
of O +
Ngn2 O -
+ O +
cells O +
in O +
the O +
DG O +
of O +
WT O +
mice B-Species +
co O -
- O -
expressed O +
the O +
mitosis O +
marker O +
Ki67 O +
( O -
Figure O +
5A O -
) O -
. O +

Inspired O +
by O +
this O +
finding O -
, O +
we O +
injected O +
BrdU O +
into O +
2 O +
week O -
- O -
old O +
WT O +
and O +
Ngn2GFP O -
/ O -
GFP O +
mice B-Species +
and O +
compared O +
cell O +
proliferation O +
in O +
the O +
DG O -
. O +

We O +
observed O +
92 O -
% O +
reduction O +
in O +
number O +
of O +
proliferating O +
cells O +
in O +
the O +
SGZ O +
of O +
Ngn2 O +
null O +
mutant O +
mice B-Species +
( O -
6.7±0.5 O -
) O +
compared O +
to O +
WT O +
( O -
83.6±1.2 O -
) O +
and O +
heterozygotic O +
( O -
data O +
not O +
shown O -
) O +
littermates O +
( O -
Figure O +
5B O -
– O -
C O -
) O -
. O +

This O +
data O +
confirm O +
the O +
importance O +
of O +
Ngn2 O +
during O +
the O +
amplification O +
of O +
granule O +
progenitor.s O -
. O +

To O +
further O +
explore O +
whether O +
Ngn2 O -
+ O +
cells O +
become O +
post O -
- O -
mitotic O +
or O +
still O +
proliferate O +
after O +
Ngn2 O +
is O +
downregulated O -
, O +
we O +
performed O +
immunohistochemistry O +
on O +
sections O +
through O +
the O +
DG O +
of O +
Ngn2+ O -
/ O -
GFP O +
mice B-Species -
. O +

We O +
stained O +
them O +
with O +
the O +
mitosis O +
marker O +
Phospho O -
- O -
histone O +
3 O +
( O -
PH3 O -
) O +
and O +
NeuroD1 O -
, O +
which O +
is O +
downstream O +
of O +
Ngn2 O +
in O +
the O +
transcriptional O +
cascade O +
controlling O +
neurogenesis O -
. O +

Thus O -
, O +
in O +
the O +
same O +
sections O +
we O +
could O +
identify O +
whether O +
cells O +
that O +
had O +
initiated O +
Ngn2 O +
expression O +
( O -
GFP O +
labeled O -
) O -
, O +
continued O +
to O +
divide O +
( O -
PH3 O -
+ O -
) O +
or O +
committed O +
to O +
neuronal O +
differentiation O +
( O -
NeuroD1 O -
+ O -
) O -
. O +

We O +
observed O +
some O +
GFP+ O +
cells O +
that O +
co O -
- O -
expressed O +
PH3 O -
. O +

They O +
all O +
exhibited O +
morphological O +
characteristics O +
of O +
one O +
of O +
the O +
five O +
mitotic O +
phases O -
: O +
prophase O -
, O +
metaphase O -
, O +
anaphase O -
, O +
telophase O +
and O +
cytokinesis O +
( O -
Figure O +
5D O +
and O +
data O +
not O +
shown O -
) O -
. O +

Unexpectedly O -
, O +
cells O +
that O +
colabeled O +
for O +
GFP O -
, O +
PH3 O +
and O +
NeuroD1 O +
( O -
Figure O +
5E O +
and O +
figure O +
S4A O +
and O +
S4B O -
) O +
were O +
rare O -
. O +

This O +
indicates O +
that O +
Ngn2 O -
+ O +
cells O +
undergo O +
division O -
/ O -
amplification O +
and O +
that O +
they O +
mature O +
into O +
post O -
- O -
mitotic O +
neurons O +
upon O +
NeuroD1 O +
expression O -
. O +

In O +
mice B-Species +
lacking O +
Ngn2 O -
, O +
we O +
found O +
the O +
cells O +
expressing O +
GFP O +
localized O +
to O +
the O +
malformed O +
ventral O +
blade O +
of O +
the O +
DG O +
( O -
Figure O +
5F O +
and O +
G O -
) O -
. O +

All O +
of O +
these O +
cells O +
were O +
Ki67 O -
+ O +
and O +
they O +
only O +
very O +
rarely O +
expressed O +
PH3 O +
( O -
Figure O +
5F O +
and O +
G O -
, O +
and O +
figure O +
S4C O -
) O +
in O +
the O +
absence O +
of O +
Ngn2 O +
most O +
of O +
the O +
cells O +
are O +
arrested O +
in O +
the O +
cell O +
cycle O +
prior O +
to O +
entering O +
the O +
M O +
phase O +
and O +
their O +
mitosis O +
is O +
impaired O -
. O +

These O +
data O +
suggest O +
that O +
the O +
mechanism O +
of O +
action O +
of O +
Ngn2 O +
is O +
conserved O +
from O +
development O +
of O +
the O +
DG O +
to O +
postnatal O +
hippocampal O +
neurogenesis O -
. O +

Our O +
findings O +
suggest O +
that O +
Ngn2 O +
regulates O +
amplification O +
and O +
cell O +
cycle O +
exit O +
of O +
DG O +
granule O +
progenitors O -
. O +

To O +
examine O +
this O +
hypothesis O -
, O +
we O +
compared O +
the O +
effects O +
of O +
Ngn2 O +
and O +
NeuroD1 O +
on O +
mitotic O +
activity O +
in O +
embryonic O +
cortico O -
- O -
hippocampal O +
neurosphere O -
- O -
derived O +
progenitors O -
, O +
5 O +
days O +
upon O +
transduction O -
, O +
in O +
vitro O -
. O +

In O +
cultures O +
transduced O +
with O +
Ngn2 O +
retrovirus O -
, O +
we O +
found O +
that O +
27.2 O -
% O +
( O -
±4.1 O -
% O -
) O +
of O +
the O +
PH3 O -
+ O +
cells O +
had O +
been O +
transduced O +
( O -
Figure O +
I1–J O -
) O -
. O +

These O +
cells O +
were O +
immunopositive O +
for O +
MAP2 O +
( O -
Figure O +
5I1 O +
and O +
I2 O -
) O +
and O +
therefore O +
represented O +
dividing O +
neuroblasts O -
. O +

By O +
contrast O -
, O +
in O +
NeuroD1 O +
transduced O +
cultures O -
, O +
only O +
7.3 O -
% O +
of O +
PH3 O -
+ O +
cells O +
were O +
GFP+ O +
( O -
Figure O +
5H1 O -
, O +
H2 O +
and O +
J O -
) O -
. O +

All O +
of O +
the O +
NeuroD1-transduced O +
cells O +
became O +
MAP2 O -
+ O +
( O -
Figure O +
5H O -
) O -
. O +

To O +
confirm O +
this O +
data O +
we O +
pulse O -
- O -
labeled O +
transduced O +
cultures O +
with O +
chlorodeoxyuridine O +
( O -
CldU O -
) O +
for O +
48 O +
hours O -
, O +
five O +
days O +
after O +
differentiation O -
. O +

In O +
contrast O +
to O +
NeuroD1-transduced O +
cultures O -
, O +
we O +
observed O +
dividing O +
cells O +
transduced O +
with O +
Ngn2 O +
retrovirus O +
that O +
were O +
positive O +
for O +
PH3 O +
and O +
that O +
had O +
incorporated O +
CldU O +
( O -
Figure O +
5K O -
– O -
L2 O -
) O -
. O +

As O +
the O +
number O +
of O +
cells O +
PH3+ O -
/ O -
CldU+ O -
/ O -
GFP+ O +
we O +
observed O +
was O +
low O -
, O +
we O +
did O +
not O +
quantify O +
this O +
finding O -
. O +

Collectively O -
, O +
we O +
have O +
shown O +
that O +
Ngn2 O +
is O +
required O +
for O +
granule O +
neuroblast O +
production O +
and O +
amplification O +
and O +
that O +
in O +
the O +
absence O +
of O +
Ngn2 O +
the O +
progenitors O +
arrest O +
in O +
the O +
cell O +
cycle O -
. O +

NeuroD1 O -
, O +
on O +
the O +
other O +
hand O -
, O +
induces O +
cell O +
cycle O +
exit O +
and O +
promotes O +
rapid O +
neuronal O +
maturation O -
. O +

NeuroD1 O +
directs O +
neuronal O +
differentiation O +
and O +
maturation O +
Based O +
on O +
our O +
previous O +
observations O +
we O +
proposed O +
that O +
Ngn2 O +
primarily O +
controls O +
amplification O +
of O +
granule O +
neuroblasts O +
and O +
NeuroD1 O +
directs O +
neuronal O +
differentiation O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
we O +
overexpressed O +
Ngn2 O +
or O +
NeuroD1 O +
in O +
E14.5 O +
cortico O -
- O -
hippocampal O +
neurospheres O +
and O +
compared O +
their O +
effects O +
after O +
5 O +
days O +
of O +
differentiation O +
of O +
the O +
progenitors O -
. O +

All O +
cortico O -
- O -
hippocampal O +
progenitors O +
expressed O +
Pax6 O +
prior O +
to O +
differentiation O +
( O -
Figure O +
S5 O -
) O -
. O +

After O +
5 O +
days O -
, O +
both O +
factors O +
suppressed O +
Pax6 O +
and O +
Sox2 O +
( O -
Figure O +
S5 O -
, O +
figure O +
6C O -
) O +
and O +
induced O +
expression O +
of O +
Tbr1 O -
, O +
Map2 O -
, O +
NeuroD1 O +
and O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
6D O +
and O +
E O -
) O -
. O +

Interestingly O -
, O +
all O +
Ngn2-overexpressing O +
cells O +
co O -
- O -
expressed O +
NeuroD1 O -
. O +

Based O +
on O +
these O +
findings O -
, O +
we O +
next O +
explored O +
whether O +
Ngn2 O +
overexpression O +
induces O +
NeuroD1 O +
expression O -
, O +
and O +
if O +
NeuroD1 O +
in O +
turn O +
directs O +
neuronal O +
differentiation O -
. O +

We O +
compared O +
the O +
effects O +
of O +
both O +
transcription O +
factors O +
in O +
progenitors O +
that O +
either O +
do O +
or O +
do O +
not O +
normally O +
express O +
them O -
. O +

Thus O -
, O +
we O +
expressed O +
Ngn2 O +
in O +
E14.5 O +
neural O +
progenitors O +
isolated O +
from O +
three O +
different O +
brain O +
regions O -
: O +
cortex O -
/ O -
hippocampus O -
, O +
lateral O +
ganglionic O +
eminence O +
( O -
LGE O -
) O +
and O +
ventral O +
mesencephalon O +
( O -
VM O -
) O -
. O +

Ngn2 O +
expression O +
in O +
the O +
developing O +
forebrain O +
is O +
normally O +
limited O +
to O +
the O +
neocortex O -
, O +
and O +
it O +
does O +
not O +
appear O +
in O +
LGE O +
tissue O +
[ O -
29 O -
] O -
. O +

In O +
the O +
developing O +
VM O -
, O +
both O +
Ngn2 O +
and O +
NeuroD1 O +
are O +
expressed O -
, O +
but O +
not O +
when O +
neural O +
progenitors O +
from O +
this O +
region O +
are O +
cultured O +
in O +
vitro O +
[ O -
30 O -
] O -
, O +
[ O -
31 O -
] O -
. O +

In O +
our O +
experiments O -
, O +
cortico O -
- O -
hippocampal O +
progenitors O +
could O +
differentiate O +
into O +
neurons O -
, O +
although O +
they O +
did O +
not O +
normally O +
express O +
NeuroD1 O +
( O -
Figure O +
6E O -
) O -
. O +

When O +
we O +
overexpressed O +
Ngn2 O +
in O +
VM O +
and O +
LGE O +
progenitors O -
, O +
the O +
cells O +
started O +
to O +
express O +
both O +
NeuroD1 O +
and O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
6F O +
and O +
G O -
) O -
. O +

We O +
then O +
overexpressed O +
NeuroD1 O +
in O +
the O +
same O +
types O +
of O +
cultured O +
progenitors O +
and O +
found O +
that O +
the O +
cells O +
became O +
immunoreactive O +
for O +
PSA O -
- O -
NCAM O +
( O -
Figure O +
6 O -
G O +
and O +
data O +
not O +
shown O -
) O -
. O +

Thus O -
, O +
NeuroD1 O +
is O +
sufficient O +
to O +
direct O +
neuronal O +
differentiation O +
in O +
cortico O -
- O -
hippocampal- O -
, O +
LGE- O +
and O +
VM O -
- O -
derived O +
progenitors O -
. O +

Our O +
results O +
from O +
in O +
vitro O +
cultures O +
and O +
the O +
analysis O +
of O +
the O +
DG O +
of O +
Ngn2 O +
mutant O +
animals O +
collectively O +
show O +
the O +
neuron O -
- O -
inducing O +
effect O +
of O +
NeuroD1 O +
in O +
hippocampal O +
granule O +
cell O +
progenitors O +
[ O -
32 O -
] O -
. O +

NeuroD1 O +
directs O +
exclusive O +
neuronal O +
differentiation O +
of O +
hippocampal O +
granule O +
neuron O +
progenitors O +
As O +
the O +
next O +
step O -
, O +
we O +
tested O +
the O +
effects O +
of O +
NeuroD1 O +
in O +
vivo O +
and O +
compared O +
them O +
with O +
those O +
of O +
Ngn2 O -
. O +

We O +
injected O +
retroviruses O +
carrying O +
the O +
gene O +
for O +
either O +
Ngn2 O +
[ O -
33 O -
] O +
or O +
NeuroD1 O -
, O +
and O +
the O +
reporter O +
gene O +
eGFP O +
into O +
the O +
ventricles O +
E15.5 O +
rat B-Species +
embryos O -
, O +
in O +
utero O +
( O -
Figure O +
7A O -
) O -
. O +

Three O +
weeks O +
later O -
, O +
when O +
the O +
rats B-Species +
were O +
about O +
two O +
weeks O +
old O -
, O +
we O +
examined O +
their O +
hippocampi O +
and O +
analyzed O +
the O +
eGFP+ O +
cells O -
. O +

The O +
rats B-Species +
injected O +
with O +
control O +
vector O +
exhibited O +
eGFP+ O +
cells O +
within O +
the O +
hippocampus O +
that O +
were O +
either O +
star O -
- O -
shaped O -
, O +
progenitor O -
/ O -
glial O -
- O -
like O +
cells O +
( O -
14.8±3.4 O -
% O -
) O +
or O +
neuron O -
- O -
like O +
cells O +
with O +
long O +
neurites O +
( O -
85.3±3.4 O -
% O -
) O +
( O -
Figure O +
7B O -
) O -
. O +

In O +
rats B-Species +
that O +
we O +
had O +
injected O +
with O +
the O +
vector O +
encoding O +
Ngn2 O -
, O +
the O +
eGFP O -
- O -
labeled O -
, O +
the O +
transduced O +
hippocampal O +
cells O +
were O +
composed O +
of O +
31.9 O -
% O +
( O -
±5.7 O -
% O -
) O +
progenitor O -
/ O -
glia O -
- O -
like O +
cells O +
and O +
69.4 O -
% O +
( O -
±6.1 O -
% O -
) O +
neuron O -
- O -
like O +
cells O +
( O -
Figure O +
7B O -
) O -
. O +

The O +
glia O -
- O -
like O +
subpopulation O +
was O +
immunopositive O +
for O +
the O +
astrocytic O +
marker O +
GFAP O +
( O -
Figure O +
7C O -
– O -
D O -
) O -
. O +

In O +
contrast O -
, O +
virtually O +
all O +
of O +
the O +
transduced O +
cells O +
in O +
rats B-Species +
injected O +
with O +
the O +
NeuroD1 O +
vector O +
became O +
neuron O -
- O -
like O +
cells O +
( O -
99.9%±0.1 O -
; O +
Figure O +
7B O -
) O -
. O +

None O +
of O +
these O +
cells O +
stained O +
for O +
GFAP O +
( O -
Figure O +
7E O +
and O +
F O -
) O -
. O +

They O +
were O +
positioned O +
in O +
the O +
external O +
layers O +
of O +
both O +
the O +
ventral O +
and O +
dorsal O +
blades O +
of O +
the O +
DG O +
( O -
Figure O +
7B3 O -
, O +
E O +
and O +
I O +
and O +
figure O +
S6A O -
) O -
. O +

When O +
we O +
examined O +
neuronal O +
maturation O +
of O +
Ngn2- O +
and O +
NeuroD1-transduced O +
cells O -
, O +
we O +
observed O +
that O +
only O +
a O +
few O +
of O +
those O +
transduced O +
with O +
the O +
NeuroD1 O +
vector O +
expressed O +
the O +
early O +
mature O +
neuronal O +
marker O +
Tbr1 O +
( O -
3.1±1.4 O -
% O -
; O +
Figure O +
7I O +
and O +
J O -
) O -
. O +

They O +
were O +
located O +
within O +
the O +
basal O +
layers O -
, O +
near O +
the O +
SGL O -
, O +
of O +
the O +
ventral O +
and O +
dorsal O +
blades O +
of O +
the O +
DG O -
. O +

In O +
contrast O -
, O +
a O +
greater O +
proportion O +
of O +
the O +
cells O +
transduced O +
with O +
Ngn2 O +
still O +
expressed O +
Tbr1 O +
( O -
19.6%±3.3 O -
% O -
; O +
Figure O +
7H O +
and O +
J O -
) O -
, O +
indicating O +
that O +
they O +
were O +
less O +
mature O +
than O +
the O +
vast O +
majority O +
of O +
the O +
NeuroD1-transduced O +
cells O -
. O +

Immunohistochemistry O +
for O +
NeuN O +
confirmed O +
these O +
data O +
( O -
Figure O +
7 O -
M O +
and O +
O O -
, O +
and O +
figure O +
S6A O -
) O -
. O +

Indeed O -
, O +
when O +
we O +
overexpressed O +
Ngn2 O +
the O +
proportion O +
of O +
hippocampal O +
progenitors O +
that O +
became O +
NeuN+ O +
was O +
no O +
greater O +
than O +
in O +
rats B-Species +
transduced O +
with O +
the O +
control O +
virus O +
( O -
Figure O +
7F O -
) O -
. O +

As O +
a O +
whole O -
, O +
our O +
in O +
utero O +
injection O +
experiments O +
confirm O +
that O +
NeuroD1 O +
has O +
a O +
stronger O +
neuron O -
- O -
inducing O +
effect O +
than O +
Ngn2 O +
when O +
overexpressed O +
in O +
hippocampal O +
progenitors O -
. O +

Involvement O +
of O +
Mash1 O -
, O +
Ngn2 O -
, O +
Tbr O +
and O +
NeuroD O +
proteins O +
during O +
human B-Species +
hippocampal O +
neurogenesis O +
Finally O -
, O +
we O +
examined O +
whether O +
the O +
transcription O +
factors O +
and O +
cellular O +
markers O +
that O +
are O +
expressed O +
in O +
rodents O +
are O +
also O +
expressed O +
in O +
human B-Species +
hippocampus O -
. O +

We O +
performed O +
immunohistochemistry O +
on O +
aged O +
human B-Species +
hippocampal O +
DG O +
and O +
found O +
GFAP- O -
, O +
Sox2- O -
, O +
Pax6- O -
, O +
Nestin- O -
, O +
Prox1- O +
and O +
NeuN O -
- O -
immunopositive O +
cells O -
. O +

This O +
indicates O +
that O +
radial O +
glia O -
- O -
like O +
stem O +
cells O -
, O +
neural O +
progenitors O +
and O +
mature O +
granule O +
neurons O +
are O +
present O +
in O +
the O +
aged O +
human B-Species +
hippocampus O +
( O -
Figure O +
8A O -
– O -
E O -
) O -
. O +

While O +
Prox1 O +
is O +
found O +
mainly O +
in O +
granule O +
neurons O -
, O +
Sox2 O +
and O +
Pax6 O +
are O +
exclusively O +
localized O +
to O +
cells O +
in O +
the O +
SGZ O +
( O -
Figure O +
8D O +
and O +
E O -
) O -
. O +

As O +
for O +
aged O +
rodents O -
, O +
we O +
did O +
not O +
observe O +
the O +
presence O +
of O +
Mash1 O -
, O +
Ngn2 O -
, O +
Tbr2 O -
, O +
Tbr1 O +
and O +
NeuroD1 O +
proteins O +
in O +
aged O +
human B-Species +
hippocampus O -
, O +
using O +
immunohistochemistry O -
. O +

However O -
, O +
we O +
could O +
identify O +
the O +
presence O +
of O +
the O +
transcripts O -
, O +
using O +
RT O -
- O -
PCR O +
( O -
Figure O +
8F O -
) O -
. O +

In O +
addition O -
, O +
we O +
detected O +
mRNA O +
for O +
Prox1 O -
, O +
Calbindin1 O +
and O +
Calbindin2 O -
/ O -
Calretinin O +
( O -
Figure O +
8F O -
) O -
. O +

Interestingly O -
, O +
we O +
also O +
observed O +
Sonic O +
Hedgehog O +
and O +
Wnt-3A O +
transcripts O -
, O +
indicating O +
that O +
they O +
are O +
present O +
in O +
the O +
human B-Species +
DG O +
and O +
supporting O +
previous O +
claims O +
that O +
they O +
are O +
important O +
for O +
the O +
regulation O +
of O +
adult O +
hippocampal O +
neurogenesis O +
( O -
Figure O +
8F O -
; O +
[ O -
34 O -
] O -
, O +
[ O -
35 O -
] O -
) O -
. O +

Finally O -
, O +
we O +
also O +
found O +
mRNA O +
for O +
GLAST O -
, O +
Pax6 O +
and O +
GFAP O +
which O +
suggests O +
that O +
radial O +
glia O -
- O -
like O +
stem O +
cells O +
are O +
present O +
in O +
the O +
adult O +
human B-Species +
hippocampus O -
, O +
and O +
may O +
play O +
a O +
role O +
in O +
adult O +
human B-Species +
hippocampal O +
neurogenesis O +
( O -
Figure O +
8F O -
; O +
[ O -
8 O -
] O -
) O -
. O +

Overall O -
, O +
our O +
data O +
show O +
that O +
different O +
proteins O +
known O +
to O +
play O +
key O +
roles O +
in O +
rodent B-Species +
hippocampal O +
granule O +
neurogenesis O +
are O +
present O +
in O +
the O +
adult O +
human B-Species +
hippocampus O -
. O +

Discussion O +
In O +
this O +
study O +
we O +
determine O +
the O +
functions O +
of O +
Ngn2 O +
and O +
NeuroD1 O +
during O +
hippocampal O +
neurogenesis O -
. O +

First O -
, O +
we O +
map O +
the O +
hierarchy O +
of O +
molecular O +
markers O +
of O +
neurogenesis O +
in O +
the O +
DG O -
. O +

Second O -
, O +
we O +
describe O +
that O +
Ngn2 O +
is O +
necessary O +
for O +
granule O +
progenitor O +
production O -
/ O -
amplification O -
. O +

Third O -
, O +
we O +
demonstrate O +
that O +
NeuroD1 O +
directs O +
neuronal O +
differentiation O +
of O +
granule O +
progenitors O -
. O +

Finally O -
, O +
we O +
show O +
that O +
different O +
cellular O +
markers O +
expressed O +
during O +
hippocampal O +
neurogenesis O +
in O +
rodents O +
are O +
present O +
in O +
human B-Species -
. O +

Sequential O +
expression O +
of O +
different O +
transcription O +
factors O +
and O +
cellular O +
markers O +
during O +
hippocampal O +
neurogenesis O +
We O +
clarified O +
the O +
pattern O +
of O +
expression O +
of O +
various O +
markers O +
expressed O +
during O +
postnatal O +
and O +
adult O +
hippocampal O +
granule O +
neurogenesis O +
in O +
detail O -
. O +

We O +
found O +
that O +
the O +
transcription O +
factor O +
Pax6 O +
is O +
initially O +
expressed O +
by O +
both O +
radial O +
glia O +
stem O +
cells O +
( O -
type-1 O -
) O +
and O +
early O +
amplifying O +
progenitors O +
( O -
type-2a O -
) O -
. O +

The O +
next O +
transcription O +
factor O +
to O +
appear O +
in O +
chronology O +
is O +
Mash1 O -
. O +

Mash1 O +
expression O +
characterizes O +
the O +
early O +
stage O +
of O +
hippocampal O +
progenitor O +
amplification O +
( O -
early O +
type-2a O -
) O -
. O +

The O +
role O +
of O +
Mash1 O +
during O +
hippocampal O +
granule O +
neurogenesis O +
is O +
still O +
unclear O -
. O +

Mash1 O +
null O +
mutant O +
mice B-Species +
do O +
not O +
display O +
any O +
clear O +
malformation O +
of O +
the O +
DG O +
[ O -
20 O -
] O -
. O +

However O -
, O +
overexpression O +
of O +
Mash1 O +
alone O +
in O +
the O +
DG O +
leads O +
to O +
the O +
generation O +
of O +
oligodendrocytes O +
[ O -
36 O -
] O -
. O +

Based O +
on O +
these O +
observations O -
, O +
we O +
hypothesize O +
that O +
Mash1-expressing O +
cells O +
are O +
not O +
yet O +
committed O +
towards O +
a O +
granule O +
cell O +
fate O -
. O +

They O +
may O +
still O +
have O +
the O +
potential O +
to O +
generate O +
both O +
neurons O +
and O +
oligodendrocytes O -
, O +
as O +
is O +
the O +
case O +
in O +
the O +
SVZ O +
[ O -
37 O -
] O -
. O +

In O +
agreement O +
with O +
different O +
developing O +
brain O +
regions O -
, O +
we O +
found O +
that O +
Ngn2 O +
starts O +
to O +
be O +
expressed O +
in O +
Mash1-positive O +
transiently O +
amplifying O +
progenitors O -
, O +
i.e. O +
" O -
late O +
type-2a O +
cells O -
" O +
according O +
to O +
the O +
classification O +
we O +
propose O -
. O +

We O +
observed O +
that O +
Pax6 O +
expression O +
persisted O +
longer O +
than O +
that O +
of O +
Mash1 O -
, O +
in O +
Ngn2-expressing O +
cells O +
( O -
late O +
type-2a O +
cells O -
) O -
, O +
in O +
juvenile O +
but O +
not O +
adult O +
DG O +
( O -
Fig. O +
1 O +
and O +
figure O +
S1 O -
) O -
. O +

Later O +
on O -
, O +
Ngn2 O +
is O +
downregulated O -
, O +
whilst O +
Tbr2 O +
expression O +
persists O +
( O -
type-2b O +
cells O -
) O -
. O +

The O +
transition O +
from O +
amplifying O +
progenitor O +
to O +
neuroblast O +
is O +
defined O +
by O +
the O +
expression O +
of O +
NeuroD1 O -
. O +

Thus O -
, O +
Ngn2 O +
is O +
expressed O +
at O +
the O +
beginning O +
of O +
the O +
transiently O +
amplifying O +
progenitor O +
phase O +
while O +
NeuroD1 O +
marks O +
the O +
end O +
of O +
that O +
period O -
. O +

This O +
applies O +
both O +
to O +
the O +
juvenile O +
and O +
adult O +
rat B-Species +
brain O +
[ O -
21 O -
] O -
, O +
[ O -
25 O -
] O -
. O +

After O +
NeuroD1 O +
is O +
turned O +
on O +
the O +
progenitors O +
leave O +
the O +
cell O +
cycle O -
, O +
gradually O +
mature O -
, O +
express O +
PSA O -
- O -
NCAM O -
, O +
NeuroD2 O -
, O +
Calretinin O -
, O +
Prox1 O -
, O +
Tbr1 O +
and O -
, O +
finally O -
, O +
NeuN. O +
NeuroD1 O +
expression O +
persists O +
at O +
low O +
levels O +
in O +
mature O +
neurons O +
( O -
Figure O +
9 O -
; O +
[ O -
10 O -
] O -
) O -
. O +

We O +
found O +
the O +
sequential O +
expression O +
of O +
these O +
markers O +
conserved O +
in O +
juvenile O +
( O -
P2 O +
and O +
2 O +
weeks O -
) O +
and O +
adult O +
rodent B-Species +
brains O -
. O +

Importantly O -
, O +
we O +
observed O +
that O +
the O +
same O +
transcription O +
factors O +
and O +
neuronal O +
markers O +
are O +
also O +
present O +
in O +
the O +
adult O +
human B-Species +
hippocampus O +
and O +
arranged O +
spatially O +
in O +
a O +
manner O +
reminiscent O +
with O +
what O +
we O +
saw O +
in O +
rodents O -
. O +

It O +
is O +
possible O -
, O +
however O -
, O +
that O +
some O +
of O +
these O +
markers O +
are O +
expressed O +
for O +
longer O +
or O +
shorter O +
periods O +
at O +
postnatal O +
and O +
adult O +
stages O +
of O +
hippocampal O +
progenitor O +
maturation O -
. O +

Moreover O -
, O +
one O +
can O +
ask O +
to O +
which O +
extent O +
the O +
number O +
of O +
divisions O +
occurring O +
during O +
neuroblasts O +
maturation O +
is O +
conserved O +
at O +
postnatal O +
and O +
adult O +
stages O +
of O +
neurogenesis O -
. O +

A O +
new O +
function O +
for O +
Ngn2 O +
in O +
maintenance O +
of O +
a O +
progenitor O +
state O +
for O +
granule O +
neuron O +
production O -
/ O -
amplification O +
during O +
embryonic O +
and O +
postnatal O +
hippocampal O +
neurogenesis O +
In O +
agreement O +
with O +
earlier O +
work O -
, O +
we O +
confirm O +
that O +
Ngn2 O +
is O +
indispensable O +
for O +
hippocampal O +
development O +
and O +
plays O +
a O +
vital O +
role O +
in O +
postnatal O +
hippocampal O +
granule O +
neurogenesis O -
. O +

Ngn2 O +
null O +
mutant O +
animals O +
display O +
a O +
reduced O +
size O +
of O +
the O +
cornu O +
ammonis O +
and O +
a O +
malformed O +
DG O +
( O -
Figure O +
3 O +
and O +
4 O -
; O +
[ O -
20 O -
] O -
) O -
. O +

We O +
show O +
that O +
the O +
number O +
of O +
newborn O +
neurons O +
( O -
incorporated O +
BrdU O -
) O +
is O +
decreased O +
in O +
absence O +
of O +
Ngn2 O -
, O +
but O +
hippocampal O +
granule O +
neuron O +
subtype O +
specification O +
is O +
not O +
affected O -
, O +
post O -
- O -
nataly O -
. O +

Likewise O -
, O +
neurons O +
from O +
other O +
brain O +
regions O -
, O +
e.g. O +
ventral O +
midbrain O +
dopamine O +
neurons O -
, O +
can O +
be O +
generated O +
in O +
the O +
absence O +
of O +
Ngn2 O +
[ O -
30 O -
] O -
, O +
[ O -
31 O -
] O -
. O +

The O +
reduced O +
numbers O +
of O +
mature O +
neurons O +
in O +
the O +
hippocampus O +
and O +
ventral O +
midbrain O +
of O +
Ngn2 O +
null O +
mutant O +
animals O +
does O +
not O +
appear O +
to O +
be O +
due O +
to O +
cell O +
death O +
or O +
migration O +
defects O +
[ O -
20 O -
] O -
, O +
[ O -
31 O -
] O -
. O +

Instead O +
it O +
may O +
be O +
due O +
to O +
a O +
defect O +
in O +
the O +
generation O +
and/or O +
amplification O +
of O +
neuronal O +
progenitors O -
. O +

Indeed O -
, O +
in O +
the O +
hippocampus O +
of O +
postnatal O +
animals O -
, O +
we O +
observed O +
that O +
cells O +
lacking O +
Ngn2 O +
arrest O +
in O +
the O +
cell O +
cycle O -
, O +
maintain O +
Pax6 O +
expression O +
and O +
cease O +
to O +
proliferate O -
. O +

When O +
overexpressed O +
in O +
neural O +
progenitors O +
in O +
vitro O -
, O +
Ngn2 O +
lead O +
to O +
up O -
- O -
regulation O +
of O +
NeuroD1 O +
and O +
caused O +
neuronal O +
differentiation O +
( O -
Figure O +
6 O -
) O -
, O +
which O +
was O +
not O +
always O +
the O +
case O +
when O +
we O +
overexpressed O +
the O +
same O +
factor O +
in O +
vivo O +
( O -
Figure O +
7L O -
, O +
N O +
and O +
O O -
) O -
. O +

We O +
also O +
saw O +
that O +
Ngn2 O +
does O +
not O +
always O +
efficiently O +
induce O +
cell O +
cycle O +
exit O -
. O +

Typically O +
some O +
mitotically O +
active O +
eGFP+ O +
cells O +
were O +
present O +
in O +
the O +
DG O +
of O +
rats B-Species +
injected O +
with O +
the O +
Ngn2 O +
retrovirus O +
( O -
Figure O +
7P O -
) O -
, O +
and O +
we O +
observed O +
that O +
cultured O +
Ngn2-transduced O +
cells O +
are O +
still O +
capable O +
of O +
dividing O -
. O +

Thus O -
, O +
Ngn2 O +
does O +
not O +
always O +
promote O +
cell O +
cycle O +
exit O +
and O +
neuronal O +
commitment O -
, O +
but O +
depending O +
on O +
the O +
state O +
of O +
the O +
cells O -
, O +
Ngn2 O +
may O +
instead O +
promote O +
alternate O +
cellular O +
fates O +
[ O -
38 O -
] O -
– O -
[ O -
40 O -
] O -
. O +

Indeed O -
, O +
an O +
earlier O +
study O +
has O +
shown O +
that O +
Ngn2-overexpressing O +
progenitors O +
generate O +
oligodendrocytes O +
when O +
grafted O +
to O +
the O +
adult O +
spinal O +
cord O +
[ O -
40 O -
] O -
. O +

We O +
have O +
also O +
seen O +
that O +
Ngn2-overexpressing O +
neural O +
progenitors O +
from O +
the O +
embryonic O +
midbrain O +
form O +
astrocytes O +
when O +
grafted O +
to O +
the O +
striatum O +
( O -
unpublished O +
observations O -
) O -
. O +

Probably O -
, O +
Ngn2 O +
can O -
not O +
influence O +
already O +
committed O +
cells O -
, O +
but O +
rather O +
would O +
control O +
neuroblasts O +
production O -
. O +

One O +
could O +
speculate O +
that O +
Ngn2 O +
oscillates O +
during O +
granule O +
neuron O +
formation O -
, O +
as O +
recently O +
demonstrated O +
during O +
neocorticogenesis O +
[ O -
41 O -
] O -
, O +
[ O -
42 O -
] O -
. O +

NeuroD1 O -
, O +
but O +
not O +
Ngn2 O -
, O +
is O +
obligatory O +
for O +
granule O +
neuron O +
progenitor O +
differentiation O +
Hippocampal O +
granule O +
progenitors O +
can O +
mature O +
and O +
express O +
Tbr1 O +
and O +
Prox1 O -
, O +
both O +
during O +
the O +
development O +
and O +
postnatally O -
, O +
even O +
in O +
the O +
absence O +
of O +
Ngn2 O -
. O +

Because O +
neuronal O +
differentiation O +
still O +
occurs O +
in O +
Ngn2 O +
null O +
mice B-Species -
, O +
it O +
is O +
clear O +
that O +
compensatory O -
, O +
Ngn2-independent O +
mechanisms O +
induce O +
NeuroD1 O +
expression O -
. O +

One O +
candidate O +
is O +
Ngn1 O -
, O +
which O +
is O +
expressed O +
during O +
neocorticogenesis O -
, O +
the O +
specification O +
of O +
olfactory O +
sensory O +
neurons O +
and O +
during O +
embryonic O +
rat B-Species +
hippocampal O +
development O +
[ O -
43 O -
] O -
– O -
[ O -
47 O -
] O -
. O +

Both O +
Ngn1 O +
and O +
Ngn2 O +
regulate O +
NeuroD1 O +
[ O -
19 O -
] O -
, O +
[ O -
48 O -
] O -
. O +

The O +
introduction O +
of O +
two O +
mutant O +
forms O +
of O +
Ngn1 O -
, O +
a O +
deletion O +
of O +
the O +
basic O +
region O +
of O +
Ngn1 O +
and O +
a O +
substitution O +
of O +
two O +
amino O +
acids O +
in O +
the O +
C O -
- O -
terminal O +
basic O +
region O -
, O +
prevents O +
NeuroD1 O +
expression O +
and O +
neuronal O +
differentiation O +
[ O -
48 O -
] O -
. O +

The O +
double O +
null O +
Ngn1 O -
/ O -
Ngn2 O +
mutant O +
displays O +
a O +
more O +
severe O +
phenotype O +
than O +
single O +
gene O +
( O -
Ngn1 O +
or O +
Ngn2 O -
) O +
mutant O +
mice B-Species -
. O +

For O +
example O -
, O +
the O +
total O +
brain O +
size O +
of O +
the O +
double O +
mutants O +
is O +
much O +
smaller O +
[ O -
10 O -
] O -
, O +
[ O -
32 O -
] O -
. O +

If O +
the O +
role O +
of O +
Ngn1 O +
during O +
hippocampal O +
neurogenesis O +
is O +
to O +
activate O +
NeuroD1 O +
and O +
that O +
of O +
Ngn2 O +
is O +
to O +
control O +
granule O +
neuroblasts O +
production O -
/ O -
amplification O -
, O +
the O +
DG O +
of O +
double O +
Ngn1 O -
/ O -
Ngn2 O +
knockout O +
mice B-Species +
should O +
resemble O +
that O +
of O +
NeuroD1 O +
null O +
mutant O +
mice B-Species -
. O +

We O +
demonstrated O +
that O +
NeuroD1 O +
directs O +
neuronal O +
differentiation O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

In O +
progenitors O +
isolated O +
from O +
different O +
embryonic O +
brain O +
regions O +
and O +
cultured O +
in O +
vitro O -
, O +
we O +
found O +
that O +
overexpression O +
of O +
NeuroD1 O +
induced O +
neuronal O +
differentiation O -
. O +

The O +
neurons O +
generated O +
expressed O +
PSA O -
- O -
NCAM O -
, O +
Dcx O +
and O +
MAP2 O -
. O +

After O +
in O +
utero O +
retroviral O +
vector O -
- O -
mediated O +
gene O +
delivery O -
, O +
virtually O +
all O +
cells O +
transduced O +
with O +
NeuroD1 O +
became O +
neurons O -
. O +

In O +
contrast O -
, O +
progenitors O +
transduced O +
with O +
Ngn2 O +
or O +
control O +
retroviruses O +
adopted O +
a O +
neuron O -
- O -
like O +
morphology O +
in O +
only O +
70–85 O -
% O +
of O +
cases O -
. O +

Under O +
in O +
vitro O +
cell O +
culture O +
conditions O -
, O +
when O +
we O +
overexpressed O +
Ngn2 O +
in O +
progenitors O +
derived O +
from O +
the O +
LGE O +
we O +
observed O +
robust O +
expression O +
of O +
NeuroD1 O +
and O +
neuronal O +
differentiation O -
. O +

These O +
in O +
vitro O +
results O +
differ O +
from O +
those O +
we O +
obtained O +
when O +
we O +
transduced O +
the O +
embryonic O +
brain O +
with O +
a O +
viral O +
vector O +
expressing O +
Ngn2 O -
. O +

In O +
this O +
latter O +
case O -
, O +
Ngn2 O +
did O +
not O +
induce O +
neurons O +
and O +
the O +
transduced O +
cells O +
did O +
not O +
express O +
NeuroD1 O -
. O +

Therefore O -
, O +
Ngn2 O +
appears O +
to O +
direct O +
non O -
- O -
neuronal O +
cell O +
type O +
specification O +
in O +
vivo O +
[ O -
38 O -
] O -
– O -
[ O -
40 O -
] O -
. O +

Taken O +
together O -
, O +
we O +
have O +
confirmed O +
that O +
NeuroD1 O +
plays O +
a O +
key O +
role O +
in O +
neuronal O +
differentiation O +
in O +
the O +
hippocampus O -
, O +
both O +
during O +
development O +
and O +
in O +
the O +
adult O +
brain O -
. O +

Concluding O +
remark O +
We O +
present O +
a O +
detailed O +
classification O +
of O +
different O +
stages O +
in O +
hippocampal O +
neurogenesis O -
. O +

Our O +
detailed O +
molecular O +
mapping O +
of O +
hippocampal O +
neurogenesis O +
allows O +
for O +
a O +
more O +
accurate O +
analysis O +
of O +
how O +
new O +
factors O +
stimulate O +
neurogenesis O +
at O +
different O +
steps O +
in O +
the O +
development O +
of O +
granule O +
neurons O -
. O +

Thereby O +
we O +
hope O +
to O +
facilitate O +
the O +
development O +
of O +
new O +
agents O -
, O +
which O +
stimulate O +
endogenous O +
progenitors O +
in O +
the O +
treatment O +
of O +
diseases O -
. O +

Materials O +
and O +
Methods O +
Animal O +
tissue O +
preparation O +
The O +
creation O +
of O +
the O +
Ngn2 O +
transgenic O +
mice B-Species +
was O +
reported O +
elsewhere O +
( O -
ref O +
guillemot O -
) O -
. O +

Heterozygote O +
male O +
and O +
female O +
mice B-Species +
were O +
crossed O +
to O +
obtain O +
WT O -
, O +
heterozygote O +
( O -
Ngn2+ O -
/ O -
GFP O -
) O +
and O +
null O +
mutant O +
( O -
Ngn2GFP O -
/ O -
GFP O -
) O +
animals O -
. O +

Tails O +
of O +
the O +
Ngn2 O +
offspring O +
were O +
used O +
to O +
obtain O +
DNA O +
for O +
determination O +
of O +
the O +
genotype O +
using O +
a O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
assay O +
as O +
previously O +
reported O +
[ O -
31 O -
] O -
. O +

As O +
null O +
mutant O +
Ngn2GFP O -
/ O -
GFP O +
do O +
not O +
survive O +
longer O +
than O +
2.5–3 O +
weeks O +
after O +
birth O -
, O +
Ngn2GFP O -
/ O -
GFP O +
and O +
their O +
littermates O +
were O +
sacrificed O +
at O +
the O +
postnatal O +
ages O +
of O +
two O +
days O +
( O -
P2 O -
) O +
or O +
two O +
weeks O +
for O +
this O +
study O -
. O +

Neurogenesis O +
was O +
assessed O +
in O +
two O +
weeks O +
or O +
two O +
months O +
old O +
WT O +
mice B-Species -
. O +

Sprague O +
Dawley O +
pregnant O +
rats B-Species +
were O +
ordered O +
from O +
B&K O +
Universal O +
Ltd O -
, O +
Sollentuna O -
, O +
Sweden O +
( O -
hppt://www.bku.com O -
) O -
. O +

All O +
animals O +
were O +
housed O +
in O +
groups O +
with O +
ad O +
libitum O +
access O +
to O +
food O +
and O +
water O +
at O +
a O +
12-h O +
light O -
/ O -
dark O +
cycle O -
. O +

All O +
experimental O +
procedures O +
conducted O +
in O +
this O +
study O +
had O +
been O +
approved O +
by O +
the O +
Ethical O +
Committee O +
at O +
Lund O +
University O -
. O +

For O +
immunohistochemical O +
analysis O -
, O +
mice B-Species +
( O -
from O +
two O +
weeks O +
old O +
and O +
adult O +
stage O -
) O +
and O +
juvenile O +
rats B-Species +
were O +
sacrificed O +
by O +
transcardial O +
perfusion O +
with O +
saline O +
for O +
5–10 O +
minutes O -
, O +
followed O +
by O +
4 O -
% O +
paraformaldehyde O +
( O -
PFA O -
) O +
for O +
10 O +
minutes O -
. O +

Brains O +
were O +
kept O +
in O +
PFA O +
overnight O +
at O +
4 O -
° O -
C O +
and O +
subsequently O +
cryopreserved O +
in O +
a O +
20–30 O -
% O +
sucrose O -
/ O -
0.1 O +
M O +
phosphate O +
buffer O +
solution O +
until O +
sectioning O +
on O +
a O +
microtome O +
apparatus O +
( O -
30 O +
µm O +
thickness O +
sections O -
, O +
Microm O +
Zeiss O -
) O -
. O +

Seven O +
series O +
of O +
coronal O +
sections O +
were O +
cut O +
throughout O +
the O +
brain O -
. O +

Free O -
- O -
floating O +
sections O +
were O +
preserved O +
in O +
antifreeze O +
solution O +
until O +
immunohistochemistry O +
was O +
performed O -
. O +

Heads O +
of O +
postanatal O +
two O +
days O +
old O +
mice B-Species +
were O +
decapitated O +
and O +
soaked O +
in O +
PFA O +
4 O -
% O +
for O +
24 O +
hours O -
, O +
at O +
4 O -
° O -
C O +
and O +
transferred O +
into O +
sucrose O +
solution O +
until O +
sectioning O +
on O +
cryostat O +
apparatus O +
( O -
16 O +
µm O +
thickness O -
; O +
Leica O +
CM3000 O -
) O -
. O +

Sections O +
were O +
mounted O +
on O +
Superfrost O +
glass O +
slides O +
and O +
stored O +
at O +
−80 O -
° O -
C O +
until O +
immunohistochemistry O +
was O +
performed O -
. O +

Cloning O -
, O +
subcloning O -
, O +
virus O +
production O +
and O +
titer O +
measurement O +
The O +
Moloney O +
leukemia O -
- O -
derived O +
retroviral O +
vectors O +
used O +
in O +
this O +
study O -
, O +
pCMMP O -
- O -
IRES2eGFP O -
- O -
WPRE O +
and O +
pCMMP O -
- O -
Ngn2-IRES2eGFP O -
- O -
WPRE O +
were O +
previously O +
described O +
[ O -
40 O -
] O -
, O +
[ O -
49 O -
] O -
. O +

To O +
generate O +
the O +
construct O +
pCMMP O -
- O -
NeuroD1-IRES2eGFP O -
- O -
WPRE O -
, O +
mouse B-Species +
NeuroD1 O +
cDNA O +
was O +
amplified O +
from O +
a O +
pCS2+mtNeuroD1 O +
plasmid O +
( O -
kindly O +
provided O +
by O +
Professor O +
Jackie O +
Lee O -
, O +
Denver O +
university O -
, O +
Boulder O -
, O +
USA O -
) O +
by O +
PCR O +
to O +
introduce O +
the O +
restriction O +
sites O +
PmeI O +
in O +
5′ O +
and O +
XhoI O +
in O +
3′. O +
Amplification O +
of O +
cDNA O +
was O +
performed O +
as O +
previously O +
described O +
[ O -
49 O -
] O -
. O +

The O +
construction O +
was O +
verified O +
by O +
enzymatic O +
restriction O +
and O +
by O +
DNA O +
sequencing O +
using O +
BigDye O +
3.1 O +
( O -
ABI O -
) O -
. O +

All O +
infectious O +
particles O +
were O +
produced O +
using O +
the O +
producer O +
cell O +
line O +
293VSV O -
- O -
G O +
and O +
as O +
previously O +
described O +
[ O -
49 O -
] O -
. O +

The O +
titer O +
of O +
each O +
retrovirus O +
was O +
measured O +
by O +
flow O -
- O -
cytometry O +
based O +
on O +
eGFP O +
expression O -
, O +
four O +
days O +
following O +
infection O +
of O +
HT1080 O +
cells O +
and O +
ranged O +
from O +
0.5 O -
× O -
109−2.1 O -
× O -
109 O +
TU O -
/ O -
ml O +
( O -
All O +
details O +
on O +
how O +
to O +
produce O +
infectious O +
particles O +
can O +
be O +
provided O +
upon O +
request O -
) O -
. O +

Neurosphere O +
generation O -
, O +
transduction O +
and O +
differentiation O +
Pregnant O +
female O +
Sprague B-Species -
- I-Species -
Dawley I-Species +
rats I-Species +
( O -
B O +
& O +
K O +
Universal O -
, O +
Sollentuna O -
, O +
Sweden O -
) O +
were O +
terminally O +
anesthetized O +
by O +
an O +
overdose O +
of O +
sodium O +
pentobarbital O +
( O -
i.p O -
. O -
, O +
60 O +
ng O -
/ O -
ml O -
) O -
. O +

Embryos O +
at O +
stage O +
embryonic O +
day O +
E14.5 O +
( O -
Plug O +
day O +
as O +
day O +
0 O -
) O +
were O +
collected O +
and O +
cortical O -
- O -
hippocampal O +
neurospheres O +
were O +
generated O +
following O +
dissection O +
of O +
the O +
dorso O -
- O -
posterior O +
part O +
of O +
the O +
cortical O +
tissue O -
, O +
and O +
generated O +
as O +
previously O +
described O +
[ O -
49 O -
] O -
. O +

In O +
this O +
study O -
, O +
second O +
passage O +
( O -
P2 O -
) O +
neurospheres O +
were O +
used O +
to O +
study O +
the O +
effect O +
of O +
the O +
overexpression O +
of O +
Ngn2 O +
and O +
NeuroD1 O +
on O +
neuronal O +
differentiation O -
. O +

Each O +
well O -
, O +
containing O +
an O +
equal O +
starting O +
population O +
of O +
200,000 O +
cells O -
/ O -
ml O -
, O +
corresponding O +
to O +
15–25 O +
neurospheres O -
, O +
was O +
transduced O +
independently O +
with O +
each O +
retrovirus O +
at O +
a O +
multiplicity O +
of O +
infection O +
( O -
MOI O -
) O +
of O +
1 O -
, O +
in O +
proliferation O +
medium O +
supplemented O +
by O +
protamine O -
- O -
sulfate O +
( O -
4 O +
mg O -
/ O -
ml O -
, O +
Sigma O -
) O -
. O +

To O +
induce O +
differentiation O -
, O +
the O +
medium O +
was O +
replaced O +
with O +
normal O +
basic O +
differentiation O +
medium O +
two O +
days O +
post O -
- O -
transduction O +
and O +
subsequently O +
changed O +
every O +
other O +
day O +
until O +
fixation O -
. O +

Immunocytochemistry O -
, O +
immunohistochemistry O +
and O +
microscopy O +
The O +
antibodies O +
used O +
in O +
this O +
study O +
are O -
: O +
rabbit B-Species +
anti O -
- O -
GFAP O +
( O -
1∶1000 O -
; O +
DAKO O -
) O -
, O +
mouse B-Species +
anti O -
- O -
Nestin O +
( O -
1∶100 O -
; O +
BD O +
PharMingen O -
) O -
, O +
guinea B-Species +
pig I-Species +
anti O -
- O -
Glast O +
( O -
1∶500 O -
; O +
Chemicon O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Prox1 O +
( O -
1∶1000 O -
; O +
Covance O -
) O -
, O +
goat B-Species +
anti O -
- O -
Ngn2 O +
( O -
1∶20 O -
; O +
Santa O +
Cruz O -
) O -
, O +
goat B-Species +
anti O -
- O -
NeuroD1 O +
( O -
1∶200 O -
; O +
Santa O +
Cruz O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Pax6 O +
( O -
1∶150 O -
; O +
Covance O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Trb2 O +
( O -
1∶500 O -
; O +
Chemicon O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Trb1 O -
: O +
( O -
1∶1000 O -
; O +
Chemicon O -
) O -
, O +
goat B-Species +
anti O -
- O -
Dcx O -
: O +
( O -
1∶500 O -
; O +
Santa O +
Cruz O -
) O -
, O +
mouse B-Species +
anti O -
- O -
PSA O -
- O -
NCAM O -
: O +
( O -
1∶500 O -
; O +
Chemicon O -
) O -
, O +
mouse B-Species +
anti O -
- O -
NeuN O +
( O -
1∶300 O -
; O +
Chemicon O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Calretinin O +
( O -
1∶500 O -
; O +
Swant O -
) O -
; O +
mouse B-Species +
anti O -
- O -
Sox2 O +
( O -
1∶100 O -
; O +
R&D O +
systems O -
) O -
, O +
mouse B-Species +
anti O -
- O -
Mash1 O +
( O -
1∶100 O -
; O +
BD O +
PharMingen O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
NeuroD2 O +
( O -
1∶300 O -
; O +
ABCAM O -
) O -
, O +
mouse B-Species +
anti O -
- O -
MAP2 O +
( O -
1∶500 O -
; O +
Sigma O -
) O -
, O +
rabbit B-Species +
anti O -
- O -
Ki67 O +
( O -
1∶150 O -
; O +
NovaCastra O -
) O +
and O +
rabbit B-Species +
anti O -
- O -
phospho O -
- O -
Histone O +
H3 O -
. O +

The O +
secondary O +
antibodies O +
( O -
1∶200 O -
) O +
Cy2 O -
, O +
FITC O -
, O +
Cy3 O +
and O +
Cy5 O +
were O +
from O +
Jackson O +
IR O +
laboratories O -
, O +
Alexa O -
- O -
fluor O +
488 O -
, O +
568 O -
, O +
595 O +
and O +
647 O +
from O +
Invitrogen O -
- O -
Molecular O +
Probes O -
. O +

DAPI O +
( O -
1∶1000 O -
) O +
was O +
purchased O +
from O +
Sigma O -
. O +

For O +
immunocytochemistry O -
, O +
cultures O +
were O +
fixed O +
in O +
4 O -
% O +
paraformaldehyde O +
at O +
day O +
five O -
, O +
rinsed O +
with O +
PBS O +
three O +
times O +
prior O +
to O +
pre O -
- O -
incubation O +
with O +
a O +
blocking O +
solution O +
( O -
10 O -
% O +
donkey B-Species +
serum O -
, O +
0.25 O -
% O +
TritonX100 O +
in O +
PBS O -
) O +
for O +
1 O +
hour O -
. O +

The O +
remainder O +
of O +
the O +
procedure O +
was O +
performed O +
as O +
previously O +
described O +
[ O -
49 O -
] O -
. O +

Specimen O +
analyses O +
were O +
performed O +
using O +
a O +
Leica O +
confocal O +
microscope O +
( O -
Leica O +
software O -
, O +
equipped O +
with O +
a O +
GreNe O +
and O +
a O +
HeNe O +
laser O -
, O +
using O +
the O +
following O +
lines O +
of O +
excitation O -
: O +
488 O +
nm O -
, O +
594 O +
nm O +
and O +
647 O +
nm O -
) O -
. O +

Samples O +
were O +
analyzed O +
using O +
20 O -
× O -
, O +
40 O -
× O +
and O +
63 O -
× O +
objectives O -
, O +
sometimes O +
zoomed O -
. O +

Figures O +
were O +
composed O +
in O +
CANVAS O -
- O -
X O +
software O -
. O +

Bromo O -
- O -
deoxyuridine O +
( O -
BrdU O -
) O +
and O +
Cloro O -
- O -
deoxyuridine O +
( O -
CldU O -
) O +
pulse O +
labeling O +
and O +
immunohisto- O +
and O +
immunocyto O -
- O -
chemistry O +
To O +
assess O +
cell O +
proliferation O +
and O +
ongoing O +
neurogenesis O +
in O +
vivo O -
, O +
animals O +
were O +
injected O +
with O +
BrdU O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
Sigma O -
) O -
, O +
two O +
hours O +
prior O +
to O +
sacrifice O +
( O -
for O +
both O +
P2 O +
and O +
two O +
weeks O +
old O +
Ngn2 O +
mice B-Species -
) O -
. O +

To O +
assess O +
neurogenesis O -
, O +
BrdU O +
( O -
100 O +
mg O -
/ O -
kg O -
) O +
was O +
injected O +
48 O +
hours O +
prior O +
to O +
sacrifice O +
( O -
for O +
P2 O +
animals O -
, O +
BrdU O +
was O +
injected O +
in O +
pregnant O +
dams O +
half O +
day O +
prior O +
to O +
give O +
birth O -
) O -
. O +

Immunohistochemistry O +
was O +
carried O +
on O +
as O +
described O +
above O +
using O +
a O +
rat B-Species +
anti O -
- O -
CldU O -
/ O -
BrdU O +
primary O +
antibody O +
( O -
1∶200 O -
, O +
monoclonal O -
, O +
Immunologicalsdirect O -
, O +
Oxfordshire O -
, O +
UK O -
) O -
, O +
with O +
an O +
additional O +
denaturation O +
in O +
1 O +
M O +
HCl O +
for O +
30 O +
minutes O +
prior O +
to O +
pre O -
- O -
incubation O +
with O +
serum O -
. O +

To O +
assess O +
the O +
neuronal O -
- O -
inducing O +
activity O +
of O +
Ngn2 O +
and O +
NeuroD1 O -
, O +
transduced O +
cultures O +
were O +
incubated O +
with O +
CldU O +
( O -
20 O +
µM O -
, O +
Sigma O -
) O +
for O +
2 O +
days O -
, O +
after O +
a O +
period O +
of O +
differentiation O +
of O +
five O +
days O -
. O +

For O +
immunocytochemistry O -
, O +
cultures O +
were O +
fixed O +
with O +
4 O -
% O +
paraformaldehyde O +
at O +
day O +
7 O -
, O +
rinsed O +
with O +
PBS O +
three O +
times O -
, O +
treated O +
with O +
1 O +
M O +
HCl O +
at O +
65 O -
° O -
C O +
for O +
5–10 O +
min O -
, O +
pre O -
- O -
incubated O +
and O +
then O +
incubated O +
with O +
a O +
rat B-Species +
anti O -
- O -
CldU O -
/ O -
BrdU O +
antibody O +
and O +
other O +
primary O +
antibodies O -
. O +

The O +
remainder O +
of O +
the O +
procedure O +
was O +
performed O +
according O +
to O +
the O +
protocol O +
for O +
immunohistochemistry O +
already O +
mentioned O -
. O +

In O +
utero O +
surgery O +
Timed O +
pregnant O +
female O +
Sprague B-Species +
Dawley I-Species +
rats I-Species +
with O +
embryos O +
at O +
gestational O +
age O +
E15.5 O +
were O +
anesthetized O +
with O +
halothane O -
. O +

The O +
mother O +
was O +
placed O +
in O +
the O +
lower O +
level O +
of O +
a O +
two O -
- O -
level O +
wooden O +
stage O -
. O +

The O +
abdomen O +
was O +
shaved O +
with O +
an O +
electric O +
razor O +
and O +
then O +
cleaned O +
with O +
70 O -
% O +
alcohol O -
. O +

A O +
2–3 O +
cm O +
midline O +
laparotomy O +
was O +
performed O -
. O +

Each O +
uterine O +
horn O +
was O +
carefully O +
taken O +
out O +
individually O +
and O +
the O +
number O +
of O +
embryos O +
recorded O -
. O +

One O +
horn O +
was O +
then O +
placed O +
back O +
inside O +
the O +
mother O -
, O +
whilst O +
the O +
other O +
horn O +
was O +
prepared O +
for O +
injection O -
. O +

The O +
embryos O +
were O +
kept O +
moist O +
with O +
constant O +
application O +
of O +
warm O +
saline O +
to O +
prevent O +
dehydration O -
. O +

Approximately O +
2 O +
µl O +
of O +
viral O +
suspension O +
( O -
1 O -
× O -
10∧9TU O -
/ O -
ml O -
) O +
was O +
injected O +
into O +
the O +
lateral O +
ventricle O +
of O +
each O +
embryo O -
, O +
except O +
for O +
the O +
embryo O +
closest O +
to O +
the O +
vagina O -
. O +

After O +
the O +
injections O -
, O +
the O +
uterine O +
horns O +
were O +
placed O +
back O +
into O +
the O +
abdomen O -
. O +

The O +
abdominal O +
wall O +
and O +
the O +
overlying O +
skin O +
were O +
then O +
sutured O -
. O +

Care O +
was O +
taken O +
not O +
to O +
damage O +
abdominal O +
muscles O +
so O +
that O +
normal O +
delivery O +
of O +
the O +
pups O +
was O +
possible O +
at O +
term O -
. O +

The O +
entire O +
surgery O +
generally O +
took O +
about O +
45 O +
minutes O +
to O +
one O +
hour O -
. O +

Each O +
mother O +
was O +
allowed O +
to O +
recover O +
in O +
her O +
cage O +
before O +
being O +
returned O +
to O +
the O +
animal O +
stable O -
. O +

Shredded O +
paper O +
was O +
added O +
to O +
each O +
cage O +
to O +
encourage O +
nesting O +
and O +
special O +
care O +
was O +
taken O +
not O +
to O +
stress O +
the O +
mothers O -
. O +

Following O +
normal O +
delivery O -
, O +
the O +
pups O +
were O +
allowed O +
to O +
develop O +
to O +
adulthood O +
up O +
to O +
two O +
weeks O -
. O +

Quantification O +
For O +
the O +
in O +
vivo O +
experiment O -
, O +
manual O +
cell O +
counting O +
was O +
performed O +
on O +
18 O +
and O +
30 O +
µm O +
thick O +
brain O +
sections O +
for O +
two O +
days O +
and O +
two O +
weeks O +
old O +
animals O -
, O +
respectively O -
. O +

The O +
brain O +
of O +
P2 O +
animals O +
was O +
cut O +
into O +
10 O +
series O +
of O +
coronal O +
sections O -
; O +
the O +
brain O +
of O +
two O -
- O -
weeks O +
old O +
animals O +
was O +
cut O +
into O +
7–8 O +
series O +
of O +
coronal O +
sections O -
. O +

For O +
each O +
staining O -
, O +
one O -
- O -
two O +
series O +
from O +
three O +
to O +
five O +
different O +
individuals O +
were O +
analyzed O +
per O +
genotype O +
using O +
a O +
confocal O +
microscope O +
with O +
1 O -
, O +
2 O +
or O +
3 O +
lines O +
of O +
excitation O -
, O +
in O +
sequential O +
scanning O +
in O +
order O +
to O +
avoid O +
false O +
positives O -
. O +

When O +
two O +
series O +
were O +
analyzed O -
, O +
only O +
one O +
series O +
was O +
counted O -
. O +

The O +
mean O +
number O +
of O +
cells O +
per O +
hippocampus O +
expressing O +
the O +
markers O +
of O +
interest O -
, O +
was O +
calculated O +
for O +
each O +
brain O -
, O +
based O +
on O +
the O +
analysis O +
of O +
6–8 O +
consecutive O +
dorsal O +
hippocampal O +
sections O -
. O +

The O +
final O +
mean O +
number O +
of O +
cells O +
per O +
section O +
was O +
calculated O +
by O +
adding O +
the O +
mean O +
number O +
from O +
each O +
individual O -
. O +

We O +
expressed O +
the O +
data O +
as O +
the O +
mean O +
number O +
of O +
positive O +
cells±standard O +
error O +
of O +
the O +
mean O +
( O -
SEM O -
) O -
. O +

In O +
this O +
study O -
, O +
more O +
than O +
25 O +
Ngn2 O +
null O -
, O +
> O -
45 O +
Ngn2 O +
heterozygotes O -
, O +
and O +
> O -
60 O +
WT O +
individuals O +
( O -
including O +
rats B-Species +
injected O +
with O +
retroviruses O -
) O +
were O +
analyzed O -
, O +
in O +
total O -
. O +

Statistical O +
comparison O +
was O +
performed O +
using O +
one O -
- O -
factor O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
with O +
transcription O +
factor O -
, O +
cellular O +
marker O -
, O +
genotype O +
or O +
time O +
as O +
variables O -
, O +
followed O +
by O +
post O -
- O -
hoc O +
analysis O +
when O +
significant O +
differences O +
were O +
observed O -
, O +
using O +
Statview O +
5.0 O +
software O +
( O -
SAS O +
institute O +
Inc. O -
) O -
. O +

For O +
cell O +
culture O +
experiments O -
, O +
three O +
independent O +
experiments O +
were O +
performed O -
, O +
each O +
in O +
duplicate O -
. O +

The O +
counting O +
was O +
based O +
on O +
seven O +
randomly O +
chosen O +
different O +
fields O +
of O +
view O -
. O +

For O +
each O +
diagram O -
, O +
the O +
level O +
of O +
significance O +
( O -
p O -
- O -
value O -
) O +
is O +
represented O +
as O +
follows O -
: O +
P<0.05 O +
= O +
* O -
; O +
P<0.001 O +
= O +
* O -
* O -
; O +
P<0.0001 O +
= O +
* O -
* O -
* O -
. O +

All O +
data O +
are O +
expressed O +
as±standard O +
error O +
of O +
the O +
mean O +
( O -
SEM O -
) O -
. O +

Human B-Species +
sample O +
and O +
RT O -
- O -
PCR O +
The O +
brain O +
from O +
a O +
64 O +
year O -
- O -
old O +
male O +
was O +
provided O +
by O +
the O +
Harvard O +
Brain O +
Tissue O +
Resource O +
Center O -
. O +

The O +
individual O +
whose O +
brain O +
tissue O +
was O +
being O +
analyzed O +
gave O +
written O +
consent O +
for O +
storage O +
and O +
use O +
of O +
his O +
tissue O +
for O +
research O -
. O +

Five O +
millimeters O +
thick O +
fresh O +
human B-Species +
hippocampal O +
tissue O +
sample O +
was O +
snap O +
frozen O -
. O +

The O +
frozen O +
tissue O +
block O +
was O +
cut O +
into O +
20 O +
series O +
of O +
coronal O +
sections O -
, O +
using O +
a O +
cryostat O -
. O +

Every O +
10 O +
sections O -
, O +
one O +
section O +
was O +
placed O +
in O +
an O +
Eppendorf O +
tube O -
, O +
on O +
dry O +
ice O -
. O +

Pooled O +
sections O +
were O +
used O +
for O +
RT O -
- O -
PCR O -
. O +

Total O +
RNA O +
was O +
prepared O +
using O +
Trizol O +
and O +
RNAeasy O -
, O +
supplemented O +
with O +
RNAGuard O +
as O +
previously O +
described O +
[ O -
49 O -
] O -
. O +

The O +
RNA O +
was O +
digested O +
with O +
shrimp O +
DNAse O +
before O +
cDNA O +
synthesis O -
, O +
which O +
was O +
performed O +
using O +
a O +
mix O +
of O +
oligo O -
- O -
dT O +
and O +
random O +
hexamer O +
primers O +
and O +
SuperscriptII O +
reverse O +
transcriptase O -
. O +

Advantage2 O +
polymerase O +
mix O +
( O -
Clontech O -
/ O -
BRL O -
) O +
was O +
used O +
for O +
PCR O -
, O +
with O +
the O +
following O +
cycling O +
conditions O -
: O +
10 O +
cycles O +
of O +
94 O -
° O +
C O +
for O +
30 O +
seconds O -
, O +
68 O -
° O -
C O +
for O +
2 O +
minutes O -
, O +
30 O +
cycles O +
of O +
94 O -
° O -
C O +
for O +
30 O +
seconds O -
, O +
60 O -
° O -
C O +
for O +
1 O +
minute O -
, O +
68 O -
° O -
C O +
for O +
1 O +
minute O +
and O +
30 O +
seconds O -
, O +
one O +
cycle O +
of O +
68 O -
° O +
C O +
for O +
2 O +
minutes O -
, O +
soak O +
at O +
16 O -
° O -
C O -
. O +

Primers O +
marked O +
* O +
were O +
designed O +
by O +
PrimerBank O -
. O +

hRPS18 O +
( O -
sense O -
) O +
5′-GCCTTTGCCATCACTGCCATT O +
and O +
hRPS18 O +
( O -
antisense O -
) O +
5′-GCCAGTGGTCTTGGTGTGCT O -
, O +
hPAX6 O +
( O -
sense O -
) O +
5′-GCCCTGGAGAAAGAGTTTGAGAGAACCCATT O +
hPAX6 O +
( O -
antisense O -
) O +
5′-GGGGAAATGAGTCCTGTTGAAGTGGTGC O -
, O +
hTBR1 O +
( O -
sense O -
) O +
5′-GCGGACACCAATGTGCAAGGAAATCG O +
and O +
hTBR1 O +
( O -
antisense O -
) O +
5′-CGAGGGGGTCAGGCGGTCCATGTCACAGC O -
, O +
hTBR2 O +
( O -
sense O -
) O +
5′-GACCTGTGGCAAAGCCGACAATAACATGC O +
and O +
hTBR2 O +
( O -
antisense O -
) O +
5′-GGGGGTGTCTCTATCCAAGAAGAGCCAAT O -
, O +
hPDHX O +
( O +
= O +
PROX1 O -
) O +
( O -
sense O -
) O +
5′-GGGACACTACGGTTCCGTTTAAGTCCAGC O +
and O +
hPDHX O +
( O -
antisense O -
) O +
5′-CTCTCCATCCCAGCTTACATTAACATCTGGCATTTGT O -
, O +
hNGN2 O +
( O -
sense O -
) O +
* O +
5′-CATCAAGAAGACCCGTAGACTGA O +
and O +
hNGN2 O +
( O -
antisense O -
) O -
* O +
5′-CAACACTGCCTCGGAGAAG O -
, O +
hMASH1 O +
( O -
sense O -
) O +
5′-CCTGGATCCGCATGGAAAGCTCTGCCAAGATGGAG O +
and O +
hMASH1 O +
( O -
antisense O -
) O +
5′-CCTGGATCCCCCCTCAGAACCAGTTGGTGAAGTCGA O -
, O +
hNEUROD1 O +
( O -
sense O -
) O +
5′-GCTCAGGACCTACTAACAACAAAGGAAATCGAAACATG O +
and O +
hNEUROD1 O +
( O -
antisense O -
) O +
5′-CAAAGCGTCTGAACGAAGGAGACCAGGT O -
, O +
hGLAST O +
( O -
sense O -
) O +
5′-CATCAGGGAAGATGGGAATGCGAGCTGTAGTCTATTAT O +
and O +
hGLAST O +
( O -
antisense O -
) O +
5′-CCACGGGGGCATACCACATTATTACTGCTACC O -
, O +
hNEST O +
( O -
sense O -
) O +
5′-CAGGAGCGGCTGCGGGCTACTGAAAAGTTCC O +
and O +
hNEST O +
( O -
antisense O -
) O +
5′-CAGGGCTGAGGGGTGGTGCCAAGGAGG O -
, O +
hGFAP O +
( O -
sense O -
) O +
5′-CCACGAGGAGGAGGTTCGGGAACTCCAGGAGC O +
and O +
hGFAP O +
( O -
antisense O -
) O +
5-GGAATGGTGATCCGGTTCTCCTCGCCCTCTAGC O -
, O +
hCALB2 O +
( O +
= O +
Calretinin O -
) O +
( O -
sense O -
) O +
5′-GGCTCTGGCATGATGTCAAAGAGTGACAACTTT O +
and O +
hCALB2 O +
( O -
antisense O -
) O +
5′-GGGCATCCAGCTCATGCTCGTCAATGTAGCC O -
, O +
hCALB1 O +
( O -
sense O -
) O +
5′-GCGAAAGAAGGCTGGATTGGAGTTATCACC O +
and O +
hCALB1 O +
( O -
antisense O -
) O +
5′-CCCTCCATCCGACAAAGCCATTATGTTCTTCTTGTATG O -
, O +
hSOX2 O +
( O -
sense O -
) O +
5′-GGAGAACCCCAAGATGCACAACTCGGAGAT O +
and O +
hSOX2 O +
( O -
antisense O -
) O +
5′-GAGGAAGAGGTAACCACAGGGGGGCTGGAGC O -
, O +
hWNT3A O +
( O -
sense O -
) O +
5′-CCGAGGGCATCAAGATTGGCATCCAGGAGTGC O +
and O +
hWNT3A O +
( O -
antisense O -
) O +
5′-TCGGGTTGCGACCACCAGCATGTCTTCACCTC O -
, O +
hSHH O -
* O +
( O -
sense O -
) O +
5′-ACTCCGAGCGATTTAAGGAACT O +
and O +
hSHH O -
* O +
( O -
antisense O -
) O +
5′-CAGACGTGGTGATGTCCACTG O -
. O +

Supporting O +
Information O +

Organization O +
and O +
structure O +
of O +
the O +
mouse B-Species +
interleukin-2 O +
gene O -
. O +

Abstract O +
We O +
have O +
cloned O +
a O +
chromosomal O +
DNA O +
segment O +
which O +
covers O +
the O +
entire O +
sequence O +
for O +
the O +
murine O +
interleukin-2 O +
gene O +
and O +
analysed O +
the O +
structure O +
of O +
the O +
gene O -
. O +

The O +
coding O +
regions O +
are O +
separated O +
into O +
four O +
blocks O +
by O +
three O +
introns O +
each O +
of O +
which O +
is O +
located O +
similarly O +
to O +
the O +
corresponding O +
human B-Species +
gene O -
. O +

The O +
exon O +
sequences O +
can O +
be O +
aligned O +
perfectly O +
with O +
the O +
previously O +
cloned O +
cDNA O +
sequence O -
. O +

Of O +
particular O +
interests O +
is O +
the O +
presence O +
of O +
sequences O +
within O +
the O +
5'-flanking O +
region O +
which O +
are O +
highly O +
conserved O +
between O +
mouse B-Species +
and O +
man B-Species -
. O +

The O +
conserved O +
region O +
which O +
spans O +
more O +
than O +
400 O +
base O +
pairs O +
may O +
play O +
a O +
role O +
in O +
the O +
regulation O +
of O +
IL-2 O +
gene O +
expression O -
. O +

Images O +
Volume O +
12 O +
Number O +
24 O +
1984 O +
Nucleic O +
Acids O +
Research O +
Organization O +
and O +
structure O +
of O +
the O +
mouse B-Species +
interleukin-2 O +
gene O +
Akira O +
Fuse O +

* O -
, O +
Takashi O +
Fujita O -
, O +
Hidetaro O +
Yasumitsu O -
, O +
Nobukazu O +
Kashima+ O -
, O +
Katsushige O +
Hasegawa O +
and O +
Tadatsugu O +
Taniguchi O -
? O +

Department O +
of O +
Biochemistry O -
, O +
Cancer O +
Institute O -
, O +
Japanese O +
Foundation O +
for O +
Cancer O +
Research O -
, O +
Toshimaku O -
, O +
Tokyo O +
170 O +
and O +
Institute O +
for O +
Molecular O +
and O +
Cellular O +
Biology O -
, O +
Osaka O +
University O -
, O +
Suita O -
- O -
shi O -
, O +

Osaka O +
565 O -
, O +
Japan O +
Received O +
10 O +
October O +
1984 O -
; O +
Revised O +
and O +
Accepted O +
20 O +
November O +
1984 O +
ABSTRACT O +
We O +
have O +
cloned O +
a O +
chromosomal O +
DNA O +
segment O +
which O +
covers O +
the O +
entire O +
sequence O +
for O +
the O +
murine O +
interleukin-2 O +
gene O +
and O +
analysed O +
the O +
structure O +
of O +
the O +
gene O -
. O +

The O +
coding O +
regions O +
are O +
separated O +
into O +
four O +
blocks O +
by O +
three O +
introns O +
each O +
of O +
which O +
is O +
located O +
similarly O +
to O +
the O +
corresponding O +
human B-Species +
gene O -
. O +

The O +
exon O +
sequences O +
can O +
be O +
aligned O +
perfectly O +
with O +
the O +
previously O +
cloned O +
cDNA O +
sequence O -
. O +

Of O +
particular O +
interests O +
is O +
the O +
presence O +
of O +
sequences O +
within O +
the O +
5'flanking O +
region O +
which O +
are O +
highly O +
conserved O +
between O +
mouse B-Species +
and O +
man B-Species -
. O +

The O +
conserved O +
region O +
which O +
spans O +
more O +
than O +
400 O +
base O +
pairs O +
may O +
play O +
a O +
role O +
in O +
the O +
regulation O +
of O +
IL-2 O +
gene O +
expression O -
. O +

INTRODUCTION O +
Interleukin-2 O +
( O -
IL-2 O -
) O +
is O +
a O +
lymphokine O +
produced O +
by O +
T O +
cells O +
upon O +
antigenic O +
or O +
mitogenic O +
stimulation O +
and O +
is O +
required O +
for O +
the O +
proliferation O +
of O +
T O +
cells O +
( O -
1,2 O -
) O -
. O +

Several O +
other O +
biological O +
activities O +
of O +
IL-2 O +
which O +
appear O +
to O +
be O +
crucial O +
in O +
the O +
immune O +
regulation O +
have O +
also O +
been O +
reported O +
( O -
3 O -
, O +
4 O -
. O +
5 O -
. O +
6 O -
. O +
7 O -
. O -
) O +
. O +

We O +
previously O +
reported O +
isolation O +
and O +
sequence O +
analysis O +
of O +
the O +
cDNA O +
for O +
human B-Species +
IL-2 O +
( O -
8) O -
, O +
as O +
well O +
as O +
the O +
chromosomal O +
gene O +
( O -
9 O -
) O -
. O +

More O +
recently O -
, O +
we O +
have O +
isolated O +
a O +
cDNA O +
which O +
encodes O +
murine O +
IL-2 O +
( O -
Kashima O +
et O +
al. O -
, O +
submitted O +
for O +
publication O -
) O -
. O +

The O +
cDNA O +
contains O +
a O +
unique O +
tandem O +
repeat O +
of O +
CAG O +
sequence O +
which O +
would O +
encode O +
12 O +
consecutive O +
glutamine O +
residues O +
in O +
the O +
active O +
IL-2 O +
molecule O -
. O +

In O +
order O +
to O +
study O +
the O +
structure O +
of O +
the O +
murine O +
IL-2 O +
chromosomal O +
gene O +
and O +
its O +
controlling O +
region O -
, O +
we O +
isolated O +
and O +
analysed O +
a O +
A O +
phage O +
clone O +
containing O +
the O +
gene O +
and O +
its O +
flanking O +
sequences O -
. O +

MATERIALS O +
AND O +
METHODS O +
Southern O +
blotting O +
of O +
total O +
mouse B-Species +
DNA O +
Mouse B-Species +
chromosomal O +
DNA O +
was O +
extracted O +
from O +
liver O +
of O +
BALB O -
/ O -
c6 O +
? O +

I O +
R O +
L O +
Press O +
Limited O -
, O +
Oxford O -
, O +
England O -
. O +

Nucleic O +
Acids O +
Research O +
Volume O +
12 O +
Number O +
24 O +
1984 O +
9323 O +
Nucleic O +
Acids O +
Research O +
mouse B-Species +
as O +
described O +
before O +
( O -
10 O -
) O -
. O +

High O +
molecular O +
genomic O +
DNA O +
was O +
digested O +
with O +
various O +
restriction O +
enzymes O +
and O +
electrophoresed O +
on O +
0.8 O -
% O +
agarose O +
gel O -
. O +

Blotting O +
analysis O +
of O +
DNA O +
was O +
carried O +
out O +
by O +
the O +
method O +
of O +
Southern O +
( O -
11 O -
) O -
. O +

Hybridization O +
was O +
carried O +
out O +
as O +
described O +
previously O +
and O +
filters O +
were O +
washed O +
either O +
in O +
3 O +
x O +
SSC O +
at O +
650C O +
( O -
lower O +
stringent O +
condition O -
) O +
or O +
in O +
0.1 O +
x O +
SSC O +
at O +
650C O +
( O -
higher O +
stringent O +
condition O -
) O -
. O +

Screening O +
of O +
genomic O +
DNA O +
library O +
A O +
bacteriophage O +
XCharon O +
4A O -
/ O -
mouse B-Species +
genomic O +
DNA O +
library O +
prepared O +
with O +
partial O +
EcoRI O +
digests O +
of O +
mouse B-Species +
DNA O +
from O +
MPC O +
11 O +
plasmacytoma O +
cells O +
was O +
kindly O +
provided O +
by O +
Dr. O +
T. O +
Honjo O -
. O +

Mouse B-Species +
IL-2-specific O +
clones O +
were O +
screened O +
by O +
the O +
method O +
of O +
Benton O +
and O +
Davis O +
( O -
12 O -
) O -
, O +
using O +
700 O +
bp O +
PstI O -
- O -
AccI O +
fragment O +
of O +
a O +
cDNA O +
clone O -
, O +
pMIL2 O -
- O -
45 O +
as O +
the O +
probe O +
( O -
Kashima O +
et O +
al. O -
, O +
submitted O +
for O +
publication O -
) O -
. O +

Hybridization O +
was O +
performed O +
as O +
described O +
previously O -
( O -
13 O -
) O -
. O +

Positive O +
clones O +
were O +
rescreened O +
at O +
least O +
twice O -
. O +

Subcloninq O +
and O +
sequencing O +
of O +
the O +
mouse B-Species +
IL-2 O +
gene O +
Two O +
EcoRI O +
fragments O +
of O +
3.3 O +
Kbp O +
and O +
2.8 O +
Kbp O +
from O +
the O +
positive O +
recombinant O +
X O +
phage O +
were O +
subcloned O +
into O +
EcoRI O +
site O +
of O +
plasmid O +
pBR322 O -
. O +

DNA O +
segments O +
derived O +
from O +
subcloned O +
3.3 O +
Kbp O +
and O +
2.8 O +
Kbp O +
fragments O +
were O +
labelled O +
at O +
either O +
3 O -
' O +
end O +
or O +
5 O -
' O +
end O -
, O +
and O +
subjected O +
to O +
sequence O +
analysis O +
by O +
the O +
chemical O +
degradation O +
method O +
( O -
14 O -
) O -
. O +

The O +
0.8 O +
Kbp O +
EcoRI O +
fragment O +
from O +
the O +
same O +
X O +
phage O +
clone O +
was O +
directly O +
subjected O +
to O +
sequence O +
analysis O +
by O +
the O +
dideoxy O +
chain O +
termination O +
method O +
( O -
15 O -
) O -
. O +

RESULTS O +
Total O +
DNA O +
blotting O +
analysis O +
In O +
order O +
to O +
study O +
structural O +
organization O +
of O +
the O +
mouse B-Species +
IL-2 O +
gene O -
, O +
we O +
first O +
subjected O +
total O +
mouse B-Species +
DNA O +
to O +
the O +
blotting O +
analysis O +
by O +
using O +
various O +
probes O +
specific O +
for O +
IL-2 O +
gene O -
. O +

When O +
mouse B-Species +
DNA O +
was O +
digested O +
with O +
various O +
restriction O +
endonucleases O +
and O +
then O +
probed O +
with O +
a O +
7 O +
kb O +
human B-Species +
chromosomal O +
DNA O +
segment O +
which O +
contains O +
the O +
human B-Species +
IL-2 O +
gene O +
and O +
its O +
flanking O +
region O +
( O -
Fig. O +
1 O +
lane O +
1 O -
- O -
8 O -
, O +
ref O -
. O +

9 O -
. O -
) O -
, O +
single O +
positive O +
band O +
appeared O +
at O +
lower O +
but O +
not O +
at O +
higher O +
stringent O +
condition O +
for O +
washing O +
the O +
filters O +
( O -
see O +
Figure O +
legend O -
) O -
. O +

Additional O +
bands O +
corresponding O +
to O +
those O +
observed O +
by O +
using O +
mouse B-Species +
IL-2 O +
cDNA O +
probes O +
( O -
lane O +
13 O -
- O -
17 O -
) O +
also O +
appeared O +
by O +
longer O +
9324 O +
Nucleic O +
Acids O +
Research O +
M O +
1 O +
2 O +
3 O +
4 O +
M O +
5 O +
6 O +
7 O +
8 O +
M O +
9 O +
101112 O +
M O +
13 O +
141516 O +
17 O +
a~ O +
~ O +
3 O +
.. O +

I O +
pMIL2 O -
- O -
45 O +
SacI O +
Acc O +
I O +
CZI~~1 O +
1 O -
t O +
L2- O +
20 O +
Acc O +
I O +
1 O +
00 O +
tp O +
lX O +
i O +
Fig. O +
1 O -
. O +

Blot O +
hybridization O +
analysis O +
of O +
mouse B-Species +
chromosomal O +
DNA O -
. O +

High O +
molecular O +
DNA O +
prepared O +
from O +
Liver O +
BALB O -
/ O -
C6 O +
mouse B-Species +
was O +
digested O +
with O +
various O +
restriction O +
endonucleases O +
( O -
BamHI O +
for O +
lanes O +
1 O -
, O +
5 O -
, O +
9 O -
, O +
13 O +
; O +
EcoRI O +
for O +
lanes O +
2 O -
, O +
6 O -
, O +
10 O -
, O +
14 O -
, O +
17 O +
; O +
HindIII O +
for O +
lanes O +
3 O -
, O +
7 O -
, O +
11 O -
, O +
15 O +
; O +
XbaI O +
for O +
lanes O +
4 O -
, O +
8 O -
, O +
12 O -
, O +
16 O +
) O -
. O +

The O +
resulting O +
digests O +
were O +
fractionated O +
on O +
0.8 O +
% O +
agarose O +
gel O +
and O +
transferred O +
to O +
a O +
nitrocellulose O +
filter O -
. O +

Filters O +
were O +
hybridized O +
by O +
the O +
published O +
procedure O +
( O -
13 O -
) O +
either O +
with O +
the O +
nick O -
- O -
translated O +
chromosomal O +
DNA O +
containing O +
human B-Species +
IL-2 O +
gene O +
and O +
its O +
flanking O +
region O +
( O -
total O +
length O -
, O +
7.0 O +
kb O -
, O +
ref O -
. O +

9 O -
) O +
( O -
lane O +
1 O -
- O -
8 O -
) O +
or O +
with O +
the O +
nick O -
- O -
translated O +
cDNA O +
for O +
mouse B-Species +
IL-2 O +
( O -
see O +
figure O -
) O -
. O +

Filters O +
were O +
then O +
washed O +
either O +
in O +
3 O +
x O +
SSC O +
at O +
65 O +
% O +
( O -
lower O +
stringent O +
condition O -
) O +
( O -
lane O +
1 O -
- O -
4 O -
, O +
9 O -
- O -
12 O -
) O +
or O +
0.1 O +
x O +
SSC O +
at O +
65 O +
OC O +
( O -
higher O +
stringent O +
condition O -
) O +
( O -
lane O +
5 O -
- O -
8 O -
, O +
13 O -
- O -
17 O -
) O -
. O +

Lane O +
M O +
each O +
contains O +
7 O +
size O +
markers O +
with O +
their O +
size O +
being O +
23.7 O +
kb O -
, O +
9.5 O +
kb O -
, O +
6.7 O +
kb O -
, O +
4.3 O +
kb O -
, O +
2.3 O +
kb O -
, O +
2.0 O +
kb O +
and O +
0.6 O +
kb O -
, O +
respectively O -
. O +

Brief O +
restriction O +
endonuclease O +
cleavage O +
map O +
for O +
the O +
mouse B-Species +
IL-2 O +
cDNAs O +
is O +
presented O +
in O +
the O +
lower O +
part O +
of O +
the O +
figure O -
. O +

exposure O +
of O +
the O +
film O +
( O -
data O +
not O +
shown O -
) O -
. O +

Those O +
results O +
suggest O +
the O +
presence O +
of O +
highly O +
conserved O +
sequences O +
between O +
human B-Species +
and O +
mouse B-Species +
DNA O +
either O +
in O +
the O +
flanking O +
regions O +
or O +
in O +
the O +
introns O +
of O +
the O +
IL-2 O +
gene O -
, O +
since O +
the O +
coding O +
regions O +
apparently O +
show O +
lower O +
degree O +
of O +
sequence O +
homology O +
as O +
evidenced O +
in O +
this O +
series O +
of O +
blotting O +
analysis O +
( O -
see O +
below O -
) O -
. O +

When O +
the O +
PstI O +
insert O +
of O +
a O +
mouse B-Species +
IL-2 O +
cDNA O +
clone O -
, O +
pMIL2 O -
- O -
20 O -
, O +
was O +
used O +
as O +
the O +
probe O -
, O +
a O +
simple O +
pattern O +
was O +
9325 O +
Nucleic O +
Acids O +
Research O +
obtained O +
at O +
higher O +
stringent O +
condition O +
( O -
lane O +
13 O -
- O -
17 O -
) O -
. O +

While O +
the O +
EcoRI O -
- O -
digested O +
DNA O +
gave O +
rise O +
to O +
two O +
positive O +
bands O +
( O -
2.8 O +
kb O +
and O +
0.8 O +
kb O -
) O -
( O -
Fig O -
. O +

1 O -
, O +
lane O +
14 O -
) O +
by O +
this O +
analysis O -
, O +
one O +
additional O +
band O +
of O +
3.3 O +
kb O +
also O +
appeared O +
when O +
the O +
same O +
DNA O +
was O +
probed O +
with O +
a O +
longer O +
cDNA O +
insert O +
from O +
another O +
clone O -
, O +
pMIL2 O -
- O -
45 O +
( O -
Fig. O +
1 O -
, O +
lane O +
17 O -
) O -
. O +

The O +
3.3 O +
kb O +
band O +
was O +
similar O +
in O +
its O +
size O +
with O +
the O +
positive O +
band O +
which O +
became O +
detectable O +
by O +
probing O +
the O +
same O +
DNA O +
with O +
the O +
7.0 O +
kb O +
human B-Species +
DNA O +
probe O +
( O -
Fig. O +
1 O -
, O +
lane O +
2 O -
) O -
. O +

Since O +
this O +
band O +
appeared O +
with O +
the O +
cDNA O +
probe O +
extending O +
further O +
upstream O -
, O +
it O +
is O +
likely O +
that O +
the O +
5 O -
' O +
region O +
of O +
the O +
gene O +
is O +
located O +
within O +
this O +
DNA O +
segment O +
( O -
see O +
below O -
) O -
. O +

Indeed O -
, O +
this O +
3.3 O +
kb O +
band O +
did O +
not O +
appear O +
even O +
after O +
longer O +
exposure O +
of O +
lane O +
14 O +
( O -
result O +
not O +
shown O -
) O -
. O +

BamHI O +
digest O +
of O +
the O +
mouse B-Species +
DNA O +
( O -
Fig. O +
1 O -
, O +
lane O +
1 O -
, O +
13 O -
) O +
constantly O +
gave O +
a O +
very O +
faint O +
signal O +
which O +
would O +
correspond O +
to O +
a O +
DNA O +
larger O +
than O +
15 O +
kb O -
. O +

Taken O +
together O -
, O +
the O +
results O +
suggested O +
the O +
presence O +
of O +
a O +
single O +
copy O +
gene O +
for O +
murine O +
IL-2 O -
. O +

On O +
the O +
other O +
hand O +
appearance O +
of O +
the O +
multiple O +
positive O +
bands O +
at O +
lower O +
stringent O +
washing O +
condition O +
( O -
lane O +
9 O -
- O -
12 O -
) O +
indicates O +
the O +
presence O +
of O +
IL-2 O +
related O +
sequences O +
within O +
the O +
mouse B-Species +
genome O -
. O +

Screening O +
of O +
recombinant O +
phaqe O +
libraries O +
We O +
next O +
screened O +
a O +
gene O +
library O +
from O +
partial O +
EcoRIdigested O +
DNA O +
from O +
MPC O +
11 O +
cells O +
and O +
by O +
using O +
0.8 O +
Kbp O +
SacI O -
- O -
AccI O +
cDNA O +
fragment O +
as O +
the O +
probe O +
and O +
isolated O +
14 O +
positive O +
clones O +
containing O +
sequences O +
specific O +
to O +
the O +
mouse B-Species +
IL-2 O +
gene O -
. O +

Three O +
of O +
the O +
clones O +
analysed O +
all O +
contained O +
three O +
EcoRI O +
fragments O +
whose O +
size O +
is O +
in O +
agreement O +
with O +
the O +
result O +
of O +
blotting O +
analysis O +
of O +
the O +
chromosomal O +
DNA O +
as O +
shown O +
in O +
Fig. O +
1 O +
( O -
lane O +
17 O -
) O -
. O +

One O +
of O +
these O +
is O +
designated O +
MIL-2G70 O -
. O +

Nucleotide O +
sequence O +
analysis O +
Two O +
DNA O +
fragments O +
of O +
3.3 O +
Kbp O +
and O +
2.8 O +
Kbp O +
were O +
excised O +
from O +
the O +
phage O +
clone O +
MIL-2G70 O +
by O +
EcoRI O +
digestion O +
and O +
they O +
were O +
subcloned O +
into O +
pBR322 O -
. O +

DNA O +
sequences O +
were O +
determined O +
for O +
selected O +
regions O +
of O +
both O +
inserts O +
and O +
compared O +
to O +
the O +
known O +
cDNA O +
sequences O +
( O -
Kashima O +
et O +
al. O -
, O +
submitted O +
for O +
publication O -
) O -
. O +

The O +
strategy O +
used O +
for O +
sequence O +
analysis O +
of O +
the O +
genomic O +
DNA O +
is O +
presented O +
in O +
Fig. O +
2 O -
. O +

Comparison O +
of O +
the O +
mouse B-Species +
genomic O +
IL-2 O +
sequence O +
with O +
mouse B-Species +
IL-2 O +
cDNA O +
sequence O +
revealed O +
that O -
, O +
like O +
the O +
human B-Species +
gene O -
, O +
the O +
gene O +
is O +
divided O +
into O +
four O +
exons O -
. O +

A O +
putative O +
9326 O +
Nucleic O +
Acids O +
Research O +
E O +
E O +
E O +
E O +
E O +
500bp O +
s O +
7S O +
P O +
HBH O +
H O +
\A O +
200 O +
bp O +

* O +
, O +
- O +
4 O +
I O +
4 O -
- O -
4 O -
- O -
--- O +

* O +
* O -
- O +
--4 O +
Fig. O +
2 O -
. O +

Restriction O +
map O +
and O +
sequencing O +
strategy O +
of O +
mouse B-Species +
IL-2 O +
gene O -
. O +

Horizontal O +
lines O +
indicate O +
the O +
length O +
of O +
mouse B-Species +
DNA O +
inserted O +
into O +
the O +
X O +
phage O +
Charon O +
4A O +
or O +
plasmid O +
subclones O -
. O +

Filled O +
blocks O -
, O +
dashed O +
blocks O +
and O +
open O +
blocks O +
indicate O +
protein O +
coding O +
regions O -
, O +
untranslated O +
regions O +
and O +
introns O -
, O +
respectively O -
. O +

Horizontal O +
arrows O +
indicate O +
the O +
direction O +
and O +
extent O +
of O +
sequence O +
determination O +
without O +
ambiguity O -
. O +

Dashed O +
arrows O -
: O +
determination O +
was O +
done O +
by O +
the O +
chain O +
termination O +
method O +
( O -
15 O -
) O +
after O +
subcloning O +
the O +
0.8 O +
kb O +
fragment O +
into O +
M13 O -
. O +

Rest O +
of O +
the O +
sequence O +
determination O +
was O +
carried O +
out O +
by O +
the O +
method O +
of O +
Maxam O +
and O +
Gilbert O +
( O -
14 O -
) O -
. O +

A O +
AccI O +
site O -
, O +
B O -
; O +
BamHI O +
site O -
, O +
E O -
; O +
EcoRI O +
site O -
, O +
H O -
; O +
HindIII O +
site O -
, O +
P O -
; O +
PstI O +
site O -
, O +
S O -
; O +
SacI O +
site O -
. O +

capping O +
site O +
or O +
the O +
transcription O +
initiation O +
site O +
was O +
located O +
32 O +
bp O +
downstream O +
from O +
a O +
TATAAA O +
consensus O +
promotor O +
sequence O +
( O -
Fig. O +
3 O -
) O -
. O +

The O +
first O +
ATG O +
triplet O +
was O +
located O +
79 O +
bp O +
downstream O +
from O +
the O +
TATA O +
box O -
. O +

As O +
seen O +
also O +
in O +
the O +
murine O +
IL-2 O +
cDNA O -
, O +
there O +
is O +
an O +
unusual O +
repeat O +
of O +
CAG O +
triplet O +
coding O +
for O +
12 O +
glutamine O +
residues O +
in O +
a O +
row O +
in O +
the O +
first O +
exon O -
. O +

The O +
second O +
exon O +
( O -
60 O +
bp O -
) O +
is O +
separated O +
from O +
the O +
first O +
exon O +
by O +
a O +
short O +
intron O +
consisting O +
of O +
97 O +
bp O -
. O +

The O +
second O -
, O +
the O +
third O +
and O +
the O +
fourth O +
exons O +
are O +
interrupted O +
by O +
longer O +
introns O +
whose O +
size O +
is O +
about O +
2.3 O +
Kbp O +
and O +
1.6 O +
Kbp O -
, O +
respectively O -
. O +

As O +
far O +
as O +
the O +
available O +
sequence O +
data O +
are O +
concerned O -
, O +
it O +
seems O +
that O -
, O +
despite O +
their O +
identical O +
location O -
, O +
intron O +
sequences O +
are O +
distinctly O +
dissimilar O +
except O +
for O +
the O +
junction O +
regions O +
between O +
the O +
human B-Species +
and O +
mouse B-Species +
IL-2 O +
genes O -
. O +

There O +
are O +
two O +
potential O +
poly O +
( O -
A O -
) O +
addition O +
signals O +
within O +
the O +
mouse B-Species +
gene O +
( O -
nucleotide O +
positions O +
793 O +
- O +
798 O +
and O +
924 O +
- O +
929 O +
in O +
Fig. O +
3 O +
) O +
and O -
, O +
based O +
on O +
our O +
sequence O +
data O +
for O +
various O +
cDNA O +
clones O -
, O +
both O +
signals O +
seem O +
to O +
function O +
and O +
give O +
rise O +
to O +
heterogeneous O +
termini O +
of O +
the O +
mRNA O +
in O +
the O +
LBRM-33 O +
cells O +
( O -
16 O -
) O -
. O +

We O +
have O +
also O +
determined O +
the O +
sequence O +
of O +
about O +
500 O +
bp O +
of O +
5'-flanking O +
region O +
of O +
mouse B-Species +
IL-2 O +
gene O -
, O +
since O +
( O -
i O -
) O +
promoter O -
/ O -
regulatory O +
sequences O +
are O +
located O +
in O +
this O +
region O +
in O +
many O +
other O +
genes O +
of O +
eukaryotes O +
and O +
( O -
ii O -
) O +
this O +
region O +
appeared O +
to O +
contain O +
sequences O +
which O +
show O +
strongest O +
cross O -
- O -
hybridization O +
between O +
human B-Species +
and O +
mouse B-Species +
DNA O +
around O +
the O +
IL-2 O +
gene O +
( O -
Fig. O +
1 O -
) O -
. O +

Comparison O +
of O +
the O +
nucleotide O +
sequences O +
for O +
the O +
5 O -
' O +
flanking O +
region O +
9327 O +
Nucleic O +
Acids O +
Research O +
-4.0 O +
TAGGAGGTAAACCATCTCGAAACGGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAG O +
-400 O +
-350 O +
GATTTATTCTTTTCATCTATCTCCTCTTGCGCCCGTCCACCACAACAGGCTGCTTACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTT O +
-300 O +
-250 O +
CATGAGTTACTTTTGTGTCTCCACCCCAAAGAGGAAAATTTTGTTCATACGAAAGGCGTTCATTGTATGAATTAAAACTGCCACCTAAGAG O +
-200 O +
-150 O +
TGGGCTAACCCGACCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATATGGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAA O +
-100 O +
-50 O +
AAACAAAGGTAATACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTAATATGTAAAACATCGTGACACCCCCATATTATTTTTC O +
CAGCATTAACAGTATAAATTGCCTCCCATGCTGAAGAGCTGCC O +
TCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGC O +
50 O +
100 O +
ATG O +
TAC O +
AGC O +
ATG O +
CAG O +
CTC O +
GCA O +
TCC O +
TGT O +
GTC O +
ACA O +
TTG O +
ACA O +
CTT O +
GTG O +
CTC O +
CTT O +
GTC O +
AAC O +
AGC O +
GCA O +
CCC O +
ACT O +
Met O +
Tyr O +
Ser O +
Met O +
Gln O +
Leu O +
Ala O +
Ser O +
Cys O +

Val O +
Thr O +
Leu O +
Thr O +
Leu O +
Val O +
Leu O +
Leu O +
Val O +
Asn O +
Ser O +
Ala O +
Pro O +
Thr O +
150 O +
TCA O +
AGC O +
TCC O +
ACT O +
TCA O +
AGC O +
TCT O +
ACA O +
GCG O +
GAA O +
GCA O +

CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
CAG O +
Ser O +
Ser O +
Ser O +
Thr O +
Ser O +
Ser O +
Ser O +
Thr O +
Ala O +
Glu O +
Ala O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
Gln O +
200 O +
CAC O +
CTG O +
GAG O +
CAG O +
CTG O +
TTG O +
ATG O +
GAC O +
CTA O +
CAG O +
GAG O +
CTC O +
CTG O +
AGC O +
AGG O +
ATG O +
GAG O +
GTAAGTGCACAGCCATCCCATC O +

His O +
Leu O +
Glu O +
Gln O +
Leu O +
Leu O +
Met O +
Asp O +
Leu O +
Gln O +
Glu O +
Leu O +
Leu O +
Ser O +

Arg O +
Met O +
Glu O +

TATAGGCAATACCTTTAGCTTTCTTGCCAAAGGCTGTGTTTAATAACCTTTAATAATAATGTTACGCTTTCTCAG O +
AAT O +
TAC O +
AGG O +
AAC O +
lAsn O +
Tyr O +
Arg O +
Asn O +
250 O +
CTG O +
AAA O +
CTC O +
CCC O +
AGG O +
ATG O +
CTC O +
ACC O +
TTC O +
AAA O +
TTT O +
TAC O +
TTG O +
CCC O +
AAG O +
CAG O +
GTGAGTGAGTTTCTGTTTAACTGGTGC O +
Leu O +
Lys O +
Leu O +

Pro O +
Arg O +
Met O +
Leu O +

Thr O +
Phe O +
Lys O +
Phe O +
Tyr O +
Leu O +
Pro O +
Lys O +
Gln O +
TCTAATG---------------------------------------------------------- O -
_ O -
_ O +
? O +

_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
_ O -
----------------------- O +
2000 O +
bp O +
--------------------?---------------------------------------------------------- O +
AATGTGAACCTTGTAGTTTCTTTGTAGATTGGAACAATAGTCTGAACTTGTGT O +
TATGCATTGGTAGAGAAACACAGACTTTTTACAAAGTCTAATGAAGCCAGAAGAGCTCACTAGAGTGGCCTAACAGTTAAGGTGACCCTTA O +
TGGTTGTGAGCTCTTGCTCTTCTAGATTTATGGCATCGATTACCTCAGTCCCCCTTTACAGAGGACAGGGAGTGGTAAAAGCTATGTGCTG O +
CCTTCTCTTGATTAGAGAGACTGCAGACTAACTTTCTGGCTCTTCAGTATGTGGTGAGCTGAGCTGATGGTTAAGCTTATTACTCCTCTAG O +
300 O +
350 O +
GCC O +
ACA O +
GAA O +
TTG O +
AAA O +
GAT O +
CTT O +
CAG O +
TGC O +
CTA O +
GAA O +
GAT O +
GAA O +
CTT O +
GGA O +
CCT O +
CTG O +
CGG O +
CAT O +
GTT O +
CTG O +
GAT O +
TTG O +
Ala O +
Thr O +
Glu O +
Leu O +
Lys O +
Asp O +
Leu O +
Gln O +
Cys O +
Leu O +
Glu O +
Asp O +
Glu O +
Leu O +

Gly O +
Pro O +
Leu O +

Arg O +

His O +
Val O +
Leu O +
Asp O +
Leu O +
490 O +
ACT O +
CAA O +
AGC O +
AAA O +
AGC O +
TTT O +
CAA O +
TTG O +
GAA O +
GAT O +
GCT O +
GAG O +
AAT O +
TTC O +
ATC O +
AGC O +
AAT O +
ATC O +
AGA O +
GTA O +
ACT O +
GTT O +

GTA O +
Thr O +
Gln O +
Ser O +
Lys O +
Ser O +
Phe O +
Gln O +
Leu O +
Glu O +
Asp O +
Ala O +
Glu O +
Asn O +
Phe O +
Ile O +
Ser O +
Asn O +
Ile O +
Arg O +
Val O +
Thr O +
Val O +
Val O +
AAA O +
CTA O +
AAG O +
GTAAGGTGTTGCTTTATTTGCTAATCTGGAAATAAAATAGAGAAGAAATGCATTTTTAAGTGGCTTGCCATTTCTGGT O +
Lys O +
Leu O +
Lys O +
CTTTGATGGGTTCTGTGCATTTAGTCAACCAAAGTTTAAAGTCACTGTGCAAGTGAATCC O +
-------------------------------------------------------------------- O +

-1000 O +
bp O +
------ O +
--------------------------------------------------------------- O +

GAATTCTACAGAAGTGTTCAGTGTTCCCATCAAATGCTCGTTGGTAATCAACTCTGGAGAGCTT O +
TATTTTTTATGCTTTACCATTTGATATCATAATAAAACATAACCCAATAATTGTGATCATTTCAGAAATGTGAATGTTCAATATATTTAAC O +
CAGTGTTAAAATAAATGCCTAAAAGCTCCGTTGAAGAATAATTATATGCAAAGTAAGCTACCTTAGCCTACAATTTTATATTCTTTTTTAG O +
450 O +
500 O +
GGC O +
TCT O +
GAC O +
AAC O +
ACA O +
TTT O +
GAG O +
TGC O +
CAA O +
TTC O +
GAT O +
GAT O +
GAG O +
TCA O +
GCA O +
ACT O +
GTG O +
GTG O +

GAC O +
TTT O +
CTG O +
AGG O +
AGA O +
Gly O +
Ser O +
Asp O +
Asn O +
Thr O +
Phe O +
Glu O +
Cys O +
Gln O +
Phe O +
Asp O +
Asp O +
GlU O +
Ser O +
Ala O +
Thr O +
Val O +
Val O +
Asp O +
Phe O +
Leu O +
Arg O +

Arg O +
550 O +
TGG O +
ATA O +
GCC O +
TTC O +
TGT O +
CAA O +
AGC O +
ATC O +
ATC O +
TCA O +
ACA O +
AGC O +
CCT O +
CAA O +
TAACTATGTACCTCCTGCTTACAACACATAAGGC O +
Trp O +
Ile O +
Ala O +
Phe O +
Cys O +
Gln O +
Ser O +
Ile O +
Ile O +
Ser O +
Thr O +
Ser O +
Pro O +
Gln O +

600 O +

650 O +
TCTCTATTTAT4TAAATATTTAACTTTAATTTATTTTTGGATGTATTGTTTACTATCTTTTGTAACTACTAGTCTTCAGATGATAAATATG O +
700 O +
750 O +
GATCTTTAAAGATTCTTTTTGTAAGCCCCAAGGGCTCAAAAATGTTTTAAACTATTTATCTGAAATTATT+ATTATATTGAATTGTTAAAT O +
< O +
4>800 O +
850 O +
ATCATGTGTAGGTAGACTcATTCA O +
TAAAAGTAmAGATGATTCAAATATAAATAAGCTCAGATGTCTGTCATTTTTAGGACAGCACAAAG O +
900 O +
0 O -
" O +
TAAGCGCTAAAATAACTTCTCAGTTATTCCTGTGAACTcTATGTTAATCAGTGTTTTCAAGAAATAAAGCTCTCCTCT O +
AAA O +
GATGGCTTGTGGGAAAAGATCTCCTCTCCAGGGAGCTAACATCAGCTCAGAGTTTACTCAAGAATTC O +
Fig. O +
3 O -
. O +
Nucleotide O +
sequence O +
of O +
mouse B-Species +
IL-2 O +
gene O -
. O +

Four O +
exons O +
are O +
framed O -
. O +

Numbers O +
refer O +
to O +
nucleotide O +
positions O +
of O +
exons O +
from O +
the O +
presumed O +
cap O +
site O -
. O +

Dots O +
and O +
open O +
circles O +
indicate O +
TATA O +
box O +
and O +
poly O +
A O +
additional O +
signals O -
, O +
respectively O -
. O +

9328 O +
Nucleic O +
Acids O +
Research O +
-4 O +
5 O +
0 O +
-400 O +
TAGGAGGT O +
AAACCA O +
T O +
CTCGAAAC O +
GGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAGGATTTATTCTTTTCATCTATCTCC O +
.0 O +

* O +
.0 O +

.- O +

* O -
. O +

* O +
.. O +

* O +
-- O -
. O +

-- O +
.*-@ O +
.. O +
............ O +
-- O +
-*- O -
* O +
* O +
TAAAAAGGTAAAACCAGTTCT O +
GAAACAGGAAACCAATACACTTCCTGTTTAATCAACAAATCTAAA O +
CATTTATTCTTTTCATCTGTTTAC O +
-350 O +
-300 O +
TCTTGCGCCCGTCCACCACAACAGGCTGCT O +
T O +
ACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTTCATGAGTTACTTTTGTGTCTC O +
TCTTGCTCTTGTTCACCACAATA O +
TGCTATTCACATGTTCAGTGTAGTTTTATGACAAAGAAAATTTTC O +
TGAGTTACTTTTGTATCCC O +
-250 O +
CA O +
CCCC O +
AAAG O +
AGGAAAATTTGTTTCATACGAAAGGCGTTCATTGTATGAATTAAAACT O +
CCACCTAAGAGTGGGCTAACCCGA O +

* O -
~~~ O +
~~ O +
..... O +

* O +
.-- O +

* O -
.. O +

- O +
* O +
.-- O +
. O +

* O -
* O +
. O +

* O -
- O -
. O +

-- O -
. O +

* O -
- O +
* O -
- O +
- O +
- O +
* O -
- O +
0 O +
@ O +

* O -
-- O +
0 O +
.. O +
. O +

CACCCCCTTAAAGAAAGGAGGAAAAACTGTTTCATACAGAAGGCGTTAATTGCATGAATTAGAGCTATCACCTAAGTGTGGGCTAATGTAA O +
-200 O +
-150 O +
CCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATAT O +
GGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAAAAACAAAGGTAA O +
CAAAGAGGGATTTCACCTACATCCATTCAGTCAGTCTTTGGGGGTTTAAA O +
AAATTCCAAAGAGTCATCAGAAGAGGAAAAATGAAGGTAA O +
-100 O +
-50 O +
TACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTXATATTAAAACATCGTGACACCCCCATATiXrTCCAGCATTAACAG O +
TGTTTTTT O +
CAGACAGGTAAAGTC O +
TTTGAAAATATGTGTAATATGTAAAACATTTTGACACCCCCATAATATTTTTCCAGAATTAACAG O +
ATAAGCCTCCCATGCTGAAGAGCTGCCTATCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGCATG O +
Mouse B-Species +
rTATGCATCTCTTGTTCAAGAGTTCCCTATCACTCTCTTTAATCACTACACACAGTAACCTCAACTCCTGCCACTATG O +
Human B-Species +
Fig. O +
4 O -
. O +

Comparison O +
of O +
5'-flanking O +
regions O +
of O +
mouse B-Species +
and O +
human B-Species +
IL-2 O +
genes O -
. O +

In O +
aligning O +
the O +
sequences O +
for O +
both O +
genes O -
, O +
gaps O +
were O +
introduced O +
to O +
maximize O +
homology O -
. O +

Dots O +
indicate O +
identical O +
nucleotide O +
sequences O -
. O +

Number O +
1 O +
indicates O +
putative O +
transcription O +
initiation O +
site O -
. O +

Inverted O +
repeats O +
are O +
indicated O +
by O +
bars O +
and O +
dashed O +
lines O -
. O +

TATA O +
box O +
is O +
framed O -
. O +

of O +
both O +
genes O +
is O +
illustrated O +
in O +
Fig. O +
4 O -
. O +

The O +
nucleotide O +
sequence O +
homology O +
from O +
the O +
TATA O +
box O +
to O +
-470 O +
is O +
85 O -
% O -
. O +

The O +
highest O +
region O +
of O +
homology O +
was O +
observed O +
between O +
the O +
TATA O +
box O +
and O +
position O +
-97 O +
( O -
60 O +
bp O +
matches O +
out O +
of O +
64 O +
bp O -
) O +
of O +
both O +
genes O -
. O +

DISCUSSION O +
We O +
have O +
isolated O +
recombinant O +
clones O +
for O +
mouse B-Species +
IL-2 O +
gene O +
from O +
a O +
phage O +
Charon O +
4A O -
/ O -
mouse B-Species +
genomic O +
DNA O +
library O +
and O +
determined O +
the O +
entire O +
sequence O +
of O +
the O +
gene O +
except O +
for O +
the O +
sequence O +
of O +
the O +
internal O +
portion O +
of O +
the O +
second O +
and O +
third O +
introns O -
. O +

The O +
mouse B-Species +
IL-2 O +
cDNA O +
sequence O +
was O +
aligned O +
with O +
the O +
genomic O +
sequence O +
and O +
both O +
sequences O +
matched O +
completely O +
each O +
other O -
. O +

The O +
unusual O +
CAG O +
repeats O +
encoding O +
12 O +
glutamines O +
which O +
was O +
found O +
previously O +
in O +
the O +
cloned O +
cDNA O +
was O +
shown O +
to O +
be O +
present O +
also O +
in O +
the O +
chromosomal O +
gene O -
. O +

This O +
finding O +
further O +
excludes O +
the O +
possibility O +
that O +
the O +
unique O +
repeat O +
is O +
generated O +
by O +
artifacts O +
during O +
the O +
cDNA O +
cloning O +
process O -
. O +

Although O +
we O +
can O +
not O +
rule O +
out O +
the O +
possibility O +
for O +
the O +
deletion O +
of O +
this O +
sequence O +
in O +
the O +
human B-Species +
IL-2 O +
gene O -
, O +
it O +
is O +
more O +
likely O +
that O +
the O +
CAG O +
repeat O +
has O +
been O +
generated O +
in O +
the O +
mouse B-Species +
genome O +
rather O +
recently O -
. O +

The O +
repeat O +
could O +
have O +
been O +
generated O +
either O +
by O +
a O +
direct O +
insertion O +
of O +
the O +
sequence O +
or O +
by O +
the O +
duplication O +
after O +
insertion O +
of O +
a O +
unit O +
sequence O -
. O +

9329 O +
Nucleic O +
Acids O +
Research O +
Organization O +
of O +
the O +
mouse B-Species +
IL-2 O +
gene O +
resembles O +
to O +
that O +
of O +
the O +
human B-Species +
gene O +
( O -
Fig. O +
2 O -
. O -
, O +
ref O -
. O +

9 O -
) O -
. O +

There O +
seems O +
to O +
be O +
little O +
sequence O +
homology O +
between O +
corresponding O +
introns O +
of O +
mouse B-Species +
and O +
human B-Species +
IL-2 O +
genes O -
, O +
except O +
for O +
the O +
intron O -
- O -
exon O +
junctions O +
part O +
of O +
which O +
is O +
thought O +
to O +
be O +
necessary O +
for O +
the O +
RNA O +
splicing O +
( O -
17 O -
, O +
18 O -
) O -
. O +

Dissimilarity O +
of O +
the O +
intron O +
sequences O +
among O +
the O +
genes O +
which O +
are O +
derived O +
from O +
a O +
common O +
ancestor O +
has O +
been O +
reported O +
in O +
other O +
genes O +
( O -
19 O -
, O +
20 O -
) O -
. O +

In O +
spite O +
of O +
the O +
divergence O +
in O +
sequence O +
of O +
introns O -
, O +
the O +
size O +
and O +
position O +
of O +
the O +
introns O +
are O +
very O +
similar O +
between O +
the O +
murine O +
and O +
human B-Species +
IL-2 O +
genes O -
. O +

Of O +
particular O +
interests O +
is O +
the O +
presence O +
of O +
highly O +
conserved O +
sequences O +
in O +
the O +
5 O -
' O +
-flanking O +
region O +
of O +
the O +
human B-Species +
and O +
mouse B-Species +
IL-2 O +
gene O +
( O -
Fig. O +
4 O -
) O -
. O +

Whereas O +
the O +
coding O +
region O +
shows O +
nucleotide O +
sequence O +
homology O +
of O +
72 O -
% O +
between O +
the O +
two O +
genes O -
, O +
the O +
5 O -
' O +
upstream O +
region O +
spanning O +
about O +
500 O +
bp O +
( O -
Fig. O +
4 O -
) O +
shows O +
85 O -
% O +
homology O +
which O +
was O +
readily O +
detectable O +
by O +
the O +
blotting O +
analysis O +
( O -
Fig. O +
1 O -
, O +
lane O +
1 O -
- O -
4 O -
) O -
. O +

Since O +
we O +
have O +
not O +
yet O +
determined O +
the O +
nucleotide O +
sequence O +
further O +
upstream O +
of O +
the O +
mouse B-Species +
gene O -
, O +
we O +
do O +
not O +
know O +
whether O +
or O +
not O +
this O +
similarity O +
extends O +
further O -
. O +

It O +
is O +
likely O +
that O +
such O +
sequences O +
are O +
involved O +
in O +
the O +
controlled O +
expression O +
of O +
the O +
IL-2 O +
genes O +
in O +
activated O +
T O -
- O -
lymphocytes O -
. O +

Work O +
is O +
in O +
progress O +
to O +
identify O +
such O +
DNA O +
sequences O +
by O +
introducing O +
the O +
cloned O +
genes O +
into O +
various O +
lymphocytic O +
cell O +
lines O -
. O +

Our O +
preliminary O +
results O +
indicate O +
that O +
the O +
5 O +
' O -
-flanking O +
sequence O +
of O +
the O +
human B-Species +
IL-2 O +
gene O +
mediates O +
mitogen O +
induced O +
expression O +
of O +
the O +
gene O +
in O +
T O -
- O -
lymphocytic O +
cells O +
( O -
Fujita O +
& O +
Taniguchi O -
, O +
unpublished O +
observation O -
) O -
. O +

ACKNOWLEDGEMENTS O +
We O +
thank O +
Dr. O +
T. O +
Honjo O +
for O +
mouse B-Species +
gene O +
library O -
. O +

We O +
are O +
also O +
indepted O +
to O +
Ms. O +
M. O +
Nagatsuka O +
for O +
typing O +
the O +
manuscript O -
. O +

This O +
work O +
was O +
supported O +
in O +
part O +
by O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Special O +
Project O +
Research O -
, O +
Cancer O -
- O -
Bioscience O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O +
and O +
Culture O -
, O +
Japan O -
. O +

? O +

To O +
whom O +
correspondence O +
should O +
be O +
addressed O +
* O -
Present O +
address O -
: O +
Department O +
of O +
Microbiology O -
, O +
School O +
of O +
Medicine O -
, O +
Chiba O +
University O -
, O +
Chiba O +
280 O -
, O +
Japan O +
+ O -
Present O +
address O -
: O +
Central O +
Research O +
Laboratory O -
, O +
Ajinomoto O +
Co. O +

Inc. O -
, O +
Totsuka O -
- O -
ku O -
, O +
Yokohama O +
244 O -
, O +
Japan O +
9330 O +
Nucleic O +
Acids O +
Research O +
REFERENCES O +
1 O -
. O +

Morgan O -
, O +
D. O +
A. O -
, O +
Ruscetti O -
, O +
F. O +
W. O +
and O +
Gallo O -
, O +
R. O +
( O -
1976 O -
) O +
Science O -
, O +
193 O -
, O +
1007 O -
- O -
1008 O -
. O +

2 O -
. O +

Gil O +
lis O -
, O +
S. O +
Ferm O -
, O +
M. O +
M. O -
, O +
Ou O -
, O +
W. O +
and O +
Smith O -
, O +
K. O +
( O -
1 O +
978 O -
) O +
J. O +
Immunol O -
. O -
, O +
120 O -
, O +
2023 O -
- O -
2027 O -
. O +

3 O -
. O +

Chen O -
, O +
B. O +
M. O +
and O +
Di O +
Sabato O -
, O +
G. O +
( O -
1976 O -
) O +
Cell O -
. O +

Immunol O -
. O -
, O +
22 O -
, O +
211 O +
224 O -
. O +

4 O -
. O +

Henney O -
, O +
C. O +
S. O -
, O +
Kuribayashi O -
, O +
K. O -
, O +
Kern O -
, O +
D. O +
E. O +
and O +
Gillis O -
, O +
S. O +
( O -
1981 O -
) O +
Nature O -
, O +
291 O -
, O +
335 O -
- O -
338 O -
. O +

5 O -
. O +

Wagner O -
, O +
H. O -
, O +
Hardt O -
, O +
C. O -
, O +
Heeg O -
, O +
K. O -
, O +
Rollinghoff O -
, O +
M. O +
and O +
Pfizenmaier O -
, O +
K. O +
( O -
1980 O -
) O +
Nature O -
, O +
284 O -
, O +
278 O -
- O -
280 O -
. O +

6 O -
. O +

Farrar O -
, O +
J. O +
J. O -
, O +
Benjamin O -
, O +
W. O +
R. O -
, O +
Hilfikr O +
M. O +
L. O -
, O +
Howard O -
, O +
M. O -
, O +
Farrar O -
, O -
W. O +
L. O +
and O +
Fuller O -
- O -
Farrar O -
, O +
J. O +
( O -
1982 O -
) O +
Immunol O -
. O +

Rev. O +
63 O -
, O +
129 O -
- O -
166 O -
. O +

7 O -
. O +

Pearlstein O -
, O +
K. O -
, O +
Palladino O -
, O +
M. O +
A. O -
, O +
Welte O -
, O +
K. O +
and O +
Vilcek O -
, O +
J. O +
( O -
1983 O -
) O +
Cell O -
. O +

Immunol O -
. O -
, O +
80 O -
, O +
1 O -
- O -
9 O -
. O +

8 O -
. O +

Taniguchi O -
, O +
T. O -
, O +
Matsui O -
, O +
H. O -
, O +
Fujita O -
, O +
T. O -
, O +
Takaoka O -
, O +
C. O -
, O +
Kashima O -
, O +
N. O -
, O +
Yoshimoto O -
, O +
R. O +
and O +
Hamuro O -
, O +
J. O +
( O -
1983 O -
) O +
Nature O +
302 O -
, O +
305 O -
- O -
310 O -
. O +

9 O -
. O +

Fujita O -
, O -
T.,Takaoka O -
, O -
C. O -
, O +
Matsui O -
, O +
H. O +
and O +
Taniguchi O +
T. O +
( O -
1983 O -
) O +
Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

USA O +
80 O -
, O +
7437 O -
- O -
7411 O -
. O +

10 O -
. O +

Ohno O -
, O +
S. O +
and O +
Taniguchi O -
, O +
T. O +
( O -
1982 O -
) O +
Nucleic O +
Acids O +
Res O -
. O +

10 O -
, O +
967 O +
977 O -
. O +

11 O -
. O +

Southern O -
, O +
E. O +
M. O +
( O -
1975 O -
) O +
J. O +
Mol O -
. O +

Biol O -
. O +

98 O -
, O +
503 O -
- O -
517 O -
. O +

12 O -
. O +

Benton O -
, O +
W. O +
D. O +
and O +
Davis O -
, O +
R. O +
W. O +
( O -
1977 O -
) O +
Science O +
196 O -
, O +
180 O -
- O -
182 O -
. O +

13 O -
. O +

Ohno O -
, O +
S. O +
and O +
Taniguchi O -
, O +
T. O +
( O -
1981 O -
) O +
Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

USA O +
78 O -
, O +
5305 O -
- O -
5309 O -
. O +

14 O -
. O +

Maxam O -
, O +
A. O +
M. O +
and O +
Gilbert O -
, O +
W. O +
( O -
1980 O -
) O +
Meth O -
. O +

Enzymol O -
. O +
65 O -
, O +
560 O +
580 O -
. O +

15 O -
. O +

Sanger O -
, O +
F. O -
, O +
Nicklen O -
, O +
S. O +
and O +
Coulson O -
, O +
A. O +
R. O +
( O -
1977 O -
) O +
Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

USA O -
, O +
74 O -
, O +
5463 O -
- O -
5467 O -
. O +

16 O -
. O +

Gillis O -
, O +
S. O -
, O +
Scheid O -
, O +
M. O +
and O +
Watson O -
, O +
J. O +
D. O -
( O -
1980 O -
) O +
J. O +
Immunol O -
. O +

, O -
125 O -
, O +
2570 O -
- O -
2580 O -
. O +

17 O -
. O +

Breathnach O -
, O +
R. O -
, O +
Benoist O -
, O +
C. O -
, O +
O'Hare O -
, O +
K. O -
, O +
Gannon O -
, O +
F. O +
and O +
Chambon O -
, O +
P. O -
( O -
1978 O -
) O +

Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

USA O -
, O +
75 O -
, O +
4853 O -
- O -
4857 O -
. O +

18 O -
. O +

Lerner O -
, O +
M. O +
R. O -
, O +
Boyle O -
, O +
J. O +
A. O -
, O +
Mount O -
, O +
S. O +
M. O -
, O +
Wolin O -
, O +
S. O +
L. O +
and O +
Steitz O -
, O +
J. O +
A. O +
( O -
1980 O -
) O +
Nature O -
, O +
283 O -
, O +
220 O -
- O -
224 O -
. O +

19 O -
. O +

Van O +
Ooyen O -
, O +
A. O -
, O +
Van O +
den O +
Berg O -
, O +
J. O -
, O +
Mantei O -
, O +
N. O +
and O +
Weissmann O -
, O +
C. O -
( O -
1979 O -
) O +
Science O -
, O +
206 O -
, O +
337 O -
- O -
344 O -
. O +

20 O -
. O +

Searle O -
, O +
P. O +
F. O -
, O +
Davison O -
, O +
B. O +
L. O -
, O +
Stuart O -
, O +
G. O +
W. O -
, O +
Wilkie O -
, O +
T. O +
M. O -
, O +
Norstedt O -
, O +
G. O +
and O +
Palmiter O -
, O +
R. O +
D. O +
( O -
1984 O -
) O +
Mol O -
. O +

Cell O -
. O +

Biol O -
. O +

4 O -
, O +
1221 O -
- O -
1230 O -
. O +

9331 O +

Preparation O +
of O +
oligodeoxyribonucleoside O +
methylphosphonates O +
on O +
a O +
polystyrene O +
support O -
. O +

Abstract O +
An O +
efficient O +
procedure O +
is O +
described O +
for O +
synthesizing O +
deoxyribonucleoside O +
methylphosphonates O +
on O +
polystyrene O +
polymer O +
supports O +
which O +
involves O +
condensing O +
5'-dimethoxytrityldeoxynucleoside O +
3'-methylphosphonates O -
. O +

The O +
oligomers O +
are O +
removed O +
from O +
the O +
support O +
and O +
the O +
base O +
protecting O +
groups O +
hydrolyzed O +
by O +
treatment O +
with O +
ethylenediamine O +
in O +
ethanol O -
, O +
which O +
avoids O +
hydrolysis O +
of O +
the O +
methylphosphonate O +
linkages O -
. O +

Two O +
types O +
of O +
oligomers O +
were O +
synthesized O -
: O +
those O +
containing O +
only O +
methylphosphonate O +
linkages O -
, O +
d O -
- O -
Np O -
( O -
Np O -
) O -
nN O -
, O +
and O +
those O +
which O +
terminate O +
with O +
a O +
5 O -
' O +
nucleotide O +
residue O -
, O +
dNp O +
( O -
Np O -
) O -
nN. O +
The O +
latter O +
oligomers O +
can O +
be O +
phosphorylated O +
by O +
polynucleotide O +
kinase O -
, O +
and O +
are O +
separated O +
by O +
polyacrylamide O +
gel O +
electrophoresis O +
according O +
to O +
their O +
chain O +
length O -
. O +

Piperdine O +
randomly O +
cleaves O +
the O +
oligomer O +
methylphosphonate O +
linkages O +
and O +
generates O +
a O +
series O +
of O +
shorter O +
oligomers O +
whose O +
number O +
corresponds O +
to O +
the O +
length O +
of O +
the O +
original O +
oligomer O -
. O +

Apurinic O +
sites O +
introduced O +
by O +
acid O +
treatment O +
spontaneously O +
hydrolyze O +
to O +
give O +
oligomers O +
which O +
terminate O +
with O +
free O +
3 O -
' O +
and O +
5 O -
' O +
OH O +
groups O -
. O +

These O +
reactions O +
may O +
be O +
used O +
to O +
characterize O +
the O +
oligomers O -
. O +

Images O +
Vlue1Nubr1193NcecAisRsah O +
Preparation O +
of O +
oligodeoxyribonucleoside O +
methylphosphonates O +
on O +
a O +
polystyrene O +
support O +
P.S.Miller O -
, O +
C.H.Agris O -
, O +
A.Murakami O -
, O +
P.M.Reddy O -
, O +
S.A.Spitz O +
and O +
P.O.P.Ts'o O +
Division O +
of O +
Biophysics O -
, O +
Johns O +
Hopkins O +
University O -
, O +
School O +
of O +
Hygiene O +
and O +
Public O +
Health O -
, O +
Baltimore O -
, O +
MD O +
21205 O -
, O +
USA O +
Received O +
26 O +
July O +
1983 O -
; O +
Accepted O +
5 O +
September O +
1983 O +
ABSTRACT O +
An O +
efficient O +
procedure O +
is O +
described O +
for O +
synthesizing O +
deoxyribonucleoside O +
methylphosphonates O +
on O +
polystyrene O +
polyner O +
supports O +
which O +
involves O +
condensing O +
5'-dimethoxytrityldeoxynucleoside O +
3'-methylphosphonates O -
. O +

The O +
oligomers O +
are O +
removed O +
from O +
the O +
support O +
and O +
the O +
base O +
protecting O +
groups O +
hydrolyzed O +
by O +
treatment O +
with O +
ethylenediamine O +
in O +
ethanol O -
, O +
which O +
avoids O +
hydrolysis O +
of O +
the O +
methylphosphonate O +
linkages O -
. O +

Two O +
types O +
of O +
oligomers O +
were O +
synthesized O -
: O +
those O +
containing O +
only O +
methylphosphonate O +
linkages O -
, O +
d O -
- O -
Np O -
( O -
Np O -
) O +
N O -
, O +
and O +
those O +
which O +
terminate O +
with O +
a O +
5 O -
' O +
nucleotide O +
residue O -
, O +
dNp O -
( O -
Np O -
) O -
N O -
.- O -
J O +
he O +
latter O +
oligomers O +
can O +
be O +
phosphorylated O +
by O +
polynucleotide O +
kinase O -
, O +
and O +
are O +
separated O +
by O +
polyacrylamide O +
gel O +
electrophoresis O +
according O +
to O +
their O +
chain O +
length O -
. O +

Piperdine O +
randomly O +
cleaves O +
the O +
oligomer O +
methylphosphonate O +
linkages O +
and O +
generates O +
a O +
series O +
of O +
shorter O +
oligomers O +
whose O +
number O +
corresponds O +
to O +
the O +
length O +
of O +
the O +
original O +
oligomer O -
. O +

Apurinic O +
sites O +
introduced O +
by O +
acid O +
treatment O +
spontaneously O +
hydrolyze O +
to O +
give O +
oligomers O +
which O +
terminate O +
with O +
free O +
3 O -
' O +
and O +
5 O -
' O +
OH O +
groups O -
. O +

These O +
reactions O +
may O +
be O +
used O +
to O +
characterize O +
the O +
oligomers O -
. O +

INTRODUCTION O +
Oligonucleoside O +
methylphosphonates O +
have O +
been O +
used O +
to O +
st O -
- O -
udy O +
the O +
function O +
of O +
specific O +
RNA O +
sequences O +
in O +
biochemical O +
and O +
intact O +
cellular O +
systems O +
( O -
1,2 O -
) O -
. O +

Since O +
these O +
nonionic O +
nucleic O +
acid O +
analogs O +
can O +
be O +
taken O +
up O +
intact O +
by O +
mammalian O +
cells O +
and O +
certain O +
bacterial O +
cells O +
in O +
culture O -
, O +
these O +
compounds O +
promise O +
to O +
be O +
useful O +
reagents O +
for O +
exploring O +
and O +
regulating O +
the O +
function O +
of O +
nucleic O +
acids O +
within O +
living O +
cells O -
. O +

In O +
order O +
to O +
carry O +
out O +
more O +
extensive O +
biochemical O +
and O +
biological O +
studies O -
, O +
an O +
efficient O +
method O +
for O +
synthesis O +
of O +
oligonucleoside O +
methylphosphonates O +
of O +
defined O +
sequence O +
is O +
needed O -
. O +

Previously O +
we O +
described O +
the O +
synthesis O +
of O +
methylphosphonate O +
analogs O +
on O +
a O +
silica O +
gel O +
support O +
( O -
3 O -
) O -
. O +

Protected O +
nucleoside O +
3'-methylphosphonic O +
chlorides O +
or O +
tetrazolides O +
were O +
used O +
as O +
synthetic O +
intermediates O -
. O +

While O +
oligothymidine O +
methylphosphonates O +
could O +
be O +
efficiently O +
synthesized O +
by O +
this O +
procedure O -
, O +
low O +
yields O +
were O +
encountered O +
when O +
other O +
nucleosides O -
, O +
particularly O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ibuG O +
were O +
used O -
. O +

Recently O +
Sinha O +
et O +
al. O +
? O -
) O +

I O +
RL O +
Press O +
Limited O -
, O +
Oxford O -
, O +
England O -
. O +

Nucleic O +
Acids O +
Research O +
Volume O +
1 O +
1 O +
Number O +
18 O +
1983 O +
6225 O +
Nucleic O +
Acids O +
Research O +
described O +
the O +
preparation O +
of O +
oligonucleoside O +
methylphosphophonates O +
on O +
a O +
glass O +
support O +
using O +
nucleoside O +
3'-methylphosphine O +
chlorides O +
as O +
reactive O +
intermediates O +
( O -
4 O -
) O -
. O +

In O +
this O +
paper O +
we O +
describe O +
a O +
set O +
of O +
useful O +
methods O +
for O +
the O +
synthesis O +
and O +
analysis O +
of O +
these O +
analogs O -
. O +

The O +
synthesis O +
involves O +
condensation O +
of O +
protected O +
nucleoside O +
3'-methylphosphonate O +
triethylammonium O +
salts O +
with O +
nucleosides O +
or O +
oligomers O +
linked O +
to O +
a O +
polystyrene O +
support O -
. O +

This O +
method O +
has O +
proven O +
to O +
be O +
easy O +
to O +
use O +
and O +
allows O +
relatively O +
rapid O +
synthesis O +
of O +
oligomers O +
of O +
defined O +
sequence O +
up O +
to O +
nine O +
nucleosides O +
in O +
length O -
. O +

We O +
have O +
also O +
developed O +
conditions O +
for O +
the O +
efficient O +
removal O +
of O +
base O +
protecting O +
groups O +
and O +
subsequent O +
purification O +
of O +
the O +
oligomers O -
. O +

A O +
novel O +
hydrolysis O +
reaction O +
which O +
can O +
be O +
used O +
as O +
a O +
basis O +
for O +
characterizing O +
and O +
sequencing O +
these O +
oligonucleotide O +
analogs O +
occurs O +
at O +
apurinic O +
sites O +
created O +
by O +
acid O +
treatment O +
of O +
the O +
oligomers O -
. O +

EXPERIMENTAL O +
Materials O +
and O +
Methods O +
Protected O +
nucleosides O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
N O -
, O +
were O +
purchased O +
from O +
P.L. O +
Biochemicals O +
and O +
were O +
used O +
without O +
further O +
purification O -
. O +

Protected O +
nucleoside O +
3'-methylphosphonate O +
triethylammoni O +
um O +
salts O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
Np*Et3NH O -
, O +
were O +
prepared O +
as O +
previously O +
described O +
( O -
3 O -
) O -
. O +

5-Dimethoxytrityl O +
protected O +
nucleosides O +
esterified O +
to O +
1 O -
% O +
or O +
2 O -
% O +
crosslinked O +
polystyrene O +
were O +
purchased O +
from O +
Chem O +
Genes O +

Inc. O +

The O +
nucleoside O +
loading O +
level O +
was O +
40 O +
to O +
120 O +
pmol O +
of O +
nucleoside O -
/ O -
g O +
of O +
support O -
. O +

Mesitylenesulfonyl-3-nitrotriazole O +
( O -
MSNT O -
) O +
was O +
purchased O +
from O +
Vega O +
Biochemicals O -
. O +

Anhydrous O +
pyridine O +
was O +
prepared O +
by O +
refluxing O +
previously O +
purified O +
pyridine O +
( O -
5 O -
) O +
over O +
calcium O +
hydride O +
chips O +
for O +
several O +
hours O +
followed O +
by O +
distillation O +
onto O +
calcium O +
hydride O +
chips O +
in O +
5 O +
ml O +
V O -
- O -
vials O +
fitted O +
with O +
Teflon O -
- O -
lined O +
septum O +
caps O +
( O -
Wheaton O +
Scientific O -
) O -
. O +

Lyophilized O +
spleen O +
phosphodiesterase O +
was O +
obtained O +
from O +
P.L. O +
Biochemicals O -
. O +

T-4 O +
polynucleotide O +
kinase O +
and O +
[ O -
y-32P O -
] O -
-ATP O +
were O +
obtained O +
from O +
New O +
England O +
Nuclear O -
. O +

Reversed O +
phase O +
high O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
was O +
carried O +
out O +
on O +
Whatman O +
Inc. O +
C-18 O +
( O -
ODS-3 O -
) O +
columns O +
( O -
0.4 O +
x O +
25 O +
cm O -
) O -
. O +

Analytical O +
columns O +
were O +
eluted O +
with O +
50 O +
ml O +
linear O +
gradients O +
of O +
acetonitrile O +
in O +
water O +
or O +
acetonitrile O +
in O +
0.1 O +
M O +
ammonium O +
acetate O +
( O -
pH O +
5.8 O -
) O +
at O +
a O +
flow O +
rate O +
of O +
2.5 O +
ml O -
/ O -
min O -
. O +

The O +
eluate O +
was O +
monitored O +
at O +
254 O +
nm O -
. O +

The O +
following O +
molar O +
extinction O +
coefficients O +
were O +
used O +
at O +
254 O +
nm O -
: O +
d O -
- O -
T O +
7,250 O -
, O +
dA O +
13,270 O -
, O +
dC O +
6,260 O -
, O +
dG O +
13,700 O -
. O +

Unless O +
otherwise O +
noted O -
, O +
all O +
reactions O +
and O +
operations O +
were O +
carried O +
out O +
at O +
room O +
temperature O -
. O +

General O +
Procedure O +
for O +
Preparing O +
Oligonucleoside O +
Methylphosphonates O -
. O +

The O +
following O +
procedure O +
represents O +
the O +
current O +
method O +
used O +
in O +
our O +
laboratory O +
to O +
6226 O +
Nucleic O +
Acids O +
Research O +
synthesize O +
methylphosphonate O +
oligomers O -
. O +

Table O +
I O +
lists O +
some O +
of O +
the O +
oligomers O +
which O +
have O +
been O +
synthesized O +
on O +
polystyrene O +
supports O -
. O +

Oligomers O +
7 O -
, O +
8 O -
, O +
and O +
10 O +
were O +
synthesized O +
as O +
described O +
below O -
. O +

The O +
other O +
oligomers O +
were O +
synthesized O +
in O +
essentially O +
the O +
same O +
manner O +
except O +
the O +
condensation O +
reactions O +
were O +
run O +
in O +
1 O +
ml O +
V O -
- O -
vials O +
or O +
in O +
glass O +
reaction O +
columns O +
purchased O +
from O +
Bachem O +
Inc. O +

When O +
the O +
reactions O +
were O +
run O +
in O +
V O -
- O -
vials O -
, O +
the O +
support O +
was O +
dried O +
by O +
several O +
evaporations O +
with O +
anhydrous O +
pyridine O +
in O +
the O +
V O -
- O -
vial O +
( O -
3 O -
) O -
. O +

When O +
the O +
reactions O +
were O +
run O +
in O +
the O +
glass O +
reaction O +
column O -
, O +
the O +
support O +
was O +
dried O +
by O +
a O +
single O +
evaporation O +
with O +
anhydrous O +
pyridine O +
overnight O +
at O +
room O +
temperature O -
. O +

Synthesis O +
of O +
Protected O +
Oligonucleoside O +
Methylphosphonates O -
. O +

The O +
synthetic O +
reactions O +
are O +
most O +
conveniently O +
carried O +
out O +
in O +
a O +
polypropylene O +
col O +
umn O +
( O -
Bio O +
Rad O +
Econo O +
column O -
) O +
fitted O +
with O +
a O +
Teflon O +
3-way O +
valve O +
( O -
Bio O +
Rad O -
) O +
and O +
a O +
rubber O +
septum O +
cap O +
( O -
Wheaton O +
Scientific O -
) O -
. O +

During O +
washing O +
operations O -
, O +
the O +
septum O +
cap O +
is O +
removed O +
and O +
the O +
3-way O +
valve O +
is O +
connected O +
to O +
a O +
filter O +
flask O +
via O +
a O +
Luerer O +
adaptor O +
and O +
tubing O +
set O +
( O -
Bio O +
Rad O -
) O -
. O +

Generally O +
vacuum O +
is O +
not O +
required O +
to O +
wash O +
the O +
support O -
. O +

During O +
the O +
drying O +
step O -
, O +
one O +
port O +
of O +
the O +
3-way O +
valve O +
is O +
connected O +
to O +
a O +
cold O +
trap O +
and O +
vacuum O +
pump O +
via O +
the O +
barrel O +
of O +
a O +
1 O +
ml O +
plastic O +
syringe O -
. O +

The O +
other O +
port O +
is O +
connected O +
to O +
a O +
Drierite O +
column O +
filled O +
with O +
dry O +
argon O -
. O +

A O +
reaction O +
cycle O +
consists O +
of O +
the O +
following O +
10 O +
steps O -
: O +
1 O -
) O +
The O +
support O +
( O -
60 O +
mg O -
, O +
1 O -
% O +
crosslinked O -
) O +
in O +
the O +
column O +
is O +
washed O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
methylene O +
chloride O -
/ O -
isopropanol O +
( O -
85:15 O -
, O +
v O -
/ O -
v O -
) O -
. O +

2 O -
) O +
The O +
support O +
is O +
treated O +
with O +
2 O +
ml O +
of O +
1 O +
M O +
zinc O +
bromide O +
in O +
methylene O +
chloride O -
/ O -
isopropanol O +
solution O -
. O +

Two O +
fiveminute O +
treatments O +
are O +
used O +
when O +
the O +
support O -
- O -
bound O +
nucleoside O +
is O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzA O +
or O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ibuG O -
, O +
while O +
four O +
treatments O +
are O +
used O +
when O +
the O +
nucleoside O +
is O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
T O +
or O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzC. O +
After O +
each O +
treatment O +
the O +
orange O +
solution O +
is O +
collected O +
in O +
a O +
clean O +
flask O -
. O +

3 O -
) O +
The O +
support O +
is O +
washed O +
with O +
two O +
2 O +
ml O +
portions O +
of O +
methylene O +
chloride O -
/ O -
isopropanol O +
and O +
the O +
washings O +
are O +
collected O +
in O +
same O +
flask O +
used O +
in O +
step O +
2 O -
) O -
. O +

The O +
solution O +
is O +
diluted O +
to O +
50 O +
ml O +
and O +
a O +
0.20 O +
ml O +
aliquot O +
is O +
dissolved O +
in O +
0.80 O +
ml O +
of O +
perchloric O +
acid O -
/ O -
ethanol O +
( O -
3:2 O -
, O +
v O -
/ O -
v O -
) O -
. O +

The O +
absorbance O +
is O +
determined O +
at O +
500 O +
nm O +
and O +
the O +
amount O +
of O +
trityl O +
cation O +
is O +
determined O +
using O +
a O +
molar O +
extinction O +
coefficient O +
of O +
89,000 O -
. O +

4 O -
) O +
The O +
column O +
is O +
attached O +
to O +
a O +
waste O +
flask O +
and O +
the O +
support O +
is O +
washed O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
0.5 O +
M O +
triethylammonium O +
acetate O +
in O +
dimethylformamide O -
; O +
three O +
2 O +
ml O +
portions O +
of O +
anhydrous O +
pyridine O +
and O +
three O +
2 O +
ml O +
portions O +
of O +
diethyl O +
ether O -
. O +

5 O -
) O +
The O +
column O +
is O +
fitted O +
with O +
the O +
septum O +
cap O +
and O +
set O +
up O +
in O +
the O +
drying O +
mode O +
under O +
house O +
vacuum O +
for O +
at O +
least O +
5 O +
min O -
. O +

6 O -
) O +
The O +
support O +
is O +
dried O +
by O +
adding O +
300 O +
jl O +
of O +
anhydrous O +
pyridine O +
via O +
a O +
gas O +
tight O +
syringe O +
( O -
Hamilton O -
) O -
. O +

After O +
the O +
support O +
has O +
swollen O -
, O +
the O +
vacuum O +
( O -
oil O +
pump O -
) O +
is O +
applied O +
and O +
the O +
support O +
is O +
warmed O +
with O +
a O +
6227 O +
Nucleic O +
Acids O +
Research O +
stream O +
of O +
air O +
from O +
a O +
hair O +
dryer O -
. O +

Evaporation O +
is O +
continued O +
for O +
10 O +
min O -
. O +

Dry O +
argon O +
is O +
then O +
admitted O +
and O +
the O +
drying O +
operation O +
is O +
repeated O +
two O +
more O +
times O -
. O +

7 O -
) O +
The O +
coupling O +
mixture O +
is O +
prepared O +
by O +
dissolving O +
0.20 O +
mmol O +
of O +
MSNT O +
in O +
320 O +
pl O +
of O +
anhydrous O +
pyridine O -
. O +

The O +
solution O +
is O +
then O +
transferred O +
to O +
the O +
vial O +
containing O +
0.06 O +
mmol O +
of O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
Np O -
- O -
Et3NH O -
. O +

The O +
nucleotide O +
is O +
dissolved O +
by O +
vortexing O +
and O +
the O +
coupling O +
solution O +
is O +
then O +
added O +
dropwise O +
to O +
the O +
support O -
. O +

It O +
is O +
important O +
to O +
add O +
the O +
solution O +
slowly O +
and O +
to O +
allow O +
the O +
support O +
to O +
swell O -
. O +

Trapped O +
gas O +
bubbles O +
may O +
be O +
removed O +
by O +
gently O +
tapping O +
the O +
column O -
. O +

This O +
entire O +
operation O +
is O +
carried O +
out O +
using O +
one O +
predried O +
syringe O -
. O +

The O +
syringe O +
is O +
left O +
in O +
the O +
V O -
- O -
vial O +
while O +
the O +
reagents O +
are O +
being O +
dissolved O -
. O +

8) O +
The O +
reaction O +
mixture O +
is O +
kept O +
at O +
room O +
temperature O +
for O +
two O +
hrs O -
. O +

9 O -
) O +
The O +
column O +
is O +
set O +
up O +
in O +
the O +
washing O +
mode O +
and O +
the O +
support O +
is O +
washed O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
anhydrous O +
pyridine O -
. O +

The O +
solution O -
, O +
which O +
contains O +
unreacted O +
nucleoside O +
3'-methylphosphonate O +
and O +
MSNT O -
, O +
is O +
collected O +
in O +
a O +
separate O +
flask O -
. O +

A O +
50 O -
% O +
aqueous O +
pyridine O +
solution O +
( O -
1 O +
ml O -
) O +
is O +
added O +
and O +
the O +
solution O +
is O +
kept O +
at O +
40C O +
for O +
later O +
purification O +
and O +
recovery O +
of O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
Np O -
. O +

10 O -
) O +
The O +
support O +
is O +
treated O +
with O +
a O +
solution O +
containing O +
2 O +
ml O +
of O +
anhydrous O +
pyridine O -
, O +
1 O +
ml O +
of O +
acetic O +
anhydride O +
and O +
20 O +
mg O +
of O +
dimethylaminopyridine O +
for O +
30 O +
min O -
. O +

( O -
This O +
step O +
was O +
not O +
included O +
for O +
the O +
synthesis O +
of O +
oligomer O +
10 O -
) O -
. O +

11 O -
) O +
Return O +
to O +
step O +
1 O -
, O +
for O +
the O +
next O +
cycle O -
. O +

Removal O +
of O +
Base O +
Protecting O +
Groups O -
. O +

The O +
following O +
general O +
procedure O +
was O +
found O +
to O +
be O +
the O +
most O +
effective O +
method O +
for O +
cleaving O +
the O +
oligonucleotide O +
from O +
the O +
1 O -
% O +
crosslinked O +
support O +
and O +
for O +
removing O +
the O +
base O +
protecting O +
groups O +
with O +
minimal O +
hydrolysis O +
of O +
the O +
phosphonate O +
backbone O -
. O +

The O +
following O +
steps O +
were O +
used O +
for O +
deprotecting O +
oligomers O +
7 O -
, O +
8 O +
and O +
10 O -
. O +

Oligomer O +
9 O +
was O +
deprotected O +
in O +
a O +
similar O +
fashion O +
except O +
step O +
4 O -
) O +
was O +
carried O +
out O +
at O +
650C O +
for O +
3 O +
hrs O -
. O +

For O +
oligomers O +
1 O -
- O -
6 O -
, O +
step O +
3 O -
) O +
was O +
not O +
included O +
and O +
step O +
4 O -
) O +
was O +
carried O +
out O +
at O +
650 O +
for O +
3 O +
hrs O -
. O +

1 O -
) O +
After O +
the O +
final O +
condensation O +
step O +
the O +
support O +
( O -
60 O +
mg O -
) O +
is O +
washed O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
anhydrous O +
pyridine O -
; O +
three O +
2 O +
ml O +
portions O +
of O +
methylene O +
chloride O -
/ O -
isopropanol O +
and O +
three O +
2 O +
ml O +
portions O +
of O +
diethyl O +
ether O -
. O +

The O +
support O +
is O +
then O +
dried O +
under O +
house O +
vacuum O -
. O +

2 O -
) O +
The O +
support O +
is O +
swollen O +
by O +
addition O +
of O +
2 O +
ml O +
of O +
pyridine O +
and O +
the O +
excess O +
is O +
removed O +
under O +
house O +
vacuum O -
. O +

3 O -
) O +
The O +
support O +
is O +
treated O +
with O +
3 O +
ml O +
of O +
0.017 O +
M O +
tetra O -
- O -
n O -
- O -
butylammonium O +
fluoride O +
in O +
tetrahydrofuran O -
/ O -
pyridine O -
/ O -
water O +
( O -
8:1:1 O -
, O +
v O -
/ O -
v O -
) O +
for O +
40 O +
hrs O +
at O +
room O +
temperature O -
. O +

No O +
shaking O +
is O +
required O -
. O +

The O +
support O +
is O +
then O +
washed O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
50 O -
% O +
pyridine O -
/ O -
water O -
; O +
three O +
2 O +
ml O +
portions O +
of O +
pyridine O -
; O +
and O +
three O +
2 O +
ml O +
portions O +
of O +
methylene O +
chloride O -
/ O -
isopropanol O -
. O +

4 O -
) O +
The O +
support O +
is O +
treated O +
with O +
3 O +
ml O +
of O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
for O +
7 O +
hrs O +
at O +
room O +
temperature O +
6228 O +
Nucleic O +
Acids O +
Research O +
without O +
shaking O -
. O +

The O +
solution O +
is O +
collected O +
and O +
the O +
support O +
is O +
washed O +
with O +
four O +
2 O +
ml O +
portions O +
of O +
pyridine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
and O +
four O +
2 O +
ml O +
portions O +
of O +
N O -
, O -
N O -
- O -
dimethylformamide O -
. O +

The O +
combined O +
eluate O +
and O +
washings O +
are O +
evaporated O +
at O +
250C O +
and O +
the O +
oily O +
residue O +
is O +
co O -
- O -
evaporated O +
several O +
time O +
with O +
50 O -
% O +
aqueous O +
ethanol O -
. O +

Purification O +
of O +
Oligonucleoside O +
Methylphosphonates O -
. O +

For O +
oligomers O +
which O +
contain O +
only O +
methylphosphonate O +
linkages O +
( O -
1 O -
- O -
6 O -
) O -
, O +
the O +
residue O +
from O +
step O +
4 O -
) O +
of O +
the O +
previous O +
section O +
is O +
dissolved O +
in O +
a O +
small O +
volume O +
of O +
50 O -
% O +
aqueous O +
ethanol O -
. O +

The O +
solution O +
is O +
chromatographed O +
on O +
a O +
C-18 O +
reversed O +
phase O +
column O +
( O -
0.46 O +
cm O +
x O +
25 O +
cm O +
for O +
100 O +
A254 O +
units O +
or O +
less O -
; O +
0.9 O +
cm O +
x O +
50 O +
cm O +
for O +
more O +
than O +
100 O +
A254 O +
units O -
) O +
using O +
a O +
linear O +
gradient O +
of O +
0 O -
% O +
to O +
25 O -
% O +
( O -
8-mer O +
or O +
less O -
) O +
or O +
0 O -
% O +
to O +
35 O -
% O +
( O -
9 O +
mer O -
) O +
acetonitrile O +
in O +
water O +
to O +
remove O +
non O -
- O -
tritylated O +
oligomers O -
. O +

The O +
desired O +
tritylated O +
oligomer O +
is O +
eluted O +
with O +
50 O -
% O +
acetonitrile O +
in O +
water O -
. O +

The O +
solvents O +
are O +
evaporated O +
and O +
the O +
residue O +
is O +
treated O +
with O +
1 O +
ml O +
of O +
80 O -
% O +
acetic O +
acid O +
in O +
water O +
for O +
1 O +
hr O +
at O +
room O +
temperature O -
. O +

The O +
solvents O +
are O +
evaporated O +
and O +
the O +
residue O +
is O +
repeatedly O +
evaporated O +
with O +
ethanol O +
to O +
ensure O +
complete O +
removal O +
of O +
acetic O +
acid O -
. O +

The O +
oligomer O +
is O +
then O +
purified O +
by O +
C-18 O +
reversed O +
phase O +
HPLC O +
using O +
a O +
0 O -
% O +
to O +
25 O -
% O +
or O +
30 O -
% O +
acetonitrile O +
in O +
water O +
gradient O -
. O +

For O +
oligomers O +
which O +
terminate O +
with O +
a O +
5'-nucleoside O +
phosphodiester O +
linkage O +
( O -
7 O -
- O -
10 O -
) O +
the O +
residue O +
from O +
step O +
4 O -
) O +
described O +
in O +
the O +
preceeding O +
section O +
is O +
treated O +
with O +
80 O -
% O +
acetic O +
acid O +
in O +
water O +
for O +
15 O +
min O +
at O +
room O +
temperature O -
. O +

After O +
removal O +
of O +
the O +
acetic O +
acid O +
by O +
evaporation O -
, O +
the O +
residue O +
is O +
dissolved O +
in O +
20 O +
ml O +
of O +
50 O -
% O +
aqueous O +
ethanol O +
and O +
the O +
solution O +
is O +
passed O +
through O +
a O +
DEAE O +
cellulose O +
column O +
( O -
2.5 O +
x O +
8 O +
cm O -
, O +
bicarbonate O +
form O -
) O +
which O +
has O +
been O +
previously O +
washed O +
with O +
50 O -
% O +
aqueous O +
ethanol O -
. O +

The O +
column O +
is O +
monitored O +
at O +
254 O +
nm O +
and O +
washed O +
with O +
50 O -
% O +
aqueous O +
ethanol O +
until O +
the O +
pen O +
returns O +
to O +
the O +
baseline O -
. O +

The O +
desired O +
oligomer O +
is O +
then O +
eluted O +
with O +
0.15 O +
M O +
triethylammonium O +
bicarbonate O +
in O +
50 O -
% O +
aqueous O +
ethanol O -
. O +

The O +
buffer O +
is O +
removed O +
by O +
evaporation O +
and O +
co O -
- O -
evaporated O +
with O +
50 O -
% O +
aqueous O +
ethanol O -
. O +

The O +
oligomer O +
is O +
then O +
further O +
purified O +
by O +
C-18 O +
reversed O +
phase O +
HPLC O +
using O +
a O +
0 O -
% O +
to O +
30 O -
% O +
acetonitrile O +
in O +
0.10 O +
M O +
ammonium O +
acetate O +
( O -
pH O +
5.8 O -
) O +
gradient O -
. O +

The O +
oligomer O +
is O +
freed O +
of O +
ammonium O +
acetate O +
by O +
desalting O +
on O +
a O +
Bio O -
- O -
Gel O +
P-2 O +
column O +
( O -
1.5 O +
x O +
20 O +
cm O -
) O -
. O +

Removal O +
of O +
the O +
5'-Terminal O +
Nucleotide O +
Unit O -
. O +

Oligomers O +
which O +
terminate O +
with O +
a O +
5'-nucleotide O +
phosphodiester O +
may O +
be O +
converted O +
to O +
the O +
oligonucleoside O +
methylphosphonate O +
by O +
the O +
following O +
procedure O -
. O +

The O +
oligomer O +
( O -
3 O +
A254 O +
units O -
) O +
is O +
dissolved O +
in O +
40 O +
pl O +
of O +
water O +
and O +
treated O +
at O +
370C O +
for O +
2 O +
hrs O +
with O +
10 O +
PI O +
( O -
1 O -
- O -
2 O +
units O -
) O +
of O +
spleen O +
phosphodiesterase O +
dissolved O +
in O +
water O -
. O +

The O +
completeness O +
of O +
the O +
reaction O +
is O +
determined O +
by O +
reversed O +
phase O +
HPLC O -
. O +

The O +
solution O +
is O +
then O +
6229 O +
Nucleic O +
Acids O +
Research O +
diluted O +
with O +
50 O +
ul O +
of O +
water O +
and O +
passed O +
through O +
a O +
DEAE O +
cellulose O +
column O +
( O -
0.5 O +
x O +
1 O +
cm O -
) O -
. O +

The O +
column O +
is O +
washed O +
with O +
500 O +
Pl O +
of O +
water O +
and O +
the O +
oligomer O +
is O +
recovered O +
by O +
lyophilization O -
. O +

Recovery O +
of O +
Protected O +
Nucleoside O +
3'-Methylphosphonates O -
. O +

The O +
aqueous O +
pyridine O +
solution O +
from O +
step O +
9 O -
) O +
described O +
in O +
General O +
Procedure O +
for O +
Preparing O +
Oligonucleoside O +
Methylphosphonates O -
, O +
is O +
evaporated O +
after O +
addition O +
of O +
0.1 O +
ml O +
of O +
triethylamine O -
. O +

The O +
residue O +
is O +
dissolved O +
in O +
50 O +
ml O +
of O +
chloroform O +
and O +
the O +
solution O +
is O +
extracted O +
twice O +
with O +
50 O +
ml O +
of O +
1 O +
M O +
ammonium O +
bicarbonate O -
. O +

The O +
chloroform O +
layer O +
is O +
dried O +
over O +
anhydrous O +
sodium O +
sulfate O -
. O +

Several O +
drops O +
of O +
triethylamine O +
are O +
added O +
to O +
clarify O +
the O +
solution O -
. O +

After O +
filtration O +
the O +
solvents O +
are O +
evaporated O +
and O +
the O +
residue O +
is O +
evaporated O +
with O +
three O +
2 O +
ml O +
portions O +
of O +
anhydrous O +
pyridine O +
on O +
an O +
oil O +
pump O -
. O +

The O +
foamy O +
residue O +
is O +
dissolved O +
in O +
2 O +
ml O +
of O +
dry O +
methylene O +
chloride O +
and O +
the O +
solution O +
is O +
added O +
dropwise O +
to O +
a O +
stirred O +
solution O +
of O +
1 O -
% O +
triethylamine O +
in O +
hexane O -
. O +

The O +
resulting O +
precipitate O +
is O +
collected O +
via O +
filtration O +
on O +
a O +
sintered O +
glass O +
filter O -
, O +
washed O +
with O +
hexane O +
and O +
dried O +
in O +
a O +
vacuum O +
desiccator O -
. O +

Removal O +
of O +
Base O +
Protecting O +
Groups O +
with O +
Ethylenediamine O -
. O +

Several O +
mg O +
of O +
d O -
- O -
I O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzA O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzC O +
and O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ibu O +
G O +
were O +
each O +
dissolved O +
in O +
250 O +
pl O +
of O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1,v O -
/ O -
v O -
) O -
. O +

The O +
solutions O +
were O +
incubated O +
at O +
room O +
temperature O -
. O +

At O +
various O +
times O +
aliquots O +
were O +
chromatographed O +
on O +
silica O +
gel O +
TLC O +
plates O +
which O +
were O +
eluted O +
with O +
10 O -
% O +
methanol O +
in O +
chloroform O -
. O +

The O +
spots O +
corresponding O +
to O +
the O +
starting O +
material O +
and O +
the O +
product O +
were O +
cut O +
out O +
and O +
treated O +
with O +
1.5 O +
ml O +
of O +
perchloric O +
acid O -
/ O -
ethanol O +
( O -
3:2 O -
, O +
v O -
/ O -
v O -
) O +
for O +
30 O +
min O -
. O +

The O +
absorbance O +
of O +
each O +
solution O +
was O +
measured O +
at O +
500 O +
nm O +
and O +
the O +
percent O +
reaction O +
was O +
determined O -
. O +

The O +
half O -
- O -
lives O +
of O +
the O +
reactions O +
are O +
given O +
in O +
Table O +
II O -
. O +

Removal O +
of O +
Protected- O +
Nucleosides O +
from O +
Polystyrene O +
Support O -
. O +

Five O +
mg O +
of O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
T O -
( O -
ED O -
( O -
1 O -
% O +
crosslinked O -
) O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzA O +
O? O -
( O -
1 O -
% O +
crosslinked O -
) O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzC O -
( O -
? O -
) O -
( O -
1 O -
% O +
and O +
2 O -
% O +
crosslinked O -
) O +
and O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ibuGcD O -
( O -
1 O -
% O +
and O +
2 O -
% O +
crosslinked O -
) O +
were O +
each O +
treated O +
with O +
500 O +
ul O +
of O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
solution O +
at O +
room O +
temperature O -
. O +

At O +
various O +
times O -
, O +
10 O +
pl O +
aliquots O +
were O +
removed O -
, O +
the O +
solvent O +
was O +
evaporated O +
and O +
the O +
residue O +
was O +
dissolved O +
in O +
1 O +
ml O +
of O +
perchloric O +
acid O -
/ O -
ethanol O +
solution O +
( O -
3:2 O -
, O +
v O -
/ O -
v O -
) O -
. O +

The O +
amount O +
of O +
dimethoxytrityl O +
cation O +
and O +
hence O +
the O +
amount O +
of O +
nucleoside O +
cleaved O +
from O +
the O +
support O +
was O +
determined O +
by O +
measuring O +
the O +
absorbance O +
at O +
500 O +
nm O -
. O +

The O +
half O +
lives O +
of O +
the O +
cleavage O +
reactions O +
are O +
given O +
in O +
Table O +
II O -
. O +

Hydrolysis O +
of O +
the O +
Methylphosphonate O +
Linkage O +
by O +
Ethylenediamine O -
. O +

Oligonucleoside O +
methylphosphonates O +
( O -
1.25 O +
A254 O +
units O +
each O -
) O +
were O +
treated O +
with O +
50 O +
il O +
of O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
room O +
temperature O -
. O +

Aliquots O +
6230 O +

Nucleic O +
Acids O +
Research O +
( O -
10 O +
pl O -
) O +
were O +
withdrawn O +
at O +
various O +
times O +
and O +
the O +
solvents O +
were O +
evaporated O -
. O +

The O +
residue O +
was O +
dissolved O +
in O +
20 O +
PI O +
of O +
50 O -
% O +
aqueous O +
ethanol O +
and O +
the O +
solution O +
examined O +
by O +
C-18 O +
reversed O +
phase O +
HPLC O +
using O +
a O +
0 O -
% O +
to O +
25 O -
% O +
acetonitrile O +
in O +
water O +
gradient O -
. O +

The O +
mole O +
percent O +
of O +
starting O +
oligomer O +
remaining O +
after O +
100 O +
hrs O +
of O +
treatment O +
is O +
given O +
in O +
Table O +
III O -
. O +

Hydrolysis O +
of O +
Oligonucleoside O +
Methylphosphonates O +
in O +
Acid O -
. O +

Six O +
A254 O +
units O +
of O +
oligomer O +
were O +
dissolved O +
in O +
100 O +
pl O +
of O +
0.01 O +
M O +
hydrochloric O +
acid O +
solution O -
. O +

The O +
solution O +
was O +
heated O +
at O +
either O +
450 O +
or O +
650C O -
. O +

Aliquots O +
( O -
10 O +
Pil O -
) O +
were O +
withdrawn O +
at O +
various O +
times O +
and O +
added O +
to O +
10 O +
pl O +
of O +
0.015 O +
M O +
ammonium O +
hydroxide O +
at O +
0?C. O +
The O +
samples O +
were O +
then O +
injected O +
directly O +
onto O +
a O +
C-18 O +
reversed O +
phase O +
column O +
which O +
was O +
eluted O +
with O +
50 O +
ml O +
of O +
a O +
linear O +
gradient O +
of O +
0 O -
% O +
to O +
25 O -
% O +
acetonitrile O +
in O +
water O +
at O +
a O +
flow O +
rate O +
of O +
2.5 O +
ml O -
/ O -
min O -
. O +

The O +
products O +
of O +
the O +
reaction O +
were O +
determined O +
by O +
comparison O +
with O +
authentic O +
samples O -
. O +

Labeling O +
5'-End O +
of O +
Oligonucleoside O +
Methylphosphonates O +
with O +
T4-Polynucleotide O +
Kinase O -
. O +

Oligonucleoside O +
methylphosphonates O +
( O -
2 O +
nmol O -
) O +
were O +
dissolved O +
in O +
a O +
buffer O +
solution O +
containing O +
50 O +
mM O +
Tris O -
- O -
HC1 O +
( O -
pH O +
9.0 O -
) O -
, O +
10 O +
mM O +
MgCl2 O -
, O +
5 O +
mM O +
dithiothreitol O -
, O +
20 O +
pM O +
spermidine O -
, O +
and O +
[ O -
y-32P O -
] O -
ATP O +
( O -
8 O +
ljCi O -
, O +
4Ci O -
/ O -
mmol O -
) O -
. O +

T4-polynucleotide O +
kinase O +
( O -
4 O +
units O -
) O +
was O +
added O +
to O +
the O +
solution O -
, O +
which O +
was O +
made O +
up O +
to O +
50 O +
ul O +
by O +
adding O +
water O -
. O +

The O +
solutions O +
were O +
incubated O +
at O +
370C O +
for O +
2 O +
hrs O -
. O +

The O +
reaction O +
was O +
checked O +
by O +
PEI O -
- O -
cellulose O +
TLC O -
. O +

The O +
PEI O -
- O -
cellulose O +
plate O +
( O -
12x2Ocm O -
, O +
Merck O -
) O +
was O +
preactivated O +
by O +
elution O +
with O +
1.2 O +
M O +
pyridinium O +
formate O +
( O -
pH O +
3.5 O -
) O -
. O +

Small O +
aliquots O +
( O -
0.1 O +
pl O -
) O +
of O +
PNK O +
reaction O +
solutions O +
were O +
applied O +
and O +
developed O +
with O +
1.5 O +
M O +
pyridinium O +
formate O +
( O -
pH O +
3.5 O -
) O -
. O +

The O +
TLC O +
plate O +
was O +
dried O +
and O +
autoradiographed O +
using O +
an O +
intensifying O +
screen O +
at O +
room O +
temperature O -
. O +

Gel O +
Electrophoresis O +
of O +
5'-Labeled O +
Oligonucleoside O +
Methylphosphonates O -
. O +

Polyacrylamide O +
gels O +
were O +
prepared O +
by O +
polymerizing O +
a O +
solution O +
containing O +
18 O -
% O +
( O -
w O -
/ O -
v O -
) O +
acrylamide O -
, O +
0.8 O -
% O +
( O -
w O -
/ O -
v O -
) O +
N O -
, O -
N'-methylenebisacrylamide O -
. O +

7 O -
M O +
urea O -
, O +
89 O +
mM O +
Tris O -
- O -
borate O +
( O -
pH O +
8.2 O -
) O -
, O +
2 O +
mM O +
EDTA O -
, O +
0.07 O -
% O +
( O -
w O -
/ O -
v O -
) O +
ammonium O +
persulfate O -
, O +
in O +
the O +
presence O +
of O +
N O -
, O -
N O -
, O -
N',N'-tetramethylethylenediamine O +
( O -
20 O +
Pil O -
/ O -
20 O +
ml O +
solution O -
) O -
. O +

The O +
solution O +
was O +
poured O +
into O +
a O +
0.75 O +
x O +
140 O +
x O +
150 O +
mm O +
mold O +
and O +
allowed O +
to O +
polymerize O +
for O +
2 O +
hrs O +
at O +
room O +
temperature O -
. O +

5'-Labeled O +
oligonucleoside O +
methylphosphonates O +
were O +
dissolved O +
in O +
10 O -
% O +
aqueous O +
glycerol O +
solution O +
containing O +
0.04 O -
% O +
bromophenol O +
blue O +
and O +
applied O +
to O +
the O +
gel O -
. O +

The O +
electrophoresis O +
was O +
run O +
using O +
89 O +
mM O +
Tris O -
- O -
Borate O +
buffer O +
containing O +
10 O +
mM O +
EDTA O -
. O +

After O +
electrophoresis O +
the O +
gel O +
was O +
dried O +
using O +
a O +
gel O -
- O -
dryer O +
and O +
autoradiographed O +
using O +
intensifying O +
screens O +
at O +
room O +
temperature O -
. O +

Pa O +
rti O +
al O +
Cl O +
eavage O +
of O +
01 O +
i O +
gonucl O +
eosi O +
de O +
Methyl O +
phosphonates O +
wi O +
th O +
Hydrochl O +
ori O +
c O +
Aci O +
d O +
or O +
Piperidine O -
. O +

Aliquots O +
( O -
1 O +
, O -
jl O -
) O +
from O +
the O +
polynucleotide O +
kinase O +
reaction O +
6231 O +
Nucleic O +
Acids O +
Research O +
mixture O +
were O +
incubated O +
with O +
1 O +
il O +
of O +
1 O +
M O +
hydrochloric O +
acid O +
at O +
37?C O +
for O +
30 O +
min O -
. O +

After O +
incubation O +
the O +
solution O +
was O +
neutralized O +
with O +
1 O +
Pl O +
of O +
1 O +
M O +
ammonium O +
hydroxide O +
and O +
then O +
allowed O +
to O +
stand O +
at O +
room O +
temperature O +
for O +
10 O +
min O +
before O +
cooling O +
to O +
00 O -
. O +

Alternatively O -
, O +
aliquots O +
( O -
1 O +
pl O -
) O +
from O +
the O +
phosphorylation O +
reaction O +
were O +
incubated O +
with O +
1 O +
ul O +
of O +
1 O +
M O +
aqueous O +
piperidine O +
at O +
370C O +
for O +
10 O +
min O +
after O +
which O +
the O +
solution O +
was O +
cooled O +
to O +
0 O -
? O +
and O +
evaporated O -
. O +

The O +
treated O +
samples O +
were O +
then O +
subjected O +
to O +
polyacrylamide O +
gel O +
electrophoresis O +
as O +
described O +
above O +
without O +
further O +
purification O -
. O +

RESULTS O +
AND O +
DISCUSSION O +
Synthesis O +
of O +
Protected O +
Oligonucleoside O +
Methylphosphonates O -
. O +

Table O +
I O +
shows O +
some O +
of O +
the O +
protected O +
oligonucleoside O +
methylphosphonates O +
which O +
have O +
been O +
synthesized O +
on O +
aminomethyl O +
succinyl O -
- O -
derivatized O +
polystyrene O +
supports O -
. O +

The O +
basic O +
synthetic O +
steps O +
which O +
are O +
shown O +
in O +
Figure O +
1 O +
are O +
described O +
in O +
detail O +
in O +
the O +
Experimental O +
section O -
. O +

These O +
steps O +
are O -
: O +
( O -
1 O -
) O +
removal O +
of O +
the O +
dimethoxytrityl O +
group O +
with O +
1 O +
M O +
zinc O +
bromide O +
solution O -
; O +
( O -
2 O -
) O +
drying O +
the O +
support O +
via O +
co O -
- O -
evaporation O +
with O +
anhydrous O +
pyridine O -
; O +
( O -
3 O -
) O +
reaction O +
of O +
the O +
support O -
- O -
bound O +
nucleoside O +
or O +
oligonucleotide O +
with O +
a O +
coupling O +
mixture O +
containing O +
0.15 O +
to O +
0.2 O +
M O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
) O -
-NpjEt3NH O +
and O +
0.3 O +
to O +
0.6 O +
M O +
mesitylenesulfonyl-3-nitrotriazole O +
in O +
anhydrous O +
pyridine O +
and O +
( O -
4 O -
) O +
acetylation O +
of O +
unreacted O +
5'-OH O +
groups O +
with O +
acetic O +
anhydride O -
. O +

The O +
reactions O +
and O +
washing O +
steps O +
were O +
most O +
conveniently O +
carried O +
out O +
in O +
a O +
polypropylene O +
Econo O +
Column O +
fitted O +
with O +
a O +
septum O +
cap O +
and O +
a O +
3-way O +
Teflon O +
DMTrO O +
, O -
O O +
Figure O +
1 O -
: O +
Preparation O +
of O +
Protected O +
Oligonucleoside O +
Methylphosphonates O +
on O +
a O +
1 O +
T O +
o O +
w O +
Polystyrene O +
Support O +
0 O +
H O +
BFvON O +
DlDTrOjO4B O +
U O +
) O -
I O +
CH3-gd O -
- O -
OEt O +
3NH O +
0 O +
6232 O +
Nucleic O +
Acids O +
Research O +
stopcock O -
. O +

Thus O +
no O +
transfers O +
of O +
the O +
support O +
are O +
required O +
using O +
this O +
apparatus O -
. O +

The O +
synthetic O +
procedure O +
is O +
analogous O +
to O +
the O +
phosphotriester O +
approach O +
used O +
to O +
prepared O +
protected O +
oligonucleotide O +
phosphotriesters O +
on O +
polystyrene O +
supports O +
( O -
6 O -
) O -
. O +

However O -
, O +
we O +
found O +
the O +
methylphosrhonate O +
coupling O +
reaction O +
to O +
be O +
extremely O +
sensitive O +
to O +
moisture O -
. O +

Drying O +
procedures O +
such O +
as O +
washing O +
with O +
anhydrous O +
solvent O +
or O +
blowing O +
dry O +
nitrogen O +
gas O +
through O +
the O +
support O +
which O +
are O +
satisfactory O +
for O +
phosphotriester O +
synthesis O +
resulted O +
in O +
low O +
yields O +
of O +
the O +
methylphosphonates O -
. O +

The O +
best O +
yields O +
were O +
obtained O +
when O +
the O +
support O +
was O +
co O -
- O -
evaporated O +
with O +
anhydrous O +
pyridine O +
by O +
directly O +
attaching O +
the O +
reaction O +
column O +
to O +
a O +
vacuum O +
pump O +
and O +
dry O -
- O -
ice O +
trap O -
. O +

Three O +
10 O +
min O +
co O -
- O -
evaporations O +
were O +
sufficient O +
to O +
render O +
the O +
support O +
anhydrous O -
. O +

The O +
protected O +
nucleoside O +
3'-methylphosphonate O +
triethylammonium O +
salts O +
used O +
in O +
the O +
coupling O +
reactions O +
were O +
prepared O +
from O +
their O +
cyanoethyl O +
ester O +
derivatives O +
( O -
3 O -
) O -
. O +

These O +
monomers O +
were O +
recovered O +
after O +
each O +
coupling O +
step O +
and O +
were O +
freed O +
of O +
unreacted O +
MSNT O +
by O +
a O +
simple O +
extraction O +
step O -
. O +

After O +
precipitation O +
and O +
drying O -
, O +
the O +
monomers O +
could O +
be O +
reused O +
for O +
other O +
syntheses O -
. O +

The O +
ability O +
to O +
recover O +
the O +
unreacted O +
monomers O +
is O +
particularly O +
important O +
for O +
large O +
scale O +
synthesis O +
since O +
large O +
excesses O +
of O +
these O +
materials O +
are O +
employed O +
in O +
the O +
coupling O +
step O -
. O +

This O +
recovery O +
step O +
represents O +
a O +
potential O +
advantage O +
over O +
the O +
phosphine O +
synthetic O +
method O +
( O -
4 O -
) O -
, O +
since O +
it O +
is O +
not O +
clear O +
that O +
nucleoside O +
3'-methylphosphine O +
chlorides O +
can O +
be O +
recovered O +
after O +
reaction O -
. O +

Two O +
types O +
of O +
methylphosphonate O +
oligomers O +
were O +
prepared O -
; O +
those O +
which O +
contain O +
only O +
methylphosphonate O +
linkages O -
, O +
oligomers O +
1 O -
- O -
6 O -
, O +
and O +
those O +
which O +
terminate O +
with O +
a O +
5'-nucleoside O +
3'-p O -
- O -
chlorophenyl O +
phosphotriester O +
moiety O -
, O +
oligomers O +
7 O -
- O -
10 O -
. O +

Oligomers O +
were O +
synthesized O +
on O +
both O +
1 O -
% O +
and O +
2 O -
% O +
crosslinked O +
supports O -
. O +

As O +
shown O +
in O +
Table O +
I O -
, O +
the O +
average O +
yield O +
per O +
coupling O +
step O +
which O +
was O +
determined O +
by O +
trityl O +
group O +
analysis O +
was O +
approximately O +
82 O -
% O -
, O +
for O +
both O +
types O +
of O +
support O -
. O +

This O +
yield O +
is O +
adequate O +
to O +
allow O +
preparation O +
of O +
protected O +
octamers O +
or O +
nonamers O +
in O +
25 O -
% O +
and O +
20 O -
% O +
overall O +
yield O -
, O +
respectively O -
. O +

Deprotection O -
. O +

Our O +
previous O +
studies O +
( O -
1 O -
) O +
and O +
those O +
of O +
Sinha O +
et O +
al. O +
( O -
4 O -
) O +
show O +
that O +
methylphosphonate O +
linkages O +
are O +
cleaved O +
by O +
base O -
. O +

We O +
found O +
this O +
hydrolysis O +
reaction O +
to O +
depend O +
to O +
some O +
extent O +
upon O +
the O +
nucleoside O +
sequence O +
of O +
the O +
oligomer O -
. O +

Hydrolysis O +
of O +
methylphosphonate O +
linkages O +
by O +
concentrated O +
ammonium O +
hydroxide O +
in O +
pyridine O +
( O -
1:1 O +
v O -
/ O -
v O -
) O -
, O +
the O +
reagent O +
commonly O +
used O +
to O +
remove O +
oligonucleotide O +
base O +
protecting O +
groups O -
, O +
can O +
be O +
largely O +
suppressed O +
if O +
the O +
reactions O +
are O +
run O +
at O +
0?C O +
( O -
1 O -
) O -
. O +

However O -
, O +
these O +
conditions O +
are O +
unsatisfactory O +
for O +
removal O +
of O +
oligonucleoside O +
methylphosphonates O +
from O +
the O +
polystyrene O +
6233 O +
Nucleic O +
Acids O +
Research O +
Table O +
I. O +
Syntheses O +
of O +
Protected O +
Oligonucleoside O +
Methylphosphonates O +
on O +
Polystyrene O +
Supports O +
Support O +
Average O +
cross- O +
yield O +
Protected O +
oligomer O +
( O -
a O -
) O +
linking O +
per O +
( O -
% O -
) O +
coupling O +
step O +
( O -
% O -
) O +
1 O +
d- O +
[ O +
( O -
MeO O -
) O +
2Tr O -
] O -
bzCpbzCpbzApT O -
- O -
O O +
1 O +
81 O +
2 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ibuGpbzCpbzCpbzApT- O +
1 O +
82 O +
3 O +
d- O +
[ O +
( O -
MeO O -
) O +
2Tr O -
] O -
bzCpbzApi O +
buGpi O +
buGpTpbzApbzA O -
- O -
G1i O +
2 O +
83 O +
4 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzCLpTpT O +
bzApbzCpbzCpTpibuG- O +
? O +

2 O +
85 O +
5 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
TpbzCpbzCpTpbzCpbzCpTpibuG- O -
( O -
? O +

2 O +
86 O +
6 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
TpTpTpbzApbzCpbzCpTpT- O -
? O +

1 O +
83 O +
7 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzApbzApbzA- O -
? O +

1 O +
83 O +
8 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzA4bzCpbzCpbzApT- O -
? O +

1 O +
81 O +
9 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzApibuGpbzCpbzApbzApibuG- O +
( O +
2 O +
74 O +
10 O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
bzApbzApbzApbzApibuGpbzCpbzApbzApibuG- O -
( O -
Q O +
1 O +
86 O +
( O -
a O -
) O +
p O +
= O +
methylphosphonate O +
linkage O +
T O +
= O +
p O -
- O -
chlorophenyl O +
phosphotriester O +
linkage O +
( O -
Q= O +
polystyrene O +
support O +
( O -
b O -
) O +
Determined O +
by O +
analysis O +
of O +
the O +
dimethoxytrityl O +
group O +
after O +
each O +
coupling O +
step O -
. O +

support O -
. O +

We O +
therefore O +
examined O +
other O +
deprotection O +
procedures O -
. O +

Recently O +
Barnett O +
and O +
Letsinger O +
described O +
removal O +
of O +
base O +
protecting O +
groups O +
from O +
oligonucleotide O +
B O -
, O -
B,0-trichloroethylphosphotriesters O +
using O +
a O +
mixture O +
of O +
ethylenediamine O +
in O +
phenol O +
( O -
7 O -
) O -
. O +

We O +
have O +
found O +
ethylenediamine O +
in O +
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
rapidly O +
and O +
cleanly O +
removes O +
benzoyl O +
and O +
isobutyryl O +
protecting O +
groups O +
from O +
dA O -
, O +
dC O +
and O +
dG O +
nucleosides O -
. O +

This O +
reagent O +
is O +
particularly O +
attractive O +
since O +
it O +
can O +
be O +
easily O +
removed O +
by O +
evaporation O -
. O +

In O +
our O +
initial O +
investigations O -
, O +
ol O +
igonucleoside O +
methylphosphonates O +
were O +
cleaved O +
from O +
the O +
support O +
and O +
base O +
protecting O +
groups O +
were O +
removed O +
by O +
treatment O +
with O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
65?C O +
for O +
3 O +
hrs O -
. O +

Although O +
preliminary O +
results O +
indicated O +
the O +
methylphosphonate O +
linkages O +
of O +
several O +
dimers O +
were O +
stable O +
to O +
these O +
conditions O -
, O +
we O +
later O +
found O +
that O +
the O +
linkages O +
of O +
onger O +
6234 O +
Nucleic O +
Acids O +
Research O +
Table O +
II O -
. O +

Hydrolysis O +
of O +
Protected O +
Nucleosides O +
by O +
Ethylenediamine O +
at O +
220C O +
Protected O +
Time O +
required O +
to O +
Time O +
required O +
to O +
nucleoside O +
remove O +
50 O -
% O +
of O +
the O +
cleave O +
50 O -
% O +
of O +
the O +
base O +
protecting O +
nucleoside O +
from O +
the O +
groups O +
( O -
min O -
) O +
1 O -
% O +
crosslinked O +
support O +
( O -
min O -
) O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
) O -
bzA O +
10 O +
105 O +
d- O -
[ O -
( O -
MeO O -
) O +
2Tr O +
bzC O +
20 O +
105 O +
d- O +
[ O +
( O -
MeO O -
) O +
2Tr O -
] O -
i O +
buG O +
40 O +
54 O +
d- O +
[ O +
( O -
MeO O -
) O +
2Tr O -
] O -
T O +
_ O +
105 O +
oligomers O +
were O +
hydrolyzed O +
to O +
various O +
extents O +
by O +
this O +
procedure O -
. O +

This O +
of O +
course O +
resulted O +
in O +
loss O +
of O +
product O +
as O +
was O +
evidenced O +
by O +
the O +
presence O +
of O +
shorter O +
oligomers O +
in O +
amounts O +
greater O +
than O +
expected O +
based O +
upon O +
the O +
coupling O +
yields O -
. O +

To O +
circumvent O +
this O +
problem O +
we O +
examined O +
the O +
deprotection O +
reactions O +
at O +
lower O +
temperatures O +
and O +
found O +
they O +
could O +
be O +
run O +
effectively O +
at O +
room O +
temperature O -
. O +

Table O +
II O +
shows O +
the O +
half O -
- O -
lives O +
for O +
removing O +
the O +
base O +
protecting O +
groups O +
from O +
nucleosides O +
at O +
room O +
temperature O -
. O +

While O +
the O +
isobutryl O +
protecting O +
group O +
is O +
removed O +
at O +
the O +
slowest O +
rate O -
, O +
all O +
the O +
groups O +
are O +
completely O +
removed O +
within O +
240 O +
min O -
. O +

The O +
sole O +
product O +
of O +
each O +
reaction O +
is O +
the O +
5'-O O -
- O -
dimethoxytritylnucleoside O +
as O +
shown O +
by O +
TLC O -
. O +

Table O +
II O +
also O +
shows O +
the O +
half O -
- O -
lives O +
for O +
cleavage O +
of O +
protected O +
nucleosides O +
from O +
the O +
1 O -
% O +
crosslinked O +
support O -
. O +

The O +
deoxyguanosine O +
nucleoside O +
is O +
cleaved O +
most O +
rapidly O +
while O +
the O +
other O +
three O +
nucleosides O +
have O +
essentially O +
the O +
same O +
rates O +
of O +
hydrolysis O -
. O +

All O +
the O +
nucleosides O +
are O +
completely O +
removed O +
from O +
the O +
support O +
within O +
7 O +
hrs O -
. O +

In O +
contrast O -
, O +
very O +
different O +
rates O +
were O +
observed O +
for O +
the O +
2 O -
% O +
crosslinked O +
supports O -
. O +

In O +
these O +
cases O -
, O +
very O +
little O +
cleavage O +
occurred O +
during O +
the O +
first O +
4 O +
hrs O +
of O +
incubation O +
after O +
which O +
increasing O +
amounts O +
of O +
nucleoside O +
were O +
released O +
over O +
a O +
24 O +
hr O +
period O -
. O +

This O +
effect O +
may O +
be O +
due O +
to O +
the O +
slower O +
swelling O +
rate O +
of O +
the O +
2 O -
% O +
crosslinked O +
support O +
versus O +
the O +
1 O -
% O +
support O -
. O +

The O +
results O +
of O +
these O +
experiments O +
suggest O +
that O -
, O +
although O +
condensation O +
reactions O +
occur O +
with O +
equal O +
efficiencies O +
on O +
both O +
the O +
1 O -
% O +
and O +
2 O -
% O +
crosslinked O +
supports O -
, O +
the O +
1 O -
% O +
support O +
is O +
preferred O +
for O +
syntheses O +
since O +
the O +
oligomers O +
can O +
be O +
removed O +
more O +
readily O +
under O +
mild O +
conditions O -
. O +

The O +
stability O +
of O +
the O +
methylphosphonate O +
linkage O +
in O +
a O +
number O +
of O +
oligomers O +
of O +
varying O +
chain O +
length O +
and O +
base O +
composition O +
was O +
examined O +
following O +
prolonged O +
exposure O +
to O +
ethylenediamine O -
/ O -
ethanol O +
at O +
room O +
temperature O -
. O +

As O +
shown O +
in O +
Table O +
III O -
, O +
some O +
of O +
these O +
oligomers O -
, O +
most O +
notably O +
the O +
dimer O +
and O +
d O -
- O -
GpGpT O -
, O +
were O +
6235 O +
Nucleic O +
Acids O +
Research O +
Table O +
III O -
. O +

Hydrolysis O +
of O +
Oligonucleoside O +
Methylphosphonates O +
by O +
Ethylenediamine O +
at O +
22?C O +
| O +
Oligomer O +
Mole O +
percent O +
of O +
oligomer O +
remaining O +
after O +
treatment O +
for O +
24 O +
hrs O +
48 O +
hrs O +
96 O +
hrs O +
d O -
- O -
T O +
A O +
100 O +
100 O +
100 O +
d O -
- O -
A5r O +
100 O +
100 O +
100 O +
d O -
- O -
TpT O +
100 O +
100 O +
100 O +
d O -
- O -
l O +
pT O +
95 O +
97 O +
91 O +
d O -
- O -
qgG O -
{ O -
T O +
100 O +
100 O +
100 O +
d O -
- O -
ApApA O +
93 O +
87 O +
75 O +
d O -
- O -
C O +
pC O +
ApT O +
92 O +
83 O +

67 O +
completely O +
stable O +
over O +
a O +
96 O +
hr O +
period O -
. O +

The O +
maximum O +
rate O +
of O +
hydrolysis O +
for O +
a O +
methylphosphonate O +
linkage O +
in O +
those O +
oligomers O +
which O +
were O +
hydrolyzed O +
is O +
estimated O +
to O +
be O +
0.13 O +
mole O +
% O -
/hr O -
. O +

The O +
results O +
of O +
these O +
studies O +
show O +
that O +
the O +
oligonucleoside O +
methylphosphonates O +
could O +
be O +
cleaved O +
from O +
the O +
1 O -
% O +
crosslinked O +
support O +
and O +
completely O +
freed O +
of O +
base O +
protecting O +
groups O +
with O +
little O +
or O +
no O +
hydrolysis O +
of O +
the O +
methylphosphonate O +
linkage O +
by O +
treatment O +
with O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
room O +
temperature O +
for O +
7 O +
hrs O -
. O +

These O +
conditions O +
were O +
subsequently O +
adopted O +
for O +
the O +
deprotection O +
step O -
. O +

Purification O +
of O +
Oligonucleoside O +
Methylphosphonates O -
. O +

Two O +
methods O +
were O +
employed O +
to O +
purify O +
oligomers O +
following O +
cleavage O +
from O +
the O +
support O -
. O +

For O +
oligomers O +
which O +
contain O +
only O +
methylphosphonate O +
linkages O -
, O +
the O +
tritylated O +
oligomer O +
was O +
isolated O +
by O +
preparative O +
reversed O +
phase O +
HPLC O -
. O +

This O +
separation O +
is O +
based O +
upon O +
the O +
greater O +
affinity O +
of O +
the O +
tritylated O +
oligomer O +
for O +
the O +
hydrophobic O +
C-18 O +
matrix O +
of O +
the O +
column O -
. O +

Shorter O -
, O +
non O -
- O -
tritylated O +
oligomers O +
were O +
first O +
eluted O +
with O +
a O +
0 O -
% O +
to O +
25 O -
% O +
or O +
0 O -
% O +
to O +
30 O -
% O +
acetonitrile O +
in O +
water O +
gradient O -
. O +

The O +
tritylated O +
product O +
was O +
then O +
eluted O +
with O +
a O +
step O +
gradient O +
of O +
50 O -
% O +
acetonitrile O +
in O +
water O -
. O +

The O +
dimethoxytrityl O +
group O +
was O +
removed O +
from O +
the O +
material O +
in O +
the O +
50 O -
% O +
acetonitrile O +
fraction O +
by O +
treatment O +
with O +
80 O -
% O +
acetic O +
acid O +
at O +
room O +
temperature O -
. O +

Because O +
these O +
oligomers O +
were O +
originally O +
cleaved O +
from O +
the O +
support O +
by O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
65?C O -
, O +
we O +
usually O +
found O +
that O +
the O +
tritylated O +
oligomer O +
fraction O +
contained O +
shorter O +
oligomers O +
in O +
addition O +
to O +
the O +
desired O +
product O -
. O +

These O +
were O +
easily O +
separated O +
by O +
preparative O +
reversed O +
phase O +
HPLC O -
. O +

While O +
this O +
purification O +
procedure O +
is O +
qualitatively O +
satisfactory O -
, O +
recoveries O +
from O +
the O +
reversed O +
phase O +
columns O +
varied O +
from O +
50 O -
% O +
to O +
90 O -
% O -
. O +

These O +
losses O +
which O +
appeared O +
to O +
be O +
due O +
to O +
irreverisble O +
absorption O +
of O +
the O +
oligomers O +
to O +
the O +
column O +
varied O +
depending O +
on O +
the O +
base O +
composition O +
of O +
the O +
oligomers O -
. O +

6236 O +
Nucleic O +
Acids O +
Research O +
Figure O +
2 O -
: O +
Purification O +
of O +
d O -
- O -
ApApApApGpCpApApG. O +
( O -
a O -
) O +
Ol O +
igomers O +
obtained O +
after O +
treatment O +
of O +
support O +
wi O +
th O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O -
. O +

( O -
b O -
) O +
Ol O +
igomers O +
obtained O +
after O +
treatment O +
of O +
the O +
mixture O +
in O +
( O -
a O -
) O +
with O +
80 O -
% O +
acetic O +
acid O -
. O +

( O -
c O -
) O +
Oligomers O +
eluted O +
from O +
DEAE O +
cellulose O +
column O +
with O +
0.15 O +
M O +
triethylammonium O +
bicarbonate O -
. O +

( O -
d O -
) O +
Nonamer O +
obtained O +
after O +
preparative O +
reversed O +
phase O +
HPLC O -
. O +

Peaks O +
marked O +
with O +
the O +
symbol O +
( O -
X O -
) O +
are O +
derived O +
from O +
impurities O +
in O +
the O +
solvents O +
used O +
to O +
elute O +
the O +
oligomer O +
from O +
the O +
polystyrene O +
support O -
. O +

d O +
" O -
AAAGCAAGc O +
O O +
I O +
t10 O +
15 O +
20 O +
25 O +
Time O +
( O +
min O +
) O +
For O +
the O +
oligomers O +
which O +
terminate O +
with O +
a O +
5'-nucleoside O +
phosphotriester O +
group O -
, O +
the O +
support O +
was O +
first O +
treated O +
for O +
40 O +
hrs O +
with O +
tetra O -
- O -
n O -
- O -
butylammonium O +
fluoride O +
( O -
8) O +
to O +
remove O +
the O +
p O -
- O -
chlorophenyl O +
protecting O +
group O -
. O +

These O +
oligomers O +
6237 O +
b O +
Nucleic O +
Acids O +

Research O +
were O +
then O +
cleaved O +
from O +
the O +
support O +
and O +
the O +
base O +
protecting O +
groups O +
were O +
removed O +
by O +
treatment O +
with O +
ethylenediamine O -
/ O -
ethanol O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
for O +
7 O +
hrs O +
at O +
room O +
temperature O -
. O +

For O +
example O -
, O +
the O +
reversed O +
phase O +
HPLC O +
profile O +
for O +
products O +
obtained O +
after O +
cleavage O +
of O +
the O +
nonamer O -
, O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
ApAjApApGpCpApApG O -
, O +
is O +
shown O +
in O +
Figure O +
2a O -
. O +

The O +
peaks O +
marked O +
with O +
( O -
X O -
) O +
are O +
from O +
impurities O +
in O +
the O +
solvents O +
used O +
to O +
elute O +
the O +
oligomer O +
from O +
the O +
support O -
. O +

The O +
tritylated O +
nonamer O +
appears O +
at O +
22 O +
min O +
in O +
the O +
chromatogram O +
and O +
is O +
eluted O +
with O +
50 O -
% O +
aqueous O +
acetonitrile O -
. O +

After O +
removal O +
of O +
the O +
dimethoxytrityl O +
group O -
, O +
the O +
nonamer O +
elutes O +
at O +
15.2 O +
min O +
( O -
Figure O +
2b O -
) O -
. O +

The O +
peaks O +
which O +
appear O +
between O +
19 O +
and O +
25 O +
min O +
are O +
shorter O +
oligomers O +
which O +
contain O +
a O +
5'-mesitylenesulfonate O +
group O -
. O +

At O +
this O +
stage O -
, O +
the O +
nonamer O +
was O +
partially O +
purified O +
by O +
ion O +
exchange O +
chromatography O +
on O +
a O +
DEAE O +
cellulose O +
column O -
. O +

This O +
step O -
, O +
which O +
resulted O +
in O +
84 O -
% O +
recovery O +
of O +
material O +
loaded O +
onto O +
the O +
column O -
, O +
removed O +
most O +
of O +
the O +
shorter O +
oligomers O +
as O +
shown O +
in O +
Figure O +
2c O -
. O +

After O +
removal O +
of O +
the O +
buffer O -
, O +
the O +
nonamer O +
was O +
purified O +
by O +
preparative O +
reversed O +
phase O +
HPLC O +
using O +
a O +
0 O -
% O +
to O +
30 O -
% O +
acetonitrile O +
in O +
0.1 O +
M O +
ammonium O +
acetate O +
gradient O -
. O +

The O +
recovery O +
of O +
material O +
from O +
the O +
column O +
( O -
84 O -
% O -
) O +
appears O +
to O +
be O +
higher O +
when O +
ammonium O +
acetate O +
is O +
used O -
. O +

The O +
pure O +
nonamer O +
( O -
Figure O +
2d O -
) O +
was O +
obtained O +
in O +
10 O -
% O +
overall O +
yield O +
based O +
on O +
the O +
amount O +
of O +
d- O -
[ O -
( O -
MeO O -
) O -
2 O +
Tr O -
] O -
ibuG O +
originally O +
bound O +
to O +
the O +
polystyrene O +
support O -
. O +

The O +
oligomer O +
was O +
desalted O +
on O +
a O +
Bio O -
- O -
Gel O +
P-2 O +
gel O +
filtration O +
column O -
. O +

Similar O +
results O +
were O +
obtained O +
for O +
the O +
other O +
oligomers O +
purified O +
by O +
this O +
method O -
. O +

Thus O -
, O +
for O +
example O +
dApApA O +
and O +
d O -
- O -
ApCpCpApT O +
were O +
obtained O +
in O +
44 O -
% O +
and O +
22 O -
% O +
isolated O +
yields O +
respectively O +
based O +
upon O +
the O +
amount O +
of O +
d- O -
[ O -
( O -
MeO O -
) O -
2Tr O -
] O -
N. O +
The O +
5'-terminal O +
nucleotide O +
may O +
be O +
removed O +
enzynatically O +
to O +
give O +
an O +
oligomer O +
which O +
contains O +
only O +
methylphosphonate O +
linkages O -
. O +

Thus O +
treatment O +
of O +
the O +
nonamer O -
, O +
d O -
- O -
ApApApApGpCpApApG O -
, O +
with O +
spleen O +
phosphodiesterase O +
gave O +
d O -
- O -
Ap O +
and O +
the O +
octamer O +
d O -
- O -
ApApApGpCpApApG O +
whose O +
retention O +
time O +
is O +
16.4 O +
min O +
on O +
the O +
reversed O +
phase O +
column O -
. O +

The O +
noncharged O +
octamer O +
was O +
freed O +
of O +
d O -
- O -
Ap O +
and O +
enzyne O +
by O +
simply O +
passing O +
it O +
through O +
a O +
small O +
DEAE O +
cellulose O +
column O -
. O +

Characterization O -
. O +

Methylphosphonate O +
linkages O +
are O +
cleaved O +
by O +
base O -
. O +

We O +
have O +
found O +
piperdine O +
is O +
particularly O +
effective O -
. O +

The O +
cleavage O +
occurs O +
in O +
a O +
random O +
manner O +
giving O +
nucleosides O -
, O +
nucleoside O +
3'- O +
or O +
5'-methylphosphonates O +
and O +
nucleoside O +
3',5'-bis O -
- O -
methylphosphonates O -
. O +

This O +
hydrolysis O +
reaction O +
may O +
be O +
used O +
to O +
characterize O +
dimers O -
, O +
since O +
the O +
identity O +
and O +
ratio O +
of O +
the O +
products O +
formed O +
are O +
easily O +
determined O +
by O +
reversed O +
phase O +
HPLC O -
. O +

However O -
, O +
the O +
method O +
becomes O +
less O +
satisfactory O +
for O +
longer O +
oligomers O -
. O +

Purine O -
- O -
containing O +
oligonucleoside O +
methylphosphonates O +
may O +
be O +
depurinated O +
by O +
treatment O +
with O +
hydrochloric O +
acid O +
at O +
650 O -
. O +

The O +
methylphosphonate O +
linkage O +
is O +
6238 O +
Nucleic O +
Acids O +
Research O +
9 O +
0 O +
OH O +
cH3P O -
: O -
O O +
cH O +
CH3P O +
9 O +
9 O +
CH O -
- O -
P O +
:O O +
C O +
cH O +
: O -
0pO O +
O~~ O +
~j4 O +
HO O +
OP O +
3 O +
0 O +
H O +
0 O +
0OH0 O +
9 O +
S O +
S O +
Figure O +
3 O -
: O +
Hydrolysis O +
of O +
the O +
internucleoside O +
methylphsophonate O +
linkages O +
at O +
an O +
apurinic O +
site O +
produced O +
by O +
treatment O +
of O +
the O +
oligomer O +
with O +
hydrochloric O +
acid O +
at O +
pH O +
2 O -
. O +

resistant O +
to O +
hydrolysis O +
by O +
these O +
conditions O +
as O +
shown O +
by O +
the O +
stability O +
of O +
d O -
- O -
TpT O +
and O +
d O -
- O -
TpTpT. O +
On O +
the O +
other O +
hand O -
, O +
dimers O +
or O +
trimers O +
containing O +
purine O +
bases O +
such O +
as O +
d O -
- O -
ApA O -
, O +
dApT O -
, O +
dTpA O +
or O +
d O -
- O -
ApApA O +
have O +
half O -
- O -
lives O +
between O +
92 O +
and O +
144 O +
min O +
in O +
0.01 O +
M O +
hydrochloric O +
acid O -
. O +

Following O +
neutralization O +
with O +
ammonium O +
hydroxide O -
, O +
the O +
products O +
of O +
these O +
reactions O +
were O +
characterized O +
by O +
reversed O +
phase O +
HPLC O -
. O +

d O -
- O -
ApA O +
gave O +
adenine O -
, O +
while O +
both O +
d O -
- O -
ApT O +
and O +
d O -
- O -
TpA O +
gave O +
adenine O +
and O +
thymidine O +
as O +
the O +
sole O +
products O +
of O +
the O +
reaction O -
. O +

Adenine O +
and O +
d O -
- O -
ApA O +
were O +
the O +
only O +
products O +
observed O +
when O +
d O -
- O -
ApApA O +
was O +
partially O +
hydrolyzed O -
. O +

When O +
d O -
- O -
CpCpApT O +
was O +
completely O +
hydrolyzed O +
in O +
acid O +
three O +
products O -
, O +
d O -
- O -
CpC O -
, O +
adenine O +
and O +
thynidine O -
, O +
were O +
observed O +
in O +
a O +
molar O +
ratio O +
of O +
1:1:1 O -
. O +

In O +
contrast O +
to O +
the O +
base O +
hydrolysis O +
of O +
the O +
methylphosphonate O +
group O -
, O +
apurinic O +
sites O +
produced O +
by O +
acid O +
treatment O +
are O +
further O +
hydrolyzed O +
to O +
nucleosides O +
or O +
oligomers O +
with O +
free O +
5'- O +
and O +
3'-OH O +
groups O -
. O +

The O +
absence O +
of O +
terminal O +
phosphonate O +
residues O +
suggests O +
hydrolysis O +
occurs O +
as O +
shown O +
in O +
Figure O +
3 O -
. O +

The O +
OH O +
group O +
on O +
the O +
4'-carbon O +
generated O +
by O +
opening O +
the O +
ribose O +
at O +
the O +
apurinic O +
site O +
may O +
participate O +
in O +
an O +
intramolecular O +
attack O +
on O +
the O +
adjacent O +
phosphonate O +
linkages O +
which O +
results O +
in O +
removal O +
of O +
the O +
phosphonate O +
residues O +
from O +
the O +
neighboring O +
nucleoside O +
hydroxyls O -
. O +

Previous O +
studies O +
by O +
Agarwal O +
and O +
Riftina O +
indicated O +
dithymidine O +
methyl- O +
or O +
phenylphosphonates O +
can O +
be O +
phosphorylated O +
by O +
polynucleotide O +
kinase O +
( O -
9 O -
) O -
. O +

Sinha O +
et O +
al. O +
reported O +
that O +
dimers O +
but O +
not O +
trimers O +
or O +
tetramers O +
served O +
as O +
substrates O +
for O +
this O +
enzyme O +
( O -
4 O -
) O -
. O +

We O +
were O +
unable O +
to O +
phosphorylate O +
tetramers O +
or O +
longer O +
oligomers O +
which O +
contain O +
only O +
methylphosphonate O +
linkages O -
. O +

However O -
, O +
those O +
oligomers O +
which O +
terminate O +
with O +
a O +
5'-dAp O -
- O -
residue O +
are O +
readily O +
6239 O +
Nucleic O +
Acids O +
Research O +
a O +
ATP O +
1 O +
1 O +
2 O +
3 O +
4 O +
b O +
6 O +
mer O +
Mik O +
6 O +
mer O +
go O +
3mer O +
a O +
a O +
a O +
X O +
2mer O +
do O +
ATP O +
411 O +
12 O +
w O +
34 O +
1 O +
2 O +
3 O +
4 O +
5 O +
6 O +
Figure O +
4 O -
: O +
( O -
a O -
) O +
PEI O -
- O -
cellulose O +
TLC O +
of O +
T4 O +
polynucleotide O +
kinase O +
reactions O -
. O +

1 O -
) O +
[ O -
y-32p O -
] O -
ATP O -
; O +
2 O -
) O +
d O -
- O -
ApApA O +
reaction O +
mixture O -
; O +
3 O -
) O +
d O -
- O -
ApGpCpApApG O +
reaction O +
mixture O -
; O +
4 O -
) O +
d O -
- O -
ApApApApG_pCpApAeG O +
reaction O +
mixture O -
. O +

The O +
chromatogram O +
was O +
eluted O +
wi O +
th1.5 O +
M O +
pyridinium O +
formate O -
, O +
pH O +
3.5 O -
. O +

( O -
b O -
) O +
Polyacrylamide O +
gel O +
electrophoresis O +
of O +
phosphoryljted O +
olihonucleoside O +
methylghosphonates O -
. O +

1 O -
) O +
markers O -
: O +
d- O +
pTpT O +
( O -
2 O +
mer O -
) O -
; O +
d-,3pApApA O +
( O -
3 O +
mer O -
) O -
; O +
d- O +
2pApGpCpApApG O +
( O -
6 O +
mer O -
) O -
; O +
d-32pApApApApGpCpApApG O +
( O -
9 O +
mer O +
. O +

Lanes O +
2 O -
- O -
4 O +
: O +
products O +
obtained O +
after O +
partTaT O +
fy?rlysis O +
of O +
dl2pApApA O +
( O -
2 O -
) O -
; O +
d- O +
2pApGpCpApApG O +
( O -
3 O -
) O +
and O +
d-32pApARApApGpCpAZARG O -
; O +
( O -
4 O -
) O +
with O +
0.5 O +
M O +
piperidine O +
at O +
377C O +
for O +
10 O +
min O +
Lanel O +
t O +
: O +
products O +
obtained O +
Wfter O +
partial O +
hydrolysis O +
of O +
d-3Kp O -
- O -
ApGRCpApApG O +
( O -
5 O -
) O +
and O +
d-32p O -
- O -
ApApAppGpjCppAjG O +
( O -
6 O -
) O +
with O +
0.5 O +
M O +
HC1 O +
at O +
371C O +
fCor30 O +
min O -
. O +

Electrophoresis O +
was O +
carried O +
out O +
at O +
constant O +
voltage O +
( O -
800 O +
v O -
) O +
until O +
the O +
bromphenol O +
blue O +
marker O +
dye O +
had O +
migrated O +
halfway O +
down O +
the O +
gel O -
. O +

phosphorylated O +
by O +
polynucleotide O +
kinase O -
. O +

The O +
phosphorylation O +
reaction O +
is O +
easily O +
followed O +
by O +
PEI O -
- O -
cellulose O +
TLC O -
. O +

As O +
shown O +
in O +
Figure O +
4a O -
, O +
the O +
phosphorylated O +
oligomers O +
have O +
a O +
higher O +
Rf O +
values O +
than O +
does O +
d O -
- O -
ATP O -
. O +

The O +
phosphorylated O +
methylphosphonate O +
oligomers O +
can O +
be O +
separated O +
according O +
to O +
their O +
chain O +
lengths O +
by O +
polyacrylamide O +
gel O +
electrophoresis O +
on O +
an O +
18 O -
% O +
gel O +
containing O +
7 O +
M O +
urea O +
as O +
shown O +
in O +
Figure O +
4 O -
( O -
b O -
) O -
. O +

Lane O +
1 O +
shows O +
the O +
separation O +
of O +
a O +
trimer O -
, O +
hexamer O +
and O +
nonamer O -
. O +

The O +
band O +
which O +
appears O +
directly O +
below O +
the O +
nonamer O +
may O +
arise O +
from O +
traces O +
of O +
contaminating O +
octamer O +
which O +
were O +
not O +
removed O +
during O +
the O +
purification O +
of O +
d O -
- O -
ApApApApGpCpApApG. O +
6240 O +
Nucleic O +
Acids O +
Research O +
When O +
the O +
oligomers O +
were O +
partially O +
hydrolyzed O +
with O +
piperidine O -
, O +
a O +
series O +
of O +
new O +
bands O +
appears O +
corresponding O +
to O +
shorter O +
oligomers O +
produced O +
via O +
hydrolysis O +
of O +
the O +
methylphosphonate O +
linkages O +
( O -
Lanes O +
2 O -
- O -
4 O -
) O -
. O +

Because O +
of O +
the O +
random O +
nature O +
of O +
this O +
cleavage O +
reaction O -
, O +
the O +
oligomers O +
should O +
terminate O +
with O +
either O +
a O +
3'-OH O +
or O +
a O +
3'-methylphosphonate O +
group O -
. O +

In O +
the O +
case O +
of O +
the O +
trimer O -
, O +
32pApApA O -
, O +
hydrolysis O +
gives O +
two O +
bands O +
which O +
correspond O +
to O +
d-32pApA O +
and O +
d-32pApAp O +
( O -
Lane O +
2 O -
) O -
. O +

The O +
same O +
products O +
are O +
observed O +
for O +
hydrolysis O +
of O +
the O +
nonamer O -
, O +
d-32pApApApApGpCpApApG O +
( O -
Lane O +
4 O -
) O -
. O +

A O +
similar O +
situation O +
is O +
observed O +
for O +
d32pApGpCpApApG O +
although O +
the O +
dimers O +
d-32pApG O +
and O +
d-32pApGp O +
have O +
somewhat O +
different O +
mobilities O +
( O -
Lane O +
3 O -
) O -
. O +

These O +
dimers O +
can O -
not O +
be O +
separated O +
when O +
the O +
gel O +
is O +
run O +
in O +
the O +
absence O +
of O +
urea O -
. O +

It O +
is O +
possible O +
to O +
determine O +
the O +
chain O +
lengths O +
of O +
the O +
original O +
oligomers O +
by O +
counting O +
the O +
number O +
of O +
oligomers O +
produced O +
by O +
partial O +
piperidine O +
hydrolysis O -
. O +

For O +
example O -
, O +
starting O +
with O +
the O +
trimer O +
band O -
, O +
one O +
can O +
observe O +
3 O +
bands O +
corresponding O +
to O +
tetramer O -
, O +
pentamer O +
and O +
hexamer O +
for O +
the O +
hydrolysis O +
products O +
of O +
d-32pApGpCpApApG O +
( O -
Lane O +
3 O -
) O +
and O +
6 O +
bands O +
corresponding O +
to O +
tetramer O -
, O +
pentamer O -
, O +
hexamer O -
, O +
heptamer O -
, O +
octamer O +
and O +
nonamer O +
for O +
the O +
hydrolysis O +
products O +
of O +
32pApApApApGpCpApApG O +
( O -
Lane O +
4 O -
) O -
. O +

The O +
positions O +
of O +
the O +
oligomers O +
of O +
the O +
same O +
chain O +
length O +
appear O +
to O +
be O +
very O +
similar O +
which O +
suggests O +
that O +
the O +
mobilities O +
are O +
not O +
greatly O +
affected O +
by O +
base O +
composition O +
on O +
the O +
urea O -
- O -
containing O +
gel O -
. O +

This O +
procedure O +
thus O +
provides O +
a O +
rapid O +
and O +
convenient O +
method O +
for O +
characterizing O +
the O +
methyl O +
phosphonate O +
ol O +
i O +
gomers O -
. O +

Treatment O +
of O +
the O +
phosphorylated O +
oligomers O +
with O +
acid O +
produces O +
shorter O +
oligomers O +
which O +
result O +
from O +
chain O +
cleavage O +
at O +
apurinic O +
sites O -
. O +

In O +
this O +
case O +
the O +
oligomers O +
terminate O +
with O +
a O +
3'-OH O +
group O -
. O +

Treatment O +
of O +
32pApGpCpApALpG O +
produces O +
an O +
intense O +
band O +
corresponding O +
to O +
the O +
pentamer O -
, O +
d-32pApGjCpAjA O +
( O -
Lane O +
5 O -
) O +
while O +
treatment O +
of O +
32pApApApApGpCpApApG O +
produces O +
an O +
intense O +
band O +
corresponding O +
to O +
the O +
octamer O +
d-32pApApAPApGpCpApA O +
and O +
fainter O +
bands O +
corresponding O +
to O +
the O +
heptamer O -
, O +
hexamer O -
, O +
tetramer O +
and O +
trimer O -
. O +

These O +
results O +
suggest O +
that O +
under O +
the O +
conditions O +
of O +
the O +
experiment O -
, O +
hydrolysis O +
occurs O +
preferentially O +
at O +
the O +
3'-terminal O +
G O +
residue O +
of O +
both O +
oligomers O -
. O +

It O +
should O +
be O +
possible O +
to O +
extend O +
this O +
methodology O +
to O +
other O +
base O +
specific O +
depurination O +
or O +
depyrimidination O +
reactions O +
similar O +
to O +
those O +
employed O +
in O +
the O +
Maxam O -
- O -
Gilbert O +
sequencing O +
method O +
( O -
10 O -
) O -
. O +

Experiments O +
directed O +
toward O +
this O +
goal O +
are O +
currently O +
in O +
progress O +
and O +
will O +
be O +
reported O +
in O +
a O +
future O +
communication O -
. O +

ACKNOWLEDGEMENT O -
: O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
the O +
following O +
grants O +
from O +
the O +
National O +
Institutes O +
of O +
Health O -
: O +
GM O +
16066 O +
( O -
P.O.P.T. O -
) O +
and O +
GM O +
31927 O +
6241 O +
Nucleic O +
Acids O +
Research O +
( O -
P.S.M. O -
) O -
, O +
and O +
from O +
a O +
grant O +
from O +
Association O +
for O +
International O +
Cancer O +
Research O -
. O +

REFERENCES O -
: O +
1 O -
. O +

MTTITr O -
, O +
P.S. O -
, O +
McParland O -
, O +
K.B. O -
, O +
Jayaraman O -
, O +
K. O +
and O +
Ts'o O -
, O +
P.O.P. O +
( O -
1981 O -
) O +
Biochemistry O +
20 O -
, O +
1874 O -
- O -
1880 O -
. O +

2 O -
. O +

Jayaraman O -
, O +
K. O -
, O +
McParland O -
, O +
K.B. O -
, O +
Miller O -
, O +
P.S. O +
and O +
Ts'o O -
, O +
P.O.P. O +
( O -
1981 O -
) O +
Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +
78 O -
, O +
1537 O -
- O -
1541 O -
. O +

3 O -
. O +

Miller O -
, O +
P.S. O -
, O +
Agris O -
, O +
C.H. O -
, O +
Blandin O -
, O +
M. O -
, O +
Murakami O -
, O +
A. O -
, O +
Reddy O -
, O +
P.M. O -
, O +
Spitz O -
, O +
S.A. O +
and O +
Ts'o O -
, O +
P.O.P. O +
( O -
1983 O -
) O +
Nucleic O +
Acids O +
Res O -
. O -
, O +
submitted O +
for O +
publ O +
ication O -
. O +

4 O -
. O +

Sinha O -
, O +
N.D. O +
Grossbruchaus O -
, O +
V. O +
and O +
Koester O -
, O +
H. O +
( O -
1983 O -
) O +
Tetrahedron O +
Letters O +
24 O -
, O +
877 O -
- O -
880 O -
. O +

5 O -
. O +

Miller O -
, O +
P.S. O -
, O +
Cheng O -
, O +
D.M. O -
, O +
Dreon O -
, O +
N. O -
, O +
Jayaraman O -
, O +
K. O -
, O +
Kan O -
, O +
L O -
.- O -
S. O -
, O +
Leutzinger O -
, O +
E.E. O -
, O +
Pulford O -
, O +
S.M. O +
and O +
Ts'o O -
, O +
P.O.P. O +
( O -
1980 O -
) O +
Biochemistry O +
19 O -
, O +
4688 O -
- O -
4698 O -
. O +

6 O -
. O +

Ito O -
, O +
H. O -
, O +
Ike O -
, O +
Y. O -
, O +
Ikuta O -
, O +
S. O +
and O +
Itakura O -
, O +
K. O -
, O +
( O -
1982 O -
) O +

Nucleic O +
Acids O +
Res O +
10 O -
, O +
1755 O -
- O -
1769 O -
. O +

7 O -
. O +

Barnett O -
, O +
R.W. O +
and O +
Letsinger O -
, O +
R.L. O +
( O -
1981 O -
) O +

Tetrahedron O +
Letters O +
22 O -
, O +
991 O -
- O -
994 O -
. O +

6242 O +

Enzymatic O +
multiplex O +
DNA O +
sequencing O -
. O +

Abstract O +
The O +
problem O +
of O +
reading O +
DNA O +
sequence O +
films O +
has O +
been O +
reformulated O +
using O +
an O +
easily O +
implemented O -
, O +
multiplex O +
version O +
of O +
enzymatic O +
DNA O +
sequencing O -
. O +

By O +
utilizing O +
a O +
uniquely O +
tagged O +
primer O +
for O +
each O +
base O -
- O -
specific O +
sequencing O +
reaction O -
, O +
the O +
four O +
reactions O +
can O +
be O +
pooled O +
and O +
electrophoresed O +
in O +
a O +
single O +
lane O -
. O +

This O +
approach O +
has O +
been O +
previously O +
proposed O +
for O +
use O +
with O +
fluorescently O +
labelled O +
probes O +
( O -
1 O -
) O -
, O +
and O +
is O +
analogous O +
to O +
the O +
principle O +
used O +
in O +
four O -
- O -
dye O +
fluorescence O +
sequencing O +
except O +
that O +
the O +
signals O +
are O +
resolved O +
following O +
electrophoresis O +
( O -
2 O -
) O -
. O +

After O +
transfer O +
to O +
a O +
nylon O +
membrane O -
, O +
images O +
are O +
obtained O +
separately O +
for O +
each O +
of O +
the O +
four O +
reactions O +
by O +
hybridization O +
using O +
oligonucleotide O +
probes O -
. O +

The O +
images O +
can O +
then O +
be O +
superimposed O +
to O +
reconstitute O +
a O +
complete O +
sequence O +
pattern O -
. O +

In O +
this O +
way O +
the O +
correction O +
of O +
gel O +
distortion O +
effects O +
and O +
accurate O +
band O +
registration O +
are O +
considerably O +
simplified O -
, O +
as O +
each O +
of O +
the O +
four O +
base O -
- O -
specific O +
ladders O +
require O +
very O +
similar O +
corrections O -
. O +

The O +
methods O +
therefore O +
provide O +
the O +
basis O +
for O +
a O +
second O +
generation O +
of O +
more O +
accurate O +
and O +
reliable O +
film O +
reading O +
programs O -
, O +
as O +
well O +
as O +
being O +
useful O +
for O +
conventional O +
multiplex O +
sequencing O -
. O +

Unlike O +
the O +
original O +
multiplex O +
protocol O +
( O -
3 O -
) O -
, O +
the O +
approach O +
described O +
is O +
suitable O +
for O +
small O +
projects O -
, O +
as O +
multiple O +
cloning O +
vectors O +
are O +
not O +
used O -
. O +

Although O +
more O +
than O +
one O +
vector O +
can O +
be O +
utilized O -
, O +
only O +
a O +
library O +
of O +
fragments O +
cloned O +
into O +
any O +
single O +
phage O -
, O +
phagemid O +
or O +
plasmid O +
vector O +
is O +
actually O +
required O -
, O +
together O +
with O +
a O +
set O +
of O +
tagged O +
oligonucleotide O +
primers O -
. O +

Images O +
Nucleic O +
Acids O +
Research O -
, O +
Vol O -
. O +

19 O -
, O +
No. O +
12 O +
3301 O +
Enzymatic O +
multiplex O +
DNA O +
sequencing O +
Mark O +
Chee O +
Medical O +
Research O +
Council O +
Laboratory O +
of O +
Molecular O +
Biology O -
, O +
Hills O +
Road O -
, O +
Cambridge O +
CB2 O +
20H O -
, O +
UK O +
Received O +
March O +
15 O -
, O +
1991 O -
; O +
Revised O +
and O +
Accepted O +
May O +
2 O -
, O +
1991 O +
ABSTRACT O +
The O +
problem O +
of O +
reading O +
DNA O +
sequence O +
films O +
has O +
been O +
reformulated O +
using O +
an O +
easily O +
implemented O -
, O +
multiplex O +
version O +
of O +
enzymatic O +
DNA O +
sequencing O -
. O +

By O +
utilizing O +
a O +
uniquely O +
tagged O +
primer O +
for O +
each O +
base O -
- O -
specific O +
sequencing O +
reaction O -
, O +
the O +
four O +
reactions O +
can O +
be O +
pooled O +
and O +
electrophoresed O +
in O +
a O +
single O +
lane O -
. O +

This O +
approach O +
has O +
been O +
previously O +
proposed O +
for O +
use O +
with O +
fluorescently O +
labelled O +
probes O +
( O -
1 O -
) O -
, O +
and O +
is O +
analogous O +
to O +
the O +
principle O +
used O +
in O +
four O -
- O -
dye O +
fluorescence O +
sequencing O +
except O +
that O +
the O +
signals O +
are O +
resolved O +
following O +
electrophoresis O +
( O -
2 O -
) O -
. O +

After O +
transfer O +
to O +
a O +
nylon O +
membrane O -
, O +
images O +
are O +
obtained O +
separately O +
for O +
each O +
of O +
the O +
four O +
reactions O +
by O +
hybridization O +
using O +
oligonucleotide O +
probes O -
. O +

The O +
images O +
can O +
then O +
be O +
superimposed O +
to O +
reconstitute O +
a O +
complete O +
sequence O +
pattern O -
. O +

In O +
this O +
way O +
the O +
correction O +
of O +
gel O +
distortion O +
effects O +
and O +
accurate O +
band O +
registration O +
are O +
considerably O +
simplified O -
, O +
as O +
each O +
of O +
the O +
four O +
basespecific O +
ladders O +
require O +
very O +
similar O +
corrections O -
. O +

The O +
methods O +
therefore O +
provide O +
the O +
basis O +
for O +
a O +
second O +
generation O +
of O +
more O +
accurate O +
and O +
reliable O +
film O +
reading O +
programs O -
, O +
as O +
well O +
as O +
being O +
useful O +
for O +
conventional O +
multiplex O +
sequencing O -
. O +

Unlike O +
the O +
original O +
multiplex O +
protocol O +
( O -
3 O -
) O -
, O +
the O +
approach O +
described O +
is O +
suitable O +
for O +
small O +
projects O -
, O +
as O +
multiple O +
cloning O +
vectors O +
are O +
not O +
used O -
. O +

Although O +
more O +
than O +
one O +
vector O +
can O +
be O +
utilized O -
, O +
only O +
a O +
library O +
of O +
fragments O +
cloned O +
into O +
any O +
single O +
phage O -
. O +

phagemid O +
or O +
plasmid O +
vector O +
is O +
actually O +
required O -
, O +
together O +
with O +
a O +
set O +
of O +
tagged O +
oligonucleotide O +
primers O -
. O +

INTRODUCTION O +
The O +
community O +
of O +
biologists O +
is O +
undertaking O +
the O +
sequencing O +
of O +
representative O +
genomes O +
of O +
various O +
free O -
- O -
living O +
organisms O -
, O +
ranging O +
in O +
size O +
from O +
Mycoplasma O +
( O -
800 O -
kb O -
) O +
to O +
mammals O +
( O -
3 O +
Gb O -
) O +
( O -
4 O -
) O -
. O +

However O -
, O +
the O +
largest O +
contiguous O +
DNA O +
sequences O +
which O +
have O +
been O +
determined O +
so O +
far O +
are O +
the O +
genomes O +
of O +
several O +
dsDNA O +
eukaryotic O +
viruses O +
( O -
5 O -
, O +
6 O -
, O +
7 O -
, O +
8 O -
, O +
9 O -
) O +
and O +
plant O +
chloroplasts O +
( O -
10 O -
, O +
11 O -
, O +
12 O -
) O -
. O +

The O +
largest O +
of O +
these O +
is O +
the O +
229 O -
kb O +
genome O +
of O +
human B-Species +
cytomegalovirus I-Species +
( O -
8) O -
. O +

The O +
difficulty O +
in O +
sequencing O +
millions O +
of O +
base O +
pairs O +
of O +
DNA O +
is O +
that O +
several O +
steps O +
in O +
the O +
methods O +
are O +
relatively O +
labour O +
intensive O -
, O +
although O +
the O +
sequencing O +
reactions O +
themselves O +
are O +
rapid O +
and O +
easily O +
performed O -
. O +

Two O +
limiting O +
steps O +
in O +
conventional O +
procedures O +
are O +
the O +
size O +
fractionation O +
of O +
sequencing O +
reaction O +
products O +
by O +
gel O +
electrophoresis O +
and O +
the O +
subsequent O +
reading O +
of O +
sequence O +
ladders O -
. O +

The O +
former O +
problem O +
can O +
be O +
overcome O +
by O +
multiplexing O -
, O +
which O +
theoretically O +
allows O +
an O +
enormous O +
amount O +
of O +
data O +
to O +
be O +
obtained O +
from O +
a O +
single O +
gel O +
by O +
processing O +
clones O +
as O +
mixtures O +
rather O +
than O +
individually O +
( O -
3 O -
) O -
. O +

Each O +
sequence O +
in O +
the O +
mixture O +
is O +
labelled O +
by O +
a O +
unique O +
short O +
oligonucleotide O +
' O -
tag O -
' O +
sequence O -
. O +

This O +
allows O +
the O +
mixture O +
to O +
be O +
resolved O +
following O +
electrophoresis O -
: O +
the O +
superimposed O +
sequence O +
ladders O +
are O +
blotted O +
from O +
the O +
gel O +
to O +
a O +
nylon O +
membrane O -
, O +
and O +
detected O +
one O +
at O +
a O +
time O +
by O +
hybridization O +
using O +
tag O -
- O -
specific O +
oligonucleotide O +
probes O -
. O +

In O +
practice O -
, O +
at O +
least O +
50 O +
sets O +
of O +
sequences O +
can O +
be O +
obtained O +
from O +
a O +
single O +
gel O +
( O -
3 O -
) O -
. O +

Unfortunately O -
, O +
a O +
bottleneck O +
in O +
the O +
multiplex O +
procedure O +
is O +
the O +
reading O +
of O +
sequence O +
films O -
. O +

In O +
previous O +
large O -
- O -
scale O +
sequencing O +
projects O +
this O +
task O +
has O +
been O +
performed O +
with O +
the O +
aid O +
of O +
a O +
sonic O +
digitizer O +
( O -
13 O -
, O +
14 O -
) O -
. O +

Although O +
film O +
reading O +
programs O +
have O +
been O +
under O +
development O +
for O +
some O +
time O +
( O -
15 O -
) O -
, O +
and O +
some O +
programs O +
are O +
commercially O +
available O -
, O +
their O +
error O +
rates O +
are O +
presently O +
more O +
variable O +
and O +
unpredictable O +
than O +
that O +
of O +
a O +
skilled O +
person O +
and O +
the O +
accurate O +
interpretation O +
of O +
film O -
- O -
imaged O +
sequence O +
ladders O +
by O +
computer O +
programs O +
is O +
difficult O +
to O +
achieve O +
in O +
routine O +
practice O -
. O +

Programs O +
specifically O +
designed O +
to O +
read O +
multiplex O +
films O +
have O +
an O +
advantage O -
. O +

This O +
is O +
because O +
a O +
sequence O +
image O +
can O +
be O +
used O +
as O +
an O +
' O -
internal O +
standard O -
' O +
to O +
help O +
interpret O +
other O +
images O +
derived O +
from O +
the O +
same O +
membrane O +
( O -
3 O -
) O -
. O +

However O -
, O +
the O +
original O +
implementation O +
of O +
the O +
multiplex O +
strategy O +
used O +
chemical O +
sequencing O +
( O -
16 O -
) O -
, O +
which O +
yields O +
a O +
more O +
complex O +
sequence O +
ladder O +
than O +
the O +
enzymatic O +
dideoxynucleotide O +
chain O -
- O -
termination O +
method O +
( O -
17 O -
) O -
. O +

Most O +
successful O +
large O +
scale O +
sequencing O +
projects O +
have O +
used O +
the O +
chaintermination O +
method O +
and O +
bacteriophage B-Species +
M13 I-Species +
vectors O -
, O +
which O +
allows O +
the O +
routine O +
production O +
of O +
clean O +
and O +
easily O +
interpretable O +
sequences O +
( O -
18 O -
) O -
. O +

It O +
was O +
therefore O +
decided O +
to O +
adapt O +
the O +
original O +
multiplex O +
protocol O +
for O +
use O +
with O +
enzymatic O +
sequencing O -
, O +
using O +
tagged O +
primers O -
. O +

MATERIALS O +
AND O +
METHODS O +
Eight O +
oligonucleotide O +
sequencing O +
primers O +
were O +
synthesized O -
, O +
each O +
37 O +
nucleotides O +
in O +
length O -
. O +

The O +
3 O -
' O +
end O +
of O +
each O +
primer O +
consists O +
of O +
the O +
17 O +
nucleotide O +
M13 O +
universal O +
priming O +
sequence O +
[ O -
GTAAAACGACGGCCAGT3 O -
' O -
] O -
. O +

The O +
5 O -
' O +
ends O +
of O +
the O +
primers O +
bear O +
different O +
20mer O +
tag O +
sequences O +
( O -
Figure O +
1 O -
) O -
. O +

In O +
four O +
of O +
the O +
primers O -
, O +
UEO1C O -
, O +
UPOIC O -
, O +
UE02C O +
and O +
UP02C O -
, O +
these O +
tags O +
are O +
complementary O +
to O +
the O +
EO1 O -
, O +
PO1 O -
, O +
E02 O +
and O +
P02 O +
probe O +
sequences O +
respectively O +
( O -
copied O +
from O +
the O +
original O +
' O -
plex O -
' O +
vectors O +
( O -
3 O -
) O -
) O -
. O +

A O +
second O +
set O +
of O +
four O +
primers O -
, O +
UJOL14C O -
, O +
UJOL15C O -
, O +
UJOL16C O +
and O +
UJOL17C O -
, O +
have O +
the O +
following O +
tag O +
sequences O -
: O +
5 O -
' O +
CAAGTTTGAAGGTACTCATT O -
, O +
TATCAATTAAATTGTllTGAC O -
, O +
GTGTTGCTACCCAAGAAGCA O -
, O +
and O +
TGTCACTAGAGCTGTCACTT O -
, O +
respectively O -
. O +

The O +
? O -
=) O +
1991 O +
Oxford O +
University O +
Press O +
3302 O +
Nucleic O +
Acids O +
Research O -
, O +
Vol O -
. O +

19 O -
, O +
No. O +
12 O +
oligonucleotides O +
were O +
gel O -
- O -
purified O +
( O -
19 O -
) O +
and O +
used O +
to O +
sequence O +
ssDNA O +
templates O +
prepared O +
by O +
phenol O +
extraction O +
( O -
20 O -
) O +
or O +
SDS O +
denaturation O +
( O -
21 O -
) O -
. O +

Conventional O +
sequencing O +
reactions O +
were O +
performed O +
as O +
previously O +
described O +
( O -
20 O -
) O -
. O +

For O +
hybridization O +
experiments O -
, O +
radioactively O +
labelled O +
nucleotides O +
were O +
omitted O +
from O +
the O +
sequencing O +
reactions O -
. O +

Instead O -
, O +
the O +
21d O +
of O +
each O +
nucleotide O +
mix O +
added O +
to O +
the O +
reaction O +
mixture O +
consisted O +
of O +
the O +
following O -
: O +
' O -
A O -
' O +
mix O -
: O +
6.25MtM O +
dATP O -
, O +
62.5lM O +
ddATP O -
; O +
' O -
C O -
' O +
mix O -
: O +
6.25MM O +
dCTP O -
, O +
40MtM O +
ddCTP O -
; O +
' O -
G O -
' O +
mix O -
: O +
6.25MtM O +
dGTP O -
, O +
80MtM O +
ddGTP O -
; O +
' O -
T O -
' O +
mix O -
: O +
6.25MM O +
dTTP O -
, O +
250yM O +
ddTTP O -
; O +
as O +
well O +
as O +
125MM O +
of O +
each O +
of O +
the O +
three O +
other O +
dNTPs O +
in O +
each O +
mix O -
. O +

Apart O +
from O +
the O +
use O +
of O +
these O +
modified O +
mixes O -
, O +
no O +
changes O +
were O +
made O +
to O +
the O +
conventional O +
sequencing O +
procedure O +
( O -
20 O -
) O -
. O +

Sequencing O +
reactions O +
were O +
pooled O +
and O +
ethanol O +
precipitated O +
as O +
appropriate O -
. O +

Precipitation O +
in O +
microtitre O +
trays O +
was O +
carried O +
out O +
as O +
follows O -
: O +
a O +
mixture O +
of O +
3.2M1 O +
3 O -
M O +
NaAc O +
pH O +
5.0 O +
and O +
112Mi1 O +
EtOH O +
was O +
dispensed O +
to O +
individual O +
wells O +
of O +
a O +
microtitre O +
plate O +
( O -
Falcon O +
3911 O +
or O +
Corning O +
25855 O -
) O +
using O +
an O +
8-channel O +
pipettor O -
. O +

Each O +
set O +
of O +
four O +
reactions O +
was O +
added O +
to O +
the O +
EtOH O -
/ O -
NaAc O +
mixture O -
, O +
and O +
the O +
tray O +
sealed O +
using O +
a O +
Falcon O +
3073 O +
plate O +
sealer O -
. O +

The O +
samples O +
were O +
mixed O +
by O +
inversion O +
and O +
stored O +
at O +
-20?C O +
for O +
30 O +
minutes O -
. O +

The O +
DNA O +
was O +
collected O +
by O +
a O +
20 O +
minute O +
centrifugation O +
at O +
4 O +
000 O +
rpm O +
in O +
an O +
IEC O +
Centra O +
3C O +
centrifuge O -
. O +

The O +
sealer O +
was O +
removed O -
, O +
and O +
the O +
plate O +
inverted O +
to O +
discard O +
the O +
supernatant O -
. O +

After O +
blotting O +
the O +
tray O +
on O +
tissue O +
paper O -
, O +
200MI O +
of O +
95 O +
% O +
EtOH O +
was O +
added O +
to O +
each O +
well O -
. O +

The O +
plate O +
was O +
covered O +
with O +
a O +
plastic O +
lid O +
and O +
recentrifuged O +
for O +
2 O +
minutes O -
. O +

The O +
EtOH O +
was O +
discarded O +
and O +
the O +
plate O +
inverted O +
for O +
several O +
minutes O +
on O +
tissue O +
paper O -
, O +
then O +
left O +
for O +
20 O +
minutes O +
to O +
air O +
dry O -
. O +

Precipitated O +
samples O +
were O +
resuspended O +
in O +
6M1 O +
deionized O +
water O +
by O +
vortexing O +
on O +
an O +
SMI O +
multi O -
- O -
tube O +
vortexer O +
for O +
1 O +
minute O -
. O +

Samples O +
were O +
denatured O +
and O +
electrophoresed O +
on O +
6 O +
% O +
polyacrylamide O +
buffer O +
gradient O +
gels O +
as O +
previously O +
described O +
( O -
20 O -
) O -
. O +

Following O +
electrophoresis O -
, O +
the O +
gel O +
was O +
transferred O +
to O +
a O +
dry O +
piece O +
of O +
Whatman O +
3MM O +
blotting O +
paper O -
, O +
and O +
placed O +
on O +
a O +
second O +
sheet O +
of O +
blotting O +
paper O +
supported O +
on O +
a O +
glass O +
plate O +
and O +
saturated O +
in O +
4 O +
x O +
SSC O +
( O -
SSC O -
: O +
150mM O +
NaCl O -
, O +
l5mM O +
trisodium O +
citrate O -
) O -
. O +

This O +
sheet O +
was O +
wicked O +
in O +
a O +
tray O +
containing O +
1 O +
litre O +
of O +
4 O +
x O +
SSC O -
. O +

The O +
DNA O +
was O +
transferred O +
to O +
a O +
nylon O +
membrane O +
( O -
Amersham O +
Hybond O +
N O -
) O +
by O +
capillary O +
blotting O +
overnight O +
( O -
22 O -
) O -
. O +

DNA O +
was O +
fixed O +
to O +
the O +
membranes O +
by O +
U.V. O +
crosslinking O +
( O -
23 O -
) O -
. O +

Plex O +
oligonucleotide O +
probes O +
were O +
a O +
kind O +
gift O +
of O +
Dr. O +

George O +
Church O -
. O +

Probes O +
were O +
tailed O +
at O +
their O +
3 O -
' O +
ends O +
using O +
[ O -
a-32p O -
] O +
dCTP O +
as O +
previously O +
described O +
( O -
3 O -
) O -
. O +

For O +
the O +
preparation O +
of O +
digoxigenin O +
( O -
DIG O -
) O +
labelled O +
probes O -
, O +
identical O +
tailing O +
reactions O +
were O +
carried O +
out O +
substituting O +
I0pmols O +
of O +
DIG O -
- O -
II O +
dUTP O +
( O -
Boehringer O +
Mannheim O -
) O +
for O +
[ O -
a-32P O -
] O +
dCTP O -
. O +

Membranes O +
were O +
prehybridized O +
for O +
at O +
least O +
10 O +
minutes O +
in O +
4 O +
x O +
SSC O -
, O +
5 O +
x O +
Denhardts O -
' O +
( O -
0.1 O +
% O +
( O -
w O -
/ O -
v O -
) O +
each O +
of O +
BSA O +
( O -
heated O +
at O +
80?C O +
for O +
30 O +
minutes O +
to O +
inactivate O +
any O +
alkaline O +
phosphatase O +
activity O -
) O -
, O +
Ficoll O +
( O -
Pharmacia O -
) O +
and O +
polyvinylpyrrolidone O -
) O -
, O +
0.5 O -
% O +
( O -
w O -
/ O -
v O -
) O +
SDS O -
, O +
5mM O +
NaHPO4 O +
( O -
23 O -
) O -
. O +

Hybridization O +
was O +
carried O +
out O +
in O +
25 O -
- O -
50M1 O +
of O +
prehybridization O +
buffer O +
per O +
cm2 O +
of O +
membrane O -
. O +

The O +
probe O +
concentration O +
was O +
approximately O +
lnM. O +
After O +
lh O +
at O +
42?C O -
, O +
unbound O +
probe O +
was O +
removed O +
by O +
five O +
1 O +
minute O +
washes O +
at O +
room O +
temperature O +
in O +
1 O +
x O +
SSC O -
, O +
0.5 O -
% O +
SDS O +
( O -
200MI O -
/ O -
cm2 O +
membrane O -
) O -
. O +

Radioactive O +
blots O +
were O +
covered O +
in O +
Saran O +
wrap O +
and O +
exposed O +
to O +
film O +
immediately O -
. O +

Detection O +
of O +
DIG O +
labelled O +
probes O +
used O +
an O +
anti O -
- O -
DIG O +
antibodyalkaline O +
phosphatase O +
conjugate O +
( O -
Boehringer O +
Mannheim O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O -
, O +
except O +
that O +
all O +
volumes O +
were O +
reduced O +
by O +
70 O -
% O +
and O +
the O +
conjugate O +
was O +
used O +
at O +
a O +
1:10 O +
000 O +
dilution O -
. O +

Blots O +
were O +
developed O +
in O +
25M1 O +
of O +
100mM O +
Tris O -
. O +

Cl O +
pH9.5 O -
, O +
mantane4-methoxy4 O -
( O -
3 O +
" O -
-phosphoryloxy O -
) O -
phenyl-1 O +
, O -
2-dioxetane O -
) O -
; O +
Tropix O -
) O -
/ O -
cm2 O +
for O +
30 O +
minutes O +
at O +
37?C O -
, O +
prior O +
to O +
exposure O +
to O +
film O -
. O +

Probes O +
and O +
dioxetane O +
were O +
stripped O +
from O +
the O +
membranes O +
by O +
two O +
10 O +
minute O +
washes O +
at O +
700C O +
with O +
0.2 O -
% O +
SDS O -
, O +
2mM O +
EDTA O +
( O -
200,ul O -
/ O -
cm2 O +
membrane O -
) O -
. O +

The O +
hybridization O +
and O +
washing O +
procedures O +
were O +
carried O +
out O +
in O +
plastic O +
bags O -
. O +

However O -
, O +
washing O +
steps O +
have O +
also O +
been O +
performed O +
with O +
gentle O +
agitation O +
in O +
a O +
perspex O +
tub O +
( O -
43 O +
x O +
27 O +
x O +
15 O -
cm O -
) O +
mounted O +
on O +
a O +
reciprocal O +
shaker O -
, O +
with O +
equivalent O +
results O -
. O +

In O +
the O +
latter O +
case O +
a O +
minimum O +
wash O +
volume O +
of O +
500mls O +
was O +
used O -
. O +

The O +
use O +
of O +
a O +
tub O +
is O +
more O +
convenient O +
for O +
batch O +
processing O +
and O +
should O +
be O +
straightforward O +
to O +
automate O -
. O +

RESULTS O +
Autoradiograms O +
revealed O +
no O +
difference O +
in O +
sequence O +
quality O +
when O +
tagged O +
primers O +
were O +
used O +
instead O +
of O +
the O +
17mer O +
universal O +
primer O +
in O +
conventional O +
[ O -
a-35S O -
] O +
dATP O +
labelled O +
sequencing O +
reactions O +
and O +
in O +
multiplex O +
hybridization O +
experiments O +
using O +
[ O -
a-32P O -
] O +
dCTP O -
- O -
tailed O +
probes O +
( O -
results O +
not O +
shown O -
) O -
. O +

Experiments O +
were O +
then O +
conducted O +
to O +
determine O +
the O +
feasibility O +
of O +
pooling O +
the O +
four O +
base O +
reactions O +
for O +
each O +
clone O +
and O +
fractionating O +
them O +
in O +
a O +
single O +
lane O +
to O +
obtain O +
a O +
superimposed O +
but O +
interpretable O +
set O +
of O +
sequence O +
ladders O -
. O +

The O +
question O +
addressed O +
was O +
whether O +
or O +
not O +
difficulties O +
in O +
band O +
registration O +
might O +
arise O +
as O +
a O +
result O +
of O +
mobility O +
differences O +
between O +
the O +
different O +
primer O +
sequences O +
and/or O +
distortion O +
of O +
the O +
membrane O +
between O +
probings O -
. O +

It O +
is O +
relevant O +
that O +
an O +
automated O +
film O +
reader O +
employing O +
an O +
internal O +
standard O +
requires O +
that O +
the O +
nylon O +
membrane O +
does O +
not O +
undergo O +
significant O +
distortions O +
between O +
probings O +
( O -
George O +
Church O -
, O +
personal O +
communication O -
) O -
. O +

Clones O +
were O +
sequenced O +
using O +
the O +
four O +
tagged O +
primers O +
UEOlC O -
, O +
UPOIC O -
, O +
UE02C O -
, O +
and O +
UP02C O -
, O +
one O +
for O +
each O +
base O +
reaction O +
( O -
Figure O +
1 O -
) O -
. O +

The O +
A O -
, O +
C O -
, O +
G O +
and O +
T O +
reactions O +
for O +
each O +
clone O +
were O +
pooled O -
, O +
and O +
processed O +
as O +
described O +
above O -
. O +

A O +
complete O +
set O +
of O +
sequence O +
autoradiograms O +
was O +
obtained O +
from O +
four O +
consecutive O +
rounds O +
of O +
probing O +
with O +
[ O -
a-32P O -
] O +
dCTP O -
- O -
labelled O +
oligonucleotides O -
. O +

Alignment O +
of O +
the O +
films O +
showed O +
that O +
sequence O -
- O -
specific O +
mobility O +
effects O +
and O +
distortion O +
of O +
the O +
membrane O +
between O +
probings O +
were O +
sufficiently O +
minor O +
to O +
allow O +
accurate O +
registration O +
of O +
the O +
bands O -
, O +
and O +
hence O +
accurate O +
reading O +
of O +
the O +
sequence O -
. O +

At O +
least O +
200 O +
nucleotides O +
of O +
sequence O +
could O +
be O +
read O +
accurately O +
from O +
a O +
single O +
clone O +
by O +
simply O +
tracing O +
the O +
four O +
sets O +
of O +
bands O +
using O +
different O +
colours O -
, O +
overlaying O +
the O +
tracings O -
, O +
and O +
reading O +
the O +
bands O +
sequentially O -
. O +

In O +
order O +
to O +
assess O +
the O +
practicality O +
of O +
reading O +
the O +
sequences O +
by O +
machine O -
, O +
the O +
images O +
were O +
scanned O +
to O +
provide O +
optical O +
density O +
profiles O +
( O -
Figure O +
2 O -
) O -
. O +

These O +
profiles O +
were O +
overlaid O -
, O +
and O +
were O +
found O +
to O +
be O +
sufficiently O +
in O +
register O +
to O +
allow O +
accurate O +
interpretation O +
of O +
the O +
sequence O +
for O +
at O +
least O +
300 O +
nucleotides O -
. O +

This O +
was O +
essentially O +
the O +
limit O +
of O +
resolution O +
of O +
the O +
gel O +
for O +
accurate O +
manual O +
reading O -
. O +

In O +
order O +
to O +
ensure O +
that O +
the O +
relatively O +
minor O +
mobility O +
differences O +
observed O +
between O +
the O +
four O +
primers O +
were O +
not O +
coincidental O +
to O +
the O +
oligonucleotides O +
used O -
, O +
a O +
second O +
set O +
of O +
four O +
tagged O +
M13 O +
universal O +
primers O +
was O +
synthesised O -
, O +
this O +
time O +
incorporating O +
20mer O +
sequences O +
derived O +
from O +
the O +
genome O +
of O +
murine O +
herpesvirus-68 O +
( O -
UJOL14C O -
, O +
15C O -
, O +
16C O -
, O +
17C O -
) O -
. O +

Sequencing O +
reactions O +
were O +
performed O +
using O +
[ O -
cx-35S O -
] O +
dATP O +
to O +
label O +
the O +
DNA O +
directly O -
. O +

Various O +
templates O +
were O +
sequenced O -
, O +
and O +
in O +
all O +
cases O +
correctly O +
ordered O +
sequence O +
ladders O +
were O +
obtained O +
following O +
conventional O +
electrophoresis O +
in O +
which O +
the O +
four O +
reactions O +
were O +
run O +
side O -
- O -
by O -
- O -
side O +
( O -
results O +
not O +
shown O -
) O -
. O +

Initial O +
hybridization O +
experiments O +
were O +
conducted O +
using O +
[ O -
f O +
-32p O -
] O +
dCTP O +
tailed O +
oligonucleotide O +
probes O -
. O +

However O -
, O +
the O +
use O +
of O +
lOOmM O +
NaCl O -
, O +
5OmM O +
MgC12 O -
, O +
0.15mM O +
AMPPD O +
( O -
[ O -
3- O -
( O -
2'-ada O +

B O +
C O +
' O -
Ordinary O -
' O +
Plex O -
' O +
4-CJ3 O +
4-rn O +
+ O +
Primeir O +
Primer O +
" O -
All O +
" O -
C O -
" O +
" O -
G O -
" O +
" O +
T O -
" O +
' O -
Plex O -
' O +
' O -
Ordinary O -
' O +
Pool O +
and O +
Vector O +
Vector O +
fractionate O +
Resolve O +
by O +
sequential O +
hybridizations O +
Sequencing O +
reactions O +
SequencingreactIo O +
product O +
Sequencing O +
reaction O +
product O +
- O +
n O -
; O +
= O +
= O +
- O +
= O +
- O +
n O -
: O +
= O +
Figure O +
1 O -
. O +

Approaches O +
to O +
enzymatic O +
multiplex O +
DNA O +
sequencing O -
. O +

a O -
) O +
A O +
set O +
of O +
sequence O -
- O -
tagged O +
vectors O +
can O +
be O +
used O -
. O +

The O +
tag O +
site O +
is O +
shown O +
in O +
red O -
, O +
and O +
the O +
insert O +
to O +
be O +
sequenced O +
in O +
blue O -
. O +

However O -
, O +
the O +
original O +
plex O +
vectors O +
( O -
3 O -
) O +
are O +
plasmids O -
, O +
and O +
therefore O +
amenable O +
only O +
to O +
dsDNA O +
sequencing O -
. O +

Sets O +
of O +
bacteriophage B-Species +
M13 I-Species +
vectors O +
have O +
been O +
constructed O +
bearing O +
either O +
one O +
( O -
32 O -
) O +
or O +
two O +
[ O -
Chee O -
, O +
unpublished O -
] O +
of O +
the O +
plex O +
tag O +
sites O +
flanking O +
the O +
polylinker O -
, O +
which O +
can O +
be O +
used O +
for O +
this O +
approach O -
. O +

b O -
) O +
The O +
strategy O +
used O +
in O +
this O +
paper O -
. O +

In O +
this O +
case O +
the O +
tag O +
site O +
is O +
carried O +
on O +
the O +
primer O -
. O +

c O -
) O +
If O +
tagged O +
primers O +
are O +
used O -
, O +
there O +
is O +
no O +
practical O +
impediment O +
to O +
performing O +
each O +
base O +
reaction O +
using O +
a O +
different O +
primer O -
, O +
as O +
depicted O -
. O +

The O +
reactions O +
can O +
then O +
be O +
pooled O +
in O +
any O +
combination O +
desired O -
. O +

The O +
configuration O +
shown O -
, O +
in O +
which O +
the O +
four O +
reactions O +
are O +
electrophoresed O +
in O +
a O +
single O +
lane O -
, O +
is O +
designed O +
to O +
facilitate O +
accurate O +
band O +
registration O +
and O +
reading O +
by O +
an O +
automatic O +
film O +
reader O -
. O +

In O +
order O +
to O +
read O +
the O +
sequence O +
manually O -
, O +
base O +
reactions O +
would O +
be O +
run O +
side O -
- O -
by O -
- O -
side O -
. O +

The O +
logistics O +
of O +
processing O +
the O +
reactions O +
are O +
essentially O +
the O +
same O +
with O +
either O +
configuration O -
; O +
the O +
same O +
number O +
of O +
probings O +
are O +
required O -
. O +

Figure O +
2 O -
. O +

Four O +
overlaid O +
one O -
- O -
dimensional O +
optical O +
density O +
profiles O +
for O +
a O +
single O +
clone O +
shown O +
in O +
two O +
overlapping O +
sections O -
. O +

The O +
optical O +
density O +
profiles O +
are O +
unprocessed O -
, O +
except O +
for O +
a O +
simple O +
transform O +
to O +
correct O +
for O +
the O +
relative O +
displacement O +
( O -
translation O +
and O +
rotation O -
) O +
of O +
the O +
four O +
images O +
from O +
which O +
they O +
are O +
extracted O -
. O +

The O +
profiles O +
read O +
5 O -
' O +
to O +
3 O -
' O +
from O +
right O +
to O +
left O -
. O +

Nucleotides O +
positions O +
66 O +
to O +
214 O +
from O +
the O +
start O +
of O +
the O +
universal O +
priming O +
site O +
are O +
shown O -
. O +

The O +
sequence O +
is O +
that O +
of O +
Bluescribe O +
M13 O -
+ O +
( O -
template O +
DNA O +
obtained O +
by O +
rescue O +
with O +
M13K07 O +
helper O +
phage O +
( O -
30 O -
) O -
) O -
, O +
and O +
was O +
determined O +
using O +
the O +
primers O +
UEOIC O -
, O +
UPOIC O -
, O +
UE02C O -
, O +
and O +
UP02C O +
for O +
the O +
T O -
, O +
C O -
, O +
G O +
and O +
A O +
specific O +
reactions O +
respectively O -
. O +

Detection O +
was O +
by O +
autoradiography O +
following O +
hybridization O +
with O +
[ O -
a- O +
32p O -
] O +
dCTP O +
tailed O +
plex O +
probes O -
. O +

A O +
Nucleic O +
Acids O +
Research O -
, O +
Vol O -
. O +

19 O -
, O +
No. O +
12 O +
3303 O +
I O +
3304 O +
Nucleic O +
Acids O +
Research O -
, O +
Vol O -
. O +

19 O -
, O +
No. O +
12 O +
a O -
) O +
175- O -
... O +

-w O +
.m O -
; O +
b O -
) O +
182 O +
a O +
: O -
...... O +

F.VW O +
an O +
- O +
w O +
-1 O +
S O +
- O +
K~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~i O +
' O -
F O +
C O +
C O -
; O +
A O +
I1 O +
' O -
CG O +
A O +
Figure O +
3 O -
. O +

Four O +
separate O +
base O -
- O -
specific O +
reactions O +
imaged O +
from O +
a O +
single O +
lane O +
using O +
chemiluminescent O +
detection O -
. O +

The O +
clones O +
sequenced O +
are O -
: O +
a O -
) O +
Bluescribe O +
M13 O +
+ O +
( O -
obtained O +
by O +
rescue O +
with O +
M13K07 O +
helper O +
phage O +
( O -
30 O -
) O -
) O +
and O +
b O -
) O +
an O +
M13 O +
recombinant O +
clone O +
prepared O +
in O +
a O +
microtitre O +
tray O +
( O -
21 O -
) O +
( O -
a O +
kind O +
gift O +
of O +
Victoria O +
Smith O -
) O -
. O +

Nucleotide O +
positions O +
shown O +
on O +
the O +
figure O +
are O +
numbered O +
from O +
the O +
start O +
of O +
the O +
universal O +
priming O +
site O -
. O +

The O +
clones O +
were O +
sequenced O +
using O +
UEOlC O -
, O +
UPOIC O -
, O +
UE02C O -
, O +
and O +
UP02C O +
for O +
the O +
T O -
, O +
C O -
, O +
G O +
and O +
A O +
specific O +
reactions O +
respectively O -
. O +

The O +
blot O +
was O +
probed O +
with O +
corresponding O +
DIG-11-dUTP O +
labelled O +
oligonucleotides O -
. O +

radioactivity O +
on O +
the O +
scale O +
envisioned O +
for O +
a O +
large O +
sequencing O +
project O +
is O +
undesirable O +
for O +
reasons O +
of O +
safety O -
. O +

The O +
relatively O +
long O +
exposure O +
times O +
required O +
( O -
6 O +
to O +
24 O +
hours O -
) O +
and O +
the O +
short O +
half O +
lives O +
of O +
the O +
probes O +
might O +
also O +
be O +
inconvenient O -
. O +

It O +
has O +
been O +
shown O +
that O +
a O +
biotin O -
/ O -
streptavidin O -
/ O -
alkaline O +
phosphatase O +
based O +
detection O +
system O +
used O +
in O +
conjunction O +
with O +
a O +
chemiluminescent O +
dioxetane O +
substrate O +
overcomes O +
these O +
disadvantages O +
( O -
24 O -
, O +
25 O -
, O +
26 O -
) O -
. O +

We O +
utilized O +
a O +
different O +
bridging O +
system O +
with O +
similar O +
results O -
. O +

Digoxigenin O +
( O -
DIG O -
) O +
labelled O +
oligonucleotide O +
probes O +
were O +
detected O +
using O +
anti O -
- O -
DIG O +
antibody O -
- O -
alkaline O +
phosphatase O +
conjugates O +
and O +
a O +
chemiluminescent O +
dioxetane O +
substrate O -
. O +

Exposure O +
times O +
of O +
10 O +
to O +
15 O +
minutes O +
were O +
typically O +
required O -
, O +
following O +
a O +
one O +
hour O +
preincubation O +
period O +
( O -
Figure O +
3 O -
) O -
. O +

In O +
our O +
hands O +
the O +
DIG O +
bridging O +
system O +
was O +
similar O +
in O +
sensitivity O +
to O +
the O +
streptavidin O +
based O +
system O +
( O -
24 O -
) O -
, O +
and O +
the O +
practical O +
lower O +
limit O +
of O +
template O +
ssDNA O +
required O +
in O +
order O +
to O +
obtain O +
an O +
easily O +
interpretable O +
sequencing O +
ladder O +
was O +
estimated O +
to O +
be O +
in O +
the O +
range O +
of O +
20 O +
to O +
50fmols O +
per O +
reaction O -
. O +

However O -
, O +
the O +
sensitivity O +
of O +
detection O +
was O +
limited O +
only O +
by O +
enzymaticallytriggered O +
background O +
luminescence O -
, O +
and O +
not O +
by O +
the O +
level O +
of O +
signal O +
obtained O -
. O +

The O +
nonradioactive O +
methods O +
described O +
have O +
been O +
used O +
successfully O +
in O +
an O +
8-plex O +
system O -
. O +

DISCUSSION O +
Although O +
the O +
original O +
multiplex O +
protocol O +
was O +
based O +
on O +
a O +
set O +
of O +
tagged O +
vectors O +
( O -
3 O -
) O -
, O +
tagged O +
primers O +
have O +
also O +
been O +
used O +
or O +
proposed O +
for O +
various O +
forms O +
of O +
multiplex O +
DNA O +
sequencing O +
( O -
George O +
Church O -
, O +
personal O +
communication O -
; O +
2 O -
, O +
27 O -
) O -
. O +

For O +
example O -
, O +
a O +
proposal O +
was O +
recently O +
put O +
forward O +
for O +
multiplex O +
sequencing O +
using O +
sequence O -
- O -
labelled O +
primers O +
and O +
fluorophor O -
- O -
labelled O +
probes O +
( O -
1 O -
) O -
, O +
similar O +
in O +
principle O +
to O +
the O +
methods O +
used O +
here O -
. O +

However O -
, O +
we O +
use O +
tagged O +
primers O +
and O +
the O +
superposition O +
of O +
the O +
four O +
sequencing O +
reactions O +
to O +
address O +
the O +
problem O +
of O +
reading O +
DNA O +
sequence O +
films O -
; O +
a O +
part O +
of O +
this O +
solution O +
is O +
to O +
utilize O +
M13 O +
dideoxynucleotide O +
sequencing O -
, O +
thereby O +
improving O +
the O +
quality O +
of O +
the O +
data O +
to O +
be O +
analyzed O -
. O +

In O +
addition O -
, O +
the O +
proposal O +
for O +
fluorophor O -
- O -
labelled O +
probes O +
does O +
not O +
take O +
into O +
consideration O +
any O +
of O +
the O +
practical O +
sequencing O +
problems O +
addressed O +
here O -
, O +
and O -
, O +
in O +
the O +
version O +
described O -
, O +
remains O +
a O +
promising O +
but O +
unproven O +
scheme O +
for O +
large O +
scale O +
DNA O +
sequencing O -
. O +

There O +
are O +
several O +
advantages O +
to O +
tagging O +
primers O +
instead O +
of O +
vectors O -
. O +

Firstly O -
, O +
there O +
is O +
no O +
need O +
to O +
prepare O +
multiple O +
libraries O +
of O +
clones O +
in O +
special O +
vectors O -
. O +

This O +
means O +
that O +
workers O +
can O +
use O +
vector O -
/ O -
host O +
combinations O +
that O +
yield O +
good O +
results O +
in O +
their O +
hands O -
, O +
and O +
an O +
increased O +
depth O +
of O +
multiplexing O +
can O +
easily O +
be O +
accomodated O +
by O +
synthesizing O +
more O +
primers O -
. O +

This O +
should O +
make O +
multiplexing O +
more O +
accessible O +
to O +
workers O +
undertaking O +
smaller O +
projects O -
. O +

A O +
theoretical O +
disadvantage O +
of O +
tagged O +
primers O +
is O +
that O +
the O +
procedure O +
can O +
only O +
be O +
multiplexed O +
following O +
primer O +
annealing O +
( O -
1 O -
) O -
, O +
or O +
following O +
the O +
sequencing O +
reactions O +
( O -
this O +
paper O -
; O +
in O +
practice O -
, O +
pooling O +
immediately O +
after O +
the O +
annealing O +
step O +
might O +
lead O +
to O +
increased O +
backgrounds O +
if O +
one O +
or O +
more O +
primers O +
were O +
present O +
in O +
excess O +
over O +
their O +
template O +
DNAs O -
) O -
. O +

This O +
is O +
a O +
relatively O +
late O +
stage O -
. O +

In O +
the O +
original O +
procedure O +
( O -
3 O -
) O -
, O +
clones O +
were O +
pooled O +
prior O +
to O +
amplification O +
by O +
growth O -
, O +
an O +
early O +
step O -
. O +

However O -
, O +
we O +
do O +
not O +
believe O +
the O +
sacrifice O +
to O +
be O +
of O +
practical O +
importance O +
when O +
using O +
phage O +
vectors O -
. O +

In O +
our O +
experience O -
, O +
recombinant O +
M13 O +
phage O +
have O +
variable O +
growth O +
rates O +
and O +
the O +
effects O +
of O +
competition O +
are O +
likely O +
to O +
severely O +
limit O +
the O +
number O +
of O +
clones O +
that O +
can O +
usefully O +
be O +
pooled O +
for O +
growth O -
. O +

In O +
contrast O -
, O +
by O +
growing O +
clones O +
individually O -
, O +
the O +
depth O +
of O +
multiplexing O +
is O +
only O +
really O +
limited O +
by O +
probe O +
sensitivity O -
. O +

We O +
have O +
not O +
investigated O +
the O +
factors O +
influencing O +
variability O +
in O +
phage O +
growth O +
rates O -
. O +

It O +
is O +
worth O +
noting O +
that O +
reliable O +
protocols O +
have O +
been O +
developed O +
for O +
growing O +
large O +
numbers O +
of O +
individual O +
M13 O +
clones O +
and O +
preparing O +
high O +
quality O +
ssDNA O +
templates O +
in O +
microtitre O +
trays O +
( O -
28 O -
, O +
21 O -
) O -
. O +

It O +
is O +
relatively O +
simple O +
to O +
prepare O +
manually O +
two O +
microtitre O +
trays O +
of O +
ssDNA O +
templates O +
( O -
192 O +
clones O -
) O +
in O +
a O +
day O -
. O +

Sufficient O +
clones O +
can O +
be O +
prepared O +
in O +
a O +
week O +
to O +
sequence O +
a O +
20 O -
kb O +
fragment O +
to O +
a O +
redundancy O +
of O +
10 O +
( O -
Victoria O +
Smith O -
, O +
personal O +
communication O -
) O -
. O +

In O +
this O +
laboratory O -
, O +
ssDNA O +
is O +
now O +
prepared O +
with O +
the O +
aid O +
of O +
a O +
commercially O +
available O +
robotic O +
workstation O +
( O -
21 O -
) O -
. O +

As O +
sequencing O +
reactions O +
are O +
also O +
carried O +
out O +
in O +
microtitre O +
trays O -
, O +
manually O +
or O +
robotically O +
( O -
20 O -
, O +
29 O -
) O -
, O +
the O +
entire O +
M13-based O +
dideoxynucleotide O +
sequencing O +
procedure O +
is O +
amenable O +
to O +
automation O +
( O -
29 O -
) O -
. O +

For O +
these O +
reasons O +
we O +
see O +
little O +
practical O +
advantage O +
in O +
pooling O +
clones O +
early O -
. O +

Finally O -
, O +
by O +
not O +
pooling O +
clones O +
early O -
, O +
the O +
ability O +
to O +
easily O +
retrieve O +
individual O +
clones O +
is O +
retained O -
, O +
which O +
may O +
facilitate O +
directed O +
sequencing O +
later O +
in O +
a O +
project O +
should O +
this O +
become O +
necessary O -
. O +

Multiplex O +
DNA O +
sequencing O +
is O +
currently O +
limited O +
by O +
the O +
lack O +
of O +
a O +
robust O +
computer O +
program O +
which O +
can O +
correct O +
for O +
the O +
large O +
variety O +
of O +
gel O +
and O +
sequencing O +
artefacts O +
that O +
are O +
normally O +
encountered O -
. O +

The O +
foundation O +
of O +
a O +
film O +
reading O +
program O +
is O +
the O +
ability O +
to O +
bring O +
into O +
register O +
precisely O +
vertical O +
arrays O +
of O +
base O -
- O -
specific O +
bands O -
. O +

This O +
requires O +
the O +
ability O +
to O +
track O +
lanes O -
, O +
correct O +
for O +
distortions O -
, O +
and O +
order O +
bands O +
based O +
on O +
their O +
relative O +
spacing O -
. O +

A O +
method O +
of O +
sequencing O +
which O +
has O +
successfully O +
overcome O +
the O +
problem O +
of O +
sequence O +
reading O +
uses O +
real O -
- O -
time O +
detection O +
of O +
fluorescently O +
labelled O +
DNA O +
samples O +
migrating O +
through O +
the O +
gel O +
( O -
2 O -
) O -
. O +

This O +
system O +
also O +
utilizes O +
the O +
principle O +
of O +
running O +
the O +
four O +
base O +
reactions O +
down O +
the O +
same O +
lane O +
( O -
2 O -
) O -
. O +

However O -
, O +
bands O +
are O +
detected O +
at O +
a O +
fixed O +
location O +
in O +
space O -
, O +
and O +
their O +
detection O +
is O +
separated O +
in O +
time O -
. O +

Hence O +
the O +
Nucleic O +
Acids O +
Research O -
, O +
Vol O -
. O +
19 O -
, O +
No. O +
12 O +
3305 O +
problem O +
of O +
gel O +
distortion O +
is O +
essentially O +
avoided O -
, O +
although O +
corrections O +
for O +
the O +
different O +
mobilities O +
of O +
the O +
four O +
dyes O +
must O +
be O +
carried O +
out O -
. O +

In O +
contrast O -
, O +
we O +
utilize O +
the O +
advantages O +
of O +
single O +
lane O +
electrophoresis O +
to O +
address O +
the O +
problem O +
of O +
superimposing O +
four O +
relatively O +
large O +
and O +
complex O +
two O -
- O -
dimensional O +
images O -
. O +

Furthermore O -
, O +
by O +
using O +
sequence O -
- O -
tagged O +
oligonucleotides O +
which O +
are O +
detected O +
by O +
hybridization O -
, O +
a O +
much O +
greater O +
depth O +
of O +
multiplexing O +
can O +
realistically O +
be O +
achieved O +
than O +
by O +
real O -
- O -
time O +
detection O -
. O +

The O +
use O +
of O +
two O -
- O -
dimensional O +
colour O +
traces O +
to O +
depict O +
the O +
processed O +
output O +
of O +
a O +
film O +
reader O +
is O +
consistent O +
with O +
the O +
method O +
of O +
displaying O +
fluorescence O +
traces O -
, O +
and O +
should O +
facilitate O +
the O +
checking O +
and O +
editing O +
of O +
sequence O +
databases O +
in O +
which O +
both O +
kinds O +
of O +
data O +
have O +
been O +
entered O -
. O +

The O +
sequence O +
compilation O +
programs O +
used O +
in O +
this O +
laboratory O -
, O +
which O +
are O +
already O +
capable O +
of O +
handling O +
large O +
shotgun O +
databases O +
( O -
8 O -
, O +
31 O -
) O -
, O +
have O +
recently O +
undergone O +
extensive O +
improvements O +
( O -
Rodger O +
Staden O -
, O +
personal O +
communication O -
) O -
. O +

There O +
is O +
now O +
an O +
interactive O +
database O +
editor O +
which O +
allows O +
the O +
graphical O +
display O +
of O +
fluorescence O +
traces O -
, O +
and O +
it O +
is O +
envisaged O +
that O +
this O +
feature O +
could O +
be O +
extended O +
to O +
allow O +
the O +
handling O +
of O +
data O +
from O +
a O +
film O +
reader O +
when O +
a O +
suitable O +
machine O +
is O +
developed O -
. O +

ACKNOWLEDGEMENTS O +

I O +
am O +
particularly O +
grateful O +
to O +
George O +
Church O +
for O +
thought O -
- O -
provoking O +
discussions O +
and O +
gifts O +
of O +
vectors O +
and O +
oligonucleotide O +
probes O +
and O +
to O +
John O +
Sulston O +
for O +
advice O -
. O +

I O +
also O +
thank O +
Victoria O +
Smith O +
for O +
the O +
gift O +
of O +
DNA O +
samples O -
, O +
Bart O +
Barrell O +
for O +
long O -
- O -
term O +
support O -
, O +
Tom O +
O'Keefe O +
of O +
Milligen O -
/ O -
Biosearch O +
for O +
lessons O +
in O +
multiplexing O +
and O +
Amersham O +
International O +
for O +
the O +
optical O +
density O +
overlays O +
shown O +
in O +
Figure O +
2 O -
. O +

M.C. O +
is O +
supported O +
by O +
a O +
fellowship O +
from O +
Applied O +
Biosystems O -
. O +

12 O -
. O +

Hiratsuka O -
, O +
J. O -
, O +
Shimada O -
, O +
H. O -
, O +
Whittier O -
, O +
R. O -
, O +
Ishibashi O -
, O +
T. O -
, O +
Sakamoto O -
, O +
M. O -
, O +
Mori O -
, O +
M. O -
, O +
Kondo O -
, O +
C. O -
, O +
Honju O -
, O +
Y. O -
, O +
Sun O -
, O +
C. O +
-R O -
, O +
Meng O -
, O +
B. O +
-Y O -
, O +
Li O -
, O +
Y. O +
-Q O -
, O +
Kanno O -
, O +
A. O -
, O +
Nisizawa O -
, O +
Y. O -
, O +
Hirai O -
, O +
A. O -
, O +
Shinozaki O -
, O +
K. O +
and O +
Sugiura O -
, O +
M. O +
( O -
1989 O -
) O +
Molecular O +
and O +
General O +
Genetics O -
, O +
217 O -
, O +
185 O -
- O -
194 O -
. O +

13 O -
. O +

Komaromy O -
, O +
M. O +
and O +
Govan O -
, O +
H. O +
( O -
1984 O -
) O +
Nucleic O +
Acids O +
Research O -
, O +
12 O -
, O +
675 O -
- O -
678 O -
. O +
14 O -
. O +

Staden O -
, O +
R. O +
( O -
1984 O -
) O +
Nucleic O +
Acids O +
Research O -
, O +
12 O -
, O +
499 O -
- O -
503 O -
. O +

15 O -
. O +

Elder O -
, O +
J. O +
K. O -
, O +
Green O -
, O +
D. O +
K. O +
and O +
Southern O -
, O +
E. O +
M. O +
( O -
1986 O -
) O +
Nucleic O +
Acids O +
Research O -
, O +
14 O -
, O +
417 O -
- O -
424 O -
. O +

16 O -
. O +

Maxam O -
, O +
A. O +
M. O +
and O +
Gilbert O -
, O +
W. O +
( O -
1977 O -
) O +
Proceedings O +
of O +
the O +
National O +
Academy O +
of O +
Sciences O -
, O +
U.S.A. O -
, O +
74 O -
, O +
560 O -
- O -
564 O -
. O +

17 O -
. O +

Sanger O -
, O +
F. O -
, O +
Nicklen O -
, O +
S. O +
and O +
Coulson O -
, O +
A. O +
R. O +
( O -
1977 O -
) O +
Proceedings O +
of O +
the O +
National O +
Academy O +
of O +
Sciences O -
, O +
U.S.A. O -
, O +
74 O -
, O +
5463 O -
- O -
5467 O -
. O +

18 O -
. O +

Sanger O -
, O +
F. O -
, O +
Coulson O -
, O +
A. O +
R. O -
, O +
Barrell O -
, O +
B. O +
G. O -
, O +
Smith O -
, O +
A. O +
J. O +
H. O +
and O +
Roe O -
, O +
B. O +
A. O +
( O -
1980 O -
) O +
Journal O +
of O +
Molecular O +
Biology O -
, O +
143 O -
, O +
161 O -
- O -
178 O -
. O +

19 O -
. O +

Applied O +
Biosystems O +
User O +
Bulletin O +
( O -
1987 O -
) O +
13 O -
, O +
11 O -
- O -
16 O -
. O +

20 O -
. O +

Bankier O -
, O +
A. O +
T. O -
, O +
Weston O -
, O +
K. O +
M. O +
and O +
Barrell O -
, O +
B. O +
G. O +
( O -
1987 O -
) O +
Methods O +
in O +
Enzymology O -
, O +
155 O -
, O +
51 O -
- O -
93 O -
. O +

21 O -
. O +

Smith O -
, O +
V. O -
, O +
Brown O -
, O +
C. O +
M. O -
, O +
Bankier O -
, O +
A. O +
T. O +
and O +
Barrell O -
, O +
B. O +
G. O +
( O -
1990 O -
) O +
DNA O +
Sequence O -
, O +
1 O -
, O +
73 O -
- O -
78 O -
. O +

22 O -
. O +

Southern O -
, O +
E. O +
M. O +
( O -
1975 O -
) O +
Journal O +
of O +
Molecular O +
Biology O -
, O +
98 O -
, O +
503 O -
- O -
517 O -
. O +

23 O -
. O +

Church O -
, O +
G. O +
M. O +
and O +
Gilbert O -
, O +
W. O +
( O -
1984 O -
) O +
Proceedings O +
of O +
the O +
National O +
Academy O +
of O +
Sciences O -
, O +
U.S.A. O -
, O +
81 O -
, O +
1991 O -
- O -
1995 O -
. O +

24 O -
. O +

Beck O -
, O +
S. O -
, O +
O'Keefe O -
, O +
T. O -
, O +
Coull O -
, O +
J. O +
M. O +
and O +
Koster O -
, O +
H. O +
( O -
1989 O -
) O +

Nucleic O +
Acids O +
Research O -
, O +
17 O -
, O +
5115 O -
- O -
5123 O -
. O +

25 O -
. O +

Tizard O -
, O +
R. O -
, O +
Cate O -
, O +
R. O +
L. O -
, O +
Ramachandran O -
, O +
K. O +
L. O -
, O +
Wysk O -
, O +
M. O -
, O +
Voyta O -
, O +
J. O +
C. O -
, O +
Murphy O -
, O +
0 O -
. O +
J. O +
and O +
Bronstein O -
, O +
I. O +
( O -
1990 O -
) O +
Proceedings O +
of O +
the O +
National O +
Academy O +
of O +
Sciences O -
, O +
U.S.A. O -
, O +
87 O -
, O +
4514 O -
- O -
4518 O -
. O +

26 O -
. O +

Beck O -
, O +
S. O +
and O +
Koster O -
, O +
H. O +
( O -
1990 O -
) O +
Analytical O +
Chemistry O -
, O +
62 O -
, O +
2558 O -
- O -
2570 O -
. O +

27 O -
. O +

Jacobson O -
, O +
K. O +
B. O -
, O +
Arlinghaus O -
, O +
H. O +
F. O -
, O +
Schmitt O -
, O +
H. O +
W. O -
, O +
Sachleben O -
, O +
R. O +
A. O -
, O +
Brown O -
, O +
G. O +
M. O -
, O +
Thonnard O -
, O +
N. O -
, O +
Sloop O -
, O +
F. O +
V. O -
, O +
Foote O -
, O +
R. O +
S. O -
, O +
Larimer O -
, O +
F. O +
W. O -
, O +
Woychik O -
, O +
R. O +
P. O -
, O +
England O -
, O +
M. O +
W. O -
, O +
Burchett O -
, O +
K. O +
L. O +
and O +
Jacobson O -
, O +
D. O +
A. O +
( O -
1991 O -
) O +
Genomics O -
, O +
9 O -
, O +
51 O -
- O -
59 O -
. O +

28 O -
. O +

Eperon O -
, O +
I. O +
C. O +
( O -
1986 O -
) O +
Analytical O +
Biochemistry O -
, O +
56 O -
, O +
406 O -
- O -
412 O -
. O +

29 O -
. O +

Bankier O -
, O +
A. O +
T. O +
and O +
Barrell O -
, O +
B. O +
G. O +
( O -
1989 O -
) O +
In O +
Howe O -
, O +
C. O +
J. O +
and O +
Ward O -
, O +
E. O +
S. O +
( O -
ed O -
) O -
, O +
Nucleic O +
acids O +
sequencing O -
: O +
a O +
practical O +
approach O -
. O +

IRL O +
Press O -
, O +
Oxford O -
, O +
Vol O -
. O +

1 O -
, O +
pp O -
. O +

37 O -
- O -
78 O -
. O +

30 O -
. O +

Vieira O -
, O +
J. O +
and O +
Messing O -
, O +
J. O +
( O -
1987 O -
) O +
Methods O +
in O +
Enzymology O -
, O +
153 O -
, O +
3 O -
- O -
11 O -
. O +
31 O -
. O +

Davison O -
, O +
A. O +
DNA O +
Sequence O -
, O +
in O +
press O -
. O +

32 O -
. O +

Heller O -
, O +
C. O -
, O +
Radley O -
, O +
E. O -
, O +
Khurshid O -
, O +
F. O +
A. O +
and O +
Beck O -
, O +
S. O +
Gene O -
, O +
in O +
press O -
. O +

REFERENCES O +
1 O -
. O +

Yang O -
, O +
M. O +
M. O +
and O +
Youvan O -
, O +
D. O +
C. O +
( O -
1989 O -
) O +
Biotechnology O -
, O +
7 O -
, O +
576 O -
- O -
580 O -
. O +

2 O -
. O +

Smith O -
, O +
L. O +
M. O -
, O +
Sanders O -
, O +
J. O +
Z. O -
, O +
Kaiser O -
, O +
R. O +
J. O -
, O +
Hughes O -
, O +
P. O -
, O +
Dodd O -
, O +
C. O -
, O +
Connell O -
, O +
C. O +
R. O -
, O +
Heiner O -
, O +
C. O -
, O +
Kent O -
, O +
S. O +
B. O +
H. O +
and O +
Hood O -
, O +
L. O +
E. O +
( O -
1986 O -
) O +
Nature O -
, O +
321 O -
, O +
674 O -
- O -
679 O -
. O +

3 O -
. O +

Church O -
, O +
G. O +
M. O +
and O +
Kieffer O -
- O -
Higgins O -
, O +
S. O +
( O -
1988 O -
) O +
Science O -
, O +
240 O -
, O +
185 O -
- O -
188 O -
. O +
4 O -
. O +

Watson O -
, O +
J. O +
D. O +
( O -
1990 O -
) O +
Science O -
, O +
248 O -
, O +
44 O -
- O -
49 O -
. O +

5 O -
. O +

Baer O -
, O +
R. O -
, O +
Bankier O -
, O +
A. O +
T. O -
, O +
Biggin O -
, O +
M. O +
D. O -
, O +
Deininger O -
, O +
P. O +
L. O -
, O +
Farrell O -
, O +
P. O +
J. O -
, O +
Gibson O -
, O +
T. O +
J. O -
, O +
Hatfull O -
, O +
G. O -
, O +
Hudson O -
, O +
G. O +
S. O -
, O +
Satchwell O -
, O +
S. O +
C. O -
, O +
Seguin O -
, O +
C. O -
, O +
Tuffnell O -
, O +
P. O +
S. O +
and O +
Barrell O -
, O +
B. O +
G. O +
( O -
1984 O -
) O +
Nature O -
, O +
310 O -
, O +
207 O -
- O -
211 O -
. O +

6 O -
. O +

Davison O -
, O +
A. O +
J. O +
and O +
Scott O -
, O +
J. O +
E. O +
( O -
1986 O -
) O +
Journal O +
of O +
General O +
Virology O -
, O +
67 O -
, O +
1759 O -
- O -
1816 O -
. O +

7 O -
. O +

McGeoch O -
, O +
D. O +
J. O -
, O +
Dalrymple O -
, O +
M. O +
A. O -
, O +
Davison O -
, O +
A. O +
J. O -
, O +
Dolan O -
, O +
A. O -
, O +
Frame O -
, O +
M. O +
C. O -
, O +
McNab O -
, O +
D. O -
, O +
Perry O -
, O +
L. O +
J. O -
, O +
Scott O -
, O +
J. O +
E. O +
and O +
Taylor O -
, O +
P. O +
( O -
1988 O -
) O +
Journal O +
of O +
General O +
Virology O -
, O +
69 O -
, O +
1531 O -
- O -
1574 O -
. O +

8 O -
. O +

Chee O -
, O +
M. O +
S. O -
, O +
Bankier O -
, O +
A. O +
T. O -
, O +
Beck O -
, O +
S. O -
, O +
Bohni O -
, O +
R. O -
, O +
Brown O -
, O +
C. O +
M. O -
, O +
Cerny O -
, O +
R. O -
, O +
Horsnell O -
, O +
T. O -
, O +
Hutchison O +
III O -
, O +
C. O +
A. O -
, O +
Kouzarides O -
, O +
T. O -
, O +
Martignetti O -
, O +
J. O +
A. O -
, O +
Satchwell O -
, O +
S. O +
C. O -
, O +
Tomlinson O -
, O +
P. O -
, O +
Weston O -
, O +
K. O +
M. O +
and O +
Barrell O -
, O +
B. O +
G. O +
( O -
1990 O -
) O +
Current O +
Topics O +
in O +
Microbiology O +
and O +
Immunology O -
, O +
154 O -
, O +
125 O -
- O -
169 O -
. O +

9 O -
. O +

Goebel O -
, O +
S. O +
J. O -
, O +
Johnson O -
, O +
G. O +
P. O -
, O +
Perkus O -
, O +
M. O +
E. O -
, O +
Davis O -
, O +
S. O +
W. O -
, O +
Winslow O -
, O +
J. O +
P. O +
and O +
Paoletti O -
, O +
E. O +
( O -
1990 O -
) O +
Virology O -
, O +
179 O -
, O +
247 O -
- O -
266 O -
. O +

10 O -
. O +

Ohyama O -
, O +
K. O -
, O +
Fukuzawa O -
, O +
H. O -
, O +
Kohchi O -
, O +
T. O -
, O +
Shirai O -
, O +
H. O -
, O +
Sano O -
, O +
T. O -
, O +
Sano O -
, O +
S. O -
, O +
Umesono O -
, O +
K. O -
, O +
Shiki O -
, O +
Y. O -
, O +
Takeuchi O -
, O +
M. O -
, O +
Chang O -
, O +
Z. O -
, O +
Aota O -
, O +
S. O +
-I O -
, O +
Inokuchi O -
, O +
H. O +
and O +
Ozeki O -
, O +
H. O +
( O -
1986 O -
) O +
Nature O -
, O +
322 O -
, O +
572 O -
- O -
574 O -
. O +

11 O -
. O +

Shinozaki O -
, O +
K. O -
, O +
Ohme O -
, O +
M. O -
, O +
Tanaka O -
, O +
M. O -
, O +
Wakasugi O -
, O +
T. O -
, O +
Hayashida O -
, O +
N. O -
, O +
Matsubayashi O -
, O +
T. O -
, O +
Zaita O -
, O +
N. O -
, O +
Chunwongse O -
, O +
J. O -
, O +
Obokata O -
, O +
J. O -
, O +
YamaguchiShinozaki O -
, O +
K. O -
, O +
Ohto O -
, O +
C. O -
, O +
Torazawa O -
, O +
K. O -
, O +
Meng O -
, O +
B. O +
Y. O -
, O +
Sugita O -
, O +
M. O -
, O +
Deno O -
, O +
H. O -
, O +
Kamogashira O -
, O +
T. O -
, O +
Yamada O -
, O +
K. O -
, O +
Kusuda O -
, O +
J. O -
, O +
Takaiwa O -
, O +
F. O -
, O +
Kato O -
, O +
A. O -
, O +
Tohdoh O -
, O +
N. O -
, O +
Shimada O -
, O +
H. O +
and O +
Sugiura O -
, O +
M. O +
( O -
1986 O -
) O +
EMBO O +
Journal O -
, O +
5 O -
, O +
2043 O -
- O -
2049 O -
. O +

Down O -
- O -
regulation O +
of O +
the O +
M6P O -
/ O -
IGF O -
- O -
II O +
receptor O +
increases O +
cell O +
proliferation O +
and O +
reduces O +
apoptosis O +
in O +
neonatal O +
rat B-Species +
cardiac O +
myocytes O +
Abstract O +
Background O +
The O +
mannose O +
6-phosphate O -
/ O -
insulin O -
- O -
like O +
growth O +
factor O -
- O -
II O +
receptor O +
( O -
M6P O -
/ O -
IGF2R O -
) O +
is O +
a O +
multi O -
- O -
functional O +
protein O +
that O +
has O +
been O +
implicated O +
in O +
regulation O +
of O +
cell O +
growth O +
and O +
apoptosis O -
. O +

Cardiac O +
myocytes O +
express O +
relatively O +
high O +
levels O +
of O +
M6P O -
/ O -
IGF2R O -
, O +
and O +
cardiomyocyte O +
apoptosis O +
has O +
been O +
identified O +
in O +
a O +
variety O +
of O +
cardiovascular O +
disorders O -
, O +
such O +
as O +
myocardial O +
infarction O +
and O +
heart O +
failure O -
. O +

However O -
, O +
involvement O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
the O +
pathogenesis O +
of O +
these O +
conditions O +
has O +
not O +
been O +
determined O -
. O +

Thus O -
, O +
the O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
role O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
regulation O +
of O +
cardiac O +
myocyte O +
growth O +
and O +
apoptosis O -
. O +

Results O +
We O +
down O -
- O -
regulated O +
the O +
expression O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
neonatal O +
rat B-Species +
cardiac O +
myocytes O +
and O +
examined O +
the O +
effect O +
on O +
cell O +
proliferation O +
and O +
apoptosis O -
. O +

Infection O +
of O +
neonatal O +
cardiomyocytes O +
with O +
an O +
adenovirus O +
expressing O +
a O +
ribozyme O +
targeted O +
against O +
the O +
M6P O -
/ O -
IGF2R O +
significantly O +
reduced O +
the O +
level O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O -
, O +
as O +
determined O +
by O +
RT O -
- O -
PCR O +
and O +
Ribonuclease O +
Protection O +
Assay O +
( O -
RPA O -
) O -
. O +

M6P O -
- O -
containing O +
protein O +
binding O +
and O +
endocytosis O +
as O +
well O +
as O +
the O +
M6P O -
/ O -
IGF2R O -
- O -
mediated O +
internalization O +
of O +
125I O -
- O -
IGF O -
- O -
II O +
were O +
lower O +
in O +
the O +
ribozyme O -
- O -
treated O +
cells O +
than O +
the O +
control O +
myocytes O -
, O +
indicating O +
that O +
the O +
number O +
of O +
functional O +
M6P O -
/ O -
IGF2R O +
in O +
the O +
ribozyme O +
treated O +
cells O +
was O +
reduced O -
. O +

Accordingly O -
, O +
a O +
marked O +
increase O +
in O +
cell O +
proliferation O +
and O +
a O +
reduced O +
cell O +
susceptibility O +
to O +
hypoxia- O +
and O +
TNF O -
- O -
induced O +
apoptosis O +
were O +
observed O +
in O +
the O +
ribozyme O -
- O -
treated O +
cells O -
. O +

Conclusions O +
These O +
findings O +
suggest O +
that O +
M6P O -
/ O -
IGF2R O +
may O +
play O +
a O +
role O +
in O +
regulation O +
of O +
cardiac O +
myocyte O +
growth O +
and O +
apoptosis O -
. O +

Down O +
regulation O +
of O +
this O +
gene O +
in O +
cardiac O +
tissues O +
might O +
be O +
a O +
new O +
approach O +
to O +
prevention O +
of O +
cell O +
death O +
or O +
promotion O +
of O +
mitogenesis O +
for O +
certain O +
heart O +
diseases O -
. O +

Background O +
The O +
mannose O +
6-phosphate O -
/ O -
insulin O -
- O -
like O +
growth O +
factor O -
- O -
II O +
receptor O +
( O -
M6P O -
/ O -
IGF2R O -
) O +
is O +
a O +
unique O +
protein O +
that O +
interacts O +
with O +
multiple O +
ligands O -
, O +
some O +
of O +
which O +
are O +
important O +
growth O +
regulatory O +
factors O +
[ O -
1 O -
] O -
. O +

The O +
M6P O -
/ O -
IGF2R O +
participates O +
in O +
internalization O +
and O +
lysosomal O +
degradation O +
of O +
IGF O -
- O -
II O -
, O +
a O +
mitogen O +
normally O +
acting O +
through O +
the O +
IGF O -
- O -
I O +
receptor O +
to O +
stimulate O +
cell O +
proliferation O +
[ O -
2 O -
] O -
. O +

The O +
M6P O -
/ O -
IGF2 O +
receptor O +
is O +
required O +
for O +
the O +
activation O +
of O +
TGF O -
- O -
β O +
[ O -
3 O -
] O -
, O +
a O +
potent O +
growth O +
inhibitor O +
for O +
many O +
cell O +
types O -
. O +

This O +
receptor O +
is O +
also O +
involved O +
in O +
the O +
binding O -
, O +
transport O +
and O +
activation O +
of O +
newly O -
- O -
synthesized O +
lysosomal O +
enzymes O -
, O +
such O +
as O +
cathepsins O +
[ O -
4,5 O -
] O -
, O +
which O +
have O +
been O +
recently O +
implicated O +
in O +
the O +
induction O +
of O +
apoptosis O +
[ O -
6 O -
] O -
. O +

On O +
the O +
basis O +
of O +
these O +
functions O -
, O +
the O +
M6P O -
/ O -
IGF2R O +
has O +
been O +
proposed O +
to O +
play O +
a O +
significant O +
role O +
in O +
regulation O +
of O +
cell O +
growth O +
and O +
apoptosis O +
[ O -
7 O -
] O -
. O +

Apoptosis O -
, O +
or O +
programmed O +
cell O +
death O -
, O +
is O +
a O +
tightly O +
regulated O +
process O +
used O +
to O +
remove O +
excess O -
, O +
hazardous O +
or O +
damaged O +
somatic O +
cells O -
, O +
and O +
is O +
crucial O +
for O +
the O +
development O -
, O +
maintenance O +
and O +
survival O +
of O +
an O +
organism O -
. O +

However O -
, O +
alterations O +
in O +
the O +
control O +
of O +
apoptosis O +
have O +
also O +
been O +
shown O +
to O +
contribute O +
to O +
human B-Species +
diseases O -
. O +

In O +
fact O -
, O +
morphological O +
and O +
biochemical O +
markers O +
of O +
apoptosis O +
have O +
been O +
identified O +
in O +
a O +
wide O +
variety O +
of O +
cardiovascular O +
disorders O -
, O +
including O +
myocardial O +
infarction O +
and O +
heart O +
failure O -
. O +

This O +
suggests O +
that O +
activation O +
of O +
apoptotic O +
pathways O +
contributes O +
to O +
cardiomyocyte O +
loss O +
and O +
subsequent O +
cardiac O +
dysfunction O +
in O +
these O +
conditions O -
. O +

A O +
number O +
of O +
factors O +
involved O +
in O +
cardiomyocyte O +
apoptosis O +
are O +
currently O +
known O +
and O +
include O +
insulin O -
- O -
like O +
growth O +
factor O -
- O -
I O +
( O -
IGF O -
- O -
I O -
) O -
, O +
stress O -
- O -
activated O +
protein O +
kinases O +
( O -
SAPKs O -
) O +
and O +
the O +
anti O -
- O -
apoptotic O +
Bcl-2 O +
family O +
[ O -
8 O -
] O -
. O +

There O +
are O +
indications O +
that O +
other O +
factors O +
may O +
be O +
involved O +
in O +
induction O +
and O +
regulation O +
of O +
cardiac O +
apoptosis O -
. O +

However O -
, O +
these O +
potential O +
factors O +
and O +
their O +
corresponding O +
mechanisms O +
have O +
not O +
been O +
identified O -
. O +

Several O +
lines O +
of O +
evidence O +
point O +
to O +
the O +
potential O +
involvement O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
cardiac O +
myocyte O +
proliferation O +
and O +
apoptosis O -
. O +

Cardiac O +
myocytes O +
express O +
relatively O +
high O +
levels O +
of O +
M6P O -
/ O -
IGF2R O +
and O +
transgenic O +
mice B-Species +
containing O +
a O +
homologous O +
deletion O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
gene O +
manifest O +
ventricular O +
hyperplasia O +
due O +
to O +
an O +
increase O +
in O +
cell O +
number O +
[ O -
9,10 O -
] O -
, O +
suggesting O +
that O +
the O +
M6P O -
/ O -
IGF2R O +
normally O +
acts O +
to O +
suppress O +
cardiac O +
myocyte O +
cell O +
growth O -
. O +

It O +
has O +
also O +
been O +
shown O +
that O +
TGF O -
- O -
β O -
, O +
a O +
potent O +
growth O +
suppressor O +
whose O +
activation O +
requires O +
the O +
binding O +
of O +
latent O +
TGF O -
- O -
β O +
to O +
M6P O -
/ O -
IGF2R O +
[ O -
3 O -
] O -
, O +
is O +
commonly O +
upregulated O +
in O +
chronic O +
heart O +
failure O +
[ O -
11 O -
] O -
. O +

Additional O +
evidence O +
for O +
the O +
involvement O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
regulation O +
of O +
apoptosis O +
comes O +
from O +
studies O +
of O +
tumorigenesis O -
. O +

It O +
has O +
been O +
shown O +
that O +
M6P O -
/ O -
IGF2R O +
expression O +
is O +
significantly O +
reduced O +
in O +
a O +
variety O +
of O +
tumors O +
and O +
loss O +
of O +
heterozygocity O +
( O -
LOH O -
) O +
at O +
the O +
M6P O -
/ O -
IGF2R O +
gene O +
locus O +
6q26 O +
have O +
been O +
found O +
in O +
breast O -
, O +
liver O +
cancers O +
and O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
lung O +
[ O -
12 O -
- O -
15 O -
] O -
. O +

Although O +
several O +
studies O +
have O +
examined O +
the O +
effect O +
of O +
M6P O -
/ O -
IGF2R O +
over O -
- O -
expression O +
on O +
cell O +
growth O +
[ O -
7 O -
] O -
, O +
it O +
is O +
not O +
known O +
whether O +
down O -
- O -
regulation O +
of O +
this O +
receptor O +
protein O +
leads O +
to O +
cellular O +
protection O +
against O +
apoptosis O -
. O +

Ribozymes O +
are O +
catalytic O +
RNA O +
molecules O +
that O +
cleave O +
a O +
complementary O +
mRNA O +
sequence O +
[ O -
16 O -
] O -
, O +
thereby O +
inactivating O +
specific O +
mRNAs O +
and O +
suppressing O +
gene O +
expression O +
in O +
vitro O +
and O +
in O +
vivo O +
[ O -
17,18 O -
] O -
. O +

Ribozymes O +
have O +
been O +
shown O +
to O +
be O +
highly O +
specific O -
, O +
efficient O +
and O +
stable O -
. O +

They O +
can O +
be O +
packaged O +
into O +
viral O +
vectors O +
to O +
enhance O +
transfer O +
into O +
cells O +
and O +
to O +
achieve O +
longer O +
expression O +
compared O +
with O +
naked O +
oligonucleotides O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
employed O +
ribozyme O +
technology O +
to O +
study O +
the O +
role O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
regulation O +
of O +
cardiac O +
myocyte O +
cell O +
growth O -
. O +

A O +
hammerhead O +
ribozyme O +
against O +
the O +
M6P O -
/ O -
IGF2R O +
mRNA O +
was O +
constructed O +
and O +
packaged O +
in O +
an O +
adenoviral O +
vector O -
. O +

We O +
then O +
examined O +
the O +
effect O +
of O +
ribozyme O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
M6P O -
/ O -
IGF2R O +
expression O +
on O +
cell O +
growth O +
and O +
hypoxia- O +
and O +
TNF O -
- O -
induced O +
apoptosis O -
. O +

Results O +
Cleavage O +
reaction O +
of O +
the O +
ribozyme O +
in O +
vitro O +
The O +
M6P O -
/ O -
IGF2R O +
ribozyme O +
we O +
constructed O +
has O +
13-bp O +
binding O +
arms O +
complementary O +
to O +
the O +
target O +
site O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O -
, O +
and O +
a O +
catalytic O +
core O +
( O -
Fig. O +
1A O -
) O -
. O +

To O +
evaluate O +
the O +
bioactivity O +
of O +
the O +
ribozyme O +
and O +
the O +
accessibility O +
of O +
the O +
target O +
site O -
, O +
a O +
cleavage O +
reaction O +
was O +
performed O +
in O +
vitro O -
. O +

The O +
substrates O -
, O +
[ O -
α-32P O -
] O +
labeled O +
RNA O +
transcripts O +
containing O +
45 O +
bp O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O +
or O +
an O +
unmatched O +
sequence O -
, O +
were O +
incubated O +
with O +
the O +
ribozyme O +
as O +
described O +
( O -
see O +
Materials O +
and O +
Methods O -
) O -
. O +

The O +
ribozyme O +
cleaved O +
only O +
the O +
specific O +
M6P O -
/ O -
IGF2R O +
mRNA O +
into O +
the O +
expected O +
products O -
. O +

In O +
the O +
assay O +
of O +
time O +
course O -
, O +
the O +
hammerhead O +
ribozyme O +
was O +
able O +
to O +
cleave O +
24.2 O -
% O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
target O +
within O +
10 O +
minutes O +
of O +
incubation O -
, O +
50.3 O -
% O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
target O +
within O +
40 O +
minutes O +
of O +
incubation O -
, O +
and O +
by O +
640 O +
minutes O -
, O +
80.8 O -
% O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
target O +
was O +
converted O +
to O +
the O +
expected O +
products O +
( O -
Fig. O +
1B O -
) O -
. O +

This O +
ribozyme O +
did O +
not O +
digest O +
the O +
unmatched O +
sequence O +
( O -
Fig. O +
1B O -
) O -
. O +

These O +
results O +
indicate O +
a O +
high O +
efficiency O +
and O +
specificity O +
of O +
the O +
ribozyme O +
in O +
vitro O -
. O +

Ribozymes O +
down O -
- O -
regulate O +
M6P O -
/ O -
IGF2R O +
expression O +
in O +
cardiac O +
myocytes O +
To O +
examine O +
the O +
ability O +
of O +
the O +
ribozyme O +
to O +
reduce O +
levels O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O +
in O +
cultured O +
cardiac O +
myocytes O -
, O +
total O +
RNA O +
was O +
extracted O +
from O +
cells O +
infected O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
or O +
Ad O -
- O -
GFP O -
, O +
and O +
subjected O +
to O +
RT O -
- O -
PCR O +
using O +
M6P O -
/ O -
IGF2R O -
- O -
specific O +
primers O -
. O +

Primers O +
specific O +
for O +
β O -
- O -
actin O +
were O +
added O +
to O +
a O +
parallel O +
reaction O +
to O +
serve O +
as O +
an O +
internal O +
standard O -
. O +

Cells O +
were O +
used O +
4 O +
days O +
after O +
infection O -
, O +
with O +
average O +
infection O +
efficiency O +
of O +
70–80 O -
% O +
( O -
for O +
which O +
a O +
viral O +
dose O +
used O +
had O +
minimal O +
cytotoxicity O -
) O -
. O +

The O +
RT O -
- O -
PCR O +
product O +
of O +
M6P O -
/ O -
IGF2R O +
was O +
856 O +
bp O -
, O +
and O +
the O +
β O -
- O -
actin O +
product O +
was O +
285 O +
bp O -
. O +

As O +
shown O +
in O +
Fig. O +
2A O -
, O +
the O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
- O -
infected O +
cells O +
exhibited O +
a O +
significantly O +
lower O +
level O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O +
than O +
Ad O -
- O -
GFP O -
- O -
infected O +
cells O -
, O +
with O +
a O +
reduction O +
of O +
about O +
50 O -
% O -
. O +

This O +
result O +
was O +
confirmed O +
by O +
ribonuclease O +
protection O +
assay O +
( O -
RPA O -
) O -
, O +
in O +
which O +
GAPDH O +
was O +
used O +
as O +
a O +
control O +
( O -
Fig. O +
2C O +
& O -
2D O -
) O -
. O +

There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
level O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O +
between O +
Ad O -
- O -
GFP O -
- O -
infected O +
cells O +
and O +
uninfected O +
cells O +
( O -
data O +
not O +
shown O -
) O -
, O +
indicating O +
that O +
infection O +
with O +
the O +
adenovirus O +
itself O +
did O +
not O +
alter O +
the O +
endogenous O +
M6P O -
/ O -
IGF2R O +
mRNA O +
level O -
. O +

The O +
results O +
demonstrated O +
that O +
the O +
ribozyme O +
was O +
highly O +
effective O +
in O +
suppressing O +
M6P O -
/ O -
IGF2R O +
expression O +
in O +
cultured O +
cardiac O +
myocytes O -
. O +

Effect O +
of O +
ribozyme O +
expression O +
on O +
the O +
functional O +
activity O +
of O +
M6P O -
/ O -
IGF2R O +
To O +
determine O +
the O +
effect O +
of O +
the O +
ribozyme O +
on O +
the O +
functional O +
activity O +
of O +
M6P O -
/ O -
IGF2R O -
, O +
binding O +
and O +
internalization O +
of O +
exogenous O +
125I O -
- O -
IGF O -
- O -
II O +
was O +
measured O +
in O +
cells O +
infected O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
. O +

As O +
shown O +
in O +
Fig. O +
3A O -
, O +
cells O +
infected O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
showed O +
a O +
54 O -
% O +
reduction O +
in O +
125I O -
- O -
IGF O -
- O -
II O +
internalization O +
when O +
compared O +
with O +
the O +
control O +
cells O +
( O -
infected O +
with O +
Ad O -
- O -
GFP O -
) O -
. O +

We O +
also O +
examined O +
the O +
effect O +
of O +
the O +
ribozyme O +
on O +
the O +
M6P O -
- O -
binding O +
activity O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
using O +
the O +
M6P O -
- O -
bearing O +
lysosomal O +
enzyme O -
, O +
β O -
- O -
glucuronidase O -
, O +
as O +
a O +
probe O -
. O +

The O +
results O +
showed O +
that O +
the O +
maximal O +
M6P O -
- O -
binding O +
capacity O +
of O +
cells O +
treated O +
with O +
the O +
ribozyme O +
was O +
about O +
50 O -
% O +
less O +
than O +
that O +
of O +
controls O +
( O -
Fig. O +
3B O -
) O -
. O +

Furthermore O -
, O +
we O +
assessed O +
the O +
ability O +
of O +
cells O +
to O +
internalize O +
exogenous O +
β O -
- O -
glucuronidase O +
after O +
treatment O +
with O +
ribozyme O -
. O +

Similarly O -
, O +
the O +
M6P O -
- O -
inhibitable O +
endocytosis O +
of O +
β O -
- O -
glucuronidase O +
by O +
ribozyme O -
- O -
treated O +
cells O +
was O +
about O +
52 O -
% O +
less O +
than O +
that O +
of O +
control O +
cells O +
( O -
Fig. O +
3C O -
) O -
. O +

These O +
results O +
confirm O +
that O +
the O +
number O +
of O +
functional O +
M6P O -
/ O -
IGF2R O +
in O +
ribozyme O -
- O -
treated O +
cells O +
was O +
reduced O -
. O +

Adenoviral O +
delivery O +
of O +
ribozymes O +
increases O +
the O +
proliferation O +
of O +
cardiac O +
myocytes O +
We O +
examined O +
the O +
effects O +
of O +
the O +
ribozyme O +
on O +
the O +
growth O +
of O +
cultured O +
neonatal O +
rat B-Species +
cardiac O +
myocytes O -
. O +

Morphological O +
evaluation O +
showed O +
a O +
remarkable O +
difference O +
in O +
growth O +
pattern O +
between O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
- O -
infected O +
cells O +
and O +
the O +
control O +
cells O -
: O +
the O +
ribozyme O -
- O -
expressing O +
cells O +
formed O +
larger O +
and O +
more O +
spread O +
colonies O +
( O -
Fig. O +
4 O -
) O -
. O +

Assessment O +
of O +
cell O +
proliferative O +
activity O +
by O +
the O +
MTT O +
assay O +
and O +
counts O +
of O +
viable O +
cells O +
showed O +
that O +
the O +
number O +
of O +
cardiac O +
myocytes O +
in O +
ribozyme O -
- O -
expressing O +
cultures O +
was O +
significantly O +
higher O +
than O +
in O +
control O +
cultures O +
( O -
Fig. O +
5 O -
) O -
. O +

These O +
results O +
indicate O +
that O +
treatment O +
with O +
M6P O -
/ O -
IGF2R O -
- O -
ribozyme O +
can O +
promote O +
cardiac O +
myocyte O +
proliferation O -
. O +

Effect O +
of O +
M6P O -
/ O -
IGF2R O -
- O -
ribozyme O +
expression O +
on O +
apoptosis O +
of O +
cardiac O +
myocytes O +
We O +
examined O +
the O +
effects O +
of O +
ribozyme O +
expression O +
on O +
TNF O -
- O -
α O +
and O +
hypoxia O -
- O -
induced O +
apoptosis O +
of O +
cultured O +
cardiac O +
myocytes O -
. O +

After O +
a O +
24 O +
hr O +
challenge O +
with O +
hypoxia O -
, O +
the O +
number O +
of O +
apoptotic O +
cells O +
in O +
M6P O -
/ O -
IGF2R O -
- O -
Rz O +
expressing O +
cultures O +
was O +
38 O -
% O +
lower O +
than O +
in O +
control O +
cultures O +
as O +
determined O +
by O +
Hoechst O +
staining O +
( O -
which O +
highlights O +
the O +
nuclei O +
of O +
apoptotic O +
cells O -
) O +
and O +
ELISA O +
( O -
Fig. O +
6A O -
, O +
7A O -
) O -
. O +

MTT O +
analysis O +
showed O +
that O +
the O +
number O +
of O +
viable O +
cells O +
in O +
ribozyme O -
- O -
treated O +
cultures O +
was O +
40 O -
% O +
higher O +
than O +
in O +
control O +
cultures O +
( O -
Fig. O +
7A O -
) O -
. O +

After O +
treatment O +
with O +
TNF O -
- O -
α O -
, O +
as O +
shown O +
in O +
Fig. O +
6B O -
, O +
a O +
large O +
number O +
of O +
control O +
cells O +
underwent O +
apoptosis O -
, O +
as O +
indicated O +
by O +
morphological O +
changes O +
( O -
small O +
round O +
shape O -
) O +
and O +
bright O +
blue O +
nuclear O +
staining O -
. O +

There O +
were O +
significantly O +
more O +
apoptotic O +
cells O +
in O +
control O +
cultures O +
than O +
in O +
cultures O +
expressing O +
the O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
. O +

The O +
number O +
of O +
apoptotic O +
cells O -
, O +
as O +
measured O +
by O +
the O +
cell O +
death O +
ELISA O +
assay O -
, O +
in O +
cultures O +
infected O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
was O +
significantly O +
( O -
about O +
40 O -
% O -
) O +
lower O +
than O +
in O +
cultures O +
infected O +
with O +
Ad O -
- O -
GFP O +
( O -
Fig. O +
7B O -
) O -
. O +

Accordingly O -
, O +
the O +
number O +
of O +
viable O +
cells O -
, O +
as O +
measured O +
by O +
MTT O +
analysis O -
, O +
in O +
cultures O +
infected O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
was O +
significantly O +
( O -
about O +
45 O -
% O -
) O +
higher O +
than O +
in O +
cultures O +
infected O +
with O +
Ad O -
- O -
GFP O +
( O -
Fig. O +
7B O -
) O -
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
decreasing O +
M6P O -
/ O -
IGF2R O +
expression O +
by O +
ribozyme O +
treatment O +
can O +
reduce O +
cell O +
apoptosis O -
. O +

Discussion O +
Some O +
62,000,000 O +
Americans O +
have O +
one O +
or O +
more O +
types O +
of O +
cardiovascular O +
disease O +
( O -
CVD O -
) O +
and O +
CVD O +
is O +
the O +
leading O +
cause O +
( O -
40.1 O -
% O -
) O +
of O +
death O +
in O +
the O +
United O +
States O -
. O +

Myocardial O +
infarction O +
and O +
heart O +
failure O -
, O +
conditions O +
accompanied O +
by O +
cardiac O +
myocyte O +
apoptosis O -
, O +
represent O +
23 O -
% O +
of O +
all O +
CVDs O +
and O +
are O +
a O +
growing O +
clinical O +
challenge O +
in O +
need O +
of O +
novel O +
therapeutic O +
strategies O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
M6P O -
/ O -
IGF2R O +
as O +
a O +
potential O +
new O +
therapeutic O +
target O +
for O +
reduction O +
of O +
cardiac O +
apoptosis O +
and O +
cardiac O +
injury O +
in O +
these O +
conditions O -
. O +

Using O +
ribozyme O +
technology O +
we O +
down O -
- O -
regulated O +
the O +
expression O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
in O +
neonatal O +
cardiac O +
myocytes O -
. O +

We O +
then O +
examined O +
cell O +
proliferation O +
and O +
apoptosis O +
under O +
normal O +
conditions O +
and O +
post O +
challenge O +
with O +
either O +
hypoxia O -
, O +
a O +
model O +
of O +
ischemia O -
- O -
reperfusion O -
, O +
or O +
TNF O -
- O -
α O -
, O +
a O +
cytokine O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
chronic O +
heart O +
failure O +
[ O -
19 O -
] O -
. O +

Our O +
results O +
demonstrate O +
an O +
association O +
of O +
a O +
decrease O +
in O +
the O +
expression O +
and O +
function O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
with O +
increased O +
cell O +
proliferation O +
and O +
decreased O +
cell O +
susceptibility O +
to O +
hypoxia- O +
and O +
TNF O -
- O -
induced O +
apoptosis O -
. O +

Expression O +
of O +
the O +
ribozyme O +
targeted O +
against O +
the O +
M6P O -
/ O -
IGF2R O +
in O +
cardiomyocytes O +
resulted O +
in O +
down O -
- O -
regulation O +
of O +
M6P O -
/ O -
IGF2R O +
expression O -
, O +
as O +
measured O +
by O +
RT O -
- O -
PCR O +
and O +
RPA O -
, O +
and O +
of O +
M6P O -
/ O -
IGF2R O +
function O -
, O +
as O +
indicated O +
by O +
a O +
decrease O +
in O +
internalization O +
of O +
125I O -
- O -
IGF O -
- O -
II O -
, O +
and O +
β O -
- O -
glucuronidase O +
binding O +
and O +
endocytosis O -
. O +

MTT O +
analysis O +
and O +
viable O +
cell O +
counts O +
showed O +
that O +
ribozyme O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
M6P O -
/ O -
IGF2R O +
resulted O +
in O +
a O +
marked O +
increase O +
in O +
cell O +
proliferation O +
of O +
cardiomyocytes O -
, O +
which O +
normally O +
express O +
high O +
levels O +
of O +
M6P O -
/ O -
IGF2R O +
[ O -
20 O -
] O +
and O +
have O +
limited O +
proliferative O +
capabilities O +
[ O -
21 O -
] O -
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
findings O +
of O +
previous O +
knockout O +
studies O +
[ O -
9,10 O -
] O -
. O +

Since O +
the O +
M6P O -
/ O -
IGF2R O +
has O +
multiple O +
actions O +
on O +
cell O +
growth O -
, O +
its O +
proliferative O +
effect O +
on O +
the O +
heart O +
cells O +
observed O +
in O +
this O +
study O +
might O +
involve O +
multiple O +
mechanisms O -
. O +

However O -
, O +
it O +
is O +
likely O +
that O +
unchecked O +
IGF O -
- O -
II O +
stimulation O +
plays O +
a O +
key O +
role O +
in O +
the O +
effect O -
. O +

Because O +
the O +
M6P O -
/ O -
IGF2R O +
is O +
believed O +
to O +
sequester O +
and O +
degrade O +
IGF O -
- O -
II O +
[ O -
2 O -
] O -
, O +
a O +
decrease O +
in O +
M6P O -
/ O -
IGF2R O +
expression O +
and O +
function O +
could O +
result O +
in O +
decreased O +
degradation O +
and O +
hence O +
increased O +
bioavailability O +
of O +
IGF O -
- O -
II O +
to O +
the O +
IGF O -
- O -
I O +
receptor O -
, O +
which O +
mediates O +
the O +
growth O -
- O -
promoting O +
effect O +
of O +
IGF O -
- O -
II O -
. O +

Supporting O +
evidence O +
for O +
the O +
involvement O +
of O +
IGF O -
- O -
II O +
in O +
the O +
proliferative O +
effect O +
resulting O +
from O +
loss O +
of O +
M6P O -
/ O -
IGF2R O +
function O +
comes O +
from O +
studies O +
of O +
M6P O -
/ O -
IGF2R O +
knock O -
- O -
out O +
mice B-Species -
. O +

M6P O -
/ O -
IGF2R O -
- O -
null O +
mice B-Species +
display O +
global O +
hyperplasia O +
that O +
coincides O +
with O +
elevated O +
levels O +
of O +
IGF O -
- O -
II O -
. O +

Most O +
importantly O -
, O +
however O -
, O +
the O +
lethal O +
nature O +
of O +
an O +
M6P O -
/ O -
IGF2R O -
- O -
null O +
phenotype O +
is O +
reversed O +
in O +
an O +
IGF O -
- O -
II O -
- O -
null O +
background O +
[ O -
9 O -
] O -
. O +

Our O +
results O +
showing O +
that O +
ribozyme O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
M6P O -
/ O -
IGF2R O +
lead O +
to O +
a O +
decrease O +
in O +
IGF O -
- O -
II O +
internalization O +
support O +
the O +
above O +
possibility O -
. O +

However O -
, O +
further O +
investigation O +
to O +
confirm O +
this O +
mechanism O +
is O +
warranted O -
. O +

More O +
importantly O -
, O +
our O +
results O +
also O +
showed O +
that O +
M6P O -
/ O -
IGF2R O +
down O -
- O -
regulation O +
resulted O +
in O +
decreased O +
sensitivity O +
of O +
cardiomyocytes O +
to O +
hypoxia- O +
and O +
TNF O -
- O -
induced O +
apoptosis O -
. O +

There O +
is O +
evidence O +
that O +
lysosomal O +
enzymes O -
, O +
such O +
as O +
cathepsins O +
B O +
and O +
D O +
contribute O +
to O +
hypoxia- O +
and O +
TNF O -
- O -
induced O +
apoptosis O +
in O +
vitro O +
[ O -
22 O -
- O -
25 O -
] O +
and O +
in O +
vivo O +
[ O -
26,27 O -
] O -
. O +

The O +
M6P O -
/ O -
IGF2R O +
has O +
been O +
shown O +
to O +
be O +
involved O +
in O +
binding O -
, O +
transport O +
and O +
activation O +
of O +
lysosomal O +
enzymes O -
, O +
including O +
cathepsins O +
[ O -
4,5 O -
] O -
. O +

Therefore O -
, O +
it O +
is O +
possible O +
that O +
down O -
- O -
regulation O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
results O +
in O +
improper O +
trafficking O +
and O +
activation O +
of O +
cathepsins O -
. O +

This O -
, O +
in O +
turn O +
would O +
eliminate O +
the O +
apoptotic O +
cascades O +
triggered O +
by O +
these O +
enzymes O +
under O +
hypoxia O +
and O +
TNF O +
stimulation O +
and O +
result O +
in O +
decreased O +
sensitivity O +
of O +
cardiomyocytes O +
to O +
apoptosis O -
. O +

It O +
has O +
also O +
been O +
shown O +
that O +
TNF O +
stimulation O +
involves O +
the O +
activation O +
of O +
TGF O -
- O -
β O +
[ O -
28 O -
- O -
30 O -
] O -
, O +
a O +
ligand O +
of O +
M6P O -
/ O -
IGF2R O +
that O +
has O +
been O +
implicated O +
in O +
the O +
progression O +
of O +
chronic O +
heart O +
failure O +
[ O -
11,31 O -
] O -
. O +

Therefore O -
, O +
down O -
- O -
regulation O +
of O +
M6P O -
/ O -
IGF2R O +
expression O +
could O +
also O +
lead O +
to O +
a O +
decreased O +
bioavailability O +
of O +
activated O +
TGF O -
- O -
β O -
, O +
thereby O +
decreasing O +
the O +
sensitivity O +
of O +
cardiomyocytes O +
to O +
the O +
TNF O -
/ O -
TGF O -
- O -
β O +
apoptotic O +
pathway O -
. O +

The O +
detailed O +
mechanism O +
of O +
the O +
observed O +
effects O +
is O +
unknown O +
and O +
requires O +
further O +
investigation O -
. O +

Conclusions O +
The O +
present O +
study O +
demonstrates O +
that O +
ribozyme O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
expression O +
and O +
functional O +
activity O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
results O +
in O +
a O +
decrease O +
in O +
the O +
susceptibility O +
of O +
cardiac O +
myocytes O +
to O +
apoptotic O +
stimuli O -
. O +

These O +
findings O +
suggest O +
that O +
this O +
receptor O +
might O +
be O +
involved O +
in O +
cardiac O +
cell O +
growth O +
and O +
apoptosis O -
. O +

The O +
ability O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
ribozyme O +
to O +
reduce O +
M6P O -
/ O -
IGF2R O +
expression O +
and O +
function O +
in O +
transfected O +
cells O +
verifies O +
the O +
utility O +
of O +
the O +
ribozyme O +
in O +
studying O +
the O +
role O +
of O +
M6P O -
/ O -
IGF2R O +
in O +
cardiomyocyte O +
growth O +
and O +
apoptosis O -
. O +

In O +
addition O +
to O +
its O +
utility O +
as O +
a O +
research O +
tool O -
, O +
the O +
ribozyme O -
, O +
with O +
further O +
exploration O +
and O +
development O -
, O +
might O +
have O +
potential O +
application O +
as O +
a O +
therapeutic O +
agent O +
to O +
prevent O +
cell O +
death O +
or O +
promote O +
mitogenesis O +
for O +
certain O +
clinical O +
conditions O -
, O +
such O +
as O -
, O +
myocardial O +
infarction O +
and O +
chronic O +
heart O +
failure O -
. O +

Methods O +
Construction O +
of O +
recombinant O +
M6P O -
/ O -
IGF2R O -
- O -
RZ O +
adenoviral O +
vector O +
The O +
nucleotide O +
numbers O +
of O +
the O +
rat B-Species +
M6P O -
/ O -
IGF2R O +
sequence O +
targeted O +
by O +
the O +
hammerhead O +
ribozyme O +
is O +
1147–1160 O +
after O +
coding O +
site O +
( O -
exon O +
9 O -
) O -
. O +

The O +
structure O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
hammerhead O +
ribozyme O +
is O +
shown O +
in O +
Fig. O +
1 O -
. O +

A O +
49 O +
bp O +
M6P O -
/ O -
IGF2R O +
ribozyme O +
oligonucleotide O -
, O +
5'-GAATTCCCC O +
ACACTG O +
ATGAGCCGCTTCGGCGGCGAAACATTCAAC O +
GCGT-3 O -
' O +
and O +
the O +
corresponding O +
reverse O +
complementary O +
strand O +
were O +
synthesized O -
. O +

The O +
fragments O +
were O +
subcloned O +
to O +
produce O +
a O +
plasmid O +
containing O +
a O +
ribozyme O +
against O +
M6P O -
/ O -
IGF2R O -
. O +

For O +
construction O +
of O +
the O +
recombinant O +
adenovirus O +
containing O +
the O +
M6P O -
/ O -
IGF2R O -
- O -
ribozyme O +
( O -
pAd O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
) O -
, O +
the O +
segments O +
containing O +
the O +
ribozymes O +
were O +
amplified O +
by O +
PCR O +
and O +
cloned O +
into O +
a O +
pAdTrack O -
- O -
CMV O +
vector O +
and O +
then O +
recombined O +
homologously O +
with O +
an O +
adenoviral O +
backbone O +
pAdEasy O +
1 O +
vector O +
to O +
generate O +
( O -
pAd O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
) O -
, O +
following O +
the O +
protocol O +
described O +
by O +
He O +
et O +
al. O +
[ O -
32 O -
] O -
. O +

The O +
pAd O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
carries O +
both O +
the O +
IGF2R O -
- O -
Rz O +
and O +
GFP O +
( O -
as O +
reporter O -
) O +
genes O -
, O +
each O +
under O +
the O +
control O +
of O +
separate O +
cytomegalovirus O +
( O -
CMV O -
) O +
promoters O -
. O +

Another O +
viral O +
vector O -
, O +
pAd O -
- O -
GFP O -
, O +
which O +
carries O +
the O +
GFP O +
gene O +
only O +
under O +
the O +
control O +
of O +
the O +
CMV O +
promoter O -
, O +
was O +
generated O +
and O +
used O +
as O +
a O +
control O +
vector O -
. O +

The O +
adenoviral O +
vector O +
DNA O +
were O +
linerized O +
with O +
Pac O +
I O +
and O +
transfected O +
into O +
the O +
replication O -
- O -
permissive O +
293 O +
cells O +
( O -
E1A O +
transcomplementing O +
cell O +
line O -
) O +
by O +
using O +
Lipofectamine O +
( O -
Life O +
Technologies O -
) O +
to O +
produce O +
E1-deleted O -
, O +
replication O -
- O -
defective O +
recombinant O +
adenovirus O +
as O +
described O +
previously O +
[ O -
33 O -
] O -
. O +

Large O -
- O -
scale O +
amplification O +
of O +
recombinant O +
adenovirus O +
in O +
293 O +
cells O +
was O +
followed O +
by O +
purification O +
using O +
a O +
discontinuous O +
CsCl O +
gradient O -
. O +

The O +
constructs O +
were O +
confirmed O +
by O +
enzymatic O +
digestion O +
and O +
DNA O +
sequencing O -
. O +

Transcription O +
and O +
cleavage O +
reaction O +
of O +
ribozyme O +
in O +
vitro O +
Plasmids O +
containing O +
the O +
ribozyme O +
or O +
the O +
substrate O +
( O -
either O +
45 O +
bp O +
of O +
M6P O -
/ O -
IGF2R O +
mRNA O +
or O +
an O +
unmatched O +
sequence O +
5'-GTGCTGTCTGTATG-3 O -
' O -
) O +
were O +
linearized O +
with O +
MluI O -
, O +
respectively O -
. O +

All O +
transcripts O +
were O +
generated O +
with O +
T7 O +
RNA O +
polymerase O +
( O -
Promega O -
) O -
. O +

Substrate O +
transcripts O +
were O +
labeled O +
by O +
incorporation O +
of O +
[ O -
α-32P O -
] O +
UTP O +
( O -
NEN O +
Life O +
Science O +
Products O -
, O +
Inc. O -
) O -
. O +

Specific O +
activity O +
of O +
the O +
[ O -
α-32P O -
] O +
UTP O +
( O -
10 O +
μCi O -
/ O -
μl O -
) O +
and O +
the O +
base O +
composition O +
of O +
each O +
substrate O +
molecule O +
were O +
used O +
to O +
calculate O +
the O +
substrate O +
concentration O -
. O +

Ribozyme O +
transcripts O +
were O +
quantified O +
spectrophotometrically O -
. O +

( O -
The O +
half O -
- O -
life O +
of O +
the O +
M6P O -
/ O -
IGF2R O +
target O +
is O +
about O +
280 O +
minutes O -
) O -
. O +

Cleavage O +
reaction O +
mixture O +
contained O +
substrate O +
RNA O +
( O -
40 O +
nM O -
) O -
, O +
increasing O +
amounts O +
of O +
ribozyme O +
( O -
60 O +
nM O -
) O -
, O +
20 O +
mM O +
MgCl2 O +
and O +
20 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH8.0 O -
, O +
in O +
a O +
final O +
volume O +
of O +
10 O +
μl O -
. O +

The O +
mixture O +
was O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
a O +
time O -
- O -
course O +
of O +
cleavage O +
reaction O +
from O +
0 O -
, O +
5 O -
, O +
10 O -
, O +
20 O -
, O +
40 O -
, O +
80 O -
, O +
160 O -
, O +
320 O -
, O +
to O +
640 O +
minutes O +
and O +
the O +
cleavage O +
reaction O +
was O +
stopped O +
by O +
addition O +
of O +
loading O +
buffer O +
( O -
80 O -
% O +
formamide O -
, O +
10 O +
mM O +
Na2EDTA O -
, O +
pH O +
8.0 O -
, O +
and O +
1 O +
mg O -
/ O -
ml O +
each O +
bromophenol O +
blue O +
and O +
xylene O +
cyanol O -
) O -
. O +

Cleavage O +
products O +
were O +
analyzed O +
on O +
a O +
15 O -
% O +
polyacrylamide O +
and O +
8 O -
M O +
urea O +
gel O -
. O +

Product O +
and O +
substrate O +
fragments O +
were O +
quantitated O +
by O +
using O +
NIH O +
Imager O -
. O +

Cell O +
cultures O +
and O +
infection O +
with O +
Ad O -
- O -
GFP O -
/ O -
Rz O -
- O -
IGF2R O +
and O +
Ad O -
- O -
GFP O +
Cardiac O +
myocytes O +
were O +
isolated O +
from O +
1-day O -
- O -
old O +
newborn O +
rats B-Species +
using O +
the O +
Neonatal O +
Cardiomyocyte O +
Isolation O +
System O +
( O -
Worthington O -
) O -
. O +

The O +
isolated O +
cells O +
were O +
plated O +
in O +
6-well O +
plates O +
and O +
cultured O +
in O +
F-10 O +
medium O +
containing O +
5 O -
% O +
( O -
vol O -
/ O -
vol O -
) O +
FBS O +
and O +
10 O -
% O +
( O -
vol O -
/ O -
vol O -
) O +
horse B-Species +
serum O +
at O +
37 O -
° O -
C O +
in O +
a O +
tissue O +
culture O +
incubator O +
with O +
5 O -
% O +
CO2 O +
and O +
98 O -
% O +
relative O +
humidity O -
. O +

Cells O +
were O +
used O +
for O +
experiments O +
after O +
2–3 O +
days O +
of O +
culture O -
. O +

Viral O +
infections O +
were O +
carried O +
out O +
by O +
adding O +
viral O +
particles O +
at O +
various O +
concentrations O +
( O -
usually O -
, O +
2 O +
× O +
108 O +
virus O +
particles O -
/ O -
ml O -
) O +
to O +
culture O +
medium O +
containing O +
2 O -
% O +
( O -
vol O -
/ O -
vol O -
) O +
FBS O -
. O +

Initially O -
, O +
optimal O +
viral O +
concentration O +
was O +
determined O +
by O +
using O +
Ad O -
- O -
GFP O +
to O +
achieve O +
an O +
optimal O +
balance O +
of O +
high O +
gene O +
expression O +
and O +
low O +
viral O +
titer O +
to O +
minimize O +
cytotoxicity O -
. O +

After O +
24 O +
hours O +
of O +
incubation O -
, O +
the O +
infection O +
medium O +
was O +
replaced O +
with O +
normal O +
( O -
15 O -
% O +
vol O -
/ O -
vol O +
serum O -
) O +
culture O +
medium O -
. O +

For O +
treatment O +
with O +
IGF O -
- O -
II O -
, O +
cells O +
were O +
incubated O +
with O +
50 O +
ng O -
/ O -
ml O +
IGF O -
- O -
II O +
after O +
24 O +
hours O +
infection O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
or O +
Ad O -
- O -
GFP O -
. O +

Four O +
days O +
after O +
infection O -
, O +
cells O +
were O +
used O +
for O +
analysis O +
of O +
gene O +
expression O +
of O +
M6P O -
/ O -
IGF2R O +
and O +
its O +
effect O +
on O +
cell O +
growth O +
and O +
apoptosis O -
. O +

Analysis O +
of O +
gene O +
expression O +
in O +
cardiac O +
myocytes O +
The O +
M6P O -
/ O -
IGF2R O +
transcripts O +
were O +
determined O +
by O +
both O +
RT O -
- O -
PCR O +
and O +
Ribonuclease O +
Protection O +
Assay O +
( O -
RPA O -
) O -
. O +

RT O -
- O -
PCR O +
was O +
performed O +
using O +
the O +
GeneAmp O +
EZ O +
rTth O +
RNA O +
PCR O +
kit O +
( O -
Roche O -
) O -
. O +

Total O +
RNA O +
was O +
extracted O +
from O +
cultured O +
cells O +
using O +
an O +
RNA O +
isolation O +
kit O +
( O -
Qiagen O -
, O -
) O -
, O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

M6P O -
/ O -
IGF2R O +
transcripts O +
were O +
amplified O +
using O +
the O +
primers O +
( O -
5'-GACAGGCTCGTTCTGACTTA-3 O -
' O -
) O +
and O +
( O -
5'-CTTCCACTCTTATCCACAGC-3 O -
' O -
) O +
specific O +
to O +
the O +
M6P O -
/ O -
IGF2R O -
. O +

Each O +
RT O -
- O -
PCR O +
assay O +
was O +
performed O +
in O +
triplicate O +
and O +
product O +
levels O +
varied O +
by O +
less O +
than O +
3.2 O -
% O +
for O +
each O +
RNA O +
sample O -
. O +

Primers O +
specific O +
for O +
β O -
- O -
actin O +
cDNA O +
were O +
added O +
to O +
a O +
parallel O +
reaction O +
to O +
standardize O +
for O +
variations O +
in O +
PCR O +
between O +
samples O -
. O +

PCR O +
products O +
were O +
resolved O +
on O +
a O +
1.0 O -
% O +
agarose O +
gel O -
, O +
visualized O +
under O +
UV O +
light O +
and O +
quantitated O +
using O +
NIH O +
Imager O -
. O +

RPA O +
was O +
performed O +
using O +
the O +
RPA O +
III O +
kit O +
( O -
Ambion O -
, O +
Austin O -
, O +
TX O -
) O -
. O +

Briefly O -
, O +
total O +
RNA O +
was O +
extracted O +
from O +
cultured O +
cells O +
using O +
a O +
total O +
RNA O +
isolation O +
reagent O +
( O -
TRIzol O -
, O +
Gibco O +
BRL O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

The O +
plasmid O +
containing O +
the O +
rat B-Species +
M6P O -
/ O -
IGF2R O +
gene O +
was O +
linearized O +
and O +
used O +
as O +
a O +
transcription O +
template O -
. O +

Antisense O +
RNA O +
probes O +
were O +
transcribed O +
in O +
vitro O +
using O +
[ O -
33P O -
] O -
-UTP O -
, O +
T7 O +
polymerase O +
( O -
Riboprobea O +
System O +
T7 O +
kit O -
, O +
Promega O -
) O -
, O +
hybridized O +
with O +
the O +
total O +
RNA O +
extracted O +
from O +
the O +
rat B-Species +
cardiomyocytes O -
, O +
and O +
digested O +
with O +
ribonuclease O +
to O +
remove O +
non O -
- O -
hybridized O +
RNA O +
and O +
probe O -
. O +

The O +
protected O +
RNA·RNA O +
was O +
resolved O +
on O +
a O +
denaturing O +
5 O -
% O +
sequence O +
gel O +
and O +
subjected O +
to O +
autoradiography O -
. O +

A O +
probe O +
targeting O +
the O +
GAPDH O +
gene O +
was O +
used O +
as O +
an O +
internal O +
control O -
. O +

Measurement O +
of O +
125I O -
- O -
IGF O -
- O -
II O +
internalization O +
Cells O +
were O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
2 O +
hrs O +
in O +
serum O -
- O -
free O +
F-10 O +
culture O +
medium O +
containing O +
125I O -
- O -
labeled O +
IGF O -
- O -
II O +
( O -
0.5 O +
ng O -
/ O -
ml O -
) O +
with O +
or O +
without O +
excess O +
unlabeled O +
IGF O -
- O -
II O +
( O -
2 O +
μg O -
/ O -
ml O -
) O -
. O +

Following O +
the O +
incubation O -
, O +
the O +
cells O +
were O +
washed O +
three O +
times O +
with O +
ice O -
- O -
cold O +
PBS O -
, O +
and O +
cell O -
- O -
associated O +
radioactivity O +
was O +
determined O +
by O +
a O +
γ O +
counter O -
. O +

Specific O +
internalized O +
125I O -
- O -
IGF O -
- O -
II O +
was O +
calculated O +
by O +
subtracting O +
the O +
count O +
of O +
samples O +
with O +
excessive O +
unlabeled O +
IGF O -
- O -
II O +
from O +
that O +
without O +
unlabeled O +
IGF O -
- O -
II O -
, O +
and O +
normalized O +
to O +
protein O +
contents O -
. O +

Beta O -
- O -
glucuronidase O +
binding O +
assay O +
Binding O +
of O +
β O -
- O -
glucuronidase O +
was O +
assayed O +
as O +
described O +
previously O +
[ O -
34,35 O -
] O -
. O +

Briefly O -
, O +
cells O +
were O +
permeabilized O +
with O +
0.25 O -
% O +
saponin O +
in O +
50 O +
mM O +
Hepes O +
( O -
pH O +
7.0 O -
) O -
, O +
150 O +
mM O +
NaCl O -
, O +
5 O +
mM O +
β O -
- O -
glycerophosphate O -
, O +
0.5 O -
% O +
human B-Species +
serum O +
albumin O -
, O +
and O +
10 O +
mM O +
mannose-6-phosphate O +
( O -
M6P O -
) O +
for O +
30 O +
minutes O +
on O +
ice O -
. O +

The O +
cells O +
were O +
washed O +
three O +
times O +
with O +
ice O -
- O -
cold O +
PBS O +
containing O +
0.05 O -
% O +
saponin O -
. O +

They O +
were O +
incubated O +
with O +
20,000 O +
units O -
/ O -
ml O +
β O -
- O -
glucuronidase O +
from O +
bovine B-Species +
liver O +
( O -
Sigma O -
) O +
in O +
50 O +
mM O +
Hepes O +
( O -
pH O +
7.5 O -
) O +
containing O +
150 O +
mM O +
NaCl O -
, O +
5 O +
mM O +
β O -
- O -
glycerophosphate O -
, O +
0.5 O -
% O +
human B-Species +
serum O +
albumin O -
, O +
0.5 O -
% O +
saponin O +
with O +
or O +
without O +
10 O +
mM O +
M6P O +
overnight O +
on O +
ice O -
. O +

Cells O +
were O +
washed O +
five O +
times O +
with O +
ice O -
- O -
cold O +
PBS O +
containing O +
0.05 O -
% O +
saponin O +
and O +
sonicated O +
in O +
100 O +
mM O +
sodium O +
acetate O +
( O -
pH O +
4.6 O -
) O -
. O +

The O +
protein O +
concentration O +
of O +
solubilized O +
cell O +
extract O +
was O +
measured O +
and O +
enzyme O +
activity O +
was O +
assayed O +
as O +
follows O -
: O +
for O +
each O +
reaction O +
50 O +
ul O +
cell O +
extract O +
were O +
added O +
to O +
500 O +
ul O +
of O +
100 O +
mM O +
sodium O +
acetate O +
( O -
pH O +
4.0 O -
) O +
containing O +
1 O +
mM O +
paranitrophenyl O +
( O -
PNP O -
) O -
-β O -
- O -
glucuronide O +
( O -
Sigma O -
) O +
as O +
substrate O -
. O +

After O +
an O +
incubation O +
period O +
of O +
3 O +
hours O +
at O +
37 O -
° O -
C O -
, O +
500 O +
ul O +
1 O +
M O +
Na2CO3 O +
were O +
added O +
to O +
each O +
reaction O +
and O +
the O +
absorbance O +
was O +
measured O +
at O +
400 O +
nm O -
. O +

Experimental O +
values O +
were O +
compared O +
to O +
a O +
standard O +
curve O +
that O +
was O +
constructed O +
using O +
1–100 O +
nM O +
solutions O +
of O +
PNP O +
( O -
Sigma O -
) O +
in O +
500 O +
ul O +
100 O +
mM O +
sodium O +
acetate O +
and O +
500 O +
u1 O +
1 O +
M O +
Na2CO3 O -
. O +

Specific O +
activity O +
was O +
calculated O +
as O +
nM O +
of O +
PNP O +
produced O -
/ O -
hour O -
/ O -
mg O +
of O +
protein O -
. O +

Beta O -
- O -
glucuronidase O +
endocytosis O +
assay O +
Beta O -
- O -
glucuronidase O +
endocytosis O +
assay O +
was O +
carried O +
out O +
as O +
described O +
previously O +
[ O -
36 O -
] O -
. O +

Briefly O -
, O +
confluent O +
cell O +
cultures O +
were O +
washed O +
twice O +
with O +
pre O -
- O -
warmed O +
serum O -
- O -
free O +
DMEM O +
followed O +
by O +
incubation O +
with O +
DMEM O +
containing O +
5 O +
mg O -
/ O -
ml O +
human B-Species +
serum O +
albumin O +
and O +
10 O +
mM O +
M6P O +
for O +
20 O +
minutes O -
. O +

Following O +
incubation O +
cells O +
were O +
washed O +
3 O +
times O +
with O +
pre O -
- O -
warmed O +
DMEM O -
. O +

Cells O +
were O +
then O +
incubated O +
in O +
DMEM O +
containing O +
5 O +
mg O -
/ O -
ml O +
human B-Species +
serum O +
albumin O +
alone O +
or O +
4000 O +
units O +
β O -
- O -
glucuronidase O +
with O +
or O +
without O +
10 O +
mM O +
M6P O +
for O +
2 O +
hours O +
at O +
37 O -
° O -
C O -
. O +

Following O +
the O +
incubation O -
, O +
the O +
cells O +
were O +
washed O +
5 O +
times O +
with O +
ice O -
- O -
cold O +
PBS O +
and O +
subjected O +
to O +
enzyme O +
activity O +
assay O +
as O +
described O +
above O -
. O +

Cell O +
proliferation O +
assay O +
( O -
MTT O +
assay O +
and O +
cell O +
counts O -
) O +
Cardiac O +
myocytes O +
were O +
grown O +
in O +
culture O +
plates O +
( O -
tissue O +
culture O +
grade O -
, O +
12 O +
wells O -
, O +
flat O +
bottom O -
) O +
in O +
a O +
final O +
volume O +
of O +
1 O +
ml O +
serum O -
- O -
containing O +
culture O +
medium O +
per O +
well O -
, O +
in O +
a O +
humidified O +
atmosphere O +
( O -
37 O -
° O -
C O +
and O +
5 O -
% O +
C02 O -
) O +
for O +
3 O +
days O -
. O +

After O +
infection O +
with O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
or O +
Ad O -
- O -
GFP O -
, O +
cells O +
were O +
incubated O +
with O +
or O +
without O +
50 O +
ng O -
/ O -
ml O +
IGF O -
- O -
II O +
for O +
4 O +
days O -
. O +

Following O +
supplementation O +
with O +
IGF O -
- O -
II O -
, O +
100 O +
μl O +
MTT O +
labeling O +
reagent O +
( O -
Roche O -
) O +
were O +
added O +
to O +
each O +
well O +
and O +
cells O +
were O +
incubated O +
for O +
4 O +
hours O -
, O +
followed O +
by O +
addition O +
of O +
1 O +
ml O +
solubilization O +
solution O +
into O +
each O +
well O -
. O +

The O +
plate O +
was O +
placed O +
in O +
an O +
incubator O +
at O +
37 O -
° O -
C O +
overnight O -
. O +

Spectrophotometrical O +
absorbency O +
of O +
the O +
samples O +
was O +
measured O +
using O +
an O +
UV O -
- O -
visible O +
Recording O +
Spectrophotometer O +
with O +
wavelength O +
of O +
550–690 O +
nm O -
. O +

In O +
addition O -
, O +
the O +
total O +
number O +
of O +
viable O +
cells O +
in O +
each O +
treatment O +
was O +
counted O +
by O +
trypan O +
blue O +
exclusion O +
method O +
using O +
a O +
hemocytometer O -
. O +

Induction O +
and O +
analysis O +
of O +
cell O +
apoptosis O +
Cells O +
were O +
infected O +
with O +
Ad O -
- O -
GFP O +
or O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
. O +

Seventy O -
- O -
two O +
hours O +
post O +
infection O -
, O +
cells O +
were O +
treated O +
with O +
TNF O +
( O -
0.1 O +
ng O -
/ O -
ml O -
) O +
for O +
24 O +
hrs O +
or O +
subjected O +
to O +
hypoxia O -
. O +

For O +
induction O +
of O +
apoptosis O +
by O +
hypoxia O -
, O +
cell O +
culture O +
medium O +
was O +
changed O +
to O +
serum O -
- O -
free O +
F-10 O +
saturated O +
with O +
95 O -
% O +
N2 O -
/ O -
5 O -
% O +
CO2 O +
and O +
cells O +
were O +
placed O +
in O +
a O +
37 O -
° O -
C O +
airtight O +
box O +
saturated O +
with O +
95 O -
% O +
N2 O -
/ O -
5 O -
% O +
CO2 O +
for O +
24 O +
hrs O -
. O +

For O +
normoxic O +
controls O -
, O +
culture O +
medium O +
was O +
changed O +
to O +
F-10 O -
/ O -
5%F O +
BS O -
/ O -
10 O -
% O +
HS O +
and O +
cells O +
were O +
placed O +
in O +
a O +
37 O -
° O -
C O -
/ O -
5 O -
% O +
CO2 O +
incubator O +
for O +
24 O +
hrs O +
before O +
analysis O -
. O +

Apoptotic O +
cells O +
were O +
identified O +
by O +
Hoechst O +
staining O +
using O +
the O +
Vybrant O -
™ O +
Apoptosis O +
Kit O +
# O -
5 O +
( O -
Molecular O +
Probes O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

In O +
addition O -
, O +
after O +
infection O +
with O +
Ad O -
- O -
GFP O +
or O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O +
and O +
challenge O +
with O +
either O +
TNF O +
or O +
hypoxia O -
, O +
cell O +
viability O +
was O +
assessed O +
using O +
the O +
MTT O +
assay O +
Kit O +
( O -
Roche O +
Molecular O +
Biochemicals O -
) O +
and O +
cell O +
apoptosis O +
was O +
determined O +
using O +
the O +
Cell O +
Death O +
Detection O +
ELISA O +
Kit O +
assay O +
( O -
Roche O +
Molecular O +
Biochemicals O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
protocol O -
. O +

Statistical O +
analysis O +
Students O -
' O +
t O -
- O -
test O +
was O +
used O +
to O +
evaluate O +
the O +
difference O +
between O +
two O +
values O -
. O +

Each O +
experiment O +
was O +
repeated O +
at O +
least O +
three O +
times O -
. O +

Statistical O +
significance O +
was O +
accepted O +
at O +
the O +
level O +
of O +
p O +
< O +
0.05 O -
. O +

List O +
of O +
abbreviations O +
used O +
Ad O -
- O -
GFP O -
, O +
adenovirus O +
carrying O +
GFP O +
gene O -
; O +
Ad O -
- O -
GFP O -
/ O -
IGF2R O -
- O -
Rz O -
, O +
adenovirus O +
carrying O +
both O +
the O +
ribozyme O +
against O +
M6P O -
/ O -
IGF2R O +
and O +
the O +
GFP O +
gene O -
; O +
GFP O -
, O +
green O +
fluorescent O +
protein O -
; O +
IGF O -
- O -
II O -
, O +
insulin O -
- O -
like O +
growth O +
factor O +
II O -
; O +
M6P O -
/ O -
IGF2R O -
, O +
mannose O +
6-phosphate O -
/ O -
insulin O -
- O -
like O +
growth O +
factor O +
II O +
receptor O -
; O +
Rz O -
, O +
ribozyme O -
. O +

Authors O -
' O +
contributions O +
ZC O +
carried O +
out O +
construction O +
of O +
the O +
ribozyme O -
, O +
production O +
of O +
the O +
viruses O -
, O +
cellular O +
experiments O -
, O +
biochemical O +
assays O +
and O +
data O +
analysis O -
. O +

YG O +
carried O +
out O +
the O +
RPA O +
assay O +
and O +
participated O +
in O +
the O +
molecular O +
biological O +
studies O -
. O +

JXK O +
conceived O +
of O +
the O +
study O -
, O +
participated O +
in O +
its O +
design O +
and O +
coordination O -
, O +
and O +
drafted O +
the O +
manuscript O -
. O +

Medicinal O +
herb O +
use O +
among O +
asthmatic O +
patients O +
attending O +
a O +
specialty O +
care O +
facility O +
in O +
Trinidad O +
Abstract O +
Background O +
There O +
is O +
an O +
increasing O +
prevalence O +
of O +
asthma O +
in O +
the O +
Caribbean O +
and O +
patients O +
remain O +
non O -
- O -
compliant O +
to O +
therapy O +
despite O +
the O +
development O +
of O +
guidelines O +
for O +
management O +
and O +
prevention O -
. O +

Some O +
patients O +
may O +
self O -
- O -
medicate O +
with O +
medicinal O +
herbs O +
for O +
symptomatic O +
relief O -
, O +
as O +
there O +
is O +
a O +
long O +
tradition O +
of O +
use O +
for O +
a O +
variety O +
of O +
ailments O -
. O +

The O +
study O +
assessed O +
the O +
prevalence O +
of O +
use O +
and O +
the O +
factors O +
affecting O +
the O +
decision O +
to O +
use O +
herbs O +
in O +
asthmatic O +
patients O +
attending O +
a O +
public O +
specialty O +
care O +
clinic O +
in O +
Trinidad O -
. O +

Methods O +
A O +
descriptive O -
, O +
cross O -
- O -
sectional O +
study O +
was O +
conducted O +
at O +
the O +
Chest O +
Clinic O +
in O +
Trinidad O +
using O +
a O +
de O +
novo O -
, O +
pilot O -
- O -
tested O -
, O +
researcher O -
- O -
administered O +
questionnaire O +
between O +
June O +
and O +
July O +
2003 O -
. O +

Results O +
Fifty O -
- O -
eight O +
out O +
of O +
191 O +
patients O +
( O -
30.4 O -
% O -
) O +
reported O +
using O +
herbal O +
remedies O +
for O +
symptomatic O +
relief O -
. O +

Gender O -
, O +
age O -
, O +
ethnicity O -
, O +
and O +
asthma O +
severity O +
did O +
not O +
influence O +
the O +
decision O +
to O +
use O +
herbs O -
; O +
however O -
, O +
62.5 O -
% O +
of O +
patients O +
with O +
tertiary O +
level O +
schooling O +
used O +
herbs O -
, O +
p O +
= O +
0.025 O -
. O +

Thirty O -
- O -
four O +
of O +
these O +
58 O +
patients O +
( O -
58.6 O -
% O -
) O +
obtained O +
herbs O +
from O +
their O +
backyards O +
or O +
the O +
supermarket O -
; O +
only O +
14 O +
patients O +
( O -
24.1 O -
% O -
) O +
obtained O +
herbs O +
from O +
an O +
herbalist O -
, O +
herbal O +
shop O +
or O +
pharmacy O -
. O +

Relatives O +
and O +
friends O +
were O +
the O +
sole O +
source O +
of O +
information O +
for O +
most O +
patients O +
( O -
70.7 O -
% O -
) O -
, O +
and O +
only O +
10.3 O -
% O +
consulted O +
an O +
herbalist O -
. O +

Ginger B-Species -
, O +
garlic B-Species -
, O +
aloes O -
, O +
shandileer B-Species -
, O +
wild O +
onion B-Species -
, O +
pepper O +
and O +
black B-Species +
sage I-Species +
were O +
the O +
most O +
commonly O +
used O +
herbs O -
. O +

Conclusions O +
Among O +
patients O +
attending O +
the O +
Chest O +
Clinic O +
in O +
Trinidad O +
the O +
use O +
of O +
herbal O +
remedies O +
in O +
asthma O +
is O +
relatively O +
common O +
on O +
the O +
advice O +
of O +
relatives O +
and O +
friends O -
. O +

It O +
is O +
therefore O +
becoming O +
imperative O +
for O +
healthcare O +
providers O +
to O +
become O +
more O +
knowledgeable O +
on O +
this O +
modality O +
and O +
to O +
keep O +
abreast O +
with O +
the O +
latest O +
developments O -
. O +

Background O +
Recent O +
reports O +
from O +
the O +
Caribbean O +
suggest O +
that O +
the O +
incidence O +
of O +
asthma O +
is O +
following O +
the O +
global O +
trend O +
of O +
increasing O +
prevalence O -
. O +

In O +
Jamaica O -
, O +
a O +
prevalence O +
of O +
20.8 O -
% O +
for O +
exercise O -
- O -
induced O +
asthma O +
was O +
estimated O +
in O +
a O +
cross O -
- O -
sectional O +
study O +
in O +
schoolchildren O +
[ O -
1 O -
] O -
. O +

About O +
one O +
in O +
ten O +
patients O +
attending O +
an O +
Accident O +
and O +
Emergency O +
Department O +
in O +
Trinidad O +
were O +
treated O +
for O +
acute O +
severe O +
asthma O +
[ O -
2 O -
] O +
and O +
over O +
15,000 O +
patients O +
attended O +
four O +
A&E O +
departments O +
throughout O +
the O +
island O +
over O +
a O +
12-month O +
period O +
[ O -
3 O -
] O -
. O +

Inhaled O +
corticosteroids O +
as O +
prophylaxis O +
and O +
' O -
as O +
required O -
' O +
bronchodilator O +
for O +
symptomatic O +
relief O +
are O +
established O +
modalities O +
for O +
asthma O +
management O +
and O +
prevention O +
and O +
the O +
Commonwealth O +
Caribbean O +
Medical O +
Research O +
Council O -
/ O -
Global O +
Initiative O +
for O +
Asthma O +
guidelines O +
were O +
adopted O +
in O +
the O +
Caribbean O +
in O +
1997 O +
[ O -
4 O -
] O -
. O +

It O +
has O +
been O +
noted O +
that O +
inefficient O +
management O +
predisposes O +
patients O +
to O +
frequent O +
hospitalization O +
and O +
reduced O +
quality O +
of O +
life O -
. O +

In O +
Trinidad O -
, O +
non O -
- O -
compliance O +
and O +
inadequate O +
inhaler O +
technique O +
negatively O +
impact O +
on O +
effective O +
disease O +
management O +
[ O -
5,6 O -
] O -
. O +

The O +
frequent O +
unavailability O +
of O +
medication O +
at O +
public O +
health O +
facilities O +
and O +
the O +
prohibitive O +
cost O +
at O +
private O +
pharmacies O +
are O +
significantly O +
associated O +
with O +
non O -
- O -
compliance O +
and O +
consequently O +
poor O +
disease O +
control O -
. O +

In O +
these O +
studies O -
, O +
some O +
patients O +
indicated O +
their O +
use O +
of O +
herbal O +
remedies O +
as O +
an O +
alternative O +
to O +
conventional O +
medicines O -
. O +

Over O +
the O +
last O +
few O +
decades O -
, O +
a O +
global O +
resurgence O +
in O +
the O +
use O +
of O +
herbal O +
remedies O +
has O +
fuelled O +
the O +
growing O +
multi O -
- O -
billion O +
dollar O +
international O +
trade O +
of O +
botanical O +
products O -
. O +

Many O +
patients O -
, O +
dissatisfied O +
with O +
conventional O +
medicines O +
because O +
they O +
expect O +
permanent O +
cures O -
, O +
believe O +
that O +
herbal O +
remedies O +
are O +
' O -
natural O -
' O +
and O +
sometimes O +
self O -
- O -
medicate O +
without O +
informing O +
their O +
attending O +
physician O -
. O +

Although O +
there O +
is O +
a O +
long O +
history O +
of O +
traditional O +
use O +
of O +
medicinal O +
herbs O +
throughout O +
the O +
Caribbean O +
[ O -
7,8 O -
] O +
few O +
studies O +
were O +
done O +
to O +
assess O +
the O +
prevalence O +
of O +
use O -
. O +

Surveys O +
in O +
Jamaica O +
reported O +
an O +
almost O +
100 O -
% O +
use O +
of O +
herbal O +
teas O +
and O +
remedies O +
by O +
respondents O +
throughout O +
the O +
island O +
[ O -
9 O -
] O +
and O +
71 O -
% O +
in O +
paediatrics O +
inpatients O +
at O +
the O +
University O +
Hospital O +
[ O -
10 O -
] O -
. O +

These O +
studies O -
, O +
however O -
, O +
assessed O +
only O +
the O +
lifetime O +
use O +
of O +
medicinal O +
herbs O +
and O +
did O +
not O +
identify O +
their O +
use O +
for O +
any O +
particular O +
disease O -
. O +

In O +
Trinidad O +
and O +
Tobago O -
, O +
the O +
use O +
of O +
' O -
bush O +
medicine O -
' O +
in O +
diabetic O +
patients O +
attending O +
primary O +
healthcare O +
facilities O +
throughout O +
the O +
island O +
was O +
assessed O +
and O +
although O +
42 O -
% O +
reportedly O +
used O +
herbs O -
, O +
only O +
24 O -
% O +
used O +
this O +
healthcare O +
modality O +
for O +
self O -
- O -
management O +
of O +
diabetes O +
[ O -
11 O -
] O -
. O +

Another O +
survey O +
conducted O +
at O +
an O +
outpatient O +
surgical O +
facility O +
in O +
Trinidad O +
indicated O +
a O +
lifetime O +
prevalence O +
of O +
86 O -
% O +
among O +
patients O +
[ O -
12 O -
] O +
for O +
any O +
healthcare O +
issue O -
. O +

This O +
study O +
was O +
undertaken O +
to O +
assess O +
the O +
extent O +
of O +
use O +
of O +
herbal O +
remedies O +
by O +
asthmatic O +
patients O +
attending O +
a O +
specialty O +
chest O +
clinic O +
in O +
Trinidad O +
for O +
symptomatic O +
relief O +
and O +
to O +
determine O +
the O +
factors O +
influencing O +
the O +
patient O -
's O +
decision O +
to O +
use O +
herbs O -
. O +

Methods O +
The O +
study O +
was O +
approved O +
by O +
the O +
Ethics O +
Committee O +
of O +
the O +
Faculty O +
of O +
Medical O +
Sciences O -
, O +
University O +
of O +
the O +
West O +
Indies O -
, O +
St. O +
Augustine O +
campus O +
and O +
permission O +
to O +
interview O +
patients O +
was O +
granted O +
by O +
the O +
Director O +
of O +
the O +
Chest O +
Clinic O +
of O +
the O +
Ministry O +
of O +
Health O -
, O +
Trinidad O +
and O +
Tobago O -
. O +

The O +
study O +
was O +
conducted O +
over O +
the O +
two O -
- O -
month O +
period O +
June O +
to O +
July O +
2003 O -
. O +

Sample O +
and O +
setting O +
The O +
Chest O +
Clinic O +
was O +
chosen O +
as O +
the O +
source O +
of O +
subjects O +
as O +
this O +
is O +
the O +
only O +
national O +
tertiary O +
level O +
health O +
facility O +
specializing O +
in O +
the O +
management O +
of O +
respiratory O +
diseases O -
. O +

Patients O +
entering O +
the O +
study O +
were O +
physician O -
- O -
diagnosed O +
asthmatics O +
based O +
on O +
self O -
- O -
reporting O +
symptoms O +
of O +
wheezing O -
, O +
chest O +
tightness O +
and O +
nocturnal O +
coughing O +
in O +
the O +
previous O +
year O -
. O +

Patients O +
were O +
recruited O +
by O +
consecutive O +
sampling O +
and O +
the O +
nature O +
and O +
purpose O +
of O +
the O +
study O +
were O +
explained O +
on O +
an O +
individual O +
basis O -
. O +

Those O +
confirming O +
their O +
willingness O +
to O +
participate O +
signed O +
their O +
informed O +
consent O +
and O +
were O +
interviewed O +
using O +
a O +
de O +
novo O -
, O +
pilot O -
- O -
tested O -
, O +
researcher O -
- O -
administered O +
questionnaire O -
. O +

Interview O +
instrument O +
The O +
questionnaire O +
assessed O +
demographic O +
data O +
such O +
as O +
age O -
, O +
gender O -
, O +
ethnicity O -
, O +
residential O +
district O -
, O +
education O -
, O +
employment O +
and O +
socioeconomic O +
status O -
. O +

Subjects O +
reported O +
their O +
disease O +
severity O +
as O +
intermittent O -
, O +
moderate O +
or O +
severe O +
as O +
determined O +
by O +
the O +
Global O +
Initiative O +
for O +
Asthma O +
( O -
GINA O -
) O +
guidelines O +
with O +
respect O +
to O +
symptom O +
frequency O +
[ O -
4 O -
] O -
. O +

Patients O +
also O +
reported O +
their O +
use O +
of O +
herbal O +
remedies O -
, O +
identified O +
the O +
herbs O +
used O -
, O +
the O +
frequency O +
of O +
use O -
, O +
source O +
of O +
herbal O +
medicines O +
and O +
the O +
reasons O +
for O +
the O +
use O +
of O +
herbs O -
. O +

Statistical O +
analysis O +
The O +
sample O +
size O +
was O +
calculated O +
as O +
185 O +
patients O +
assuming O +
a O +
prevalence O +
of O +
86 O -
% O +
[ O -
13 O -
] O +
with O +
a O +
confidence O +
level O +
of O +
95 O -
% O -
. O +

Since O +
all O +
variables O +
were O +
categorical O -
, O +
χ2 O +
tests O +
were O +
performed O +
to O +
determine O +
whether O +
there O +
were O +
statistically O +
significant O +
associations O +
between O +
the O +
use O +
of O +
herbs O +
and O +
these O +
variables O -
. O +

The O +
p O +
value O +
was O +
set O +
at O +
< O -
0.05 O +
for O +
statistical O +
significance O -
. O +

The O +
data O +
was O +
analyzed O +
using O +
SPSS O +
for O +
Windows O +
( O -
Version O +
9.0 O -
, O +
Chicago O -
, O +
IL O -
) O -
. O +

Results O +
Demography O +
During O +
the O +
study O +
period O +
one O +
hundred O +
and O +
ninety O +
one O +
patients O +
consented O +
to O +
participate O -
. O +

The O +
demographic O +
details O +
of O +
the O +
sample O +
are O +
given O +
in O +
Table O +
1 O -
. O +

Patients O +
between O +
35 O +
and O +
64 O +
years O +
of O +
age O +
formed O +
the O +
largest O +
portion O +
of O +
the O +
sample O +
( O -
62.3 O -
% O -
) O -
. O +

There O +
was O +
a O +
significant O +
gender O +
difference O +
with O +
females O +
outnumbering O +
males O +
by O +
a O +
2:1 O +
ratio O -
, O +
p O +
< O +
0.01 O -
. O +

Most O +
patients O +
were O +
of O +
Asian O +
Indian O +
origin O +
( O -
58.1 O -
% O -
) O +
and O +
resided O +
in O +
suburban O +
areas O +
( O -
60.2 O -
% O -
) O -
. O +

There O +
was O +
a O +
high O +
level O +
of O +
unemployment O +
( O -
30.4 O -
% O -
) O -
; O +
this O +
could O +
be O +
correlated O +
to O +
primary O +
schooling O +
( O -
seven O +
or O +
less O +
years O +
of O +
formal O +
education O -
) O +
being O +
the O +
highest O +
educational O +
level O +
attained O +
in O +
52.9 O -
% O +
and O +
no O +
formal O +
schooling O +
in O +
5.2 O -
% O +
of O +
the O +
sample O +
population O -
. O +

Income O +
was O +
low O -
, O +
with O +
42.9 O -
% O +
of O +
the O +
sample O +
population O +
earning O +
below O +
US$ O -
4,000 O +
per O +
year O -
. O +

Antiasthmatic O +
drug O +
use O +
The O +
GINA O +
guidelines O +
were O +
recently O +
adopted O +
in O +
the O +
Caribbean O +
and O +
asthmatic O +
patients O +
are O +
currently O +
treated O +
according O +
to O +
their O +
symptom O +
severity O -
. O +

In O +
our O +
sample O +
population O -
, O +
particularly O +
in O +
patients O +
with O +
moderate O +
and O +
severe O +
symptoms O -
, O +
corticosteroids O +
( O -
controllers O -
) O +
and O +
β2-agonists O +
( O -
relievers O -
) O +
were O +
prescribed O +
at O +
very O +
high O +
rates O -
, O +
Table O +
2 O -
. O +

Almost O +
90 O -
% O +
of O +
all O +
patients O +
with O +
moderate O +
symptoms O +
were O +
prescribed O +
drugs O +
in O +
these O +
classes O -
. O +

Almost O +
all O +
patients O +
with O +
severe O +
symptoms O +
were O +
prescribed O +
β2-agonists O -
. O +

This O +
high O +
level O +
of O +
prescription O +
and O +
use O +
of O +
β2-agonists O +
suggest O +
a O +
lack O +
of O +
symptomatic O +
control O +
in O +
our O +
sample O +
population O -
. O +

Theophylline O +
and O +
anticholinergics O +
were O +
prescribed O +
in O +
both O +
categories O +
of O +
patients O -
, O +
but O +
to O +
a O +
lesser O +
extent O -
. O +

Factors O +
influencing O +
the O +
use O +
of O +
herbal O +
remedies O +
Gender O -
, O +
age O -
, O +
ethnicity O -
, O +
residential O +
district O -
, O +
employment O +
status O -
, O +
income O +
and O +
asthma O +
severity O +
had O +
no O +
statistically O +
significant O +
effect O +
on O +
the O +
use O +
of O +
herbal O +
remedies O +
within O +
the O +
sample O +
population O -
, O +
Table O +
3 O -
. O +

However O -
, O +
almost O +
two O -
- O -
thirds O +
( O -
62.5 O -
% O -
) O +
of O +
patients O +
with O +
tertiary O +
education O +
used O +
herbal O +
remedies O +
for O +
asthma O -
, O +
p O +
= O +
0.025 O -
. O +

Characteristics O +
of O +
patients O +
using O +
herbal O +
remedies O +
Most O +
patients O +
( O -
70.7 O -
% O -
) O +
using O +
herbs O +
were O +
advised O +
by O +
a O +
relative O +
or O +
friend O +
and O +
only O +
10.3 O -
% O +
sought O +
the O +
advice O +
of O +
an O +
herbalist O -
, O +
Table O +
4 O -
. O +

A O +
cultural O -
/ O -
traditional O +
basis O +
was O +
the O +
reason O +
for O +
herbal O +
remedy O +
usage O +
in O +
twenty O -
- O -
one O +
( O -
36.2 O -
% O -
) O +
patients O +
and O +
another O +
twelve O +
( O -
20.7 O -
% O -
) O +
patients O +
used O +
herbs O +
because O +
they O +
felt O +
that O +
were O +
either O +
' O -
natural O -
' O +
or O +
' O -
healthy O -
' O -
. O +

Twelve O +
( O -
20.7 O -
% O -
) O +
patients O +
used O +
herbs O +
because O +
they O +
believed O +
that O +
their O +
physician O -
- O -
prescribed O +
allopathic O +
medicines O +
were O +
not O +
working O -
. O +

Most O +
patients O +
( O -
58.6 O -
% O -
) O +
obtained O +
their O +
herbs O +
or O +
medicinal O +
plants O +
from O +
either O +
their O +
backyards O +
or O +
the O +
supermarket O -
. O +

Only O +
fourteen O +
( O -
24.1 O -
% O -
) O +
obtained O +
their O +
herbal O +
supplies O +
from O +
an O +
herbalist O -
, O +
herbal O +
shop O +
or O +
pharmacy O -
. O +

Seventeen O +
( O -
29.3 O -
% O -
) O +
of O +
these O +
patients O +
reported O +
using O +
herbs O +
within O +
the O +
last O +
week O +
and O +
most O +
these O +
patients O +
( O -
60.3 O -
% O -
) O +
used O +
herbs O +
within O +
the O +
last O +
six O +
months O -
. O +

Many O +
of O +
these O +
patients O +
were O +
using O +
both O +
physician O -
- O -
prescribed O +
antiasthmatic O +
drugs O +
and O +
herbal O +
remedies O -
, O +
Table O +
5 O -
. O +

No O +
patient O +
with O +
either O +
moderate O +
or O +
severe O +
symptoms O +
indicated O +
that O +
herbal O +
remedies O +
alone O +
were O +
sufficient O +
to O +
relieve O +
symptomatic O +
episodes O -
. O +

It O +
is O +
interesting O +
to O +
note O +
that O +
most O +
patients O +
with O +
moderate O +
symptoms O +
( O -
57.1 O -
% O -
) O +
believed O +
that O +
concurrent O +
use O +
of O +
conventional O +
medications O +
and O +
herbs O +
gave O +
better O +
symptomatic O +
relieve O -
. O +

One O +
the O +
other O +
hand O -
, O +
most O +
patients O +
with O +
severe O +
symptoms O +
( O -
53.8 O -
% O -
) O +
believed O +
that O +
physician O -
- O -
prescribed O +
medications O +
worked O +
better O +
than O +
herbal O +
remedies O -
, O +
while O +
23.1 O -
% O +
believed O +
that O +
neither O +
relieved O +
their O +
symptoms O -
. O +

Herbs O +
used O +
in O +
asthma O +
Most O +
patients O +
in O +
the O +
sample O +
used O +
more O +
than O +
one O +
medicinal O +
herb O +
simultaneously O -
, O +
which O +
were O +
usually O +
prepared O +
and O +
administered O +
as O +
mixtures O +
in O +
teas O -
. O +

Almost O +
one O +
in O +
four O +
patients O +
using O +
medicinal O +
herbs O +
( O -
22.5 O -
% O -
) O +
used O +
either O +
garlic B-Species +
( O -
Allium B-Species +
sativum I-Species -
) O +
or O +
ginger B-Species +
( O -
Zingiber B-Species +
officinale I-Species -
) O +
for O +
symptomatic O +
relief O +
of O +
asthma O -
, O +
Table O +
6 O -
. O +

Aloes O +
( O -
Aloe B-Species +
vera I-Species -
) O +
shandileer B-Species +
( O -
Leonotis B-Species +
nepetifolia I-Species -
) O -
, O +
wild O +
onion B-Species +
( O -
Hymenocallis B-Species +
tubiflora I-Species -
) O -
, O +
pepper O +
( O -
Capsicum O +
spp O -
. O -
) O +

tulsi B-Species +
( O -
Ocimum B-Species +
gratissimum I-Species -
) O -
, O +
black B-Species +
sage I-Species +
( O -
Cordia B-Species +
curassavica I-Species -
) O -
, O +
shadon B-Species +
beni I-Species +
( O -
Eryngium B-Species +
foetidium I-Species -
) O -
, O +
lemongrass B-Species +
( O -
Cymbopogon B-Species +
citratus I-Species -
) O +
and O +
nutmeg B-Species +
( O -
Myristica B-Species +
fragrans I-Species -
) O +
were O +
the O +
more O +
popular O +
traditional O +
indigenous O +
West O +
Indian O +
medicinal O +
plants O +
used O -
. O +

Two O +
patients O +
reported O +
using O +
marijuana O +
( O -
leaves O +
and O +
roots O -
) O -
. O +

Herbs O +
of O +
European O +
and O +
North O +
American O +
origin O -
, O +
identified O +
as O +
Echinacea O +
( O -
Echinacea B-Species +
purpurea I-Species -
) O -
, O +
Golden B-Species +
Seal I-Species +
( O -
Hydrastis B-Species +
canadensis I-Species -
) O +
and O +
Chamomile B-Species +
( O -
Matricaria B-Species +
chamomilla I-Species -
) O +
were O +
less O +
frequently O +
used O -
. O +

Five O +
patients O +
reported O +
using O +
trade O +
name O +
imported O +
tablets O +
for O +
asthma O -
. O +

Effect O +
of O +
income O +
and O +
education O +
on O +
the O +
use O +
of O +
herbs O +
Patients O +
using O +
easily O +
accessible O +
herbs O +
such O +
as O +
ginger B-Species +
( O -
Zingiber B-Species +
officinale I-Species -
) O +
and O +
aloes O +
( O -
Aloe B-Species +
vera I-Species -
) O -
, O +
and O +
traditional O +
indigenous O +
medicinal O +
herbs O +
such O +
as O +
shandileer B-Species +
( O -
Leonotis B-Species +
nepetifolia I-Species -
) O +
and O +
tulsi B-Species +
( O -
Ocimum B-Species +
gratissimum I-Species -
) O +
were O +
more O +
likely O +
to O +
be O +
earning O +
less O +
than O +
US$ O -
12,000 O -
, O +
Table O +
7 O -
. O +

Herbs O +
of O +
European O +
or O +
North O +
American O +
origin O +
( O -
Echinacea B-Species +
purpurea I-Species +
and O +
Matricaria B-Species +
chamomilla I-Species -
) O +
were O +
more O +
likely O +
to O +
be O +
used O +
by O +
patients O +
earning O +
in O +
excess O +
of O +
US$ O -
12,000 O +
per O +
annum O -
. O +

Income O +
did O +
not O +
affect O +
the O +
use O +
of O +
either O +
garlic B-Species +
or O +
cocoa O +
onion B-Species -
. O +

Aloes O +
( O -
Aloe B-Species +
vera I-Species -
) O -
, O +
tulsi B-Species +
( O -
Ocimum B-Species +
gratissimum I-Species -
) O +
and O +
golden O +
seal O +
were O +
preferred O +
in O +
patients O +
with O +
at O +
least O +
twelve O +
years O +
of O +
formal O +
education O -
, O +
Table O +
7 O -
. O +

Garlic B-Species +
and O +
Echinacea B-Species +
were O +
the O +
preferred O +
herbal O +
medicines O +
in O +
patients O +
with O +
more O +
than O +
twelve O +
years O +
formal O +
education O -
. O +

Educational O +
level O +
did O +
not O +
affect O +
the O +
patients O -
' O +
decision O +
to O +
use O +
shandileer B-Species +
( O -
Leonotis B-Species +
nepetifolia I-Species -
) O -
, O +
wild O +
onion B-Species +
( O -
Hymenocallis B-Species +
tubiflora I-Species -
) O +
or O +
ginger B-Species +
( O -
Zingibe B-Species +
officinale I-Species -
) O -
. O +

Discussion O +
This O +
is O +
the O +
first O +
study O +
of O +
its O +
kind O +
in O +
the O +
Caribbean O +
to O +
assess O +
the O +
use O +
of O +
medicinal O +
herbs O +
by O +
asthmatic O +
patients O +
attending O +
a O +
specialty O +
care O +
clinic O -
. O +

The O +
findings O +
of O +
this O +
study O +
are O +
instructive O +
as O +
the O +
use O +
of O +
medicinal O +
herbs O +
for O +
self O -
- O -
medication O +
in O +
disease O +
management O +
has O +
far O +
reaching O +
implications O +
on O +
the O +
quality O +
of O +
healthcare O +
delivery O +
[ O -
14 O -
] O -
. O +

We O +
report O +
a O +
prevalence O +
of O +
30.4 O -
% O +
in O +
our O +
patient O +
sample O -
, O +
which O +
is O +
significantly O +
higher O +
than O +
that O +
in O +
the O +
UK O -
, O +
Denmark O -
, O +
Singapore O +
and O +
in O +
the O +
US O +
[ O -
15 O -
- O -
18 O -
] O -
. O +

Most O +
patients O +
using O +
medicinal O +
herbs O +
relied O +
on O +
the O +
advice O +
of O +
relatives O +
and O +
friends O +
as O +
their O +
sole O +
source O +
of O +
information O -
, O +
as O +
were O +
caregivers O +
of O +
children O +
in O +
a O +
US O +
study O +
[ O -
19 O -
] O -
. O +

We O +
suggest O +
that O +
this O +
information O +
on O +
the O +
use O +
of O +
medicinal O +
plants O +
could O +
have O +
come O +
from O +
traditional O -
/ O -
cultural O +
knowledge O -
, O +
anecdotal O +
evidence O +
or O +
from O +
the O +
greater O +
public O +
awareness O +
through O +
information O +
networks O +
such O +
as O +
the O +
internet O +
on O +
the O +
potential O +
medicinal O +
benefits O +
of O +
herbs O -
. O +

Asthma O +
is O +
an O +
emerging O +
chronic O +
disease O +
in O +
the O +
Caribbean O +
and O +
we O +
suggest O +
that O +
the O +
traditional O +
knowledge O +
in O +
this O +
area O +
may O +
be O +
relatively O +
' O -
new O -
' O +
and O +
exist O +
in O +
relation O +
to O +
other O +
diseases O +
affecting O +
the O +
respiratory O +
tract O -
, O +
such O +
as O +
cough O -
, O +
the O +
common O +
cold O +
and O +
the O +
flu O -
. O +

This O +
may O +
be O +
one O +
of O +
the O +
reasons O +
for O +
the O +
low O +
prevalence O +
of O +
use O +
of O +
herbs O +
in O +
elderly O +
asthmatic O +
patients O -
, O +
as O +
a O +
strong O +
traditional O +
knowledge O +
may O +
not O +
have O +
existed O -
. O +

We O +
expected O +
a O +
higher O +
prevalence O +
of O +
herbal O +
use O +
in O +
individuals O +
living O +
in O +
rural O +
areas O +
as O +
these O +
districts O +
are O +
depots O +
for O +
traditional O +
knowledge O +
as O +
was O +
reported O +
in O +
Jamaica O +
where O +
rural O +
respondents O +
used O +
a O +
larger O +
variety O +
of O +
herbs O +
than O +
those O +
living O +
in O +
urban O +
areas O +
[ O -
10 O -
] O -
. O +

As O +
suggested O +
earlier O -
, O +
we O +
suspect O +
that O +
due O +
to O +
the O +
recent O +
emergence O +
of O +
asthma O +
as O +
a O +
chronic O +
disease O +
in O +
the O +
Caribbean O +
it O +
is O +
reasonable O +
to O +
expect O +
that O +
traditional O +
knowledge O +
in O +
the O +
management O +
of O +
this O +
disease O +
is O +
not O +
strong O +
and O +
our O +
results O +
are O +
indicative O +
of O +
this O -
. O +

We O +
suspected O +
that O +
employment O +
status O +
could O +
have O +
predicted O +
the O +
use O +
of O +
herbs O -
, O +
however O -
, O +
this O +
was O +
not O +
the O +
case O +
in O +
our O +
study O +
sample O -
. O +

Unemployed O +
patients O +
did O +
not O +
improvise O +
more O +
in O +
their O +
use O +
of O +
herbal O +
remedies O +
than O +
those O +
in O +
other O +
income O +
groups O -
, O +
even O +
though O +
most O +
of O +
the O +
herbs O +
used O +
were O +
relatively O +
common O -
, O +
readily O +
available O +
and O +
cheap O -
. O +

The O +
low O +
socioeconomic O +
status O +
of O +
the O +
majority O +
of O +
the O +
sample O +
may O +
have O +
prohibited O +
both O +
consultation O +
with O +
qualified O +
herbalists O +
and O +
the O +
purchase O +
of O +
imported O -
, O +
processed O +
herbs O +
that O +
would O +
have O +
incurred O +
additional O +
out O -
- O -
of O -
- O -
pocket O +
expense O +
to O +
the O +
patient O -
. O +

What O +
we O +
noted O +
was O +
that O +
there O +
was O +
no O +
difference O +
in O +
the O +
use O +
of O +
herbs O +
across O +
the O +
income O +
ranges O +
and O +
that O +
in O +
fact O -
, O +
patients O +
earning O +
relatively O +
modest O +
annual O +
incomes O +
between O +
$ O -
US12,000 O +
and O +
$ O -
US19,999 O +
were O +
most O +
likely O +
to O +
use O +
herbs O -
, O +
although O +
this O +
did O +
not O +
reach O +
statistical O +
significance O -
. O +

Attaining O +
a O +
higher O +
education O +
positively O +
influence O +
the O +
decision O +
to O +
use O +
herbs O -
. O +

We O +
suggest O +
that O +
in O +
the O +
absence O +
of O +
traditional O +
knowledge O +
regarding O +
the O +
medicinal O +
use O +
of O +
herbs O +
for O +
asthma O -
, O +
a O +
higher O +
educational O +
level O +
may O +
predispose O +
an O +
individual O +
to O +
greater O +
access O +
to O +
general O +
knowledge O -
, O +
especially O +
with O +
greater O +
exposure O +
to O +
the O +
internet O +
and O +
other O +
sources O +
of O +
information O -
, O +
and O +
this O +
could O +
be O +
a O +
factor O +
in O +
positively O +
influencing O +
the O +
individual O -
's O +
decision O +
to O +
use O +
medicinal O +
herbs O -
. O +

The O +
availability O +
of O +
scientific O +
evidence O -
- O -
based O +
information O +
on O +
the O +
efficacy O +
of O +
herbs O +
for O +
diverse O +
healthcare O +
problems O +
may O +
be O +
particularly O +
significant O +
in O +
patients O +
with O +
the O +
resources O +
to O +
avail O +
themselves O +
to O +
such O +
information O -
, O +
particularly O +
those O +
with O +
higher O +
educational O +
and O +
income O +
levels O -
. O +

This O +
is O +
particularly O +
true O +
for O +
garlic B-Species +
and O +
Echinacea B-Species -
, O +
which O +
have O +
been O +
extensively O +
researched O +
and O +
furthermore O +
patients O +
with O +
higher O +
educational O +
and O +
income O +
levels O +
would O +
be O +
more O +
likely O +
be O +
at O +
an O +
advantage O +
to O +
access O +
information O +
via O +
literature O +
or O +
on O +
the O +
world O +
wide O +
web O +
regarding O +
the O +
use O +
of O +
these O +
medicinal O +
plants O -
. O +

Patients O +
using O +
imported O -
, O +
processed O -
, O +
and O +
obviously O +
more O +
expensive O +
herbal O +
medications O +
were O +
on O +
the O +
higher O +
end O +
of O +
the O +
socioeconomic O +
scale O +
and O +
were O +
more O +
likely O +
to O +
afford O +
these O +
medications O -
. O +

It O +
was O +
also O +
observed O +
that O +
garlic B-Species +
and O +
Echinacea B-Species +
were O +
the O +
herbs O +
of O +
choice O +
in O +
patients O +
with O +
higher O +
educational O +
levels O -
. O +

These O +
herbs O +
have O +
a O +
long O +
tradition O +
of O +
use O +
and O +
are O +
widely O +
researched O +
in O +
Europe O +
and O +
North O +
America O -
. O +

The O +
traditional O +
use O +
and O +
strong O +
scientific O +
evidence O +
to O +
support O +
their O +
therapeutic O +
efficacy O +
could O +
be O +
important O +
factors O +
influencing O +
the O +
patient O -
's O +
decision O -
. O +

It O +
has O +
been O +
suggested O +
elsewhere O +
that O +
patients O +
with O +
higher O +
educational O +
levels O +
also O +
tend O +
be O +
more O +
involved O +
in O +
the O +
management O +
of O +
their O +
health O -
; O +
they O +
tend O +
to O +
self O -
- O -
medicate O +
or O +
even O +
suggest O +
to O +
their O +
physicians O +
the O +
course O +
of O +
therapy O -
. O +

Although O +
one O +
in O +
five O +
patients O +
using O +
medicinal O +
herbs O +
stated O +
that O +
" O -
conventional O +
medicines O +
were O +
not O +
working O -
" O +
as O +
the O +
reason O +
for O +
using O +
this O +
alternative O +
healthcare O +
modality O -
, O +
we O +
noted O +
that O +
asthma O +
severity O +
does O +
not O +
affect O +
the O +
decision O +
to O +
use O +
herbs O -
. O +

In O +
previous O +
studies O -
, O +
poor O +
management O +
was O +
associated O +
with O +
non O -
- O -
compliance O +
with O +
prescribed O +
pharmacotherapy O +
and O +
poor O +
inhaler O +
technique O +
[ O -
5,6 O -
] O -
. O +

The O +
backyard O +
and O +
home O +
garden O +
were O +
major O +
sources O +
of O +
readily O +
available O +
herbs O +
such O +
as O +
aloes O -
, O +
shadon B-Species +
beni I-Species +
and O +
lemongrass B-Species -
. O +

Wild O +
growing O +
' O -
weeds O -
' O +
such O +
as O +
shandileer B-Species -
, O +
tulsi B-Species -
, O +
cocoa O +
onion B-Species +
and O +
black B-Species +
sage I-Species +
were O +
also O +
identified O -
. O +

The O +
supermarket O +
was O +
a O +
major O +
source O +
of O +
inexpensive O +
common O +
medicinal O +
herbs O +
such O +
as O +
garlic B-Species -
, O +
ginger B-Species +
and O +
nutmeg B-Species -
. O +

The O +
identification O +
of O +
these O +
medicinal O +
herbs O +
provides O +
an O +
opportunity O +
to O +
investigate O +
West O +
Indian O +
plants O +
used O +
to O +
treat O +
asthma O +
to O +
determine O +
whether O +
they O +
possess O +
pharmacological O +
properties O -
. O +

Scientific O +
investigations O +
have O +
shown O +
that O +
some O +
of O +
these O +
herbs O +
possess O +
pharmacological O +
and O +
anti O -
- O -
inflammatory O +
properties O -
, O +
and O +
these O +
may O +
be O +
useful O +
in O +
suppressing O +
the O +
characteristic O +
exaggerated O +
immune O +
response O +
in O +
asthma O +
[ O -
20 O -
- O -
24 O -
] O -
. O +

Pepper O +
and O +
bayleaf B-Species +
have O +
also O +
been O +
shown O +
to O +
exhibit O +
anti O -
- O -
inflammatory O +
properties O +
[ O -
[ O -
25,26 O -
] O -
27 O -
] O -
. O +

There O +
is O +
an O +
imperative O +
to O +
commence O +
scientific O +
investigations O +
on O +
traditional O +
West O +
Indian O +
medicinal O +
plants O +
to O +
determine O +
their O +
therapeutic O +
efficacy O +
and O +
safety O -
. O +

The O +
survey O +
instrument O +
specifically O +
asked O +
questions O +
on O +
the O +
use O +
of O +
medicinal O +
herbs O +
in O +
asthma O +
and O +
did O +
not O +
inquire O +
about O +
the O +
use O +
of O +
herbs O +
as O +
customary O +
teas O +
or O +
tonics O -
. O +

We O +
therefore O +
did O +
not O +
determine O +
lifetime O +
prevalence O +
for O +
the O +
use O +
of O +
herbs O +
in O +
our O +
patient O +
sample O -
, O +
but O +
we O +
suppose O +
that O +
had O +
this O +
been O +
included O +
that O +
there O +
might O +
have O +
been O +
a O +
prevalence O +
similar O +
to O +
those O +
reported O +
in O +
the O +
Jamaica O +
[ O -
10,11 O -
] O +
and O +
Trinidad O +
[ O -
13 O -
] O +
surveys O -
. O +

The O +
survey O +
was O +
also O +
limited O +
in O +
that O +
by O +
electing O +
to O +
conduct O +
the O +
study O +
at O +
a O +
public O +
health O +
facility O +
we O +
obviously O +
had O +
a O +
bias O +
towards O +
patients O +
at O +
the O +
lower O +
rung O +
of O +
the O +
socioeconomic O +
ladder O -
, O +
with O +
lower O +
income O +
and O +
educational O +
status O -
. O +

As O +
a O +
consequence O -
, O +
the O +
results O +
reflected O +
patients O +
from O +
this O +
demographic O +
background O -
. O +

We O +
may O +
have O +
expected O +
a O +
different O +
outcome O +
in O +
asthmatic O +
patients O +
attending O +
private O +
institutions O -
, O +
where O +
their O +
characteristics O +
would O +
have O +
been O +
slightly O +
different O -
, O +
as O +
we O +
noted O +
that O +
even O +
in O +
our O +
sample O +
the O +
small O +
number O +
of O +
persons O +
with O +
higher O +
income O +
and O +
educational O +
status O +
tended O +
to O +
use O +
more O +
medicinal O +
herbs O +
for O +
symptomatic O +
relief O -
. O +

We O +
did O +
not O +
assess O +
whether O +
patients O +
informed O +
their O +
attending O +
physician O +
at O +
the O +
clinic O +
about O +
their O +
use O +
of O +
herbs O +
or O +
determined O +
whether O +
the O +
knowledge O +
or O +
attitudes O +
of O +
these O +
physicians O +
regarding O +
the O +
use O +
of O +
herbs O +
influenced O +
the O +
patients O -
' O +
decision O +
to O +
use O +
herbs O -
. O +

The O +
study O +
was O +
also O +
limited O +
in O +
that O +
we O +
did O +
not O +
ascertain O +
the O +
out O -
- O -
of O -
- O -
pocket O +
expense O +
for O +
herbal O +
remedies O +
by O +
patients O -
, O +
although O +
most O +
stated O +
that O +
herbal O +
medicines O +
( O -
which O +
we O +
supposed O +
were O +
processed O -
, O +
imported O +
products O -
) O +
were O +
more O +
expensive O +
than O +
conventional O +
medicines O -
. O +

We O +
assumed O +
that O +
an O +
additional O +
expense O +
would O +
have O +
only O +
been O +
incurred O +
by O +
those O +
patients O +
purchasing O +
processed O -
, O +
imported O +
herbs O +
obtained O +
from O +
a O +
herbalist O -
, O +
herbal O +
shop O +
or O +
pharmacy O +
( O -
24.1 O -
% O -
) O +
and O +
who O +
actually O +
consulted O +
a O +
herbalist O +
( O -
10.3 O -
% O -
) O -
. O +

We O +
also O +
reasoned O +
that O +
since O +
all O +
the O +
other O +
herbs O +
used O +
were O +
inexpensive O +
and O +
available O +
from O +
either O +
the O +
backyard O +
garden O +
or O +
supermarket O +
( O -
58.6 O -
% O -
) O +
that O +
the O +
cost O +
to O +
patients O +
selecting O +
these O +
remedies O +
was O +
minimal O -
. O +

Conclusions O +
The O +
findings O +
of O +
this O +
study O +
are O +
important O +
in O +
that O +
local O +
medicinal O +
plants O +
in O +
Trinidad O +
have O +
been O +
identified O +
in O +
the O +
self O -
- O -
management O +
of O +
asthma O +
in O +
a O +
significant O +
number O +
of O +
patients O +
attending O +
the O +
specialty O +
clinic O -
. O +

These O +
identified O +
herbs O +
can O +
now O +
be O +
targeted O +
for O +
scientific O +
investigation O +
to O +
determine O +
whether O +
their O +
pharmacological O +
efficacy O +
will O +
assist O +
in O +
the O +
development O +
of O +
viable O +
healthcare O +
alternatives O +
in O +
a O +
developing O +
country O -
. O +

These O +
findings O +
are O +
also O +
important O +
for O +
policymakers O +
in O +
the O +
health O +
sector O +
who O +
are O +
given O +
the O +
mandate O +
to O +
regulate O +
issues O +
pertaining O +
to O +
the O +
public O -
's O +
health O -
. O +

We O +
are O +
also O +
becoming O +
more O +
aware O +
of O +
the O +
potential O +
for O +
critical O +
interplay O +
between O +
herbs O +
and O +
drugs O +
when O +
taken O +
concomitantly O +
to O +
produce O +
life O -
- O -
threatening O +
interactions O -
. O +

Since O +
herbs O +
are O +
here O +
to O +
stay O +
and O +
patients O +
will O +
continue O +
to O +
self O -
- O -
medicate O +
with O +
increasing O +
frequency O -
, O +
it O +
is O +
imperative O +
that O +
healthcare O +
providers O +
become O +
more O +
knowledgeable O +
on O +
this O +
modality O +
and O +
keep O +
abreast O +
with O +
the O +
latest O +
developments O +
in O +
herbal O +
therapy O -
. O +

Competing O +
interests O +
The O +
author O -
( O -
s O -
) O +
declare O +
that O +
they O +
have O +
no O +
competing O +
interests O -
. O +

Authors O -
' O +
contributions O +
YNC O +
was O +
the O +
P.I. O +
in O +
this O +
study O -
. O +

He O +
was O +
responsible O +
for O +
the O +
study O +
concept O -
, O +
development O +
of O +
methodology O -
, O +
coordinating O +
the O +
research O +
activities O -
, O +
analyzing O +
the O +
data O -
, O +
and O +
writing O +
the O +
manuscript O -
. O +

AFW O +
was O +
responsible O +
for O +
data O +
input O +
and O +
analysis O -
. O +

DA O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O -
, O +
data O +
input O +
and O +
analysis O +
and O +
presentation O +
at O +
regional O +
conference O -
. O +

RC O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O -
, O +
data O +
input O +
and O +
analysis O -
. O +

NW O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O +
and O +
input O -
. O +

RM O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O +
and O +
input O -
. O +

OS O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O +
and O +
input O -
. O +

DW O +
was O +
involved O +
in O +
methodological O +
development O -
, O +
data O +
collection O +
and O +
input O -
. O +

All O +
authors O +
read O +
and O +
approved O +
the O +
final O +
manuscript O -
. O +

Pre O -
- O -
publication O +
history O +
The O +
pre O -
- O -
publication O +
history O +
for O +
this O +
paper O +
can O +
be O +
accessed O +
here O -
: O +

